<SEC-DOCUMENT>0000059478-21-000083.txt : 20210217
<SEC-HEADER>0000059478-21-000083.hdr.sgml : 20210217
<ACCEPTANCE-DATETIME>20210217105912
ACCESSION NUMBER:		0000059478-21-000083
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		140
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210217
DATE AS OF CHANGE:		20210217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		21643120

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lly-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:245edc66-3d73-4ffb-b61a-7d5e03b3f1e4,g:f11d2b17-0882-47f8-a810-701878e7e2df,d:a8e8b06f04404e6fb09e313103495f8e--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:lly="http://www.lilly.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV8yLTEtMS0xLTA_a10b5315-74c4-4c71-a598-8178eca3f891">true</ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV8zLTEtMS0xLTA_c4ab0c30-64ed-414c-9a36-64e51b5f5cda">false</ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV80LTEtMS0xLTA_834b5404-fedc-4e0b-a427-de815c53980c">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV81LTEtMS0xLTA_e0fa3135-5fb7-4d12-8828-142be32315d7">2020</ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV82LTEtMS0xLTA_fe85aca0-36ef-45b7-b84d-60dc50f7f7ef">FY</ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV83LTEtMS0xLTA_b3c20d44-c2fd-403c-b090-89b82d08de61">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="ie8d870ddf29742b896587158690bd8a2_I20190101" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8yMzIyL2ZyYWc6OGViOGRkYzQzMmRjNGNkMGFjZjEzZmFiYjNkM2Q3YzQvdGV4dHJlZ2lvbjo4ZWI4ZGRjNDMyZGM0Y2QwYWNmMTNmYWJiM2QzZDdjNF8zMjk4NTM0ODgzNTkz_058a92ba-a31a-4d16-8453-13f5785f1df7">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2b00c742d1fa4c71b1069e0936d163d8_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ1MTk_0bf7a79a-03a8-4be9-83df-152315c973ca">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ic6db0bc1ab684eb9bec935aafa00cbe4_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3Mg_22167169-de32-49e2-8061-fe64a7bff538">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8yMjkyL2ZyYWc6MzZjZjY1NTliMzY4NDg5OTk0YjZmZDhjMjRiMzdiMWQvdGV4dHJlZ2lvbjozNmNmNjU1OWIzNjg0ODk5OTRiNmZkOGMyNGIzN2IxZF8zMjk4NTM0ODgzMzY4_49b0528d-255b-483a-8bd9-fcacd97eacff">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8yMjkyL2ZyYWc6MzZjZjY1NTliMzY4NDg5OTk0YjZmZDhjMjRiMzdiMWQvdGV4dHJlZ2lvbjozNmNmNjU1OWIzNjg0ODk5OTRiNmZkOGMyNGIzN2IxZF8zMjk4NTM0ODgzMzY4_54b56473-7004-4c68-b02d-7a1fe69533a0">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8916531131184faea7af74d7cde93d3f_D20191201-20191231" name="lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODQvZnJhZzowZmFiODU4ZDhmOTA0NzdmODZjYTJjMDYzZTcyNDE2Ny90ZXh0cmVnaW9uOjBmYWI4NThkOGY5MDQ3N2Y4NmNhMmMwNjNlNzI0MTY3XzI1OQ_1925f4d9-883a-40db-a86a-cf8f536230e0">P21D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i137275eafd4c40f59313788c6e8bc624_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef7d2358d3d4624831eba2ba35e625c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf054c1e69d548fabc27199bc26a11da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3db037c2fb245969975a8e68da5d13f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa23ebc91dc4948b44e17114afcbe93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6337489efeaf470db72beaad17305bf8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c82f670af140a8bac93e72206aac4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d00685b69642528d03b4781524325b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i61b9de7700734098b07f8a46f43d9497_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i86a8c3eb7a2a4ef48d31b3028fe3303f_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iebfe9598260a447ba9e16ba1e9c6ed68_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e0527046d9420eba85c2e7997c4b79_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f87322c97e42a2b941ec910aed2655_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8341671b44cc41d5a18d4af59468c567_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e87e689a45f429e8cf9eefc3f7fadc6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab11f7e22e3d4369a89e0b9a64389e84_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88bd65697e614b36971bc989aebab0f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e7e33eb088468895e308da89cb151e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184cadb6a52c45e68d6a9a4c2738bc68_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27083e2ab25e4d04a25e1ef83d0b7877_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045bb911bff14e9aa36f1a05bf3e92a5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib70725e180744eb1954d643e7a5a963a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae684e1f51624a5884d558a8b1eea7ab_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i724dac2e02db4426bbe5e17f9903b032_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03c1c5fc9e8a49c99deefea40e94e712_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i636193b834b64dd6bb822cf51cc578f7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28716e79250245dd90132d730ab4c041_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f64538c2968464bb7e99808fc376334_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7bf2897e1304a7b9d39c16325786d60_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157d7cc7dd0a4ce7a83fbaec2dded32f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe5ce62fdd544ff38d36deef307ad126_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10e3cdfa36f041fc98dc2d1a6961d3d4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c9d052fc1b4535a183d69045981ee8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d46f703015a40e68e2bbe1d001af462_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a89936fa8a4137a7ff3506ba792c52_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93b724bf8864d4c9fa270f354b1916a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafa5205837f6490198d5eec282d9367d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie391d487b3784a9b8e753e02edd132b4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19bfa0a6cac84e13bceb037831a4f867_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1c048117e4436eb1290866218298ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473e4514c71444c9988eb5ff37da3471_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fa49af8d0b4b4fb6114b249eda120f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida935f3e75bd41ffb87686123bd54de1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3987bdd473cd49b4a9449fe4eafc3bc0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i688adb3e04c845998ca0228971320c29_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47de201d5d5443239956a13daaf044fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifefa16ca5afc4eaea5068a01f7896ad4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f62bf81439d4ae4bf4ba4e32bd50761_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa954877e0c7448982c196e66891eed8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if36805f1fb89427dbd2741f45ab5adbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027fb322c12e404ab2d69c9acb6af89d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036da0197efe483db4434ecbe172adae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9187cdb56548338bf4141df49d64ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i787f9b28041442e7ad4a920214784c1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e3601cdaa94bf89622d6fc8cfe46fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9627925923524961a92f6c7efb50a362_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c0d14f77974e70adc19b8346937884_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50acc48e0eed414dafcaecf50e0217b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e05a36e47a4388bbf774447f54fdf7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc6994314b0437780a92cc7d6dc54bd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icf5a8d8b13ec45be88c05cc0494020eb_I20190311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">lly:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d870ddf29742b896587158690bd8a2_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aa7ce2db08d4fc7af3dfaea6237b261_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01ed1b80ae7748c6ae7aefbbfc4c08c3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e90af870b3d47a4bd1770c53c1a74b9_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">lly:AccountingStandardsUpdate201616aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec2a6e9e71f43729a2ef0804b5d5688_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">lly:AccountingStandardsUpdate201616aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b760635fa6d431c9dbbba9b762de382_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f36d7a75f14e72b8ff0e498de5ad74_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f006ccd7dcf492e906b2da535a904b2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22c268eadac048a8bed666bf74cab1f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a7d3b63876485d87034526a86d8ded_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ede8557fbe4f02a6f390d0e6822798_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie64e6e64f4cd4c3bb6d2fef573bc1cb7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a61dcc93ff4861bcfc64e6431e4d71_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2123f59cc857450a91ae3b7c97124bf4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a3fa17ced44cf6911c558bcef7ce7e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i697978618d86456cbf1a2759d0f32502_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf1ad720b4c43bf8e96a192f4292dde_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d4d013544c649448fda0d85a40880f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df231a5cbb94e458fd1cf844f24d8d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ae1b15ab56b43bc9a7777c2071ecf3a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72b23fff2282489ca3c0f894bb18cc07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55059f768986433ba6bcc5c4b2726cb8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9ceecaa70744b5b18f2b550ef85ab7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddba0e6da38240e58e8ef1983e1c0432_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5562538495445b2b19f079d4c482ee1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2352e466ca6e45d1aefb7efed013e9cf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56db8c7d699d4b908d30e96ead023336_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23b300ee7c04c219019df6e1ab48341_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0bb72cacc846c4b1660192fa13fb2d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728a6f151f344cd5a4e1658f4456e4a4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6884b0346ff74a868a23cc494081187a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9d66c70ab574ec1a1e5591f1bb6849a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85836dd8d7c24266be724f2fd23636b0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie247b454823c4c899728fa1e7c3c6488_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1561cbf5143e496389f63ec127805cec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24bf00d544347dd91396c4ce0a786d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec05ae419fb4e2fad130ef8bcbacb60_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14247b991aa4660aaeff59ba9087029_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28072632c66a42a99ffb45b515d993c2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i191e8f8614e54664b788c1acd1a1b343_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc75f49bc8dc4f318a19c8b6ce2d8bab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i715dfb4b6d894d1c879e0379cbf8a8f4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c183a74083641c0ac1bf8f66c7aac92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c928d58286344fb8bcd47e90bf5d627_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id975590de3cd4ec99467e999df92c9e6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2830a10550f04092843207d0fdc28a94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e42ce139e604186891333c227fa7f7a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a798b0c03524583b15477c45770fbf4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27309ca3061448f8aed7d50699b44c3b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8238834ae2044c7c8f8d0f0b08cbd9bf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifde87f830aaa4e7e95c3b4d0b564bc58_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64cbb8b5cf6f445e96a2f444f379af93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e1e237c47e47c9828a59209311c512_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i085f2ef402e2415c9ef431e7b9de5970_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134d638c9b8442bcb2b54a0dcf99244a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35093190cc994e6184aeba18c6d4e4e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca91803bf7b4a89952e0d15df9e7d20_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b03da787f1046dda25e71c726ed0cc8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ad299c9ff445079d8abfe019fefba6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8cd43064bc54a9e901c418b624a14af_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1421efbb7afe46ce9044e5d41f1e6871_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8251cd1ee5a241ecacce9020401be466_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa14db9f257a4f7b8ca0845e9421f91b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bbd5d25f80c44ab94954c63d53de368_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb30e7b8f241492da7454e9da0b979d6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic12680d1b9124165bc4f6d955d85bd82_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i429185bfc6e449d7be22df700c5813fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25dfe0449994ce68da67470b4776d8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b9545410a04c8da65e3c6e319a22d1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22cfb8009ead41cca1ae3072cccf9499_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8dc99127224767a2f12d03a5092d3b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca7b28a537c43b2af1ddf727727ce40_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85186ccd9d984ef4932e09feef978a06_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e9cf6601c143cdb1b8d32ae6fd5480_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea814fafc7fb443db887570f7ea72927_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib05835511e414ca89be73a8916fad2e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b3024a931a4657a4060b07b0425e72_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c1fe9ccbbb45969203d906ca0f642c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09cd8e4a702840b6b077b52bb0fc885a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie21841be70ab492085d716fac088fb9e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73c0cb2f4924c719860a7896ccb64a1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ff519fc32f47c2a0c49159fe2e34b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie914cb56ec4e4ed1ba232fbfee390bd3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966ea8089e9c4d68b34e188c500666d6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9679e5d6124967a685918cd9edf0fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea5fe8155344887ba522b8118049b2f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3931b370dc143f9a310450ae75b2907_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15d2a58303ae4d49b78490eb27aa3acb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbcdae9c84da42e5aeffa936f33600fc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88519de09ce340f2a440994d3a26273d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9859caf33c4d129baaae6f1b8a77a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e90d63bd7f04d43b87e44bc9cf80dd9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6f19b22df74b2997a2a5a704b7566f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae16d89f887948a1bdfcbcfa51d0d3ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00a47ec3ac9242599fb0534acfcf50c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7e75f9a985435381e8a50f0510b63f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18759d9c174433d92652e5cecea16b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121c5d89d6f84862b7a81c70128ff4bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c089c556dbe4b988097309eea2debbe_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7338fb226246619bd2bbf15851f0e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if209842982b343139ff9db8653d11910_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic909dda5665e4ba29f047d0b8e1bcf5f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86f3bd326f604139a90da118ac9c06c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1c0080f9e714abea664e5caa8d145d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb52b4c8c5542df810d31d40cd2b4b5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf91ad79a82a4ec5b3a916c3289276f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de717625dca44c78e1e0e949939a76e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b654e430e44c46b106bcb63224dd6a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7fbcc61f59a45d9a37e569ed5965f58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d13169d2141455bb4a93b34de2a366e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1a6364df78042fa901d2f1c28c93754_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e09d571eb774bd5b689a1bb4eb4de7f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2dc9d878a14c9ab4c5b052d73bad3f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie48cc43a68c8427793e98a1018af69e1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14522eae3f4432ca88eefdbd852a7fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f778c41acb14e25af188e39dbcf6369_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e201e3b4b174110a0451d32f28f8212_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc9993567a2444faa53e3c75a8e44e1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db6d4c2a25b4bb0bc740c90579b0f05_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf78497fb94a405aa4fa741353f71471_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6279b04ecce545a2a6ccd1edd954a346_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic653dbcb57f34df2a7cdbe7b36ad01d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2f75b6ec544748a1740ef4680b574b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382d0dc50c7442e584209c6d42e6be90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib27a0a7bc70a4f50a74d2e0dacdf5b43_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca201e6a4584a94adee1b47b0e65d3a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d3783f314a422f9244251ce8f5d9f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f653f3992f470ca575e3abea9ae426_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78c414a5e65d42939a3f580b88d368a9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54e1b52fe0945a18f903058aed5a173_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092485a179404990a1b3f5d43565922d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbcfad66d94c42699bde82b3cc71bb61_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d67124e0304de6aa72358898ffee74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7465980476074ec1b9f2cf051bd93aab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i405fef2f42e9480580d5e77115611bc8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie21029b52e3a4a25b8fa5ac32c01193d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e3ba10cc2340fcb7a501bb4088f695_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i194d5e8204d94e729dce3e5167479788_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42aed1d813ba440d989563043cbf63d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if93e5c1a7b044586b825fb8d87adef56_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6282183e9fda43d6a25c5ce5f92ff949_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3164ae1013b84936a3990cdd7069cef8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6226f69ada1b4d4293ca0d61745f5115_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i464b09a2e18141e18ffa754a848112c9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471982bd0b034ecbbe77d99805441a0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia76bec07f3464f1c8021d24050c68ea6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia39a7fc11f9746e597092068de88f47b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic60748556476451f97a39a8498268861_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ce9eaf6546546d389e4f26520e4930d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856f4e27d0e54f3f8f678504c46706a3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1246f125dde64914934faf191b569fad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac47103ffb8e4db3ba8420ae1884ba32_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971612ddc6f84ff5ab4cebc6bc9b7489_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd4460d0fbe7498caa8faf2ab1635509_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie954542f232d49269cf42f99d87610b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if596ee8084b746c1884dfb23161b95a2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4c40ad02014289884f8f89f9cd98a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d98f1e0f63d4944acdd4049c11f843e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b22a1b043d84461acbaead22e49cd3a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c01d5260804ef2aefb47f37eac34b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6ecf87283c4add86844acf0df92029_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e5420c07a564b57bce98a24d8094aea_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3730e62c21c49eeb0a31d079c88843e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b39e0b4d84459b937f1252cad92e0c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe81f38456364de09c2c37f4eb63cfc5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf1659ec78a740ca9d2960b4d4f4fea4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb82d9ffde3c4a3a8affb2c0815b56d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576e907b609447808b7b5933c0df5f34_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33620d8d08d44b8b383b1f866bf2e64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbec8a0db57b47818082aea617fcb08e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49f010469e74c1fbbb54018a3403a10_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1f8bd5f6e7439cbf1c41e604f947cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e9913b2677a470782bee3b901368718_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a98260337a41c7bf70c5041273cf30_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69dd705bb5be40cda1cf159e67bfe51f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254787900e9a4e7182dcb921c4b5d695_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5671e1d40a394d5aa617890df516c413_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4d6c27c076414ba7e9464801d0140b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51e1b22d70974fcc95c281ec5f6e788d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67ee0b00db446ecacd2b9f627d621d3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf51f9d513a64c25a6eeaf8e33921e20_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia079d10886be402287aaa123fc31ddf0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b37da845eb34ab9aa5276ef319e7926_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bd92d27afd4390915113b0bb32dba6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie311a24502de4314b71b45580255cb57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff5458bec1b144e5afafc2f8657e9b86_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8656193e314466a66ea72a95a19692_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756013fb987e4ec49313e27c98887d9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48736069f07d435ea802718ad0061329_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f15eb6661ce4b1abb626c73e242befc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55080d1515744962b9aef976d3cfdc53_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie546cf165ddd419e9f13ce7b33b842b3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1485142ec4594191aa24ebdd7a9ee8bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e49c0f20674d7eb574b88861a45d59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5388a613eeb490eb1588c4dca37c078_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16fbcb5755144a989fd1a37e01482bcf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e93087d035441c7b9196cf48b975ccf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056be4f4187a4d8ba5795cb66a7c63e2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ff3b39dc584d80ad523e152d9aac2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9042f18954a44f338ab7c4c38402701e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231c072e54b14e93bb61feda90673766_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f9aa8b13a844198c584392ffe612ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75eac947e5c24423826502ab09453d22_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf5ac51274948a2a524006ba7646b34_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie404784c5a4c4f23bdcd42cf33eca1b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f19444ca5d74e42b8447a4f2274754d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04bae10a0f824b3db0e8166ff0c20364_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d3b673fac540279a7f2aacdfaa0069_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792013c79753444599d13628b640dc41_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b32d9391794988a11cc682565b7a80_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a0d2e470af549b4881425b33c0ad415_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6137d276b0f47409d9ce0335e227625_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0163d1b6ab54735a54f26743f4772ea_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0447dee610924071bcc739ab2cface2b_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39f7cc613994dd990be73fcc3b87286_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd24952151d6401a8d349f6aa9770ddb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44351e94bb742d683da05ff0074d5c2_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56fecb64135f4cca97024ac5ee838679_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:SelpercatinibLOXO292Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911edaec6d6642ce8d5278f65d8639f8_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d91ff7b27004f208f75b0a5c87e5819_D20190215-20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-15</xbrli:startDate><xbrli:endDate>2019-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9219272b6237462ebdaca8970a975081_D20190201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817bc774c0a8475dbbe3fec31acb4ee2_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec4b9cb82304fe1a9d510e0419943f5_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4c539b649e4eb2b5f76577e83e9100_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2dc373598f440289cea2acfc3527726_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:UndisclosedAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e93668371324e1ca8c0ee4bcbd18801_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:EvoxTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb9be66049641c9ac68c3d117603a04_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba61e61e3baa4e2997fa60b1e4f4971e_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DisarmTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec4ba9fe07284d088597742e1436f206_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:FochonPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9280278cfd44c43961529cec49d61e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdaa22fe62fc496280072ca3fca4be80_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ImmuNextInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb0a2d07df0d4feda7f5fd4749d43715_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AvidityBiosciencesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639e2336e84c4b14a58a28b021459d91_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:CentrexionTherapeuticsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840bb93977c84d32a309ff7a8196c494_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:SigilonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9269ad1f97554a34afb28d633cb92685_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AurkaPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6890b2b6dd4c4f7cb1263fb822f41093_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ARMOBiosciencesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da5e2bb6fb443248dc40e30fed39f7a_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AnimaBiotechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib406c368ebb248a6905e51cdc446be75_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:SIGATechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a390840d5f4630bf6cdb7e10975ac5_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ChugaiPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbd61d5c90aa43c0a362a60341c2d2ad_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:NextCureInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i162940fb176e48c1a385b23fcc164f0c_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DicernaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e25f473eb845d2843f5335d4f49aed_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:HydraBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28cd09163e9a470f87436cbc6e159574_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a68330743054dfd8a5f47bd40a19db8_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3922fb112aac468ba7f7550c759a6166_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="medicine"><xbrli:measure>lly:medicine</xbrli:measure></xbrli:unit><xbrli:context id="i2ab202db20bf44e79b70b6fe34785936_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24260a2966224f0aaff14390ed8899c7_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd2f82569394ceb825c6ab486475ce3_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i456272c8da464ab0977d30b650506a1b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lly:AssetAcquisitionAxis">lly:PrecisionBioSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a914a9a3184c15824f6ca6f22e6887_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lly:AssetAcquisitionAxis">lly:PrecisionBioSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f0e3d4afc04fa5958a6ff84edcb67c_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:AssetAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11c18de10e047e29fc8f48ccd7ad3d9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:AssetAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib592ca19ca78498fa6f8c390254088c8_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5102763567ac4b82ad95c44a59000d4b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if000a6bc5ce54a1b991ab37772234f3b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8269e026df1a41b2b0895893b55d57cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea5f2373f024fc4b990b56206bdc2c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib012a6676aaa4eb8bc9506fa646b3402_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8456d682a58d41a3a50ddf018b0a4c6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173297e573b146f7bc78c4ada3a83d7a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d4009f20bb48cf9ec030239f052ee7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5bdf1152ee426093323505e09cb233_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1fc8d9d4d2a4410ace81efc24eba1a9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d36ed57bb9940dba66fd60498e5d762_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4ed102c3ad148a0a31d237f28a5df12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312288bed3e9413faa61bb6376a13576_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i308e5f2dc1ac4bf9bf1df82123fa7ad5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc2c951fea140efb3bf430c16795a63_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78597bb677aa4ac4a976a0e803853b22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c6e7782eae44e479a4ba6833152bf86_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85207b20c9354258883eacc250729894_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic88f51f077b644278fd68d0fa5ad4dc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i710d1f304d724efc85f13dc60bf62fad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82dbabd3686d4eb9b13b54382cf6bcc4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93249b60bed44a7946fd8491b3b85d9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d0178a6cd14c4fa5fd77920bb4abbd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43add1f443e64f3db8290de104acfbce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied1732da693a41bdab698fa5a39ba0a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadf97eda073b42fda0623d5c29db2c5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77a2552c6e24c67bf8d94ce91e0e5d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i252ecfb1d7a840d9806b0dc46157e963_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf82252c7f64ef49980a721ff43e8f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8457b21557264435b2547d9a774dabe2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57723ff321a4ac09c2ddd06857d6267_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9040b40c375e44ec953ab4747d1dbaa8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5e6e4c1ddb437a8f9faeba8093fafa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c2329f83d54c2daf23fe9a43a89933_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OutsideUSAndJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if51e456d8c22452895dde4067048ed49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9a899efcc14002a419189d81ad60c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a5b403f3e84dd588ce7e797609bcbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278ff628156c4188a73f68b4511dfb68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e398d4d6ace4b53b2313b073d764cee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1db56f028e486bad99686da3f343bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifafea5b05f3f452394ff8d36dbcc9f7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a7062879db495387dd023ff0ac4b13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76593a635ee74f569d9d5d26e369257d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsdSellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="if292dce18b8742949a04f94a69f513e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11921f0731440e8b2d7e35e232cb20c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i2c1ec7ea3e4544bebd2209221d0a8ad2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyGBPSellUSDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734b5d697bdb4d96b38be8ba20e2e66a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i885be083614a4d18a19870c3bd50973b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib71d03b9d5404ef7859e43ce06d40102_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3781eb7aed394d3aaa09742b6bce2f1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15da0b294a6b4817b66312409c265245_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4c33e1edc444e5b4e9a8500e0eab88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied0653ffc6e14aeca59c89fb6a86121c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic757ba5b7d1b442d93291ea03decee5f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79bdb56a9d7144029b1e5522c593614e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d9065de7764cc19c33a225a0d50880_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i177b2d67f8ba418284926e505024a276_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i559cde7a86934d01957c68c16475b1cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i089038df2aa140c192a89e32082775b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic259a5c22c4b4a7aa701a9d5367ffc26_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a4d2134a40b4c75849277ff51f28c3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c9ccd3865e45e69f040a91ca7dd298_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d6995b66cf841668e6e05a116f49a16_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b825c2201274dc188cf256f122e086c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f82f22527524999a91aa71e61c6641a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325ca753011c477b8ba2959a5e5c7d2b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0813de855ef747abaaca53ef36e4c1f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670c43f24d5e48ca995ca3f9f935644c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfaa8924bd4f438b86a6705d72934fe8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1e85a5c0bc9421ea34d9822b4a94e72_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2513e6302b4030a3b2c52c6326a063_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a17ef8639b4116914b2853f39ee356_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5eadeb2c29d4945b2f705b7dd6bac6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id899c3b3d5a645f5bb38fa729003c1d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0876e8c76a9c4c308a34aff4f59ba314_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107cda2404e146cab37a3274549bd9d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1614e22518944c76b247484e7a60ca8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie269f3b3bfdf44ce9b4f6626338c067e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c51b75c2fa14c1684c56a1e7d8fc1f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec12cf461774e1182bafa64c823d98d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i566cfafb34514a41ac32d09adc9ee29a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ab34fc33aa445d9f82bf362c674439_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97251102c68a4c478e1a1be501688a22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82e0f1e2870e41769f1affa474d182bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758fcf4cf3c74497807165838ee0ac9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077c04533e3743c8b36a16e643d4b688_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0432603227427ab677d8fa8d0e0872_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b249a1451654e4f94d47645b0fccafc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867f4d052cf54d0c85d6df1946dbc24a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b0011562854b1d95ba84ae4e1bcf37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ad918d4090746489ff767a295639e94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436c38c65cce425daad44c655b754e71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9398ca058d0048cb85257c2485125ee7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id952bb8455ac4064b262c91cc977ddc7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2749eddf3fad4a5db6ba0abcec58bcf3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cdb65ba392744f79ff27b54d5a5f83f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3a5cb729034c68b87c779b4e84d7cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2013b0dbf62424d9350c6b71c35d2d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79afb23fd84842b88431983432e6faca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec93f4a79eab4a1586228b07068c14db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8881e2925d8b4caf9fdfdf020b93932b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e008d687ea4305ab1f7e75dfbff408_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30940c5e536f4d5ead427a4782d61c94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i435e18e4a6f549a399937585428a9956_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f46ae367c8745948b6623087118c537_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91d8fae795ac469da2155b12eb39aec8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie512126811f64a28b96cb6c61ff78085_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53ce320a0cf45c193d1cff9384dd062_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f275b97cc004a86855de7192fb8f764_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb5a016ad964daebc62766f4f82a19c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19985e9c706e44848bff87eb752a0939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33645495135840a59fbcf0e39deb55d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie198dbef2f4e4399a10d5932355eb939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b7bb38ed4d4d11aeb324f32e415e81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36eeb1bd9f04842a9851c91ab5e895e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icea21507ec1d49be826960b15a6c42f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3050ce166b0e433687c88c87676b070b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4081e5bd91e244058a3844645c6f7e8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6b82be3c6d47cf90e800e560194078_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ef89d353cf247e0864a754f5b062e45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b870b023711491387d9d2d2fda73e1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d94ce65a684af8bf51656da3e6449c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea3ae02f6cff4631aab6491d4ae1ea8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca2871b4ff44e13a1ae66a9204f2c5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36a35200b6214f8d862d1879f4522cf7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f04b7c762cb464abacab6b4977a1b29_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4686f8cb62994a9a9bc8e6b7817e8410_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9de1473493a442ab6ca0ee29d148543_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ec43bf672b4ad99e62859afb69e618_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e269ce360814b8e84f97f774fd1c803_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46aacafc18444898a49130e3d437b45_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11555512f15843b78cb5d74c0d0637cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55e9794059e54793bf573b9748798eeb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd767fb99dc9410291e52fe3a05701b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b9447fb59048a28d7f41123a0643b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea08714d01bb4abbaffdf5f5e1634598_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af641dbca0f401696c62e23d843bbf0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if911451758b0451ba9dd43374b7caeb9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie85afc85494d45deac992b5b655352c6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe41ef9074154d9c86b0d0beee80732a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8beb739ebd1649a2aa6dbb7bed7cb98a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b086fb17f3400d87543e41a70f9221_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a79d730f284ce99e15280ddb18014c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i896ba5d04f154341a7f226e1768613b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7430c4dd94c4647ae735ab5dcbe41a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c04854fd114be5a2ed27c2c259efd8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if547dc6573ac4235ba2a0eca5f36102c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c8506c4f9b64daab27077e623773d22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88b2998a44a42adadb3c56fdaf02670_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f61406987b0462d929eef8f4acd716e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bcb5c5899344364a60904c18340c133_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ba6d352d364d3494b2a7fe4c35e283_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i335aa482d73640a395372f1fe66486ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5991d2f6863348dd894ea4182e0e6ae3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1edb578fe2b146dfa9398c23136bd036_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa6955b8d2b4b22bd3c25a51caf5bfc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fc3ed55b43049169f584d6511c15e2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab7928a68fd4d8b989433ccbf30af4f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i037e599f78cf4eb193c194c14da7e6c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5595324df32f48359938231bb46a08db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8f10afd1f4e4de39bf7a81a91f20180_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a044b0ff45b498f991a1e4bc212927d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b7565646be4ec6aee7375271c85a7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc2dd7aabbe1457a85f6382dfb21b03d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e19515eb414ea3950645ec1bd6e029_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e32fe5c4d1480b80157e3bf4f1e8fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6474a7ae8a415c8a0c7443dcfb85d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0360e6926e5a4ee19a921dff273528d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7727cb3da004ae0a84be29679fa8e8a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeacddff780c45eca88800cb052b4f1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3597dd720a74b66a0a24bd7e5f6336c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2025050fac34c4bac2c4ba461347a3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26823dabd1b64b328190517078c87d4f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8339c07c793c4080bbff3b4f3508d6c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff9b4655ccd1401e9984bb3b5ee74b96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bd4cb1fd99f4fae868921a774fda59b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3f83e4500c4b8785248a7a70fa84b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2c22552802430ea404ce1f2936a291_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e9bed57fe694231ab6166019b90e496_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc63939ce42a42b4b7c2ce2910cbad4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78564906ca1644298e4c0fa5785b3dc8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e562e62e4d4490ca21252c3fad46bda_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f157e5e59dd4d41821a1ba8e732b05f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9dad78832c4368859b28c2f6894c72_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id845d0c7f9964ee0bf08e79d645dd1ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf0dd8585de44468add60f95d78c62ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df764752add48c48282f4351f5aea77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa54dda0cead4e039cb3c37fdbf005b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a5d2355fe924260b94ae1755b5115f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f99babb106943a48c2ef126347a18da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3140c9a521e845898dff7af991e1d21b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e14b4632c2342cd8bdd5d6e1be3f3d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc9ed839ea824eea97ca2b8fed80d1ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a345f6cc3914c7f9e7fe94738f6cb7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e42ef743d4049b8b98c528fd36eceac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99493aa1fbc341b58c3254bd5c14e0c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19aa55084b624b149f91667988733b94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bb79e31f68c462a8bfdd0a9e8cb0126_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1161a1814827464d8d0bf447a827298e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f85dff2b99430d9ea18be88db32363_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54194fef9ee44f0baa1198b79b989cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49bb3cfe0c224730b91be93a08a94d91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab9280585474937b6956aacac7dcc43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a130b6c9674334bb31349bb3084485_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i698fbd8d92b24eaa80fb4794ec8b22db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c44cbf91e34245b319839db6f762e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7188b3764a4f06b9d801cc32c022eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47944dddbf22476e9864a6d86fca6c07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b04120333d14c7bb3721e9afbb4f200_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f3f64f550448648f5d119e75baab9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46ab1f4827641929600f4d8e579cba6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3a5e140926245c3b898ab1b8b0aa810_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i571b62f2272c4f0c9864c655bacb5f43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2faee0bc39a1435ab2737a04a112a0d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7397b614fa4d0aa289843e505c0338_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i499a38e64d144a59b3902cd77fe676e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a53f7cc64140b6ae991b885dbec6c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib769bb44d96b4ec6b1ff4f8945d14c74_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7790a8ee4fb2414eac30e7a9561da8aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f567bd4e42740019b3174c50d5bcd76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3567afa62a444c229ff7c02310132308_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a257a5c3988421daab1c5c94873c7b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea105f73e09247b896eb5002be1fa817_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901470ea1dcc46daa707e313c0151f74_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d8bd5466554120bcef2a7280d5a0cd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i605c9e12226d4404b17da90d7bcf0a01_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8ea6d64d6b48f185da2f7945e93913_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if97d81ab32d741d5a50a9e919be3b610_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb8e2a45e4548bbba35a9682ef87298_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd8e5bcf3a7042e997ecff32c5ddeb26_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68533791086c4a66b4e85509ed1bbd21_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018a7fe95440493cb5b194a242c36530_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4080399399ba43068553348c4be8ea2f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc07496027d844728e4f422d09488b8b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e3a32202c54bff815b9d7e2d3e22fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a6f81ea634490dad4edeff649d1781_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38207da496841d290edd3833837d8da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifec2b5844ba24dc08ff7dd52e6d6c8f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1c802688094a8889c8d0228f9ee2c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i662262e67b5f40cea96bdb9a5cd66701_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5102bbe8737b4c2da4a4243cb207ce90_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1083cf7137cf44a588e913c40a07246d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4236ef82f62541ebab48555f05d6cb37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42c7c598e6f49feaae76a07d1b3d85b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bfb71fb8b9f42c794f44a765001ec7e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b00c742d1fa4c71b1069e0936d163d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4f0d9411ad485cb55e50fad753c51d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6440d866422d4fcea9a1a914dc919853_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic681b92a73ce4099bf3dcd5b07e95e90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6db0bc1ab684eb9bec935aafa00cbe4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabdd19152304e26964b75c2240169f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11faf3ad2f94548b0a09cf8f35a15f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2594deedacf54880b1db0ef581e435e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d7beba7c48404cae7014e52512b95b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cbfb7a17f9438a8d7adf6e5a09c448_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c64ede2b9f24bd2bb0d6f97ff8dc7ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia528dbed284d4ed0b3acc05cf5e1b356_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39118bdcc684cd68b2c6725d353ce58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8211a0f8b8da413db4f2efbb3213d634_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de9e70275e246d6a582111588810286_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02f615487ab04c708fef493a3fa4ecef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c1211b430f4ba58b2eba2c97c976f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie245631a64f040e0bf885d77689fdecf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eafba22b49e42f1a090d404e4b1ccd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe45934df5346e4a6a0d715944c15b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia221e6819a7d4e69b484d963df327dfd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida41079f1ceb4961915954043ad0b801_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71a0b4c817a43a9aee24da56d63c0e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id641d973aee741acb44e0f58ced70bf1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0dbe73367c474aa66b9eb7c4937520_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba8e44c95e6f480eb82a83d06e179514_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fc9ebff5d804b3587da0025635f268e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3562490080194bc8b92c4d7b39b14b4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic52fe587003244e18fb9abdb9be4e63d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07507ae169e74357a231b2d9c239eedc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6bfd9e9e45a473a9f90d4f41a08ea48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1136f1586cde4061a489a0824879f7d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bfd288269624c7b86651f8fc813d3bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9cd37cd7aad40bda3f214b57cab2f2d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a50eaec3e7a4ba69d1ffdc4a120b39e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea8fc22978f41d7932c87f65b0366c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57c890b8a2244d1a7018e62567f926a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451d9a3273804f14955cc5a82111caa6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d7b6ad2f874ca7ab2452e56d10ca29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb059df82e0b43cd84033edf1b400448_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3112631bb974c85a5318fe1efa3d51b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c0b90ff61e4adeab7beb2122db8cc8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c5eb420e4649c487d09089e7cf9f49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c6c23acfade4500ab9b57e874f2b87c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ee2a27f08884a89b9bf33bf08bd0da6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9874bc66d90145f4bd3eea521b23dad8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2078c3a852d54d1385e1a1b24d15e8c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bb8be0259a04e968746158d9c7ebfdd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7858b711bd2147f994af875c0dbac9d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f9df676ae84ca4ab5a863a59e0e05c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i030c208576224dff9839b8198a359ca8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c29e053597c4404a0c3274d3ae71277_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d11e1f18c324cb68f63c1d7111e4aba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867c6c8331db465fb6d11fa19654d49b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie846943d9ed4494daf24040e9d7a4b3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i234b44d7a5c647d483338639b9fee082_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i656b092512744da59aaf0680fcbf4678_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d0bfcf2438249eda212a31a4a731f1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0965d791ab43490fb6cdab898b7eb5cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a9613dbf90422496652cb4fe3df34e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bf9bc896ba444c18c22af719b4f6ca2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bcf1e62803246f8afcd362547cd42bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i655dc81cd7ca4a969575979d59347169_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i532a4d8d7fa0495f9850719f1d105b79_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda582f88fad4b44bb89a7b65fa5e8b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f74451c169b4c4bb0905d735b168f81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0b1156a4f441f3a4c0ef9e8fe20b38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85629be20441417e81c8bc15187610f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92154592e663424992dbf36c8086e56f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i576355b801554d9dace08e37a3e790a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc42a52c34fb4cbe8b9fc2a34c409158_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacba47193c1c41d9b33bebc61b930bc4_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61181bb3188f4ceab623c97f733dd40b_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id260d3c811084dc9bebde09aaeb73bee_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cdb23950c784a95a855f5d0ce652a38_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b0a7cb640f45d6b8c83fc4de5fec01_D20200801-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:SeniorNotesDueMay2050AndSeptember2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781b0d1c65df4f598bf4ca78d40c03f6_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7caac5fec4c34319b3ee7518fa0cee6d_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195f7ecf4b4c48a592446e3d876daf86_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27939a1114f4155b7e6b1134d719999_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01a37470a5b047e994577c37bc40b277_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01dca931c8514af0bd8dca2a456bd02a_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0b3f18d85446cd9abefc7f5431210a_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bfd42d26c474945ab26097d61bb99b9_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb88d176a73247459d0ce6d57d7f2362_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:November2019EuroDenominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id425e417e4ad4c45a09f17f9caed0ff2_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61be1551dd32425daa8be3c06f520dd7_D20191101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3b8c3ecb8934c7cb012f8fe970195e6_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3517b05124e542ba94be70caac0c6932_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73d344ee1fd84e0a9a617d23c99aff1e_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc7c545c888b441abae0763fd9a5afbd_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:November2019YenDenominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida5a3ee36c55473f9c1d1258483a8afa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9bc19fd1fb41c9bce540130ed1021d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85cea205afe42e1b0277f50024d6b30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7de296eb32347a98b984561470f50ad_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487211e627d94b84b6b40cd96ed51f9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f6fbe788a645a88588285341425783_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id745c20da55347c7945337736eb25cfb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a21324627e04ff9b171760e0f6aa512_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93c53abcafb49fba5f4a407366d5857_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3346772108a84c5d82eb7b473c264e9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">lly:A2018RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a7cf1bd4cd4a2198d3b916f9809c4b_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">lly:A2018RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846b4a3017ec4ae5aa560b3976992beb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:CarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b7f44c96794ab582d1cdf6a9643b7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expirationin6YearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b893702d44405d985be5d52a729ef7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationIn12To18YearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7fdc4cf740436c9e25779df853a90f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e427ba0deb48549a21b2af98646bb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc037a98b204a1b85b9d162f20d5932_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idba58d0fe8d4499db02b60b0661239fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expirationwithin5yearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87d4bdf6f7b4a8788ffa5277ada15bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expiration5to20YearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdf7908d101449948e44a8d01c8ce72f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847eca29310b48cda35b0cd11f7c52fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8253b9821a464bffb6ab718d922a8b60_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lly:TaxYears2013To2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11b4d29868245268d0dca888203dbf6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lly:TaxYears2013To2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87fab925dba44dc0ae21de713975768c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic62914e39c2446a7965d109d4b06fac3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860ee37306f64cf8a0c232ead17d7745_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06f37af72aea43beb8bfcd105c157384_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5917c0f9aaa488a8f07e138effe57cd_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be18783045647b39417db291e131c68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134f03f4da5745c881d151356389c114_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i125f0871aaaa45a8a006a3aa90bec2b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fbb551c5b8a4f8e89d479bf7ee2465d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b85c4afc43f4f51a83ef0ea6a014ca7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6c571cd27e4e94bc5717d1000ca256_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12e2651b0ae044eb8ad0fd855f1413bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb25b81194d4853b020cf54c8f8f7ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4815fcd3e33549bca6c2313f6a96f168_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e92ae2ebc9d40ac889ffb3518784b30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03078573edd84526a0fb7f4dfd971e8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3287458586b346ae8b32053866574079_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2bff6b24d574258816b0a18efea4481_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7c8721f31747da9656f229d82e19ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icccd9f0f2bc240d68bf932d1486745c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8fc4192c93948e58c908295ada7c788_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7df1b1312447bdb91336635231a328_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ddf32d59d541b2a516001cd682c531_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if54348410ce84f2fb7e320ea814b26a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40b8bd104f4d4282bb55fcd040b18ad7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21defbad19c4c63a7ca3efa0bbb49a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dcfa724c16044a9a047270245e9f5d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i122ffbfb116d49aaa94e76c271df840c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11541505d134091a7960e590f9c55a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894a88d4a4a34371980d69bf29256285_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3721c158dd7b4d129f7d61430f4502a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if741b3f8c66d4f398ea1e526a37195c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if98890f41b7346c2906b80139874cde3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35b819438ccf430b853a4465244e6fdd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b85d3256ef6437c86432f6208104ca9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f6978eac114b1a9a4b9b3e6d1c2d54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1a4fbe91fca4349a3619d62f21b5192_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c325faa849646d8877f6217a8e9e5fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8a1be41667140c28d82974e25d6f978_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb1a00b260143129cd18a27fae9066d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab85a851be0049e384a77f9bed8c7112_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ebb158dc6c4c529380297ca491bc83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i787b7132e99c493ca562e8bc24ca4fe8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic467e27a1bec45deaeede4746d725b3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacdcb2d995cf4fff8171cbe33cc965cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia422ad3b45604fe2b5412d14ccab5f5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided7419ed04c4ee390c6ecdfeea4be0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5dde6acc2364d7895ab68140b8a940e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c7762e89bc4b6c8400f5c82637267f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa71c7d9d0a44cfea6f52f788e4f63d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fa4144a81a64effba21e1069fac6bde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cd95c05c6f044669e6cdc5f23c27a03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa4949f8ddfa462d8b08ae8a55ca4e3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i522080a183f64b32b7dbc33f0a805a7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09f8a5ddfd884b47966968ab578e45b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if438221acf6341a39b8a9a65a4e65e8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47ad8d27d2d46cea9c0a971df416313_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20afb20108144023830d742a2375621b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a506494bf44549a25ef7d8a77149fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i367a0762cac945bfa3136660561bb3ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i119de4bad3f6477f971e2f4b9d1269d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18771cf6e66e4cb7be08134942326069_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7d6c9f167c4c5683298223b4ef8af1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1dd6bf74c204da0a0cd97309e7b08e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313357f190a941efb7646635222fa28c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i434273c7f8d842699b6b037c72ff2cc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0d982e51da34404b680672535a771da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01c1b63878e543bab94f0bc61bd810c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd8fa233f8fa45ad8d9997db7e5e3cac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id10a4106c36d48c080be874880a0c5f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia95a10a1f5f14bf0974550095d634caa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f8ae3d75184ec2b1e3758df93f149b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1fcfa7a99c4781a6ff659d054315b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5aba2572834b96bf2e805a8e72d50d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b41b01976fe4459b0b2e05e4a78ecec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe3ce3f963884db0be993dd43a273d48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17084e6a4674e82adf22fef4ff88b90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice675a2c24d8440490e242dd88655d53_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0340e5bcf8b2492f877571f5e4badb72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie290f1153a8746b4b6cd78f8378492fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie61e568a671e4a80821d53844eb24240_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd146d4e0d24f1eba383583c4714d33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad95d8440b74627bd1f07f9cbaaf547_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb310846a874a2896fe227840a6a94d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0844638a1d4c2094a1f495d509e3a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a23c7481934f7c9cbc0f8e5d7819cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e024a2361694af8af62b9b106fb4091_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i893d604481e5414a876d424c5bb3853b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514ee23678874da6a78affbcc11e2d13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782e6897c57141f3a206f658e2c32404_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3def2cfb16eb45eb825321e9107e8557_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24f5a064fb248b9a1c67cd62d6ed476_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c28a1b50d047e48ca4cc3357ad9d44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933d218234f842788e1c269114faae5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ceb71c1fa14063ba529ff4695b2287_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i685a0d4729324a28b26de39802342a21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic736258b57814a4182d5d6987fb420c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045d7c5fdf0e49c18f983e9217f0b15e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4c6c31184e47f3b704a0eae7e42331_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib384b4a9c4e24e259a0e4f91d0193602_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28a156345f7417e99d42b66e3b9aceb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058f847612d74099976ba37d7f71f906_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia708e12046a5423f8cffea676c33483e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife201fa234a44463aaae78e3178b7591_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1612094a408f4d40b21352521bf6c97e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedde0139af294cff8fdcea9f72f645be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea7b43b8b5c450c817a947965d81b01_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c72734140b24d3f8f463831c8c59882_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474e96cc45a343bd880e15f5e3e7dcb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331eecd2fcab475bb2c445750bf65683_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd771e0257d642dcadc5d74119bdfefa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41f3e1cb00c44d82927f246e6c5166c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e5945ce8ccc4948bac9a0451e12d1e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3273ded1db9c4c9596e118619286ba07_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b1995d069c040efab6457b44f15e8b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba0bb9a358a4901bea4e4cd5c7f55f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6960c498f4476188e66f546a6935bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd365bf0efab46af86e6bbb643db823c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i675961e5fc46462c956548b162c65ca8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbbec282c576404eb0ec8d2d0fdf9653_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f323b9fa21c499dbdf0daf714c57f36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf32c3dcfc14cdaa8060800039f3e79_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf52a977346b49d798c932533814bf59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c3e31523404f2ebfc936c17c16b324_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4629fb029e734ace817a97c424776664_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4c387153e294bcb9eaecfe60743c646_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77389ce093254e6ab4f11f9dd0728471_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3313ee63caf64afab4f2c93fbc54124d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e9fd581d4d433aae76ee66caa8183b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3fcf315c0347f0b121686f96a2c53f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb8686f5c76e4a7c83ddc6959064840b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19da2e5ec2ab4bb580c7155fdc8fdfa3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i006db6e632504a099cb649312ea0cba3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic37e46cbf2c242d8899925fc7a112670_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847b2decf9404ab2a7d6680fdccdf305_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecfde700f02a48f7a31316d1f567cd5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id435bbff99ed49dfa19a3cb32dd76386_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f75c558ed1e49339a2e52215ae52fc0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i701917bbad004fc8b8d81a751eea303d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65b328d8d2c49c1be2ef55b3625103c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1221e8e34e4275b4db34697e4ca8b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564ffd90f9084692ab88b0cf933a98f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f13162a2f8d4549a141594e5f80d879_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ef9b73660f4b9fadce03cc33bd22f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a8eb2e429e4d4b9559c6a8a87ef504_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36e443e3d434b15af03feda51e6777d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50fb13104c73464cb06b6701e9af3093_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60bea6be43f4ed4804c1fc6a9298e09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8724bdcd3854eaf92373c5d1a807169_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42c51f1ef8b4c618cd8e6b21c234c55_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifada303dfc0a48749b857d690254e679_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5ba9215cf52449385b12a520287a98a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a44a9521bad4096b6d02caf364c65b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19985d737da40e0bd8d5ac7bcda0e3d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7b8e68d1946469abfb59f6c6fda184a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42a83760ddde47c48011002561464667_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1c2c6447034265b3f50c7be9a87b41_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idabb35ff3f03404f8c6130a1eeb49f61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e2cdb6c127441b909e910815d3dbbb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f03d4b0fdcb41bd9bebfa7ede027236_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i895e2b3cafef45acb1012b1e03d39ffc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1066e9b68a6348ab93c9493b56791fe8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1595e10ff0084e819adb888f4c577f76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4f8156acc564caab08a1624e564a10c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81d715fd04f41c4b0fb15cbc97ded7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bcd75701e244eda1dc59a0f6acf303_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i945c96b3eea1403fa18115aaefba9877_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8a5d8801736420b82120164f7c0089a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9181cc52ee8e454c89c0e1c42c853e15_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38af461ee606432d82a7474978332d8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373b829238f74628b948e23e7d5c164c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e4134c43ad43bab33caec94bc82d47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb2a002bc0ef442bb111f2a7206ee130_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i510f34cc51b4405db4a91992d32b1c34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22b766219ce347188ad03e3849166f80_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708ee2efc8f448d3b331e38fcbd4a915_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc36c3791284cabb24ca762698700d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1dc7058692f46668106cf1d6a1e73c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea800c25a6674e09a0af56692d7b5dd1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe300c1a64c647b69fe7bf20e0541942_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d6294050b0144ebb52f2b5cb557783a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69a0b8e765cb46099127a2188cb007e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6428acbb884c4334bce83f1ace7ab19d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id719e5a1d3de4031989293711aa38d3c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2aaec08b63468499905c6159f8e3da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60dad62f6fb1485a99fd7d1430fc110d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaff3c08ba9d4d03bd33fcb7a5bbd1fb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534b8b956faa4f71ab4ccda780e39214_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib078dfc1c37e44c9a48bbe3f9a469f3c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0406531f0094a13b3244c8fcabda0cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e9def9531e94f7ea8588aedd9f265d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c938f472b04e1ea9b5d3856f56cf27_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i500e87bc01cc4b5f93691f5fb1d50fad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3858c30cf5044e598ca275f01991c28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996aa7b86fc24b07a4288e7ba5f7df03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7482d3bafbc41eeac363718494d0f83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i362e3e575b774c4397566b4c1a34e5c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfef4993c67240b2a0bc234322e964af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id022f4c867cb4232a897b833e40eb0df_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4833bcba5f4d461da0967d8871780d3b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie600f398f9404e8fbfd23a4c663f06ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3b618356b1e4a8396dee41b547db32f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb89163b193490c80c31c918380523b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="ia08920fe3f514f89bc0bd568c9df9ba5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563701b19f014569b06746781df763bf_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id838bc258f094c568ea090ce38f5434e_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0380a187e28a42edbd210299d61d308e_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="iecb392cbb3fe4cb8a6314dcd6654394c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc7264a5345342d8aea87087c230aba3_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae544e01daa4812a088e089d18c14e7_I20120731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d2d51a9d7de4602a53112f3a2e3d04c_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i411602cb723743c380152402a7c692f2_I20130131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4cce461525f410b826a4889ad0f3ea6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>lly:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="icea9f6147fa941e4a11404f04d76bc42_D20090301-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449428738c2940d49d82f1876796900e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f737098bb3145ceb2c97bdfcc33c357_D20090301-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib194555003c24fe5a77a184233bd6cba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e65f3f67c2d459f9a64e4b7a3a7d1b5_D20090301-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b680abb10c24ec5b54b2120fdc7058f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07adf913f1f54ca989ef31ee491cc698_D20090301-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290630da973e431eb29fcd22cd423503_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89fbc9d584994ea8be0227e0a79821e4_D20090301-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb83157010844ce786703b9c9bb67d43_D20090301-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1409b6c99dad4d6da1691bc35c7de3cb_D20090301-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>lly:claimant</xbrli:measure></xbrli:unit><xbrli:context id="i1b0cea540b384bc08e0afbcf20bece39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib285d2fd260145229843a0c1bf1263f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="iaeccac6f45794f4a92f62a164ea4c0ca_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f52969f387d4ef7ad755da5ae0ffdbf_D20201231-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i684d16bbfe9e4db78119c3012111fe94_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfeb86b846074fb89e884673987dab5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if595b7685be743c89bc5dc09daf08440_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="request"><xbrli:measure>lly:request</xbrli:measure></xbrli:unit><xbrli:context id="i8916531131184faea7af74d7cde93d3f_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:DrReddysLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6404d71a3154085b2ffbe7918c52fdf_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida3f134ccefd4f4a994809b05af014c1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied12274b6db14234b7de3a19eb3f0d2c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ce9bb84e004603a5019d1c6da66946_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91a7d9b32f3a4db9a00591e1adce82a6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6923db7df05a4e6e922a6bb5db8a3b41_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7766703b17514542b192609b6e561393_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d75213e1aba4f7eadb741cb0d1cc298_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib784e78bc05f4285945fc78bbb738f91_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4a4a1e1c3745e59d68927cad94276a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc74b3eb01ad4e50bc04a6977d715d2d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb39193d2a16435281dd19dfabba3b42_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20fb3a01e3c6484686b01e6156c1acd8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cce948975cd45cfa58c1e76158f0f33_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae9df0fe048449392c43fb7186ca248_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2a384242290465588799dfbd2e7ee83_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39bb81b83d844b11b7cacd7fcb2e07d3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022a194d782540f8a8fdfc2d9b226688_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbc0a2c1f894a5fa0c07c97d49cc299_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080fb50d8cac4747bda1c482bee979d5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615ad14cefcc4ce1a88ced50887fbf6d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24efbe2abb2349b59ae25141fedb34da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if749975463d649e68e1bc14730e552fa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae30dfeeb2e4879a0c3b21b26111cad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569a261af70b4d8ba9f60a58c0e2b9f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i135c068cec7c43d3896b245ca3cde3bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae1e86516684e95b54071890a6e557b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22e1113b5f54e35a4a4df39e3e917bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb975f9779f54232a351634d3fd2cd32_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad7ca588e4b4a668bd791165ae19818_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7d4dca490147faac33fdce0f0d354d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i964f0a9d08134a599b06447de48f472d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9496ec064a41e6bacfab535e35a9b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b2f813fac6448c7b98cc7598ddd6c1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib667086cf32f420988bbee8738114965_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie45e19b6d14441ea88cddc6e941da5ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4baa1ec009c445486118e3b4579ec89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b131f4aa2c4cb88d271c82f1b47bc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f7cbd1f19a34b6789d5526dc3008179_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a895cde5a54bb5be22a7b5806d3386_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc47e8810d6412bbab29c0eacb89745_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2c054d8c5c84127b1e160c82886953d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4da867daad1840d6b255ab18e08ebcd6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7a83c1653f4b8eaedba242be6d6ff7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb8b4f8723f4f02a681499b646ccb15_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8513120f404c39a420b6b793e39fbc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011e32aa84f34a07861fc5d8d38eae10_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c36f2ee8cff49ec82af74c218b0ace1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i007d6fe10f55466ebb1af3bb02b9b84a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i767785ec05f74127a9246bc6ce2f190b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27dbf880100447d9bf589531096741f5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bdb72715a234bc193e62ede32a5bbed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee3110d1c0a44663b08bc95d12a2e990_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i193696830a4742cdba4be29dcd7f5251_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a3ec013676433f815344f9f683499a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ce3929549c42488c9d78815eb40512_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd52235d591400ebdc756d6a1cb0bc9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27470f38a1f14522ba67a5d022af05bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69664129e7348b3b8fd52f216426461_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43b02af87ac54ca3a6bfb1bc0e3b200e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9799a363894e447a88d58efd03f0b2ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0433259992642cd84137af8b232a207_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c2fcfe7ae7240f8aea48b8993890007_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42bc8b84cba2465299f8b30a76d2180d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id31f634abe9b49d087c5ebeb30996e11_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabbc7b2ea00947e8b902df09566e6317_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26304d3b80a542b5ab77edf4000be691_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1e386970d94f0abc18ef065866675b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0df68c6465184e8b8f60cebcf0de49e4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4be7a2068245ffa89edf317572504d_D20180924-20180924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-24</xbrli:startDate><xbrli:endDate>2018-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45097dbde81e4b5a8ddc8854e29196ac_I20180924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i601d8831c2a84dc6a94bf8abcae67dcf_I20180924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d16807ca45467296773da1a768103c_D20180924-20180924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-24</xbrli:startDate><xbrli:endDate>2018-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25de516d8b1a468d869b65f28c3c0ae4_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:TermFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0841fa6d26e546d4acee688c1214ee2b_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:TermFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4759a8743edb4111b4e4b16db8cb6680_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52daa1d7665e48ae8d99c5d280d6bd5a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b83214520b341e28e9c3eb65c9a0efa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a3e673a3e6740eba162b41a6b7818e2_D20190311-20190311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-11</xbrli:startDate><xbrli:endDate>2019-03-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia8e8b06f04404e6fb09e313103495f8e_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">United States</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities and Exchange Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTI3_2660f4bc-aa7e-499d-ba9e-dc27da129866">10-K</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual report pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">for the fiscal year ended <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8xMDk5NTExNjMwMzA5_a68ea918-356a-4587-bfac-fcf3b937b5e6"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8xMDk5NTExNjMwMzA5_3b0c9c93-e9f1-4a83-89d0-4d12c23e6683">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzI3_fa18864e-3030-4454-a669-e07d92bee8a7">001-06351</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8xMDk5NTExNjQ0MjE4_d0972d1b-781a-4317-a2b0-c03663306e5b">ELI LILLY AND COMPANY</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.432%"><tr><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWY1YWM0MDFhNDcxNGM2NGIzMTJhZmVkNTg1N2I1MjcvdGFibGVyYW5nZTplZjVhYzQwMWE0NzE0YzY0YjMxMmFmZWQ1ODU3YjUyN18wLTItMS0xLTA_c27a168f-f249-422c-a2c9-72106502cb8c">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWY1YWM0MDFhNDcxNGM2NGIzMTJhZmVkNTg1N2I1MjcvdGFibGVyYW5nZTplZjVhYzQwMWE0NzE0YzY0YjMxMmFmZWQ1ODU3YjUyN18wLTYtMS0xLTA_144b491f-67df-425e-b993-5987abadf30e">35-0470950</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTMw_a1622488-183c-4f26-9f8d-8c487dec0df5">Lilly Corporate Center</ix:nonNumeric>, <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTE5_ebc0c27d-2ad5-472a-963b-9ef42ad49015">Indianapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTI2_553ad931-4eff-4df6-9b66-78ad965e4df3">Indiana</ix:nonNumeric> <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTIw_8725f42a-8b86-43c3-ad1a-4be13f228168">46285</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzI5_1a561d19-149a-434a-bec7-2d8f7205a514">317</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzMz_c07d5673-b068-4fe0-91cd-dfae88708314">276-2000</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i137275eafd4c40f59313788c6e8bc624_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8xLTAtMS0xLTA_b11cfa2b-78ba-4060-9add-f8f84822e4b5">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i137275eafd4c40f59313788c6e8bc624_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8xLTEtMS0xLTA_4eb82b06-c73b-4668-8604-c5df2fc5c3d8">LLY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i137275eafd4c40f59313788c6e8bc624_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8xLTItMS0xLTA_0f8b2bab-936d-4684-967e-24040c99d4ac">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ef7d2358d3d4624831eba2ba35e625c_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8yLTAtMS0xLTA_7101f591-d1b0-4c40-bc95-4be5f5f3cd0e">1.000% Notes due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ef7d2358d3d4624831eba2ba35e625c_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8yLTEtMS0xLTA_34e290bb-faaf-411f-a3b7-f83aaba84a3b">LLY22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ef7d2358d3d4624831eba2ba35e625c_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8yLTItMS0xLTA_d66abeb6-fe3d-412f-b198-4d939cdd6e33">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf054c1e69d548fabc27199bc26a11da_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8zLTAtMS0xLTA_73a9a0c9-e6a4-4c38-8ecc-a4aa2c6ab5aa">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf054c1e69d548fabc27199bc26a11da_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8zLTEtMS0xLTA_3373056c-898f-4ed2-82c5-2e1f54fd7f2c">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf054c1e69d548fabc27199bc26a11da_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8zLTItMS0xLTA_b5943dd0-8c48-4643-9464-5e124d7ed294">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3db037c2fb245969975a8e68da5d13f_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl80LTAtMS0xLTA_39063de5-2e17-418d-a01b-826ac2d6bbd2">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3db037c2fb245969975a8e68da5d13f_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl80LTEtMS0xLTA_4ad636ef-bdf0-4875-a819-bd8100802410">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3db037c2fb245969975a8e68da5d13f_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl80LTItMS0xLTA_c5f26e38-f1e3-44da-bc96-e6e0078d22ac">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7fa23ebc91dc4948b44e17114afcbe93_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl81LTAtMS0xLTA_f19b3440-5ad9-4b20-8905-e81472d350d2">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7fa23ebc91dc4948b44e17114afcbe93_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl81LTEtMS0xLTA_de05706d-ec89-4d52-9461-aabbc3793973">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7fa23ebc91dc4948b44e17114afcbe93_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl81LTItMS0xLTA_f20334fb-d4fe-43e5-9a4f-b0344dc7a70a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6337489efeaf470db72beaad17305bf8_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl82LTAtMS0xLTA_3dac96bd-ad48-4b28-8510-fed9887aff27">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6337489efeaf470db72beaad17305bf8_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl82LTEtMS0xLTA_ed6ecfba-1bc4-4b73-a6e7-cbf86b5bffea">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6337489efeaf470db72beaad17305bf8_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl82LTItMS0xLTA_3484be37-b985-4c2e-992e-60ee130fbd8f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08c82f670af140a8bac93e72206aac4e_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl83LTAtMS0xLTA_1cc1095d-0999-45ae-ae65-12ac5e541888">6.77%&#160;Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08c82f670af140a8bac93e72206aac4e_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl83LTEtMS0xLTA_dc7722b2-7088-4727-b3ee-d004c9651b48">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08c82f670af140a8bac93e72206aac4e_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl83LTItMS0xLTA_32a02ec2-e01e-462b-857a-54bfa7bd8a9c">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if9d00685b69642528d03b4781524325b_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl84LTAtMS0xLTA_63bd2d93-0a5b-403d-91dc-f6b815a0a303">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if9d00685b69642528d03b4781524325b_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl84LTEtMS0xLTA_4e982e47-42fb-4e93-a5e5-56c822c531e3">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if9d00685b69642528d03b4781524325b_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl84LTItMS0xLTA_8b696168-59ba-43a0-809d-40f072415caa">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTE4_645d9321-49d3-4daf-93be-082e3be54b58">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Exchange Act. Yes&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTIy_1e80f27b-9ccf-4b4d-afd3-b0047e4caadb">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTI5_5af5e9c0-1f5d-47e1-a55d-90e9156f420f">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTIz_1acadc3f-d639-4f6a-bdda-43a543b87443">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWQ0YmJjODU1ZDIwNDJhODk1NDc1YjA1MTg5M2UzMjUvdGFibGVyYW5nZTplZDRiYmM4NTVkMjA0MmE4OTU0NzViMDUxODkzZTMyNV8wLTAtMS0xLTA_c6cf0fa7-34d8-44ad-8ecd-a0dedb485be8">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWQ0YmJjODU1ZDIwNDJhODk1NDc1YjA1MTg5M2UzMjUvdGFibGVyYW5nZTplZDRiYmM4NTVkMjA0MmE4OTU0NzViMDUxODkzZTMyNV8xLTctMS0xLTA_858dc86f-ea91-436b-9f13-01b0a6f1b37f">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWQ0YmJjODU1ZDIwNDJhODk1NDc1YjA1MTg5M2UzMjUvdGFibGVyYW5nZTplZDRiYmM4NTVkMjA0MmE4OTU0NzViMDUxODkzZTMyNV8yLTctMS0xLTA_ed50865d-3a8d-496c-a3d4-16f7056d03b7">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzI2_2c022f0e-5d3c-4ec3-9504-060f019ebf27">&#9746;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzM0_9e41ff50-4dfe-4775-8aae-a3aca98f7625">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Aggregate market value of the common equity held by non-affiliates computed by reference to the price at which the common equity was last sold as of the last business day of the Registrant&#8217;s most recently completed second fiscal quarter: approximately $<ix:nonFraction unitRef="usd" contextRef="i61b9de7700734098b07f8a46f43d9497_I20200630" decimals="-6" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yMjQz_47af833f-fa58-4693-a110-3e52d578b6f8">138,907,000,000</ix:nonFraction>.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of shares of common stock outstanding as of February&#160;12, 2021: <ix:nonFraction unitRef="shares" contextRef="i86a8c3eb7a2a4ef48d31b3028fe3303f_I20210212" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yMzAy_67901873-35d3-4759-96c6-73583d8d808b">958,425,693</ix:nonFraction></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjQzNTU5MzAzNzM5OQ_8e71fa79-c438-40fb-a8ac-ee5eaa67c9ad" escape="true">Portions of the Registrant&#8217;s Proxy Statement for the 2021 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2020 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:8.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_16">Part I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_19">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_19">Business</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_22">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_25">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_28">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_28">Properties</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_28">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_31">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_31">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_34">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_34">31</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_37">Part II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_40">Item 5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_40">Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_40">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_46">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_46">[Reserved]</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_46">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_52">Item 7.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_52">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_52">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_79">Item 7A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_79">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_79">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_82">Item 8.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_82">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_82">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_211">Item 9.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_211">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_211">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_214">Item 9A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_214">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_214">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_217">Item 9B.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_217">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_217">120</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_220">Part III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_223">Item 10.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_223">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_223">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_226">Item 11.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_226">Executive Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_226">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_229">Item 12.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_229">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_229">122</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_235">Item 13.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_235">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_235">122</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_238">Item 14.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_238">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_238">122</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_241">Item 15.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_241">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_241">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_244">Item 16.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_244">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia8e8b06f04404e6fb09e313103495f8e_244">125</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management's Discussion and Analysis of Results of Operations and Financial Condition&#8221; includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;continue,&#8221; or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the evolving COVID-19 pandemic and the global response thereto;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties related to our efforts to develop potential treatments for COVID-19;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of acquisitions and business development transactions and related integration costs;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market uptake of recently launched products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our IT systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues with product supply stemming from manufacturing difficulties or disruptions;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory changes or other developments;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions regarding currently marketed products; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">devaluations in foreign currency exchange rates or changes in interest rates, and inflation;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">asset impairments and restructuring charges;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global macroeconomic conditions and trade disruptions or disputes; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory compliance problems or government investigations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should also carefully read the factors described under Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause our actual results to differ from those expressed in forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and under Item 1A, &#8220;Risk Factors&#8221; to be a complete statement of all potential risks and uncertainties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Annual Report and are expressly qualified in their entirety by the risk factors and cautionary statements included in this Annual Report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part I</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_19"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment&#8212;human pharmaceutical products. In March 2019, we completed the disposition of our ownership in Elanco Animal Health Incorporated (Elanco), an animal health business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Most of the products we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and 8 other countries. Our products are sold in approximately 120 countries.</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products include:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diabetes products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Baqsimi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a nasal powder formulation for the treatment of severe hypoglycemia in patients with diabetes</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a long-acting human insulin analog for the treatment of diabetes</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog Mix 75/25,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog U-100,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog U-200,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humalog Mix 50/50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">insulin lispro,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">insulin lispro protamine</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> insulin lispro mix 75/25, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human insulin analogs for the treatment of diabetes </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Humulin 70/30, Humulin N, Humulin R, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humulin U-500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human insulins of recombinant DNA origin for the treatment of diabetes</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of type 2 diabetes and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lyumjev</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a rapid-acting human insulin analog for the treatment of diabetes</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of type 2 diabetes</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncology products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the first-line treatment, in combination with two other agents, of advanced non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology and no EGFR or ALK genomic tumor aberrations; for the first-line treatment, in combination with another agent, of advanced non-squamous NSCLC; for the second-line treatment of advanced non-squamous NSCLC; as monotherapy for the maintenance treatment of advanced non-squamous NSCLC in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agent for the treatment of malignant pleural mesothelioma</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for use as monotherapy or in combination with another agent as a second-line treatment of advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma; in combination with another agent as a second-line treatment of metastatic NSCLC; in combination with another agent as a second-line treatment of metastatic colorectal cancer; as a monotherapy as a second-line treatment of hepatocellular carcinoma; and in combination with another agent as a first-line treatment of adult patients with metastatic NSCLC with activating epidermal growth factor receptor mutations </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, indicated both as monotherapy and in combination with another agent for the treatment of certain types of colorectal cancers; and as monotherapy, in combination with chemotherapy, or in combination with radiation therapy for the treatment of certain types of head and neck cancers</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of metastatic NSCLC in adult patients; for the treatment of advanced metastatic medullary thyroid cancer who require systemic therapy in adult and pediatric patients; and for the treatment of advanced metastatic thyroid cancer in adult and pediatric patients who require systemic therapy and are radioactive iodin-refractory</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of relapsed or refractory classic Hodgkin&#8217;s lymphoma and for the first-line treatment of non-squamous NSCLC in combination with Alimta and another agent in China</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for use as monotherapy or in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunology products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of adults with moderately-to-severely active rheumatoid arthritis</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Baricitinib</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was granted Emergency Use Authorization (EUA) in 2020 for the treatment of suspected or laboratory confirmed COVID-19, in combination with remdesivir, in hospitalized adults and pediatric patients </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of adults and pediatric patients aged 6 years or older with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuroscience products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for migraine prevention and the treatment of episodic cluster headache in adults</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Reyvow</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the acute treatment of migraine, with or without aura, in adults</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other therapies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Bamlanivimab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing (EUA granted in 2020)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Bamlanivimab </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> etesevimab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, administered together, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing (EUA granted in 2021)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for the treatment of erectile dysfunction and benign prostatic hyperplasia</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing and Distribution</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell most of our products worldwide. We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote our major products in the U.S. through sales representatives who call upon physicians and other health care professionals. We also promote to healthcare providers in medical journals and online health care channels, distribute literature and samples of certain products to physicians, and exhibit at medical meetings. In addition, we advertise certain products directly to consumers in the U.S. and we maintain websites with information about our major products. We supplement our employee sales force with contract sales organizations to leverage our resources and reach additional patients in need.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. We enter into arrangements with these organizations providing for discounts or rebates on our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., most of our products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. In 2020, 2019, and 2018, three wholesale distributors in the U.S.&#8212;McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc.&#8212;each accounted for between 15 percent and 20 percent of our consolidated revenue. No other customer accounted for more than 10&#160;percent of our consolidated revenue in any of these years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., we promote our products to healthcare providers primarily through sales representatives and online health care channels. While the products we market vary from country to country, diabetes products constitute the largest single group of our consolidated revenue. Distribution patterns for our products also vary from country to country. In most countries in which we operate, we maintain our own sales organizations, but in some smaller countries we market our products through independent distributors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are marketed in arrangements with other pharmaceutical companies.  For example, we and Boehringer Ingelheim have a global agreement to develop and commercialize a portfolio of diabetes products, including Trajenta, Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jardiance, Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XR, and Basaglar. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Item 8, "Financial Statements and Supplementary Data - Note 4, Collaborations and Other Arrangements."</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products compete globally with many other pharmaceutical products in highly competitive markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important competitive factors include effectiveness, safety, and ease of use; formulary placement, price, and demonstrated cost-effectiveness; marketing effectiveness; and research and development of new products, processes, modalities, and uses. Most new products that we introduce must compete with other branded or generic products already on the market or products that are later developed by competitors. When competitors introduce new products or delivery systems with therapeutic or cost advantages, including by developing new modalities, our products become subject to decreased sales, progressive price reductions, or both. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our long-term competitive success depends on discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective products that provide improved outcomes for patients and deliver value to payers, and continuously improving the productivity of our operations in a highly competitive environment. There can be no assurance that our efforts will result in commercially successful products, and it is possible that our products will be, or will become, uncompetitive from time to time as a result of products developed by our competitors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Pharmaceuticals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the biggest competitive challenges we face is from generic pharmaceuticals. In the U.S. and Europe, the regulatory approval process for pharmaceuticals (other than biological products (biologics)) exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy of the innovator product. As a result, generic manufacturers generally invest far fewer resources than we do in research and development and can price their products significantly lower than our branded products. Accordingly, when a branded non-biologic pharmaceutical loses its market exclusivity, it normally faces intense price competition from generic forms of the product, which can cause us to lose a significant portion of the product&#8217;s revenue in a very short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, public and private payers typically encourage the use of generics as alternatives to brand-name drugs in their healthcare programs. Laws in the U.S. generally allow, and in many cases require, pharmacists to substitute generic drugs that have been rated under government procedures to be essentially equivalent to a brand-name drug. Where substitution is mandatory, it must be made unless the prescribing physician expressly forbids it. In many countries outside the U.S., intellectual property protection is weak, and we must compete with generic or counterfeit versions of our products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our products and approximately half of the potential new medicines in our clinical-stage pipeline are biologics. In the U.S., the U.S. Food and Drug Administration (FDA) regulates biologics under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, and implementing regulations. Competition for Lilly&#8217;s biologics may be affected by the approval of follow-on biologics, also known as biosimilars. A biosimilar is a subsequent version of an approved innovator biologic that, due to its analytical and clinical similarity to the innovator biologic, may be approved based on an abbreviated data package that relies in part on the full testing required of the innovator biologic. Approval by the FDA ultimately depends on many factors, including a showing that the biosimilar is &#8220;highly similar&#8221; to the original product and has no clinically meaningful differences from the original product in terms of safety, purity, and potency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, most governments have developed abbreviated regulatory pathways to approve biosimilars as follow-ons to innovator-developed biologics, including the Biologics Price Competition and Innovation Act of 2009 (the BPCIA) in the U.S., and a number of biosimilars have been licensed under the BPCIA and in Europe. The patent and regulatory exclusivity for the existing innovator biologic generally must expire in a given market before biosimilars may enter that market. However, in the U.S., the product exclusivity period under the BPCIA could be affected by recent government proposals and litigation. See &#8220;- Patents, Trademarks, and Other Intellectual Property Rights.&#8221; In addition, the extent to which a biosimilar, once approved, will be substituted for the innovator biologic in a way that is similar to traditional generic substitution for non-biologic products is not yet entirely clear, and will depend on a number of regulatory and marketplace factors that are still developing. In the U.S., currently only a biosimilar product that is determined to be &#8220;interchangeable&#8221; will be considered substitutable for the original biologic product without the intervention of the health care provider who prescribed the original biologic product. To prove that a biosimilar product is interchangeable, the applicant must demonstrate that the product can be expected to produce the same clinical results as the original biologic product in any given patient, and if the product is administered more than once in a patient, that safety risks and potential for diminished efficacy of alternating or switching between the use of the interchangeable biosimilar biologic product and the original biologic product is no greater than the risk of using the original biologic product without switching. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilars may present both competitive challenges and opportunities. For example, a competitor company has developed a version of insulin lispro that competes with our product Humalog. On the other hand, in collaboration with Boehringer Ingelheim, we developed Basaglar, a new insulin glargine product, which has the same amino acid sequence as a product currently marketed by a competitor and has launched as a follow-on biologic in the U.S., and as a biosimilar in Europe and Japan. However, in March 2020, the FDA began regulating all of our insulin products as &#8220;biologics&#8221; rather than &#8220;drugs.&#8221; Based on FDA draft guidance, this change may lower the requirements for competitor biosimilar products to enter the market, some of which could be designated as interchangeable and therefore substituted for our insulin products at U.S. pharmacies. As such, in June 2020, Mylan N.V. announced that the FDA approved its New Drug Application (NDA) for Semglee, a new insulin glargine product, which it launched as a follow-on biologic in the U.S. that competes with Basaglar. The laws regulating biosimilars continue to be interpreted and implemented by the FDA and remain subject to substantial uncertainty, including with respect to their impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Private Sector Dynamics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. private sector, consolidation and integration among healthcare providers significantly affects the competitive marketplace for pharmaceuticals. Health plans, pharmacy benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. Private third-party insurers, as well as governments, typically maintain formularies that specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer) to control costs by negotiating discounted prices in exchange for formulary inclusion. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels, and higher deductibles. Consequently, pharmaceutical companies compete for formulary placement not only on the basis of product attributes such as efficacy, safety profile, or patient ease of use, but also by providing rebates. Value-based agreements, where pricing is based on achievement (or not) of specified outcomes, are another tool that may be utilized between payers and pharmaceutical companies as formulary placement and pricing are negotiated. Price is an increasingly important factor in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. We expect these downward pricing pressures will continue to negatively affect our consolidated results of operations. In addition to formulary placement, changes in insurance designs continue to drive greater consumer cost-sharing through high deductible plans and higher co-insurance or co-pays. For additional information on pricing and reimbursement for our pharmaceutical products, see &#8220;- Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access - U.S.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents, Trademarks, and Other Intellectual Property Rights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property protection is critical to our ability to successfully commercialize our life sciences innovations and invest in the search for new medicines. We own, have applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulations, and manufacturing processes. In addition, as discussed below, for some products we have effective intellectual property protection in the form of data protection under pharmaceutical regulatory laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent protection anticipated to be of most relevance to pharmaceuticals is provided by national patents claiming the active ingredient (the compound patent), particularly those in major markets such as the U.S., various European countries, and Japan. These patents may be issued based upon the filing of international patent applications, usually filed under the Patent Cooperation Treaty (PCT). Patent applications covering compounds are generally filed during the Discovery Phase of the drug discovery process, which is described in the &#8220;Research and Development&#8221; section below. In general, national patents in each relevant country are available for a period of 20 years from the filing date of the PCT application, which is often years prior to the launch of a commercial product. Further patent term adjustments and restorations may extend the original patent term:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent term adjustment is a statutory right available to all U.S. patent applicants to provide relief in the event that a patent grant is delayed during examination by the United States Patent and Trademark Office (USPTO).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent term restoration is a statutory right provided to U.S. patent holders that claim inventions subject to review by the FDA. To make up for a portion of the time invested in clinical trials and the FDA review process, a single patent for a pharmaceutical product may be eligible for patent term restoration. Patent term restoration is limited by a formula and cannot be calculated until product approval due to uncertainty about the duration of clinical trials and the time it takes the FDA to review an application. There is a five-year cap on any restoration, and no patent's expiration date may be extended beyond 14 years from FDA approval. Some countries outside the U.S. also offer forms of patent term restoration. For example, Supplementary Protection Certificates are available to extend the life of a European patent up to an additional five years (subject to a 15-year cap from European Medicines Agency (EMA) approval). Similarly, in Japan, South Korea, and Australia, patent terms can be extended up to five years, depending on the length of regulatory review and other factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of effective patent protection for pharmaceuticals, especially for non-biologic products, typically results in the loss of effective market exclusivity for the product, which often results in severe and rapid decline in revenues for the product. However, in some cases the innovator company may retain exclusivity despite approval of the generic, biosimilar, or other follow-on versions of a new medicine beyond the expiration of the compound patent through manufacturing trade secrets, later-expiring patents on manufacturing processes, methods of use or formulations, or data protection that may be available under pharmaceutical regulatory laws. Changes to the laws and regulations governing these protections could result in earlier loss of effective market exclusivity. The primary forms of data protection are as follows:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory authorities in major markets generally grant data package protection for a period of years following new drug approvals in recognition of the substantial investment required to complete clinical trials. Data package protection prohibits other manufacturers from submitting regulatory applications for marketing approval based on the innovator company&#8217;s regulatory submission data for the drug. The base period of data package protection depends on the country. For example, the period is generally five years in the U.S. (12 years for new biologics as described below), effectively 10 years in Europe, and eight years in Japan. The period begins on the date of product approval and runs concurrently with the patent term for any relevant patent.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the BPCIA, the FDA has the authority to approve biosimilars. A competitor seeking approval of a biosimilar must file an application to show its molecule is highly similar to an approved innovator biologic and include a certain amount of safety and efficacy data that the FDA will consider on a case-by-case basis. Under the data protection provisions of this law, the FDA cannot approve a biosimilar application until 12 years after initial marketing approval of the innovator biologic, subject to certain conditions. The BPCIA is part of the Affordable Care Act, the constitutionality of which is currently being litigated. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the U.S., the FDA has the authority to grant additional data protection for approved drugs where the sponsor conducts specified testing in pediatric or adolescent populations within a specified time period. If granted, this &#8220;pediatric exclusivity&#8221; provides an additional six months of exclusivity, which is added to the term of data protection as well as to the term of any relevant patents, to the extent these protections have not already expired. While the term of the pediatric exclusivity attaches to the term of any relevant patent, pediatric exclusivity is a regulatory exclusivity&#8212;i.e., a bar to generic approval, not a patent right.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the U.S. orphan drug law, a specific use of a drug or biologic can receive "orphan" designation if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or affecting more than 200,000&#160;people but not reasonably expected to recover its development and marketing costs through U.S. sales. Among other benefits, orphan designation entitles the particular use of the drug to seven years of market exclusivity, meaning that the FDA cannot (with limited exceptions) approve another marketing application for the same drug for the same indication until expiration of the seven-year period. Unlike pediatric exclusivity, the orphan exclusivity period is independent of and runs in parallel with any applicable patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the major markets, the adequacy and effectiveness of intellectual property protection for pharmaceuticals varies widely, and in a number of these markets we are unable to patent our products or to enforce the patents we receive for our products. Under the Trade-Related Aspects of Intellectual Property Agreement (TRIPs) administered by the World Trade Organization, more than 140 countries have agreed to provide non-discriminatory protection for most pharmaceutical inventions and to assure that adequate and effective rights are available to patent owners. Certain developing countries limit protection for biopharmaceutical products under their interpretation of &#8220;flexibilities&#8221; allowed under the agreement. Thus, some types of patents, such as those on new uses of compounds or new forms of molecules, are not available in certain developing countries. Further, many developing countries, and some developed countries, do not provide effective data package protection even though it is specified in TRIPs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Intellectual Property Portfolio</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider intellectual property protection for certain products, processes, uses, and formulations&#8212;particularly with respect to those products discussed below&#8212;to be important to our operations. In addition to the data protection and patents identified below, we may hold patents on manufacturing processes, formulations, devices, or uses that extend exclusivity beyond the dates shown below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most relevant U.S. patent protection or data protection and associated expiry dates for our top-selling or recently launched patent-protected marketed products are as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Alimta is protected by a vitamin regimen patent (2021) plus pediatric exclusivity (May 2022). See Item 8, &#8220;Financial Statements and Supplementary Data - Note 16, Contingencies,&#8221; for information regarding our settlement agreement with Eagle Pharmaceuticals, Inc. (Eagle) and its impact on our exclusivity for Alimta.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Baqsimi is protected by data protection (July 2022).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza is protected by a compound patent and biologics data protection (2026).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality is protected by a compound patent (2033) and biologics data protection (2030).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance, and the related combination product Glyxambi, is protected by a compound patent (2028). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant is protected by a compound patent (2032). </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retevmo is protected by a compound patent (2037) and by data protection (2025).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reyvow is protected by a compound patent (2025, not including possible patent extension).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz is protected by a compound patent (2030) and by biologics data protection (2028).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicity is protected by a compound patent (2027) and by biologics data protection (2026).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio is protected by a compound patent (2031) and by data protection (2022).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., important patent protection or data protection includes: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Alimta is protected by patents covering its use to treat cancer in major European countries and in Japan (June 2021).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Baqsimi is protected by data protection in Japan (2026).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyramza is protected by a compound patent (2028) and by data protection (2024) in major European countries.  Additionally, Cyramza is protected by a compound patent (2026) and by data protection (2023) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Emgality is protected by a compound patent (2033) and by data protection (2028) in major European countries, and by a compound patent (2031, not including possible patent extension) and by data protection (2029) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jardiance is protected by a compound patent in major European countries (2029) and Japan (2030).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Olumiant is protected by a compound patent (2032) and by data protection (2027) in major European countries, and by a compound patent (2033) and by data protection (2025) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reyvow is protected by a compound patent (2023, not including possible patent extension) in major European countries. Reyvow is also protected by a compound patent (2023, not including possible patent extension) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retsevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by a compound patent (2037) and by data protection (2031) in major European countries. Retevmo is protected by a compound patent in Japan (2037, not including possible patent extension).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Taltz is protected by a compound patent (2031) and data protection (2027) in major European countries and a compound patent (2030) and data protection (2024) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trulicity is protected by a compound patent (2029) and by data protection (2024) in major European countries and by a compound patent (2029) and by data protection (2023) in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Verzenio is protected by a compound patent (2033) and data protection (2028) in major European countries and by a compound patent (2034) and data protection (2026) in Japan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reyvow has been submitted for regulatory review in certain major European countries for the acute treatment of migraine, where it is expected to be protected by data protection upon approval (10 years). Additionally, Reyvow has been submitted for regulatory review in Japan for the acute treatment of migraine, where it is expected to be protected by data protection upon approval (8 years).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retevmo has been submitted for regulatory review in Japan for the treatment of lung cancer, where it is expected to be protected by data protection upon approval (8 years).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tanezumab is protected by a compound patent (2023, not including possible patent extension) in the U.S. Additionally, tanezumab has been submitted for regulatory review in the U.S. for the treatment of osteoarthritis pain, where it is expected to be protected by data protection upon approval (12 years). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, we sell all of our major products under trademarks consisting of our product names, logos, and unique product appearances (e.g., the appearance of our Trulicity autoinjector) which we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms. Trademark protection often extends beyond the patent and data protection for a product. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Licenses and Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our major products are not subject to significant license and collaboration agreements. For information on our license and collaboration agreements, including our agreement with Incyte Corporation related to Olumiant, see Item 8, "Financial Statements and Supplementary Data - Note 4, Collaborations and Other Arrangements." </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Challenges </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, authorizes the FDA to approve generic versions of innovative pharmaceuticals (other than biologics, which are discussed below in more detail) when the generic manufacturer has not conducted safety and efficacy studies but files an Abbreviated New Drug Application (ANDA). In an ANDA, the generic manufacturer must demonstrate only &#8220;bioequivalence&#8221; between the generic version and the NDA-approved drug&#8212;not safety and efficacy. Establishing bioequivalence is generally straightforward and inexpensive for the generic company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absent a patent challenge, the FDA cannot approve an ANDA until after certain of the innovator&#8217;s patents expire. However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA alleging that one or more or all of the patents listed in the innovator&#8217;s NDA are invalid or not infringed. This allegation is commonly known as a &#8220;Paragraph IV certification.&#8221; If the innovator responds by filing suit against the generic manufacturer, the FDA is then prohibited from approving the generic company&#8217;s application for a 30-month period (which can be shortened or extended by the trial court judge hearing the patent challenge). If one or more of the NDA-listed patents are challenged, the first filer(s) of a Paragraph IV certification may be entitled to a 180-day period of market exclusivity over all other generic manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers use Paragraph IV certifications extensively to challenge patents on innovative pharmaceuticals. In addition, generic companies have shown willingness to launch &#8220;at risk,&#8221; i.e., after receiving ANDA approval but before final resolution of their patent challenge. We are currently in Hatch-Waxman litigation involving Alimta with a single generic manufacturer. For more information on Hatch-Waxman litigation involving the company, see Item&#160;8, &#8220;Financial Statements and Supplementary Data - Note 16, Contingencies.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, the FDA cannot approve an application for a biosimilar product until data protection expires, 12 years after initial marketing approval of the innovator biologic, and an application may not be submitted until four years following the date the innovator biologic was first approved. However, the BPCIA does provide a mechanism for a competitor to challenge the validity of an innovator&#8217;s patents as early as four years after initial marketing approval of the innovator biologic. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA as well as courts. Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration. Further, in the U.S., the increased likelihood of generic and biosimilar challenges to innovators&#8217; intellectual property has increased the risk of loss of innovators&#8217; market exclusivity. See also &#8220;- Competition - Biosimilars.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there is a procedure in U.S. patent law, known as inter partes review (IPR), which allows any member of the public to file a petition with the USPTO seeking the review of any issued U.S. patent for validity. IPRs are conducted before Administrative Patent Judges in the USPTO using a lower standard of proof than used in federal district court. In addition, the challenged patents are not accorded the presumption of validity as they are in federal district court. Generic drug companies and even some investment firms have engaged in the IPR process in attempts to invalidate our patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the legal doctrines and processes by which pharmaceutical patents can be challenged vary widely. In recent years, we have experienced an increase in patent challenges from generic manufacturers in many countries outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on administrative challenges and litigation involving our intellectual property rights, see Item 8, &#8220;Financial Statements and Supplementary Data - Note 16, Contingencies.&#8221; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span><span style="color:#bf2115;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Our Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are regulated extensively by numerous national, state, and local agencies. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation of Products </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lengthy process of laboratory and clinical testing, data analysis, manufacturing development, and regulatory review necessary for governmental approvals of our products is extremely costly and can significantly delay product introductions and revenue generation. In addition, our operations are subject to complex federal, state, local, and foreign laws and regulations concerning relationships with healthcare providers and suppliers, the environment, occupational health and safety, and data privacy. Compliance with the laws and regulations affecting the manufacture and sale of current products and the discovery, development, and introduction of new products will continue to require substantial effort, expense, and capital investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of particular importance to our business is regulation by the FDA in the U.S. Pursuant to laws and regulations that include the Federal Food, Drug, and Cosmetic Act, the FDA has jurisdiction over all of our products and devices in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, promotion, advertising, dissemination of information, and post-marketing surveillance of those products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval, our products remain subject to regulation by various agencies in connection with labeling, import, export, storage, recordkeeping, advertising, promotion, and safety reporting. We conduct extensive post-marketing surveillance of the safety of the products we sell. The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after a product reaches the market. The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA extensively regulates all aspects of manufacturing quality for pharmaceuticals under its current Good Manufacturing Practices (cGMP) regulations. Outside the U.S., our products and operations are subject to similar regulatory requirements, notably by the EMA in Europe and the Ministry of Health, Labor and Welfare in Japan. Specific regulatory requirements vary from country to country.  Regulatory requirements and approval processes outside the U.S. may differ from those in the U.S. and may involve additional costs and uncertainties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make substantial investments of capital and operating expenses to implement comprehensive, company-wide quality systems and controls in our manufacturing, product development, and process development operations in an effort to ensure sustained compliance with cGMP and similar regulations. However, in the event we fail to adhere to these requirements, we become subject to potential government investigations, interruptions in production, fines and penalties, delays in new product approvals, and reputational harm. Certain of our products are manufactured by third parties, and their failure to comply with these regulations could adversely affect us through failure to supply product to us or delays in new product approvals. Any determination by the FDA or other regulatory authorities of manufacturing or other deficiencies could adversely affect our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to a variety of federal, state, and local environmental, health and safety, and other laws and regulations that may affect our research, development or production efforts. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergency Use Authorizations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Secretary of Health and Human Services may authorize unapproved medical products to be manufactured, marketed, and sold in the context of an actual or potential emergency that has been designated by the government. After an emergency has been announced, the Secretary of Health and Human Services may authorize EUAs for the use of specific products based on criteria established by statute, including that the product at issue may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. An EUA is subject to additional conditions and restrictions, such as the obligation to provide facts sheets for healthcare providers administering the product and those to whom it is administered, adverse event monitoring and reporting, and recordkeeping and reporting requirements by product manufacturers. The FDA may also establish additional discretionary conditions of authorization that the FDA deems necessary or appropriate to protect the public health, including conditions related to product distribution, product administration and data collection and analysis concerning the safety and effectiveness of the product. In issuing an EUA, the FDA considers the totality of available scientific evidence regarding quality, safety and efficacy, including the known and potential risks of such products and the adequacy and availability of approved alternatives, among other factors.  An EUA is not a substitute for obtaining FDA approval, licensure, or clearance for use of a product. An EUA terminates when the emergency determination underlying the EUA terminates, and EUAs can be revoked under other circumstances, the timing of which may occur unexpectedly or be difficult to predict.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the emergency use of medical products is subject to regulatory processes and requirements that differ from those in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has been designated as a national emergency in the U.S. On the basis of such determination, the Secretary of Health and Human Services declared that circumstances exist justifying the authorization of emergency use of drugs and biologics during the COVID-19 pandemic. The FDA has granted EUAs for bamlanivimab, bamlanivimab and etesevimab administered together, and baricitinib in combination with remdesivir, and similar actions have been taken by other regulators in certain jurisdictions outside the U.S. We intend to submit bamlanivimab and etesevimab administered together to the FDA for approval in the second half of 202</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to various other U.S. federal and state laws, as well as analogous foreign laws and regulations, including the federal anti-kickback statute, the False Claims Act, and state laws governing kickbacks, false claims, unfair trade practices, and consumer protection. These laws are administered by, among others, the Department of Justice, the Office of Inspector General of the Department of Health and Human Services, the Federal Trade Commission, the Office of Personnel Management, and state attorneys general. Over the past several years, state and federal governments have increased their oversight, enforcement activities, and intra-agency coordination with respect to pharmaceutical companies. Further, several claims brought by these agencies against us and other companies under these and other laws have resulted in corporate criminal sanctions and very substantial civil settlements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Office of Inspector General of the U.S. Department of Health and Human Services and the Centers for Medicare &amp; Medicaid Services issued final rules expanding and modifying existing, and adding new, regulatory &#8220;safe harbors&#8221; and exceptions, respectively, under the anti-kickback statute and the Ethics in Patient Referrals Act. We are currently evaluating the impact, if any, these regulatory amendments will have upon becoming effective on our consolidated results of operations, liquidity, and financial position, which is uncertain at this time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act of 1977 (FCPA) prohibits certain individuals and entities, including U.S. publicly traded companies, from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the company obtain or retain business or gain any improper advantage. The FCPA also imposes specific recordkeeping and internal controls requirements on U.S. publicly traded companies. As noted above, outside the U.S., our business is heavily regulated and therefore involves significant interaction with foreign officials. Additionally, in many countries outside the U.S., healthcare providers who prescribe pharmaceuticals are employed by the government and purchasers of pharmaceuticals are government entities; therefore, our interactions with these prescribers and purchasers are subject to regulation under the FCPA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the U.S. application and enforcement of the FCPA, the various jurisdictions in which we operate and supply our products have laws and regulations aimed at preventing and penalizing corrupt and anticompetitive behavior. In recent years, several jurisdictions have enhanced their laws and regulations in this area, increased their enforcement activities, and/or increased the level of cross-border coordination and information sharing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and could in the future become subject to administrative and legal proceedings and actions, which could include claims for civil penalties (including treble damages under the False Claims Act), criminal sanctions, and administrative remedies, including exclusion from U.S. federal and other health care programs. It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to a variety of federal, state, and local environmental, health and safety, and other laws and regulations that may affect our research, development or production efforts. </span></div><div style="margin-top:9pt"><span style="color:#bf2115;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continues to be considerable public and government scrutiny of pharmaceutical pricing, and measures to address the perceived high cost of pharmaceuticals are being considered at various levels of state and federal government. In addition, U.S. government action to reduce federal spending on entitlement programs, including Medicare and Medicaid, may affect payment for our products or services associated with the provision of our products. Additionally, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. The regulatory priorities of the current U.S. presidential administration could further intensify these efforts, which could have a material adverse impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we are required to provide rebates to the federal government and respective state governments on their purchases of our pharmaceuticals under various federal and state healthcare programs, including state Medicaid and Medicaid Managed Care programs (minimum of 23.1 percent plus adjustments for price increases over time) and discounts to private entities who treat patients in certain types of health care facilities intended to serve low-income and uninsured patients (known as 340B facilities). No rebates are required at this time in the Medicare Part B (physician and hospital outpatient) program where reimbursement is set on an &#8220;average sales price plus 4.3 percent&#8221; formula.  Additionally, an annual fee is imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs. Since 2019, the Bipartisan Budget Act has required manufacturers of brand-name drugs, biologics, and biosimilars to provide a discount of 70 percent of the cost of branded prescription drugs for Medicare Part D participants who are in the &#8220;doughnut hole&#8221; (the coverage gap in Medicare prescription drug coverage), an increase from the previous 50 percent discount.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates are also negotiated in the private sector. We pay rebates to private payers who provide prescription drug benefits to seniors covered by Medicare and to private payers who provide prescription drug benefits to their customers. These rebates are affected by the introduction of competitive products and generics in the same class. Our approach to the rebates we offer to private payers who provide prescription drug benefits to seniors covered by Medicare may be impacted by recent regulatory amendments included in the anti-kickback statute final rule that will become effective on January 1, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, public and private payers are increasingly restricting access to pharmaceuticals based on assessments of comparative effectiveness and value, including through the establishment of formal health technology assessment processes. In addition, third-party organizations, including professional associations, academic institutions, and non-profit entities associated with payers, are conducting and publishing comparative effectiveness and cost/benefit analyses on medicines, the impact of which are uncertain at this time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most international markets, we operate in an environment of government-mandated cost-containment programs, which may include price controls, international reference pricing (to other countries&#8217; prices), discounts and rebates, therapeutic reference pricing (to other, often generic, pharmaceutical choices), restrictions on physician prescription levels, and mandatory generic substitution. We may experience additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the extent to which our business may be affected by these or other potential future legislative, regulatory, or payer developments. However, in general we expect to see continued focus on regulating pricing resulting in additional state, federal, and international legislative and regulatory developments that could have further negative effects on pricing and reimbursement for our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 7, &#8220;Management's Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access&#8221; for additional information regarding recent legislative, administrative, and other pricing initiatives and their impact on our results.</span></div><div style="margin-top:9pt"><span style="color:#bf2115;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to research and development dates back more than 140 years. We invest heavily in research and development because we believe it is critical to our long-term competitiveness. At the end of 2020, we employed approximately 7,600 people in pharmaceutical research and development activities, including a substantial number of physicians, scientists holding graduate or postgraduate degrees, and highly skilled technical personnel. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal pharmaceutical research focuses primarily on the areas of diabetes, oncology, immunology, neurodegeneration, and pain. During 2020, we also focused on researching and developing potential treatments for COVID-19. In addition to discovering and developing new medicines, we seek to expand the value of existing products through new uses, formulations, and therapeutic approaches that provide additional value to patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal efforts, we collaborate with others, including academic institutions and research-based pharmaceutical and biotechnology companies. We use the services of physicians, hospitals, medical schools, and other research organizations worldwide to conduct clinical trials to establish the safety and effectiveness of our medicines. We actively invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including, among others, licensing arrangements, co-development agreements, co-promotion arrangements, joint ventures, acquisitions, and equity investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical development is time-consuming, expensive, and risky. Very few of the candidates discovered by researchers ultimately become approved medicines. The process from discovery to regulatory approval can take over a decade. Candidates can fail at any stage of the process, and even late-stage candidates sometimes fail to receive regulatory approval or achieve commercial success. The following describes in more detail the research and development process for pharmaceutical products:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phases of New Drug Development</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">Discovery Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discovery phase, scientists identify, design, and synthesize promising candidates by analyzing their effect on biological targets thought to play a role in disease. Targets are often unproven and only candidates that have the desired effect on the target and meet other design criteria move to the next phase of development, which includes the initiation of studies in animals to support regulatory and safety requirements for clinical research in humans. The discovery phase can take years and the probability of any one candidate becoming a medicine is extremely low.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Early Development Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early development includes initial testing for safety and efficacy and early analyses of manufacturing requirements. Safety testing is initially performed in laboratory tests and animals, as necessary. In general, the first human tests (often referred to as Phase I) are conducted in small groups of subjects to assess safety and evaluate the potential dosing range. Subsequently, larger populations of patients are studied (Phase II) to identify initial signs of efficacy while continuing to assess safety. In parallel, scientists work to identify safe, effective, and economical manufacturing processes. Long-term animal studies continue to test for potential safety issues. Of the candidates that enter the early development phase, approximately 10 percent move to the late development phase. The early development phase varies but can take several years to complete.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Late Development Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Late phase development projects (typically Phase III) have met initial safety requirements and shown initial evidence of efficacy in earlier studies. As a result, these candidates generally have a higher likelihood of success and trials include larger patient populations to demonstrate safety and efficacy in the disease. These studies are designed to demonstrate the benefit and risk of the potential new medicine and may be compared to competitive therapies, placebo, or both.  Phase III studies are generally conducted globally and are designed to support regulatory filings for marketing approval. The duration of Phase III testing varies by disease and may take two to four years.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Submission Phase</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a potential new medicine is submitted to regulatory agencies, the time to final marketing approval can vary from several months to several years, depending on the disease state, the strength and complexity of available data, the degree of unmet need, and the time required for the regulatory agency(ies) to evaluate the submission, which can depend on prioritization by regulators and other factors. There is no guarantee that a potential medicine will receive marketing approval, or that decisions on marketing approvals or indications will be consistent across geographic areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our investments in research, both internally and in collaboration with others, have resulted in a robust pipeline of potential new medicines and new treatment indications in all stages of development.  We currently have approximately 45 candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase. See Item 7, &#8220;Management's Discussion and Analysis - Results of Operations - Executive Overview - Late-Stage Pipeline,&#8221; for more information on certain of our product candidates.</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raw Materials and Product Supply</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw or intermediate materials primarily from only one source. We generally seek to maintain sufficient inventory to supply the market until an alternative source of supply could be implemented, in the event one of these suppliers was unable to provide the materials or product. However, in the event of an extended failure of a supplier or significant unanticipated increases in demand on a supplier, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue comes from products produced in our own facilities. Our principal active ingredient manufacturing occurs at sites we own in the U.S., including Puerto Rico, and Ireland. Finishing operations, including formulation, filling, assembling, delivery device manufacturing, and packaging, take place at a number of sites throughout the world. We utilize third parties for certain active ingredient manufacturing and finishing operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that is intended to allow us to meet all expected product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand. To maintain a stable supply of our products, we use a variety of techniques including comprehensive quality systems, inventory management, and back-up sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, pharmaceutical production processes are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience unplanned plant shutdowns at one of our own facilities, significant failure of a contract supplier, or significant unanticipated increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, COVID-19 could also have an adverse impact on our manufacturing operations, global supply chain, and distribution systems, which could impact our ability to produce and distribute our products and affect the ability of third parties on which we rely to fulfill their obligations to us, and could increase our expenses. For more information, see Item 1A, "Risk Factors - Risks Related to Our Business - The COVID-19 pandemic and efforts to reduce its spread have impacted, and may in future periods negatively impact, our business and operations.&#8221; and Item 7, &#8220;Management's Discussion and Analysis - Results of Operations - Executive Overview - COVID-19 Pandemic.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Assurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in great measure on customer confidence in the quality of our products and in the integrity of the data that support their safety and effectiveness. Product quality arises from a total commitment to quality in all parts of our operations, including research and development, purchasing, facilities planning, manufacturing, distribution, and dissemination of information about our medicines. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality of production processes involves strict control of ingredients, equipment, facilities, manufacturing methods, packaging materials, and labeling. We perform tests at various stages of production processes and on the final product in an effort to ensure that the product meets all applicable regulatory requirements and our internal standards. These tests may involve chemical and physical chemical analyses, microbiological testing, testing in animals, or a combination thereof. Additional assurance of quality is provided by quality assurance groups that audit and monitor all aspects of quality related to pharmaceutical manufacturing procedures and systems in company operations and at third-party suppliers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers of the Company</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding our current executive officers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of office for each executive officer expires on the date of the annual meeting of the board of directors, to be held on May 3, 2021 in connection with the company's annual meeting of shareholders, or on the date his or her successor is chosen and qualified. No director or executive officer has a &#8220;family relationship&#8221; with any other director or executive officer of the company, as that term is defined for purposes of this disclosure requirement. There is no understanding between any executive officer or director and any other person pursuant to which the executive officer was selected.</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.597%"><tr><td style="width:1.0%"></td><td style="width:16.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Titles and Business Experience</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">David A. Ricks</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chairman, President, and Chief Executive Officer (CEO) (since 2017).  Previously, Mr. Ricks held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines. Mr. Ricks has 24 years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anat Ashkenazi </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer (since 2021). Previously, Ms. Ashkenazi held various leadership roles with Lilly, including senior vice president, controller and chief financial officer, Lilly Research Laboratories, and vice president, finance and chief financial officer, Lilly Diabetes and Lilly global manufacturing and quality. Ms. Ashkenazi has 19 years of service with Lilly. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Melissa S. Barnes</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer (since 2013). Previously, Ms. Barnes held various leadership roles with Lilly, including vice president, deputy general counsel. Ms. Barnes has 26 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stephen F. Fry</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President, Human Resources and Diversity (since 2011). Previously, Mr. Fry held various leadership roles with Lilly, including vice president, human resources. Mr. Fry has 33 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anat Hakim</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Secretary (since 2020). Prior to joining Lilly, Ms. Hakim was senior vice president, general counsel and secretary of WellCare Health Plans, Inc. (WellCare) from 2016 to 2018, and executive vice president, general counsel and secretary of WellCare from 2018 to 2020. Prior to joining WellCare, she served as divisional vice president and associate general counsel of intellectual property litigation at Abbott Laboratories from 2010 to 2013 and divisional vice president and associate general counsel of litigation from 2013 to 2016. Ms. Hakim has one year of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patrik Jonsson</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President, President, Lilly USA, and Chief Customer Officer (since 2020).  Previously, Mr. Jonsson held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan. Mr. Jonsson has 30 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael B. Mason </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and President, Lilly Diabetes (since 2020). Previously, Mr. Mason held various leadership roles with Lilly, including senior vice president, connected care and insulins and vice president of U.S. Diabetes. Mr. Mason has 31 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johna L. Norton</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President, Global Quality (since 2017). Previously, Ms. Norton held various leadership roles with Lilly, including vice president, global quality assurance API manufacturing and product research and development. Ms. Norton has 30 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Myles O'Neill</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and President, Manufacturing Operations (since 2018). Previously, Mr. O&#8217;Neill held various leadership roles with Lilly, including senior vice president of global parenteral drug product, delivery devices, and regional manufacturing. Mr. O&#8217;Neill has 18 years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leigh Ann Pusey</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President, Corporate Affairs and Communications (since 2017). Prior to joining Lilly, Ms. Pusey was president and chief executive officer of the American Insurance Association from 2009 to 2017. Ms. Pusey has three years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aarti Shah, Ph.D.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and Chief Information and Digital Officer (since 2018). Previously, Dr. Shah held various leadership roles with Lilly, including senior vice president information technology and chief information officer and global brand development leader. Dr. Shah has 27 years of service with Lilly.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Daniel M. Skovronsky, M.D., Ph.D.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President, Chief Scientific Officer, and President, Lilly Research Laboratories (since 2018). Previously, Dr. Skovronsky held various leadership roles with Lilly, including senior vice president, clinical and product development. Dr. Skovronsky has 10 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anne E. White</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President and President, Lilly Oncology (since 2018). Previously, Ms. White held various leadership roles with Lilly, including vice president of Portfolio Management, Chorus and Next Generation Research and Development. Ms. White has 25 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ilya Yuffa</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Senior Vice President and President, Lilly Bio-Medicines (since 2020). Previously, Mr. Yuffa held various leadership roles with Lilly, including vice president of U.S. Diabetes general manager of Italy Hub, and vice president, global ethics and compliance officer since 2014. Mr. Yuffa has 24 years of service with Lilly.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alfonso Zulueta</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and President, Lilly International (since 2014). Previously, Mr. Zulueta held various leadership roles with Lilly, including president of emerging markets and of Lilly Japan. Mr. Zulueta has 32 years of service with Lilly.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core values&#8212;integrity, excellence, and respect for people&#8212;shape our approach to attracting, retaining, engaging, and developing a highly skilled and ethical workforce, which is critical to executing our strategy. We believe the strength of our workforce significantly contributes to our financial performance and enables us to make life better for people around the world. For instance, most of the products we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We believe that fostering a positive culture that values the contributions of our talented colleagues helps drive our success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to creating a safe, supportive, ethical, and rewarding work environment through strategic focus on our human capital management process, fairness and nondiscrimination in our employment practices, robust training and development opportunities, and competitive pay and benefits. We believe our dedication to promoting diversity and inclusion (D&amp;I) within our company reflects our values and is a key driver of business success and growth. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly conduct anonymous employee surveys to seek feedback from our workforce on a variety of topics.  These results are reviewed and analyzed by our leaders in order to implement changes to our policies and benefits designed to improve our employees' well-being.  As a result of our efforts, we believe that we have a highly performing, cohesive workforce and that our employee relations are good.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2020, we employed approximately 35,000 people, including approximately 19,500 employees outside the U.S. Our employees include approximately 7,600 people engaged in research and development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy and Oversight</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build diverse and inclusive teams, our CEO and executive committee set expectations for inclusive leadership and hold leaders accountable for achieving results.  Because dedication to human capital management is also a core component of our corporate governance, our board of directors regularly engages with management and facilitates a system of reporting designed to monitor human capital management initiatives and progress as part of the overarching framework that guides how we attract, retain, engage, and develop a workforce that aligns with our values and mission. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diversity and Inclusion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to fairness and nondiscrimination in our employment practices, and we deeply value diverse backgrounds, skills, and global perspectives. To fulfill our purpose, we believe we must look at challenges from multiple viewpoints and understand the diverse experiences of the patients who depend on us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that fostering D&amp;I begins with understanding. For example, our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Journeys </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research has yielded important insights about the experiences of women, Black/African American, Latinx, Asian, and lesbian, gay, bisexual, transgender, or queer (LGBTQ) employees at Lilly. The results of this research are reviewed by our senior leadership, and we deploy actions and activities in response to these insights to improve our workplace and corporate culture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2017, we have committed to increasing the number of women, Black/African American, Latinx, and Asian populations in leadership roles, and we actively monitor our progress. From the end of 2017 through the end of 2020, we increased the number of women in management globally from 41 percent to 46 percent. For minority group members (MGM) in the U.S. over the same period, we increased management representation from 16 percent to 22 percent. Across all levels of our workforce, from the end of 2017 through the end of 2020, we have seen increased representation for MGMs in the U.S. and women globally. Our focus on D&amp;I is also evident at our executive committee and board of directors. Seven of 15 members (approximately 47 percent) of our executive committee (which includes our CEO) are women and two are MGM, including one MGM woman. In addition, the company&#8217;s 15-member board of directors includes six women and seven members of underrepresented groups (including MGM as well as LGBTQ individuals).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts in D&amp;I and workplace benefits have garnered numerous recognitions, including, in 2020 and early 2021, Top 50 Companies for Diversity by DiversityInc., America&#8217;s Best Employers for Diversity by Forbes, America&#8217;s Most JUST Companies and Forbes JUST 100 by Forbes and JUST Capital, Perfect Score on the Human Rights Campaign Foundation Corporate Equality Index (2020 and 2021), World&#8217;s Most Ethical Companies by Ethisphere, Leading Disability Employer by the National Organization on Disability, Top Employers by Science Magazine, America&#8217;s Most Responsible Companies by Newsweek, and 100 Best Companies, Top 75 Companies for Executive Women, Best Companies for Dads, and Best Companies for Multicultural Women by Working Mother Magazine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe talent begins with the hiring process. We therefore require hiring managers to consider a diverse pool of candidates and we strive to provide a diverse panel of interviewers for open positions. We believe that hiring in this way helps ensure that people from all backgrounds have equal opportunity to advance their careers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer training to enable our employees to perform their duties in our highly regulated industry. We also strive to cultivate a culture that promotes ongoing learning by encouraging employees to seek further education and growth experiences, helping them build rewarding careers. We have introduced online programming to facilitate access to our learning and development offerings. Many training courses are designed to improve accessibility for people with disabilities and other unique needs. Across Lilly, we are working to design learning experiences to be more inclusive and effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further improve our talent programs and processes, in 2019, we introduced </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Explore Your Career</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a global framework of tools and resources for our employees. We believe </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Explore Your Career</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides broader access and transparency about career development and advancement at Lilly. In 2018, we introduced </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emerge</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a three-day program led by our CEO that is designed to develop MGM talent at Lilly, and three cohorts comprising Black/African American women, Latinx and Asian women, and MGM men have participated in this enterprise-level program since its inception.  Lilly also offers established leadership development programs for women and earlier career multi-cultural talent, as well as leaders at all levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee resource groups (ERGs) are another important component of developing talent at Lilly. We currently have 10 ERGs representing groups including women, MGMs, LGBTQ individuals, and people with disabilities. ERGs offer our diverse workforce opportunities to build relationships, engage with senior leaders, advance our caring community, and offer unique insights and perspectives to improve our business. Membership in our ERGs continues to grow, with an estimated 11,430 people participating worldwide at the end of 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In furtherance of our efforts to create an inclusive workplace, in 2020 we expanded </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Make it Safe to Thrive</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an education and awareness program to help employees and leaders understand how individual psychological safety can be created and enhanced, with the goal of ensuring that all employees feel safe to speak up and to share their ideas at work.  The program includes live and online training and a monthly video series.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Health and Safety</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have consistently focused on protecting the health and safety of our employees, the COVID-19 pandemic has emphasized the importance of this critical priority. In response to the pandemic, we have taken measures to protect our workforce, maximize social distancing, and inform employees about our policies. For example, we instituted travel restrictions and remote working arrangements for employees whose roles do not require on-site presence. To support employee well-being in the U.S., we enhanced local benefits related to health care, childcare, and time off, and expanded reimbursement for home office ergonomic support expenditures.  In the U.S., we provide full coverage for COVID-19 diagnostic testing and treatment, and at our corporate headquarters in Indianapolis, we provide free on-site testing for employees and members of their household. In addition, as part of our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Make it Safe to Thrive</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program, we partnered with our ERGs to offer a series of programs highlighting and addressing challenges faced by ERG members during the COVID-19 pandemic, aiming to build understanding of different experiences and to offer ways to be inclusive.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Available on Our Website</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company website is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">www.lilly.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the information accessible on or through our website is incorporated into this Annual Report on Form 10-K. We make available through the website, free of charge, our company filings with the SEC as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. These include our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents. The link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Governance portion of our website includes our corporate governance guidelines, board of directors and committee information (including committee charters), and our articles of incorporation and bylaws. The link to our corporate governance information is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">lilly.com/leadership/governance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">22</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Risk Factors</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information contained in this Annual Report on Form 10-K, the following risk factors should be considered carefully in evaluating our company. It is possible that our business, financial condition, liquidity, cash flows, or results of operations could be materially adversely affected by any of these risks. Certain of these risks could also adversely affect the company's reputation. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could also adversely affect our business and reputation.</span></div><div style="margin-top:9pt"><span style="color:#bf2115;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic and efforts to reduce its spread have impacted, and may in future periods negatively impact, our business and operations.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has substantially burdened healthcare systems worldwide. The focus of resources on COVID-19 and widespread protective measures implemented to control the spread of the pandemic have impacted discovery, research, development, manufacturing, and sales of our medicines as well as those of the broader pharmaceutical industry. Significant delays or unexpected issues, such as higher discontinuation rates or delays accumulating data, affecting the timing, conduct, or regulatory review of our clinical trials, could adversely affect our ability to commercialize some assets in our product pipeline. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lack of normal access and fewer in-person interactions by patients and our employees with the healthcare system, along with concern about the continued supply of medications, has resulted, and may continue to result, in changes in buying patterns throughout the supply chain, impacting demand for our products and negatively impacting the consolidated operating results of our underlying business. In certain locations in the U.S and around the world with COVID-19 outbreaks, we temporarily halted in-person interactions by our employees with healthcare providers and increased virtual interactions. While in-person interactions have resumed in many locations, we may decide to halt such activity in the future and, in those cases, expect to resume such interactions as it is safe to do so and in compliance with applicable guidance and requirements.  The COVID-19 pandemic could also have an adverse impact on our manufacturing operations, global supply chain, and distribution systems, which could impact our ability to produce and distribute our products and affect the ability of third parties on which we rely to fulfill their obligations to us, and could increase our expenses. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face unique risks and uncertainties related to our development, manufacture, and uptake of potential treatments for COVID-19, including vulnerability to supply chain disruptions, higher manufacturing costs, difficulties in manufacturing sufficient quantities of our therapies, restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us. Expedited authorization processes, including our EUAs for bamlanivimab and bamlanivimab and etesevimab administered together, have allowed restricted distribution of products with less than typical safety and efficacy data, and additional data that become available may call into question the safety or effectiveness of our COVID-19 therapies. Additionally, the availability of superior or competitive therapies, or preventative measures such as vaccines, coupled with the transient nature of pandemics, could negatively impact or eliminate demand for our COVID-19 therapies. In addition, we may be required to accept returns of certain product previously shipped pursuant to EUAs if the relevant EUA is revoked or terminated. Mutations or the spread of other variants of the coronavirus could also render our therapies ineffective. Any of these risks could prevent us from recouping our substantial investments in the research, development, and manufacture of our COVID-19 therapies. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the conditions created by the COVID-19 pandemic intensify other risks inherent in our business, including, among other things, risks related to drug pricing and access, the conduct of clinical trials, workplace safety and productivity, intellectual property protection, product liability and other litigation, and the impact of adverse global and local economic conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced negative impacts to our underlying business, including demand for our products, due to the COVID-19 pandemic but the pandemic has not negatively impacted our liquidity position. Given the evolving nature of the virus, the financial impact of the COVID-19 pandemic on our results of operations, financial condition, liquidity, and cash flows in future periods could change, perhaps materially. The degree to which the COVID-19 pandemic affects us will depend on developments that are highly uncertain and beyond our knowledge or control, including, but not limited to, the duration and severity of the pandemic, the actions taken to reduce its transmission, including widespread availability of vaccines, and the speed with which, and extent to which, more stable economic and operating conditions resume. Should the COVID-19 pandemic and any associated recession or depression continue for a prolonged period, our results of operations, financial condition, liquidity, and cash flows could be materially impacted by lower revenues and profitability and a lower likelihood of effectively and efficiently developing and launching new medicines.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmaceutical research and development is very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products sufficient in number or value to replace revenues of products that have lost or will soon lose intellectual property protection or are displaced by competing products or therapies.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many difficulties and uncertainties inherent in pharmaceutical research and development, the introduction of new products, and business development activities to expand our product pipeline. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies continue to establish high hurdles for the efficacy and safety of new products. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot state with certainty when or whether our products now under development will be approved or launched; whether, if initially granted, such approval will be maintained; whether we will be able to develop, license, or otherwise acquire additional product candidates or products; or whether our products, once launched, will be commercially successful. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must maintain a continuous flow of successful new products and successful new indications or brand extensions for existing products, both through our internal efforts and our business development activities, sufficient both to cover our substantial research and development costs and to replace revenues that are lost as profitable products lose intellectual property exclusivity or are displaced by competing products or therapies. Failure to do so in the short-term or long-term would have a material adverse effect on our business, results of operations, cash flows, and financial position. Our business development activities to enhance our product pipeline may include acquisitions, strategic alliances, collaborations, investments, and licensing arrangements. There are substantial risks associated with identifying business development targets and consummating related transactions, which may not be completed in a timely manner, if at all, may not result in successful commercialization of any product, and may give rise to legal proceedings or regulatory scrutiny.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis - Results of Operations - Executive Overview - Late-Stage Pipeline,&#8221; for more details about our current product pipeline. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; we have lost or will lose effective intellectual property protection for many of those products in the next few years, which has resulted and is likely to continue to result in rapid and severe declines in revenues.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our top-selling products, including Alimta and Forteo, have recently lost, or will lose in the next few years, significant patent protection and/or data protection in the U.S. as well as key countries outside the U.S. We have faced and remain exposed to generic competition following the loss of such intellectual property protection. In particular, we expect that the entry of generic competition for Alimta in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue for the product and have a material adverse effect on our consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain other significant products no longer have effective exclusivity through patent protection or data protection. For non-biologic products, loss of exclusivity (whether by expiration of legal rights or by termination thereof as a consequence of litigation) typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. Historically, outside the U.S., the market penetration of generics following loss of exclusivity has not been as rapid or pervasive as in the U.S.; however, generic market penetration is increasing in many markets outside the U.S., including Japan, Europe, and many countries in emerging markets. For biologics (such as Humalog, Humulin, Erbitux, Cyramza, Trulicity, Taltz, and Emgality), loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory pathways for approval of the competitor versions. Generic pharmaceutical companies could also introduce a generic product before resolution of any related patent litigation.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged. Moreover, patents relating to particular products, uses, formulations, or processes do not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products. In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property. See Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Patent Matters,&#8221; and Item 1, "Business - Patents, Trademarks, and Other Intellectual Property Rights," for more details. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new drugs to the market.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations. Changes to such laws and regulations could reduce protections for our innovative products. In the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biologic products, the Hatch-Waxman Act provides generic companies powerful incentives to seek to invalidate our other pharmaceutical patents. As a result, we expect that our U.S. patents on major pharmaceutical products will continue to be routinely challenged in litigation and may not be upheld. In addition, a separate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR process allows competitors to request review of issued patents by the USPTO without the protections of the Hatch-Waxman Act. Our patents may be invalidated through this expedited review process. Although such a decision can be appealed to the courts, in certain circumstances a loss in such a proceeding could result in a competitor entering the market, while a win provides no precedential value, meaning the same patent can be challenged by other competitors. We face many generic manufacturer challenges to our patents outside the U.S. as well. The entry of generic competitors typically results in rapid and severe declines in revenues. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales. See Item&#160;1, &#8220;Business - Patents, Trademarks, and Other Intellectual Property Rights,&#8221; and Item 8, "Financial Statements and Supplementary Data - Note 16, Contingencies," for more details.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We and our products face intense competition from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers, and such competition could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with a large number of multinational pharmaceutical companies, biotechnology companies, and generic pharmaceutical companies. To compete successfully, we must continue to deliver to the market innovative, cost-effective products that meet important medical needs. Our product revenues can be adversely affected by the introduction by competitors of branded products that are perceived as superior by the marketplace, by generic or biosimilar versions of our branded products, and by generic or biosimilar versions of other products in the same therapeutic class as our branded products. Our revenues can also be adversely affected by treatment innovations that eliminate or minimize the need for treatment with our drugs.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation of generic and biosimilar products varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agencies and courts. Particularly for biosimilars, recent government proposals could make it easier, less expensive, and less time consuming for competitor products to enter the market, some of which could be substituted for our products by pharmacies. Given the importance of biologic products to our clinical-stage pipeline, such regulation could have a material adverse effect on our business. See Item 1, &#8220;Business - Competition&#8221; and "Business - Research and Development," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Failure, inadequacy, or breach of our IT systems or our business processes regarding confidential information and other data, unauthorized access to our confidential information or violations of data protection laws could result in material harm to our business and reputation.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A great deal of confidential information owned by us or our business partners or other third parties is stored in our information systems, networks, and facilities or those of third parties. This includes valuable trade secrets and intellectual property, clinical trial information, corporate strategic plans, marketing plans, customer information, and personally identifiable information, such as employee and patient information (collectively, confidential information). We also rely, to a large extent, on the efficient and uninterrupted operation of complex information technology systems, infrastructure, and hardware (together, IT systems), some of which are within our control and some of which are within the control of third parties, to accumulate, process, store, and transmit large amounts of confidential information and other data. We are subject to a variety of continuously evolving and developing laws and regulations around the world related to privacy, data protection, and data security. Maintaining the confidentiality, integrity and availability of our IT systems and confidential information is vital to our business.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IT systems are vulnerable to system inadequacies, operating failures, service interruptions or failures, security breaches, malicious intrusions, or cyber-attacks from a variety of sources. Cyber-attacks are growing in their frequency, sophistication, and intensity, and are becoming increasingly difficult to detect, mitigate, or prevent. Cyber-attacks come in many forms, including the deployment of harmful malware, exploitation of vulnerabilities (including those third-party software or systems), denial-of-service attacks, the use of social engineering, and other means to compromise the confidentiality, integrity and availability of our IT systems, confidential information, and other data. Breaches resulting in the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized disclosure or use of confidential information, or the unauthorized access to, disruption of, or interference with our products and services, can occur in a variety of ways, including but not limited to, negligent or wrongful conduct by employees or others with permitted access to our systems and information, or wrongful conduct by hackers, competitors, certain governments or nation-states, or other current or former company personnel. Our third-party partners, including third-party providers of data hosting or cloud services, as well as suppliers, distributors, alliances, and other third-party service providers, face similar risks, which could affect us directly or indirectly. The healthcare industry has been and continues to be a target for cyber-attacks, and the number of threats has only increased during the COVID-19 pandemic. Numerous federal agencies that monitor and regulate internet and cyber-crime have issued guidance, alerts and directives warning of software vulnerabilities that require immediate patching, malicious actors targeting healthcare related systems and nation-state sponsored hacking designed to steal valuable information, including related to potential COVID-19 treatments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure or inadequacy of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to disclosure or use of confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; and cause us to lose trade secrets or other competitive advantages. Unauthorized disclosure of personally identifiable information could expose us to significant sanctions for violations of data privacy laws and regulations around the world and could damage public trust in our company. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, system inadequacies, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, cyber-attacks, and the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized disclosure or use of confidential information have not had a material impact on our consolidated results of operations. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses that may result from an interruption or breach of our IT systems. We continue to implement measures in an effort to protect, detect, respond to, and minimize or prevent these risks and to enhance the resiliency of our IT systems; however, these measures may not be successful and we may fail to detect or remediate security breaches, malicious intrusions, cyber-attacks, or other compromises of our systems. Any of these events could result in material financial, legal, commercial, or reputational harm to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Significant economic downturns or international trade disruptions or disputes could adversely affect our business and operating results.&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While pharmaceuticals have not generally been sensitive to overall economic cycles, prolonged economic slowdowns, including as a result of COVID-19, could lead to decreased utilization of our products, affecting our sales volume. Declining tax revenues attributable to economic downturns increase the pressure on governments to reduce health care spending, leading to increasing government efforts to control drug prices and utilization. Additionally, some customers, including governments or other entities reliant upon government funding, may be unable to pay for our products in a timely manner. Also, if our customers, suppliers, or collaboration partners experience financial difficulties, we could experience slower customer collections, greater bad debt expense, and performance defaults by suppliers or collaboration partners. Similarly, in the event of a significant economic downturn, we could have difficulty accessing credit markets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant portions of our business are conducted in Europe, including the United Kingdom, Asia, and other international geographies.&#160;Trade disputes and interruptions in international relationships, including pandemic diseases, such as COVID-19, could result in changes to regulations governing our products and our intellectual property, or otherwise affect our ability to do business. While we do not expect either circumstance to materially affect our business in a direct manner, these and similar events could adversely affect us, or our business partners or customers.&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmaceutical products can develop unexpected safety or efficacy concerns, which could have a material adverse effect on our revenues, income, and reputation.&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pharmaceutical products receive regulatory approval based on data obtained in controlled clinical trials of limited duration. After approval, the products are used for longer periods of time by much larger numbers of patients. Accordingly, we and others (including regulatory agencies and private payers) collect extensive information on the efficacy and safety of our marketed products by continuously monitoring the use of our products in the marketplace. In addition, we or others may conduct post-marketing clinical studies on efficacy and safety of our marketed products. New safety or efficacy data from both market surveillance and post-marketing clinical studies may result in product label changes or other measures that could reduce the product's market acceptance and result in declining sales. Serious safety or efficacy issues that arise after product approval could result in voluntary or mandatory product recalls or withdrawals from the market. Safety issues could also result in costly product liability claims. See also &#8220; - The COVID-19 pandemic and efforts to reduce its spread have impacted, and may in future periods negatively impact, our business and operations.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We face litigation and investigations related to our products and our pricing practices and are self-insured; we could face large numbers of claims in the future, which could&#160;adversely affect our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a substantial number of product liability claims involving various products, as well as litigation and investigations related to the pricing of our products. See Item&#160;8, &#8220;Financial Statements and Supplementary Data - Note 16, Contingencies&#8221; for more information on our current product liability litigation, as well as pricing litigation, investigations, and inquiries. Because of the nature of pharmaceutical products, we are and could in the future become subject to large numbers of product liability claims for these or other products, or to further litigation or investigations, including related to pricing or other commercial practices. Such matters could affect our results of operations or require us to recognize substantial charges to resolve and, if involving marketed products, could adversely affect sales of the product. Due to a very restrictive market for liability insurance, we are self-insured for product liability losses for all our currently marketed products, as well as for litigation or investigations related to our pricing practices or other similar matters. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacturing difficulties or disruptions could lead to product supply problems.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical manufacturing is complex and highly regulated. Manufacturing or quality assurance difficulties at our facilities or contracted facilities, or the failure or refusal of a supplier or contract manufacturer to supply contracted quantities, could result in product shortages, leading to lost revenue. Such difficulties or disruptions could result from quality, oversight, or regulatory compliance problems; natural disasters or pandemic disease; equipment, mechanical, data, or information technology system vulnerabilities, such as system inadequacies, inadequate controls or procedures, operating failures, service interruptions or failures, security breaches, malicious intrusions, or cyber-attacks from a variety of sources; or inability to obtain single-source raw or intermediate materials. In addition, given the difficulties in predicting sales of new products and the very long lead times necessary for the expansion and regulatory qualification of pharmaceutical manufacturing capacity, it is possible that we could have difficulty meeting unanticipated demand for new products. See Item&#160;1, &#8220;Business - Raw Materials and Product Supply,&#8221; for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Reliance on third-party relationships and outsourcing arrangements could adversely affect our business. </span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties, including suppliers, distributors, alliances, and collaborations with other pharmaceutical and biotechnology companies, and third-party service providers, for selected aspects of product development, manufacturing, commercialization, support for information technology systems, product distribution, and certain financial transactional processes. For example, we outsource the day-to-day management and oversight of our clinical trials to contract research organizations.&#160;Outsourcing these functions involves the risk that the third parties may not perform to our standards or legal requirements; may not produce reliable results; may not perform in a timely manner; may not maintain the confidentiality, integrity, and availability of confidential and proprietary information relating to us, our clinical trial subjects, or patients; may experience disruption or fail to perform due to information technology system vulnerabilities, breaches, cyber-attacks, or inadequate controls or procedures; or may fail to perform at all. Failure of these third parties to meet their contractual, regulatory, confidentiality, privacy, security, or other obligations to us, our clinical trial subjects, and our patients could have a material adverse effect on our business. </span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#bf2115;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Our business is subject to increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our reputation or business.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and private payers continue to take aggressive steps to control their expenditures for pharmaceuticals by placing restrictions on pricing and reimbursement for, and patient access to, our medications. These pressures could continue to negatively affect our future revenues and net income.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect governments and private payers worldwide to intensify their scrutiny of, and actions intended to address, pricing, reimbursement, and access to pharmaceutical products. Additional regulations, legislation, or enforcement, including as a result of the current U.S. presidential administration, could adversely impact our revenue. However, we cannot predict the likelihood, nature, or extent of current and future health care reform efforts. We also may experience potential additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more details, see Item 1, &#8220;Business - Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access,&#8221; and Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access.&#8221;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Changes in foreign currency rates or interest rate risks could materially affect our revenue, cost of sales, and operating expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates. While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on our revenue, cost of sales, and operating expenses. In the event of an extreme devaluation of local currency, the price of our products could become unsustainable in the relevant market. See Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis - Financial Condition and Liquidity&#8221; for more details.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Unanticipated changes in our tax rates or exposure to additional tax liabilities could increase our income taxes and decrease our net income.&#160;</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and numerous foreign jurisdictions, and in the course of our business, we make judgments about the expected tax treatment of various transactions and events. Changes in relevant tax laws, regulations, administrative practices, principles, and interpretations, as well as events that differ from our expectations, could adversely affect our future effective tax rates. In addition, global tax authorities routinely examine our tax returns and are expected to become more aggressive in their examinations of profit allocations among jurisdictions which could affect our anticipated tax liabilities. In December 2017, the U.S. enacted tax reform legislation significantly revising U.S. tax laws, and a number of other countries are also actively considering or enacting tax changes. Significant uncertainty currently exists regarding proposed tax policies of the current U.S. presidential administration including repeal of certain aspects of the 2017 tax law. Modifications to key elements of the U.S. or international tax framework could have a material adverse effect on our consolidated operating results and cash flows. See Item 7, &#8220;Management&#8217;s Discussion and Analysis - Results of Operations - Executive Overview - Other Matters - Tax Matters&#8221; and Item 8, "Financial Statements and Supplementary Data - Note 14, Income Taxes," for more details.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken the position, based on an opinion of tax counsel, that our divestiture of Elanco common stock in connection with the 2019 separation of Elanco qualifies as a transaction that is tax-free for U.S. federal income tax purposes. If any facts, assumptions, representations, and undertakings from Lilly and Elanco regarding the past and future conduct of their respective businesses and other matters are incorrect or not otherwise satisfied, the divestiture may not qualify for tax-free treatment, which could result in significant U.S. federal income tax liabilities for us and our shareholders who exchanged their stock for Elanco stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Regulatory compliance problems could be damaging to the company.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to extensive regulation. Many companies, including us, have been subject to claims related to these practices asserted by federal, state, and foreign governmental authorities, private payers, and consumers. These claims have resulted in substantial expense and other significant consequences to us. We are and could in the future become subject to such investigations, the outcomes of which could include criminal charges and fines, penalties, or other monetary or non-monetary remedies, including exclusion from U.S. federal and other health care programs. Such investigations may intensify as a result of the regulatory priorities of the current U.S. presidential administration. In addition, regulatory issues concerning compliance with cGMP, quality assurance, and similar regulations (and comparable foreign regulations) for our products can lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products pending resolution of the issues, and reputational harm, any of which would adversely affect our business. See Item 1, &#8220;Business - Government Regulation of Our Operations,&#8221; for more details. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">30</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Unresolved Staff Comments</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_28"></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 2.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Properties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal domestic and international executive offices are located in Indianapolis. At December&#160;31, 2020, we owned 9 production and distribution sites in the U.S., including Puerto Rico. Together with the corporate administrative offices, these facilities contain an aggregate of approximately 8.2 million square feet of floor area dedicated to production, distribution, and administration. Major production sites include Indianapolis, Indiana; Carolina, Puerto Rico; and Branchburg, New Jersey.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own production and distribution sites in 8 countries outside the U.S., containing an aggregate of approximately 4.4&#160;million square feet of floor area. Major production sites include facilities in Ireland, France, Spain, Italy, and China.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., our research and development facilities contain an aggregate of approximately 4.2 million square feet of floor area, primarily consisting of owned facilities located in Indianapolis. We also lease smaller sites in San Diego, California; San Francisco, California; and New York, New York. Outside the U.S., we own a small research and development facility in Spain and lease a small site in Singapore.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that none of our properties is subject to any encumbrance, easement, or other restriction that would detract materially from its value or impair its use in the operation of the business. The buildings we own are of varying ages and in good condition.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_31"></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 3.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. Information pertaining to legal proceedings is described in Item 8, "Financial Statements and Supplementary Data - Note 16, Contingencies," and incorporated by reference herein. </span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_34"></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 4.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Mine Safety Disclosures</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">31</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part II</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_40"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 5.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock and related stockholder matters is described in Item 7, "Management's Discussion and Analysis of Results of Operations and Financial Condition" and Item 12, "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters." This information is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 12, 2021, there were approximately 21,650 holders of record of our common stock based on information provided by our transfer agent. Our common stock is listed under the ticker symbol LLY on the New York Stock Exchange (NYSE). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the fourth quarter ended December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(in&#160;thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid<br/>per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of&#160;Shares<br/>Purchased as Part of<br/>Publicly Announced<br/>Plans or Programs<br/>(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate&#160;Dollar&#160;Value<br/>of&#160;Shares&#160;that&#160;May&#160;Yet&#160;Be<br/>Purchased Under the<br/>Plans or Programs<br/>(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 19pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 46pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 46pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2020</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 46pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2020, we did not repurchase any shares under the $8.00 billion share repurchase program authorized in June 2018. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">32</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE GRAPH</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the return on Lilly stock with that of the Standard&#160;&amp; Poor&#8217;s (S&amp;P) 500 Stock Index and our peer group for the years 2016 through 2020. The graph assumes that, on December&#160;31, 2015, a person invested $100 each in Lilly stock, the S&amp;P 500 Stock Index, and the peer group's collective common stock. The graph measures total shareholder return, which takes into account both stock price and dividends. It assumes that dividends paid by a company are immediately reinvested in that company&#8217;s stock. </span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Value of $100 Invested on Last Business Day of 2015 Comparison of Five-Year Cumulative Total Shareholder Return Among Lilly, S&amp;P 500 Stock Index, and Peer Group</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span><br/></span></div><div style="text-align:center"><img src="lly-20201231_g1.jpg" alt="lly-20201231_g1.jpg" style="height:434px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"/></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.598%"><tr><td style="width:1.0%"></td><td style="width:16.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lilly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peer&#160;Group</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">S&amp;P&#160;500</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-15</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-17</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.61&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.86&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.40&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-19</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.29&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.80&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.49&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec-20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">We constructed the peer group as the industry index for this graph. It is comprised of the following companies in the pharmaceutical and biotechnology industries: AbbVie Inc.; Allergan plc; Amgen Inc.; AstraZeneca PLC; Biogen Inc.; Bristol-Myers Squibb Company; Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson&#160;&amp; Johnson; Merck&#160;&amp; Co., Inc.; Novartis AG.; Novo Nordisk A/S; Pfizer Inc.; Roche Holding AG; Sanofi S.A.; and Takeda Pharmaceutical Company Limited. The peer group used for performance benchmarking aligns with the peer group used for executive compensation purposes for 2020 other than our peer group for performance benchmarking excludes Celgene Corporation and Shire plc as they were acquired in 2019.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">33</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_52"></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 7.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_55"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_58"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes in Item 8 of Part II of this Annual Report on Form 10-K. Certain statements in this Item 7 of Part II of this Annual Report on Form 10-K constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" and Item&#160;1A, &#8220;Risk Factors,&#8221; may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have been focused on maintaining a reliable supply of our medicines; reducing the strain on the medical system; developing treatments for COVID-19; protecting the health, safety, and well-being of our employees; supporting our communities; and ensuring affordability of and access to our medicines, particularly insulin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced negative impacts to our underlying business due to the COVID-19 pandemic, including decreases in new prescriptions as a result of fewer patient visits to physician&#8217;s offices to begin or change treatment, changes in payer segment mix, and the use of patient affordability programs in the United States (U.S.) due to rising unemployment. Additionally, we have experienced, and may continue to experience, decreased demand as a result of lack of normal access and fewer in-person interactions by patients and our employees with the healthcare system. In certain locations in the U.S. and around the world with COVID-19 outbreaks, we temporarily halted in-person interactions by our employees with healthcare providers and increased virtual interactions. While in-person interactions have resumed in many locations, we may decide to halt such activity in the future and, in those cases, expect to resume such interactions as it is safe to do so and in compliance with applicable guidance and requirements. We may experience additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to discovering and developing new treatments for the patients we serve. At the beginning of the COVID-19 pandemic, we paused new clinical trial starts and enrollment in new trials in order to reduce the strain on the medical system, and we have resumed this activity in our clinical trials. However, significant delays or unexpected issues, such as higher discontinuation rates or delays accumulating data, affecting the timing, conduct, or regulatory review of our clinical trials, could adversely affect our ability to commercialize some assets in our product pipeline if the COVID-19 pandemic continues for a protracted period. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regards to COVID-19 therapies, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorizations (EUA) for bamlanivimab and bamlanivimab and etesevimab administered together for higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19 and for baricitinib in combination with remdesivir in hospitalized COVID-19 patients. We are actively working with a variety of organizations, including governmental agencies, to facilitate access to our COVID-19 treatments in various countries. However, we face unique risks and uncertainties in our development, manufacture, and uptake of potential treatments for COVID-19, including vulnerability to supply chain disruptions, higher manufacturing costs, difficulties in manufacturing sufficient quantities of our therapies, restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us. Expedited authorization processes, including our EUAs for bamlanivimab and bamlanivimab and etesevimab administered together, have allowed restricted distribution of products with less than typical safety and efficacy data, and additional data that become available may call into question the safety or effectiveness of our COVID-19 therapies. Additionally, the availability of superior or competitive therapies, or preventative measures, such as vaccines, coupled with the transient nature of pandemics, could negatively impact or eliminate demand for our COVID-19 therapies. In addition, we may be required to accept returns of certain product previously shipped pursuant to EUAs if the relevant EUA is revoked or terminated. Mutations or the spread of other variants of the coronavirus could also render our therapies ineffective. Any of these risks could prevent us from recouping our substantial investments in the research, development, and manufacture of our COVID-19 therapies. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to operate without significant negative impacts will in part depend on our ability to protect our employees and our supply chain. We have taken steps to protect our employees worldwide, with particular measures in place for those working in our manufacturing sites and distribution facilities. For 2020, we were able to largely maintain our normal operations. However, uncertainty resulting from the COVID-19 pandemic could have an adverse impact on our manufacturing operations, global supply chain, and distribution systems, which could impact our ability to produce and distribute our products and the ability of third parties on which we rely to fulfill their obligations to us, and could increase our expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the COVID-19 pandemic has affected our operations and demand for our products, it has not negatively impacted our liquidity position. We expect to continue to generate cash flows to meet our short-term liquidity needs and to have access to liquidity via the short-term and long-term debt markets. We also have not observed any material impairments of our assets or significant changes in the fair value of assets due to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree to which the COVID-19 pandemic will continue to impact our business operations, financial results, and liquidity will depend on future developments, is highly uncertain, and cannot be predicted due to, among other things, the duration and severity of the pandemic, the actions taken to reduce its transmission, including widespread availability of vaccines, and the speed with which, and extent to which, more stable economic and operating conditions resume. Should the COVID-19 pandemic and any associated recession or depression continue for a prolonged period, our results of operations, financial condition, liquidity, and cash flows could be materially impacted by lower revenues and profitability and a lower likelihood of effectively and efficiently developing and launching new medicines. See &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K for additional information on risk factors that could impact our results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elanco Animal Health (Elanco) Disposition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer. As a result, we recognized a gain on the disposition of approximately $3.7 billion in the first quarter of 2019 and now operate as a single segment. See Note 19 to the consolidated financial statements for further discussion. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our key operating results:</span></div><div style="margin-bottom:5pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:54.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.697%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,539.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,056.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,598.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,206.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,808.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">660.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">131.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,229.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,036.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,193.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,637.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,193.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,318.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS from continuing operations</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.96&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased in 2020 driven by increased volume, partially offset by lower realized prices. Operating expenses, defined as the sum of research and development and marketing, selling, and administrative expenses, increased in 2020, driven primarily by approximately $450 million of development expenses for COVID-19 therapies. The decreases in net income and EPS in 2020 were driven primarily by the approximately $3.7 billion gain recognized on the disposition of Elanco in 2019, partially offset by higher gross margin and higher other income in 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlighted items affect comparisons of our 2020 and 2019 financial results:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development (IPR&amp;D) (Note 3 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $660.4 million resulting from the acquisitions of Disarm Therapeutics, Inc. (Disarm) and a pre-clinical stage company as well as collaborations with Innovent Biologics, Inc. (Innovent), Sitryx Therapeutics Limited (Sitryx), Fochon Pharmaceuticals, Ltd. (Fochon), AbCellera Biologics Inc. (AbCellera), Evox Therapeutics Ltd (Evox), and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $131.2 million primarily related to severance costs incurred as a result of actions taken worldwide to reduce our cost structure, as well as acquisition and integration costs incurred as part of the acquisition of Dermira, Inc. (Dermira).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (Note 18 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $1.44 billion of net investment gains on equity securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019 </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D (Note 3 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $239.6 million resulting from collaborations with AC Immune SA (AC Immune), Centrexion Therapeutics Corporation (Centrexion), ImmuNext, Inc. (ImmuNext), and Avidity Biosciences, Inc. (Avidity). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (Note 5 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $575.6 million primarily associated with the accelerated vesting of Loxo Oncology, Inc. (Loxo) employee equity awards as part of the acquisition of Loxo.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (Note 18 to the consolidated financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $401.2 million of net investment gains on equity securities. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a gain of $309.8 million on the sale of our antibiotics business in China. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a debt extinguishment loss of $252.5 million related to the repurchase of debt. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Income from Discontinued Operations (Note 19 to the consolidated financial statements)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a gain related to the disposition of Elanco of approximately $3.7 billion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new molecular entities (NMEs) and diagnostic agent are currently in Phase III clinical trials or have been submitted for regulatory review or have received first regulatory approval in the U.S., Europe, or Japan in 2020. In addition, the following table includes certain NMEs currently in Phase II clinical trials. The following table reflects the status of these NMEs and diagnostic agent, including certain other developments since January&#160;1, 2020.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.278%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COVID-19 Therapies </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The FDA granted EUA for higher-risk patients recently diagnosed with mild-to-moderate COVID-19 in the fourth quarter of 2020.  Announced in January 2021 that a Phase III trial met the primary and all key secondary endpoints. Additional Phase III trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab and etesevimab administered together</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in January 2021 that a Phase III trial met the primary and all key secondary endpoints. The FDA granted EUA for higher-risk patients recently diagnosed with mild-to-moderate COVID-19 in January 2021. Additional Phase III trials are ongoing. We intend to submit to the FDA for approval in the second half of 2021. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Endocrinology</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultra-rapid Lispro (Lyumjev</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched in Japan in the second quarter of 2020 and in the U.S. and Europe in the third quarter of 2020. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:53pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the fourth quarter of 2020 and in February 2021 that Phase III trials met the primary and all key secondary endpoints. Additional Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal Insulin-Fc</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.278%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in Dermira acquisition in February 2020. The FDA granted Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's Disease</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Psoriasis</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the third quarter of 2020 that Phase III trials met the primary and all key secondary endpoints. Additional Phase III trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CXCR1/2 Ligands Monoclonal Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis Suppurativa</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the third quarter of 2020.  </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL-2 Conjugate</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic Lupus Erythematosus</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Neuroscience</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lasmiditan (Reyvow</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute treatment of migraine</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Launched</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Received Schedule V classification from the Drug Enforcement Agency and launched in the U.S. in the first quarter of 2020. Submitted in Europe and Japan in the fourth quarter of 2020.</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flortaucipir (Tauvid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer's disease diagnostic</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched in the U.S. in the fourth quarter of 2020. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tanezumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osteoarthritis pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted to the FDA in 2019. The FDA intends to hold an Advisory Committee meeting, expected to occur in March 2021, to discuss the submission. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2020 that a Phase III trial for people with dominantly inherited Alzheimer's disease (DIAD) did not meet the primary endpoint. We do not plan to pursue submission for DIAD. Phase III trial is ongoing for Anti-Amyloid Treatment in Asymptomatic Alzheimer's.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer&#8217;s disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in January 2021 that a Phase II trial met the primary endpoint. Additional Phase II trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epiregulin/TGFa mAb</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials initiated in the third quarter of 2020. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACAP38 Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the fourth quarter of 2020. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials initiated in the fourth quarter of 2020. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zagotenemab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer&#8217;s disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted accelerated approval</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> by the FDA based on Phase II data and launched in the U.S. in the second quarter of 2020. Submitted in Japan in the fourth quarter of 2020. Granted conditional marketing authorisation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe in February 2021. Phase III trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOXO-305</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hematological cancers</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the second quarter of 2020. Presented positive data at the American Society of Hematology Annual Meeting in the fourth quarter of 2020. </span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Almirall, S.A. (Almirall) in Europe.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Fast Track designation is designated to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Pfizer, Inc.  </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration with Innovent, we plan to pursue registration of sintilimab injection (Tyvyt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in the U.S. and other markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products are currently in Phase II or Phase III clinical testing, have been submitted for regulatory review, or have received first regulatory approval in the U.S., Europe, or Japan for use in the indication described in 2020. The following table reflects the status of certain NILEX products, including certain other developments since January 1, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Endocrinology</span></td></tr><tr style="height:33pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with reduced ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S., Europe and Japan in the fourth quarter of 2020.</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing.</span></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr style="height:68pt"><td colspan="3" rowspan="4" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baricitinib (Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2020 that a Phase III trial met the primary and all key secondary endpoints. Submitted in the U.S. in the second quarter of 2020. Approved in Europe in the third quarter of 2020 and in Japan in the fourth quarter of 2020.</span></div></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The FDA granted EUA in combination with remdesivir in hospitalized COVID-19 patients in the fourth quarter of 2020.</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alopecia areata</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The FDA granted Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing.</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:42pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjuvant breast cancer</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Submitted</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the second quarter of 2020 that a Phase III trial met the primary endpoint. Submitted in the U.S. and Europe in the fourth quarter of 2020. </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trials are ongoing. </span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designated to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many difficulties and uncertainties inherent in pharmaceutical research and development and the introduction of new products, as well as a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, limited scope of approved uses, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies continue to establish high hurdles for the efficacy and safety of new products. Delays and uncertainties in drug approval processes can result in delays in product launches and lost market opportunity. In addition, it can be very difficult to predict revenue growth rates of new products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage research and development spending across our portfolio of potential new medicines. A delay in, or termination of, any one project will not necessarily cause a significant change in our total research and development spending. Due to the risks and uncertainties involved in the research and development process, we cannot reliably estimate the nature, timing, and costs of the efforts necessary to complete the development of our research and development projects, nor can we reliably estimate the future potential revenue that will be generated from any successful research and development project. Each project represents only a portion of the overall pipeline, and none is individually material to our consolidated research and development expense. While we do accumulate certain research and development costs on a project level for internal reporting purposes, we must make significant cost estimations and allocations, some of which rely on data that are neither reproducible nor validated through accepted control mechanisms. Therefore, we do not have sufficiently reliable data to report on total research and development costs by project, by preclinical versus clinical spend, or by therapeutic category.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our formulation patents for Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expired in December 2018, and our use patents expired in August 2019 in major European markets and the U.S. Both the formulation patent and the use patent expired in August 2019 in Japan. We expect further volume decline as a result of the anticipated entry of generic and biosimilar competition following the loss of patent exclusivity in these markets. In the aggregate, we expect that the decline in revenue will have a material adverse effect on our consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vitamin regimen patents, which we expect to provide us with patent protection for Alimta through June 2021 in Japan and major European countries, and through May 2022 in the U.S., have been challenged in each of these jurisdictions. In the U.S., most challenges have been finally resolved in our favor, and one remains in active litigation. We and Eagle Pharmaceuticals, Inc. (Eagle) reached an agreement in December 2019 to settle all pending litigation, allowing Eagle a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition in the U.S. either from an unfavorable outcome to the patent challenge or following the loss of patent exclusivity, will cause a rapid and severe decline in revenue and have a material adverse effect on our consolidated results of operations and cash flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that generic competitors may choose to attempt a launch at risk. Following a final decision in the Supreme Court of Germany in July 2020 overturning the lower court and upholding the validity of our Alimta patent, several generics that were on the market at risk in Germany left. We have removed the remaining generics from the market in Germany by obtaining preliminary injunctions in our favor. In September 2020, the Paris Court of First Instance in France issued a final decision upholding the validity of our Alimta patent and found infringement by Fresenius Kabi France and Fresenius Kabi Groupe France&#8217;s (collectively, Kabi) pemetrexed product. The court issued an injunction against Kabi and provisionally awarded us damages. In January 2021, that same court issued a preliminary injunction against Zentiva France S.A.S. (Zentiva), the last remaining company with a generic pemetrexed product on the French market, and provisionally awarded us damages. In October 2020, the Court of Appeal of the Netherlands overturned a lower court decision and ruled that our Alimta patent is valid and infringed and reinstated an injunction against Kabi, thereby removing Kabi's pemetrexed product from the Netherlands market. Kabi has appealed this decision to the Netherlands Supreme Court. Kabi's generic pemetrexed product was the only at risk generic on the market in the Netherlands. Our vitamin regimen patents have also been challenged in other smaller European jurisdictions. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that further entry of generic competition for Alimta in major European markets following either the loss of effective patent protection or of patent exclusivity will cause a rapid and severe decline in revenue. See Note 16 to the consolidated financial statements for a more detailed account of the legal proceedings currently pending in the U.S., Europe, and Japan regarding, among others, our Alimta patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compound patent for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A competitor launched a similar version of insulin lispro in certain European markets in 2017 and in the U.S. in the second quarter of 2018. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patent protection for Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in Japan in January 2020. We expect generics to enter the market in mid-2021. We expect that the entry of generic competition will cause a rapid and severe decline in revenue and will have a material adverse effect on our consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Rates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro and Japanese yen. While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on our revenue, cost of sales, and operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could negatively impact our future consolidated results of operations and cash flows. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., public concern over access to and affordability of pharmaceuticals continues to drive the regulatory and legislative debate.&#160;These policy and political issues increase the risk that taxes, fees, rebates, or other cost control measures may be enacted to manage federal and state budgets. Key health policy initiatives affecting biopharmaceuticals include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Coronavirus Aid, Relief, and Economic Security (CARES) Act and subsequent stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis, </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign reference pricing in Medicare and private insurance,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modifications to Medicare Parts B and D,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provisions that would allow the Department of Health and Human Services (HHS) to negotiate prices for biologics and drugs in Medicare,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reduction in biologic data exclusivity,</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proposals related to Medicaid prescription drug coverage and manufacturer drug rebates,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proposals that would require biopharmaceutical manufacturers to disclose proprietary drug pricing information, and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state-level proposals related to prescription drug prices and reducing the cost of pharmaceuticals purchased by government health care programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2020 and September 13, 2020, former U.S. President Donald Trump signed Executive Orders related to the 340B Prescription Drug Program, rebate reform in Medicare Part D, drug importation including insulin, and foreign reference pricing in Medicare Part B and Part D. Although their current status is unclear given the change in presidential administration, these Executive Orders, if implemented, could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. On September 1, 2020, Lilly announced it would distribute all 340B ceiling priced products directly to covered entities and their child sites only. Lilly provides 340B discounts to a contract pharmacy only if it is a wholly owned subsidiary of a covered entity, if a covered entity does not have an in-house pharmacy or, in the case of insulin, if the subject covered entity and its contract pharmacies agree to pass along the discount to patients without any markup for dispensing fees and without billing insurance or collecting duplicate discounts. Lilly has been transparent with regulators on its distribution activity and continues to comply with all 340B program requirements. Certain covered entities and their trade associations have threatened litigation, questioning whether Lilly&#8217;s program, and similar actions by other manufacturers, violate 340B program requirements. On October 9, 2020, three covered entities sued HHS and the Health Resources and Services Administration (HRSA) in the U.S. District Court for the District of Columbia seeking to compel the agencies to take enforcement action against Lilly and three other companies, among other requested relief. On October 21, 2020, a trade association representing certain covered entities sued HHS in the same court seeking to compel the agency to promulgate administrative dispute resolution regulations. On December 11, 2020, a number of associations and entities filed suit against HHS in the U.S. District Court for the Northern District of California requesting immediate enforcement of the contract pharmacy guidance. On December 31, 2020, the General Counsel of HHS issued an advisory opinion alleging that honoring contract pharmacy agreements is mandatory. In January 2021, Lilly filed suit against HHS, the Secretary of HHS, the HRSA, and the Administrator of the HRSA in the U.S. District Court for the Southern District of Indiana seeking a declaratory judgment that HHS's attempt to require manufacturers to permit contract pharmacy distribution is unlawful and a preliminary injunction enjoining implementation of the alternative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. The cases are pending and the impact of these cases and any subsequent litigation is uncertain. See Note 16 to the consolidated financial statements for additional information.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California and several other states have enacted legislation related to prescription drug pricing transparency and it is unclear the effect this legislation will have on our business. Several states have also passed importation legislation, including Colorado, Florida, Maine, New Hampshire, New Mexico, and Vermont. As of late 2020 several of these states were actively working with the former presidential administration to implement an importation program from Canada. On November 22, 2020, Florida announced it submitted a proposed importation plan to the U.S. In 2020, HHS and the FDA also took several actions to advance state importation initiatives, including issuing requests for proposals for personal importation and reimportation of insulin and a final rule on the Importation of Prescription Drugs. Additionally, on November 27, 2020, the Canadian Minister of Health issued an interim order to ensure that participation in bulk importation frameworks, such as the one recently established by the U.S., does not cause or exacerbate a drug shortage in Canada. We continue to review these state proposals and legislation, as well as federal rules and guidance published by HHS and the FDA, the impact of which is uncertain at this time. Currently, it is unclear if the current presidential administration will adopt any of the importation initiatives put forth by the former presidential administration. We will continue to monitor and assess these developments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the private sector, consolidation and integration among healthcare providers significantly affects the competitive marketplace for pharmaceuticals.&#160;Health plans, pharmacy benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance.&#160;Private third-party insurers, as well as governments, typically maintain formularies that specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to control costs by negotiating discounted prices in exchange for formulary inclusion. Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels, and higher deductibles. Consequently, pharmaceutical companies compete for formulary placement not only on the basis of product attributes such as efficacy, safety profile, or patient ease of use, but also by providing rebates. Value-based agreements, where pricing is based on achievement (or not) of specified outcomes, are another tool that may be utilized between payers and pharmaceutical companies as formulary placement and pricing are negotiated. Price is an increasingly important factor in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. We expect these downward pricing pressures will continue to negatively affect our consolidated results of operations. In addition to formulary placement, changes in insurance designs continue to drive greater consumer cost-sharing through high deductible plans and higher co-insurance or co-pays. We continue to invest in patient affordability solutions (resulting in lower revenue) in an effort to assist patients in affording their medicines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main coverage expansion provisions of the Affordable Care Act (ACA) are currently in effect through both state-based exchanges and the expansion of Medicaid.&#160;A trend has been the prevalence of benefit designs containing high out-of-pocket costs for patients, particularly for pharmaceuticals. In addition to the coverage expansions, many employers in the commercial market continue to evaluate strategies such as private exchanges and wider use of consumer-driven health plans to reduce their healthcare liabilities over time.&#160;Federal legislation, litigation, or administrative actions to repeal or modify some or all of the provisions of the ACA could have a material adverse effect on our consolidated results of operations and cash flows. At the same time, the broader paradigm shift towards performance-based reimbursement and the launch of several value-based purchasing initiatives have placed demands on the pharmaceutical industry to offer products with proven real-world outcomes data and a favorable economic profile.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International operations also are generally subject to extensive price and market regulations.&#160;Cost-containment measures exist in a number of countries, including additional price controls and mechanisms to limit reimbursement for our products.&#160;Such policies are expected to increase in impact and reach, given the pressures on national and regional health care budgets that come from a growing, aging population and ongoing economic challenges. As additional reforms are finalized, we will assess their impact on future revenues. In addition, governments in many emerging markets are becoming increasingly active in expanding health care system offerings.&#160;Given the budget challenges of increasing health care coverage for citizens, policies may be proposed that promote generics and biosimilars only and reduce current and future access to branded pharmaceutical products. The COVID-19 pandemic is also creating additional pressure on health systems worldwide. As a result, cost containment and other measures may intensify as governments manage and emerge from the pandemic.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations could affect our effective tax rate, results of operations, and cash flows. Countries around the world, including the U.S., are actively considering and enacting tax law changes. The current presidential administration's tax proposal contains significant changes, including the rate at which income of U.S. companies would be taxed. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax policy in countries in which we operate. In addition, global tax authorities routinely examine our tax returns and are expected to become more aggressive in their examinations of profit allocations among jurisdictions, which could affect our anticipated tax liabilities.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strategically invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including acquisitions, strategic alliances, collaborations, investments, and licensing arrangements. We view our business development activity as an important way to achieve our strategies, as we seek to bolster our pipeline and enhance shareholder value. We continuously evaluate business development transactions that have the potential to strengthen our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we acquired all shares of Loxo for a purchase price of $6.92 billion, net of cash acquired. Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib, an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we acquired all shares of Dermira for a purchase price of $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cloth, a medicated cloth for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail Therapeutics Inc. (Prevail) for a purchase price of approximately $880 million in cash plus one non-tradable contingent value right (CVR). The CVR entitles Prevail stockholders to up to an additional approximately $160 million payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. Under the terms of the agreement, we acquired a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated financial statements for further discussion regarding our recent acquisitions.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">44</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results&#8212;2020 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,229.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,310.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,596.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,539.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the revenue increase in 2020 was driven by increased volume primarily for Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, bamlanivimab, and Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Excluding bamlanivimab revenue, U.S. revenue grew 5 percent. The increase in revenue due to volume was partially offset by a decrease in realized prices. The decrease in realized prices in the U.S. was primarily driven by increased rebates to gain and maintain broad commercial access across the portfolio and, to a lesser extent, unfavorable segment mix and changes to estimates for rebates and discounts, most notably impacting Humalog. The decrease in realized prices in the U.S. was partially offset by modest list price increases and lower utilization in the 340B segment. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the revenue increase in 2020 was driven by increased volume primarily for Tyvyt, Trulicity, Alimta, and Olumiant. The increase in revenue due to volume was partially offset by lower realized prices primarily for Tyvyt and Alimta. The increase in volume and decrease in realized prices for Tyvyt and Alimta was driven primarily by their inclusion in government reimbursement programs in China. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity in 2020 compared with 2019:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:35.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside&#160;U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,835.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,232.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,068.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,485.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,140.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,625.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,265.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,064.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,329.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,288.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,788.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">866.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,259.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">533.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,153.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">842.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">282.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,124.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">510.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">536.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,046.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">618.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">912.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">871.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">725.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">767.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">575.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">638.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">545.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">607.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">480.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">536.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">406.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">362.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">358.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">548.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,099.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,648.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,229.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,310.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,539.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not meaningful</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Bamlanivimab sales are pursuant to EUA.  </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Trajenta revenue includes Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity, a treatment for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, increased 22 percent in the U.S., driven by increased volume, partially offset by lower realized prices primarily due to higher contracted rebates. Revenue outside the U.S. increased 27 percent, primarily driven by increased volume.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humalog, an injectable human insulin analog for the treatment of diabetes, decreased 11 percent in the U.S., driven by lower realized prices, partially offset by higher demand. Revenue outside the U.S. decreased 1 percent, primarily driven by the unfavorable impact of foreign exchange rates. Included in the revenue of Humalog in the U.S. are our own insulin lispro authorized generics, which began launching in the second quarter of 2019 in order to lower out-of-pocket costs for patients. While it is difficult to estimate the severity of the impact of similar insulin lispro products entering the market, we do not expect and have not experienced a rapid severe decline in revenue. However, due to the impact of competition and due to pricing pressure in the U.S. and some international markets, we expect some price decline and loss of market share to continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Alimta, a treatment for various cancers, increased 4 percent in the U.S., primarily driven by higher realized prices. Revenue outside the U.S. increased 19 percent, primarily driven by increased volume in China and Germany, partially offset by lower realized prices. We will lose our patent protection for Alimta in Japan and major European countries in June 2021. We expect the limited entry of generic competition in the U.S. starting February 2022 and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition following the loss of exclusivity will cause a rapid and severe decline in revenue. See "Results of Operations - Executive Overview - Other Matters" for more information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis, increased 27 percent in the U.S., primarily driven by increased demand. Revenue outside the U.S. increased 43 percent, primarily driven by increased volume. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humulin, an injectable human insulin for the treatment of diabetes, decreased 2 percent in the U.S., driven by lower realized prices, partially offset by higher volume. Revenue outside the U.S. decreased 4 percent, driven by decreased volume and the unfavorable impact of foreign exchange rates, partially offset by higher realized prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance, a treatment for type 2 diabetes and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, increased 10 percent in the U.S., driven by increased volume. Revenue outside the U.S. increased 41 percent, driven primarily by increased volume. See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Basaglar, a long-acting human insulin analog for the treatment of diabetes, decreased 4 percent in the U.S., driven by lower realized prices. Revenue outside the U.S. increased 19 percent, driven primarily by increased volume. See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim involving Basaglar. A competitor launched a similar version of glargine in the U.S. in 2020. Due to the impact of competitive pressures, we expect some price decline and loss of market share over time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women, decreased 21 percent in the U.S., primarily driven by decreased demand. Revenue outside the U.S. decreased 29 percent, driven by decreased volume and, to a lesser extent, lower realized prices. We expect further volume declines as a result of the anticipated entry of generic and biosimilar competition due to the loss of patent exclusivity in the U.S., Japan, and major European markets. See "Executive Overview - Other Matters - Patent Matters" for more information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Cyramza, a treatment for various cancers, increased 14 percent in the U.S., driven primarily by increased demand and, to a lesser extent, higher realized prices. Revenue outside the U.S. increased 10 percent, driven primarily by increased volume. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio, a treatment for HR+, HER2- metastatic breast cancer, increased 36 percent in the U.S., driven by increased demand and, to a lesser extent, higher realized prices. Revenue outside the U.S. increased $169.5 million driven by higher volume.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue was 77.7 percent in 2020, a decrease of 1.1 percentage points compared with 2019, primarily due to the impact of lower realized prices on revenue, the unfavorable effect of foreign exchange rates on international inventories sold, and higher intangibles amortization expense related to Retevmo, partially offset by charges in 2019 resulting from the withdrawal of Lartruvo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and greater manufacturing efficiencies. Gross margin percent for 2020 was also negatively impacted as a result of bamlanivimab sales in the fourth quarter of 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased 9 percent to $6.09 billion in 2020, driven primarily by approximately $450 million of development expenses for COVID-19 therapies. Excluding these expenses related to COVID-19 therapies, research and development expenses were relatively flat. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses decreased 1 percent to $6.12 billion in 2020 primarily due to lower marketing activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D charges of $660.4 million in 2020 resulting from the acquisitions of Disarm and a pre-clinical stage company as well as collaborations with Innovent, Sitryx, Fochon, AbCellera, Evox, and Junshi Biosciences. In 2019, we recognized acquired IPR&amp;D charges of $239.6 million resulting from collaborations with AC Immune, Centrexion, ImmuNext, and Avidity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $131.2 million in 2020. The charges were primarily related to severance costs incurred as a result of actions taken worldwide to reduce our cost structure, as well as acquisition and integration costs incurred as part of the acquisition of Dermira. In 2019, we recognized $575.6 million of asset impairment, restructuring, and other special charges primarily associated with the accelerated vesting of Loxo employee equity awards as part of the acquisition of Loxo.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8212;net, (income) expense was income of $1.17 billion in 2020 compared to income of $291.6 million in 2019 primarily driven by higher net gains on investment securities.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate was 14.3 percent in 2020, compared with an effective tax rate of 11.9 percent in 2019 driven by net discrete tax benefits in 2019. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results&#8212;2019 </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our results of operations pertaining to 2019 and 2018 see Item 7, "Management's Discussion and Analysis of Results of Operations and Financial Condition" in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10xk.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2019.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">48</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND LIQUIDITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements, which include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">working capital requirements, including related to employee payroll, clinical trials, manufacturing materials, and taxes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital expenditures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share repurchases and dividends;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repayment of outstanding short-term and long-term borrowings; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contributions to our defined benefit pension and retiree health benefit plans;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">milestone and royalty payments; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential business development activities, including acquisitions, strategic alliances, collaborations, investments, and licensing arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management continuously evaluates our liquidity and capital resources, including our access to external capital, to ensure we can adequately and efficiently finance our capital requirements. As of December 31, 2020, our material cash requirements primarily related to purchases of goods and services to produce our products and conduct our operations, capital equipment expenditures, dividends, repayment of outstanding borrowings, the remaining obligations for the one-time repatriation transition tax (also known as the 'Toll Tax') from the Tax Cuts and Jobs Act (2017 Tax Act), leases, unfunded commitments to invest in venture capital funds, and retirement benefits (see Notes 11, 14, 10, 7, and 15 to the consolidated financial statements). We anticipate our cash requirements related to ordinary course purchases of goods and services and capital equipment expenditures will be consistent with our past levels relative to revenues. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents increased to $3.66 billion as of December&#160;31, 2020, compared with $2.34 billion at December&#160;31, 2019. Net cash provided by operating activities was $6.50 billion in 2020, compared with $4.84 billion in 2019. Net cash provided by operating activities in 2019 included approximately $360 million of cash paid to settle the accelerated vesting of Loxo employee equity awards (see Note 5 to the consolidated financial statements). Refer to the consolidated statements of cash flows for additional details on the significant sources and uses of cash for the years ended December&#160;31, 2020 and 2019. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $2.99 billion and $2.06 billion as of December&#160;31, 2020 and 2019, respectively. See Note 7 to the consolidated financial statements for additional details.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we completed our acquisition of Dermira for&#160;$18.75&#160;per share, or approximately&#160;$1.1 billion, which was funded through cash on hand and the issuance of commercial paper. In February 2019, we completed our acquisition of Loxo for $235 per share or approximately $6.9 billion, which was funded through a mixture of cash and debt. See Note 3 to the consolidated financial statements for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, total debt was $16.60 billion, an increase of $1.28 billion compared with $15.32&#160;billion at December&#160;31, 2019. The increase primarily related to the net proceeds from the issuance of $1.00 billion of 2.25 percent fixed-rate notes in May 2020, as well as the net proceeds from the issuance of an additional $250.0 million of 2.25 percent fixed-rate notes and the issuance of $850.0 million of 2.50 percent fixed-rate notes in August 2020. We used the net proceeds from the sale of these notes for general corporate purposes, which included the repayment of outstanding commercial paper used to fund a portion of the purchase price for our acquisition of Dermira. See Note 11 to the consolidated financial statements for additional information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had a total of $5.24 billion of unused committed bank credit facilities, $5.00 billion of which is available to support our commercial paper program. See Note 11 to the consolidated financial statements for additional details. We believe that amounts accessible through existing commercial paper markets should be adequate to fund any short-term borrowing needs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consecutive year, we distributed dividends to our shareholders. Dividends of $2.96 per share and $2.58 per share were paid in 2020 and 2019, respectively. In the fourth quarter of 2020, effective for the dividend to be paid in the first quarter of 2021, the quarterly dividend was increased to $0.85 per share, resulting in an indicated annual rate for 2021 of $3.40 per share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures of $1.39 billion during 2020, compared to $1.03 billion in 2019.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we repurchased $500.0 million of shares under our $8.00 billion share repurchase program authorized in June 2018. As of December&#160;31, 2020, we had $1.00 billion remaining under this program. See Note 13 to the consolidated financial statements for additional details.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer, which resulted in a reduction in shares of our common stock outstanding by approximately 65 million as of that date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we completed our acquisition of Prevail for $22.50 per share, or approximately $880 million in cash, plus one non-tradable CVR that entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions. This acquisition was funded primarily through cash on hand and the issuance of commercial paper. See Note 3 to the consolidated financial statements for additional information.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Results of Operations - Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; and various international government funding levels. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates, currency values, and fair values of equity securities. These fluctuations can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of this risk management program is to limit the impact on earnings of fluctuations in interest and currency exchange rates. All derivative activities are for purposes other than trading.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt positions and may enter into interest rate derivatives to help maintain that balance. Based on our overall interest rate exposure at December&#160;31, 2020 and 2019, including derivatives and other interest rate risk-sensitive instruments, a hypothetical 10 percent change in interest rates applied to the fair value of the instruments as of December&#160;31, 2020 and 2019, respectively, would not have a material impact on earnings, cash flows, or fair values of interest rate risk-sensitive instruments over a one-year period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency risk exposure results from fluctuating currency exchange rates, primarily the U.S. dollar against the euro and Japanese yen. We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We&#160;may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates (principally the euro and the Japanese yen). Our corporate risk-management policy outlines the minimum and maximum hedge coverage of such exposures. Gains and losses on these derivative contracts offset, in part, the impact of currency fluctuations on the existing assets and liabilities. We periodically analyze the fair values of the outstanding foreign currency derivative contracts to determine their sensitivity to changes in foreign exchange rates. A hypothetical 10 percent change in exchange rates (primarily against the U.S. dollar) applied to the fair values of our outstanding foreign currency derivative contracts as of December&#160;31, 2020 and 2019, would not have a material impact on earnings, cash flows, or financial position over a one-year period. This sensitivity analysis does not consider the impact that hypothetical changes in exchange rates would have on the underlying foreign currency denominated transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fair value risk exposure relates primarily to our public equity investments and to equity investments that do not have readily determinable fair values. As of December 31, 2020 and 2019, our carrying values of these investments were $2.04 billion and $1.12 billion, respectively. A hypothetical 20 percent change in fair value of the equity instruments would have impacted other-net, (income) expense by $407.6 million and $224.7 million as of December 31, 2020 and 2019, respectively.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and collaborate on potential products still in development and enter into research and development arrangements with third parties that often require milestone and royalty payments to the third party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required contingent upon the successful achievement of an important point in the development life cycle of the pharmaceutical product (e.g., approval for marketing by the appropriate regulatory agency or upon the achievement of certain sales levels). If required by the arrangement, we may make royalty payments based upon a percentage of the sales of the product in the event that regulatory approval for marketing is obtained. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individually, these arrangements are generally not material in any one annual reporting period. However, if milestones for multiple products covered by these arrangements were reached in the same reporting period, the aggregate expense or aggregate milestone payments made could be material to our results of operations or cash flows, respectively, in that period. See Note 4 to the consolidated financial statements for additional details. These arrangements often give us the discretion to unilaterally terminate development of the product, which would allow us to avoid making the contingent payments; however, we are unlikely to cease development if the compound successfully achieves milestone objectives. We also note that, from a business perspective, we view these payments as positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate cash flows from sales of products.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">51</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APPLICATION OF CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our financial statements in accordance with accounting principles generally accepted in the U.S. (GAAP), we must often make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be subjective and complex, and consequently actual results could differ from those estimates. For any given individual estimate or assumption we make, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop different estimates. We believe that, given current facts and circumstances, it is unlikely that applying any such other reasonable judgment would cause a material adverse effect on our consolidated results of operations, financial position, or liquidity for the periods presented in this report. Our most critical accounting estimates have been discussed with our audit committee and are described below.</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition and Sales Return, Rebate, and Discount Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. For product sales to customers, provisions for returns, rebates and discounts are established in the same period the related product sales are recognized. To determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates. The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback contracts in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to the consolidated financial statements for further information on revenue recognition and sales return, rebate, and discount accruals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances. Our global rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet. Our global sales return liability is included in other current liabilities and other noncurrent liabilities on our consolidated balance sheet. As of December&#160;31, 2020, a 5 percent change in our global sales return, rebate, and discount liability would have led to an approximate $313 million effect on our income before income taxes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of our global sales return, rebate, and discount liability resulting from sales of our products in the U.S. was approximately 90 percent as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a roll-forward of our most significant U.S. sales return, rebate, and discount liability balances, including managed care, Medicare, Medicaid, chargebacks, and patient assistance programs:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:75.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales return, rebate, and discount liabilities, beginning of year</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,635.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of net sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,668.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,490.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,903.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,525.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales return, rebate, and discount liabilities, end of year</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,400.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,635.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments of the estimates for these returns, rebates, and discounts to actual results were less than 2 percent of consolidated net sales for each of the years presented.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Litigation Liabilities and Other Contingencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product litigation liabilities and other contingencies are, by their nature, uncertain and based upon complex judgments and probabilities. The factors we consider in developing our product litigation liability reserves and other contingent liability amounts include the merits and jurisdiction of the litigation, the nature and the number of other similar current and past matters, the nature of the product and the current assessment of the science subject to the litigation, and the likelihood of settlement and current state of settlement discussions, if any. In addition, we accrue for certain product liability claims incurred, but not filed, to the extent we can formulate a reasonable estimate of their costs based primarily on historical claims experience and data regarding product usage. We accrue legal defense costs expected to be incurred in connection with significant product liability contingencies when both probable and reasonably estimable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also consider the insurance coverage we have to diminish the exposure for periods covered by insurance. In assessing our insurance coverage, we consider the policy coverage limits and exclusions, the potential for denial of coverage by the insurance company, the financial condition of the insurers, and the possibility of and length of time for collection. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products. In addition to insurance coverage, we consider any third-party indemnification to which we are entitled or under which we are obligated. With respect to our third-party indemnification rights, these considerations include the nature of the indemnification, the financial condition of the indemnifying party, and the possibility of and length of time for collection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The litigation accruals and environmental liabilities and the related estimated insurance recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether acquisitions or licensing transactions should be accounted for as a business combination or as an asset acquisition, we make certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the acquired set of activities and assets meets the definition of a business, assets acquired and liabilities assumed are required to be recorded at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an acquisition of assets and, therefore, any acquired IPR&amp;D that does not have an alternative future use is charged to expense at the acquisition date, and goodwill is not recorded. Refer to Note 3 to the consolidated financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as estimated asset lives, can materially affect our consolidated results of operations. The fair values of intangible assets, including acquired IPR&amp;D, are determined using information available near the acquisition date based on estimates and assumptions that are deemed reasonable by management. Significant estimates and assumptions include, but are not limited to, probability of technical success, revenue growth and discount rate. Depending on the facts and circumstances, we may deem it necessary to engage an independent valuation expert to assist in valuing significant assets and liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets are primarily determined using an "income method," as described in Note 8 to the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Indefinite-Lived and Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset (or asset group) may not be recoverable. We identify impairment by comparing the projected undiscounted cash flows to be generated by the asset (or asset group) to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset&#8217;s net book value over its fair value, and the cost basis is adjusted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several methods may be used to determine the estimated fair value of acquired IPR&amp;D, all of which require multiple assumptions. We utilize the &#8220;income method,&#8221; as described in Note 8 to the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired IPR&amp;D assets, the risk of failure has been factored into the fair value measure and there can be no certainty that these assets ultimately will yield a successful product, as discussed previously in &#8220;Results of Operations - Executive Overview - Late-Stage Pipeline." The nature of the pharmaceutical business is high-risk and requires that we invest in a large number of projects to maintain a successful portfolio of approved products. As such, it is likely that some acquired IPR&amp;D assets will become impaired in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates of future cash flows, based on what we believe to be reasonable and supportable assumptions and projections, require management&#8217;s judgment. Actual results could vary materially from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefits Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined benefit pension plan and retiree health benefit plan costs include assumptions for the discount rate, expected return on plan assets, and retirement age. These assumptions have a significant effect on the amounts reported. In addition to the analysis below, see Note 15 to the consolidated financial statements for additional information regarding our retirement benefits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annually, we evaluate the discount rate and the expected return on plan assets in our defined benefit pension and retiree health benefit plans. We use an actuarially determined, plan-specific yield curve of high quality, fixed income debt instruments to determine the discount rates. In evaluating the expected return on plan assets, we consider many factors, with a primary analysis of current and projected market conditions, asset returns and asset allocations (approximately 65 percent of which are growth investments); and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the discount rates and expected return on plan assets of other companies, where applicable. In evaluating our expected retirement age assumption, we consider the retirement ages of our past employees eligible for pension and medical benefits together with our expectations of future retirement ages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annually, we determine the fair value of the plan assets in our defined benefit pension and retiree health benefit plans. Approximately 35 percent of our plan assets are in hedge funds and private equity-like investment funds (collectively, alternative assets). We value these alternative investments using significant unobservable inputs or using the net asset value reported by the counterparty, adjusted as necessary. Inputs include underlying net asset values, discounted cash flows valuations, comparable market valuations, and adjustments for currency, credit, liquidity and other risks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the 2020 discount rate for the U.S. defined benefit pension and retiree health benefit plans (U.S. plans) were to change by a quarter percentage point, income before income taxes would change by $21.6 million. If the 2020 expected return on plan assets for U.S. plans were to change by a quarter percentage point, income before income taxes would change by $28.8 million. If our assumption regarding the 2020 expected age of future retirees for U.S. plans were adjusted by one year, our income before income taxes would be affected by $52.0 million. The U.S. plans, including Puerto Rico, represent approximately 75 percent and 80 percent of the total projected benefit obligation and total plan assets, respectively, at December&#160;31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to the fair value of plan assets are not recognized in pension and retiree health benefit expense in the year that the adjustments occur. Such changes are deferred, along with other actuarial gains and losses, and are amortized into expense over the expected remaining service life of employees.</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare and file tax returns based upon our interpretation of tax laws and regulations, and we record estimates based upon these interpretations. Our tax returns are routinely subject to examination by various taxing authorities, which could result in future tax, interest, and penalty assessments. Inherent uncertainties exist in estimates of many tax positions due to changes in tax law resulting from legislation and regulation as concluded through the various jurisdictions&#8217; tax court systems. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution. The amount of unrecognized tax benefits is adjusted for changes in facts and circumstances. For example, adjustments could result from changes to existing tax law, the issuance of regulations by the taxing authorities, new information obtained during a tax examination, or resolution of a tax examination. We believe our estimates for uncertain tax positions are appropriate and sufficient to pay assessments that may result from examinations of our tax returns. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded valuation allowances against certain of our deferred tax assets, primarily those that have been generated from net operating losses and tax credit carryforwards in certain taxing jurisdictions. In evaluating whether we would more likely than not recover these deferred tax assets, we have not assumed future taxable income in the jurisdictions associated with these carryforwards where history does not support such an assumption. Implementation of tax planning strategies to recover these deferred tax assets or to generate future taxable income in these jurisdictions could lead to the reversal of all or a portion of these valuation allowances and a reduction of income tax expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, a 5 percent change in the amount of uncertain tax positions and the valuation allowance would result in a change in net income of $83.4 million and $40.8 million, respectively.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_73"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL AND REGULATORY MATTERS </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to certain legal proceedings can be found in Note 16 to the consolidated financial statements and is incorporated here by reference.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_76"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL EXPECTATIONS FOR 2021 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the full year of 2021, we expect EPS to be in the range of $7.10 to $7.75, which excludes estimated acquisition and integration costs related to the acquisition of Prevail. We anticipate total revenue between $26.5 billion and $28.0 billion, including an estimated $1 billion to $2 billion of revenue from COVID-19 therapies. Revenue growth is expected to be driven by volume from Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Cyramza, Emgality, Tyvyt, and Retevmo, as well as by COVID-19 therapies. Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity. We expect mid-single digit net price declines globally in 2021. In the U.S., we expect low-to-mid-single digit net price declines, driven primarily by increased rebates to maintain broad commercial access and segment mix, partially offset by lower utilization in the 340B segment. Outside the U.S., we expect net price declines in China, Japan, and Europe. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that gross margin as a percent of revenue will be approximately 77 percent in 2021. Research and development expenses are expected to be in the range of $6.5 billion to $6.7 billion, including approximately $300 million to $400 million of continued investment in COVID-19 therapies. Marketing, selling, and administrative expenses are expected to be in the range of $6.2 billion to $6.4 billion. Other&#8212;net, (income) expense is expected to be expense in the range of $200 million to $300 million. The 2021 effective tax rate is expected to be approximately 15 percent.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_79"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You can find quantitative and qualitative disclosures about market risk (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> interest rate risk) at Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis - Financial Condition and Liquidity.&#8221; That information is incorporated by reference herein.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">56</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 8.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Financial Statements and Supplementary Data</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_85"></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:37.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions and shares in thousands, except per-share data)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMS00LTEtMS0w_3716c715-c3f4-488c-abc1-91b844baf37a">24,539.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMS02LTEtMS0w_f66e91ff-6da6-43a0-af55-196046989c79">22,319.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMS04LTEtMS0w_537e5cc1-aa01-42c8-8dac-9a74a06ee98b">21,493.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMy00LTEtMS0w_d26383d9-edbd-4689-b7b0-afef5527b4bf">5,483.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMy02LTEtMS0w_dd2a6442-137c-4bca-b716-8e0a88e226be">4,721.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMy04LTEtMS0w_d6891eee-8b96-43dd-836e-086c9abde013">4,681.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNC00LTEtMS0w_a3a58120-668e-47cf-b601-12aebb1a0c12">6,085.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNC02LTEtMS0w_35354b43-c4ea-46b2-a0e1-bf4dd7b4afd1">5,595.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNC04LTEtMS0w_4c360ba4-11c1-42f5-9739-2d8d46cc35f9">5,051.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNS00LTEtMS0w_d58d7ecf-21e3-4580-ad51-f1e2c486e7ce">6,121.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNS02LTEtMS0w_ca1965b3-9859-440d-9360-41ad89ae45be">6,213.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNS04LTEtMS0w_b56c0318-25b7-48a4-af18-056a0496915a">5,975.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNi00LTEtMS0w_7644fb85-2cef-46fb-86c4-b0a620b5739e">660.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNi02LTEtMS0w_7bf7be82-e73a-42f0-8500-b4e7e2021415">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNi04LTEtMS0w_555125b5-4da5-4c65-a1ce-6cff430afef1">1,983.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges <br/>(Note 5)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNy00LTEtMS0w_8fc23adb-8d3b-4cd1-b288-5a86a2eab1af">131.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNy02LTEtMS0w_7b970192-df19-44d5-b010-96dd70c3134f">575.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNy04LTEtMS0w_0bde3f06-10b1-4559-990a-34de17434d54">266.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense (Note 18)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOC00LTEtMS0w_21e9ab5f-2bb1-4aa0-a13c-eda8cce85a8d">1,171.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOC02LTEtMS0w_01871237-1092-465e-a3af-7623a6081fc2">291.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOC04LTEtMS0w_29458611-195f-4246-a3f2-0e3b8685ed8d">145.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOS00LTEtMS0w_e58cabb7-bfb0-4c75-a595-8aa918a9d7be">17,309.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOS02LTEtMS0w_253f6247-c839-438b-8f5d-6591adc34ceb">17,053.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOS04LTEtMS0w_a3303a13-1e39-4c63-8482-1d5e48d460cd">17,813.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTAtNC0xLTEtMA_b3a03f5b-f8e4-419d-b124-557f8440d2c3">7,229.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTAtNi0xLTEtMA_2b3f2ef5-dce4-4ece-a486-d8fc2bedb52a">5,265.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTAtOC0xLTEtMA_3c25438c-6a0b-47ce-84db-8796fde029ac">3,680.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 14)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTEtNC0xLTEtMA_169a7392-7255-4495-ad59-d4ee84e47b13">1,036.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTEtNi0xLTEtMA_95ff2293-7b6c-4708-b943-27faf82e646d">628.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTEtOC0xLTEtMA_71d7addd-422e-4450-a8f0-fe9cc627bf3a">529.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTItNC0xLTEtMA_65878936-09c7-4191-b971-33cc36ddd95a">6,193.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTItNi0xLTEtMA_66163094-7c65-4952-8c94-91266af63cc0">4,637.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTItOC0xLTEtMA_7461e336-ea60-4306-9064-618cecc0f968">3,150.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations (Note 19)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTMtNC0xLTEtMA_5f72cdec-5f2b-4bda-abb4-dbc896253f12">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTMtNi0xLTEtMA_b33271bc-a7d4-4811-a574-41ab536c1a82">3,680.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTMtOC0xLTEtMA_ffa4fe41-02d2-42bc-9026-99f0bb50fe48">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTQtNC0xLTEtMA_aa9be0e8-1cd6-48a2-a963-c1892051c019">6,193.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTQtNi0xLTEtMA_67b28038-7fdf-4858-8f1e-2af9de4d04bf">8,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTQtOC0xLTEtMA_0419c352-67cd-41e2-a26f-5f578afcb3ae">3,232.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="9" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings from continuing operations - basic</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTctNC0xLTEtMA_327263a1-6320-4c51-ad1e-e9ff65c6bd14">6.82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTctNi0xLTEtMA_2dc8b9cd-9baa-4453-81c8-809026fcd2e5">4.98</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTctOC0xLTEtMA_b51a4583-244a-4b6b-a444-b3b3c15f2f77">3.07</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings from discontinued operations - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTgtNC0xLTEtMA_01fd4b8a-0241-4d63-bd6a-069353b0eb65">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTgtNi0xLTEtMA_ed0a8182-f1a5-480a-975c-dd16de9c4f4f">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTgtOC0xLTEtMA_03c0ea5f-e5ee-43b7-a91e-dea51b06d3d5">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - basic</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTktNC0xLTEtMA_845c2569-31a0-405f-b270-ac5790d76728">6.82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTktNi0xLTEtMA_23f89dcb-28aa-4ca8-8ee8-fce14059f2cc">8.93</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTktOC0xLTEtMA_23f267a5-6120-4a08-a19f-b11acfe82a94">3.14</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings from continuing operations - diluted</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjEtNC0xLTEtMA_17f4c7bd-651f-4724-8a2a-4d80eb6582bb">6.79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjEtNi0xLTEtMA_d8acaabb-c408-4eee-a692-65513f739c9c">4.96</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjEtOC0xLTEtMA_87fa2e7f-d2bd-4b50-b806-d611332c9663">3.05</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings from discontinued operations - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjItNC0xLTEtMA_3db66488-54ce-4d34-92d0-ec0fa41ac127">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjItNi0xLTEtMA_f5684416-7f0b-46f4-b82a-d6d9fc90c6f6">3.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjItOC0xLTEtMA_546fd9b6-dd62-4c45-96ea-475c436fdbee">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjMtNC0xLTEtMA_73dd2064-88d9-4a24-82b8-0a30ed487c27">6.79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjMtNi0xLTEtMA_07f79549-a89d-438d-b09e-c007b0f9ec37">8.89</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjMtOC0xLTEtMA_08629497-44ed-4fb1-b656-bb8f4bd3fd40">3.13</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjYtNC0xLTEtMA_ad6f48be-d709-4427-8203-468a0b03d5e0">907,634</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjYtNi0xLTEtMA_17f28502-ecf7-4286-bd4a-b8d7fdf15cf8">931,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjYtOC0xLTEtMA_55d9f929-2364-4fe9-9fed-c65220a52a0b">1,027,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjctNC0xLTEtMA_6ef41d0a-ad6a-4796-ac82-8bb6797acc3c">912,505</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjctNi0xLTEtMA_4f5a1c21-c7c0-40c9-8bf7-b018ef34f4d3">935,684</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjctOC0xLTEtMA_ca500ee9-e0a4-4514-8d72-04f6e3a7d471">1,033,667</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">57</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMS00LTEtMS0w_a2c06e30-3e98-4462-a063-0d910978a3fc">6,193.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMS02LTEtMS0w_c3ba4f70-b78b-451f-99fb-04d3f1419e8e">8,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMS04LTEtMS0w_ee6a7c7f-9bbc-47cd-bdbf-b3b1a90ad7f4">3,232.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) from continuing operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation gains (losses)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMy00LTEtMS0w_d9e8842e-3fe4-4aba-9ed4-c61bfefcc625">122.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMy02LTEtMS0w_36b5cb12-532e-4ab6-8bd4-9f82c3c38135">89.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMy04LTEtMS0w_b666d56d-2542-4fc8-bcde-3cbc73a560ee">429.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in net unrealized gains (losses) on securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNC00LTEtMS0w_e23df812-a834-40d4-8bfa-4b692911cab9">14.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNC02LTEtMS0w_ea8034d2-d88d-410b-ae20-6ec8b5e6a108">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNC04LTEtMS0w_c8131ee0-5aee-438a-b9f4-128ff7573f8c">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in defined benefit pension and retiree health benefit plans (Note 15)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNS00LTEtMS0w_9b764153-c690-4bcb-ace3-e409be4f4102">157.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNS02LTEtMS0w_c3dee13a-1e98-4dc9-af41-389980e78458">970.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNS04LTEtMS0w_886c17b9-88d8-4aba-a78e-0683564dbcc7">544.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in effective portion of cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNi00LTEtMS0w_c4bc9f59-eb71-4a30-b66e-5816d633b747">152.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNi02LTEtMS0w_66a84d07-4b1c-4edb-891d-1a8857a7be29">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNi04LTEtMS0w_e27794e1-673f-4884-838e-74bc31c3a810">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) from continuing operations before income taxes</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNy00LTEtMS0w_9b01297c-5613-4800-9cc0-cc9d8eee5a73">173.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNy02LTEtMS0w_5b777469-0fa9-4606-afbb-948bf970e4c1">991.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNy04LTEtMS0w_c3ba6a5e-0045-4d55-afdf-f56dfeb3d3c0">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOC00LTEtMS0w_de767a44-0fff-42b6-8a95-70f9551dceda">200.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOC02LTEtMS0w_948c53a7-76f9-49bc-98ba-80d0327340cb">151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOC04LTEtMS0w_f0d84c71-af4c-4e21-b799-5374524b5ec1">30.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) from continuing operations, net of tax (Note 17)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfe9598260a447ba9e16ba1e9c6ed68_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOS00LTEtMS0w_6bb8280b-e57f-4dab-a90e-ec528e754b4d">27.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8e0527046d9420eba85c2e7997c4b79_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOS02LTEtMS0w_70d46e63-97b4-4e2a-854d-23da2486728a">840.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f87322c97e42a2b941ec910aed2655_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOS04LTEtMS0w_cb32b8d0-1f74-43ef-924a-3f955e9c00b3">69.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income from discontinued operations, net of tax (Note 17)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8341671b44cc41d5a18d4af59468c567_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTAtNC0xLTEtMA_3360dc8c-d98a-4c31-94e2-96f8dab95036">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e87e689a45f429e8cf9eefc3f7fadc6_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTAtNi0xLTEtMA_4aaec611-8df8-4f95-bf52-d82d081241e5">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab11f7e22e3d4369a89e0b9a64389e84_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTAtOC0xLTEtMA_25d6ede8-58a0-4c8a-ab36-943fa330255c">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax (Note 17)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTEtNC0xLTEtMA_e46ed519-de8a-47fb-9b75-f0b5b0480649">27.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTEtNi0xLTEtMA_09d06c3a-db3b-44da-9431-661edc2b38f1">783.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTEtOC0xLTEtMA_b3af3714-45c6-43b1-acb3-817cc874a42a">83.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTItNC0xLTEtMA_0a50aa7d-0119-490a-ba1b-4476cab37ebb">6,220.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTItNi0xLTEtMA_cccd933e-229a-4d10-9884-ca4845512a40">7,535.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTItOC0xLTEtMA_60a05a0f-5be8-44d6-a0bd-94de329b40f7">3,315.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">58</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions, shares in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 7)</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMy00LTEtMS0w_1cd81659-9fbf-4b20-b784-a647e6479427">3,657.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMy02LTEtMS0w_9b5a73ef-1f24-42a1-83ce-264aa4a00cf8">2,337.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNC00LTEtMS0w_71fd4300-ea64-473d-901e-68e41bfadefc">24.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNC02LTEtMS0w_988bd81b-510f-4ec0-a8c4-969dfabac3be">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNS0wLTEtMS0wL3RleHRyZWdpb246MDRhNjlkYWI3N2VhNDhlNDg5MDQyNmU0MWZkZjdlZGFfMTA5OTUxMTYyNzk1MQ_98c5b337-4dd9-4d35-95b1-3febac205697">25.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2020)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and $<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNS0wLTEtMS0wL3RleHRyZWdpb246MDRhNjlkYWI3N2VhNDhlNDg5MDQyNmU0MWZkZjdlZGFfMTA5OTUxMTYyNzk1OA_66bfd9d1-0599-4446-bcae-d6008f1e441b">22.4</ix:nonFraction> (2019)</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNS00LTEtMS0w_aceea3db-b987-4a27-bcb4-4b21add28d6c">5,875.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNS02LTEtMS0w_429d6c71-0379-4d17-8bf0-6b48eb729b4d">4,547.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNi00LTEtMS0w_e6003538-9b72-4956-8641-9ace94ae3c67">1,053.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:OtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNi02LTEtMS0w_12e1e60a-766c-40c8-8b23-57bf3945d7d1">994.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 6)</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNy00LTEtMS0w_c12f5e6b-aa14-45dc-b61f-2ab2bb65f8b7">3,980.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNy02LTEtMS0w_c66400b3-5a7f-439d-a375-835db4a0cb63">3,190.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfOC00LTEtMS0w_73c5b198-f9dc-4c63-bcc9-8f23bd224170">2,871.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfOC02LTEtMS0w_ff4a8e2b-8c2c-4c20-a576-8ca463e799a7">2,538.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTAtNC0xLTEtMA_6ce3a32d-4c28-45e3-bf6d-45abcfe379a2">17,462.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTAtNi0xLTEtMA_484bdcd2-a0a7-4298-bd54-6d43a5a7263e">13,709.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTEtNC0xLTEtMA_c6311356-1993-469c-9a7f-a3d7144ff155">2,966.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTEtNi0xLTEtMA_da7bb58f-c525-4ad0-a8a7-adbccf7602c5">1,962.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 8)</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTItNC0xLTEtMA_047ac968-c230-4072-81d8-04c6d468aa2a">3,766.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTItNi0xLTEtMA_9b305c08-f9e9-4a35-9269-0ccc821c2306">3,679.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTMtNC0xLTEtMA_e6336d08-61ee-401b-a5bb-eca65373e4ec">7,450.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTMtNi0xLTEtMA_612c59c9-b5eb-46a3-9312-c75259f01a7c">6,618.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (Note 14)</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTQtNC0xLTEtMA_2726ad91-a489-4f3d-bf14-8f64ded9aff1">2,830.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTQtNi0xLTEtMA_6bb53aeb-30b9-41fb-a29e-4945e54ed750">2,572.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTUtNC0xLTEtMA_7de041b7-a343-469c-ba8b-6b9627e4f10f">8,681.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTUtNi0xLTEtMA_67a0ef7e-701e-48fc-ba41-6aa16466e2d2">7,872.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTctNC0xLTEtMA_c875b222-cd8a-46b4-8ded-af289179b759">3,475.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTctNi0xLTEtMA_7dd8fe8e-662b-419f-abe1-f470d3779c92">2,871.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTktNC0xLTEtMA_36fb666f-9db2-49e0-8dd1-1ceef39a4b94">46,633.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTktNi0xLTEtMA_7f195467-779b-4a4b-828b-121458c724d4">39,286.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt (Note 11)</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjItNC0xLTEtMA_9f4d687f-0735-450c-9797-1deb10f8c5bd">8.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjItNi0xLTEtMA_f07d7174-ba43-4879-a48b-c00b393dc786">1,499.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjMtNC0xLTEtMA_864e0fd6-0729-415e-a488-97d587fa7433">1,606.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjMtNi0xLTEtMA_eb76be37-bdaf-4419-ac38-144c5a4c34e5">1,405.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjQtNC0xLTEtMA_f2fefaff-419e-40c9-8707-d69dd1316681">997.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjQtNi0xLTEtMA_c0727fb3-2982-4f32-ba8c-d85bc9569011">915.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:SalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjUtNC0xLTEtMA_4a098dc8-d18e-4b7a-9483-79e323d51d3e">5,853.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lly:SalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjUtNi0xLTEtMA_cdbd8327-508f-4a01-ab11-bce085fba399">4,933.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjYtNC0xLTEtMA_c098d284-63db-4bbc-b995-3a22fd2d2706">770.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjYtNi0xLTEtMA_4c4d9bbb-272a-41ca-87a9-a0a0e086514e">671.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjctNC0xLTEtMA_e94b5e4e-2e6c-461d-85b8-cbacbadbba95">495.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjctNi0xLTEtMA_5c7beee7-0d35-4769-ad9a-13cd19166098">160.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjgtNC0xLTEtMA_76110027-d9fc-4e35-87c8-e093ed81e911">2,750.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjgtNi0xLTEtMA_020acbaf-7f0c-4b6c-8849-c340f7a24fd4">2,189.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzAtNC0xLTEtMA_693cbdd6-9e2d-4a4a-89be-7892c8233a24">12,481.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzAtNi0xLTEtMA_84fea7be-60d4-4f30-953d-e598482ecdef">11,775.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzItNC0xLTEtMA_0a4bd51c-cf2c-42d3-a9cf-4690fbe57c34">16,586.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzItNi0xLTEtMA_17743dcb-3748-4232-ac2d-44a93e916653">13,817.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 15)</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzQtNC0xLTEtMA_af350e79-2490-4caa-91f2-b943a0bb42f8">4,094.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzQtNi0xLTEtMA_dac9a0cf-bec0-4121-9837-fb1063dd5d6c">3,698.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzUtNC0xLTEtMA_d4cacabe-001c-4807-a922-dc6b51a63faf">3,837.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzUtNi0xLTEtMA_08b57e5e-b423-4ab1-aed6-07457ec2e839">3,607.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzYtNC0xLTEtMA_3f9cba6c-9a7f-4e1a-bcf1-dae211a0e599">1,707.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzYtNi0xLTEtMA_47d01b8b-2494-4dc3-af1d-01755dcead16">1,501.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzctNC0xLTEtMA_b0d2f201-3ce9-47b2-ad25-d018ae62e39c">2,099.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzctNi0xLTEtMA_4e39313c-dd02-4e3a-8ae7-65a96a138c35">2,187.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzktNC0xLTEtMA_0ec23cb4-6a28-4f06-8c6e-c96dc46aefc3">28,326.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzktNi0xLTEtMA_bf606bac-6a20-4017-a7f4-a05c3e2b1dfc">24,811.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 16)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDAtNC0xLTEtMA_81d3ef60-ca54-4dd2-b67f-d5b834e1c968"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDAtNi0xLTEtMA_ee2291d3-0126-4404-ad39-e1b04b9a1b68"></ix:nonFraction></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;no par value<br/>   Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmU3NTQ1ODg5MDllNTQ5MDdhNGZlNjY2ZWFjMjRhNDlmXzEwOTk1MTE2MjgwMzU_8348d565-333e-42bd-9a55-f37203b4f74b"><ix:nonFraction unitRef="shares" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmU3NTQ1ODg5MDllNTQ5MDdhNGZlNjY2ZWFjMjRhNDlmXzEwOTk1MTE2MjgwMzU_f050bda0-b7ee-4f54-96ab-7d866ed24bc1">3,200,000</ix:nonFraction></ix:nonFraction><br/>   Issued shares: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmU3NTQ1ODg5MDllNTQ5MDdhNGZlNjY2ZWFjMjRhNDlmXzEwOTk1MTE2MjgwMTY_dc0b96ad-25a7-445e-bcf1-1f08efd6d225">957,077</ix:nonFraction> (2020)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and <ix:nonFraction unitRef="shares" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmU3NTQ1ODg5MDllNTQ5MDdhNGZlNjY2ZWFjMjRhNDlmXzEwOTk1MTE2Mjc5MDE_35c24d91-1fb6-484c-aafa-ea57170327d9">958,056</ix:nonFraction> (2019)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItNC0xLTEtMA_14336526-3ee3-4cbe-a7e4-6001605069c8">598.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItNi0xLTEtMA_047f8032-729d-42f1-b1a3-31bef468a73c">598.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDMtNC0xLTEtMA_4a65b13a-db3f-4733-a5ba-4805d7abd6fd">6,778.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDMtNi0xLTEtMA_b0196f9c-f29f-4bbc-80c6-bb900d65214e">6,685.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDQtNC0xLTEtMA_63471e39-09b3-4d17-8bd4-1c043be2f4bf">7,830.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDQtNi0xLTEtMA_b155bb57-1379-43d3-a818-759bac10068d">4,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDUtNC0xLTEtMA_bf4f7370-143f-49d3-9fd5-c0b62cbd882d">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDUtNi0xLTEtMA_55ebd3a1-889e-4a4d-8b53-184d5b490df1">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 17)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDYtNC0xLTEtMA_172fbd8c-4608-453d-b972-ce508d403393">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDYtNi0xLTEtMA_4d06fecf-5729-49ee-a83d-c7f3f234172f">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDctNC0xLTEtMA_f07949fb-0cb8-4862-a9d3-3b4acb91d8fb">55.7</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDctNi0xLTEtMA_88bc186c-3092-4e81-a40f-733e03146bcb">60.8</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDgtNC0xLTEtMA_304b5a50-94ff-47d5-94cb-7e83969cfec7">5,641.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDgtNi0xLTEtMA_6eb0eff1-b430-4de3-9f07-de6276dfe4d1">2,606.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDktNC0xLTEtMA_a58e1f4d-ffaf-4890-95d7-1fb85248b840">183.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDktNi0xLTEtMA_4d21dd28-9fca-491a-a542-74e0fe4f65fb">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNTAtNC0xLTEtMA_63e3dcf4-5b7f-4281-a935-51aecff9586e">5,825.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNTAtNi0xLTEtMA_cbfd7755-a6e9-4dc5-ae42-3a9288a32289">2,699.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNTEtNC0xLTEtMA_dda399b5-0f6c-4184-9458-756efaae2ac1">46,633.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNTEtNi0xLTEtMA_6c58ebf4-0c14-4a08-96fe-a9f6189dc36e">39,286.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">59</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Shareholders' Equity</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.918%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions, shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interest</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2018</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i184cadb6a52c45e68d6a9a4c2738bc68_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xLTEtMS0w_6438e784-7765-4f35-95aa-d5a769c3b90c">1,100,672</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184cadb6a52c45e68d6a9a4c2738bc68_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0zLTEtMS0w_a44c43c1-53e9-4fd3-a1e6-8750a3854cd8">687.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27083e2ab25e4d04a25e1ef83d0b7877_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy01LTEtMS0w_cbc15713-e261-4c32-a93d-ccfdaf9642ab">5,817.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045bb911bff14e9aa36f1a05bf3e92a5_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy03LTEtMS0w_7f943f70-3f69-492e-af10-33656f4dc8d9">13,894.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib70725e180744eb1954d643e7a5a963a_I20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy05LTEtMS0w_fe989f99-3e54-4394-8d7f-d42137fcd7c8">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae684e1f51624a5884d558a8b1eea7ab_I20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xMS0xLTEtMA_55217dfd-edb6-49d0-a6f1-846b0817a1a3">5,718.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i724dac2e02db4426bbe5e17f9903b032_I20171231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xMy0xLTEtMA_59ac2078-6063-496f-a51f-6a43aa830446">664</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i724dac2e02db4426bbe5e17f9903b032_I20171231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xNS0xLTEtMA_e87de40a-ad1a-4e5b-ae86-c61b09c83c7f">75.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c1c5fc9e8a49c99deefea40e94e712_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xNy0xLTEtMA_2d042376-03d3-403d-be10-56b368b2e6cd">75.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636193b834b64dd6bb822cf51cc578f7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNC03LTEtMS0w_bd7a8771-63ca-4db8-b40e-7d6ca2fd12ed">3,232.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28716e79250245dd90132d730ab4c041_D20180101-20181231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNC0xNy0xLTEtMA_f750fc8b-6a84-47e1-a496-9dea584f851b">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNS0xMS0xLTEtMA_ad47df89-516e-4be5-b704-d080b2735705">85.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28716e79250245dd90132d730ab4c041_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNS0xNy0xLTEtMA_497d60db-1843-49d0-ac52-11b04bf3cef4">2.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNi0wLTEtMS0xNTIwMS90ZXh0cmVnaW9uOmVhZGUxMjk1NTA1MjQ2MzlhOWIxZDdjMjk4NzFmZWVmXzEwOTk1MTE2Mjc4MjE_604c94d3-b417-4a95-b85b-ed050dcc6f0e">2.33</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i636193b834b64dd6bb822cf51cc578f7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNi03LTEtMS0w_4d922175-c395-4327-ab98-4b572673cdcc">2,372.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy0xLTEtMS0w_63d364de-941c-4783-a1f0-e2934fe3f2c4">45,882</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy0zLTEtMS0w_d515327e-2dc3-4343-bb2a-7ad028350509">28.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i636193b834b64dd6bb822cf51cc578f7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy03LTEtMS0w_44d84af4-bd36-4963-b952-113fd5d7d1a1">4,122.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy0xMy0xLTEtMA_c1ec5395-2532-42d0-b325-ca07b3dbad51">45,882</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy0xNS0xLTEtMA_313a502b-8c63-4a02-9f4d-f563cff9736f">4,150.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOC0xMy0xLTEtMA_c584f2c1-a1e6-48e3-976f-83e51514c2fb">45,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOC0xNS0xLTEtMA_7b152a10-1c78-4c69-a10f-732c475b00a9">4,150.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS0xLTEtMS0w_72dd5a7c-fff6-42d6-91aa-ecf7ccb06a4b">2,849</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS0zLTEtMS0w_71bc88e5-be55-41a3-a247-acb6610d3b39">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f64538c2968464bb7e99808fc376334_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS01LTEtMS0w_5db4372d-4994-47ac-86b1-74d2b078ba6d">139.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS0xMy0xLTEtMA_3db86d43-e4bf-418b-9eda-8bcb6da4569a">60</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS0xNS0xLTEtMA_7c077c99-0f04-4099-89a6-52ee68d01275">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f64538c2968464bb7e99808fc376334_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTAtNS0xLTEtMA_a49a7fdc-876d-46e3-9b09-ed2f95ae26a5">279.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adoption of new accounting standards (Note 1)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7bf2897e1304a7b9d39c16325786d60_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTEtNy0xLTEtMA_29c9c2cb-c060-427e-b784-40036b68eb38">763.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i157d7cc7dd0a4ce7a83fbaec2dded32f_I20171231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTEtMTEtMS0xLTA_7a4e40e1-b913-43f3-88d0-c32bd4b4a10c">105.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sale of Elanco Stock (Note 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f64538c2968464bb7e99808fc376334_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTItNS0xLTEtNTE1_706a1cfd-7d37-472e-b1c4-6993cce80204">629.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTItMTEtMS0xLTUyNQ_42b1d2aa-cb0c-403f-9c52-89ade9264e6d">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTItMTctMS0xLTUzMQ_6cc78f28-6827-4049-aeb0-7c298e1b4843">1,017.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f64538c2968464bb7e99808fc376334_D20180101-20181231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtNS0xLTEtNTIw_abb42499-bb89-4540-b0c9-927f5c399490">3.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28716e79250245dd90132d730ab4c041_D20180101-20181231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTItMTctMS0xLTA_d7cff2d7-a184-4427-8ad5-98548173a095">14.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe5ce62fdd544ff38d36deef307ad126_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMS0xLTEtMA_142d1c20-2d22-4160-ab84-6ff66862de9b">1,057,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5ce62fdd544ff38d36deef307ad126_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMy0xLTEtMA_6b0c6e4b-31e5-4f99-9db6-f99587090305">661.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e3cdfa36f041fc98dc2d1a6961d3d4_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtNS0xLTEtMA_eca9bd04-8124-4d92-b13a-89d72cbd3947">6,583.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c9d052fc1b4535a183d69045981ee8_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtNy0xLTEtMA_132cd00d-cce1-497f-880c-3b9086fb1e4d">11,395.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d46f703015a40e68e2bbe1d001af462_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtOS0xLTEtMA_3357b072-476d-453a-8536-c8b4f7bbf1b5">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1a89936fa8a4137a7ff3506ba792c52_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMTEtMS0xLTA_21e8decc-d723-469f-b575-49dc4d527bfc">5,729.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie93b724bf8864d4c9fa270f354b1916a_I20181231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMTMtMS0xLTA_c6024a0e-bd72-40a0-8419-1a2276153609">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie93b724bf8864d4c9fa270f354b1916a_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMTUtMS0xLTA_428f09cc-5d97-404e-8d7b-dd85132d5f93">69.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa5205837f6490198d5eec282d9367d_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMTctMS0xLTA_613e6c22-d171-4b15-b796-637ceaec1e46">1,080.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie391d487b3784a9b8e753e02edd132b4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTQtNy0xLTEtMA_79f52ee5-1bf6-4d96-9b39-0e3af99e69f1">8,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTQtMTctMS0xLTA_e1ee423e-444e-4563-907b-e537eac21bc6">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19bfa0a6cac84e13bceb037831a4f867_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTUtMTEtMS0xLTA_c957f3a8-5552-45ee-a310-33d104c23ff7">794.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTUtMTctMS0xLTA_b8886d2b-eefb-4638-a647-0e355d3c61bc">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMC0xLTEtMTUyMDQvdGV4dHJlZ2lvbjo1ZThkMTRjOTQzNmE0ODAwYjU3OTA4ZGEyZjY5YTk3N18xMDk5NTExNjI3ODIx_84a78473-1e32-4f74-aafe-9e8d99e5b064">2.68</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie391d487b3784a9b8e753e02edd132b4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTYtNy0xLTEtMA_b15cf3b9-4e89-4b96-a07f-17ebf660bc01">2,430.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d1c048117e4436eb1290866218298ab_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMS0xLTEtMA_c463bdd7-a9db-43dc-99ba-b1fa955884c6">102,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d1c048117e4436eb1290866218298ab_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMy0xLTEtMA_26a51516-a707-4e81-baad-b52006f6f65a">64.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie391d487b3784a9b8e753e02edd132b4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctNy0xLTEtMA_c5a23c00-b0a0-48b9-8a0b-87afa99390b6">12,363.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMTMtMS0xLTA_f9d92ebf-6343-46be-9364-b5daa0f07ebc">102,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMTUtMS0xLTA_4833ca1f-5d71-408f-a596-b93033219413">12,427.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTgtMTMtMS0xLTA_3ff2a021-d8e3-466b-bce9-fafb531dbd53">37,639</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTgtMTUtMS0xLTA_61e4dede-fd58-4014-a5b2-4f1cf928d57c">4,400.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d1c048117e4436eb1290866218298ab_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktMS0xLTEtMA_ede2cb2b-5b98-44cf-93ab-ef2ee2ee7c20">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1c048117e4436eb1290866218298ab_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktMy0xLTEtMA_c00f7ba7-90b5-48b7-b25b-23f2d5e7e906">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i473e4514c71444c9988eb5ff37da3471_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktNS0xLTEtMA_41c4f046-b105-4658-82a8-d50b8b4c9824">210.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktMTMtMS0xLTA_e99a160e-11b8-49df-8997-0efd95ea7a4f">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktMTUtMS0xLTA_c423c48a-f9ea-4a49-abef-78e56e463559">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473e4514c71444c9988eb5ff37da3471_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjAtNS0xLTEtMA_81c45727-e01f-4d4b-8ce3-32eb04405122">312.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition of common stock in exchange offer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="lly:StockAcquiredDuringPeriodSharesExchangeOffer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjItMTMtMS0xLTUzOA_77fc9425-8c2e-43b6-96c8-8ca633de1940">65,001</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lly:StockAcquiredDuringPeriodValueExchangeOffer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjItMTUtMS0xLTU0MQ_604d0b86-7eb3-4645-9e95-e113b843e016">8,027.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deconsolidation of Elanco</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="lly:ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjItMTctMS0xLTA_6c046717-06ee-4058-901c-cdfade3261fe">1,028.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjMtMTctMS0xLTA_79e867cc-74fb-4906-bae0-3be624aedfa5">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6fa49af8d0b4b4fb6114b249eda120f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMS0xLTEtMA_d0d01fbf-39e8-43bc-b761-731729578cbd">958,056</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fa49af8d0b4b4fb6114b249eda120f_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMy0xLTEtMA_4f881f4c-3fcf-4f21-8a76-37269370eb93">598.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida935f3e75bd41ffb87686123bd54de1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtNS0xLTEtMA_88f8b260-9582-4b6a-aaf5-82a17b33ab27">6,685.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3987bdd473cd49b4a9449fe4eafc3bc0_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtNy0xLTEtMA_a042aba0-8a88-4f86-82be-a1fa21286560">4,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i688adb3e04c845998ca0228971320c29_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtOS0xLTEtMA_8ebec6e2-7bc5-482c-bcd7-43d76c92813b">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47de201d5d5443239956a13daaf044fe_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMTEtMS0xLTA_5ba285ae-eea7-43b1-8828-5eb28700de78">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifefa16ca5afc4eaea5068a01f7896ad4_I20191231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMTMtMS0xLTA_38397d90-fb27-4c7b-81cb-03b430c09f11">530</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifefa16ca5afc4eaea5068a01f7896ad4_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMTUtMS0xLTA_f705ea90-5dd9-4ca8-91be-c9a0a2e4a903">60.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f62bf81439d4ae4bf4ba4e32bd50761_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMTctMS0xLTA_ca4011ba-d994-4d0e-8249-e84f42676a62">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa954877e0c7448982c196e66891eed8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjUtNy0xLTEtMA_f779fde3-c085-4d87-b9d0-cf1ca9bce34b">6,193.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36805f1fb89427dbd2741f45ab5adbb_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjUtMTctMS0xLTA_865d3883-be25-410e-8603-0eb0a563143f">126.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027fb322c12e404ab2d69c9acb6af89d_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjYtMTEtMS0xLTA_b8945587-55b7-4667-8c08-f227df819707">27.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if36805f1fb89427dbd2741f45ab5adbb_D20200101-20201231" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjYtMTctMS0xLTA_89f38857-11d7-4a91-9bb5-991f28f1e979"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMC0xLTEtMTUyMDcvdGV4dHJlZ2lvbjo1YTk4OWIyODUzOTk0ZTE4YmUwNzQ1Y2UyNWM2NTM4YV8xMDk5NTExNjI3OTAz_348886a1-7dac-4b41-aae7-749dd5cb5a75">3.07</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa954877e0c7448982c196e66891eed8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjctNy0xLTEtMA_068b9a4d-9c64-459b-b780-4d488c4acf50">2,786.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMS0xLTEtMA_7bb9bfa3-be91-4e6f-a8b3-44b95d5b31a6">3,627</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMy0xLTEtMA_a4b00aae-f92f-4114-ae7c-53fccf2b1855">2.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa954877e0c7448982c196e66891eed8_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtNy0xLTEtMA_d701c1bf-1d8a-4b51-881b-e5b4176d7a2d">497.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMTMtMS0xLTA_d12c6bd7-d7d4-44ca-942a-487fe84f10b9">3,627</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMTUtMS0xLTA_88092319-c855-44ab-80da-85d8930db25c">500.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjktMTMtMS0xLTA_1df6c3a7-6e27-436e-85af-2a3e761473b3">3,627</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjktMTUtMS0xLTA_aec1507b-d1da-466a-b575-9e8ef976232a">500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtMS0xLTEtMA_aceedc53-bb95-4758-aa6d-fd38ac25c5dc">2,648</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtMy0xLTEtMA_da3609f7-01c9-4fa9-9736-fe1e73142f84">1.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i036da0197efe483db4434ecbe172adae_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtNS0xLTEtMA_3a0c3ac2-3a08-438a-97d2-5f121cb18f64">212.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtMTMtMS0xLTA_21f358a6-bb69-401b-8766-5f9497561168">43</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtMTUtMS0xLTA_184bf3a2-2709-4e7e-8536-9ba73f55a393">5.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036da0197efe483db4434ecbe172adae_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzEtNS0xLTEtMA_ec61e6f7-7e43-4ecd-b5ac-2efaf675c4b1">308.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i036da0197efe483db4434ecbe172adae_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzQtNS0xLTEtMA_ea1634a0-ab07-4a09-8ac1-e61a7142a91d">2.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if36805f1fb89427dbd2741f45ab5adbb_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzQtMTctMS0xLTA_648df8b5-495a-411e-a684-6d69bac543c2">35.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba9187cdb56548338bf4141df49d64ae_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMS0xLTEtMA_d95be60f-5f3b-49f0-a9f1-fc1b98219bcd">957,077</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9187cdb56548338bf4141df49d64ae_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMy0xLTEtMA_ce2ca0ed-5b16-4049-b621-f5ccd79eb551">598.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787f9b28041442e7ad4a920214784c1c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtNS0xLTEtMA_05f70719-cd9e-4fa5-aa14-b0408871f811">6,778.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e3601cdaa94bf89622d6fc8cfe46fa_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtNy0xLTEtMA_a53c6791-9286-41c7-b8e9-1ded009f3bb9">7,830.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9627925923524961a92f6c7efb50a362_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtOS0xLTEtMA_0033707f-0cbc-4ba7-9ee0-87bdd2c9bdef">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c0d14f77974e70adc19b8346937884_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMTEtMS0xLTA_a75d4512-dcc8-462f-9bed-41206fa56979">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50acc48e0eed414dafcaecf50e0217b5_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMTMtMS0xLTA_7b5e88f9-1935-4451-8d57-34ee5a1b2439">487</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50acc48e0eed414dafcaecf50e0217b5_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMTUtMS0xLTA_ff9debc9-92d2-482f-a19d-3c9a1185851b">55.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e05a36e47a4388bbf774447f54fdf7_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMTctMS0xLTA_a0199618-fbc6-42a4-8cc5-5ede2993aab3">183.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">60</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.537%"><tr><td style="width:1.0%"></td><td style="width:40.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY AND SUBSIDIARIES<br/>(Dollars in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzItNC0xLTEtMA_a2c06e30-3e98-4462-a063-0d910978a3fc">6,193.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzItNi0xLTEtMA_c3ba4f70-b78b-451f-99fb-04d3f1419e8e">8,318.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzItOC0xLTEtMA_ee6a7c7f-9bbc-47cd-bdbf-b3b1a90ad7f4">3,232.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain related to disposition of Elanco (Note 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQtNC0xLTEtMA_38086779-3196-473b-b385-8ee8fbb2d486">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQtNi0xLTEtMA_69b5b4a7-80e1-43eb-a38a-9e872f8b557a">3,680.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQtOC0xLTEtMA_083d94e7-2c1d-446b-aa06-9b2fe9b83729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of antibiotic business in China (Note 3)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzUtNC0xLTEtMA_4e679d30-f1a0-462d-a64b-a11b1a419bf8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzUtNi0xLTEtMA_d6878d76-50b8-4e96-bd6a-50eb9bcee4ae">309.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzUtOC0xLTEtMA_0530225b-f3b7-4b7a-8768-608988cdb168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzYtNC0xLTEtMA_b936d733-3b45-4f18-850a-3b4e7b72d468">1,323.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzYtNi0xLTEtMA_f529e6ff-2a46-44ae-97d7-1e0205f37782">1,232.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzYtOC0xLTEtMA_5a22b79d-cb40-4f6d-97d1-0e98056ff610">1,609.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzctNC0xLTEtMA_426ce563-6178-4684-a53e-39a30a4616db">134.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzctNi0xLTEtMA_8a830f12-a7d0-4dc2-adf7-ca4758117b13">62.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzctOC0xLTEtMA_6fc01461-ea23-4784-b821-42061cec3b6b">326.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzgtNC0xLTEtMA_70d0a707-9041-440a-b933-d2c43dbda207">308.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzgtNi0xLTEtMA_ba967001-08b3-43a6-88f4-613943c4c51e">312.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzgtOC0xLTEtMA_f5dcb4f5-6d37-4b25-a1fd-365d385f2b1c">279.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktNC0xLTEtOTU1OA_05dec00a-32d8-454e-b982-d7ee59869254">1,438.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktNi0xLTEtOTU1OA_f432cc35-f273-49d1-b470-7665da0cf82e">403.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktOC0xLTEtOTU1OA_53a3aef3-2b49-4b0e-b6f8-6d867092c23d">27.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktNC0xLTEtMA_30290852-fe27-48d2-addf-7233cb4987d9">660.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktNi0xLTEtMA_8e60da52-df7a-4c73-abee-de514a0e0ce5">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktOC0xLTEtMA_79b3bbb3-9b86-4d8c-b62b-eb26c7b6a638">1,983.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash operating activities, net</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEwLTQtMS0xLTA_e2e08762-94c9-41ce-998c-c5396af105a8">333.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEwLTYtMS0xLTA_99cf0607-3386-407e-9849-56f4c7841d6c">751.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEwLTgtMS0xLTA_0e1a6ac6-d117-4dce-aa23-07b08c27587f">499.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEyLTQtMS0xLTA_0738cc2b-d01d-4e34-857b-e318efac2256">1,350.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEyLTYtMS0xLTA_d9731918-a70f-4922-85c4-a34cecbede86">127.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEyLTgtMS0xLTA_fcd6a242-f647-4490-800d-57f8bd3b86df">996.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEzLTQtMS0xLTA_56434253-6030-433c-bb86-8d0ec87c112e">533.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEzLTYtMS0xLTA_11fc5a64-5839-47de-b936-b4ada2f136e4">258.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEzLTgtMS0xLTA_37e31107-07b7-4128-94b7-865ea1a343aa">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets&#8212;(increase) decrease</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE0LTQtMS0xLTA_f64704ae-6270-46b5-9b00-ae4a250405ac">457.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE0LTYtMS0xLTA_16d60b3a-52c3-4721-badc-3e958e84c37c">602.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE0LTgtMS0xLTA_5c934388-9a77-4cc6-827a-78c89ea820c5">980.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable&#8212;increase (decrease)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE1LTQtMS0xLTA_efefdcb3-0b27-49d4-8dd1-e3ff12c3ca72">322.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE1LTYtMS0xLTA_0a0572c2-0be4-412a-9c2b-58f99c82547e">221.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE1LTgtMS0xLTA_de092e31-1735-4532-9ef2-0a9bfb6b7832">125.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities&#8212;increase (decrease)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE2LTQtMS0xLTA_3bc959b0-5fad-4959-990d-0d89392785a0">1,271.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE2LTYtMS0xLTA_cf0990cd-cb83-48fe-9327-30b419edd411">477.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE2LTgtMS0xLTA_8acb78f4-5f0a-4045-82d0-cbb21d456fac">284.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE3LTQtMS0xLTA_74c065ca-0991-4f62-bc9e-61a0796aa435">6,499.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE3LTYtMS0xLTA_81842bed-f5a6-42e2-a6ea-933ccc3b0545">4,836.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE3LTgtMS0xLTA_95168ae9-c9ce-40e4-a7e4-4df9800a67b3">5,524.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE5LTQtMS0xLTA_650ded70-7f50-46df-8d56-27541d90dcf1">1,387.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE5LTYtMS0xLTA_8fc76068-a9ee-428d-be53-28084bad710d">1,033.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE5LTgtMS0xLTA_dcede2e6-2c18-4a74-a1fd-9998a549b43f">1,210.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIwLTQtMS0xLTA_bdf95827-f15b-4d56-9d95-d2aeb170bb05">129.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIwLTYtMS0xLTA_4d3eea6a-bd92-477a-813c-be5fef661b79">136.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIwLTgtMS0xLTA_ae1bc948-08c5-4c8b-a3ea-1d51db8f1a6a">2,552.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIxLTQtMS0xLTA_8ea8e679-621f-4dc0-96ad-02d0155d9b77">11.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIxLTYtMS0xLTA_5718b4f0-390b-434d-b1a7-9711a87be2e1">42.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIxLTgtMS0xLTA_ba96172e-5373-400c-8e74-0edd681ad04b">112.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of noncurrent investments</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIyLTQtMS0xLTA_6bce9f55-e175-4c19-9ae2-b1a2026df7f6">757.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIyLTYtMS0xLTA_54d650ca-22c3-4f74-b31e-780407a708e1">609.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIyLTgtMS0xLTA_2f321387-82fe-4938-8ce2-56a1519cf914">3,509.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIzLTQtMS0xLTA_829e707f-67f8-4a22-a7af-95cdd98c89a5">358.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIzLTYtMS0xLTA_5b1f4842-275b-4793-a0d6-f164a8e1d707">247.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIzLTgtMS0xLTA_d8491619-6b30-4a3e-9124-8a868f3be503">837.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI0LTQtMS0xLTA_c87ccffb-5dc1-44cb-b418-e3121fce2fde">641.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI0LTYtMS0xLTA_939b53f9-bad1-4f64-9aea-3fcf5a4353ba">319.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI0LTgtMS0xLTA_234178b8-53d0-4500-985b-288f3d89cf27">1,807.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI1LTQtMS0xLTA_be6da1e7-958b-4969-8d30-809cabf92aab">849.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI1LTYtMS0xLTA_a6c1593d-f2bb-4e07-8122-02b08d8b0551">6,917.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI1LTgtMS0xLTA_1f00e208-1aeb-4e02-ac93-47da759371a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash distributed to Elanco upon disposition</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashDivestedFromDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI2LTQtMS0xLTA_187c9162-772c-4466-8d36-ca74da674c56">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:CashDivestedFromDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI2LTYtMS0xLTA_2a276cb1-6041-4c91-83e1-e7cd9dc71643">374.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashDivestedFromDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI2LTgtMS0xLTA_032503da-f847-47df-9db0-d24efe2d96ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for sale of antibiotic business in China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI3LTQtMS0xLTA_a1a13476-17f2-4aee-892c-23865b9bf725">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI3LTYtMS0xLTA_9c81307c-01e3-4c2f-8a17-307b7fdbeb96">354.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI3LTgtMS0xLTA_9541390e-3533-40cc-b6c0-2f2e04c93bdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI4LTQtMS0xLTA_0075f099-581b-4b54-b4fe-76dbd49aaad8">102.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI4LTYtMS0xLTA_6cacdac0-3b48-4a0f-9ae1-c2b1c1af0992">248.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI4LTgtMS0xLTA_b8ec6ecf-89b0-4ad8-9796-c89701ec75e5">187.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by (Used for) Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI5LTQtMS0xLTA_16853626-ffd4-4823-a7a2-8c55af47f310">2,258.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI5LTYtMS0xLTA_09e5bc0e-dadd-4bf7-8d34-717bfded2ad2">8,082.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI5LTgtMS0xLTA_5e18d2ee-c6e6-4b15-a17d-b01dd4d3ae2a">1,906.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMxLTQtMS0xLTA_84daed20-edac-48e8-9cd5-ace130d40ebf">2,687.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMxLTYtMS0xLTA_b2618dab-156e-4306-9026-2553ca7e28b8">2,409.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMxLTgtMS0xLTA_56be3403-8eca-49ea-8ace-2e88bb523d0d">2,311.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMyLTQtMS0xLTA_4b8caaaa-ba22-40ab-ab10-87568b5cada9">1,494.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMyLTYtMS0xLTA_cd62e3e1-9641-40e2-ac4c-486f1b6602ca">995.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMyLTgtMS0xLTA_f11db602-e535-44cb-adcf-04aea0de80dc">2,197.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMzLTQtMS0xLTA_a13bfe78-72cf-474c-9fbc-2cbb5a2fa105">2,062.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMzLTYtMS0xLTA_b829ec5f-7a9a-4380-9391-89407cfb1c77">6,556.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMzLTgtMS0xLTA_9d2a467f-ede4-43c9-b389-d34fcee722e4">2,477.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM0LTQtMS0xLTA_96af561a-8d2f-493a-907f-6a9e0ef00fea">276.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM0LTYtMS0xLTA_e99fb89c-00d7-4bbd-8883-56fea366c26e">2,866.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM0LTgtMS0xLTA_3e40ed1f-39a1-4ff7-9efe-4f18bd205ac8">1,009.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM1LTQtMS0xLTA_deecb998-03c0-4f61-aa3e-8838f13d1a35">500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM1LTYtMS0xLTA_dd74fa3f-a66d-43fe-93c2-1e27de8f35de">4,400.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM1LTgtMS0xLTA_524038fc-70f5-4987-873e-38952a1e36da">4,150.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from Elanco initial public offering (Note 19)</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM2LTQtMS0xLTA_fc76254b-dad8-4f61-9bfe-dc5db637951b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM2LTYtMS0xLTA_990e6204-5624-4c89-9c76-d9638f820978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM2LTgtMS0xLTA_c6a59682-3201-40ac-9274-a100185554d3">1,659.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM3LTQtMS0xLTA_b547b7b4-eacd-43b8-8967-ad1320938393">241.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM3LTYtMS0xLTA_7eef07a3-b831-4977-9ce9-38bce6f62924">200.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM3LTgtMS0xLTA_fd45f3e6-35a7-4eaa-916f-41bbe69d2367">372.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Financing Activities</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM4LTQtMS0xLTA_ca3ffb2c-edc5-48e7-b45e-cd3e5d25bde8">3,137.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM4LTYtMS0xLTA_fe228d33-e9d6-4ab7-910b-73b4fd6b6bbd">2,324.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM4LTgtMS0xLTA_2082d888-2e04-436d-b965-463bd764fb2b">5,904.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM5LTQtMS0xLTA_53824256-a965-4aa5-8171-adff000ce01f">216.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM5LTYtMS0xLTA_e9d3baa5-5957-4f5b-94e6-f733b0dae262">89.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM5LTgtMS0xLTA_8d2b939e-f6a7-44a3-94bd-3f911a8749b2">63.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQwLTQtMS0xLTA_885c542c-0e65-44de-838f-af10172b90f5">1,319.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQwLTYtMS0xLTA_076d860c-da5f-49c6-8742-5d84ab0834a1">5,660.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQwLTgtMS0xLTA_08014293-8c27-442c-b593-6457ad46de78">1,462.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year (includes $<ix:nonFraction unitRef="usd" contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxODlhYzY4YTgxYzY0Mzk3OTNmNDkxZDY4ZjdjYTQxOV8xMDk5NTExNjI3OTA0_4079f89e-4dff-4b4b-8ce1-0076cd285bd0">677.5</ix:nonFraction> (2019) and $<ix:nonFraction unitRef="usd" contextRef="i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxODlhYzY4YTgxYzY0Mzk3OTNmNDkxZDY4ZjdjYTQxOV8xMDk5NTExNjI3ODk3_4a827fc6-e122-4e11-8f25-732580330df1">324.4</ix:nonFraction> (2018) of discontinued operations)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTQtMS0xLTA_a61fd90b-200d-4fd5-a610-644ea7553de7">2,337.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTYtMS0xLTA_053c8ebe-9980-442e-b074-bacc8cd40ad0">7,998.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTgtMS0xLTA_bc83aa0a-038c-48e1-9322-ece799cd0dcb">6,536.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at End of Year (includes $<ix:nonFraction unitRef="usd" contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQyLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NDY2ZjQ5MTNiYWM0MjdkOTUxNzIxZjQyMzg3ZWJjY18xMDk5NTExNjI3ODcz_6a0b5f7b-8111-4bc7-be25-21a008819603">677.5</ix:nonFraction> (2018) of discontinued operations)</span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQyLTQtMS0xLTA_67cfa52e-04d7-4860-a298-dadfe79c522b">3,657.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQyLTYtMS0xLTA_914dd172-7594-454e-91a0-825e1c4acd42">2,337.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQyLTgtMS0xLTA_be98961e-7629-45da-b985-d8efcccde3a9">7,998.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">61</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="margin-bottom:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_112"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;1:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkzMDU_7e722dfd-6ad6-4ce0-b0f3-ae450f99348f" continuedAt="i3a4d9a03c0a0405fb350da21924a8748" escape="true">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</ix:nonNumeric></span></div><ix:continuation id="i3a4d9a03c0a0405fb350da21924a8748" continuedAt="idf7c74ca0e1c4245a92334ea9e739fae"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders&#8217; interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2019, we completed the disposition of our remaining <ix:nonFraction unitRef="number" contextRef="icf5a8d8b13ec45be88c05cc0494020eb_I20190311" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzE0OTQ_2045f3b1-6f32-4240-98eb-3d0879ffd079">80.2</ix:nonFraction> percent ownership of Elanco Animal Health Incorporated (Elanco) common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of the disposition of Elanco, we now operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkyOTY_b22027ee-9b7c-40d0-91aa-cf3e65c54704" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development costs, which are expensed as incurred.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expense includes the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkyNzk_9b860cc4-44de-4aa8-8be6-de3b94a2de79" continuedAt="i8c19e3e92e6a4a92a22cc1be5d12ff86" escape="true">Earnings Per Share (EPS)</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c19e3e92e6a4a92a22cc1be5d12ff86">We calculate basic EPS based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="idf7c74ca0e1c4245a92334ea9e739fae" continuedAt="idbdb20b7c0ab4ceebd71edd08ae4d597"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkyODY_4ef10fd0-7d7b-4b02-9822-555d62be7f32" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkzMDA_a13c14df-1665-4b9b-b8b3-059c42846354" continuedAt="i50d213a8a5df4a778180ad44959f52de" escape="true">Advertising Expenses</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i50d213a8a5df4a778180ad44959f52de">Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.</ix:continuation> Advertising expenses, comprised primarily of television, radio, print media, and Internet advertising, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0MjQ_c1f934be-1fc0-4b21-935d-7bc27dc596a6">1.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0Mjg_86bb26ac-05e5-4c29-8123-91fc67f20dbb">1.1</ix:nonFraction> billion, and $<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0MzY_8e57d252-427c-44c7-b0ed-403e4d1ffeee">900</ix:nonFraction> million in 2020, 2019, and 2018, respectively, which was less than <ix:nonFraction unitRef="number" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="lly:AdvertisingExpensePercentageOfRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0OTg_091e8999-4bb2-499d-ab9c-61ce3a19a1f4"><ix:nonFraction unitRef="number" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="lly:AdvertisingExpensePercentageOfRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0OTg_b4ba67e7-8175-4c00-acf2-8134b678e050"><ix:nonFraction unitRef="number" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="lly:AdvertisingExpensePercentageOfRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0OTg_c3f59ece-931d-4f2a-aaef-146c4be43abd">5</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of revenue each year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkyODA_72c4b44b-a560-410b-91db-7b0a6af618d9" continuedAt="ia58ac8b48a8b496eb2cacdb5057b733a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, we adopted Accounting Standards Update 2016-02, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transitional practical expedients. The adoption of this standard resulted in recording of operating lease assets of approximately $<ix:nonFraction unitRef="usd" contextRef="ie8d870ddf29742b896587158690bd8a2_I20190101" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzUwODQ_2384afa2-93fc-4bfd-b732-f894af12378e">530</ix:nonFraction> million, which included reclassifying approximately $<ix:nonFraction unitRef="usd" contextRef="i1aa7ce2db08d4fc7af3dfaea6237b261_I20190101" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzUxMzE_308a98b5-7cc2-4c4c-b456-0e70c444d654">65</ix:nonFraction> million of deferred rent and lease incentives, net of prepaid rent, as a component of the operating lease assets as of January 1, 2019. The adoption also resulted in recording operating lease liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="ie8d870ddf29742b896587158690bd8a2_I20190101" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzUzNDc_d1bf8504-4ba0-4013-bffd-1d3a26716c9f">595</ix:nonFraction> million as of January 1, 2019. Our accounting for finance leases remained substantially unchanged. Adoption of this standard did not result in a material change in net income in the year of adoption. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other related updates. This standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We applied this standard to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don&#8217;t believe the effect of applying this practical expedient resulted in material differences. We applied this standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $<ix:nonFraction unitRef="usd" contextRef="i01ed1b80ae7748c6ae7aefbbfc4c08c3_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzY1NTk_abf7b61b-6c0d-4712-b070-c3fe19f8a7b5">5</ix:nonFraction> million to retained earnings as of January 1, 2018. Adoption of this standard did not result in a material change in revenue or net income in the year of adoption.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2016-01 (ASU 2016-01), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). We applied the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $<ix:nonFraction unitRef="usd" contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzc2NDg_9e66f744-8880-4e22-bb73-32ad89ee6f03"><ix:nonFraction unitRef="usd" contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzc2NDg_f43bcd07-607c-464a-ac85-f586c97cf69a">105</ix:nonFraction></ix:nonFraction> million as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2016-16, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. We adopted this standard using a modified retrospective approach. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $<ix:nonFraction unitRef="usd" contextRef="i8e90af870b3d47a4bd1770c53c1a74b9_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzgyMjI_667d0fc0-5869-4260-9997-2dbb94ea3634">700</ix:nonFraction> million to retained earnings, $<ix:nonFraction unitRef="usd" contextRef="i3ec2a6e9e71f43729a2ef0804b5d5688_I20171231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzgyNDc_c2e59db1-afe3-4c2a-90c8-ed762c0b6466">2.5</ix:nonFraction> billion to deferred tax assets, and $<ix:nonFraction unitRef="usd" contextRef="i3ec2a6e9e71f43729a2ef0804b5d5688_I20171231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzgyNzg_d32efe12-51b8-4c8a-8490-95f4451ca66a">1.8</ix:nonFraction> billion to deferred tax liabilities as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="idbdb20b7c0ab4ceebd71edd08ae4d597"><ix:continuation id="ia58ac8b48a8b496eb2cacdb5057b733a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Accounting Principle for Retirement Benefit Plan Assets</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective during the third quarter of 2020, we adopted a voluntary change in our method of applying an accounting principle for certain of our retirement benefit plans. Refer to Note 15 for additional information.</span></div></ix:continuation></ix:continuation><div id="ia8e8b06f04404e6fb09e313103495f8e_118"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;2:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzMyOTg1MzQ4OTk1MzI_cc007d67-efc6-4afe-822c-93e179525231" continuedAt="ic78315096da842eea8a1e9ccabcbcb8c" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ic78315096da842eea8a1e9ccabcbcb8c" continuedAt="i6c0829c95060469082aad67ac33a1ea8"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzEzMzgx_8ae661a8-888f-41a6-b247-93b38001d41b" continuedAt="i0f28c5c9c94e42ddab394022898d65a0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b760635fa6d431c9dbbba9b762de382_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzEtMS0xLTEtMA_10d98997-87b3-4465-8c2a-a7ac63ceacc0">22,694.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f36d7a75f14e72b8ff0e498de5ad74_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzEtMy0xLTEtMA_22b46cc7-eae4-4f63-bede-7811a747bdff">20,377.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f006ccd7dcf492e906b2da535a904b2_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzEtNS0xLTEtMA_f0e2e412-1271-4a05-81ab-af8c4334432e">19,866.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c268eadac048a8bed666bf74cab1f6_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzItMS0xLTEtMA_c8c5fc93-01c8-490b-ab27-51b9375f1517">1,845.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a7d3b63876485d87034526a86d8ded_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzItMy0xLTEtMA_ecde8a12-3dea-463f-ba8e-5c30e06ae71a">1,942.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ede8557fbe4f02a6f390d0e6822798_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzItNS0xLTEtMA_d4cbaafe-39b9-480e-b9cc-22fe8e45d1af">1,626.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzMtMS0xLTEtMA_b6334512-8ebe-4b70-9c18-fe0925ac9ed3">24,539.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzMtMy0xLTEtMA_bc22b593-1aa2-4592-901d-4f26ad181672">22,319.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzMtNS0xLTEtMA_bc20c4f0-2994-435b-8aac-0f0c00f06f44">21,493.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonFraction unitRef="usd" contextRef="ie64e6e64f4cd4c3bb6d2fef573bc1cb7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzIyOA_d871e24d-0d88-42d8-a8e3-67ff5043482c">135.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i08a61dcc93ff4861bcfc64e6431e4d71_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzIzMg_9dd45215-c7c9-4107-93e5-2d29349092e8">301.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i2123f59cc857450a91ae3b7c97124bf4_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI0MA_d386448e-ed4a-483a-9957-548c22420c2e">303.2</ix:nonFraction> million during the years ended December 31, 2020, 2019, and 2018, respectively.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:durday" name="lly:RevenuefromContractPaymentTermMinimum" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzE0Njk_8a6ca513-b712-4366-8ad9-504f090334da">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:durday" name="lly:RevenuefromContractPaymentTermMaximum" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzMyOTg1MzQ4OTY3Mzk_cca368d8-3a31-4e52-b472-ab8ec8eef10a">70</ix:nonNumeric> days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:durwordsen" name="lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzE3MzY_e6e80b39-886a-4115-8435-f636ae9cd21a">one year</ix:nonNumeric> or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December&#160;31, 2020, 2019, and 2018, our three largest wholesalers each accounted for between <ix:nonFraction unitRef="number" contextRef="ic6a3fa17ced44cf6911c558bcef7ce7e_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2ODY_24078815-2cd1-49c4-8bac-f13e8eee9c6b"><ix:nonFraction unitRef="number" contextRef="i697978618d86456cbf1a2759d0f32502_D20190101-20191231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2ODY_5ee05c04-680d-4b86-90c6-d1457bad6158"><ix:nonFraction unitRef="number" contextRef="iacf1ad720b4c43bf8e96a192f4292dde_D20180101-20181231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2ODY_e31c59fc-4637-44e9-81b9-d90f54c089bf">15</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i1d4d013544c649448fda0d85a40880f3_D20190101-20191231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2OTM_655c0aa5-da51-4a89-a0ba-4f92b5276b13"><ix:nonFraction unitRef="number" contextRef="i9df231a5cbb94e458fd1cf844f24d8d7_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2OTM_7b9ba721-ae42-4651-b62d-f2e7dbfb8edd"><ix:nonFraction unitRef="number" contextRef="i4ae1b15ab56b43bc9a7777c2071ecf3a_D20180101-20181231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2OTM_fccd799f-6ddf-43bd-9273-4a6335a4abc4">20</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of consolidated revenue. Further, they each accounted for between <ix:nonFraction unitRef="number" contextRef="i72b23fff2282489ca3c0f894bb18cc07_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI3Njg_794f1c13-9a84-42c3-9883-0ba14e828a1a"><ix:nonFraction unitRef="number" contextRef="i55059f768986433ba6bcc5c4b2726cb8_D20190101-20191231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI3Njg_c6e93746-a2f2-40dc-8e36-bd6736c2e676">19</ix:nonFraction></ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i3b9ceecaa70744b5b18f2b550ef85ab7_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI3NzU_00712337-3d52-4bbc-b6f5-d8dc70617cd0"><ix:nonFraction unitRef="number" contextRef="iddba0e6da38240e58e8ef1983e1c0432_D20190101-20191231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI3NzU_7e97c758-1419-46e4-838e-c708d125fbcd">27</ix:nonFraction></ix:nonFraction> percent of accounts receivable as of December&#160;31, 2020 and 2019. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts and returns. The following describe the most significant of these judgments:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Rebates and Discounts - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i6c0829c95060469082aad67ac33a1ea8" continuedAt="i1e5a114705f04283b1f458b9d411558c"><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, chargeback, and patient assistance programs in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:durwordsen" name="lly:RevenuePerformanceObligationSalesRebatePaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzQ4MDU_0eab1310-7e73-48f3-a7b6-859392841f58">six months</ix:nonNumeric> later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Returns - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:durmonth" name="lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzU3NTM_30124f38-773a-4995-bad5-e2391d6e50ba">24</ix:nonNumeric> months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. In the U.S. we allow bamlanivimab to be returned if the Emergency Use Authorization (EUA) is revoked. If the EUA were to be revoked, we could experience an elevated level of product returns of bamlanivimab, dependent on the amount of product remaining in the distribution channel. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:durwordsen" name="lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzc1MTk_7fe622b9-b65a-4ac0-9412-2da3f6f572ef">one month</ix:nonNumeric> or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i1e5a114705f04283b1f458b9d411558c" continuedAt="id2f2186a62a74c52a1b6a8129d015b49"><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual U.S. product returns have been less than <ix:nonFraction unitRef="number" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="2" format="ixt:numdotdecimal" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzgxOTM_008d33fc-b3dc-4942-acb8-d8799d753750"><ix:nonFraction unitRef="number" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzgxOTM_0add62a2-5657-4e50-a4f2-a3edabfc9beb"><ix:nonFraction unitRef="number" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="2" format="ixt:numdotdecimal" name="lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzgxOTM_83e324ad-e3cc-444c-801c-61f7a5617a84">2</ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of our U.S. revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for the judgments described above for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods were approximately <ix:nonFraction unitRef="number" contextRef="ia5562538495445b2b19f079d4c482ee1_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzg3MTU_6952ddd5-8449-44ce-ae2e-bc6b7c1a4480">1</ix:nonFraction> percent,  <ix:nonFraction unitRef="number" contextRef="i2352e466ca6e45d1aefb7efed013e9cf_D20190101-20191231" decimals="2" format="ixt:numdotdecimal" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzg3MjI_4d315b4b-a846-418d-8bc8-bd0677878a62">2</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i56db8c7d699d4b908d30e96ead023336_D20180101-20181231" decimals="2" format="ixt:numdotdecimal" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzMyOTg1MzQ4OTk1MTg_021a919a-7299-4567-9cfc-6a5c36cb4705">1</ix:nonFraction> percent of U.S revenue during 2020, 2019, and 2018, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Other Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="id2f2186a62a74c52a1b6a8129d015b49" continuedAt="iafda8e83b69641fcbe9109fa6a8e5d4b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzEzMzg4_a5872f4f-3c23-4283-98d3-d06aa309a40b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTpmNGViMTM4N2ZkNmQ0MmVkOTVkZjA0MDIyZjgxM2YwNC90YWJsZXJhbmdlOmY0ZWIxMzg3ZmQ2ZDQyZWQ5NWRmMDQwMjJmODEzZjA0XzEtMS0xLTEtMA_cb729596-dea7-42b2-a157-5bedef10fde7">276.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTpmNGViMTM4N2ZkNmQ0MmVkOTVkZjA0MDIyZjgxM2YwNC90YWJsZXJhbmdlOmY0ZWIxMzg3ZmQ2ZDQyZWQ5NWRmMDQwMjJmODEzZjA0XzEtMy0xLTEtMA_663a25ba-b9c0-4eb5-b5e5-08b91b56839c">264.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities balances disclosed above as of December&#160;31, 2020 and 2019 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019, and 2018, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iafda8e83b69641fcbe9109fa6a8e5d4b" continuedAt="i0d5b0f026bec49498fa42b2a628cb667"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><ix:continuation id="i0f28c5c9c94e42ddab394022898d65a0" continuedAt="ia38db0d4d0e243758d618ab23a545530"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23b300ee7c04c219019df6e1ab48341_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtMy0xLTEtMA_994b54e4-6702-41ff-a973-10647821a186">3,835.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0bb72cacc846c4b1660192fa13fb2d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtNS0xLTEtMA_df12441f-5402-46b9-83f3-279acb86cfa5">3,155.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728a6f151f344cd5a4e1658f4456e4a4_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtNy0xLTEtMA_8d8e4f8d-6e9e-4cf4-9d09-cc6968c749c4">2,515.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6884b0346ff74a868a23cc494081187a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtOS0xLTEtMA_92736192-49bd-4d7d-94a6-f7cd383f289d">1,232.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d66c70ab574ec1a1e5591f1bb6849a_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtMTEtMS0xLTA_44987abe-a4d7-4e9f-a6ae-66447d0c80d7">972.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85836dd8d7c24266be724f2fd23636b0_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtMTMtMS0xLTA_240d8e26-8aea-4abf-b358-4df06bc98a8e">683.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie247b454823c4c899728fa1e7c3c6488_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctMy0xLTEtMA_5e88bcfb-2a4f-4e91-bc29-076dc71cf62a">1,485.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1561cbf5143e496389f63ec127805cec_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctNS0xLTEtMA_127d913c-b217-4e34-9863-e1cca3acdceb">1,669.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie24bf00d544347dd91396c4ce0a786d0_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctNy0xLTEtMA_2a1a8ef2-b5e1-4bc9-a9cd-59a9daffce4d">1,787.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec05ae419fb4e2fad130ef8bcbacb60_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctOS0xLTEtMA_df7975fb-8369-4fcf-8796-c1dea83bf3a6">1,140.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14247b991aa4660aaeff59ba9087029_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctMTEtMS0xLTA_ae3d7412-62be-4191-8027-0fcc141a844f">1,151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28072632c66a42a99ffb45b515d993c2_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctMTMtMS0xLTA_a369895c-5b9f-4e08-b417-5528cb311428">1,208.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191e8f8614e54664b788c1acd1a1b343_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMy0xLTEtMA_4f812aea-b451-4cfa-a800-c27ac72d9c30">866.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc75f49bc8dc4f318a19c8b6ce2d8bab_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktNS0xLTEtMA_6e8509ea-8e4a-46a5-bccd-3164b2beda68">879.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715dfb4b6d894d1c879e0379cbf8a8f4_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktNy0xLTEtMA_0daf56d0-f1da-4458-ac0a-286aa1c27911">910.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c183a74083641c0ac1bf8f66c7aac92_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktOS0xLTEtMA_d572d04c-cf73-4750-9dc5-c66f7e1ec8d3">393.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c928d58286344fb8bcd47e90bf5d627_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMTEtMS0xLTA_f8736aab-2017-4699-896d-ee62e994030e">410.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id975590de3cd4ec99467e999df92c9e6_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMTMtMS0xLTA_76bea735-ba30-4acb-95cb-8abac3698879">421.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2830a10550f04092843207d0fdc28a94_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMy0xLTEtNDQ0Mw_f5980449-4027-4853-b35d-975c911ca7b6">620.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e42ce139e604186891333c227fa7f7a_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktNS0xLTEtNDQ0Mw_69200ec7-29e9-4b0a-85c3-40a6de4aab82">565.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a798b0c03524583b15477c45770fbf4_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktNy0xLTEtNDQ0Mw_d9a0f27b-61a1-4283-b19c-f4e5eeaac913">400.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27309ca3061448f8aed7d50699b44c3b_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktOS0xLTEtNDQ0Mw_7d1ff01e-611f-48ea-ad56-0d06c1a4865d">533.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8238834ae2044c7c8f8d0f0b08cbd9bf_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMTEtMS0xLTQ0NDM_b4a724dd-ccca-4254-9b9e-77e690dd2155">378.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde87f830aaa4e7e95c3b4d0b564bc58_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMTMtMS0xLTQ0NDM_0ec6ec3b-6b5d-4339-8aea-00bd95c61540">258.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cbb8b5cf6f445e96a2f444f379af93_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTMtMS0xLTA_7bfd02f2-ad9b-461c-8046-67be2c3082ac">842.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e1e237c47e47c9828a59209311c512_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTUtMS0xLTA_8c61888b-c9eb-40b4-960e-4f2dc2e94acf">876.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085f2ef402e2415c9ef431e7b9de5970_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTctMS0xLTA_91d61356-2405-4af2-95db-cd8b940c4ecc">622.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134d638c9b8442bcb2b54a0dcf99244a_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTktMS0xLTA_036e435f-9004-4b01-85c7-bf32acaf7fc1">282.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35093190cc994e6184aeba18c6d4e4e5_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTExLTEtMS0w_ef378304-2001-4fae-b25d-d95dea154fac">236.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca91803bf7b4a89952e0d15df9e7d20_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTEzLTEtMS0w_f3177f93-c8d5-4c1b-8219-6294c0a5f293">178.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b03da787f1046dda25e71c726ed0cc8_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTMtMS0xLTA_09aee125-e9cb-4cf6-809d-42202f7e5f82">95.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ad299c9ff445079d8abfe019fefba6_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTUtMS0xLTA_9d87b4d1-cee6-4193-af6b-c77830de98d6">224.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8cd43064bc54a9e901c418b624a14af_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTctMS0xLTA_2dec32ee-e0e8-4a75-ae42-1509fd89fc65">224.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1421efbb7afe46ce9044e5d41f1e6871_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTktMS0xLTA_b8716674-81d8-45cd-9e8f-f80a770cfa2d">263.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8251cd1ee5a241ecacce9020401be466_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTExLTEtMS0w_4fe9819b-fd69-4fa1-8dc1-07e184a8ce69">365.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa14db9f257a4f7b8ca0845e9421f91b_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTEzLTEtMS0w_f1366d0f-b111-4f4a-903e-b4af5339ba4c">350.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bbd5d25f80c44ab94954c63d53de368_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTMtMS0xLTA_cc65d603-6f60-4937-8f64-852266f743fd">162.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb30e7b8f241492da7454e9da0b979d6_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTUtMS0xLTA_39a9a18d-c92b-426e-a42b-2f7413606eb1">158.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12680d1b9124165bc4f6d955d85bd82_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTctMS0xLTA_eef3eb58-4390-4cde-9ae1-828d96f2fe25">146.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i429185bfc6e449d7be22df700c5813fa_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTktMS0xLTA_c085f76e-0505-4ffc-8f31-b9e17d2eaddd">81.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25dfe0449994ce68da67470b4776d8e_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTExLTEtMS0w_27b93b22-6667-4455-a093-a38545e64b77">88.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8b9545410a04c8da65e3c6e319a22d1_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTEzLTEtMS0w_c90ed063-660b-4e8c-9a71-7d32a7a95baa">112.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cfb8009ead41cca1ae3072cccf9499_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTMtMS0xLTA_461135a3-d112-44fd-9d9c-7e4931be9979">7,909.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8dc99127224767a2f12d03a5092d3b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTUtMS0xLTA_064a3b6f-1e5f-4c46-8583-fd46dfe2c1bb">7,529.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca7b28a537c43b2af1ddf727727ce40_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTctMS0xLTA_8ea886b0-5ebd-45c9-8f15-ca2b3bc55724">6,607.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85186ccd9d984ef4932e09feef978a06_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTktMS0xLTA_489a434c-0aba-4fe1-8e67-f77c9d36f005">3,925.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e9cf6601c143cdb1b8d32ae6fd5480_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTExLTEtMS0w_08a1377e-69b3-46db-94c3-b2f6e82eeb49">3,602.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea814fafc7fb443db887570f7ea72927_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTEzLTEtMS0w_6d334be2-4a32-474b-9544-68295788361e">3,212.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05835511e414ca89be73a8916fad2e3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTMtMS0xLTA_2361495c-49fd-46af-87b0-1be2261fef75">1,265.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b3024a931a4657a4060b07b0425e72_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTUtMS0xLTA_29a9f499-f49b-42a5-a76c-36bb24fcc4a0">1,219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c1fe9ccbbb45969203d906ca0f642c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTctMS0xLTA_2ba580e9-255c-40ae-bf0a-3b8f98047128">1,131.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09cd8e4a702840b6b077b52bb0fc885a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTktMS0xLTA_0e3b1ada-30ce-41e0-ae18-0c0bbd3ad7b0">1,064.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21841be70ab492085d716fac088fb9e_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTExLTEtMS0w_b1a1c033-51b7-491a-a866-fdaea6fb421c">896.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73c0cb2f4924c719860a7896ccb64a1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTEzLTEtMS0w_0769f714-1e94-4f8f-83f0-5795f1f4ba8a">1,001.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ff519fc32f47c2a0c49159fe2e34b7_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTMtMS0xLTA_0b2fad3b-2bd8-4e8a-b581-8515b1626b17">381.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie914cb56ec4e4ed1ba232fbfee390bd3_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTUtMS0xLTA_91097a02-6735-4e71-9f8d-ab0da15135e2">335.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966ea8089e9c4d68b34e188c500666d6_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTctMS0xLTA_83fd16fa-cd53-4f59-9c55-a69a477de1d9">291.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9679e5d6124967a685918cd9edf0fa_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTktMS0xLTA_1ac3baa4-97dc-4916-8f76-22d392fd94c4">650.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea5fe8155344887ba522b8118049b2f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTExLTEtMS0w_f604d152-a153-471e-bce6-bfa80ddded8d">589.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3931b370dc143f9a310450ae75b2907_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTEzLTEtMS0w_138dd6f2-e49b-4c59-ba72-3ab7ad30f53c">529.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d2a58303ae4d49b78490eb27aa3acb_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTMtMS0xLTA_7901db92-2e80-42f5-b6f2-10dcc7846123">618.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbcdae9c84da42e5aeffa936f33600fc_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTUtMS0xLTA_fc24d5ed-050c-4b27-9d4d-bb322d836592">454.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88519de09ce340f2a440994d3a26273d_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTctMS0xLTA_bd3340c6-9a1a-4553-ac61-aad5498d1ef6">248.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9859caf33c4d129baaae6f1b8a77a0_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTktMS0xLTA_575dd200-bf3c-4b73-9235-f70d77817d99">294.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e90d63bd7f04d43b87e44bc9cf80dd9_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTExLTEtMS0w_42be6c0e-f97a-4433-8210-45efc5e54d81">124.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6f19b22df74b2997a2a5a704b7566f_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTEzLTEtMS0w_61119222-8eec-4281-8505-f5e35e8e37e7">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae16d89f887948a1bdfcbcfa51d0d3ff_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTMtMS0xLTA_bdbb8f60-890c-4046-8318-2b20c2e99ec0">480.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a47ec3ac9242599fb0534acfcf50c0_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTUtMS0xLTA_241b0595-b46c-4c8d-8eea-f5af068c13db">487.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7e75f9a985435381e8a50f0510b63f_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTctMS0xLTA_9c98dc03-b4cd-41d4-9e42-c55ea936cfd8">531.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18759d9c174433d92652e5cecea16b9_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTktMS0xLTA_99ec7790-ed05-4f3f-bacc-cfcfbd249d3f">56.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i121c5d89d6f84862b7a81c70128ff4bc_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTExLTEtMS0w_be424126-6c4b-428a-ae6d-d59edfde9cd6">55.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c089c556dbe4b988097309eea2debbe_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTEzLTEtMS0w_41f7f877-15f1-4b94-ac55-c467ca618973">103.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f7338fb226246619bd2bbf15851f0e3_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTMtMS0xLTA_eb3f0a55-03d7-4e48-a88d-0914f291e31e">46.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if209842982b343139ff9db8653d11910_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTUtMS0xLTA_ee605673-87ab-47a1-8847-928b5a239e96">111.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic909dda5665e4ba29f047d0b8e1bcf5f_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTctMS0xLTA_35d0e3f4-0f80-4bfc-ae7e-972487a79a2b">200.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f3bd326f604139a90da118ac9c06c4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTktMS0xLTA_04d6d5ce-ac2e-4f5f-9dff-076cd8493974">461.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c0080f9e714abea664e5caa8d145d9_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTExLTEtMS0w_6777bd72-d805-4aaf-928e-d903adc7f075">339.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb52b4c8c5542df810d31d40cd2b4b5_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTEzLTEtMS0w_4813b201-7861-458e-b8b9-ee495b5f6316">215.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf91ad79a82a4ec5b3a916c3289276f9_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTMtMS0xLTA_4f23d55f-ecdc-4b1a-ad9c-fe2e6c936838">2,792.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de717625dca44c78e1e0e949939a76e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTUtMS0xLTA_9b4f9848-a24b-4f54-a8a0-86a0428d0681">2,608.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b654e430e44c46b106bcb63224dd6a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTctMS0xLTA_25f37a1c-f0e6-44b5-a271-03285fe2fb2b">2,403.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fbcc61f59a45d9a37e569ed5965f58_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTktMS0xLTA_b57a3705-92be-4e2b-b695-66fe298670a4">2,527.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d13169d2141455bb4a93b34de2a366e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTExLTEtMS0w_e598c3ec-7e6c-44a2-b8cc-60a2ac1e816f">2,005.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a6364df78042fa901d2f1c28c93754_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTEzLTEtMS0w_19c97f89-d4ba-4c33-ae5e-854226876674">1,857.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e09d571eb774bd5b689a1bb4eb4de7f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTMtMS0xLTA_289f6912-3dad-4bb0-96bb-2723aa531614">1,288.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2dc9d878a14c9ab4c5b052d73bad3f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTUtMS0xLTA_ff318635-95b8-4d58-94e0-e3f0a9074ea3">1,016.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48cc43a68c8427793e98a1018af69e1_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTctMS0xLTA_1778f9a7-a967-4c68-affd-6effa47f186a">738.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14522eae3f4432ca88eefdbd852a7fe_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTktMS0xLTA_320cadc9-c946-4eca-977f-245748333850">500.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f778c41acb14e25af188e39dbcf6369_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTExLTEtMS0w_f0e21bbd-c0fb-4594-907e-b70cea1fd6c4">349.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e201e3b4b174110a0451d32f28f8212_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTEzLTEtMS0w_dbf87b26-8e3d-4a7e-8119-1a710e55056e">198.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9993567a2444faa53e3c75a8e44e1a_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTMtMS0xLTA_ef0708b5-70e5-46db-8f8e-af45ef8534b4">63.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db6d4c2a25b4bb0bc740c90579b0f05_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTUtMS0xLTA_4e8abba9-a12e-47d5-b1be-62dbaab18bac">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf78497fb94a405aa4fa741353f71471_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTctMS0xLTA_f249987f-5fd2-4912-a99f-bcaca83c2d16">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6279b04ecce545a2a6ccd1edd954a346_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTktMS0xLTA_97096b51-d9a0-4fa9-a9f5-a7a5da8b708d">575.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic653dbcb57f34df2a7cdbe7b36ad01d2_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTExLTEtMS0w_9a29e9da-9d27-4b94-8bb0-5b1ec045edd4">384.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2f75b6ec544748a1740ef4680b574b_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTEzLTEtMS0w_8416b8af-cef1-45c9-90b0-1266b73dba42">195.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382d0dc50c7442e584209c6d42e6be90_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTMtMS0xLTQyNzI_595d2745-ee81-4d19-a2ba-95d0d1886267">20.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27a0a7bc70a4f50a74d2e0dacdf5b43_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTUtMS0xLTEzMDgy_56af49a9-0988-4f1d-a32f-89c2f6bc0a6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca201e6a4584a94adee1b47b0e65d3a_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTctMS0xLTEzMDgy_40888523-ddda-4b8a-99e3-e6b67586c16e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d3783f314a422f9244251ce8f5d9f8_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTktMS0xLTQyODM_ecb86832-aff5-43eb-a3d0-3db92b34ec55">14.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f653f3992f470ca575e3abea9ae426_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTExLTEtMS0xMzA4Mg_75fa913c-5d54-4a9d-a296-3ff797b55958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c414a5e65d42939a3f580b88d368a9_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTEzLTEtMS0xMzA4Mg_0db45616-8fa6-4b74-a045-61287414db4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54e1b52fe0945a18f903058aed5a173_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTMtMS0xLTA_507942a5-49df-47ac-bc32-f7a192026e80">1,372.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092485a179404990a1b3f5d43565922d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTUtMS0xLTA_ebabc61c-76d1-4d48-9957-84fdc305c1d2">1,059.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbcfad66d94c42699bde82b3cc71bb61_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTctMS0xLTA_746422af-76d4-455b-a31f-ef547e9a6090">745.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d67124e0304de6aa72358898ffee74_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTktMS0xLTA_1340fcaf-eac0-4f1d-98c7-75903056ecf5">1,089.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7465980476074ec1b9f2cf051bd93aab_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTExLTEtMS0w_833ee73e-b1f6-4527-a5ee-8e98ee2655d7">734.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i405fef2f42e9480580d5e77115611bc8_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTEzLTEtMS0w_f3ff8a32-a17e-4370-ae1a-0b97e3108280">394.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21029b52e3a4a25b8fa5ac32c01193d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTMtMS0xLTA_3f304877-0cc9-4ee2-8157-4b369178e93e">42.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e3ba10cc2340fcb7a501bb4088f695_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTUtMS0xLTA_453a683b-09c0-4af8-8df2-95b305ff6add">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i194d5e8204d94e729dce3e5167479788_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTctMS0xLTA_78fe7c36-d51d-463c-abcd-5cd9b1e2a5f7">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42aed1d813ba440d989563043cbf63d9_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTktMS0xLTA_52d9654d-fc76-4e4d-9a9f-6cb6f881a94d">725.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93e5c1a7b044586b825fb8d87adef56_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTExLTEtMS0w_f2ceed23-fe5d-4e8c-8b4e-5762f8fc1f3d">675.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6282183e9fda43d6a25c5ce5f92ff949_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTEzLTEtMS0w_a998712c-ebef-4391-a08c-06b092bd8f9a">653.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3164ae1013b84936a3990cdd7069cef8_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTMtMS0xLTA_40cc25b0-74fb-4c29-bebd-6a4083e572fa">46.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6226f69ada1b4d4293ca0d61745f5115_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTUtMS0xLTA_a17bbefe-a81b-4e8c-a7e4-46f39eef9948">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i464b09a2e18141e18ffa754a848112c9_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTctMS0xLTA_f90b1d9f-263d-4f9d-b801-936a7f5dd886">36.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471982bd0b034ecbbe77d99805441a0f_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTktMS0xLTA_58e2720a-9ca8-43e6-ae4e-e0ea8ba19e76">360.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76bec07f3464f1c8021d24050c68ea6_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTExLTEtMS0w_6e66d44c-479b-404f-b0a1-d0ebaad8737a">377.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39a7fc11f9746e597092068de88f47b_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTEzLTEtMS0w_5a206d26-6e7c-42b7-a1c1-2836aaf9f5fb">435.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic60748556476451f97a39a8498268861_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTMtMS0xLTA_31df4496-61e6-4b61-b3f5-0f7cc542e063">325.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ce9eaf6546546d389e4f26520e4930d_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTUtMS0xLTA_bab4053a-a84a-4618-8d4f-c55b7952b6d9">154.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856f4e27d0e54f3f8f678504c46706a3_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTctMS0xLTA_6a580921-7184-45c9-82a1-ca5e7a53abdb">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1246f125dde64914934faf191b569fad_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTktMS0xLTA_c94c62b0-cd0c-418f-8fc5-efda8a63aafc">37.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac47103ffb8e4db3ba8420ae1884ba32_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTExLTEtMS0w_1008d669-4f20-4dc3-8897-83200f3ff0a4">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971612ddc6f84ff5ab4cebc6bc9b7489_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTEzLTEtMS0w_5036ea00-fde7-4d96-9d8e-fcf5ff611187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4460d0fbe7498caa8faf2ab1635509_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTMtMS0xLTA_bd85f2c6-e795-4ee8-afea-4ab77f3288e5">73.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie954542f232d49269cf42f99d87610b5_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTUtMS0xLTA_e7cd4971-384c-4b51-87fe-a66b5c924a79">111.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if596ee8084b746c1884dfb23161b95a2_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTctMS0xLTA_e38d1fa8-74b4-4842-8d02-c1406ce35cf7">182.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4c40ad02014289884f8f89f9cd98a0_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTktMS0xLTA_503e9449-7455-4b48-a602-8207a0fc6589">220.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d98f1e0f63d4944acdd4049c11f843e_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTExLTEtMS0w_3ae9949a-be3b-4db2-a3bd-6cac68cfc643">305.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b22a1b043d84461acbaead22e49cd3a_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTEzLTEtMS0w_492d2616-6460-43bd-955f-f2296abf520d">454.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c01d5260804ef2aefb47f37eac34b9_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTMtMS0xLTA_62d35583-6545-4e29-888a-7c3a32f3e285">487.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6ecf87283c4add86844acf0df92029_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTUtMS0xLTA_392ca81e-c068-4ac9-ac6c-62e833cae0f1">356.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5420c07a564b57bce98a24d8094aea_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTctMS0xLTA_70030851-7cac-4fba-98b6-65bc2d61a4d6">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3730e62c21c49eeb0a31d079c88843e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTktMS0xLTA_2b491e86-52e6-49ce-912e-39e6190eabf2">1,344.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b39e0b4d84459b937f1252cad92e0c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTExLTEtMS0w_7dc921d3-9ed8-40dc-a7b2-c7f51c141757">1,366.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe81f38456364de09c2c37f4eb63cfc5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTEzLTEtMS0w_b239909c-a7ad-4252-bc1e-4f69e6ef24db">1,543.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1659ec78a740ca9d2960b4d4f4fea4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTMtMS0xLTE2NDM_bcb19323-4c1f-40f2-ad68-3b14132ffcd8">510.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb82d9ffde3c4a3a8affb2c0815b56d2_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTUtMS0xLTE2NDM_23508da6-3fbc-4e51-a51b-bf934ddafb5b">645.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i576e907b609447808b7b5933c0df5f34_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTctMS0xLTE2NDM_953a188c-a327-4e67-985d-2ca215bf65e5">757.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33620d8d08d44b8b383b1f866bf2e64_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTktMS0xLTE2NDM_948f1142-1bc0-4287-9f53-a228ea7ad40d">536.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbec8a0db57b47818082aea617fcb08e_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTExLTEtMS0xNjQz_0b00d541-0e4f-4149-aa6d-4c686687e0ba">759.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49f010469e74c1fbbb54018a3403a10_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTEzLTEtMS0xNjQz_89c31a8e-95cf-4161-a206-06b10a2d411e">817.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bamlanivimab </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1f8bd5f6e7439cbf1c41e604f947cd_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTMtMS0xLTQ0NDg_7243adea-0cca-4b77-aaee-f199131ff267">850.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9913b2677a470782bee3b901368718_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTUtMS0xLTEzMDkx_e0bc23b5-31e9-4f18-92ff-f793cec1b640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a98260337a41c7bf70c5041273cf30_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTctMS0xLTEzMDkx_61da493d-b610-4157-8d26-57de47c2a341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69dd705bb5be40cda1cf159e67bfe51f_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTktMS0xLTQ0NDg_28b86798-a69a-4398-8b05-9a198234f064">21.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i254787900e9a4e7182dcb921c4b5d695_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTExLTEtMS0xMzA5MQ_384fe1d8-3945-46d3-9c50-c1e1d2aee397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5671e1d40a394d5aa617890df516c413_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTEzLTEtMS0xMzA5MQ_f7ce7d43-652e-46bc-a69c-980a50fc8ebc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4d6c27c076414ba7e9464801d0140b_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTMtMS0xLTA_c7ccb026-75e4-476a-aeef-9afc11ccf509">61.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e1b22d70974fcc95c281ec5f6e788d_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTUtMS0xLTA_86edb975-c759-4762-890f-4e3cedd67b12">231.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67ee0b00db446ecacd2b9f627d621d3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTctMS0xLTA_4b95ad0c-cc99-464e-9e0f-06f78f8fb37a">1,129.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf51f9d513a64c25a6eeaf8e33921e20_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTktMS0xLTA_5063afb7-d257-40bd-9600-7404e7db510f">545.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia079d10886be402287aaa123fc31ddf0_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTExLTEtMS0w_437a8e40-0f05-41b5-b639-163a1c9fed4c">658.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b37da845eb34ab9aa5276ef319e7926_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTEzLTEtMS0w_be582992-f9c5-4cab-a73b-e4b787596c81">722.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91bd92d27afd4390915113b0bb32dba6_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTMtMS0xLTA_7ad1229b-db5a-4159-864d-c8f6f2d36e27">246.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie311a24502de4314b71b45580255cb57_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTUtMS0xLTA_afd4a6b6-90fa-4ec2-9c17-085a40c3c3f0">291.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff5458bec1b144e5afafc2f8657e9b86_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTctMS0xLTA_4051e24b-7aac-4ad1-8ef9-096b42a73038">471.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8656193e314466a66ea72a95a19692_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTktMS0xLTA_c9564c60-6349-47ac-b4b7-9ab52d0f4d43">321.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756013fb987e4ec49313e27c98887d9b_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTExLTEtMS0w_612b29f0-5b20-4077-9830-b29a12c51add">469.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48736069f07d435ea802718ad0061329_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTEzLTEtMS0w_da080c31-1d6f-4876-8e5b-b440d9c6bbb3">553.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f15eb6661ce4b1abb626c73e242befc_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTMtMS0xLTA_ead935c4-1900-4372-938a-35de2bff6663">1,668.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55080d1515744962b9aef976d3cfdc53_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTUtMS0xLTA_c40d600e-f4f5-49c9-b588-fc01fbc32ca0">1,169.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie546cf165ddd419e9f13ce7b33b842b3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTctMS0xLTA_7250fade-b879-49b6-ad46-7da06d00fe6d">2,358.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1485142ec4594191aa24ebdd7a9ee8bd_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTktMS0xLTA_4960fc4f-0a7a-41e8-867f-7545f89766b4">1,424.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e49c0f20674d7eb574b88861a45d59_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTExLTEtMS0w_753f0ad4-ad8f-46a6-b051-a6a37e6dde0b">1,887.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5388a613eeb490eb1588c4dca37c078_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTEzLTEtMS0w_4f637647-7f05-4b18-885c-7d225660c7ed">2,093.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fbcb5755144a989fd1a37e01482bcf_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTMtMS0xLTA_111520ec-23fa-4d0a-b92d-f3de40eb1329">14,229.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e93087d035441c7b9196cf48b975ccf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTUtMS0xLTA_04deb0c4-9266-4613-b4ac-84ca523ecd82">12,722.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056be4f4187a4d8ba5795cb66a7c63e2_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTctMS0xLTA_dd6b5bfb-d85b-45bb-895c-d7f734dade41">12,391.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ff3b39dc584d80ad523e152d9aac2a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTktMS0xLTA_39c70f19-7293-483a-82ac-4e1928d04bce">10,310.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9042f18954a44f338ab7c4c38402701e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTExLTEtMS0w_301156f1-c836-41ce-bf90-f79c13c5bfae">9,596.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231c072e54b14e93bb61feda90673766_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTEzLTEtMS0w_254a32d1-5780-4b92-9da9-8e49112d0b9a">9,101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trajenta revenue includes Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Bamlanivimab sales are pursuant to EUA.  </span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i0d5b0f026bec49498fa42b2a628cb667"><ix:continuation id="ia38db0d4d0e243758d618ab23a545530"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:38.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fbcb5755144a989fd1a37e01482bcf_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzMtNC0xLTEtMA_6ff908a3-7e1b-47df-b1ae-d7dc195a86a1">14,229.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e93087d035441c7b9196cf48b975ccf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzMtNi0xLTEtMA_a9e44b4d-5bd4-44f1-a80b-4eade618b6dd">12,722.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056be4f4187a4d8ba5795cb66a7c63e2_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzMtOC0xLTEtMA_ea5a6eca-548c-4834-923d-e85459909309">12,391.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f9aa8b13a844198c584392ffe612ae_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzQtNC0xLTEtMA_b2c8bfc5-2240-4b6f-b0d6-3cb21e26ec1a">4,187.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75eac947e5c24423826502ab09453d22_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzQtNi0xLTEtMA_de6dc188-583e-434d-ac5c-7a24f90de4ac">3,765.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf5ac51274948a2a524006ba7646b34_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzQtOC0xLTEtMA_c4343421-1885-4c37-98aa-555fe92e2853">3,663.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie404784c5a4c4f23bdcd42cf33eca1b1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzUtNC0xLTEtMA_62e1901d-a5a5-403a-adf2-b883432c46b3">2,583.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f19444ca5d74e42b8447a4f2274754d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzUtNi0xLTEtMA_fceda363-ef41-44c3-8146-1034d8005263">2,547.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04bae10a0f824b3db0e8166ff0c20364_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzUtOC0xLTEtMA_fb4825af-ecfd-426c-9f3f-286b1badd79b">2,407.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d3b673fac540279a7f2aacdfaa0069_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtNC0xLTEtMzI2Mg_0ba17281-fb2a-4a90-994d-4fbe453fe1ac">1,116.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792013c79753444599d13628b640dc41_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtNi0xLTEtMzI2Ng_5d386193-3f8e-426f-936a-a3fab07c9cb0">939.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b32d9391794988a11cc682565b7a80_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtOC0xLTEtMzI3MA_2a70f92e-d01e-4d7a-a786-00b361f4c73c">750.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0d2e470af549b4881425b33c0ad415_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtNC0xLTEtMA_f16bbb89-d68d-4dd3-b2e9-9d1e96a0868e">2,422.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6137d276b0f47409d9ce0335e227625_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtNi0xLTEtMA_f80b5dc3-f46c-42f7-9e2e-bd6e7f682dc3">2,344.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0163d1b6ab54735a54f26743f4772ea_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtOC0xLTEtMA_dfdb378e-13ff-492c-8c33-993d684d1890">2,280.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzctNC0xLTEtMA_5c23846b-f4d0-4a1d-9887-71939f8c0c76">24,539.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzctNi0xLTEtMA_ad0b91e3-bf60-43c4-8cf0-ebe450fd9ad8">22,319.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzctOC0xLTEtMA_ad19d2f6-475b-453b-9d8e-dfef1f6ff86a">21,493.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div></ix:continuation></ix:continuation><div style="padding-left:9pt"><span><br/></span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_124"></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzU4NDM_82371910-22ba-496c-b086-d141a1d11611" continuedAt="i1732d11757cc4c22807cf8ce9dc4dd34" escape="true">Acquisitions and Divestiture</ix:nonNumeric></span></div><ix:continuation id="i1732d11757cc4c22807cf8ce9dc4dd34" continuedAt="ibc9db26d48f3474cbac891602ec04895"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 and 2019, we completed the acquisitions of Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzU4MzI_3a6a617d-fa61-4a62-a4c2-37b6a9c64930" continuedAt="i9dc31ff8670c4de1870a778a6252a1c3" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development in 2020, 2019, and 2018, which are further discussed in this note below in Asset Acquisitions. <ix:continuation id="i9dc31ff8670c4de1870a778a6252a1c3">Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use.</ix:continuation> For the years ended December&#160;31, 2020, 2019, and 2018, we recorded acquired IPR&amp;D charges of $<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzExODM_87bd13f3-326a-4804-b6a9-653203cba8bf">660.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzExODc_dffb96f4-6fee-4b1c-8f89-9277319d42f4">239.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzExOTU_5b7904e5-20f9-40fb-a45b-6e55f05d0749">1.98</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i0447dee610924071bcc739ab2cface2b_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzM3Nzg_5409bc59-3060-42b8-b597-08d4abbf7b57">849.3</ix:nonFraction> million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the U.S. Food and Drug Administration (FDA). We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $<ix:nonFraction unitRef="usd" contextRef="ib39f7cc613994dd990be73fcc3b87286_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUwMzA_60323d9c-7a3d-41ac-827d-239d00949aec">86.8</ix:nonFraction> million, other intangibles of $<ix:nonFraction unitRef="usd" contextRef="ib39f7cc613994dd990be73fcc3b87286_I20200229" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUwNTY_8d037ccd-0b70-41d8-964a-72099663258a">1.20</ix:nonFraction> billion primarily related to lebrikizumab, deferred income tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="ib39f7cc613994dd990be73fcc3b87286_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUxMzA_92cc5d6b-3423-4ca5-84cc-e178933e40fd">49.5</ix:nonFraction> million, and long-term debt of $<ix:nonFraction unitRef="usd" contextRef="ib39f7cc613994dd990be73fcc3b87286_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUxNTc_a26167e7-0bae-4795-a476-ef98c90f4d35">375.5</ix:nonFraction> million. After the acquisition, we repaid $<ix:nonFraction unitRef="usd" contextRef="ibd24952151d6401a8d349f6aa9770ddb_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUxOTU_3f742ad5-c397-48cd-8553-ba782458dce6">276.2</ix:nonFraction> million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the year ended December 31, 2020. We are unable to provide the results of operations for the year ended December 31, 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our results of operations for the years ended December 31, 2020 and 2019.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ibc9db26d48f3474cbac891602ec04895" continuedAt="i20a30bd59b934fabb1a17fae50eb9c81"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Loxo Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired all shares of Loxo for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="ic44351e94bb742d683da05ff0074d5c2_D20190201-20190228" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEzNTM_3b6e81ce-f97d-41a9-a901-3b2e8bc4c2c0">6.92</ix:nonFraction> billion, net of cash acquired. The accelerated vesting of Loxo employee equity awards was recognized as transaction expense included in asset impairment, restructuring, and other special charges during the year ended December 31, 2019 (see Note 5).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib (LOXO-292), an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. At the time of approval, we reclassified our $<ix:nonFraction unitRef="usd" contextRef="i56fecb64135f4cca97024ac5ee838679_I20190215" decimals="-7" format="ixt:numdotdecimal" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTYzNzI_ef7db691-54c3-4bc8-9280-00252e6a3890">4.60</ix:nonFraction>&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived intangible assets to finite-lived intangible assets and began amortizing straight line over its estimated useful life.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzU4MjY_effe9acd-28c2-497b-9d55-4a07432c882b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at February 15, 2019</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215" decimals="-5" format="ixt:numdotdecimal" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzEtMS0xLTEtMA_3cf8539d-5f8c-4972-b816-2c8f5f429a55">4,670.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangibles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzItMS0xLTEtMA_98d85e65-f81c-4430-9b84-851d9fa94ea5">980.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzMtMS0xLTEtMA_f3896e36-78db-4585-a22e-fd500e76e6ab">1,032.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzQtMS0xLTEtMA_0eaf69b3-5ec1-4b90-b02b-775bbc7495e1">26.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzUtMS0xLTEtMA_b3efdcda-0b33-434f-92b5-75df3c70c4d5">4,590.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzYtMS0xLTEtMA_06564147-114d-4e4b-90b7-61e481752cf5">2,326.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred - net of cash acquired</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzctMS0xLTEtMA_7c480bf3-8d92-446f-b119-798437f45916">6,917.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i56fecb64135f4cca97024ac5ee838679_I20190215" decimals="-7" format="ixt:numdotdecimal" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzIwMzQ_01c8d46f-3325-47f1-a194-59392c71590b">4.60</ix:nonFraction> billion of the acquired IPR&amp;D relates to selpercatinib (LOXO-292).</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract-based intangibles (primarily related to Vitrakvi) which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of approximately <ix:nonNumeric contextRef="i6d91ff7b27004f208f75b0a5c87e5819_D20190215-20190215" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzIzMzI_c6d14b35-0468-4a8a-9aa5-d4e1875e98cc">12</ix:nonNumeric> years from the acquisition date. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated statement of operations for the year ended December 31, 2019 includes revenue attributable to assets acquired in the Loxo acquisition of $<ix:nonFraction unitRef="usd" contextRef="i9219272b6237462ebdaca8970a975081_D20190201-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzI2NzE_d76cf1fe-fa54-4a97-8690-f9813e726689">136.7</ix:nonFraction> million, primarily due to regulatory approval and sales milestones received. We are unable to provide the results of operations for the year ended December 31, 2019 attributable to Loxo as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our results of operations for the years ended December 31, 2019 and 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzU4Mzk_b26576bc-48a9-4842-86e5-8d62c952e537" continuedAt="ibe9fa9a65aef41378931f4df333498af" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and narrative summarize our asset acquisitions during 2020, 2019, and 2018.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817bc774c0a8475dbbe3fec31acb4ee2_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEtNi0xLTEtNjU4_62dde002-e847-4ab5-9f89-a94dde4024f0">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatement and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec4b9cb82304fe1a9d510e0419943f5_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzItNi0xLTEtNjcx_c4fa1584-54fc-4978-b66b-1b7dbf9a7f69">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4c539b649e4eb2b5f76577e83e9100_D20200501-20200531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzMtNi0xLTEtNjc4_7a2418a7-a1d8-4b96-8553-a4944b6f3568">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i20a30bd59b934fabb1a17fae50eb9c81" continuedAt="i135388343ebc414186450e0b26595f4e"><ix:continuation id="ibe9fa9a65aef41378931f4df333498af"><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical target that could lead to potential new medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2dc373598f440289cea2acfc3527726_D20200501-20200531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzQtNi0xLTEtNjg0_3b73d8b4-e4c7-411b-95a4-d21fc42e6df8">174.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Ltd</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical research collaboration for the potential treatment of neurological disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e93668371324e1ca8c0ee4bcbd18801_D20200601-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzUtNi0xLTEtNjkw_55d86e83-25ff-490a-a2ef-8c9e40e00351">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb9be66049641c9ac68c3d117603a04_D20201001-20201031" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzYtNi0xLTEtNjk2_0230e72c-1ecf-4704-8294-4b478900e0a8">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. (Disarm)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba61e61e3baa4e2997fa60b1e4f4971e_D20201001-20201031" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzctNi0xLTEtNzAz_a5036b92-21a5-44d3-8ecc-90dcd0d9877a">126.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fochon Pharmaceuticals, Ltd. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical molecule targeting  hematological malignancies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec4ba9fe07284d088597742e1436f206_D20201101-20201130" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzgtNi0xLTEtNTQ3Ng_6be54d8c-87a4-43a5-b072-2067ad47516a">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AC Immune SA</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2019 &amp; September 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9280278cfd44c43961529cec49d61e7_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEtNi0xLTEtMA_43c44e0d-4ed8-44be-a58c-e47bd46ff3e0">127.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmuNext, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel immunometabolism target</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdaa22fe62fc496280072ca3fca4be80_D20190301-20190331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzItNi0xLTEtMA_603face9-9ece-4618-adc5-1334b9fd9016">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avidity Biosciences, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential new medicines in immunology and other select indications</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0a2d07df0d4feda7f5fd4749d43715_D20190401-20190430" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzMtNi0xLTEtMA_c511f041-c57f-4d76-9bc2-faa79c2fb300">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centrexion Therapeutics Corporation</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639e2336e84c4b14a58a28b021459d91_D20190701-20190731" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzQtNi0xLTEtMA_c95ea8f5-a106-44b5-8833-9e78ef72b7ff">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sigilon Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encapsulated cell therapies for the potential treatment of type 1 diabetes</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840bb93977c84d32a309ff7a8196c494_D20180401-20180430" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzYtNi0xLTEtMA_793f590a-524e-4314-823a-00d6df0465a9">66.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AurKa Pharma Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK-01, an Aurora kinase A inhibitor</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9269ad1f97554a34afb28d633cb92685_D20180601-20180630" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzctNi0xLTEtMA_ab6a9964-2d4c-4bd4-b159-fd7f4c8021e6">81.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARMO BioSciences, Inc. (ARMO) </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer therapy - pegilodecakin</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6890b2b6dd4c4f7cb1263fb822f41093_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzgtNi0xLTEtMA_9672d73c-5363-46fe-982a-3e8d1b87bbfc">1,475.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anima Biotech Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation inhibitors for selected neuroscience targets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da5e2bb6fb443248dc40e30fed39f7a_D20180701-20180731" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzktNi0xLTEtMA_be63775b-a9a4-4b8b-95af-186e95f14c93">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIGA Technologies, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib406c368ebb248a6905e51cdc446be75_D20181001-20181031" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEwLTYtMS0xLTA_0c18d5bf-8fdd-4e2b-acdf-2ff69232f181">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chugai Pharmaceutical Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OWL833, an oral non-peptidic GLP-1 receptor agonist</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a390840d5f4630bf6cdb7e10975ac5_D20181001-20181031" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzExLTYtMS0xLTA_c8499a8e-ab97-49fc-a551-b6cbf32d95d1">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NextCure, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology cancer therapies</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd61d5c90aa43c0a362a60341c2d2ad_D20181101-20181130" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEyLTYtMS0xLTA_b3feba55-ed55-4277-b959-a93944eb68e3">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dicerna Pharmaceuticals Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardio-metabolic disease, neurodegeneration, and pain</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162940fb176e48c1a385b23fcc164f0c_D20181201-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEzLTYtMS0xLTA_30b0567d-2938-46d3-821f-b8b6fa6a67c0">148.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hydra Biosciences</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 antagonists program for the potential treatment of chronic pain syndromes</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2e25f473eb845d2843f5335d4f49aed_D20181201-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzE0LTYtMS0xLTA_61198c4c-cad6-40a1-b951-51db209ba3fa">22.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized the acquired IPR&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="i28cd09163e9a470f87436cbc6e159574_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTYzODc_9d9b4ac2-17c4-456a-a28d-4df730f00822">25.0</ix:nonFraction>&#160;million in May 2020 upon closing of the transaction. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expenses of $<ix:nonFraction unitRef="usd" contextRef="i9a68330743054dfd8a5f47bd40a19db8_D20190101-20190131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzM0Mzc_3d463f3a-ed0f-4c4c-833b-25286c43caa8">96.9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in January 2019 upon entering into a license agreement and $<ix:nonFraction unitRef="usd" contextRef="i3922fb112aac468ba7f7550c759a6166_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzM0OTk_5f093905-ab55-4000-88a3-2e33f2a0020a">30.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in September 2019 upon entering into an amendment to the license agreement.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This research and development collaboration agreement terminated effective March 2020.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i135388343ebc414186450e0b26595f4e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestiture</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we completed a transaction in which we sold the rights in China for <ix:nonFraction unitRef="medicine" contextRef="i2ab202db20bf44e79b70b6fe34785936_D20191001-20191031" decimals="INF" format="ixt-sec:numwordsen" name="lly:NumberOfMedicinesRightsToSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzQwNjQ_ef145467-29aa-4d35-84cb-b7de64b2583a">two</ix:nonFraction> legacy antibiotic medicines, as well as a manufacturing facility in Suzhou, China to Eddingpharm, a China-based specialty pharmaceutical company. In connection with the sale, we received net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i2ab202db20bf44e79b70b6fe34785936_D20191001-20191031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzQyNzU_58c9abc3-6243-4305-bc21-9a3f26700366">354.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i24260a2966224f0aaff14390ed8899c7_I20191031" decimals="-5" format="ixt:numdotdecimal" name="lly:DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzQ5NDc4MDIzMzQ1MzI_54912d7a-5fdb-4f29-9bf2-e0b6a4f2a857">40.3</ix:nonFraction> million from Eddingpharm in 2019 and 2020, respectively. We accounted for the transaction as the sale of a business. We recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="i0bd2f82569394ceb825c6ab486475ce3_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzQ0Mzg_7920f962-1809-40d6-b392-bdafd90630c0">309.8</ix:nonFraction> million in Other&#8212;net, (income) expense upon closing the transaction in 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Precision BioSciences, Inc. (Precision)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a research collaboration and exclusive license agreement with Precision to utilize Precision's proprietary ARCUS genome editing platform for the research and development of potential in vivo therapies for genetic disorders. Under terms of the agreement, we paid an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i456272c8da464ab0977d30b650506a1b_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0MDI_0f0b9755-8db9-41dd-af1f-6d24fddf70c5">100.0</ix:nonFraction>&#160;million and invested $<ix:nonFraction unitRef="usd" contextRef="i456272c8da464ab0977d30b650506a1b_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0MTg_05498df2-6d35-495c-bd17-9513028c21b4">35.0</ix:nonFraction>&#160;million in Precision's common stock at a premium. As a result of the transaction, we will record an acquired IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="i98a914a9a3184c15824f6ca6f22e6887_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2Mzk0ODI_fd923d4e-8b52-44d7-97cc-80b579542389">107.8</ix:nonFraction> million in the first quarter of 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Merus N.V. (Merus) </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a research collaboration and exclusive license agreement with Merus to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. Under the terms of the agreement, we paid Merus an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i80f0e3d4afc04fa5958a6ff84edcb67c_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0MzM_82e780ed-104c-41d5-9f94-19086c478f15">40.0</ix:nonFraction>&#160;million and invested $<ix:nonFraction unitRef="usd" contextRef="i80f0e3d4afc04fa5958a6ff84edcb67c_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0NDY_bafa4090-701e-4707-9bd8-ccbaec53ddaf">20.0</ix:nonFraction>&#160;million in Merus common shares at a premium. As a result of the transaction, we will record an acquired IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="id11c18de10e047e29fc8f48ccd7ad3d9_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0NTk_ad69a74a-0849-477e-8582-8fec9e273b08">46.5</ix:nonFraction>&#160;million in the first quarter of 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Therapeutics Inc. (Prevail) </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we completed our acquisition of Prevail. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that will be anchored by Prevail&#8217;s portfolio of clinical-stage and preclinical neuroscience assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired all shares of Prevail for $<ix:nonFraction unitRef="usdPerShare" contextRef="ib592ca19ca78498fa6f8c390254088c8_I20210131" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0NzQ_15c346a1-d5a1-4858-8d1e-14cc1355fa1f">22.50</ix:nonFraction> per share (approximately $<ix:nonFraction unitRef="usd" contextRef="i5102763567ac4b82ad95c44a59000d4b_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0ODI_2094ad66-a860-44aa-9b91-ab3080541b57">880</ix:nonFraction>&#160;million) in cash plus one non-tradable contingent value right (CVR). The CVR entitles Prevail stockholders to up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="ib592ca19ca78498fa6f8c390254088c8_I20210131" decimals="2" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0OTY_c8270c52-1642-498c-a494-0d06885bf0fe">4.00</ix:nonFraction> per share in cash (or an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="ib592ca19ca78498fa6f8c390254088c8_I20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY1MDM_f9e97552-157c-4078-8e34-1dc8122a1ab1">160</ix:nonFraction>&#160;million) payable, subject to terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom (U.K.), Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately <ix:nonFraction unitRef="usdPerShare" contextRef="ib592ca19ca78498fa6f8c390254088c8_I20210131" decimals="3" name="lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY1MTY_0648b990-1c13-4abb-992d-7d3eb9bb56e7">8.3</ix:nonFraction> cents per month until December 1, 2028, at which point the CVR will expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting impact of this acquisition and the results of the operations for Prevail will be included in our consolidated financial statements beginning in the first quarter of 2021.The initial accounting for this acquisition is incomplete. Significant, relevant information needed to complete the initial accounting is not available because the valuation of assets acquired and liabilities assumed is not complete. As a result, determining these values is not practicable, and we are unable to disclose these values or provide other related disclosures at this time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Asahi Kasei Pharma Corporation (Asahi)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a license agreement with Asahi to acquire the exclusive rights for AK1780, an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies for the potential treatment of chronic pain conditions. As a result of the transaction, we will pay Asahi an upfront cash payment and record an acquired IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="if000a6bc5ce54a1b991ab37772234f3b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY1MTg_3101cfbb-6151-40df-8a9d-02860a0b5a2c">20.0</ix:nonFraction>&#160;million in the first quarter of 2021.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">72</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;4:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzMyOTg1MzQ5MTYwOTc_4f3c54e7-d364-46d1-b46b-2857a739f270" continuedAt="i144ff6b93c6c4f0a85723744a41f77d2" escape="true">Collaborations and Other Arrangements</ix:nonNumeric></span></div><ix:continuation id="i144ff6b93c6c4f0a85723744a41f77d2" continuedAt="i20e4ed52c4e647bf9e7ba15e545a9224"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#8217;s oral diabetes products: Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, and Trijardy XR as well as our basal insulin, Basaglar. Jentadueto is included in the Trajenta product family. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. </span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzgwODE_90cfb889-9ee8-4e72-a48f-235680250422" continuedAt="i791f7867c77c454a9f4c51928448e6cf" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestones </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Deferred) Capitalized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8269e026df1a41b2b0895893b55d57cc_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpjMjUxNzhkOGJmMmU0ZDExYTBkZmEzOGQ1ZWNlMWE1MS90YWJsZXJhbmdlOmMyNTE3OGQ4YmYyZTRkMTFhMGRmYTM4ZDVlY2UxYTUxXzEtMi0xLTEtMA_2b1b0ce0-266b-464a-973b-30d3adaba90a">446.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea5f2373f024fc4b990b56206bdc2c9_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpjMjUxNzhkOGJmMmU0ZDExYTBkZmEzOGQ1ZWNlMWE1MS90YWJsZXJhbmdlOmMyNTE3OGQ4YmYyZTRkMTFhMGRmYTM4ZDVlY2UxYTUxXzItMi0xLTEtMA_69dde84f-c66c-4a9f-a2d8-ba811c19002f">289.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib012a6676aaa4eb8bc9506fa646b3402_I20201231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpjMjUxNzhkOGJmMmU0ZDExYTBkZmEzOGQ1ZWNlMWE1MS90YWJsZXJhbmdlOmMyNTE3OGQ4YmYyZTRkMTFhMGRmYTM4ZDVlY2UxYTUxXzMtMi0xLTEtMA_a6774453-2ac9-4ce8-baec-68172c56d130">250.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2019, in the most significant markets, we and Boehringer Ingelheim shared equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We recorded our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We recorded our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we recorded our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company was entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments may have resulted in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may have been reduced by any performance payments we made related to these products. Similarly, performance payments we may have received related to Basaglar effectively reduced Boehringer Ingelheim's share of the gross margin, which reduced our cost of sales.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i20e4ed52c4e647bf9e7ba15e545a9224" continuedAt="ie96d44d519a9463788dbef6de92acf83"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, we and Boehringer Ingelheim modernized the alliance. In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs and commercialization costs for the Jardiance product family. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales. For the Jardiance product family, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds.</span></div><ix:continuation id="i791f7867c77c454a9f4c51928448e6cf" continuedAt="ib1b7c051c03e493d97b249358d03043f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8456d682a58d41a3a50ddf018b0a4c6a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzEtMS0xLTEtMA_6d7dc4f9-f96b-4b9e-8c00-6e43d526b9b5">1,124.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173297e573b146f7bc78c4ada3a83d7a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzEtMy0xLTEtMA_007abd23-c4ae-434b-9ee2-e27b6f61f467">1,112.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d4009f20bb48cf9ec030239f052ee7_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzEtNS0xLTEtMA_dbacc5d7-2a78-4740-b1ca-9904604355da">801.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5bdf1152ee426093323505e09cb233_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzItMS0xLTEtMA_bb1f3662-c77d-4437-8715-a0b6be732978">1,153.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fc8d9d4d2a4410ace81efc24eba1a9_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzItMy0xLTEtMA_613004f8-35cf-42d1-9ebb-50a43e083957">944.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d36ed57bb9940dba66fd60498e5d762_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzItNS0xLTEtMA_57a1cc92-487e-4443-8123-2b61c92259c6">658.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ed102c3ad148a0a31d237f28a5df12_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzMtMS0xLTEtMA_b0c43908-1cfb-465a-bcbe-e2a41d711c35">358.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312288bed3e9413faa61bb6376a13576_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzMtMy0xLTEtMA_2c8bd339-1c7e-4447-864e-022a6d77460b">590.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308e5f2dc1ac4bf9bf1df82123fa7ad5_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzMtNS0xLTEtMA_ac629491-02e2-457f-a8b4-045a2245aa5f">574.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on  global net sales with rates ranging up to <ix:nonFraction unitRef="number" contextRef="icfc2c951fea140efb3bf430c16795a63_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTM1OTE_d433276d-77e6-41f4-9513-cf43e8ae01c0">20</ix:nonFraction> percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In the first half of 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i78597bb677aa4ac4a976a0e803853b22_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzQyOTQ_9d46865d-268a-4046-89e2-bab4db9cda5f">210.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c6e7782eae44e479a4ba6833152bf86_I20191231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzQyNzc_dd23ee36-dc16-475a-817e-a6aa6c2c3013">180.0</ix:nonFraction> million were capitalized as intangible assets as of December 31, 2020 and 2019, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Incyte is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i85207b20c9354258883eacc250729894_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzY0MTM_212f0418-46c8-4811-be7c-2357b0d13177">100.0</ix:nonFraction>&#160;million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ic88f51f077b644278fd68d0fa5ad4dc6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzY1NjU_17f40311-103d-4353-8a03-4ddaf6a963bf">150.0</ix:nonFraction> million of potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="ib1b7c051c03e493d97b249358d03043f" continuedAt="ifca56eaa408642fea20fc30dd983f1fb">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="ifca56eaa408642fea20fc30dd983f1fb"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i710d1f304d724efc85f13dc60bf62fad_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZToxOTM3NTM1YjQwN2Q0MmY5YmU2MTNjOTA0NGRiNDE3NS90YWJsZXJhbmdlOjE5Mzc1MzViNDA3ZDQyZjliZTYxM2M5MDQ0ZGI0MTc1XzEtMS0xLTEtMA_2032683b-a29d-4b0b-a468-722cb911bf67">638.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dbabd3686d4eb9b13b54382cf6bcc4_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZToxOTM3NTM1YjQwN2Q0MmY5YmU2MTNjOTA0NGRiNDE3NS90YWJsZXJhbmdlOjE5Mzc1MzViNDA3ZDQyZjliZTYxM2M5MDQ0ZGI0MTc1XzEtMy0xLTEtMA_ae2b7fba-3fe8-4500-b6a9-f42ec752a56d">426.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia93249b60bed44a7946fd8491b3b85d9_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZToxOTM3NTM1YjQwN2Q0MmY5YmU2MTNjOTA0NGRiNDE3NS90YWJsZXJhbmdlOjE5Mzc1MzViNDA3ZDQyZjliZTYxM2M5MDQ0ZGI0MTc1XzEtNS0xLTEtMA_d9f678fe-972e-42d9-ad72-6e839ab0c8d2">202.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ie96d44d519a9463788dbef6de92acf83" continuedAt="i013ee33117594935aec9cf6e81d67002"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibody therapies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. In connection with this transaction, we recognized an acquired IPR&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="i55d0178a6cd14c4fa5fd77920bb4abbd_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNDE_1e5e6712-caef-45c0-bdd3-755da766ef07">25.0</ix:nonFraction> million in 2020. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales. Pursuant to an EUA, we recognized $<ix:nonFraction unitRef="usd" contextRef="i43add1f443e64f3db8290de104acfbce_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwMzY_c6387fef-44af-4d22-aa9a-87f9657f3972">871.2</ix:nonFraction> million of net product revenue associated with our sales of bamlanivimab to third parties during the year ended December&#160;31, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of Greater China (which includes mainland China, Hong Kong and Macau Special Administrative Regions and Taiwan) and Junshi Biosciences maintains all rights in Greater China. In connection with this transaction, we recognized an acquired IPR&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="ied1732da693a41bdab698fa5a39ba0a2_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNDY_4acd2ac5-06a8-41e4-90f1-10a94b345744">20.0</ix:nonFraction> million in 2020. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our future net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. As of December 31, 2020, Junshi Biosciences is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="iadf97eda073b42fda0623d5c29db2c5d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNTE_c7e13a22-0e26-4651-86bb-800b7407189a">75.0</ix:nonFraction> million of additional payments contingent upon certain success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="id77a2552c6e24c67bf8d94ce91e0e5d3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNTU_942cd18e-80a9-4749-b669-e53c901d3de7">120.0</ix:nonFraction> million of potential sales-based milestones, contingent upon the commercial success of etesevimab. During the year ended December&#160;31, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i252ecfb1d7a840d9806b0dc46157e963_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNzI_88bf380d-6c29-4255-b832-5f24e69e948c">50.0</ix:nonFraction> million of research and development expenses related to development milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tyvyt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent to jointly develop and commercialize Tyvyt (sintilimab injection) in China. In 2019, we and Innovent began co-commercializing Tyvyt in China. We record our sales of Tyvyt to third parties as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We also report as revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. Our Tyvyt revenue in China, which is primarily recorded as net product revenue, was $<ix:nonFraction unitRef="usd" contextRef="i7bf82252c7f64ef49980a721ff43e8f8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzMxNzk_3de48adc-9ad7-4fd4-8387-dd915f828c43">308.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8457b21557264435b2547d9a774dabe2_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzMxODg_ae32feea-5590-4848-86da-617b25f3661b">134.0</ix:nonFraction> million in 2020 and 2019, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we obtained an exclusive license for Tyvyt from Innovent for geographies outside of China and plan to pursue registration of Tyvyt in the U.S. and other markets. We recorded an acquired IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="id57723ff321a4ac09c2ddd06857d6267_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzE3Nzk_fa0a8320-2129-4d7b-9220-a31d978c0ca7">200.0</ix:nonFraction> million in 2020 associated with the upfront payment to Innovent.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Innovent is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i9040b40c375e44ec953ab4747d1dbaa8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzM1MTA_92353d93-5b0e-417a-9dbe-7ef05c14bf6c">825.0</ix:nonFraction> million for geographies outside of China and up to $<ix:nonFraction unitRef="usd" contextRef="i9c5e6e4c1ddb437a8f9faeba8093fafa_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzE4MDA_4171c58c-ca09-4e49-9739-d6be6dd6cb85">75.0</ix:nonFraction> million in China in success-based regulatory and sales-based milestones.  Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tanezumab</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. The companies equally share the ongoing development costs and, if successful, in the U.S. will co-commercialize and equally share in gross margin and certain commercialization expenses. As a result of an amendment to the agreement in the third quarter of 2020, Pfizer will be responsible for commercialization activities and costs outside the U.S., and we have the right to receive tiered royalties in percentages from the high teens to mid-twenties for net sales in Japan as well as low double digit royalties on annual net sales greater than $<ix:nonFraction unitRef="usd" contextRef="ie7c2329f83d54c2daf23fe9a43a89933_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzMyOTg1MzQ5MTU5ODA_ee576308-c486-47e5-be0d-66c02f0a4dca">150.0</ix:nonFraction>&#160;million in all other territories outside of the U.S. and Japan. As of December&#160;31, 2020, Pfizer is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="if51e456d8c22452895dde4067048ed49_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzc5MTQ_66f8201f-2aa1-4e16-8149-ef43327b25e8">147.5</ix:nonFraction> million in success-based regulatory milestones based on current development plans and up to $<ix:nonFraction unitRef="usd" contextRef="icf9a899efcc14002a419189d81ad60c4_I20201231" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzc5NjY_291bf4db-d4e0-4e56-bc2d-a177efd4e474">1.23</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2020, Roche is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i02a5b403f3e84dd588ce7e797609bcbb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTExMjE_aaef3218-c5f7-4927-b955-68963af02047">180.0</ix:nonFraction> million of payments from us contingent upon the achievement of success-based regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i278ff628156c4188a73f68b4511dfb68_I20201231" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTEyMjc_a6c06f99-9819-4590-b342-02cfb780a103">1.03</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i013ee33117594935aec9cf6e81d67002" continuedAt="i0b6f96f63a8f408992f31cef8e783635">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2020, we are eligible to receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="i2e398d4d6ace4b53b2313b073d764cee_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTE4ODU_7b42c101-37be-411e-b8d7-72c9e7bc4cba">85.0</ix:nonFraction> million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i4e1db56f028e486bad99686da3f343bc_I20201231" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTE5ODQ_2c687932-1b38-4e4e-84db-1e2155e6bfd7">1.25</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</ix:continuation></span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b6f96f63a8f408992f31cef8e783635">As of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ifafea5b05f3f452394ff8d36dbcc9f7a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzQ0MTk_368dbe96-f473-4cc9-ba1a-61185c3db00a">29.7</ix:nonFraction> million was recorded as a contract liability on the consolidated balance sheet and is expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the twelve months ended December&#160;31, 2020, milestones received and collaboration and other revenue recognized were not material.</ix:continuation> </span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_130"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;5:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90ZXh0cmVnaW9uOmQ0MjE0Y2VkNGQ1NzQyN2FhYjcyNTRhNzVkODU0ZTgxXzIyMDc_8d229bb7-411e-4f7f-a13c-8b553e9aac19" continuedAt="i8f0a516193af4b3fbd5347b615bba4c2" escape="true">Asset Impairment, Restructuring, and Other Special Charges</ix:nonNumeric></span></div><ix:continuation id="i8f0a516193af4b3fbd5347b615bba4c2"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90ZXh0cmVnaW9uOmQ0MjE0Y2VkNGQ1NzQyN2FhYjcyNTRhNzVkODU0ZTgxXzIyMDA_55ecc9da-e251-47bd-98f4-8b42ff5e377b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzEtMS0xLTEtMA_f042ea9e-814b-4d2f-8f79-6f9379bd9b1d">151.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzEtMy0xLTEtMA_1e6e3b60-4db5-4428-a2eb-20272fa43d4f">77.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzEtNS0xLTEtMA_a5fe8126-7139-45b8-9374-d2d16bf85644">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzMtMS0xLTEtMA_f906fd35-a414-46aa-b249-7976f56d1c6a">20.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzMtMy0xLTEtMA_bec8608d-de54-490c-bc86-e0791197d903">497.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzMtNS0xLTEtMA_83984f84-84e5-4e8f-a5ef-dc996208e0ed">139.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzQtMS0xLTEtMA_a73f2c33-8bb6-42d3-a57b-637d1223f874">131.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzQtMy0xLTEtMA_5903ec88-49eb-45a2-8c3d-bd4b39dfdcf0">575.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzQtNS0xLTEtMA_188aaef2-4de9-4eec-b109-b23e4664fef7">266.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance costs recognized during the years ended December&#160;31, 2020, 2019 and 2018 were incurred as a result of actions taken worldwide to reduce our cost structure. Substantially all of the severance costs incurred during the year ended December&#160;31, 2020 are expected to be paid in the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment and other special charges recognized during the year ended December 31, 2019 resulted primarily from $<ix:nonFraction unitRef="usd" contextRef="id5a7062879db495387dd023ff0ac4b13_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90ZXh0cmVnaW9uOmQ0MjE0Y2VkNGQ1NzQyN2FhYjcyNTRhNzVkODU0ZTgxXzkwNQ_6bc1f39a-bd34-4bbc-afd7-b802a9cb402b">400.7</ix:nonFraction> million of other special charges related to the acquisition of Loxo, substantially all of which is associated with the accelerated vesting of Loxo employee equity awards. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment and other special charges recognized during the year ended December 31, 2018 resulted primarily from asset impairment and other special charges related to the sale of the Posilac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rbST) brand and the associated Augusta, Georgia manufacturing site.</span></div></ix:continuation><div id="ia8e8b06f04404e6fb09e313103495f8e_133"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;6:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzYwNw_f940e64a-6dc5-4493-86a5-220939c807eb" continuedAt="ia862b76084eb46d9870b2559016d11b2" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ia862b76084eb46d9870b2559016d11b2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzYwOQ_13ef364b-5aa5-45b3-adce-2cd85d2ccba2" escape="true">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.</ix:nonNumeric> Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. </span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzYxMg_ce91a548-f1a5-4c3c-96bb-35de9ef5891f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzEtMS0xLTEtMA_6536ac9e-3a57-40df-824c-c607e8461121">758.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzEtMy0xLTEtMA_93182079-6e7b-48b2-bee5-3f0b2bf271c0">647.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzItMS0xLTEtMA_29a44667-e0d7-4c67-9f94-9944b63011fa">2,535.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzItMy0xLTEtMA_ae4bb8c2-85ad-4120-a521-f66c86498c0c">2,067.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzMtMS0xLTEtMA_0aa485f0-3634-4d3f-906f-9e3a64695689">651.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzMtMy0xLTEtMA_1c16bf2b-0524-46a2-a7ad-38270d3edb07">424.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzQtMS0xLTEtMA_d60a60f0-2537-4bf6-a00a-9aefef8e9a0b">3,945.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzQtMy0xLTEtMA_fcfcb484-4499-4187-9fab-5b1c11cd1ea5">3,139.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" sign="-" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzUtMS0xLTEtMA_1c3d8e8f-e5fe-46b3-9b44-d41a7ac89b4a">34.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" sign="-" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzUtMy0xLTEtMA_24cb87e8-8fb2-40f2-904a-ff07d2000b16">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzYtMS0xLTEtMA_c175eb43-6c56-4e96-ac80-ea92192bee57">3,980.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzYtMy0xLTEtMA_6dd292ae-d7f1-4f8d-811b-e9fdc05aae44">3,190.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LIFOInventoryAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzUzOA_ce55b729-3014-4dd8-9e8f-e2570b6496af">1.21</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LIFOInventoryAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzU0NQ_0b0712bb-901e-43ea-88f1-0308e64387a7">1.20</ix:nonFraction> billion of total inventories at December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">76</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;7:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzI4_046f5be8-9547-463b-8e48-401edca6ca5a" continuedAt="i68ed23b9513c4a59867dc1ddab41280f" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i68ed23b9513c4a59867dc1ddab41280f" continuedAt="i1234039ee41a44dc90843eadb69960c9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzE1_4c421e99-4640-4b48-968c-7fb33d904b5e" escape="true">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0Mzk3_42c746eb-33df-46c7-b3e2-b171946d709d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0NDIz_f2e86ef6-f2c1-4e78-98ec-abcee22a9839" continuedAt="i0922709a659c4cd9a1cfa10178cc02f1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0922709a659c4cd9a1cfa10178cc02f1" continuedAt="ib36333cad3b04545935fe6e2a56fe532">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.</ix:continuation> Forward contracts generally have maturities not exceeding <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQzMzQ_a80bd846-8d79-45fc-8a41-ebe1938733b5">12</ix:nonNumeric> months. At December&#160;31, 2020, we had outstanding foreign currency forward commitments to purchase <ix:nonFraction unitRef="usd" contextRef="i76593a635ee74f569d9d5d26e369257d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ0MjA_6abdf07d-7220-4805-b693-a2366cb90d0a">647.9</ix:nonFraction> million U.S. dollars and sell <ix:nonFraction unitRef="eur" contextRef="i76593a635ee74f569d9d5d26e369257d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ0NDU_1b5401c6-2a00-41bb-acd4-3fadfc4ccb02">530.7</ix:nonFraction> million euro; commitments to purchase <ix:nonFraction unitRef="eur" contextRef="if292dce18b8742949a04f94a69f513e9_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ0Nzg_fb6f66f2-aa75-464b-a72f-92c3328e5ef6">2.97</ix:nonFraction> billion euro and sell <ix:nonFraction unitRef="usd" contextRef="if292dce18b8742949a04f94a69f513e9_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ0OTU_d409d6bf-8e0a-4af4-bd90-296ed763d227">3.62</ix:nonFraction>&#160;billion U.S. dollars; commitments to purchase <ix:nonFraction unitRef="usd" contextRef="ie11921f0731440e8b2d7e35e232cb20c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ1MzY_a27cabba-5fad-4d7d-a984-a2cf26e98273">180.7</ix:nonFraction> million U.S. dollars and sell <ix:nonFraction unitRef="jpy" contextRef="ie11921f0731440e8b2d7e35e232cb20c_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ1NjE_2acd0464-cc4e-4134-a52e-ce55502c9081">18.64</ix:nonFraction> billion Japanese yen, and commitments to purchase <ix:nonFraction unitRef="gbp" contextRef="i2c1ec7ea3e4544bebd2209221d0a8ad2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ2NzI_72888664-5c9b-4c33-9063-c6d232757605">272.2</ix:nonFraction> million British pounds and sell <ix:nonFraction unitRef="usd" contextRef="i2c1ec7ea3e4544bebd2209221d0a8ad2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ2OTk_464a4bd5-158b-4bb9-96d6-9b723136af96">363.9</ix:nonFraction> million U.S. dollars which all settled within <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:durday" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ3NDA_00b3b877-2597-4ec2-b4be-e80246da419d">30</ix:nonNumeric> days.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i1234039ee41a44dc90843eadb69960c9" continuedAt="i9d007b5fd31c4301ae148a5344362ccb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $<ix:nonFraction unitRef="usd" contextRef="i734b5d697bdb4d96b38be8ba20e2e66a_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ5MzU_5f5ab600-6bf9-4d56-8c7a-40f96cca6170">6.02</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i885be083614a4d18a19870c3bd50973b_I20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ5NDI_ddec8255-d3d1-4644-a887-fed531461fa6">5.49</ix:nonFraction> billion as of December&#160;31, 2020 and 2019, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ5ODY_3c61f979-0254-4d06-a288-20f448b149ee">4.50</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ5OTM_5ee26505-f051-4e85-a2b4-53e3f55ef74b">4.10</ix:nonFraction> billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations as of December&#160;31, 2020 and 2019, respectively. At December&#160;31, 2020, we had outstanding cross currency swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ib71d03b9d5404ef7859e43ce06d40102_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzUyMzU_2498fb21-ffc9-4bc2-9331-63e8be03ae38">3.76</ix:nonFraction> billion swapping U.S. dollars to euro and $<ix:nonFraction unitRef="usd" contextRef="i3781eb7aed394d3aaa09742b6bce2f1c_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzUyNjk_afaf952b-ca38-43d2-aafa-9da46449599b">1.00</ix:nonFraction> billion swapping swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib36333cad3b04545935fe6e2a56fe532" continuedAt="i58959571efd640ce896838485188d9e2">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i58959571efd640ce896838485188d9e2" continuedAt="i5d0d63f90a2b472197f0f1e35add7a1a">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.</ix:continuation> At December&#160;31, 2020, substantially all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonFraction unitRef="number" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzcwOTc_fb4776cd-2926-40a4-82f2-afba6a058ae4">9</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5d0d63f90a2b472197f0f1e35add7a1a">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.</ix:continuation> As of December&#160;31, 2020, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonFraction unitRef="usd" contextRef="i15da0b294a6b4817b66312409c265245_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzc4MDY_3c51c509-4ce9-4669-a007-73753003aecf">1.75</ix:nonFraction> billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Effect of Risk Management Instruments on the Consolidated Statements of Operations</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0Mzcw_57e829cd-dfe5-4712-9b6a-c686afc42b8c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4c33e1edc444e5b4e9a8500e0eab88_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzItMS0xLTEtMA_c270e3bb-b8a7-4c5a-bd45-d3a694d71c4c">86.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied0653ffc6e14aeca59c89fb6a86121c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzItMy0xLTEtMA_75aeddc5-be88-490c-a3ce-061aa8ff5d12">112.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic757ba5b7d1b442d93291ea03decee5f_D20180101-20181231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzItNS0xLTEtMA_7dbc6fb5-56ed-4324-97f5-be61f805d09a">40.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79bdb56a9d7144029b1e5522c593614e_D20200101-20201231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzMtMS0xLTEtMA_393c7206-92b2-4b75-a93c-6674d726a5ca">86.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60d9065de7764cc19c33a225a0d50880_D20190101-20191231" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzMtMy0xLTEtMA_ac7ad74b-2184-4ab2-8d28-c83f9196ad3c">112.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177b2d67f8ba418284926e505024a276_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzMtNS0xLTEtMA_b94b5727-b587-49df-b2f0-2be9c8c0ec38">40.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79bdb56a9d7144029b1e5522c593614e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzUtMS0xLTEtMA_7b01df9f-8514-4eea-910a-7a8b770a21f7">16.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d9065de7764cc19c33a225a0d50880_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzUtMy0xLTEtMA_12c7ac07-25f7-4e57-b01b-15eb84566a32">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177b2d67f8ba418284926e505024a276_D20180101-20181231" decimals="-5" name="us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzUtNS0xLTEtMA_e82d7b0e-436c-4806-a28f-df3333a73631">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i559cde7a86934d01957c68c16475b1cb_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzYtMS0xLTEtMA_dc49d149-9169-49b5-843a-820d67f5331f">102.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i089038df2aa140c192a89e32082775b5_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzYtMy0xLTEtMA_16d8d2c4-4d4e-4593-9552-ba4b8970daab">17.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic259a5c22c4b4a7aa701a9d5367ffc26_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzYtNS0xLTEtMA_9fbcfc7d-e55e-4e43-bc62-07f995625e9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a4d2134a40b4c75849277ff51f28c3f_D20200101-20201231" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzctMS0xLTEtMA_635ddf17-dbb7-401b-9a5b-3d210a1cf39b">123.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c9ccd3865e45e69f040a91ca7dd298_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzctMy0xLTEtMA_38497af4-5725-48a9-8dad-5549f9295524">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d6995b66cf841668e6e05a116f49a16_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzctNS0xLTEtMA_0727c002-26b6-4d1d-a532-5011a38ad86b">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzgtMS0xLTEtMA_d16071a3-23f3-4a26-b2cd-95296f92f88a">209.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzgtMy0xLTEtMA_138b6764-96c4-4a25-9483-18a889f4a15f">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzgtNS0xLTEtMA_755dcd09-3aef-43ec-83c5-30439036a43d">114.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i9d007b5fd31c4301ae148a5344362ccb" continuedAt="id6db248b830242d4a31805c633b180fb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzQx_83e76131-ffc2-4a67-bd40-b65193eb2efc" escape="true"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzQx_e223c44a-5ae9-4388-8322-77fe752fa58d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b825c2201274dc188cf256f122e086c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzItMS0xLTEtMA_c1f815cc-db4e-44ce-8f16-d14cd62ccce6">404.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f82f22527524999a91aa71e61c6641a_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzItMy0xLTEtMA_ae09adc2-487a-4701-b8d5-dea6d3fc28b8">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325ca753011c477b8ba2959a5e5c7d2b_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzItNS0xLTEtMA_7d60324b-9aba-4809-b576-2bdbf5a0a284">110.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0813de855ef747abaaca53ef36e4c1f6_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzMtMS0xLTEtMA_7741d314-34eb-4865-a142-377514ca7e33">207.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670c43f24d5e48ca995ca3f9f935644c_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzMtMy0xLTEtMA_70fc3fe3-3ced-4484-bbf9-897edb251acd">47.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfaa8924bd4f438b86a6705d72934fe8_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzMtNS0xLTEtMA_792a5bbf-8e51-4490-9933-7e414a616856">96.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e85a5c0bc9421ea34d9822b4a94e72_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzQtMS0xLTEtMA_8ef343df-c821-4a2d-b3ec-93e3e22775dc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2513e6302b4030a3b2c52c6326a063_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzQtMy0xLTEtMA_8cd9588d-b735-49bd-a9ea-7b8ed212d739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a17ef8639b4116914b2853f39ee356_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzQtNS0xLTEtMA_cc9c754c-b5df-4c49-9f0e-74c2f67d9469">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></div></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5eadeb2c29d4945b2f705b7dd6bac6a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzYtMS0xLTEtMA_7489c743-63c2-4958-b35d-5ac0b5487678">110.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id899c3b3d5a645f5bb38fa729003c1d1_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzYtMy0xLTEtMA_0d6120dc-3135-40a6-898f-510764fac9f5">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0876e8c76a9c4c308a34aff4f59ba314_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzYtNS0xLTEtMA_78bad62a-71ee-42cc-8512-c8e31c8c631f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0813de855ef747abaaca53ef36e4c1f6_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzctMS0xLTEtMA_9a0c30ce-cf7f-429c-a3d8-40c18b93f0ff">53.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i670c43f24d5e48ca995ca3f9f935644c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzctMy0xLTEtMA_f4d555fc-cc41-4785-87b5-4cff935dd6f9">8.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107cda2404e146cab37a3274549bd9d0_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzctNS0xLTEtMA_2046ed47-186c-49e0-aebd-66782057cc34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12 months, we expect to reclassify $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzg4MTc_18bc4a9d-477a-4360-b50f-d4d214fd4962">16.8</ix:nonFraction> million of net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the years ended December&#160;31, 2020, 2019 and 2018, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="id6db248b830242d4a31805c633b180fb" continuedAt="i652b0160572e4e57b65ed29833778b73"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzIz_818527dd-5a31-4582-b349-333ec51eb92d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtMS0xLTEtMA_08e30268-5496-421f-be1f-ca1e81f136c4">2,097.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie269f3b3bfdf44ce9b4f6626338c067e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtMy0xLTEtMA_9306722a-bd4d-4724-8f53-9f6b2f1433fb">2,097.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c51b75c2fa14c1684c56a1e7d8fc1f5_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtNS0xLTEtMA_01942dd6-f809-4b74-aac4-b82f81d72bdf">2,097.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec12cf461774e1182bafa64c823d98d_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtNy0xLTEtMA_8b181d63-06d2-4bfe-a136-1d7cbc8b30f5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566cfafb34514a41ac32d09adc9ee29a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtOS0xLTEtMA_e9d98a30-3515-427a-83fd-283b865f220d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ab34fc33aa445d9f82bf362c674439_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtMTEtMS0xLTA_1a14193e-5484-4f71-90f1-5cbe1d68290b">2,097.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97251102c68a4c478e1a1be501688a22_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtMS0xLTEtMA_5d01b58c-8de9-4cfa-a6da-04f9f3a28b4d">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e0f1e2870e41769f1affa474d182bd_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtMy0xLTEtMA_4c44ba4b-ceda-4f0f-a9b2-27d83aeafdca">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758fcf4cf3c74497807165838ee0ac9c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtNS0xLTEtMA_d61fd178-341c-4c5c-b5e8-f52b26d0942b">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077c04533e3743c8b36a16e643d4b688_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtNy0xLTEtMA_43a1f4df-fd72-4341-83a5-99ca3dbcd769">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0432603227427ab677d8fa8d0e0872_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtOS0xLTEtMA_ace73098-006c-4911-abad-aa5624a4f368">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b249a1451654e4f94d47645b0fccafc_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtMTEtMS0xLTA_4c04f0c9-6c85-40d5-b91f-14ff9df1e881">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4d052cf54d0c85d6df1946dbc24a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtMS0xLTEtMA_ec00bcac-e419-4e1c-992c-fd3d2473a206">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b0011562854b1d95ba84ae4e1bcf37_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtMy0xLTEtMA_574824c1-b1cc-4e5e-b62c-80237be0fc86">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad918d4090746489ff767a295639e94_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtNS0xLTEtMA_ed88043c-a8dd-4881-8f7b-593937074fe3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436c38c65cce425daad44c655b754e71_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtNy0xLTEtMA_f6dcbc78-a6e1-4241-a427-ec0ef005b90c">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9398ca058d0048cb85257c2485125ee7_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtOS0xLTEtMA_ebd8abd8-70ea-42be-b86f-98f2114d3bc4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id952bb8455ac4064b262c91cc977ddc7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtMTEtMS0xLTA_e1827a5d-9d14-42d7-b5e2-86c346c18dbf">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2749eddf3fad4a5db6ba0abcec58bcf3_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctMS0xLTEtMA_358e366c-64e5-4308-bfda-df792c0fc14a">1.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cdb65ba392744f79ff27b54d5a5f83f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctMy0xLTEtMA_d3023208-2080-4819-81d5-5c11840caaad">1.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3a5cb729034c68b87c779b4e84d7cb_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctNS0xLTEtMA_e4d6d259-331d-41a7-b84e-6288526bcdaa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2013b0dbf62424d9350c6b71c35d2d6_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctNy0xLTEtMA_7875e884-3b84-4e7d-ab1e-479095287271">1.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79afb23fd84842b88431983432e6faca_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctOS0xLTEtMA_d7054803-0276-44e6-9445-0a8508a156d6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec93f4a79eab4a1586228b07068c14db_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctMTEtMS0xLTA_4393775d-dbf9-4d98-8442-c8c8fa58f326">1.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8881e2925d8b4caf9fdfdf020b93932b_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtMS0xLTEtMA_19225a34-982b-420e-8725-ca9f18e3cff3">10.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e008d687ea4305ab1f7e75dfbff408_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtMy0xLTEtMA_f1262436-80b9-412b-81af-575fb13be95a">10.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30940c5e536f4d5ead427a4782d61c94_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtNS0xLTEtMA_670d1c4c-c288-4ea4-bb7d-0fa058c291aa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435e18e4a6f549a399937585428a9956_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtNy0xLTEtMA_e637149a-7a9e-4f49-8a39-20f8c347e60a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f46ae367c8745948b6623087118c537_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtOS0xLTEtMA_0300fc15-c8e9-4dbd-80fb-4de1816ab3cc">10.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91d8fae795ac469da2155b12eb39aec8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtMTEtMS0xLTA_449befba-9cd9-426e-bba5-6a42e2129c1e">10.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEwLTEtMS0xLTA_f6c5bf20-bbe8-44fd-93b1-63732fff45b6">24.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97251102c68a4c478e1a1be501688a22_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTEtMS0xLTA_46423871-bc31-4bb6-b051-6e47a4a165f6">78.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e0f1e2870e41769f1affa474d182bd_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTMtMS0xLTA_b9917f21-57c5-4707-81bb-11b7e42c54c3">74.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758fcf4cf3c74497807165838ee0ac9c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTUtMS0xLTA_36c7f0ed-2c98-4cbe-9839-60d71fb33965">78.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077c04533e3743c8b36a16e643d4b688_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTctMS0xLTA_34cf4a36-19a3-4ae4-a08f-30b9a3989def">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0432603227427ab677d8fa8d0e0872_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTktMS0xLTA_ef8edf95-7794-4e71-8ec1-c76c898a9c9d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b249a1451654e4f94d47645b0fccafc_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTExLTEtMS0w_f1c4b941-15cf-4699-8d83-e4b88d6208fd">78.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4d052cf54d0c85d6df1946dbc24a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTEtMS0xLTA_b32fc2bf-db62-488e-9b53-6ddbe36a9d3b">137.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b0011562854b1d95ba84ae4e1bcf37_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTMtMS0xLTA_85aaf68c-6c19-4671-916c-9336a1e7958e">126.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad918d4090746489ff767a295639e94_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTUtMS0xLTA_10811bd9-809a-4271-a4f7-b3c4df7fdb0e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436c38c65cce425daad44c655b754e71_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTctMS0xLTA_b7f0387f-67a7-4de8-9726-b32031a7cd43">137.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9398ca058d0048cb85257c2485125ee7_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTktMS0xLTA_0969f498-9cce-4d4d-a963-35c1e0be7df8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id952bb8455ac4064b262c91cc977ddc7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTExLTEtMS0w_4b4a8781-f524-4b52-b39f-a0336cd9925b">137.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie512126811f64a28b96cb6c61ff78085_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTEtMS0xLTA_069c9203-8c16-4d9d-b99f-b8e67a199822">106.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53ce320a0cf45c193d1cff9384dd062_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTMtMS0xLTA_cfee00c7-8ee6-42eb-89e8-6aac5b0d761e">101.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f275b97cc004a86855de7192fb8f764_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTUtMS0xLTA_826fb5e2-9a0c-4f4a-8757-e62569d0fa50">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb5a016ad964daebc62766f4f82a19c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTctMS0xLTA_3886f324-0867-4e2a-a94d-dae06d150726">106.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19985e9c706e44848bff87eb752a0939_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTktMS0xLTA_ec8f74ac-bdaf-46a9-8603-0c33ba0b21e2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33645495135840a59fbcf0e39deb55d1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTExLTEtMS0w_478283da-5fe3-4146-a4d9-48e86b3321c1">106.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2749eddf3fad4a5db6ba0abcec58bcf3_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTEtMS0xLTA_7896f9c0-a5ff-46b7-8b89-dd11b7b5542a">24.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cdb65ba392744f79ff27b54d5a5f83f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTMtMS0xLTA_a582e7ca-d7d7-4a79-a4fc-c4ea4e25296e">23.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3a5cb729034c68b87c779b4e84d7cb_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTUtMS0xLTA_c9fcdd62-f801-4ea0-9f1c-a26f8bdf9cdd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2013b0dbf62424d9350c6b71c35d2d6_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTctMS0xLTA_7de6f129-f2bc-4757-be0c-09184d5bf97b">24.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79afb23fd84842b88431983432e6faca_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTktMS0xLTA_7d9d6b6e-0a73-49e3-bd55-451cb5d5b79d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec93f4a79eab4a1586228b07068c14db_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTExLTEtMS0w_ca63a5db-1d6f-48f7-aca9-c9d512d4621a">24.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie198dbef2f4e4399a10d5932355eb939_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTEtMS0xLTA_04aed329-7c3c-48ed-9a58-d3d33cd3510a">110.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b7bb38ed4d4d11aeb324f32e415e81_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTMtMS0xLTA_19eb5e3d-1f2d-4aeb-a3ac-05697cb023ed">31.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36eeb1bd9f04842a9851c91ab5e895e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTUtMS0xLTA_bebf8305-7325-4de9-9ba0-757be3525411">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea21507ec1d49be826960b15a6c42f7_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTctMS0xLTA_faceceac-1212-4725-8b18-b729e1f72d96">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3050ce166b0e433687c88c87676b070b_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTktMS0xLTA_a4e6e314-7950-47b2-87b1-384473820adc">110.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4081e5bd91e244058a3844645c6f7e8d_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTExLTEtMS0w_504e7d9a-c34f-41af-a76f-ac39965a534c">110.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6b82be3c6d47cf90e800e560194078_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTEtMS0xLTA_0fdb2645-163e-4217-b983-d68f51b51944">1,664.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef89d353cf247e0864a754f5b062e45_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTMtMS0xLTA_a1800663-c398-4e3e-9d52-5546439be777">311.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b870b023711491387d9d2d2fda73e1d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTUtMS0xLTA_65eaccf0-fa82-4af3-9c17-8654c5f4b8c8">1,664.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d94ce65a684af8bf51656da3e6449c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTctMS0xLTA_a6726aeb-4bf2-4a04-977f-1a8776be7fb2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3ae02f6cff4631aab6491d4ae1ea8c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTktMS0xLTA_2e8636f6-90a8-408b-8bae-3436d6705fce">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca2871b4ff44e13a1ae66a9204f2c5e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTExLTEtMS0w_70e42311-e93b-4074-980b-55fc7af3c7b9">1,664.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE4LTEtMS0xLTA_4a4992e5-d471-4388-9b3f-61b0dd9c1707">373.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a35200b6214f8d862d1879f4522cf7_I20201231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE5LTEtMS0xLTA_678c7d8b-8e66-48df-8e48-ab4be9dbc1c0">471.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIwLTEtMS0xLTA_6945c823-a343-4e09-a155-a56c53ff484c">2,966.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTEtMS0xLTA_13878948-1c95-4b60-b50f-6ffce4cb7343">1,025.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4686f8cb62994a9a9bc8e6b7817e8410_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTMtMS0xLTA_afbde8a6-622f-49f5-a76b-281b1a5d6e97">1,025.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de1473493a442ab6ca0ee29d148543_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTUtMS0xLTA_f7412873-789a-4385-9ac1-56a51859b8b6">1,025.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ec43bf672b4ad99e62859afb69e618_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTctMS0xLTA_c1194009-a1d2-4c74-906d-31ea4c118e07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e269ce360814b8e84f97f774fd1c803_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTktMS0xLTA_f45f35d8-a5c8-4b33-bf7a-5b9445ff4ce5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46aacafc18444898a49130e3d437b45_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTExLTEtMS0w_278d8479-fe88-4540-af8a-7fdb41d73558">1,025.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11555512f15843b78cb5d74c0d0637cc_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTEtMS0xLTA_995569ed-e29c-4ee6-a35b-72675ee6de47">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e9794059e54793bf573b9748798eeb_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTMtMS0xLTA_89cd70f6-71fc-492a-9287-eb28888d3a64">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd767fb99dc9410291e52fe3a05701b9_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTUtMS0xLTA_58c3f848-3dcc-48e2-bf44-285b6b407493">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b9447fb59048a28d7f41123a0643b5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTctMS0xLTA_1553c472-fdb3-4ce9-b136-ac8496b33000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea08714d01bb4abbaffdf5f5e1634598_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTktMS0xLTA_10b9fd0a-579b-4ea3-bd9e-b772219d9c77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af641dbca0f401696c62e23d843bbf0_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTExLTEtMS0w_d8b9712c-04ec-4c1e-88ec-37f5b0d5c0a3">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if911451758b0451ba9dd43374b7caeb9_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTEtMS0xLTA_ae08c955-284e-4d65-aa35-4e07661c17f9">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85afc85494d45deac992b5b655352c6_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTMtMS0xLTA_f5e0e13c-4b72-476a-890c-bee6f5573dae">81.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe41ef9074154d9c86b0d0beee80732a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTUtMS0xLTA_8e6fe00d-ede9-4285-8922-b937bb03187c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8beb739ebd1649a2aa6dbb7bed7cb98a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTctMS0xLTA_3edeb394-8a57-409a-94e0-e08a72f2e6aa">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b086fb17f3400d87543e41a70f9221_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTktMS0xLTA_4680e83e-d69f-4538-b876-e4d171dd12b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a79d730f284ce99e15280ddb18014c_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTExLTEtMS0w_ab375140-2f9c-4d50-b111-3b5cc4014a0f">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i896ba5d04f154341a7f226e1768613b6_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTEtMS0xLTA_23b6b160-3510-4219-9df7-480497003573">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7430c4dd94c4647ae735ab5dcbe41a9_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTMtMS0xLTA_cc60e746-0b59-4476-ad91-3b7360c8edd3">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c04854fd114be5a2ed27c2c259efd8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTUtMS0xLTA_20ddf265-9e4a-4dd3-9ad2-b34c410b82e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if547dc6573ac4235ba2a0eca5f36102c_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTctMS0xLTA_36203e4a-2c43-492f-a507-9347d701bbca">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8506c4f9b64daab27077e623773d22_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTktMS0xLTA_ccef4cf0-7eae-4b25-b0fa-6a8d1729d5ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88b2998a44a42adadb3c56fdaf02670_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTExLTEtMS0w_feee1b1c-0ab3-43d6-9fb8-2ceca3749072">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f61406987b0462d929eef8f4acd716e_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTEtMS0xLTA_5acceaf3-073e-4b56-90c6-168dea1f59a0">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcb5c5899344364a60904c18340c133_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTMtMS0xLTA_1f56d977-537f-4e94-be67-f38ed580d639">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ba6d352d364d3494b2a7fe4c35e283_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTUtMS0xLTA_4a543960-2db9-4c69-86be-9957992c4615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335aa482d73640a395372f1fe66486ac_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTctMS0xLTA_bfa3357a-6456-4f2a-bc18-10d7ac506f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5991d2f6863348dd894ea4182e0e6ae3_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTktMS0xLTA_68a17a6e-51f3-475c-af00-e3134bac7c71">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1edb578fe2b146dfa9398c23136bd036_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTExLTEtMS0w_36d68d24-a6f5-4cba-b81a-1cf74c693faa">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMwLTEtMS0xLTA_e22781d8-e69a-40d3-9d80-daf4303b2155">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11555512f15843b78cb5d74c0d0637cc_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTEtMS0xLTA_86f27a48-6678-4793-8b64-3d7c88b6718b">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e9794059e54793bf573b9748798eeb_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTMtMS0xLTA_86cd4385-561f-42dc-a759-ef81150127c2">76.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd767fb99dc9410291e52fe3a05701b9_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTUtMS0xLTA_157e55bc-4f87-42cd-9986-955dc14be2b0">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b9447fb59048a28d7f41123a0643b5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTctMS0xLTA_3d63c5b9-1897-464b-a19e-59b20399169e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea08714d01bb4abbaffdf5f5e1634598_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTktMS0xLTA_37bd5674-8009-4fe1-8aed-cf68957ca04d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af641dbca0f401696c62e23d843bbf0_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTExLTEtMS0w_79388e53-28ab-437f-81b8-3897c6983626">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if911451758b0451ba9dd43374b7caeb9_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTEtMS0xLTA_86e9e045-8bed-45ed-942b-ff6a2bf2d298">271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85afc85494d45deac992b5b655352c6_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTMtMS0xLTA_6a5e8417-fe75-46f1-90b4-f9c355874a5b">267.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe41ef9074154d9c86b0d0beee80732a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTUtMS0xLTA_e1d862a8-a357-44a5-9f2d-dfa5be7ef28e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8beb739ebd1649a2aa6dbb7bed7cb98a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTctMS0xLTA_08eebd41-e2f5-40d2-814e-81cf5476f16e">271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b086fb17f3400d87543e41a70f9221_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTktMS0xLTA_cf9514ef-8d56-4c49-845a-d0aa8250a425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a79d730f284ce99e15280ddb18014c_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTExLTEtMS0w_5662574a-db5c-44e1-8213-4ac89ab1cb37">271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa6955b8d2b4b22bd3c25a51caf5bfc_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTEtMS0xLTA_8cba7b66-3a6f-4f85-b657-13e439dd6d43">101.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fc3ed55b43049169f584d6511c15e2b_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTMtMS0xLTA_2fb6b7e5-1d3a-449b-a6c5-7e74516c9f3a">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab7928a68fd4d8b989433ccbf30af4f_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTUtMS0xLTA_284f12f1-48ef-4ae2-9aa5-6d9e4a46d663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i037e599f78cf4eb193c194c14da7e6c9_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTctMS0xLTA_71660c35-c04a-4f91-9414-45b18b2a4b78">101.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5595324df32f48359938231bb46a08db_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTktMS0xLTA_c2f19be6-ac52-428e-acca-02e75c1b1ed0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f10afd1f4e4de39bf7a81a91f20180_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTExLTEtMS0w_ba8c69a4-e643-46c3-b42a-5732543c17cb">101.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i896ba5d04f154341a7f226e1768613b6_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTEtMS0xLTA_e66c3e51-0e80-4eb1-923e-b2fd47b41123">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7430c4dd94c4647ae735ab5dcbe41a9_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTMtMS0xLTA_bbc5790f-a12a-4e51-9994-4952fc96f5e1">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c04854fd114be5a2ed27c2c259efd8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTUtMS0xLTA_086b0916-f858-4a26-aa67-4ced85022c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if547dc6573ac4235ba2a0eca5f36102c_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTctMS0xLTA_7bc501c0-b84d-4eb5-9fda-073ebd11f9da">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8506c4f9b64daab27077e623773d22_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTktMS0xLTA_4858fb8c-19b5-4282-8633-197430a727b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88b2998a44a42adadb3c56fdaf02670_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTExLTEtMS0w_3a744013-c3dd-4d49-acff-856aba785781">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a044b0ff45b498f991a1e4bc212927d_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTEtMS0xLTA_776e1b37-9443-4ab2-a4ce-318f4e73d8b7">60.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b7565646be4ec6aee7375271c85a7b_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTMtMS0xLTA_b3fa64a9-6165-4cfa-a54d-bb6b929013d3">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2dd7aabbe1457a85f6382dfb21b03d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTUtMS0xLTA_2574e6fa-87b7-4c6f-a0c9-8f33861a5bb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e19515eb414ea3950645ec1bd6e029_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTctMS0xLTA_291aa530-1938-47a1-a0de-02bb1940e9bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e32fe5c4d1480b80157e3bf4f1e8fe_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTktMS0xLTA_aab72ca5-c0b9-44bf-86ab-c531e7d427b8">60.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6474a7ae8a415c8a0c7443dcfb85d4_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTExLTEtMS0w_6f4b6610-bece-483d-9819-29131b2fe8d7">60.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360e6926e5a4ee19a921dff273528d3_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTEtMS0xLTA_92dd7a2f-2738-4194-827b-23d5c0c53d24">718.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7727cb3da004ae0a84be29679fa8e8a_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTMtMS0xLTA_8b173c64-ee9a-4d69-a0b7-1b561ee5e758">254.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeacddff780c45eca88800cb052b4f1b_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTUtMS0xLTA_cbe224ef-6750-47ac-b4f8-19929b92e19f">718.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3597dd720a74b66a0a24bd7e5f6336c_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTctMS0xLTA_583b10e0-dc4d-4554-9509-68c889ffcbaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2025050fac34c4bac2c4ba461347a3f_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTktMS0xLTA_0e3ab662-cb42-4e8c-b174-9730e9e2c41e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26823dabd1b64b328190517078c87d4f_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTExLTEtMS0w_e8581075-2af4-436b-8291-ecfff7747cef">718.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM4LTEtMS0xLTA_05af70df-1553-45c2-a938-a7cd71483281">405.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8339c07c793c4080bbff3b4f3508d6c4_I20191231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM5LTEtMS0xLTA_7cbadbac-34c9-4ba2-bafe-cff439518403">299.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzQwLTEtMS0xLTA_d4781fb0-e70a-4709-928d-60ee0a4bdc2b">1,962.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0Mzgx_2667c65e-07ae-46d4-8db1-45bd8de91a10" continuedAt="idfe80328250145958068d7596f09fd33" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="i652b0160572e4e57b65ed29833778b73" continuedAt="id12f51ac3bc44401a33890b94f1f935e"><ix:continuation id="idfe80328250145958068d7596f09fd33"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term commercial paper borrowings</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9b4655ccd1401e9984bb3b5ee74b96_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtMS0xLTEtMA_c40436aa-caf6-41c2-a35f-c478c2d1cd01">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd4cb1fd99f4fae868921a774fda59b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtMy0xLTEtMA_08bab8d5-5d3e-4402-87f6-0677ce46c650">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3f83e4500c4b8785248a7a70fa84b9_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtNS0xLTEtMA_653653f2-a734-48bf-a228-51b2b57fc7d7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2c22552802430ea404ce1f2936a291_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtNy0xLTEtMA_cc031c6c-363c-4ff6-b95c-15203abb5f9a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9bed57fe694231ab6166019b90e496_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtOS0xLTEtMA_a6751911-1ec1-43d6-9c5c-bf80da97856c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc63939ce42a42b4b7c2ce2910cbad4b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtMS0xLTEtMA_dba2ca22-e268-4360-8cbe-3e5a1041aea1">1,494.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78564906ca1644298e4c0fa5785b3dc8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtMy0xLTEtMA_3fc396ca-c9bd-4ca1-b702-b0a6aeb33337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e562e62e4d4490ca21252c3fad46bda_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtNS0xLTEtMA_1068adf0-eb0b-42ae-9efe-d6a741d67080">1,491.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f157e5e59dd4d41821a1ba8e732b05f_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtNy0xLTEtMA_4a76a385-a036-4241-8f44-b942caf1e48f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b9dad78832c4368859b28c2f6894c72_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtOS0xLTEtMA_c3e2f887-9017-43eb-8462-f581fcb9d25e">1,491.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctMS0xLTEtMA_36382fac-392a-4847-bf7a-0493e5dd0ec8">16,595.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c51b75c2fa14c1684c56a1e7d8fc1f5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctMy0xLTEtMA_77454b6d-7a29-4a92-ab75-6cdaf032a7cc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ec12cf461774e1182bafa64c823d98d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctNS0xLTEtMA_7de83157-7345-4cf1-885c-369db53a709d">19,038.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i566cfafb34514a41ac32d09adc9ee29a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctNy0xLTEtMA_ade1edb6-ccb5-4fc9-b5e4-b2497e0d1be3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2ab34fc33aa445d9f82bf362c674439_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctOS0xLTEtMA_3bcf0614-8038-4e9e-a7ca-945dda10c986">19,038.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtMS0xLTEtMA_815bf512-6484-4f18-8937-175f92180e0e">13,823.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de1473493a442ab6ca0ee29d148543_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtMy0xLTEtMA_34b2d2f7-47d4-4736-a54b-08036d9e811b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3ec43bf672b4ad99e62859afb69e618_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtNS0xLTEtMA_7b47680a-b21b-42a8-a8e2-7ef0c408c8e1">15,150.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e269ce360814b8e84f97f774fd1c803_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtNy0xLTEtMA_a67de47b-5d44-475a-9120-868267a6d1b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia46aacafc18444898a49130e3d437b45_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtOS0xLTEtMA_0e332094-85df-4d6d-9606-d6c246842da4">15,150.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzY2_ea518941-2b31-4f97-bc83-e0eb7c260047" continuedAt="i8346fc62240040bf9cbc091cffb767da" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="id12f51ac3bc44401a33890b94f1f935e" continuedAt="i11a156cab541485695946206340a8cd1"><div style="margin-bottom:5pt;margin-top:11pt"><ix:continuation id="i8346fc62240040bf9cbc091cffb767da"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.863%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id845d0c7f9964ee0bf08e79d645dd1ce_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtMS0xLTEtMA_b7fdbb18-ea60-42a1-a47c-7bc777ef017d">158.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0dd8585de44468add60f95d78c62ff_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtMy0xLTEtMA_6e7a0cc0-0a60-495b-af67-b89c22d4412f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6df764752add48c48282f4351f5aea77_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtNS0xLTEtMA_be0e57d2-3c99-440b-875b-fa6928286de7">158.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa54dda0cead4e039cb3c37fdbf005b3_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtNy0xLTEtMA_3c779bd0-fcf6-40e3-ac0f-05ee434735cf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a5d2355fe924260b94ae1755b5115f1_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtOS0xLTEtMA_4b245dd1-6db7-4e3b-843e-0e62ca6058e5">158.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f99babb106943a48c2ef126347a18da_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktMS0xLTEtMA_ee547bcd-dc24-4ba5-9d88-9e0b77f26293">38.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3140c9a521e845898dff7af991e1d21b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktMy0xLTEtMA_84a0ced1-814b-4876-8650-b144725bef4c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e14b4632c2342cd8bdd5d6e1be3f3d5_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktNS0xLTEtMA_46d43e35-28bf-4bd5-8ec2-eb80adb733c5">38.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9ed839ea824eea97ca2b8fed80d1ca_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktNy0xLTEtMA_6409867e-7b59-4663-b2d8-561c48b35038">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a345f6cc3914c7f9e7fe94738f6cb7f_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktOS0xLTEtMA_ef0e8f7d-72a5-47f0-8d06-16c975fdc6f5">38.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f99babb106943a48c2ef126347a18da_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTEtMS0xLTg5MDA_6e197e30-3294-44ed-b84f-9a014bd3f860">97.8</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3140c9a521e845898dff7af991e1d21b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTMtMS0xLTg5MDQ_9753e415-e44f-4de7-8ff9-75e3a6b86580">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e14b4632c2342cd8bdd5d6e1be3f3d5_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTUtMS0xLTg5MDQ_8f3b962a-170b-4dc8-8d57-48def2a8842c">97.8</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9ed839ea824eea97ca2b8fed80d1ca_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTctMS0xLTg5MDQ_2185bb7f-4b47-4f39-b863-bbb5417f94a5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a345f6cc3914c7f9e7fe94738f6cb7f_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTktMS0xLTg5MDQ_c953497c-d378-4296-b79a-ad6386ca1295">97.8</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e42ef743d4049b8b98c528fd36eceac_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTEtMS0xLTA_3e09babc-8b4e-425d-8807-2ea24287380b">92.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99493aa1fbc341b58c3254bd5c14e0c4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTMtMS0xLTA_9155599e-c795-4638-bcb6-0a31947283bc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19aa55084b624b149f91667988733b94_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTUtMS0xLTA_861f4d6c-f51f-4536-9fd4-32c1fa96bd0e">92.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb79e31f68c462a8bfdd0a9e8cb0126_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTctMS0xLTA_23eccf6b-c888-4fb9-95a9-ba2577063fc0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1161a1814827464d8d0bf447a827298e_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTktMS0xLTA_f43b149e-4fea-4472-ad62-67a33ac4f427">92.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e42ef743d4049b8b98c528fd36eceac_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTEtMS0xLTA_91a6812b-12c6-4408-9169-efc6580a99a0">97.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99493aa1fbc341b58c3254bd5c14e0c4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTMtMS0xLTA_dc558b7f-d293-4495-b783-a3e8f1bb93cc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19aa55084b624b149f91667988733b94_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTUtMS0xLTA_325aa439-8d0e-458c-8a63-01d3fe4ff0a8">97.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb79e31f68c462a8bfdd0a9e8cb0126_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTctMS0xLTA_987175c5-3aa4-4dff-96f5-d0a70216bf01">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1161a1814827464d8d0bf447a827298e_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTktMS0xLTA_2bd6f244-f10a-4e29-9889-10c30038b202">97.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f85dff2b99430d9ea18be88db32363_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTEtMS0xLTA_d56a9cf7-cec7-4d75-b49d-63fe7e897bf8">34.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54194fef9ee44f0baa1198b79b989cd_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTMtMS0xLTA_145f99f2-a5c7-49c1-a383-071fb5c6bb14">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bb3cfe0c224730b91be93a08a94d91_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTUtMS0xLTA_c36bcf82-a354-4a1c-8a39-0aa5df1bc120">34.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab9280585474937b6956aacac7dcc43_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTctMS0xLTA_88c31712-14c9-463a-8a76-0a21bafd699f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a130b6c9674334bb31349bb3084485_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTktMS0xLTA_9196aa8f-5b74-43c0-b05a-c5b6eba6b889">34.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5f85dff2b99430d9ea18be88db32363_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTEtMS0xLTA_52babded-3902-41e2-a0a8-1bc7ec221ac9">2.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54194fef9ee44f0baa1198b79b989cd_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTMtMS0xLTA_2915708f-e088-420f-bd8f-64e15fc398b9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49bb3cfe0c224730b91be93a08a94d91_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTUtMS0xLTA_3dac4ea7-46b9-4bda-9dfc-1093c7c5faf5">2.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab9280585474937b6956aacac7dcc43_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTctMS0xLTA_96b56d41-c714-4a6b-b7bc-46682b407024">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2a130b6c9674334bb31349bb3084485_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTktMS0xLTA_38a7e021-9f77-4af5-9930-bb38df85dfeb">2.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i698fbd8d92b24eaa80fb4794ec8b22db_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTEtMS0xLTA_c16e0071-794c-4973-bd9f-8cb0be1fab9f">41.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c44cbf91e34245b319839db6f762e1_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTMtMS0xLTA_5f9c3c41-72e9-4f92-beb8-64425b7a7bb0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7188b3764a4f06b9d801cc32c022eb_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTUtMS0xLTA_b34a973b-26fb-492f-a974-6fc456a5a72f">41.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47944dddbf22476e9864a6d86fca6c07_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTctMS0xLTA_2063aa3f-4e9f-4996-b16b-046b4b2ed11e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b04120333d14c7bb3721e9afbb4f200_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTktMS0xLTA_f615d49e-8990-4358-964a-b620d27b0fbc">41.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i698fbd8d92b24eaa80fb4794ec8b22db_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTEtMS0xLTA_07bd9348-5929-4675-9376-a594c9ad1554">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c44cbf91e34245b319839db6f762e1_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTMtMS0xLTA_eb195e9c-aa0e-4370-a044-0cedcaaf0c0f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a7188b3764a4f06b9d801cc32c022eb_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTUtMS0xLTA_94ec149c-d47a-4024-bf8f-390fc24e4660">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47944dddbf22476e9864a6d86fca6c07_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTctMS0xLTA_47de1eb8-bd67-4d02-bdb0-1d3ccee74a31">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b04120333d14c7bb3721e9afbb4f200_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTktMS0xLTA_136257f5-16cb-4e52-b492-be02318dbd96">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f3f64f550448648f5d119e75baab9f_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTEtMS0xLTA_81ab73c3-0712-4f97-b527-85326c24ea81">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46ab1f4827641929600f4d8e579cba6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTMtMS0xLTA_349a4913-17cf-41f5-9df6-781584c35896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a5e140926245c3b898ab1b8b0aa810_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTUtMS0xLTA_04345392-4fdb-416e-b6e4-a9c4bb5d3a25">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i571b62f2272c4f0c9864c655bacb5f43_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTctMS0xLTA_01b74ca3-7932-4ea0-a078-f6ff3df6f36d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faee0bc39a1435ab2737a04a112a0d0_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTktMS0xLTA_6dba116e-613e-409c-8bc8-659c89bcc3d6">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7397b614fa4d0aa289843e505c0338_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTEtMS0xLTg5NA_9569b8a6-9c96-40ab-8702-0ab14edf5cae">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499a38e64d144a59b3902cd77fe676e6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTMtMS0xLTkxMQ_80a9c91e-9907-4860-b5dc-15e963488020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a53f7cc64140b6ae991b885dbec6c7_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTUtMS0xLTkwMA_53262f66-696e-4f17-ac1f-51f56cc34eec">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib769bb44d96b4ec6b1ff4f8945d14c74_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTctMS0xLTkwNA_0a5fa56c-fcea-48bb-8b62-2080f5b2ddc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7790a8ee4fb2414eac30e7a9561da8aa_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTktMS0xLTkwNA_dbf0668b-a854-44d6-86db-0b70f2269cb6">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f567bd4e42740019b3174c50d5bcd76_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTEtMS0xLTA_63384865-c67b-463f-bf2f-00c007439c70">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3567afa62a444c229ff7c02310132308_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTMtMS0xLTA_3ad099c1-fb60-4fdd-9ab0-8bbf5ed26c78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a257a5c3988421daab1c5c94873c7b2_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTUtMS0xLTA_06bb40c1-a821-40de-901d-1b6245b18372">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea105f73e09247b896eb5002be1fa817_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTctMS0xLTA_9e14e41c-7e4f-43d7-8f56-2b9ed75fad99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901470ea1dcc46daa707e313c0151f74_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTktMS0xLTA_aee7a27d-4d92-4f9d-8e6d-d3b614c8caf2">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f567bd4e42740019b3174c50d5bcd76_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTEtMS0xLTA_411ac5d2-f69d-4c52-916b-577b89a9c9a1">21.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3567afa62a444c229ff7c02310132308_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTMtMS0xLTA_8bdafa76-74b6-43d2-9a5f-12fa880c4db2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a257a5c3988421daab1c5c94873c7b2_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTUtMS0xLTA_1f028823-76f2-4b36-a94c-684409fdf95f">21.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea105f73e09247b896eb5002be1fa817_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTctMS0xLTA_5c39c6ca-e436-4051-9fa7-5be01c831cc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i901470ea1dcc46daa707e313c0151f74_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTktMS0xLTA_744bbec7-b629-41df-b656-3248a5b249bf">21.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f567bd4e42740019b3174c50d5bcd76_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTEtMS0xLTA_3c50eddd-44b4-439f-a903-9491b140c6cd">5.7</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3567afa62a444c229ff7c02310132308_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTMtMS0xLTA_e332289d-68c3-4981-b7cd-565e5fba4ef7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a257a5c3988421daab1c5c94873c7b2_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTUtMS0xLTA_0a2220f7-5b29-4f4e-ab70-7b772ac9f245">5.7</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea105f73e09247b896eb5002be1fa817_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTctMS0xLTA_9bdeea02-cfa1-45a8-ac4f-b41003b2439a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i901470ea1dcc46daa707e313c0151f74_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTktMS0xLTA_b80cf94b-c2dd-41c9-8ff3-3619bf50dec2">5.7</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d8bd5466554120bcef2a7280d5a0cd_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTEtMS0xLTkyNw_defaf9e3-3170-4256-8da6-12340821bed2">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i605c9e12226d4404b17da90d7bcf0a01_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTMtMS0xLTkyMg_d01676b1-365a-4a9a-b61c-d99ba8facf64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8ea6d64d6b48f185da2f7945e93913_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTUtMS0xLTkyMg_072d74a5-adb1-4194-8c41-83e1fed60269">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if97d81ab32d741d5a50a9e919be3b610_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTctMS0xLTkyMg_f8cacc83-fa5e-49bd-80c6-acbb3936c2f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb8e2a45e4548bbba35a9682ef87298_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTktMS0xLTkyMg_0aec427c-22fd-40a3-b674-198352f48af2">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd8e5bcf3a7042e997ecff32c5ddeb26_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTEtMS0xLTA_559e3868-0e06-4e71-afce-a2267bd276f7">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68533791086c4a66b4e85509ed1bbd21_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTMtMS0xLTA_3ffb6787-bf72-4cd0-8652-8aa15dbf34ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i018a7fe95440493cb5b194a242c36530_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTUtMS0xLTA_407be0e1-d770-4f76-aaab-1159550531b3">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4080399399ba43068553348c4be8ea2f_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTctMS0xLTA_5de777eb-c310-42a9-82cd-2a0e392baac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc07496027d844728e4f422d09488b8b_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTktMS0xLTA_fe6f804d-5f77-4258-a0a2-5a11a55f9d10">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e3a32202c54bff815b9d7e2d3e22fd_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTEtMS0xLTA_a038cba9-d275-4882-818e-4d3f910a4641">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a6f81ea634490dad4edeff649d1781_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTMtMS0xLTA_67114681-ee25-4fcc-8559-88f08151d779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38207da496841d290edd3833837d8da_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTUtMS0xLTA_a35e5908-0dbc-4268-a0b0-0909a1ee0dd8">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec2b5844ba24dc08ff7dd52e6d6c8f0_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTctMS0xLTA_bbd3f4c9-9658-4355-bbf6-c262ea27be7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1c802688094a8889c8d0228f9ee2c4_I20191231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTktMS0xLTA_d4e77216-6192-4632-b87f-5d317e383a7c">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6e3a32202c54bff815b9d7e2d3e22fd_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTEtMS0xLTA_453919fc-7753-488b-9db7-808664412402">11.9</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a6f81ea634490dad4edeff649d1781_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTMtMS0xLTA_d7bce1e8-6e74-4e69-a76c-68a9c16b9a46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic38207da496841d290edd3833837d8da_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTUtMS0xLTA_7dc8b706-58ad-4230-8c9d-aa49cef4ce62">11.9</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec2b5844ba24dc08ff7dd52e6d6c8f0_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTctMS0xLTA_1b475c8a-5476-45c7-9e1a-3212a95c624f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1c802688094a8889c8d0228f9ee2c4_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTktMS0xLTA_5fdadd65-f4e2-4186-a18f-b01ff45abf58">11.9</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i11a156cab541485695946206340a8cd1" continuedAt="ifae3669c4bd8480884e65dcdb30edaf2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available. As of December 31, 2020, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzcxNDY4MjU1OTgyNTU_2ba51d3c-625f-4283-afcf-057cef27e0ed">687</ix:nonFraction>&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:duryear" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzMyOTg1MzQ5MDE1OTg_4151dd5d-b4af-46cc-8301-5634958ff30a">10</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0Mzc2_3a25fcad-3c1c-43e4-bd1a-c1c09f571833" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:42.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5      Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10    Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItMS0xLTEtMA_489759a0-aa49-4001-a6b6-34d91529d337">360.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItMy0xLTEtMA_51669176-2c48-48db-b736-35af5de451fb">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItNS0xLTEtMA_f280f347-319f-433a-be04-9628d9ca17ce">135.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItNy0xLTEtMA_0852e460-9c8a-4bf9-b937-c940ba900c67">82.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItOS0xLTEtMA_d5271d9d-b797-4904-ba6a-b64837c36d7b">128.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains recognized in our consolidated statements of operations for equity securities were $<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzExMDA5_d2a294be-69de-429f-8853-fb074efa29e3">1,442.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzExMDE2_7dca2b6b-944d-4283-95e2-023937a68982">401.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzcxNDY4MjU1OTgwMjc_5a8b2791-8376-47e6-8577-90be04b94514">72.6</ix:nonFraction>&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The net gains/losses recognized for the years ended December 31, 2020, 2019 and 2018 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December&#160;31, 2020, 2019 and 2018 were not material.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0NDAz_2788039b-00f5-4fcc-a7e5-db599fa6156b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzEtMS0xLTEtMA_75a426ea-edb2-4c18-a388-91b26329365f">20.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzEtMy0xLTEtMA_461d38aa-6646-4536-8fc9-0ee7a70a047a">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzItMS0xLTEtMA_dc89a72f-4a8d-4f07-bd0d-f776ec3d86da">0.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzItMy0xLTEtMA_8500bde0-3735-4255-9b63-910312f719c1">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzMtMS0xLTEtMA_8a3c4579-6fd6-4c9d-a5ec-bceca4a41f3a">348.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzMtMy0xLTEtMA_4ee5d1e2-e048-4651-8b02-06a8c8f6dfdc">429.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzQtMS0xLTEtMA_67281714-2234-427d-a3e9-9e7c4e3a9c10">11.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzQtMy0xLTEtMA_c1c37f92-4bd5-46a6-9333-93a5237ff6ca">141.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment and credit losses.  The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonFraction unitRef="number" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzEyNzA4_010b6894-7a9a-4429-897a-f72d122d7c8e">86</ix:nonFraction> percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2020, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ifae3669c4bd8480884e65dcdb30edaf2"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0NDE0_3c577be7-446e-4834-9382-5d50f6b039f8" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzEtMS0xLTEtMA_8787ff31-1040-478f-983d-72921a5d0748">264.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzEtMy0xLTEtMA_1adf09c1-7a67-452f-9950-013e1f0be2a0">431.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzEtNS0xLTEtMA_11125705-8f05-48a6-afd0-5a547b4c6553">5,529.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzItMS0xLTEtMA_7ece99e5-080b-4d8b-807c-fdb9a9d3e813">4.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzItMy0xLTEtMA_151542a7-8d7a-4cdb-a7b2-2381ca781f74">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzItNS0xLTEtMA_b946e0d1-d575-4f3d-9f39-c295c377d681">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzMtMS0xLTEtMA_2cb9b981-36de-446d-9fe3-e3388fa6bcef">8.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzMtMy0xLTEtMA_63ad286e-be31-416e-a962-3fc94c6246e3">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzMtNS0xLTEtMA_382624d7-0c7c-439b-ae36-586356535950">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MDcz_76ac06aa-0254-46af-be8c-69ad0065042f">754.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MDgw_0fe97e72-eb96-4e68-990f-c2a98b9e08ad">678.8</ix:nonFraction> million&#160;of accounts receivable as of December&#160;31, 2020 and 2019, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2020, 2019, and 2018 were not material.</span></div></ix:continuation><div id="ia8e8b06f04404e6fb09e313103495f8e_142"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;8: <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUwNjQ_c9debc17-e7e7-46dd-a46d-ceb51def33a1" continuedAt="i93a179d746af4956b9e5d7449ee2120c" escape="true">Goodwill and Other Intangibles</ix:nonNumeric></span></div><ix:continuation id="i93a179d746af4956b9e5d7449ee2120c" continuedAt="icd833eb6a78b4abaa7688d27ecc26d1a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUwODM_f7c173fd-7856-4e8b-9e49-7c3e98bf2116" continuedAt="icd4791c1188b4245b30a69a566afc268" escape="true">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.</ix:nonNumeric> The changes in goodwill during 2020 and 2019 were primarily related to our acquisitions of Dermira and Loxo, respectively. See Note 3 for further discussion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0Xzc5Ng_05ffae94-a015-4af6-bdc1-4a8d8554c727"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0Xzc5Ng_dfa13135-4cbb-4964-ae57-5be4d3c50595"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0Xzc5Ng_e5da0bf1-3a3e-45a3-b1ef-dc2352f1c9dd">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2020, 2019, and 2018.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUwNjg_a31016bf-632b-4c55-87c0-7864d9f2cb80" escape="true"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUxMDA_8a5762ca-0632-44f5-b492-328091a8bbe2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:26.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i662262e67b5f40cea96bdb9a5cd66701_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtMS0xLTEtMA_d100e774-c595-4d8a-bbcc-8acc12c42f83">7,984.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i662262e67b5f40cea96bdb9a5cd66701_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtMy0xLTEtMA_4e247705-8487-4789-b470-5dae40ee2bcd">1,659.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i662262e67b5f40cea96bdb9a5cd66701_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtNS0xLTEtMA_76378924-2463-41e2-a43e-0a9c2870c316">6,324.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5102bbe8737b4c2da4a4243cb207ce90_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtNy0xLTEtMA_64aa939e-33f8-412c-82d6-c9f1bdf38a2a">3,150.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5102bbe8737b4c2da4a4243cb207ce90_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtOS0xLTEtMA_2ac98c29-fbc8-4855-991b-f9305e6a0474">1,244.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5102bbe8737b4c2da4a4243cb207ce90_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtMTEtMS0xLTA_97d46b6f-26a9-4d63-bf8c-6476fc02cae8">1,905.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1083cf7137cf44a588e913c40a07246d_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtMS0xLTEtMA_1229b924-6e8b-4e97-a7cf-b3c5181d9256">92.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1083cf7137cf44a588e913c40a07246d_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtMy0xLTEtMA_573becf6-485d-4fa4-8c28-4842a548a1c1">68.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1083cf7137cf44a588e913c40a07246d_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtNS0xLTEtMA_554c99de-babb-4929-a268-e833e6228fc3">24.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4236ef82f62541ebab48555f05d6cb37_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtNy0xLTEtMA_a0065e92-eefc-4ac8-b31d-c0b3d18198ff">94.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4236ef82f62541ebab48555f05d6cb37_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtOS0xLTEtMA_7b25a8ed-905e-4193-a342-6625ba67c75d">51.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4236ef82f62541ebab48555f05d6cb37_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtMTEtMS0xLTA_384ab087-641c-44c6-a06b-1196b22f9555">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtMS0xLTEtMA_16834d2e-043d-4604-846f-cd7b07259aa0">8,076.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtMy0xLTEtMA_e5e1a1d7-6506-45d8-b27f-76d9006de52d">1,727.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtNS0xLTEtMA_c50489a4-15df-4142-bab0-7aba90a8d373">6,349.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtNy0xLTEtMA_82b83aef-652a-4d3c-921c-bb1087e1341c">3,244.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtOS0xLTEtMA_80cb9062-0738-44e0-8096-574c6a6d030f">1,296.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtMTEtMS0xLTA_29ee2887-9435-4479-9e6c-b5b44e3ba4a7">1,948.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42c7c598e6f49feaae76a07d1b3d85b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzctMS0xLTEtMA_02038630-151c-429a-9ab9-03304998a124">1,101.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42c7c598e6f49feaae76a07d1b3d85b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzctNS0xLTEtMA_f87086d5-e9b2-46ea-93ab-62507a987dfb">1,101.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfb71fb8b9f42c794f44a765001ec7e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzctNy0xLTEtMA_f05fbc0e-8111-4bf2-8fe1-a9a08591794a">4,670.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfb71fb8b9f42c794f44a765001ec7e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzctMTEtMS0xLTA_503e51dc-07b9-4464-9bfd-c69565b1a382">4,670.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtMS0xLTEtMA_aaae11ac-2d8a-4e7f-b249-08aacf65e7fd">9,177.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtMy0xLTEtMA_00272a60-10d4-43bf-aa92-64ad28f3f969">1,727.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtNS0xLTEtMA_9e4be299-19f9-44bf-91d8-587b44c3a22c">7,450.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtNy0xLTEtMA_8259d02d-120d-4ba9-9cba-fb3149c25d33">7,914.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtOS0xLTEtMA_08bffc0a-3fc3-463a-a6af-62416b2abe32">1,296.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtMTEtMS0xLTA_576121f7-e176-44bd-b3e6-021566eaac11">6,618.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. <ix:continuation id="icd4791c1188b4245b30a69a566afc268" continuedAt="iaaaee4587db54b6293e7a77e3531dfec">For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="icd833eb6a78b4abaa7688d27ecc26d1a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of the fair values of acquired IPR&amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. <ix:continuation id="iaaaee4587db54b6293e7a77e3531dfec" continuedAt="i325d92f5a6424611a8c6c4ba17a48c7e">The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;D projects that had no alternative future use. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i325d92f5a6424611a8c6c4ba17a48c7e" continuedAt="idb3b750034bc4d8898bcff708b2a9be1">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the &#8220;income method,&#8221; which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in marketed products and the decrease in acquired IPR&amp;D in 2020 primarily relates to the reclassification of our $<ix:nonFraction unitRef="usd" contextRef="i56fecb64135f4cca97024ac5ee838679_I20190215" decimals="-7" format="ixt:numdotdecimal" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzMyOTg1MzQ4OTIyMDM_e2ea22f1-b712-4f33-b842-2933e442b8b9">4.60</ix:nonFraction>&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived to finite-lived as it was approved by the FDA in the second quarter of 2020. This decrease in acquired IPR&amp;D in 2020 was partially offset by the addition of acquired IPR&amp;D for lebrikizumab as a result of the Dermira acquisition. The increases in marketed products and acquired IPR&amp;D intangible assets in 2019 were primarily related to our acquisition of Loxo. See Note 3 for further discussion of intangible assets acquired in recent business combinations and Note 4 for additional discussion of recent capitalized milestone payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I<ix:continuation id="idb3b750034bc4d8898bcff708b2a9be1">ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ1MTk_0bf7a79a-03a8-4be9-83df-152315c973ca">three</span> to <ix:nonNumeric contextRef="i0d4f0d9411ad485cb55e50fad753c51d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ1MjU_f14d64c0-d2db-4c66-b196-6ad9af0fdb34">20</ix:nonNumeric> years. As of December&#160;31, 2020, the remaining weighted-average amortization period for finite-lived intangible assets was approximately <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ2NDM_d1b976da-606f-42a1-a26e-88e854f4f921">15</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUwODY_7dd0e223-f5f8-4b9a-85ca-ab83df6086a7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTozNDk3YjdiM2FhMDk0YjkwYWJhNzJhZmY3OWUwMGU3Zi90YWJsZXJhbmdlOjM0OTdiN2IzYWEwOTRiOTBhYmE3MmFmZjc5ZTAwZTdmXzEtMS0xLTEtMA_7d916b59-afcf-4be3-aad9-41cfdc298d2c">428.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTozNDk3YjdiM2FhMDk0YjkwYWJhNzJhZmY3OWUwMGU3Zi90YWJsZXJhbmdlOjM0OTdiN2IzYWEwOTRiOTBhYmE3MmFmZjc5ZTAwZTdmXzEtMy0xLTEtMA_bc1b7249-0951-4d2e-82db-5a01639cae84">225.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTozNDk3YjdiM2FhMDk0YjkwYWJhNzJhZmY3OWUwMGU3Zi90YWJsZXJhbmdlOjM0OTdiN2IzYWEwOTRiOTBhYmE3MmFmZjc5ZTAwZTdmXzEtNS0xLTEtMA_49e4a51b-47b2-4162-8673-167dcffa15f8">361.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUxMDU_fa411a9d-c40a-42a0-84fa-2165a45e2a00" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:49.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtMS0xLTEtMA_3390bc03-081d-4263-863c-84686e5aa297">517.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtMy0xLTEtMA_4c25b024-f2e1-4dd1-8ff8-c6ce77c815d4">513.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtNS0xLTEtMA_ee95b545-a928-43ff-b9c6-5d5a63bc0602">501.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtNy0xLTEtMA_4801f7c8-c22b-4bc1-aeb5-81099c6c8109">449.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtOS0xLTEtMA_48c2cd27-eaf3-4735-9be6-13c1756b8049">432.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">85</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;9: <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzEyMjI_9a7a23ce-654f-4890-8cc7-dadc513d602f" continuedAt="i4e44f7a29c1d4b5bb35f00d17f4a615e" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i4e44f7a29c1d4b5bb35f00d17f4a615e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzEyMjc_414e68f8-487d-4dd8-9ae3-1cfa03827631" escape="true">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (<ix:nonNumeric contextRef="i6440d866422d4fcea9a1a914dc919853_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI0NQ_c1ac3b35-d649-43e0-8815-32a5e2cd0e7f">12</ix:nonNumeric> to <ix:nonNumeric contextRef="ic681b92a73ce4099bf3dcd5b07e95e90_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI1MQ_d5e8929d-3eb8-4bc0-86c6-0a482b3f9f38">50</ix:nonNumeric> years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3Mg_22167169-de32-49e2-8061-fe64a7bff538">three</span> to <ix:nonNumeric contextRef="ibabdd19152304e26964b75c2240169f7_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3OA_8d3f45b2-8412-4885-876c-11344efaabf0">25</ix:nonNumeric> years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset&#8217;s net book value over its fair value, and the cost basis is adjusted.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzEyMjg_ae09e36b-9afa-45ed-bcee-838bc5c91c42" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzEtMS0xLTEtMA_5afb0c6a-9efa-4ce1-9860-01531b2fbd89">226.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzEtMy0xLTEtMA_3e9fcbd6-9006-410c-a008-50ad4ba2e3ac">169.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzItMS0xLTEtMA_7fbf63f6-436e-420f-9038-9a648f6dd4a6">7,326.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzItMy0xLTEtMA_2864df8a-7e9b-40d1-b496-1c01529661e6">7,067.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzMtMS0xLTEtMA_94e8affd-b0cc-4042-a71f-d0dfb4c0d826">8,560.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzMtMy0xLTEtMA_ef8ca772-127e-48e5-8943-82a693346f64">7,913.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzUtMS0xLTEtMA_115df887-b280-48d4-9993-c1667433e0bd">2,138.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzUtMy0xLTEtMA_49ef30ff-a2dc-4373-abc4-a5327413cc2a">1,884.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzYtMS0xLTEtMA_4a20eb34-c792-4288-a10b-412d9306223d">18,252.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzYtMy0xLTEtMA_fe075439-b330-4f55-b350-2012945c7c33">17,034.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzctMS0xLTEtMA_a2ea7f38-ff22-4bb1-991a-505a9bfdda04">9,570.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzctMy0xLTEtMA_e9eee64c-e24f-4050-8294-685379f8be57">9,161.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzgtMS0xLTEtMA_6b200c1b-eb05-459d-af30-c5856f39c7a9">8,681.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzgtMy0xLTEtMA_221b85bf-ce0d-4b7a-86fb-68b4ceac9705">7,872.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:69.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZToxZDZhMjRhMWJlN2I0NWJhOWYyN2I5NTUxZTc4OGQzYi90YWJsZXJhbmdlOjFkNmEyNGExYmU3YjQ1YmE5ZjI3Yjk1NTFlNzg4ZDNiXzEtMS0xLTEtMA_85bfde41-9765-44c3-ae0a-f625bcbea678">765.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZToxZDZhMjRhMWJlN2I0NWJhOWYyN2I5NTUxZTc4OGQzYi90YWJsZXJhbmdlOjFkNmEyNGExYmU3YjQ1YmE5ZjI3Yjk1NTFlNzg4ZDNiXzEtMy0xLTEtMA_6d077322-3931-40dd-b648-0413c8130445">814.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZToxZDZhMjRhMWJlN2I0NWJhOWYyN2I5NTUxZTc4OGQzYi90YWJsZXJhbmdlOjFkNmEyNGExYmU3YjQ1YmE5ZjI3Yjk1NTFlNzg4ZDNiXzEtNS0xLTEtMA_c4589f3e-d8f6-4cf6-9aa3-dc48af3c1e0f">797.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest costs were not material for the years ended December&#160;31, 2020, 2019, and 2018. </span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzEyMTA_f2f48dae-b0e3-4d3a-a54d-11ba1324031e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:38.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib11faf3ad2f94548b0a09cf8f35a15f6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzMtNC0xLTEtMA_334149f7-f99a-4f1c-a938-0de2d2224734">6,113.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2594deedacf54880b1db0ef581e435e1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzMtNi0xLTEtMA_19c8d74e-a8b5-4ad8-8799-1a1aef8ddd38">5,595.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d7beba7c48404cae7014e52512b95b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzQtNC0xLTEtMA_ce9c7410-3b86-486e-b3ef-e75e1e46cf40">1,786.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cbfb7a17f9438a8d7adf6e5a09c448_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzQtNi0xLTEtMA_46c0e993-45a5-4891-8c7d-7182491da891">1,454.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c64ede2b9f24bd2bb0d6f97ff8dc7ab_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzUtNC0xLTEtMA_a0074181-5b33-435e-a4ab-c40a94c0d853">1,747.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia528dbed284d4ed0b3acc05cf5e1b356_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzUtNi0xLTEtMA_5addee84-6012-4790-85a0-bb03e215c907">1,758.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzYtNC0xLTEtMA_c93d62a1-a100-4523-82c3-e71b5421f130">9,648.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzYtNi0xLTEtMA_5551204a-bb7f-4417-ad36-41897fafa2dc">8,808.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div></ix:nonNumeric></ix:continuation><div id="ia8e8b06f04404e6fb09e313103495f8e_154"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;10:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzI2ODM_50f9de6a-ba8f-4d90-8f80-97f4bb8e354a" continuedAt="ia7ff398b739e497cbee51388e35ffa1a" escape="true"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzI2ODQ_7daa3b72-b14a-43e4-98bd-89058dabda32" continuedAt="i99dfe606e0ee4f19829809076128dd05" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ia7ff398b739e497cbee51388e35ffa1a" continuedAt="ibcb976cb15474ff98a6f79680875d96c"><ix:continuation id="i99dfe606e0ee4f19829809076128dd05" continuedAt="i4ab980faa61c41a4a6fae7b73668b942"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" format="ixt-sec:duryear" name="lly:LesseeLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzEwOQ_4a60e8d6-9db5-46bd-a7d6-59bca94d96d8">12</ix:nonNumeric> years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="ibcb976cb15474ff98a6f79680875d96c"><ix:continuation id="i4ab980faa61c41a4a6fae7b73668b942"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzE1NTc_b0ed7479-0e9f-4ea5-a51f-a779c9abfce9">154.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzMyOTg1MzQ4ODYzMTA_c80d393b-b933-4eef-a5c7-f0f2dcfc608d">172.8</ix:nonFraction>&#160;million during the years ended December&#160;31, 2020 and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2020 and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzI2ODU_f5636e42-9210-4dc0-9125-f379312c5bfd" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTo1OTdiOTA1N2YxNzk0ZDhiODU5OGQwYTFiZjZmMDBjNi90YWJsZXJhbmdlOjU5N2I5MDU3ZjE3OTRkOGI4NTk4ZDBhMWJmNmYwMGM2XzEtMi0xLTEtMzMyNA_76e4bdc8-fdbe-4f53-9097-288942148d2c">7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTo1OTdiOTA1N2YxNzk0ZDhiODU5OGQwYTFiZjZmMDBjNi90YWJsZXJhbmdlOjU5N2I5MDU3ZjE3OTRkOGI4NTk4ZDBhMWJmNmYwMGM2XzEtMi0xLTEtMA_88e20777-1ef0-4bfa-a1ba-c35e77dec95a">8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTo1OTdiOTA1N2YxNzk0ZDhiODU5OGQwYTFiZjZmMDBjNi90YWJsZXJhbmdlOjU5N2I5MDU3ZjE3OTRkOGI4NTk4ZDBhMWJmNmYwMGM2XzItMi0xLTEtMzMyNA_3177714e-d079-4ca2-b110-0d658d5594fd">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTo1OTdiOTA1N2YxNzk0ZDhiODU5OGQwYTFiZjZmMDBjNi90YWJsZXJhbmdlOjU5N2I5MDU3ZjE3OTRkOGI4NTk4ZDBhMWJmNmYwMGM2XzItMi0xLTEtMA_cce37c55-df38-4562-af01-c21e70cb08f2">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.955%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZToxMTI3YjMzOTdmMTI0YTFiOGY2NTI4NTI1NjExZWUzZS90YWJsZXJhbmdlOjExMjdiMzM5N2YxMjRhMWI4ZjY1Mjg1MjU2MTFlZTNlXzEtMi0xLTEtMzM1Mg_8b19ed13-918f-487d-b6ff-73a142dd3a93">160.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZToxMTI3YjMzOTdmMTI0YTFiOGY2NTI4NTI1NjExZWUzZS90YWJsZXJhbmdlOjExMjdiMzM5N2YxMjRhMWI4ZjY1Mjg1MjU2MTFlZTNlXzEtMi0xLTEtMA_80eb5da8-799f-41c7-a164-36f1d62d4efc">153.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZToxMTI3YjMzOTdmMTI0YTFiOGY2NTI4NTI1NjExZWUzZS90YWJsZXJhbmdlOjExMjdiMzM5N2YxMjRhMWI4ZjY1Mjg1MjU2MTFlZTNlXzItMi0xLTEtMzM1Mg_588e616f-322e-418b-b206-571d78f650cc">136.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZToxMTI3YjMzOTdmMTI0YTFiOGY2NTI4NTI1NjExZWUzZS90YWJsZXJhbmdlOjExMjdiMzM5N2YxMjRhMWI4ZjY1Mjg1MjU2MTFlZTNlXzItMi0xLTEtMA_94763843-ebc7-4248-9f0d-b22b033c28a2">81.2</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzI2ODY_5d2a621c-16bc-466d-9d21-b90c74e854f3" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.740%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzEtMS0xLTEtMA_e898dee8-ee90-49a3-bb0c-97157bb7f4d1">150.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzItMS0xLTEtMA_e2018f97-969d-4464-931a-733d18efda1b">120.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 3</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzMtMS0xLTEtMA_acffa8ec-dc22-4423-82de-2e66ac881124">94.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 4</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzQtMS0xLTEtMA_56426b42-0130-42ed-9a23-0d1e65d52d11">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 5</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzUtMS0xLTEtMA_0a77aeed-f618-404d-9034-1f7be1204478">63.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Year 5</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzYtMS0xLTEtMA_1c18cfb0-d00e-45a1-85a6-c7a6a40027f5">258.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzctMS0xLTEtMA_a3ad1557-0645-4ee5-a6a8-202049f039be">761.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzgtMS0xLTEtMA_95b627b3-50a5-4edf-9124-abf550e7033d">97.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzktMS0xLTEtMA_0e5ac1da-8db4-4306-b95f-240d63f18d21">663.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental expense for all leases, including contingent rentals (not material), was $<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzMyOTg1MzQ4ODYzMjY_350507ac-e272-4896-af0e-911d8875c705">175.7</ix:nonFraction>&#160;million for the year ended December 31, 2018. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">87</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyOTg1MzQ4ODg2NzM_b1dea002-e5d0-445c-aba9-18dc47ea2f4d" continuedAt="i26efee958065492a88bb7e61b1423e57" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="i26efee958065492a88bb7e61b1423e57" continuedAt="i51866c209f584a77aa17340b7c0a8172"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyODM_5ef7af4f-0012-44c6-8c7d-d69ce89e2f25" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzEtMS0xLTEtMA_efa00fb9-938a-4c3f-8dea-142776c86550">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzEtMy0xLTEtMA_c5f3ea80-6b45-4981-9dac-00c5f7b12646">1,494.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzItMS0xLTEtMA_7794edce-15be-41c6-940b-4109c77185c9">16,348.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzItMy0xLTEtMA_39d1a467-83b7-4520-9e9d-2990ca96e9b2">13,638.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:OtherNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzMtMS0xLTEtMA_27c26db1-8cf9-4b1e-bdd8-e993d6270306">14.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:OtherNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzMtMy0xLTEtMA_4b4f020a-0851-4aec-ab67-eb24e0c170f1">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzQtMS0xLTEtMA_9aad8dcc-1bb0-4fbd-ab29-ef8adb482941">89.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzQtMy0xLTEtMA_b95a5951-7575-40c9-ae6a-ceb3abbb3187">73.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="lly:LongTermDebtFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzUtMS0xLTEtMA_f50a9621-76b2-4ad9-a810-a76b20a3a6a3">320.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="lly:LongTermDebtFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzUtMy0xLTEtMA_f1a661f6-edcd-42f0-8266-9fe7db65f94f">245.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzYtMS0xLTEtMA_02a73d0f-7243-4155-9ccd-db440b9d5b9d">16,595.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzYtMy0xLTEtMA_b8d2b17f-e3ef-45f2-bf21-3588332ee576">15,317.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzctMS0xLTEtMA_b40559a7-3df7-4c69-b5dc-0ebbd64856f7">8.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzctMy0xLTEtMA_e43f5cd6-12b9-487f-a8d9-e1f30ecdbd91">1,499.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzgtMS0xLTEtMA_a1ba75f9-2b41-46ee-a51d-15d2aef1fb0d">16,586.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzgtMy0xLTEtMA_bc05ed20-ce0d-4332-a0ba-3b65b65c68a0">13,817.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span><br/></span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyOTg1MzQ4ODg2NzI_5408f4a1-0bba-4313-ac7b-12c060155dd4" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.179%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2019</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie39118bdcc684cd68b2c6725d353ce58_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEtMC0xLTEtMTM1ODAvdGV4dHJlZ2lvbjpmOGM5MjRhNThlZmM0ZGExOWM5YTg1YzZmNWQ1OGZiZl8xMDk5NTExNjI3ODAw_db964dec-97e5-4494-985c-74eef15ff675">2.35</ix:nonFraction>% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39118bdcc684cd68b2c6725d353ce58_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEtMS0xLTEtNTY5NQ_d0ec2695-42d5-44ee-a93d-fa067ab0afdd">750.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8211a0f8b8da413db4f2efbb3213d634_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEtMy0xLTEtNTY5NQ_95f6fde1-f51e-4de0-a6c7-fe58ec8013cb">750.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i2de9e70275e246d6a582111588810286_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzItMC0xLTEtMTM1OTkvdGV4dHJlZ2lvbjphMDY4YzdlOTRlNGM0N2U1OTEwOTBjNTJjZTZkYjIzYl8xMDk5NTExNjI3ODAz_27da027f-ae33-44bf-a8a5-ea32bc219601">3.00</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2de9e70275e246d6a582111588810286_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzItMS0xLTEtNTY5NQ_8eb4e784-1b27-46b7-a978-37d3ebe56dde">99.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f615487ab04c708fef493a3fa4ecef_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzItMy0xLTEtNTY5NQ_94b32b2e-6c5b-4c28-8258-688aa0be45fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i61c1211b430f4ba58b2eba2c97c976f5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMtMC0xLTEtMTM2MDEvdGV4dHJlZ2lvbjozNWI1NmI5ZDhlZjc0Zjg1YTdiZTlkZmU5ZjJkOTA3M18xMDk5NTExNjI3ODIw_fc8c5334-d9e7-43f5-869e-3c9b49a75961">1.00</ix:nonFraction>% Euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i61c1211b430f4ba58b2eba2c97c976f5_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMtMS0xLTEtNTY5NQ_ceb7a978-1f95-4243-9ca4-d23009cf1cfb">737.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie245631a64f040e0bf885d77689fdecf_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMtMy0xLTEtNTY5NQ_e265da62-eca1-44a2-b582-34077a1fbecf">671.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i2eafba22b49e42f1a090d404e4b1ccd1_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzQtMC0xLTEtMTM2MDMvdGV4dHJlZ2lvbjo2MWMxYjk3ODk3OWU0MzQ0YmNmODA5ODVhNmMyYzBiOF8xMDk5NTExNjI3ODI5_30aef227-c610-450a-ab98-2e2e5bdac9f7">0.15</ix:nonFraction>% Swiss Franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2eafba22b49e42f1a090d404e4b1ccd1_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzQtMS0xLTEtNTY5NQ_3d9a6057-76b5-44a5-9237-177eed70c7ac">679.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5fe45934df5346e4a6a0d715944c15b5_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzQtMy0xLTEtNTY5NQ_4dde12c9-85c8-4f82-82fb-19fae12af794">618.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ia221e6819a7d4e69b484d963df327dfd_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzUtMC0xLTEtMTM2MDUvdGV4dHJlZ2lvbjoxZGM2ZDA2ZDJiMTA0NDA1YTJlYjE5ZjIwM2JkMzJhMF8xMDk5NTExNjI3ODA3_4f1739dd-0a2b-42ea-9a36-937022a00666">7.125</ix:nonFraction>% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia221e6819a7d4e69b484d963df327dfd_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzUtMS0xLTEtNTY5NQ_17cf2d8d-b61d-4d57-b0cf-eeb909eca4e0">229.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ida41079f1ceb4961915954043ad0b801_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzUtMy0xLTEtNTY5NQ_4c73d8d6-edaa-4340-87fd-bed83a745f6f">229.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ia71a0b4c817a43a9aee24da56d63c0e5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzYtMC0xLTEtMTM2MDcvdGV4dHJlZ2lvbjo2ZDU4ZDQyZWQyOGM0MTNjYTNjYTc1ZTM5ZjU2MWE5Y18xMDk5NTExNjI3ODA1_cb5ce7f8-fe2c-4156-a9a4-b912b264b8c6">2.75</ix:nonFraction>% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia71a0b4c817a43a9aee24da56d63c0e5_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzYtMS0xLTEtNTY5NQ_a9af9a31-e501-4dd9-8c18-346852f16495">560.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id641d973aee741acb44e0f58ced70bf1_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzYtMy0xLTEtNTY5NQ_80408ac5-275e-48eb-9e9b-373f00ddb12e">560.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i5e0dbe73367c474aa66b9eb7c4937520_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzctMC0xLTEtMTM2MDkvdGV4dHJlZ2lvbjpiYmQ4MjAwNTQ4NTU0Njc5OTc3OTlmODdkMzUwOWU0N18xMDk5NTExNjI3ODI0_294f545d-7d10-481f-a091-0d4d357f29c0">1.625</ix:nonFraction>% Euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5e0dbe73367c474aa66b9eb7c4937520_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzctMS0xLTEtNTY5NQ_8c6fd0b6-1c4d-405d-a42f-259e864f3111">922.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iba8e44c95e6f480eb82a83d06e179514_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzctMy0xLTEtNTY5NQ_b2cac8d7-986d-40d2-9914-120c496d8781">839.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0fc9ebff5d804b3587da0025635f268e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzgtMC0xLTEtMTM2MTEvdGV4dHJlZ2lvbjo5MzZmNWU4ZGUzNDE0ZmJiOTIyOGVmZTY0OTc0NzFlZl8xMDk5NTExNjI3ODAz_f4591c27-e021-44da-a75b-f999e24151c7">5.5</ix:nonFraction>% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0fc9ebff5d804b3587da0025635f268e_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzgtMS0xLTEtNTY5NQ_d37ccf6a-811e-4aa6-b7f0-4ae28b41392b">377.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3562490080194bc8b92c4d7b39b14b4a_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzgtMy0xLTEtNTY5NQ_5dc96634-d595-477e-a7ca-fa5199854853">377.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ic52fe587003244e18fb9abdb9be4e63d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzktMC0xLTEtMTM2MTMvdGV4dHJlZ2lvbjo2ZGQyN2NiMzliN2Q0M2ExYWQzYTEzYzI5NjZhZDVhOV8xMDk5NTExNjI3ODAz_205535b1-701d-46fd-b5bc-d713f9fbc0a5">3.1</ix:nonFraction>% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic52fe587003244e18fb9abdb9be4e63d_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzktMS0xLTEtNTY5NQ_10815983-18a3-46ce-97fc-d8686aa86839">401.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i07507ae169e74357a231b2d9c239eedc_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzktMy0xLTEtNTY5NQ_278b8a78-673c-4e92-af0b-3c57363a4673">401.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ic6bfd9e9e45a473a9f90d4f41a08ea48_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEwLTAtMS0xLTEzNjE1L3RleHRyZWdpb246Nzc1N2NlMTY3NzU5NGRiZGI4NDhhMTRjNzQwNTQxNDBfMTA5OTUxMTYyNzgyOQ_bbeef7b5-195d-4541-9c8a-e978f67dbed8">0.45</ix:nonFraction>% Swiss Franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic6bfd9e9e45a473a9f90d4f41a08ea48_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEwLTEtMS0xLTU2OTU_9bcaceb8-7b34-4990-ad32-dffc3b0e4783">453.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1136f1586cde4061a489a0824879f7d9_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEwLTMtMS0xLTU2OTU_1da7e603-7ee4-4a9d-86fb-77c97b92dcaa">412.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i2bfd288269624c7b86651f8fc813d3bf_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzExLTAtMS0xLTEzNjE3L3RleHRyZWdpb246YTEzZGRlOGY2ZGQ2NGVjYjkwYzZjOTVmY2Y3OTUzNTNfMTA5OTUxMTYyNzgwNw_38f170b3-3323-452e-8ccd-fa8d27e1542c">3.375</ix:nonFraction>% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2bfd288269624c7b86651f8fc813d3bf_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzExLTEtMS0xLTU2OTU_8dbfa7d8-2801-4ce1-99f1-54ed52e0454a">1,150.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia9cd37cd7aad40bda3f214b57cab2f2d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzExLTMtMS0xLTU2OTU_5f50adeb-8277-48a7-8d36-02602b3b29ce">1,150.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i6a50eaec3e7a4ba69d1ffdc4a120b39e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEyLTAtMS0xLTEzNjE5L3RleHRyZWdpb246YTUxZGU3ZDViMTA0NDVhMmJiNjhlNDZkYWMzMjA0MjhfMTA5OTUxMTYyNzgzMA_80eeb3b9-c373-4b5a-8f6f-6b7c9d80c889">0.42</ix:nonFraction>% Japanese Yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i6a50eaec3e7a4ba69d1ffdc4a120b39e_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEyLTEtMS0xLTU2OTU_f37a043d-9fda-4348-92c6-f3f0e8dc6441">222.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibea8fc22978f41d7932c87f65b0366c0_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEyLTMtMS0xLTU2OTU_f3d58acf-1725-436d-a4e7-3235f1d893eb">209.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="id57c890b8a2244d1a7018e62567f926a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEzLTAtMS0xLTEzNjIxL3RleHRyZWdpb246NzU0ZTIxMWUzMzg1NDRiN2IxMTJmMjQ4OTdlMjZlMDBfMTA5OTUxMTYyNzgyNA_a9d64f38-d09d-419c-85bf-92fd886756fe">2.125</ix:nonFraction>% Euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id57c890b8a2244d1a7018e62567f926a_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEzLTEtMS0xLTU2OTU_4fb29b4b-9a7f-49c8-b2e9-d3d6f427488c">922.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i451d9a3273804f14955cc5a82111caa6_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEzLTMtMS0xLTU2OTU_52f49af2-9665-4971-ba9c-e6be3921b744">839.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie9d7b6ad2f874ca7ab2452e56d10ca29_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE0LTAtMS0xLTEzNjIzL3RleHRyZWdpb246ZmY2ZGEyOTA3ZjhkNGExM2EwNzM1ODRmYWVjNDE3OWZfMTA5OTUxMTYyNzgyNA_154a6f95-5738-48eb-9d17-3ad31b7ca813">0.625</ix:nonFraction>% Euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie9d7b6ad2f874ca7ab2452e56d10ca29_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE0LTEtMS0xLTU2OTU_ffe0370d-7b06-4c61-9862-23c65a32e266">737.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ieb059df82e0b43cd84033edf1b400448_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE0LTMtMS0xLTU2OTU_349bfb0a-ebe9-4dae-8ce0-684fa50f7d0f">671.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ib3112631bb974c85a5318fe1efa3d51b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE1LTAtMS0xLTEzNjI1L3RleHRyZWdpb246MDQ3ODg4YmVkNmNkNGQ5Yzg5Y2U0ZTQzODVkNTk1ZDhfMTA5OTUxMTYyNzgzMA_4daafe89-3d01-4795-98c0-32082e065314">0.56</ix:nonFraction>% Japanese Yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ib3112631bb974c85a5318fe1efa3d51b_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE1LTEtMS0xLTU2OTU_59b470b1-f7d7-4391-9610-79831a65c6b7">90.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie3c0b90ff61e4adeab7beb2122db8cc8_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE1LTMtMS0xLTU2OTU_c2e3470a-736d-49ce-b800-9efceebca933">85.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i65c5eb420e4649c487d09089e7cf9f49_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE2LTAtMS0xLTEzNjI3L3RleHRyZWdpb246OTY2ZTUzOWFhMGM4NGJjZmFhNjU5ZWM3MThlZjYxNmFfMTA5OTUxMTYyNzgwNQ_3dbd67c4-e9f2-453e-9107-00dbfb072df8">6.77</ix:nonFraction>% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i65c5eb420e4649c487d09089e7cf9f49_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE2LTEtMS0xLTU2OTU_b9ea561e-c9a4-4927-a8fe-e8eb12022dd0">174.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0c6c23acfade4500ab9b57e874f2b87c_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE2LTMtMS0xLTU2OTU_b12e51d6-204d-4ef7-94dd-cba4f7fe4101">174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i6ee2a27f08884a89b9bf33bf08bd0da6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE3LTAtMS0xLTEzNjI5L3RleHRyZWdpb246OTUwZmVjMDVhNjM0NDA0Nzk1MGYzNjljMjJhNzNjMmRfMTA5OTUxMTYyNzgwNQ_34fafcb0-d298-4211-ab7f-e7ada1f1cee8">5.55</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i6ee2a27f08884a89b9bf33bf08bd0da6_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE3LTEtMS0xLTU2OTU_ad47ad8e-c0db-4afd-8295-14e195838772">476.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i9874bc66d90145f4bd3eea521b23dad8_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE3LTMtMS0xLTU2OTU_462a3558-9626-4c6f-b94e-4235dc123481">476.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i2078c3a852d54d1385e1a1b24d15e8c5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE4LTAtMS0xLTEzNjMxL3RleHRyZWdpb246MzhjMmM0MmJjM2IzNDMyZTg3YzI2ZmM1MjY3Y2ZiNTRfMTA5OTUxMTYyNzgwNQ_7f22f8b4-16ac-49c6-a276-abd304893b89">5.95</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2078c3a852d54d1385e1a1b24d15e8c5_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE4LTEtMS0xLTU2OTU_ea22c800-dae0-42f4-a216-795baea5afca">284.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7bb8be0259a04e968746158d9c7ebfdd_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE4LTMtMS0xLTU2OTU_af402e9c-5a79-4382-80cd-d97d3ef6e3bd">284.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i7858b711bd2147f994af875c0dbac9d2_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE5LTAtMS0xLTEzNjMzL3RleHRyZWdpb246ODFhNTgxODhlNjgyNDllNDg4MWE1N2M2OGU3MDhlZDZfMTA5OTUxMTYyNzgwNw_dc30aafb-3f50-4170-b3c5-d5201d99f10d">3.875</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7858b711bd2147f994af875c0dbac9d2_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE5LTEtMS0xLTU2OTU_d344dc66-74b5-4914-afef-861424e67e02">360.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i94f9df676ae84ca4ab5a863a59e0e05c_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE5LTMtMS0xLTU2OTU_423c3aa3-14ba-48b5-8b8f-f6562e9d96de">360.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i030c208576224dff9839b8198a359ca8_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIwLTAtMS0xLTEzNjM1L3RleHRyZWdpb246OTYzZmQxOWEyNDhhNDY2YmE2YjIwMmMyZmQxNjFhN2NfMTA5OTUxMTYyNzgwNQ_bc5e902b-c5fa-4a4d-b107-3c93e8716d0c">4.65</ix:nonFraction>% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i030c208576224dff9839b8198a359ca8_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIwLTEtMS0xLTU2OTU_8bc67439-990a-4dbb-a987-39685310b1a2">43.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4c29e053597c4404a0c3274d3ae71277_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIwLTMtMS0xLTU2OTU_f29ae576-f070-4303-8ee1-4eaecae9e3a4">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0d11e1f18c324cb68f63c1d7111e4aba_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIxLTAtMS0xLTEzNjM3L3RleHRyZWdpb246YzliNTBhMWNiOGQ4NGJiOWE5MzEyNGNlZjlhY2Q4YTFfMTA5OTUxMTYyNzgwMw_dfdded98-bf37-4bb6-b6df-e7a9365e6a4f">3.7</ix:nonFraction>% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0d11e1f18c324cb68f63c1d7111e4aba_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIxLTEtMS0xLTU2OTU_1a602c18-4cb6-4530-a102-0b6503831825">412.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i867c6c8331db465fb6d11fa19654d49b_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIxLTMtMS0xLTU2OTU_a05ce4b4-755b-4515-a47d-25fea3f3649c">412.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie846943d9ed4494daf24040e9d7a4b3b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIyLTAtMS0xLTEzNjM5L3RleHRyZWdpb246ZjQ5YzFiNmJkNjMxNGY1OGI0ZmQ5MzEyMWUyOTU4ZGJfMTA5OTUxMTYyNzgwNQ_5bb415bc-446e-4045-847b-27f211d439c8">3.95</ix:nonFraction>% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie846943d9ed4494daf24040e9d7a4b3b_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIyLTEtMS0xLTU2OTU_2f39a4b0-c861-4f2c-871b-14d0b9e9dfdc">436.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i234b44d7a5c647d483338639b9fee082_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIyLTMtMS0xLTU2OTU_3e204158-2f99-4b50-95cb-c2753694a4b7">436.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i656b092512744da59aaf0680fcbf4678_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIzLTAtMS0xLTEzNjQxL3RleHRyZWdpb246Y2IwZmFiOWRjYmU0NGVkNWEwY2IzNTk0MWZlNDAxOWZfMTA5OTUxMTYyNzgwNQ_17e44c56-4592-446d-ae54-ee119dc96687">3.95</ix:nonFraction>% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i656b092512744da59aaf0680fcbf4678_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIzLTEtMS0xLTU2OTU_a8677626-fd7d-432f-b355-5a6ba9ae0e77">1,500.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1d0bfcf2438249eda212a31a4a731f1b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIzLTMtMS0xLTU2OTU_f642a2f6-7121-46c9-84ed-0e6450522fc8">1,500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0965d791ab43490fb6cdab898b7eb5cc_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI0LTAtMS0xLTEzNjQzL3RleHRyZWdpb246MGY1MTQyOTJhMjY0NGZiNGFkYmQyNDEyNWNkNGFhYWRfMTA5OTUxMTYyNzgyMA_28e9d0fa-a555-4e93-801d-15a1e98a30dc">1.7</ix:nonFraction>% Euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0965d791ab43490fb6cdab898b7eb5cc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI0LTEtMS0xLTU2OTU_612310cf-09a0-4b23-9cea-99bdee8fdbe7">1,229.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i62a9613dbf90422496652cb4fe3df34e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI0LTMtMS0xLTU2OTU_49d3fbba-adef-4ecd-a061-8367338c4b00">1,119.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i7bf9bc896ba444c18c22af719b4f6ca2_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI1LTAtMS0xLTEzNjQ1L3RleHRyZWdpb246YzVmODE5MGRlYzdjNDc1Mjk5NDQ3Y2YxYTEwZWFhZTJfMTA5OTUxMTYyNzgzMA_c8214367-26f0-448b-a8bf-39e1f484c364">0.97</ix:nonFraction>% Japanese Yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7bf9bc896ba444c18c22af719b4f6ca2_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI1LTEtMS0xLTU2OTU_f95038a5-3380-4e3f-8a07-f7b0111ae9cc">74.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i9bcf1e62803246f8afcd362547cd42bd_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI1LTMtMS0xLTU2OTU_eb5ee354-a466-41bc-9a05-5db7d8c8c8f8">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i655dc81cd7ca4a969575979d59347169_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI2LTAtMS0xLTEzNjQ3L3RleHRyZWdpb246ZGJjOTY4Yzc0YTJlNDFlOGI5ZmM4YTAyMGVlYzQ0NzZfMTA5OTUxMTYyNzgwNQ_7edf650c-f700-4426-af29-3e6f84c01f31">2.25</ix:nonFraction>% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i655dc81cd7ca4a969575979d59347169_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI2LTEtMS0xLTU2OTU_6a1e7c3c-0374-4a86-961c-4aa87b837a16">1,250.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i532a4d8d7fa0495f9850719f1d105b79_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI2LTMtMS0xLTU2OTU_834123cb-e579-4e70-9476-5d34563ade25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="idda582f88fad4b44bb89a7b65fa5e8b7_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI4LTAtMS0xLTEzNjQ5L3RleHRyZWdpb246ZmUzMjAwYTE1MDRkNDZhYTk0ZDUyNzJjOGM5NTgxMDhfMTA5OTUxMTYyNzgwNQ_b9416d2a-2567-45fe-a2ad-9a8dc45a154f">4.15</ix:nonFraction>% notes due 2059</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idda582f88fad4b44bb89a7b65fa5e8b7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI4LTEtMS0xLTU2OTU_f7dbb0f2-885a-4675-ad6b-d4da2c072cc6">1,000.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3f74451c169b4c4bb0905d735b168f81_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI4LTMtMS0xLTU2OTU_7d659c31-720b-4dc2-b273-cb55e55ac7b2">1,000.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i2f0b1156a4f441f3a4c0ef9e8fe20b38_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI5LTAtMS0xLTEzNjUxL3RleHRyZWdpb246NzhkYzQ3M2Q4ODYwNDE4ZjgzNDdjZGQ4Y2I4YjVmMTFfMTA5OTUxMTYyNzgwMw_aa5a2b16-4511-4d6b-9ed7-50ca28f02f3f">2.5</ix:nonFraction>% notes due 2060</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2f0b1156a4f441f3a4c0ef9e8fe20b38_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI5LTEtMS0xLTU2OTU_f9cae00c-5341-4343-b7c9-b4acf4124d4d">850.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85629be20441417e81c8bc15187610f6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI5LTMtMS0xLTU2OTU_5d5e0acf-97f0-4643-9902-0071bbcefd95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMwLTEtMS0xLTU2OTk_b85924b0-f4c9-4914-96ca-c528aa013fe0">76.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMwLTMtMS0xLTU2OTk_6ad42964-1e5b-434a-a463-d057a9eb3dd1">55.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMxLTEtMS0xLTEzNTg4_b41da516-7f0c-4402-b63b-54ab5dbe8bc2">16,348.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMxLTMtMS0xLTEzNjU1_c2d5cc2f-bd75-4c1b-a350-685a860effa5">13,638.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i51866c209f584a77aa17340b7c0a8172"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average effective borrowing rate on outstanding commercial paper at December&#160;31, 2019 was <ix:nonFraction unitRef="number" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODQ2Njg_1b6faa67-923b-490b-89de-e727cce46e75">1.65</ix:nonFraction> percent. The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had a total of $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5Mw_100ffbd7-6cf6-4d78-986d-2253a45671d2">5.24</ix:nonFraction> billion of unused committed bank credit facilities, which consisted primarily of a $<ix:nonFraction unitRef="usd" contextRef="i92154592e663424992dbf36c8086e56f_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzI3MQ_94c37d9b-3e36-4730-8ea4-24af899697f7">3.00</ix:nonFraction> billion credit facility that expires in December 2024 and a $<ix:nonFraction unitRef="usd" contextRef="i576355b801554d9dace08e37a3e790a4_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyNg_2b5cc853-96e9-4173-8265-272851bb1ed5">2.00</ix:nonFraction> billion <ix:nonNumeric contextRef="icc42a52c34fb4cbe8b9fc2a34c409158_D20200101-20201231" format="ixt-sec:durday" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyOQ_6cb4d973-a52f-4fdb-962a-839903fe0107">364</ix:nonNumeric>-day facility that expires in December 2021, both of which are available to support our commercial paper program. We have not drawn against the $<ix:nonFraction unitRef="usd" contextRef="i92154592e663424992dbf36c8086e56f_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzQ3NQ_94c37d9b-3e36-4730-8ea4-24af899697f7">3.00</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i576355b801554d9dace08e37a3e790a4_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzQ4Mg_2b5cc853-96e9-4173-8265-272851bb1ed5">2.00</ix:nonFraction> billion facilities as of December&#160;31, 2020. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2020 and 2019 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="iacba47193c1c41d9b33bebc61b930bc4_I20200531" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0MDE_45ff1e1b-f309-4a17-b968-9e835f7c8027">1.00</ix:nonFraction>&#160;billion of <ix:nonFraction unitRef="number" contextRef="iacba47193c1c41d9b33bebc61b930bc4_I20200531" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0MjA_63550cec-73a0-47be-8115-0b1710d90f71">2.25</ix:nonFraction> percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="i61181bb3188f4ceab623c97f733dd40b_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0Mzg_f060b591-23e6-4b7d-af03-75fd08ef95e9">988.6</ix:nonFraction> million for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued $<ix:nonFraction unitRef="usd" contextRef="id260d3c811084dc9bebde09aaeb73bee_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0NTY_c5b11355-76fb-4678-89f6-3e8260a97305">850.0</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="id260d3c811084dc9bebde09aaeb73bee_I20200831" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0NzM_2b4f7be2-aa1e-45f4-b9c1-97541a8c657a">2.50</ix:nonFraction> percent fixed-rate notes due in September 2060 and an additional $<ix:nonFraction unitRef="usd" contextRef="i3cdb23950c784a95a855f5d0ce652a38_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0OTA_039a1ab0-b5b8-4105-96e8-0bf114773347">250.0</ix:nonFraction> million of our <ix:nonFraction unitRef="number" contextRef="i3cdb23950c784a95a855f5d0ce652a38_I20200831" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU1MDk_9ea1690f-f264-45fc-80a5-84e2d990ac18">2.25</ix:nonFraction> percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="i66b0a7cb640f45d6b8c83fc4de5fec01_D20200801-20200930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU1MjY_8f3d2a4d-5cfb-4124-8587-782e998e5337">1.07</ix:nonFraction> billion for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we issued $<ix:nonFraction unitRef="usd" contextRef="i781b0d1c65df4f598bf4ca78d40c03f6_I20190228" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzc5OQ_adaed2ae-f8fd-43ec-b488-4bcfd7ab618b">1.15</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i781b0d1c65df4f598bf4ca78d40c03f6_I20190228" decimals="5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzgwNQ_a85a1100-c11d-4431-a0c3-fbd4c0536dac">3.375</ix:nonFraction> percent fixed-rate notes due in March 2029, $<ix:nonFraction unitRef="usd" contextRef="i7caac5fec4c34319b3ee7518fa0cee6d_I20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzg0NA_04645026-81cf-4dc3-bca8-d14dd7983bbb">850.0</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i7caac5fec4c34319b3ee7518fa0cee6d_I20190228" decimals="5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzg1MA_041ffd08-3e0f-4b13-a30c-eb40b34c8e78">3.875</ix:nonFraction> percent fixed-rate notes due in March 2039, $<ix:nonFraction unitRef="usd" contextRef="i195f7ecf4b4c48a592446e3d876daf86_I20190228" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzg4OQ_bbda21d5-0791-4743-b4be-12bb395316ae">1.50</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i195f7ecf4b4c48a592446e3d876daf86_I20190228" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzg5NQ_3328908b-e4e9-4090-84df-42d8c83d27c0">3.95</ix:nonFraction> percent fixed-rate notes due in March 2049, and $<ix:nonFraction unitRef="usd" contextRef="ie27939a1114f4155b7e6b1134d719999_I20190228" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzkzOA_3f8fba34-2959-4f2b-950b-9db8cb846b55">1.00</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="ie27939a1114f4155b7e6b1134d719999_I20190228" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzk0NA_2f4640bc-4681-48ad-bf82-506c42a5ec0c">4.15</ix:nonFraction> percent fixed-rate notes due in March 2059, with interest to be paid semi-annually. We used the net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i01a37470a5b047e994577c37bc40b277_D20190201-20190228" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEwNTE_cee8b95c-d492-4f0f-9d7d-da13c4e9b0de">4.45</ix:nonFraction> billion from the offering to repay commercial paper that was issued in connection with the acquisition of Loxo and for general corporate purposes. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="i01dca931c8514af0bd8dca2a456bd02a_I20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEyNjA_e0fa7c7c-d19d-4e12-8309-7f364ba8dbc8">600.0</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i01dca931c8514af0bd8dca2a456bd02a_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEyNjY_deb22571-ed2f-48f1-8917-47e6092383c9">0.625</ix:nonFraction> percent fixed-notes due November 2031 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i0b0b3f18d85446cd9abefc7f5431210a_I20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEzMTI_94237870-ae47-4aa1-81fb-83d9c6d4fd31">1.00</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i0b0b3f18d85446cd9abefc7f5431210a_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEzMTg_d4f2994e-2b6d-4c03-ac6b-9db9580f9a0d">1.70</ix:nonFraction> percent fixed-rate notes due in November 2049 with interest to be paid annually. We paid $<ix:nonFraction unitRef="usd" contextRef="i7bfd42d26c474945ab26097d61bb99b9_D20191101-20191130" decimals="-7" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE0MTA_27219ad6-f0ec-4e92-91e5-d5d1b36c7f92">2.27</ix:nonFraction> billion, comprised of $<ix:nonFraction unitRef="usd" contextRef="icb88d176a73247459d0ce6d57d7f2362_D20191101-20191130" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE0Mjc_02f884e8-c9eb-4b15-bd69-82cddbf8ba3c">1.75</ix:nonFraction> billion of net cash proceeds from the offering and proceeds from commercial paper, to purchase and redeem certain higher interest rate U.S. dollar denominated notes with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="id425e417e4ad4c45a09f17f9caed0ff2_I20191130" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE2MjU_7a11154f-172a-49d4-bb5e-3a1fcd918cad">2.00</ix:nonFraction> billion and a net carrying value of $<ix:nonFraction unitRef="usd" contextRef="id425e417e4ad4c45a09f17f9caed0ff2_I20191130" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE2NTY_3241b47f-aa63-47e6-a880-4e5d65c859e8">2.01</ix:nonFraction> billion, resulting in a debt extinguishment loss of $<ix:nonFraction unitRef="usd" contextRef="i61be1551dd32425daa8be3c06f520dd7_D20191101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE3MDM_71b77143-340d-4d5a-931e-0f4591d45f64">252.5</ix:nonFraction> million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we issued Japanese Yen-denominated notes consisting of &#165;<ix:nonFraction unitRef="jpy" contextRef="if3b8c3ecb8934c7cb012f8fe970195e6_I20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5MjA_486f6219-d7bb-492d-820d-d19a866bcb51">22.92</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="if3b8c3ecb8934c7cb012f8fe970195e6_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5MjY_2e75261d-d71d-47a6-84df-b9d31bb464e9">0.42</ix:nonFraction> percent fixed-rate notes due in November 2029, &#165;<ix:nonFraction unitRef="jpy" contextRef="i3517b05124e542ba94be70caac0c6932_I20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5Nzc_770b621e-5538-44fc-a9bf-10b6c3b55d1b">9.28</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i3517b05124e542ba94be70caac0c6932_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5ODM_12111e85-d704-442b-9ce9-173ee9911019">0.56</ix:nonFraction> percent fixed-rate notes due in November 2034, and &#165;<ix:nonFraction unitRef="jpy" contextRef="i73d344ee1fd84e0a9a617d23c99aff1e_I20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzIwMzg_f94eb8fe-ac44-48b7-a81c-47e80123d17f">7.64</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i73d344ee1fd84e0a9a617d23c99aff1e_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzIwNDQ_4bb3fd20-fc5c-4c16-888e-9f77b6c986cc">0.97</ix:nonFraction> percent fixed-rate notes due in November 2049, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $<ix:nonFraction unitRef="usd" contextRef="ifc7c545c888b441abae0763fd9a5afbd_D20191101-20191130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzIxODU_8b0b94fe-a3fa-400e-9a19-0dcaf6d1bd44">356.6</ix:nonFraction> million for general corporate purposes, including the repayment of outstanding commercial paper.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyNjk_cd6fd0c6-871d-4ebe-9ba4-849dfe67dc6c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:49.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtMS0xLTEtMA_bae79c88-09aa-4496-8913-34598c8d54b9">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtMy0xLTEtMA_6a03aa33-0d82-4a5b-96a7-2cbdb3e57b84">1,590.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtNS0xLTEtMA_d5599ed6-02b4-4c91-ae3b-342b1eb29389">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtNy0xLTEtMA_e6f40230-4692-40bd-a913-de66f2aaf2cc">681.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtOS0xLTEtMA_9fecdf11-9e7e-491c-837f-97fb7b5815ad">790.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have converted approximately <ix:nonFraction unitRef="number" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="2" format="ixt:numdotdecimal" name="lly:DescriptionOfDerivativeActivityVolumePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzIzOTc_8c1bee7e-a3f1-4dc8-b6be-69428b608974">9</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2020 and 2019, including the effects of interest rate swaps for hedged debt obligations, were <ix:nonFraction unitRef="number" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzI2ODc_b0c8331b-ff31-48f9-aca6-68fabe08b18d">2.61</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzI2OTQ_f104bd26-d1c0-4ef9-bff1-ec4f9982a730">2.88</ix:nonFraction> percent, respectively.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyOTQ_9a82e68c-0ea0-4165-86f8-03f4530f39c6" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo3ZGE5NzJmYWM4MjQ0NDc3YmE5YjZhM2Q1MjE4OWVkZi90YWJsZXJhbmdlOjdkYTk3MmZhYzgyNDQ0NzdiYTliNmEzZDUyMTg5ZWRmXzEtMS0xLTEtMA_44a63250-f2ec-4df2-a7bd-aac4b4e089bf">345.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo3ZGE5NzJmYWM4MjQ0NDc3YmE5YjZhM2Q1MjE4OWVkZi90YWJsZXJhbmdlOjdkYTk3MmZhYzgyNDQ0NzdiYTliNmEzZDUyMTg5ZWRmXzEtMy0xLTEtMA_be183e35-2d1c-449c-b2e4-527a622b14c7">305.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo3ZGE5NzJmYWM4MjQ0NDc3YmE5YjZhM2Q1MjE4OWVkZi90YWJsZXJhbmdlOjdkYTk3MmZhYzgyNDQ0NzdiYTliNmEzZDUyMTg5ZWRmXzEtNS0xLTEtMA_d23ebc5f-0f2a-4050-bb31-fcfd5259336e">223.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt&#8217;s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">89</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQxNjA_74ce4265-8b25-4102-bea8-94482cac3c57" continuedAt="i419a7467ebfe4cafaa08208a10aa28c5" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i419a7467ebfe4cafaa08208a10aa28c5" continuedAt="idb79e0aac83747bcbb1a01157327c40f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQxNjE_4dc1f443-ec0f-4b0c-b072-e47df5062aba" escape="true">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQxNjc_6db8f9f3-35cb-439a-bf3d-52256ec4e690" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzEtMS0xLTEtMA_3d03805b-9c55-4a03-bada-34de3e272916">308.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzEtMy0xLTEtMA_f7829951-c1b4-4968-ae58-fcc41718f8b7">306.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzEtNS0xLTEtMA_c11ff8a0-61ee-4774-ba08-94e56dfc996b">253.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzItMS0xLTEtMA_39d6a374-0bf5-4155-9b9b-1b36f06b3d73">64.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzItMy0xLTEtMA_698c5cb3-4448-4d45-a447-0fd23ed5c1a7">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzItNS0xLTEtMA_19cb8c97-4cfa-4c7c-9976-d689048300af">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than <ix:nonFraction unitRef="shares" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzY2MQ_307d144c-f50f-49a7-a9a6-b151d0a0c187">53.9</ix:nonFraction> million additional shares. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a <ix:nonNumeric contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMyOTg1MzQ4ODc1MjM_631d1fd3-183f-4a83-b049-67741f4e081a">two-year</ix:nonNumeric> period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2020, 2019, and 2018 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzExODQ_9ef743c2-cc15-400f-815c-4b2bfac53ba0">137.33</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ida5a3ee36c55473f9c1d1258483a8afa_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzExODg_9d53d152-3f48-4b2a-a2ba-6471cc926b1c">112.09</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i6c9bc19fd1fb41c9bce540130ed1021d_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzExOTY_de43973b-377f-4eac-9182-fbb9421103f7">71.63</ix:nonFraction>, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately <ix:nonFraction unitRef="shares" contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzEzNzQ_b80bc483-1fbe-4886-b123-267f0ddb4221">1.1</ix:nonFraction> million shares, <ix:nonFraction unitRef="shares" contextRef="ida5a3ee36c55473f9c1d1258483a8afa_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzEzODU_3b19c20b-31f8-40b8-8897-d6cf1835b5fa">1.2</ix:nonFraction> million shares, and <ix:nonFraction unitRef="shares" contextRef="i6c9bc19fd1fb41c9bce540130ed1021d_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzE0MDA_f8b77f91-1439-47ba-9068-2bbb94d0fb1e">0.9</ix:nonFraction> million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzE0ODk_8742400e-27cd-4b92-804c-56b46c6482a8">0.8</ix:nonFraction> million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested PAs was $<ix:nonFraction unitRef="usd" contextRef="id85cea205afe42e1b0277f50024d6b30_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzE2MjI_87be521f-79f4-4d39-963c-926f85657ad0">77.3</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg5MDA_10bc7d89-6852-4317-9a75-f209660c2236">12</ix:nonNumeric> months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Value Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the <ix:nonNumeric contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMyOTg1MzQ4ODc1MjQ_f7e659c9-dc7d-41f5-bc76-8bfc39d59a8a">three-year</ix:nonNumeric> vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQxODU_d613ed5a-2a80-45b2-a9d2-0af3f87e5a5e" continuedAt="i911140db287848ed92c51ff8c7260d00" escape="true">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2020, 2019, and 2018 were $<ix:nonFraction unitRef="usdPerShare" contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI3ODM_753eb7ca-38a2-49f9-b48f-9e5e194c4db2">139.14</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI3ODc_b3d0b162-30c1-428d-b195-380a733a6ae2">95.01</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI3OTU_0932c3e0-2d05-43de-8ef8-ae8f231eb190">48.51</ix:nonFraction>, respectively, determined using the following assumptions:</ix:nonNumeric></span></div><div style="margin-bottom:11pt;margin-top:11pt"><ix:continuation id="i911140db287848ed92c51ff8c7260d00" continuedAt="i08b82695a47a4a8ea422a5d5e022d5e7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzEtMS0xLTEtMA_ee468169-198f-44b6-9ab5-07617869de41">2.50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzEtMy0xLTEtMA_52de12d2-dd82-4351-9123-a389bab5ea5a">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzEtNS0xLTEtMA_66754348-16e9-45b2-9363-a313af32ab29">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzItMS0xLTEtMA_a8550634-105a-4c52-a9b7-909eebd677ac">1.38</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzItMy0xLTEtMA_bfa104de-3182-4713-a1c0-fe80543dafe4">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzItNS0xLTEtMA_2b82afa8-a5d2-4f7f-9fda-46df4f256942">2.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzMtMS0xLTEtMA_83000656-65e7-4542-a38a-6257193a3362">20.90</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzMtMy0xLTEtMA_ff4a1394-9d8a-4026-aecc-7b981543fb6b">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzMtNS0xLTEtMA_e6568974-6d8e-4fa2-8a04-93630cfc4c29">22.26</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, approximately <ix:nonFraction unitRef="shares" contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI4OTk_f37e7a8e-217f-4207-982c-d06bdfdb5c5e">0.8</ix:nonFraction> million shares, <ix:nonFraction unitRef="shares" contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI5MTA_effa83f9-bcdd-4b39-a3da-7b8d6839cc38">1.0</ix:nonFraction> million shares, and <ix:nonFraction unitRef="shares" contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI5MjU_f966563b-604d-4ea8-99e4-443170c99ab3">0.7</ix:nonFraction> million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMwMTQ_5d188429-03ce-473b-a4d3-f4dd57518ffc">1.0</ix:nonFraction> million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested SVAs was $<ix:nonFraction unitRef="usd" contextRef="i487211e627d94b84b6b40cd96ed51f9c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMxNDg_899b530c-0949-4b71-8e10-d701ba53a6e2">48.8</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg5MTA_15b47a04-6c21-4e28-aaf3-6997e207dc30">20</ix:nonNumeric> months.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="idb79e0aac83747bcbb1a01157327c40f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relative Value Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we granted RVAs to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the <ix:nonNumeric contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMyOTg1MzQ4OTI1NjY_f61a097b-3155-4fc3-ac3a-d1b23a8f8178">three-year</ix:nonNumeric> vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. <ix:continuation id="i08b82695a47a4a8ea422a5d5e022d5e7" continuedAt="i1dfab6c9a56c4f6ba054b09135b2d5e9">The weighted-average fair value of the RVA units granted during the year ended December&#160;31, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTgzODU_dc3078de-095d-4a64-894c-b64d05045ddd">179.90</ix:nonFraction>, determined using the following assumptions:</ix:continuation></span></div><div style="margin-bottom:11pt;margin-top:11pt"><ix:continuation id="i1dfab6c9a56c4f6ba054b09135b2d5e9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTo4ZjczNzk1ZmY3ZGM0MWZhODNiNWY5OTExYzkyMzkyMi90YWJsZXJhbmdlOjhmNzM3OTVmZjdkYzQxZmE4M2I1Zjk5MTFjOTIzOTIyXzEtMS0xLTEtNDcxOA_58ae272e-eec3-43fc-93ad-c193e13fdb5f">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTo4ZjczNzk1ZmY3ZGM0MWZhODNiNWY5OTExYzkyMzkyMi90YWJsZXJhbmdlOjhmNzM3OTVmZjdkYzQxZmE4M2I1Zjk5MTFjOTIzOTIyXzItMS0xLTEtNDcxOA_872a8008-ba38-46c4-b246-0807c5bb49c5">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTo4ZjczNzk1ZmY3ZGM0MWZhODNiNWY5OTExYzkyMzkyMi90YWJsZXJhbmdlOjhmNzM3OTVmZjdkYzQxZmE4M2I1Zjk5MTFjOTIzOTIyXzMtMS0xLTEtNDcxOA_4ae34175-019f-4a4f-81d4-b267760dfec5">19.89</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested RVAs was $<ix:nonFraction unitRef="usd" contextRef="i73f6fbe788a645a88588285341425783_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg2Njk_2a4e5f41-06f1-4918-a756-7a65242b6ba8">13.7</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg2NzM_1dba384d-6fbd-4bce-b1fb-7d0c2c9a110b">24</ix:nonNumeric> months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically <ix:nonNumeric contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg5MjU_5116750b-fabf-4d11-bb37-52dc0a906ac4">three years</ix:nonNumeric>. The fair values of RSU awards granted during the years ended December&#160;31, 2020, 2019, and 2018 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM2MTE_082b89b6-26ae-4ecb-9006-28af744f748c">135.42</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="id745c20da55347c7945337736eb25cfb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM2MTU_a39d5dd3-3b0e-4cbf-bd53-9b20c6e44115">108.43</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i4a21324627e04ff9b171760e0f6aa512_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM2MjM_3ba7237a-67d0-4487-897e-89761817ed52">70.95</ix:nonFraction>, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, <ix:nonFraction unitRef="shares" contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM3Nzg_fe400b8b-1be1-4e18-a93b-0276cb0c3b42">1.1</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="id745c20da55347c7945337736eb25cfb_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM3ODI_13626383-df26-453c-9212-7663fd02a6a0">1.5</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i4a21324627e04ff9b171760e0f6aa512_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM3OTA_d77e2aca-ce30-4c7b-a98e-f7870b700252">1.3</ix:nonFraction> million shares were granted and approximately <ix:nonFraction unitRef="shares" contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM4MzE_ac7341b8-e891-436f-b7c5-120640b8bc39">0.6</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="id745c20da55347c7945337736eb25cfb_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM4MzU_473ab111-93c6-4d10-980c-2304e6fd29f0">0.8</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i4a21324627e04ff9b171760e0f6aa512_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM4NDM_44707e1c-156a-4a15-91ce-d64891b7b698">1.0</ix:nonFraction> million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately <ix:nonFraction unitRef="shares" contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM5MzI_7d59436b-f943-44c3-a6f4-735091e4d3d5">0.6</ix:nonFraction> million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested RSUs was $<ix:nonFraction unitRef="usd" contextRef="id93c53abcafb49fba5f4a407366d5857_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQwNjY_fe1b8e54-8eb9-4878-8425-06e2e7ba8f33">179.2</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of <ix:nonNumeric contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg4OTY_c8dab340-3ebf-4ae9-940c-067832f30b82">31</ix:nonNumeric> months.</span></div></ix:continuation><div id="ia8e8b06f04404e6fb09e313103495f8e_169"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;13:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzk4Mg_5639b1e1-c141-49dc-b2ce-3cbee32ca25d" continuedAt="i67211ace89574e1da85cbd873e790f66" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i67211ace89574e1da85cbd873e790f66"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019, and 2018, we repurchased $<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzcz_8cfc9479-34ee-480a-bbc6-18a6456294fd">500.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzc3_1c98faaf-8111-4dfe-bafe-318f46bc1bd6">4.40</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzg0_4fb2c168-7913-4e39-85b3-c8267daf0ba3">4.15</ix:nonFraction> billion, respectively, of shares associated with our share repurchase programs. As of December&#160;31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i3346772108a84c5d82eb7b473c264e9a_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzE3Ng_bbcfad3c-680f-42be-8770-0c642a7aa6ec">1.00</ix:nonFraction> billion remaining under our $<ix:nonFraction unitRef="usd" contextRef="i87a7cf1bd4cd4a2198d3b916f9809c4b_I20180630" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzE5OQ_0965ef56-260d-47ca-8117-3ca1a09e5b34">8.00</ix:nonFraction> billion share repurchase program that our board authorized in June 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="shares" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzI3NQ_89926e3d-7198-4ea0-a56f-76007295a08d">5.0</ix:nonFraction> million authorized shares of preferred stock. As of December&#160;31, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzMzMw_334062cb-b985-4291-8205-5b9f48a056f6"><ix:nonFraction unitRef="shares" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzMzMw_6ef97fd2-b39e-478e-bfe1-cd7487ab54e8">no</ix:nonFraction></ix:nonFraction> preferred stock was issued.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee benefit trust that held <ix:nonFraction unitRef="shares" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrustShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzQwOA_b518126a-d030-4e5a-9553-a3341e46f9ac"><ix:nonFraction unitRef="shares" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrustShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzQwOA_ca675058-2caa-43cc-9657-c841f7f40555">50.0</ix:nonFraction></ix:nonFraction> million shares of our common stock at both December&#160;31, 2020 and 2019, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzYxNQ_7a5dc723-4ea0-4b40-a691-b59fc194ec32"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzYxNQ_b2b42988-121c-4cc6-811c-1c5f2ed03ec1">3.01</ix:nonFraction></ix:nonFraction>&#160;billion at both December&#160;31, 2020 and 2019, and is shown as a reduction of shareholders&#8217; equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2020, 2019, and 2018.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">91</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_175"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;14:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3MDc_b590acc0-6d26-491c-8e5d-bfbfc16ed9af" continuedAt="i32ef1c499107410aa8769980d49fdcdf" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i32ef1c499107410aa8769980d49fdcdf" continuedAt="i6e7b2ad4ac484084ab8725425a020f32"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMyOTg1MzQ5MDU2NjA_fc013fde-25b2-4c33-be09-44aac697507b" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to GILTI, global intangible low-taxed income, are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Job Act (the 2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, such as the reduction in the corporate income tax rate from 35 percent to 21 percent, transition to a territorial tax system, changes to business related exclusions, deductions and credits, and modifications to international tax provisions, including a one-time repatriation transition tax (also known as the &#8216;Toll Tax&#8217;) on unremitted foreign earnings and GILTI, a new U.S. minimum tax on the earnings of our foreign subsidiaries. In 2018, we recorded $<ix:nonFraction unitRef="usd" contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231" decimals="-5" format="ixt:numdotdecimal" name="lly:TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzEwNTk_16a1e80d-5abf-4524-8f54-1a0483f6c466">313.3</ix:nonFraction> million of income tax benefit, mainly attributable to measurement period adjustments to the Toll Tax and GILTI.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3MjM_5cc33cfb-1ee3-4df5-be74-373deb615b69" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzItMS0xLTEtMA_9bd5dd7b-a4d5-4b8c-a4ef-fcb284b95048">567.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzItMy0xLTEtMA_25486c95-4c4a-4199-b35d-eca89b08b7ce">280.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzItNS0xLTEtMA_54b8ca99-9e0a-4c24-9bf5-346f89ac0dd5">169.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzMtMS0xLTEtMA_c4916387-8f02-44d8-99fc-dbbee35ed004">650.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzMtMy0xLTEtMA_5858e569-cb3a-47eb-884f-d9715d1baf5f">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzMtNS0xLTEtMA_882f7d99-9423-4ad1-8bf3-3651b1bf19a9">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzQtMS0xLTEtMA_4a4396d6-5df5-4703-a9b4-8eb2fff55267">47.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzQtMy0xLTEtMA_5179b96d-9756-432d-b76a-9737bc8a6a56">14.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzQtNS0xLTEtMA_d1a020f4-0047-4921-8245-ad70611b5a29">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzUtMS0xLTEtMA_043e55b4-6d13-4601-82d1-e5cc36734ca3">1,170.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzUtMy0xLTEtMA_d1bd3a7e-8fba-4919-97cb-98277c4ab243">565.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzUtNS0xLTEtMA_909f2944-18e7-41db-ad93-05276c264874">281.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzctMS0xLTEtMA_fd82e8bf-3f02-47a2-af73-7db59778e791">97.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzctMy0xLTEtMA_01e9491c-c329-479d-b25c-b7b83f195a9e">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzctNS0xLTEtMA_e563893e-e24b-4f13-baaf-b9783beb4849">3.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzgtMS0xLTEtMA_48a560b3-f5d8-40ce-9b44-ab9b97019805">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzgtMy0xLTEtMA_34957e48-5deb-4fe2-a226-c6714503053f">24.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzgtNS0xLTEtMA_544c76e6-6626-41ea-93e8-6f1328585916">248.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzktMS0xLTEtMA_9a314aa8-0213-4a87-b7df-6fed77db9e51">20.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzktMy0xLTEtMA_4cf7ab72-a17e-4571-b744-3c959aa8131a">54.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzktNS0xLTEtMA_0aa2d2f2-93e9-4518-972f-0ce4c05d1ba4">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzEwLTEtMS0xLTA_f9d12727-2bfb-4556-b71d-82475422de4f">134.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzEwLTMtMS0xLTA_64f654e5-9470-44bd-b0ce-f247e722474b">62.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzEwLTUtMS0xLTA_3f0f4960-6aa3-4c2e-931f-2583c2ab63bc">248.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzExLTEtMS0xLTA_21ac9830-4cd3-4667-8a91-4b5633ee7b60">1,036.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzExLTMtMS0xLTA_4de90d24-d91f-4e44-aeef-17a366338e1c">628.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzExLTUtMS0xLTA_71340c32-2e6d-419a-9219-88075a47a6c3">529.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The 2020 and 2019 current tax expense includes $<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzE5NDc_479e9e08-2738-498f-aba0-877262f9fba2">144.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="lly:CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzIwNjY_2d0882b1-4485-4638-83b2-66f816af7526">153.1</ix:nonFraction> million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards. The 2018 current tax expense includes $<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="lly:CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzIwNzM_22ec8431-fbcd-44e2-910b-bd510dc17df9">201.5</ix:nonFraction> million of tax expense related to effects of the 2017 Tax Act.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The 2018 deferred tax benefit includes $<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="lly:DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzIxOTg_d7bb317b-8adf-467f-aafb-7c1c48e94589">26.2</ix:nonFraction> million of tax benefit related to effects of the 2017 Tax Act.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i6e7b2ad4ac484084ab8725425a020f32" continuedAt="i7fb73736264e45e496f2af35ffb5025e"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3NDM_519b0300-5532-4cee-b52c-6fe7bcb6736c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:73.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzItMS0xLTEtMA_ff6b48ae-1679-4073-91ff-8a6936e0c792">2,560.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzItMy0xLTEtMA_5a20c2f9-5c6e-444a-883a-03974a3ecdec">2,512.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzMtMS0xLTEtMA_d524fcf3-fc02-4cd1-8176-91cba25068cc">1,045.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzMtMy0xLTEtMA_e6e3f851-c8a9-4614-a21c-09772cbca266">934.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzQtMS0xLTEtMA_33971506-4cfb-4dc2-85b1-55961f0e4762">523.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzQtMy0xLTEtMA_4b4cabff-a3d1-4440-ace9-a3a61fa5f207">455.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzUtMS0xLTEtMA_8e5d4f82-2c8b-45d1-98ad-b8dd0d452457">488.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzUtMy0xLTEtMA_18c3a5a6-ebf7-4194-a073-f93a5291c970">318.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="lly:DeferredTaxAssetsSalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzYtMS0xLTEtMA_a954738b-f5d0-44de-b400-4585d74a60cb">461.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="lly:DeferredTaxAssetsSalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzYtMy0xLTEtMA_0ccf43a7-c38f-4726-9288-89585a4b77d2">197.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="lly:DeferredTaxAssetsCorrectiveTaxAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzctMS0xLTEtMTI5ODg_eb053612-929c-49a8-8f55-4b089d869c18">404.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="lly:DeferredTaxAssetsCorrectiveTaxAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzctMy0xLTEtMTI5OTI_41eafd46-14b4-4cf9-a979-18a5de98441c">219.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="lly:DeferredTaxAssetsForeignTaxRedeterminations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzgtMS0xLTEtMTMwMDA_04852330-ede3-4746-9eca-93111539ce2e">242.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="lly:DeferredTaxAssetsForeignTaxRedeterminations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzgtMy0xLTEtMTMwMDM_ae17d696-3660-4650-bb71-8fd4e1b1a416">156.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="lly:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzctMS0xLTEtMA_3eaedb88-c318-43d0-9a50-ae9b8f550dba">150.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="lly:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzctMy0xLTEtMA_c29bc84c-55f2-4b74-bed9-b76e4b2d687c">140.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzgtMS0xLTEtMTA5Nzk_0169d12b-83b8-4bc3-96a2-adf3558d0a11">135.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzgtMy0xLTEtMTA5ODM_682b4e10-513d-4627-8d32-37326a6e15f7">75.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzExLTEtMS0xLTA_41ce3b3c-dbcd-41c3-a38d-6a95f1aac09b">605.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzExLTMtMS0xLTA_8b5490bd-d887-45af-8b88-97509494b3b1">595.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzEyLTEtMS0xLTA_2fc73c2e-4948-4cb9-8d27-22f94348f1a2">6,618.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzEyLTMtMS0xLTA_4fa8871c-ed1e-4737-bc86-cbe65379afe9">5,606.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzEzLTEtMS0xLTA_efe4a0ff-1fe5-44d0-ac7f-fda47e00b728">816.3</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzEzLTMtMS0xLTA_8fc5b578-ee7a-4c19-9e0c-64850facd301">616.5</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE0LTEtMS0xLTA_004d7677-75ef-4934-ad52-715e3c8d4955">5,801.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE0LTMtMS0xLTA_5f83205c-c48f-4346-bea0-0a8e60ee1420">4,990.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE2LTEtMS0xLTA_83d30737-03ca-4920-9b8b-2830be7bb439">1,905.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE2LTMtMS0xLTA_4951f57c-483f-4139-90ad-6f994d436a4e">1,776.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE3LTEtMS0xLTA_4343d4c5-2547-41a5-b9a2-da94eae1c0cd">1,465.7</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE3LTMtMS0xLTA_89353445-4b81-4319-bca9-6ae0bd73d42d">1,298.0</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE4LTEtMS0xLTA_daace6d8-7103-4846-9a61-e7c1e8d3ee98">623.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE4LTMtMS0xLTA_d3931626-d6b5-4493-8166-1f040a1b33ea">686.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE5LTEtMS0xLTA_28a4546c-92fc-4ccd-98eb-68e0c5d0296f">410.1</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE5LTMtMS0xLTA_578f6a52-e41a-4c82-ac64-bac01a15ef83">305.9</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIwLTEtMS0xLTA_a889c689-772f-475b-a86d-bee442b76abc">315.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIwLTMtMS0xLTA_6bd727d8-7d12-45f7-bf6a-7c7fbe6e0dc3">274.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIxLTEtMS0xLTA_89ea3ba4-82b6-47e9-a208-0d94e09c41e9">216.9</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIxLTMtMS0xLTA_4ee7d4f9-d181-40e4-bfda-d92df7819047">139.4</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIyLTEtMS0xLTA_4bd14ca1-a1c2-4119-88ff-13622b892932">134.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIyLTMtMS0xLTA_92801a2e-7c00-44cb-bf02-f218f3f871e0">124.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIzLTEtMS0xLTA_e5b0a2eb-a8dc-4658-b5f3-d3f7ce4ddb85">5,071.2</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIzLTMtMS0xLTA_77e31e80-3e1c-4902-87d6-203148ffae97">4,604.9</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzI0LTEtMS0xLTA_112ac5f4-5962-4347-8050-0266112d991f">730.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzI0LTMtMS0xLTA_f3074e71-8666-4388-9383-db426ba9aef6">385.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, based on filed tax returns we have tax credit carryforwards and carrybacks of $<ix:nonFraction unitRef="usd" contextRef="i846b4a3017ec4ae5aa560b3976992beb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI2OTU_bf769617-9fc6-4499-a198-2ce13a73e1db">887.3</ix:nonFraction> million available to reduce future income taxes; $<ix:nonFraction unitRef="usd" contextRef="i63b7f44c96794ab582d1cdf6a9643b7a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI3Mzk_c73dd9c8-d48a-42fc-970d-077e8aff692b">148.8</ix:nonFraction> million, if unused, will expire by 2026, and $<ix:nonFraction unitRef="usd" contextRef="ic0b893702d44405d985be5d52a729ef7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI3Nzc_8587314c-139f-4fe5-b623-ddc9b2e1aea2">16.1</ix:nonFraction> million, if unused, will expire between 2029 and 2039. The remaining portion of the tax credit carryforwards is related to federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="i2d7fdc4cf740436c9e25779df853a90f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI5MTQ_ce569530-7058-45f3-99e5-b64e716a2fd5">84.8</ix:nonFraction> million, international tax credits of $<ix:nonFraction unitRef="usd" contextRef="i58e427ba0deb48549a21b2af98646bb0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI5NDc_38d1377e-39ff-4706-bd93-014f7e48e970">121.9</ix:nonFraction> million, and state tax credits of $<ix:nonFraction unitRef="usd" contextRef="icdc037a98b204a1b85b9d162f20d5932_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI5NzY_5b1f5c92-2279-40a4-b496-97632d8c0e3b">515.7</ix:nonFraction> million, all of which are fully reserved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="i846b4a3017ec4ae5aa560b3976992beb_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMxNjU_052be866-28f8-4c59-9b1d-4054c862f2e1">1.52</ix:nonFraction> billion: $<ix:nonFraction unitRef="usd" contextRef="idba58d0fe8d4499db02b60b0661239fe_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMxNjk_c6e1bbf7-f251-49ad-939b-f6a9e558282f">162.6</ix:nonFraction> million will expire by 2025; $<ix:nonFraction unitRef="usd" contextRef="id87d4bdf6f7b4a8788ffa5277ada15bb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMxOTE_ad6cb275-19d6-4691-a5a9-fcbd8fc9662a">781.7</ix:nonFraction>&#160;million will expire between 2026 and 2040; and $<ix:nonFraction unitRef="usd" contextRef="ibdf7908d101449948e44a8d01c8ce72f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMyMjk_9cc1f768-8226-46d3-a854-7bada7f3d164">576.3</ix:nonFraction> million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i847eca29310b48cda35b0cd11f7c52fe_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzM0NTc_66d444f0-c4f7-4d11-a0cc-fad4cfb93474">175.6</ix:nonFraction> million are fully reserved as of December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and Puerto Rican companies contributed approximately <ix:nonFraction unitRef="number" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzM2MDI_eb1f247e-1524-4858-bb08-4a0aa42ca650">39</ix:nonFraction> percent, <ix:nonFraction unitRef="number" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="2" format="ixt:numdotdecimal" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzM2MDY_efbb919b-68cc-4768-b4e3-d14bc0b5961f">44</ix:nonFraction> percent, and <ix:nonFraction unitRef="number" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="2" format="ixt:numdotdecimal" name="lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzM2MTQ_c79028df-ae30-44b7-ba0d-acf1a66c2cd0">15</ix:nonFraction> percent for the years ended December&#160;31, 2020, 2019, and 2018, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i7fb73736264e45e496f2af35ffb5025e" continuedAt="id2d5aca0ae674dccbbee2e0f4db442cd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December 31, 2020 and December 31, 2019, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3Mzg_e6d73361-8847-4dae-a6d2-ab46a984e614" continuedAt="i73dec14658ea4084b102def8a9fd6f5c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTowZDY5ZmNhY2U4Y2Y0NzI0YmQ3ZWMxY2EwZGU5MWExNi90YWJsZXJhbmdlOjBkNjlmY2FjZThjZjQ3MjRiZDdlYzFjYTBkZTkxYTE2XzEtMS0xLTEtMA_a45ac57b-abfb-468f-9a6a-a9d3308fa6ba">954.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTowZDY5ZmNhY2U4Y2Y0NzI0YmQ3ZWMxY2EwZGU5MWExNi90YWJsZXJhbmdlOjBkNjlmY2FjZThjZjQ3MjRiZDdlYzFjYTBkZTkxYTE2XzEtMy0xLTEtMA_6f758c65-c078-4fa1-ac45-6a30ab62df6a">1,180.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTowZDY5ZmNhY2U4Y2Y0NzI0YmQ3ZWMxY2EwZGU5MWExNi90YWJsZXJhbmdlOjBkNjlmY2FjZThjZjQ3MjRiZDdlYzFjYTBkZTkxYTE2XzEtNS0xLTEtMA_92e595ff-f49d-4723-b2e3-a7206e2222a1">1,076.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight year period beginning in 2018 through 2025. <ix:continuation id="i73dec14658ea4084b102def8a9fd6f5c" continuedAt="i689ebe3f94ee4861987f6c2be8884868">Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2020 are as follows:</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i689ebe3f94ee4861987f6c2be8884868"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years </span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:TaxCutAndJobsActTollTaxToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo5MzRkYmVlZjhmYTM0N2ZjYWJhYmRlNDk1NmIyOGZlZC90YWJsZXJhbmdlOjkzNGRiZWVmOGZhMzQ3ZmNhYmFiZGU0OTU2YjI4ZmVkXzEtMS0xLTEtMTA5MTk_c0f5da3a-8de1-4755-8f9d-5d9be1f5479d">2,403.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo5MzRkYmVlZjhmYTM0N2ZjYWJhYmRlNDk1NmIyOGZlZC90YWJsZXJhbmdlOjkzNGRiZWVmOGZhMzQ3ZmNhYmFiZGU0OTU2YjI4ZmVkXzEtMi0xLTEtMTA5MzM_c6bec15c-5670-406b-ad3b-fed512c3d42a">253.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" name="lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo5MzRkYmVlZjhmYTM0N2ZjYWJhYmRlNDk1NmIyOGZlZC90YWJsZXJhbmdlOjkzNGRiZWVmOGZhMzQ3ZmNhYmFiZGU0OTU2YjI4ZmVkXzEtMy0xLTEtMTA5NDc_558d05da-6c03-4569-b1ee-b7b6b86333a8">729.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo5MzRkYmVlZjhmYTM0N2ZjYWJhYmRlNDk1NmIyOGZlZC90YWJsZXJhbmdlOjkzNGRiZWVmOGZhMzQ3ZmNhYmFiZGU0OTU2YjI4ZmVkXzEtNC0xLTEtMTA5NTc_e22c5f95-ba10-4e9f-9e42-3a581d591b68">1,420.1</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have additional noncurrent income tax payables of $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-7" format="ixt:numdotdecimal" name="lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMyOTg1MzQ5MDU2NDY_c2599e13-2313-42d3-8cb2-859d1110ebcb">1.69</ix:nonFraction>&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. </span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3NDU_af6928e4-ecdd-4939-b37c-01a9fbe6cd70" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div style="margin-bottom:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzEtMS0xLTEtMA_c3cb1048-7d10-4e98-bc1b-07628fa8f9f0">1,518.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzEtMy0xLTEtMA_c9db6a40-5d18-4805-b8b3-9e0b8f71a9b4">1,105.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzEtNS0xLTEtMA_2cffd046-31bd-4604-b7f2-5ef1c14dea7b">772.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzMtMS0xLTEtMA_bad71b33-4151-45ce-9c74-309d63aa05a5">297.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzMtMy0xLTEtMA_edd779ef-0c63-42e9-8999-a4ac9a687ffa">242.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzMtNS0xLTEtMA_0462c09b-cec6-4a8d-ab23-a7afbcd69383">627.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzQtMS0xLTEtMA_5366d337-8151-4e2b-a02d-dab0c5cf100b">97.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzQtMy0xLTEtMA_9cb1454b-14b9-4ce8-b9aa-873bab038f99">108.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzQtNS0xLTEtMA_a7787dc5-af8f-409f-9559-d691c023b360">87.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzUtMS0xLTEtMA_891a3191-c51f-43ba-8cd2-510b50f88b2a">63.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzUtMy0xLTEtMA_89db4ace-fb75-4cd6-9144-70bd6b0f51c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzUtNS0xLTEtMA_0b1a3005-6258-4866-bc6f-a6c0ccb74c3a">309.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzYtMS0xLTEtMA_a57c5063-4f5c-4864-b010-34e88cf32854">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzYtMy0xLTEtMA_c687b40c-d8a3-4520-bb63-c711440b28db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzYtNS0xLTEtMA_6bd3d653-27f2-422a-89df-c6d85082ead3">175.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzctMS0xLTEtMA_8130dcc0-abeb-4687-abeb-840d4ba686ef">150.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzctMy0xLTEtMA_3e3a0d97-f848-474d-ae17-5cef17065374">127.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzctNS0xLTEtMA_bcb90a2f-8951-433f-b2b2-1624564d2514">14.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzgtMS0xLTEtMA_65dac00c-56ab-432b-9706-c991dbaf3c3a">1,036.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzgtMy0xLTEtMA_57cb8a23-1fc3-4032-8b9e-4aa94bc73312">628.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzgtNS0xLTEtMA_ee64d283-cc4b-41e2-8ce2-257b09721086">529.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-deductible acquired IPR&amp;D was related to the acquisitions of Disarm and a pre-clinical stage company in 2020 and ARMO in 2018. See Note 3 for additional information related to acquisitions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3NTE_47dcfe8b-9d84-4690-bcc2-2d6dac02b553" continuedAt="i71fc6f85721440888706b84cd66c5c27" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzEtMS0xLTEtMA_58797d5b-db56-4d81-9eb8-5fda544d4530">2,108.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzEtMy0xLTEtMA_352fb7f2-612d-40e9-b886-5bc518bfa6b5">2,034.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzEtNS0xLTEtMA_19bd4632-578b-4d05-95e9-a2539d3e03c4">1,000.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzItMS0xLTEtMA_7991d76d-509b-4a7e-99c5-32f54aad947d">225.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzItMy0xLTEtMA_6842e49a-201c-47b2-9a2a-6457363118d8">187.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzItNS0xLTEtMA_2527d613-ca8b-4813-9a2b-91911f79b331">798.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzMtMS0xLTEtMA_6a583e17-a0ac-472e-bf21-ed850e6e5050">310.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzMtMy0xLTEtMA_f140f907-cfad-44c8-a947-31940d406fba">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzMtNS0xLTEtMA_e39261ed-355c-4bc8-9152-d7c09a10be0f">410.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzQtMS0xLTEtMA_ceb7398c-1a17-4025-9f4d-05cae88505b8">52.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzQtMy0xLTEtMA_64e6eaa5-caac-410a-b8d9-af387e396cad">100.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzQtNS0xLTEtMA_be704a64-5b12-472f-be45-b4e924c6837f">115.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzUtMS0xLTEtMA_bc8ed7d1-3cad-4896-af00-9b855dc2cd75">72.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzUtMy0xLTEtMA_7247488f-251d-4375-be5b-2e3ae534823d">260.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzUtNS0xLTEtMA_f5a0256e-000a-48b8-b5a6-89c9272c4858">33.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzYtMS0xLTEtMA_6feb2f83-50a7-46ca-baca-bbae2076f78b">41.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzYtMy0xLTEtMA_3cd0045b-b7fa-4079-b113-93c6b2ca3354">161.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzYtNS0xLTEtMA_e13881cd-cc10-4b18-9ad3-9ee7c1009d2a">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzctMS0xLTEtMA_9bb6db4e-faf0-4d8e-b106-1449bd515567">73.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzctMy0xLTEtMA_efc61705-7f35-4b2c-96ab-bb58be2b96ae">16.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzctNS0xLTEtMA_1b620b23-c4aa-4ceb-8089-ca77f60e8f37">6.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzgtMS0xLTEtMA_596497fa-dc4d-40a3-a7bb-b6a8b9b47a43">2,551.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzgtMy0xLTEtMA_2643ec00-f2e6-4c36-9f98-041da9adddea">2,108.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzgtNS0xLTEtMA_4f2ae33a-6f2f-492c-a55f-e4f71253013e">2,034.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzU0MTI_65fd55b6-4d5c-46f7-b3ab-c7d652e43732">1.67</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzU0MTk_29a2ef4d-21b8-4817-b314-6ec83982da6c">1.53</ix:nonFraction> billion at December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="id2d5aca0ae674dccbbee2e0f4db442cd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months. For tax years 2013-2015, all matters were effectively settled in 2019. As a result, our gross uncertain tax positions were reduced by approximately $<ix:nonFraction unitRef="usd" contextRef="i8253b9821a464bffb6ab718d922a8b60_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzU5Mjk_2f258978-3c7e-4274-b884-b6f0d10aef52">200</ix:nonFraction> million, we made a cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="id11b4d29868245268d0dca888203dbf6_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="lly:PaymentsForIncomeTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzU5NzM_65d20049-bdbf-4c88-9430-1ccddfdaddb3">125</ix:nonFraction> million, and our consolidated results were benefited by an immaterial reduction in tax expense. </span></div><ix:continuation id="i71fc6f85721440888706b84cd66c5c27"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:</span></div><div style="margin-bottom:17pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpkMWQ3ZTcxOWRlYTA0ZDMxOTdmNGQ3MzBlYmFmMDM5MC90YWJsZXJhbmdlOmQxZDdlNzE5ZGVhMDRkMzE5N2Y0ZDczMGViYWYwMzkwXzEtMS0xLTEtMA_0ce0f22a-67e9-41e7-86de-182a81b9ad5a">34.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpkMWQ3ZTcxOWRlYTA0ZDMxOTdmNGQ3MzBlYmFmMDM5MC90YWJsZXJhbmdlOmQxZDdlNzE5ZGVhMDRkMzE5N2Y0ZDczMGViYWYwMzkwXzEtMy0xLTEtMA_8df454dc-6844-447c-85b8-d1d784c2f228">26.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpkMWQ3ZTcxOWRlYTA0ZDMxOTdmNGQ3MzBlYmFmMDM5MC90YWJsZXJhbmdlOmQxZDdlNzE5ZGVhMDRkMzE5N2Y0ZDczMGViYWYwMzkwXzEtNS0xLTEtMA_c5156c86-4800-4a99-a15e-3c22a7bcd6fb">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, our accruals for the payment of interest and penalties totaled $<ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY2Nzk_0c7326f2-4516-4acc-a272-76e039ba1f73">196.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY2ODY_42ca805f-5d37-49c7-a3ad-5bb319f832aa">150.8</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">95</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_178"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjk2_103227a8-5842-4b16-a8be-4db81bde35f1" continuedAt="ica6b376e47ba4c43a5d108422fc5bdf7" escape="true">Retirement Benefits</ix:nonNumeric></span></div><ix:continuation id="ica6b376e47ba4c43a5d108422fc5bdf7" continuedAt="id33770d655154dc48d4aaf2e8a872f14"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjg4_23a6d1a3-a567-45bd-badd-b32c1b79121a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzMtMS0xLTEtMA_f8a0f044-7b49-4faf-9724-2250f73a5368">16,251.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62914e39c2446a7965d109d4b06fac3_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzMtMy0xLTEtMA_50120889-9fcc-45e0-aa8c-79df6e3efaae">13,427.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzMtNS0xLTEtMA_2d464c44-9dcf-490e-b82a-3183294e07e0">1,601.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860ee37306f64cf8a0c232ead17d7745_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzMtNy0xLTEtMA_900c65bb-3b01-43da-b637-c80d222f53ec">1,540.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzQtMS0xLTEtMA_9e04cdb9-a883-4fee-95cc-290a948a98ed">325.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzQtMy0xLTEtMA_04a84695-dd91-4f2d-9c4e-05fe76118886">250.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzQtNS0xLTEtMA_990076b1-fe3c-4b37-a446-f6bb79a1826f">40.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzQtNy0xLTEtMA_112dbfa9-6afe-4297-b242-667ee6f38f81">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzUtMS0xLTEtMA_d41d4a43-5def-4fa1-a71f-6a26687653bd">425.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzUtMy0xLTEtMA_333501d9-5ae9-4f10-b64b-5b840c3f3d42">486.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzUtNS0xLTEtMA_5a07b1f4-78cd-4a3a-988d-8ecd47f195ed">43.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzUtNy0xLTEtMA_e6ba1c02-a352-4f93-8f68-aa7f4a06a2ee">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzYtMS0xLTEtMA_c8cab360-769b-4327-adca-85cfd9f86c18">1,563.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzYtMy0xLTEtMA_d6ce586c-d79d-4fd6-ae14-a3be6367a664">2,631.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzYtNS0xLTEtMA_12645586-f60d-4fe9-8472-7f123cc7a56b">142.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzYtNy0xLTEtMA_f1d92298-3453-4651-add1-8fd9c8d774ec">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzctMS0xLTEtMA_5e058f91-cb44-43b3-bcd6-cc7c7aa1d29a">587.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzctMy0xLTEtMA_3f6f7fe1-db86-4245-b42e-119d931876e8">584.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzctNS0xLTEtMA_c4c54a19-3c7c-47ab-bb79-90d9f0b2fe51">75.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzctNy0xLTEtMA_13cdac6b-0add-4934-8ece-97422d463c70">87.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment (gain) loss</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzktMS0xLTEtMA_cbab85cb-73c2-48af-97f0-7af6a08ffa54">2.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzktMy0xLTEtMA_9c1f85cd-1852-441b-9125-41e8ce9bbf44">16.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzktNS0xLTEtMA_92d66a9c-7d24-40b0-86e6-bf66cbf90d02">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzktNy0xLTEtMA_5b9e5d3e-2946-43aa-bf55-9419cb10062e">0.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzEwLTEtMS0xLTA_e3e018b5-1b62-477e-97fc-b33157f8d795">245.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzEwLTMtMS0xLTA_f5520d6e-22b7-4fc2-9ec9-5c92b0fb8c2b">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzEwLTUtMS0xLTA_16b9679c-0155-4cd1-b5a7-3050be3dd5e9">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzEwLTctMS0xLTA_4310c182-7037-4ece-ba42-ad0bf26e90e7">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzExLTEtMS0xLTA_61c84afc-ad4d-4063-b512-70737dbac5b4">18,225.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzExLTMtMS0xLTA_a003ecc6-6c9c-4849-87fc-cf0f82463f43">16,251.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzExLTUtMS0xLTA_3b4767ca-37c5-4080-99ae-ebb64bb822ed">1,753.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzExLTctMS0xLTA_7bf82c53-f00d-4a77-8acc-8618edb114a6">1,601.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:14pt"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjk0_5dd3df4e-29f9-4c18-9beb-7f8f53c76b8a" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzEtMS0xLTEtMA_b172a5a6-526a-4193-8c92-85e6820e4e06">12,858.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62914e39c2446a7965d109d4b06fac3_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzEtMy0xLTEtMA_5068ae42-d8d0-4451-a2c3-29e42aeb46f4">10,932.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzEtNS0xLTEtMA_8642be6e-2bd1-4b9d-87d1-02bea6599903">2,768.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860ee37306f64cf8a0c232ead17d7745_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzEtNy0xLTEtMA_ec9bf1fe-87bd-4d92-8022-371f94c0b8b0">2,398.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzItMS0xLTEtMA_875359b6-6877-4c2c-8fb2-d492f8edcacd">1,802.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzItMy0xLTEtMA_66c245fe-cb64-42c6-8895-b57738ff165d">2,012.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzItNS0xLTEtMA_0c979bc3-ea08-4805-ab71-115baca63581">539.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzItNy0xLTEtMA_286adeed-d3c4-4783-be5a-f571fa682af9">444.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzMtMS0xLTEtMA_e3abd34f-fca8-4316-b5df-32d031419452">318.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzMtMy0xLTEtMA_af76b5ac-16ec-4375-8fca-40a7a7cda10d">429.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzMtNS0xLTEtMA_1695d20e-c012-4e55-b272-e93e1dbfa211">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzMtNy0xLTEtMA_663f5594-bb10-429e-b5c9-32f23ade4ed9">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzQtMS0xLTEtMA_0486d4cf-4ce6-4de8-9d21-389a3d9ca7d0">587.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzQtMy0xLTEtMA_a43a80a7-3ce3-4cb2-a418-e18076ee8d27">584.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzQtNS0xLTEtMA_a23b6778-e0cd-43ec-9c11-c56d691e87d6">75.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzQtNy0xLTEtMA_9a4a3100-926c-4e7a-be85-3aaa590d74d5">87.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzUtMS0xLTEtMA_76e105ea-97c9-4cd8-ade5-b6969e10946b">187.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzUtMy0xLTEtMA_5f1d5788-2f9e-46cf-b295-39d8757dd63c">67.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzUtNS0xLTEtMA_71f79d7b-f1ad-4221-a011-6656f54601e8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzUtNy0xLTEtMA_729fde96-f857-4c48-8599-589f7fa7ec2e">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzYtMS0xLTEtMA_4f6d7847-9f98-4d6c-b9bb-06e4ed01b606">14,579.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzYtMy0xLTEtMA_adb4d4ef-77dc-41a6-94ea-2202ddac12a9">12,858.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzYtNS0xLTEtMA_f680c220-8129-42f3-9f73-3e7e398c1bf6">3,227.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzYtNy0xLTEtMA_4a5309ff-2a54-4cb1-b0ca-2e4999e4d207">2,768.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:5pt;margin-top:14pt"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfNetFundedStatusTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjg1_6a99589d-1565-4735-b8e5-b141385cc391" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzAtMS0xLTEtMA_0783ca27-1e38-4f12-b8a1-7614886b98f2">3,646.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzAtMy0xLTEtMA_3ff90730-0c06-4e28-8f2f-c29b3a3eb114">3,393.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzAtNS0xLTEtMA_8cf34c0a-f951-425c-8951-4b6fdb29c96d">1,473.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzAtNy0xLTEtMA_26a303e4-fe25-45aa-bc6e-c72f2d1543ec">1,166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzEtMS0xLTEtMA_a633b061-4449-4a9f-a9a0-5cdb5cd2b068">6,515.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzEtMy0xLTEtMA_81870b47-cc82-4071-9655-320e6573ae49">6,177.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzEtNS0xLTEtMA_16c95543-99f4-405f-b32d-0ca759a1cd97">349.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzEtNy0xLTEtMA_ee5f1299-3734-4cb7-8adb-e6b0602fcb48">111.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzItMS0xLTEtMA_d39ee622-9159-4cb4-97d3-7e259bd4301c">15.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzItMy0xLTEtMA_164b2a3d-f517-45df-bc66-c63e01cf3cbd">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzItNS0xLTEtMA_de8d6779-f65c-4e08-8219-4350907058df">177.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzItNy0xLTEtMA_aec75df9-4249-42df-8356-6529bcbdc3a0">236.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzMtMS0xLTEtMA_59abed98-dc64-4630-928b-241bae44dfb7">2,884.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzMtMy0xLTEtMA_f2dccf3e-a827-4b70-bbdb-7aaf7d02981c">2,802.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzMtNS0xLTEtMA_fa0a9a10-6950-4248-a3f4-1d7ed71a8198">946.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzMtNy0xLTEtMA_7502d146-23ef-499a-834b-917f97ad24ad">818.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:5pt;margin-top:14pt"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzEx_fafa8aca-922a-4ba2-a5ec-41a4cbac4197" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzEtMS0xLTEtMA_8de1ab04-2ab1-47be-951f-84b419ef9947">299.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzEtMy0xLTEtMA_67cfce7f-3e08-430a-9512-726840da3a04">163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzEtNS0xLTEtMA_cff18630-856b-4090-889b-9cf949ec73d9">1,697.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzEtNy0xLTEtMA_419f2f8f-5001-4f0d-8f07-d61e594db71b">1,381.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzItMS0xLTEtMA_d21d1efe-8fec-4a33-b3e8-54101dcd2cc1">67.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzItMy0xLTEtMA_a8db8da3-caa0-4eba-8c50-9dc044c38d73">65.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzItNS0xLTEtMA_6cf9b457-3c38-4997-baf2-508130ad3ba2">7.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzItNy0xLTEtMA_99859d12-876d-410e-a51e-6431dfbc87c7">7.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzMtMS0xLTEtMA_c83a92fe-5dda-49cb-a655-209d75dcbd64">3,878.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzMtMy0xLTEtMA_bbf0ade3-3d3a-45a9-8fdf-33516f697faf">3,491.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzMtNS0xLTEtMA_cfdd01da-ac5b-430c-bf27-774be5276d52">216.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzMtNy0xLTEtMA_65b37c93-148e-486b-9e2d-8f12dac6b5f3">207.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzQtMS0xLTEtMA_4118c8b1-b0a5-482d-89da-0859c52d6952">6,530.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzQtMy0xLTEtMA_f8dcf8b5-ad28-4741-8034-686dd2b71106">6,195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzQtNS0xLTEtMA_03c99d36-bda7-45df-8efb-353cece832d7">526.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzQtNy0xLTEtMA_6ce97072-2e31-4d67-bbb1-18e04c9d0a70">348.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzUtMS0xLTEtMA_5454b63a-5e50-47ce-b8ad-95c91221a69e">2,884.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzUtMy0xLTEtMA_5a3f5d26-f2c4-4d1b-b8f6-0e2677cec7c0">2,802.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzUtNS0xLTEtMA_1697502d-71d0-4a75-b44a-920ee54e1aee">946.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzUtNy0xLTEtMA_8ddaf622-5e19-4f66-b2a9-dfd1729aa2ed">818.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized net actuarial loss (gain) and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2020 and 2019.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="id33770d655154dc48d4aaf2e8a872f14" continuedAt="iaaa82fe992f949789ac72a40d58fffaa"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective during the third quarter of 2020, we adopted a voluntary change in our method of applying an accounting principle for certain of our retirement benefit plans. The new accounting method changes the computation of expected returns on U.S. dollar denominated investment grade debt securities and derivatives in such plans from a calculated value that includes changes in the fair values over a period of five years to actual fair value. This change in accounting principle is preferable because changes in the fair value of this class of assets will be amortized into net periodic pension and retiree health cost sooner. No change is being made to the accounting principle for the other classes of pension assets. The impact of the adoption of this change in accounting method was not material to our historical and current consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decrease in the discount rate was the primary driver for the $<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzMyOTg1MzQ5MDAzMzQ_dd653426-9065-41d8-a9cd-e84f0c43f647">2.13</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzMyOTg1MzQ5MDAzMTk_9013f84a-9045-49f7-b269-3d9044be9c5a">2.89</ix:nonFraction>&#160;billion increase in the benefit obligation in 2020 and 2019, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans&#8217; benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of $<ix:nonFraction unitRef="usd" contextRef="if5917c0f9aaa488a8f07e138effe57cd_D20180701-20180731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzExMDQ_bf006258-b40d-4bde-96da-a8b12c7b3ef5">28.0</ix:nonFraction> million, which was recorded in asset impairment, restructuring, and other special charges.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzEy_69bd6d51-3c0d-4a20-8e4e-700e03442763" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItMS0xLTEtMA_86931da1-8d6c-4dbb-9e8e-eefc8bec8299">2.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItMy0xLTEtMA_1627e6f0-844e-4c13-ab28-6f01a2738efc">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic62914e39c2446a7965d109d4b06fac3_I20181231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItNS0xLTEtMA_33777f56-1b0a-4218-8a2f-822ec3b17928">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItNy0xLTEtMA_cb89034e-5c7a-4f61-9e44-8043ebaf7eaf">2.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItOS0xLTEtMA_3de6af21-03c8-4366-b98f-67b78009adcd">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i860ee37306f64cf8a0c232ead17d7745_I20181231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItMTEtMS0xLTA_a213aabb-576d-4504-844b-caa4f99ad15b">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtMS0xLTEtMA_ee025de1-998d-49f2-a769-1c228c7b1111">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtMy0xLTEtMA_6452e642-cbfd-4757-9225-69b9458704e6">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtNS0xLTEtMA_2ff5f720-c5c9-4ae6-a0d4-2ace1a3fdef0">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtNy0xLTEtMA_1dc57971-05d8-4ccc-9ef5-2a33f9b59bc7">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtOS0xLTEtMA_03620a88-17ab-4504-a71b-9f5a5d1eff8c">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtMTEtMS0xLTA_e9719a79-e53c-4434-a55a-c32bf2fcd362">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzQtMS0xLTEtMA_8caec55e-5887-4b83-9f45-fb816ff1fce9">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzQtMy0xLTEtMA_6eb5160d-254a-460c-bba5-ece06d2ecf03">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic62914e39c2446a7965d109d4b06fac3_I20181231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzQtNS0xLTEtMA_50760854-141f-404b-b153-a464aaebf52c">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzUtMS0xLTEtMA_04436c59-2214-4736-a1ab-9cbce5024aaf">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzUtMy0xLTEtMA_f338a452-e359-4f78-9c6e-47403231c7d0">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzUtNS0xLTEtMA_68ef9fd9-c73e-418b-80f6-f3fc502c0a0d">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtMS0xLTEtMA_88bfe5e3-3912-4ea9-b37c-94a0933b5585">7.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtMy0xLTEtMA_286c4392-a95d-4e20-8cc9-4a0295b06dae">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtNS0xLTEtMA_4a099ae3-45a7-4e42-b687-fc41343802b6">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtNy0xLTEtMA_0aecb511-87ba-4efd-9905-77b77b45855d">6.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtOS0xLTEtMA_ba313f40-b5d0-48ee-85ac-b8693e5d0abc">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtMTEtMS0xLTA_fcf5e794-d76d-4d2e-86c3-498b4f5262e1">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iaaa82fe992f949789ac72a40d58fffaa" continuedAt="i1bd6c709165044959e75e6c85d0984d1"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzE1_949498dd-e6d2-421e-b956-1e29c37ec223" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtMS0xLTEtMA_20385bb3-9163-4a7d-970a-7610ad9ed9c1">639.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtMy0xLTEtMA_92839faf-6ea2-4c3d-be2d-c175d1b6d3f1">635.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtNS0xLTEtMA_cd661f44-81c5-405a-aa1d-ae43b689835c">645.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtNy0xLTEtMA_ea215675-cc47-4e91-9e9f-4e409cf41d9e">673.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtOS0xLTEtMA_384271b3-779a-4d76-a9ee-cc04042db82e">689.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtMTEtMS0xLTA_260da76b-f36b-4c6e-8480-58e1aeb0b47d">3,800.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItMS0xLTEtMA_fbe9a845-270f-49c8-ba6e-88700468ffe7">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItMy0xLTEtMA_713d7edb-b73c-4c14-b3a3-bb629dd892fe">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItNS0xLTEtMA_46ab9469-2f62-4525-91de-4ba9256df9ff">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItNy0xLTEtMA_f77f1e3a-bc14-42ee-93c0-8c2fc263ff1a">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItOS0xLTEtMA_08f9c169-dd37-40f9-a4b5-782d915766a5">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItMTEtMS0xLTA_52daeee3-a73f-4c9b-bbb3-d9ad91a064b9">481.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjI3_c5a19095-0dfd-4f09-a50f-0559bbb6dde5" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODk2YjExNWRhYTE0MjYyOWM4YzJjOTVjNDhiYWQ3OS90YWJsZXJhbmdlOjM4OTZiMTE1ZGFhMTQyNjI5YzhjMmM5NWM0OGJhZDc5XzEtMS0xLTEtMA_3688c5a9-47dc-4c26-a383-61bff4d53c06">15,770.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODk2YjExNWRhYTE0MjYyOWM4YzJjOTVjNDhiYWQ3OS90YWJsZXJhbmdlOjM4OTZiMTE1ZGFhMTQyNjI5YzhjMmM5NWM0OGJhZDc5XzEtMy0xLTEtMA_bb7550da-ec44-45b9-a211-e66e499ddd0c">14,039.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODk2YjExNWRhYTE0MjYyOWM4YzJjOTVjNDhiYWQ3OS90YWJsZXJhbmdlOjM4OTZiMTE1ZGFhMTQyNjI5YzhjMmM5NWM0OGJhZDc5XzItMS0xLTEtMA_db9a83f1-769f-472b-9970-846a2af150d2">11,824.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e7e33eb088468895e308da89cb151e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODk2YjExNWRhYTE0MjYyOWM4YzJjOTVjNDhiYWQ3OS90YWJsZXJhbmdlOjM4OTZiMTE1ZGFhMTQyNjI5YzhjMmM5NWM0OGJhZDc5XzItMy0xLTEtMA_9e1c40ee-abeb-4ef9-86e4-e49c491ad0f7">10,483.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjg0_2aabed7b-df45-469b-a940-272160fefd84" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzItMS0xLTEtMA_0a3c5dae-d2b6-4bfe-8886-94f985d56d70">14,682.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzItMy0xLTEtMA_7508b166-a386-495f-a8d0-710f78897b75">13,063.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzItNS0xLTEtMA_0204d0ce-1031-4e02-8dc7-0e05303348d3">223.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzItNy0xLTEtMA_caac2c2c-f71e-40ee-aaaf-f2bead27a503">214.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzMtMS0xLTEtMA_ae6aa316-c8e5-49f7-9438-c864bf09ef2b">11,824.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzMtMy0xLTEtMA_695f40b5-8dc0-4bc9-9dbb-c40a5b967c6b">10,483.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzMtNS0xLTEtMA_4ee8e7ce-66f0-457a-96bd-e6d4f8256024">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzMtNy0xLTEtMA_74c1f56b-0754-4aa5-b365-b1a015fd2ae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total accumulated benefit obligation for our defined benefit pension plans was $<ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzMyNDM_2a1d69a1-0f13-4a0c-b743-96b63354f9e6">17.03</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzMyNTA_7bfc66fc-5032-4797-8a83-5895a54e3303">15.17</ix:nonFraction>&#160;billion at December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i1bd6c709165044959e75e6c85d0984d1" continuedAt="id1d6a4fd83d44e768152ebcbe8064445"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzQy_3a639348-d585-4ec6-99d2-82ad0d523882" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:38.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtMS0xLTEtMA_e8c1e252-71d1-4c59-9d0b-937a7c087012">325.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtMy0xLTEtMA_0f9562ce-a408-407d-9e82-34023aedb697">250.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtNS0xLTEtMA_c80ed05b-65df-4a1b-b07d-a09f238cddc0">292.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtNy0xLTEtMA_6eb8f6b2-eef3-4bbf-b705-0f0e82562733">40.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtOS0xLTEtMA_56e627d0-b271-46fc-9fbb-53d2e35e5a55">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtMTEtMS0xLTA_0e2e9bbf-653d-4281-b10b-c5d94f332736">41.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtMS0xLTEtMA_ba8190bf-8685-40fb-9044-270fcfd60e11">425.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtMy0xLTEtMA_ac1ec527-434f-416f-b8e0-f98922985b2d">486.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtNS0xLTEtMA_630635c9-37df-495e-a706-edf198950735">458.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtNy0xLTEtMA_7b7429f5-f179-4373-8bd7-289835c0c271">43.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtOS0xLTEtMA_6cf185b8-6bdf-4c66-86fc-ad7ce70287e7">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtMTEtMS0xLTA_b8fd7f76-2753-414c-9040-3e467044792e">57.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtMS0xLTEtMA_0da07c9a-6dbf-45c6-98dd-d953d750029b">901.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtMy0xLTEtMA_e51db595-b3e6-40cc-b303-44472973d3b8">839.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtNS0xLTEtMA_c23e7e30-e48c-440a-93d5-7e786492cea8">842.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtNy0xLTEtMA_91c0ae50-b1c9-4615-8354-6359b3ebf3b5">158.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtOS0xLTEtMA_14e4489c-0528-4a50-a696-fd43a4baae89">144.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtMTEtMS0xLTA_134b6b14-7012-4fe4-8c3d-9b63283f4f03">177.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtMS0xLTEtMA_42b884df-eb39-45a9-9fb9-f06cfb0c3b12">4.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtMy0xLTEtMA_d79d3bac-1605-41a9-9a07-3894fe47bd83">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtNS0xLTEtMA_d841d8f4-9e06-4a1d-91bc-2a0c989907fc">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtNy0xLTEtMA_c6e6a2b2-586a-4131-89c2-dbe6fcc2b647">59.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtOS0xLTEtMA_33a8a948-cb69-4418-802b-a5a2566da103">62.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtMTEtMS0xLTA_2af0e01e-451f-4385-852e-00fa57d69677">79.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss (gain)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctMS0xLTEtMA_df986b47-fce0-4fd9-a515-9493edce843e">396.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctMy0xLTEtMA_0286f4c0-f5ee-4d8f-84b4-6c45693ab13b">284.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctNS0xLTEtMA_dece6ef5-75b7-4d7b-927a-6e3cc2daf4cd">332.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctNy0xLTEtMA_35d6b7fc-2c98-4505-91a0-bc1021847622">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctOS0xLTEtMA_f5de0868-fa6b-4387-80ab-ee0c86a17305">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctMTEtMS0xLTA_7701421a-8330-4394-98f6-a8fb452d4c50">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtMS0xLTEtMA_f237bb54-2ac9-42dc-bb62-09391df34a8e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtMy0xLTEtMA_c37fdd66-5f05-407e-a788-b93cd06d8344">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtNS0xLTEtMA_83047f61-e69d-4f7f-ada5-b1b8c3fa9f05">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtNy0xLTEtMA_1c77832d-1e51-48fe-88af-845ed34bb200">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtOS0xLTEtMA_fc74bb6d-a4ce-49da-b52a-c82664e78267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtMTEtMS0xLTA_6abb02f4-2be3-4ed7-aed1-688e314c5be4">29.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTEtMS0xLTA_db12f3ac-3a19-4503-8cc5-4afeb6835365">250.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTMtMS0xLTA_d4962a9b-e72f-4948-af53-cc95fdbc0589">190.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTUtMS0xLTA_d13604b5-ae5b-4d1f-abc5-96b82c8c9e9d">247.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTctMS0xLTA_4258bd22-f799-4a9b-a201-abf28f82be12">136.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTktMS0xLTA_f4299a8a-8631-4e03-9287-dd7f9b548827">111.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTExLTEtMS0w_15342f44-5d0b-4512-bea5-6ebfbaa081f6">181.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzI3_767e4b33-87b4-480f-a33a-98a4ed1dbe4c" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019, and 2018:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItMS0xLTEtMA_864c9679-f975-4fd4-8558-41007c55dabf">663.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItMy0xLTEtMA_2fd18acd-dfa1-4a2d-857e-1886cfdb0c48">1,461.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItNS0xLTEtMA_637750a6-6cc3-4875-bfcd-86ef2a73b132">182.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItNy0xLTEtMA_73d4bd55-5fb2-4580-88b5-ab5d78e3ea9b">238.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItOS0xLTEtMA_16e8304e-67b3-4153-8240-caeed5209ef2">246.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItMTEtMS0xLTA_65647110-f3f0-40b2-a10a-b870b93c82cd">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtMS0xLTEtMA_bcfe660b-ed59-474f-b081-b96c6c09cfa3">2.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtMy0xLTEtMA_db7d7466-dc90-49e1-b82a-fd1d84bb8c5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtNS0xLTEtMA_f42adb1d-3fc9-4462-8def-a2104d69cd05">17.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtNy0xLTEtMA_eb00e72e-aece-416d-8dbe-96c7c6fba800">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtOS0xLTEtMA_589b689d-3873-4fa2-8d1a-3bca68dc0356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtMTEtMS0xLTA_5324ecc5-e67d-4f5b-8c15-a551c9a5e879">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtMS0xLTEtMA_2330e828-e69c-4b08-acd3-12c843966d47">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtMy0xLTEtMA_e3866293-6915-4319-90f7-492e1e88edde">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtNS0xLTEtMA_01c4ce2d-2ee4-4753-879c-1b60d9a59577">45.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtNy0xLTEtMA_5cc67c9b-cd66-4919-b208-b9c5f312089a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtOS0xLTEtMA_d76dcb20-72d9-4dd2-a63d-ae83b5388fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtMTEtMS0xLTA_3c84b4e5-6933-4f87-ba55-ef360e65454e">31.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtMS0xLTEtMA_aef36751-9ad5-4749-9116-02ce9e3e85d5">4.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtMy0xLTEtMA_ff2bf147-900a-4188-bd9f-ec3665ce191e">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtNS0xLTEtMA_f7a0fe7f-34e4-44c0-87f6-82bd43a05bff">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtNy0xLTEtMA_e176b2f6-3d6d-4e11-85de-c24fc6cc04ae">59.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtOS0xLTEtMA_a6a653e6-ee49-4c79-a427-690a0ed37f64">62.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtMTEtMS0xLTA_3197ed15-a32d-40bf-8af3-ef80a35008b7">79.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtMS0xLTEtMA_089b233f-8b0b-4005-9a14-7df597a7db69">396.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtMy0xLTEtMA_0900035e-a64f-4c07-8c8f-348660adbb2b">284.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtNS0xLTEtMA_c8f977ec-fd50-47a8-b7ac-b87a3be1b7e1">332.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtNy0xLTEtMA_5c5f8077-6b82-408c-9483-fe81730834a9">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtOS0xLTEtMA_e13b98c8-10ca-4f87-83e0-c11ae4fe7a3a">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtMTEtMS0xLTA_e1d171f6-9f84-49c1-b0ad-b653af4792cc">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctMS0xLTEtMA_d89edfa6-e96d-4d10-9735-8212f7fc9e48">71.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctMy0xLTEtMA_4747c10a-c2ad-40eb-b78d-69f8c2d198aa">7.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctNS0xLTEtMA_91621666-3c1c-43e6-95c3-2ad191af50d6">47.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctNy0xLTEtMA_c16f58fa-6409-444f-a315-9fb30264ffb9">2.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctOS0xLTEtMA_b44323b7-b6fb-47f0-9546-02adddfc85a1">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctMTEtMS0xLTA_d57821fc-6def-409a-91b9-bdeb17389aad">0.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtMS0xLTEtMA_28613181-4c90-4994-9590-cf7de3eaabb2">335.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtMy0xLTEtMA_94221461-d2ab-4f29-963a-be7bd6707dc8">1,158.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtNS0xLTEtMA_5f1f1a50-3626-45c3-bc01-99dbf31ac3bc">594.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtNy0xLTEtMA_3c7c81fb-c888-4021-9a1e-a86915fe2c78">178.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtOS0xLTEtMA_fa0a9620-0199-46ab-8b92-5f720ebcd9d0">188.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtMTEtMS0xLTA_5a370220-cdc4-4bd5-9460-2697f63d2d80">53.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzM4NTM_beb1ffa9-8d77-4cbe-8ebf-51905e82d366">164.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzM4NTc_21260903-feac-4ecf-a0d9-bf7043154abf">145.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzM4NjU_4ac56f3b-ccd5-4779-af1a-0edf833d938d">132.6</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019, and 2018, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2020, 2019, and 2018 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit Plan Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately <ix:nonFraction unitRef="number" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzQ0MDQ_340784d4-a785-4a61-a904-3c0b93deff24">80</ix:nonFraction> percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="id1d6a4fd83d44e768152ebcbe8064445" continuedAt="iefb02f04827b455f86a71dd5bb4e9a73"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately <ix:nonFraction unitRef="number" contextRef="i0be18783045647b39417db291e131c68_I20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzYwOTk_661667d1-a880-4cd6-815a-962d854d8a26">65</ix:nonFraction> percent growth investments and <ix:nonFraction unitRef="number" contextRef="i134f03f4da5745c881d151356389c114_I20201231" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzYxMjU_eebe54ad-b3d9-4bdf-923c-89b0a264cdb1">35</ix:nonFraction> percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets include cash and cash equivalents and mark-to-market value of derivatives.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iefb02f04827b455f86a71dd5bb4e9a73" continuedAt="i4f297c992a5e42eb9e951c1eaddff6da"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjUw_e485cc38-fd31-495f-8228-3465f4d63708" continuedAt="i50a0aaed6cd543e2a105a2686f016407" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:30.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i125f0871aaaa45a8a006a3aa90bec2b7_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtMS0xLTEtMA_8b579fc8-3ee5-4d86-aabe-a399c6e276f9">737.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fbb551c5b8a4f8e89d479bf7ee2465d_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtMy0xLTEtMA_2b0b90e7-742b-4026-9ded-da2b6b360639">476.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b85c4afc43f4f51a83ef0ea6a014ca7_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtNS0xLTEtMA_975a083a-c49f-44aa-b28d-f8c0b07a6bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6c571cd27e4e94bc5717d1000ca256_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtNy0xLTEtMA_408aefe1-7e2e-49cb-b5da-bc942b202fb2">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12e2651b0ae044eb8ad0fd855f1413bb_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtOS0xLTEtMA_ba631066-3433-46cd-b31c-6684b3ae2e44">260.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb25b81194d4853b020cf54c8f8f7ac_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtMS0xLTEtMA_d51067c3-40b9-4f61-9087-fd8f5c9be231">2,635.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4815fcd3e33549bca6c2313f6a96f168_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtMy0xLTEtMA_7bef72fe-8e88-4ba5-815f-d80d3b4eba2c">1,102.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e92ae2ebc9d40ac889ffb3518784b30_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtNS0xLTEtMA_868f6fa2-749a-4a94-9e6f-6cfe3f1ec8b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03078573edd84526a0fb7f4dfd971e8c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtNy0xLTEtMA_4922665d-7b54-49ac-a0a7-44e37610af76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3287458586b346ae8b32053866574079_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtOS0xLTEtMA_b34b2d2d-6aca-4543-9153-30989ba107a4">1,533.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2bff6b24d574258816b0a18efea4481_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctMS0xLTEtMA_b8481692-b126-453f-b053-50c2dbb84437">4,301.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7c8721f31747da9656f229d82e19ee_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctMy0xLTEtMA_41d9f3e0-f998-4d3a-b831-f4a63b66935a">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icccd9f0f2bc240d68bf932d1486745c3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctNS0xLTEtMA_96f6d7b7-6fa6-4a8d-83b6-bcc9a8d9e71b">3,179.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fc4192c93948e58c908295ada7c788_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctNy0xLTEtMA_91a5c643-ded0-4ee5-a58c-b931a699bdc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7df1b1312447bdb91336635231a328_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctOS0xLTEtMA_19cc55fa-a577-4dad-8f70-58972a5e4716">1,119.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44ddf32d59d541b2a516001cd682c531_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtMS0xLTEtMA_d91964c9-2c02-465e-9787-7ff47713cac7">1,670.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54348410ce84f2fb7e320ea814b26a6_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtMy0xLTEtMA_718cfa40-b0ae-4c4f-9907-e83b616d4ae0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40b8bd104f4d4282bb55fcd040b18ad7_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtNS0xLTEtMA_f1d0ec3e-0dcb-454f-bb74-898eeb632d86">1,670.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21defbad19c4c63a7ca3efa0bbb49a8_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtNy0xLTEtMA_93d73ffe-1495-4d76-9786-42390e630a35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcfa724c16044a9a047270245e9f5d2_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtOS0xLTEtMA_f3a1ed8f-2320-4f05-9d34-a425a890985d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122ffbfb116d49aaa94e76c271df840c_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktMS0xLTEtMA_5b90a908-4325-47e8-9428-ccba808c2c6c">631.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11541505d134091a7960e590f9c55a5_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktMy0xLTEtMA_877d0a90-c2db-44fa-84d1-4eeb2008a0af">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894a88d4a4a34371980d69bf29256285_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktNS0xLTEtMA_226ea21c-0e2a-48b4-ac2f-be6acd8c8e27">262.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3721c158dd7b4d129f7d61430f4502a1_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktNy0xLTEtMA_5d058c9a-8259-4044-9c4c-711c7e7a36fd">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if741b3f8c66d4f398ea1e526a37195c9_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktOS0xLTEtMA_ae8855b9-72cd-484d-ae99-8e0028869d92">354.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98890f41b7346c2906b80139874cde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTEtMS0xLTA_66a59b56-9b06-411a-8058-473e13591d31">2,661.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b819438ccf430b853a4465244e6fdd_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTMtMS0xLTA_3d94ad79-a343-4a05-b017-a38d5b31273d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b85d3256ef6437c86432f6208104ca9_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTUtMS0xLTA_2ab415a3-c99c-4404-b142-af0821ccb2d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f6978eac114b1a9a4b9b3e6d1c2d54_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTctMS0xLTA_933abdb5-2ef9-499f-83eb-75bab83a7463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a4fbe91fca4349a3619d62f21b5192_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTktMS0xLTA_7bdc89ca-4e12-4dc6-baf5-73bf39f83234">2,661.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c325faa849646d8877f6217a8e9e5fc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTEtMS0xLTA_b6681a4b-0b8c-493f-8f55-f8fc1c0952c2">2,844.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a1be41667140c28d82974e25d6f978_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTMtMS0xLTA_867e9bb6-6b49-4d80-9826-7e26578e173e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb1a00b260143129cd18a27fae9066d_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTUtMS0xLTA_b993e0b4-08a6-495c-a184-a7c8934d0aad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab85a851be0049e384a77f9bed8c7112_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTctMS0xLTA_a9e08397-f88d-4a40-9f18-3a35c6633fea">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90ebb158dc6c4c529380297ca491bc83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTktMS0xLTA_47ebffa6-4641-4515-bcb4-9770f5082eb1">2,827.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787b7132e99c493ca562e8bc24ca4fe8_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTEtMS0xLTA_d134f7e4-9825-41fd-b53c-0dd4b65968bb">558.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic467e27a1bec45deaeede4746d725b3b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTMtMS0xLTA_9aaa2dfc-b675-4e4d-a47a-0265fae335bc">259.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacdcb2d995cf4fff8171cbe33cc965cc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTUtMS0xLTA_c869ff71-17b5-4d14-8a1c-21fd2fad627a">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia422ad3b45604fe2b5412d14ccab5f5d_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTctMS0xLTA_fd5b01ab-3b1f-4350-a440-f5645ed74951">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided7419ed04c4ee390c6ecdfeea4be0a_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTktMS0xLTA_f7748f98-5bf0-44f7-ab0c-d13314896abd">286.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5dde6acc2364d7895ab68140b8a940e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTEtMS0xLTA_302e2fb8-2423-4fb4-bae0-31add2bf78d6">1,879.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7762e89bc4b6c8400f5c82637267f_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTMtMS0xLTA_cd3bcd18-94d9-4dfc-a4f2-edba3ad747de">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa71c7d9d0a44cfea6f52f788e4f63d1_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTUtMS0xLTA_fbea8d21-6ba0-4fb8-9353-59d5e23d6174">301.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa4144a81a64effba21e1069fac6bde_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTctMS0xLTA_0877fa87-7224-421d-a1e8-d01ce4defef4">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd95c05c6f044669e6cdc5f23c27a03_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTktMS0xLTA_224e6dba-eac1-437d-bc67-8bb5bc81e758">1,499.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTEtMS0xLTA_b2361c1e-eaad-4527-9b9c-b1b6a5769b55">14,579.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa4949f8ddfa462d8b08ae8a55ca4e3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTMtMS0xLTA_3f711937-8615-413a-b603-464848565e35">1,915.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522080a183f64b32b7dbc33f0a805a7f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTUtMS0xLTA_89db55d7-30e8-4308-b276-3d912161b8a7">2,079.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f8a5ddfd884b47966968ab578e45b0_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTctMS0xLTA_75eb0608-250d-433f-8f1d-eba89547edae">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if438221acf6341a39b8a9a65a4e65e8c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTktMS0xLTA_f25bb04b-8b6b-4ccc-af71-20d9e85ad2df">10,542.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if47ad8d27d2d46cea9c0a971df416313_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTEtMS0xLTA_332a145f-28fc-42b7-aba0-1dc9c7289e1d">68.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20afb20108144023830d742a2375621b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTMtMS0xLTA_a0e7999d-1aa7-4e82-a21c-c6109705071f">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a506494bf44549a25ef7d8a77149fa_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTUtMS0xLTA_ed162250-1fcf-485b-ba20-f252db2a54e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367a0762cac945bfa3136660561bb3ca_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTctMS0xLTA_8317d11a-a48a-4498-a8de-2c8d75942d2f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119de4bad3f6477f971e2f4b9d1269d2_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTktMS0xLTA_7e3b68dc-5cff-403b-99b1-26c0638cf6b3">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18771cf6e66e4cb7be08134942326069_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTEtMS0xLTA_c1662dab-5f21-4aea-adc7-c2e4ef1bf767">162.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7d6c9f167c4c5683298223b4ef8af1_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTMtMS0xLTA_cecd6747-a177-43df-b329-af7cc07461f4">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1dd6bf74c204da0a0cd97309e7b08e4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTUtMS0xLTA_ce96b644-4196-4538-abc8-eb17255315c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313357f190a941efb7646635222fa28c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTctMS0xLTA_cbd10663-6b30-4366-b590-6be1423a8210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434273c7f8d842699b6b037c72ff2cc8_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTktMS0xLTA_a66915a2-dc5e-4e3f-b45a-cfc6e01d55db">104.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d982e51da34404b680672535a771da_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTEtMS0xLTA_a1698298-7105-4dd6-a65d-b5d172d095bc">101.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c1b63878e543bab94f0bc61bd810c8_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTMtMS0xLTA_829ac603-7387-49a2-84c9-579a1d89c902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8fa233f8fa45ad8d9997db7e5e3cac_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTUtMS0xLTA_4e433328-0c32-4d02-828a-bf049dfdc23a">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id10a4106c36d48c080be874880a0c5f0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTctMS0xLTA_e0fc1845-cd71-4518-b82e-dee639cdf8cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95a10a1f5f14bf0974550095d634caa_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTktMS0xLTA_deb12f7b-ca1e-4e9c-ba0e-eea5d22c58bf">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f8ae3d75184ec2b1e3758df93f149b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTEtMS0xLTA_af8acfa6-e2d4-47f5-a8af-d29b772d9e59">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1fcfa7a99c4781a6ff659d054315b6_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTMtMS0xLTA_6b8c371a-3908-445e-ba37-d68e9e9b918b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd5aba2572834b96bf2e805a8e72d50d_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTUtMS0xLTA_892760ad-99e7-4908-b2cf-023d053563ef">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b41b01976fe4459b0b2e05e4a78ecec_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTctMS0xLTA_af423a13-157e-4230-b00d-fc7c3bf04cd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3ce3f963884db0be993dd43a273d48_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTktMS0xLTA_1e52891b-ffe8-4825-92f9-d9913999234f">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17084e6a4674e82adf22fef4ff88b90_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTEtMS0xLTA_d34fad04-8e08-4f34-a8b8-63db08d3c27b">229.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice675a2c24d8440490e242dd88655d53_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTMtMS0xLTA_19992d1c-5b4d-471f-ad60-75d3571910c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0340e5bcf8b2492f877571f5e4badb72_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTUtMS0xLTA_f499dad1-6954-43b5-b486-0142c75188c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie290f1153a8746b4b6cd78f8378492fb_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTctMS0xLTA_e5c4bb12-5311-4e9e-bffa-72ec6f1c1ee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61e568a671e4a80821d53844eb24240_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTktMS0xLTA_d7f4fe8c-93d1-45f6-b9a4-4eaaa262d298">229.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd146d4e0d24f1eba383583c4714d33_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTEtMS0xLTA_452053d9-bcb4-4e30-8bf0-a009f6d61156">223.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad95d8440b74627bd1f07f9cbaaf547_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTMtMS0xLTA_e93dab7e-7334-4226-89f7-d72f2f3bca6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb310846a874a2896fe227840a6a94d_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTUtMS0xLTA_1ce9e65c-2e0b-4574-a139-7bce59d9efe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0844638a1d4c2094a1f495d509e3a0_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTctMS0xLTA_5ee74c8e-fcc3-45ce-91e8-bb8c90791782">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a23c7481934f7c9cbc0f8e5d7819cc_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTktMS0xLTA_e0a60df1-5416-4044-abf1-0afec8006b79">221.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e024a2361694af8af62b9b106fb4091_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTEtMS0xLTA_a4c0a45d-e6c8-4870-8454-9ebc99d36ca2">2,204.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893d604481e5414a876d424c5bb3853b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTMtMS0xLTA_f055bfe8-34a2-4415-83cc-40359b29d682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514ee23678874da6a78affbcc11e2d13_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTUtMS0xLTA_f5b258e9-5987-4533-ad67-a9d61a64b3bb">2,204.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782e6897c57141f3a206f658e2c32404_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTctMS0xLTA_4c4d3cb8-df55-40a2-b9d0-ae9655525484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3def2cfb16eb45eb825321e9107e8557_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTktMS0xLTA_25ed6360-6394-4136-9e47-2494678f442b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24f5a064fb248b9a1c67cd62d6ed476_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTEtMS0xLTA_7cb416f8-9440-453e-af1f-9ce91aeeb0c9">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c28a1b50d047e48ca4cc3357ad9d44_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTMtMS0xLTA_4dbbdc57-22d2-46cf-badd-322a5737f5f8">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933d218234f842788e1c269114faae5b_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTUtMS0xLTA_f0e257d5-a5c2-47ad-a42b-318888895d8b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ceb71c1fa14063ba529ff4695b2287_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTctMS0xLTA_d8a95768-d5b6-4c61-be81-aa0feed4f8fd">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685a0d4729324a28b26de39802342a21_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTktMS0xLTA_d9b00e2d-6217-4089-8472-e066a8aeb2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic736258b57814a4182d5d6987fb420c2_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTEtMS0xLTA_a601ac4b-3d40-47db-9705-9c881195df8f">157.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045d7c5fdf0e49c18f983e9217f0b15e_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTMtMS0xLTA_cfbdb7e7-a47a-4397-957f-fd1a45f1f2bf">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4c6c31184e47f3b704a0eae7e42331_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTUtMS0xLTA_0032745b-e933-4da5-8865-6896f0dfc0e5">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib384b4a9c4e24e259a0e4f91d0193602_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTctMS0xLTA_6e33fcb7-423c-4c0e-97ff-f7ceb45353c3">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28a156345f7417e99d42b66e3b9aceb_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTktMS0xLTA_bf1b414a-8823-4c29-8df5-43a8d7ab49f3">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTEtMS0xLTA_477c0b2f-8c52-4ad2-ade9-ea41eb0750ec">3,227.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058f847612d74099976ba37d7f71f906_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTMtMS0xLTA_2d8ac096-22f1-4796-8388-7b8a4d335d44">141.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia708e12046a5423f8cffea676c33483e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTUtMS0xLTA_017b2641-40e8-4913-b9f6-9e791d0e7de3">2,331.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife201fa234a44463aaae78e3178b7591_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTctMS0xLTA_dac33793-8dab-4381-9952-b6e41ed3f6d2">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1612094a408f4d40b21352521bf6c97e_I20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTktMS0xLTA_b1d86ae2-57f8-4ca1-8c8b-ae5c7e0220af">749.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2020. The activity in the Level 3 investments during the year ended December&#160;31, 2020 was not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i4f297c992a5e42eb9e951c1eaddff6da" continuedAt="i4657b0951dd24f588c37f26cd12acf71"><ix:continuation id="i50a0aaed6cd543e2a105a2686f016407"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2019 by asset category were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:30.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedde0139af294cff8fdcea9f72f645be_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtMS0xLTEtMA_7fd3297f-f544-43a4-b854-5b7207241950">794.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea7b43b8b5c450c817a947965d81b01_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtMy0xLTEtMA_6f2bab8a-6c3e-4dd1-b986-2e915a8eaeca">532.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c72734140b24d3f8f463831c8c59882_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtNS0xLTEtMA_d96803c2-9bf9-4eef-ba0b-09effa2f4366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i474e96cc45a343bd880e15f5e3e7dcb2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtNy0xLTEtMA_bfc9ccbc-802b-4a84-bc8e-309f47a07618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331eecd2fcab475bb2c445750bf65683_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtOS0xLTEtMA_53b7405a-687e-4ef1-9f0f-1a2a4356e589">261.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd771e0257d642dcadc5d74119bdfefa_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtMS0xLTEtMA_9fe58fc4-eb35-46c3-869c-8665174e389a">2,439.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f3e1cb00c44d82927f246e6c5166c5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtMy0xLTEtMA_59749e81-3b0f-4a5a-9b4a-ec823f949a73">1,046.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e5945ce8ccc4948bac9a0451e12d1e8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtNS0xLTEtMA_15764aad-e638-447e-8f89-690bfc88a1b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3273ded1db9c4c9596e118619286ba07_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtNy0xLTEtMA_078561c9-8a58-4a7b-a61a-9dde7df98970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b1995d069c040efab6457b44f15e8b4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtOS0xLTEtMA_6ee34ec6-24ab-4944-97f7-99336d335c83">1,392.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba0bb9a358a4901bea4e4cd5c7f55f6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctMS0xLTEtMA_aa8ceff9-0fdb-4168-80aa-615fb96101a8">3,661.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6960c498f4476188e66f546a6935bc_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctMy0xLTEtMA_e574977e-d64a-400f-afbe-075d15828ae9">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd365bf0efab46af86e6bbb643db823c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctNS0xLTEtMA_05b1b7c4-fe06-4f91-8b24-395bd6135fe8">2,658.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675961e5fc46462c956548b162c65ca8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctNy0xLTEtMA_434bedf2-17be-44d7-abaf-b7f4873e1f2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbec282c576404eb0ec8d2d0fdf9653_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctOS0xLTEtMA_0fc856ba-1c14-4fc8-8723-a73fe98db0b1">997.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f323b9fa21c499dbdf0daf714c57f36_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtMS0xLTEtMA_8840b71d-dff5-4b50-bd6f-c174ad7ac7e0">1,659.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf32c3dcfc14cdaa8060800039f3e79_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtMy0xLTEtMA_3f9d1f61-21ec-4955-bd9e-b729f6232dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf52a977346b49d798c932533814bf59_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtNS0xLTEtMA_2f3afc30-fe7a-4737-83dc-a0871baa74fd">1,659.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c3e31523404f2ebfc936c17c16b324_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtNy0xLTEtMA_099a6526-cf9d-4104-bc6b-fd2d39bf5808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4629fb029e734ace817a97c424776664_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtOS0xLTEtMA_2e856961-8297-44ae-9340-aff70ad40ef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c387153e294bcb9eaecfe60743c646_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktMS0xLTEtMA_0f869184-0d9f-4dac-83b7-8c60562e36ef">648.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77389ce093254e6ab4f11f9dd0728471_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktMy0xLTEtMA_ee8a9cf7-5bcf-4789-8d8f-91f2d0ecbd3f">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3313ee63caf64afab4f2c93fbc54124d_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktNS0xLTEtMA_e5190ddb-c83c-4de9-bda7-20381ba772fb">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e9fd581d4d433aae76ee66caa8183b_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktNy0xLTEtMA_6f42135f-033e-422b-9cc9-2cb2a44d2aa5">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3fcf315c0347f0b121686f96a2c53f_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktOS0xLTEtMA_e61a3992-ce38-48bb-8502-38d660a4fcfe">348.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8686f5c76e4a7c83ddc6959064840b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTEtMS0xLTA_867e9f7b-7620-4704-ae47-8bb567851cc1">2,897.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19da2e5ec2ab4bb580c7155fdc8fdfa3_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTMtMS0xLTA_63b3bdc4-825f-4ed5-8495-306cc9a9094b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i006db6e632504a099cb649312ea0cba3_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTUtMS0xLTA_dea9b1e0-8825-450a-9224-e89f1cfc7a93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e46cbf2c242d8899925fc7a112670_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTctMS0xLTA_63d50b63-33b0-4aa1-ac54-ec1364b49653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847b2decf9404ab2a7d6680fdccdf305_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTktMS0xLTA_ae4a2510-e2e6-42aa-bae8-b2a09d9748d8">2,897.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfde700f02a48f7a31316d1f567cd5b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTEtMS0xLTA_99c90773-e84e-4cae-aeb3-6eee928c1751">2,279.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id435bbff99ed49dfa19a3cb32dd76386_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTMtMS0xLTA_43368d0d-48af-4e28-8444-28ff517ae213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f75c558ed1e49339a2e52215ae52fc0_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTUtMS0xLTA_44d1a532-a370-41a6-9367-6f989d74ca1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701917bbad004fc8b8d81a751eea303d_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTctMS0xLTA_aec2709b-89ca-49e2-8111-4172a9783fd7">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65b328d8d2c49c1be2ef55b3625103c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTktMS0xLTA_6fe89335-a1d2-400d-bcd2-a0924d5aa228">2,262.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1221e8e34e4275b4db34697e4ca8b2_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTEtMS0xLTA_2c234a80-fb67-4165-88b5-c77f2b2590c1">570.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564ffd90f9084692ab88b0cf933a98f4_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTMtMS0xLTA_32e262a8-ef35-45d8-8fee-1cff82ae6d98">166.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f13162a2f8d4549a141594e5f80d879_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTUtMS0xLTA_f8589e44-51af-495f-b02b-a3b0bdf035e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ef9b73660f4b9fadce03cc33bd22f6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTctMS0xLTA_331aae46-f71c-44e6-99fe-a23a88b48d30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a8eb2e429e4d4b9559c6a8a87ef504_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTktMS0xLTA_2adc88cd-df26-427c-8834-2a1d28ce7bdf">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36e443e3d434b15af03feda51e6777d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTEtMS0xLTA_fbf0c576-738b-49e0-ad81-6d78397a79bc">1,226.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50fb13104c73464cb06b6701e9af3093_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTMtMS0xLTA_e5ad4b35-2aaf-46b7-b58e-43d94dae9ced">62.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60bea6be43f4ed4804c1fc6a9298e09_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTUtMS0xLTA_3e053e36-f108-428f-9d4b-8338c8de2027">222.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8724bdcd3854eaf92373c5d1a807169_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTctMS0xLTA_7c39b707-e38b-484d-9dfb-bbcafa2c2e53">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42c51f1ef8b4c618cd8e6b21c234c55_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTktMS0xLTA_9973b644-0e9d-4636-854f-ddef5e9f30f3">934.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fab925dba44dc0ae21de713975768c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTEtMS0xLTA_0204ec5e-7fc6-483e-bf24-565f32536ad7">12,858.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifada303dfc0a48749b857d690254e679_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTMtMS0xLTA_f0864eb9-a9f6-4571-8b33-dd0799b70f9e">1,831.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ba9215cf52449385b12a520287a98a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTUtMS0xLTA_b77a1580-2843-4e98-aaff-d79cdbc42056">1,499.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a44a9521bad4096b6d02caf364c65b5_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTctMS0xLTA_e05515fb-77c4-4f89-9bc1-9cb1582ef2e0">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19985d737da40e0bd8d5ac7bcda0e3d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTktMS0xLTA_09e07d17-a07d-403b-927b-9208b86a5119">9,499.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b8e68d1946469abfb59f6c6fda184a_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTEtMS0xLTA_85e7cc29-de32-4b4f-90ce-00299f5373a6">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a83760ddde47c48011002561464667_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTMtMS0xLTA_a818c136-3349-4493-ad18-a848bbb9b4b7">52.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1c2c6447034265b3f50c7be9a87b41_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTUtMS0xLTA_aa015ba9-bc1f-48ab-98c2-f1e75756817c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabb35ff3f03404f8c6130a1eeb49f61_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTctMS0xLTA_a40777b4-473b-4fea-bdf8-c061707844fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e2cdb6c127441b909e910815d3dbbb_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTktMS0xLTA_27d1a483-7451-43c7-ae9f-1307fff7badf">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f03d4b0fdcb41bd9bebfa7ede027236_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTEtMS0xLTA_bc5886d3-a289-4fc6-8e03-59df51f39ae0">152.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i895e2b3cafef45acb1012b1e03d39ffc_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTMtMS0xLTA_3f0ce0c0-818c-473f-bf74-52ca136e7488">60.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1066e9b68a6348ab93c9493b56791fe8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTUtMS0xLTA_e1fc2934-f85f-4288-ba83-5c1aa2e240bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1595e10ff0084e819adb888f4c577f76_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTctMS0xLTA_468e3da2-bdf0-42f2-b883-eba067a0d6d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f8156acc564caab08a1624e564a10c_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTktMS0xLTA_b5949546-1399-4392-8975-3cc54108ee18">91.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81d715fd04f41c4b0fb15cbc97ded7b_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTEtMS0xLTA_95138b2f-f465-45e2-a470-02271be2aec3">82.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bcd75701e244eda1dc59a0f6acf303_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTMtMS0xLTA_b0a271c4-6b8a-437d-988f-250bcb205bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i945c96b3eea1403fa18115aaefba9877_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTUtMS0xLTA_2dfad43b-0e4c-4d00-97b9-39fa86fadf14">56.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a5d8801736420b82120164f7c0089a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTctMS0xLTA_7bf3a0fe-0ebe-4bb7-be30-718ed8a1bd39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9181cc52ee8e454c89c0e1c42c853e15_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTktMS0xLTA_27ebd551-5a6b-42de-a927-3511e45c4928">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38af461ee606432d82a7474978332d8c_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTEtMS0xLTA_7bcf3fc7-d152-468b-b3ae-1bf2c6d21375">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373b829238f74628b948e23e7d5c164c_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTMtMS0xLTA_6ce344ba-b6cf-4a75-80d8-dd14c326a9aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e4134c43ad43bab33caec94bc82d47_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTUtMS0xLTA_d1c9d3e7-306c-46cc-82cf-5190d59a10de">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2a002bc0ef442bb111f2a7206ee130_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTctMS0xLTA_6fa7314e-019d-4e0c-9d16-f8bd13916e9b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510f34cc51b4405db4a91992d32b1c34_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTktMS0xLTA_b15c045a-1c62-4d76-a97f-b347c1a06e10">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b766219ce347188ad03e3849166f80_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTEtMS0xLTA_dffb0c03-3aa2-4d74-858b-3867789b3b6f">250.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708ee2efc8f448d3b331e38fcbd4a915_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTMtMS0xLTA_d7961e21-dd72-4ba4-8e21-7898fd4816ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc36c3791284cabb24ca762698700d3_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTUtMS0xLTA_71cea13c-bdbc-4682-ad77-0fef7fc4bba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dc7058692f46668106cf1d6a1e73c8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTctMS0xLTA_a493a973-f2a6-4c13-a7b0-444923cddd63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea800c25a6674e09a0af56692d7b5dd1_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTktMS0xLTA_2faa0684-ba97-41d1-80ed-3710b937ac5f">250.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe300c1a64c647b69fe7bf20e0541942_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTEtMS0xLTA_3bb0fcea-a66b-4347-be98-654add83332e">187.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6294050b0144ebb52f2b5cb557783a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTMtMS0xLTA_bfca8050-2595-4ae0-ae0b-4a3ffbd08da1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a0b8e765cb46099127a2188cb007e6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTUtMS0xLTA_debfc842-eb39-49de-ac38-d9eef4388c72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6428acbb884c4334bce83f1ace7ab19d_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTctMS0xLTA_4e1f16e5-4915-433b-ad0d-8187f6dc850c">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id719e5a1d3de4031989293711aa38d3c_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTktMS0xLTA_cf22c072-f274-4af4-ac46-5ccc365bf37f">185.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a2aaec08b63468499905c6159f8e3da_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTEtMS0xLTA_e5db59ca-e6e3-4f13-9af0-4a6ce06f78f5">1,832.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dad62f6fb1485a99fd7d1430fc110d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTMtMS0xLTA_78847bf6-a0a6-4b52-9286-4f363a744da8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaff3c08ba9d4d03bd33fcb7a5bbd1fb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTUtMS0xLTA_50949a00-9b1d-40ea-b270-53d96fa915ed">1,832.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534b8b956faa4f71ab4ccda780e39214_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTctMS0xLTA_d7c33ddc-a217-4e10-8803-1d7cb79a4b01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib078dfc1c37e44c9a48bbe3f9a469f3c_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTktMS0xLTA_00476075-f4a9-45d0-b5f8-6eebb7e0508b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0406531f0094a13b3244c8fcabda0cb_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTEtMS0xLTA_95b755eb-8769-4c5a-9af4-bee40997b063">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9def9531e94f7ea8588aedd9f265d8_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTMtMS0xLTA_922d4917-47fa-4d69-b6bf-811eb48b105f">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c938f472b04e1ea9b5d3856f56cf27_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTUtMS0xLTA_76da15d1-b8e3-4e42-bbe7-a5b716bad500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500e87bc01cc4b5f93691f5fb1d50fad_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTctMS0xLTA_25b57c10-36b2-480b-b7a7-6bf226076c6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3858c30cf5044e598ca275f01991c28_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTktMS0xLTA_bae71877-f4d7-4a68-b1b6-79d1f059a5ad">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996aa7b86fc24b07a4288e7ba5f7df03_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTEtMS0xLTA_4643024d-3f7d-4f5a-8b66-0d34f71872b7">96.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7482d3bafbc41eeac363718494d0f83_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTMtMS0xLTA_85afea80-48b8-459e-a783-4cf23efb0534">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362e3e575b774c4397566b4c1a34e5c4_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTUtMS0xLTA_5d51d8c4-c679-49c1-89cc-aaae104a5d19">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfef4993c67240b2a0bc234322e964af_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTctMS0xLTA_518f58c3-4698-4134-b4cd-931b9446ae03">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id022f4c867cb4232a897b833e40eb0df_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTktMS0xLTA_a56e0fd4-ac3b-4c16-a671-909de364183b">76.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTEtMS0xLTA_e6858de5-9491-42bf-bc1a-a3a57541e30f">2,768.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4833bcba5f4d461da0967d8871780d3b_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTMtMS0xLTA_a3ed6604-ce6f-47ce-94dd-1922c3796b5c">140.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie600f398f9404e8fbfd23a4c663f06ab_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTUtMS0xLTA_701c5d2d-0a53-4fc7-9a67-bc25a8852cfa">1,923.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b618356b1e4a8396dee41b547db32f_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTctMS0xLTA_0d58f454-c387-4b67-8b76-3d627570b686">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb89163b193490c80c31c918380523b_I20191231" decimals="-5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTktMS0xLTA_4ee03074-fee6-4cca-8939-694ae357e030">701.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2019. The activity in the Level 3 investments during the year ended December 31, 2019 was not material.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4657b0951dd24f588c37f26cd12acf71">In 2021, we expect to contribute approximately $<ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMDUx_334f7d4b-7a2d-47fa-89bb-d1d17be74df4">40</ix:nonFraction> million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We expect to contribute approximately $<ix:nonFraction unitRef="usd" contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231" decimals="-6" format="ixt:numdotdecimal" name="lly:DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1Xzk4OTU2MDQ2NjYwMzU_80a4970e-1695-4984-8555-2cb62b1516fe">10</ix:nonFraction> million in additional discretionary contributions in 2021</ix:continuation>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">102</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16: <ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzU3Mjk_81caf48c-f0f3-43e0-9d8d-f5df7d6ac841" continuedAt="i2820ae8f45314ff39ca91bc9b394d4dc" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i2820ae8f45314ff39ca91bc9b394d4dc" continuedAt="i6152b2730aa7413ca6e18e3612c3035d"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzE3NjAy_b7b78049-82f2-485b-833a-86a5f7be1d10" continuedAt="i37b4679259f048c48d21db5a5cced009" escape="true">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i37b4679259f048c48d21db5a5cced009">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alimta Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of manufacturers are seeking approvals in the U.S., a number of countries in Europe, and Japan to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers.&#160;However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail.&#160;An unfavorable outcome in the U.S. could have a material adverse impact on our future consolidated results of operations and cash flows.&#160;We expect that a loss of exclusivity for Alimta in any of the below jurisdictions would result in a rapid and severe decline in future revenue for the product in the relevant market.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">U.S. Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) is protected by a vitamin regimen patent until 2021, plus pediatric exclusivity through May 2022. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Apotex Inc. (Apotex) alleging infringement of Alimta's vitamin regimen patent for its application to market a pemetrexed product. In December 2019, the U.S. District Court for the Southern District of Indiana granted our motion for summary judgment of infringement, and in December 2020, the U.S. Court of Appeals for the Federal Circuit affirmed that ruling. Apotex did not request reconsideration or a rehearing of that ruling. However, Apotex could petition the U.S. Supreme Court to review the case. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i6152b2730aa7413ca6e18e3612c3035d" continuedAt="iaf79ede285ea41778ad01c6ebd3c89c0"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">European Patent Litigation</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings are ongoing regarding our Alimta patents in various national courts throughout Europe. We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that generic competitors may choose to launch at risk. Following a final decision in the Supreme Court of Germany in July 2020 overturning the lower court and upholding the validity of our Alimta patent, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several generics that were on the market at risk left. We have removed the remaining generics from the market by obtaining preliminary injunctions in our favor. In September 2020, the Paris Court of First Instance in France issued a final decision upholding the validity of our Alimta patent and found infringement by Fresenius Kabi France and Fresenius Kabi Groupe France&#8217;s (collectively, Kabi) pemetrexed product. The court issued an injunction against Kabi and provisionally awarded us damages. In January 2021, that same court issued a preliminary injunction against Zentiva France S.A.S. (Zentiva), the last remaining company with a generic pemetrexed product on the French market, and provisionally awarded us damages. In October 2020, the Court of Appeal of the Netherlands overturned a lower court decision and ruled that our Alimta patent is valid and infringed and reinstated an injunction against Kabi, thereby removing Kabi's pemetrexed product from the Netherlands market. Kabi has appealed this decision to the Netherlands Supreme Court. Kabi's generic pemetrexed product was the only at risk generic on the market in the Netherlands.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vitamin regimen patents have also been challenged in other smaller European jurisdictions. We will continue to seek to remove any generic pemetrexed products launched at risk in other European markets, seek damages with respect to such launches, and defend our patents against validity challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Japanese Administrative Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Japanese Patent Office (JPO) issued notices closing Hopira Inc.'s (Hospira) invalidation against our Japanese Alimta patents. As a result, Hospira filed a withdrawal notice with the JPO and the JPO accepted the withdrawal in November. This matter is now closed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emgality Patent Litigation</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in <ix:nonFraction unitRef="patent" contextRef="ia08920fe3f514f89bc0bd568c9df9ba5_I20201231" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQyNjg_002ea1ad-0786-4f79-85e9-76ef71e70b2e">nine</ix:nonFraction> different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in ad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ults. Trial is expected in December 2021. Separat</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely, the U.S. Patent and Trademark Office (USPTO) granted our request to initiate an&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(IPR) to reexamine the validity of the <ix:nonFraction unitRef="patent" contextRef="ia08920fe3f514f89bc0bd568c9df9ba5_I20201231" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ2NzE_002ea1ad-0786-4f79-85e9-76ef71e70b2e">nine</ix:nonFraction> Teva patents asserted against us in the litigation. In February 2020, the USPTO ruled in our favor and found that the claims asserted against us in <ix:nonFraction unitRef="patent" contextRef="i563701b19f014569b06746781df763bf_D20200201-20200229" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsClaimsDismissed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ4MjM_7260675d-dff0-4f07-9f49-064a96c54b70">six</ix:nonFraction> of Teva's <ix:nonFraction unitRef="patent" contextRef="id838bc258f094c568ea090ce38f5434e_I20200229" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ4Mzc_f4f9c49a-18a8-40ef-a27e-e86a0759c2a3">nine</ix:nonFraction> patents were invalid. In March 2020, the USPTO ruled against us on the remaining <ix:nonFraction unitRef="patent" contextRef="i0380a187e28a42edbd210299d61d308e_D20200301-20200331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsRuledUnpatentable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ5MjI_c53ad02c-3edd-4dd6-90a7-77add80aa81f">three</ix:nonFraction> Teva patents, finding that we failed to show that the remaining <ix:nonFraction unitRef="patent" contextRef="i0380a187e28a42edbd210299d61d308e_D20200301-20200331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsRuledUnpatentable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ5OTA_612db87a-f07c-4216-a558-fb641e23a3f8">three</ix:nonFraction> patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the USPTO&#8217;s March 2020 ruling, and Teva appealed the USPTO&#8217;s February 2020 ruling to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Court of Appeals for the Federal Circuit</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The district court litigation will proceed in parallel with the IPR appeals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jardiance Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from Alkem Laboratories Ltd.'s (Alkem) and Ascend Laboratories, LLC's (Ascend) submissions of Abbreviated New Drug Applications (ANDA) seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, Alkem's and Ascend's ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. Trial was scheduled for April 2021 but has been postponed.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iaf79ede285ea41778ad01c6ebd3c89c0" continuedAt="if1f97bec987b4be198dd3622aac2d1a3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we were </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">named as a defendant in litigation filed by Genentech, Inc. (Genentech) in Germany seeking a ruling that Genentech&#8217;s patent would be in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fringed by our continued sales of Taltz in Germany. After it sold its patent rights to Novartis Pharma AG (Novartis) in June 2020, Genentech withdrew its infringement litigation and Novartis subsequently filed litigation against us in Germany asserting infringement based on sales of Taltz. In January 2021, we entered into a settlement agreement with Novartis whereby all pending litigation in Germany related to the Taltz patent has been withdrawn and this matter has concluded. We were also named in litigation in the U.K. in which Genentech asserted similar claims regarding its corresponding U.K. patent. Novartis purchased Genentech's U.K. patent rights for Taltz, sought substitution for Genentech in the U.K. litigation and then sought dismissal of all appeals. Orders to this effect were issued by the Patents Court and Court of Appeal in November 2020 and these matters have concluded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zyprexa Canada Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000&#8217;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Canadian Federal Court of Appeals denied our appeal of a lower court's decision</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hat certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. Trial is expected in 2021 or 2022.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actos</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="iecb392cbb3fe4cb8a6314dcd6654394c_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxMzE_1d58944b-baa1-4cb0-bb25-71d4f7741be7">four</ix:nonFraction> purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including <ix:nonFraction unitRef="lawsuit" contextRef="icc7264a5345342d8aea87087c230aba3_I20111231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyNDM_df581c2a-e8a3-42eb-90dc-c3da9dc95895">one</ix:nonFraction> in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonFraction unitRef="lawsuit" contextRef="i9ae544e01daa4812a088e089d18c14e7_I20120731" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNDA_7a38bf3b-7631-413d-83aa-8b9514876690">one</ix:nonFraction> in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonFraction unitRef="lawsuit" contextRef="i4d2d51a9d7de4602a53112f3a2e3d04c_I20171130" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNDE_bc40bbc0-be1e-480c-8ad9-3cbe715715f2">one</ix:nonFraction> in Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and <ix:nonFraction unitRef="lawsuit" contextRef="i411602cb723743c380152402a7c692f2_I20130131" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNTY_880be136-bcf1-4b15-9c79-bb0217948f7d">one</ix:nonFraction> in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Byetta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in March 2009, we are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="ib4cce461525f410b826a4889ad0f3ea6_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNjU_29b82de7-be25-44ef-ad96-4488866607b3">570</ix:nonFraction> Byetta product liability lawsuits in the U.S. involving approximately <ix:nonFraction unitRef="plaintiff" contextRef="icea9f6147fa941e4a11404f04d76bc42_D20090301-20201231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNzA_33120b5d-2258-41a2-aaff-fe19f4817920">810</ix:nonFraction> plaintiffs. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i449428738c2940d49d82f1876796900e_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNzU_032dbde1-71c6-49a5-84fa-644cf6f44ad3">55</ix:nonFraction> of these lawsuits, covering about <ix:nonFraction unitRef="plaintiff" contextRef="i2f737098bb3145ceb2c97bdfcc33c357_D20090301-20201231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNzk_e3586447-5c84-4247-b07e-0a1eb685c531">285</ix:nonFraction> plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="ib194555003c24fe5a77a184233bd6cba_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxODQ_bc6f02d4-bc08-46c6-b6b5-23179ef87158">515</ix:nonFraction> of the lawsuits, covering about <ix:nonFraction unitRef="plaintiff" contextRef="i9e65f3f67c2d459f9a64e4b7a3a7d1b5_D20090301-20201231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxODk_ad1167c5-a363-451e-9e14-4526fe9334f1">515</ix:nonFraction> plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. <ix:nonFraction unitRef="lawsuit" contextRef="i6b680abb10c24ec5b54b2120fdc7058f_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxOTM_f10b8019-12d4-45d6-acc1-03ee23e63a13">Three</ix:nonFraction> lawsuits, representing approximately <ix:nonFraction unitRef="plaintiff" contextRef="i07adf913f1f54ca989ef31ee491cc698_D20090301-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyNTE_1b6f990f-d4e1-499d-94be-e8366531359d">four</ix:nonFraction> plaintiffs, have also been filed in various state courts. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i290630da973e431eb29fcd22cd423503_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMDU_021f11f0-4049-4dc1-a89b-46b0b22e1536">565</ix:nonFraction> of the lawsuits, involving approximately <ix:nonFraction unitRef="plaintiff" contextRef="i89fbc9d584994ea8be0227e0a79821e4_D20090301-20201231" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMTA_61d408e5-65b9-4822-8d04-57f63200c99f">800</ix:nonFraction> plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while <ix:nonFraction unitRef="plaintiff" contextRef="ieb83157010844ce786703b9c9bb67d43_D20090301-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMTQ_72ad4265-335c-4eb3-b391-c80d795c2fe8">six</ix:nonFraction> plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, <ix:nonFraction unitRef="plaintiff" contextRef="i1409b6c99dad4d6da1691bc35c7de3cb_D20090301-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMjI_c3e20a35-a31f-49fe-ad92-fc5d04f439dc">one</ix:nonFraction> case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court's grant of summary judgment based on that court's discovery rulings and remanded the cases for further proceedings. In November 2018, the California Court of Appeal reversed the state court's grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. We are aware of approximately <ix:nonFraction unitRef="claimant" contextRef="ib4cce461525f410b826a4889ad0f3ea6_I20201231" decimals="0" name="lly:LossContingencyNumberOfClaimants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMzE_c55796ff-5005-4d5d-ab11-9fbe73da6675">20</ix:nonFraction> additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="if1f97bec987b4be198dd3622aac2d1a3" continuedAt="i70c67d0751fa4ec5b80460affaa257db"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in August 2015, we are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i1b0cea540b384bc08e0afbcf20bece39_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMzU_18f75e3b-76e7-4ac5-92b8-8e68ad7d68e8">350</ix:nonFraction> Cialis product liability lawsuits in the U.S. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#174;. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jardiance Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="ib285d2fd260145229843a0c1bf1263f4_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyNDA_42b9f803-c397-4ca2-afe8-a9a2dab76f4f">95</ix:nonFraction> product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#8217; Fournier&#8217;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">340B Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the alternative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. A hearing on our motion for preliminary injunction has been scheduled for February 26, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administration Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i70c67d0751fa4ec5b80460affaa257db" continuedAt="i16f0f6fa1ae844c6809d4da161fbadc4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brazil Litigation &#8211; Cosmopolis Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Labor Attorney Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;<ix:nonFraction unitRef="brl" contextRef="iaeccac6f45794f4a92f62a164ea4c0ca_D20180701-20180731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzA1NzU_fc3993f0-c60b-48c2-9961-75b1e4fb3366">300</ix:nonFraction>&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately&#160;<ix:nonFraction unitRef="brl" contextRef="i8f52969f387d4ef7ad755da5ae0ffdbf_D20201231-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzA1MjM_e90cb376-98db-4e64-80a9-ef8dd5617474">950</ix:nonFraction>&#160;million Brazilian real (approximately $<ix:nonFraction unitRef="usd" contextRef="i8f52969f387d4ef7ad755da5ae0ffdbf_D20201231-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzU4MDI_33beda9c-7dbc-4138-8b2a-8afb7a838f3f">180</ix:nonFraction>&#160;million as of December 31, 2020). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#8217;s appeal to the superior labor court. The cost of any such health coverage has not been determined.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#8217;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit of <ix:nonFraction unitRef="brl" contextRef="i684d16bbfe9e4db78119c3012111fe94_D20190701-20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEyNTM5_a81df544-23a6-4750-80d5-95ac9d8e9b9f">500</ix:nonFraction> million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted. In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#8217;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Individual Former Employee Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2003, we have also been named in approximately <ix:nonFraction unitRef="lawsuit" contextRef="idfeb86b846074fb89e884673987dab5f_I20201231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEzMzYx_8f649ba6-0ab7-4467-a3d7-e71fbd2c7c55">30</ix:nonFraction>&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">China NDRC Antitrust Matter </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, are named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for February 2022.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i16f0f6fa1ae844c6809d4da161fbadc4" continuedAt="i0d59762597ee4202bbd82656c5feb5cc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#8217;s motion to dismiss the relator&#8217;s second amended complaint. In January 2020, the relator appealed the District Court&#8217;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. We are also named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="if595b7685be743c89bc5dc09daf08440_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyODI_fe29b1c3-0268-4d0c-8811-4065eed972c5">two</ix:nonFraction> similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a decision by the U.S. Court of Appeals for the Fifth Circuit on the aforementioned District Court appeal.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pricing Litigation, Investigations, and Inquires</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi-Aventis U.S. LLC (Sanofi) and Novo Nordisk, Inc. (Novo Nordisk) were named as defendants in a consolidated purported class action lawsuit,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. Also, filed in the same court in November 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and anti-trust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#8217; motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General&#8217;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. Additionally, in May 2019, the Kentucky Attorney General&#8217;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, federal and state anti-trust law, and the state deceptive trade practices-consumer protection act. Harris County also alleges common law claims such as fraud, unjust enrichment, and civil conspiracy. This lawsuit relates to our insulin products as well as Trulicity. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="i0d59762597ee4202bbd82656c5feb5cc" continuedAt="i423cc558f6e34fcc8f041f32f74b3aca"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investigations, Subpoenas, and Inquiries</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a subpoena from the New York a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market. We received <ix:nonFraction unitRef="request" contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfRequestsForInformation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzA1OTQ_ec0fd51e-eb7b-43ef-83b4-6dc28f6d811e">two</ix:nonFraction>&#160;requests from the House of Representatives&#8217; Committee on Energy and Commerce and a request from the Senate&#8217;s Committee on Health, Education, Labor, and Pensions seeking certain information related to the pricing of insulin products, among other issues. We also received requests from the House of Representatives&#8217; Committee on Oversight and Reform and the Senate&#8217;s Committee on Finance, which seek detailed commercial information and business records. In January 2021, the Senate&#8217;s Committee on Finance released a report summarizing the findings of its investigation. We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Corporation Technologies, Inc. </span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i423cc558f6e34fcc8f041f32f74b3aca">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. A trial date has not been set.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">109</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzIxMTE_80320188-7920-4620-b50f-12d06479e2e6" continuedAt="id7b5405839b4426a96f448bfd09a09b8" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="id7b5405839b4426a96f448bfd09a09b8" continuedAt="iaa08b642c417405aa049ab277f66d1d2"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzIxMDQ_cb067180-8c37-437e-9efd-f3ad9e4a59a4" continuedAt="i26a40f5afd59487ba11bfc1dfdf298e5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:27.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#d8d8d8;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2018 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6404d71a3154085b2ffbe7918c52fdf_I20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItMS0xLTEtMA_9e4a9d09-5084-4701-a30f-39aed4052da9">1,191.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3f134ccefd4f4a994809b05af014c1_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItMy0xLTEtMA_b86d44bd-2211-49f6-9e05-cf6f8f5fa881">113.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied12274b6db14234b7de3a19eb3f0d2c_I20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItNS0xLTEtMA_e6eb5fb8-6d4b-440b-a928-5c0a5331dabe">4,311.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4ce9bb84e004603a5019d1c6da66946_I20171231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItNy0xLTEtMA_ebff2d6d-09ee-4ed5-ba88-cc23660cefcf">234.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91a7d9b32f3a4db9a00591e1adce82a6_I20171231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItOS0xLTEtMA_4cab86dd-44f9-4ee6-83e6-cf79bd35e6e5">71.1</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6923db7df05a4e6e922a6bb5db8a3b41_I20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItMTEtMS0xLTA_290e187d-ae1c-48d5-81e3-0e2395809f50">5,694.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification due to adoption of new accounting standard</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7766703b17514542b192609b6e561393_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzMtMy0xLTEtODI3_5cc64403-d63d-4570-b61f-aeb7222b2d01">128.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d75213e1aba4f7eadb741cb0d1cc298_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzMtMTEtMS0xLTgyNw_ab085f1c-8d89-4989-9d9c-4a6126702be0">128.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib784e78bc05f4285945fc78bbb738f91_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtMS0xLTEtMA_9b8aa326-8783-4072-9c64-83331f3fa93c">378.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7766703b17514542b192609b6e561393_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtMy0xLTEtMA_83f2d6ef-dbce-4874-99b7-22b9351dc3be">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4a4a1e1c3745e59d68927cad94276a_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtNS0xLTEtMA_c3e4ecb6-4a4b-48c2-aef8-3eb84f9b13ff">250.7</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc74b3eb01ad4e50bc04a6977d715d2d_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtNy0xLTEtMA_47d81836-7076-44cc-a313-227cb17de38b">16.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb39193d2a16435281dd19dfabba3b42_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtOS0xLTEtMA_ae04af03-c703-43a9-907e-d3dcdea2f907">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtMTEtMS0xLTA_e7fb1e7e-7644-4fb1-9ebd-de50337e0dd7">106.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib784e78bc05f4285945fc78bbb738f91_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtMS0xLTEtMA_3f45379d-29c2-4056-90a0-750e2e038d83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7766703b17514542b192609b6e561393_D20180101-20181231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtMy0xLTEtMA_6b80cd3e-b1c7-4e16-86a4-405a9974c89f">31.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4a4a1e1c3745e59d68927cad94276a_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtNS0xLTEtMA_f8676a36-af62-4a25-b169-83318e06afaf">207.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc74b3eb01ad4e50bc04a6977d715d2d_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtNy0xLTEtMA_338b8673-e2a4-40fa-8efb-b26736de17a5">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb39193d2a16435281dd19dfabba3b42_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtOS0xLTEtMA_6b8f32c4-916d-4119-9ec9-d3919d7122ab">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtMTEtMS0xLTA_35cb8315-c3d9-4ce4-8116-0b7da9d59890">190.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib784e78bc05f4285945fc78bbb738f91_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtMS0xLTEtMA_dfef44fa-4bb9-4b91-a34c-0b7c3809fc7f">378.0</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7766703b17514542b192609b6e561393_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtMy0xLTEtMA_40085618-6c3c-45eb-b658-4a69c8bd3823">6.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4a4a1e1c3745e59d68927cad94276a_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtNS0xLTEtMA_a40e4b83-56cc-40d5-84dd-154993b9574e">458.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc74b3eb01ad4e50bc04a6977d715d2d_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtNy0xLTEtMA_bf32a9b8-6800-47d0-ad48-02d9d1705516">4.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb39193d2a16435281dd19dfabba3b42_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtOS0xLTEtMA_4fe42d49-9d45-4925-ac51-09dfaeeaa853">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtMTEtMS0xLTA_b4b1b2d3-617a-4504-bc8f-a1e1798af7f3">83.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20fb3a01e3c6484686b01e6156c1acd8_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTEtMS0xLTA_b7b45e64-c270-43fa-b23d-514d8531ac09">1,569.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cce948975cd45cfa58c1e76158f0f33_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTMtMS0xLTA_63f8bc5a-ab57-44de-b6da-2887edfd9090">22.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ae9df0fe048449392c43fb7186ca248_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTUtMS0xLTA_dac0f0cc-64e0-44cd-90e8-bad817f5970f">3,852.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2a384242290465588799dfbd2e7ee83_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTctMS0xLTA_9377502d-9e31-4308-9495-3127be8e3141">238.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39bb81b83d844b11b7cacd7fcb2e07d3_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTktMS0xLTA_01b8c330-9598-44da-9e92-58f0e479a23d">56.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i022a194d782540f8a8fdfc2d9b226688_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTExLTEtMS0w_4e95fa00-6201-425b-874e-7afc777ffbc7">5,740.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bbc0a2c1f894a5fa0c07c97d49cc299_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTEtMS0xLTA_e88c58c0-68dc-4605-929a-1070443cbf9f">46.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080fb50d8cac4747bda1c482bee979d5_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTMtMS0xLTA_c070747c-0f4d-419a-bad1-dd669b82e662">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i615ad14cefcc4ce1a88ced50887fbf6d_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTUtMS0xLTA_32c4f49f-fa3a-441a-92d9-3a2abe51ef29">967.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24efbe2abb2349b59ae25141fedb34da_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTctMS0xLTA_496a63f4-c2d6-40ab-9c66-a43dc9eb1e7a">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if749975463d649e68e1bc14730e552fa_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTktMS0xLTA_3febb46b-9ca7-4bb9-9be7-49824a819117">27.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTExLTEtMS0w_053f1402-e031-4308-bf11-3e3294e59acc">997.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bbc0a2c1f894a5fa0c07c97d49cc299_D20190101-20191231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTEtMS0xLTA_5e329cac-c901-4aaa-82f2-93e9e72e62f5">62.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i080fb50d8cac4747bda1c482bee979d5_D20190101-20191231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTMtMS0xLTA_9c28de0f-4dc6-4e67-a3ca-a48fca19e479">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615ad14cefcc4ce1a88ced50887fbf6d_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTUtMS0xLTA_c6f25008-c877-4208-b510-ceedc96d2db5">181.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24efbe2abb2349b59ae25141fedb34da_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTctMS0xLTA_10c97004-e81d-46fd-a2c0-6aea3d0805bf">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if749975463d649e68e1bc14730e552fa_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTktMS0xLTA_6039909b-c831-470b-ac11-52ba5a7a9b91">84.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTExLTEtMS0w_223ca3bf-8788-4286-9d73-56b1363775bd">214.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bbc0a2c1f894a5fa0c07c97d49cc299_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTEtMS0xLTA_e107b5a0-fef2-4901-a549-260220735695">108.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080fb50d8cac4747bda1c482bee979d5_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTMtMS0xLTA_993615fb-64cb-4760-8cff-97198b3c7d49">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i615ad14cefcc4ce1a88ced50887fbf6d_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTUtMS0xLTA_4502a3a1-a6ff-479e-9b48-689422c40327">785.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24efbe2abb2349b59ae25141fedb34da_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTctMS0xLTA_e4fb20f1-e54d-46e8-9600-40551f59f9ef">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if749975463d649e68e1bc14730e552fa_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTktMS0xLTA_2c540b2d-1911-429b-8d8e-815d68169759">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTExLTEtMS0w_c85fd865-0852-4117-a076-e9e2293b4af7">783.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ae30dfeeb2e4879a0c3b21b26111cad_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTEtMS0xLTA_366af562-e90c-4c6e-8556-39e3236bfdcd">1,678.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569a261af70b4d8ba9f60a58c0e2b9f8_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTMtMS0xLTA_ab4d7ac1-5adf-4ea8-bcad-9e2115dbe5e1">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135c068cec7c43d3896b245ca3cde3bd_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTUtMS0xLTA_4171b858-ed66-4285-92b1-b6f96af7f82c">4,638.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ae1e86516684e95b54071890a6e557b_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTctMS0xLTA_4a6c97ad-9342-483d-aefd-a796188123a5">211.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22e1113b5f54e35a4a4df39e3e917bd_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTktMS0xLTA_300b1f00-ace9-4c93-a02b-12481c8f9896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb975f9779f54232a351634d3fd2cd32_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTExLTEtMS0w_be37815f-7908-455a-9280-ae2c8585a9e3">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7ca588e4b4a668bd791165ae19818_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTEtMS0xLTA_c37349dc-07f3-426c-bb7d-326835ad5b45">250.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba7d4dca490147faac33fdce0f0d354d_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTMtMS0xLTA_8ea346df-4182-4938-b50e-bf2c4d0ba8e5">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i964f0a9d08134a599b06447de48f472d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTUtMS0xLTA_9932dfc2-b805-4ca2-99e5-ae360f8b501c">379.7</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba9496ec064a41e6bacfab535e35a9b1_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTctMS0xLTA_30f5c06f-b11e-4c6f-9498-b9a9ef47e919">133.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2f813fac6448c7b98cc7598ddd6c1a_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTktMS0xLTA_7ab9933c-d1ef-4730-baf5-dd1c9f39f021">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTExLTEtMS0w_8948f375-6d91-4831-b076-40ea3c508852">256.2</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7ca588e4b4a668bd791165ae19818_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTEtMS0xLTA_3a7d6a63-7323-4142-a124-8b3fdc2af108">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba7d4dca490147faac33fdce0f0d354d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTMtMS0xLTA_257493a3-2cf4-4e99-bd4d-e83e57f91676">3.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964f0a9d08134a599b06447de48f472d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTUtMS0xLTA_feeaaed1-5932-4353-aaa9-6f2821812621">267.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9496ec064a41e6bacfab535e35a9b1_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTctMS0xLTA_78ad7b09-78a9-48e1-ba2c-31ddb1a77a64">13.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2f813fac6448c7b98cc7598ddd6c1a_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTktMS0xLTA_3d3407a2-8ade-490c-b905-ad477fef6b0a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTExLTEtMS0w_7ac2d988-9cb3-4db8-9551-3a4610190dbe">283.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7ca588e4b4a668bd791165ae19818_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTEtMS0xLTA_f1ae42dc-2532-4bcd-b75a-0c6bf62c89df">250.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba7d4dca490147faac33fdce0f0d354d_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTMtMS0xLTA_7187b134-d4c0-4132-bd52-754cd010c269">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i964f0a9d08134a599b06447de48f472d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTUtMS0xLTA_9711eb95-b524-4b34-85e5-ff211430da08">112.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba9496ec064a41e6bacfab535e35a9b1_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTctMS0xLTA_246e261b-b7a8-4072-9e9c-3fc197c11d0b">120.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2f813fac6448c7b98cc7598ddd6c1a_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTktMS0xLTA_b8e15049-7076-417e-b33f-5926203e1804">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTExLTEtMS0w_47d42d94-60df-40b0-8527-6f6041381457">27.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib667086cf32f420988bbee8738114965_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTEtMS0xLTA_343863d1-ae8f-4f51-a67a-59dfea9379d1">1,427.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45e19b6d14441ea88cddc6e941da5ed_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTMtMS0xLTA_fe70c170-c46b-4c87-8150-0de802472648">14.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4baa1ec009c445486118e3b4579ec89_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTUtMS0xLTA_e18215c3-be44-4c6b-8b11-c5da61a992ba">4,751.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8b131f4aa2c4cb88d271c82f1b47bc3_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTctMS0xLTA_130d128c-70bb-4364-808f-c58fba5ea7cc">332.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7cbd1f19a34b6789d5526dc3008179_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTktMS0xLTA_ca6f1e4b-c727-4b41-bc54-efc17d0e9594">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a895cde5a54bb5be22a7b5806d3386_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTExLTEtMS0w_c04c35b8-7f7f-48d8-84b3-76604e5f3274">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of January 1, 2018 consists of $<ix:nonFraction unitRef="usd" contextRef="iae684e1f51624a5884d558a8b1eea7ab_I20171231" decimals="-7" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc0OTA_6b5fa264-acc6-4679-90bb-ce8e628649cf">5.72</ix:nonFraction>&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $<ix:nonFraction unitRef="usd" contextRef="idbc47e8810d6412bbab29c0eacb89745_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMxOA_44370a46-7118-4c5f-8db3-5f616b020244">23.7</ix:nonFraction> million of accumulated other comprehensive income attributable to noncontrolling interest. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This reclassification consists of $<ix:nonFraction unitRef="usd" contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc1MzU_f084260c-8a40-414a-ae61-04177e03fbf7">105.2</ix:nonFraction>&#160;million of accumulated other comprehensive income attributable to controlling interest and $<ix:nonFraction unitRef="usd" contextRef="idbc47e8810d6412bbab29c0eacb89745_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc1NTE_06406f7d-69fe-4756-9859-1a6946b09210">23.7</ix:nonFraction>&#160;million of accumulated other comprehensive income attributable to noncontrolling interest. Refer to Note 1 for further details regarding the reclassification due to the adoption of ASU 2016-01.  </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2018 consists of $<ix:nonFraction unitRef="usd" contextRef="ic1a89936fa8a4137a7ff3506ba792c52_I20181231" decimals="-7" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc1MDU_97166b8f-5c6f-4668-8b9f-b12649e5f2a6">5.73</ix:nonFraction>&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $<ix:nonFraction unitRef="usd" contextRef="ic2c054d8c5c84127b1e160c82886953d_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc1MjA_a3e64c00-131f-4437-98a2-5ff2e6181871">11.0</ix:nonFraction>&#160;million of accumulated other comprehensive loss attributable to noncontrolling interest. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><ix:continuation id="iaa08b642c417405aa049ab277f66d1d2"><ix:continuation id="i26a40f5afd59487ba11bfc1dfdf298e5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da867daad1840d6b255ab18e08ebcd6_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzEtMS0xLTEtMA_5c8e5481-1443-4ec8-ba05-b5ba7514a071">128.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd7a83c1653f4b8eaedba242be6d6ff7_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzEtMy0xLTEtMA_4c09b5ee-1487-46a7-992c-be2308ede0d9">18.4</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb8b4f8723f4f02a681499b646ccb15_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzEtNS0xLTEtMA_2000c26d-02f7-4559-9784-441c1838d169">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a8513120f404c39a420b6b793e39fbc_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzItMS0xLTEtMA_eeba1c34-8115-4a09-bb2a-a326722262d6">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i011e32aa84f34a07861fc5d8d38eae10_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzItMy0xLTEtMA_dc508c64-de66-40fa-984f-783b7c19c820">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c36f2ee8cff49ec82af74c218b0ace1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzItNS0xLTEtMA_0e361840-cae2-4ea8-9155-e99e1ae7cf9c">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007d6fe10f55466ebb1af3bb02b9b84a_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzMtMS0xLTEtMA_3c362fcc-f0a6-4856-ae35-d94ac9930cd6">44.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767785ec05f74127a9246bc6ce2f190b_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzMtMy0xLTEtMA_4339d4ec-1f41-44a3-8f15-2c192b905d15">184.1</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27dbf880100447d9bf589531096741f5_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzMtNS0xLTEtMA_70dcac66-8c97-45ef-bdb9-a57ca698d6ff">85.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bdb72715a234bc193e62ede32a5bbed_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzQtMS0xLTEtMA_ccaf45f4-0c12-43df-b578-058f0c8903fc">32.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee3110d1c0a44663b08bc95d12a2e990_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzQtMy0xLTEtMA_a8070d8d-d95c-4961-bac0-29c96668c252">7.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193696830a4742cdba4be29dcd7f5251_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzQtNS0xLTEtMA_63b788c2-c3a0-472d-8bf1-a180b7d89296">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzUtMS0xLTEtMA_d954552c-a519-444a-aca9-4d75f56613db">200.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzUtMy0xLTEtMA_31505624-71c1-4f69-8d13-710a3726732d">151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzUtNS0xLTEtMA_29457189-2445-496e-8845-2b4d7a30cbb7">30.3</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.</span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzIxMTM_1a0b890e-1164-4a97-b24f-a3aa489cfa87" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.230%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7a3ec013676433f815344f9f683499a_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzMtMS0xLTEtMA_141b3a4d-6851-487d-9be8-25e35c8f6928">55.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32ce3929549c42488c9d78815eb40512_D20190101-20191231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzMtMy0xLTEtMA_41b20357-2fe0-45f7-9ee2-7b55eb7f3d91">56.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dd52235d591400ebdc756d6a1cb0bc9_D20180101-20181231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzMtNS0xLTEtMA_b0442a90-d5f0-4223-bf39-884e2b94e2ed">74.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27470f38a1f14522ba67a5d022af05bf_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzQtMS0xLTEtMA_f28ddc92-6430-45aa-ae6a-6aed757a0e7b">393.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69664129e7348b3b8fd52f216426461_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzQtMy0xLTEtMA_331aa270-7c8f-4e19-881a-e7db63dcde38">286.8</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b02af87ac54ca3a6bfb1bc0e3b200e_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzQtNS0xLTEtMA_a978c2ac-fea3-4055-9d77-891c76b2d817">338.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9799a363894e447a88d58efd03f0b2ab_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzUtMS0xLTEtMA_a71c9f13-4324-4c84-b2af-bbf6cab0e3b3">338.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0433259992642cd84137af8b232a207_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzUtMy0xLTEtMA_772cdecd-067e-403b-82f3-d8ff05a43e95">230.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2fcfe7ae7240f8aea48b8993890007_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzUtNS0xLTEtMA_e3834310-e6f3-4809-a84c-9fb3ea3e3a4a">263.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9799a363894e447a88d58efd03f0b2ab_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzYtMS0xLTEtMA_9fe4fcf1-0817-426a-b1fb-ae1f919cff0e">71.0</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0433259992642cd84137af8b232a207_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzYtMy0xLTEtMA_9b0650c0-1b2d-4927-80ab-306bd233fb50">48.3</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c2fcfe7ae7240f8aea48b8993890007_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzYtNS0xLTEtMA_86f19703-8103-4a6b-862d-24fc244bb782">55.8</ix:nonFraction>)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9799a363894e447a88d58efd03f0b2ab_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzctMS0xLTEtMA_202796d9-7346-46b1-b903-f345c9ac7fad">267.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0433259992642cd84137af8b232a207_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzctMy0xLTEtMA_27788ec2-032a-46f7-9bac-8fe7a55d272f">181.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2fcfe7ae7240f8aea48b8993890007_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzctNS0xLTEtMA_fca0ec9a-2a9f-439c-9b2f-98a7d554fd8f">207.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42bc8b84cba2465299f8b30a76d2180d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE0LTEtMS0xLTA_d718c51a-c1c8-42f6-8410-9d4f783844e3">16.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31f634abe9b49d087c5ebeb30996e11_D20190101-20191231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE0LTMtMS0xLTA_86f3caf2-653c-4a78-a770-8b889443269c">51.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabbc7b2ea00947e8b902df09566e6317_D20180101-20181231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE0LTUtMS0xLTA_a2628da1-2e6f-44c1-8a10-2481a2047dbd">19.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from continuing operations (net of tax)</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26304d3b80a542b5ab77edf4000be691_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE1LTEtMS0xLTA_28543e49-7b48-4aa6-9d28-8f4561149f93">283.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1e386970d94f0abc18ef065866675b_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE1LTMtMS0xLTA_d3da3b91-85ae-4a2d-88cc-ea9821435e4a">130.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df68c6465184e8b8f60cebcf0de49e4_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE1LTUtMS0xLTA_55a8460f-dc79-4d2c-a08b-6830799dbe12">188.4</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from discontinued operations (net of tax)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26304d3b80a542b5ab77edf4000be691_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE2LTEtMS0xLTA_75d4800d-a63a-41a0-92bb-10c13a544d5d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1e386970d94f0abc18ef065866675b_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE2LTMtMS0xLTA_84e65494-c1e3-42e2-a1a3-63f025c8c555">84.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df68c6465184e8b8f60cebcf0de49e4_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE2LTUtMS0xLTA_766999a0-dfd4-4f37-aa90-370d75a7f972">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26304d3b80a542b5ab77edf4000be691_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE3LTEtMS0xLTA_c6a20f87-c7e7-4e4d-ae08-d558a12813f8">283.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1e386970d94f0abc18ef065866675b_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE3LTMtMS0xLTA_6c89747c-64a8-446d-bb12-4670c5032475">214.2</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df68c6465184e8b8f60cebcf0de49e4_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE3LTUtMS0xLTA_b8929b75-1654-462c-9706-fec3b93e9a2b">190.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">111</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_190"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90ZXh0cmVnaW9uOmI0MzVmYzBiNDc4MzRkY2FiNTUwODcyY2YwY2Y3MzAyXzIxOQ_5c5374f3-4b18-4556-b2cf-046fbea4456d" continuedAt="i901f05bf9fc54ff8ade45437b8c43002" escape="true">Other&#8211;Net, (Income) Expense</ix:nonNumeric></span></div><ix:continuation id="i901f05bf9fc54ff8ade45437b8c43002" continuedAt="i24e4f75f2ea5486181c47417cdb5bcd9"><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90ZXh0cmVnaW9uOmI0MzVmYzBiNDc4MzRkY2FiNTUwODcyY2YwY2Y3MzAyXzIyMg_938dc167-07d5-428c-8897-0685abb6f828" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:60.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzEtMS0xLTEtMA_4743c81d-7230-4c9b-b5d8-ea4ee88e9033">359.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzEtMy0xLTEtMA_74b34838-a0b6-4ccb-9cf4-9f850aa5f451">400.6</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzEtNS0xLTEtMA_e736fd46-dce2-4c15-a5d0-490df53b7ea1">242.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzItMS0xLTEtMA_72af047f-e8cd-4a4a-b16e-84e4ea7aea2c">33.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzItMy0xLTEtMA_254c711e-e727-4d32-91da-f67099735b76">80.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzItNS0xLTEtMA_8ba6be90-8445-48d1-80ad-2ea496f0ff63">159.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzMtMS0xLTEtMA_35d72388-664b-46c9-aa4f-9286ee096a2d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzMtMy0xLTEtMA_163ca2d1-935b-4f53-a12d-fd7889045f6c">252.5</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzMtNS0xLTEtMA_a0857295-2885-4bb5-b258-82a7ee5b8ac6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of antibiotic business in China (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzQtMS0xLTEtMA_c1fd906a-ec94-4278-8b00-b6693e193508">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzQtMy0xLTEtMA_884c3297-f407-49f6-9639-e8130c719702">309.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzQtNS0xLTEtMA_edb11470-1d45-40bd-be4d-d418cff92bef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzUtMS0xLTEtMA_730f2429-dbcb-4668-adf8-6904974816fe">251.8</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzUtMy0xLTEtMA_9ffcfbb6-a4e0-457c-a099-28f137b04ba4">209.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzUtNS0xLTEtMA_7f5cc7b6-5fef-40f8-8d8b-7d6f6985ca5a">240.5</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzYtMS0xLTEtMA_242aa58a-9adf-40bc-b164-5a6eae562c31">1,246.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzYtMy0xLTEtMA_2ff7312c-5c67-4871-bad0-415d6ba4f8aa">344.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzYtNS0xLTEtMA_921621ff-cdf3-4fd8-8c88-fddd9d658d3a">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzctMS0xLTEtMA_eeeee7e3-12eb-4dc9-8687-81db13dcd2c7">1,171.9</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzctMy0xLTEtMA_dfd7ea0c-7ab3-4b83-90ac-c1ccaf4361b5">291.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzctNS0xLTEtMA_2626d07f-cfb1-453f-981e-cfcc8fee209b">145.6</ix:nonFraction>)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i24e4f75f2ea5486181c47417cdb5bcd9">For the years ended December&#160;31, 2020 and 2019, other income was primarily related to net gains on investments (Note 7).</ix:continuation> </span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_193"></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19:&#160;<ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzMwNjA_8d4120c7-7241-48eb-978c-8868842ecb0a" continuedAt="i87021682cebf41e4be9149a630b84139" escape="true">Discontinued Operations</ix:nonNumeric></span></div><ix:continuation id="i87021682cebf41e4be9149a630b84139"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 24, 2018, Elanco completed its initial public offering (IPO) resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="ifc4be7a2068245ffa89edf317572504d_D20180924-20180924" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzE0MQ_f8768a98-faea-4172-806d-be19a16dba2d">72.3</ix:nonFraction> million shares of its common stock, which represented <ix:nonFraction unitRef="number" contextRef="ifc4be7a2068245ffa89edf317572504d_D20180924-20180924" decimals="3" format="ixt:numdotdecimal" name="lly:SaleOfStockPercentageOfStockSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzE5MA_83475924-997e-4244-afcd-c87d2643b773">19.8</ix:nonFraction> percent of Elanco's outstanding shares, at $<ix:nonFraction unitRef="usdPerShare" contextRef="i45097dbde81e4b5a8ddc8854e29196ac_I20180924" decimals="0" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzIyOA_a4763655-a8a7-420c-8507-48722fa08035">24</ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that formed its business.&#160;In exchange, Elanco transferred to us consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i601d8831c2a84dc6a94bf8abcae67dcf_I20180924" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzQ4OA_f71f889d-8e21-4066-a6c2-172a619b1107">4.2</ix:nonFraction> billion, which consisted primarily of the net proceeds from the IPO and the net proceeds from a $<ix:nonFraction unitRef="usd" contextRef="ia8d16807ca45467296773da1a768103c_D20180924-20180924" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzU3OQ_45abfbf8-3b1d-4c02-8f22-455ce4a0cfb0">2.00</ix:nonFraction> billion debt offering and a $<ix:nonFraction unitRef="usd" contextRef="i25de516d8b1a468d869b65f28c3c0ae4_I20180831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzYwMg_06483919-89df-4dd5-9134-5ab7b9c20f5b">500.0</ix:nonFraction> million <ix:nonNumeric contextRef="i0841fa6d26e546d4acee688c1214ee2b_D20180801-20180831" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzMyOTg1MzQ4ODYzOTA_47366ff6-1bb8-438c-913c-5d886e78e8c9">three-year</ix:nonNumeric> term loan facility entered into by Elanco in August 2018. The consideration that we received was used for debt repayment, dividends, and share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was $<ix:nonFraction unitRef="usd" contextRef="i601d8831c2a84dc6a94bf8abcae67dcf_I20180924" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzg2Ng_827b6407-dc19-43f0-b331-a02744a4da06">629.2</ix:nonFraction> million and was recorded in additional paid-in capital. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 11, 2019, we continued to consolidate Elanco, as we retained control over Elanco. We completed the disposition of our remaining <ix:nonFraction unitRef="number" contextRef="icf5a8d8b13ec45be88c05cc0494020eb_I20190311" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzEyMDQ_3878daeb-a857-4519-9120-5a3433d22bda">80.2</ix:nonFraction> percent ownership of Elanco common stock through a tax-free exchange offer that closed on March 11, 2019 (the disposition date). The earnings attributable to the divested, noncontrolling interest for the period from the IPO until disposition were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the disposition, in the first quarter of 2019, we recognized a gain related to the disposition of approximately $<ix:nonFraction unitRef="usd" contextRef="i4759a8743edb4111b4e4b16db8cb6680_D20190101-20190331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzE1OTE_8c3125a5-b0e4-4ac0-9559-0fe5513915e7">3.7</ix:nonFraction> billion, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated financial statements for all periods presented. </span></div><ix:nonNumeric contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzMwNjE_9f1f815d-04f0-49c5-9043-4462d9e9ba79" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets summarizes revenue and net income from discontinued operations:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52daa1d7665e48ae8d99c5d280d6bd5a_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90YWJsZTpiNDQwODBiMGJlMWM0ZjZjYjE5ODQyZThiMDViZDg5OC90YWJsZXJhbmdlOmI0NDA4MGIwYmUxYzRmNmNiMTk4NDJlOGIwNWJkODk4XzEtMy0xLTEtMA_2dfec65c-2e8c-4874-a00f-ca5d1cd24273">580.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b83214520b341e28e9c3eb65c9a0efa_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90YWJsZTpiNDQwODBiMGJlMWM0ZjZjYjE5ODQyZThiMDViZDg5OC90YWJsZXJhbmdlOmI0NDA4MGIwYmUxYzRmNmNiMTk4NDJlOGIwNWJkODk4XzEtNS0xLTEtMA_a4f25f2f-8685-4725-b457-cd6d8c9843fa">3,062.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52daa1d7665e48ae8d99c5d280d6bd5a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90YWJsZTpiNDQwODBiMGJlMWM0ZjZjYjE5ODQyZThiMDViZDg5OC90YWJsZXJhbmdlOmI0NDA4MGIwYmUxYzRmNmNiMTk4NDJlOGIwNWJkODk4XzItMy0xLTEtMA_96b8a128-7d94-491d-8871-12b361bb03a6">3,680.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b83214520b341e28e9c3eb65c9a0efa_D20180101-20181231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90YWJsZTpiNDQwODBiMGJlMWM0ZjZjYjE5ODQyZThiMDViZDg5OC90YWJsZXJhbmdlOmI0NDA4MGIwYmUxYzRmNmNiMTk4NDJlOGIwNWJkODk4XzItNS0xLTEtMA_2434c0f7-c35a-4733-8e92-d3e1045535ae">81.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain related to the disposition of Elanco in the consolidated statement of cash flows includes the operating results of Elanco through the disposition date, which were not material. Net cash flows of our discontinued operations for operating activities were not material for the year ended December 31, 2019. Net cash provided by operating activities related to our discontinued operations was approximately $<ix:nonFraction unitRef="usd" contextRef="i4b83214520b341e28e9c3eb65c9a0efa_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzI0MDU_f9a44ff8-b00c-45fb-943f-62727d64e6c8">500</ix:nonFraction> million for the year ended December 31, 2018. The net cash flows of our discontinued operations for investing activities were not material for any period presented. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a transitional services agreement (TSA) with Elanco that is designed to facilitate the orderly transfer of various services to Elanco. The TSA relates primarily to administrative services, which are generally to be provided over <ix:nonNumeric contextRef="i9a3e673a3e6740eba162b41a6b7818e2_D20190311-20190311" format="ixt-sec:durmonth" name="lly:DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzI4NjI_ad22ac06-98a6-4356-ac02-9a0801e632fb">24</ix:nonNumeric> months from the disposition date. This agreement is not material and does not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">112</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_202"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Reports</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report for Financial Statements&#8212;Eli Lilly and Company and Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of Eli Lilly and Company and subsidiaries is responsible for the accuracy, integrity, and fair presentation of the financial statements. The statements have been prepared in accordance with generally accepted accounting principles in the United States and include amounts based on judgments and estimates by management. In management&#8217;s opinion, the consolidated financial statements present fairly our financial position, results of operations, and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the system of internal accounting controls, we maintain a code of conduct (known as "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that applies to all employees worldwide, requiring proper overall business conduct, avoidance of conflicts of interest, compliance with laws, and confidentiality of proprietary information. All employees must take training annually on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and are required to report suspected violations. A hotline number is available on our lilly.com website and on the internal LillyNow website to enable reporting of suspected violations anonymously. Employees who report suspected violations are protected from discrimination or retaliation by the company. In addition to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Red Book</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the chief executive officer and all financial management must sign a financial code of ethics, which further reinforces their ethical and fiduciary responsibilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm. Their responsibility is to examine our consolidated financial statements in accordance with generally accepted auditing standards of the Public Company Accounting Oversight Board (United&#160;States). Ernst&#160;&amp; Young&#8217;s opinion with respect to the fairness of the presentation of the statements is included in Item&#160;8 of our annual report on Form 10-K. Ernst&#160;&amp; Young reports directly to the audit committee of the board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee includes six nonemployee members of the board of directors, all of whom are independent from our company. The committee charter, which is available on our website, outlines the members&#8217; roles and responsibilities. It is the audit committee&#8217;s responsibility to appoint an independent registered public accounting firm subject to shareholder ratification, pre-approve both audit and non-audit services performed by the independent registered public accounting firm, and review the reports submitted by the firm. The audit committee meets several times during the year with management, the internal auditors, and the independent public accounting firm to discuss audit activities, internal controls, and financial reporting matters, including reviews of our externally published financial results. The internal auditors and the independent registered public accounting firm have full and free access to the committee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to ensuring that we maintain the high standards of financial accounting and reporting that we have established. We are committed to providing financial information that is transparent, timely, complete, relevant, and accurate. Our culture demands integrity and an unyielding commitment to strong internal practices and policies. Finally, we have the highest confidence in our financial reporting, our underlying system of internal controls, and our people, who are objective in their responsibilities, operate under a code of conduct and are subject to the highest level of ethical standards.</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting&#8212;Eli Lilly and Company and Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of Eli Lilly and Company and subsidiaries is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. We have global financial policies that govern critical areas, including internal controls, financial accounting and reporting, fiduciary accountability, and safeguarding of corporate assets. Our internal accounting control systems are designed to provide reasonable assurance that assets are safeguarded, that transactions are executed in accordance with management&#8217;s authorization and are properly recorded, and that accounting records are adequate for preparation of financial statements and other financial information. A staff of internal auditors regularly monitors, on a worldwide basis, the adequacy and effectiveness of internal accounting controls. The general auditor reports directly to the audit committee of the board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in "Internal Control&#8212;Integrated Framework" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our evaluation under this framework, we concluded that our internal control over financial reporting was effective as of December&#160;31, 2020. However, because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of internal control over financial reporting as of December&#160;31, 2020 has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report, which appears herein. Their responsibility is to evaluate whether internal control over financial reporting was designed and operating effectively.</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.919%"><tr><td style="width:1.0%"></td><td style="width:48.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chairman, President, and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President&#160;and Chief Financial Officer</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;17, 2021 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">114</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_205"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="margin-top:0.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Eli Lilly and Company</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Eli Lilly and Company and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), shareholders&#8216; equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8220;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 17, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Medicaid, Managed Care, and Medicare sales rebate accruals</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As described in Note 2 to the consolidated financial statements under the caption &#8220;Net Product Revenue,&#8221; the Company establishes provisions for sales rebate and discounts in the same period as the related sales occur. At December 31, 2020 the Company had $5,853.0 million in sales rebate and discount accruals. A large portion of these accruals are rebates associated with sales in the United States for which payment for purchase of the product is covered by Medicaid, Managed Care, and Medicare. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing the Medicaid, Managed Care, and Medicare sales rebate and discount liabilities is challenging because of the subjectivity of certain assumptions required to estimate the rebate liabilities. In calculating the appropriate accrual amount, the Company considers historical Medicaid, Managed Care, and Medicare rebate payments by product as a percentage of their historical sales as well as any significant changes in sales trends, the lag in payment timing, an evaluation of the current Medicaid and Medicare laws and interpretations, the percentage of products that are sold via Medicaid, Managed Care, and Medicare, and product pricing. For Medicaid, there is significant complexity associated with calculating the legislated Medicaid rebates. Management utilizes employees with legislative experience and knowledge in developing assumptions used to calculate Medicaid rebates.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Similarly, for Managed Care and Medicare, given variability in prescription drug costs, continued historical year over year increases in enrollees and variability in prescription data, historical rebate information may not be predictive for management to estimate the rebate accrual and thus, management supplements its historical data analysis with qualitative adjustments based upon current utilization.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We tested the Company&#8217;s controls addressing the identified risks of material misstatement related to the valuation of the sales rebate and discount liabilities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This included testing controls over management&#8217;s review of the significant assumptions used to calculate the Medicaid, Managed Care, and Medicare rebate liabilities, including the significant assumptions discussed above.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This testing also included management&#8217;s control to compare actual activity to forecasted activity and controls to ensure the data used to evaluate the significant assumptions was complete and accurate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit procedures included, among others, evaluating for reasonableness the significant assumptions in light of economic trends, product profiles, and other regulatory factors. Our testing involved assessing the historical accuracy of management&#8217;s estimates by comparing actual activity to previous estimates and performing analytical procedures, based on internal and external data sources, to evaluate the completeness of the reserves. Additionally, our procedures included reviewing a sample of contracts, testing a sample of rebate payments and testing the underlying data used in management&#8217;s evaluation. For Medicaid, we involved our professional with an understanding of the statutory reimbursement requirements to assess the consistency of the Company&#8217;s calculation methodologies with the applicable government regulations and policy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Medicare we evaluated the reasonableness of assumptions made by management in estimating the Medicare coverage gap liability.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Retirement Benefits - Valuation of Alternative Investments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As described in Note 15 to the consolidated financial statements under the caption &#8220;Benefit Plan Investments,&#8221; the Company&#8217;s benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. At December 31, 2020 the Company had $17,806.0 million in plan assets related to the defined benefit pension plans and retiree health benefit plans. Approximately 33% of the total pension and retiree health assets are in hedge funds and private equity-like investment funds (&#8220;alternative investments&#8221;). These alternative investments are valued using significant unobservable inputs or are valued at net asset value (NAV) reported by the counterparty, adjusted as necessary.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing the fair value of these alternative investments is challenging because of the higher estimation uncertainty of the inputs to the fair value calculations, including the underlying net asset values (&#8220;NAVs&#8221;), discounted cash flow valuations, comparable market valuations, and adjustments for currency, credit, liquidity and other risks. Additionally, certain information regarding the fair value of these alternative investments is based on unaudited information available to management at the time of valuation. </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We tested the Company&#8217;s controls addressing the risks of material misstatement relating to valuation of alternative investments. This included testing management&#8217;s review controls over alternative investment valuation, which included a comparison of returns to benchmarks and in-person or telephonic meetings with investment firms to discuss valuation policies and procedures, as well as portfolio performance. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit procedures included, among others, comparing fund returns to selected relevant benchmarks and understanding variations, obtaining the latest audited financial statements and comparing to the Company&#8217;s estimated fair values and reconciling any differences. We also inquired of management about changes to the investment portfolio and/or related investment strategies and considerations. We assessed the historical accuracy of management&#8217;s estimates by comparing actual activity to previous estimates. We evaluated for contrary evidence by confirming the fair value of the investments and ownership interest directly with the trustees and a sample of managers at year end. </span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:51.543%"><tr><td style="width:1.0%"></td><td style="width:78.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Ernst &amp; Young LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8216;s auditor since 1940. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indianapolis, Indiana</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;17, 2021 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">117</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_208"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Eli Lilly and Company</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited Eli Lilly and Company and subsidiaries&#8217; internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Eli Lilly and Company and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), shareholders&#8216; equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February 17, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:53.549%"><tr><td style="width:1.0%"></td><td style="width:75.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Ernst &amp; Young LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indianapolis, Indiana</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;17, 2021 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">119</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_211"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.99pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_214"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable Securities and Exchange Commission (SEC) regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company&#8217;s &#8220;disclosure controls and procedures,&#8221; which are defined generally as controls and other procedures designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form&#160;10-K) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David A. Ricks, president and chief executive officer, and Anat Ashkenazi, senior vice president and chief financial officer, evaluated our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December&#160;31, 2020, and concluded that they were effective.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Ricks and Ms.&#160;Ashkenazi provided a report on behalf of management on our internal control over financial reporting, in which management concluded that the company&#8217;s internal control over financial reporting is effective at December&#160;31, 2020 based on the framework in "Internal Control&#8212;Integrated Framework" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States. Due to the inherent limitations, no evaluation over internal control can provide absolute assurance that no material misstatements or fraud exist.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Ernst&#160;&amp; Young LLP, the company&#8217;s independent registered public accounting firm, issued an attestation report on the company&#8217;s internal control over financial reporting as of December&#160;31, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You can find the full text of management&#8217;s report and Ernst&#160;&amp; Young&#8217;s attestation report in Item&#160;8.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_217"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2pt">Other Information</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">120</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_220"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Part&#160;III</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_223"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 10.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Directors, Executive Officers, and Corporate Governance</span></div><div style="margin-top:12pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors and Executive Officers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our board of directors is found in our Definitive Proxy Statement, to be dated on or about March&#160;19, 2021 (Proxy Statement), under &#8220;Governance - Board Operations and Governance&#8221; and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our executive officers is found at Item 1, &#8220;Business - Executive Officers of the Company&#8221; and is incorporated by reference herein. </span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our code of ethics is found in our Proxy Statement under &#8220;Governance - Board Oversight of Strategy, Compliance, and Risk Management - Code of Ethics&#8221; and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the procedures by which shareholders can recommend nominees to our board of directors is found in our Proxy Statement under &#8220;Shareholder Engagement on Governance Issues - Shareholder Recommendations and Nominations for Director Candidates" is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors has appointed an audit committee consisting entirely of independent directors in accordance with applicable SEC and New York Stock Exchange requirements for audit committees. Information about our audit committee is found in our Proxy Statement under &#8220;Governance - Membership and Meetings of the Board and Its Committees - Audit Committee&#8221; and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_226"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 11.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Executive Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on director compensation, executive compensation, and compensation committee matters can be found in the Proxy Statement under &#8220;Governance - Director Compensation,&#8221; &#8220;- Membership and Meetings of the Board and Its Committees - Compensation Committee,&#8221; &#8220;Compensation - Compensation Discussion and Analysis,&#8221; and &#8220;- Executive Compensation.&#8221; Such information is incorporated in this Annual Report on Form 10-K by reference. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">121</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_229"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 12.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:12pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to ownership of the company&#8217;s common stock by management and by persons known by the company to be the beneficial owners of more than five percent of the outstanding shares of common stock is found in the Proxy Statement under &#8220;Ownership of Company Stock&#8221; and incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information as of December&#160;31, 2020 regarding the company's compensation plans under which shares of the company's common stock have been authorized for issuance.</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a) Number of securities to be issued upon exercise of outstanding options, warrants, and rights </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b) Weighted-average exercise price of outstanding options, warrants, and rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 19pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,510,908&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plan not approved by security holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,510,908&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 9,192,921 shares are underlying outstanding equity awards other than options.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_235"></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-72pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 13.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:12pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Person Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the policies and procedures for approval of related person transactions by our board of directors can be found in the Proxy Statement under &#8220;Governance - Highlights of the Company&#8217;s Corporate Governance - Conflicts of Interest and Transactions with Related Persons.&#8221; Such information is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to director independence can be found in the Proxy Statement under &#8220;Governance - Director Independence&#8221; and is incorporated in this Annual Report on Form 10-K by reference.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_238"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 14.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Principal Accountant Fees and Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the fees and services of our principal independent accountants, Ernst &amp; Young LLP, can be found in the Proxy Statement under &#8220;Audit Matters - Item 3. Ratification of the Appointment of the Independent Auditor - Audit Committee Report - Services Performed by the Independent Auditor&#8221; and &#8220;- Independent Auditor Fees.&#8221; Such information is incorporated in this Annual Report on Form 10-K by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">122</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_241"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 15.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Exhibits and Financial Statement Schedules</span></div><div style="margin-top:12pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following consolidated financial statements of the company and its subsidiaries are found at Item&#160;8:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Operations&#8212;Years Ended December&#160;31, 2020, 2019, and 2018 </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Comprehensive Income (Loss)&#8212;Years Ended December&#160;31, 2020, 2019, and 2018</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Balance Sheets&#8212;December&#160;31, 2020 and 2019</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Shareholders' Equity&#8212;Years Ended December&#160;31, 2020, 2019, and 2018</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated Statements of Cash Flows&#8212;Years Ended December&#160;31, 2020, 2019, and 2018</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Notes to Consolidated Financial Statements</span></div><div style="margin-top:9pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)2.&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statement schedules of the company and its subsidiaries have been omitted because they are not required, are inapplicable, or are adequately explained in the financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statements of interests of 50&#160;percent or less, which are accounted for by the equity method, have been omitted because they do not, considered in the aggregate as a single subsidiary, constitute a significant subsidiary.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)3.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.537%"><tr><td style="width:1.0%"></td><td style="width:6.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated January 5, 2019, among the Company, Bowfin Acquisition Corporation and Loxo Oncology, Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended Articles of Incorporation</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bylaws, as amended</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas, as successor trustee to Citibank, N.A., as Trustee</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tripartite Agreement dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed in Exhibit 4.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Company's Common Stock</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Company's 1.000% Notes due 2022, 1.625% Notes due 2026, and 2.125% Notes due 2030</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Company's 6.77% Notes due 2036</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Company's 7 1/8% Notes due 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Company's 0.625% Notes due 2031 and 1.700% Notes due 2049</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2002 Lilly Stock Plan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance Award under the 2002 Lilly Stock Plan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance Award under the 2002 Lilly Stock Plan (non-executive officer)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Shareholder Value Award under the 2002 Lilly Stock Plan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Shareholder Value Award under the 2002 Lilly Stock Plan (non-executive officer)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Relative Value Award under the 2002 Lilly Stock Plan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Unit Award to Michael Harrington under the 2002 Lilly Stock Plan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Lilly Deferred Compensation Plan, as amended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Lilly Directors' Deferral Plan, as amended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Eli Lilly and Company Bonus Plan, as amended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2007 Change in Control Severance Pay Plan for Select Employees, as amended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">List of Subsidiaries</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Independent Registered Public Accounting Firm</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rule 13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rule 13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1350 Certification</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data File</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">124</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_244"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%">Item 16.</span><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.98pt">Form 10-K Summary</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia8e8b06f04404e6fb09e313103495f8e_247"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this report:</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Location</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1581720/000119312519003083/d674169dex21.htm">2.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1581720/000119312519003083/d674169dex21.htm">Agreement and Plan of Merger, dated January 5, 2019, among the Company, Bowfin Acquisition Corporation and Loxo Oncology, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1581720/000119312519003083/d674169dex21.htm">Incorporated by reference to Exhibit 2.1 to the Current</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1581720/000119312519003083/d674169dex21.htm"> Report on Form 8-K filed by Loxo Oncology, Inc. on January 7, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">Amended Articles of Incorporation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">Incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm"> </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000119312521033302/d111779dex31.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000119312521033302/d111779dex31.htm">Bylaws, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000119312521033302/d111779dex31.htm">Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on February 9, 2021 </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas, as successor trustee to Citibank, N.A., as Trustee</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947813000010/exhibit41-indenturedatedfe.htm">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-3, Registration No. 333-186979</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">4.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">Tripartite Agreement, dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed in Exhibit 4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000095015209001897/c49534exv4w2.htm">Incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2008</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit43.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit43.htm">Description of the Company's Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit43.htm">Incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit44.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit44.htm">Description of the Company's 1.000% Notes due 2022, 1.625% Notes due 2026, and 2.125% Notes due 2030</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit44.htm">Incorporated by reference to Exhibit 4.4 to the  Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit45.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit45.htm">Description of the Company's 6.77% Notes due 2036</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit45.htm">Incorporated by reference to Exhibit 4.5 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit46.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit46.htm">Description of the Company's 7 1/8% Notes due 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit46.htm">Incorporated by reference to Exhibit 4.6 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit47.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit47.htm">Description of the Company's 0.625% Notes due 2031 and 1.700% Notes due 2049</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit47.htm">Incorporated by reference to Exhibit 4.7 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">Amended and Restated 2002 Lilly Stock Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947818000188/lly-6302018x10qxexhibit101.htm">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit102.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit102.htm">Form of Performance Award under the 2002 Lilly Stock Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit102.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit103.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit103.htm">Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit103.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit104.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit104.htm">Form of Performance Award under the 2002 Lilly Stock Plan (non-executive officer)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit104.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit105.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit105.htm">Form of Shareholder Value Award under the 2002 Lilly Stock Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit105.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit106.htm">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit106.htm">Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit106.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit107.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit107.htm">Form of Shareholder Value Award under the 2002 Lilly Stock Plan (non-executive officer)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit107.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit108.htm">10.8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit108.htm">Form of Relative Value Award under the 2002 Lilly Stock Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit108.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit109.htm">10.9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit109.htm">Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit109.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1010.htm">10.10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1010.htm">Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1010.htm">Attached </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit105.htm">10.11</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit105.htm">Restricted Stock Unit Award to Michael Harrington under the 2002 Lilly Stock Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10kexhibit105.htm">Incorporated by reference to Exhibit 10.5 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">The Lilly Deferred Compensation Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit105.htm">Incorporated by reference to Exhibit 10.5 to the Company's annual report on Form 10-K for the year ended December 31, 2013</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">The Lilly Directors' Deferral Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/lly-6302017x10qxexhibit10.htm">Incorporated by reference to Exhibit 10 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1014.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1014.htm">The Eli Lilly and Company Bonus Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1014.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1015.htm">10.15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1015.htm">2007 Change in Control Severance Pay Plan for Select Employees, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit1015.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit21.htm">21</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit21.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit21.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit23.htm">23</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit23.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit23.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit311.htm">Rule 13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit311.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit312.htm">Rule 13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit312.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit32.htm">32</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit32.htm">Section 1350 Certification</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-20201231x10kexhibit32.htm">Attached</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data File</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attached</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attached</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">126</span></div></div></div><div id="ia8e8b06f04404e6fb09e313103495f8e_250"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:14pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eli Lilly and Company</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.185%"><tr><td style="width:1.0%"></td><td style="width:5.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;David A. Ricks</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">David A. Ricks</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President,&#160;and&#160;Chief&#160;Executive&#160;Officer</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;17, 2021 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February&#160;17, 2021 by the following persons on behalf of the Registrant and in the capacities indicated.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:50.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;David A. Ricks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President, and Chief Executive Officer (principal executive officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DAVID A. RICKS</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Anat Ashkenazi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer (principal financial officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANAT ASHKENAZI</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Donald A. Zakrowski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance, and Chief Accounting Officer (principal accounting officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DONALD A. ZAKROWSKI</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Ralph Alvarez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RALPH ALVAREZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Katherine Baicker, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KATHERINE BAICKER, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Carolyn R. Bertozzi, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLYN R. BERTOZZI, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael L. Eskew</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MICHAEL L. ESKEW</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. Erik Fyrwald</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. ERIK FYRWALD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Jamere Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JAMERE JACKSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KIMBERLY H. JOHNSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;William G. Kaelin, Jr., M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WILLIAM G. KAELIN, JR., M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Juan R. Luciano</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JUAN R. LUCIANO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Marschall S. Runge, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MARSCHALL S. RUNGE, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Kathi P. Seifert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KATHI P. SEIFERT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; Gabrielle Sulzberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GABRIELLE SULZBERGER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Jackson P. Tai</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JACKSON P. TAI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Karen Walker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KAREN WALKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:9pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#c21128;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks Used In This Report</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks or service marks owned by Eli Lilly and Company or its affiliates, when first used in each item of this report, appear with an initial capital and are followed by the symbol </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as applicable. In subsequent uses of the marks in the item, the symbols may be omitted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actos</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Takeda Pharmaceutical Company Limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Byetta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Amylin Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are trademarks of Boehringer Ingelheim GmbH.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Posilac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a trademark of Union Agener and Elanco US Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Innovent Biologics (Suzhou) Co., Ltd. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viagra</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark of Pfizer Inc.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">129</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>lly-20201231x10kexhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9a06e06b8f774a50b11b4942d5881e88_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.2 Form of Performance Award under the 2002 Lilly Stock Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Performance Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">(for Executive Officers)</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Performance Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance Levels&#58;</font></div><div><img alt="image1a.jpg" src="image1a.jpg" style="height:205px;margin-bottom:5pt;vertical-align:text-bottom;width:689px"></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2021 &#8211; December 31, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service Vesting Date&#58; &#160;&#160;&#160;&#160;February 1, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i9a06e06b8f774a50b11b4942d5881e88_75"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</font></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.406%"><tr><td style="width:1.0%"></td><td style="width:92.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Performance Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></td></tr></table></div><div style="padding-left:76.5pt;text-indent:-64.5pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Grant of Performance Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Performance Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#34;Target Number of Shares&#34;).   </font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Performance Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Vesting</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of units eligible to vest (&#8220;Performance Units&#8221;) based on the actual cumulative Earnings Per Share (&#34;EPS&#34;) for the Performance Period and using the Non-GAAP EPS (as adjusted to the extent determined by the Committee) for the year immediately prior to the commencement of the Performance Period as a reference point (as shown on page 1 of this document) (&#8220;EPS Growth&#8221;), the corresponding payout multiple and the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The actual cumulative EPS for the Performance Period shall be computed using the following procedures&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">A determination of adjusted consolidated net income ascertained from the Company's audited consolidated financial statements shall be made for each fiscal year in the Performance Period in accordance with accounting principles currently applicable in the United States (&#34;US GAAP&#34;), adjusted to the extent deemed appropriate by the Committee for any unusual items deemed significant by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-25.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">The number of shares of outstanding Lilly Common Stock used to compute consolidated EPS shall be determined as of the end of each fiscal year in the Performance Period on a diluted basis or its equivalent in accordance with US GAAP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">To calculate consolidated EPS for each fiscal year in the Performance Period, the adjusted consolidated net income shall be divided by the number of shares of outstanding Lilly Common Stock as computed in accordance with subsection (ii) above and the quotient rounded to the nearest cent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">To determine the cumulative EPS for the Performance Period, the EPS amounts for each fiscal year as determined above shall be added.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The payout multiple corresponding to the EPS Growth (as shown on page 1 of this document) shall then be applied to the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">The number of Performance Units under this Performance Award will be the number resulting from the calculation described in subsection (b) above. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event the Grantee&#8217;s Service is terminated prior to the Service Vesting Date for any reason or in any circumstance other than as described in Section 3 below, the Award, including any accrued Dividend Equivalent Rights, shall be forfeited.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Impact of Certain Employment Status Changes </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s Service is terminated (i) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the Performance Units shall vest, provided that if the Qualifying Termination occurs prior to the last day of the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under the Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Notwithstanding Section 3(c)(i), in the event the Grantee's Service is terminated due to retirement as a &#8220;retiree&#8221; (as defined in Section 3(c)) subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Performance Units, if any, shall continue to accrue Dividend Equivalent Rights and the Performance Units and Dividend Equivalent Rights shall vest on the Service Vesting Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Grantee who has not received a year-end individual performance rating and (i) is on final written warning (or equivalent as determined by the Committee) for unsatisfactory performance and elects to retire in lieu of a termination of employment&#59; or (ii) elects to retire in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to retirement as described herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, cancel this Performance Award or reduce the number of Performance Units, prorated according to time or other measure as determined appropriate by the Company, if during any period prior to the Service Vesting Date the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Final Written Warning</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If the Grantee is placed on final written warning (or its equivalent as determined by the Committee) at any time subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Grantee shall forfeit the Performance Units and Dividend Equivalent Rights scheduled to vest on the Service Vesting Date to the extent the Award is the next subsequent Award (when compared to other Awards held by the Grantee) that is scheduled to vest following the date that the Grantee is placed on final written warning (it being understood that all other Awards, if any, that are scheduled to vest on the Service Vesting Date shall also be forfeited).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Change in Control</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Performance Units, to be calculated in a manner consistent with Section 2, but the cumulative EPS shall equal the Company&#8217;s cumulative EPS expected results (as determined by the Company&#8217;s last approved forecast prior to the consummation of the Transaction, not considering the impact of the Transaction) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.  </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">The following shall apply in the event of a Transaction that occurs subsequent to the last day of the Performance Period but prior to the Service Vesting Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">In the event that the Performance Units are not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Performance Units shall vest automatically in full.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">In the event that the Performance Units are converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination prior to the Service Vesting Date, then immediately as of the date of the Covered Termination, the Performance Units shall vest automatically in full.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Except as provided below, a vested Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the Service Vesting Date, including if the Award vests pursuant to Sections 3(b) or 3(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 3(b) subsequent to the last day of the Performance Period, the Award shall be paid to the Grantee no later than sixty (60) days following the date of the Grantee&#8217;s termination of Service under Section 3(b), provided that if the Award is considered an item of nonqualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;), the Award shall be paid within sixty (60) days following the date the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;409A Separation&#8221;), provided that  if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (i) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (ii) the date of the Grantee&#8217;s death, as applicable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Award vests pursuant to Section 4(b)(i) or Section 4(c)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered NQ Deferred Compensation and the Transaction does not constitute a &#8220;change in control event&#8221; under Section 409A of the Code (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 4(b)(ii) or Section 4(c)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At the time of settlement provided in this Section 5, Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(f) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">At any time prior to the Service Vesting Date or until the Performance Units are paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Performance Units in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Restriction Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(d).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Dividend Equivalent Rights, if any, that accrue hereunder shall be settled in cash.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Performance Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Performance Award is settled and Shares are issued or transferred to the Grantee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  On each date that the Company pays a cash dividend to holders of Shares during the period commencing on the date the number of Performance Units are determined continuing through the date the Performance Units are settled, the Grantee shall be credited with Dividend Equivalent Rights in an amount equal to the total number of Performance Units, multiplied by the dollar amount of the cash dividend paid per Share by the Company on such date.  Dividend Equivalent Rights shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  The Dividend Equivalent Rights shall be subject to the same vesting conditions and restrictions as the Performance Units to which the Dividend Equivalent Rights relate, and the Dividend Equivalent Rights shall be forfeited in the event that the Performance Units with respect to which such Dividend Equivalent Rights were credited are forfeited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the grant of the Performance Award, the vesting of the Performance Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the accrual and payment of Dividend Equivalent Rights, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">If the Performance Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-25.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Grantee&#8217;s Acknowledgments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award and any Dividend Equivalent Rights after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any shares of Lilly Stock that may be issued pursuant to this Award.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Performance Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity and construction of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of Indiana, and agree that such litigation shall be conducted in the courts of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the three years following the date on which the number of Performance Units subject to the Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">(i)&#160;&#160;&#160;&#160;the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>lly-20201231x10kexhibit103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i89ca531aed10477680b825dca0b0d06a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.3 Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Performance Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">(for Executive Officers)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Performance Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><img alt="image1a.jpg" src="image1a.jpg" style="height:198px;margin-bottom:5pt;vertical-align:text-bottom;width:667px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Period&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1, 2021 &#8211; December 31, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service Vesting Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 1, 2024</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><div id="i89ca531aed10477680b825dca0b0d06a_72"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</font></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.406%"><tr><td style="width:1.0%"></td><td style="width:93.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Performance Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></td></tr></table></div><div style="padding-left:76.5pt;text-indent:-64.5pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Grant of Performance Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Performance Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#34;Target Number of Shares&#34;).   </font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Performance Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Vesting</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of units eligible to vest (&#8220;Performance Units&#8221;) based on the actual cumulative Earnings Per Share (&#34;EPS&#34;) for the Performance Period and using the Non-GAAP EPS (as adjusted to the extent determined by the Committee) for the year immediately prior to the commencement of the Performance Period as a reference point (as shown on page 1 of this document) (&#8220;EPS Growth&#8221;), the corresponding payout multiple and the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The actual cumulative EPS for the Performance Period shall be computed using the following procedures&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">A determination of adjusted consolidated net income ascertained from the Company's audited consolidated financial statements shall be made for each fiscal year in the Performance Period in accordance with accounting principles currently applicable in the United States (&#34;US GAAP&#34;), adjusted to the extent deemed appropriate by the Committee for any unusual items deemed significant by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-25.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">The number of shares of outstanding Lilly Common Stock used to compute consolidated EPS shall be determined as of the end of each fiscal year in the Performance Period on a diluted basis or its equivalent in accordance with US GAAP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">To calculate consolidated EPS for each fiscal year in the Performance Period, the adjusted consolidated net income shall be divided by the number of shares of outstanding Lilly Common Stock as computed in accordance with subsection (ii) above and the quotient rounded to the nearest cent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">To determine the cumulative EPS for the Performance Period, the EPS amounts for each fiscal year as determined above shall be added.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The payout multiple corresponding to the EPS Growth (as shown on page 1 of this document) shall then be applied to the Target Number of Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">The number of Performance Units under this Performance Award will be the number resulting from the calculation described in subsection (b) above. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event the Grantee&#8217;s Service is terminated prior to the Service Vesting Date for any reason or in any circumstance other than as described in Section 3 below, the Award, including any accrued Dividend Equivalent Rights, shall be forfeited.  </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Impact of Certain Employment Status Changes </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) following the Retirement Vesting Date due to the Grantee&#8217;s Retirement&#59; (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the Performance Units shall vest, provided that if the Qualifying Termination occurs prior to the last day of the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Post-Performance Period Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Notwithstanding Section 3(b), in the event the Grantee's Service is terminated due to Retirement subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Performance Units, if any, shall continue to accrue Dividend Equivalent Rights and the Performance Units and Dividend Equivalent Rights shall vest on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Grantee who has not received a year-end individual performance rating and (i) is on final written warning (or equivalent as determined by the Committee) for unsatisfactory performance and elects to retire in lieu of a termination of employment&#59; or (ii) elects to retire in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to retirement as described herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, cancel this Performance Award or reduce the number of Performance Units, prorated according to time or other measure as determined appropriate by the Company, if during any period prior to the Service Vesting Date the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Final Written Warning</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If the Grantee is placed on final written warning (or its equivalent as determined by the Committee) at any time subsequent to the last day of the Performance Period but prior to the Service Vesting Date, the Grantee shall forfeit the Performance Units and Dividend Equivalent Rights scheduled to vest on the Service Vesting Date to the extent the Award is the next subsequent Award (when compared to other Awards held by the Grantee) that is scheduled to vest following the date that the Grantee is placed on final written warning (it being understood that all other Awards, if any, that are scheduled to vest on the Service Vesting Date shall also be forfeited).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Change in Control</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Performance Units, to be calculated in a manner consistent with Section 2, but the cumulative EPS shall equal the Company&#8217;s cumulative EPS expected results (as determined by the Company&#8217;s last approved forecast prior to the consummation of the Transaction, not considering the impact of the Transaction) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.  </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">The following shall apply in the event of a Transaction that occurs subsequent to the last day of the Performance Period but prior to the Service Vesting Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">In the event that the Performance Units are not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Performance Units shall vest automatically in full.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">In the event that the Performance Units are converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination prior to the Service Vesting Date, then immediately as of the date of the Covered Termination, the Performance Units shall vest automatically in full.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Except as provided below, a vested Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the Service Vesting Date, including if the Award vests pursuant to Sections 3(b) or 3(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 3(b)(ii) or (iii) subsequent to the last day of the Performance Period, the Award shall be paid to the Grantee no later than sixty (60) days following the date of the Grantee&#8217;s termination of Service under Section 3(b)(ii) or (iii), provided that if the Award is considered an item of nonqualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;), the Award shall be paid within sixty (60) days following the date the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;409A Separation&#8221;), provided that  if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (i) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (ii) the date of the Grantee&#8217;s death, as applicable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Award vests pursuant to Section 4(b)(i) or Section 4(c)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered NQ Deferred Compensation and the Transaction does not constitute a &#8220;change in control event&#8221; under Section 409A of the Code (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the Service Vesting Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 4(b)(ii) or Section 4(c)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experiences a 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At the time of settlement provided in this Section 5, Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(f) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">At any time prior to the Service Vesting Date or until the Performance Units are paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Performance Units in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Restriction Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(d).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Dividend Equivalent Rights, if any, that accrue hereunder shall be settled in cash.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Performance Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Performance Award is settled and Shares are issued or transferred to the Grantee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  On each date that the Company pays a cash dividend to holders of Shares during the period commencing on the date the number of Performance Units are determined continuing through the date the Performance Units are settled, the Grantee shall be credited with Dividend Equivalent Rights in an amount equal to the total number of Performance Units, multiplied by the dollar amount of the cash dividend paid per Share by the Company on such date.  Dividend Equivalent Rights shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  The Dividend Equivalent Rights shall be subject to the same vesting conditions and restrictions as the Performance Units to which the Dividend Equivalent Rights relate, and the Dividend Equivalent Rights shall be forfeited in the event that the Performance Units with respect to which such Dividend Equivalent Rights were credited are forfeited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Performance Award, the vesting of the Performance Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the accrual and payment of Dividend Equivalent Rights, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">If the Performance Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-25.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">If the Performance Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Grantee&#8217;s Acknowledgments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award and any Dividend Equivalent Rights after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any shares of Lilly Stock that may be issued pursuant to this Award.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1) Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.    </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2) Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (i)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (ii)&#160;any officer, director, executive or senior management capacity or function&#59; (iii)&#160;any research and development capacity or function&#59; (iv)&#160;any sales management or business development management capacity or function&#59; (v)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (vi)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges and agrees that during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third-party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity.</font><font style="color:#c00000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Performance Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13. Governing Law and Choice of Venue</font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14. Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15. Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the three years following the date on which the number of Performance Units subject to the Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">(i)&#160;&#160;&#160;&#160;the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16. Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>lly-20201231x10kexhibit104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3805b4ec139f4caabf792d19262632c5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.4 Form of Performance Award under the 2002 Lilly Stock Plan (non-executive officer)</font></div><div><font><br></font></div><div style="padding-left:11.25pt;padding-right:11.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Performance Award Agreement</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Performance Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance Levels&#58;</font></div><div><img alt="image1a.jpg" src="image1a.jpg" style="height:203px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance Period&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">                  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2021 &#8211; December 31, 2022</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Table of Contents</font></div><div><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 1.        Grant of Performance Award ........................................................................................................... 3</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 2.        Vesting ............................................................................................................................................ 3</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 3.        Impact of Certain Employment Status Changes ............................................................................. 4</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 4.        Change in Control ........................................................................................................................... 5</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 5.        Settlement ....................................................................................................................................... 5</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 6.        Rights of the Grantee ...................................................................................................................... 6</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 7.        Prohibition Against Transfer ............................................................................................................ 6</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 8.        Responsibility for Taxes ..............................................................................................................&#8230;  6</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 9.        Section 409A Compliance ............................................................................................................... 8</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 10.     Grantee&#8217;s Acknowledgement ........................................................................................................... 8</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 11.     Data Privacy ..................................................................................................................................... 9</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 12.     Additional Terms and Conditions ................................................................................................&#8230; 10</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 13.     Governing Law and Choice of Venue ............................................................................................. 11</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 14.     Miscellaneous Provisions ............................................................................................................... 11</font></div><div style="text-indent:12.25pt"><font><br></font></div><div style="text-indent:12.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Section 15.     Award Subject to Acknowledgement of Acceptance ...................................................................... 12</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 2</font></div></div></div><div id="i3805b4ec139f4caabf792d19262632c5_50"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1. Grant of Performance Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Performance Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Performance Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Target Number of Shares&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Performance Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2. Vesting</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares eligible to vest based on the actual cumulative Earnings Per Share (&#8220;EPS&#8221;) for the Performance Period and using the Non-GAAP EPS (as adjusted to the extent determined by the Committee) for the year immediately prior to the commencement of the Performance Period as a reference point (as shown on page 1 of this document) (&#8220;EPS Growth&#8221;), the corresponding payout multiple and the Target Number of Shares.</font></div><div style="margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The actual cumulative EPS for the Performance Period shall be computed using the following procedures&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-26.88pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">A determination of adjusted consolidated net income ascertained from the Company's audited consolidated financial statements shall be made for each fiscal year in the Performance Period in accordance with accounting principles currently applicable in the United States (&#8220;US GAAP&#8221;), adjusted to the extent deemed appropriate by the Committee for any unusual items deemed significant by the Committee.</font></div><div style="margin-top:6pt;padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-29.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">The number of shares of outstanding Lilly Common Stock used to compute consolidated EPS shall be determined as of the end of each fiscal year in the Performance Period on a diluted basis or its equivalent in accordance with US GAAP.</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-31.32pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">To calculate consolidated EPS for each fiscal year in the Performance Period, the adjusted consolidated net income shall be divided by the number of shares of outstanding Lilly Common Stock as computed in accordance with subsection (ii) above and the quotient rounded to the nearest cent.</font></div><div style="margin-top:6pt;padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-31.88pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">To determine the cumulative EPS for the Performance Period, the EPS amounts for each fiscal year as determined above shall be added.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The payout multiple corresponding to the EPS Growth (as shown on page 1 of this document) shall then be applied to the Target Number of Shares.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">The number of Shares eligible to vest under this Performance Award will be the number of Shares resulting from the calculation described in subsection (b) above. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 3</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.3pt;text-indent:-4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3. Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Committee determines, in its sole discretion, that such adjustments are not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s Service is terminated (i) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee&#8217;s Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under the Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements&#59; or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee may, in its sole discretion, cancel this Performance Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company. </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 4</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee and&#47;or the Company&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee&#8217;s Service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4. Change in Control</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, to be calculated in a manner consistent with Section 2, but the cumulative EPS shall equal the Company&#8217;s cumulative EPS expected results (as determined by the Company&#8217;s last approved forecast prior to the consummation of the Transaction, not considering the impact of the Transaction) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Employees or the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (both as amended from time to time) or any successor plan or arrangement thereto, as applicable.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:40.3pt;text-indent:-4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5. Settlement  </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days following the last day of the Performance Period.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 5</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i)&#160;the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s 409A Separation (the &#8220;409A Delayed Payment Date&#8221;), (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the earliest of (1) the 409A Delayed Payment Date and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6. Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Performance Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Performance Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.3pt;text-indent:-4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7. Prohibition Against Transfer</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.3pt;text-indent:-4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8. Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">i. Regardless of any action Lilly and&#47;or the Grantee&#8217;s Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 6</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Performance Award, the vesting of the Performance Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) If the Performance Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Performance Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A)&#160;withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B)&#160;arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) If the Performance Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 7</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.3pt;text-indent:-4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9. Section 409A Compliance</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10. Grantee&#8217;s Acknowledgement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 8</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.  </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11. Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 9</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on applicable law and that, depending on where the Grantee is based and subject to the conditions set out in such applicable law, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12. Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Performance Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Performance Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 10</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.3pt;text-indent:-4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13. Governing Law and Choice of Venue</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity and construction of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of Indiana, and agree that such litigation shall be conducted in the courts of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.3pt;text-indent:-4.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14. Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 11</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15. Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 12</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>lly-20201231x10kexhibit105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic321d6e9260844959d0cdbbb5a673b13_1"></div><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.5 &#8212; Form of Shareholder Value Award under the 2002 Lilly Stock Plan</font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Shareholder Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Shareholder Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-left:18pt;padding-right:39.6pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Stock Price Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div id="ic321d6e9260844959d0cdbbb5a673b13_47"></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.074%"><tr><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Payout</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 3</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 4</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 5</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Level 6</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Final Lilly Stock Price</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#60; $140.70</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$140.70 - $160.36</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$160.37 - $180.02</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$180.03 - $199.69</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$199.70 - $219.36</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$219.37 - $239.03</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#62; $239.03</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percent of Target</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">0%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">50%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">75%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">125%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">150%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">175%</font></td></tr></table></div><div style="padding-left:28.8pt;padding-right:28.8pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2021 &#8211; December 31, 2023</font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.931%"><tr><td style="width:1.0%"></td><td style="width:92.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Shareholder Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="ic321d6e9260844959d0cdbbb5a673b13_50"></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Grant of Shareholder Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Shareholder Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Shareholder Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Percent of Target, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-40.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Percent of Target</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the percentage set forth in the Lilly Stock Price Performance Levels table set forth on the first page of this document representing the attainment level of the Final Lilly Stock Price measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-43.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s Service is terminated (i) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under the Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-25.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.43pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee may, in its sole discretion, cancel this Shareholder Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;) (subject to the six (6) month delay described in Section 5(c) below if Grantee is a &#8220;specified employee&#8221;), the date of the Grantee&#8217;s death and the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Shareholder Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Shareholder Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Shareholder Value Award, the vesting of the Shareholder Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">If the Shareholder Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any Shares subject to, or issued pursuant to the Award.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Shareholder Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Shareholder Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity and construction of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of Indiana, and agree that such litigation shall be conducted in the courts of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>6
<FILENAME>lly-20201231x10kexhibit106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1c90134f5b3a4cd3b045ddd7c8c92c14_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.6 Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div><font><br></font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Shareholder Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">(for Executive Officers)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Shareholder Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Stock Price Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:14.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No Payout</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 4</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 5</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 6</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Final Lilly Stock Price</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#60; $140.70</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$140.70 &#8211;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$160.36</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$160.37</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$180.02</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$180.03</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$199.69</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$199.70</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$219.36</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$219.37</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$239.03</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;$239.03</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent of Target</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175%</font></td></tr></table></div><div style="padding-right:39.6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2021 &#8211; December 31, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i1c90134f5b3a4cd3b045ddd7c8c92c14_37"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.265%"><tr><td style="width:1.0%"></td><td style="width:93.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Shareholder Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i1c90134f5b3a4cd3b045ddd7c8c92c14_40"></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Grant of Shareholder Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Shareholder Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Shareholder Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Percent of Target, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Percent of Target</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the percentage set forth in the Lilly Stock Price Performance Levels table set forth on the first page of this document representing the attainment level of the Final Lilly Stock Price measured against the performance goal attainment levels set forth in the table.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) following the Retirement Vesting Date due to the Grantee&#8217;s Retirement&#59; (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-25.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee may, in its sole discretion, cancel this Shareholder Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee's service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;) (subject to the six (6) month delay described in Section 5(c) below if Grantee is a &#8220;specified employee&#8221;), the date of the Grantee&#8217;s death and the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Shareholder Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Shareholder Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Shareholder Value Award, the vesting of the Shareholder Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">If the Shareholder Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">the Company has communicated share ownership guidelines that apply to the Grantee, and the Grantee understands and agrees that those guidelines may impact any Shares subject to, or issued pursuant to the Award.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Shareholder Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (i)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (ii)&#160;any officer, director, executive or senior management capacity or function&#59; (iii)&#160;any research and development capacity or function&#59; (iv)&#160;any sales management or business development management capacity or function&#59; (v)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (vi)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges and agrees that during the course of Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award settled shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity. </font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Shareholder Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div style="padding-left:288pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>7
<FILENAME>lly-20201231x10kexhibit107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8b882168dd0147ad8ad8738f1dd279c0_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.7 &#8212; Form of Shareholder Value Award under the 2002 Lilly Stock Plan (non-executive officer)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Shareholder Value Award Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Shareholder Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Stock Price Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.922%"><tr><td style="width:1.0%"></td><td style="width:12.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No Payout</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 4</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 5</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 6</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-5.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Final Lilly </font></div><div style="padding-right:-5.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Price</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#60; $76.08</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$76.08</font></div><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$160.36</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$160.37</font></div><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="padding-right:-2.7pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$180.02</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$180.03</font></div><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$199.69</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$199.70</font></div><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$219.36</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$219.37</font></div><div style="padding-left:3.9pt;padding-right:3.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$239.03</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;$239.03</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent of Target</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Period&#58;&#160;&#160;&#160;&#160;January 1, 2021 &#8211; December 31, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i8b882168dd0147ad8ad8738f1dd279c0_37"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:92.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Shareholder Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr></table></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">2</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Grant of Shareholder Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Shareholder Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Shareholder Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Target Number of Shares&#8221;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Shareholder Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Percent of Target, where&#58; </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">&#8220;Percent of Target&#8221; shall mean the percentage set forth in the Lilly Stock price Performance Levels table set forth on the first page of this document representing the attainment level of the Final Stock Price measured against the performance goal attainment levels set forth in the table, and</font></div><div style="padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">&#8220;Final Lilly Stock Price&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58; </font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="padding-left:58.5pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s Service is terminated (i) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="padding-left:58.5pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee&#8217;s Service under any one of the following circumstances&#58;  </font></div><div style="padding-left:58.5pt;text-align:justify"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under the Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements&#59; or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59;</font></div><div style="padding-left:103.5pt;text-align:justify"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="padding-left:103.5pt;text-align:justify"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="padding-left:58.5pt"><font><br></font></div><div style="padding-left:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="padding-left:58.5pt"><font><br></font></div><div style="padding-left:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="padding-left:58.5pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee may, in its sole discretion, cancel this Shareholder Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i)&#160;subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company. </font></div><div style="padding-left:58.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee and&#47;or the Company&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or retirement, (3) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in force, and (4) the Grantee&#8217;s Service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">4</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">In the event of a Transaction that occurs prior to the last day of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:94.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.51pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="padding-left:94.5pt;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:94.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.29pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the last day of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Employees or the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (both as amended from time to time) or any successor plan or arrangement thereto, as applicable.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Settlement  </font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of (i) the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), provided that if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of the Section 409A Separation, the Award shall instead be paid on the first day following the six (6) month anniversary of the Grantee&#8217;s 409A Separation (the &#8220;409A Delayed Payment Date&#8221;), (ii) the date of the Grantee&#8217;s death and (iii) the date set forth in Section 5(a) above.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">5</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the date of the Section 409A Separation, the Award shall instead be paid on the earliest of (1) the 409A Delayed Payment Date and (2) the date of the Grantee&#8217;s death.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="padding-left:58.5pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c).</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.46pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Rights of the Grantee</font></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Shareholder Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Shareholder Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Responsibility for Taxes</font></div><div style="padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Shareholder Value Award, the vesting of the Shareholder Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">6</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.17pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">If the Shareholder Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A)&#160;withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B)&#160;arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C)&#160;withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee. </font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">If the Shareholder Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above. </font></div><div><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.57pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:108pt;text-indent:-90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:40.01pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">7</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">8</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.01pt">Data Privacy</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Shareholder Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on applicable law and that, depending on where the Grantee is based and subject to the conditions set out in such applicable law, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">9</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.01pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Shareholder Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.  </font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Shareholder Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.01pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity and construction of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of Indiana, and agree that such litigation shall be conducted in the courts of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">10</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.01pt">Miscellaneous Provisions</font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:35.51pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">11</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:104%">12</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:104%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>8
<FILENAME>lly-20201231x10kexhibit108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9995d212bcbc4a57b5de32058bce9a34_32"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.8 Form of Relative Value Award under the 2002 Lilly Stock Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Relative Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">(for Executives)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Relative Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Relative Total Shareholder Return Performance Levels&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Absolute Percentage Point (pp) Difference from Peer Median TSR</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#60;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -30pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-24.0 pp</font></div><div style="padding-right:-1.85pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-1.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-29.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-18.0 pp</font></div><div style="padding-right:-2pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-2pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-23.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12.0 pp</font></div><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-17.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-1.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6.0 pp</font></div><div style="padding-right:-1.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-1.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-0.01 pp</font></div><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5.9 pp</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Peer Median</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+5.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+6.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+11.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+12.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+17.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+18.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+23.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+24.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+29.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> +30 pp</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payout Multiple</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.25</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.40</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.55</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.70</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.85</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.00</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.15</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.30</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.60</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.75</font></td></tr></table></div><div style="padding-left:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2021 &#8211; December 31, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9995d212bcbc4a57b5de32058bce9a34_44"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.931%"><tr><td style="width:1.0%"></td><td style="width:92.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Relative Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div style="padding-right:31.5pt"><font><br></font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9995d212bcbc4a57b5de32058bce9a34_47"></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Grant of Relative Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Relative Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Relative Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Payout Multiple, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payout Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the payout multiple set forth in the Lilly Relative Total Shareholder Return Performance Levels table set forth on the first page of this document, representing the attainment level of Lilly&#8217;s rTSR, measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the quotient of (i) the Final Lilly Stock Price or Final Peer Stock Price, as applicable, minus the corresponding Beginning Stock Price, including the impact of Dividend reinvestment on each ex-dividend date, if any, paid by the applicable issuer during the Performance Period, divided by (ii) the corresponding Beginning Stock Price.   </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      The stock prices and cash dividend payments reflected in the calculation of TSR shall be adjusted to reflect stock splits during the Performance Period and dividends shall be assumed to be reinvested in the relevant issuer&#8217;s shares for purposes of the calculation of TSR.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Relative Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">rTSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the comparison between Lilly&#8217;s TSR and the TSR of the Peer Group over the Performance Period, measured as the absolute percentage point difference in the performance of the Company&#8217;s TSR compared to the Peer Group&#8217;s median TSR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Beginning Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the average closing price of a share of Lilly Common Stock on the New York Stock Exchange or a share of each Peer Group company&#8217;s stock, as applicable, for each trading day in the two month period immediately preceding the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Final Peer Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the average of the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, for each trading day in the last two months of the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean ordinary or extraordinary cash dividends paid by Lilly or a Peer Group company to its shareholders of record at any time during the Performance Period.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Peer Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean all companies identified and most recently approved by the Committee as a member of the Company&#8217;s Peer Group in effect as of the Grant Date.  Companies that are members of the Peer Group at the beginning of the Performance Period that subsequently cease to be traded on a market where an independent share price can be determined shall be excluded from the Peer Group. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change employment status of the Grantee during the Performance Period will be as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s Service is terminated (i) due to the Grantee&#8217;s death, or (ii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under the Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee may, in its sole discretion, cancel this Relative Value Award or reduce the number of Shares eligible to vest, prorated according to time or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or retirement, (3) the Grantee&#8217;s Service has been terminated as a result a direct result of either a plant closing or a reduction in force and (4) the Grantee&#8217;s Service has been terminated of </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction and the Final Peer Stock Price shall be equal to the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, on the date the Transaction closes (or if such day is not a trading date, the first trading date immediately preceding such date) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;) (subject to the six (6) month delay described in Section 5(c) below if Grantee is a &#8220;specified employee&#8221;), the date of the Grantee&#8217;s death and the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Relative Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Relative Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Relative Value Award, the vesting of the Relative Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">If the Relative Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.   </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Relative Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Additional Terms and Conditions</font></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="padding-left:58.5pt;text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Relative Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Relative Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity and construction of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of Indiana, and agree that such litigation shall be conducted in the courts of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>9
<FILENAME>lly-20201231x10kexhibit109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibf064df72bb64ba3bdfbff0fba14557e_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.9 &#8212; Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete) </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Relative Value Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">(for Executives)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-right:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Relative Value Award has been granted on &#91;&#8226;&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;).</font></div><div style="padding-left:18pt;padding-right:39.6pt"><font><br></font></div><div style="padding-right:39.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Relative Total Shareholder Return Performance Levels&#58;</font></div><div style="padding-right:39.6pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"></td><td style="width:10.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Absolute Percentage Point (pp) Difference from Peer Median TSR</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#60;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> -30pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-24.0 pp</font></div><div style="padding-right:-1.85pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-1.9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-29.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-18.0 pp</font></div><div style="padding-right:-2pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-2pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-23.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-12.0 pp</font></div><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-17.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-1.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-6.0 pp</font></div><div style="padding-right:-1.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-1.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-11.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.01 pp</font></div><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="padding-right:-2.1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-5.9 pp</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Peer Median</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">+5.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+6.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+11.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+12.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+17.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+18.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+23.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+24.0 pp</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+29.9 pp</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">&#62;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> +30 pp</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payout Multiple</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.0</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.25</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.40</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.55</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.70</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">0.85</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.00</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.15</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.30</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.60</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.75</font></td></tr></table></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance Period&#58; &#160;&#160;&#160;&#160;January 1, 2021 &#8211; December 31, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="ibf064df72bb64ba3bdfbff0fba14557e_37"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="padding-left:15.3pt;padding-right:15.3pt;text-align:center"><font><br></font></div><div style="padding-left:19.8pt;padding-right:19.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.000%"><tr><td style="width:1.0%"></td><td style="width:93.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Relative Value Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Impact of Certain Employment Status Changes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></td></tr></table></div><div style="padding-left:23.75pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:128.25pt;padding-right:128.25pt;text-align:center;text-indent:-198pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="ibf064df72bb64ba3bdfbff0fba14557e_40"></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Grant of Relative Value Award</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Relative Value Award Agreement (the &#8220;Grantee&#8221;) a Performance-Based Award (the &#8220;Relative Value Award&#8221; or the &#8220;Award&#8221;) with respect to the target number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (the &#34;Target Number of Shares&#34;).</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Relative Value Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 12 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Vesting</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As soon as reasonably practicable following the end of the Performance Period, the Committee shall determine the number of Shares that are eligible to vest which shall be equal to the product of (i) the Target Number of Shares, multiplied by (ii)&#160;the Payout Multiple, where&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payout Multiple</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the payout multiple set forth in the Lilly Relative Total Shareholder Return Performance Levels table set forth on the first page of this document, representing the attainment level of Lilly&#8217;s rTSR, measured against the performance goal attainment levels set forth in the table.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Final Lilly Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the average of the closing price of a share of Lilly Common Stock on the New York Stock Exchange for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the quotient of (i) the Final Lilly Stock Price or Final Peer Stock Price, as applicable, minus the corresponding Beginning Stock Price, including the impact of Dividend reinvestment on each ex-dividend date, if any, paid by the applicable issuer during the Performance Period, divided by (ii) the corresponding Beginning Stock Price. </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock prices and cash dividend payments reflected in the calculation of TSR shall be </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjusted to reflect stock splits during the Performance Period and dividends shall be </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumed to be reinvested in the relevant issuer&#8217;s shares for purposes of the calculation of</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TSR. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Relative Total Shareholder Return</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">rTSR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the comparison between Lilly&#8217;s SR and the TSR of the Peer Group over the Performance Period, measured as the absolute percentage point difference in the performance of the Company&#8217;s TSR compared to the Peer Group&#8217;s median TSR.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Beginning Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the average closing price of a share of Lilly Common Stock on the New York Stock Exchange or a share of each Peer Group company&#8217;s stock, as applicable, for each trading day in the two month period immediately preceding the Performance Period, rounded to the nearest cent.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Final Peer Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the average of the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, for each trading day in the last two months of the Performance Period, rounded to the nearest cent. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividend</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean ordinary or extraordinary cash dividends paid by Lilly or a Peer Group company to its shareholders of record at any time during the Performance Period. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Peer Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean all companies identified and most recently approved by the Committee as a member of the Company&#8217;s Peer Group in effect as of the Grant Date.  Companies that are members of the Peer Group at the beginning of the Performance Period </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that subsequently cease to be traded on a market where an independent share price can be determined shall be excluded from the Peer Group. </font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Grantee&#8217;s Service is terminated prior to the end of the Performance Period for any reason or in any circumstance other than as described in Section 3 below, the Award shall be forfeited.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Impact of Certain Employment Status Changes</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Committee determines, in its sole discretion, that such treatment is not advisable after consideration of Applicable Laws, the number of Shares that are eligible to vest upon a change in employment status of the Grantee during the Performance Period will be as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee is on an approved leave of absence during the Performance Period, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Retirement&#59; Death&#59; Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as otherwise provided below (including Section 12), in the event the Grantee&#8217;s Service is terminated (i) following the Retirement Vesting Date due to the Grantee&#8217;s Retirement&#59; (ii) due to the Grantee&#8217;s death, or (iii) by reason of Grantee&#8217;s Disability, the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above.  For the avoidance of any doubt, the Award shall be forfeited in the event the Grantee&#8217;s Service is terminated prior to the Retirement Vesting Date due to the Grantee&#8217;s Retirement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Retirement&#8221; means retirement as a &#8220;retiree,&#8221; which is a person who is (A) a retired employee under The Lilly Retirement Plan&#59; (B) a retired employee under the retirement plan or program of an Affiliate&#59; (C) a retired employee under a retirement program specifically approved by the Committee&#59; (D) required to retire under local law, to the extent authorized by the Company to address such local requirements or (E) otherwise determined to be a retired employee in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Retirement Vesting Date&#8221; means the date that is on or following December 31 immediately following the commencement of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Disability&#8221; for purposes of this Award Agreement means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the event the Grantee&#8217;s employment is subject to a Qualifying Termination (as defined below), the number of Shares eligible to vest shall be the number determined in accordance with Section 2 above, reduced proportionally for the portion of the total days during the Performance Period in which the Grantee was not in active Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, a &#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Demotions, Disciplinary Actions and Misconduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Committee may, in its sole discretion, cancel this Relative Value Award or reduce the number of Shares eligible to vest, prorated according to time </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other measure as determined appropriate by the Committee, if during any portion of the Performance Period the Grantee has been (i) subject to disciplinary action by the Company or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company, as determined in the sole discretion of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination as to whether (1) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service, (2) the Grantee&#8217;s Service has been terminated by reason of Disability or Retirement, (3) the Grantee&#8217;s Service has been terminated as a result a direct result of either a plant closing or a reduction in force and (4) the Grantee&#8217;s Service has been terminated of as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment shall be final and binding on the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The only Change in Control event that shall result in a benefit under this Section 4 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of a Transaction that occurs prior to the end of the Performance Period, the Grantee will be credited with an award of Restricted Stock Units equal to the number of Shares eligible to vest, calculated in a manner consistent with Section 2, but the Final Lilly Stock Price shall be equal to the value of Shares established for the consideration to be paid to holders of Shares in the Transaction and the Final Peer Stock Price shall be equal to the closing price of a share of each Peer Group company&#8217;s stock, on Nasdaq, the New York Stock Exchange, or other market where an independent share price can be determined, on the date the Transaction closes (or if such day is not a trading date, the first trading date immediately preceding such date) (the &#8220;Credited RSU Award&#8221;).  The Credited RSU Award shall be eligible to vest on the last day of the Performance Period, subject to the Grantee&#8217;s continued Service through the last day of the Performance Period, except as provided below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">In the event that the Credited RSU Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Credited RSU Award shall vest automatically in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">In the event that the Credited RSU Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Performance Period, then immediately as of the date of the Covered Termination, the Credited RSU Award shall vest automatically in full. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 3(b) and (c), Grantee&#8217;s termination of Service without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (as amended from time to time) or any successor plan or arrangement thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 4, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Settlement  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the last day of the Performance Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Award vests pursuant to Section 4(b)(i), the Award shall be paid to the Grantee immediately prior to the Transaction, provided that if the Award is considered an item of non-qualified deferred </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation subject to Section 409A of the Code (&#8220;NQ Deferred Compensation&#8221;) and the Transaction does not constitute a &#8220;change in control event,&#8221; within the meaning of the U.S. Treasury Regulations (a &#8220;409A CIC&#8221;), then the Award shall be paid in cash (calculated based on the value of the Shares established for the consideration to be paid to holders of Shares in the Transaction) on the earliest of the date that the Grantee experiences a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;) (subject to the six (6) month delay described in Section 5(c) below if Grantee is a &#8220;specified employee&#8221;), the date of the Grantee&#8217;s death and the date set forth in Section 5(a) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">If the Award vests pursuant to Section 4(b)(ii), the Award shall be paid to the Grantee as soon as practicable, but in no event later than sixty (60) days, following the date the Grantee is subject to a Covered Termination, provided that if the Award is NQ Deferred Compensation, (i) the Award shall be paid within sixty (60) days following the date the Grantee experiences a Section 409A Separation, and (ii)&#160;if the Grantee is a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the payment date, the Award shall instead be paid on the earliest of (1) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation and (2) the date of the Grantee&#8217;s death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At the time of settlement provided in this Section 5,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 5(e) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At any time prior to the end of the Performance Period or until the Award is paid in accordance with this Section 5, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares.  The amount of cash shall be calculated based on the Fair Market Value of the Shares on the last day of the Performance Period in the case of payment pursuant to Section 5(a) and on the date of payment in the case of a payment pursuant to Section 5(c). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Rights of the Grantee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Relative Value Award does not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Relative Value Award is settled and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Responsibility for Taxes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Regardless of any action Lilly and&#47;or the Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Relative Value Award, the </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vesting of the Relative Value Award, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">If the Relative Value Award is paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or (D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">If the Relative Value Award is paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 8(b)(ii)(A) and (B) above</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee.  In the event of over-withholding, the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 8. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.57pt">Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Grantee&#8217;s Acknowledgment</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future Performance-Based Awards, or benefits in lieu thereof, even if Performance-Based Awards have been granted in the past&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">all decisions with respect to future Performance-Based Awards or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee&#8217;s employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence) in accordance with Section 409A&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">the Grantee is solely responsible for investigating and complying with any laws applicable to him or her in connection with the Award&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.   </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Data Privacy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Relative Value Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent.  Where required under Applicable Laws, Data may also be disclosed to certain securities or other regulatory authorities where the Company&#8217;s securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the Applicable Laws.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and its service providers are based in the United States.  The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company&#8217;s legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on Applicable Laws and that, depending on where the Grantee is based and subject to the conditions set out in such Applicable Laws, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale, or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold, or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.    </font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">Directly or indirectly solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person's business with, or representation of, Lilly or a Covered Affiliate. </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Competively-Sensitive Capacity&#8221; means&#58; (i)&#160;the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (ii)&#160;any officer, director, executive or senior management capacity or function&#59; (iii)&#160;any research and development capacity or function&#59; (iv)&#160;any sales management or business development management capacity or function&#59; (v)&#160;any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (vi)&#160;any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information Lilly or a Covered Affiliate.  For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (a)&#160;absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (b)&#160;such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information.  In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges and agrees that during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage.  The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the one-year restricted period.  And the Grantee acknowledges and </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates.  For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests, and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever extent would be reasonable and enforceable under applicable law.  Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed to in the past, including those in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees to in the future.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not be adequate relief for such injury.  As a result, the Grantee agrees that Lilly (including any third party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that the Grantee has violated any applicable provisions of this Section 12, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 12 shall not be Lilly&#8217;s exclusive remedies.  Lilly reserves all other rights and remedies available to it at law or in equity.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Country-Specific Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In addition, the Award shall be subject to any special terms and conditions set forth in any Appendix to this Award Agreement for the Grantee&#8217;s country.  Moreover, if the Grantee relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Award Agreement.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell, or otherwise dispose of Shares, rights to acquire Shares (e.g., the Relative Value Award) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Without limitation to the foregoing, the Grantee agrees that the Relative Value Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana.  For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana, and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Miscellaneous Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Compensation Recovery</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the three years following the date on which the number of Shares eligible to vest under this Award has been determined under Section 2 above, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any Shares that have been issued or cash that has been paid pursuant to this Award if&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">(i) the number of Shares or the amount of the cash payment was calculated based, directly or indirectly, upon the achievement of financial results that were subsequently the subject of a restatement of all or a portion of the Company&#8217;s financial statements, (ii) the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and (iii) the number of Shares or the amount of cash payment that would have been issued or paid to the Grantee had the financial results been properly reported would have been lower than the number of Shares actually issued or the amount of cash actually paid&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such misconduct causes significant harm to the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event the number of Shares issued or cash paid pursuant to this Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will (A) seek restitution of the Shares or cash paid pursuant to this Award to the extent that the number of Shares issued or the amount paid exceeded the number of Shares that would have been issued or the amount that would have been paid had the inaccuracy or error not occurred, or (B) issue additional Shares or make additional payment to the extent that the number of Shares issued or the amount paid was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Section 15 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:90pt;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.01pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee&#8217;s discretion for unforeseen circumstances. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:274.5pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>10
<FILENAME>lly-20201231x10kexhibit1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i75b13c76879c4321a91beac3ca173d2e_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i75b13c76879c4321a91beac3ca173d2e_37"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.10 &#8212; Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:120%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:400;line-height:120%">Restricted Stock Unit</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:120%">(for Executive Officer)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Restricted Stock Unit Award has been granted on &#91;&#8226;&#93;, by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to Grantee.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:198pt;text-indent:-162pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Log into Merrill Lynch recordkeeping information at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restriction Lapse&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;&#8226;&#93;</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160; (except as otherwise provided in this instrument)</font></div><div style="margin-top:12pt;padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</font></div><div style="padding-right:1.8pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:93.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.  Recitals</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.  Restricted Stock Unit</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.  Number of Restricted Stock Units</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.  Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.  Restriction Period</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.  Retirement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.  Record of the Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.  Conditions During Restriction Period</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.  Consequences of Breach of Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8. Committee Election to Pay Cash</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.  Lapse of Restrictions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.  Revocation or Modification of Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.  Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.  Notices, Payments and Electronic Delivery and Participation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.  Waiver</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.  Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.  Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.  Severability and Section Headings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 17.  Determinations by Committee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 18.  Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 19.  Nature of 2002 Plan and Award</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 20.  No Advice Regarding Grant</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 21.  Insider Trading Restrictions&#47;Market Abuse Laws</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22.  Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 23.  Effective Date</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 24.  Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 25.  Language</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 26.  Adjustments to Number of Shares</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 27.  Imposition of Other Requirements</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 28.  Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 29.  Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;padding-right:-2.7pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.  Recitals </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the AMENDED AND RESTATED 2002 LILLY STOCK PLAN (&#8220;2002 Plan&#8221;), the Compensation Committee (&#8220;Committee&#8221;) has determined the form of this Restricted Stock Unit Award (&#8220;Award&#8221;) and selected the Grantee, an Eligible Employee of the Company or one of its subsidiaries, to receive a Restricted Stock Unit Award.  The applicable terms of the 2002 Plan are incorporated in this Restricted Stock Unit Award by reference, including the definitions of terms contained in the 2002 Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.  Restricted Stock Unit</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly grants to the Grantee this Award of Restricted Stock Units, with each Restricted Stock Unit representing the right to receive one share of Eli Lilly and Company Common Stock (&#8220;Lilly Stock&#8221;), plus an amount of cash pursuant to Section 2 (b), subject to certain restrictions and on the terms and conditions contained in this Award and the 2002 Plan.  In the event of any conflict between the terms of the 2002 Plan and this Award, the terms of the 2002 Plan shall govern, except as specifically provided in Sections 3, 7 and 9.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.  Number of Restricted Stock Units  </font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to adjustment as provided in Section 26, the Grantee may receive the number of shares of Lilly Stock as outlined on the first page of this document.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 2.  Rights of the Grantee</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Restricted Stock Units granted pursuant to this Award do not and shall not entitle Grantee to any rights of a shareholder of Lilly Stock until the Restricted Stock Units vest and shares of Lilly Stock are issued or transferred.  No shares of Lilly Stock shall be issued or transferred to Grantee prior to the date on which the Restricted Stock Units vest and the restrictions with respect to the Restricted Stock Units lapse.  The rights of Grantee with respect to the Restricted Stock Units shall remain forfeitable at all times prior to the date on which the Restricted Stock Units become vested and the restrictions with respect to the Restricted Stock Units lapse.</font></div><div style="padding-left:45pt;padding-right:36pt;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:36.9pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt;text-decoration:underline">Dividend Equivalent Units</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As long as the Grantee holds Restricted Stock Units granted pursuant to this Award, the Company shall accrue for the Grantee, on each date that the Company pays a cash dividend to holders of Lilly Stock, Dividend Equivalent Units equal to the total number of Restricted Stock Units credited to the Grantee under this Award multiplied by the dollar amount of the cash dividend paid per share of Lilly Stock by the Company on such date. Dividend Equivalent Units shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  The accrued Dividend Equivalent Units shall be subject to the same restrictions as the Restricted Stock Units to which the Dividend Equivalent Units relate, and the Dividend Equivalent Units shall be forfeited in the event that the Restricted Stock Units with respect to which such Dividend Equivalent Units were credited are forfeited.</font></div><div style="padding-left:45pt;padding-right:36pt;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:36.9pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.73pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award nor any action pursuant to or in accordance with this Award shall be construed to create a trust of any kind.  The right of Grantee to receive payments of cash or Lilly Stock under this Award shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 3.  Restriction Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of restriction (&#8220;Restriction Period&#8221;) under this Award shall commence on the effective date of the Award and expire at the close of business on the earliest of the following dates&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">&#91;&#8226;&#93;, or</font></div><div style="margin-top:6pt;padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">the date the Grantee&#8217;s employment is subject to a Qualifying Termination.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:45pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;Qualifying Termination&#8221; means any one of the following&#58;</font></div><div style="margin-top:6pt;padding-left:90pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">the date of death of the Grantee while in the active service of the Company or any subsidiary&#59;</font></div><div style="padding-left:90pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">the date the Grantee&#8217;s employment is terminated by reason of &#8220;disability,&#8221; within the meaning of Section 409A of the U.S. Internal Revenue Code (the &#8220;Code&#8221;)&#59; </font></div><div style="padding-left:90pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">the date the Grantee suffers a &#8220;separation from service&#8221; from Lilly or the Employer, within the meaning of Section 409A of the Code (a &#8220;Section 409A Separation&#8221;), and such separation from service is due to a plant closing or reduction in workforce as defined below, or, in the event that the Award constitutes an item of non-qualified deferred compensation subject to Section 409A of the Code, the date that the Grantee suffers a Section 409A Separation&#59;</font></div><div style="padding-left:90pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">the date the Grantee&#8217;s employment is terminated as a result of the Grantee&#8217;s failure to locate a position within the Company or any of its subsidiaries or affiliates following the placement of the Grantee on reallocation or medical reassignment in the United States (or its equivalent outside the United States as determined by the Committee).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plant closing means the closing of a plant site or other corporate location that directly results in termination of employment. Reduction in workforce means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of employment.  </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination as to whether (i) the Grantee&#8217;s employment has been terminated by reason of disability, (ii) a leave of absence or a transfer of employment between Lilly and a subsidiary or between Lilly subsidiaries constitutes a termination of employment, (iii) a Grantee&#8217;s termination is a direct result of either a plant closing or a reduction in workforce, or (iv) the Grantee&#8217;s employment has been terminated as a result of the failure to locate a position within the Company or any of its subsidiaries or affiliates following reallocation or medical reassignment (or its equivalent outside the United States as determined by the Committee), shall be final and binding on the Grantee.  Notwithstanding anything in Section 10(a) of the 2002 Plan to the contrary, the Committee shall not modify the expiration dates set forth in this Award so as to accelerate the termination of the Restriction Period.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 4.  Retirement</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Grantee&#8217;s employment is terminated due to retirement, the Award will continue pursuant to the established Restriction Period schedule.  The Award will be paid in full to the retiree upon the lapse of all restrictions as noted in Section 9.  A retiree is a person who is (i) a retired employee under the Lilly Retirement Plan&#59; (ii) a retired employee under the retirement plan or program of a Lilly subsidiary&#59; or (iii) a retired employee under a retirement program specifically approved by the Committee. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Grantee who has not received a year-end individual performance rating and (i) is on employment probation (or its equivalent outside the United States, as determined by the Committee) for unsatisfactory performance and takes retirement in lieu of a termination of employment&#59; or (ii) takes retirement in lieu of termination of employment because of an immediately terminable offense (e.g., absence of three days without notice, insubordination, violation of substance abuse policy, possession of firearms, misconduct) will not be considered to have terminated due to retirement as described herein.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.  Record of the Award</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Restriction Period, records of the Award and accumulated Dividend Equivalent Units</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will reside in an account at the Company or an Equity Administration Agent designated by the Company.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 6.  Conditions During Restriction Period</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">During the entire Restriction Period, the employment of the Grantee with the Company (or a subsidiary of the Company) must not terminate except for reasons specified in Sections 3(b) or 4.  &#8220;Termination of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employment&#8221; shall mean the cessation for any reason of the relationship of employer and employee between the Grantee and the Company (or a subsidiary of the Company).</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">The Committee may, at its discretion, cancel this Restricted Stock Unit Award or reduce the number of Restricted Stock Units and any accrued Dividend Equivalent Units, prorated according to time or other measure as deemed appropriate by the Committee, if during any portion of the Award Period, including the Restriction Period, the Grantee has been (i) subject to disciplinary action by the Company, or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 7.  Consequences of Breach of Conditions  </font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the conditions that must continue to be satisfied during the Restriction Period under Section 6(a) is breached during the Restriction Period, either by act of the Grantee or otherwise, the Grantee, by accepting this Award, agrees that upon such breach all interest of the Grantee in the Restricted Stock Units and associated Dividend Equivalent Units shall terminate and be forfeited.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination regarding the conditions specified in Section 6 (and any breach thereof) shall be final and binding on the Grantee.  The Company shall incur no liability to the Grantee under this Award by terminating the Grantee's status as an Eligible Employee, whether by action with respect to the Grantee individually, either with or without cause, or by dissolution or liquidation of Lilly or merger or consolidation of Lilly with a corporation in which Lilly is not the surviving corporation, or otherwise.  Notwithstanding anything in Section 10(a) of the 2002 Plan to the contrary, the Committee shall not waive the breach of the conditions set forth in Section 6.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 8. Committee Election to Pay Cash </font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the Restriction Period or until paid in accordance with Section 9, the Committee may, if it so elects, determine to pay part or all of the Restricted Stock Units in cash in lieu of issuing or transferring shares of Lilly Stock. The amount of cash shall be based upon the fair market value of Lilly Stock at the end of the Restriction Period as outlined in Section 9.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 9.  Lapse of Restrictions</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the Restriction Period, if the conditions specified in Section 6 have not been breached during the Restriction Period, all restrictions shall terminate.  The Award shall be paid to Grantee within a sixty-day period starting the day after the end of the Restriction Period and ending on the sixtieth day after the end of the Restriction Period, but no later than December 31 of the year in which the Restriction Period ends, as follows&#58;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;padding-right:28.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Lilly shall issue or transfer to the Grantee shares of Lilly Stock or the cash equivalent, as described in Section 8 above, equal to one share per Restricted Stock Unit subject to the withholding tax provisions in Section 14 below.  In the event Grantee is entitled to a fractional share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="padding-left:49.5pt;padding-right:28.8pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;padding-right:28.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Lilly shall pay to the Grantee in cash all accrued Dividend Equivalent Units following deduction for Tax-Related Items in accordance with Section 13 below.</font></div><div style="padding-left:22.5pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the Restriction Period ends by reason of death of the Grantee, the payments as described above shall be made to the Successor Grantee.  Notwithstanding anything in Section 10(a) of the 2002 Plan to the contrary, the Committee shall not direct that the restrictions on this Award will lapse other than as expressly set forth in this Award.  Notwithstanding the foregoing, if the Grantee is treated as a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code as of the date of any payment hereunder, the commencement of any payment shall be delayed in accordance with Section 15 below.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 10.  Revocation or Modification of Award </font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Award shall be irrevocable except that Lilly shall have the right to revoke or modify this Award under Sections 13(e) and&#47;or 13(k) of the 2002 Plan or pursuant to Section 7 above or Section 27 below.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 11.  Prohibition Against Transfer</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Lilly Stock and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of Grantee or to a Successor Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award.  A Grantee may not assign, sell, pledge, or otherwise transfer Lilly Stock or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 12.  Notices, Payments and Electronic Delivery and Participation</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any notice to be given by the Grantee or Successor Grantee shall be in writing, and any notice or payment shall be deemed to have been given or made only upon receipt thereof by the Treasurer of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any Successor Grantee, at the address specified in writing to Lilly by the Successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the 2002 Plan by electronic means or request the Grantee&#8217;s consent to participate in the 2002 Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the 2002 Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 13.  Waiver </font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this instrument at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this instrument at any subsequent time or for any other purpose.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 14.  Responsibility for Taxes</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of any action Lilly and&#47;or the Grantee&#8217;s employer (the &#8220;Employer&#8221;) takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to the Grantee&#8217;s participation in the 2002 Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (a)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Restricted Stock Units, the accrual of Dividend Equivalent Units, the vesting of the Restricted Stock Units and the lapse of restrictions, the transfer and issuance of any shares of Lilly Stock, the receipt of any cash payment pursuant to the Award, the receipt of any dividends and the sale of any shares of Lilly Stock acquired pursuant to this Award&#59; and (b)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">In the case of Dividend Equivalent Units paid to the Grantee in cash and in the case of any Restricted Stock Units paid to the Grantee in cash in lieu of shares of Lilly Stock, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.   </font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">If the Restricted Stock Units are paid in shares of Lilly Stock and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the 1934 Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (i) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (ii) arrange for the sale of shares of Lilly Stock to be issued upon the expiration of the Restriction Period (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale, and&#47;or (iii) withhold in shares of Lilly Stock otherwise issuable to the Grantee pursuant to this Award.</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.73pt">If the Restricted Stock Units are paid in shares of Lilly Stock and the Grantee is subject to the short-swing profit rules of Section 16(b) of the 1934 Act, Lilly will withhold in shares of Lilly Stock otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by applicable law or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 14(b)(i) and (ii) above.  </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates, in which case the Grantee may receive a refund of any over-withheld amount in cash as soon as practicable and without interest and will not be entitled to the equivalent amount in shares of Lilly Stock. If the obligation for Tax Related Items is satisfied by withholding shares of Lilly Stock as described in Section 14(b)(iii) or Section 14(c) above, for tax purposes, the Grantee will be deemed to have been issued the full number of shares of Lilly Stock to which he or she is entitled pursuant to this Award, notwithstanding that a number of shares of Lilly Stock are withheld to satisfy the obligation for Tax Related Items.  Lilly may require the Grantee to pay Lilly and&#47;or the Employer any amount of Tax Related Items that Lilly and&#47;or the Employer may be required to withhold or account for as a result of any aspect of this Award that cannot be satisfied by the means previously described.  Lilly may refuse to deliver shares of Lilly Stock or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 14.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.  Section 409A Compliance</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.  Notwithstanding anything elsewhere in this Award to the contrary, if the Award constitutes an item of non-qualified deferred compensation subject to Section 409A (&#8220;NQ Deferred Compensation&#8221;) and the Grantee is treated as a &#8220;specified employee&#8221; as of the date of any payment pursuant to the Award in connection with the Grantee&#8217;s Section 409A Separation, as determined by the Company in accordance with its procedures, then, to the extent required, the Award shall be paid on the earliest of (a) the date set forth in Section 3(a), (b) the first day following the six (6) month anniversary of the Grantee&#8217;s Section 409A Separation, (c) the date of a &#8220;change in control event&#8221; within the meaning of Section 409A (a &#8220;Section 409A CIC&#8221;), and (c) the date of the Grantee&#8217;s death.  This Award is subject to Section 13(k) of the 2002 Plan concerning Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 16.  Severability and Section Headings</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of the provisions of this instrument shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this instrument to be construed so as to foster the intent of this Award and the 2002 Plan.  </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this instrument are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 17.  Determinations by Committee  </font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determinations by the Committee pursuant to any provision of the 2002 Plan, pursuant to rules, regulations, and procedures adopted by the Committee, or pursuant to this instrument, including what constitutes &#8220;misconduct&#8221; for purposes of Section 28 below and any other determinations under Section 28, shall be final and binding on the Grantee and any Successor Grantee.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 18.  Change in Control</font></div><div style="margin-bottom:12pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 12(a) of the 2002 Plan apply to this Award with the following modifications&#58;</font></div><div style="margin-bottom:12pt;padding-left:49.5pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">The only Change in Control event that shall result in a benefit under this Section 18 shall be the consummation of a change in ownership of the Company as defined in Section 12(b)(i) of the 2002 Plan (a &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:49.5pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">In the event that the acquiring entity or successor to the Company does not assume, continue or substitute the Award in connection with the Transaction, then the Company shall issue or transfer to the Grantee shares of Lilly Stock, as noted in Section 9, immediately prior to the consummation of the Transaction in order to allow the shares of Lilly Stock to be outstanding and for the Grantee to be eligible to receive the consideration being paid to Lilly shareholders in connection with the Transaction&#59; provided, however, that if (i) the Grantee is subject to U.S. taxation and (ii) the Award constitutes NQ Deferred Compensation and the Transaction is not a Section 409A CIC, then the Grantee shall receive an equivalent amount in cash (based on the fair market value of the Lilly Stock at the time of the consummation of the Transaction) at the time provided under Section 9.</font></div><div style="margin-bottom:12pt;padding-left:49.5pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.23pt">In the event that the acquiring entity or successor to the Company assumes, continues or substitutes the Award in connection with the Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to the end of the Restriction Period, the Award shall vest automatically in full and shall be settled in stock of the acquiring or successor corporation within sixty (60) days of the date of the Covered Termination&#59; provided however, that in the event that the Award constitutes NQ Deferred Compensation, the Award shall instead be settled within sixty (60) days of a Covered Termination that also constitutes a  Section 409A Separation, but in no event later than December 31 of the year in which the Section 409A Separation occurs. </font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Covered Termination&#8221; for purposes of this Award shall mean a Qualifying Termination, Grantee&#8217;s termination due to retirement, Grantee&#8217;s termination without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Employees or the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (both as amended from time to time) or any successor plan or arrangement thereto, as applicable.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 18, then references to shares of Lilly Stock in this instrument shall be read to mean stock of the acquiring entity or successor to the Company as and when applicable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 19.  Nature of 2002 Plan and Award</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">the 2002 Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the 2002 Plan&#59;</font></div><div style="padding-left:45pt;padding-right:36.9pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future awards of Restricted Stock Units and&#47;or Dividend Equivalent Units, or benefits in lieu thereof, even if Restricted Stock Units and&#47;or Dividend Equivalent Units have been granted in the past&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.73pt">all decisions with respect to future awards of Restricted Stock Units, Dividend Equivalent Units or other grants, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">the Grantee&#8217;s participation in the 2002 Plan is voluntary&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">the Award and any shares of Lilly Stock subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.96pt">the Award and any shares of Lilly Stock subject to the Award, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar payments&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">unless otherwise agreed with Lilly, the Award and any shares of Lilly Stock subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of a subsidiary of Lilly&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">neither the Award nor any provision of this instrument, the 2002 Plan or the policies adopted pursuant to the 2002 Plan confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any subsidiary of Lilly&#59; </font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.51pt">the future value of the underlying shares of Lilly Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.51pt">the value of shares of Lilly Stock acquired upon lapse of the Restriction Period may increase or decrease, even below the tax valuation price&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.73pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.51pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or a subsidiary of the Company and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee's employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee's employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence)&#59; and</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:2.4pt">unless otherwise provided in the 2002 Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or substituted for, in connection with any corporate transaction affecting the shares of Lilly Stock.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 20.  No Advice Regarding Grant</font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the 2002 Plan or the Grantee&#8217;s acquisition or sale of the underlying shares of Lilly Stock.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the 2002 Plan before taking any action related to the 2002 Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 21.  Insider Trading Restrictions&#47;Market Abuse Laws</font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges that he or she may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell,&#160; or otherwise dispose of shares of Lilly Stock or rights to acquire shares of Lilly Stock (e.g., Restricted Stock Units) under the 2002 Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22.  Data Privacy</font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Grantee&#8217;s personal data as described in this Award and any other Award materials by and among, as applicable, the Employer, Lilly, its subsidiaries and its affiliates for the exclusive purpose of implementing, administering and managing the Grantee&#8217;s participation in the 2002 Plan.</font></div><div style="padding-left:22.3pt;text-align:justify"><font><br></font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee understands that Lilly and the Employer may hold certain personal information about the Grantee and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance, passport, or other identification number (e.g. resident registration number), salary, nationality, job title, any shares of stock or directorships held in Lilly, details of all Awards or any other entitlement to shares of stock awarded, canceled, vested, unvested or outstanding in the Grantee&#8217;s favor, for the purpose of implementing, administering and managing the 2002 Plan (&#8220;Data&#8221;).</font></div><div style="padding-left:22.3pt;text-align:justify"><font><br></font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee understands that Data will be transferred to Merrill Lynch, KPMG and&#47;or any other stock plan service provider or tax or legal advisor as may be selected by the Company in the future, which is assisting in the implementation, administration and management of the 2002 Plan.  Where required under applicable law, Data may also be disclosed to certain securities or other regulatory authorities where Lilly's securities are listed or traded or regulatory filings are made.  The Grantee understands that these recipients may be located in the Grantee&#8217;s country, or elsewhere, and that the recipient&#8217;s country may have different data privacy laws and protections than the Grantee&#8217;s country.  The Grantee understands that he or she may request a list with the names and addresses of any potential recipients of Data by contacting the Grantee&#8217;s local human resources representative.  The Grantee authorizes the Company, Merrill Lynch, KPMG and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering, and managing the 2002 Plan  to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Grantee&#8217;s participation in the 2002 Plan, including any requisite transfer of such Data as may be required to a broker, escrow agent or other third party with whom any shares or cash received pursuant to the Award may be deposited.  The Grantee understands that Data will be held only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the 2002 Plan.  The Grantee understands that the Grantee may, at any time, request an equity award transaction statement, request any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Grantee&#8217;s local human </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources representative.  Further, the Grantee understands that he or she is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke his or her consent, the Grantee&#8217;s employment status or service with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant the Grantee the Award or other equity awards or administer or maintain such awards.  Therefore, the Grantee understands that refusal or withdrawal of consent may affect the Grantee&#8217;s ability to participate in the 2002 Plan.  For more information on the consequences of the Grantee&#8217;s refusal to consent or withdrawal of consent, the Grantee understands that the Grantee may contact the Grantee&#8217;s local human resources representative.</font></div><div style="padding-left:22.3pt;text-align:justify"><font><br></font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, upon request of the Company or the Employer, the Grantee agrees to provide an executed data privacy consent form (or any other agreements or consents) that the Company and&#47;or the Employer may deem necessary to obtain from the Grantee for the purpose of administering the Grantee&#8217;s participation in the 2002 Plan in compliance with the data privacy laws in the Grantee&#8217;s country, either now or in the future.&#160; The Grantee understands and agrees that he or she will not be able to participate in the 2002 Plan if he or she fails to provide any such consent or agreement requested by the Company and&#47;or the Employer.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 23.  Effective Date  </font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective date of this instrument shall be the date of grant.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 24.  Governing Law and Choice of Venue</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity and construction of this Award shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws.  For purposes of litigating any dispute that arises under this Award, the parties hereby submit to and consent to the jurisdiction of the State of Indiana, and agree that such litigation shall be conducted in the courts of Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 25.  Language</font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Grantee has received this instrument or any other document related to the 2002 Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 26.  Adjustments to Number of Shares</font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of Lilly Stock subject to this Award shall be subject to adjustment in accordance with the provisions of Section 4(b) of the 2002 Plan for certain corporate recapitalizations and other events.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 27.  Imposition of Other Requirements</font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reserves the right to impose other requirements on the Award and any shares of Lilly Stock acquired under the 2002 Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing. Without limitation to the foregoing, the Grantee agrees that the Restricted Stock Unit Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under applicable laws or any compensation recovery policy of the Company that reflects the provisions of applicable laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 28.  Compensation Recovery</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;padding-right:28.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the three years following the date on which the number of shares of Lilly Stock subject to this Award was determined, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any&#160;shares&#160;of Lilly Stock subject to or issued (or cash paid) pursuant to this Award if&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:67.5pt;padding-right:28.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. (i)&#160;&#160;&#160;&#160;the number of&#160;shares of Lilly Stock subject to the Award was calculated based, directly or indirectly, upon the achievement of&#160;financial results (e.g., earnings per share) that were subsequently the subject of restatement of all or a portion of the Company&#8217;s financial statements&#59;</font></div><div style="padding-left:67.5pt;padding-right:28.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="padding-left:67.5pt;padding-right:28.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the number of&#160;shares of Lilly Stock that would have been subject to the Award had the financial results been properly reported would have been lower than the number of&#160;shares&#160;of Lilly Stock actually&#160;subject to the Award.</font></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:28.8pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the company.</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;padding-right:28.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the number of shares of Lilly Stock subject to the Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will&#58;</font></div><div style="padding-left:45pt;padding-right:28.8pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">seek restitution of the shares of Lilly Stock subject to or issued (or cash paid) pursuant to this Award to the extent that the number of shares of Lilly Stock subject to the Award exceeded the number of shares of Lilly Stock that would have been subject to the Award had the inaccuracy or error not occurred, or</font></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:28.8pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">issue additional shares of Lilly Stock or make additional cash payment to the extent that the number of shares of Lilly Stock subject to the Award was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Section 28 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 29.  Award Subject to Acknowledgement of Acceptance</font></div><div style="padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this instrument, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM. (EDT) &#91;&#8226;&#93; through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM. (EDT) &#91;&#8226;&#93;, the Award will be cancelled, subject to the Committee's discretion for unforeseen circumstances.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>11
<FILENAME>lly-20201231x10kexhibit1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia0954266f35e4bda8972ed5c1adf9977_32"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="ia0954266f35e4bda8972ed5c1adf9977_37"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.14 &#8212; The Eli Lilly and Company Bonus Plan, as amended</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">The Eli Lilly and Company Bonus Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">(as amended effective August 26, 2020)</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia0954266f35e4bda8972ed5c1adf9977_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:93.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.  PURPOSE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.  DEFINITIONS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.  ADMINISTRATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.  PARTICIPATION IN THE PLAN</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 5.  DEFINITION AND COMPUTATION OF COMPANY BONUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.  TIME OF PAYMENT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.  ADMINISTRATIVE GUIDELINES</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.  MISCELLANEOUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.  AMENDMENT, SUSPENSION, OR TERMINATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></td></tr></table></div><div><font><br></font></div><div id="ia0954266f35e4bda8972ed5c1adf9977_43"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Eli Lilly and Company Bonus Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(as amended effective August 26, 2020)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 1.  PURPOSE</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of The Eli Lilly and Company Bonus Plan is to encourage and promote eligible employees to create and deliver innovative pharmaceutical-based health care solutions that enable people to live longer, healthier and more active lives, to outgrow our competitors through a constant stream of pharmaceutical innovation, and to materially increase shareholder value.  The Plan is designed to accomplish the following key objectives&#58;</font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:42.68pt">motivate superior employee performance through the implementation of a performance-based bonus system for all eligible management employees, United States employees (including those in Puerto Rico) and other employees as may be designated from time to time&#59; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:87pt;text-indent:-51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:42pt">create a direct relationship between key company measurements and individual bonus payouts&#59; and </font></div><div><font><br></font></div><div style="padding-left:87pt;text-indent:-51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:42.68pt">enable the Company to attract and retain employees that will be instrumental in driving sustained growth and performance of Eli Lilly and Company by providing a competitive bonus program that rewards outstanding performance consistent with the Company&#8217;s mission, values and increased shareholder value. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 2.  DEFINITIONS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following words and phrases as used in this Plan will have the following meanings unless a different meaning is clearly required by the context.  Masculine pronouns will refer both to males and to females&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the calendar year immediately preceding the year in which payment of the Company Bonus is payable pursuant to Section 6.  For example, the Applicable Year for 2020 payout is January 1, 2019 through December 31, 2019.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the percentage of Participant Earnings for each Participant as described in Section 5.6(a) below.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Internal Revenue Code of 1986, as amended from time to time.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means (i) with respect to the Executive Officers of Lilly, the Compensation Committee, the members of which will be selected by the Board of Directors of Lilly, from among its members&#59; and (ii) with respect to all other Eligible Employees, the Compensation Committee of the Board of Directors or its designee.  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means Eli Lilly and Company and its subsidiaries.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 1 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the amount of bonus compensation payable to a Participant as described in Section 5 below.  Notwithstanding the foregoing, however, the Committee may determine, in its sole discretion, to reduce the amount of a Participant&#8217;s Company Bonus if such Participant becomes eligible to participate in such other bonus program of the Company as may be specifically designated by the Committee. Such reduction may be by a stated percentage up to and including 100% of the Company Bonus.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Performance Bonus Multiple</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the amount as calculated in Sections 5.3 and 5.4 below.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disabled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a Participant who (i) has become eligible for a payment under The Lilly Long-Term Disability Plan, assuming eligibility to participate in that plan, or (ii) for those employees ineligible to participate in The Lilly Long-Term Disability Plan, has become otherwise &#8220;disabled&#8221; under the applicable disability benefit plan or program for the Participant, or, in the event that there is no such disability benefit plan or program, has become disabled under applicable local law.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings Per Share (EPS)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the diluted earnings per share of the Company as reported in the Company&#8217;s &#8220;Consolidated Statements of Income&#8221; in accordance with generally accepted accounting principles and Section 3.4 below. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings Per Share Change (EPS Change)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the percentage increase or decrease in EPS in the Applicable Year compared to the prior year.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means January 1, 2004, as amended from time to time.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">with respect to employees of Lilly, Lilly USA, LLC., ImClone Systems LLC or Lilly&#8217;s subsidiaries with operations in Puerto Rico, a person (1) who is employed as an employee by the Company on a scheduled basis of twenty (20) or more hours per week and is scheduled to work at least five (5) months per year&#59; and (2) who is receiving compensation, including short-term disability under The Lilly Short-Term Disability Program or similar short-term disability program, from the Company for services rendered as an employee.  Notwithstanding anything herein to the contrary, the term &#8220;Eligible Employee&#8221; will not include&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a person who has reached Retirement with the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a person who is Disabled&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a person who is a &#8220;leased employee&#8221; within the meaning of Section 414(n) of the Internal Revenue Code of 1986, as amended, or whose basic compensation for services on behalf of the Company is not paid directly by the Company&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a person who is classified as a &#8220;Fixed Duration Employee&#8221;, as that term is used by Lilly, except as otherwise designated by the Committee&#59; </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a person who is classified as a special status employee because his employment status is temporary, seasonal, or otherwise inconsistent with regular employment status&#59; </font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a person who is eligible to participate in the Eli Lilly and Company Prem1er Rewards Plan, a bonus or incentive plan for eligible employees of Loxo Oncology, Inc. or such other Company bonus or incentive program as may be specifically designated by the Committee or its designee&#59; or </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a person who submits to the Committee in writing a request that he not be considered eligible for participation in the Plan or is a member of the Board of Directors of Lilly unless he or she is also an Eligible Employee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">any other category of employees designated by the Committee in its discretion with respect to any Applicable Year.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">with respect to those employees who are employed by the Company, but not by Lilly, Lilly USA, LLC., or a Puerto Rican subsidiary, an employee of the Company designated by the Committee as a Participant in the Plan with respect to any Applicable Year.  In its discretion, the Committee may designate Participants either on an individual basis or by determining that all employees in specified job categories, classifications, levels, subsidiaries or other appropriate classification will be Participants. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Notwithstanding anything herein to the contrary, the term Eligible Employee will not include any person who is not so recorded on the payroll records of the Company, including any such person who is subsequently reclassified by a court of law or regulatory body as a common law employee of the Company.  Consistent with the foregoing, and for purposes of clarification only, the term employee or Eligible Employee does not include any individual who performs services for the Company as an independent contractor or under any other non-employee classification.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lilly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means Eli Lilly and Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lilly Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a Participant who has been designated by the Board of Directors of Lilly as an executive officer pursuant to Rule&#160;3b7 under the Securities Exchange Act of 1934, as amended, and who has remained in an executive officer position through the end of the Applicable Year</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an Eligible Employee who is participating in the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.16 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant Earnings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means (A) those amounts described below that are paid during the portion of the Applicable Year during which the employee is a Participant in the Plan&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">regular compensation (including applicable deferred compensation amounts), overtime, shift premiums and other forms of additional compensation determined by and paid currently pursuant to an established formula or procedure&#59; </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">salary reduction contributions to The Lilly Employee 401(k) Plan or elective contributions under any similar tax-qualified plan that is intended to meet the requirements of Section 401(k) of the Internal Revenue Code or similar Company savings program&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">elective contributions to any cafeteria plan that is intended to meet the requirements of Section 125 of the Internal Revenue Code or other pre-tax contributions to a similar Company benefit plan&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">payments made under the terms of The Lilly Short-Term</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Disability Program or other similar Company or government-required leave program during an Applicable Year to a Participant who is on approved leave of absence and is receiving one hundred percent (100%) of his base pay&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">the July 2020 onetime amount designated by Lilly as a &#8220;special payment&#8221; for Eligible Employees in the United States in connection with the Company&#8217;s implementation of Workday&#59; and  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">other legally-mandated or otherwise required pre-tax deductions from a Participant&#8217;s base salary. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;The term &#34;Participant Earnings&#34; does not include&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">compensation paid in lieu of earned vacation&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">amounts contributed to the Retirement Plan or any other qualified plan, except as provided in clause (A)(ii), above&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">payments made under the terms of The Lilly Short-Term Disability Program or other similar Company or government-required leave program during an Applicable Year to a Participant who is on approved leave of absence and is receiving less than the full amount of his base pay&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">amounts paid under this Plan or other bonus or incentive program of the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">payments made under The Lilly Severance Pay Plan, The Severance Pay Plan for Eli Lilly Affiliate Employees in Puerto Rico or any other severance-type benefit (whether company-sponsored or mandated by law) arising out of or relating to a Participant&#8217;s termination of employment&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">payments based upon the discretion of the Company except as described above with respect to the July 2020 &#8220;special payment&#8221; in conjunction with the Company&#8217;s implementation of Workday&#59;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">in the case of a person employed by a Lilly subsidiary, foreign service, cost of living, or other allowances that would not be paid were the person employed by Lilly&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">amounts paid as commissions, sales bonuses, or Market Premiums (as defined under the Retirement Plan)&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:153pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">earnings with respect to the exercise, vesting, or payment of any equity-based awards, including but not limited to stock options, restricted stock units, restricted stock, and performance share units.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.17 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Benchmarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> mean the amounts as calculated in Section 5.3 below.  The Performance Benchmarks will be established based on Lilly&#8217;s internal business plan as reviewed and approved by the Board of Directors of the Company and based on performance measures as described in Section 5.2. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.18 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pipeline Metrics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> mean the measurements of the Company&#8217;s research and development pipeline established and approved by the Compensation Committee in consultation with the Science and Technology Committee of the Board of Directors of Lilly to be used for purposes of bonus calculations as described below.  Such measures may include, but are not limited to, the number and type of product approvals within an Applicable Year, the number of new molecular entities that enter Phase III clinical trials during an Applicable Year, the assessed progress of the Company&#8217;s portfolio against predicted outcomes (i.e., delivery reliability) and the assessed quality of the pipeline products, as determined by the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.19 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means The Eli Lilly and Company Bonus Plan as set forth herein and as hereafter modified or amended from time to time.  The Plan is an incentive compensation program and is not subject to the Employee Retirement Income Security Act of 1974, as amended (&#8220;ERISA&#8221;), pursuant to Department of Labor Regulation Section 2510.3.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.20 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plant Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the closing of a plant site or other Company location that directly results in termination of employment.  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.21 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reduction in Workforce</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of employment.  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.22 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the cessation of employment upon the attainment of age fifty-five with at least ten years of service (55 and 10), age sixty-five with at least five years of service (65 and 5) or at least eighty (80) points, as determined by the provisions of the Retirement Plan as amended from time to time, assuming eligibility to participate in that plan.  For persons who are not participants in the Retirement Plan, Retirement means the cessation of employment as a retired employee under the applicable retirement benefit plan or program as provided by the Company or applicable law.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.23 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retirement Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means The Lilly Retirement Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.24 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, for any Applicable Year, the consolidated net revenue of the Company as set&#160;forth in the &#8220;Statements of Operations&#8221; as reported by the Company in accordance with generally accepted accounting principles and Section 3.4 below.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.25 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the percentage increase or decrease in Revenue in the Applicable Year compared to the prior year.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.26 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Service </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the aggregate time of employment of an Eligible Employee by the Company.</font><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 3.  ADMINISTRATION</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Plan will be administered by the Compensation Committee of the Board of Directors of Eli Lilly and Company or, if the name of the Compensation Committee is changed, the Plan will be administered by such successor committee.  For all Eligible Employees other than Lilly Executive Officers, the Compensation Committee may delegate all or a portion of its responsibilities within its sole discretion by resolution.  Any reference in this Plan to the Committee or its authority will be deemed to include such designees (other than with respect to Lilly Executive Officers or a member of the Board of Directors or for purposes of Section 9).</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Powers of the Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Committee will have the full power and authority in its discretion to</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">interpret the terms and provisions of the Plan and to determine any and all questions arising under the Plan, including, without limitation, the right to remedy possible ambiguities, inconsistencies, or omissions by a general rule or particular decision&#59;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">adopt, amend and rescind rules consistent with the Plan&#59;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">make exceptions in particular cases to the rules of eligibility for participation in the Plan (except with respect to Lilly Executive Officers)&#59; </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">determine whether, to what extent, and under what circumstances payments made or to be made should be recovered or forfeited under the Company&#8217;s Executive Compensation Recovery Policy as in effect from time to time&#59; and </font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">delegate authority for administration of the Plan with respect to any Eligible Employee except for Lilly Executive Officers or a member of the Board of Directors.  The Committee will take all necessary action to establish annual Performance Benchmarks and approve the timing of payments, as necessary.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certification of Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Before any amount is paid under the Plan, the Committee will certify in writing the calculation of EPS, EPS Change, Revenue, Revenue Change and Pipeline Metrics (or other applicable performance measures) for the Applicable Year and the satisfaction of all other material terms of the calculation of the Company Performance Bonus Multiple and Company Bonus.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments for Significant Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Not later than 90 days after the beginning of an Applicable Year, the Committee may specify with respect to Company Bonuses for the Applicable Year that the performance measures described in Section 5.2 will be determined </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 6 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">before the effects of acquisitions, divestitures, restructurings or special charges or gains, changes in corporate capitalization, accounting changes, and&#47;or events that are treated as extraordinary items for accounting purposes.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Finality of Committee Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any determination by the Committee of Revenue, Revenue Change, EPS, EPS Change, Pipeline Metrics, any other performance measure, Performance Benchmarks and the level and entitlement to Company Bonus, and any interpretation, rule, or decision adopted by the Committee under the Plan or in carrying out or administering the Plan, will be final and binding for all purposes and upon all interested persons, their heirs, and personal representatives.  The Committee may rely conclusively on determinations made by Lilly and its auditors to determine Revenue, Revenue Change, EPS, EPS Change and related information for administration of the Plan, whether such information is determined by the Company, auditors or a third-party vendor engaged specifically to provide such information to the Company.  This subsection is not intended to limit the Committee&#8217;s power, to the extent it deems proper in its discretion, to take any action permitted under the Plan.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 4.  PARTICIPATION IN THE PLAN</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Only Eligible Employees may participate in and receive payments under the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement of Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  An Eligible Employee will become a Participant in the Plan as follows&#58; (i) in the case of Eligible Employees under Section 2.12(a), on the date on which the individual completes at least one hour of employment as an Eligible Employee within the United States or Puerto Rico, and (ii) in the case of Eligible Employees under Section 2.12(b), the later of the date on which the individual completes at least one hour of employment as an Eligible Employee or the date as of which the Committee has designated the individual to become a Participant in the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  An Eligible Employee will cease to be a Participant upon termination of employment with the Company for any reason, or at the time he otherwise ceases to be an Eligible Employee under the Plan&#59; provided, however, a terminated Participant shall be eligible for a Company Bonus to the extent provided in Section 5.8.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 5.  DEFINITION AND COMPUTATION OF COMPANY BONUS</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Computation for Eligible Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Company Bonus amounts will depend significantly on Company performance as well as whether Participants met their job expectations for certain Eligible Employees.  As more specifically described below, a Participant&#8217;s Company Bonus is calculated by multiplying the Participant&#8217;s Bonus Target by his Participant Earnings and the Company Performance Bonus Multiple.  For eligible management and Lilly employees and those Participants designated by the Committee, whether an individual met their job expectations will also impact the Company Bonus calculation, as described in Section 5.6(c) below.  Company Bonuses are paid out to eligible Participants in the manner provided below. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 7 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Establishment of Performance Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Not later than 90 days after the beginning of each Applicable Year, the Committee will, in its sole discretion, determine appropriate performance measures for use in calculating Company Bonus amounts.  These performance measures may include, but are not limited to, Revenue Change, EPS Change, growth in net income, return on assets, return on equity, Pipeline Metrics, total shareholder return, EVA, MVA or any of the foregoing before the effect of acquisitions, divestitures, accounting changes, restructurings and special charges or gains.  Unless otherwise specified pursuant to a written resolution adopted by the Committee for the Applicable Year, the Committee will use as performance measures EPS Change, Revenue Change and Pipeline Metrics, in each case before the effect of acquisitions, divestitures, accounting changes, restructurings and special charges or gains (determined as described above) as performance measures.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Establishment of Performance Benchmarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Not later than 90 days after the beginning of each Applicable Year, the Committee will establish Performance Benchmarks for the Company based on the performance measures described in Section 5.2 above.  Unless otherwise specified pursuant to a written resolution adopted by the Committee for the Applicable Year, the Performance Benchmarks will correspond with EPS Change and Revenue Change amounts for the Applicable Year, established with reference to Lilly&#8217;s internal business plan as reviewed and approved by the Board of Directors of the Company, and Pipeline Metrics as approved by the Committee in consultation with the Science and Technology Committee.  The Performance Benchmarks will correspond to EPS Change, Revenue Change and Pipeline Metric multiples equal to 1.0.  The Committee will also adopt a formula that will determine the extent to which the performance measure multiples will vary as the Company&#8217;s actual results relative to the internal plan approved by the Board of Directors of the Company vary from the Performance Benchmarks.  Notwithstanding the foregoing, each performance measure multiple established above will be no less than 0.0 or greater than 2.0 in any Applicable Year, regardless of the Company&#8217;s actual results.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Performance Bonus Multiple</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise specified pursuant to a written resolution adopted by the Committee not later than 90 days after the beginning of the Applicable Year, the Company Performance Bonus Multiple is equal to the product of the EPS Change multiple and 0.50 plus the product of the Revenue Change multiple and 0.25 plus the product of the Pipeline Metrics multiple and 0.25 (i.e., Company Performance Bonus Multiple &#61; (EPS Change multiple * 0.50) + (Revenue Change multiple * 0.25) + (Pipeline Metrics multiple * 0.25)). </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Performance Bonus Multiple Threshold and Ceiling&#59; Committee&#8217;s Downward Discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding Sections 5.3 and 5.4, the Company Performance Bonus Multiple will not be less than 0.25 or greater than 2.0 in an Applicable Year.  If the calculations described in Sections 5.3 and 5.4 above result in a number that is less than 0.25, the Company Performance Bonus Multiple will equal 0.25 for the Applicable Year.  Notwithstanding the foregoing Sections 5.3, 5.4, and 5.5, at any time prior to certification as described in Section 3.3, the Committee in its discretion may </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">reduce the Company Performance Bonus Multiple (including but not limited to a reduction below 0.25) for some or all Eligible Employees, or</font></div><div style="padding-left:54pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 8 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">increase one or more Performance Benchmarks.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant Company Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;text-decoration:underline">Bonus Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Not later than 90 days after the beginning of the Applicable Year, the Bonus Target for each Participant, whether such Participant is designated on an individual basis or by specified job categories, classifications, levels, subsidiaries or other appropriate classification, will be determined by the Committee on a basis that takes into consideration a Participant's pay grade level and job responsibilities.  The Bonus Target for each Participant for the Applicable Year will be expressed as a percentage of Participant Earnings as of December 31 of the Applicable Year.  No later than early in the Applicable Year, each Participant will receive information regarding the Participant&#8217;s Bonus Target.  In the event that a Participant&#8217;s pay grade level changes during the Applicable Year (e.g., because of promotion, demotion or otherwise), the Participant&#8217;s Bonus Target will be prorated based on the Bonus Target applicable to each pay grade level (with related job responsibilities) and the percentage of time that the Participant is employed at each pay grade level during the Applicable Year.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Company Bonus Calculation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as described in Section 5.6(c) below, a Participant&#8217;s Company Bonus will equal the product of the Company Performance Bonus Multiple and the Participant&#8217;s Bonus Target and the Participant&#8217;s Earnings.  </font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;text-decoration:underline">Adjustment for Individual Performance Multiplier, if Applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything herein to the contrary, all eligible management employees (except Lilly Executive Officers), United States employees and other employees as may be designated from time to time by the Committee are subject to individual performance multipliers.  For all such Participants subject to an individual performance multiplier, the amount calculated in Section 5.6(b) above will be adjusted based on whether the Participant met job expectations as determined by the Company at the end of the Applicable Year.  If a Participant does not meet such job expectations, the Participant will receive an individual performance multiplier equal to either 0.0 or 0.5, as determined by the Company.  In that event, the individual performance multiplier will be multiplied by the amount described in Section 5.6(b) above to calculate the Participant&#8217;s Company Bonus.  If a Participant meets job expectations, the Participant&#8217;s Company Bonus will equal the amount calculated in Section 5.6(b) above.  In addition, if a Participant meets job expectations, the Company may increase the Participant&#8217;s Company Bonus by an additional amount based on its determination of the Participant&#8217;s individual performance and related factors.  Not later than 90 days after the beginning of the Applicable Year, the Committee will determine applicable multipliers for meeting job expectations or ranges for the applicable rating system in effect for the Participant.  For each such Participant, such rating will be determined by the Participant&#8217;s supervision.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 9 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that a Participant does not receive a year-end performance rating, but is otherwise eligible for a Company Bonus, the amount calculated in Section 5.6(b) will be multiplied by 1.0 so that the Participant&#8217;s actual Company Bonus will be the amount calculated in Section 5.6(b) above.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions on Company Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Payment of any Company Bonus is neither guaranteed nor automatic.  A Participant&#8217;s Company Bonus is not considered to be any form of compensation, wages, or benefits, unless and until paid.  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Required Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as provided below in this Section 5.8, required by applicable law or as otherwise designated by the Committee, if a Participant is not employed by the Company on the last day of the Applicable Year, or is otherwise not an Eligible Employee on that date, the Participant is not entitled to any Company Bonus payment under this Plan for that Applicable Year.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Participant who, on the last day of the Applicable Year, is on approved leave of absence under the Family and Medical Leave Act of 1993, military leave under the Uniformed Services Employment and Reemployment Rights Act, or such other approved leave of absence will be considered to be an Eligible Employee on that date for purposes of this Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  An employee who is a Participant in this Plan for a portion of the Applicable Year and then transfers to a position within the Company in which he is ineligible to participate in this Plan, but who remains employed by the Company on the last day of the Applicable Year, will be treated as satisfying the last-day-of-Applicable Year requirement for purposes of this Plan.  In that event, his Company Bonus will be based on his Participant Earnings for the portion of the Applicable Year in which the employee was a Participant in the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;text-decoration:underline">Retirement, Disability or Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as described below, a Participant who was an Eligible Employee for some portion of the Applicable Year and then takes Retirement, becomes and remains Disabled through the end of the Applicable Year, or dies during the Applicable Year will be considered to satisfy the last-day-of-Applicable-Year requirement described in this Section 5.8 for purposes of this Plan.  Notwithstanding the foregoing, an Eligible Employee in the United States who has not received a year-end performance rating and (1) is on employment probation (or its equivalent outside the United States) and takes Retirement in lieu of a termination of employment&#59; or (2) takes Retirement in lieu of termination of employment because of an immediately terminable offense (e.g. absence of three days without notice, insubordination, violation of drug policy, possession of firearms, misconduct) will not be considered to satisfy the last day of Applicable Year requirement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Reallocation, Medical Reassignment, Plant Closing or Reduction in Workforce</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Participant who was an Eligible Employee for some portion of the Applicable Year and whose employment is terminated as a result of his failure to locate a position following his reallocation or medical reassignment in the United States, or a Plant Closing or Reduction in Workforce will be considered to satisfy the last-day-of-Applicable Year requirement described in this Section 5.8 for </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 10 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">purposes of this Plan.  The Committee or its designee&#8217;s determination regarding whether a Participant&#8217;s termination is a direct result of either a Plant Closing or a Reduction in Workforce will be final and binding.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;text-decoration:underline">Expiration of Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;  A Participant who was an Eligible Employee for some portion of the Applicable Year and is subject to an agreement that describes a specific end date of employment and whose employment ends as a direct result of the expiration (not termination) of the agreement prior to the end of the Applicable Year will be considered to satisfy the last-day-of-Applicable Year requirement described in this Section 5.8 for purposes of this Plan.  The Committee or its designee&#8217;s determination regarding whether a Participant&#8217;s end of employment is a direct result of the expiration of the individual&#8217;s agreement will be final and binding.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt;text-decoration:underline">Notice of Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition, a Participant who submits a notice of resignation from employment with the Company prior to the end of the Applicable Year and whose effective date of resignation is two (2) weeks or less from the date of notice of resignation (or as otherwise required by law) will be considered employed by the Company for purposes of this Plan until the end of his specified notice period.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">New Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If an Eligible Employee began participation in the Plan during an Applicable Year and is eligible for a Company Bonus, his Company Bonus will be based on Participant Earnings paid after the employee became a Participant.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of the Plan, the minimum total amount of Company Bonus payable to Participants in the aggregate as a group or applicable subgroup (the &#8220;Minimum Amount&#8221;) may be fixed through a resolution of the Board of Directors of Lilly or the Committee, made before the end of the Applicable Year.  The Minimum Amount shall not be reduced or eliminated by the Company, including by either the Board of Directors of Lilly or the Committee, following the end of the Applicable Year, but shall be payable to Participants as determined by the Company and consistent with the terms of the Plan.  In addition, the Minimum Amount shall not be reduced by any discretionary action to reduce a particular Participant&#8217;s Company Bonus and shall be payable to persons, as determined by the Company, who are Participants in the Plan during the Applicable Year and eligible to receive a Company Bonus.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 6.  TIME OF PAYMENT</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Payment under the Plan will be made in the year following the Applicable Year on or prior to March 15 of such year.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terminated Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as provided in Section 5.8 above, in the event an Eligible Employee&#8217;s employment with the Company ends for any reason prior to the last day of the Applicable Year, he will not receive any Company Bonus for the Applicable Year.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deceased Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event an Eligible Employee dies before payment under the Plan is made, the Committee may, in its sole discretion, authorize the Company to pay to his </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 11 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">personal representative or beneficiary an amount not to exceed the amount established by the Committee to reflect the payment accrued at the date of death.  Any such payment would be paid consistent with the timing requirements described in subsection 6.1 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 7.  ADMINISTRATIVE GUIDELINES</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Establishment and Amendment by the Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Committee may establish objective and nondiscriminatory written guidelines for administering those provisions of the Plan that expressly provide for the determination of eligibility, Company Bonus or benefits on the basis of rules established by the Committee.  The Committee may, from time to time, amend or supplement the administrative guidelines established in accordance with this subsection 7.1.  The administrative guidelines established or amended in accordance with this subsection 7.1 will not be effective to the extent that they materially increase the Plan's liability, or to the extent that they are inconsistent with, or purport to amend, any provision of the Plan set forth in a document other than such administrative guidelines.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment by Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any administrative guidelines established by the Committee pursuant to subsection 7.1 may be amended or revoked by the Board of Directors, either prospectively or retroactively, in accordance with the general amendment procedures set forth in section 9 below.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 8.  MISCELLANEOUS</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Vested Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No employee, participant, beneficiary, or other individual will have a vested right to a Company Bonus or any part thereof until payment is made to him under Section 6. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Employment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No provision of the Plan or any action taken by the Company, the Board of Directors of the Company, or the Committee will give any person any right to be retained in the employ of the Company.  The right and power of the Company to dismiss or discharge any Participant for any reason or no reason, with or without notice, is specifically reserved.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  After the certification of the calculation of EPS, EPS Change, Revenue, Revenue Change, Pipeline Metrics and any other material terms of the calculation of the Company Performance Bonus Multiple and Company Bonus for the Applicable Year as described in Section 3.3 above, no adjustments will be made to reflect any subsequent change in accounting, the effect of federal, state, or municipal taxes later assessed or determined, or otherwise.  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Compensation Recovery Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of the Plan, including Section 8.3, all payments made or to be made pursuant to the Plan are subject to the Company's Executive Compensation Recovery Policy, as in effect from time to time.  In addition, nothing herein shall limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its recurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner that it deems appropriate. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 12 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing contained in this Plan, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind, or a fiduciary relationship between the Company and any employee, participant, beneficiary, legal representative, or any other person.  Although Participants generally have no right to any payment from this Plan, to the extent that any Participant acquires a right to receive payments from the Company under the Plan, such right will be no greater than the right of an unsecured general creditor of the Company.  All payments to be made hereunder will be paid from the general funds of the Company and no special or separate fund will be established, and no segregation of assets will be made, to assure payment of such amount.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company will make such provisions and take such steps as it may deem necessary or appropriate for the withholding of all federal, state, local, and other taxes required by law to be withheld with respect to Company Bonus payments under the Plan, including, but not limited to, deducting the amount required to be withheld from the amount of cash otherwise payable under the Plan, or from salary or any other amount then or thereafter payable to an employee, Participant, beneficiary, or legal representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company Bonus will be based on the currency in which the highest portion of base pay is regularly paid.  The Committee will determine the appropriate foreign exchange conversion methodology in its discretion.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Plan on other Company plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing contained in this Plan is intended to amend, modify, terminate, or rescind other benefit or compensation plans established or maintained by the Company.  Whether and to what extent a Participant&#8217;s Company Bonus is taken into account under any other plan will be determined solely in accordance with the terms of such plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Plan and all the rights thereunder will be governed by, and construed in accordance with, the laws of the state of Indiana, without reference to the principles of conflicts of law thereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice to be given to the Company or Committee pursuant to the provisions of the Plan will be in writing and directed to Secretary, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 9.  AMENDMENT, SUSPENSION, OR TERMINATION</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board of Directors of the Company will have the right to amend, modify, suspend, revoke, or terminate the Plan, in whole or in part, at any time and without notice, by written resolution of the Board of Directors.  The Committee also will have the right to amend the Plan, except that the Committee may not amend this Section 9.  </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 13 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>12
<FILENAME>lly-20201231x10kexhibit1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6f11ded0f9704fda9d7057cc695a8df4_32"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 10.15 2007 Change in Control Severance Pay Plan for Select Employees, as amended</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">2007 CHANGE IN CONTROL SEVERANCE PAY PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">FOR SELECT EMPLOYEES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">As Amended Effective January 1, 2018</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            1.         PURPOSE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This Eli Lilly and Company 2007 Change in Control Severance Pay Plan For Select Employees has been established by the Company to provide for the payment of severance pay and benefits to Eligible Employees whose employment with a Participating Employer terminates due to certain conditions created by a Change in Control of the Company.  The purpose of the Plan is to assure continuity in operations of the Company during a period of Change in Control by allowing employees to focus on their responsibilities to the Company knowing that they have certain financial security in the event of their termination of employment.  The accomplishment of this purpose is in the best interests of the Company and its shareholders.  The Plan replaces the Change in Control Severance Pay Plan for Select Employees that was originally adopted by the Board on March 1, 1995, and became operative immediately upon the expiration of such plan with respect to a Change in Control occurring on or after March 1, 2007. The Plan as amended by action of the Board of Directors of the Company on October 18, 2010 became effective on October 18, 2012. The Plan as amended by action of the Board of Directors of the Company on December 11, 2017 shall become effective on January 1, 2018.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">           2.         DEFINITIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The terms defined in this Section 2 shall have the meanings given below&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (a)        &#34;Base Salary&#34; means an Eligible Employee's gross annualized rate of base salary at the time of any determination hereunder, before any deductions, exclusions or any deferrals or contributions under any Participating Employer plan or program, but excluding bonuses, incentive awards or compensation, employee benefits or any other non-salary form of compensation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (b)        &#34;Board&#34; means the Board of Directors of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (c)        &#34;Change in Control&#34; has the meaning given in Section 3.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (d)       &#34;Code&#34; means the Internal Revenue Code of 1986, as amended.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (e)        &#34;Committee&#34; means the Compensation Committee of the Board, or such other committee appointed by the Board to perform the functions of the Committee under the Plan, provided that at all times the Committee shall be constituted solely of directors who are Continuing Directors (as defined in Section 3) to the extent any such directors remain on the Board and are willing to serve in such capacity.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (f)        &#34;Company&#34; means Eli Lilly and Company, an Indiana corporation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (g)        &#34;Covered Termination&#34; has the meaning given in Section 6.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (h)        &#34;Eligible Employee&#34; has the meaning given in Section 5.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (i)         &#34;ERISA&#34; means the Employee Retirement Income Security Act of 1974, as amended.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (j)         &#34;Exchange Act&#34; means the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (k)        &#34;Participating Employer&#34; has the meaning given in Section 4.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (l)         &#34;Plan&#34; means this Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (m)       &#8220;Retirement Age&#8221; means the date the Eligible Employee reaches age 65, unless the Company&#8217;s senior-most officer responsible for the Human Resources department has approved a later date as the Retirement Age for the Eligible Employee.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (n)        &#8220;Section 409A&#8221; shall mean Section 409A of the Code and the applicable rulings and regulations promulgated thereunder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (o)        &#8220;Separation from Service&#8221; shall mean a &#8220;separation from service&#8221; from a Participating Employer within the meaning of Section 409A.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            (p)        &#34;Severance Period&#34; means the two (2) year period immediately following a Covered Termination.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            3.         CHANGE IN CONTROL</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For purposes of the Plan, a &#34;Change in Control&#34; of the Company shall be deemed to have occurred upon&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (a)        the acquisition by any &#34;person,&#34; as that term is used in Sections 13(d) and 14(d) of the Exchange Act (other than (i) the Company, (ii) any subsidiary of the Company, (iii) any employee benefit plan or employee stock plan of the Company or a subsidiary of the Company or any trustee or fiduciary with respect to any such plan when acting in that capacity, or (iv) Lilly Endowment, Inc.) of &#34;beneficial ownership,&#34; as defined in Rule 13d-3 under the Exchange Act, directly or indirectly, of 20% or more of the shares of the Company's capital stock the holders of which have general voting power under ordinary circumstances to elect at least a majority of the Board (or which would have such voting power but for the application of the Indiana Control Shares Statute) (&#34;Voting Stock&#34;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">that an acquisition of Voting Stock directly from the Company shall not constitute a Change in Control under this Section 3(a)&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (b)        the first day on which less than one-half of the total membership of the Board shall be Continuing Directors (as that term is defined in Article 13(f) of the Company's Articles of Incorporation)&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (c)        consummation of a merger, share exchange, or consolidation of the Company (a &#34;Transaction&#34;), other than a Transaction which would result in the Voting Stock of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 60% of the Voting Stock of the Company or such surviving entity immediately after such Transaction&#59; or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (d)       a complete liquidation of the Company or a sale or disposition of all or substantially all the assets of the Company, other than a sale or disposition of assets to any subsidiary of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For purposes of this Section 3 only, the term &#34;subsidiary&#34; means a corporation or limited liability company of which the Company owns directly or indirectly fifty (50) percent or more of the voting power.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            4.         PARTICIPATING EMPLOYERS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">A.        Designation of Participating Employers.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company and each subsidiary corporation of which the Company owns directly or indirectly one-hundred (100) percent of the voting power at the time of the Change in Control shall be Participating Employers under the Plan.  In addition, the Committee may designate other affiliates of the Company as Participating Employers under the Plan, from time to time and under such terms and conditions, as shall be specified by an action in writing by the Committee.  Such terms and conditions may impose limitations on the extent to which any such affiliate participates in the Plan (including but not limited to the duration of any such participation), but shall not provide rights or benefits to Eligible Employees that are broader than those set forth in the Plan.  Any entity that is a Participating Employer at the time of a Change in Control shall continue to be a Participating Employer following a Change in Control, and any person, firm or business that is a successor to the business or interests of a Participating Employer following a Change in Control shall be treated as a Participating Employer under the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">B.        Limitations in Foreign Jurisdictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  Notwithstanding the foregoing or anything elsewhere in the Plan to the contrary, the Committee shall have the discretionary authority, as specified below, to exclude from participation or limit the participation of any Participating Employer with respect to individuals employed outside of the United States.  The Committee shall exercise this authority only by an action in writing taken prior to a Change in Control on the basis of a good faith determination that, as a result of the specific effect of applicable local law or practice with respect to the Plan or severance benefits generally, it would be in the best interests of the Company to so exclude or limit such participation.  In addition, unless otherwise specified by the Committee, the severance payments and benefits under the Plan shall offset or be offset by the benefits otherwise payable to any such Eligible Employee under severance arrangements that exist by reason of applicable local law, practice or policy, in accordance with applicable law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            5.         ELIGIBLE EMPLOYEES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">All employees of the Participating Employers, including executive officers (as defined in Rule 3b-7 under the Exchange Act), who are classified by the Company as R8 or M5-M8 global job level or other groups or individuals as designated by the Committee (or any successor classifications) immediately prior to the Change in Control shall be eligible to participate in the Plan and shall be considered an Eligible Employee for all purposes hereunder.  Any person who is an Eligible Employee in accordance with the foregoing shall continue to be an Eligible Employee notwithstanding any change in his&#47;her position or classification following a Change in Control, subject to Section 6 hereof relating to certain terminations of employment that are not treated as a Covered Termination.  The Committee shall notify each Eligible Employee of his&#47;her participation in the Plan prior to the Change in Control&#59; provided that any failure to so notify shall not affect the Eligible Employee&#8217;s participation in the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            6.         COVERED TERMINATIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">A.        General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  An Eligible Employee shall be treated as having suffered a &#34;Covered Termination&#34; hereunder if he&#47;she incurs a Separation from Service within a period of two (2) years immediately following the date of a Change in Control, (i) by a Participating Employer other than for &#34;Cause&#34;, or (ii) by the Eligible Employee for &#34;Good Reason.&#34;.  For purposes of the foregoing, the two (2) year time period specified above within which a Separation from Service may be treated as a Covered Termination shall commence on the date the Change in Control becomes effective.  For purposes of the Plan, a Separation from Service shall be effective as of the last date of the Eligible Employee's employment with the Participating Employer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">An Eligible Employee shall not be treated as having suffered a Covered Termination in the event of (1) death, (2) total disability (within the meaning of the Company's Extended Disability Plan), (3) transfer of employment among Participating Employers (unless such transfer results in a Separation from Service for &#34;Good Reason&#34;), </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(4) involuntary termination by the Participating Employer for &#34;Cause&#34;, (5) voluntary termination by the Eligible Employee other than for Good Reason, (6) a termination of employment for any reason by either the Participating Employer or the Eligible Employee that does not occur during the two (2) year time period specified above or (7) a termination of employment for any reason by either the Participating Employer or the Eligible Employee after the Eligible Employee reaches Retirement Age.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">B.        Termination For Cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  For purposes hereof, an Eligible Employee's Separation from Service by the Participating Employer shall be deemed to be for &#34;Cause&#34; if as a result of&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (i)         the willful refusal of the Eligible Employee to perform, without legal cause, his&#47;her material duties to the Participating Employer, resulting in demonstrable economic harm to any Participating Employer, which the Eligible Employee has failed to cure after thirty (30) calendar days' advance written notice from the Company&#59; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (ii)        any act of fraud, dishonesty or gross misconduct of the Eligible Employee resulting in significant economic harm to any Participating Employer or other significant harm to the business reputation of any Participating Employer&#59; or   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (iii)       the conviction of the Eligible Employee by a court of competent jurisdiction of any crime (or the entering of a plea of guilty or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">nolo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to a charge of any crime) constituting a felony.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">A termination for Cause shall be communicated to the Eligible Employee in writing by the </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Participating Employer and shall specify the provisions of the Plan and factual matters relied upon in making the Cause determination.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">C.        Termination for Good Reason.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  For purposes hereof, an Eligible Employee&#8217;s Separation from Service by the Eligible Employee shall be deemed to be for &#34;Good Reason&#34; if as a result of&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (i)         a material diminution in the nature or status of the Eligible Employee's position, title, reporting relationship, duties, responsibilities or authority, or the assignment to him&#47;her of additional responsibilities that materially increase his&#47;her workload&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (ii)        any reduction in the Eligible Employee's then-current Base Salary&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (iii)        a material reduction in the Eligible Employee's opportunities to earn incentive bonuses below those in effect for the year most recently completed before the date of the Change in Control, taking into account all material bonus factors such as targeted bonus amounts and corporate performance measures&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (iv)       a material reduction in the Eligible Employee's employee benefits and coverages (including, without limitation, pension, profit sharing and all welfare, retiree welfare and fringe benefits) that are provided to the Eligible Employee from the benefit levels in effect immediately prior to the Change in Control&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (v)        the failure to grant to the Eligible Employee stock options, stock units, performance shares or similar incentive rights during each twelve (12) month period following the Change in Control on the basis of a number of shares or units and all other material terms (including vesting requirements) at least as favorable to the Eligible Employee as those rights granted to him&#47;her on an annualized average basis for the three (3) year period immediately prior to the Change in Control&#59; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (vi)       relocation of the Eligible Employee by more than fifty (50) miles from his&#47;her regularly assigned workplace existing immediately prior to the date of the Change in Control&#59; or</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (vii)       any failure by a successor entity to the Company (including any entity that succeeds to the business or assets of the Company) in connection with a Change in Control to assume by operation of law or otherwise the obligations of the Company under the Plan, or any attempted amendment, termination or repudiation of the Plan by such successor entity, other than pursuant to the provisions of Section 15.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For purposes of the foregoing, but without limitation of the Eligible Employee&#8217;s right to otherwise terminate employment for Good Reason, if the Eligible Employee is in charge of a principal business unit, division or function of the Company immediately prior to a Change in Control, Good Reason shall not be deemed to exist based solely on the fact that the Eligible Employee is not in charge of such principal business unit, division or function of the combined entity following the Change in Control</font><font style="color:#800080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">unless as a result thereof, the Eligible Employee suffers a material diminution in the nature or status of the Eligible Employee's position, title, reporting relationship, duties, responsibilities or authority or suffers some other Good Reason event.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">A termination for Good Reason shall be communicated to the Participating Employer in writing by the Eligible Employee within thirty (30) days following his&#47;her knowledge of the circumstances constituting Good Reason, and shall specify the provisions of the Plan and the factual matters relied upon in making the Good Reason determination.  The Participating Employer shall have the opportunity to cure the circumstances constituting Good Reason within 15 days following receipt of such written notice from the Eligible Employee, and if such circumstances are fully cured, such circumstances shall cease to constitute the basis for a Good Reason termination hereunder.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            7.         SEVERANCE PAYMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">A.        Amount of Severance Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The amount of the severance payment to be paid by the Company to an Eligible Employee who is treated as having suffered a Covered Termination hereunder shall equal two (2) times the sum of&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (i)         the Eligible Employee's Base Salary at the time of Covered Termination (calculated without regard to any reduction in Base Salary that results in a Good Reason termination) or, if greater, at the time of the Change in Control,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> plus</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                        (ii)        the Eligible Employee's target annual cash incentive bonus for the year of Covered Termination or if there is no target-based annual cash incentive bonus, then the annual cash bonus paid or payable for the most recently completed calendar year prior to the Change in Control.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">B.        Payment of Severance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Subject to Section 18, the severance payment to be made hereunder shall be paid to the Eligible Employee in a single lump-sum cash payment, less any required tax withholding, on the date that is sixty (60) calendar days following the date of the Eligible Employee's Covered Termination, conditioned upon the Eligible Employee having complied, prior to that date with the requirements of Section 10 hereof regarding a release of claims. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            8.         OTHER SEVERANCE BENEFITS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In addition to the severance payment provided under Section 7, an Eligible Employee shall be entitled to the following benefits and other rights in the event of his&#47;her Covered Termination&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">A.        Welfare Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Eligible Employee shall continue to participate, on the same basis as active employees of the Participating Employer, for eighteen (18) months immediately following a Covered Termination (&#8220;Continuation Period&#8221;) in the Participating Employer&#8217;s medical and dental plans (but not to include flexible spending plans), group life insurance plans, company-provided death benefit, supplemental life </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">insurance and long-term disability plans for which he&#47;she was eligible at the time of Covered Termination (or, if it would provide benefits or other terms more favorable to the Eligible Employee, at the time of the Change in Control), as though his&#47;her Separation from Service had not occurred (the &#34;Welfare Continuation Coverages&#34;).  All Welfare Continuation Coverages shall apply to the Eligible Employee and any of his&#47;her dependents who would have been eligible for coverage if the Eligible Employee remained employed for the Continuation Period.  The Company may provide the Eligible Employee with the Welfare Continuation Coverages under arrangements other than its generally applicable welfare benefit plans, provided that the benefit coverages so provided are at least as favorable to the Eligible Employee as coverage under the otherwise applicable Welfare Continuation Coverages, on a coverage by coverage basis, and taking into account all tax consequences to the Eligible Employee.  At the expiration of the Continuation Period, the Eligible Employee shall be treated as a then terminating employee with respect to the right to elect continued medical and dental coverages in accordance with Section 4980B of the Code (or any successor provision thereto). Notwithstanding the foregoing, if the Eligible Employee becomes eligible to participate in welfare benefit coverages from a subsequent employer of the same type as provided under one or more of the Welfare Continuation Coverages, then the applicable Welfare Continuation Coverages provided by this Section 8.A, on a coverage by coverage basis, shall be terminated.  If and to the extent that any benefit under this Section 8.A or under Section 8.B. is not eligible for exemption from Section 409A pursuant to Treasury Regulation &#167; 1.409A-1(b)(9)(v) (or any successor regulation) or otherwise, the Company shall, pursuant to Section 18 hereof, take such actions as it deems necessary to comply with the requirements of Treasury Regulation &#167; 1.409A-3(i)(1)(iv) (or any successor regulation), including, without limitation, by providing that (i) the amount of the benefit under this Section 8.A or under Section 8.B. in any calendar year shall not affect the amount of the benefit thereunder for any other calendar year, (ii) any reimbursement of expenses under this Section 8.A or under Section 8.B. be made not later than the last day of the calendar year following the year in which the Eligible Employee incurred such expenses, and (iii) in no event shall any right to reimbursement or receipt of in-kind benefits under this Section 8.A. or under Section 8.B. be subject to liquidation or exchange for another benefit.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">B.        Retiree Welfare Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  For purposes of determining eligibility, but not for the purpose of determining the amount of any benefit, for the retiree medical and dental plans applicable to Eligible Employee (the &#8220;Retiree Welfare Plans&#8221;), the Eligible Employee shall receive additional credit for two years for purposes of both age and service requirements under the Retiree Welfare Plans, but not beyond the Retirement Age of the Eligible Employee.  If an Eligible Employee shall be eligible for participation in the Retiree Welfare Plans at the time of Covered Termination (including by reason of this Section 8.B.), then (i) for the Continuation Period, he&#47;she shall be entitled to continue to participate in the Welfare Continuation Coverage pursuant to Section 8.A. hereof, and (ii) following the Continuation Period, he&#47;she shall be entitled to continue to participate in the retiree welfare benefit program on the same basis and subject to the same terms and conditions as provided to retired employees of the Participating Employer generally, or if no such program is provided, the program of the successor entity following the Change in Control, if any.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">C.        Accrued Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Eligible Employee shall be entitled to the following payments and benefits in respect of accrued compensation rights at the time of a Covered Termination, in addition to all other rights provided under the Plan&#58;  (i) immediate payment of any accrued but unpaid Base Salary through the date of Covered Termination&#59; (ii) payment within thirty (30) calendar days of Covered Termination of any accrued but unpaid annual cash bonus for the most recently completed calendar year prior to the Covered Termination&#59; (iii) payment within thirty (30) calendar days of Covered Termination of the accrued annual cash bonus for the year in effect on the date of the Covered Termination, determined on the basis of the bonus earned under terms of the applicable bonus plan through the date of termination or, if greater, the pro-rata amount of the target annual cash bonus for the period of such year through the date of termination&#59; and (iv) all benefits and rights accrued under the employee benefit plans, fringe benefit programs and payroll practices of a Participating Employer in accordance with their terms (including, without limitation, employee pension, employee welfare, incentive bonus and stock incentive plans). </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">D.        Outplacement&#59; Relocation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Eligible Employee shall be provided, at the Company's sole expense, with professional outplacement services selected by the Eligible Employee consistent with his&#47;her duties or profession and of a type and level customary for persons in his&#47;her position&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the Company shall not be required to pay fees in connection with the foregoing in an amount greater than fifteen (15) percent of the Eligible Employee's Base Salary as determined under clause (i) of Section 7.A.  The Company shall honor any prior agreement or understanding with an Eligible Employee who has suffered a Covered Termination to reimburse his&#47;her relocation expenses to the Indianapolis, Indiana metropolitan area or, if it does not result in a greater cost to the Company, to such other location selected by the Eligible Employee. Payment for any such outplacement service services or relocation expense shall be made on the business day that is six (6) months following the date of the Covered Termination.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">E.        Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  With respect to any Eligible Employee who is, immediately prior to a Change in Control or a Covered Termination, indemnified by the Company for his&#47;her service as a director, officer or employee of a Participating Employer, the Company shall indemnify such Eligible Employee to the fullest extent permitted by applicable law, and the Company shall maintain in full force and effect, for the duration of all applicable statute of limitation periods, insurance policies at least as favorable to the Eligible Employee as those maintained by the Company for the benefit of its directors and officers at the time of Change in Control, provided that such insurance policies are commercially available from carriers of recognized standing, with respect to all costs, charges and expenses whatsoever (including payment of expenses in advance of final disposition of a proceeding) incurred or sustained by the Eligible Employee in connection with any action, suit or proceeding to which he&#47;she may be made a party by reason of being or having been a director, officer or employee of a Participating Employer or serving or having served any other enterprise as a director, officer or employee at the request of a Participating Employer.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            9.         REDUCTION OF TOTAL PAYMENTS</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)        In the event it shall be determined that any payment, right or distribution by the Company or any other person or entity to or for the benefit of an Eligible Employee pursuant to the terms of the Plan or otherwise, in connection with, or arising out of, his&#47;her employment with a Participating Employer or a change in ownership or effective control of the Company or a substantial portion of its assets (a &#34;Payment&#34;) would be a &#34;parachute payment&#34; within the meaning of Section 280G of the Code on account of the aggregate value of the Payments due to the Eligible Employee being equal to or greater than three times the &#8220;base amount,&#8221; as defined in Section 280G(b)(3) of the Code, (the &#8220;Parachute Threshold&#8221;) so that the Eligible Employee would be subject to the excise tax imposed by Section 4999 of the Code, </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and reducing the aggregate value of the Payments would result in an increase in the aggregate Payments to be received by the Eligible Employee (after taking into account the excise tax imposed pursuant to Section 4999 of the Code, any tax imposed by any comparable provision of state law, and any applicable federal, state, and local income and employment taxes), the Company shall reduce the total Payments by the amount necessary to maximize the aggregate value of Payments to such Eligible Employee determined on an after-tax basis, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">reducing first any taxable Payments, and thereafter any other non-taxable Payments.  </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For purposes of determining the amount of an Eligible Employee&#8217;s aggregate value of Payments on an after-tax basis, the Eligible Employee shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation in the calendar year in which the Payments are to be made, and state and local income taxes at the highest marginal rate of taxation in the state and locality of such Eligible Employee&#8217;s residence on the effective date of the Covered Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)        </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In the event the Internal Revenue Service adjusts any item included in the Company&#8217;s computations under subsection 9(a) above so that such Eligible Employee did not receive the full net benefit intended under the provisions of this Section 9, the Company shall reimburse such Eligible Employee, by the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:115%">end of the calendar year following the year of such adjustment, for all or a portion of the taxes imposed pursuant to such adjustment to the extent necessary to make such Eligible Employee whole.</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)        All determinations required to be made under this Section 9, including whether any Payment is a &#8220;parachute payment&#8221; and the assumptions to be utilized in arriving at such determination, shall be made by a nationally recognized accounting firm designated by the Company which is not the auditor of the Company or another party involved in the Change in Control (the &#34;Accounting Firm&#34;) and shall be based upon &#34;substantial authority&#34; (within the meaning of Section 6662 of the Code).  All fees and expenses of the Accounting Firm shall be borne by the Company. Any determination by the Accounting Firm shall be binding upon the Company and the Eligible Employee.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            10.       RELEASE OF CLAIMS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">All payments and benefits that may be made to an Eligible Employee upon a Covered Termination under the Plan shall be contingent upon the Eligible Employee entering into and not revoking a general release of employment law claims against the Company and the Participating Employer in substantially the form attached hereto as Exhibit A, subject to such modifications as may be determined by the Committee in good faith to take into account changes in employment laws or differences in employment laws in other jurisdictions.  The Company will provide the general release to the Eligible Employee within five (5) business days of the Covered Termination. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">11.       NO MITIGATION OR OFFSET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Eligible Employee shall be under no obligation to minimize or mitigate damages by seeking other employment, and the obtaining of any such other employment shall in no event effect any reduction of the Company's obligation to make the payments and provide the benefits required under the Plan.  Except as provided in Section 10, the Company's obligation to make the payments and provide the benefits required under the Plan shall not be affected by any circumstances, including, without limitation, any set-off, counterclaim, recoupment, defense or other rights which a Participating Employer may have against the Eligible Employee.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            12.       UNFUNDED STATUS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Plan is intended to constitute an employee pension benefit plan under ERISA which is unfunded and is maintained primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees, and shall be interpreted and administered accordingly.  The payments and benefits provided hereunder shall be paid from the general assets of the Company.  Nothing herein shall be construed to require the Company to maintain any fund or to segregate any amount for the benefit of any employee, and no employee or other person shall have any right against, right to, or security or other interest in any fund, account or asset of the Company from which the payment pursuant to the Plan may be made.  Consistent with the foregoing, the Company may, in its sole discretion, deposit funds in a grantor trust or otherwise establish arrangements to pay amounts that become due under the Plan, and, notwithstanding anything elsewhere in the Plan to the contrary, the payments and benefits due under the Plan shall be reduced to reflect the amount of any payment made in respect of any Eligible Employee from a grantor trust or other arrangement established for this purpose.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            13.       ADMINISTRATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Committee shall be the named fiduciary of the Plan and the plan administrator for purposes of ERISA.  The Committee shall be responsible for the overall operation of the Plan and shall have the fiduciary responsibility for the general operation of the Plan.  The Committee may allocate to any one or more of the Company's employees any responsibility the Committee may have under the Plan and may designate any other person or </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">persons to carry out any of the Committee's responsibilities under the Plan.  As plan administrator, the Committee shall maintain records pursuant to the Plan's provisions and shall be responsible for the handling, processing and payment of any claims for benefits under the Plan.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            14.       CLAIMS AND DISPUTES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">A.         Filing a Claim. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Within thirty (30) calendar days following a Covered Termination, the Company shall notify each Eligible Employee whom the Company determines is entitled to payments and benefits under the Plan of his&#47;her entitlement to such payments and benefits.  An Eligible Employee who is not so notified may submit a claim for payments and benefits under the Plan in writing to the Company within ninety (90) calendar days after becoming entitled to such benefits as described in Section 6. Claims filed after such ninety (90) calendar day period will be denied.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">All claims must be in writing and contain the following information&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">The name of the Eligible Employee filing the claim&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">The name of the Plan&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">A statement that the Eligible Employee is making a claim under the Plan and the basis for such claim.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">All claims must be timely delivered to the Company at the address below&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Eli Lilly and Company</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Attention&#58; General Counsel</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Lilly Corporate Center</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Indianapolis, Indiana 46285</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">B.        Process for Determining Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Company will notify each claimant of its decision to approve or deny the claimant&#8217;s claim within a reasonable period of time, but not later than ninety (90) days after the date the claim was received by the Company. In special circumstances, the Company may have up to an additional ninety (90) days to provide the claimant with such written notice, provided that the Company must notify the claimant prior to the expiration of the initial ninety (90) day period, state the reason(s) for such extension and state the date by which the Company expects to make its determination. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">C.        Content of Initial Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. If the claimant&#8217;s claim is denied in whole or in part, the Company will provide written or electronic notice of its adverse benefit determination that includes the following information&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">The specific reason(s) for the adverse benefit determination&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Reference to the specific provision(s) of the Plan on which the determination is based&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">A description of any additional material or information necessary for the claimant to perfect his or her claim and an explanation of why such material or information is necessary&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">A description of the Plan&#8217;s appeals procedures and the time limits applicable to such procedures&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">A statement of the claimant&#8217;s rights to bring a civil action under Section 502(a) of ERISA following an adverse benefit determination on appeal.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">D.        Filing an Appeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. A claimant may appeal a denied claim within sixty (60) days following receipt of written notice of the adverse benefit determination. Appeals may include any written comments, documents, records, or other information relating to the claim, and must include the following information&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">The name of the Eligible Employee filing the appeal&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">The name of the Plan&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Information identifying the initial adverse benefit determination&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">The basis for appeal of the initial adverse benefit determination.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claimant&#8217;s claim, as determined by the Company under applicable federal regulations. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">All appeals must be timely delivered to the Company at the address below&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Eli Lilly and Company</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Attention&#58; General Counsel</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Lilly Corporate Center</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Indianapolis, Indiana 46285</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">E.        Process for Determining Appeals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Company&#8217;s review on appeal will take into account all comments, documents, records, and other information submitted by the claimant relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. The Company will notify each claimant of its decision on appeal within a reasonable period of time, but not later than sixty (60) days after the date the request for appeal was received by the Company. In special circumstances, the Company may have up to an additional sixty (60) days to provide the claimant with such written notice, provided that the Company must notify the claimant prior to the expiration of the initial sixty (60) day period, state the reason for such extension and state the date by which the Company expects to make its determination on appeal.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">F.         Content of Appeal Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   If the claimant&#8217;s appeal is denied in whole or in part, the Company will provide written or electronic notice of its adverse benefit determination that includes the following information&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">The specific reason(s) for the adverse benefit determination&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">Reference to the specific provision(s) of the Plan on which the determination is based&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">A statement of the claimant&#8217;s right to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claimant&#8217;s claim, as determined by the Company under applicable federal regulations&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:13.8pt">A statement of the claimant&#8217;s rights to bring a civil action under Section 502(a) of ERISA.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">G.        Authorized Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Eligible Employees may authorize a representative to pursue any claim or appeal on their behalf.  The Company will recognize a person as an Eligible Employee&#8217;s authorized representative if such person submits a writing that has been signed by such Eligible Employee and notarized stating that the authorized representative is authorized to act on your behalf.  A court order stating that a person is authorized to submit claims on behalf of an Eligible Employee will also be recognized.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">H.        Tolling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. If an extension of time is required, either during the initial review or on appeal,  due to the claimant&#8217;s failure to submit additional information requested by the Company, the period for making the benefit determination may, in the sole discretion of the Company, be tolled from the date on which the notification of extension is sent to the claimant until the date on which the claimant responds to the request for additional information.  If the claimant does not respond in a timely fashion, as determined by the Company in its sole discretion, the Company will decide the appeal without such additional information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhaustion Requirement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">No</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">action at law or at equity to recover payments or benefits under the Plan may be brought by an Eligible Employee (or an authorized representative thereof) until such Eligible Employee or authorized representative has exhausted the claims and appeals procedures described in this Section 14.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            15.       TERM AND AMENDMENT   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Plan became effective as on July 1, 2004, but only became operative with respect to a Change in Control occurring on or after March 1, 2007, the date as of which the Plan as previously in effect was terminated by action of the Board.  The Plan as amended by action of the Board of Directors of the Company on October 18, 2010 became effective with respect to a Change in Control occurring on or after October 18, 2012. The Plan as amended by action of the Board of Directors of the Company on December 11, 2017 shall become effective on January 1, 2018. The Plan shall continue to be effective until terminated in accordance with this Section 15.  The Board shall have the right, by resolution or other written action, to terminate or amend the Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the Plan may only be terminated or amended prior to a Change in Control, and then only (i) with respect to an amendment or termination that becomes effective upon the second (2nd) anniversary of the date of Board approval thereof, or (ii) to the extent any such amendment is of a technical or clarifying nature, or increases the rights or benefits of all affected Eligible Employees, and does not in any manner reduce the rights or benefits of any Eligible Employee, unless the Company has obtained the express written consent, in return for good and valuable consideration, of all affected Eligible Employees in respect of any such amendment. Notwithstanding the foregoing, in the event of a Change in Control, the Plan shall continue in effect, and no termination or amendment of the Plan shall occur, until the satisfaction of all severance payments and benefits to which Eligible Employees are or may become entitled to under the Plan.  Upon the occurrence of a Change in Control during the term of the Plan, the Plan shall not be operative with respect to any subsequent Change in Control.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">            16.       SUCCESSORS AND ASSIGNS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Plan shall be binding upon any person, firm or business that is a successor to the business or interests of the Company, whether as a result of a Change in Control of the Company or otherwise.  Any successor to the Company shall be required to assume the Plan in writing and honor the obligations of the Company and the Participating Employers hereunder.  All payments and benefits that become due to an Eligible Employee under the Plan shall inure to the benefit of his&#47;her heirs, assigns, designees or legal representatives.  </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">17.       ENFORCEABILITY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company intends the Plan to constitute a legally enforceable obligation between it and each Eligible Employee, and that the Plan confer vested rights on each Eligible Employee in accordance with the terms of the Plan, with each Eligible Employee being a third-party beneficiary thereof.  Nothing in the Plan, however, shall be construed to confer on any Eligible Employee any right to continue in the employ of a Participating Employer or affect the right of a Participating Employer to terminate the employment or change the terms and conditions of employment of an Eligible Employee, with or without notice or cause, prior to a Change in Control, or to take any such action following a Change in Control, subject to the consequences specified by the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Plan shall be construed and enforced in accordance with ERISA and the laws of the State of Indiana to the extent not preempted by ERISA, regardless of the law that might otherwise govern under applicable principles or provisions of choice or conflict of law doctrines.  To the extent any provision of the Plan shall be invalid or unenforceable under any applicable law, it shall be considered deleted herefrom and all other provisions of the Plan shall be unaffected and shall continue in full force and effect.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">18. SECTION 409A COMPLIANCE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">To the extent applicable, it is intended that the Plan and all payments hereunder comply with the requirements of Section 409A, and the Plan shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.  In the event that any provision of the Plan is determined by the Committee to not comply with the applicable requirements of Section 409A, the Committee shall have the authority to take such actions and to make such changes to the Plan as the Committee deems necessary to comply with such requirements.  In no event whatsoever shall the Company be liable for any tax, interest or penalties that may be imposed on the Eligible Employee by or any damages for failing to comply with Section 409A. Notwithstanding the foregoing or anything elsewhere in the Plan to the contrary, if an Eligible Employee is treated as a &#8220;specified employee&#8221; as of the date of any payment under the Plan, then, to the extent required, the commencement of any payment under the Plan shall be delayed until the date that is six (6) months following the date of the Eligible Employee&#8217;s Separation from Service.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT A</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">SEVERANCE AGREEMENT AND RELEASE OF CLAIMS</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>13
<FILENAME>lly-20201231x10kexhibit21.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6479707b9c0341e096abacf72aefdfec_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21 &#8212; List of Subsidiaries&#160;&#38; Affiliates</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The following are subsidiaries and affiliated corporations of the company at December&#160;31, 2020.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain subsidiaries have been omitted as they are not significant in the aggregate.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1096401 B.C. Unlimited Liability Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acanthas Pharma, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alnara Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andean Technical Operations Center</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARMO Biosciences, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AurKa Pharma, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avid Radiopharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CoLucid Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compania Farmaceutica Eli Lilly de Centro America S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guatemala</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermira, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermira Canada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista Ilac Ticaret Ltd. Sti.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dista-Produtos Quimicos &#38; Farmaceuticos, LDA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elanco Animal Health Ireland Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elanco Switzerland Holding Sarl</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Dominicana SRL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO for Trade and Marketing, S.A.E.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Insurance Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELCO Management, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELGO Insurance Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Malaysia) Sdn. Bhd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Philippines), Incorporated</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (S.A.) (Proprietary) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Singapore) Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly (Suisse) S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELI LILLY AND COMPANY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (India) Pvt. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (Ireland) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (N.Z.) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (Taiwan), Inc.  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Asia Pacific SSC Sdn Bhd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Asia, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Australia Pty. Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Benelux S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly B-H d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bosnia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Bienes y Servicios S de RL de CV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Canada Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Cork Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly CR s.r.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Danmark A&#47;S</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly do Brasil Limitada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Egypt, for Trading</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly European Clinical Trial Services SA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Export S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly farmacevtska druzba, d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Finance, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Ges.m.b.H.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Group Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Holdings Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Hrvatska d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Interamerica Inc., y Compania Limitada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Interamerica, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly International Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Ireland Holdings Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Israel Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Italia S.p.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Japan K.K.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Kinsale Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Nederland B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Nigeria Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Norge A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Pakistan (Pvt.) Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Polska Sp.z.o.o. (Ltd.)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Regional Operations GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Romania SRL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Saudi Arabia Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Services India Private Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Slovakia s.r.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Sweden AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly Vostok S.A., Geneva</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly y Compania de Mexico, S.A. de C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly y Compania de Venezuela, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glycostasis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greenfield-Produtos Farmaceuticos, Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICOS Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone Systems Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImClone Systems LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or Jurisdiction<br>of Incorporation<br>or Organization</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irisfarma S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDH I Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly (Shanghai) Management Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asia Ventures Fund I, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asia Ventures Fund II, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Asian Ventures Fund III, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Cayman Holdings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Centre for Clinical Pharmacology PTE. LTD.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly China Research and Development Co., Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly del Caribe, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Deutschland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly France S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Global Nederland Holdings B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Global Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Holding GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Holdings B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Hungaria KFT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly ila&#231; ticaret limited &#351;irketi</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Japan Financing G.K.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Korea Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Nederland Finance B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Nederland Finance B.V. - GCC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Nederland Holding B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Pharma Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Portugal - Produtos Farmaceuticos, Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Suzhou Pharmaceutical Co. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Trading Co. LTD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly USA, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly Ventures Fund I LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loxo Oncology, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OY Eli Lilly Finland AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaserve-Lilly S.A.C.I.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT. Eli Lilly Indonesia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGX Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spaly Bioquimica, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB Eli Lilly Lietuva</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valquifarma S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vital Pharma Productos Farmaceuticos</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>14
<FILENAME>lly-20201231x10kexhibit23.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0fe617e35cfd4d2aacc9f20000d84ce8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit 23</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the Registration Statements (Form S-3 ASR No. 333-229735&#59; and Form S-8 Nos. 333-104057 and 333-172422) of Eli Lilly and Company and in the related Prospectus of our reports dated February&#160;17, 2021, with respect to the consolidated financial statements of Eli Lilly and Company and subsidiaries, and the effectiveness of internal control over financial reporting of Eli Lilly and Company and subsidiaries, included in this Annual Report (10-K) for the year ended December&#160;31, 2020.</font></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47; Ernst and Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Indianapolis, Indiana</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:144%">February&#160;17, 2021 </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>15
<FILENAME>lly-20201231x10kexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9856f6b7baa7466e84dd482e9747ad0f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 Rule 13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David A. Ricks, Chairman, President, and Chief Executive Officer, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-K of Eli Lilly and Company&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;17, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:52.777%"><tr><td style="width:1.0%"></td><td style="width:6.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President, and Chief&#160;Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>16
<FILENAME>lly-20201231x10kexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie7db292a0f944c20a392119139d3bb2f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 Rule 13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anat Ashkenazi, Senior Vice President and Chief Financial Officer, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-K of Eli Lilly and Company&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:4.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:13.5pt"><font><br></font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;17, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.637%"><tr><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>17
<FILENAME>lly-20201231x10kexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i962ce216659a4c75a6b2b014cacc1c43_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32 Section&#160;1350 Certification </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the &#8220;Company&#8221;), does hereby certify that, to the best of his knowledge&#58; </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President, and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 17, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and<br>Chief Financial Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>lly-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:245edc66-3d73-4ffb-b61a-7d5e03b3f1e4,g:f11d2b17-0882-47f8-a810-701878e7e2df-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>000010001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations">
        <link:definition>100010002 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>100020003 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets">
        <link:definition>100030004 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040005 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityStatement" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement">
        <link:definition>100050006 - Statement - Consolidated Statements of Shareholders' Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>100060007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>100070008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>100080009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards">
        <link:definition>210011001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies">
        <link:definition>220022001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails" roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails">
        <link:definition>240034001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.lilly.com/role/Revenue">
        <link:definition>210041002 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.lilly.com/role/RevenueTables">
        <link:definition>230053001 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenueRecognizedDetails" roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails">
        <link:definition>240064002 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.lilly.com/role/RevenueNarrativeDetails">
        <link:definition>240074003 - Disclosure - Revenue (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesDetails" roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails">
        <link:definition>240084004 - Disclosure - Revenue (Contract Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyProductDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails">
        <link:definition>240094005 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyGeographicalAreaDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
        <link:definition>240104006 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestiture" roleURI="http://www.lilly.com/role/AcquisitionsandDivestiture">
        <link:definition>210111003 - Disclosure - Acquisitions and Divestiture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitureTables" roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureTables">
        <link:definition>230123002 - Disclosure - Acquisitions and Divestiture (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitureNarrativeDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails">
        <link:definition>240134007 - Disclosure - Acquisitions and Divestiture (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestiturePurchasePriceAllocationDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails">
        <link:definition>240144008 - Disclosure - Acquisitions and Divestiture (Purchase Price Allocation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitureAssetAcquisitionsDetails" roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails">
        <link:definition>240154009 - Disclosure - Acquisitions and Divestiture (Asset Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements">
        <link:definition>210161004 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsTables" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables">
        <link:definition>230173003 - Disclosure - Collaborations and Other Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails">
        <link:definition>240184010 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsNetProductRevenueDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails">
        <link:definition>240194011 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsNarrativeDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails">
        <link:definition>240204012 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialCharges" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges">
        <link:definition>210211005 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesTables" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables">
        <link:definition>230223004 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails">
        <link:definition>240234013 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails">
        <link:definition>240244014 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.lilly.com/role/Inventories">
        <link:definition>210251006 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.lilly.com/role/InventoriesTables">
        <link:definition>230263005 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.lilly.com/role/InventoriesDetails">
        <link:definition>240274015 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.lilly.com/role/FinancialInstruments">
        <link:definition>210281007 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.lilly.com/role/FinancialInstrumentsTables">
        <link:definition>230293006 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>240304016 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofEffectofRiskManagementDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails">
        <link:definition>240314017 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofFairValueMeasurementDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails">
        <link:definition>240324018 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails">
        <link:definition>240334019 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails">
        <link:definition>240344020 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofContractualMaturitiesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails">
        <link:definition>240354021 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails">
        <link:definition>240364022 - Disclosure - Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails">
        <link:definition>240374023 - Disclosure - Financial Instruments (Schedule of Investment Portfolio Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibles" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangibles">
        <link:definition>210381008 - Disclosure - Goodwill and Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesTables" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables">
        <link:definition>230393007 - Disclosure - Goodwill and Other Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesNarrativeDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails">
        <link:definition>240404024 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails">
        <link:definition>240414025 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails">
        <link:definition>240424026 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails">
        <link:definition>240434027 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.lilly.com/role/PropertyandEquipment">
        <link:definition>210441009 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.lilly.com/role/PropertyandEquipmentTables">
        <link:definition>230453008 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>240464028 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>240474029 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofDepreciationExpenseDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails">
        <link:definition>240484030 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofGeographicInformationDetails" roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails">
        <link:definition>240494031 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.lilly.com/role/Leases">
        <link:definition>210501010 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.lilly.com/role/LeasesTables">
        <link:definition>230513009 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.lilly.com/role/LeasesNarrativeDetails">
        <link:definition>240524032 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" roleURI="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails">
        <link:definition>240534033 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>240544034 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>240544034 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.lilly.com/role/Borrowings">
        <link:definition>210551011 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.lilly.com/role/BorrowingsTables">
        <link:definition>230563010 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails">
        <link:definition>240574035 - Disclosure - Borrowings (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtDetails_1" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1">
        <link:definition>240574035 - Disclosure - Borrowings (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsSummaryofLongtermNotesDetails" roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails">
        <link:definition>240584036 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails">
        <link:definition>240594037 - Disclosure - Borrowings (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofDebtMaturitiesDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails">
        <link:definition>240604038 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" roleURI="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails">
        <link:definition>240614039 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.lilly.com/role/StockBasedCompensation">
        <link:definition>210621012 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.lilly.com/role/StockBasedCompensationTables">
        <link:definition>230633011 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>240644040 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>240654041 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedDetails" roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails">
        <link:definition>240664042 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.lilly.com/role/ShareholdersEquity">
        <link:definition>210671013 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.lilly.com/role/ShareholdersEquityDetails">
        <link:definition>240684043 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lilly.com/role/IncomeTaxes">
        <link:definition>210691014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.lilly.com/role/IncomeTaxesTables">
        <link:definition>230703012 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>240714044 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails">
        <link:definition>240724045 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails">
        <link:definition>240734046 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails">
        <link:definition>240744047 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails">
        <link:definition>240754048 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails">
        <link:definition>240764049 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>240774050 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails">
        <link:definition>240784051 - Disclosure - Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefits" roleURI="http://www.lilly.com/role/RetirementBenefits">
        <link:definition>210791015 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsTables" roleURI="http://www.lilly.com/role/RetirementBenefitsTables">
        <link:definition>230803013 - Disclosure - Retirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails">
        <link:definition>240814052 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails">
        <link:definition>240824053 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsNarrativeDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails">
        <link:definition>240834054 - Disclosure - Retirement Benefits (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails">
        <link:definition>240844055 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails">
        <link:definition>240854056 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsScheduleofFairValueDisclosuresDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails">
        <link:definition>240864057 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.lilly.com/role/Contingencies">
        <link:definition>210871016 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.lilly.com/role/ContingenciesDetails">
        <link:definition>240884058 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>210891017 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>230903014 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails">
        <link:definition>240914059 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails">
        <link:definition>240924060 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>240934061 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpense" roleURI="http://www.lilly.com/role/OtherNetIncomeExpense">
        <link:definition>210941018 - Disclosure - Other-Net, (Income) Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseTables" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables">
        <link:definition>230953015 - Disclosure - Other - Net, (Income) Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseDetails" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails">
        <link:definition>240964062 - Disclosure - Other - Net, (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.lilly.com/role/DiscontinuedOperations">
        <link:definition>210971019 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.lilly.com/role/DiscontinuedOperationsTables">
        <link:definition>230983016 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsNarrativeDetails" roleURI="http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails">
        <link:definition>240994063 - Disclosure - Discontinued Operations (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails" roleURI="http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails">
        <link:definition>241004064 - Disclosure - Discontinued Operations (Summary of Revenue and Net Income from Discontinued Operations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_DomicileOfLitigationDomain" abstract="true" name="DomicileOfLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" abstract="false" name="CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" abstract="false" name="RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" abstract="false" name="AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ForteoMember" abstract="true" name="ForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A17EuroDeonominatedNotesDue2049Member" abstract="true" name="A17EuroDeonominatedNotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherDiabetesMember" abstract="true" name="OtherDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PaymentsForIncomeTaxSettlements" abstract="false" name="PaymentsForIncomeTaxSettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" abstract="false" name="DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A31NotesDue2027Member" abstract="true" name="A31NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatentsClaimsDismissed" abstract="false" name="LossContingencyNumberOfPatentsClaimsDismissed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_AccountingStandardsUpdate201616aMember" abstract="true" name="AccountingStandardsUpdate201616aMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DicernaPharmaceuticalsMember" abstract="true" name="DicernaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EvoxTherapeuticsMember" abstract="true" name="EvoxTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TrajentaBIMember" abstract="true" name="TrajentaBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1625EuroDenominatedNotesDue2026Member" abstract="true" name="A1625EuroDenominatedNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AddDeductAbstract" abstract="true" name="AddDeductAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_DermiraInc.Member" abstract="true" name="DermiraInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TaxYears2013To2015Member" abstract="true" name="TaxYears2013To2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_FochonPharmaceuticalsLtdMember" abstract="true" name="FochonPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" abstract="false" name="AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_LosAngelesMember" abstract="true" name="LosAngelesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" abstract="true" name="LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ElancoAnimalHealthIncorporatedMember" abstract="true" name="ElancoAnimalHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" abstract="false" name="CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_EppVTakedaCanadaIncEtAlMember" abstract="true" name="EppVTakedaCanadaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A37NotesDue2045Member" abstract="true" name="A37NotesDue2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" abstract="false" name="RevenuePerformanceObligationSalesRebatePaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_A30NotesDue2022Member" abstract="true" name="A30NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SeniorNotesDueMay2050AndSeptember2060Member" abstract="true" name="SeniorNotesDueMay2050AndSeptember2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_VariousStateDomicilesMember" abstract="true" name="VariousStateDomicilesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DescriptionOfDerivativeActivityVolumePercent" abstract="false" name="DescriptionOfDerivativeActivityVolumePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" abstract="false" name="FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_PancreaticCancerOrThyroidCancerMember" abstract="true" name="PancreaticCancerOrThyroidCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A555NotesDue2037Member" abstract="true" name="A555NotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A677NotesDue2036Member" abstract="true" name="A677NotesDue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_HumalogHumulinAndForteoMember" abstract="true" name="HumalogHumulinAndForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DefineBenefitPlanOtherMember" abstract="true" name="DefineBenefitPlanOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_FixedIncomeFundsEmergingMarketsMember" abstract="true" name="FixedIncomeFundsEmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" abstract="true" name="MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsRightsObligations" abstract="false" name="CollaborativeArrangementRightsAndObligationsRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CollaborationandOtherRevenueMember" abstract="true" name="CollaborationandOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BuyEuroSellUsDollarMember" abstract="true" name="BuyEuroSellUsDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" abstract="false" name="DebtSecuritiesAvailableforsaleUnrealizedGainPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lly_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" abstract="false" name="TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OutsideUSAndJapanMember" abstract="true" name="OutsideUSAndJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_TermFacilityMember" abstract="true" name="TermFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A10EuroDenominatedNotesDue2022Member" abstract="true" name="A10EuroDenominatedNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CentrexionTherapeuticsCorporationMember" abstract="true" name="CentrexionTherapeuticsCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CyramzaMember" abstract="true" name="CyramzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" abstract="false" name="CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_UNITEDSTATESAndPUERTORICOMember" abstract="true" name="UNITEDSTATESAndPUERTORICOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DerivativeInstrumentsGainLossRecognized" abstract="false" name="DerivativeInstrumentsGainLossRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_JardianceMember" abstract="true" name="JardianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" abstract="false" name="ProceedsfromSaleofEquityandAvailableforSaleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A7125NotesDue2025Member" abstract="true" name="A7125NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" abstract="true" name="TaxCutAndJobsActTollTaxPaymentDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" abstract="false" name="RevenuePerformanceObligationSalesReturnsProductExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_DomicileOfLitigationAxis" abstract="true" name="DomicileOfLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lly_HumulinMember" abstract="true" name="HumulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PancreatitisMember" abstract="true" name="PancreatitisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_Expirationin6YearsMember" abstract="true" name="Expirationin6YearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" abstract="false" name="DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BuyUSdollarSellJapaneseYenMember" abstract="true" name="BuyUSdollarSellJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A225NotesDue2050Member" abstract="true" name="A225NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A625EuroDeonominatedNotesDue2031Member" abstract="true" name="A625EuroDeonominatedNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AvidityBiosciencesInc.Member" abstract="true" name="AvidityBiosciencesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CostOfSalesOperatingExpensesAndOtherNet" abstract="false" name="CostOfSalesOperatingExpensesAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" abstract="false" name="BusinessAcquisitionContingentValueRightAdditionalPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" abstract="false" name="LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_LesseeLeaseRemainingLeaseTerm" abstract="false" name="LesseeLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_MaturityDate2019Member" abstract="true" name="MaturityDate2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A3875NotesDue2039Member" abstract="true" name="A3875NotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A56YenDenominatedNotesDue2034Member" abstract="true" name="A56YenDenominatedNotesDue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsSalesRebatesAndDiscounts" abstract="false" name="DeferredTaxAssetsSalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_MilestonePaymentsSuccessBasedRegulatoryMember" abstract="true" name="MilestonePaymentsSuccessBasedRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ACImmuneSAMember" abstract="true" name="ACImmuneSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" abstract="false" name="ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_PrecisionBioSciencesIncMember" abstract="true" name="PrecisionBioSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ErbituxMember" abstract="true" name="ErbituxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ThreeLargestWholesalesMember" abstract="true" name="ThreeLargestWholesalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" abstract="true" name="AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SalesRebatesAndDiscounts" abstract="false" name="SalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AdvertisingExpensePercentageOfRevenue" abstract="false" name="AdvertisingExpensePercentageOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_ChugaiPharmaceuticalCompanyMember" abstract="true" name="ChugaiPharmaceuticalCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PurchasedInProcessResearchAndDevelopment" abstract="false" name="PurchasedInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" abstract="false" name="RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lly_AmpullaryCancerMember" abstract="true" name="AmpullaryCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AlimtaMember" abstract="true" name="AlimtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherProductMember" abstract="true" name="OtherProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A465NotesDue2044Member" abstract="true" name="A465NotesDue2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A2125EuroDenominatedNotesDue2030Member" abstract="true" name="A2125EuroDenominatedNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_ShareholderValueAwardsMember" abstract="true" name="ShareholderValueAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ImmuNextInc.Member" abstract="true" name="ImmuNextInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DisarmTherapeuticsIncMember" abstract="true" name="DisarmTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" abstract="false" name="RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" abstract="false" name="DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsCorrectiveTaxAdjustments" abstract="false" name="DeferredTaxAssetsCorrectiveTaxAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_RelativeValueAwardsMember" abstract="true" name="RelativeValueAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A395NotesDue2049Member" abstract="true" name="A395NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AsahiKaseiPharmaCorporationMember" abstract="true" name="AsahiKaseiPharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ExpirationIn12To18YearsMember" abstract="true" name="ExpirationIn12To18YearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MerusNVMember" abstract="true" name="MerusNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TanezumabMember" abstract="true" name="TanezumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A25NotesDue2060Member" abstract="true" name="A25NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OlumiantMember" abstract="true" name="OlumiantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PrevailTherapeuticsIncMember" abstract="true" name="PrevailTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" abstract="false" name="BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lly_NonCHINAMember" abstract="true" name="NonCHINAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_FairValueHedgeAbstract" abstract="true" name="FairValueHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SigilonTherapeuticsMember" abstract="true" name="SigilonTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A415NotesDue2059Member" abstract="true" name="A415NotesDue2059Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A42YenDenominatedNotesDue2029Member" abstract="true" name="A42YenDenominatedNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A2018RepurchaseProgramMember" abstract="true" name="A2018RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" abstract="false" name="TaxCutAndJobsActTollTaxToBePaidWithinOneYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" abstract="false" name="AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" abstract="true" name="MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LongTermDebtFairValueAdjustment" abstract="false" name="LongTermDebtFairValueAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_RevenuefromContractPaymentTermMinimum" abstract="false" name="RevenuefromContractPaymentTermMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_AssetAcquisitionAxis" abstract="true" name="AssetAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lly_HumalogMember" abstract="true" name="HumalogMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentAndRegulatoryMember" abstract="true" name="MilestonePaymentsDevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ActosMember" abstract="true" name="ActosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_InnoventBiologicsIncMember" abstract="true" name="InnoventBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LebrikizumabMember" abstract="true" name="LebrikizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A235NotesDue2022Member" abstract="true" name="A235NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_NumberOfMedicinesRightsToSold" abstract="false" name="NumberOfMedicinesRightsToSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_OtherProductTotalMember" abstract="true" name="OtherProductTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" abstract="false" name="RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_StockAcquiredDuringPeriodSharesExchangeOffer" abstract="false" name="StockAcquiredDuringPeriodSharesExchangeOffer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lly_A275NotesDue2025Member" abstract="true" name="A275NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SaleOfStockPercentageOfStockSold" abstract="false" name="SaleOfStockPercentageOfStockSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaid" abstract="false" name="TaxCutAndJobsActTollTaxToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_TYVYTMember" abstract="true" name="TYVYTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SwapSwissFrancsToU.S.DollarsMember" abstract="true" name="SwapSwissFrancsToU.S.DollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_StockAcquiredDuringPeriodValueExchangeOffer" abstract="false" name="StockAcquiredDuringPeriodValueExchangeOffer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A3375NotesDue2029Member" abstract="true" name="A3375NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_RevenuefromContractPaymentTermMaximum" abstract="false" name="RevenuefromContractPaymentTermMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" abstract="false" name="ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lly_A1.000NotesDueJune22022Member" abstract="true" name="A1.000NotesDueJune22022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EmployeeLitigationMember" abstract="true" name="EmployeeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CymbaltaMember" abstract="true" name="CymbaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A015SwissFrancDenominatedNotesDue2024Member" abstract="true" name="A015SwissFrancDenominatedNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatentsRuledUnpatentable" abstract="false" name="LossContingencyNumberOfPatentsRuledUnpatentable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_A595NotesDue2037Member" abstract="true" name="A595NotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfClaimants" abstract="false" name="LossContingencyNumberOfClaimants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" abstract="false" name="AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_SouthernDistrictOfCaliforniaMember" abstract="true" name="SouthernDistrictOfCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EmgalityPatentLitigationMember" abstract="true" name="EmgalityPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DiabetesMember" abstract="true" name="DiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_HedgedFixedRateDebtMember" abstract="true" name="HedgedFixedRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherForeignCountriesMember" abstract="true" name="OtherForeignCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DrReddysLabMember" abstract="true" name="DrReddysLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A55NotesDue2027Member" abstract="true" name="A55NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PlaintiffAllegationsAxis" abstract="true" name="PlaintiffAllegationsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lly_TaltzMember" abstract="true" name="TaltzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SitryxTherapeuticsLimitedMember" abstract="true" name="SitryxTherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A045SwissFrancDenominatedNotesDue2028Member" abstract="true" name="A045SwissFrancDenominatedNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TrulicityMemberMember" abstract="true" name="TrulicityMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AssetAcquisitionDomain" abstract="true" name="AssetAcquisitionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_UndisclosedAssetAcquisitionMember" abstract="true" name="UndisclosedAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PlaintiffAllegationsDomain" abstract="true" name="PlaintiffAllegationsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_NextCureInc.Member" abstract="true" name="NextCureInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_JunshiBiosciencesMember" abstract="true" name="JunshiBiosciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" abstract="true" name="CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_Expiration5to20YearsMember" abstract="true" name="Expiration5to20YearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_HydraBiosciencesMember" abstract="true" name="HydraBiosciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EddingpharmMember" abstract="true" name="EddingpharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AurkaPharmaMember" abstract="true" name="AurkaPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MaturityDate2023Member" abstract="true" name="MaturityDate2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DeferredTaxAssetsForeignTaxRedeterminations" abstract="false" name="DeferredTaxAssetsForeignTaxRedeterminations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OtherEquitySecuritiesMember" abstract="true" name="OtherEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_BuyUsdSellEuroMember" abstract="true" name="BuyUsdSellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsSalesBasedMember" abstract="true" name="MilestonePaymentsSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CashFlowHedgeAbstract" abstract="true" name="CashFlowHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" abstract="false" name="DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BamlanivimabMember" abstract="true" name="BamlanivimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" abstract="false" name="TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_LoxoOncologyInc.Member" abstract="true" name="LoxoOncologyInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SIGATechnologiesMember" abstract="true" name="SIGATechnologiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A395NotesDue2047Member" abstract="true" name="A395NotesDue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EquityMethodAndOtherInvestmentsMember" abstract="true" name="EquityMethodAndOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfRequestsForInformation" abstract="false" name="LossContingencyNumberOfRequestsForInformation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_A97YenDeonominatedNotesDue2049Member" abstract="true" name="A97YenDeonominatedNotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" abstract="false" name="SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" abstract="false" name="DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_VerzenioMember" abstract="true" name="VerzenioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_November2019YenDenominatedNotesMember" abstract="true" name="November2019YenDenominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ZyprexaMember" abstract="true" name="ZyprexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EmgalityMember" abstract="true" name="EmgalityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SelpercatinibLOXO292Member" abstract="true" name="SelpercatinibLOXO292Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AbCelleraBiologicsInc.Member" abstract="true" name="AbCelleraBiologicsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AnimaBiotechMember" abstract="true" name="AnimaBiotechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_WeilerVTakedaCanadaIncEtAlMember" abstract="true" name="WeilerVTakedaCanadaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ByettaMember" abstract="true" name="ByettaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CialisMember" abstract="true" name="CialisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BuyGBPSellUSDMember" abstract="true" name="BuyGBPSellUSDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BasaglarMember" abstract="true" name="BasaglarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_Expirationwithin5yearsMember" abstract="true" name="Expirationwithin5yearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary" abstract="false" name="ProceedsfromIssuanceorSaleofEquityfromSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ARMOBiosciencesInc.Member" abstract="true" name="ARMOBiosciencesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DesignatedUnusableMember" abstract="true" name="DesignatedUnusableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_November2019EuroDenominatedNotesMember" abstract="true" name="November2019EuroDenominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_WhyteEtAlVEliLillyEtAlMember" abstract="true" name="WhyteEtAlVEliLillyEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_FixedIncomeFundsRepurchasedAgreementsMember" abstract="true" name="FixedIncomeFundsRepurchasedAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CarryforwardMember" abstract="true" name="CarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" abstract="false" name="TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>lly-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:245edc66-3d73-4ffb-b61a-7d5e03b3f1e4,g:f11d2b17-0882-47f8-a810-701878e7e2df-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f6c11a82-fb98-46a0-989e-6efec7f08ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ab963f7e-94a6-4b16-8c0f-0d2c9a7e73a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_f6c11a82-fb98-46a0-989e-6efec7f08ec0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ab963f7e-94a6-4b16-8c0f-0d2c9a7e73a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_02e56d94-c29d-46a2-961f-ed19570b79c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_f6c11a82-fb98-46a0-989e-6efec7f08ec0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_02e56d94-c29d-46a2-961f-ed19570b79c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8fc60ec6-f56b-4410-bf65-3f74d5d5d8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e384b8b-9a26-435d-ac40-1c7ba49a86c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8fc60ec6-f56b-4410-bf65-3f74d5d5d8ad" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e384b8b-9a26-435d-ac40-1c7ba49a86c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f79dc3a2-67be-4bdd-939f-5bc16fe16bb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8fc60ec6-f56b-4410-bf65-3f74d5d5d8ad" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f79dc3a2-67be-4bdd-939f-5bc16fe16bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_17a291a8-222a-47ca-b295-492ce6d89ad4" xlink:href="lly-20201231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_93acf528-b6da-4aed-9b3e-35dbade72900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_17a291a8-222a-47ca-b295-492ce6d89ad4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_93acf528-b6da-4aed-9b3e-35dbade72900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d4dd6d46-bda9-4e14-9f72-97619f8997b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_17a291a8-222a-47ca-b295-492ce6d89ad4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d4dd6d46-bda9-4e14-9f72-97619f8997b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0524d66b-8a08-40e5-8dec-d7d2d8c14d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_17a291a8-222a-47ca-b295-492ce6d89ad4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0524d66b-8a08-40e5-8dec-d7d2d8c14d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_36194f01-c8a3-4427-afc7-921f6898f51f" xlink:href="lly-20201231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_17a291a8-222a-47ca-b295-492ce6d89ad4" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_36194f01-c8a3-4427-afc7-921f6898f51f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_9f5d4618-4169-4e14-97da-5dc6d87a3be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_17a291a8-222a-47ca-b295-492ce6d89ad4" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_9f5d4618-4169-4e14-97da-5dc6d87a3be4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c03abb39-3462-4e22-91e1-aeec4a7d4e98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_17a291a8-222a-47ca-b295-492ce6d89ad4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c03abb39-3462-4e22-91e1-aeec4a7d4e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58a6d3b8-7387-4f93-9f19-ad0ec470eeee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_82b34d64-d215-4ee7-b212-b1e4ff40c3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58a6d3b8-7387-4f93-9f19-ad0ec470eeee" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_82b34d64-d215-4ee7-b212-b1e4ff40c3b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d8fabe46-59ba-43f1-a83b-b19eac8cca94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58a6d3b8-7387-4f93-9f19-ad0ec470eeee" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d8fabe46-59ba-43f1-a83b-b19eac8cca94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2203debc-c3a3-46f7-9995-9998592dfcc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_298c0247-40a9-4d9d-961f-5666cfa3f731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_2203debc-c3a3-46f7-9995-9998592dfcc2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_298c0247-40a9-4d9d-961f-5666cfa3f731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_6d1e6d5e-a01f-4a31-a4e2-2f6b7284a56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_2203debc-c3a3-46f7-9995-9998592dfcc2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_6d1e6d5e-a01f-4a31-a4e2-2f6b7284a56b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9193ad66-bbb8-4842-a4ff-67702714e0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_03a24f18-ab90-4764-a406-9dfde0ab3313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9193ad66-bbb8-4842-a4ff-67702714e0c8" xlink:to="loc_us-gaap_Revenues_03a24f18-ab90-4764-a406-9dfde0ab3313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_37290ed2-7b80-4856-bae7-7ad835149c38" xlink:href="lly-20201231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9193ad66-bbb8-4842-a4ff-67702714e0c8" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_37290ed2-7b80-4856-bae7-7ad835149c38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_53c0acaf-90aa-49bc-935d-3cc7e3518e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5623d07e-e544-4e79-aaa8-5d4072da2014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_53c0acaf-90aa-49bc-935d-3cc7e3518e59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5623d07e-e544-4e79-aaa8-5d4072da2014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_a0484a27-d1fd-48ff-b98b-0dbfb4932f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_53c0acaf-90aa-49bc-935d-3cc7e3518e59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_a0484a27-d1fd-48ff-b98b-0dbfb4932f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c32d593a-5790-40ce-a249-263e3763838a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49aa2802-f6f0-4edb-8f3b-8370667b17e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c32d593a-5790-40ce-a249-263e3763838a" xlink:to="loc_us-gaap_NetIncomeLoss_49aa2802-f6f0-4edb-8f3b-8370667b17e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55de7816-f807-4e78-a289-6b46af2e2b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c32d593a-5790-40ce-a249-263e3763838a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55de7816-f807-4e78-a289-6b46af2e2b6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5a859078-626f-42e8-8b86-ceabced26947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_80305fb0-dec8-4149-b8a3-5415fa82306b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5a859078-626f-42e8-8b86-ceabced26947" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_80305fb0-dec8-4149-b8a3-5415fa82306b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_34471e7f-4a2d-4a54-9a9e-dd210c0a3340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5a859078-626f-42e8-8b86-ceabced26947" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_34471e7f-4a2d-4a54-9a9e-dd210c0a3340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_5cd48b5a-331c-47dc-b607-202572c7510f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5a859078-626f-42e8-8b86-ceabced26947" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_5cd48b5a-331c-47dc-b607-202572c7510f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_00d87c18-4950-45fb-8e82-1d36bf40387f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5a859078-626f-42e8-8b86-ceabced26947" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_00d87c18-4950-45fb-8e82-1d36bf40387f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_ad2d9136-d06b-4426-8c66-e8c295ee481d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_5a859078-626f-42e8-8b86-ceabced26947" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_ad2d9136-d06b-4426-8c66-e8c295ee481d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_288b741e-ac10-4eb3-8515-e794e6a8e148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fd51b647-17f7-47cf-96a3-544f08bbd4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_288b741e-ac10-4eb3-8515-e794e6a8e148" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fd51b647-17f7-47cf-96a3-544f08bbd4c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_57cec496-f6e4-4e9a-98c4-6a59717d5128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_288b741e-ac10-4eb3-8515-e794e6a8e148" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_57cec496-f6e4-4e9a-98c4-6a59717d5128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_d41e254f-40ef-4ba7-bcbf-3d0b40dcb350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_288b741e-ac10-4eb3-8515-e794e6a8e148" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_d41e254f-40ef-4ba7-bcbf-3d0b40dcb350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5ac39605-bea8-4179-b16b-a8775c9e6a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_288b741e-ac10-4eb3-8515-e794e6a8e148" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5ac39605-bea8-4179-b16b-a8775c9e6a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_afa7e98f-1f68-447b-9f2e-b7631ccb92cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_288b741e-ac10-4eb3-8515-e794e6a8e148" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_afa7e98f-1f68-447b-9f2e-b7631ccb92cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_efdebbdf-372e-4fa8-8bb7-2acf0a876dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d108c139-534c-4993-86ae-190a8ee9d648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_efdebbdf-372e-4fa8-8bb7-2acf0a876dc6" xlink:to="loc_us-gaap_CommonStockValue_d108c139-534c-4993-86ae-190a8ee9d648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_072567bf-30c2-472a-b75f-b16057ee79d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_efdebbdf-372e-4fa8-8bb7-2acf0a876dc6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_072567bf-30c2-472a-b75f-b16057ee79d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f3450e1-feb0-4c93-aa94-c89463dc5df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_efdebbdf-372e-4fa8-8bb7-2acf0a876dc6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f3450e1-feb0-4c93-aa94-c89463dc5df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_930a995e-cba5-406a-9b24-7baf9b3156d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_efdebbdf-372e-4fa8-8bb7-2acf0a876dc6" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_930a995e-cba5-406a-9b24-7baf9b3156d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21a346f9-b823-48fa-8988-26295a8b4811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_efdebbdf-372e-4fa8-8bb7-2acf0a876dc6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21a346f9-b823-48fa-8988-26295a8b4811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5919c71e-c3f4-4c9c-b634-9813d5be936c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_efdebbdf-372e-4fa8-8bb7-2acf0a876dc6" xlink:to="loc_us-gaap_TreasuryStockValue_5919c71e-c3f4-4c9c-b634-9813d5be936c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6a24ad99-3425-4249-8312-71b9164f0568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_255aab26-6c75-4739-b554-0ee28c59bb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6a24ad99-3425-4249-8312-71b9164f0568" xlink:to="loc_us-gaap_DebtCurrent_255aab26-6c75-4739-b554-0ee28c59bb29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6160c84a-6f8e-414d-a638-799db098622c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6a24ad99-3425-4249-8312-71b9164f0568" xlink:to="loc_us-gaap_AccountsPayableCurrent_6160c84a-6f8e-414d-a638-799db098622c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c623956a-f610-4eae-bbbb-f6d2eb3a147b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6a24ad99-3425-4249-8312-71b9164f0568" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c623956a-f610-4eae-bbbb-f6d2eb3a147b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_2c6ccfb7-c9cf-46dd-93eb-69758639b2ec" xlink:href="lly-20201231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6a24ad99-3425-4249-8312-71b9164f0568" xlink:to="loc_lly_SalesRebatesAndDiscounts_2c6ccfb7-c9cf-46dd-93eb-69758639b2ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_b3525e7e-edbe-4b6b-a2ac-6a1a825f088e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6a24ad99-3425-4249-8312-71b9164f0568" xlink:to="loc_us-gaap_DividendsPayableCurrent_b3525e7e-edbe-4b6b-a2ac-6a1a825f088e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_d2c8a014-0276-412e-906b-ab3ddafa4f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6a24ad99-3425-4249-8312-71b9164f0568" xlink:to="loc_us-gaap_TaxesPayableCurrent_d2c8a014-0276-412e-906b-ab3ddafa4f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_de164a4e-b28b-49be-9d6b-7fa91feb3765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6a24ad99-3425-4249-8312-71b9164f0568" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_de164a4e-b28b-49be-9d6b-7fa91feb3765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e6f7345a-cd87-423e-82f4-0dfa7aefbae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3ea64add-cadb-455b-af75-9abe37df921c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f7345a-cd87-423e-82f4-0dfa7aefbae4" xlink:to="loc_us-gaap_AssetsCurrent_3ea64add-cadb-455b-af75-9abe37df921c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_ceda06ec-e3c1-40ea-b846-40e89a2e7582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f7345a-cd87-423e-82f4-0dfa7aefbae4" xlink:to="loc_us-gaap_LongTermInvestments_ceda06ec-e3c1-40ea-b846-40e89a2e7582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bf974c71-f09a-45cc-a86d-956d2779aed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f7345a-cd87-423e-82f4-0dfa7aefbae4" xlink:to="loc_us-gaap_Goodwill_bf974c71-f09a-45cc-a86d-956d2779aed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_057dacba-bc12-4faa-b779-82b6d362d86e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f7345a-cd87-423e-82f4-0dfa7aefbae4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_057dacba-bc12-4faa-b779-82b6d362d86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b293fb77-3c2a-478c-839e-cb2b357e5c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f7345a-cd87-423e-82f4-0dfa7aefbae4" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b293fb77-3c2a-478c-839e-cb2b357e5c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6a075bf8-121c-49a5-8fae-51c9f668065f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f7345a-cd87-423e-82f4-0dfa7aefbae4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6a075bf8-121c-49a5-8fae-51c9f668065f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_8ccb5f47-6cb3-47fb-90ba-822862a6d83c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e6f7345a-cd87-423e-82f4-0dfa7aefbae4" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_8ccb5f47-6cb3-47fb-90ba-822862a6d83c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09282331-7fb3-41ac-b91a-a0770f649642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_30fc5e0d-d573-4898-a521-be0f3eb9db73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09282331-7fb3-41ac-b91a-a0770f649642" xlink:to="loc_us-gaap_CommonStockValue_30fc5e0d-d573-4898-a521-be0f3eb9db73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_688ae711-6559-4eb1-a79d-8eab4c072252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09282331-7fb3-41ac-b91a-a0770f649642" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_688ae711-6559-4eb1-a79d-8eab4c072252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f246fe8-7b6c-4c0e-8d8e-98c0bb536e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09282331-7fb3-41ac-b91a-a0770f649642" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f246fe8-7b6c-4c0e-8d8e-98c0bb536e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_db3c4276-c843-47da-b5f5-460b3308c6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09282331-7fb3-41ac-b91a-a0770f649642" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_db3c4276-c843-47da-b5f5-460b3308c6f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2041923e-5e14-4f79-8b1c-38c2ef19452b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09282331-7fb3-41ac-b91a-a0770f649642" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2041923e-5e14-4f79-8b1c-38c2ef19452b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_97c126f5-35e0-4db8-b0c1-ad12eff2f7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09282331-7fb3-41ac-b91a-a0770f649642" xlink:to="loc_us-gaap_TreasuryStockValue_97c126f5-35e0-4db8-b0c1-ad12eff2f7f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7584602f-7705-4021-a161-58025787b96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09282331-7fb3-41ac-b91a-a0770f649642" xlink:to="loc_us-gaap_MinorityInterest_7584602f-7705-4021-a161-58025787b96c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd644c45-02fd-4294-9e07-420b5839d166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5f43c9a8-1d30-4841-ab97-592086cee92d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd644c45-02fd-4294-9e07-420b5839d166" xlink:to="loc_us-gaap_LiabilitiesCurrent_5f43c9a8-1d30-4841-ab97-592086cee92d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_144cbb13-9d91-4659-a85d-33b54ad42227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd644c45-02fd-4294-9e07-420b5839d166" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_144cbb13-9d91-4659-a85d-33b54ad42227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b2d980e6-9550-4ba1-a9c7-acbb45be89c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd644c45-02fd-4294-9e07-420b5839d166" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b2d980e6-9550-4ba1-a9c7-acbb45be89c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f8d09471-1fe4-4b2e-bdd6-71080d5c39c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd644c45-02fd-4294-9e07-420b5839d166" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f8d09471-1fe4-4b2e-bdd6-71080d5c39c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c88d6348-917e-4f16-b543-210e9d1b96bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_7e4bd057-1fa5-421c-901b-795c00098c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c88d6348-917e-4f16-b543-210e9d1b96bb" xlink:to="loc_us-gaap_ShortTermInvestments_7e4bd057-1fa5-421c-901b-795c00098c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d502db6d-b594-47b4-b533-230887ace155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c88d6348-917e-4f16-b543-210e9d1b96bb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d502db6d-b594-47b4-b533-230887ace155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c4f06d40-8b78-4f01-9c9b-6d85b6f24204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c88d6348-917e-4f16-b543-210e9d1b96bb" xlink:to="loc_us-gaap_InventoryNet_c4f06d40-8b78-4f01-9c9b-6d85b6f24204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8b439fed-d8c8-4227-bd1d-33b4b2c3f319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c88d6348-917e-4f16-b543-210e9d1b96bb" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_8b439fed-d8c8-4227-bd1d-33b4b2c3f319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_071510df-3820-488f-aa16-5bf3c75ada46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c88d6348-917e-4f16-b543-210e9d1b96bb" xlink:to="loc_us-gaap_OtherReceivables_071510df-3820-488f-aa16-5bf3c75ada46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d43c8da1-d520-4c7e-a65a-b43c0718fd70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c88d6348-917e-4f16-b543-210e9d1b96bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d43c8da1-d520-4c7e-a65a-b43c0718fd70" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofShareholdersEquityStatement"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a227ca6-4ce7-43a1-8781-da0444e0ec9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c58290d1-7f5a-478d-84c6-4dc4a46d6dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a227ca6-4ce7-43a1-8781-da0444e0ec9a" xlink:to="loc_us-gaap_PaymentsOfDividends_c58290d1-7f5a-478d-84c6-4dc4a46d6dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_5f101b8c-2fd0-4669-b090-7bb50790cac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a227ca6-4ce7-43a1-8781-da0444e0ec9a" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_5f101b8c-2fd0-4669-b090-7bb50790cac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9d4e99ac-74ad-40c0-a1aa-eb283ebcfee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a227ca6-4ce7-43a1-8781-da0444e0ec9a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9d4e99ac-74ad-40c0-a1aa-eb283ebcfee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1eb14c2c-18f9-473f-95bb-456219b0d85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a227ca6-4ce7-43a1-8781-da0444e0ec9a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1eb14c2c-18f9-473f-95bb-456219b0d85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_70d31a00-7b0d-4e7f-bc5a-93624794921e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a227ca6-4ce7-43a1-8781-da0444e0ec9a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_70d31a00-7b0d-4e7f-bc5a-93624794921e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ccac0608-4bf0-45c3-813d-7545f0b01151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a227ca6-4ce7-43a1-8781-da0444e0ec9a" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ccac0608-4bf0-45c3-813d-7545f0b01151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary_7c72b935-22db-42a7-a2e9-b888b5866a1b" xlink:href="lly-20201231.xsd#lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a227ca6-4ce7-43a1-8781-da0444e0ec9a" xlink:to="loc_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary_7c72b935-22db-42a7-a2e9-b888b5866a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87b43348-625f-4fc4-a7d0-af3898e46e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16edb35a-3e9e-4e7a-9fb5-c78db6442c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87b43348-625f-4fc4-a7d0-af3898e46e7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16edb35a-3e9e-4e7a-9fb5-c78db6442c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40c81596-8420-428f-9a98-0ca50534d46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87b43348-625f-4fc4-a7d0-af3898e46e7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40c81596-8420-428f-9a98-0ca50534d46a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_abac6d5a-ddcd-487d-b7ba-173a03c6eb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87b43348-625f-4fc4-a7d0-af3898e46e7f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_abac6d5a-ddcd-487d-b7ba-173a03c6eb8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f96e5bd8-d6ab-4c8d-ae8b-fbc35f992915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87b43348-625f-4fc4-a7d0-af3898e46e7f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f96e5bd8-d6ab-4c8d-ae8b-fbc35f992915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_57d02a3a-509d-48b6-8428-9be95c4a47f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_57d02a3a-509d-48b6-8428-9be95c4a47f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b6faaf6d-7883-4ff4-971f-f56861e77d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b6faaf6d-7883-4ff4-971f-f56861e77d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d679a7ff-fbde-4df0-8091-2dbf38a8b651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d679a7ff-fbde-4df0-8091-2dbf38a8b651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d6dcd5f0-8da0-4b2a-8154-55996d2eb4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_ShareBasedCompensation_d6dcd5f0-8da0-4b2a-8154-55996d2eb4e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_55303fb6-1688-4663-a885-548b4b8f9f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_55303fb6-1688-4663-a885-548b4b8f9f2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_d0cd9f77-a5fa-4cb3-aa38-6762f2a0d0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_d0cd9f77-a5fa-4cb3-aa38-6762f2a0d0d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ef3c63ee-42a2-4641-aa5c-944bff6b7527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ef3c63ee-42a2-4641-aa5c-944bff6b7527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_71486a98-6ebd-47d5-91bd-7b73802075f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_71486a98-6ebd-47d5-91bd-7b73802075f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_66269ce6-c0ab-45e3-b4f7-8d3c62a05a02" xlink:href="lly-20201231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_66269ce6-c0ab-45e3-b4f7-8d3c62a05a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ec49a55d-38c5-4008-ab5b-5ba092af5e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ec49a55d-38c5-4008-ab5b-5ba092af5e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c71dc068-2dc4-44ff-bc19-c5661c592dee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_NetIncomeLoss_c71dc068-2dc4-44ff-bc19-c5661c592dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_6870b5c5-5d42-48d8-80ac-b0bad6354225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_6870b5c5-5d42-48d8-80ac-b0bad6354225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_cf19ea9b-4110-424f-8e03-c254ae7ef7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_GainLossOnInvestments_cf19ea9b-4110-424f-8e03-c254ae7ef7e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_f92eb27e-db5b-4acf-a26d-a4ef00bf5c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9db9a77a-4510-4b0b-a3f1-c97b60c71dde" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_f92eb27e-db5b-4acf-a26d-a4ef00bf5c52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_f3e9f453-bb48-4709-9d89-96cf65b2c779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_f3e9f453-bb48-4709-9d89-96cf65b2c779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_49f5a136-8556-4a37-9268-d8194ac8540b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_49f5a136-8556-4a37-9268-d8194ac8540b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c7079a08-460b-426d-ae39-2d6c6cd0d4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c7079a08-460b-426d-ae39-2d6c6cd0d4a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_d601b01e-d1f3-4b5a-95ad-39be4cb0a1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_d601b01e-d1f3-4b5a-95ad-39be4cb0a1ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_e138f93d-1371-414d-a4b3-a70b8a3214c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_e138f93d-1371-414d-a4b3-a70b8a3214c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_144ed65d-21cf-4ce6-ae09-c27415fbb655" xlink:href="lly-20201231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_144ed65d-21cf-4ce6-ae09-c27415fbb655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_15593eb1-800c-4f6a-a019-5f6644d03bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_15593eb1-800c-4f6a-a019-5f6644d03bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_72bbd02b-2753-4bf5-bc2d-5036ca1ed28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_72bbd02b-2753-4bf5-bc2d-5036ca1ed28d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_3f6dd3b0-1c00-4c03-8cd8-234f4892263d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_3f6dd3b0-1c00-4c03-8cd8-234f4892263d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ab351528-8a40-472e-a61a-e8d5730692f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca8b7c34-7203-4855-ab32-f4cdc8044b52" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ab351528-8a40-472e-a61a-e8d5730692f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20201231.xsd#Revenue"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiture" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestiture"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiture" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureTables" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestiturePurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_410bc825-46bc-4ec9-ae3f-91c50368cb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ca7a160a-504f-41d2-b7e8-0a196124fcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_410bc825-46bc-4ec9-ae3f-91c50368cb25" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ca7a160a-504f-41d2-b7e8-0a196124fcb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d118b062-3de3-4cf3-a159-b7974ad3229f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_410bc825-46bc-4ec9-ae3f-91c50368cb25" xlink:to="loc_us-gaap_Goodwill_d118b062-3de3-4cf3-a159-b7974ad3229f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d7538932-8f0f-4da7-b4e3-0ceda8d447c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_1f791f26-cdbe-43cb-89da-50fdbf40f5e3" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d7538932-8f0f-4da7-b4e3-0ceda8d447c8" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_1f791f26-cdbe-43cb-89da-50fdbf40f5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_25c3accc-8cd6-46aa-b847-3775d7e23e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d7538932-8f0f-4da7-b4e3-0ceda8d447c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_25c3accc-8cd6-46aa-b847-3775d7e23e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_47df1a33-a31f-431b-807c-e558f05801e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d7538932-8f0f-4da7-b4e3-0ceda8d447c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_47df1a33-a31f-431b-807c-e558f05801e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_caef619b-0ae6-4543-96df-a75e2f792ef5" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d7538932-8f0f-4da7-b4e3-0ceda8d447c8" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_caef619b-0ae6-4543-96df-a75e2f792ef5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureAssetAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangements"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_6c2b3a75-f824-4140-b9cc-02b420f28276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4c7cfb0f-9ea1-4fb8-9eec-cbf377d60e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_6c2b3a75-f824-4140-b9cc-02b420f28276" xlink:to="loc_us-gaap_SeveranceCosts1_4c7cfb0f-9ea1-4fb8-9eec-cbf377d60e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_1b91504f-c092-4ef7-8a71-e5128172acc7" xlink:href="lly-20201231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_6c2b3a75-f824-4140-b9cc-02b420f28276" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_1b91504f-c092-4ef7-8a71-e5128172acc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Inventories" xlink:type="simple" xlink:href="lly-20201231.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_4528b878-3062-491a-b143-1172230c155a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_93f75d4e-8236-4578-b966-69eac815fcc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_4528b878-3062-491a-b143-1172230c155a" xlink:to="loc_us-gaap_InventoryFinishedGoods_93f75d4e-8236-4578-b966-69eac815fcc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_45cc42e3-a690-4f6f-a7c5-88fc0e72f561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_4528b878-3062-491a-b143-1172230c155a" xlink:to="loc_us-gaap_InventoryWorkInProcess_45cc42e3-a690-4f6f-a7c5-88fc0e72f561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_3b4f1e5a-7b9c-48dd-b3e9-75bfaaf8a182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_4528b878-3062-491a-b143-1172230c155a" xlink:to="loc_us-gaap_InventoryRawMaterials_3b4f1e5a-7b9c-48dd-b3e9-75bfaaf8a182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1f308c3c-7eb9-4d8d-b7d4-ec51e018dcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_20536f55-d99f-4f0f-8d16-7034425d59ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_1f308c3c-7eb9-4d8d-b7d4-ec51e018dcb0" xlink:to="loc_us-gaap_InventoryGross_20536f55-d99f-4f0f-8d16-7034425d59ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_5c817fa0-7780-46a1-b181-0822fe0a27ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_1f308c3c-7eb9-4d8d-b7d4-ec51e018dcb0" xlink:to="loc_us-gaap_InventoryLIFOReserve_5c817fa0-7780-46a1-b181-0822fe0a27ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_8ae7c440-4abf-40c2-a325-1c221e0bedee" xlink:href="lly-20201231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e6815cb9-2a03-49fa-a5e8-3ec397037729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_8ae7c440-4abf-40c2-a325-1c221e0bedee" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e6815cb9-2a03-49fa-a5e8-3ec397037729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_17638d69-5b6d-419d-aeef-8aa6a49cc480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_8ae7c440-4abf-40c2-a325-1c221e0bedee" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_17638d69-5b6d-419d-aeef-8aa6a49cc480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_fae3c013-6e68-4aa0-80cf-8123905df6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_8ae7c440-4abf-40c2-a325-1c221e0bedee" xlink:to="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_fae3c013-6e68-4aa0-80cf-8123905df6bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3de43748-0201-4dcc-b4e0-f047371f5e22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_8ae7c440-4abf-40c2-a325-1c221e0bedee" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3de43748-0201-4dcc-b4e0-f047371f5e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f992c0b6-45b5-4de5-b6ff-8fae0f1bfc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_8ae7c440-4abf-40c2-a325-1c221e0bedee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f992c0b6-45b5-4de5-b6ff-8fae0f1bfc3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_c14889a6-6242-487d-b264-40f055b5b9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_0ecfd46b-0996-4efe-940c-e20da38ac244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_c14889a6-6242-487d-b264-40f055b5b9c4" xlink:to="loc_us-gaap_OtherLongTermInvestments_0ecfd46b-0996-4efe-940c-e20da38ac244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_6cb71229-4ac6-47cf-8573-5cdfba8b9480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_c14889a6-6242-487d-b264-40f055b5b9c4" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_6cb71229-4ac6-47cf-8573-5cdfba8b9480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_de8ab5aa-c179-41cb-889e-a044acb28cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_c14889a6-6242-487d-b264-40f055b5b9c4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_de8ab5aa-c179-41cb-889e-a044acb28cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_94a2f4f8-d787-47a9-8c7c-7f1cd0c518ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_c14889a6-6242-487d-b264-40f055b5b9c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_94a2f4f8-d787-47a9-8c7c-7f1cd0c518ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0895cd10-6718-4804-99e1-2f21f6ef367e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7faf7850-060e-4f83-8845-0711b4afc62f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0895cd10-6718-4804-99e1-2f21f6ef367e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7faf7850-060e-4f83-8845-0711b4afc62f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ff55ef84-81e8-4517-9da2-b59882d36888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0895cd10-6718-4804-99e1-2f21f6ef367e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ff55ef84-81e8-4517-9da2-b59882d36888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_a78fde8c-2813-4a9d-b4a6-e6610f0fbe5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0895cd10-6718-4804-99e1-2f21f6ef367e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_a78fde8c-2813-4a9d-b4a6-e6610f0fbe5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_8819d59b-5368-4435-bfbf-a2bb20c49d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0895cd10-6718-4804-99e1-2f21f6ef367e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_8819d59b-5368-4435-bfbf-a2bb20c49d3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangibles"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16997dc2-8d4b-412f-b5a0-6ae90eb6f106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f176889a-8263-4c52-b5ed-67bedb8a81eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16997dc2-8d4b-412f-b5a0-6ae90eb6f106" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f176889a-8263-4c52-b5ed-67bedb8a81eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca0fca0f-7316-436a-92a9-41ed82158dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16997dc2-8d4b-412f-b5a0-6ae90eb6f106" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca0fca0f-7316-436a-92a9-41ed82158dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ac446f2f-0300-4a6f-9b2c-ca6d0bf5de06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2a5d9654-7c57-4a1b-b7cc-558c8ee4a456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ac446f2f-0300-4a6f-9b2c-ca6d0bf5de06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2a5d9654-7c57-4a1b-b7cc-558c8ee4a456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7bea5171-8795-4217-9177-790bc1a81a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ac446f2f-0300-4a6f-9b2c-ca6d0bf5de06" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7bea5171-8795-4217-9177-790bc1a81a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_51514988-b821-4076-b7fc-89117e95b758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_14e2ce7a-48a1-4d65-bcac-88f0ebac093b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_51514988-b821-4076-b7fc-89117e95b758" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_14e2ce7a-48a1-4d65-bcac-88f0ebac093b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_64f9d18b-b8f4-4137-ab10-75fb3dcded25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_51514988-b821-4076-b7fc-89117e95b758" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_64f9d18b-b8f4-4137-ab10-75fb3dcded25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_22ad991e-58cd-443a-b65c-d0df0a93160b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_487e6b67-ef15-41fa-957f-f357c7f40389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_22ad991e-58cd-443a-b65c-d0df0a93160b" xlink:to="loc_us-gaap_Land_487e6b67-ef15-41fa-957f-f357c7f40389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_6d534bbd-ddd9-44f1-a3f3-ccfb5cd43f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_22ad991e-58cd-443a-b65c-d0df0a93160b" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_6d534bbd-ddd9-44f1-a3f3-ccfb5cd43f1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_db471229-6c0e-48a9-84cf-d4c5a09daceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_22ad991e-58cd-443a-b65c-d0df0a93160b" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_db471229-6c0e-48a9-84cf-d4c5a09daceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_b74a75e9-3781-4f20-852f-7d024c9d64f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_22ad991e-58cd-443a-b65c-d0df0a93160b" xlink:to="loc_us-gaap_ConstructionInProgressGross_b74a75e9-3781-4f20-852f-7d024c9d64f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_db71860f-d610-483d-9fe0-d16d526e786b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9217ef17-e210-4247-b6a5-239078e7e2f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_db71860f-d610-483d-9fe0-d16d526e786b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9217ef17-e210-4247-b6a5-239078e7e2f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_426bfcfd-d531-433b-b621-3992398f46a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_db71860f-d610-483d-9fe0-d16d526e786b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_426bfcfd-d531-433b-b621-3992398f46a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofDepreciationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofGeographicInformationDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Leases" xlink:type="simple" xlink:href="lly-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2a9b87db-0ece-4020-a41e-d8c7e881353c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c8196910-da7a-4f93-be00-1725d51955aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2a9b87db-0ece-4020-a41e-d8c7e881353c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c8196910-da7a-4f93-be00-1725d51955aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bdf3c87d-a508-43a5-92b5-02ed417c69d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2a9b87db-0ece-4020-a41e-d8c7e881353c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bdf3c87d-a508-43a5-92b5-02ed417c69d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0d2ffe39-b9b3-4aed-962e-31e64eec00fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2a9b87db-0ece-4020-a41e-d8c7e881353c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0d2ffe39-b9b3-4aed-962e-31e64eec00fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d811c52c-38f1-4ddd-a6a8-a74655b03098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2a9b87db-0ece-4020-a41e-d8c7e881353c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d811c52c-38f1-4ddd-a6a8-a74655b03098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d8d594ef-0bac-4f6c-a32a-1fc1ddea5b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2a9b87db-0ece-4020-a41e-d8c7e881353c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d8d594ef-0bac-4f6c-a32a-1fc1ddea5b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_528a6193-32b6-42ef-8cdf-b457b7cc381e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2a9b87db-0ece-4020-a41e-d8c7e881353c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_528a6193-32b6-42ef-8cdf-b457b7cc381e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00894490-3abf-4cd4-83f7-ab43305121bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9d087703-e7a2-4bf2-aa7b-371a28253fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00894490-3abf-4cd4-83f7-ab43305121bf" xlink:to="loc_us-gaap_OperatingLeaseLiability_9d087703-e7a2-4bf2-aa7b-371a28253fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_200db9f5-8467-4520-8078-f69ddcd73be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00894490-3abf-4cd4-83f7-ab43305121bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_200db9f5-8467-4520-8078-f69ddcd73be4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Borrowings" xlink:type="simple" xlink:href="lly-20201231.xsd#Borrowings"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/Borrowings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_09c939d7-a06a-419b-9b7f-4751075a03a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_e2213cda-5059-453b-bf72-2218636c6f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_09c939d7-a06a-419b-9b7f-4751075a03a0" xlink:to="loc_us-gaap_DebtCurrent_e2213cda-5059-453b-bf72-2218636c6f23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5105b834-dda9-4135-b7f9-6a2a48345ac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_09c939d7-a06a-419b-9b7f-4751075a03a0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5105b834-dda9-4135-b7f9-6a2a48345ac4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_88cb89d4-42f4-4d50-b379-07632226395b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_baf0409e-7937-4aca-aeeb-2fcfd23f7a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_88cb89d4-42f4-4d50-b379-07632226395b" xlink:to="loc_us-gaap_CommercialPaper_baf0409e-7937-4aca-aeeb-2fcfd23f7a4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ee0f7ba7-c0eb-443f-9fad-cc20f4711df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_88cb89d4-42f4-4d50-b379-07632226395b" xlink:to="loc_us-gaap_NotesPayable_ee0f7ba7-c0eb-443f-9fad-cc20f4711df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable_5fc7b7dd-b13d-41bc-bd08-71ef5e1f20a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_88cb89d4-42f4-4d50-b379-07632226395b" xlink:to="loc_us-gaap_OtherNotesPayable_5fc7b7dd-b13d-41bc-bd08-71ef5e1f20a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_8e4902c0-be59-4314-ac7a-5e82621a6775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_88cb89d4-42f4-4d50-b379-07632226395b" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_8e4902c0-be59-4314-ac7a-5e82621a6775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment_302f82f3-46dc-48a6-bfb9-0d2d3f484b4b" xlink:href="lly-20201231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_88cb89d4-42f4-4d50-b379-07632226395b" xlink:to="loc_lly_LongTermDebtFairValueAdjustment_302f82f3-46dc-48a6-bfb9-0d2d3f484b4b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a5ea82cb-ef42-4f95-9123-582ba55a03cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4632c860-ba55-47e0-ad58-64288a6bd48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a5ea82cb-ef42-4f95-9123-582ba55a03cc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4632c860-ba55-47e0-ad58-64288a6bd48f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_fd73d631-48a0-4a2e-82cd-b22547d3adac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a5ea82cb-ef42-4f95-9123-582ba55a03cc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_fd73d631-48a0-4a2e-82cd-b22547d3adac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationScheduleofAssumptionsUsedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="lly-20201231.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#ShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3fa6bd18-3792-44a9-be09-26f042a55ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_771b4a94-14ae-4e92-a4ae-8a8a3e00a3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3fa6bd18-3792-44a9-be09-26f042a55ab0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_771b4a94-14ae-4e92-a4ae-8a8a3e00a3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_23f2c45b-655c-4974-aa81-91f917365de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3fa6bd18-3792-44a9-be09-26f042a55ab0" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_23f2c45b-655c-4974-aa81-91f917365de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f5bcaa02-2e50-4f87-994e-8b55e1e86214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3fa6bd18-3792-44a9-be09-26f042a55ab0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f5bcaa02-2e50-4f87-994e-8b55e1e86214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4e2cb70e-a187-4714-85bc-78713d568605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_17242394-752b-496a-811c-fb4ae479644e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4e2cb70e-a187-4714-85bc-78713d568605" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_17242394-752b-496a-811c-fb4ae479644e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6cf3f7a5-0bfa-40a6-85e6-befa52c971c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4e2cb70e-a187-4714-85bc-78713d568605" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6cf3f7a5-0bfa-40a6-85e6-befa52c971c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5241c7ff-dcd1-4dd2-993f-17dccc7229c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_884c23bc-95c1-418f-b0b9-ce3d7c50981a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5241c7ff-dcd1-4dd2-993f-17dccc7229c2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_884c23bc-95c1-418f-b0b9-ce3d7c50981a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_38514071-47d7-4463-b170-0662f4e4b903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5241c7ff-dcd1-4dd2-993f-17dccc7229c2" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_38514071-47d7-4463-b170-0662f4e4b903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8f1c8363-09ec-4f25-ae70-18a3192297c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5241c7ff-dcd1-4dd2-993f-17dccc7229c2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8f1c8363-09ec-4f25-ae70-18a3192297c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1b5ee9e5-c1c8-4e24-80c4-fb218d2f227b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_355e7c96-4fb5-4635-bb19-53990b684035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1b5ee9e5-c1c8-4e24-80c4-fb218d2f227b" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_355e7c96-4fb5-4635-bb19-53990b684035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e838baa9-e328-4816-845e-659067d06553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1b5ee9e5-c1c8-4e24-80c4-fb218d2f227b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e838baa9-e328-4816-845e-659067d06553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ff2351a8-37cd-4a69-9737-35f685c85886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_309981b2-3261-4833-9f98-226966935507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ff2351a8-37cd-4a69-9737-35f685c85886" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_309981b2-3261-4833-9f98-226966935507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0bfda444-179a-41c7-9323-d0768fa29959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ff2351a8-37cd-4a69-9737-35f685c85886" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0bfda444-179a-41c7-9323-d0768fa29959" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9eb0ddfb-c601-4889-b4b3-aea098f6a658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_9c44f41c-8131-4a66-a340-1694fc2f3f82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9eb0ddfb-c601-4889-b4b3-aea098f6a658" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_9c44f41c-8131-4a66-a340-1694fc2f3f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ea039d11-b30b-4f57-bcbc-e697aeee4b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9eb0ddfb-c601-4889-b4b3-aea098f6a658" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_ea039d11-b30b-4f57-bcbc-e697aeee4b82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_94110ee3-b77e-472d-bf03-415499e05a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9eb0ddfb-c601-4889-b4b3-aea098f6a658" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_94110ee3-b77e-472d-bf03-415499e05a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7bcaf503-fc54-450e-a0c3-8f6a2d6bbc91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9eb0ddfb-c601-4889-b4b3-aea098f6a658" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7bcaf503-fc54-450e-a0c3-8f6a2d6bbc91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_1087b497-2381-4424-ab08-771682da3fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9eb0ddfb-c601-4889-b4b3-aea098f6a658" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_1087b497-2381-4424-ab08-771682da3fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_25a9ffa7-151e-4f83-aad2-2d8dcd41e1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9eb0ddfb-c601-4889-b4b3-aea098f6a658" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_25a9ffa7-151e-4f83-aad2-2d8dcd41e1c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e9a3b55f-ccea-4832-9f6f-d75d6af99842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9eb0ddfb-c601-4889-b4b3-aea098f6a658" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e9a3b55f-ccea-4832-9f6f-d75d6af99842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4ded316e-0893-4922-b804-b0f382270bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4ded316e-0893-4922-b804-b0f382270bbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_58e161dc-4a04-406a-ab8b-f7a53b6c2dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_58e161dc-4a04-406a-ab8b-f7a53b6c2dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_c16e2b80-1d25-4fbd-b1ff-7014ba1ba169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_c16e2b80-1d25-4fbd-b1ff-7014ba1ba169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_fc8d73c5-ca23-4a03-abc6-eb2f3b1fcdb6" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_fc8d73c5-ca23-4a03-abc6-eb2f3b1fcdb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_50d0478d-6ee1-4a6c-aa83-52d616caeb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_50d0478d-6ee1-4a6c-aa83-52d616caeb01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_a4934e6f-9f32-47a2-a52e-10cf5af976ab" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_a4934e6f-9f32-47a2-a52e-10cf5af976ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_022143fa-cf8a-4c40-a71e-8a48d6aeff6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_022143fa-cf8a-4c40-a71e-8a48d6aeff6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_d2893ce7-9344-4a09-8c5f-13be319df83a" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_d2893ce7-9344-4a09-8c5f-13be319df83a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_b5347985-faf7-4073-b08b-035e75a86961" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_b5347985-faf7-4073-b08b-035e75a86961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2a444172-6b5d-407f-a364-a85027030e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0fdf37ac-6bd5-4735-b4cd-c3663435197f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2a444172-6b5d-407f-a364-a85027030e80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid_8d1fbb9d-c1dd-4f15-b9bd-1d9272728af7" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_c93da8a6-9240-4675-9cc7-a51a7e8cdd56" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid_8d1fbb9d-c1dd-4f15-b9bd-1d9272728af7" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_c93da8a6-9240-4675-9cc7-a51a7e8cdd56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_fc214cc7-0ce7-4b8c-ab20-0df8fd062572" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid_8d1fbb9d-c1dd-4f15-b9bd-1d9272728af7" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_fc214cc7-0ce7-4b8c-ab20-0df8fd062572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_8fcc963a-e2d0-4819-b885-5b4ffd40442d" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid_8d1fbb9d-c1dd-4f15-b9bd-1d9272728af7" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_8fcc963a-e2d0-4819-b885-5b4ffd40442d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_29503931-849e-48d8-89e8-b0440105e056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0730aa34-8a63-400a-9fe0-b8dfa9f7495e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_29503931-849e-48d8-89e8-b0440105e056" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0730aa34-8a63-400a-9fe0-b8dfa9f7495e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_08668234-c684-41e7-a0f8-d9955b844eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_29503931-849e-48d8-89e8-b0440105e056" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_08668234-c684-41e7-a0f8-d9955b844eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_e712992f-51b4-4003-b8a5-8c0175d64d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_29503931-849e-48d8-89e8-b0440105e056" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_e712992f-51b4-4003-b8a5-8c0175d64d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_4da723d8-c363-4be0-aa6a-d17ef459e957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_29503931-849e-48d8-89e8-b0440105e056" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_4da723d8-c363-4be0-aa6a-d17ef459e957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_35318157-d514-4db5-8122-8229849f48c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_29503931-849e-48d8-89e8-b0440105e056" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_35318157-d514-4db5-8122-8229849f48c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount_c37aaf57-2ff5-4705-95b9-74b81d2b54cc" xlink:href="lly-20201231.xsd#lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_29503931-849e-48d8-89e8-b0440105e056" xlink:to="loc_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount_c37aaf57-2ff5-4705-95b9-74b81d2b54cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefits"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f314a18e-9c74-4794-8387-6e9eb7cf654b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ec9e6641-78c9-479b-9437-ccaafc58330c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f314a18e-9c74-4794-8387-6e9eb7cf654b" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ec9e6641-78c9-479b-9437-ccaafc58330c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_fd61a2ed-06b3-4e54-950c-933f9f09a20a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f314a18e-9c74-4794-8387-6e9eb7cf654b" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_fd61a2ed-06b3-4e54-950c-933f9f09a20a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_7fefa83d-a7e0-4e7d-83f4-66d89574229c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_f314a18e-9c74-4794-8387-6e9eb7cf654b" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_7fefa83d-a7e0-4e7d-83f4-66d89574229c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_62bd96a5-9674-40e8-a15b-50f1448d3e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_8e944d7e-6bb4-4c40-8bec-af519a4ff9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_62bd96a5-9674-40e8-a15b-50f1448d3e48" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_8e944d7e-6bb4-4c40-8bec-af519a4ff9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3a3a8cdf-86d7-42f0-a636-68c0406b7a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_62bd96a5-9674-40e8-a15b-50f1448d3e48" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3a3a8cdf-86d7-42f0-a636-68c0406b7a52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_270a978b-54ae-4aea-a6d5-73c0938983b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_62bd96a5-9674-40e8-a15b-50f1448d3e48" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_270a978b-54ae-4aea-a6d5-73c0938983b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_29a6d3f7-58ec-4525-b5b3-3b0f447a84de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_62bd96a5-9674-40e8-a15b-50f1448d3e48" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_29a6d3f7-58ec-4525-b5b3-3b0f447a84de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_3596fc94-e74a-4a4c-acb9-3ac1fe38262c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_cfea6622-50b0-48b6-b38e-a8431ae40329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_3596fc94-e74a-4a4c-acb9-3ac1fe38262c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_cfea6622-50b0-48b6-b38e-a8431ae40329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_212a2e25-fee4-4640-b838-183958ead2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_3596fc94-e74a-4a4c-acb9-3ac1fe38262c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_212a2e25-fee4-4640-b838-183958ead2c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_af8d0d82-5c7f-44cf-abce-796329d92fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_3596fc94-e74a-4a4c-acb9-3ac1fe38262c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_af8d0d82-5c7f-44cf-abce-796329d92fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9bc3a494-1db8-43d2-ba2f-9bfa99feca2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_3596fc94-e74a-4a4c-acb9-3ac1fe38262c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_9bc3a494-1db8-43d2-ba2f-9bfa99feca2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_b3074d17-2e91-49f8-a22e-c2d78f72cf0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_3596fc94-e74a-4a4c-acb9-3ac1fe38262c" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_b3074d17-2e91-49f8-a22e-c2d78f72cf0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_7a0a5ee1-c16d-451b-ae6a-a8e84885deeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_3596fc94-e74a-4a4c-acb9-3ac1fe38262c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_7a0a5ee1-c16d-451b-ae6a-a8e84885deeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4fd67bd-e2c6-4c8b-9488-f39c7ef3d6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ef4ed0e7-47e4-4370-a55e-5da695e3ee89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4fd67bd-e2c6-4c8b-9488-f39c7ef3d6b9" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ef4ed0e7-47e4-4370-a55e-5da695e3ee89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_94b20256-8fed-436a-b21d-6c0e6f76a912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4fd67bd-e2c6-4c8b-9488-f39c7ef3d6b9" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_94b20256-8fed-436a-b21d-6c0e6f76a912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b9d91c8a-85cd-4b6a-bd1e-799034b2b5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4fd67bd-e2c6-4c8b-9488-f39c7ef3d6b9" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b9d91c8a-85cd-4b6a-bd1e-799034b2b5eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_23a678b9-44b8-4b5e-bc54-09d07bc75ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4fd67bd-e2c6-4c8b-9488-f39c7ef3d6b9" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_23a678b9-44b8-4b5e-bc54-09d07bc75ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a9839fd8-8b78-4fdd-b8ba-8fbbb794667a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4fd67bd-e2c6-4c8b-9488-f39c7ef3d6b9" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a9839fd8-8b78-4fdd-b8ba-8fbbb794667a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_d527f938-f1b0-4daf-a07b-e07d675ab1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4fd67bd-e2c6-4c8b-9488-f39c7ef3d6b9" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_d527f938-f1b0-4daf-a07b-e07d675ab1e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofFairValueDisclosuresDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20201231.xsd#Contingencies"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#ContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9184ffa0-6de9-46dd-b222-25f87eee8da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_74d9ca29-6c88-407d-a4b7-9d066f2d39e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9184ffa0-6de9-46dd-b222-25f87eee8da4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_74d9ca29-6c88-407d-a4b7-9d066f2d39e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c2560af8-5c93-493f-9d68-45accfd079d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9184ffa0-6de9-46dd-b222-25f87eee8da4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c2560af8-5c93-493f-9d68-45accfd079d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpense"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpenseTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5df53ca7-e470-4191-aa72-cc64d2846fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1c4cba12-ed32-41c5-9ff3-2525a82aa698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5df53ca7-e470-4191-aa72-cc64d2846fd3" xlink:to="loc_us-gaap_InterestExpense_1c4cba12-ed32-41c5-9ff3-2525a82aa698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_085fdc8b-6f4f-4dc4-9109-9a4c87085a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5df53ca7-e470-4191-aa72-cc64d2846fd3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_085fdc8b-6f4f-4dc4-9109-9a4c87085a1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_94714a6a-8dcf-4add-b2cf-1b1daa63bce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5df53ca7-e470-4191-aa72-cc64d2846fd3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_94714a6a-8dcf-4add-b2cf-1b1daa63bce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_efbafcf3-015f-4b84-8753-52ab46f82ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5df53ca7-e470-4191-aa72-cc64d2846fd3" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_efbafcf3-015f-4b84-8753-52ab46f82ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_0336e6c5-4d47-4116-be2d-780e7e92586a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5df53ca7-e470-4191-aa72-cc64d2846fd3" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_0336e6c5-4d47-4116-be2d-780e7e92586a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8683ed53-fa96-4b3e-9348-0d0e95740dad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5df53ca7-e470-4191-aa72-cc64d2846fd3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8683ed53-fa96-4b3e-9348-0d0e95740dad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperations"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>lly-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:245edc66-3d73-4ffb-b61a-7d5e03b3f1e4,g:f11d2b17-0882-47f8-a810-701878e7e2df-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="i2417e011ca544dfd9a712aa594cfd223_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3a0fd9ff-0978-44f2-8db8-3dbcc245b606" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentType_3a0fd9ff-0978-44f2-8db8-3dbcc245b606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_0d6e160e-7884-4507-940f-5a2a02f36e89" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentAnnualReport_0d6e160e-7884-4507-940f-5a2a02f36e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9a0216c0-23ca-4eff-a004-05edb6c1132d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentPeriodEndDate_9a0216c0-23ca-4eff-a004-05edb6c1132d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b71159a6-72b9-49ff-9a60-071c1815834a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_CurrentFiscalYearEndDate_b71159a6-72b9-49ff-9a60-071c1815834a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f760de75-5884-43d5-9cc2-7696196d6f42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityFileNumber_f760de75-5884-43d5-9cc2-7696196d6f42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5abf2929-58d3-43b3-bd16-8cc0c6e90165" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityRegistrantName_5abf2929-58d3-43b3-bd16-8cc0c6e90165" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_88f19064-61b7-4d0a-afe2-5cbe580f1827" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityIncorporationStateCountryCode_88f19064-61b7-4d0a-afe2-5cbe580f1827" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_521fbc61-9d89-4275-9b34-7b573f88c986" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityTaxIdentificationNumber_521fbc61-9d89-4275-9b34-7b573f88c986" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_30502293-c64e-45ef-a9ea-54aaa2300801" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityAddressAddressLine1_30502293-c64e-45ef-a9ea-54aaa2300801" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_735fc7f7-deed-480e-865b-d31070e598a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityAddressCityOrTown_735fc7f7-deed-480e-865b-d31070e598a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ff67e102-0eb5-4d43-9f2d-0470fa58c605" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityAddressStateOrProvince_ff67e102-0eb5-4d43-9f2d-0470fa58c605" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d6e6e9ae-c99e-4569-9e19-d757a6a45778" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityAddressPostalZipCode_d6e6e9ae-c99e-4569-9e19-d757a6a45778" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_942fccef-f13e-4d4a-b6b0-de3df5ceb740" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_CityAreaCode_942fccef-f13e-4d4a-b6b0-de3df5ceb740" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_841016c2-565e-4f3c-9941-967eedea7ca6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_LocalPhoneNumber_841016c2-565e-4f3c-9941-967eedea7ca6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3e26c902-cfc2-4a9b-8850-e0361cf0c7fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_Security12bTitle_3e26c902-cfc2-4a9b-8850-e0361cf0c7fa" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0a4447c5-1f8c-48f2-8212-8480cabeb8a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_TradingSymbol_0a4447c5-1f8c-48f2-8212-8480cabeb8a9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9d096305-056a-40a1-88f3-6f9901895a93" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_SecurityExchangeName_9d096305-056a-40a1-88f3-6f9901895a93" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a5e83a48-6fa0-490f-bbad-6cac47427722" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a5e83a48-6fa0-490f-bbad-6cac47427722" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_a7271b0e-e5c1-405c-92f5-86c49628e369" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityVoluntaryFilers_a7271b0e-e5c1-405c-92f5-86c49628e369" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ef406952-387f-4d25-976f-b5bea58ff03c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityCurrentReportingStatus_ef406952-387f-4d25-976f-b5bea58ff03c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1ad67630-f189-4272-9f31-1b080c0e881d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityInteractiveDataCurrent_1ad67630-f189-4272-9f31-1b080c0e881d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ee2cf632-da51-48b8-9fc8-b34f41909753" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityFilerCategory_ee2cf632-da51-48b8-9fc8-b34f41909753" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2d3dfe6e-7b6a-46ea-8fe3-83c2b65c55ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntitySmallBusiness_2d3dfe6e-7b6a-46ea-8fe3-83c2b65c55ea" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6512b6e5-1c75-4cd2-a649-15a59d8fad11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityEmergingGrowthCompany_6512b6e5-1c75-4cd2-a649-15a59d8fad11" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_af6d0356-f76c-40ed-9032-bde4ec5a65ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_IcfrAuditorAttestationFlag_af6d0356-f76c-40ed-9032-bde4ec5a65ae" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5422df02-3280-49e2-9d5d-57d7d288e612" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityShellCompany_5422df02-3280-49e2-9d5d-57d7d288e612" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_68cdc328-8c7b-4a59-876c-fd9aba7e9f3b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityPublicFloat_68cdc328-8c7b-4a59-876c-fd9aba7e9f3b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_680744f7-f9eb-4782-9666-edb23a237ad8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_680744f7-f9eb-4782-9666-edb23a237ad8" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b4551227-67a1-4df4-ab6a-84fdde3feb24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentTransitionReport_b4551227-67a1-4df4-ab6a-84fdde3feb24" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5c87755c-2e70-4043-8191-5fb813bd142e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_AmendmentFlag_5c87755c-2e70-4043-8191-5fb813bd142e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_529a401c-5913-4ea6-8cd5-c895f27ac596" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentFiscalYearFocus_529a401c-5913-4ea6-8cd5-c895f27ac596" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_da917654-ffc2-4828-b5de-5b760e1588b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentFiscalPeriodFocus_da917654-ffc2-4828-b5de-5b760e1588b2" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ad5168c5-dedd-4a4c-acfc-3cc2f00b0390" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityCentralIndexKey_ad5168c5-dedd-4a4c-acfc-3cc2f00b0390" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c077553b-48cf-47de-86ba-5a9dde52177e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c077553b-48cf-47de-86ba-5a9dde52177e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_fe82346e-5c8d-4ee4-86a7-49a09f589cd9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentInformationTable_fe82346e-5c8d-4ee4-86a7-49a09f589cd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19cb0042-d9ef-455e-b928-014465486dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_fe82346e-5c8d-4ee4-86a7-49a09f589cd9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19cb0042-d9ef-455e-b928-014465486dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_19cb0042-d9ef-455e-b928-014465486dbd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19cb0042-d9ef-455e-b928-014465486dbd" xlink:to="loc_us-gaap_ClassOfStockDomain_19cb0042-d9ef-455e-b928-014465486dbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19cb0042-d9ef-455e-b928-014465486dbd" xlink:to="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_56b9ab17-8b6a-4a0c-ac46-72f36f44d757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_us-gaap_CommonClassAMember_56b9ab17-8b6a-4a0c-ac46-72f36f44d757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_ee1a1d32-0e44-4411-9f87-7d0bf6b79774" xlink:href="lly-20201231.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A1.000NotesDueJune22022Member_ee1a1d32-0e44-4411-9f87-7d0bf6b79774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_5b83a2df-dc8b-4e37-a760-5f8096da1433" xlink:href="lly-20201231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A718NotesDueJune12025Member_5b83a2df-dc8b-4e37-a760-5f8096da1433" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_1b0b2d64-b8ac-40ab-8521-0b9b892e7a35" xlink:href="lly-20201231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A1.625NotesDueJune22026Member_1b0b2d64-b8ac-40ab-8521-0b9b892e7a35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_c08dd853-5e43-4165-bd20-a779b84ea4e5" xlink:href="lly-20201231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A2.125NotesDueJune32030Member_c08dd853-5e43-4165-bd20-a779b84ea4e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_32948fb1-1b70-4490-b91d-38ce05397bc6" xlink:href="lly-20201231.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A625Notesdue2031Member_32948fb1-1b70-4490-b91d-38ce05397bc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_b1f9c94a-f02d-4103-9175-d50d25df4989" xlink:href="lly-20201231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_b1f9c94a-f02d-4103-9175-d50d25df4989" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_28b88862-71dd-418d-800d-af9ab54e3b70" xlink:href="lly-20201231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A1.700Notesdue2049Member_28b88862-71dd-418d-800d-af9ab54e3b70" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i55f32b18dde4497d9c41b8ee9953765c_ConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="i04c8e25862874ed4ab0702745d2756f7_ConsolidatedStatementsofComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d47f6690-f0f7-40fa-915e-2ecfdd809510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_NetIncomeLoss_d47f6690-f0f7-40fa-915e-2ecfdd809510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_c4a1d887-5317-4332-840d-1087da68ff57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_c4a1d887-5317-4332-840d-1087da68ff57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_805cc0ae-df8d-4c2d-8a56-51d3f69ee218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_805cc0ae-df8d-4c2d-8a56-51d3f69ee218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_22f3afff-1a84-4c66-8bab-e14cb43590a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_22f3afff-1a84-4c66-8bab-e14cb43590a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_b34d9d77-640c-4532-910a-e263d86be8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_b34d9d77-640c-4532-910a-e263d86be8cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_34988130-eec5-49f0-96a4-a7a581405869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_34988130-eec5-49f0-96a4-a7a581405869" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_ea41d0dc-449f-4a0a-84d2-3840410180f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_ea41d0dc-449f-4a0a-84d2-3840410180f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_e6d92b98-5b43-4afc-b258-9e8cf99a6bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_e6d92b98-5b43-4afc-b258-9e8cf99a6bcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_33bf627d-54c0-468d-82a5-d8ee5d0cf44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_33bf627d-54c0-468d-82a5-d8ee5d0cf44b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c5babab5-d468-4da5-b1de-de067116cff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c5babab5-d468-4da5-b1de-de067116cff5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8291f5ae-5dfa-455f-af09-4cc923192ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_StatementTable_8291f5ae-5dfa-455f-af09-4cc923192ca0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_0acda52c-c933-4b67-bf96-ebdf69ff12ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8291f5ae-5dfa-455f-af09-4cc923192ca0" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_0acda52c-c933-4b67-bf96-ebdf69ff12ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_0acda52c-c933-4b67-bf96-ebdf69ff12ce_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_0acda52c-c933-4b67-bf96-ebdf69ff12ce" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_0acda52c-c933-4b67-bf96-ebdf69ff12ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_bcfeae86-59bc-4ddb-8fcf-412856afb4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_0acda52c-c933-4b67-bf96-ebdf69ff12ce" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_bcfeae86-59bc-4ddb-8fcf-412856afb4c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_8d40beab-bde2-4813-9215-0756712c1140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_bcfeae86-59bc-4ddb-8fcf-412856afb4c2" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_8d40beab-bde2-4813-9215-0756712c1140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_10685977-31f5-4baa-bee1-58b321594c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_bcfeae86-59bc-4ddb-8fcf-412856afb4c2" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_10685977-31f5-4baa-bee1-58b321594c4c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="ibae7e8b4c3814126af0c50fe3c89d549_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i63e06414e9f14ae78c27cfcf5762bceb_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofShareholdersEquityStatement"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="extended" id="ibaa2787760ca49d88d5261f94182d57c_ConsolidatedStatementsofShareholdersEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_94a8bf07-499e-42cf-9f01-0e4028b8f07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94a8bf07-499e-42cf-9f01-0e4028b8f07a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8df9e29d-21f6-426f-838a-c4019ca91e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_SharesIssued_8df9e29d-21f6-426f-838a-c4019ca91e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14f41d87-f5fe-4330-8956-87117b451adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14f41d87-f5fe-4330-8956-87117b451adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_85e1b42d-77da-44c3-a1c9-dca7d75ce2e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_ProfitLoss_85e1b42d-77da-44c3-a1c9-dca7d75ce2e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abae81c1-f71f-47c3-8784-8d8c26a70376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abae81c1-f71f-47c3-8784-8d8c26a70376" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_abc05e47-2c8d-4500-8506-eed3c546fc67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_Dividends_abc05e47-2c8d-4500-8506-eed3c546fc67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_1ca507d1-e416-4503-8765-864c2e1974b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_1ca507d1-e416-4503-8765-864c2e1974b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_db4b7ed3-b4bc-43c0-bd7e-9c54738e9f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_db4b7ed3-b4bc-43c0-bd7e-9c54738e9f81" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1ddcb853-9c32-4d58-b26b-c3e5c1842406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1ddcb853-9c32-4d58-b26b-c3e5c1842406" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e3c83d5e-3f4e-4b02-b257-2594f2741e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e3c83d5e-3f4e-4b02-b257-2594f2741e28" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_23e68e5c-a7fd-4b65-b42c-da85f7f1b43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_23e68e5c-a7fd-4b65-b42c-da85f7f1b43a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e6faef54-dffb-40d6-b1fa-361204fef344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e6faef54-dffb-40d6-b1fa-361204fef344" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_adcac459-7381-4ab8-9572-c57e16e10240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_adcac459-7381-4ab8-9572-c57e16e10240" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6b75d3c-7b7e-4190-b7b1-135c89477f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6b75d3c-7b7e-4190-b7b1-135c89477f57" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer_c9a0981e-3594-4dc3-88d5-a15879dd882f" xlink:href="lly-20201231.xsd#lly_StockAcquiredDuringPeriodSharesExchangeOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer_c9a0981e-3594-4dc3-88d5-a15879dd882f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer_b423ba18-e56a-4311-a47e-8abe529b06f4" xlink:href="lly-20201231.xsd#lly_StockAcquiredDuringPeriodValueExchangeOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer_b423ba18-e56a-4311-a47e-8abe529b06f4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_991c375a-3eb9-4e02-ad5d-115ae7e1a5e8" xlink:href="lly-20201231.xsd#lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_991c375a-3eb9-4e02-ad5d-115ae7e1a5e8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_dd554dd5-a418-4a84-8e98-c25ae27c5b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockholdersEquityOther_dd554dd5-a418-4a84-8e98-c25ae27c5b06" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_43c20017-66cf-47e4-9a30-a3650ba5ac6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61e7edf4-7178-4da5-b55f-f0203e503a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_94a8bf07-499e-42cf-9f01-0e4028b8f07a" xlink:to="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7" xlink:to="loc_us-gaap_EquityComponentDomain_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7" xlink:to="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e8cfd2a0-390d-4364-99e3-57ca8337f1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_CommonStockMember_e8cfd2a0-390d-4364-99e3-57ca8337f1fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ba384e56-7dd1-4321-b2e3-4d485dec9386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ba384e56-7dd1-4321-b2e3-4d485dec9386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f42cc0db-73ad-4ac5-924c-30e6c5be7286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_RetainedEarningsMember_f42cc0db-73ad-4ac5-924c-30e6c5be7286" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_f77c9ef7-458f-48b6-94d7-575a96b12134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_f77c9ef7-458f-48b6-94d7-575a96b12134" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6590fb60-4b77-4bee-9cc1-0cc97a98c65c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6590fb60-4b77-4bee-9cc1-0cc97a98c65c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_417c1144-3eaf-45d8-9478-8cbf958c0e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_TreasuryStockMember_417c1144-3eaf-45d8-9478-8cbf958c0e93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_06ecd782-bafe-4047-9b18-1deace9cfa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_06ecd782-bafe-4047-9b18-1deace9cfa95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e738b930-a874-4715-8fb1-8292d4ff9fd3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e738b930-a874-4715-8fb1-8292d4ff9fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_15a2770c-031b-471b-bcd3-e08173b519d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e738b930-a874-4715-8fb1-8292d4ff9fd3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_15a2770c-031b-471b-bcd3-e08173b519d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended" id="i446fe801aa234d14af84368674859196_ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="id1fd13208d3343caa016de7a67c679fe_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="i3a5628fa85a242cd9947e74db083925e_ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" xlink:type="extended" id="ibe5460e61cf545df92c28e69870462a6_SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards"/>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies" xlink:type="extended" id="i02b8ba6637c94919a3146fb7cb2d0ce4_SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"/>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails" xlink:type="extended" id="if76c4048b88b427ba8a60d7880563200_SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_45a47247-1cf5-4b2a-bbd3-c76d1dda36fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_45a47247-1cf5-4b2a-bbd3-c76d1dda36fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_c58e4081-c95c-4941-87a0-00616c982de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_AdvertisingExpense_c58e4081-c95c-4941-87a0-00616c982de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AdvertisingExpensePercentageOfRevenue_92c59fa2-9e12-4ef4-bbc1-00129000bc0b" xlink:href="lly-20201231.xsd#lly_AdvertisingExpensePercentageOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_lly_AdvertisingExpensePercentageOfRevenue_92c59fa2-9e12-4ef4-bbc1-00129000bc0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_65cda945-7749-409f-b43a-5a5079a8c4ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_65cda945-7749-409f-b43a-5a5079a8c4ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5baa7f1e-950f-42dc-a976-2f70bffb1427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5baa7f1e-950f-42dc-a976-2f70bffb1427" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7ed3f417-b69d-4113-a9fe-d639dc70d68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_OperatingLeaseLiability_7ed3f417-b69d-4113-a9fe-d639dc70d68d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_7eb56712-1a98-47f5-9a47-ae9b7409d8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_7eb56712-1a98-47f5-9a47-ae9b7409d8bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7ea649ae-a89e-437a-ad3f-b28b37cb3f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7ea649ae-a89e-437a-ad3f-b28b37cb3f9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_0351871e-744a-446c-a386-6ed9abfd4617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_0351871e-744a-446c-a386-6ed9abfd4617" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3d500192-f91d-4a0a-aa2a-b00b42967f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3d500192-f91d-4a0a-aa2a-b00b42967f2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_bf09bd56-a674-47f7-9bf7-0fa64701d42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_DeferredTaxLiabilities_bf09bd56-a674-47f7-9bf7-0fa64701d42a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f89912be-838a-4c70-9613-9df6ac09d794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f89912be-838a-4c70-9613-9df6ac09d794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f89912be-838a-4c70-9613-9df6ac09d794_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f89912be-838a-4c70-9613-9df6ac09d794" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f89912be-838a-4c70-9613-9df6ac09d794_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f89912be-838a-4c70-9613-9df6ac09d794" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_ac756347-fc18-49fa-985c-9c6bc9963009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_ac756347-fc18-49fa-985c-9c6bc9963009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_fb8e4ae8-0224-488a-b83e-6f823e1bb13a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_fb8e4ae8-0224-488a-b83e-6f823e1bb13a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccountingStandardsUpdate201616aMember_79098087-e409-4ce7-859e-af4ecd91d570" xlink:href="lly-20201231.xsd#lly_AccountingStandardsUpdate201616aMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:to="loc_lly_AccountingStandardsUpdate201616aMember_79098087-e409-4ce7-859e-af4ecd91d570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_4c49954e-9c08-40f9-8775-f97e0f2981c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_4c49954e-9c08-40f9-8775-f97e0f2981c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4c49954e-9c08-40f9-8775-f97e0f2981c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4c49954e-9c08-40f9-8775-f97e0f2981c8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4c49954e-9c08-40f9-8775-f97e0f2981c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_435c5e75-4b4c-4916-a722-f7da46b384ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4c49954e-9c08-40f9-8775-f97e0f2981c8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_435c5e75-4b4c-4916-a722-f7da46b384ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_19acf3e8-5114-4b3d-bf60-5be4ece779ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_435c5e75-4b4c-4916-a722-f7da46b384ca" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_19acf3e8-5114-4b3d-bf60-5be4ece779ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0eb189c1-d6bd-4765-b4cc-03797f29c13d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0eb189c1-d6bd-4765-b4cc-03797f29c13d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0eb189c1-d6bd-4765-b4cc-03797f29c13d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0eb189c1-d6bd-4765-b4cc-03797f29c13d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0eb189c1-d6bd-4765-b4cc-03797f29c13d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93800b3f-f2fe-45b1-a503-0c982cd5220c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0eb189c1-d6bd-4765-b4cc-03797f29c13d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93800b3f-f2fe-45b1-a503-0c982cd5220c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_a16f9081-3565-413a-a025-62f1b5d0d1d0" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93800b3f-f2fe-45b1-a503-0c982cd5220c" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_a16f9081-3565-413a-a025-62f1b5d0d1d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68dcaef7-4b54-4b8a-95ae-6c2174577c9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68dcaef7-4b54-4b8a-95ae-6c2174577c9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_68dcaef7-4b54-4b8a-95ae-6c2174577c9e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68dcaef7-4b54-4b8a-95ae-6c2174577c9e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_68dcaef7-4b54-4b8a-95ae-6c2174577c9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4bd7e5db-21f9-4fab-a01c-93e9a224a53a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68dcaef7-4b54-4b8a-95ae-6c2174577c9e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4bd7e5db-21f9-4fab-a01c-93e9a224a53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_bd815487-10fc-488f-b318-73aef3148cc8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4bd7e5db-21f9-4fab-a01c-93e9a224a53a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_bd815487-10fc-488f-b318-73aef3148cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_733ab6fb-028b-41ba-ab25-6f28bfbe5006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_733ab6fb-028b-41ba-ab25-6f28bfbe5006" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_733ab6fb-028b-41ba-ab25-6f28bfbe5006_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_733ab6fb-028b-41ba-ab25-6f28bfbe5006" xlink:to="loc_us-gaap_EquityComponentDomain_733ab6fb-028b-41ba-ab25-6f28bfbe5006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f08b2141-6819-4b3d-bd27-8cbc1a285d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_733ab6fb-028b-41ba-ab25-6f28bfbe5006" xlink:to="loc_us-gaap_EquityComponentDomain_f08b2141-6819-4b3d-bd27-8cbc1a285d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_48c4fabf-0609-41c5-badf-4178eba68572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f08b2141-6819-4b3d-bd27-8cbc1a285d9e" xlink:to="loc_us-gaap_RetainedEarningsMember_48c4fabf-0609-41c5-badf-4178eba68572" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34d0ea5a-816d-4bc5-be33-764a9ff70063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f08b2141-6819-4b3d-bd27-8cbc1a285d9e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34d0ea5a-816d-4bc5-be33-764a9ff70063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9882bf43-f4f1-438f-ab44-2deec01ca13a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_srt_OwnershipAxis_9882bf43-f4f1-438f-ab44-2deec01ca13a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9882bf43-f4f1-438f-ab44-2deec01ca13a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_9882bf43-f4f1-438f-ab44-2deec01ca13a" xlink:to="loc_srt_OwnershipDomain_9882bf43-f4f1-438f-ab44-2deec01ca13a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ebaa9516-c19c-483f-8143-098087f5c307" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_9882bf43-f4f1-438f-ab44-2deec01ca13a" xlink:to="loc_srt_OwnershipDomain_ebaa9516-c19c-483f-8143-098087f5c307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember_e5c7e30a-af0b-4c37-8e65-59f04b79858c" xlink:href="lly-20201231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ebaa9516-c19c-483f-8143-098087f5c307" xlink:to="loc_lly_EliLillyAndCompanyMember_e5c7e30a-af0b-4c37-8e65-59f04b79858c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20201231.xsd#Revenue"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended" id="i1dd8100f09ef41bbaa76886267bf6847_Revenue"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended" id="i2624c5a4f09543d6874eda87b89ecceb_RevenueTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended" id="i7240c84b468f411aa521dcef5d6ac38c_RevenueSummaryofRevenueRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a8703edb-1d91-47b3-8c42-f43651ab27dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4d17ee76-fa14-49b9-b78a-9fe0c23a0d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8703edb-1d91-47b3-8c42-f43651ab27dc" xlink:to="loc_us-gaap_Revenues_4d17ee76-fa14-49b9-b78a-9fe0c23a0d0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_13604448-380a-440a-9270-991cb3e1ac88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8703edb-1d91-47b3-8c42-f43651ab27dc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_13604448-380a-440a-9270-991cb3e1ac88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_13604448-380a-440a-9270-991cb3e1ac88" xlink:to="loc_srt_ProductOrServiceAxis_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e" xlink:to="loc_srt_ProductsAndServicesDomain_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e" xlink:to="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_943d6d05-958e-4d6b-9f69-9653bb3063d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:to="loc_us-gaap_ProductMember_943d6d05-958e-4d6b-9f69-9653bb3063d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_0f8680b2-dfc2-4f56-9d86-8c4ac230b1f9" xlink:href="lly-20201231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:to="loc_lly_CollaborationandOtherRevenueMember_0f8680b2-dfc2-4f56-9d86-8c4ac230b1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_f8e1e062-a96d-4455-a592-2d6f81509152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:to="loc_us-gaap_RoyaltyMember_f8e1e062-a96d-4455-a592-2d6f81509152" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="extended" id="if9275d885475415b96b62bbbf5f4a33a_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum_43497b5b-5ebf-4a26-93e3-df21b9258423" xlink:href="lly-20201231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuefromContractPaymentTermMinimum_43497b5b-5ebf-4a26-93e3-df21b9258423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum_c384eb17-6d17-4b76-8db8-ba7a42ef2543" xlink:href="lly-20201231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuefromContractPaymentTermMaximum_c384eb17-6d17-4b76-8db8-ba7a42ef2543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_11a89909-14b6-4c56-b5c6-3be078700750" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_11a89909-14b6-4c56-b5c6-3be078700750" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a5f595a3-7be5-4efd-91f5-f07398310cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a5f595a3-7be5-4efd-91f5-f07398310cf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_8ee2d2b8-54a1-4af5-85ce-8f0da0e71e7b" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_8ee2d2b8-54a1-4af5-85ce-8f0da0e71e7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3b201008-2fa6-45eb-b0db-a4655f6337ab" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3b201008-2fa6-45eb-b0db-a4655f6337ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_8effe789-3a3f-49c0-ae7c-5a3feff20a94" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_8effe789-3a3f-49c0-ae7c-5a3feff20a94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_5495bf7d-c55d-470c-ae1f-5267570d33bf" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_5495bf7d-c55d-470c-ae1f-5267570d33bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_7b8453a4-13ca-441f-a808-7d62b00c0934" xlink:href="lly-20201231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_7b8453a4-13ca-441f-a808-7d62b00c0934" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a422ca25-dc47-440e-98e1-0109734f5d72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_srt_MajorCustomersAxis_a422ca25-dc47-440e-98e1-0109734f5d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a422ca25-dc47-440e-98e1-0109734f5d72_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a422ca25-dc47-440e-98e1-0109734f5d72" xlink:to="loc_srt_NameOfMajorCustomerDomain_a422ca25-dc47-440e-98e1-0109734f5d72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3341a854-1863-4910-b241-de4408da8506" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a422ca25-dc47-440e-98e1-0109734f5d72" xlink:to="loc_srt_NameOfMajorCustomerDomain_3341a854-1863-4910-b241-de4408da8506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember_20b13a8b-e195-4ef7-8d81-41d4c33f0941" xlink:href="lly-20201231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3341a854-1863-4910-b241-de4408da8506" xlink:to="loc_lly_ThreeLargestWholesalesMember_20b13a8b-e195-4ef7-8d81-41d4c33f0941" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddd34164-6004-414a-9f78-35fe3a17b459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddd34164-6004-414a-9f78-35fe3a17b459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ddd34164-6004-414a-9f78-35fe3a17b459_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddd34164-6004-414a-9f78-35fe3a17b459" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ddd34164-6004-414a-9f78-35fe3a17b459_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_99b60396-a8b0-4c38-ae96-31d856b64e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddd34164-6004-414a-9f78-35fe3a17b459" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_99b60396-a8b0-4c38-ae96-31d856b64e67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0b65c364-23bb-41ee-99ed-9401f6f1bd52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_99b60396-a8b0-4c38-ae96-31d856b64e67" xlink:to="loc_us-gaap_SalesRevenueNetMember_0b65c364-23bb-41ee-99ed-9401f6f1bd52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_49b61d80-2629-4509-a06d-ca82ed2a2bba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_99b60396-a8b0-4c38-ae96-31d856b64e67" xlink:to="loc_us-gaap_AccountsReceivableMember_49b61d80-2629-4509-a06d-ca82ed2a2bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_49760f71-bd98-4086-beb0-34c3cd94592f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_srt_RangeAxis_49760f71-bd98-4086-beb0-34c3cd94592f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49760f71-bd98-4086-beb0-34c3cd94592f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_49760f71-bd98-4086-beb0-34c3cd94592f" xlink:to="loc_srt_RangeMember_49760f71-bd98-4086-beb0-34c3cd94592f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0fbe0d1-b1a7-43d8-85b6-8ff2d5b83847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_49760f71-bd98-4086-beb0-34c3cd94592f" xlink:to="loc_srt_RangeMember_d0fbe0d1-b1a7-43d8-85b6-8ff2d5b83847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b2574ff6-428b-4d0e-9b3e-e2dea6c3911a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0fbe0d1-b1a7-43d8-85b6-8ff2d5b83847" xlink:to="loc_srt_MinimumMember_b2574ff6-428b-4d0e-9b3e-e2dea6c3911a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fe56e820-b82a-4a00-8735-2f6295a8c1da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0fbe0d1-b1a7-43d8-85b6-8ff2d5b83847" xlink:to="loc_srt_MaximumMember_fe56e820-b82a-4a00-8735-2f6295a8c1da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_srt_StatementGeographicalAxis_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb" xlink:to="loc_srt_SegmentGeographicalDomain_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6dfd6ce8-fc47-43db-8f6a-cabbeeb01eed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb" xlink:to="loc_srt_SegmentGeographicalDomain_6dfd6ce8-fc47-43db-8f6a-cabbeeb01eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3c5d6fc8-10c0-4b86-9b58-923d0c12d5d4" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6dfd6ce8-fc47-43db-8f6a-cabbeeb01eed" xlink:to="loc_country_US_3c5d6fc8-10c0-4b86-9b58-923d0c12d5d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5f20dca4-6024-485f-9762-97855114fe0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5f20dca4-6024-485f-9762-97855114fe0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5f20dca4-6024-485f-9762-97855114fe0c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5f20dca4-6024-485f-9762-97855114fe0c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5f20dca4-6024-485f-9762-97855114fe0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ca77976d-013e-4468-87fb-be82213fa22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5f20dca4-6024-485f-9762-97855114fe0c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ca77976d-013e-4468-87fb-be82213fa22d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_dc255c6e-2287-4ddb-bd6f-6081e841c157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ca77976d-013e-4468-87fb-be82213fa22d" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_dc255c6e-2287-4ddb-bd6f-6081e841c157" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended" id="i016efad8db8b441fbfe39c4271600138_RevenueContractLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended" id="id8228b79bd4c40af8f67aeacae9bdc60_RevenueDisaggregationofRevenuebyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_32160e1f-c0be-4177-8b65-32142990f313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fdd48509-7330-4c87-a404-05b0bc61595c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_32160e1f-c0be-4177-8b65-32142990f313" xlink:to="loc_us-gaap_Revenues_fdd48509-7330-4c87-a404-05b0bc61595c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_32160e1f-c0be-4177-8b65-32142990f313" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8400f3cb-a98b-438c-8074-480a39c49480" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:to="loc_srt_ProductOrServiceAxis_8400f3cb-a98b-438c-8074-480a39c49480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8400f3cb-a98b-438c-8074-480a39c49480_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8400f3cb-a98b-438c-8074-480a39c49480" xlink:to="loc_srt_ProductsAndServicesDomain_8400f3cb-a98b-438c-8074-480a39c49480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8400f3cb-a98b-438c-8074-480a39c49480" xlink:to="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:href="lly-20201231.xsd#lly_DiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_c892d4e7-c4ad-44d9-bf0b-ddb09edd2902" xlink:href="lly-20201231.xsd#lly_TrulicityMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_TrulicityMemberMember_c892d4e7-c4ad-44d9-bf0b-ddb09edd2902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_76aa0b74-dc3e-4d55-a8e0-4586408c476f" xlink:href="lly-20201231.xsd#lly_HumalogMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_HumalogMember_76aa0b74-dc3e-4d55-a8e0-4586408c476f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_57624db1-4259-4cb1-a6cf-66c4a7ec30ca" xlink:href="lly-20201231.xsd#lly_HumulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_HumulinMember_57624db1-4259-4cb1-a6cf-66c4a7ec30ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_c44140d8-4f46-4a8a-b195-49c2993cbb66" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_JardianceMember_c44140d8-4f46-4a8a-b195-49c2993cbb66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_a9df6af9-0def-4fb8-9c60-8d0f0076fa12" xlink:href="lly-20201231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_BasaglarMember_a9df6af9-0def-4fb8-9c60-8d0f0076fa12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_9c1880a4-b884-4c73-97ab-230f0f741a1b" xlink:href="lly-20201231.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_TrajentaBIMember_9c1880a4-b884-4c73-97ab-230f0f741a1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_bd5cf9e3-7876-4a46-a247-eda88d2e6d00" xlink:href="lly-20201231.xsd#lly_OtherDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_OtherDiabetesMember_bd5cf9e3-7876-4a46-a247-eda88d2e6d00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:href="lly-20201231.xsd#lly_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_6c52288c-575f-478f-9a1c-a219e2c28ef7" xlink:href="lly-20201231.xsd#lly_AlimtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_AlimtaMember_6c52288c-575f-478f-9a1c-a219e2c28ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_856bf81c-af96-431b-8daf-28548cfdd29b" xlink:href="lly-20201231.xsd#lly_CyramzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_CyramzaMember_856bf81c-af96-431b-8daf-28548cfdd29b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_12cdf77c-b257-4bc6-81d6-2475907ca3db" xlink:href="lly-20201231.xsd#lly_VerzenioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_VerzenioMember_12cdf77c-b257-4bc6-81d6-2475907ca3db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_140eccc0-578b-4c40-bbb6-1fba6fde1d14" xlink:href="lly-20201231.xsd#lly_ErbituxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_ErbituxMember_140eccc0-578b-4c40-bbb6-1fba6fde1d14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_0d40e03c-5900-4f89-8442-bbeaf8b8e660" xlink:href="lly-20201231.xsd#lly_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_OtherOncologyMember_0d40e03c-5900-4f89-8442-bbeaf8b8e660" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:href="lly-20201231.xsd#lly_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_aa23f541-8a16-4cf1-aa1a-f3896d46082f" xlink:href="lly-20201231.xsd#lly_TaltzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:to="loc_lly_TaltzMember_aa23f541-8a16-4cf1-aa1a-f3896d46082f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_9f700b68-a01f-4f92-b755-fabbff7a1ba8" xlink:href="lly-20201231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:to="loc_lly_OlumiantMember_9f700b68-a01f-4f92-b755-fabbff7a1ba8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_42cc5200-9212-4b71-97ab-3d4854da0bc5" xlink:href="lly-20201231.xsd#lly_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:to="loc_lly_OtherImmunologyMember_42cc5200-9212-4b71-97ab-3d4854da0bc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:href="lly-20201231.xsd#lly_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_ebe4d44f-0bb6-4503-8626-1483d66500af" xlink:href="lly-20201231.xsd#lly_CymbaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:to="loc_lly_CymbaltaMember_ebe4d44f-0bb6-4503-8626-1483d66500af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_bb6391a1-b2fd-47fe-8f0c-55834ef870c3" xlink:href="lly-20201231.xsd#lly_ZyprexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:to="loc_lly_ZyprexaMember_bb6391a1-b2fd-47fe-8f0c-55834ef870c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_2d56c208-e58a-4981-aa7e-52b3bcca5399" xlink:href="lly-20201231.xsd#lly_EmgalityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:to="loc_lly_EmgalityMember_2d56c208-e58a-4981-aa7e-52b3bcca5399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_3e1a3d14-9c36-42f2-aad2-f5d3544b2519" xlink:href="lly-20201231.xsd#lly_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:to="loc_lly_OtherNeuroscienceMember_3e1a3d14-9c36-42f2-aad2-f5d3544b2519" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:href="lly-20201231.xsd#lly_OtherProductTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_16cdf599-70bb-4014-b08b-ecb9b9ed9eb2" xlink:href="lly-20201231.xsd#lly_ForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:to="loc_lly_ForteoMember_16cdf599-70bb-4014-b08b-ecb9b9ed9eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BamlanivimabMember_60c0d5c7-9fda-4924-a252-dd5701fce48f" xlink:href="lly-20201231.xsd#lly_BamlanivimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:to="loc_lly_BamlanivimabMember_60c0d5c7-9fda-4924-a252-dd5701fce48f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_8dbda9e4-14da-47cb-8483-5a05580eff46" xlink:href="lly-20201231.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:to="loc_lly_CialisMember_8dbda9e4-14da-47cb-8483-5a05580eff46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_1c0583b0-f32d-4fa5-8600-9c575d6e1a24" xlink:href="lly-20201231.xsd#lly_OtherProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:to="loc_lly_OtherProductMember_1c0583b0-f32d-4fa5-8600-9c575d6e1a24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dd36d851-e0c0-4bb5-8090-ddc317f43022" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:to="loc_srt_StatementGeographicalAxis_dd36d851-e0c0-4bb5-8090-ddc317f43022" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dd36d851-e0c0-4bb5-8090-ddc317f43022_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dd36d851-e0c0-4bb5-8090-ddc317f43022" xlink:to="loc_srt_SegmentGeographicalDomain_dd36d851-e0c0-4bb5-8090-ddc317f43022_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2bbecf0d-c63a-4b8b-b753-c0b166b15024" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dd36d851-e0c0-4bb5-8090-ddc317f43022" xlink:to="loc_srt_SegmentGeographicalDomain_2bbecf0d-c63a-4b8b-b753-c0b166b15024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ba1974ce-16f5-41b4-b19c-eaa574f24352" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2bbecf0d-c63a-4b8b-b753-c0b166b15024" xlink:to="loc_country_US_ba1974ce-16f5-41b4-b19c-eaa574f24352" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_90cbf493-ed45-43c8-ade2-4586493c6bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2bbecf0d-c63a-4b8b-b753-c0b166b15024" xlink:to="loc_us-gaap_NonUsMember_90cbf493-ed45-43c8-ade2-4586493c6bf1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended" id="icc013dcfa9b64fe3a538ea82eeb4fe09_RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_044fd680-b2f1-4565-8e9d-84ad41748105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_94b89331-ec44-4bfb-be21-82bc0532888d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_044fd680-b2f1-4565-8e9d-84ad41748105" xlink:to="loc_us-gaap_Revenues_94b89331-ec44-4bfb-be21-82bc0532888d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_64a3c4e8-155e-4563-b2fb-6ab64ab783e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_044fd680-b2f1-4565-8e9d-84ad41748105" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_64a3c4e8-155e-4563-b2fb-6ab64ab783e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5aac6c17-ede2-4501-a74f-79eb420f1d0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64a3c4e8-155e-4563-b2fb-6ab64ab783e8" xlink:to="loc_srt_StatementGeographicalAxis_5aac6c17-ede2-4501-a74f-79eb420f1d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5aac6c17-ede2-4501-a74f-79eb420f1d0c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5aac6c17-ede2-4501-a74f-79eb420f1d0c" xlink:to="loc_srt_SegmentGeographicalDomain_5aac6c17-ede2-4501-a74f-79eb420f1d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5aac6c17-ede2-4501-a74f-79eb420f1d0c" xlink:to="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a6549c3b-b518-434f-a31c-c26934f064df" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_country_US_a6549c3b-b518-434f-a31c-c26934f064df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_9737faea-bf35-48d1-b9d6-0901c94eee54" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_srt_EuropeMember_9737faea-bf35-48d1-b9d6-0901c94eee54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_23fe7714-6431-4267-b900-ea51ee4ef660" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_country_JP_23fe7714-6431-4267-b900-ea51ee4ef660" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_b941f0c9-8d63-4e96-ac7a-1369c2739633" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_country_CN_b941f0c9-8d63-4e96-ac7a-1369c2739633" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_aa5c7a6f-a56e-4a34-80cc-62a449e69bb7" xlink:href="lly-20201231.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_lly_OtherForeignCountriesMember_aa5c7a6f-a56e-4a34-80cc-62a449e69bb7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiture" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestiture"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiture" xlink:type="extended" id="i9a7737e4591e41c1a1f0bdd246413f86_AcquisitionsandDivestiture"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureTables" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureTables" xlink:type="extended" id="i2bd566e925ae4ad3bde2121e3fa41af3_AcquisitionsandDivestitureTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="extended" id="i7121b1ac68f74845b3026b9ddd3b492c_AcquisitionsandDivestitureNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_62debbff-176c-4712-b1ee-71f0cdb98630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_62debbff-176c-4712-b1ee-71f0cdb98630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b88dcf3-f68d-410b-8062-4338df25da9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b88dcf3-f68d-410b-8062-4338df25da9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a4e64398-6a70-4fb8-9635-b8bc57953432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_Goodwill_a4e64398-6a70-4fb8-9635-b8bc57953432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6a44202b-5abb-4422-a6c3-8bd5b623c67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6a44202b-5abb-4422-a6c3-8bd5b623c67e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_089f6f5d-85ac-489a-bbb1-077e6c9cadc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_089f6f5d-85ac-489a-bbb1-077e6c9cadc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9f5b8fec-8d3a-417d-b719-8c5accafa6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9f5b8fec-8d3a-417d-b719-8c5accafa6ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4106bd58-c7a7-4ae0-a97f-5f0bf1e27d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4106bd58-c7a7-4ae0-a97f-5f0bf1e27d43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_b3098177-4a53-4ad1-9500-b97c2754b01e" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_b3098177-4a53-4ad1-9500-b97c2754b01e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_12c0418c-d029-4d4a-9a7c-53a01e8998fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_12c0418c-d029-4d4a-9a7c-53a01e8998fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NumberOfMedicinesRightsToSold_3779e469-786f-4d7b-b2ad-da8898c91c19" xlink:href="lly-20201231.xsd#lly_NumberOfMedicinesRightsToSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_NumberOfMedicinesRightsToSold_3779e469-786f-4d7b-b2ad-da8898c91c19" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_d4244248-3a64-4f42-926e-8151989a58d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_d4244248-3a64-4f42-926e-8151989a58d5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_3fc33790-b71c-4f58-9614-acaf80b88d76" xlink:href="lly-20201231.xsd#lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_3fc33790-b71c-4f58-9614-acaf80b88d76" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_546691d1-ff94-43f0-8364-782357f5e188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_546691d1-ff94-43f0-8364-782357f5e188" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b19b8251-d0d0-4f75-9234-619031d78411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b19b8251-d0d0-4f75-9234-619031d78411" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_37c3d7b2-f2c2-4fad-a293-fcbd7077238c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_37c3d7b2-f2c2-4fad-a293-fcbd7077238c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_f90d0845-c843-41a4-b441-6a1cee0efabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_f90d0845-c843-41a4-b441-6a1cee0efabe" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_a8fe8e1a-40eb-4b95-95d1-9d3ecb0401da" xlink:href="lly-20201231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_a8fe8e1a-40eb-4b95-95d1-9d3ecb0401da" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_c85c9176-d7bd-4315-9d64-732b56bd17a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_c85c9176-d7bd-4315-9d64-732b56bd17a9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_6c1b1a38-a888-45fb-8937-5aa4e7c03bfe" xlink:href="lly-20201231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_6c1b1a38-a888-45fb-8937-5aa4e7c03bfe" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f75fe8ff-f266-40b4-8aab-161a8535e861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f75fe8ff-f266-40b4-8aab-161a8535e861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f75fe8ff-f266-40b4-8aab-161a8535e861_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f75fe8ff-f266-40b4-8aab-161a8535e861" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f75fe8ff-f266-40b4-8aab-161a8535e861_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_af7ea9ef-30d3-49f8-8517-92cfa8110726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f75fe8ff-f266-40b4-8aab-161a8535e861" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_af7ea9ef-30d3-49f8-8517-92cfa8110726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_21c73359-5165-4aac-ad67-4a71d3148ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_af7ea9ef-30d3-49f8-8517-92cfa8110726" xlink:to="loc_us-gaap_SubsequentEventMember_21c73359-5165-4aac-ad67-4a71d3148ef6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1add8263-7021-4536-9c36-046a89976c01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_1add8263-7021-4536-9c36-046a89976c01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1add8263-7021-4536-9c36-046a89976c01_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1add8263-7021-4536-9c36-046a89976c01" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1add8263-7021-4536-9c36-046a89976c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7f89eb5e-35e4-4cb6-9fd2-e9fdb9963da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1add8263-7021-4536-9c36-046a89976c01" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7f89eb5e-35e4-4cb6-9fd2-e9fdb9963da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5b602f53-9552-4d16-9b0a-c5f2ba365ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7f89eb5e-35e4-4cb6-9fd2-e9fdb9963da4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5b602f53-9552-4d16-9b0a-c5f2ba365ce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_39542dd8-748b-46cb-945a-345fdf430942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_39542dd8-748b-46cb-945a-345fdf430942" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_39542dd8-748b-46cb-945a-345fdf430942_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_39542dd8-748b-46cb-945a-345fdf430942" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_39542dd8-748b-46cb-945a-345fdf430942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5411c11-21e3-4e95-9a9d-3fa2ff88f7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_39542dd8-748b-46cb-945a-345fdf430942" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5411c11-21e3-4e95-9a9d-3fa2ff88f7b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_b47998a4-fe73-4c83-96d7-9dc2ae0147d4" xlink:href="lly-20201231.xsd#lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5411c11-21e3-4e95-9a9d-3fa2ff88f7b6" xlink:to="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_b47998a4-fe73-4c83-96d7-9dc2ae0147d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_023af711-eafc-45ba-ab2a-7d7ef7937717" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_srt_CounterpartyNameAxis_023af711-eafc-45ba-ab2a-7d7ef7937717" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_023af711-eafc-45ba-ab2a-7d7ef7937717_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_023af711-eafc-45ba-ab2a-7d7ef7937717" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_023af711-eafc-45ba-ab2a-7d7ef7937717_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20b2eca9-7dc8-480e-9d3f-5c2f68df6a4f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_023af711-eafc-45ba-ab2a-7d7ef7937717" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20b2eca9-7dc8-480e-9d3f-5c2f68df6a4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EddingpharmMember_c948f9c6-6c2e-4f9d-9189-490c129abb34" xlink:href="lly-20201231.xsd#lly_EddingpharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20b2eca9-7dc8-480e-9d3f-5c2f68df6a4f" xlink:to="loc_lly_EddingpharmMember_c948f9c6-6c2e-4f9d-9189-490c129abb34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a3c6af9f-1a65-400a-8db3-dd7d8245ff24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a3c6af9f-1a65-400a-8db3-dd7d8245ff24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c6af9f-1a65-400a-8db3-dd7d8245ff24_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a3c6af9f-1a65-400a-8db3-dd7d8245ff24" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3c6af9f-1a65-400a-8db3-dd7d8245ff24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a3c6af9f-1a65-400a-8db3-dd7d8245ff24" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_29dd77b1-b728-4bc8-9f31-9bbeaee8d600" xlink:href="lly-20201231.xsd#lly_DermiraInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_DermiraInc.Member_29dd77b1-b728-4bc8-9f31-9bbeaee8d600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_5e22989e-69f3-4f50-97c5-ab22e98ff045" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_LoxoOncologyInc.Member_5e22989e-69f3-4f50-97c5-ab22e98ff045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBioSciencesIncMember_4e20919f-080e-4b96-8e4c-db51161555ec" xlink:href="lly-20201231.xsd#lly_PrecisionBioSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_PrecisionBioSciencesIncMember_4e20919f-080e-4b96-8e4c-db51161555ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_c288d384-7ec9-403d-9d5d-781909979475" xlink:href="lly-20201231.xsd#lly_MerusNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_MerusNVMember_c288d384-7ec9-403d-9d5d-781909979475" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_f08f279d-6401-4666-a0e5-4a2e4c65d2ee" xlink:href="lly-20201231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_PrevailTherapeuticsIncMember_f08f279d-6401-4666-a0e5-4a2e4c65d2ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember_56d2f9cf-fcf0-4f7a-a685-7cc5a675d6ae" xlink:href="lly-20201231.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_AsahiKaseiPharmaCorporationMember_56d2f9cf-fcf0-4f7a-a685-7cc5a675d6ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cb572c79-ac81-40a1-a5c0-d6f2986f914f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_srt_ProductOrServiceAxis_cb572c79-ac81-40a1-a5c0-d6f2986f914f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cb572c79-ac81-40a1-a5c0-d6f2986f914f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cb572c79-ac81-40a1-a5c0-d6f2986f914f" xlink:to="loc_srt_ProductsAndServicesDomain_cb572c79-ac81-40a1-a5c0-d6f2986f914f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1f9c1df-dacd-4894-a90e-2f8138040856" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cb572c79-ac81-40a1-a5c0-d6f2986f914f" xlink:to="loc_srt_ProductsAndServicesDomain_f1f9c1df-dacd-4894-a90e-2f8138040856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_8e98b0aa-5f9a-4a7c-937e-d4efafc02a92" xlink:href="lly-20201231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1f9c1df-dacd-4894-a90e-2f8138040856" xlink:to="loc_lly_SelpercatinibLOXO292Member_8e98b0aa-5f9a-4a7c-937e-d4efafc02a92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_948ed60c-06fa-4b6a-8068-31d1eb80f52c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_srt_StatementScenarioAxis_948ed60c-06fa-4b6a-8068-31d1eb80f52c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_948ed60c-06fa-4b6a-8068-31d1eb80f52c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_948ed60c-06fa-4b6a-8068-31d1eb80f52c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_948ed60c-06fa-4b6a-8068-31d1eb80f52c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6ebd7959-7e0d-4e84-a707-163f4e6f2c96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_948ed60c-06fa-4b6a-8068-31d1eb80f52c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6ebd7959-7e0d-4e84-a707-163f4e6f2c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2bb76717-59b0-4e8d-b757-dd93145a146c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6ebd7959-7e0d-4e84-a707-163f4e6f2c96" xlink:to="loc_srt_ScenarioForecastMember_2bb76717-59b0-4e8d-b757-dd93145a146c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetAcquisitionAxis_0b767d31-6aec-44ae-bf5d-9f9dd591f067" xlink:href="lly-20201231.xsd#lly_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_lly_AssetAcquisitionAxis_0b767d31-6aec-44ae-bf5d-9f9dd591f067" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetAcquisitionDomain_0b767d31-6aec-44ae-bf5d-9f9dd591f067_default" xlink:href="lly-20201231.xsd#lly_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_AssetAcquisitionAxis_0b767d31-6aec-44ae-bf5d-9f9dd591f067" xlink:to="loc_lly_AssetAcquisitionDomain_0b767d31-6aec-44ae-bf5d-9f9dd591f067_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetAcquisitionDomain_f9e45b84-0197-496b-bf20-99437d3b2f56" xlink:href="lly-20201231.xsd#lly_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_AssetAcquisitionAxis_0b767d31-6aec-44ae-bf5d-9f9dd591f067" xlink:to="loc_lly_AssetAcquisitionDomain_f9e45b84-0197-496b-bf20-99437d3b2f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBioSciencesIncMember_545bcf3f-4562-4e4d-9ba4-2e90a27ff1d0" xlink:href="lly-20201231.xsd#lly_PrecisionBioSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_AssetAcquisitionDomain_f9e45b84-0197-496b-bf20-99437d3b2f56" xlink:to="loc_lly_PrecisionBioSciencesIncMember_545bcf3f-4562-4e4d-9ba4-2e90a27ff1d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_5b6496d0-b42b-441d-8604-219e7d74266c" xlink:href="lly-20201231.xsd#lly_MerusNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_AssetAcquisitionDomain_f9e45b84-0197-496b-bf20-99437d3b2f56" xlink:to="loc_lly_MerusNVMember_5b6496d0-b42b-441d-8604-219e7d74266c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestiturePurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="extended" id="iaea40d68afd04f8f891749030d56fbee_AcquisitionsandDivestiturePurchasePriceAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_7655b211-7011-43b7-807f-fa906580e2ff" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_7655b211-7011-43b7-807f-fa906580e2ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e1c5464e-cbf1-4cdf-b1ca-66416b47d468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e1c5464e-cbf1-4cdf-b1ca-66416b47d468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_daf9f486-302f-4cfd-a5c6-7c7b09c31cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_daf9f486-302f-4cfd-a5c6-7c7b09c31cbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_0266c633-92f0-4000-999c-bd31bdc81977" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_0266c633-92f0-4000-999c-bd31bdc81977" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c386893e-37e7-4a06-b2b4-bb8541e6be8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c386893e-37e7-4a06-b2b4-bb8541e6be8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_90a20990-3068-4feb-b82d-12d891da32fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_Goodwill_90a20990-3068-4feb-b82d-12d891da32fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_65c3ceea-7ed6-456b-99e0-21b5cddfe51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_65c3ceea-7ed6-456b-99e0-21b5cddfe51c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_039a740b-0e66-4324-9019-cf4e76f340bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_039a740b-0e66-4324-9019-cf4e76f340bb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_52d908a3-bbce-4f96-bdb3-5b3709b3125d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:to="loc_srt_ProductOrServiceAxis_52d908a3-bbce-4f96-bdb3-5b3709b3125d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52d908a3-bbce-4f96-bdb3-5b3709b3125d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_52d908a3-bbce-4f96-bdb3-5b3709b3125d" xlink:to="loc_srt_ProductsAndServicesDomain_52d908a3-bbce-4f96-bdb3-5b3709b3125d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e978c7e5-d7e6-473b-a8bc-9a401a79297c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_52d908a3-bbce-4f96-bdb3-5b3709b3125d" xlink:to="loc_srt_ProductsAndServicesDomain_e978c7e5-d7e6-473b-a8bc-9a401a79297c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_46104873-1a35-4e30-be6d-f1dcde6f4669" xlink:href="lly-20201231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e978c7e5-d7e6-473b-a8bc-9a401a79297c" xlink:to="loc_lly_SelpercatinibLOXO292Member_46104873-1a35-4e30-be6d-f1dcde6f4669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e66bda37-8fc3-4c13-9cab-4892277d9fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e66bda37-8fc3-4c13-9cab-4892277d9fd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e66bda37-8fc3-4c13-9cab-4892277d9fd1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e66bda37-8fc3-4c13-9cab-4892277d9fd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e66bda37-8fc3-4c13-9cab-4892277d9fd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d7d89ae9-b166-4c9e-98e6-7732799d305b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e66bda37-8fc3-4c13-9cab-4892277d9fd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d7d89ae9-b166-4c9e-98e6-7732799d305b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_b437728d-492b-46d0-a241-b9c03ea61330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d7d89ae9-b166-4c9e-98e6-7732799d305b" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_b437728d-492b-46d0-a241-b9c03ea61330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8988dac7-674c-4b7b-9636-7d6b1c232c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8988dac7-674c-4b7b-9636-7d6b1c232c28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8988dac7-674c-4b7b-9636-7d6b1c232c28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8988dac7-674c-4b7b-9636-7d6b1c232c28" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8988dac7-674c-4b7b-9636-7d6b1c232c28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116af751-58a1-4b8f-89de-1b7ea12208a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8988dac7-674c-4b7b-9636-7d6b1c232c28" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116af751-58a1-4b8f-89de-1b7ea12208a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_1a198aff-ca76-406c-9aff-9a1975f7f230" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116af751-58a1-4b8f-89de-1b7ea12208a5" xlink:to="loc_lly_LoxoOncologyInc.Member_1a198aff-ca76-406c-9aff-9a1975f7f230" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureAssetAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="extended" id="ia161ef98b80a48c981fa74b111cb0f05_AcquisitionsandDivestitureAssetAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c2d95828-8985-4353-b601-26bd3d5aaeea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_83e38103-b1b4-4f32-b14c-b51bf9a31526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c2d95828-8985-4353-b601-26bd3d5aaeea" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_83e38103-b1b4-4f32-b14c-b51bf9a31526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa13e22-62c7-4707-a162-df5919949710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c2d95828-8985-4353-b601-26bd3d5aaeea" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa13e22-62c7-4707-a162-df5919949710" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4eee4757-28a0-4f1e-8e1e-a2b78981fd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa13e22-62c7-4707-a162-df5919949710" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4eee4757-28a0-4f1e-8e1e-a2b78981fd87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eee4757-28a0-4f1e-8e1e-a2b78981fd87_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4eee4757-28a0-4f1e-8e1e-a2b78981fd87" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4eee4757-28a0-4f1e-8e1e-a2b78981fd87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4eee4757-28a0-4f1e-8e1e-a2b78981fd87" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember_919aa3d9-a36c-4726-ac2c-3a5629e3aa44" xlink:href="lly-20201231.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_SitryxTherapeuticsLimitedMember_919aa3d9-a36c-4726-ac2c-3a5629e3aa44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_c493e44c-c09d-43de-a23b-6f70b0712f78" xlink:href="lly-20201231.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_c493e44c-c09d-43de-a23b-6f70b0712f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_9dc12937-5670-47a2-b303-7559cda75a59" xlink:href="lly-20201231.xsd#lly_JunshiBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_JunshiBiosciencesMember_9dc12937-5670-47a2-b303-7559cda75a59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UndisclosedAssetAcquisitionMember_deb8592a-29e6-4042-a05f-2b72c1336281" xlink:href="lly-20201231.xsd#lly_UndisclosedAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_UndisclosedAssetAcquisitionMember_deb8592a-29e6-4042-a05f-2b72c1336281" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember_4fe5bbb4-8c3a-4783-8cfc-b17ddbb2d0d6" xlink:href="lly-20201231.xsd#lly_EvoxTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_EvoxTherapeuticsMember_4fe5bbb4-8c3a-4783-8cfc-b17ddbb2d0d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_60a40347-315d-49c0-ab1c-a7931c915955" xlink:href="lly-20201231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_InnoventBiologicsIncMember_60a40347-315d-49c0-ab1c-a7931c915955" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember_a035ee10-7912-4d6c-b804-0bc968be7d5e" xlink:href="lly-20201231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_DisarmTherapeuticsIncMember_a035ee10-7912-4d6c-b804-0bc968be7d5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FochonPharmaceuticalsLtdMember_f688aea7-e44d-4852-908c-ba5459348305" xlink:href="lly-20201231.xsd#lly_FochonPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_FochonPharmaceuticalsLtdMember_f688aea7-e44d-4852-908c-ba5459348305" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ACImmuneSAMember_3209b12f-a86b-4d9d-b76a-d7634a1db6aa" xlink:href="lly-20201231.xsd#lly_ACImmuneSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_ACImmuneSAMember_3209b12f-a86b-4d9d-b76a-d7634a1db6aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmuNextInc.Member_e13a7606-b33f-4564-bffa-234f01278e7b" xlink:href="lly-20201231.xsd#lly_ImmuNextInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_ImmuNextInc.Member_e13a7606-b33f-4564-bffa-234f01278e7b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvidityBiosciencesInc.Member_ee9657bd-d41a-401b-9f56-8eede1f96186" xlink:href="lly-20201231.xsd#lly_AvidityBiosciencesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_AvidityBiosciencesInc.Member_ee9657bd-d41a-401b-9f56-8eede1f96186" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CentrexionTherapeuticsCorporationMember_efedfb02-ed7a-470a-9eac-185e0577d851" xlink:href="lly-20201231.xsd#lly_CentrexionTherapeuticsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_CentrexionTherapeuticsCorporationMember_efedfb02-ed7a-470a-9eac-185e0577d851" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SigilonTherapeuticsMember_cf5b513c-08b8-43d6-86e3-5c040cd540dd" xlink:href="lly-20201231.xsd#lly_SigilonTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_SigilonTherapeuticsMember_cf5b513c-08b8-43d6-86e3-5c040cd540dd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AurkaPharmaMember_67f49d77-b454-4f1b-b6dd-0d989a641df1" xlink:href="lly-20201231.xsd#lly_AurkaPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_AurkaPharmaMember_67f49d77-b454-4f1b-b6dd-0d989a641df1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ARMOBiosciencesInc.Member_ecf1a67c-3cae-4c55-a6c6-08d11f55498e" xlink:href="lly-20201231.xsd#lly_ARMOBiosciencesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_ARMOBiosciencesInc.Member_ecf1a67c-3cae-4c55-a6c6-08d11f55498e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AnimaBiotechMember_9c3fc43c-9ed6-4bb4-a391-2eadf1b01a7e" xlink:href="lly-20201231.xsd#lly_AnimaBiotechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_AnimaBiotechMember_9c3fc43c-9ed6-4bb4-a391-2eadf1b01a7e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SIGATechnologiesMember_4fefd56a-819f-4ca9-a392-3dc3699f5581" xlink:href="lly-20201231.xsd#lly_SIGATechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_SIGATechnologiesMember_4fefd56a-819f-4ca9-a392-3dc3699f5581" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ChugaiPharmaceuticalCompanyMember_4c85aa93-1692-40fb-b5e6-93d1e0b4db5b" xlink:href="lly-20201231.xsd#lly_ChugaiPharmaceuticalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_ChugaiPharmaceuticalCompanyMember_4c85aa93-1692-40fb-b5e6-93d1e0b4db5b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NextCureInc.Member_1b921ecc-558f-4236-99ef-4e3985861d28" xlink:href="lly-20201231.xsd#lly_NextCureInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_NextCureInc.Member_1b921ecc-558f-4236-99ef-4e3985861d28" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DicernaPharmaceuticalsMember_318e213a-91d6-4667-97bd-ab5320c4dd83" xlink:href="lly-20201231.xsd#lly_DicernaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_DicernaPharmaceuticalsMember_318e213a-91d6-4667-97bd-ab5320c4dd83" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HydraBiosciencesMember_cd6b7f49-1f6c-4cd7-a155-cb406d61a8dc" xlink:href="lly-20201231.xsd#lly_HydraBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_HydraBiosciencesMember_cd6b7f49-1f6c-4cd7-a155-cb406d61a8dc" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangements"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended" id="idfd8b3651cf946a59654e9fddffcf339_CollaborationsandOtherArrangements"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended" id="idf6f674a697a4872a6c9cb490dd8a723_CollaborationsandOtherArrangementsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended" id="ib63a9099ca76482e953b7f5baebfe6ba_CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66ce37dc-d405-4567-9dfe-82ec233e9bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_bc1d4bc6-fe8f-4f57-9997-63fdb986427d" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66ce37dc-d405-4567-9dfe-82ec233e9bac" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_bc1d4bc6-fe8f-4f57-9997-63fdb986427d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66ce37dc-d405-4567-9dfe-82ec233e9bac" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_870eb035-3bc6-48c6-8216-451f966175eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:to="loc_us-gaap_TypeOfArrangementAxis_870eb035-3bc6-48c6-8216-451f966175eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_870eb035-3bc6-48c6-8216-451f966175eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_870eb035-3bc6-48c6-8216-451f966175eb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_870eb035-3bc6-48c6-8216-451f966175eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_334b7aa7-4ad3-4d9f-98e6-5708a72ce098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_870eb035-3bc6-48c6-8216-451f966175eb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_334b7aa7-4ad3-4d9f-98e6-5708a72ce098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_d13a96ba-ee70-421e-98b0-b9475336f0bf" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_334b7aa7-4ad3-4d9f-98e6-5708a72ce098" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_d13a96ba-ee70-421e-98b0-b9475336f0bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80a0687e-7277-47f3-932f-940f9718be29" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:to="loc_srt_ProductOrServiceAxis_80a0687e-7277-47f3-932f-940f9718be29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80a0687e-7277-47f3-932f-940f9718be29_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_80a0687e-7277-47f3-932f-940f9718be29" xlink:to="loc_srt_ProductsAndServicesDomain_80a0687e-7277-47f3-932f-940f9718be29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_80a0687e-7277-47f3-932f-940f9718be29" xlink:to="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_97ce74f8-12e6-4316-86ea-da6592d42052" xlink:href="lly-20201231.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:to="loc_lly_TrajentaBIMember_97ce74f8-12e6-4316-86ea-da6592d42052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_cb3e8116-212c-497b-a8dd-d1ffdb6b1a2c" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:to="loc_lly_JardianceMember_cb3e8116-212c-497b-a8dd-d1ffdb6b1a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_f9d0dbbd-5cd0-4a14-8fac-5bfc15769d4b" xlink:href="lly-20201231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:to="loc_lly_BasaglarMember_f9d0dbbd-5cd0-4a14-8fac-5bfc15769d4b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended" id="i80037e0f0a0b4b86a1a13f77b433604d_CollaborationsandOtherArrangementsNetProductRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c63b4d8-84d4-4c6a-a9f4-49a7b1f0ccd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a1645c0-31da-411f-86c8-8e7c18aae84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c63b4d8-84d4-4c6a-a9f4-49a7b1f0ccd1" xlink:to="loc_us-gaap_Revenues_4a1645c0-31da-411f-86c8-8e7c18aae84d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44e6c52b-8068-45a4-ac46-623e365013ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c63b4d8-84d4-4c6a-a9f4-49a7b1f0ccd1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44e6c52b-8068-45a4-ac46-623e365013ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44e6c52b-8068-45a4-ac46-623e365013ce" xlink:to="loc_srt_ProductOrServiceAxis_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce" xlink:to="loc_srt_ProductsAndServicesDomain_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce" xlink:to="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_2245f154-2cca-4027-a09c-2476c7635fb7" xlink:href="lly-20201231.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:to="loc_lly_BasaglarMember_2245f154-2cca-4027-a09c-2476c7635fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_b481f150-d979-4fbf-8a24-f7bb3087bf25" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:to="loc_lly_JardianceMember_b481f150-d979-4fbf-8a24-f7bb3087bf25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_2d1a04b7-f272-4bd7-a956-9c12a4c82955" xlink:href="lly-20201231.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:to="loc_lly_TrajentaBIMember_2d1a04b7-f272-4bd7-a956-9c12a4c82955" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_cc9966e5-027b-40a4-b9b7-b1b888f55106" xlink:href="lly-20201231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:to="loc_lly_OlumiantMember_cc9966e5-027b-40a4-b9b7-b1b888f55106" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended" id="i577c63e1693743c49b7556201392576a_CollaborationsandOtherArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_c119e9fb-33b0-46d3-91b8-cbad5f4c711d" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_c119e9fb-33b0-46d3-91b8-cbad5f4c711d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_7211a385-5dc9-40d9-b611-f7a9d339e65a" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_7211a385-5dc9-40d9-b611-f7a9d339e65a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f2b41964-0fad-42e7-b151-ec67525c57ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f2b41964-0fad-42e7-b151-ec67525c57ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ff4181df-b6f4-41e1-96b8-f74d475ce9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_us-gaap_Revenues_ff4181df-b6f4-41e1-96b8-f74d475ce9e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_1b08f2ad-990d-4157-9369-3a9b7f86efd6" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_1b08f2ad-990d-4157-9369-3a9b7f86efd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6bfb2748-8cfd-4562-bb39-6e5d856bec67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6bfb2748-8cfd-4562-bb39-6e5d856bec67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_921f2359-22ae-4fdd-b702-d39739785503" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_srt_ProductOrServiceAxis_921f2359-22ae-4fdd-b702-d39739785503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_921f2359-22ae-4fdd-b702-d39739785503_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_921f2359-22ae-4fdd-b702-d39739785503" xlink:to="loc_srt_ProductsAndServicesDomain_921f2359-22ae-4fdd-b702-d39739785503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_921f2359-22ae-4fdd-b702-d39739785503" xlink:to="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_501fac1c-dfcd-4dc1-9ea5-698d3d4c95f8" xlink:href="lly-20201231.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_OlumiantMember_501fac1c-dfcd-4dc1-9ea5-698d3d4c95f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BamlanivimabMember_ee832149-a1eb-4340-9e08-d3ef2d65de34" xlink:href="lly-20201231.xsd#lly_BamlanivimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_BamlanivimabMember_ee832149-a1eb-4340-9e08-d3ef2d65de34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_cce9d954-677e-4cf6-a216-03d2997c2e8d" xlink:href="lly-20201231.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_TYVYTMember_cce9d954-677e-4cf6-a216-03d2997c2e8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TanezumabMember_b3bebe7a-52c7-47c3-b2c5-85f7fcb269f5" xlink:href="lly-20201231.xsd#lly_TanezumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_TanezumabMember_b3bebe7a-52c7-47c3-b2c5-85f7fcb269f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_835bd4b2-4aa7-4509-b1f9-f3f6dcea4397" xlink:href="lly-20201231.xsd#lly_LebrikizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_LebrikizumabMember_835bd4b2-4aa7-4509-b1f9-f3f6dcea4397" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a35e82c4-30e8-4f54-b2e8-47fb48e87fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a35e82c4-30e8-4f54-b2e8-47fb48e87fed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a35e82c4-30e8-4f54-b2e8-47fb48e87fed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a35e82c4-30e8-4f54-b2e8-47fb48e87fed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a35e82c4-30e8-4f54-b2e8-47fb48e87fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a35e82c4-30e8-4f54-b2e8-47fb48e87fed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_94cca5db-c286-429f-b184-d0202accb7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_94cca5db-c286-429f-b184-d0202accb7af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_675459c2-6422-4411-ae9f-9ff59a5b7e75" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_675459c2-6422-4411-ae9f-9ff59a5b7e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_975f6262-fdf7-43d5-830d-6ffc52b6b770" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_975f6262-fdf7-43d5-830d-6ffc52b6b770" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_cd1748b6-9368-4f93-a881-83e036d145c5" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_cd1748b6-9368-4f93-a881-83e036d145c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_15868057-0308-4347-9ae8-d8530dada784" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_cd1748b6-9368-4f93-a881-83e036d145c5" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_15868057-0308-4347-9ae8-d8530dada784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember_76892c16-0184-4315-a324-28e8907201b3" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_cd1748b6-9368-4f93-a881-83e036d145c5" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember_76892c16-0184-4315-a324-28e8907201b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e39fbaec-26da-48e7-b2b3-bfc1dc37f033" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_srt_StatementGeographicalAxis_e39fbaec-26da-48e7-b2b3-bfc1dc37f033" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e39fbaec-26da-48e7-b2b3-bfc1dc37f033_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e39fbaec-26da-48e7-b2b3-bfc1dc37f033" xlink:to="loc_srt_SegmentGeographicalDomain_e39fbaec-26da-48e7-b2b3-bfc1dc37f033_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e39fbaec-26da-48e7-b2b3-bfc1dc37f033" xlink:to="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember_1df20d58-f724-47cc-a2a0-c2ddb49f2d31" xlink:href="lly-20201231.xsd#lly_NonCHINAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:to="loc_lly_NonCHINAMember_1df20d58-f724-47cc-a2a0-c2ddb49f2d31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_787d630c-2cfe-4964-acea-b8cc74133e52" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:to="loc_country_CN_787d630c-2cfe-4964-acea-b8cc74133e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OutsideUSAndJapanMember_88a46f89-32d7-4ee8-a3cb-aa8054fd67ee" xlink:href="lly-20201231.xsd#lly_OutsideUSAndJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:to="loc_lly_OutsideUSAndJapanMember_88a46f89-32d7-4ee8-a3cb-aa8054fd67ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f010ee98-a244-4bd2-bde3-c86956e3f231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f010ee98-a244-4bd2-bde3-c86956e3f231" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f010ee98-a244-4bd2-bde3-c86956e3f231_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f010ee98-a244-4bd2-bde3-c86956e3f231" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f010ee98-a244-4bd2-bde3-c86956e3f231_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b723426d-487c-41fe-ba95-c1b6b1b2850c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f010ee98-a244-4bd2-bde3-c86956e3f231" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b723426d-487c-41fe-ba95-c1b6b1b2850c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_2ba90391-c74e-4b0e-b8e3-1c3e21b29442" xlink:href="lly-20201231.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b723426d-487c-41fe-ba95-c1b6b1b2850c" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_2ba90391-c74e-4b0e-b8e3-1c3e21b29442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_ee455604-98dc-4a4f-a787-072555e27d78" xlink:href="lly-20201231.xsd#lly_JunshiBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b723426d-487c-41fe-ba95-c1b6b1b2850c" xlink:to="loc_lly_JunshiBiosciencesMember_ee455604-98dc-4a4f-a787-072555e27d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c2c52750-83f4-4fcd-a7d8-02a7706a100e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_dei_LegalEntityAxis_c2c52750-83f4-4fcd-a7d8-02a7706a100e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c2c52750-83f4-4fcd-a7d8-02a7706a100e_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c2c52750-83f4-4fcd-a7d8-02a7706a100e" xlink:to="loc_dei_EntityDomain_c2c52750-83f4-4fcd-a7d8-02a7706a100e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_eeab41ed-cfac-4226-9db8-5fd300e9859c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c2c52750-83f4-4fcd-a7d8-02a7706a100e" xlink:to="loc_dei_EntityDomain_eeab41ed-cfac-4226-9db8-5fd300e9859c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_ee3a450b-2174-486d-8cf6-7abcd4b55826" xlink:href="lly-20201231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_eeab41ed-cfac-4226-9db8-5fd300e9859c" xlink:to="loc_lly_InnoventBiologicsIncMember_ee3a450b-2174-486d-8cf6-7abcd4b55826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_003e0c90-1bc8-412c-976f-4997b8533aa8" xlink:href="lly-20201231.xsd#lly_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_eeab41ed-cfac-4226-9db8-5fd300e9859c" xlink:to="loc_lly_RocheMember_003e0c90-1bc8-412c-976f-4997b8533aa8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended" id="ie9f063d3494e45ee90d68634cce318b9_AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended" id="i79d8eacf0811422b9e7bb03f3e7e77f1_AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended" id="i80fecc9da905445086946ba2d9cc8ab6_AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="extended" id="ib7c7b01dc44f480ab01dfd074d01d621_AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0007f5d5-593e-4375-a41a-39f47bcfe393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_a5bc149c-78ab-49fe-9ca4-5b8cf393a599" xlink:href="lly-20201231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0007f5d5-593e-4375-a41a-39f47bcfe393" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_a5bc149c-78ab-49fe-9ca4-5b8cf393a599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c5f905c6-21be-425d-8ee7-ac85ef8a2474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0007f5d5-593e-4375-a41a-39f47bcfe393" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c5f905c6-21be-425d-8ee7-ac85ef8a2474" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_19250c6b-4767-4fc0-8f40-bc2e6030b19c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c5f905c6-21be-425d-8ee7-ac85ef8a2474" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_19250c6b-4767-4fc0-8f40-bc2e6030b19c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19250c6b-4767-4fc0-8f40-bc2e6030b19c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19250c6b-4767-4fc0-8f40-bc2e6030b19c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19250c6b-4767-4fc0-8f40-bc2e6030b19c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fac00ae-0643-40d8-9f5f-8184b170b527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19250c6b-4767-4fc0-8f40-bc2e6030b19c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fac00ae-0643-40d8-9f5f-8184b170b527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_e4e9e0ab-c356-4bdf-a979-9f619e46f2c3" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fac00ae-0643-40d8-9f5f-8184b170b527" xlink:to="loc_lly_LoxoOncologyInc.Member_e4e9e0ab-c356-4bdf-a979-9f619e46f2c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Inventories" xlink:type="simple" xlink:href="lly-20201231.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/Inventories" xlink:type="extended" id="iab659cda78de4bf6a4f39d4898f28238_Inventories"/>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/InventoriesTables" xlink:type="extended" id="i6149c033d6274fe5972c1835afdc877d_InventoriesTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#InventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/InventoriesDetails" xlink:type="extended" id="ifaa9f31973d34308bbe4e28213ac3b90_InventoriesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended" id="i8b280b2148b24dc188a130fdf31349cc_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended" id="i8d36c0403a514322888ff38de4d3dd01_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i3760b42bcd194faba72f472d319637e7_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_41a2311b-1073-4b50-b195-8c79e88e288b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_41a2311b-1073-4b50-b195-8c79e88e288b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_00d023da-1ae2-4ab3-8a1b-7f6d524fa524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_00d023da-1ae2-4ab3-8a1b-7f6d524fa524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_6e6c381f-1d50-49d4-88a4-b511a62f0d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_6e6c381f-1d50-49d4-88a4-b511a62f0d7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_5a36fc09-7cd1-4ef7-82d0-1b27ec31441a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_5a36fc09-7cd1-4ef7-82d0-1b27ec31441a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2dbde5f4-17f7-4908-baa5-be80754276fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_LongTermDebt_2dbde5f4-17f7-4908-baa5-be80754276fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_0015c66c-ae7c-4f08-a701-2a4dbec89878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_0015c66c-ae7c-4f08-a701-2a4dbec89878" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_c6f6e21c-b310-49fd-974c-63ea18aa5862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_c6f6e21c-b310-49fd-974c-63ea18aa5862" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7bb14c19-1a69-4fc0-b6b1-526646efedf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7bb14c19-1a69-4fc0-b6b1-526646efedf6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bc170394-bf90-4c83-a227-101d58db805a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bc170394-bf90-4c83-a227-101d58db805a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_1401e234-da22-4fa5-a18a-25d545aa031e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_1401e234-da22-4fa5-a18a-25d545aa031e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_a4fa56bc-737d-4caf-a8fd-8bd10de958c8" xlink:href="lly-20201231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_a4fa56bc-737d-4caf-a8fd-8bd10de958c8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_88038ee0-295c-40c5-bce7-3524c79cf2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_88038ee0-295c-40c5-bce7-3524c79cf2ad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_d277339e-ef76-4c1d-8861-679f8b21953d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_d277339e-ef76-4c1d-8861-679f8b21953d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_7303e67a-f0fb-4c93-a681-641a9566fa0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_7303e67a-f0fb-4c93-a681-641a9566fa0c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e7cab13c-63e7-4c1e-9b59-fd43f2049031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e7cab13c-63e7-4c1e-9b59-fd43f2049031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e7cab13c-63e7-4c1e-9b59-fd43f2049031_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e7cab13c-63e7-4c1e-9b59-fd43f2049031" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e7cab13c-63e7-4c1e-9b59-fd43f2049031_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_6a734148-ce4a-4402-ad54-10af80e2437a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e7cab13c-63e7-4c1e-9b59-fd43f2049031" xlink:to="loc_us-gaap_HedgingRelationshipDomain_6a734148-ce4a-4402-ad54-10af80e2437a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9069cce1-b6c1-4fee-90b8-4ec39f6ed42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_6a734148-ce4a-4402-ad54-10af80e2437a" xlink:to="loc_us-gaap_CashFlowHedgingMember_9069cce1-b6c1-4fee-90b8-4ec39f6ed42b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6442544a-365e-4e41-869b-05ad9223d6a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_HedgingDesignationAxis_6442544a-365e-4e41-869b-05ad9223d6a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6442544a-365e-4e41-869b-05ad9223d6a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6442544a-365e-4e41-869b-05ad9223d6a7" xlink:to="loc_us-gaap_HedgingDesignationDomain_6442544a-365e-4e41-869b-05ad9223d6a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d7546244-0340-4908-83be-a001edb5f0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6442544a-365e-4e41-869b-05ad9223d6a7" xlink:to="loc_us-gaap_HedgingDesignationDomain_d7546244-0340-4908-83be-a001edb5f0bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0a4619fc-f023-41dd-9099-44c4aaab60d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d7546244-0340-4908-83be-a001edb5f0bb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0a4619fc-f023-41dd-9099-44c4aaab60d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3bf05728-a700-47f9-8516-a96418ec29b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3bf05728-a700-47f9-8516-a96418ec29b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3bf05728-a700-47f9-8516-a96418ec29b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3bf05728-a700-47f9-8516-a96418ec29b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3bf05728-a700-47f9-8516-a96418ec29b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a76b1746-4364-4ef7-a6c9-e32cff3a530a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3bf05728-a700-47f9-8516-a96418ec29b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a76b1746-4364-4ef7-a6c9-e32cff3a530a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_49f5de81-4247-444f-bfaf-8004f9b452b6" xlink:href="lly-20201231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a76b1746-4364-4ef7-a6c9-e32cff3a530a" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_49f5de81-4247-444f-bfaf-8004f9b452b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_38687c4c-2e76-4663-b312-ad94ae7d4fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_38687c4c-2e76-4663-b312-ad94ae7d4fff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_38687c4c-2e76-4663-b312-ad94ae7d4fff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38687c4c-2e76-4663-b312-ad94ae7d4fff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_38687c4c-2e76-4663-b312-ad94ae7d4fff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38687c4c-2e76-4663-b312-ad94ae7d4fff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember_b5eb234a-75cc-445f-8af9-0c1b205aff5f" xlink:href="lly-20201231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_BuyUsdSellEuroMember_b5eb234a-75cc-445f-8af9-0c1b205aff5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_127ed22c-63b1-454c-8299-3b164e677b57" xlink:href="lly-20201231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_BuyEuroSellUsDollarMember_127ed22c-63b1-454c-8299-3b164e677b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_a029f8b3-ead5-48db-8997-cb1e29583ddc" xlink:href="lly-20201231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_a029f8b3-ead5-48db-8997-cb1e29583ddc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember_31e24947-7e79-4477-b702-51a67222a390" xlink:href="lly-20201231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_BuyGBPSellUSDMember_31e24947-7e79-4477-b702-51a67222a390" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_d7f3fc25-c293-4c9f-9109-da7343fb5d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_us-gaap_CurrencySwapMember_d7f3fc25-c293-4c9f-9109-da7343fb5d13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_897f4174-aed4-4ed7-abef-edfdcbdff094" xlink:href="lly-20201231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_897f4174-aed4-4ed7-abef-edfdcbdff094" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b2a91781-8165-44c7-98b2-e083f5c4ba75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_us-gaap_InterestRateSwapMember_b2a91781-8165-44c7-98b2-e083f5c4ba75" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended" id="i8afef6533bff43e6ad8cc54014092776_FinancialInstrumentsScheduleofEffectofRiskManagementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_78912367-2a80-45b4-861c-7dda096a9011" xlink:href="lly-20201231.xsd#lly_FairValueHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_lly_FairValueHedgeAbstract_78912367-2a80-45b4-861c-7dda096a9011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e9380273-18f2-44e9-a01b-7da8cf4d1619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_78912367-2a80-45b4-861c-7dda096a9011" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e9380273-18f2-44e9-a01b-7da8cf4d1619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_493ad92c-515d-4fd4-a317-0914ae479c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_78912367-2a80-45b4-861c-7dda096a9011" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_493ad92c-515d-4fd4-a317-0914ae479c4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_21f63270-1122-418e-b3d6-4cb6882e4a97" xlink:href="lly-20201231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_lly_CashFlowHedgeAbstract_21f63270-1122-418e-b3d6-4cb6882e4a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_aa5658b7-9e4f-433d-9bdf-aa64b3f15c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_CashFlowHedgeAbstract_21f63270-1122-418e-b3d6-4cb6882e4a97" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_aa5658b7-9e4f-433d-9bdf-aa64b3f15c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_a83610ad-0341-425d-be44-d73b01ec8f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_CashFlowHedgeAbstract_21f63270-1122-418e-b3d6-4cb6882e4a97" xlink:to="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_a83610ad-0341-425d-be44-d73b01ec8f18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f4d40d07-e95f-4ea8-a66b-df1a72b3c51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f4d40d07-e95f-4ea8-a66b-df1a72b3c51c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_80e7df07-63e4-4c54-b875-d0a356bccb64" xlink:href="lly-20201231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_80e7df07-63e4-4c54-b875-d0a356bccb64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1186a26c-4760-4b98-8472-eb5c61a09e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1186a26c-4760-4b98-8472-eb5c61a09e47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7c814d36-8311-49ee-9a97-a2a285256e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7c814d36-8311-49ee-9a97-a2a285256e70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_4922c10e-f273-466a-84ab-c46a58614398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_4922c10e-f273-466a-84ab-c46a58614398" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:to="loc_us-gaap_HedgingDesignationAxis_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5" xlink:to="loc_us-gaap_HedgingDesignationDomain_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_35f75017-aad4-4d97-b5f6-8bfb27cbfb60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5" xlink:to="loc_us-gaap_HedgingDesignationDomain_35f75017-aad4-4d97-b5f6-8bfb27cbfb60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_072135c9-cffe-4271-a910-85a7ded951f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_35f75017-aad4-4d97-b5f6-8bfb27cbfb60" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_072135c9-cffe-4271-a910-85a7ded951f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1b95e69a-3a10-49f8-8209-fe3aea62a5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_35f75017-aad4-4d97-b5f6-8bfb27cbfb60" xlink:to="loc_us-gaap_NondesignatedMember_1b95e69a-3a10-49f8-8209-fe3aea62a5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_400194c2-2714-4e91-bf22-f843830bb97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_400194c2-2714-4e91-bf22-f843830bb97c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_400194c2-2714-4e91-bf22-f843830bb97c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_400194c2-2714-4e91-bf22-f843830bb97c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_400194c2-2714-4e91-bf22-f843830bb97c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ffeaad6c-3890-4d1b-adee-ebe4037a0e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_400194c2-2714-4e91-bf22-f843830bb97c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ffeaad6c-3890-4d1b-adee-ebe4037a0e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_194129eb-c7b3-49e3-9eeb-4fd89fc39647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ffeaad6c-3890-4d1b-adee-ebe4037a0e69" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_194129eb-c7b3-49e3-9eeb-4fd89fc39647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c079e3a9-aa77-4f92-875b-5371962f54c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ffeaad6c-3890-4d1b-adee-ebe4037a0e69" xlink:to="loc_us-gaap_CashFlowHedgingMember_c079e3a9-aa77-4f92-875b-5371962f54c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_ce7fbc2f-997a-4543-a2c2-20a2abf816cf" xlink:href="lly-20201231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_lly_HedgedFixedRateDebtMember_ce7fbc2f-997a-4543-a2c2-20a2abf816cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_b8a20fdd-0cad-493a-973a-8cc72cdbe83b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_us-gaap_InterestRateContractMember_b8a20fdd-0cad-493a-973a-8cc72cdbe83b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1ebdb07e-fb79-49e8-84ca-426ecfd66435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1ebdb07e-fb79-49e8-84ca-426ecfd66435" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_0ad91bc7-607d-428f-9d03-e89fd0d4b0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_us-gaap_InterestRateSwapMember_0ad91bc7-607d-428f-9d03-e89fd0d4b0bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_5c5c630b-d525-4d87-af1f-76e31a125214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_5c5c630b-d525-4d87-af1f-76e31a125214" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended" id="ic26f2bff70104551a0423dfc01869fcb_FinancialInstrumentsScheduleofFairValueMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a28d63e9-be71-4a86-8cf9-4501df3f2d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a28d63e9-be71-4a86-8cf9-4501df3f2d06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_9d5b1514-5dcd-4fbc-933d-bccc21317f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_9d5b1514-5dcd-4fbc-933d-bccc21317f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_632f0e42-6ef0-412b-8e22-54402ae308d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_9d5b1514-5dcd-4fbc-933d-bccc21317f8e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_632f0e42-6ef0-412b-8e22-54402ae308d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_218459ad-bf34-46fb-9385-b030eb815f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_218459ad-bf34-46fb-9385-b030eb815f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_862b45be-b806-4e36-b9ca-186e12e2c05b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_862b45be-b806-4e36-b9ca-186e12e2c05b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_507f4ea9-002a-4e0e-8319-43c1d129faa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_507f4ea9-002a-4e0e-8319-43c1d129faa7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_ea3dcc23-8be3-4b73-b2a7-1713b636290f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_OtherLongTermInvestments_ea3dcc23-8be3-4b73-b2a7-1713b636290f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_7955e9ae-60e1-4150-974e-a2d99974487f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_LongTermInvestments_7955e9ae-60e1-4150-974e-a2d99974487f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b3f9f593-83c6-4e39-bdc6-2501c718831e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b3f9f593-83c6-4e39-bdc6-2501c718831e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b3f9f593-83c6-4e39-bdc6-2501c718831e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b3f9f593-83c6-4e39-bdc6-2501c718831e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b3f9f593-83c6-4e39-bdc6-2501c718831e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b3f9f593-83c6-4e39-bdc6-2501c718831e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3c962fea-1032-45ce-9611-a235be8bc88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3c962fea-1032-45ce-9611-a235be8bc88f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f5ca9c7a-f320-4699-a6f7-540411ab30cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f5ca9c7a-f320-4699-a6f7-540411ab30cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d88cf72f-08bd-4108-a02e-0211864f5126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d88cf72f-08bd-4108-a02e-0211864f5126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_7f0b5a65-42a6-4b88-b87a-0ac1dec1b0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_7f0b5a65-42a6-4b88-b87a-0ac1dec1b0ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_c555876b-9ba9-4cc4-a9b3-f54e64361c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_c555876b-9ba9-4cc4-a9b3-f54e64361c19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_be9934ff-f8ff-443e-ab82-1fc80589299c" xlink:href="lly-20201231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_lly_OtherEquitySecuritiesMember_be9934ff-f8ff-443e-ab82-1fc80589299c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_9046a3e0-bb06-43e7-b6ae-e97cc96c258f" xlink:href="lly-20201231.xsd#lly_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_lly_MarketableSecuritiesMember_9046a3e0-bb06-43e7-b6ae-e97cc96c258f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_cbb64d01-df21-4aac-b19c-c83049fa0305" xlink:href="lly-20201231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_cbb64d01-df21-4aac-b19c-c83049fa0305" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_7a8728c7-3cee-409e-90d7-f04c3b494e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_7a8728c7-3cee-409e-90d7-f04c3b494e51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7a8728c7-3cee-409e-90d7-f04c3b494e51_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7a8728c7-3cee-409e-90d7-f04c3b494e51" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_7a8728c7-3cee-409e-90d7-f04c3b494e51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7a8728c7-3cee-409e-90d7-f04c3b494e51" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c2a447a2-7daa-4e1d-9ef4-d7f947f0131b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c2a447a2-7daa-4e1d-9ef4-d7f947f0131b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_17c3ef97-03a4-4ff9-917e-539fd00cb1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_17c3ef97-03a4-4ff9-917e-539fd00cb1b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_e6fddf49-0060-4606-a3cb-9bc6a09a3bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_e6fddf49-0060-4606-a3cb-9bc6a09a3bfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_df021bab-977d-4847-a68f-4bf4fdd4191a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_df021bab-977d-4847-a68f-4bf4fdd4191a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dcc344c-f996-49fa-91b0-13a038c2d8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dcc344c-f996-49fa-91b0-13a038c2d8e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9dcc344c-f996-49fa-91b0-13a038c2d8e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dcc344c-f996-49fa-91b0-13a038c2d8e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9dcc344c-f996-49fa-91b0-13a038c2d8e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dcc344c-f996-49fa-91b0-13a038c2d8e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d59384f8-1cb2-46b5-a0c9-574e2227fdce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d59384f8-1cb2-46b5-a0c9-574e2227fdce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_56f00ad0-23a4-4a5d-acc2-615b275c4c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_56f00ad0-23a4-4a5d-acc2-615b275c4c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0bec89f5-9d2d-4834-b297-c245805f0763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0bec89f5-9d2d-4834-b297-c245805f0763" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended" id="id5474125675c4b3aad6a98cb724d88ec_FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3409fad6-ca0e-4a10-86ec-3e52691e940a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_0b3f123d-6c45-4621-a08d-e4505d3f59d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3409fad6-ca0e-4a10-86ec-3e52691e940a" xlink:to="loc_us-gaap_CommercialPaper_0b3f123d-6c45-4621-a08d-e4505d3f59d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8e62fda2-80cb-4ba0-9e69-ebca93b05dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3409fad6-ca0e-4a10-86ec-3e52691e940a" xlink:to="loc_us-gaap_LongTermDebt_8e62fda2-80cb-4ba0-9e69-ebca93b05dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3409fad6-ca0e-4a10-86ec-3e52691e940a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_77b6cc90-331b-4204-86a3-be048ee22a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_77b6cc90-331b-4204-86a3-be048ee22a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_77b6cc90-331b-4204-86a3-be048ee22a9d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_77b6cc90-331b-4204-86a3-be048ee22a9d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_77b6cc90-331b-4204-86a3-be048ee22a9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_06b4232e-8b9e-4285-a883-3d94c7789f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_77b6cc90-331b-4204-86a3-be048ee22a9d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_06b4232e-8b9e-4285-a883-3d94c7789f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_492a06d1-a59a-4510-ba00-1c0ecef95e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_06b4232e-8b9e-4285-a883-3d94c7789f38" xlink:to="loc_us-gaap_CommercialPaperMember_492a06d1-a59a-4510-ba00-1c0ecef95e7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44746e6d-ed00-48c0-a669-6b229391cd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44746e6d-ed00-48c0-a669-6b229391cd4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44746e6d-ed00-48c0-a669-6b229391cd4c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44746e6d-ed00-48c0-a669-6b229391cd4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44746e6d-ed00-48c0-a669-6b229391cd4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44746e6d-ed00-48c0-a669-6b229391cd4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e02bf01c-3c42-4cfa-b1ef-14cca2f500e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e02bf01c-3c42-4cfa-b1ef-14cca2f500e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_76c49c54-b392-49a5-9db1-8696472e1903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_76c49c54-b392-49a5-9db1-8696472e1903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_89a64327-98a2-435b-a955-fcc69ea49ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_89a64327-98a2-435b-a955-fcc69ea49ffd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_10023e97-7a02-42d5-ac59-c98dc7fa36d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_10023e97-7a02-42d5-ac59-c98dc7fa36d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_10023e97-7a02-42d5-ac59-c98dc7fa36d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_10023e97-7a02-42d5-ac59-c98dc7fa36d6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_10023e97-7a02-42d5-ac59-c98dc7fa36d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_10023e97-7a02-42d5-ac59-c98dc7fa36d6" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_979a0db4-9fdc-412b-959f-b8912902e1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_979a0db4-9fdc-412b-959f-b8912902e1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_34b80fae-d59d-426d-ab38-ae34b638f73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_34b80fae-d59d-426d-ab38-ae34b638f73a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9fd40522-1723-4e6e-a02a-d7ec92be3f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9fd40522-1723-4e6e-a02a-d7ec92be3f43" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended" id="i52ed81213ef346c0a08a95ee07e01e44_FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_c06e0aaa-61df-4bfa-a161-452105961773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_c06e0aaa-61df-4bfa-a161-452105961773" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_ea55a290-b366-44e4-8c2c-edb9b078e680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_ea55a290-b366-44e4-8c2c-edb9b078e680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_87365ffe-646e-4431-87e9-a7909ff2bc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_87365ffe-646e-4431-87e9-a7909ff2bc3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_de9c8480-e0a8-4194-9e6c-11960ac50a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_de9c8480-e0a8-4194-9e6c-11960ac50a25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_152ba51c-fb98-46fc-8a28-cc5c66457b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_152ba51c-fb98-46fc-8a28-cc5c66457b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_152ba51c-fb98-46fc-8a28-cc5c66457b23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_152ba51c-fb98-46fc-8a28-cc5c66457b23" xlink:to="loc_us-gaap_HedgingRelationshipDomain_152ba51c-fb98-46fc-8a28-cc5c66457b23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_152ba51c-fb98-46fc-8a28-cc5c66457b23" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_ce04602b-0ab7-444f-918b-a14bb2e72754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:to="loc_us-gaap_FairValueHedgingMember_ce04602b-0ab7-444f-918b-a14bb2e72754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_84988b99-bfeb-4fce-b2a5-3828d8ba4ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:to="loc_us-gaap_CashFlowHedgingMember_84988b99-bfeb-4fce-b2a5-3828d8ba4ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_7762570b-ae69-4c49-9171-48cbda9b9a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_7762570b-ae69-4c49-9171-48cbda9b9a32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_aee0bbd4-249d-49e0-9a8e-2ae017261464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_aee0bbd4-249d-49e0-9a8e-2ae017261464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aee0bbd4-249d-49e0-9a8e-2ae017261464_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_aee0bbd4-249d-49e0-9a8e-2ae017261464" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aee0bbd4-249d-49e0-9a8e-2ae017261464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_aee0bbd4-249d-49e0-9a8e-2ae017261464" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6272fe78-42a0-4908-b095-1ce7f1852930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6272fe78-42a0-4908-b095-1ce7f1852930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_48bd50a4-9d97-4435-85a1-77c622d67d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_48bd50a4-9d97-4435-85a1-77c622d67d80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_50b08165-cf4c-44c9-9b42-5c30a1009b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_50b08165-cf4c-44c9-9b42-5c30a1009b2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ca3073bd-534a-4835-ab2d-6bebed5502d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_HedgingDesignationAxis_ca3073bd-534a-4835-ab2d-6bebed5502d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ca3073bd-534a-4835-ab2d-6bebed5502d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ca3073bd-534a-4835-ab2d-6bebed5502d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_ca3073bd-534a-4835-ab2d-6bebed5502d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_48fbdcee-87b1-49cb-a71f-861cc430a7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ca3073bd-534a-4835-ab2d-6bebed5502d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_48fbdcee-87b1-49cb-a71f-861cc430a7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3d971aa4-eb87-432a-912a-7ef82c0b1eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_48fbdcee-87b1-49cb-a71f-861cc430a7bb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3d971aa4-eb87-432a-912a-7ef82c0b1eae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_d0e246c8-3e1a-453c-9245-127b8163d68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_48fbdcee-87b1-49cb-a71f-861cc430a7bb" xlink:to="loc_us-gaap_NondesignatedMember_d0e246c8-3e1a-453c-9245-127b8163d68e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_eaba030c-dc86-4f82-a462-af4749036f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_eaba030c-dc86-4f82-a462-af4749036f0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_eaba030c-dc86-4f82-a462-af4749036f0c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_eaba030c-dc86-4f82-a462-af4749036f0c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_eaba030c-dc86-4f82-a462-af4749036f0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_eaba030c-dc86-4f82-a462-af4749036f0c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_e100de9c-2378-4e76-9ec0-e6bb8e4f98d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:to="loc_us-gaap_InterestRateContractMember_e100de9c-2378-4e76-9ec0-e6bb8e4f98d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_2ee6c2c0-4797-4803-8fb8-972a81ab791a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_2ee6c2c0-4797-4803-8fb8-972a81ab791a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d07cb286-a70d-495d-aa22-0e797afe8168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d07cb286-a70d-495d-aa22-0e797afe8168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14dce7d2-a810-4806-a944-bb6761d41b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14dce7d2-a810-4806-a944-bb6761d41b4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14dce7d2-a810-4806-a944-bb6761d41b4e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14dce7d2-a810-4806-a944-bb6761d41b4e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14dce7d2-a810-4806-a944-bb6761d41b4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14dce7d2-a810-4806-a944-bb6761d41b4e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_997aae69-9488-4f07-9f42-1e36bdef7c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_997aae69-9488-4f07-9f42-1e36bdef7c19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e6414c32-1fab-4cad-9264-3dcd6d7e99ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e6414c32-1fab-4cad-9264-3dcd6d7e99ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_915cad71-e044-42f8-8261-ad3367575e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_915cad71-e044-42f8-8261-ad3367575e1e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended" id="i665d04b51cfa401998255742ad00c158_FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" xlink:type="extended" id="if3331e072c374f8cb904082a08ee8b89_FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" xlink:type="extended" id="idbb5d80416f74863bbd362ffbe828a64_FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangibles"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="extended" id="i851abf2b25d8452fb7923bad96f0c9c6_GoodwillandOtherIntangibles"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended" id="i244b4b0a672244ffa059630ea2b6ee09_GoodwillandOtherIntangiblesTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended" id="ia6380fef0b3b40d3b5ebc4d9b564517b_GoodwillandOtherIntangiblesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e95271c5-1585-4eec-b016-481e348108a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e95271c5-1585-4eec-b016-481e348108a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_618d9961-fae1-4bb7-8a13-61fd13528ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_618d9961-fae1-4bb7-8a13-61fd13528ffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a3ff57c0-db0a-405c-941d-ab466af59665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a3ff57c0-db0a-405c-941d-ab466af59665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_13b56415-c805-400e-883f-1baf188eccc4" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_13b56415-c805-400e-883f-1baf188eccc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc7109ec-60aa-4e03-87d4-95fd91b67032" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:to="loc_srt_RangeAxis_bc7109ec-60aa-4e03-87d4-95fd91b67032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc7109ec-60aa-4e03-87d4-95fd91b67032_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bc7109ec-60aa-4e03-87d4-95fd91b67032" xlink:to="loc_srt_RangeMember_bc7109ec-60aa-4e03-87d4-95fd91b67032_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ffa86eec-ad34-45ee-aba6-ac3980813155" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bc7109ec-60aa-4e03-87d4-95fd91b67032" xlink:to="loc_srt_RangeMember_ffa86eec-ad34-45ee-aba6-ac3980813155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_be45109d-741b-4f3a-9201-f1008943ac71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ffa86eec-ad34-45ee-aba6-ac3980813155" xlink:to="loc_srt_MinimumMember_be45109d-741b-4f3a-9201-f1008943ac71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8c63a304-06ae-445c-b7f1-7316f10db836" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ffa86eec-ad34-45ee-aba6-ac3980813155" xlink:to="loc_srt_MaximumMember_8c63a304-06ae-445c-b7f1-7316f10db836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:to="loc_srt_ProductOrServiceAxis_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb" xlink:to="loc_srt_ProductsAndServicesDomain_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cefe3305-9f94-4188-aa9c-4e6e0802143c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb" xlink:to="loc_srt_ProductsAndServicesDomain_cefe3305-9f94-4188-aa9c-4e6e0802143c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_e22671f5-f5ef-455b-9d3a-6138d39d5b4a" xlink:href="lly-20201231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cefe3305-9f94-4188-aa9c-4e6e0802143c" xlink:to="loc_lly_SelpercatinibLOXO292Member_e22671f5-f5ef-455b-9d3a-6138d39d5b4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_636f8ffc-34ec-4e77-a1b8-7299560bda60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_636f8ffc-34ec-4e77-a1b8-7299560bda60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_636f8ffc-34ec-4e77-a1b8-7299560bda60_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636f8ffc-34ec-4e77-a1b8-7299560bda60" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_636f8ffc-34ec-4e77-a1b8-7299560bda60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22c8c2af-62c1-4bea-9926-d80444f444b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636f8ffc-34ec-4e77-a1b8-7299560bda60" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22c8c2af-62c1-4bea-9926-d80444f444b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_5781819c-7962-4d75-9787-d6cde1062fb4" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22c8c2af-62c1-4bea-9926-d80444f444b7" xlink:to="loc_lly_LoxoOncologyInc.Member_5781819c-7962-4d75-9787-d6cde1062fb4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended" id="i6c3d24b1139f492785cc8b316656daae_GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3c907ffc-f985-4e34-a3fb-c02fde161921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3c907ffc-f985-4e34-a3fb-c02fde161921" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_78ee7619-0512-4874-b780-f1fbe9a48759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_78ee7619-0512-4874-b780-f1fbe9a48759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_662f1024-5da3-4ee8-ad4f-22c740f1a787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_662f1024-5da3-4ee8-ad4f-22c740f1a787" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ff89a932-18b8-4e1f-a4aa-27379fe68530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ff89a932-18b8-4e1f-a4aa-27379fe68530" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ae13608d-eb3f-49cb-b9d6-10996394da40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ff89a932-18b8-4e1f-a4aa-27379fe68530" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ae13608d-eb3f-49cb-b9d6-10996394da40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae13608d-eb3f-49cb-b9d6-10996394da40_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ae13608d-eb3f-49cb-b9d6-10996394da40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae13608d-eb3f-49cb-b9d6-10996394da40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b7df04-0d98-451d-a221-03397d69973c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ae13608d-eb3f-49cb-b9d6-10996394da40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b7df04-0d98-451d-a221-03397d69973c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_785909dd-9148-432b-9444-cf2491a9efd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b7df04-0d98-451d-a221-03397d69973c" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_785909dd-9148-432b-9444-cf2491a9efd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1614095b-448e-49fa-b2bc-57087ace9669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b7df04-0d98-451d-a221-03397d69973c" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1614095b-448e-49fa-b2bc-57087ace9669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_22746d9a-2204-457f-9cae-55f600630995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_deaa4161-0b34-47aa-b250-db83fb96cd77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_22746d9a-2204-457f-9cae-55f600630995" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_deaa4161-0b34-47aa-b250-db83fb96cd77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2b22b754-011e-40d4-ae74-a3ba354062a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_22746d9a-2204-457f-9cae-55f600630995" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2b22b754-011e-40d4-ae74-a3ba354062a4" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2eb744c7-8a5f-4355-b404-bc45bbc207c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2b22b754-011e-40d4-ae74-a3ba354062a4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2eb744c7-8a5f-4355-b404-bc45bbc207c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2eb744c7-8a5f-4355-b404-bc45bbc207c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2eb744c7-8a5f-4355-b404-bc45bbc207c8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2eb744c7-8a5f-4355-b404-bc45bbc207c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7a7cc0f-d7a7-4008-82ea-0f97924245b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2eb744c7-8a5f-4355-b404-bc45bbc207c8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7a7cc0f-d7a7-4008-82ea-0f97924245b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d54c9443-3e85-4cf5-b0dd-4f8283384e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7a7cc0f-d7a7-4008-82ea-0f97924245b2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d54c9443-3e85-4cf5-b0dd-4f8283384e48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_55787350-ec3c-491a-9d87-13fd87966f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7a7cc0f-d7a7-4008-82ea-0f97924245b2" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_55787350-ec3c-491a-9d87-13fd87966f1d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="extended" id="if11c6a6a1ee640fc82f10806410e6ff5_GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="extended" id="i52eb68bc801244818a127a1a29c3807e_GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipment" xlink:type="extended" id="i8470f9a455c9490991a207f1333236b1_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="extended" id="i4ebf58d450aa40da9b9ca0fe95b91984_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended" id="i9165f882fffe4550a60533adacaa1d6b_PropertyandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d768187-3dd4-4b81-aaa8-c62a75572f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_03bfa824-9428-410d-bfa6-0d95702108f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d768187-3dd4-4b81-aaa8-c62a75572f16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_03bfa824-9428-410d-bfa6-0d95702108f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d768187-3dd4-4b81-aaa8-c62a75572f16" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9387a858-14c3-402c-8919-5f490750a628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9387a858-14c3-402c-8919-5f490750a628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9387a858-14c3-402c-8919-5f490750a628_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9387a858-14c3-402c-8919-5f490750a628" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9387a858-14c3-402c-8919-5f490750a628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ec54cfc-688f-413c-8283-e7b47dc4088d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9387a858-14c3-402c-8919-5f490750a628" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ec54cfc-688f-413c-8283-e7b47dc4088d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_7df73a64-4751-465b-99fd-3a22aa20b519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ec54cfc-688f-413c-8283-e7b47dc4088d" xlink:to="loc_us-gaap_BuildingMember_7df73a64-4751-465b-99fd-3a22aa20b519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_91119fb0-5686-4f95-8a54-b89ebb1df805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ec54cfc-688f-413c-8283-e7b47dc4088d" xlink:to="loc_us-gaap_EquipmentMember_91119fb0-5686-4f95-8a54-b89ebb1df805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1789b1a-edac-4f55-ba85-750f105cf475" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:to="loc_srt_RangeAxis_d1789b1a-edac-4f55-ba85-750f105cf475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1789b1a-edac-4f55-ba85-750f105cf475_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d1789b1a-edac-4f55-ba85-750f105cf475" xlink:to="loc_srt_RangeMember_d1789b1a-edac-4f55-ba85-750f105cf475_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e36e7dd6-dff3-4653-bf29-00401bfc8464" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d1789b1a-edac-4f55-ba85-750f105cf475" xlink:to="loc_srt_RangeMember_e36e7dd6-dff3-4653-bf29-00401bfc8464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_723b8a37-1fdb-4f36-9d6c-0ac6e1810492" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e36e7dd6-dff3-4653-bf29-00401bfc8464" xlink:to="loc_srt_MinimumMember_723b8a37-1fdb-4f36-9d6c-0ac6e1810492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1586951c-aa9a-45ae-83ce-03bc770f1fc1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e36e7dd6-dff3-4653-bf29-00401bfc8464" xlink:to="loc_srt_MaximumMember_1586951c-aa9a-45ae-83ce-03bc770f1fc1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="i5833ef063f7c42f3962a19cb42a66f22_PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofDepreciationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="extended" id="i51fd58337e2849ca870f7b3130ba4ad9_PropertyandEquipmentScheduleofDepreciationExpenseDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="extended" id="i0963c7f070ce433ebd9921574a444d37_PropertyandEquipmentScheduleofGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e1838f46-6063-4cad-8c94-2d312b69259d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_dde1fe89-a938-44aa-a379-8c1a2abd5acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e1838f46-6063-4cad-8c94-2d312b69259d" xlink:to="loc_us-gaap_NoncurrentAssets_dde1fe89-a938-44aa-a379-8c1a2abd5acd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30aeca4f-e284-4b1f-a8dc-5931c22fc135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e1838f46-6063-4cad-8c94-2d312b69259d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30aeca4f-e284-4b1f-a8dc-5931c22fc135" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30aeca4f-e284-4b1f-a8dc-5931c22fc135" xlink:to="loc_srt_StatementGeographicalAxis_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1" xlink:to="loc_srt_SegmentGeographicalDomain_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1" xlink:to="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember_a1074fee-ebac-4acb-8933-b0cc52abc84a" xlink:href="lly-20201231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:to="loc_lly_UNITEDSTATESAndPUERTORICOMember_a1074fee-ebac-4acb-8933-b0cc52abc84a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_75cacc6a-417e-4d34-8d20-24927c79d3e4" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:to="loc_country_IE_75cacc6a-417e-4d34-8d20-24927c79d3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_f816bb93-715e-4b4c-8802-df376633fe89" xlink:href="lly-20201231.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:to="loc_lly_OtherForeignCountriesMember_f816bb93-715e-4b4c-8802-df376633fe89" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Leases" xlink:type="simple" xlink:href="lly-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/Leases" xlink:type="extended" id="icc3c2512b49d48d39ed462b4f7cba22c_Leases"/>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/LeasesTables" xlink:type="extended" id="if94e4efa1b454c9094085145097d83c2_LeasesTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i6c3de65062a245eeb09ae725c66e7bb6_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="extended" id="i8ed601a637ca4ec0a9af5167d08beb7a_LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended" id="ifd4f807ddfdf4aa9b36430a650f959ad_LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Borrowings" xlink:type="simple" xlink:href="lly-20201231.xsd#Borrowings"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/Borrowings" xlink:type="extended" id="i3c646188b61a437d830e9ce67fdc2164_Borrowings"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsTables" xlink:type="extended" id="if750ed90cdda4b18b619ad70c663a2a6_BorrowingsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="extended" id="if78caefce0814f6394ebb2b1d4c6f4f1_BorrowingsScheduleofDebtDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended" id="i86e5297ce3f540df93a55b6c16a0b061_BorrowingsSummaryofLongtermNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6c3f5a58-1546-4838-9d77-42f4b4121694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6c3f5a58-1546-4838-9d77-42f4b4121694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f27daa6a-386f-46d4-aeb1-1795fd71285d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_NotesPayable_f27daa6a-386f-46d4-aeb1-1795fd71285d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ec204cee-7ecf-4a95-80b5-8b3aba592692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ec204cee-7ecf-4a95-80b5-8b3aba592692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3743459c-fdb0-4896-b8c5-e9f1472613b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3743459c-fdb0-4896-b8c5-e9f1472613b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_07d37a46-09ab-4f4c-863b-9aa7f402b9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_LongTermDebt_07d37a46-09ab-4f4c-863b-9aa7f402b9a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_396460c4-c602-46b6-b688-c297cfd7ac5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_396460c4-c602-46b6-b688-c297cfd7ac5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_396460c4-c602-46b6-b688-c297cfd7ac5e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_396460c4-c602-46b6-b688-c297cfd7ac5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_396460c4-c602-46b6-b688-c297cfd7ac5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba1f7c92-189b-48f4-b5af-52823402442c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_396460c4-c602-46b6-b688-c297cfd7ac5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba1f7c92-189b-48f4-b5af-52823402442c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5f56459f-0164-4a65-a800-12a95e876fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba1f7c92-189b-48f4-b5af-52823402442c" xlink:to="loc_us-gaap_SeniorNotesMember_5f56459f-0164-4a65-a800-12a95e876fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8c8036bf-e67e-4ea0-a579-72a67afb3abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:to="loc_us-gaap_DebtInstrumentAxis_8c8036bf-e67e-4ea0-a579-72a67afb3abb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8c8036bf-e67e-4ea0-a579-72a67afb3abb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8c8036bf-e67e-4ea0-a579-72a67afb3abb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8c8036bf-e67e-4ea0-a579-72a67afb3abb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8c8036bf-e67e-4ea0-a579-72a67afb3abb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member_64cce021-6c9d-49fd-8cdb-e68e7240a7c8" xlink:href="lly-20201231.xsd#lly_A235NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A235NotesDue2022Member_64cce021-6c9d-49fd-8cdb-e68e7240a7c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member_22a97083-2599-4d51-bb2c-8f4d82d36855" xlink:href="lly-20201231.xsd#lly_A30NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A30NotesDue2022Member_22a97083-2599-4d51-bb2c-8f4d82d36855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member_d1b21915-9125-408a-982d-a4affb6040f7" xlink:href="lly-20201231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A10EuroDenominatedNotesDue2022Member_d1b21915-9125-408a-982d-a4affb6040f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_d54e3cd1-8e67-4b1b-9005-449d8be3da5e" xlink:href="lly-20201231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_d54e3cd1-8e67-4b1b-9005-449d8be3da5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member_d178cd0a-1a3e-4e1e-b356-6d0a3e29224e" xlink:href="lly-20201231.xsd#lly_A7125NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A7125NotesDue2025Member_d178cd0a-1a3e-4e1e-b356-6d0a3e29224e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member_ccc7a710-6cc6-47d6-9557-4eeae4cea38e" xlink:href="lly-20201231.xsd#lly_A275NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A275NotesDue2025Member_ccc7a710-6cc6-47d6-9557-4eeae4cea38e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member_34e69f0f-b62b-481a-8c22-c5007da0c8e0" xlink:href="lly-20201231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A1625EuroDenominatedNotesDue2026Member_34e69f0f-b62b-481a-8c22-c5007da0c8e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member_e2ff3ef5-bad5-4e6c-b493-ed2f3f9ca829" xlink:href="lly-20201231.xsd#lly_A55NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A55NotesDue2027Member_e2ff3ef5-bad5-4e6c-b493-ed2f3f9ca829" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member_36e04b5d-0950-49d5-a253-89af9e4e69f9" xlink:href="lly-20201231.xsd#lly_A31NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A31NotesDue2027Member_36e04b5d-0950-49d5-a253-89af9e4e69f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_8ef4bd92-fb6d-415c-ba01-6af5b3f3e970" xlink:href="lly-20201231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_8ef4bd92-fb6d-415c-ba01-6af5b3f3e970" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_18a6f09a-3dee-4b79-acfd-b37c6753c402" xlink:href="lly-20201231.xsd#lly_A3375NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A3375NotesDue2029Member_18a6f09a-3dee-4b79-acfd-b37c6753c402" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_b63e28fa-9eca-44df-9ca7-1d37efb962e6" xlink:href="lly-20201231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_b63e28fa-9eca-44df-9ca7-1d37efb962e6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member_641c2a77-9a9d-4d92-ade6-ec9ae57f6c8e" xlink:href="lly-20201231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A2125EuroDenominatedNotesDue2030Member_641c2a77-9a9d-4d92-ade6-ec9ae57f6c8e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member_c672d432-6231-4c0f-a0c6-c7d145902926" xlink:href="lly-20201231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A625EuroDeonominatedNotesDue2031Member_c672d432-6231-4c0f-a0c6-c7d145902926" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_7fd00f9f-3c5b-4fac-a29c-8622e0c3db10" xlink:href="lly-20201231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_7fd00f9f-3c5b-4fac-a29c-8622e0c3db10" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member_0b53505e-bcf3-45c9-b314-d60b463fe1db" xlink:href="lly-20201231.xsd#lly_A677NotesDue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A677NotesDue2036Member_0b53505e-bcf3-45c9-b314-d60b463fe1db" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member_d5824e6d-5091-4db1-83d5-45f4398881fd" xlink:href="lly-20201231.xsd#lly_A555NotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A555NotesDue2037Member_d5824e6d-5091-4db1-83d5-45f4398881fd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member_61922efe-0082-4b5d-bd8c-5ab536f9aa0a" xlink:href="lly-20201231.xsd#lly_A595NotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A595NotesDue2037Member_61922efe-0082-4b5d-bd8c-5ab536f9aa0a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_29e5ab42-4367-4695-975b-585775d97c80" xlink:href="lly-20201231.xsd#lly_A3875NotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A3875NotesDue2039Member_29e5ab42-4367-4695-975b-585775d97c80" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member_301dd9ff-72d0-411f-bace-98a05ca96595" xlink:href="lly-20201231.xsd#lly_A465NotesDue2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A465NotesDue2044Member_301dd9ff-72d0-411f-bace-98a05ca96595" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member_63d37c96-d1f4-4e03-a799-0ad6c76a7912" xlink:href="lly-20201231.xsd#lly_A37NotesDue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A37NotesDue2045Member_63d37c96-d1f4-4e03-a799-0ad6c76a7912" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member_e98cc603-1ca7-48ce-acec-90f3295ef307" xlink:href="lly-20201231.xsd#lly_A395NotesDue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A395NotesDue2047Member_e98cc603-1ca7-48ce-acec-90f3295ef307" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_20170da6-663d-481a-817d-5ece1156f4cf" xlink:href="lly-20201231.xsd#lly_A395NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A395NotesDue2049Member_20170da6-663d-481a-817d-5ece1156f4cf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member_ccfb9027-3494-4bde-9657-dafe705d3e12" xlink:href="lly-20201231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A17EuroDeonominatedNotesDue2049Member_ccfb9027-3494-4bde-9657-dafe705d3e12" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member_b1b8147b-afb5-480e-93f8-81529b967f06" xlink:href="lly-20201231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A97YenDeonominatedNotesDue2049Member_b1b8147b-afb5-480e-93f8-81529b967f06" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_c950b1a5-61af-4ad0-9c61-9f003adae112" xlink:href="lly-20201231.xsd#lly_A225NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A225NotesDue2050Member_c950b1a5-61af-4ad0-9c61-9f003adae112" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_befe8c27-965b-48df-8f46-f2b02f586872" xlink:href="lly-20201231.xsd#lly_A415NotesDue2059Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A415NotesDue2059Member_befe8c27-965b-48df-8f46-f2b02f586872" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_47ddd46a-4780-47b5-989b-cdea151b385c" xlink:href="lly-20201231.xsd#lly_A25NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A25NotesDue2060Member_47ddd46a-4780-47b5-989b-cdea151b385c" xlink:type="arc" order="27"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i9a1c97bbe3134b26a3a65ce990027634_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_f2de0863-2276-4d3a-987e-cd88f8f8deb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_f2de0863-2276-4d3a-987e-cd88f8f8deb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c519dbfb-ffc1-4633-b4d8-577dfaf823b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c519dbfb-ffc1-4633-b4d8-577dfaf823b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a694a1e6-189b-4436-a0fa-09bfaaeca70c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a694a1e6-189b-4436-a0fa-09bfaaeca70c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_35302988-bd50-4a14-bdf6-6d6fa17f33ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentTerm_35302988-bd50-4a14-bdf6-6d6fa17f33ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1279dae-a597-4823-abfd-df6ba80bcc58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1279dae-a597-4823-abfd-df6ba80bcc58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3318dd3-1b30-4491-ac2a-3a6e6e06c0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3318dd3-1b30-4491-ac2a-3a6e6e06c0fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e415bdea-e38a-49dc-a864-5dd9f0e66f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e415bdea-e38a-49dc-a864-5dd9f0e66f86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_7061cb4c-4c08-4a29-9f4e-0d0071f37b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_7061cb4c-4c08-4a29-9f4e-0d0071f37b84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_bcb4f433-218a-402e-b4a8-a618266678f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_bcb4f433-218a-402e-b4a8-a618266678f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_22c5f9b7-3098-46b9-946d-5e21938673b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_22c5f9b7-3098-46b9-946d-5e21938673b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_03515ef8-6e7f-4eb6-9cd6-de69f11edb10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_03515ef8-6e7f-4eb6-9cd6-de69f11edb10" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_e22c024a-b2c1-4e96-9075-e32e959bd54e" xlink:href="lly-20201231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_e22c024a-b2c1-4e96-9075-e32e959bd54e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fb93a9ff-0876-449b-af04-0e31b5a576fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fb93a9ff-0876-449b-af04-0e31b5a576fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7c017f20-2384-48af-a813-3956b27fe1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7c017f20-2384-48af-a813-3956b27fe1d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f2d93ac5-2a78-4f62-ba77-4c71535b28df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c017f20-2384-48af-a813-3956b27fe1d8" xlink:to="loc_us-gaap_SeniorNotesMember_f2d93ac5-2a78-4f62-ba77-4c71535b28df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_03ad286a-23dd-423d-ac91-23203f439676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_03ad286a-23dd-423d-ac91-23203f439676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_03ad286a-23dd-423d-ac91-23203f439676_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_03ad286a-23dd-423d-ac91-23203f439676" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_03ad286a-23dd-423d-ac91-23203f439676_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c095e56f-246a-438a-a3f6-3a7d3736be33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_03ad286a-23dd-423d-ac91-23203f439676" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c095e56f-246a-438a-a3f6-3a7d3736be33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member_b199fa65-eac8-4752-9970-98f35d744c14" xlink:href="lly-20201231.xsd#lly_MaturityDate2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c095e56f-246a-438a-a3f6-3a7d3736be33" xlink:to="loc_lly_MaturityDate2023Member_b199fa65-eac8-4752-9970-98f35d744c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2019Member_8c6a3185-3f8e-4de5-aecf-cedcb134e02d" xlink:href="lly-20201231.xsd#lly_MaturityDate2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c095e56f-246a-438a-a3f6-3a7d3736be33" xlink:to="loc_lly_MaturityDate2019Member_8c6a3185-3f8e-4de5-aecf-cedcb134e02d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d61d74dd-5957-4c1c-ac7d-80e5332c4367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:to="loc_us-gaap_DebtInstrumentAxis_d61d74dd-5957-4c1c-ac7d-80e5332c4367" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d61d74dd-5957-4c1c-ac7d-80e5332c4367_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d61d74dd-5957-4c1c-ac7d-80e5332c4367" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d61d74dd-5957-4c1c-ac7d-80e5332c4367_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d61d74dd-5957-4c1c-ac7d-80e5332c4367" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_bd532273-fbe0-4c2e-9cef-f4ad6cf47297" xlink:href="lly-20201231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_bd532273-fbe0-4c2e-9cef-f4ad6cf47297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_6502efc3-111a-4a35-91db-91dfd501d038" xlink:href="lly-20201231.xsd#lly_A225NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_bd532273-fbe0-4c2e-9cef-f4ad6cf47297" xlink:to="loc_lly_A225NotesDue2050Member_6502efc3-111a-4a35-91db-91dfd501d038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_da1112c4-138a-4867-b298-0fe4d327a63e" xlink:href="lly-20201231.xsd#lly_A25NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_bd532273-fbe0-4c2e-9cef-f4ad6cf47297" xlink:to="loc_lly_A25NotesDue2060Member_da1112c4-138a-4867-b298-0fe4d327a63e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_58632004-fc42-4e11-875d-582f1e5fa558" xlink:href="lly-20201231.xsd#lly_A3375NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A3375NotesDue2029Member_58632004-fc42-4e11-875d-582f1e5fa558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_054a0dd7-c95a-4bbc-a1d0-1c2cdc9f6bfd" xlink:href="lly-20201231.xsd#lly_A3875NotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A3875NotesDue2039Member_054a0dd7-c95a-4bbc-a1d0-1c2cdc9f6bfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_207364eb-1048-49c6-aa3c-e1478e4e8e44" xlink:href="lly-20201231.xsd#lly_A395NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A395NotesDue2049Member_207364eb-1048-49c6-aa3c-e1478e4e8e44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_4c284468-6b01-4bb3-a9cc-75ab06ff294b" xlink:href="lly-20201231.xsd#lly_A415NotesDue2059Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A415NotesDue2059Member_4c284468-6b01-4bb3-a9cc-75ab06ff294b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019EuroDenominatedNotesMember_631e99c2-0db0-459e-9fcf-02d0de3c5b81" xlink:href="lly-20201231.xsd#lly_November2019EuroDenominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_November2019EuroDenominatedNotesMember_631e99c2-0db0-459e-9fcf-02d0de3c5b81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member_c7e605bf-4664-43ca-bd35-809b4bea6961" xlink:href="lly-20201231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019EuroDenominatedNotesMember_631e99c2-0db0-459e-9fcf-02d0de3c5b81" xlink:to="loc_lly_A625EuroDeonominatedNotesDue2031Member_c7e605bf-4664-43ca-bd35-809b4bea6961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member_8d387d22-3821-4cc0-baf1-ebd27d4f65d1" xlink:href="lly-20201231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019EuroDenominatedNotesMember_631e99c2-0db0-459e-9fcf-02d0de3c5b81" xlink:to="loc_lly_A17EuroDeonominatedNotesDue2049Member_8d387d22-3821-4cc0-baf1-ebd27d4f65d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019YenDenominatedNotesMember_df1dc090-f89c-4984-81fa-09b2ab282079" xlink:href="lly-20201231.xsd#lly_November2019YenDenominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_November2019YenDenominatedNotesMember_df1dc090-f89c-4984-81fa-09b2ab282079" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_ed05a5ef-bf79-43d2-a9ff-8d033493a40e" xlink:href="lly-20201231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019YenDenominatedNotesMember_df1dc090-f89c-4984-81fa-09b2ab282079" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_ed05a5ef-bf79-43d2-a9ff-8d033493a40e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_c002eeeb-c3d0-4f89-a2ee-9eb124ce4484" xlink:href="lly-20201231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_November2019YenDenominatedNotesMember_df1dc090-f89c-4984-81fa-09b2ab282079" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_c002eeeb-c3d0-4f89-a2ee-9eb124ce4484" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member_fd3e9932-72b7-4b98-96d6-a0211eea6d59" xlink:href="lly-20201231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A97YenDeonominatedNotesDue2049Member_fd3e9932-72b7-4b98-96d6-a0211eea6d59" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofDebtMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="extended" id="idd43bb2ae66a48f2b6bc31145ff90484_BorrowingsScheduleofDebtMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="extended" id="i2e8ab96117d548d19bfa0d0fcad135cd_BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensation" xlink:type="extended" id="ifda5b7259ed54702817c7c114a31a29b_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="extended" id="i12d71360c6ab44f5a18b5dc7cdb46e4d_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="iff9edcc598724112871f93dad31d0059_StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ib47e2cc8f0184ba1804ccbc66c4b0a57_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a5b007c-d53d-4356-9bdf-aab402d3754f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a5b007c-d53d-4356-9bdf-aab402d3754f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_acb3bf0e-d836-4ca4-afe9-d2581f7a11b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_acb3bf0e-d836-4ca4-afe9-d2581f7a11b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ced15353-f80c-4334-919c-6642a347f4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ced15353-f80c-4334-919c-6642a347f4af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_fc788dde-2e19-4f4c-856f-49fcec8f77b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_fc788dde-2e19-4f4c-856f-49fcec8f77b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_eabf90d3-79e6-4fcc-ab9f-2da4a17858f4" xlink:href="lly-20201231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_eabf90d3-79e6-4fcc-ab9f-2da4a17858f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9b9aec9-bc0e-4031-9c17-cc622cb7d0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9b9aec9-bc0e-4031-9c17-cc622cb7d0c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4be82ec-a8b3-430d-91d4-efb6dfd776c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4be82ec-a8b3-430d-91d4-efb6dfd776c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dc109b95-1960-407c-b699-fdcaee9cc49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dc109b95-1960-407c-b699-fdcaee9cc49e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f69748-374a-47d4-a47b-b5f3388c3d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f69748-374a-47d4-a47b-b5f3388c3d51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e8c94fc5-d150-44e5-86f4-f13c2de11fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f69748-374a-47d4-a47b-b5f3388c3d51" xlink:to="loc_us-gaap_AwardTypeAxis_e8c94fc5-d150-44e5-86f4-f13c2de11fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8c94fc5-d150-44e5-86f4-f13c2de11fcc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e8c94fc5-d150-44e5-86f4-f13c2de11fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8c94fc5-d150-44e5-86f4-f13c2de11fcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e8c94fc5-d150-44e5-86f4-f13c2de11fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3a9c8ba5-65e7-42d3-b75f-655a526d8775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:to="loc_us-gaap_PerformanceSharesMember_3a9c8ba5-65e7-42d3-b75f-655a526d8775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_a855da74-39b0-4e63-95be-23ec73a58abf" xlink:href="lly-20201231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:to="loc_lly_ShareholderValueAwardsMember_a855da74-39b0-4e63-95be-23ec73a58abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_3b00bd8e-c9b5-45d8-b87f-09f0d3ccb038" xlink:href="lly-20201231.xsd#lly_RelativeValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:to="loc_lly_RelativeValueAwardsMember_3b00bd8e-c9b5-45d8-b87f-09f0d3ccb038" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3f41c00d-ec7f-4702-854d-b91c1be180f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3f41c00d-ec7f-4702-854d-b91c1be180f8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationScheduleofAssumptionsUsedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="extended" id="i85c87108be2e4ea0a0e001f1ed71fd0b_StockBasedCompensationScheduleofAssumptionsUsedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f0581cfa-f69f-4eb8-9426-782fe855adf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f0581cfa-f69f-4eb8-9426-782fe855adf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_227214ad-73f1-4b8a-a0a1-4b57d721c3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_227214ad-73f1-4b8a-a0a1-4b57d721c3d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_082003e2-87b5-4b28-ae13-c4cee68c55f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_082003e2-87b5-4b28-ae13-c4cee68c55f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932ada2d-4cd6-4b0d-ab51-33e853bbfbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932ada2d-4cd6-4b0d-ab51-33e853bbfbe7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_61765d3d-c223-48d9-add3-f37c472e5b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932ada2d-4cd6-4b0d-ab51-33e853bbfbe7" xlink:to="loc_us-gaap_AwardTypeAxis_61765d3d-c223-48d9-add3-f37c472e5b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61765d3d-c223-48d9-add3-f37c472e5b1a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_61765d3d-c223-48d9-add3-f37c472e5b1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61765d3d-c223-48d9-add3-f37c472e5b1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324c1139-be0d-404b-bdbc-03b9d0667843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_61765d3d-c223-48d9-add3-f37c472e5b1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324c1139-be0d-404b-bdbc-03b9d0667843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_7ce0b5b0-d2a8-4bb2-b58d-b64ac4ba838f" xlink:href="lly-20201231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324c1139-be0d-404b-bdbc-03b9d0667843" xlink:to="loc_lly_ShareholderValueAwardsMember_7ce0b5b0-d2a8-4bb2-b58d-b64ac4ba838f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_575955a8-a849-4757-ae13-51530eece7bd" xlink:href="lly-20201231.xsd#lly_RelativeValueAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324c1139-be0d-404b-bdbc-03b9d0667843" xlink:to="loc_lly_RelativeValueAwardsMember_575955a8-a849-4757-ae13-51530eece7bd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="lly-20201231.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ShareholdersEquity" xlink:type="extended" id="i8431397c131048ffb2b4bed37932fbf1_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="extended" id="iedc055c2c2d24b498f11f6d2b7d005b9_ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_03d42981-b766-40e6-8da0-c1be614c78f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_03d42981-b766-40e6-8da0-c1be614c78f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2da71079-5d5f-4f56-ad60-4998ff2e66a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2da71079-5d5f-4f56-ad60-4998ff2e66a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9610e14b-6a89-4f57-bdc5-817aa1a473f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9610e14b-6a89-4f57-bdc5-817aa1a473f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bb2e827a-ea54-4769-88f8-f7889c781914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bb2e827a-ea54-4769-88f8-f7889c781914" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_aa53a966-d929-4f54-af5a-3b860eb002b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_aa53a966-d929-4f54-af5a-3b860eb002b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_2e8000ee-7df2-42ad-a4cc-eb7c8c30df3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrustShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_2e8000ee-7df2-42ad-a4cc-eb7c8c30df3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_5361d71a-3d50-40e3-b2ac-c41f938ae758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_5361d71a-3d50-40e3-b2ac-c41f938ae758" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a4ba9ff4-f568-4973-8ebc-9c15df61f8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a4ba9ff4-f568-4973-8ebc-9c15df61f8e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_b3336100-da41-47ec-8af4-1814e7af18eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a4ba9ff4-f568-4973-8ebc-9c15df61f8e6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_b3336100-da41-47ec-8af4-1814e7af18eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b3336100-da41-47ec-8af4-1814e7af18eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b3336100-da41-47ec-8af4-1814e7af18eb" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b3336100-da41-47ec-8af4-1814e7af18eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_05ed4af6-eade-4d09-9a37-1647c6e777c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b3336100-da41-47ec-8af4-1814e7af18eb" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_05ed4af6-eade-4d09-9a37-1647c6e777c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2018RepurchaseProgramMember_f80468a1-241d-4674-87e6-63fcb6d1da5b" xlink:href="lly-20201231.xsd#lly_A2018RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_05ed4af6-eade-4d09-9a37-1647c6e777c8" xlink:to="loc_lly_A2018RepurchaseProgramMember_f80468a1-241d-4674-87e6-63fcb6d1da5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended" id="i85b38dbee43e42488baa573fb0c9622c_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="extended" id="i97295aab4a8a4ae9a64499f332af03db_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ib27b69ed6f624600b45b701d12a177a3_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision_67287e0e-8cce-4e62-9634-21b084addcc7" xlink:href="lly-20201231.xsd#lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision_67287e0e-8cce-4e62-9634-21b084addcc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_075d1e2b-36aa-47a2-81b0-048f4ca684d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_075d1e2b-36aa-47a2-81b0-048f4ca684d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a962ba67-a580-42e9-99dd-3af008a78972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a962ba67-a580-42e9-99dd-3af008a78972" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2afb7135-e447-450d-9b0e-61aa4fb67efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2afb7135-e447-450d-9b0e-61aa4fb67efc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_8a9b36fd-d014-40c4-984a-e0eb367bdc82" xlink:href="lly-20201231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_8a9b36fd-d014-40c4-984a-e0eb367bdc82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_9eb16902-94ae-48b0-bd3d-9b47657495b2" xlink:href="lly-20201231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_9eb16902-94ae-48b0-bd3d-9b47657495b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_830c3144-456f-41ef-8e0a-0d4568ad0279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_830c3144-456f-41ef-8e0a-0d4568ad0279" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_dea32564-771c-41fe-b91e-36578412224a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_dea32564-771c-41fe-b91e-36578412224a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForIncomeTaxSettlements_32a699aa-f7a6-4d45-b9d7-bbd7b7777ecf" xlink:href="lly-20201231.xsd#lly_PaymentsForIncomeTaxSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_lly_PaymentsForIncomeTaxSettlements_32a699aa-f7a6-4d45-b9d7-bbd7b7777ecf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_67587a4c-a39e-41d5-978b-5c638edf4521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_67587a4c-a39e-41d5-978b-5c638edf4521" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_87dd0ddc-0e74-4b25-b102-e2233eda25d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:to="loc_us-gaap_TaxPeriodAxis_87dd0ddc-0e74-4b25-b102-e2233eda25d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_87dd0ddc-0e74-4b25-b102-e2233eda25d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_87dd0ddc-0e74-4b25-b102-e2233eda25d9" xlink:to="loc_us-gaap_TaxPeriodDomain_87dd0ddc-0e74-4b25-b102-e2233eda25d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_10915aa0-2c73-4a7a-9df9-09d97227065f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_87dd0ddc-0e74-4b25-b102-e2233eda25d9" xlink:to="loc_us-gaap_TaxPeriodDomain_10915aa0-2c73-4a7a-9df9-09d97227065f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxYears2013To2015Member_6761a44e-5860-4ba3-ac8b-f50372c3a0f1" xlink:href="lly-20201231.xsd#lly_TaxYears2013To2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_10915aa0-2c73-4a7a-9df9-09d97227065f" xlink:to="loc_lly_TaxYears2013To2015Member_6761a44e-5860-4ba3-ac8b-f50372c3a0f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_4d5ad7a9-8ba3-4670-a135-2c54962cd18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_4d5ad7a9-8ba3-4670-a135-2c54962cd18f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_4d5ad7a9-8ba3-4670-a135-2c54962cd18f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_4d5ad7a9-8ba3-4670-a135-2c54962cd18f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_4d5ad7a9-8ba3-4670-a135-2c54962cd18f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_4d5ad7a9-8ba3-4670-a135-2c54962cd18f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember_c4443cf5-26b2-49c9-ae09-37356a1759dd" xlink:href="lly-20201231.xsd#lly_CarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_CarryforwardMember_c4443cf5-26b2-49c9-ae09-37356a1759dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationin6YearsMember_9102640b-5054-4412-a817-41e72a50a3c8" xlink:href="lly-20201231.xsd#lly_Expirationin6YearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_Expirationin6YearsMember_9102640b-5054-4412-a817-41e72a50a3c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationIn12To18YearsMember_90f1757e-deb5-486a-9b8c-87e97b0b8ea9" xlink:href="lly-20201231.xsd#lly_ExpirationIn12To18YearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_ExpirationIn12To18YearsMember_90f1757e-deb5-486a-9b8c-87e97b0b8ea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember_5abf33f4-b445-4975-bcb8-e1c2204ede6f" xlink:href="lly-20201231.xsd#lly_DesignatedUnusableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_DesignatedUnusableMember_5abf33f4-b445-4975-bcb8-e1c2204ede6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationwithin5yearsMember_cd3fcd4e-c57c-4375-9a0a-050cacd753f6" xlink:href="lly-20201231.xsd#lly_Expirationwithin5yearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_Expirationwithin5yearsMember_cd3fcd4e-c57c-4375-9a0a-050cacd753f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expiration5to20YearsMember_f3c90707-96df-4563-beed-e283842db2e9" xlink:href="lly-20201231.xsd#lly_Expiration5to20YearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_Expiration5to20YearsMember_f3c90707-96df-4563-beed-e283842db2e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember_6bdf7ade-af10-4693-aa45-8a51eea9ffae" xlink:href="lly-20201231.xsd#lly_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_NoExpirationMember_6bdf7ade-af10-4693-aa45-8a51eea9ffae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5a8e2b8a-c543-4167-b547-803a6fa1bd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5a8e2b8a-c543-4167-b547-803a6fa1bd8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5a8e2b8a-c543-4167-b547-803a6fa1bd8e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5a8e2b8a-c543-4167-b547-803a6fa1bd8e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5a8e2b8a-c543-4167-b547-803a6fa1bd8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5a8e2b8a-c543-4167-b547-803a6fa1bd8e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_30d010c1-5188-40a5-8a48-17b95c5528f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_30d010c1-5188-40a5-8a48-17b95c5528f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_88857d8f-431b-418f-a6aa-dc4b6ec45377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:to="loc_us-gaap_ForeignCountryMember_88857d8f-431b-418f-a6aa-dc4b6ec45377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_34e9e5c9-2165-43be-8476-95d88627fe54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_34e9e5c9-2165-43be-8476-95d88627fe54" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="extended" id="idc71a29fbb5c42589be652bd461922ca_IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended" id="i858a052c67f0469187f9e1f8540789ec_IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="extended" id="i469d7d9c62be4f69918b42b6061bc140_IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="extended" id="i758896521d134f24bcabbca2227f9cf1_IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="extended" id="i7caf107073ae450fa0f197859d1cd4a7_IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="if717658286224c9b9b3ad9b26bc134e4_IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" xlink:type="extended" id="i99e614005be54ee68e989d78ed262c5a_IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefits"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended" id="ie72eaf7bf1eb4dc7a560582bddd84c26_RetirementBenefits"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended" id="if15e9d9f4fab49aa8604715c8f900317_RetirementBenefitsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended" id="ia0915ef8e4044f1a970a655974bbeb00_RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a650f85f-d1f5-4e15-8286-b98f5581ece2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a650f85f-d1f5-4e15-8286-b98f5581ece2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_99ce5c0c-c114-4960-934c-dcef4c53adf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_99ce5c0c-c114-4960-934c-dcef4c53adf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_3dc622ad-f70b-447b-bf8c-ab2f0b260dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_3dc622ad-f70b-447b-bf8c-ab2f0b260dbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7f77128e-968e-46be-9b03-0cf08de54bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7f77128e-968e-46be-9b03-0cf08de54bf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_31934fc7-b33e-4c66-bb52-27569cf0c119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_31934fc7-b33e-4c66-bb52-27569cf0c119" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_5e35e221-35a8-4e29-bd98-c1082ea566a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_5e35e221-35a8-4e29-bd98-c1082ea566a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_e6f42554-d09d-4819-8a30-f16035c2a0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_e6f42554-d09d-4819-8a30-f16035c2a0c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ddd1b1a3-2904-4948-a92c-dfa399e7770f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_982a3d5a-94a3-49aa-bf20-81d998974dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_982a3d5a-94a3-49aa-bf20-81d998974dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_4169e698-110f-4fc5-a4cf-80179c4c3c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_4169e698-110f-4fc5-a4cf-80179c4c3c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1c4a41e1-3527-47df-b447-89e701fcfda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1c4a41e1-3527-47df-b447-89e701fcfda8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_c55202b9-7e47-4292-a617-aa9bcfb3e1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_c55202b9-7e47-4292-a617-aa9bcfb3e1f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_0e24abc6-288c-4696-8e8c-5c64475e207a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_0e24abc6-288c-4696-8e8c-5c64475e207a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f6f47dea-5690-469f-a606-21c791e41775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_bab27178-70a2-416a-96b0-4ab94e963f78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_bab27178-70a2-416a-96b0-4ab94e963f78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e19712e8-6917-4449-ac3c-afef30ebe06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e19712e8-6917-4449-ac3c-afef30ebe06e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_2ffabac4-bfe0-4f66-b203-acb3d76ff52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_2ffabac4-bfe0-4f66-b203-acb3d76ff52d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_1a4f0cf9-7a69-48a0-bcb2-dd8d5696255b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_1a4f0cf9-7a69-48a0-bcb2-dd8d5696255b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d3bd912f-f1e2-41ff-a5ed-38c42bcb1027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d3bd912f-f1e2-41ff-a5ed-38c42bcb1027" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a6d5fc3c-bd92-479a-bb78-c76823e832d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d3bd912f-f1e2-41ff-a5ed-38c42bcb1027" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a6d5fc3c-bd92-479a-bb78-c76823e832d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a6d5fc3c-bd92-479a-bb78-c76823e832d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a6d5fc3c-bd92-479a-bb78-c76823e832d8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a6d5fc3c-bd92-479a-bb78-c76823e832d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ce232f12-4fb4-4748-b4f7-13051a87b949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a6d5fc3c-bd92-479a-bb78-c76823e832d8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ce232f12-4fb4-4748-b4f7-13051a87b949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d3dcd93b-6291-4427-806b-599ca055583b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ce232f12-4fb4-4748-b4f7-13051a87b949" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d3dcd93b-6291-4427-806b-599ca055583b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_f57ff697-d947-45a3-b3de-39102ca9fbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ce232f12-4fb4-4748-b4f7-13051a87b949" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_f57ff697-d947-45a3-b3de-39102ca9fbc5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="ic7c1f8127a0a4ef6941127b7721ac5b5_RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_64f574f6-48cd-4821-bb37-e9d68b8dcd79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_64f574f6-48cd-4821-bb37-e9d68b8dcd79" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_205e8d71-4dab-42b5-b3df-cb7f27519716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_205e8d71-4dab-42b5-b3df-cb7f27519716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_159cdd7f-7cce-4d2d-854c-481dd8698f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_159cdd7f-7cce-4d2d-854c-481dd8698f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1605b090-d103-432c-a1d1-44926f023696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1605b090-d103-432c-a1d1-44926f023696" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a204a9e3-7389-468a-8de4-225a6a900d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a204a9e3-7389-468a-8de4-225a6a900d51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_8442d22c-c6f4-4526-9a87-882fc6a0b8d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_8442d22c-c6f4-4526-9a87-882fc6a0b8d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4e150e1-af73-411e-9bfa-401766f1490d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_64f574f6-48cd-4821-bb37-e9d68b8dcd79" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4e150e1-af73-411e-9bfa-401766f1490d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_43470f8c-f971-4e59-aef3-fc759dce291b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4e150e1-af73-411e-9bfa-401766f1490d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_43470f8c-f971-4e59-aef3-fc759dce291b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_43470f8c-f971-4e59-aef3-fc759dce291b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_43470f8c-f971-4e59-aef3-fc759dce291b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_43470f8c-f971-4e59-aef3-fc759dce291b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a1bc06b7-2150-4dd9-8a79-160035ca38a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_43470f8c-f971-4e59-aef3-fc759dce291b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a1bc06b7-2150-4dd9-8a79-160035ca38a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_0e9bc4d2-dbc0-4beb-b222-fbe6fd3870f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a1bc06b7-2150-4dd9-8a79-160035ca38a5" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_0e9bc4d2-dbc0-4beb-b222-fbe6fd3870f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_e0b481ab-e538-4c9c-b0f6-b99b9556910e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a1bc06b7-2150-4dd9-8a79-160035ca38a5" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_e0b481ab-e538-4c9c-b0f6-b99b9556910e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended" id="if8f8c09246054d4b9a416fcd64881c7e_RetirementBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_63934817-8ef1-408d-b1f8-435707d6ccf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_63934817-8ef1-408d-b1f8-435707d6ccf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_b2faa2b4-e43e-4985-af95-f690af85fd38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_b2faa2b4-e43e-4985-af95-f690af85fd38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_01cb3e15-b7a6-4746-817e-2d265440f75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_01cb3e15-b7a6-4746-817e-2d265440f75c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_dd72947d-889a-4cd7-a762-075c2c7d5bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_dd72947d-889a-4cd7-a762-075c2c7d5bc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_d6af318a-c9ee-4ce4-8e2c-80a21ff14c50" xlink:href="lly-20201231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_d6af318a-c9ee-4ce4-8e2c-80a21ff14c50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_3e3e9921-301d-47d1-ab64-ac4a786ba401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_3e3e9921-301d-47d1-ab64-ac4a786ba401" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_793ca676-3e95-4362-b3c0-12bae14b149a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_793ca676-3e95-4362-b3c0-12bae14b149a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear_1fd56490-0cd4-42c8-9ea5-83e2a80d228a" xlink:href="lly-20201231.xsd#lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear_1fd56490-0cd4-42c8-9ea5-83e2a80d228a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8a0fdf54-a56d-4b22-96d6-9f5c13363300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8a0fdf54-a56d-4b22-96d6-9f5c13363300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8a0fdf54-a56d-4b22-96d6-9f5c13363300_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8a0fdf54-a56d-4b22-96d6-9f5c13363300" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8a0fdf54-a56d-4b22-96d6-9f5c13363300_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b0f8bd1c-c9b8-4e7d-9d83-ce621e558938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8a0fdf54-a56d-4b22-96d6-9f5c13363300" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b0f8bd1c-c9b8-4e7d-9d83-ce621e558938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_dda7db35-10ee-4b0e-9a99-af4c05180294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b0f8bd1c-c9b8-4e7d-9d83-ce621e558938" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_dda7db35-10ee-4b0e-9a99-af4c05180294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_3327694b-895a-4c82-87eb-c98478a8e7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b0f8bd1c-c9b8-4e7d-9d83-ce621e558938" xlink:to="loc_us-gaap_FixedIncomeFundsMember_3327694b-895a-4c82-87eb-c98478a8e7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b301f080-617f-4f22-a77f-cd79bbcbd7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b301f080-617f-4f22-a77f-cd79bbcbd7b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b301f080-617f-4f22-a77f-cd79bbcbd7b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b301f080-617f-4f22-a77f-cd79bbcbd7b5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b301f080-617f-4f22-a77f-cd79bbcbd7b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b754c730-870d-47de-94a1-03b572604351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b301f080-617f-4f22-a77f-cd79bbcbd7b5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b754c730-870d-47de-94a1-03b572604351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ed20c340-70e6-486c-be6b-657f0f8f8e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b754c730-870d-47de-94a1-03b572604351" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ed20c340-70e6-486c-be6b-657f0f8f8e5c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended" id="i0b7f614b72f14feaa5d6983d63e60c52_RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_ab67f2ed-efbb-4628-81b2-b6f907b2040f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_ab67f2ed-efbb-4628-81b2-b6f907b2040f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_4d5e2d2d-40b8-428f-92b6-faf561048663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_4d5e2d2d-40b8-428f-92b6-faf561048663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_0414560c-8a16-4d25-988c-9e960b6b6de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_0414560c-8a16-4d25-988c-9e960b6b6de9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_9b4d3be7-6e79-4a3c-9963-2158e4f294e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_9b4d3be7-6e79-4a3c-9963-2158e4f294e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_23ac4973-c6a9-4463-b091-8518a27f5016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_23ac4973-c6a9-4463-b091-8518a27f5016" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ada938a-6b25-4c29-8d4f-74759963788b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ada938a-6b25-4c29-8d4f-74759963788b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bb28200b-d1fd-4568-a7b4-77a16bf99421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ada938a-6b25-4c29-8d4f-74759963788b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bb28200b-d1fd-4568-a7b4-77a16bf99421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bb28200b-d1fd-4568-a7b4-77a16bf99421_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb28200b-d1fd-4568-a7b4-77a16bf99421" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bb28200b-d1fd-4568-a7b4-77a16bf99421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_71512360-316c-4b3a-a1d3-f52c4c57612c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb28200b-d1fd-4568-a7b4-77a16bf99421" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_71512360-316c-4b3a-a1d3-f52c4c57612c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_808f4aa9-559f-47d2-bddf-66430277d416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_71512360-316c-4b3a-a1d3-f52c4c57612c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_808f4aa9-559f-47d2-bddf-66430277d416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_ffab9e49-d5a8-436a-91af-54daf6c86ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_71512360-316c-4b3a-a1d3-f52c4c57612c" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_ffab9e49-d5a8-436a-91af-54daf6c86ac1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended" id="i7a2157ff11e844c69cc4f680aa467402_RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_020d5e4a-b86a-4895-aed0-3c02f2341881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_020d5e4a-b86a-4895-aed0-3c02f2341881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_edda9174-8907-4620-be89-56e538026ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_edda9174-8907-4620-be89-56e538026ca1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c075a7b8-1d2f-47db-8eae-ce39adbd21a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c075a7b8-1d2f-47db-8eae-ce39adbd21a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_3c32fbee-c548-47a2-9bce-be4d19420cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_3c32fbee-c548-47a2-9bce-be4d19420cfa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_955a1551-18b8-44c2-838f-1d57263e26f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_955a1551-18b8-44c2-838f-1d57263e26f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_bf28bea1-8fe0-4d98-ba8a-a4480f089af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_bf28bea1-8fe0-4d98-ba8a-a4480f089af9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_71c85809-36e4-435a-b3d1-20fa74bc109e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_71c85809-36e4-435a-b3d1-20fa74bc109e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_bde70d49-b690-48b3-9864-b0ceed9a4df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_71c85809-36e4-435a-b3d1-20fa74bc109e" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_bde70d49-b690-48b3-9864-b0ceed9a4df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_62d1492d-4260-46a1-990e-9a0153e31231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_71c85809-36e4-435a-b3d1-20fa74bc109e" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_62d1492d-4260-46a1-990e-9a0153e31231" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_5bada99f-b628-4693-a8c8-4b10fc2225dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_5bada99f-b628-4693-a8c8-4b10fc2225dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_0f5281b9-b19e-4e66-aa5f-7490617ef934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_5bada99f-b628-4693-a8c8-4b10fc2225dd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_0f5281b9-b19e-4e66-aa5f-7490617ef934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d11b16a0-276c-4b59-8527-8c9facf7d8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_79bed6fc-577f-44f3-8eb7-43380c28adf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_79bed6fc-577f-44f3-8eb7-43380c28adf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_91ab4aa8-e654-446a-bf3d-06b96fb2238f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_91ab4aa8-e654-446a-bf3d-06b96fb2238f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3852ec39-3499-4446-b208-808c5a50118d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3852ec39-3499-4446-b208-808c5a50118d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_62a1f1b9-2b05-4f2e-a5e6-a8c6aa2e733e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_62a1f1b9-2b05-4f2e-a5e6-a8c6aa2e733e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7559f0d4-311a-4307-a249-13274de292e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7559f0d4-311a-4307-a249-13274de292e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_32908f49-ff8c-4bf9-aae5-093cfdfeb673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_32908f49-ff8c-4bf9-aae5-093cfdfeb673" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6c6c238c-fc8e-47b5-823c-f4178d6f5547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6c6c238c-fc8e-47b5-823c-f4178d6f5547" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_0cd171d3-0f9f-4ecd-a428-49948a0e5826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_0cd171d3-0f9f-4ecd-a428-49948a0e5826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9cb17065-9498-410a-b426-994abadff064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9cb17065-9498-410a-b426-994abadff064" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_dadbc059-1514-4776-8fc7-ffcdf6d4f92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_dadbc059-1514-4776-8fc7-ffcdf6d4f92e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_5c1be3dc-3d75-4333-8c15-fc8302550e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_5c1be3dc-3d75-4333-8c15-fc8302550e72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_821e156a-29be-4bc8-831b-79dfa3bfc7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_821e156a-29be-4bc8-831b-79dfa3bfc7d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_12ab264d-966f-47d4-b969-16e551a60ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_12ab264d-966f-47d4-b969-16e551a60ca7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_f46a9f22-b6f6-4ec8-973f-f63e725776d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_f46a9f22-b6f6-4ec8-973f-f63e725776d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3bb9c622-9031-4dee-ada2-0590922dc45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3bb9c622-9031-4dee-ada2-0590922dc45b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_d87f17cb-3e34-4502-a1b1-0cf50b8b1980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3bb9c622-9031-4dee-ada2-0590922dc45b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_d87f17cb-3e34-4502-a1b1-0cf50b8b1980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d87f17cb-3e34-4502-a1b1-0cf50b8b1980_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d87f17cb-3e34-4502-a1b1-0cf50b8b1980" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d87f17cb-3e34-4502-a1b1-0cf50b8b1980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fa6b6a23-e566-45f1-a3db-f04a893fb8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d87f17cb-3e34-4502-a1b1-0cf50b8b1980" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fa6b6a23-e566-45f1-a3db-f04a893fb8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_16ce4632-fc45-44c3-a462-7f27079eacdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fa6b6a23-e566-45f1-a3db-f04a893fb8a7" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_16ce4632-fc45-44c3-a462-7f27079eacdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6ba0cdd6-dab6-4afe-92e6-589827f403ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fa6b6a23-e566-45f1-a3db-f04a893fb8a7" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6ba0cdd6-dab6-4afe-92e6-589827f403ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofFairValueDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="extended" id="ia741bbd1519e480886b6e29554ca879f_RetirementBenefitsScheduleofFairValueDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_35efa5e3-a814-4916-84cd-91c69e5ee547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1224da3a-9f79-45d8-94bb-faaff18fbc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_35efa5e3-a814-4916-84cd-91c69e5ee547" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1224da3a-9f79-45d8-94bb-faaff18fbc3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_35efa5e3-a814-4916-84cd-91c69e5ee547" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_febb02da-a8e4-48c6-93ea-b864ac0e9d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_febb02da-a8e4-48c6-93ea-b864ac0e9d5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_febb02da-a8e4-48c6-93ea-b864ac0e9d5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_febb02da-a8e4-48c6-93ea-b864ac0e9d5b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_febb02da-a8e4-48c6-93ea-b864ac0e9d5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_febb02da-a8e4-48c6-93ea-b864ac0e9d5b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a964a6de-002d-4f2b-b0a2-98ab99d5727f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a964a6de-002d-4f2b-b0a2-98ab99d5727f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_503c6f84-513b-418b-8bc8-35bb81a6628a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_503c6f84-513b-418b-8bc8-35bb81a6628a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_57aafad3-4d57-4b4c-afbf-ba8152bf7cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_57aafad3-4d57-4b4c-afbf-ba8152bf7cc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_1fa9613e-2cca-4112-99b6-bafd574bcb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_1fa9613e-2cca-4112-99b6-bafd574bcb99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5b21f99f-5e58-4fae-bd11-ea1218cd8827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5b21f99f-5e58-4fae-bd11-ea1218cd8827" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_5b21f99f-5e58-4fae-bd11-ea1218cd8827_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5b21f99f-5e58-4fae-bd11-ea1218cd8827" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_5b21f99f-5e58-4fae-bd11-ea1218cd8827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5b21f99f-5e58-4fae-bd11-ea1218cd8827" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_a30696c6-c71a-49f0-a3a7-8eaf8bd28c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_a30696c6-c71a-49f0-a3a7-8eaf8bd28c03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_b1372b0d-a45d-4fb2-8542-5a87476aa642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_b1372b0d-a45d-4fb2-8542-5a87476aa642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_4de6ba04-b554-4302-85fa-2f81c6f6025d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_FixedIncomeFundsMember_4de6ba04-b554-4302-85fa-2f81c6f6025d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_50b72e5c-8d71-4476-a047-f64b38576cfd" xlink:href="lly-20201231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_50b72e5c-8d71-4476-a047-f64b38576cfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember_fb5d322c-f123-4d44-8eab-47378c9eefff" xlink:href="lly-20201231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_lly_FixedIncomeFundsEmergingMarketsMember_fb5d322c-f123-4d44-8eab-47378c9eefff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_4a6a9435-b02b-47a7-93ad-53985b8392a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_HedgeFundsMember_4a6a9435-b02b-47a7-93ad-53985b8392a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_d77bf397-7c44-4feb-9f26-96b14d017574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_EquityFundsMember_d77bf397-7c44-4feb-9f26-96b14d017574" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_cc20082e-cb64-47b6-9cd7-64e9c91ac8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_OtherContractMember_cc20082e-cb64-47b6-9cd7-64e9c91ac8ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_471c4ddd-378d-428b-be0c-d804eb714a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_471c4ddd-378d-428b-be0c-d804eb714a6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember_877c3df7-a3c8-4d20-8db5-d54439f02ae5" xlink:href="lly-20201231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_lly_DefineBenefitPlanOtherMember_877c3df7-a3c8-4d20-8db5-d54439f02ae5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ee28453e-ed79-4311-b819-ba996372819d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ee28453e-ed79-4311-b819-ba996372819d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ee28453e-ed79-4311-b819-ba996372819d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ee28453e-ed79-4311-b819-ba996372819d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ee28453e-ed79-4311-b819-ba996372819d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0eca99ba-2c39-4799-9cd0-3fc3f78ea3e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ee28453e-ed79-4311-b819-ba996372819d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0eca99ba-2c39-4799-9cd0-3fc3f78ea3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_58d893f8-6d63-4d16-a946-63440eec13c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0eca99ba-2c39-4799-9cd0-3fc3f78ea3e4" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_58d893f8-6d63-4d16-a946-63440eec13c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_9c24c8f7-3eba-4fb3-83f1-55b634561fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0eca99ba-2c39-4799-9cd0-3fc3f78ea3e4" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_9c24c8f7-3eba-4fb3-83f1-55b634561fa3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20201231.xsd#Contingencies"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended" id="i39804375151f49809e2368921175f4b8_Contingencies"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended" id="i25825d8032a24dc7b0514f86dfa4815e_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_bcd09ec5-74fd-4957-99db-55216c4dd128" xlink:href="lly-20201231.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_bcd09ec5-74fd-4957-99db-55216c4dd128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_ab0e9b63-60bf-4b77-9649-27d1a7d71846" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfPatents_ab0e9b63-60bf-4b77-9649-27d1a7d71846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_70939202-2206-4052-9618-8ccaff39d266" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_70939202-2206-4052-9618-8ccaff39d266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_a0b68841-186a-49ae-bd18-c309601bd6a4" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_a0b68841-186a-49ae-bd18-c309601bd6a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_ccaa5759-1606-4b07-8a5b-12046be7aa2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_ccaa5759-1606-4b07-8a5b-12046be7aa2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_853d4332-48c5-43f7-9e85-00705a2badd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_853d4332-48c5-43f7-9e85-00705a2badd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants_93e9f1d4-ceb8-4ade-953e-ed9eb0c942f9" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfClaimants_93e9f1d4-ceb8-4ade-953e-ed9eb0c942f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9ec41a88-ada9-40ed-a017-51acaddb8ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_9ec41a88-ada9-40ed-a017-51acaddb8ec2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfRequestsForInformation_661836ac-a720-4d98-89b5-60665453c8fb" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfRequestsForInformation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfRequestsForInformation_661836ac-a720-4d98-89b5-60665453c8fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7bef4c30-7a48-4e31-a50d-1e192c378871" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_srt_StatementGeographicalAxis_7bef4c30-7a48-4e31-a50d-1e192c378871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7bef4c30-7a48-4e31-a50d-1e192c378871_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7bef4c30-7a48-4e31-a50d-1e192c378871" xlink:to="loc_srt_SegmentGeographicalDomain_7bef4c30-7a48-4e31-a50d-1e192c378871_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b96c2b9e-4154-4bd1-a47d-182657b7cfe9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7bef4c30-7a48-4e31-a50d-1e192c378871" xlink:to="loc_srt_SegmentGeographicalDomain_b96c2b9e-4154-4bd1-a47d-182657b7cfe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_08526be9-6c11-493f-b236-b7db255d9a71" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b96c2b9e-4154-4bd1-a47d-182657b7cfe9" xlink:to="loc_country_BR_08526be9-6c11-493f-b236-b7db255d9a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4c4a48f4-027e-49d7-93e5-935ddc6020c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_srt_LitigationCaseAxis_4c4a48f4-027e-49d7-93e5-935ddc6020c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4c4a48f4-027e-49d7-93e5-935ddc6020c5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4c4a48f4-027e-49d7-93e5-935ddc6020c5" xlink:to="loc_srt_LitigationCaseTypeDomain_4c4a48f4-027e-49d7-93e5-935ddc6020c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4c4a48f4-027e-49d7-93e5-935ddc6020c5" xlink:to="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember_ca657c31-212b-45fd-9164-fcde29ee869b" xlink:href="lly-20201231.xsd#lly_DrReddysLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_DrReddysLabMember_ca657c31-212b-45fd-9164-fcde29ee869b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_7bdd423e-a621-4c32-bd1e-58cc0072051d" xlink:href="lly-20201231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_EmgalityPatentLitigationMember_7bdd423e-a621-4c32-bd1e-58cc0072051d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_fc372fb9-cbf4-49ab-a061-15e795bcaa01" xlink:href="lly-20201231.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_fc372fb9-cbf4-49ab-a061-15e795bcaa01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember_842b42bf-5987-426b-9ee2-335d4d14fa89" xlink:href="lly-20201231.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_WhyteEtAlVEliLillyEtAlMember_842b42bf-5987-426b-9ee2-335d4d14fa89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember_87fb59e0-3e43-4fc7-8c71-a8fae77c7fe6" xlink:href="lly-20201231.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_WeilerVTakedaCanadaIncEtAlMember_87fb59e0-3e43-4fc7-8c71-a8fae77c7fe6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember_111e560b-446c-492d-a561-885b50ec582f" xlink:href="lly-20201231.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_EppVTakedaCanadaIncEtAlMember_111e560b-446c-492d-a561-885b50ec582f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_6dfe7c0c-cfd5-47b8-98ec-e206ed7f3e48" xlink:href="lly-20201231.xsd#lly_EmployeeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_EmployeeLitigationMember_6dfe7c0c-cfd5-47b8-98ec-e206ed7f3e48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_srt_ProductOrServiceAxis_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4" xlink:to="loc_srt_ProductsAndServicesDomain_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4" xlink:to="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember_2137575d-5e5d-4b72-b598-383e0f0604e7" xlink:href="lly-20201231.xsd#lly_ActosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_ActosMember_2137575d-5e5d-4b72-b598-383e0f0604e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_7e8fa4dc-d6e4-418a-a32e-7128a891cdfc" xlink:href="lly-20201231.xsd#lly_ByettaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_ByettaMember_7e8fa4dc-d6e4-418a-a32e-7128a891cdfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_4729820c-7476-4bba-86dd-31b2cfe0e42d" xlink:href="lly-20201231.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_CialisMember_4729820c-7476-4bba-86dd-31b2cfe0e42d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_5a4b5ce3-d716-47e5-ace9-8fefe1a302ef" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_JardianceMember_5a4b5ce3-d716-47e5-ace9-8fefe1a302ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_7b376fda-a870-4619-b1c5-499d51e977ec" xlink:href="lly-20201231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_HumalogHumulinAndForteoMember_7b376fda-a870-4619-b1c5-499d51e977ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis_2418f0aa-3ec6-449c-bddf-4f89e45a9654" xlink:href="lly-20201231.xsd#lly_DomicileOfLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_lly_DomicileOfLitigationAxis_2418f0aa-3ec6-449c-bddf-4f89e45a9654" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_2418f0aa-3ec6-449c-bddf-4f89e45a9654_default" xlink:href="lly-20201231.xsd#lly_DomicileOfLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_DomicileOfLitigationAxis_2418f0aa-3ec6-449c-bddf-4f89e45a9654" xlink:to="loc_lly_DomicileOfLitigationDomain_2418f0aa-3ec6-449c-bddf-4f89e45a9654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:href="lly-20201231.xsd#lly_DomicileOfLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_DomicileOfLitigationAxis_2418f0aa-3ec6-449c-bddf-4f89e45a9654" xlink:to="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember_dcf206f6-be4e-4571-af0d-acbe1dea7b0a" xlink:href="lly-20201231.xsd#lly_LosAngelesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:to="loc_lly_LosAngelesMember_dcf206f6-be4e-4571-af0d-acbe1dea7b0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember_f62f859c-a617-48f0-9758-216361a85d14" xlink:href="lly-20201231.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:to="loc_lly_SouthernDistrictOfCaliforniaMember_f62f859c-a617-48f0-9758-216361a85d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember_b3b29835-3e77-463c-819f-f73ba5304415" xlink:href="lly-20201231.xsd#lly_VariousStateDomicilesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:to="loc_lly_VariousStateDomicilesMember_b3b29835-3e77-463c-819f-f73ba5304415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis_10322fa7-5cea-4bf1-aefe-fec35cfdd20f" xlink:href="lly-20201231.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_lly_PlaintiffAllegationsAxis_10322fa7-5cea-4bf1-aefe-fec35cfdd20f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_10322fa7-5cea-4bf1-aefe-fec35cfdd20f_default" xlink:href="lly-20201231.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_PlaintiffAllegationsAxis_10322fa7-5cea-4bf1-aefe-fec35cfdd20f" xlink:to="loc_lly_PlaintiffAllegationsDomain_10322fa7-5cea-4bf1-aefe-fec35cfdd20f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:href="lly-20201231.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_PlaintiffAllegationsAxis_10322fa7-5cea-4bf1-aefe-fec35cfdd20f" xlink:to="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember_78c593a1-aa76-490a-886f-7e652781743f" xlink:href="lly-20201231.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:to="loc_lly_PancreaticCancerOrThyroidCancerMember_78c593a1-aa76-490a-886f-7e652781743f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember_c9122585-dfc5-4c04-b1f8-101012fb1e16" xlink:href="lly-20201231.xsd#lly_PancreatitisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:to="loc_lly_PancreatitisMember_c9122585-dfc5-4c04-b1f8-101012fb1e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember_3ae6ede8-96ec-4112-93e7-703162352376" xlink:href="lly-20201231.xsd#lly_AmpullaryCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:to="loc_lly_AmpullaryCancerMember_3ae6ede8-96ec-4112-93e7-703162352376" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bfd7a56a-4361-41b1-8802-679f5a933999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bfd7a56a-4361-41b1-8802-679f5a933999" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_bfd7a56a-4361-41b1-8802-679f5a933999_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bfd7a56a-4361-41b1-8802-679f5a933999" xlink:to="loc_us-gaap_LossContingencyNatureDomain_bfd7a56a-4361-41b1-8802-679f5a933999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6c632fee-e64b-4e4a-9b6a-4a12ac46fa53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bfd7a56a-4361-41b1-8802-679f5a933999" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6c632fee-e64b-4e4a-9b6a-4a12ac46fa53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_e56f8373-1e69-448e-94d4-45393638f8ce" xlink:href="lly-20201231.xsd#lly_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6c632fee-e64b-4e4a-9b6a-4a12ac46fa53" xlink:to="loc_lly_ProductLiabilityMember_e56f8373-1e69-448e-94d4-45393638f8ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended" id="id2552de68d214c2a8535fa5edd719cfc_OtherComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended" id="i52cb7477fa414718b2c02b210be5a3f8_OtherComprehensiveIncomeLossTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i7cb74ab6b4184882beacfd0b8aaf5d9e_OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_15db9820-ae97-4111-8757-e16bc06a5da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_15db9820-ae97-4111-8757-e16bc06a5da5" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43995466-64fb-4678-b8c4-6ebeda598a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43995466-64fb-4678-b8c4-6ebeda598a42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_52d86b9f-4509-4b46-bc5b-f135ff53c3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_52d86b9f-4509-4b46-bc5b-f135ff53c3da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1cd42d7d-66ff-46a9-ba6d-34c4b57b800c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1cd42d7d-66ff-46a9-ba6d-34c4b57b800c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6ae19699-69d2-4166-b1bf-e1af9aaa94fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6ae19699-69d2-4166-b1bf-e1af9aaa94fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c6d61da-c0c8-4d94-b642-8170d45e7040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c6d61da-c0c8-4d94-b642-8170d45e7040" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c53b17b2-9d71-44ca-b62c-a29a559896bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e895d94-9f8c-4812-a380-2b55b4254cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_15db9820-ae97-4111-8757-e16bc06a5da5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e895d94-9f8c-4812-a380-2b55b4254cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_15db9820-ae97-4111-8757-e16bc06a5da5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_679343f1-8c75-4156-aeed-c6c5ae5f6ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_679343f1-8c75-4156-aeed-c6c5ae5f6ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_679343f1-8c75-4156-aeed-c6c5ae5f6ee0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_679343f1-8c75-4156-aeed-c6c5ae5f6ee0" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_679343f1-8c75-4156-aeed-c6c5ae5f6ee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_4eadc59b-e4ac-42dd-b3fc-4a6db42c7d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_679343f1-8c75-4156-aeed-c6c5ae5f6ee0" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_4eadc59b-e4ac-42dd-b3fc-4a6db42c7d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_0550cb34-8900-4048-bd09-04f73aa7e745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_4eadc59b-e4ac-42dd-b3fc-4a6db42c7d92" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_0550cb34-8900-4048-bd09-04f73aa7e745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_e485935e-e5ce-488b-b453-9433ddbbee6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_4eadc59b-e4ac-42dd-b3fc-4a6db42c7d92" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_e485935e-e5ce-488b-b453-9433ddbbee6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e7db5be9-3de3-4aa0-89e1-f3796f254436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e7db5be9-3de3-4aa0-89e1-f3796f254436" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e7db5be9-3de3-4aa0-89e1-f3796f254436_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e7db5be9-3de3-4aa0-89e1-f3796f254436" xlink:to="loc_us-gaap_EquityComponentDomain_e7db5be9-3de3-4aa0-89e1-f3796f254436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6ddac66-abc9-45c7-8ae7-33dfd9f11438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e7db5be9-3de3-4aa0-89e1-f3796f254436" xlink:to="loc_us-gaap_EquityComponentDomain_f6ddac66-abc9-45c7-8ae7-33dfd9f11438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f6ddac66-abc9-45c7-8ae7-33dfd9f11438" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_668d56ac-5367-4961-bfbd-4aaa1e5ca5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_668d56ac-5367-4961-bfbd-4aaa1e5ca5fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_897d7f55-db43-4c69-9db8-e450d6a126ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_897d7f55-db43-4c69-9db8-e450d6a126ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e6e0b291-cd44-4fdf-a484-d05e44668be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e6e0b291-cd44-4fdf-a484-d05e44668be2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_2f1eeebf-c12e-45ad-ae6b-568fe7784063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_2f1eeebf-c12e-45ad-ae6b-568fe7784063" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_454b1f59-7c09-4d68-8fec-8d53768f0427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_454b1f59-7c09-4d68-8fec-8d53768f0427" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_994114f9-d9c1-4d59-b7b9-2b8beaad713b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_994114f9-d9c1-4d59-b7b9-2b8beaad713b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_01d6d0f2-0f2c-48fc-9cff-871af550fa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_01d6d0f2-0f2c-48fc-9cff-871af550fa04" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="extended" id="i2c79db98b384447ca77a5b5ee173ef37_OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22b6adfb-ac27-4d9b-88f0-ee2b4fe28db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_42112124-cd7a-4158-b457-637ed24bfbec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22b6adfb-ac27-4d9b-88f0-ee2b4fe28db4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_42112124-cd7a-4158-b457-637ed24bfbec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_30ae7f1f-1df0-4c1d-8a8a-2f8dba01f0df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22b6adfb-ac27-4d9b-88f0-ee2b4fe28db4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_30ae7f1f-1df0-4c1d-8a8a-2f8dba01f0df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d54892ac-f06b-4a8d-a48b-ec01940a8c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_30ae7f1f-1df0-4c1d-8a8a-2f8dba01f0df" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d54892ac-f06b-4a8d-a48b-ec01940a8c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d54892ac-f06b-4a8d-a48b-ec01940a8c9f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d54892ac-f06b-4a8d-a48b-ec01940a8c9f" xlink:to="loc_us-gaap_EquityComponentDomain_d54892ac-f06b-4a8d-a48b-ec01940a8c9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d54892ac-f06b-4a8d-a48b-ec01940a8c9f" xlink:to="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a7cba686-ab83-4281-b249-a984b1638f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a7cba686-ab83-4281-b249-a984b1638f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_bee76e2a-0c50-4168-9498-5b201953b077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_bee76e2a-0c50-4168-9498-5b201953b077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_010c1e3c-5abd-4c28-b727-e164a6996c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_010c1e3c-5abd-4c28-b727-e164a6996c3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c28d1138-e593-4ff8-8b5b-283eadb8595c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c28d1138-e593-4ff8-8b5b-283eadb8595c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="ib4917237332c46bfa2d105e8e3b524c0_OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8c3ca1d5-4d39-46b9-892e-8f7331c2e2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8c3ca1d5-4d39-46b9-892e-8f7331c2e2f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a5b7806-8ffe-467e-a6b7-dcf6c9ad705b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a5b7806-8ffe-467e-a6b7-dcf6c9ad705b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1c5f1fad-54fe-42ef-8d86-d976ded59290" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1c5f1fad-54fe-42ef-8d86-d976ded59290" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_01258777-e216-4747-a5ae-3d604cd418dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_01258777-e216-4747-a5ae-3d604cd418dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a825f83e-4d01-4158-ac93-90a1f4af1229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a825f83e-4d01-4158-ac93-90a1f4af1229" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f082b757-5043-45d2-8529-e05a4cacf5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_ProfitLoss_f082b757-5043-45d2-8529-e05a4cacf5ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8d39068a-d41e-4798-a56e-31af285f675b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8d39068a-d41e-4798-a56e-31af285f675b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8d39068a-d41e-4798-a56e-31af285f675b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d39068a-d41e-4798-a56e-31af285f675b" xlink:to="loc_us-gaap_EquityComponentDomain_8d39068a-d41e-4798-a56e-31af285f675b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f22716f-ccac-40c3-967b-686cf754a8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d39068a-d41e-4798-a56e-31af285f675b" xlink:to="loc_us-gaap_EquityComponentDomain_7f22716f-ccac-40c3-967b-686cf754a8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_58498748-f02a-41a9-b31b-58a6edc803b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f22716f-ccac-40c3-967b-686cf754a8b7" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_58498748-f02a-41a9-b31b-58a6edc803b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_c644efd6-d06d-414a-8ea9-84611ceefebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_58498748-f02a-41a9-b31b-58a6edc803b6" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_c644efd6-d06d-414a-8ea9-84611ceefebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_d454da43-1926-4496-bc4a-73a97b4f1720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_58498748-f02a-41a9-b31b-58a6edc803b6" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_d454da43-1926-4496-bc4a-73a97b4f1720" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_37800a97-99b0-4baa-af83-7ee816422b1a" xlink:href="lly-20201231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7f22716f-ccac-40c3-967b-686cf754a8b7" xlink:to="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_37800a97-99b0-4baa-af83-7ee816422b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_62df7962-7821-4a27-8f5e-9a1441f894a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_62df7962-7821-4a27-8f5e-9a1441f894a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_62df7962-7821-4a27-8f5e-9a1441f894a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_62df7962-7821-4a27-8f5e-9a1441f894a1" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_62df7962-7821-4a27-8f5e-9a1441f894a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37ee610f-3bf0-4dda-9428-fb0b8ae45d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_62df7962-7821-4a27-8f5e-9a1441f894a1" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37ee610f-3bf0-4dda-9428-fb0b8ae45d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_eaee1d99-1467-409c-abf7-d5cfe26cd1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37ee610f-3bf0-4dda-9428-fb0b8ae45d8b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_eaee1d99-1467-409c-abf7-d5cfe26cd1a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpense"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended" id="i8eda6647ebce441f904677f8a9c9c529_OtherNetIncomeExpense"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpenseTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended" id="ie4b2add15e1249909106f23020efb159_OtherNetIncomeExpenseTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended" id="ideb5e9590e894be582cac8de66a304a9_OtherNetIncomeExpenseDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperations"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/DiscontinuedOperations" xlink:type="extended" id="i9b42f4637edc4225b10ad32085421e5f_DiscontinuedOperations"/>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsTables" xlink:type="extended" id="i0b60919010bb4605b4508a65cf2f86ea_DiscontinuedOperationsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="extended" id="ie602de9e085d4dd9a74d7eb598644fda_DiscontinuedOperationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_139c2975-0195-4eda-bd01-d222f46f1800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_139c2975-0195-4eda-bd01-d222f46f1800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SaleOfStockPercentageOfStockSold_909715c3-47dd-430f-ae65-e0f954d1df25" xlink:href="lly-20201231.xsd#lly_SaleOfStockPercentageOfStockSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_lly_SaleOfStockPercentageOfStockSold_909715c3-47dd-430f-ae65-e0f954d1df25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_db791345-5630-458b-9b31-6b596d5fadbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_db791345-5630-458b-9b31-6b596d5fadbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_e8d60803-03ea-47b1-af24-d59911a4a576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_e8d60803-03ea-47b1-af24-d59911a4a576" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_8d75786e-7670-4b72-917c-f86942d3ba8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_8d75786e-7670-4b72-917c-f86942d3ba8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4c951ea5-d8a5-4982-9762-1fee4f030645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4c951ea5-d8a5-4982-9762-1fee4f030645" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_90002d94-b150-4d71-a143-5f5b6024ad02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_DebtInstrumentTerm_90002d94-b150-4d71-a143-5f5b6024ad02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dca63257-edd1-4766-9c32-fa44d37a0e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dca63257-edd1-4766-9c32-fa44d37a0e60" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_82f16d0d-36e6-4f8a-97d7-ed3f9a599412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_82f16d0d-36e6-4f8a-97d7-ed3f9a599412" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_4d0607e8-f83e-4ce6-948c-02ba03659882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_4d0607e8-f83e-4ce6-948c-02ba03659882" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_9687c3f2-6043-4aa2-b896-550ffc1ed717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_9687c3f2-6043-4aa2-b896-550ffc1ed717" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_a1872649-a1eb-4b64-b730-83f10c90a55a" xlink:href="lly-20201231.xsd#lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_a1872649-a1eb-4b64-b730-83f10c90a55a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6b1138ac-cb6a-441d-970b-5172219b2ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6b1138ac-cb6a-441d-970b-5172219b2ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b1138ac-cb6a-441d-970b-5172219b2ae7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6b1138ac-cb6a-441d-970b-5172219b2ae7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b1138ac-cb6a-441d-970b-5172219b2ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c9b848b-be52-496a-b402-cb96ecb06ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6b1138ac-cb6a-441d-970b-5172219b2ae7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c9b848b-be52-496a-b402-cb96ecb06ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_2bee06c3-bdd2-4129-99d3-bcb3e71b460e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c9b848b-be52-496a-b402-cb96ecb06ce4" xlink:to="loc_us-gaap_IPOMember_2bee06c3-bdd2-4129-99d3-bcb3e71b460e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ff10821f-c8d7-4206-ba3c-27cdc4dec61f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_dei_LegalEntityAxis_ff10821f-c8d7-4206-ba3c-27cdc4dec61f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ff10821f-c8d7-4206-ba3c-27cdc4dec61f_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ff10821f-c8d7-4206-ba3c-27cdc4dec61f" xlink:to="loc_dei_EntityDomain_ff10821f-c8d7-4206-ba3c-27cdc4dec61f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_30efe76f-e885-4ee1-9fee-de7aff4312b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ff10821f-c8d7-4206-ba3c-27cdc4dec61f" xlink:to="loc_dei_EntityDomain_30efe76f-e885-4ee1-9fee-de7aff4312b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_c95e3978-d578-41a8-8d74-493b7f3e2a83" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_30efe76f-e885-4ee1-9fee-de7aff4312b1" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_c95e3978-d578-41a8-8d74-493b7f3e2a83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a2e00fa7-f376-4e25-94c4-517057b3fa32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a2e00fa7-f376-4e25-94c4-517057b3fa32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a2e00fa7-f376-4e25-94c4-517057b3fa32_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a2e00fa7-f376-4e25-94c4-517057b3fa32" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a2e00fa7-f376-4e25-94c4-517057b3fa32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_373f0877-a90e-4be4-ae24-50d870117be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a2e00fa7-f376-4e25-94c4-517057b3fa32" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_373f0877-a90e-4be4-ae24-50d870117be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TermFacilityMember_81101154-f63e-490d-89fc-6ec5e46f3ffc" xlink:href="lly-20201231.xsd#lly_TermFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_373f0877-a90e-4be4-ae24-50d870117be3" xlink:to="loc_lly_TermFacilityMember_81101154-f63e-490d-89fc-6ec5e46f3ffc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_85866dd9-ec47-4fdd-be0f-8861a608b5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_85866dd9-ec47-4fdd-be0f-8861a608b5b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85866dd9-ec47-4fdd-be0f-8861a608b5b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_85866dd9-ec47-4fdd-be0f-8861a608b5b3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85866dd9-ec47-4fdd-be0f-8861a608b5b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a113d75-1ea8-4b30-9b33-19a29d513f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_85866dd9-ec47-4fdd-be0f-8861a608b5b3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a113d75-1ea8-4b30-9b33-19a29d513f66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_ed1fcb4a-84c4-47a2-bbc7-afb3bc0d94af" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a113d75-1ea8-4b30-9b33-19a29d513f66" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_ed1fcb4a-84c4-47a2-bbc7-afb3bc0d94af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6753f8b0-ce25-4d27-85df-f178918c94d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6753f8b0-ce25-4d27-85df-f178918c94d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6753f8b0-ce25-4d27-85df-f178918c94d2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6753f8b0-ce25-4d27-85df-f178918c94d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6753f8b0-ce25-4d27-85df-f178918c94d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c7ab893d-d0fe-4524-bdac-83db8437429e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6753f8b0-ce25-4d27-85df-f178918c94d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c7ab893d-d0fe-4524-bdac-83db8437429e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e25bb7de-5cd4-45ce-bd1b-abf7d9d17152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c7ab893d-d0fe-4524-bdac-83db8437429e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e25bb7de-5cd4-45ce-bd1b-abf7d9d17152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_srt_OwnershipAxis_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3" xlink:to="loc_srt_OwnershipDomain_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_00c5f62b-a58c-4b0d-ad96-a04657cd3c0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3" xlink:to="loc_srt_OwnershipDomain_00c5f62b-a58c-4b0d-ad96-a04657cd3c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember_e34a9b6f-366a-472f-b6d1-7f0bfdda1485" xlink:href="lly-20201231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_00c5f62b-a58c-4b0d-ad96-a04657cd3c0a" xlink:to="loc_lly_EliLillyAndCompanyMember_e34a9b6f-366a-472f-b6d1-7f0bfdda1485" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails" xlink:type="extended" id="i41a38672100c4235bdcc35d135d6b631_DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bb2c025b-aab6-4e90-811b-9d55905c265b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aa077792-9070-4487-b08e-e0ca4edacca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bb2c025b-aab6-4e90-811b-9d55905c265b" xlink:to="loc_us-gaap_Revenues_aa077792-9070-4487-b08e-e0ca4edacca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c16cfa01-e5f8-435f-890a-5710334691f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bb2c025b-aab6-4e90-811b-9d55905c265b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c16cfa01-e5f8-435f-890a-5710334691f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bb2c025b-aab6-4e90-811b-9d55905c265b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_47343ab7-7a60-4a0b-8f58-6f90ac1987cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_47343ab7-7a60-4a0b-8f58-6f90ac1987cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47343ab7-7a60-4a0b-8f58-6f90ac1987cd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_47343ab7-7a60-4a0b-8f58-6f90ac1987cd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47343ab7-7a60-4a0b-8f58-6f90ac1987cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbf4d138-73dd-40e3-91f6-917d578ec28a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_47343ab7-7a60-4a0b-8f58-6f90ac1987cd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbf4d138-73dd-40e3-91f6-917d578ec28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_7c1ee6dc-443a-46cf-9062-96b0ab8ba520" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbf4d138-73dd-40e3-91f6-917d578ec28a" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_7c1ee6dc-443a-46cf-9062-96b0ab8ba520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f43061c9-04fb-4342-90bf-610f540631d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f43061c9-04fb-4342-90bf-610f540631d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f43061c9-04fb-4342-90bf-610f540631d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f43061c9-04fb-4342-90bf-610f540631d3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f43061c9-04fb-4342-90bf-610f540631d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_57cc07c1-37cb-4a1e-b6ec-2a5dc5812724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f43061c9-04fb-4342-90bf-610f540631d3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_57cc07c1-37cb-4a1e-b6ec-2a5dc5812724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_a7f3d211-ab95-4ec9-aa83-1903279df0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_57cc07c1-37cb-4a1e-b6ec-2a5dc5812724" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_a7f3d211-ab95-4ec9-aa83-1903279df0a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>lly-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:245edc66-3d73-4ffb-b61a-7d5e03b3f1e4,g:f11d2b17-0882-47f8-a810-701878e7e2df-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lly_AmpullaryCancerMember_fda05346-898d-4547-a7d2-77d5f5e076d4_terseLabel_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer</link:label>
    <link:label id="lab_lly_AmpullaryCancerMember_label_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer [Member]</link:label>
    <link:label id="lab_lly_AmpullaryCancerMember_documentation_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember" xlink:href="lly-20201231.xsd#lly_AmpullaryCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AmpullaryCancerMember" xlink:to="lab_lly_AmpullaryCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b1a231f5-67f8-4955-810b-ff0b7a756605_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OlumiantMember_3b462967-2ddb-40cd-9ed6-9a2d65dff991_terseLabel_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant&#174;</link:label>
    <link:label id="lab_lly_OlumiantMember_label_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:label id="lab_lly_OlumiantMember_documentation_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember" xlink:href="lly-20201231.xsd#lly_OlumiantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OlumiantMember" xlink:to="lab_lly_OlumiantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_0a66a54a-985d-4fc1-b562-69850c921784_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets, target allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_86cd6765-97b0-42d8-b1ce-633802e82dde_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future employer contributions, next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_fc943efd-1162-4881-ba0b-50422fff3735_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in benefit obligation:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_170b8132-6f3c-4b58-bdda-e3f0b53e6035_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_22af7780-3a3f-4d5a-9ccf-0ba464d914cd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e8822b6e-70cb-4f30-868a-a06614099792_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_99b4645a-d99a-4d8c-9f1d-132ec8bb6a63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LebrikizumabMember_114b315b-a39a-494d-8ba1-6ca9bbb09ea3_terseLabel_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab</link:label>
    <link:label id="lab_lly_LebrikizumabMember_label_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:label id="lab_lly_LebrikizumabMember_documentation_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember" xlink:href="lly-20201231.xsd#lly_LebrikizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LebrikizumabMember" xlink:to="lab_lly_LebrikizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NeuroscienceMember_32bb80b6-867f-4298-afbe-8318ce5500ba_terseLabel_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_lly_NeuroscienceMember_label_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_lly_NeuroscienceMember_documentation_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Neuroscience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember" xlink:href="lly-20201231.xsd#lly_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NeuroscienceMember" xlink:to="lab_lly_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_992cc42b-5d8b-44c3-ba2c-f1c9fafcb40f_terseLabel_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO Inventory Amount</link:label>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_label_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO Inventory Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LIFOInventoryAmount" xlink:to="lab_us-gaap_LIFOInventoryAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13dbeb48-4b43-4f00-a292-f20336b762c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year (includes $677.5 (2019) and $324.4 (2018) of discontinued operations)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c465eca0-36e3-4995-a8f9-2892d08ca641_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at End of Year (includes $677.5 (2018) of discontinued operations)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A7125NotesDue2025Member_d59981f6-70af-4fa5-bced-00eaf65175a2_terseLabel_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% notes due 2025</link:label>
    <link:label id="lab_lly_A7125NotesDue2025Member_label_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_lly_A7125NotesDue2025Member_documentation_en-US" xlink:label="lab_lly_A7125NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.125% Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member" xlink:href="lly-20201231.xsd#lly_A7125NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A7125NotesDue2025Member" xlink:to="lab_lly_A7125NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SelpercatinibLOXO292Member_7042cffb-9f62-469b-8e2e-d40a03a378a6_terseLabel_en-US" xlink:label="lab_lly_SelpercatinibLOXO292Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selpercatinib (LOXO-292)</link:label>
    <link:label id="lab_lly_SelpercatinibLOXO292Member_label_en-US" xlink:label="lab_lly_SelpercatinibLOXO292Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selpercatinib (LOXO-292) [Member]</link:label>
    <link:label id="lab_lly_SelpercatinibLOXO292Member_documentation_en-US" xlink:label="lab_lly_SelpercatinibLOXO292Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selpercatinib (LOXO-292) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member" xlink:href="lly-20201231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SelpercatinibLOXO292Member" xlink:to="lab_lly_SelpercatinibLOXO292Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_edc7ed05-19d4-44b9-8cc6-1f2796782eba_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_63bbb2f2-84e0-457f-99b5-2de25dd00740_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Postemployment Benefit Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherDiabetesMember_92128fdf-02f6-4430-a268-c76a28f711e9_terseLabel_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_label_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_documentation_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember" xlink:href="lly-20201231.xsd#lly_OtherDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherDiabetesMember" xlink:to="lab_lly_OtherDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DermiraInc.Member_57163ae2-f485-4776-96c3-1dbbebc7cd31_terseLabel_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira</link:label>
    <link:label id="lab_lly_DermiraInc.Member_label_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:label id="lab_lly_DermiraInc.Member_documentation_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member" xlink:href="lly-20201231.xsd#lly_DermiraInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DermiraInc.Member" xlink:to="lab_lly_DermiraInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_7c7b5d96-caff-459b-80c4-f8c61df40255_terseLabel_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, information used to determine revenue recognized, change in accounting estimate, percent</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_label_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_documentation_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:href="lly-20201231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:to="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1ab98206-08a2-42c8-a206-06caaf9fd672_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5fd0e29d-e2ee-4508-b4c8-1015b2edfe08_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c9c5f70-6bc5-4af9-92e2-091f8c196bf0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LoxoOncologyInc.Member_1d7953f8-dc5e-4163-b212-12c37365b86e_terseLabel_en-US" xlink:label="lab_lly_LoxoOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loxo Oncology, Inc.</link:label>
    <link:label id="lab_lly_LoxoOncologyInc.Member_label_en-US" xlink:label="lab_lly_LoxoOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loxo Oncology, Inc. [Member]</link:label>
    <link:label id="lab_lly_LoxoOncologyInc.Member_documentation_en-US" xlink:label="lab_lly_LoxoOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loxo Oncology, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LoxoOncologyInc.Member" xlink:to="lab_lly_LoxoOncologyInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5cbfddf4-1aec-4f2b-954c-dfced7fd6829_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_eddda1bb-461c-4ddd-bbab-141d1c267429_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f0e209a7-27be-44b6-ad9b-362915ba140c_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0ac199da-214f-4d3b-bba0-fbf2c4ffd43e_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ed219723-355f-4668-b265-552cbf4fa350_netLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b7df210a-54c8-463f-9280-bc3a10c07dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_3a677697-0726-4862-848c-7d1ace2797a3_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_d03c1c79-4402-48d1-a9f4-d7a2400b3fa7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e41ee609-e907-40e4-80cb-99adf67fdf81_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_ea603cbd-a6dc-476b-b4c9-963dc0581c52_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailment (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MarketableSecuritiesMember_9f7d9d61-920b-450a-af84-911d067919c4_terseLabel_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_label_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember" xlink:href="lly-20201231.xsd#lly_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MarketableSecuritiesMember" xlink:to="lab_lly_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_ca7f32b7-92ee-4627-adc4-dd16996fcce7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_6022daef-1ea2-47ac-a8b1-e4af326ffe4e_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_e602c3b0-0cf4-4b32-a754-28d6e48b4003_terseLabel_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims settled and dismissed, limited initial market entry, supply term</link:label>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_label_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</link:label>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_documentation_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:href="lly-20201231.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:to="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_723b570e-164a-4e42-9f39-4a5ade22576d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d8bb347c-02e9-4be0-b452-7b89ad6ea752_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9e6f7fc1-bf9f-4167-8e76-26f9788bcfe9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_508f1e41-c1da-4e15-9dd1-992996f67192_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_d4092983-6521-4c9a-af42-1e4435f238b0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e373ceeb-ade9-4bf2-8e0f-6dd3aecffedd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b3316c58-f78c-40f6-931c-5cea3e1d7c98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_e8697f75-ab94-4633-a2ce-2a93df21f266_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_45f53ecf-2e76-489f-8799-22d3ed94031b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40d1bd12-0e05-48a9-a61c-3859474a7e7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_4b1fb4bd-1907-4132-b145-7e9d03461191_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fdf79123-0e0e-4259-8681-b6c484a747d1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5f8c877d-ab9c-417a-8e05-7e308aa467fb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 1</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_c9ff0764-3bf3-4830-a4c4-ce3e71be6e33_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a5a31209-8846-492c-a1e8-e64adfee5957_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 4</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ad15c721-2907-4443-82a0-fb78316d01c1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_71ee0ff7-32dd-4c28-a812-03e3b9e2896f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_fd9e7530-bb6a-44db-b769-f3ad55a4b6d0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3a335663-255d-4096-be5f-89997a972f8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings from continuing operations - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DesignatedUnusableMember_352a8baa-d136-4ce9-8a28-03b114452ee2_terseLabel_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated Unusable</link:label>
    <link:label id="lab_lly_DesignatedUnusableMember_label_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated Unusable [Member]</link:label>
    <link:label id="lab_lly_DesignatedUnusableMember_documentation_en-US" xlink:label="lab_lly_DesignatedUnusableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember" xlink:href="lly-20201231.xsd#lly_DesignatedUnusableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DesignatedUnusableMember" xlink:to="lab_lly_DesignatedUnusableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JunshiBiosciencesMember_1c06baf3-d004-432b-9927-eb3f8085f291_terseLabel_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</link:label>
    <link:label id="lab_lly_JunshiBiosciencesMember_label_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences [Member]</link:label>
    <link:label id="lab_lly_JunshiBiosciencesMember_documentation_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember" xlink:href="lly-20201231.xsd#lly_JunshiBiosciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JunshiBiosciencesMember" xlink:to="lab_lly_JunshiBiosciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_3f8a0a91-12c2-42e5-9a8a-17049de63c0d_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_be00180a-5512-4a4d-982c-2d800cb57bf0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_c497d5a2-7e32-44dc-8c91-297583d83464_terseLabel_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment on hedged long-term notes</link:label>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_label_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value Adjustment</link:label>
    <link:label id="lab_lly_LongTermDebtFairValueAdjustment_documentation_en-US" xlink:label="lab_lly_LongTermDebtFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment to carrying value of long term debt to arrive at total fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment" xlink:href="lly-20201231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LongTermDebtFairValueAdjustment" xlink:to="lab_lly_LongTermDebtFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EvoxTherapeuticsMember_bcb66cc2-044d-4eb3-ac5a-63bae2d47536_terseLabel_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics Ltd</link:label>
    <link:label id="lab_lly_EvoxTherapeuticsMember_label_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics [Member]</link:label>
    <link:label id="lab_lly_EvoxTherapeuticsMember_documentation_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember" xlink:href="lly-20201231.xsd#lly_EvoxTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EvoxTherapeuticsMember" xlink:to="lab_lly_EvoxTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2fe3cd23-6227-4a71-bf4c-1a999f8fada5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_fd2b5b5d-4d3e-452e-a726-cef271cdfb55_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets (Note 14)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmployeeLitigationMember_040b8b1c-9076-4580-9b5e-5c916de5fcef_terseLabel_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_label_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_documentation_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember" xlink:href="lly-20201231.xsd#lly_EmployeeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmployeeLitigationMember" xlink:to="lab_lly_EmployeeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_3f3ebcf8-eaf6-460c-b326-32ab4fbddb06_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BR_001d1c06-f1b1-478f-b14a-b0251481dcee_terseLabel_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_label_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_eff88040-eed3-4af4-bbd2-2160986a983b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_5490513e-d817-4a5f-8e63-306d75a20617_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_dbe04bc7-b83c-4400-a6d5-4d82b70c9d1f_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92d78193-53f9-4340-92d9-c70c42a2b5ac_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_d5930e3e-f7b4-4c1b-8163-e587027a5253_terseLabel_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments to invest in venture capital funds, anticipated payment period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_label_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_documentation_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:href="lly-20201231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:to="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SigilonTherapeuticsMember_a7813a6d-f30a-43b9-87c5-f0d7aedd8bbf_terseLabel_en-US" xlink:label="lab_lly_SigilonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigilon Therapeutics, Inc.</link:label>
    <link:label id="lab_lly_SigilonTherapeuticsMember_label_en-US" xlink:label="lab_lly_SigilonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigilon Therapeutics [Member]</link:label>
    <link:label id="lab_lly_SigilonTherapeuticsMember_documentation_en-US" xlink:label="lab_lly_SigilonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigilon Therapeutics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SigilonTherapeuticsMember" xlink:href="lly-20201231.xsd#lly_SigilonTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SigilonTherapeuticsMember" xlink:to="lab_lly_SigilonTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2d21f62d-a646-4445-9530-21aa1f50196a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 6)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_f6a943c2-5adf-415d-9f5c-1736fd5727de_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0f06df62-7682-4ef2-b074-fe1fd046a1c3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8fa53c24-ae1a-40ec-adb2-17ac62ad8324_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications from continuing operations (net of tax)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_ffea2e93-ca51-4374-a45e-c09b4f9f3c80_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_a036e616-8c56-45e1-9c4b-1c32a3c847f3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6-10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_713a4221-155d-4ddd-840b-b51cb3bc3fca_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2e062635-a364-45d4-9573-ab65714a0b98_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BamlanivimabMember_247eeb8f-40c2-4c6c-82d6-14f752b68725_terseLabel_en-US" xlink:label="lab_lly_BamlanivimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bamlanivimab</link:label>
    <link:label id="lab_lly_BamlanivimabMember_label_en-US" xlink:label="lab_lly_BamlanivimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bamlanivimab [Member]</link:label>
    <link:label id="lab_lly_BamlanivimabMember_documentation_en-US" xlink:label="lab_lly_BamlanivimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bamlanivimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BamlanivimabMember" xlink:href="lly-20201231.xsd#lly_BamlanivimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BamlanivimabMember" xlink:to="lab_lly_BamlanivimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_3b69d952-97fb-4533-b860-62ff4faccefb_negatedTerseLabel_en-US" xlink:label="lab_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred federal income tax benefit, effect of 2017 Tax Act</link:label>
    <link:label id="lab_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_label_en-US" xlink:label="lab_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act</link:label>
    <link:label id="lab_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_documentation_en-US" xlink:label="lab_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:href="lly-20201231.xsd#lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:to="lab_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_7fed9eac-29a8-4425-9258-8d111fb2e5b8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8715e762-e753-430f-94bd-afb3f1afac4c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InnoventBiologicsIncMember_21e1f373-0f7d-4a0e-91b1-698a66ebe6d0_terseLabel_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. (Innovent)</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_label_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. [Member]</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_documentation_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember" xlink:href="lly-20201231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InnoventBiologicsIncMember" xlink:to="lab_lly_InnoventBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_c3ea7cf5-744d-4c54-8b1f-fc4c3bca5345_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, percentage of net revenue (less than)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_82e4614e-96e8-4e09-addd-cb2933a40c7c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NoExpirationMember_d355fcb5-d1f2-4a72-8353-59dc625f660b_terseLabel_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration</link:label>
    <link:label id="lab_lly_NoExpirationMember_label_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration [Member]</link:label>
    <link:label id="lab_lly_NoExpirationMember_documentation_en-US" xlink:label="lab_lly_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Those operating loss/tax credit carryforwards/carrybacks included that have no expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember" xlink:href="lly-20201231.xsd#lly_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NoExpirationMember" xlink:to="lab_lly_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_8b64fcc7-a55e-4717-a2a2-96b762502730_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_5a8f8536-2d55-4fde-b31d-6567c3cddb02_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85c43644-bd50-4262-bad4-0fb030b6e91d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f82bd668-fd61-4a21-aaaf-e1b738595c3f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_6c90d535-6090-422a-ac82-6ad3a58cd59b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_34fab350-b92c-462d-8f35-f029554d1053_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_934f24f5-2946-47ea-944d-ff0ab018afea_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_83a9aaeb-dbec-495a-a226-1ef360e095b3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFundsMember_28c9434d-afd5-4640-96c6-f8f17b19f0f2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-like funds</link:label>
    <link:label id="lab_us-gaap_EquityFundsMember_label_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFundsMember" xlink:to="lab_us-gaap_EquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ByettaMember_2ecd492a-2224-43b4-af75-58346a0fcf46_terseLabel_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:label id="lab_lly_ByettaMember_label_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta [Member]</link:label>
    <link:label id="lab_lly_ByettaMember_documentation_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember" xlink:href="lly-20201231.xsd#lly_ByettaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ByettaMember" xlink:to="lab_lly_ByettaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_3d118355-f80a-4214-939a-e229a1541b83_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherForeignCountriesMember_ecb37285-7d0a-4c5b-9efb-4b1d6ebf1a9c_terseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_436e205d-6055-45d8-b0f5-3c90a8a6fac2_verboseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_label_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_documentation_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember" xlink:href="lly-20201231.xsd#lly_OtherForeignCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherForeignCountriesMember" xlink:to="lab_lly_OtherForeignCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_5e462eb5-59cc-4874-9803-66046fe7c830_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_69e30ff8-8722-443b-9e31-3d0ec78bca1d_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones payments</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Rights (Obligations)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cd21b04b-ef80-4f91-9feb-5ebe425eb3b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ACImmuneSAMember_3cbc7193-5580-4661-ba15-2819fe218717_terseLabel_en-US" xlink:label="lab_lly_ACImmuneSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AC Immune SA</link:label>
    <link:label id="lab_lly_ACImmuneSAMember_label_en-US" xlink:label="lab_lly_ACImmuneSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AC Immune SA [Member]</link:label>
    <link:label id="lab_lly_ACImmuneSAMember_documentation_en-US" xlink:label="lab_lly_ACImmuneSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AC Immune SA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ACImmuneSAMember" xlink:href="lly-20201231.xsd#lly_ACImmuneSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ACImmuneSAMember" xlink:to="lab_lly_ACImmuneSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BasaglarMember_53cfd2c7-3ebd-4267-8901-a3464e0b7250_verboseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar&#174;</link:label>
    <link:label id="lab_lly_BasaglarMember_label_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:label id="lab_lly_BasaglarMember_documentation_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember" xlink:href="lly-20201231.xsd#lly_BasaglarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BasaglarMember" xlink:to="lab_lly_BasaglarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3777e2bc-1115-41e8-b52f-bdcc09d99f2a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_197de922-b5ef-4296-9cf4-775f560716b2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_220c6b20-91eb-4e71-98a9-e3f2d9b68295_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac2599fa-0d9d-4712-acd2-b5632c414f0c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_ba1cecec-f0e8-4110-95c4-adcf31633f1d_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, monthly reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:href="lly-20201231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2aed7119-f852-4efa-bccc-300e94c96b97_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_f9bd4a2f-96db-4520-a4f6-7e6f13a93f27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_cca975a0-6759-44fd-af23-bcfc70da26b3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial loss included in net income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_19a6d860-5364-4742-beb6-2e9c21456e76_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b6e8fa2a-7e38-444c-8c59-025b61933d7f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0f1c775-0a4f-4b45-b5d0-b7480bafd904_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_23ebff02-de6e-4cb8-8280-43abf24a3ee0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals for the payment of interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2a957107-cd0b-4919-8c81-e8a87513f647_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_df8edf2a-0901-4c06-b07b-2bfb1ed69db9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_4886688b-d4ce-464e-9a8f-75b46441cc0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held in employee trust (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrustShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrustShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a0fa167-88a6-4373-8d47-169f35b38fba_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision_592b8aff-3938-4e83-8c8b-8b39fec75f05_terseLabel_en-US" xlink:label="lab_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Tax Act, deferred taxes related to GILTI</link:label>
    <link:label id="lab_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision_label_en-US" xlink:label="lab_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision</link:label>
    <link:label id="lab_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision_documentation_en-US" xlink:label="lab_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" xlink:href="lly-20201231.xsd#lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" xlink:to="lab_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_fd766532-c3ac-4c48-9ccf-66eb7bb43ff3_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_e940aff6-149d-4afa-90a1-20d366ac337b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_af848e2b-466f-427d-ad17-6b1300f83114_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_03a38d98-296b-467c-9450-1f2bead6e62e_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:to="lab_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_fa4fa134-34c5-42f5-ba09-3c1d820c6301_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_49f07475-96fe-4803-aa36-212a2fb0d84d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaltzMember_800a0bda-5373-4e60-a680-21505f30d128_terseLabel_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz&#174;</link:label>
    <link:label id="lab_lly_TaltzMember_label_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:label id="lab_lly_TaltzMember_documentation_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember" xlink:href="lly-20201231.xsd#lly_TaltzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaltzMember" xlink:to="lab_lly_TaltzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_3be03f82-e672-4629-99ec-0fcb1e2e3dcc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable (Note 14)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_a7783fe4-9e01-4bff-b53b-fea418050fe1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A30NotesDue2022Member_60d1b812-4f36-4c8a-95ab-7d237dc5110f_terseLabel_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2022</link:label>
    <link:label id="lab_lly_A30NotesDue2022Member_label_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.0% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A30NotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A30NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.0% Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member" xlink:href="lly-20201231.xsd#lly_A30NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A30NotesDue2022Member" xlink:to="lab_lly_A30NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9ee42f61-f31a-4b86-8d86-adfb92b6cf89_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A395NotesDue2049Member_43355fb3-2ee7-461b-9a82-9a0e9ad56730_terseLabel_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% notes due 2049</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_label_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member" xlink:href="lly-20201231.xsd#lly_A395NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A395NotesDue2049Member" xlink:to="lab_lly_A395NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a7c99b4a-04bc-4d88-b8cf-f2a9f387a2cc_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VerzenioMember_1b400f94-2487-49b4-a153-6808ac877c0c_terseLabel_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio&#174;</link:label>
    <link:label id="lab_lly_VerzenioMember_label_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:label id="lab_lly_VerzenioMember_documentation_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember" xlink:href="lly-20201231.xsd#lly_VerzenioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VerzenioMember" xlink:to="lab_lly_VerzenioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A415NotesDue2059Member_5c0e5ea1-f6c9-4e49-972a-7b886fbb940f_terseLabel_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% notes due 2059</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_label_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_documentation_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member" xlink:href="lly-20201231.xsd#lly_A415NotesDue2059Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A415NotesDue2059Member" xlink:to="lab_lly_A415NotesDue2059Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_fd547caa-8189-495b-919d-e620f1d195d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Portion of Cash&#160;Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fa66d5d9-be5a-43e1-ac8f-38bf0b2ee943_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 2</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3f2c0310-b894-45ad-b7fb-db65ce866105_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_070d5a35-1dbb-472c-8fac-2e941edb873b_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd032ee7-0261-4bea-8c76-bc55e65a8d23_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_aa2f79f5-2950-4515-93c3-cee4596e840e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, selling, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_77476533-fc46-4cd2-9067-12236f027db8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_11cb9e32-f36e-4eee-9039-bb91feec2a71_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c2c4b618-3cf2-4e85-a9aa-c98b3eeaa089_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impact of Leases to Consolidated Condensed Financial Statements</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_df3c6ee4-acb6-4ba3-8192-812df4a689b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 3</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_463987ab-f0b6-4c26-a3e7-2250342d0335_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A595NotesDue2037Member_280eb5b4-c8b1-46f2-b3a5-a133e1a503d7_terseLabel_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% notes due 2037</link:label>
    <link:label id="lab_lly_A595NotesDue2037Member_label_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes Due 2037 [Member]</link:label>
    <link:label id="lab_lly_A595NotesDue2037Member_documentation_en-US" xlink:label="lab_lly_A595NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes Due 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member" xlink:href="lly-20201231.xsd#lly_A595NotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A595NotesDue2037Member" xlink:to="lab_lly_A595NotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7b6e0af4-0057-4557-93c5-598c82f78bbe_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_ed1a4260-a42b-45f1-acc9-4c66e109d132_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PancreatitisMember_9794edb3-1f94-4beb-a963-e2ae4b9ab015_terseLabel_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis</link:label>
    <link:label id="lab_lly_PancreatitisMember_label_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis [Member]</link:label>
    <link:label id="lab_lly_PancreatitisMember_documentation_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember" xlink:href="lly-20201231.xsd#lly_PancreatitisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PancreatitisMember" xlink:to="lab_lly_PancreatitisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_d09b9464-2890-4776-babf-bd407f3485de_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmuNextInc.Member_8cb2e3cf-eeb8-4a0e-b496-6b244b2a67b0_terseLabel_en-US" xlink:label="lab_lly_ImmuNextInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext, Inc.</link:label>
    <link:label id="lab_lly_ImmuNextInc.Member_label_en-US" xlink:label="lab_lly_ImmuNextInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext, Inc. [Member]</link:label>
    <link:label id="lab_lly_ImmuNextInc.Member_documentation_en-US" xlink:label="lab_lly_ImmuNextInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmuNextInc.Member" xlink:href="lly-20201231.xsd#lly_ImmuNextInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmuNextInc.Member" xlink:to="lab_lly_ImmuNextInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_cacb3436-ad07-40ec-94e1-3e87acbe8033_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_b59f953b-739b-449f-84d0-fb4a16466b1f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5b06ad96-40e2-4961-a6d4-c19602beeaf8_negatedLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of antibiotic business in China (Note 3)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_1798c7ef-3a34-4e32-b64f-fbcc55b673e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to disposition</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4a2c547d-9692-490c-8ad6-ded7923c1b5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of antibiotic business in China (Note 3)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8b573924-7631-4a7c-a455-3738f6f43772_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4626ae6a-8f4c-4be4-b57b-f95db657ff2e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_ab16f1d5-ca7f-4a70-8fae-d68a9d39df5a_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities - net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_label_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_documentation_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" xlink:to="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_bf763001-2594-45d4-a462-c78aa65f9bb8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5fd37ea2-170b-44ef-a1d4-71d423d8c1bd_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestiture</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherOncologyMember_f075d888-b3c8-472f-a8c4-62f5910afc85_terseLabel_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology</link:label>
    <link:label id="lab_lly_OtherOncologyMember_label_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_lly_OtherOncologyMember_documentation_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember" xlink:href="lly-20201231.xsd#lly_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherOncologyMember" xlink:to="lab_lly_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625EuroDeonominatedNotesDue2031Member_3eb45123-6819-4cb1-8d80-229624d45e7c_terseLabel_en-US" xlink:label="lab_lly_A625EuroDeonominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Euro denominated notes due 2031</link:label>
    <link:label id="lab_lly_A625EuroDeonominatedNotesDue2031Member_label_en-US" xlink:label="lab_lly_A625EuroDeonominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Euro-deonominated Notes Due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625EuroDeonominatedNotesDue2031Member_documentation_en-US" xlink:label="lab_lly_A625EuroDeonominatedNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Euro-deonominated Notes Due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member" xlink:href="lly-20201231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625EuroDeonominatedNotesDue2031Member" xlink:to="lab_lly_A625EuroDeonominatedNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_e84059f2-42be-44d0-ba94-88d58cf9cbc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_8968fe10-61fb-4ea5-946e-ec2a3888236a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_7f05a284-488e-4e97-8bc7-2f09693bb65f_terseLabel_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_label_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt [Member]</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_documentation_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed-Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember" xlink:href="lly-20201231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HedgedFixedRateDebtMember" xlink:to="lab_lly_HedgedFixedRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_36989792-2abd-48a8-9ffa-3ddaa6e3c360_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derecognized</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CarryforwardMember_28696256-2016-4d8b-b200-f493fa9c58c0_terseLabel_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carryforward</link:label>
    <link:label id="lab_lly_CarryforwardMember_label_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carryforward [Member]</link:label>
    <link:label id="lab_lly_CarryforwardMember_documentation_en-US" xlink:label="lab_lly_CarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember" xlink:href="lly-20201231.xsd#lly_CarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CarryforwardMember" xlink:to="lab_lly_CarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_afe15dd5-906a-4ce0-8447-40f230fc5e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_8224974e-2c80-415f-a269-e0824d42b5d3_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_54cf8d20-b24e-403d-9017-f0d0fa7e95f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_cea01e44-aeef-420f-8de2-66ee793aef42_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accumulated benefit obligation for our defined benefit pension plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_98e248ea-459f-4e9b-a715-a2e7bf4f3b33_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_eaf25188-23c1-409d-b5ee-8e35574a21b4_terseLabel_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation</link:label>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_label_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation [Member]</link:label>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_documentation_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember" xlink:href="lly-20201231.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AsahiKaseiPharmaCorporationMember" xlink:to="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd1a56dd-ba7f-4171-865b-e9b329acf242_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8e3a611-1f57-4a0a-ae34-b964b80b0538_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_426b6f6a-c8a3-4d97-8d38-57cce758decd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0b2a36ea-2bb6-4ea4-8871-a37dca8be744_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e09e142c-74ff-4078-9f4a-29f92903ca36_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxYears2013To2015Member_9a8f6cd9-89d0-4d1d-bfce-6448e55b9441_terseLabel_en-US" xlink:label="lab_lly_TaxYears2013To2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years 2013 to 2015</link:label>
    <link:label id="lab_lly_TaxYears2013To2015Member_label_en-US" xlink:label="lab_lly_TaxYears2013To2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years 2013 To 2015 [Member]</link:label>
    <link:label id="lab_lly_TaxYears2013To2015Member_documentation_en-US" xlink:label="lab_lly_TaxYears2013To2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years 2013 To 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxYears2013To2015Member" xlink:href="lly-20201231.xsd#lly_TaxYears2013To2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxYears2013To2015Member" xlink:to="lab_lly_TaxYears2013To2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueHedgeAbstract_6b2356cb-a13e-47f8-a5aa-5b1c76f4c289_terseLabel_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges:</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_label_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_documentation_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract" xlink:href="lly-20201231.xsd#lly_FairValueHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueHedgeAbstract" xlink:to="lab_lly_FairValueHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_30cd71b3-1f66-48a0-9072-3f2b4455bec8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_bef32987-7b26-4da5-ae1c-4b97f1af50f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_bb9e1531-3365-49fb-9b57-3209aa7e3934_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates replacement cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_ed39463d-c8bb-4760-a99c-9839dff3a0ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash operating activities, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b6b54d19-ce3f-4ebf-98e1-04e5498ba724_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_9271206a-a02a-46dc-b32d-63a0b742446d_verboseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AlimtaMember_be12a261-7509-4f7d-883a-705ec7407831_terseLabel_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta&#174;</link:label>
    <link:label id="lab_lly_AlimtaMember_label_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:label id="lab_lly_AlimtaMember_documentation_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember" xlink:href="lly-20201231.xsd#lly_AlimtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AlimtaMember" xlink:to="lab_lly_AlimtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_6b85f129-58d8-4851-8544-90982fc7ba96_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_27d224c1-8ee7-40d1-accf-713cc9286ab1_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_18b19367-5ba2-4d2e-b8f9-b22ce1e1b96f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_31af202a-a07e-48cd-8ccf-e4f4a7f49b91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings from continuing operations - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_b7148d61-45ea-4b76-b151-f41964554538_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_b54c835c-4886-4ba5-bb29-4aa50c5f351c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b3e64825-d9b6-43c9-936c-584883d3bcdb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_2c36a56c-1d15-4bb1-a305-87fc04f463ee_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3-5 Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e0febb3a-ac76-4fbf-b81e-3b21b4d1f4fa_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7be40667-13fa-4049-a9f5-5a0a5e3fad12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_a13ad4fa-2191-4bfe-b664-42866bf3467e_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_97cbeda4-ffba-4305-8249-5f4d5a7d4900_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired (Note 3)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_550e1408-5f53-4ec2-8725-ac2a7ff49d55_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_65f1963b-d540-4b88-8f5c-37ab6b99662f_totalLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ccbebadd-6f1f-4ac3-867b-40d05ec69a84_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_96a833b5-7c99-48c6-8a07-bfaf72a5e848_terseLabel_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Trust</link:label>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_label_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust for Benefit of Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:to="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5c342d9f-7383-4268-9280-76aa359d0027_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_83c95fbf-0f7c-43cb-baac-13d60d5affd0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_November2019EuroDenominatedNotesMember_2b0dda2b-37df-4527-9185-a29c3fad7305_terseLabel_en-US" xlink:label="lab_lly_November2019EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Euro-denominated Notes</link:label>
    <link:label id="lab_lly_November2019EuroDenominatedNotesMember_label_en-US" xlink:label="lab_lly_November2019EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Euro-denominated Notes [Member]</link:label>
    <link:label id="lab_lly_November2019EuroDenominatedNotesMember_documentation_en-US" xlink:label="lab_lly_November2019EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Euro-denominated Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019EuroDenominatedNotesMember" xlink:href="lly-20201231.xsd#lly_November2019EuroDenominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_November2019EuroDenominatedNotesMember" xlink:to="lab_lly_November2019EuroDenominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_fa1e3519-6904-4da3-bcfd-73875312cfad_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20201231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6e37b73a-460b-4b9f-80f9-64b4f77217a1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_Expiration5to20YearsMember_dd80d974-95f7-4296-8fab-d7d59e09d75d_terseLabel_en-US" xlink:label="lab_lly_Expiration5to20YearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration 5 to 20 Years</link:label>
    <link:label id="lab_lly_Expiration5to20YearsMember_label_en-US" xlink:label="lab_lly_Expiration5to20YearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration 5 to 20 Years [Member]</link:label>
    <link:label id="lab_lly_Expiration5to20YearsMember_documentation_en-US" xlink:label="lab_lly_Expiration5to20YearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration 5 to 20 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expiration5to20YearsMember" xlink:href="lly-20201231.xsd#lly_Expiration5to20YearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_Expiration5to20YearsMember" xlink:to="lab_lly_Expiration5to20YearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c1c9ddc3-3927-454c-9a0b-caf0196e21fd_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AssetAcquisitionAxis_9894ad66-e723-4784-9d0c-512abca59245_terseLabel_en-US" xlink:label="lab_lly_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_lly_AssetAcquisitionAxis_label_en-US" xlink:label="lab_lly_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_lly_AssetAcquisitionAxis_documentation_en-US" xlink:label="lab_lly_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetAcquisitionAxis" xlink:href="lly-20201231.xsd#lly_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AssetAcquisitionAxis" xlink:to="lab_lly_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9c0f8607-f752-4d7f-88ea-4256a36dbeb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5fc027de-48c1-40f1-87b2-88aae46e653d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_6e4658c0-826a-49fe-bd0f-77465e67c78d_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Borrowings Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:href="lly-20201231.xsd#lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_bbe10810-cc95-4b5e-b87a-6bbe57db2d61_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_f73fd05a-7a73-468b-8d6d-c2b8314de8a6_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by operating activities, discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_ad271ab6-2612-4218-996d-f4a9a46b08ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets related to state net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_a9fae0cf-88f8-4805-ab82-3b2553a8e7d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_603c5a39-7a65-4ab0-8740-4c3fa7ce3b5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmunologyMember_06442348-797c-4efe-ba1f-427cbb9fecac_terseLabel_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_lly_ImmunologyMember_label_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_lly_ImmunologyMember_documentation_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember" xlink:href="lly-20201231.xsd#lly_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmunologyMember" xlink:to="lab_lly_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_f3c3768b-6b55-470d-9785-1fc900776e9c_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProductLiabilityMember_985dd0cc-978f-4efb-963e-858c6eaaf8c8_terseLabel_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_label_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_documentation_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember" xlink:href="lly-20201231.xsd#lly_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProductLiabilityMember" xlink:to="lab_lly_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_dd46e294-1f48-4059-b638-513449f81cc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_67589e8b-a810-4e62-820d-56b4987d0fed_negatedLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_c149cb02-abcd-4529-93bd-0ca697967dee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_a87a8926-9204-40c0-9fd7-44ac315393b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_dbc68de2-01e8-4514-b58c-f6d41ea5dd16_terseLabel_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Euro denominated notes due 2026</link:label>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_label_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Euro-denominated Notes Due 2026 [Member]</link:label>
    <link:label id="lab_lly_A1625EuroDenominatedNotesDue2026Member_documentation_en-US" xlink:label="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Euro-denominated Notes Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member" xlink:href="lly-20201231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625EuroDenominatedNotesDue2026Member" xlink:to="lab_lly_A1625EuroDenominatedNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_794bce23-4899-470e-b1a5-ac0b676647b5_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_cda6d10f-11e5-4a2a-ac51-dac82430c33d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d9863df2-229d-4ada-9214-fb4880ae3f22_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_3e499ad8-ada2-4211-93b9-1a4ce85adc4a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_c52ec288-95fa-4f67-95e8-dd897b110431_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_78821a98-4145-48f3-9ca4-81acb17a9ddf_terseLabel_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross gains on sales</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_label_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_documentation_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:href="lly-20201231.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:to="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_b4c5277a-98f9-4195-9003-93c59dca0ef0_terseLabel_en-US" xlink:label="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, not discontinued operation, payment to be received</link:label>
    <link:label id="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_label_en-US" xlink:label="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Payment To Be Received</link:label>
    <link:label id="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_documentation_en-US" xlink:label="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Payment To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:href="lly-20201231.xsd#lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:to="lab_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_81fb1f57-3638-4b59-ad80-d8d34e91b859_terseLabel_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss Franc denominated notes due 2024</link:label>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_label_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss Franc-denominated Notes Due 2024 [Member]</link:label>
    <link:label id="lab_lly_A015SwissFrancDenominatedNotesDue2024Member_documentation_en-US" xlink:label="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% Swiss Franc-denominated Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:href="lly-20201231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:to="lab_lly_A015SwissFrancDenominatedNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_3e76cc05-8d46-454c-91dc-df48a1385a30_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_e4fc7521-7ab4-4343-ad67-cc550c6f6522_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_0d2ccb1f-9894-4ac6-9556-87b581cb520d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c8b62047-9bf7-49db-aebf-89bd42efc5eb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_2622127d-30c5-40d5-898b-545e2093d4d0_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026-2030</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1c7b5957-b006-4878-a275-9fbfb5d2f90d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_edbe4dae-3ba7-40cd-aad4-531be1ea9b61_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_a980accc-1cd0-477c-b9ab-8a2ef984b8c9_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_28ec9e9a-6f8d-4a78-b9df-e054e46a7ae8_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_c1f3c3eb-4d4e-420c-88a1-e4a41948ebce_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_1d173c7f-84d6-4c8c-8d2b-93bbb5b3b8a2_terseLabel_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Euro denominated notes due 2030</link:label>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_label_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Euro-denominated Notes Due 2030 [Member]</link:label>
    <link:label id="lab_lly_A2125EuroDenominatedNotesDue2030Member_documentation_en-US" xlink:label="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Euro-denominated Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member" xlink:href="lly-20201231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2125EuroDenominatedNotesDue2030Member" xlink:to="lab_lly_A2125EuroDenominatedNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_0b84bb2b-9d9a-4259-b622-e328f1aff942_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Operating Cost and Expense, by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_de5809fc-18d5-485b-aa0d-176e677c793f_terseLabel_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current federal tax expense, effect of 2017 Tax Act</link:label>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_label_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act</link:label>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_documentation_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:href="lly-20201231.xsd#lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:to="lab_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_47a6afb0-4791-4901-bd2d-59af57ac438c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A235NotesDue2022Member_4a3c5f19-a67e-471c-bc50-085a464145b8_terseLabel_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_lly_A235NotesDue2022Member_label_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A235NotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A235NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member" xlink:href="lly-20201231.xsd#lly_A235NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A235NotesDue2022Member" xlink:to="lab_lly_A235NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_2a326246-4cd4-4b18-9af8-1bf38434078a_terseLabel_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</link:label>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_label_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member]</link:label>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:href="lly-20201231.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:to="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_b6396f3e-1988-4212-8dd5-72e70675d9b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_dbb2f646-4763-44fa-b545-543ad41a5ab5_terseLabel_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_label_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_documentation_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:href="lly-20201231.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:to="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_92ed8e4b-16ed-471b-998e-1b0b1666c661_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in effective portion of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_d8a37f8f-5602-4dd4-b989-2d3c2648f3ea_terseLabel_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.42% Japanese Yen denominated notes due 2029</link:label>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_label_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.42% Yen-denominated Notes Due 2029 [Member]</link:label>
    <link:label id="lab_lly_A42YenDenominatedNotesDue2029Member_documentation_en-US" xlink:label="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.42% Yen-denominated Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member" xlink:href="lly-20201231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A42YenDenominatedNotesDue2029Member" xlink:to="lab_lly_A42YenDenominatedNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cb6088da-a3fc-4ada-9424-fbe835321efe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_c54155c8-3ca2-47ee-8a09-d47eb2c65597_terseLabel_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_label_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler V. Takeda Canada Inc. Et Al. [Member]</link:label>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler V. Takeda Canada Inc. Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:href="lly-20201231.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:to="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_08157d2e-194d-4f23-802e-74a1f3756c00_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations percent</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations Percent</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_6633043f-b603-49c2-8f5b-e8b46bb9979e_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-3 Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_64324629-a32e-4efa-8c87-a564c6ff28a7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_398110cc-7c09-43ea-a56c-eab2a9d61c49_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79814687-f7d4-41b0-88f8-f2ec95b83dcc_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrulicityMemberMember_c106aafe-5f3f-48e1-8654-059f05eb95d3_terseLabel_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity&#174;</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_label_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_documentation_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember" xlink:href="lly-20201231.xsd#lly_TrulicityMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrulicityMemberMember" xlink:to="lab_lly_TrulicityMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c692cfdb-409b-4553-abf2-0066da71afe1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_fdd9449c-36c6-4064-9919-3732f1472f58_negatedTerseLabel_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:href="lly-20201231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:to="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DiabetesMember_0228d25d-5f44-447f-8b55-2b9cba583df3_terseLabel_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_lly_DiabetesMember_label_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:label id="lab_lly_DiabetesMember_documentation_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember" xlink:href="lly-20201231.xsd#lly_DiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DiabetesMember" xlink:to="lab_lly_DiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_42227648-df20-41bd-a98a-e938ebd3a25b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VariousStateDomicilesMember_34f93a4f-ec43-439b-b0bb-900e91a86f14_terseLabel_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles</link:label>
    <link:label id="lab_lly_VariousStateDomicilesMember_label_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles [Member]</link:label>
    <link:label id="lab_lly_VariousStateDomicilesMember_documentation_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember" xlink:href="lly-20201231.xsd#lly_VariousStateDomicilesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VariousStateDomicilesMember" xlink:to="lab_lly_VariousStateDomicilesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_820e24e7-5423-45e0-a531-03b2063ed438_terseLabel_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross losses on sales</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_label_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_documentation_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:href="lly-20201231.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:to="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_57037957-fb07-4726-af90-7f2c25cdb72f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvidityBiosciencesInc.Member_606a7907-a4f1-4707-9868-652212991c05_terseLabel_en-US" xlink:label="lab_lly_AvidityBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avidity Biosciences, Inc.</link:label>
    <link:label id="lab_lly_AvidityBiosciencesInc.Member_label_en-US" xlink:label="lab_lly_AvidityBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avidity Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_AvidityBiosciencesInc.Member_documentation_en-US" xlink:label="lab_lly_AvidityBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avidity Biosciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvidityBiosciencesInc.Member" xlink:href="lly-20201231.xsd#lly_AvidityBiosciencesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvidityBiosciencesInc.Member" xlink:to="lab_lly_AvidityBiosciencesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_d627b8a8-cb28-4f39-9cf6-5ca13af35c30_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_5e7339fb-84cb-49e6-a44b-34e0abf4742f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_31d16d51-926b-4eba-bfab-cdba2d21afb2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward-starting interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f598bba7-ddf7-4543-a932-bb89625dcb78_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_00d861ba-86f6-44a8-b850-be171a56719e_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_2da3005d-526b-4b5f-8d64-01558995a1c7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3782bf3c-6739-46b8-9257-9b105d5e34bd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4c9a3ec0-49b4-473a-8224-401ed177afdb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_f2e8a063-3bf1-4422-9805-8ee31e360624_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_39d7e589-26b3-4f56-ae45-3f40aef50d02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EliLillyAndCompanyMember_0670fd44-28e3-4d17-b273-b093a6015f24_terseLabel_en-US" xlink:label="lab_lly_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company</link:label>
    <link:label id="lab_lly_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_lly_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_lly_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_lly_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember" xlink:href="lly-20201231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EliLillyAndCompanyMember" xlink:to="lab_lly_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_905380df-adf9-4b52-a0bc-710e3d5fda58_terseLabel_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_label_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp V. Takeda Canada Inc. Et Al. [Member]</link:label>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp V. Takeda Canada Inc. Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember" xlink:href="lly-20201231.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EppVTakedaCanadaIncEtAlMember" xlink:to="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AurkaPharmaMember_8c5fb7a8-cd12-4344-a2f3-8159b653a43d_terseLabel_en-US" xlink:label="lab_lly_AurkaPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AurKa Pharma Inc.</link:label>
    <link:label id="lab_lly_AurkaPharmaMember_label_en-US" xlink:label="lab_lly_AurkaPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurka Pharma [Member]</link:label>
    <link:label id="lab_lly_AurkaPharmaMember_documentation_en-US" xlink:label="lab_lly_AurkaPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurka Pharma [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AurkaPharmaMember" xlink:href="lly-20201231.xsd#lly_AurkaPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AurkaPharmaMember" xlink:to="lab_lly_AurkaPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TanezumabMember_45cbf32d-bdd9-4f0f-ae4a-5fd245be7a5a_terseLabel_en-US" xlink:label="lab_lly_TanezumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tanezumab</link:label>
    <link:label id="lab_lly_TanezumabMember_label_en-US" xlink:label="lab_lly_TanezumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tanezumab [Member]</link:label>
    <link:label id="lab_lly_TanezumabMember_documentation_en-US" xlink:label="lab_lly_TanezumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tanezumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TanezumabMember" xlink:href="lly-20201231.xsd#lly_TanezumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TanezumabMember" xlink:to="lab_lly_TanezumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_1e2ee0fa-b429-4554-98fe-5838c4411a41_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation, period increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1ed61a8d-e6ba-4f02-9ae4-4f49a0735667_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_188c8bfc-162c-4ac3-9cf3-1f27eabeb0e0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1392b99d-51c9-4415-9179-5ebbec3e73e8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_278e4caf-3425-424e-8de6-366e9172beed_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5828b952-aa55-474c-9130-ebd0be4d1e93_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_4443c8a9-c6b1-4da7-a6e3-7dd9fe86094d_terseLabel_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, days from date of shipment, maximum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_label_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Maximum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMaximum_documentation_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum" xlink:href="lly-20201231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuefromContractPaymentTermMaximum" xlink:to="lab_lly_RevenuefromContractPaymentTermMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_855b992c-1d84-4ab6-9d61-4f987fb956b1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_529ac324-95f0-45d3-9015-17359e8a46a2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_9c307c00-e7c4-4a87-a5de-8cd3fa172881_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_81f6d78d-f9d5-499a-9429-c1ecee4f48f7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A3875NotesDue2039Member_4e93a120-89c5-43c9-8468-03ce5abc3bd0_terseLabel_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2039</link:label>
    <link:label id="lab_lly_A3875NotesDue2039Member_label_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2039 [Member]</link:label>
    <link:label id="lab_lly_A3875NotesDue2039Member_documentation_en-US" xlink:label="lab_lly_A3875NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member" xlink:href="lly-20201231.xsd#lly_A3875NotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A3875NotesDue2039Member" xlink:to="lab_lly_A3875NotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_e3dd0b15-77eb-4185-93b8-8c528e87b151_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_45cd73ac-bdba-4913-8a71-07e6669b975a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Portion of Cash&#160;Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_e18a7a1e-1fa4-48ff-b596-feac186b4c9d_terseLabel_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Puerto Rican companies contribution</link:label>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_label_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Puerto Rican Contribution to Income before Income Taxes</link:label>
    <link:label id="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_documentation_en-US" xlink:label="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:href="lly-20201231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:to="lab_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_caf3db53-742b-4e4c-a087-5a81d94b1048_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 8)</link:label>
    <link:label id="lab_us-gaap_Goodwill_7db76e06-3853-4fc6-badb-ab5013a78dd0_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ffb88db1-e60b-4ec0-adf5-3fdf6d3bb98a_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_075b978d-09a7-430f-8aab-7ec79c20a705_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_41d193e6-3b36-4ab1-865d-e4d636c44fa2_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20201231.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba1e5d1b-13ff-48fe-b277-1dc2c40f2df1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6061a4e7-7fee-4e77-b2f0-836fd67e4cde_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards and carrybacks</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_3ecbff4c-260c-4fb3-9e50-46a9631b3caa_terseLabel_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, payment terms, days from date of shipment, minimum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_label_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term, Minimum</link:label>
    <link:label id="lab_lly_RevenuefromContractPaymentTermMinimum_documentation_en-US" xlink:label="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum" xlink:href="lly-20201231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuefromContractPaymentTermMinimum" xlink:to="lab_lly_RevenuefromContractPaymentTermMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5e44aba6-510a-4ab9-9c73-9d7ea642b061_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable&#8212;increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_9bcbc5d3-1ab0-4c79-8de4-5d52388b7d1c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_96123c84-32ab-41ce-89f5-5ec16879eee4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_4528fed7-9399-4511-8d3d-d081226e6368_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International operations, including Puerto Rico</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear_44ceec27-3970-4e0d-a572-9573a45fcc72_terseLabel_en-US" xlink:label="lab_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future employer discretionary contributions, next fiscal year</link:label>
    <link:label id="lab_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear_label_en-US" xlink:label="lab_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Discretionary Contributions, Next Fiscal Year</link:label>
    <link:label id="lab_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear_documentation_en-US" xlink:label="lab_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Discretionary Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" xlink:href="lly-20201231.xsd#lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" xlink:to="lab_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_11703998-186a-4ee4-8f97-58bae11a297a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c0bfa147-5352-4462-b55b-92e3f6a0044f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1643e6e4-9ecc-43ae-9b83-ee01e516e4ca_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_5d408484-15dc-4e5a-b7f8-1c64d2644972_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a6b9f066-29be-4262-a0e3-37424bfb71cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ba587d3f-535c-463e-9a9a-9e93c57e3044_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_374f519b-c007-4a26-9791-329726bdb750_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3761a4f6-6b9b-4276-8bbc-2f0cbaa25b9c_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, product expiration date</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Product Expiration Date</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Product Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_9ad16f99-7f6c-48f7-89b1-9a0fc6566404_terseLabel_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited</link:label>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_label_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited [Member]</link:label>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember" xlink:href="lly-20201231.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SitryxTherapeuticsLimitedMember" xlink:to="lab_lly_SitryxTherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_08802727-d36c-438b-8ee0-2ad0e90f3fa8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d2b8dbf9-a49b-4805-a92e-8f74b2a5ab07_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ARMOBiosciencesInc.Member_34889f87-9e3a-41c3-991c-ae4ea60fc30d_terseLabel_en-US" xlink:label="lab_lly_ARMOBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARMO BioSciences, Inc. (ARMO)</link:label>
    <link:label id="lab_lly_ARMOBiosciencesInc.Member_label_en-US" xlink:label="lab_lly_ARMOBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARMO Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_ARMOBiosciencesInc.Member_documentation_en-US" xlink:label="lab_lly_ARMOBiosciencesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARMO Biosciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ARMOBiosciencesInc.Member" xlink:href="lly-20201231.xsd#lly_ARMOBiosciencesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ARMOBiosciencesInc.Member" xlink:to="lab_lly_ARMOBiosciencesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_a72b8d28-2e08-4ca4-ba9e-5571bc3f73f5_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_086154c7-7164-4ebe-a835-2591941c50cb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ddf6bf48-91b3-4b7d-b8d8-2b9bffa846d7_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_411aaec0-1336-459e-b961-8a54fa13a891_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_bbb49b6a-1dc7-452a-bdcc-83ef3a9cdba4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MaturityDate2023Member_a5adeb6f-34dc-4dc4-a049-9161cd3e9978_terseLabel_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2023</link:label>
    <link:label id="lab_lly_MaturityDate2023Member_label_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2023 [Member]</link:label>
    <link:label id="lab_lly_MaturityDate2023Member_documentation_en-US" xlink:label="lab_lly_MaturityDate2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member" xlink:href="lly-20201231.xsd#lly_MaturityDate2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MaturityDate2023Member" xlink:to="lab_lly_MaturityDate2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NonCHINAMember_95b43b03-dc8c-4004-ba23-6521b89ced18_terseLabel_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of China</link:label>
    <link:label id="lab_lly_NonCHINAMember_label_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA [Member]</link:label>
    <link:label id="lab_lly_NonCHINAMember_documentation_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember" xlink:href="lly-20201231.xsd#lly_NonCHINAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NonCHINAMember" xlink:to="lab_lly_NonCHINAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AnimaBiotechMember_5e3ef0db-1580-47cf-94e0-4f9bbb906022_terseLabel_en-US" xlink:label="lab_lly_AnimaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anima Biotech Inc.</link:label>
    <link:label id="lab_lly_AnimaBiotechMember_label_en-US" xlink:label="lab_lly_AnimaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anima Biotech [Member]</link:label>
    <link:label id="lab_lly_AnimaBiotechMember_documentation_en-US" xlink:label="lab_lly_AnimaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anima Biotech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AnimaBiotechMember" xlink:href="lly-20201231.xsd#lly_AnimaBiotechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AnimaBiotechMember" xlink:to="lab_lly_AnimaBiotechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4c5a7579-7219-4e7b-8f68-15448b504b20_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ea7de71f-5749-4c63-a840-4101d3ff600c_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_2dc68457-e09a-473c-8692-480c8af007b1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6e35e3fe-5297-4c63-ae75-5ce25396190d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_363c9894-ac6b-4ad0-b73e-f0b02238caa2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value&#8232; Authorized shares: 3,200,000&#8232; Issued shares: 957,077 (2020)&#160;and 958,056 (2019)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_a3c83782-cbe6-43ae-b540-37313fae0a24_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments (Note 7)</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_4299d4b0-09d0-4e86-9005-2836bf0e64be_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_b886c31f-7a32-4801-9fae-e8c656a09013_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8b10ac9b-664d-4dae-bd72-9884a4c23c84_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a0d75881-2f9f-4ff6-afd8-194dfcd6ae5d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_b6719134-2280-4a82-b912-b12fab47002c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3fdc933a-e9d8-4ada-a1f2-8ab9f662de38_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_afafe04d-fa9d-4762-94ce-74ef2127ea52_terseLabel_en-US" xlink:label="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China</link:label>
    <link:label id="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_label_en-US" xlink:label="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member]</link:label>
    <link:label id="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_documentation_en-US" xlink:label="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:href="lly-20201231.xsd#lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:to="lab_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_50e32e22-061b-463e-a4d1-5916dcb0a641_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation at beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_6421cd22-72eb-45ad-80e9-c2f48218e784_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation at end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_b39af3fd-f5bd-4669-81ee-0fbc025204f4_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f5d45e36-b217-47a8-8b81-52d77ca25c77_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_599537b8-dd50-4e06-b817-c7d4726d7651_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer_cabf3911-065d-4aa0-bfb2-4705d2a01d97_negatedTerseLabel_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of common stock in exchange offer</link:label>
    <link:label id="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer_label_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Acquired During Period, Value, Exchange Offer</link:label>
    <link:label id="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer_documentation_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Acquired During Period, Value, Exchange Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:href="lly-20201231.xsd#lly_StockAcquiredDuringPeriodValueExchangeOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:to="lab_lly_StockAcquiredDuringPeriodValueExchangeOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_95b7a3bb-9966-4675-8ff4-b46cc4345937_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and current maturities of long-term debt (Note 11)</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_a9058943-f85f-492e-aaa3-ea286d0d653d_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A37NotesDue2045Member_e1c41215-f4af-4692-87d1-e76fb4684bb7_terseLabel_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% notes due 2045</link:label>
    <link:label id="lab_lly_A37NotesDue2045Member_label_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% Notes Due 2045 [Member]</link:label>
    <link:label id="lab_lly_A37NotesDue2045Member_documentation_en-US" xlink:label="lab_lly_A37NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.7% Notes Due 2045</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member" xlink:href="lly-20201231.xsd#lly_A37NotesDue2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A37NotesDue2045Member" xlink:to="lab_lly_A37NotesDue2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_0550421b-cd90-42b4-893b-db52af14ab86_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e99fc43f-af7f-4e55-939c-ea3b2e187329_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share (EPS)</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a7903dea-b843-4e80-96fe-4b201762e99d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A97YenDeonominatedNotesDue2049Member_d8cd51e1-0c45-41ac-854d-5e4c94d40bfa_terseLabel_en-US" xlink:label="lab_lly_A97YenDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.97% Japanese Yen denominated notes due 2049</link:label>
    <link:label id="lab_lly_A97YenDeonominatedNotesDue2049Member_label_en-US" xlink:label="lab_lly_A97YenDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.97% Yen-deonominated Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A97YenDeonominatedNotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A97YenDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.97% Yen-deonominated Notes Due 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member" xlink:href="lly-20201231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A97YenDeonominatedNotesDue2049Member" xlink:to="lab_lly_A97YenDeonominatedNotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ElancoAnimalHealthIncorporatedMember_b6626ca9-022b-49a9-b076-bac6111ab092_verboseLabel_en-US" xlink:label="lab_lly_ElancoAnimalHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco</link:label>
    <link:label id="lab_lly_ElancoAnimalHealthIncorporatedMember_label_en-US" xlink:label="lab_lly_ElancoAnimalHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco Animal Health Incorporated [Member]</link:label>
    <link:label id="lab_lly_ElancoAnimalHealthIncorporatedMember_documentation_en-US" xlink:label="lab_lly_ElancoAnimalHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elanco Animal Health Incorporated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ElancoAnimalHealthIncorporatedMember" xlink:to="lab_lly_ElancoAnimalHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_9e226ce3-1b52-4795-bb91-2ce670603a78_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_39ba8e96-267a-48b4-be95-90aa5e2d5e66_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_409a4954-d231-456c-bb54-1c91ecc728c0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8e7e9ef9-7ef6-4af4-9820-d005e9082a46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_31420106-0d84-4c1a-9cae-b4b1e9adaf35_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Note 7)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_5b87639e-c579-47f0-b6ed-dbef16cdd2ff_totalLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaid_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SaleOfStockPercentageOfStockSold_2aa65d1a-708d-4cb8-b37f-fdad8a0fce87_terseLabel_en-US" xlink:label="lab_lly_SaleOfStockPercentageOfStockSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock sold</link:label>
    <link:label id="lab_lly_SaleOfStockPercentageOfStockSold_label_en-US" xlink:label="lab_lly_SaleOfStockPercentageOfStockSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Percentage Of Stock Sold</link:label>
    <link:label id="lab_lly_SaleOfStockPercentageOfStockSold_documentation_en-US" xlink:label="lab_lly_SaleOfStockPercentageOfStockSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Percentage Of Stock Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SaleOfStockPercentageOfStockSold" xlink:href="lly-20201231.xsd#lly_SaleOfStockPercentageOfStockSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SaleOfStockPercentageOfStockSold" xlink:to="lab_lly_SaleOfStockPercentageOfStockSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_5a0b405e-450e-4950-98bd-2885c7078c76_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized gain position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:href="lly-20201231.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:to="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_54da9688-5026-43e5-b512-69e9d855a66f_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:href="lly-20201231.xsd#lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyGBPSellUSDMember_8595bb6d-54cc-4c23-9514-34ca81c0ad4e_terseLabel_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD</link:label>
    <link:label id="lab_lly_BuyGBPSellUSDMember_label_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD [Member]</link:label>
    <link:label id="lab_lly_BuyGBPSellUSDMember_documentation_en-US" xlink:label="lab_lly_BuyGBPSellUSDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy GBP Sell USD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember" xlink:href="lly-20201231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyGBPSellUSDMember" xlink:to="lab_lly_BuyGBPSellUSDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8434eb8b-192a-493f-aa44-9b39ce17bd3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_fa90bf13-9620-4e4a-8ea8-5d4033caf48c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_660ddae7-f683-4627-ab73-8977508cc1b4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns, rebates, and discounts</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_f757e139-9ce6-4fca-a871-bd3b7a9ff342_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_Expirationwithin5yearsMember_c624f64f-e195-4cb2-9af9-570c8abace34_terseLabel_en-US" xlink:label="lab_lly_Expirationwithin5yearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration within 5 years</link:label>
    <link:label id="lab_lly_Expirationwithin5yearsMember_label_en-US" xlink:label="lab_lly_Expirationwithin5yearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration within 5 years [Member]</link:label>
    <link:label id="lab_lly_Expirationwithin5yearsMember_documentation_en-US" xlink:label="lab_lly_Expirationwithin5yearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration within 5 years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationwithin5yearsMember" xlink:href="lly-20201231.xsd#lly_Expirationwithin5yearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_Expirationwithin5yearsMember" xlink:to="lab_lly_Expirationwithin5yearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e1393f0d-3ba1-4d18-b41a-1770e8d8cc17_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 11)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_399f53db-79fd-44ec-93c3-702715b6b094_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_616ecf6b-5b4e-4b46-8c3e-dc96102396d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_6dcc0480-2383-47f8-8260-a62f7fda67ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_80c9bb1b-ad3a-405c-83be-c2f6d51f3922_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_93c107f5-787c-49ce-a353-5bdf569206ae_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Eli Lilly and Company shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_50228d0e-7ca8-491a-aeb2-d0afb45398f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_4f57cec1-b540-492e-89b8-63418487cf0d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bfb565b4-252a-4cdf-8b86-4b600cf7e23f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_2d572834-f975-47cf-a6bd-2339fb9f04a4_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term notes</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9008e2f3-9947-4b70-bf01-1176833753bf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba3f9fee-fe33-43ae-b5ed-e0a9dc8b1eb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_d30979fd-f16b-489f-b3e8-723651367deb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D charges</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5db616e9-a4b7-480e-80ae-34ffe6607c53_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_f91758eb-01d1-4926-82f1-a1fe37919538_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_4af1a64e-faf6-4925-92e5-6757fbb402ef_verboseLabel_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_label_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES And PUERTO RICO [Member]</link:label>
    <link:label id="lab_lly_UNITEDSTATESAndPUERTORICOMember_documentation_en-US" xlink:label="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES And PUERTO RICO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember" xlink:href="lly-20201231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_UNITEDSTATESAndPUERTORICOMember" xlink:to="lab_lly_UNITEDSTATESAndPUERTORICOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e4faf2ee-365d-4a9a-a5b2-0791cdb1ca3b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 5</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f79d937b-9f43-45df-9012-15671e37f102_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_b42cdf67-2647-4e47-974b-ddbf6b784e83_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_4dfd943f-f722-4fee-b562-834d6ec42244_terseLabel_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_label_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_documentation_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember" xlink:href="lly-20201231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityPatentLitigationMember" xlink:to="lab_lly_EmgalityPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_7ae1b044-0ff4-4337-8a66-2462fb9dd73d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d33f1ca4-1e9c-41d1-984d-463aabcfa83c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_5ad99def-4d04-4e4c-84d7-baac222e5e1c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) from continuing operations:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d879ff3a-fa40-4e44-8596-59e26fb4a1dc_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5e7e994e-a396-486f-93ff-5f1743635a33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_b67f6770-28f6-4c87-aa2c-942d31fdf896_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20201231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_c61c2e6c-d6fe-432f-9007-94df4d123ba9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8e5794c4-d72e-45c7-b7d2-a4a5b164e417_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_70465012-9351-41e1-be49-40df2cccf5f3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_c4d87cf4-0cd5-42ac-8a78-0ae93d82151f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bf8ee9be-192b-4a67-bf0a-6bb6777cb4ab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ActosMember_a1a9ac3a-4136-4d22-b3b0-9290babee9f9_terseLabel_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos</link:label>
    <link:label id="lab_lly_ActosMember_label_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos [Member]</link:label>
    <link:label id="lab_lly_ActosMember_documentation_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember" xlink:href="lly-20201231.xsd#lly_ActosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ActosMember" xlink:to="lab_lly_ActosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomicileOfLitigationDomain_a45fe751-aec4-47d4-8f8b-ed556f21551c_terseLabel_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile of Litigation [Domain]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationDomain_label_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation [Domain]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationDomain_documentation_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain" xlink:href="lly-20201231.xsd#lly_DomicileOfLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomicileOfLitigationDomain" xlink:to="lab_lly_DomicileOfLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_01a4678c-6d7a-4e51-8e47-205f187171c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_99abc9d0-8442-4a21-af0b-f448a2069102_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_c99d4747-0f18-4d05-8296-f24efa73b776_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a62077f7-9c37-4b3f-ba9b-3573ec0c0c4d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d41ad11b-8bb1-4110-820f-3c62876c9d66_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0ecf2004-a7d9-4d24-9bc2-0f625b36679c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5ce65ec8-8af6-4c62-a434-d0ec0bddb9f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1c549522-ecf0-4ce6-87a3-12d54464a995_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_928114ef-c513-4830-81de-8577313fac39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_5f769364-6e21-4453-a583-df1cb5b8ab57_terseLabel_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transitional services agreement, term</link:label>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_label_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term</link:label>
    <link:label id="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_documentation_en-US" xlink:label="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:href="lly-20201231.xsd#lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:to="lab_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6e7a0d0a-b536-4f7f-ba20-729a80e6756b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (benefit) cost included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_913dc8c1-4405-4372-be61-a90dd399e2a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Valued at Net Asset Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_0dc2e6d9-54dd-4c83-b48b-fd01e28c311c_terseLabel_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% Euro denominated notes due 2022</link:label>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_label_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.0% Euro-denominated Notes Due 2022 [Member]</link:label>
    <link:label id="lab_lly_A10EuroDenominatedNotesDue2022Member_documentation_en-US" xlink:label="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.0% Euro-denominated Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member" xlink:href="lly-20201231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A10EuroDenominatedNotesDue2022Member" xlink:to="lab_lly_A10EuroDenominatedNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_53df5a43-f593-4fb2-917e-12edb14a2d1c_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to disposition of Elanco (Note 19)</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_e4c4103b-d444-4b95-a346-25eb9de8e590_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to disposition</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d693c091-db01-4486-84b3-8475368012ba_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_cd64d616-96e6-44f9-b83f-2ac29c06f702_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c3677238-8ef8-452c-9eba-581cbef7afe7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_bd6aa25d-e1d1-4a5e-b039-5eae857ebdf6_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales returns, average inventory level (or less)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Average Inventory Level</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Returns, Average Inventory Level</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:to="lab_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityMember_116bc69b-8b85-48d2-9152-56994d6933e4_terseLabel_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality&#174;</link:label>
    <link:label id="lab_lly_EmgalityMember_label_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:label id="lab_lly_EmgalityMember_documentation_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember" xlink:href="lly-20201231.xsd#lly_EmgalityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityMember" xlink:to="lab_lly_EmgalityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_06fe5c59-e759-4811-b866-09651b196f62_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_31fb773e-e565-4a87-8b53-3fe450796e3c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_7a910629-a17a-4d46-9771-ac1dad9a1fa7_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20201231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_a3c06bcc-909b-4b09-bfec-965998ca5f54_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes related to the impact of foreign currency translation, increase</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8913de61-8b37-4488-b2bd-c6d4a92a596f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9fdd7e34-2516-4d0a-a9bd-c53cd6160ec2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_de32c536-da10-4440-9d2a-b0e9d4e293ee_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_bf47e516-5f3e-4282-9b2c-1b62a360c163_terseLabel_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts" xlink:href="lly-20201231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SalesRebatesAndDiscounts" xlink:to="lab_lly_SalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_c1dfd484-e0f3-4d0b-bfce-ecb306ae9feb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CentrexionTherapeuticsCorporationMember_7d410e70-6b64-443d-a563-ea052155e55c_terseLabel_en-US" xlink:label="lab_lly_CentrexionTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centrexion Therapeutics Corporation</link:label>
    <link:label id="lab_lly_CentrexionTherapeuticsCorporationMember_label_en-US" xlink:label="lab_lly_CentrexionTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centrexion Therapeutics Corporation [Member]</link:label>
    <link:label id="lab_lly_CentrexionTherapeuticsCorporationMember_documentation_en-US" xlink:label="lab_lly_CentrexionTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centrexion Therapeutics Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CentrexionTherapeuticsCorporationMember" xlink:href="lly-20201231.xsd#lly_CentrexionTherapeuticsCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CentrexionTherapeuticsCorporationMember" xlink:to="lab_lly_CentrexionTherapeuticsCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DrReddysLabMember_f88a9b63-6bc8-492c-9872-edfef00eab1c_terseLabel_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab</link:label>
    <link:label id="lab_lly_DrReddysLabMember_label_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab [Member]</link:label>
    <link:label id="lab_lly_DrReddysLabMember_documentation_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember" xlink:href="lly-20201231.xsd#lly_DrReddysLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DrReddysLabMember" xlink:to="lab_lly_DrReddysLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_00c4427b-fa93-46a7-8a43-2bfddd69ae83_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_58966b2b-ffa8-4e0c-b7ca-90a8b0b1e6bd_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_520e1b59-2cec-4113-88ab-d3cb34530769_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense under the plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_09257378-d6c6-4d76-abc5-2409b1cd3f07_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_45fc0aee-6a10-49f4-a865-f0da5ac152b8_negatedTotalLabel_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_label_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_documentation_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain(loss) Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:href="lly-20201231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:to="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CialisMember_9372bf1a-8c56-42fb-b334-744d81534f55_terseLabel_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis&#174;</link:label>
    <link:label id="lab_lly_CialisMember_label_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:label id="lab_lly_CialisMember_documentation_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember" xlink:href="lly-20201231.xsd#lly_CialisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CialisMember" xlink:to="lab_lly_CialisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_b13c044e-801d-42df-a12f-6520bd8fb523_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in the consolidated balance sheet consisted&#160;of:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_d0ef260c-6b3c-4537-8aaf-4d73b508a218_terseLabel_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_documentation_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember" xlink:href="lly-20201231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherEquitySecuritiesMember" xlink:to="lab_lly_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_04b25532-6ee6-441d-846c-c0aba744fe28_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_838630c0-8c61-44e2-8e03-ba042997f694_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_f3d08fab-2d67-419c-8b1c-cb0db0e85098_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_79888f29-e35a-450a-bb73-4bede11ed013_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_2307da76-dc1d-448d-bd56-1cb16a2bb087_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2911c1f0-caa8-4aed-86f4-e3f416275f9b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_797603eb-f665-4f25-8c98-41271c10a12f_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8212;net, (income) expense (Note 18)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_fecb9f13-f3c1-4288-9e23-66a2d1dc085c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_3e752bcd-e60f-44d5-8ce3-bc349b96eec8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_0a9e893b-fb3d-4f17-8973-a59b5595067e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from hedged fixed-rate debt</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_383b8892-0e79-4d54-b304-53714f933163_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gains&#160;(Losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_c6f66b94-d6d9-47ac-ab6b-0d8b5a6ed775_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_9dc6f533-1dd0-4af8-b55f-bdb126ff9d6d_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3ce45e6b-0a5d-45cc-940d-daeac7385662_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_3266a799-d0bd-4fe7-a4fc-3f2526fcb16d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Net Gains (Losses) on&#160;Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_53eff2ca-0f58-4183-965b-d9cdcac0f098_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b355ea9d-7b65-4387-bc5c-a3d382b5a716_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_52ac56c7-cd77-401a-8259-cce0ad6c0325_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_2f24d6aa-02b6-4341-8d17-b3b99bda6440_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_3c49e007-211b-423a-88f8-0d3d7e1b2373_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_bfad7987-cbca-44fd-afed-d4c1f5b2a7ac_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for interest on borrowings</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_1bce3a2b-9fc7-4efb-b716-183d09d63b05_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_9d7c52a1-03a2-400a-ac4a-424de4b42488_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities on long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A3375NotesDue2029Member_8756c88a-5ccc-4a02-a538-f8817aa7071a_terseLabel_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% notes due 2029</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_label_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_documentation_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member" xlink:href="lly-20201231.xsd#lly_A3375NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A3375NotesDue2029Member" xlink:to="lab_lly_A3375NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c6c0c6c7-c15c-4972-b7c9-aaaa1117c75c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc92dd80-3792-40a4-9b7c-e95eb0e91372_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3c83464e-3a5f-4c3a-9f0e-e00115e6fd03_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5c95299-b6db-4405-ab66-9b1a397f8783_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aeaac85e-96a2-45bb-91da-f9e2e7004477_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8846fc94-c843-47d3-a949-1a1587b3b3c9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ced49834-9f2e-4cb7-8635-912a9d0ccce7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable_f8aa7c68-f7c4-4a7c-be46-421aa03434d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase and redemption of notes payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_2c343b94-4236-41cf-ac3b-e8d71e32467d_terseLabel_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense, percentage of revenue</link:label>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_label_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense, Percentage Of Revenue</link:label>
    <link:label id="lab_lly_AdvertisingExpensePercentageOfRevenue_documentation_en-US" xlink:label="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense, Percentage Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AdvertisingExpensePercentageOfRevenue" xlink:href="lly-20201231.xsd#lly_AdvertisingExpensePercentageOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AdvertisingExpensePercentageOfRevenue" xlink:to="lab_lly_AdvertisingExpensePercentageOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9978f247-8abd-41fe-906c-53e107d4577b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4d28ff20-d3b9-4638-8343-4f6013972044_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_18d55b46-228f-4d65-9973-7084826c827d_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from discontinued operations</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_78bf9e61-d326-4128-b11c-4fd706ed707e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_39eb4b71-f11b-43e2-9911-7c2098fdff9a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for sale of antibiotic business in China</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_20e5b8d7-81cc-4e68-ac46-66b381227706_terseLabel_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_7e594c22-22d7-40bc-819b-2a8d90e78a66_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents ruled unpatentable</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents Ruled Unpatentable</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents Ruled Unpatentable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:to="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a365c25f-a917-4a88-8584-285bf4a9bdb3_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_59d2689b-4f8e-4fa3-b556-81a249949f8e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_963affa9-9087-4c7f-979d-07e7c481c1c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_c0284d15-ad41-46b9-93e3-bf57320639e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForteoMember_a79241c9-a593-4a0b-8a1a-4f32a85c72de_terseLabel_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo&#174;</link:label>
    <link:label id="lab_lly_ForteoMember_label_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:label id="lab_lly_ForteoMember_documentation_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember" xlink:href="lly-20201231.xsd#lly_ForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForteoMember" xlink:to="lab_lly_ForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_3074e191-10c0-4821-9864-d5cff7d1ffe0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7c58f546-19f3-4e94-9d77-93d7a1da4d37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long-term Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d53f3a57-6690-4c90-ab39-6d99d1028794_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4003194d-ea3e-473f-8c84-d76c9a1f6451_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_c967d551-7135-40eb-824d-4557515f71cc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_afb20122-b4e2-478d-8704-80eea013d423_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of businesses, net of cash divested</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8443227a-670e-46f4-87bc-a1f47e930f11_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_47f7ef93-c768-4a48-b14d-149d4b4cda6a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0271ae67-c689-4d26-a488-e81d94530065_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RocheMember_a3ad3e77-b726-4a83-acaa-fb4ec41d5c9b_terseLabel_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_lly_RocheMember_label_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_lly_RocheMember_documentation_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember" xlink:href="lly-20201231.xsd#lly_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RocheMember" xlink:to="lab_lly_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_917e08c5-b976-4414-9b6e-fc1f952a4ffe_terseLabel_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares expected to be issued (in shares)</link:label>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_label_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued</link:label>
    <link:label id="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_documentation_en-US" xlink:label="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares expected to be issued in the next twelve months under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:href="lly-20201231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:to="lab_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e23c98e-679e-458b-b86c-3e8b237c42be_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_16dde248-fbf8-4ccf-84f6-ee0ae03dbaaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_6f4de53a-592f-4911-bf0f-7c36846fa7e2_terseLabel_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell USD</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_label_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell Us Dollar [Member]</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_documentation_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Commitment to Buy euro Sell US dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember" xlink:href="lly-20201231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyEuroSellUsDollarMember" xlink:to="lab_lly_BuyEuroSellUsDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_41624822-5436-4dba-aae8-40f319d9c2aa_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2eef88b3-b540-4453-811d-658bc9d59211_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_6d7bf467-0bb3-4eba-bf07-7f4af2b4c8a8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_4b0b9b0d-b906-482f-9f27-8c4d38d46b0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_63cee50b-dacf-41b1-85e4-fc59059e2d91_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_9f131285-cb60-4e97-b4c6-9cbbb0297d42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments to invest in venture capital funds</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_9e516e1e-7f50-4911-b020-9281ccb7cbde_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual net sales threshold (greater than)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Terms, Annual Net Sales Threshold</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_94021957-0540-4719-b445-8855eafbdb78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in effective portion of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_93f37ba6-df9f-4650-a5f7-d76dfbf11242_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9de274da-2be5-4bb9-9992-ea5552f73ab6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer_89744272-9a66-4ec3-b048-33cd61e7fd5a_terseLabel_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of common stock in exchange offer (in shares)</link:label>
    <link:label id="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer_label_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Acquired During Period, Shares, Exchange Offer</link:label>
    <link:label id="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer_documentation_en-US" xlink:label="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Acquired During Period, Shares, Exchange Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:href="lly-20201231.xsd#lly_StockAcquiredDuringPeriodSharesExchangeOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:to="lab_lly_StockAcquiredDuringPeriodSharesExchangeOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ffc23d42-83ae-4485-8790-651c16a61715_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AssetAcquisitionDomain_ef317180-6cb2-4bd0-883e-8c03f9dedf58_terseLabel_en-US" xlink:label="lab_lly_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_lly_AssetAcquisitionDomain_label_en-US" xlink:label="lab_lly_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_lly_AssetAcquisitionDomain_documentation_en-US" xlink:label="lab_lly_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetAcquisitionDomain" xlink:href="lly-20201231.xsd#lly_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AssetAcquisitionDomain" xlink:to="lab_lly_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1338cb75-be20-47bc-a9fa-f44d4beec30f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_7456673e-69a5-4735-bbda-1c3353d4c444_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_b096ccde-b639-4db8-ae6c-935917435968_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment, restructuring, and other special charges (Note 5)</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_cc5c2bc7-3d7c-4fe5-b0dc-a0a06fcf9c3f_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_label_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Settlement and Impairment Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_122fec92-678e-49f6-8a6b-89dc85a293cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b424c0c-c838-4f7b-adea-d214612f6785_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_4ef5f49e-e505-4aec-9104-ad529cb53777_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_bd050495-7025-4fd5-8556-d4e8454694c0_terseLabel_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of derivative activity volume percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_label_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_documentation_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:href="lly-20201231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:to="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_54f588d3-de2c-4214-a8f4-deb4757f26a5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_49c5d664-e590-4c77-955a-523bb7e8a7d2_terseLabel_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. (AbCellera)</link:label>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_label_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. [Member]</link:label>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_documentation_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member" xlink:href="lly-20201231.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AbCelleraBiologicsInc.Member" xlink:to="lab_lly_AbCelleraBiologicsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ZyprexaMember_742c5844-a98c-4966-896b-a1c5a2b4e366_terseLabel_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa&#174;</link:label>
    <link:label id="lab_lly_ZyprexaMember_label_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:label id="lab_lly_ZyprexaMember_documentation_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember" xlink:href="lly-20201231.xsd#lly_ZyprexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ZyprexaMember" xlink:to="lab_lly_ZyprexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_46ebdffd-532d-4142-926f-e708c6a556c5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_99149f70-ad13-4450-936b-b3a934e7c559_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_db926146-fe23-4cb9-a48a-c28e92691cb0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_4404dc07-cc60-4b66-9d97-5bfdf8ba017d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_27525c92-755d-4fd9-968f-3fe1496f2bb3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e672e99f-ec72-4e06-ba84-32bd6f23463d_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_5808d147-a4cf-4389-b1e6-f97215233fde_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e92d0491-aed1-4d4d-aeef-2775b337713f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities&#8212;increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_a4ad0983-c29a-42be-89aa-7559e9cfcd4e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock in Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_ddc363c7-84dd-45d7-8523-9d73f5349f0b_terseLabel_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes due 2022</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_label_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_documentation_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member" xlink:href="lly-20201231.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.000NotesDueJune22022Member" xlink:to="lab_lly_A1.000NotesDueJune22022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_606c435a-60c7-46c2-8318-1d27af59af04_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember_95ce05b2-c211-42a1-921c-1fde2399d15c_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_769dc100-c724-4258-bf2d-ceb353061cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_a8774cc2-8f3a-4be2-9a02-6ead3693697a_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherContractMember_92b813e8-56ad-4462-b17d-255a2959fe0b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash value of trust owned insurance contract</link:label>
    <link:label id="lab_us-gaap_OtherContractMember_label_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherContractMember" xlink:to="lab_us-gaap_OtherContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_76ea73ad-1327-45a3-809c-e146b2d87fee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_38094650-79a7-4b93-9dcb-66657d1f2431_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_8e4756a7-0f98-4dc5-bdf0-67a8feafe91c_terseLabel_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss Franc denominated notes due 2028</link:label>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_label_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss Franc Denominated Notes Due 2028 [Member]</link:label>
    <link:label id="lab_lly_A045SwissFrancDenominatedNotesDue2028Member_documentation_en-US" xlink:label="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.45% Swiss Franc Denominated Notes Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:href="lly-20201231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:to="lab_lly_A045SwissFrancDenominatedNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_ca1aeb81-cd51-42ab-ae74-5580b69dbb9f_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8a1c6b0e-2f02-4c0c-a1c5-abbd0c35a425_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-5 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A555NotesDue2037Member_2fe253b1-d7fa-434d-9721-ce88793dc178_terseLabel_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% notes due 2037</link:label>
    <link:label id="lab_lly_A555NotesDue2037Member_label_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% Notes Due 2037 [Member]</link:label>
    <link:label id="lab_lly_A555NotesDue2037Member_documentation_en-US" xlink:label="lab_lly_A555NotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.55% Notes Due 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member" xlink:href="lly-20201231.xsd#lly_A555NotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A555NotesDue2037Member" xlink:to="lab_lly_A555NotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_afc5f0d8-60e6-49f6-aec7-7bb79cda397d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8fb567a2-99c2-472d-a4e7-002f99d01e87_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities (Note 14)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_7ddf3c0e-fc19-409b-afdd-ada1ac25e563_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c6f512d7-fe2c-4f49-b3bc-3985f23a1ec2_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net (Note 8)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1c40f4be-e8da-4cb7-9520-a2ae465f7460_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary_99843059-7ae4-4dca-a053-60fdbb080072_terseLabel_en-US" xlink:label="lab_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from Elanco initial public offering (Note 19)</link:label>
    <link:label id="lab_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary_label_en-US" xlink:label="lab_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity from Subsidiary</link:label>
    <link:label id="lab_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary_documentation_en-US" xlink:label="lab_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity from Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary" xlink:href="lly-20201231.xsd#lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary" xlink:to="lab_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_f9d79773-b5ea-4b28-ae94-4c692ab7efc6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CashFlowHedgeAbstract_40bd6eb6-2ab1-4a11-9f2a-94a5155fead1_terseLabel_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_label_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_documentation_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract" xlink:href="lly-20201231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CashFlowHedgeAbstract" xlink:to="lab_lly_CashFlowHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_712ba99c-50fd-4c26-9026-53a7b8a1abb8_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_bfce196a-574e-4a56-bfa4-ee97dcd74cc9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recorded for Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_432246cc-a1f8-4a60-bd65-a2fc336e9cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_19c38fe3-67dd-4ba9-a8fa-09f92c5dca1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_69fc2432-b4d9-447e-87c6-cf159035d658_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_3711c423-ab15-43fd-960e-ae76a6508ab9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_01d73bbb-abfc-4b52-b211-5bd190a02e24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_aa38007d-fc4c-4f74-91bd-14387c76499b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Year 5</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_81a7edc0-a537-4724-ae9d-7a973c4d494d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable (Note 14)</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_118fa9f5-350b-4165-9d0e-f9b50302c600_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_630f55bf-d52e-4c99-ba26-773f7712e24f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax at the U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_dccc58d1-52ea-4040-8092-35480ec1d2d4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_509f4877-c4fa-46b0-8230-ebe71a62ce03_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_3529388d-5ca1-45dc-8c78-2e1d8ed53aa8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e78bd853-f737-43da-996a-0a39616d05c2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7e1a87cf-d53b-4f45-80d5-e225150dbaf5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_55eefaac-e012-4c5f-b86a-285dc280919d_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1bd714d5-0c88-4cd3-853d-fc41a7b8efb4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment loss (Note 11)</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_e9796c83-77f5-4f13-a7ec-ed6d5f952e47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized note discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A677NotesDue2036Member_0de58987-c45e-49b3-811d-ad7fd81c4448_terseLabel_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% notes due 2036</link:label>
    <link:label id="lab_lly_A677NotesDue2036Member_label_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes Due 2036 [Member]</link:label>
    <link:label id="lab_lly_A677NotesDue2036Member_documentation_en-US" xlink:label="lab_lly_A677NotesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes Due 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member" xlink:href="lly-20201231.xsd#lly_A677NotesDue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A677NotesDue2036Member" xlink:to="lab_lly_A677NotesDue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4f410018-a879-4347-a749-4f73a19d6f17_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_88616531-94d4-4b54-879e-c809fab84c05_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_96d4b299-51cc-4b22-9522-5229efb98be8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90b9c7b9-7609-4e48-92cf-2cdac0eb2dc4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_88ddd36b-a1fd-4cfa-9da8-6170b6e1d69f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUsdSellEuroMember_d757a3b4-b117-4d09-8456-edcb59292a4f_terseLabel_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro</link:label>
    <link:label id="lab_lly_BuyUsdSellEuroMember_label_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro [Member]</link:label>
    <link:label id="lab_lly_BuyUsdSellEuroMember_documentation_en-US" xlink:label="lab_lly_BuyUsdSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember" xlink:href="lly-20201231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUsdSellEuroMember" xlink:to="lab_lly_BuyUsdSellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MerusNVMember_4cdacf36-a9a8-467d-b2a5-8067333df875_terseLabel_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V.</link:label>
    <link:label id="lab_lly_MerusNVMember_label_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V. [Member]</link:label>
    <link:label id="lab_lly_MerusNVMember_documentation_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember" xlink:href="lly-20201231.xsd#lly_MerusNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MerusNVMember" xlink:to="lab_lly_MerusNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_85ef4fa4-e54d-41e5-86f0-9f675e321ee4_terseLabel_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment (gain) and other special charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_label_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_documentation_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:href="lly-20201231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:to="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_e9bdf01a-e1d9-4b08-8372-8791b07910aa_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_c0052951-3b9e-42af-b55e-8119f2b7e277_terseLabel_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District of California</link:label>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_label_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District Of California [Member]</link:label>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_documentation_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District Of California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember" xlink:href="lly-20201231.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SouthernDistrictOfCaliforniaMember" xlink:to="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_d1b5ba81-3c3e-4e6a-a9a2-b938a3782ce5_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes related to the impact of foreign currency translation, decrease</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3cb00715-f4b8-45b5-a942-e8949a62c478_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_9296e72c-65ca-45c9-b5fa-8d68373def7a_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_0becf425-2efd-4542-ba12-ecc420d726eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings from discontinued operations - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_0577045a-b3d1-4e7f-b718-22ef83cbd107_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_0d97f51c-985d-49b9-86a7-d3824dd94e1b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of nonperforming assets</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5bc9764c-f953-4033-839e-267c97230942_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_d060a6e5-3798-4a24-9f12-1d2dc78254fe_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Sales Rebates And Discounts</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Sales Rebates And Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:to="lab_lly_DeferredTaxAssetsSalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_d09bff1f-9191-4225-8ff6-8583e5f2a731_terseLabel_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, lease, remaining lease term (up to)</link:label>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Remaining Lease Term</link:label>
    <link:label id="lab_lly_LesseeLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LesseeLeaseRemainingLeaseTerm" xlink:href="lly-20201231.xsd#lly_LesseeLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LesseeLeaseRemainingLeaseTerm" xlink:to="lab_lly_LesseeLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_e58170e0-7553-472d-b727-f9ae3d454f91_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_1929a212-321c-4092-b705-80ca5ebae724_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MaturityDate2019Member_4830c489-221a-4494-b2d8-2c3e0f1f77e0_terseLabel_en-US" xlink:label="lab_lly_MaturityDate2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2019</link:label>
    <link:label id="lab_lly_MaturityDate2019Member_label_en-US" xlink:label="lab_lly_MaturityDate2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2019 [Member]</link:label>
    <link:label id="lab_lly_MaturityDate2019Member_documentation_en-US" xlink:label="lab_lly_MaturityDate2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2019Member" xlink:href="lly-20201231.xsd#lly_MaturityDate2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MaturityDate2019Member" xlink:to="lab_lly_MaturityDate2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_214e1dd5-547b-410f-85e8-ce6480923570_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d47b855b-09bd-40fc-afde-267059dec919_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_4fe9459d-cd93-4553-ae10-d67eaada4a21_terseLabel_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Axis]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_label_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Axis]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_documentation_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis" xlink:href="lly-20201231.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PlaintiffAllegationsAxis" xlink:to="lab_lly_PlaintiffAllegationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A31NotesDue2027Member_6847787d-8f35-4e65-8852-16c7da92e587_terseLabel_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% notes due 2027</link:label>
    <link:label id="lab_lly_A31NotesDue2027Member_label_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% Notes Due 2027 [Member]</link:label>
    <link:label id="lab_lly_A31NotesDue2027Member_documentation_en-US" xlink:label="lab_lly_A31NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.1% Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member" xlink:href="lly-20201231.xsd#lly_A31NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A31NotesDue2027Member" xlink:to="lab_lly_A31NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_8f059317-d36a-4e7d-9c3f-f9a1c60a9e4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5de703ca-6efd-491c-8740-ffd9a525e8e9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ceedbe3-6653-4969-80a9-2f55e3900d27_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherNeuroscienceMember_1b3d5ce6-72c2-435b-9558-cebd20390f9d_terseLabel_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_label_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember" xlink:href="lly-20201231.xsd#lly_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherNeuroscienceMember" xlink:to="lab_lly_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_48a01e49-73c1-4997-8d7e-10140bf7ece4_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets</link:label>
    <link:label id="lab_us-gaap_FixedIncomeFundsMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeFundsMember" xlink:to="lab_us-gaap_FixedIncomeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b38a4ed6-6e04-496f-aa6a-72566a116537_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_bc59296a-55d6-4388-a9e1-dc7f4cc7f4d3_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c84e62d8-81a9-4593-b2ee-ccc94a0ccb1a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e48b18b7-6342-4d6e-99a8-9afa1936c5af_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_51daf9a6-bd77-472b-9e26-79dc389b108b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_33840236-985d-4c45-bc09-e5d2b0a10a63_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claimants</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claimants</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claimants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfClaimants" xlink:to="lab_lly_LossContingencyNumberOfClaimants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_75f0e9b5-3fa6-4246-b5cd-442871a9b2be_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More Than 10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b64b525d-19a6-4991-b85a-b907d62c52d6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FochonPharmaceuticalsLtdMember_8295a528-bb99-41c1-b68a-cdfb79d0eb45_terseLabel_en-US" xlink:label="lab_lly_FochonPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fochon Pharmaceuticals, Ltd.</link:label>
    <link:label id="lab_lly_FochonPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_lly_FochonPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fochon Pharmaceuticals, Ltd. [Member]</link:label>
    <link:label id="lab_lly_FochonPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_lly_FochonPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fochon Pharmaceuticals, Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FochonPharmaceuticalsLtdMember" xlink:href="lly-20201231.xsd#lly_FochonPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FochonPharmaceuticalsLtdMember" xlink:to="lab_lly_FochonPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_59f5590f-e6e4-45f0-be4c-7c64144d0160_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a72f0080-a866-4ee6-adc0-e11d7d95e007_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_6257add3-c32e-4d0f-a93f-f5639b7058ee_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_67092071-5aca-4e1d-9658-fee385dfe03a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_02fb6bcc-8e8a-4abf-96d7-36efd42f89e2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A25NotesDue2060Member_42a2da65-b5c8-411f-b8df-4191e4b10387_terseLabel_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% notes due 2060</link:label>
    <link:label id="lab_lly_A25NotesDue2060Member_label_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Notes Due 2060 [Member]</link:label>
    <link:label id="lab_lly_A25NotesDue2060Member_documentation_en-US" xlink:label="lab_lly_A25NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Notes Due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member" xlink:href="lly-20201231.xsd#lly_A25NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A25NotesDue2060Member" xlink:to="lab_lly_A25NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_14f329ca-8a89-435e-852f-717afecfdd43_terseLabel_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, sales rebate payment period (up to)</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_label_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Rebate Payment Period</link:label>
    <link:label id="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_documentation_en-US" xlink:label="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Sales Rebate Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:to="lab_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_e16b0c1d-0f21-4772-ab8f-0c6dedf3d3af_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_9cb2bfa3-370f-4d10-a1ed-ad4850d37169_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_521362af-1ec6-4a71-934f-b28dbe8f537a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_97fa8512-83a9-4c81-9208-b11a9022b9a8_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payments Received</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_82580bf0-8029-4af7-99d7-090c35774895_negatedLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_9af439f1-7973-4a61-9d96-03b813003fc0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_dad4133e-7185-452a-bead-e3d63b2deb7f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_64f2cf51-4fcc-4387-a338-9f623bc638ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_06750990-a3ea-41ef-99ec-f7e23f8611d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_d92a6b4a-aaf2-4a4e-b1dd-958815239e10_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatents" xlink:to="lab_lly_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_142a55e1-08b0-4eb5-be74-0576d8e504bb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_99bedfa0-8120-4757-830c-ab01fb845a6c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_c4cf742d-b210-4825-b5d6-70160cc97ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d9b27ab0-5e0b-433f-81df-9db7133a816b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fbd650de-97b1-4a44-bdc2-ddb574157ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_b4867ab2-3b99-4a2e-a338-439efee8007f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_508cce34-1ed4-47cc-bbf5-499e475a69d2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_86788c91-1bb8-4907-b51c-61b8e36149c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-lived Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_2bb18b5f-68f2-4fa7-b64f-16253e964b1f_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_34f5dc10-7879-426c-8010-d4dc89e7c04f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_26664256-bcd4-49ed-8523-f48b9063a3b8_terseLabel_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used</link:label>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</link:label>
    <link:label id="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_documentation_en-US" xlink:label="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:href="lly-20201231.xsd#lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:to="lab_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EddingpharmMember_e5f3286c-7f32-4d81-9a66-894d6d3c9167_terseLabel_en-US" xlink:label="lab_lly_EddingpharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eddingpharm</link:label>
    <link:label id="lab_lly_EddingpharmMember_label_en-US" xlink:label="lab_lly_EddingpharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eddingpharm [Member]</link:label>
    <link:label id="lab_lly_EddingpharmMember_documentation_en-US" xlink:label="lab_lly_EddingpharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eddingpharm [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EddingpharmMember" xlink:href="lly-20201231.xsd#lly_EddingpharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EddingpharmMember" xlink:to="lab_lly_EddingpharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_c62d3871-353c-4b2a-ac51-fd43aaecfa3d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_af7ad2b3-c434-468e-9726-79784f8fd66b_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TermFacilityMember_afeb3982-8dd7-4acb-9742-b6c2e8acc879_terseLabel_en-US" xlink:label="lab_lly_TermFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility</link:label>
    <link:label id="lab_lly_TermFacilityMember_label_en-US" xlink:label="lab_lly_TermFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility [Member]</link:label>
    <link:label id="lab_lly_TermFacilityMember_documentation_en-US" xlink:label="lab_lly_TermFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TermFacilityMember" xlink:href="lly-20201231.xsd#lly_TermFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TermFacilityMember" xlink:to="lab_lly_TermFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d64f3a30-4060-4c97-9aa6-dc4139dbbab4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_cfda8b80-ef71-436d-9c9e-f5d7f471c556_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a83244f-1a09-40de-b23e-e637c7ef57fb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_4b0696cf-6588-49a7-bd16-c2c319780528_terseLabel_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales</link:label>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_label_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales [Member]</link:label>
    <link:label id="lab_lly_ThreeLargestWholesalesMember_documentation_en-US" xlink:label="lab_lly_ThreeLargestWholesalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Wholesales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember" xlink:href="lly-20201231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ThreeLargestWholesalesMember" xlink:to="lab_lly_ThreeLargestWholesalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7bd983e5-c58d-49aa-8523-145e65474459_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5133aef3-817a-46cb-a947-152f415fec6d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OutsideUSAndJapanMember_8afbf565-70fa-45d2-a1f3-ff829711a40d_terseLabel_en-US" xlink:label="lab_lly_OutsideUSAndJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside US And Japan</link:label>
    <link:label id="lab_lly_OutsideUSAndJapanMember_label_en-US" xlink:label="lab_lly_OutsideUSAndJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside US And Japan [Member]</link:label>
    <link:label id="lab_lly_OutsideUSAndJapanMember_documentation_en-US" xlink:label="lab_lly_OutsideUSAndJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside US And Japan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OutsideUSAndJapanMember" xlink:href="lly-20201231.xsd#lly_OutsideUSAndJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OutsideUSAndJapanMember" xlink:to="lab_lly_OutsideUSAndJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_d981ad37-7d4d-425e-a6d0-f492bc9f2065_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in defined benefit pension and retiree health benefit plans (Note 15)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_a4a5b792-519e-40a2-997d-5b1225574e1f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss) during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_1eee6825-9516-4f61-8fcc-902a6914a687_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses expected to be reclassified in the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_87700bea-fa67-40fe-b140-4b76eb7743a4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_abd77dd1-aa28-410d-815e-80502db5a845_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_6abef5ad-ef66-4dec-99f9-ee4f27c55e13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_47331f12-51b1-4fdc-9308-7a0929128067_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_bf339da3-5299-4d3d-9ff2-5bfadefad6da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendments during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_897aeb95-37cc-4ac2-9b84-4e8d8983b1c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Elanco Stock (Note 19)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_a538058e-f853-48b6-b31b-4909ba607959_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_5d23c8e0-2455-4c7c-88b9-8bc724bf2e41_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_c8731ed1-eacc-40bd-b90b-4d4f13c88e8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_b21d952f-0a61-4b5e-9751-80fb9af32363_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_55ad1899-e555-48df-abba-980de078dfa0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, reclassification from AOCI to retained earnings, tax effect</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_47621c58-1b24-4673-8edc-54faf8471107_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification due to adoption of new accounting standard</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_8cad379d-2448-48ff-b29d-c4ac0c9cb266_terseLabel_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_label_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Investments [Member]</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_documentation_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:href="lly-20201231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:to="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d250c48b-32bc-4240-9182-bbc35537a871_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2018RepurchaseProgramMember_1fceaf6b-1bc7-4006-8a65-c84bea5ac063_terseLabel_en-US" xlink:label="lab_lly_A2018RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Repurchase Program</link:label>
    <link:label id="lab_lly_A2018RepurchaseProgramMember_label_en-US" xlink:label="lab_lly_A2018RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Repurchase Program [Member]</link:label>
    <link:label id="lab_lly_A2018RepurchaseProgramMember_documentation_en-US" xlink:label="lab_lly_A2018RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2018RepurchaseProgramMember" xlink:href="lly-20201231.xsd#lly_A2018RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2018RepurchaseProgramMember" xlink:to="lab_lly_A2018RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_7c3841f6-bea6-4a1b-b005-e85078017cd3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_b7b7c325-7398-47d6-aac6-28b4c838cdfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses from equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_935cc580-fd63-4b6b-b2bb-8fdc68e13e82_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_bdc46b95-4f70-4cde-87d3-fb4990a1d95d_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_bff492a1-7677-472c-a3d9-0510156385a2_terseLabel_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_label_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Whyte Et Al. V. Eli Lilly Et Al. [Member]</link:label>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_documentation_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Whyte Et Al. V. Eli Lilly Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember" xlink:href="lly-20201231.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_WhyteEtAlVEliLillyEtAlMember" xlink:to="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_b2c95eac-5eb2-4bdc-9721-912e98203d25_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_80ca1104-98c3-48b3-85f5-f9756781c23b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a95a2af9-add5-44d9-9570-76dc55ffe4bb_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_2f568967-cd99-4b0f-b4f6-67c10a08d252_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" xlink:to="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_018292a4-bf8b-4635-894d-3e5b42a8ca9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c30ff57b-814b-4fd2-b9ae-3f88dc6e4445_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6708b52c-3309-4574-8d2f-aa7c047fd56a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_e477d7c2-413d-4105-998b-cd0c7f8d5327_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_744f73e6-5dbb-4c54-a9be-154c27d10a1d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f63d02a1-dd2e-44a9-8b37-a446680e46b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from interest rate contracts</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_8d3685b7-d8bd-4ef2-98c0-2f24ddac2f8f_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_25e9c371-bf1c-4f0b-9a78-6a0694294d1f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition of the compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_cd0c91dd-7eeb-46c2-8978-f320691b20c4_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_78c27a8c-5c35-403e-b26b-5735892a87d0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_ee8c5a0e-306d-44ca-b61f-213029d98f22_verboseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development (Note 3)</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:href="lly-20201231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNotesPayable_321a46eb-a973-4425-952f-655b470d3c15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_OtherNotesPayable_label_en-US" xlink:label="lab_us-gaap_OtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNotesPayable" xlink:to="lab_us-gaap_OtherNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_1ea17c87-04ed-48a5-9899-3eebfa0d4fea_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ca7ae518-673c-40c0-ab6b-33dbc0d8c1bc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of retirement benefit items</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7a19289e-9579-44d0-91d5-d5934d3c77f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c3e007ba-a05f-4043-89f5-165bad0a3503_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccountingStandardsUpdate201616aMember_d62632e9-dc7e-4888-b01a-645381ed5101_terseLabel_en-US" xlink:label="lab_lly_AccountingStandardsUpdate201616aMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-16</link:label>
    <link:label id="lab_lly_AccountingStandardsUpdate201616aMember_label_en-US" xlink:label="lab_lly_AccountingStandardsUpdate201616aMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-16a [Member]</link:label>
    <link:label id="lab_lly_AccountingStandardsUpdate201616aMember_documentation_en-US" xlink:label="lab_lly_AccountingStandardsUpdate201616aMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-16a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccountingStandardsUpdate201616aMember" xlink:href="lly-20201231.xsd#lly_AccountingStandardsUpdate201616aMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccountingStandardsUpdate201616aMember" xlink:to="lab_lly_AccountingStandardsUpdate201616aMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_6a2c69ed-bf6f-47f5-93be-6c2cc7966154_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-based intangibles</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4c9cebb0-0971-4bd4-8247-a2567bcaa396_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_a143bfea-9440-45b8-8533-c8dd1568ce4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_53e28e91-7559-4a4e-87e5-ccf0e868b9eb_terseLabel_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_label_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Income Tax Disclosures [Table Text Block]</link:label>
    <link:label id="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Income Tax Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:href="lly-20201231.xsd#lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:to="lab_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9f780508-aa57-44ac-9177-d730d34203e4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a1713681-4b9b-4fba-99e0-14078666de77_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A275NotesDue2025Member_a8a53b6f-cfa3-437a-8b2e-932d492bd532_terseLabel_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2025</link:label>
    <link:label id="lab_lly_A275NotesDue2025Member_label_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_lly_A275NotesDue2025Member_documentation_en-US" xlink:label="lab_lly_A275NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member" xlink:href="lly-20201231.xsd#lly_A275NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A275NotesDue2025Member" xlink:to="lab_lly_A275NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_095b0143-bafa-4b3c-b996-4ed0f99915f8_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_88672eca-a744-4104-8b8c-f6e9317215bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_884c147e-29d4-4090-9bed-fefc00432a8e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45b0a05a-51b3-4c5d-8280-582b1c59561a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6a18ff4d-a03f-4e59-8a93-7ef36dbb3556_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_5a772d2e-692f-46b0-aa34-68d664730464_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount_57f1d570-04bb-4d49-8cc8-661115760759_terseLabel_en-US" xlink:label="lab_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount_label_en-US" xlink:label="lab_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount</link:label>
    <link:label id="lab_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount_documentation_en-US" xlink:label="lab_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" xlink:href="lly-20201231.xsd#lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" xlink:to="lab_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_fd8ea993-49a8-4923-9ae7-f86d4e1cd8f4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AddDeductAbstract_421795b2-e908-4d82-8b40-b19274f78226_terseLabel_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (deduct):</link:label>
    <link:label id="lab_lly_AddDeductAbstract_label_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (Deduct) [Abstract]</link:label>
    <link:label id="lab_lly_AddDeductAbstract_documentation_en-US" xlink:label="lab_lly_AddDeductAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add (Deduct) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AddDeductAbstract" xlink:href="lly-20201231.xsd#lly_AddDeductAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AddDeductAbstract" xlink:to="lab_lly_AddDeductAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_November2019YenDenominatedNotesMember_4b40ce05-4307-42b3-9c40-e8c30d4b1071_terseLabel_en-US" xlink:label="lab_lly_November2019YenDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Yen-denominated Notes</link:label>
    <link:label id="lab_lly_November2019YenDenominatedNotesMember_label_en-US" xlink:label="lab_lly_November2019YenDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Yen-denominated Notes [Member]</link:label>
    <link:label id="lab_lly_November2019YenDenominatedNotesMember_documentation_en-US" xlink:label="lab_lly_November2019YenDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2019 Yen-denominated Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019YenDenominatedNotesMember" xlink:href="lly-20201231.xsd#lly_November2019YenDenominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_November2019YenDenominatedNotesMember" xlink:to="lab_lly_November2019YenDenominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_d7712896-bc62-4508-b0c3-678598fcaff4_terseLabel_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs to USD</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_label_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_documentation_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:href="lly-20201231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:to="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8657aea9-f4e9-4762-9412-8137f6f8003f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fa521f76-3145-4687-8ec4-07d06928669f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_23ca9e51-4eb2-473d-9b74-50e313eb3faa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_8cc2a43d-1acb-4544-9e0e-68d5814547ad_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_881b1199-9570-4e2e-a812-86252cc7d506_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue associated with prior period transfers of intellectual property</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ErbituxMember_f4cfc4e5-0ab6-4caa-b9a6-5ed967c0a8da_terseLabel_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux&#174;</link:label>
    <link:label id="lab_lly_ErbituxMember_label_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:label id="lab_lly_ErbituxMember_documentation_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember" xlink:href="lly-20201231.xsd#lly_ErbituxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ErbituxMember" xlink:to="lab_lly_ErbituxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_50b4c868-eca1-4612-a412-f0344d0fcf2e_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency-denominated notes, designated as hedge</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_76797c08-70a9-47b7-a4e6-29e9daf1f03d_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ef95720b-6734-46ef-8bb3-a5135f387d36_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9002529c-1d3c-4bee-b9a2-32efa626daff_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_521c8d94-aa24-4748-90fd-34face6a2760_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_Expirationin6YearsMember_8ecc444c-e941-4120-90b9-3b56f485deab_terseLabel_en-US" xlink:label="lab_lly_Expirationin6YearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 6 Years</link:label>
    <link:label id="lab_lly_Expirationin6YearsMember_label_en-US" xlink:label="lab_lly_Expirationin6YearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 6 Years [Member]</link:label>
    <link:label id="lab_lly_Expirationin6YearsMember_documentation_en-US" xlink:label="lab_lly_Expirationin6YearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 6 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationin6YearsMember" xlink:href="lly-20201231.xsd#lly_Expirationin6YearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_Expirationin6YearsMember" xlink:to="lab_lly_Expirationin6YearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_d4e1b828-d6f2-4c23-bf62-eeb295df61c3_totalLabel_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_label_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_documentation_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:href="lly-20201231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:to="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_81a33959-2578-452c-93c0-b23cf03050a4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_ef91c046-7462-414d-9955-613d3f69a3b5_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomicileOfLitigationAxis_ec3fc939-a8e5-41b3-b69a-c9b2eb9e24ca_terseLabel_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile of Litigation [Axis]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationAxis_label_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation [Axis]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationAxis_documentation_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis" xlink:href="lly-20201231.xsd#lly_DomicileOfLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomicileOfLitigationAxis" xlink:to="lab_lly_DomicileOfLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a7b822cb-f237-4d8b-a962-01de677a7684_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_176dd048-8f7d-4bbd-8144-42c48e4303e5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b0512f6-1001-40e4-b2e2-cafd82a44bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_f7bfef7a-40e0-4c9c-abe4-914f9dd3073f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_51fe164c-b208-4d4d-a764-0db5cb61ecea_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e76533f6-88fd-4a3a-911a-6a5d338a8387_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b55c50c2-bac8-4d67-80e9-5cbc464e9a06_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_83b5e3c0-447a-4da1-9abe-416980331319_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:to="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_ca62a14d-4161-4fd5-a338-bbd1aede3389_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase for benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_b511498e-c0c8-41d9-b754-f78d264428dc_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4bc58b61-ec69-48c7-84cf-808481a4664c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3f86ddd7-dcc0-4120-b48e-aa0a31af3d94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_22f8c265-626b-4c34-bdab-feb155076dfd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_5b3d9880-2a9a-4368-88dd-b0cc6df4f51b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_3c17e60d-278f-43a8-bdc6-51d20edb73e9_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_33a77c95-714d-4054-99fa-0f29617e3b97_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_cffd6552-423f-4392-aac9-090aec46c5fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailment gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_0e59ac70-53ab-41b3-a0ed-083c6eeff9c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f04c0595-cc31-40e4-b2ab-009ef2fb6460_negatedLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications for the period, net of tax</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_07c905a0-eda7-430f-a0a7-643dfc6e091e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5128dcc5-d10e-43da-815b-c8ffff3d21f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5e263e07-5dda-4878-8ac8-3f5c352e17b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_85474a26-c111-4bc8-8753-9307eeda96a7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e442a52c-ef4c-4595-ae1c-7bd9378d3df4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_c0d3cf19-83b6-462f-bdc6-317f02d4375a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductTotalMember_9c0b27be-9a6b-4ae3-a062-2cd4f181967f_terseLabel_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_label_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_documentation_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember" xlink:href="lly-20201231.xsd#lly_OtherProductTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductTotalMember" xlink:to="lab_lly_OtherProductTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c5073a3d-ef74-4fab-aec2-7e18a2497672_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A465NotesDue2044Member_046fe2cc-7fdd-4292-bb05-7ec9a85c2b93_terseLabel_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% notes due 2044</link:label>
    <link:label id="lab_lly_A465NotesDue2044Member_label_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% Notes Due 2044 [Member]</link:label>
    <link:label id="lab_lly_A465NotesDue2044Member_documentation_en-US" xlink:label="lab_lly_A465NotesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.65% Notes Due 2044</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member" xlink:href="lly-20201231.xsd#lly_A465NotesDue2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A465NotesDue2044Member" xlink:to="lab_lly_A465NotesDue2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_093bc8ec-6442-4100-9c43-16fb9820df29_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e20cfe2b-dcff-43ad-9427-6ddaef3359c1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A225NotesDue2050Member_17f78c82-9d09-403b-8518-73be189047df_terseLabel_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% notes due 2050</link:label>
    <link:label id="lab_lly_A225NotesDue2050Member_label_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes Due 2050 [Member]</link:label>
    <link:label id="lab_lly_A225NotesDue2050Member_documentation_en-US" xlink:label="lab_lly_A225NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes Due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member" xlink:href="lly-20201231.xsd#lly_A225NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A225NotesDue2050Member" xlink:to="lab_lly_A225NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_87efa267-78a8-4e63-a17e-f64a841424cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_70f60cc0-5014-4c1b-8180-037e7f390b60_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_2ed416a1-8919-455e-ae68-7dfb7b890c8a_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_593fe910-901a-468b-b3d4-02d71d34d0f5_terseLabel_en-US" xlink:label="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Elanco</link:label>
    <link:label id="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_label_en-US" xlink:label="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact on Equity of Sale of Noncontrolling Interest in Subsidiary</link:label>
    <link:label id="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_documentation_en-US" xlink:label="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact on Equity of Sale of Noncontrolling Interest in Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:href="lly-20201231.xsd#lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:to="lab_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_8451dcbe-2308-414f-8ea1-dd40657302a0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_0a3e4054-1daa-40d7-b5fe-4ad59d3d8c36_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_2d8166d6-e52b-48d3-a959-13197ad4af9f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d75cfb28-8ffc-4bdd-ab82-6d69f0e55ae2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_f1d324a1-7bd7-4635-8b91-6f60397bd6c9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_490ff564-8698-4101-8463-e3534cbf9052_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_bcd53492-b575-4ae7-b281-696d555b8a5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-Net, (Income) Expense</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8878ba62-a4d6-4c36-96f3-90f708ebaf9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_610998e4-7247-4c1a-b87a-4f43e3f60503_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ede6cf60-afd8-4b7d-aa69-31e92bd8e9b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_21cc3604-5353-4a26-a6b8-5b57954a3e4c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_ba9e19d4-2a38-490a-846a-90aed7ef59e1_terseLabel_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin and Forteo</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_label_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo [Member]</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_documentation_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember" xlink:href="lly-20201231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogHumulinAndForteoMember" xlink:to="lab_lly_HumalogHumulinAndForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_c2b658fa-24c0-43e3-8d09-d5bf40e27027_terseLabel_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of global investments in plan assets</link:label>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_label_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage of Global Investments in Plan Assets</link:label>
    <link:label id="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_documentation_en-US" xlink:label="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:href="lly-20201231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:to="lab_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfRequestsForInformation_4a351f2f-e415-42ec-b34c-6a78ab4e8ca8_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfRequestsForInformation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of requests for information</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfRequestsForInformation_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfRequestsForInformation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Requests For Information</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfRequestsForInformation_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfRequestsForInformation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Requests For Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfRequestsForInformation" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfRequestsForInformation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfRequestsForInformation" xlink:to="lab_lly_LossContingencyNumberOfRequestsForInformation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_be75cdca-0b7d-4a36-a8a8-2051f1a13c3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1207f656-0f54-441b-a055-383f78185bdd_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_be5352e7-2107-4ae3-a067-fd4b7be0f51a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CyramzaMember_148270fc-374f-49f8-bf8a-df7ebd7d034b_terseLabel_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza&#174;</link:label>
    <link:label id="lab_lly_CyramzaMember_label_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:label id="lab_lly_CyramzaMember_documentation_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember" xlink:href="lly-20201231.xsd#lly_CyramzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CyramzaMember" xlink:to="lab_lly_CyramzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_341aff94-8581-4a8b-a7e1-11fd904b9f70_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20201231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_1f3798a3-4534-4c52-b0f0-fb30ea31e67b_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A17EuroDeonominatedNotesDue2049Member_4d5b52e7-55ab-4d0f-a1eb-c7447705c001_terseLabel_en-US" xlink:label="lab_lly_A17EuroDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.7% Euro denominated notes due 2049</link:label>
    <link:label id="lab_lly_A17EuroDeonominatedNotesDue2049Member_label_en-US" xlink:label="lab_lly_A17EuroDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.7% Euro-deonominated Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A17EuroDeonominatedNotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A17EuroDeonominatedNotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.7% Euro-deonominated Notes Due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member" xlink:href="lly-20201231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A17EuroDeonominatedNotesDue2049Member" xlink:to="lab_lly_A17EuroDeonominatedNotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_e0aa5de8-212e-4a2b-a661-d83ad178cb0b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_47a89c8e-fb44-4718-8ee1-9a7f70fee5d9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_b04d594e-d3e2-4395-84e3-089fbb8e63d3_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_438b0318-fa50-4b50-b1ba-d6c785b1e0b3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_24e521a2-f66c-415b-a916-e93fd8cc7031_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductMember_a2fe2777-2b67-422b-8c32-56e9ecab68be_terseLabel_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductMember_label_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:label id="lab_lly_OtherProductMember_documentation_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember" xlink:href="lly-20201231.xsd#lly_OtherProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductMember" xlink:to="lab_lly_OtherProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_0c93bbb8-d89b-4203-98ee-7d6ae95b0b21_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_lly_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_ee5c4eb5-6cec-4064-b4d8-e714aa3be832_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_9afa6097-2e3f-457b-a15c-c2e819ef99f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial loss (gain)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_8ccd61f1-9afd-4164-b05e-1f44ca609794_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_b6d4ffcc-e7b1-4120-b4b4-7e5bbdf5c560_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7fa2774b-d874-4a36-9155-97ae6b5cc759_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a9374236-1782-4cae-91d6-fc56dbd69992_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3ce03339-3e29-45c3-829b-013a1a2e8f2f_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_ef8c5b0d-e0bb-4a70-a10d-ea399e29efd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5942d21-a89e-4754-82f4-532308a83340_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3a631149-f77b-4597-ae00-d4c99e6a58fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SIGATechnologiesMember_64591ec2-866b-48e0-acc5-2403e6d37bf5_terseLabel_en-US" xlink:label="lab_lly_SIGATechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGA Technologies, Inc.</link:label>
    <link:label id="lab_lly_SIGATechnologiesMember_label_en-US" xlink:label="lab_lly_SIGATechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGA Technologies [Member]</link:label>
    <link:label id="lab_lly_SIGATechnologiesMember_documentation_en-US" xlink:label="lab_lly_SIGATechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGA Technologies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SIGATechnologiesMember" xlink:href="lly-20201231.xsd#lly_SIGATechnologiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SIGATechnologiesMember" xlink:to="lab_lly_SIGATechnologiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1cbcc3dc-0a58-4835-8289-10ee33e597a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_95f1cccb-8fa3-4a19-97bd-0460db219d06_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8b5fd3da-f6c9-4b78-bddd-b43642f1ded8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_4e3bf88c-21fa-4a7e-afdf-3deb461cba64_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b49309e3-a0b0-4623-9034-bb0473149ac3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_ea7e35a6-485d-4265-bd95-c0fb397a1ec0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:to="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_76127193-6269-40f9-a444-3039c1463dfa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_26a20e6e-67e0-4ba1-9a3c-aa3623ecc18e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_0788beef-7f81-4038-b795-778b9492fd8a_terseLabel_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable, estimated timing of future cash outflows not possible</link:label>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_label_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</link:label>
    <link:label id="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_documentation_en-US" xlink:label="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:href="lly-20201231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:to="lab_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_988433d5-9ad3-4537-a70b-ad202f8828d5_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PaymentsForIncomeTaxSettlements_60ec85ca-f302-41de-9529-740d17d5d9dc_terseLabel_en-US" xlink:label="lab_lly_PaymentsForIncomeTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for income tax settlements</link:label>
    <link:label id="lab_lly_PaymentsForIncomeTaxSettlements_label_en-US" xlink:label="lab_lly_PaymentsForIncomeTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Income Tax Settlements</link:label>
    <link:label id="lab_lly_PaymentsForIncomeTaxSettlements_documentation_en-US" xlink:label="lab_lly_PaymentsForIncomeTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Income Tax Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForIncomeTaxSettlements" xlink:href="lly-20201231.xsd#lly_PaymentsForIncomeTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PaymentsForIncomeTaxSettlements" xlink:to="lab_lly_PaymentsForIncomeTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5186b9e8-7ae0-4932-b8cc-e06a6ce64b0a_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_34669731-a045-468a-aefa-5f2342b0e129_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_e0b4735b-5bb6-4bcc-a66c-1fc941190c6d_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share (in dollars per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:href="lly-20201231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_bcaf685a-3528-4539-ac65-72d9a9f41252_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_d1dd06dd-d25a-48f6-8c84-015b7a2bdf79_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment, Restructuring, And Other Special Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A395NotesDue2047Member_632c1f23-4755-40d7-a56c-cdbf3b2239ff_terseLabel_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% notes due 2047</link:label>
    <link:label id="lab_lly_A395NotesDue2047Member_label_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2047 [Member]</link:label>
    <link:label id="lab_lly_A395NotesDue2047Member_documentation_en-US" xlink:label="lab_lly_A395NotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2047</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member" xlink:href="lly-20201231.xsd#lly_A395NotesDue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A395NotesDue2047Member" xlink:to="lab_lly_A395NotesDue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_77bd6c40-621a-4ba9-8151-538ef74e7c4e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_364980ef-73b3-4102-bffc-3a3d668371db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_ec2b1340-fce5-4fb0-90c7-984c3ef585b6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_9107b3e0-fd06-4ac5-adb0-5274f0e761d7_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b3ac53de-bb8f-49ac-b5cd-5e2d404ded3a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_40c1afa7-10a0-404d-9ebe-71282d0c4a55_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $25.9 (2020)&#160;and $22.4 (2019)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_4edaf261-0d14-4393-ac2c-abd334fd408b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished products</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_57bf40aa-7191-41cc-b2e8-de94c4164309_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_acec2cd1-1945-4148-9772-0ec20a9576ed_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposition of ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_1d626969-dd23-4ebf-a71c-3af4b96339ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_0f4abf0e-85d3-4098-985b-f463113dcd19_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_5ef3493e-50c6-49f9-8a2e-ee6f748217d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c8e64551-009a-4254-b49d-11716ca789d3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CymbaltaMember_53472212-3489-4a8e-88a7-2afac6820179_terseLabel_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta&#174;</link:label>
    <link:label id="lab_lly_CymbaltaMember_label_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:label id="lab_lly_CymbaltaMember_documentation_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember" xlink:href="lly-20201231.xsd#lly_CymbaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CymbaltaMember" xlink:to="lab_lly_CymbaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_7914c26e-f504-4a1d-b949-532f21578f39_terseLabel_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets</link:label>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_label_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds Emerging Markets [Member]</link:label>
    <link:label id="lab_lly_FixedIncomeFundsEmergingMarketsMember_documentation_en-US" xlink:label="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember" xlink:href="lly-20201231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FixedIncomeFundsEmergingMarketsMember" xlink:to="lab_lly_FixedIncomeFundsEmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e901e6ad-a5ce-422b-bd05-d665287342f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d9982f33-3f0e-499e-b3b2-2342c8970f37_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 1 Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7f75ba80-abb2-4c7e-87e9-011ac956a93a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_cf72e9b1-0620-4043-8a45-a0c27c655e1b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_9172d870-564f-4ee6-809e-6f4128f43c95_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_20a0c07f-8f81-4ee4-a2fb-0d64363e471e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net unrealized gains (losses) on securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_0d82c5a2-6ef1-4cc8-bd90-c232b9284c5f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid employee benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5b4f6920-6235-4140-82cd-4bd192938619_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_ec3c9543-0b52-42fe-916d-e54fe5f1165c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HydraBiosciencesMember_ba20e28a-7c3d-4655-91a8-fb74ed3ebe05_terseLabel_en-US" xlink:label="lab_lly_HydraBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hydra Biosciences</link:label>
    <link:label id="lab_lly_HydraBiosciencesMember_label_en-US" xlink:label="lab_lly_HydraBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hydra Biosciences [Member]</link:label>
    <link:label id="lab_lly_HydraBiosciencesMember_documentation_en-US" xlink:label="lab_lly_HydraBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hydra Biosciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HydraBiosciencesMember" xlink:href="lly-20201231.xsd#lly_HydraBiosciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HydraBiosciencesMember" xlink:to="lab_lly_HydraBiosciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c35ad595-50fd-4531-80e4-dc0e9fadb179_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic (benefit) cost:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_b042b3ce-799e-4987-82dd-00c31f4b23c7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retiree Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Health Coverage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:to="lab_us-gaap_DefinedBenefitPostretirementHealthCoverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_7db6a06f-d766-4b04-9240-9569e9922cde_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_49ae7864-6b02-484f-93fd-996e1ef09318_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings from discontinued operations - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_8e93574c-0ed1-43f3-b2a9-cce96ba268e1_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ExpirationIn12To18YearsMember_c21f8a9e-7005-4a9e-8a1d-d5c3bc63ac3c_terseLabel_en-US" xlink:label="lab_lly_ExpirationIn12To18YearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration in 12 to 18 Years</link:label>
    <link:label id="lab_lly_ExpirationIn12To18YearsMember_label_en-US" xlink:label="lab_lly_ExpirationIn12To18YearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration In 12 To 18 Years [Member]</link:label>
    <link:label id="lab_lly_ExpirationIn12To18YearsMember_documentation_en-US" xlink:label="lab_lly_ExpirationIn12To18YearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration In 12 To 18 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationIn12To18YearsMember" xlink:href="lly-20201231.xsd#lly_ExpirationIn12To18YearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ExpirationIn12To18YearsMember" xlink:to="lab_lly_ExpirationIn12To18YearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_9ffe2fd4-27b4-45f4-9bc7-029ea72bdc7f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_42d58f1b-cebc-45a1-9494-e6521ebef146_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c5cee155-20a0-4d8e-9d23-71334db82a19_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_eb82e45f-7af8-4497-b41a-d3a3ca5fff43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9df15ce7-a582-40c4-9b5c-ab3b649857bb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_13185ddf-15f9-4ce3-b208-f61110e284a6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailment gain</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_890f46eb-4b2c-4191-8ed8-5dca92c1225b_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailment (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_80c1602e-6b61-4b22-8887-2affffe27338_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits (Note 15)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_5af3a137-8c26-4912-a320-35ff99231d23_negatedNetLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_7efbe9bd-b39f-4004-a018-4e13ced2e473_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_475b520c-bdca-463f-9636-f146c0e653cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_5e44a226-a3cc-4fdc-bb5b-a269c3ec1120_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount recognized</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_bb364cd1-6859-490f-9d8c-b5d06b4050ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations (Note 19)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2d2681f3-372e-4310-b36e-01c7bf5894e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications from discontinued operations (net of tax)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8da0f743-ace7-49bb-826b-edb156c3b871_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ba1ab0d7-770f-4e38-8089-c4448abe1eca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenue and Net Income from Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6f343808-f2fc-4e85-998d-bcdd893bc4b4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized prior service (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c9b18294-1130-4e52-85c4-a839b8534576_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ab27b5e8-39af-4d31-8f3d-f4c61619e48f_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_46b3e437-114c-45a4-b38b-a3484732d42a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_fb3277bf-8079-4c38-9b62-5fac65a4a21d_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b173ac1d-2801-4bde-8624-c24b258dd55a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d967b346-61e9-432b-84f1-3efb82a7f93c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_42b9baa5-2ca4-4fc4-860e-af2219ef6484_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherImmunologyMember_ba82fe5e-e784-478b-a569-a1ef4da16446_terseLabel_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_label_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_documentation_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember" xlink:href="lly-20201231.xsd#lly_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherImmunologyMember" xlink:to="lab_lly_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_0ffe8b0c-1948-49eb-a418-2e9bc1401fc3_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_37b9352f-984c-4151-8ab9-612d619a8b39_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_335eccb2-99e4-4acf-afe6-9e2acee70488_terseLabel_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 and September 2060</link:label>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_label_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 And September 2060 [Member]</link:label>
    <link:label id="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member_documentation_en-US" xlink:label="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due May 2050 And September 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:href="lly-20201231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:to="lab_lly_SeniorNotesDueMay2050AndSeptember2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_3dbe9fcc-e7fa-48da-8caf-0260695582be_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_9bcb0c7e-957f-44d2-8558-eed611333520_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents, claims dismissed</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents, Claims Dismissed</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents, Claims Dismissed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:to="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_2e0a3ccb-797b-4ddb-bf18-d5db899f70d7_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7e946897-0b2d-47f8-b3c2-9068e72f162b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_60c9ee4b-4487-4195-a8d3-42d60d443c54_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_e3ea46d5-4b25-4aff-bb35-a0b7bd6c42c9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66d9d55e-4fd0-4a80-8c9f-a32e57d2c146_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LosAngelesMember_5a9f3490-00cc-477c-9d40-e92a761d576f_terseLabel_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:label id="lab_lly_LosAngelesMember_label_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles [Member]</link:label>
    <link:label id="lab_lly_LosAngelesMember_documentation_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember" xlink:href="lly-20201231.xsd#lly_LosAngelesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LosAngelesMember" xlink:to="lab_lly_LosAngelesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3a70abba-38f4-42ac-a340-2a83a5271fa2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_235856b3-55b0-4604-b265-558bd5950178_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_5c3d0d65-f474-4e2e-8f0c-6da8a521006e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_17ac981b-13a5-4994-abe7-291429547548_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_0b77c3a8-067f-4ba9-a8f5-29ed98a640ff_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_976a8b0a-6cee-4e44-acf9-afbd4a20143c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A55NotesDue2027Member_0de40468-8ace-461a-8e77-014dc61730b1_terseLabel_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% notes due 2027</link:label>
    <link:label id="lab_lly_A55NotesDue2027Member_label_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% Notes Due 2027 [Member]</link:label>
    <link:label id="lab_lly_A55NotesDue2027Member_documentation_en-US" xlink:label="lab_lly_A55NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.5% Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member" xlink:href="lly-20201231.xsd#lly_A55NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A55NotesDue2027Member" xlink:to="lab_lly_A55NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_49f48805-090f-41e9-8d30-696361e13617_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_eb263758-fcc8-4e8c-858e-631cffce5026_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_d0ecae14-59e7-4b09-a5df-65964212ae83_terseLabel_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:href="lly-20201231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_49dc2181-64ee-4120-883a-71a2488bbbd8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_c7c2cdf0-1b18-4af8-bdc9-d5a3d189092c_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_b351e38a-8268-4c8d-b56f-a288ce83e91c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_0448422b-4945-4f4e-8642-db186795a0d4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e4b7f94-0cbb-4600-940e-322fbd9e4b53_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss (Note 17)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_67697a5a-536b-437a-9431-b58b7871b936_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_06b472e7-b4fd-40a3-a44b-2fe4da855062_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_f722ecb5-7285-48f9-9b76-5c8f0ece3f54_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_474e66bd-53b2-453e-b506-d0d5f25116d2_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_dc32f606-8fc3-4647-b969-4c398ad7802e_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapses of statutes of limitation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5eb9c14a-1872-44cf-aaed-02ee48fc49df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a930e27c-ce76-4200-9c0a-828500054342_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred - net of cash acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_936a0e2b-38ae-4750-96a7-8b47dfbf37a9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9f6fc872-b0d7-4810-98f4-04968ff7b25c_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1047980c-6548-4b12-b168-5e3b973aab6a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_73b9ba7e-a76b-4f83-8348-aff21611241f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c065c805-3094-4a1e-a131-f8fa3ccfb4af_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_135336e4-6dd1-4232-9efc-4fe1b13a8e40_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_5a937f0f-aede-488a-8c75-50ccdce9f576_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_39f247d3-6571-4ac8-8612-17d14aa82b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_23dee8fb-aecf-49d8-aca1-a149c8f8004e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net (Note 9)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c3d2fe65-c098-41ed-941d-317c419f7c31_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_5cbe3dda-b7aa-4273-a3bc-e8e78b65352b_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax redeterminations</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Redeterminations</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Redeterminations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:to="lab_lly_DeferredTaxAssetsForeignTaxRedeterminations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_612441fb-e454-4ed8-b40c-8bdf59c14e02_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_ec03a4fc-1059-441c-8e56-32642947adfc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate changes and other adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgeFundsMember_89193c9a-c74a-4113-91cb-bbceaf6b2692_terseLabel_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge funds</link:label>
    <link:label id="lab_us-gaap_HedgeFundsMember_label_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgeFundsMember" xlink:to="lab_us-gaap_HedgeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ce75eb91-19b6-4642-b238-0ef39d0d5faa_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_26e56929-f8ac-446b-a4ea-ffea634679ab_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4be9ef69-7080-4ac5-9346-c3e4ea684088_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f537e10b-5aad-4a13-a2bb-56a420f8a222_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3c52597e-d03d-468e-9c4b-5109493402d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_3abfba8e-e709-49f5-9998-47be5cd32e50_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DicernaPharmaceuticalsMember_d440aa92-984c-4863-8484-3b72407f3df3_terseLabel_en-US" xlink:label="lab_lly_DicernaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dicerna Pharmaceuticals Inc.</link:label>
    <link:label id="lab_lly_DicernaPharmaceuticalsMember_label_en-US" xlink:label="lab_lly_DicernaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dicerna Pharmaceuticals [Member]</link:label>
    <link:label id="lab_lly_DicernaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_lly_DicernaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dicerna Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DicernaPharmaceuticalsMember" xlink:href="lly-20201231.xsd#lly_DicernaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DicernaPharmaceuticalsMember" xlink:to="lab_lly_DicernaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_daf92d38-66ef-46a0-bf89-98d982673302_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TYVYTMember_db5571e5-b0b2-4124-93b5-6e48049cebe5_terseLabel_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyvyt</link:label>
    <link:label id="lab_lly_TYVYTMember_label_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT [Member]</link:label>
    <link:label id="lab_lly_TYVYTMember_documentation_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember" xlink:href="lly-20201231.xsd#lly_TYVYTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TYVYTMember" xlink:to="lab_lly_TYVYTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NumberOfMedicinesRightsToSold_02d16fea-0fc9-4009-b2b9-52bcff1d6b62_terseLabel_en-US" xlink:label="lab_lly_NumberOfMedicinesRightsToSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of legacy antibiotic medicines rights sold</link:label>
    <link:label id="lab_lly_NumberOfMedicinesRightsToSold_label_en-US" xlink:label="lab_lly_NumberOfMedicinesRightsToSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Medicines, Rights To, Sold</link:label>
    <link:label id="lab_lly_NumberOfMedicinesRightsToSold_documentation_en-US" xlink:label="lab_lly_NumberOfMedicinesRightsToSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Medicines, Rights To, Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NumberOfMedicinesRightsToSold" xlink:href="lly-20201231.xsd#lly_NumberOfMedicinesRightsToSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NumberOfMedicinesRightsToSold" xlink:to="lab_lly_NumberOfMedicinesRightsToSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_c52c728f-ecbb-4f57-a1ee-69c45b3fbef7_terseLabel_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current federal tax expense, utilization of net operating loss carryforward</link:label>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_label_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</link:label>
    <link:label id="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_documentation_en-US" xlink:label="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:href="lly-20201231.xsd#lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:to="lab_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_3b6abf66-5e54-488e-9ca9-be4d7c16495a_terseLabel_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer or Thyroid Cancer</link:label>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_label_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer Or Thyroid Cancer [Member]</link:label>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_documentation_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer Or Thyroid Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember" xlink:href="lly-20201231.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PancreaticCancerOrThyroidCancerMember" xlink:to="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_55b5d5d0-d14c-483a-91b6-ff2dd54eb7c9_terseLabel_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correlative tax adjustments</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_label_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Corrective Tax Adjustments</link:label>
    <link:label id="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_documentation_en-US" xlink:label="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Corrective Tax Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:to="lab_lly_DeferredTaxAssetsCorrectiveTaxAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e963099a-01f5-4ba5-b5c6-8f827c22cdbd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ec679fad-7b1e-4649-a1d7-6f49b0491102_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_3fe5b7bb-2351-4ff3-b26a-cbddc070a8e3_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed products</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_82026a75-cd58-414c-8ee6-9fafe598843f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards and carrybacks</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_394c3847-6c5e-4b64-921c-6c2e75bf0caf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OncologyMember_46721caf-bbb7-4876-8a81-b4be5f3df09f_terseLabel_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_lly_OncologyMember_label_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_lly_OncologyMember_documentation_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember" xlink:href="lly-20201231.xsd#lly_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OncologyMember" xlink:to="lab_lly_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_8b6f5774-9426-400e-8ce4-eaf2c49c5a9a_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ShareholderValueAwardsMember_e30c3d6a-4bc9-4dee-a334-6052509f0b68_terseLabel_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards</link:label>
    <link:label id="lab_lly_ShareholderValueAwardsMember_label_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards [Member]</link:label>
    <link:label id="lab_lly_ShareholderValueAwardsMember_documentation_en-US" xlink:label="lab_lly_ShareholderValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember" xlink:href="lly-20201231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ShareholderValueAwardsMember" xlink:to="lab_lly_ShareholderValueAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_907b1d01-acea-4692-a911-58eb5325fc1f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_0838ecb7-c015-4fac-99fd-63f6ab1900ed_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxPaymentDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:to="lab_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8175be75-68df-4e5d-a3f7-390f8a1f33df_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_c1fae969-cee2-414b-82b7-4c5f7deb3dab_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_UndisclosedAssetAcquisitionMember_06ac530c-7211-47ec-90ea-506ac8c93463_terseLabel_en-US" xlink:label="lab_lly_UndisclosedAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undisclosed</link:label>
    <link:label id="lab_lly_UndisclosedAssetAcquisitionMember_label_en-US" xlink:label="lab_lly_UndisclosedAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undisclosed Asset Acquisition [Member]</link:label>
    <link:label id="lab_lly_UndisclosedAssetAcquisitionMember_documentation_en-US" xlink:label="lab_lly_UndisclosedAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undisclosed Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UndisclosedAssetAcquisitionMember" xlink:href="lly-20201231.xsd#lly_UndisclosedAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_UndisclosedAssetAcquisitionMember" xlink:to="lab_lly_UndisclosedAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_42901495-fc12-4d28-96eb-4166cdd6d836_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_bbd14b82-75a5-4a25-915c-2b2a199670a4_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20201231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f762bdf2-a019-4c16-b2a2-8aaba3a6ec13_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_230343b9-c7db-4f24-a700-1c373c089f85_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f4e4ce13-4625-44d6-bdc8-5b7d77caeb1f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_ef168cef-ab81-4d08-bd3c-3727d3953712_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDerivatives_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64348b03-7b1a-4dc8-afff-00f7880b2712_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_86da3cb9-8e51-40b5-a253-a8384fb4d621_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_bc0c7c63-4cff-42bc-91cf-8808e55960dd_negatedNetLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_0be32c70-e43b-4057-8943-0b0132a1e0ad_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_50445a20-0961-4a33-bd7d-a044518875a9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4899c83b-fc90-4ace-8feb-e8c4a01af294_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (income) loss before income taxes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_be7797af-08cd-43ef-85d5-97208c52c74d_terseLabel_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net of tax</link:label>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_label_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:href="lly-20201231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:to="lab_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4855145d-0402-42d4-ae58-34f0644c5e96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_90ec2c9b-edce-46aa-beb9-03e7c580a2c9_terseLabel_en-US" xlink:label="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d3b73d76-ad8a-4dc9-89b3-33b83953a9fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_a01d8d1f-19fb-40e1-9c88-9c8a7590acf4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized net actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_cf6d6aec-c435-4ace-b53d-8209d3335b9b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RelativeValueAwardsMember_94c80c53-e6e5-4f4a-bdbd-efbf4f617268_terseLabel_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards</link:label>
    <link:label id="lab_lly_RelativeValueAwardsMember_label_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards [Member]</link:label>
    <link:label id="lab_lly_RelativeValueAwardsMember_documentation_en-US" xlink:label="lab_lly_RelativeValueAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Value Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember" xlink:href="lly-20201231.xsd#lly_RelativeValueAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RelativeValueAwardsMember" xlink:to="lab_lly_RelativeValueAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_6a07d842-e466-41b0-9059-f23285839f4a_verboseLabel_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_label_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_documentation_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember" xlink:href="lly-20201231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborationandOtherRevenueMember" xlink:to="lab_lly_CollaborationandOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_3ee25150-52d4-40f5-9643-44d14576125d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_887ad6f1-381e-434b-8d4e-e6abfd917f58_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_2437dd4f-affe-407b-89d9-d2a5027583e7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd469a54-df6e-4b2a-860b-2302f89ae2c2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6f4b4541-2c7c-4d64-ac1c-a7299cacf08e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_c58c901c-ec1b-41a1-8dae-9a7d9507e023_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_53c6115b-62c6-4eb0-b56f-4efbe32eae5b_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrecisionBioSciencesIncMember_142a8d19-dbbb-4ceb-af3a-ed7ae01908d3_terseLabel_en-US" xlink:label="lab_lly_PrecisionBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision BioSciences, Inc.</link:label>
    <link:label id="lab_lly_PrecisionBioSciencesIncMember_label_en-US" xlink:label="lab_lly_PrecisionBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision BioSciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_PrecisionBioSciencesIncMember_documentation_en-US" xlink:label="lab_lly_PrecisionBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision BioSciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBioSciencesIncMember" xlink:href="lly-20201231.xsd#lly_PrecisionBioSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrecisionBioSciencesIncMember" xlink:to="lab_lly_PrecisionBioSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_41bc03f1-6508-47e0-bd83-aa2074b091a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ChugaiPharmaceuticalCompanyMember_e272229e-502f-4a61-8580-c1f7fc9a7c6f_terseLabel_en-US" xlink:label="lab_lly_ChugaiPharmaceuticalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chugai Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_lly_ChugaiPharmaceuticalCompanyMember_label_en-US" xlink:label="lab_lly_ChugaiPharmaceuticalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chugai Pharmaceutical Company [Member]</link:label>
    <link:label id="lab_lly_ChugaiPharmaceuticalCompanyMember_documentation_en-US" xlink:label="lab_lly_ChugaiPharmaceuticalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chugai Pharmaceutical Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ChugaiPharmaceuticalCompanyMember" xlink:href="lly-20201231.xsd#lly_ChugaiPharmaceuticalCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ChugaiPharmaceuticalCompanyMember" xlink:to="lab_lly_ChugaiPharmaceuticalCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_bfc6f2db-cbab-435d-b3b8-4fb3405ac512_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b77e2d61-ba84-405d-813b-2349e1f6479a_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_08124be6-0651-4c14-a549-bb83613758cb_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_ef80faec-24dc-41d0-9e50-cabe46efe697_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_1eed7b08-011d-4f46-baab-84b5d6363f31_terseLabel_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 Year</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_label_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</link:label>
    <link:label id="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_documentation_en-US" xlink:label="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:to="lab_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3c0af73d-2a5a-4e63-8299-5c6bde67c494_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_88afcc16-f13e-457b-9c4d-ad20c02b8d11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_1f144b55-4ed7-485b-912d-01017d0b258f_terseLabel_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember" xlink:href="lly-20201231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrevailTherapeuticsIncMember" xlink:to="lab_lly_PrevailTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumulinMember_0a53363f-268d-4f95-9d99-083f755d3afc_terseLabel_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin&#174;</link:label>
    <link:label id="lab_lly_HumulinMember_label_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:label id="lab_lly_HumulinMember_documentation_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember" xlink:href="lly-20201231.xsd#lly_HumulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumulinMember" xlink:to="lab_lly_HumulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_52e07968-51ef-48ed-8484-7511c6082bd4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_94c8c82d-c691-43ba-923f-8e6bf7a7f2cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (Note 14)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7aeec2ca-cc2a-461b-ad0c-8b7fc0db03dd_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fe55fbc5-7a59-4b71-8c3e-c25ec5037d7b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JardianceMember_9aa0ef6f-3dc0-42d1-bc3c-455a80f307e7_verboseLabel_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance&#174;</link:label>
    <link:label id="lab_lly_JardianceMember_d9da78c7-49ca-4ad3-b3e3-72e31dbb3473_terseLabel_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance</link:label>
    <link:label id="lab_lly_JardianceMember_label_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:label id="lab_lly_JardianceMember_documentation_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JardianceMember" xlink:to="lab_lly_JardianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogMember_313b0cf6-ed58-4331-879b-3b63a7f32d8f_terseLabel_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog&#174;</link:label>
    <link:label id="lab_lly_HumalogMember_label_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:label id="lab_lly_HumalogMember_documentation_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember" xlink:href="lly-20201231.xsd#lly_HumalogMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogMember" xlink:to="lab_lly_HumalogMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_2e4975da-b086-4f06-8add-209e56ca6eae_terseLabel_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Domain]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_label_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Domain]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_documentation_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain" xlink:href="lly-20201231.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PlaintiffAllegationsDomain" xlink:to="lab_lly_PlaintiffAllegationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8dab2f6d-88a3-4c6a-9a24-21042151e8a3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2d2bcec0-a39e-4d2f-8562-e865bbc90a2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_d078c57f-301a-4b2c-b738-407b98e88a6c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, equity interests purchased</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db89a07e-3ba2-4ebc-a295-2de43befda5b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NextCureInc.Member_90281b4d-8025-4ec8-aef0-befe888a9612_terseLabel_en-US" xlink:label="lab_lly_NextCureInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NextCure, Inc.</link:label>
    <link:label id="lab_lly_NextCureInc.Member_label_en-US" xlink:label="lab_lly_NextCureInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NextCure, Inc. [Member]</link:label>
    <link:label id="lab_lly_NextCureInc.Member_documentation_en-US" xlink:label="lab_lly_NextCureInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NextCure, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NextCureInc.Member" xlink:href="lly-20201231.xsd#lly_NextCureInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NextCureInc.Member" xlink:to="lab_lly_NextCureInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b5475479-a6da-44b5-81c3-69ae79808d37_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_4307972d-75a2-448b-868e-11d979c64078_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_aef37819-d311-4bbc-8889-6c4d35a878d0_terseLabel_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc. (Disarm)</link:label>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lly_DisarmTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_DisarmTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disarm Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember" xlink:href="lly-20201231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DisarmTherapeuticsIncMember" xlink:to="lab_lly_DisarmTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_30d8e548-cf63-4480-9514-c2f03d0f7963_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f5d62201-9dac-41c5-b2a8-223fc610334f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_f291cd42-a1b9-4813-b17a-df4a3a988b61_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_ebc2d7a6-5f78-4fe3-8e46-10849de2737c_verboseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_38717ca2-71a7-486e-9623-c37f7c2c6b7b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_c4e00cc1-b60c-4e18-a402-ebe13d22312f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_e3545be9-1be9-46e7-b45e-6bce727a9908_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_339b2d42-4d74-46c6-af7e-d5d60dd9ee58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-lived Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_814731b5-6019-4ce9-8c04-9c3c341b8a02_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service benefits, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_aafbfe77-62cd-4b8a-b7ec-624e86a65678_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term notes, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6e81a3e1-411e-4068-820d-86a18a100cdd_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrajentaBIMember_310acd0c-b49f-4781-ae1a-74618a1433fb_verboseLabel_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta&#174;</link:label>
    <link:label id="lab_lly_TrajentaBIMember_label_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:label id="lab_lly_TrajentaBIMember_documentation_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember" xlink:href="lly-20201231.xsd#lly_TrajentaBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrajentaBIMember" xlink:to="lab_lly_TrajentaBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_75a7b70e-3e3f-418a-a6ff-253dfb1dc334_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d99942d8-ef40-40f6-a70e-dafde7698c95_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_93ff9c5a-56d0-4fd3-b1da-dae7c91fbb9e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets&#8212;(increase) decrease</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9a5713f8-4cae-4d46-8933-a3bafb4d13f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1aba4f16-1596-4af5-a670-51eae40e93bc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share, aggregate amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f6d4209e-bb22-4bab-b312-5a6fc7c5c715_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_505571ec-eab0-4179-bf44-defed63885af_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a0cc2066-2236-4bba-aaa0-5dc9975ec216_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c42a3418-3d46-4020-89c0-d05590a5224c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_98b15991-8888-431c-b2b8-290126f4bee1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate for net benefit costs</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_d1e81b0c-f3bb-4914-b360-7af0e0759fbe_negatedLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_03216fe6-d76e-44c9-8492-46331e2f2124_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term commercial paper borrowings</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_1af0b6f6-db0d-4091-adec-206ba891bb17_terseLabel_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy USD Sell Japanese Yen</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_label_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_documentation_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:href="lly-20201231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:to="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_52e408fa-8fe4-4fe3-8728-7b3f28a1f07d_terseLabel_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_label_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Define Benefit Plan, Other [Member]</link:label>
    <link:label id="lab_lly_DefineBenefitPlanOtherMember_documentation_en-US" xlink:label="lab_lly_DefineBenefitPlanOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Define Benefit Plan, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember" xlink:href="lly-20201231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DefineBenefitPlanOtherMember" xlink:to="lab_lly_DefineBenefitPlanOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a46ba801-b3e5-4891-ba62-09dd9a6d57ce_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_64cff37c-32ca-4474-826a-16baeb4421d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_9916a86a-ccdc-441f-af35-fa1f2b4a2d23_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_a1833b14-17f5-4925-a096-3046e01d554c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_476b013f-6098-4d8d-9391-37d1c805f6f9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used for) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_252097ab-401b-400d-a0d0-fc9543ee3c8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_54722c7b-2622-4511-a535-4983f16d0575_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_0797669c-167f-4423-b037-f5f82efcb9a5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_0acf715f-2b3f-437b-b534-a7c2446210bf_terseLabel_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets - repurchase agreements</link:label>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_label_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds - Repurchased Agreements [Member]</link:label>
    <link:label id="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember_documentation_en-US" xlink:label="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Funds - Repurchased Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:href="lly-20201231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:to="lab_lly_FixedIncomeFundsRepurchasedAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_dfb4c7a1-39ac-4435-a684-cdfcc5867770_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8f7710b2-94a9-4402-b81b-35e8d595411d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_5ae04f4a-167d-4559-9c7a-9853a0b85a80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash distributed to Elanco upon disposition</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_78989a59-4a66-4958-ae0c-0feb596b43d7_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_977d6935-1bb5-4a96-bed9-f3b3b618ca68_terseLabel_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.56% Japanese Yen denominated notes due 2034</link:label>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_label_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.56% Yen-denominated Notes Due 2034 [Member]</link:label>
    <link:label id="lab_lly_A56YenDenominatedNotesDue2034Member_documentation_en-US" xlink:label="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.56% Yen-denominated Notes Due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member" xlink:href="lly-20201231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A56YenDenominatedNotesDue2034Member" xlink:to="lab_lly_A56YenDenominatedNotesDue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7e1859ae-918f-4ee2-b410-8b99aeefbf85_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_d73a2e19-5743-41d7-8488-65ffe0036337_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_2762e73f-1ce2-4a90-ad15-3650be207889_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_13adf32b-1b00-4c0e-99dd-e86ad50322c4_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of common stock in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_db02357a-983f-4994-ab2d-ed303d7c48e7_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_4e6bae6a-5fad-4ce2-9aac-46429a5ea8dc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate for benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3900b587-f50c-46d4-aa3a-ebd5f9f31fb9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d21ec28c-9d2b-4be3-83b0-6a2b6d2f830b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation of New Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b005a306-0870-4260-aae4-e68f6883b2ed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_c0d7aab6-44a4-4325-bfa7-71abd650cfb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments (Note 7)</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>lly-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:245edc66-3d73-4ffb-b61a-7d5e03b3f1e4,g:f11d2b17-0882-47f8-a810-701878e7e2df-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b3fb0a46-e9e2-4ca1-a2cc-619ee2544f21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_fe82346e-5c8d-4ee4-86a7-49a09f589cd9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3fb0a46-e9e2-4ca1-a2cc-619ee2544f21" xlink:to="loc_dei_DocumentInformationTable_fe82346e-5c8d-4ee4-86a7-49a09f589cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19cb0042-d9ef-455e-b928-014465486dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_fe82346e-5c8d-4ee4-86a7-49a09f589cd9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19cb0042-d9ef-455e-b928-014465486dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19cb0042-d9ef-455e-b928-014465486dbd" xlink:to="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_56b9ab17-8b6a-4a0c-ac46-72f36f44d757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_us-gaap_CommonClassAMember_56b9ab17-8b6a-4a0c-ac46-72f36f44d757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_ee1a1d32-0e44-4411-9f87-7d0bf6b79774" xlink:href="lly-20201231.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A1.000NotesDueJune22022Member_ee1a1d32-0e44-4411-9f87-7d0bf6b79774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_5b83a2df-dc8b-4e37-a760-5f8096da1433" xlink:href="lly-20201231.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A718NotesDueJune12025Member_5b83a2df-dc8b-4e37-a760-5f8096da1433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_1b0b2d64-b8ac-40ab-8521-0b9b892e7a35" xlink:href="lly-20201231.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A1.625NotesDueJune22026Member_1b0b2d64-b8ac-40ab-8521-0b9b892e7a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_c08dd853-5e43-4165-bd20-a779b84ea4e5" xlink:href="lly-20201231.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A2.125NotesDueJune32030Member_c08dd853-5e43-4165-bd20-a779b84ea4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_32948fb1-1b70-4490-b91d-38ce05397bc6" xlink:href="lly-20201231.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A625Notesdue2031Member_32948fb1-1b70-4490-b91d-38ce05397bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_b1f9c94a-f02d-4103-9175-d50d25df4989" xlink:href="lly-20201231.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_b1f9c94a-f02d-4103-9175-d50d25df4989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_28b88862-71dd-418d-800d-af9ab54e3b70" xlink:href="lly-20201231.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e91ed1a5-b2db-4695-8a66-27e430f5cbe1" xlink:to="loc_lly_A1.700Notesdue2049Member_28b88862-71dd-418d-800d-af9ab54e3b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_fe82346e-5c8d-4ee4-86a7-49a09f589cd9" xlink:to="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3a0fd9ff-0978-44f2-8db8-3dbcc245b606" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentType_3a0fd9ff-0978-44f2-8db8-3dbcc245b606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_0d6e160e-7884-4507-940f-5a2a02f36e89" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentAnnualReport_0d6e160e-7884-4507-940f-5a2a02f36e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9a0216c0-23ca-4eff-a004-05edb6c1132d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentPeriodEndDate_9a0216c0-23ca-4eff-a004-05edb6c1132d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b71159a6-72b9-49ff-9a60-071c1815834a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_CurrentFiscalYearEndDate_b71159a6-72b9-49ff-9a60-071c1815834a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f760de75-5884-43d5-9cc2-7696196d6f42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityFileNumber_f760de75-5884-43d5-9cc2-7696196d6f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5abf2929-58d3-43b3-bd16-8cc0c6e90165" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityRegistrantName_5abf2929-58d3-43b3-bd16-8cc0c6e90165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_88f19064-61b7-4d0a-afe2-5cbe580f1827" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityIncorporationStateCountryCode_88f19064-61b7-4d0a-afe2-5cbe580f1827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_521fbc61-9d89-4275-9b34-7b573f88c986" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityTaxIdentificationNumber_521fbc61-9d89-4275-9b34-7b573f88c986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_30502293-c64e-45ef-a9ea-54aaa2300801" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityAddressAddressLine1_30502293-c64e-45ef-a9ea-54aaa2300801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_735fc7f7-deed-480e-865b-d31070e598a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityAddressCityOrTown_735fc7f7-deed-480e-865b-d31070e598a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ff67e102-0eb5-4d43-9f2d-0470fa58c605" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityAddressStateOrProvince_ff67e102-0eb5-4d43-9f2d-0470fa58c605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d6e6e9ae-c99e-4569-9e19-d757a6a45778" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityAddressPostalZipCode_d6e6e9ae-c99e-4569-9e19-d757a6a45778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_942fccef-f13e-4d4a-b6b0-de3df5ceb740" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_CityAreaCode_942fccef-f13e-4d4a-b6b0-de3df5ceb740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_841016c2-565e-4f3c-9941-967eedea7ca6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_LocalPhoneNumber_841016c2-565e-4f3c-9941-967eedea7ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3e26c902-cfc2-4a9b-8850-e0361cf0c7fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_Security12bTitle_3e26c902-cfc2-4a9b-8850-e0361cf0c7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0a4447c5-1f8c-48f2-8212-8480cabeb8a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_TradingSymbol_0a4447c5-1f8c-48f2-8212-8480cabeb8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9d096305-056a-40a1-88f3-6f9901895a93" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_SecurityExchangeName_9d096305-056a-40a1-88f3-6f9901895a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a5e83a48-6fa0-490f-bbad-6cac47427722" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a5e83a48-6fa0-490f-bbad-6cac47427722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_a7271b0e-e5c1-405c-92f5-86c49628e369" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityVoluntaryFilers_a7271b0e-e5c1-405c-92f5-86c49628e369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ef406952-387f-4d25-976f-b5bea58ff03c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityCurrentReportingStatus_ef406952-387f-4d25-976f-b5bea58ff03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1ad67630-f189-4272-9f31-1b080c0e881d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityInteractiveDataCurrent_1ad67630-f189-4272-9f31-1b080c0e881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ee2cf632-da51-48b8-9fc8-b34f41909753" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityFilerCategory_ee2cf632-da51-48b8-9fc8-b34f41909753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2d3dfe6e-7b6a-46ea-8fe3-83c2b65c55ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntitySmallBusiness_2d3dfe6e-7b6a-46ea-8fe3-83c2b65c55ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6512b6e5-1c75-4cd2-a649-15a59d8fad11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityEmergingGrowthCompany_6512b6e5-1c75-4cd2-a649-15a59d8fad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_af6d0356-f76c-40ed-9032-bde4ec5a65ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_IcfrAuditorAttestationFlag_af6d0356-f76c-40ed-9032-bde4ec5a65ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5422df02-3280-49e2-9d5d-57d7d288e612" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityShellCompany_5422df02-3280-49e2-9d5d-57d7d288e612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_68cdc328-8c7b-4a59-876c-fd9aba7e9f3b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityPublicFloat_68cdc328-8c7b-4a59-876c-fd9aba7e9f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_680744f7-f9eb-4782-9666-edb23a237ad8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_680744f7-f9eb-4782-9666-edb23a237ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b4551227-67a1-4df4-ab6a-84fdde3feb24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentTransitionReport_b4551227-67a1-4df4-ab6a-84fdde3feb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5c87755c-2e70-4043-8191-5fb813bd142e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_AmendmentFlag_5c87755c-2e70-4043-8191-5fb813bd142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_529a401c-5913-4ea6-8cd5-c895f27ac596" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentFiscalYearFocus_529a401c-5913-4ea6-8cd5-c895f27ac596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_da917654-ffc2-4828-b5de-5b760e1588b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentFiscalPeriodFocus_da917654-ffc2-4828-b5de-5b760e1588b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ad5168c5-dedd-4a4c-acfc-3cc2f00b0390" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_EntityCentralIndexKey_ad5168c5-dedd-4a4c-acfc-3cc2f00b0390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c077553b-48cf-47de-86ba-5a9dde52177e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_eec5584f-d960-4f92-9784-8c6b716c5248" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c077553b-48cf-47de-86ba-5a9dde52177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_696e713b-7508-455a-9c7f-5eef678baf69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_Revenues_696e713b-7508-455a-9c7f-5eef678baf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_653a94ca-b49d-4306-a3b4-5e78c368f0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_653a94ca-b49d-4306-a3b4-5e78c368f0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_534bc661-b191-4912-884c-bcbc60ee3399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_534bc661-b191-4912-884c-bcbc60ee3399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_85e99686-c5a7-4992-8e07-dc95820dfb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_85e99686-c5a7-4992-8e07-dc95820dfb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_9916e186-731e-47ac-8841-1dbf05dbcfdf" xlink:href="lly-20201231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_9916e186-731e-47ac-8841-1dbf05dbcfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_89f6fe3b-335e-448a-a1ca-c5d3c9dc01ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_89f6fe3b-335e-448a-a1ca-c5d3c9dc01ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f1ebd6ab-bb46-471e-bae4-cfb44df04ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f1ebd6ab-bb46-471e-bae4-cfb44df04ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_96adc795-eed5-4838-8b99-dfe63f474c7e" xlink:href="lly-20201231.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f8eb2a21-1d65-4793-aabf-40527fb3c2ff" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_96adc795-eed5-4838-8b99-dfe63f474c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1b485baa-8caa-4b86-84cc-892614797f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1b485baa-8caa-4b86-84cc-892614797f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_533c67c7-ea89-4013-9712-48485c97c861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_533c67c7-ea89-4013-9712-48485c97c861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0247d04e-c374-46b3-863a-e2222ab8abe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0247d04e-c374-46b3-863a-e2222ab8abe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1871480f-3682-4b37-971a-346bbf22fa98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1871480f-3682-4b37-971a-346bbf22fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cdc0822b-83f6-4422-839b-f11a840bfe2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_NetIncomeLoss_cdc0822b-83f6-4422-839b-f11a840bfe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1572ebd8-e087-4e1f-ac4f-47b0f1ab2a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1572ebd8-e087-4e1f-ac4f-47b0f1ab2a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_8002a09a-95c4-4e6f-bc74-26606cd8d8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1572ebd8-e087-4e1f-ac4f-47b0f1ab2a28" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_8002a09a-95c4-4e6f-bc74-26606cd8d8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_42b58992-51d5-4bc7-b6df-1f0f342364f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1572ebd8-e087-4e1f-ac4f-47b0f1ab2a28" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_42b58992-51d5-4bc7-b6df-1f0f342364f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7ecb8e6d-1054-437c-9649-93b9f0220892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1572ebd8-e087-4e1f-ac4f-47b0f1ab2a28" xlink:to="loc_us-gaap_EarningsPerShareBasic_7ecb8e6d-1054-437c-9649-93b9f0220892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_28d55530-7d3a-471a-9912-6d4df98716ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1572ebd8-e087-4e1f-ac4f-47b0f1ab2a28" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_28d55530-7d3a-471a-9912-6d4df98716ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_580af049-c485-4a60-8641-6bb775ea6cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1572ebd8-e087-4e1f-ac4f-47b0f1ab2a28" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_580af049-c485-4a60-8641-6bb775ea6cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a4139bf3-cbc5-4ec9-8932-deaed3c9985b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1572ebd8-e087-4e1f-ac4f-47b0f1ab2a28" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a4139bf3-cbc5-4ec9-8932-deaed3c9985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_85996722-b4cd-43d0-89b1-1221d3639b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dcbef58d-c847-4840-a136-ae1780c4e51b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_85996722-b4cd-43d0-89b1-1221d3639b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1c3cfe4e-6828-4310-8a15-41b2f1bc7e49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_85996722-b4cd-43d0-89b1-1221d3639b21" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1c3cfe4e-6828-4310-8a15-41b2f1bc7e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1925a69-0f48-4df9-a325-617f328978b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_85996722-b4cd-43d0-89b1-1221d3639b21" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1925a69-0f48-4df9-a325-617f328978b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c13b3166-e6b2-4828-90d8-a239e88ecdb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8291f5ae-5dfa-455f-af09-4cc923192ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c13b3166-e6b2-4828-90d8-a239e88ecdb9" xlink:to="loc_us-gaap_StatementTable_8291f5ae-5dfa-455f-af09-4cc923192ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_0acda52c-c933-4b67-bf96-ebdf69ff12ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8291f5ae-5dfa-455f-af09-4cc923192ca0" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_0acda52c-c933-4b67-bf96-ebdf69ff12ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_bcfeae86-59bc-4ddb-8fcf-412856afb4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_0acda52c-c933-4b67-bf96-ebdf69ff12ce" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_bcfeae86-59bc-4ddb-8fcf-412856afb4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_8d40beab-bde2-4813-9215-0756712c1140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_bcfeae86-59bc-4ddb-8fcf-412856afb4c2" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_8d40beab-bde2-4813-9215-0756712c1140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_10685977-31f5-4baa-bee1-58b321594c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_bcfeae86-59bc-4ddb-8fcf-412856afb4c2" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_10685977-31f5-4baa-bee1-58b321594c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8291f5ae-5dfa-455f-af09-4cc923192ca0" xlink:to="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d47f6690-f0f7-40fa-915e-2ecfdd809510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_NetIncomeLoss_d47f6690-f0f7-40fa-915e-2ecfdd809510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_c4a1d887-5317-4332-840d-1087da68ff57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_c4a1d887-5317-4332-840d-1087da68ff57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_805cc0ae-df8d-4c2d-8a56-51d3f69ee218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_805cc0ae-df8d-4c2d-8a56-51d3f69ee218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_22f3afff-1a84-4c66-8bab-e14cb43590a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_22f3afff-1a84-4c66-8bab-e14cb43590a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_b34d9d77-640c-4532-910a-e263d86be8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_b34d9d77-640c-4532-910a-e263d86be8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_34988130-eec5-49f0-96a4-a7a581405869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax_34988130-eec5-49f0-96a4-a7a581405869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_ea41d0dc-449f-4a0a-84d2-3840410180f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_c9735b69-fc97-47e2-81db-541ae07c2d40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_ea41d0dc-449f-4a0a-84d2-3840410180f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_e6d92b98-5b43-4afc-b258-9e8cf99a6bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_e6d92b98-5b43-4afc-b258-9e8cf99a6bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_33bf627d-54c0-468d-82a5-d8ee5d0cf44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_33bf627d-54c0-468d-82a5-d8ee5d0cf44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c5babab5-d468-4da5-b1de-de067116cff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c03adf72-d737-4ce7-a070-5f3943985e8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c5babab5-d468-4da5-b1de-de067116cff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5830ca73-8ec8-4ee9-92e4-98a0c248b88a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5830ca73-8ec8-4ee9-92e4-98a0c248b88a" xlink:to="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1fb90afc-70a6-4dfc-a972-d3fe4123eb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1fb90afc-70a6-4dfc-a972-d3fe4123eb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ba316b9b-6100-483b-8267-157340feecf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:to="loc_us-gaap_ShortTermInvestments_ba316b9b-6100-483b-8267-157340feecf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2edf5a5e-999e-4182-89c8-d48d3a6aee94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2edf5a5e-999e-4182-89c8-d48d3a6aee94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_77316b3a-afa4-45ee-a253-1906f2bfb4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:to="loc_us-gaap_OtherReceivables_77316b3a-afa4-45ee-a253-1906f2bfb4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9c3ecce2-67a6-4d49-92b7-e6a8a06ca348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:to="loc_us-gaap_InventoryNet_9c3ecce2-67a6-4d49-92b7-e6a8a06ca348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1995c20d-f1d8-4dd9-b5a5-94fdb88d7fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1995c20d-f1d8-4dd9-b5a5-94fdb88d7fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1189b731-3deb-45f3-b62d-fcc320aa129e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5260595f-2a56-4259-99a2-aa1e3b7490ff" xlink:to="loc_us-gaap_AssetsCurrent_1189b731-3deb-45f3-b62d-fcc320aa129e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_ab62810a-4b40-4600-9e9e-bea0c9648491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:to="loc_us-gaap_LongTermInvestments_ab62810a-4b40-4600-9e9e-bea0c9648491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bbecfe7b-1798-403b-959e-5c279354ae1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:to="loc_us-gaap_Goodwill_bbecfe7b-1798-403b-959e-5c279354ae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29f13659-9cd0-49fd-9dd7-ca9642e01be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29f13659-9cd0-49fd-9dd7-ca9642e01be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_eb4c54da-25bc-4040-9760-0d5765616a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_eb4c54da-25bc-4040-9760-0d5765616a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5ef1cdf1-3acc-4add-aa52-3934f32b5330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5ef1cdf1-3acc-4add-aa52-3934f32b5330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_2ec15b65-a91a-4987-945a-c3b7da9e863d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_2ec15b65-a91a-4987-945a-c3b7da9e863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_54c5fe46-3f2a-4b5d-997e-01ed5415a428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_035047d4-0010-4ccb-8613-f6f4d0dbaeaa" xlink:to="loc_us-gaap_Assets_54c5fe46-3f2a-4b5d-997e-01ed5415a428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cb75a517-f784-45df-838a-e4b43c263e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5830ca73-8ec8-4ee9-92e4-98a0c248b88a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cb75a517-f784-45df-838a-e4b43c263e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cb75a517-f784-45df-838a-e4b43c263e11" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_11ff899a-54a5-420e-b3fd-1ce2dd4351d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:to="loc_us-gaap_DebtCurrent_11ff899a-54a5-420e-b3fd-1ce2dd4351d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_51f0976a-55d1-45d3-9470-ffa0131e326e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:to="loc_us-gaap_AccountsPayableCurrent_51f0976a-55d1-45d3-9470-ffa0131e326e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a583ae3d-da10-4b88-860b-8d63f94bc1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a583ae3d-da10-4b88-860b-8d63f94bc1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_facfa88a-fd21-4aba-a119-7bc36aaec03f" xlink:href="lly-20201231.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:to="loc_lly_SalesRebatesAndDiscounts_facfa88a-fd21-4aba-a119-7bc36aaec03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_ff513ea8-830c-44dc-bff2-3f2eed600f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:to="loc_us-gaap_DividendsPayableCurrent_ff513ea8-830c-44dc-bff2-3f2eed600f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_a39692bf-b5d3-4c98-897b-fa174c3357e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:to="loc_us-gaap_TaxesPayableCurrent_a39692bf-b5d3-4c98-897b-fa174c3357e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f07d9fb2-84e2-447f-bd52-78a6d2cb3804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f07d9fb2-84e2-447f-bd52-78a6d2cb3804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ea69a759-a479-4a73-9b41-4511bc2e083b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dd2e5649-4e57-4556-8a26-f4fb2815ac9b" xlink:to="loc_us-gaap_LiabilitiesCurrent_ea69a759-a479-4a73-9b41-4511bc2e083b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_e481bee5-a053-4782-9e02-7ab9b2ba605e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cb75a517-f784-45df-838a-e4b43c263e11" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_e481bee5-a053-4782-9e02-7ab9b2ba605e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7561617a-2953-46cd-8e4b-956c6c633fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e481bee5-a053-4782-9e02-7ab9b2ba605e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7561617a-2953-46cd-8e4b-956c6c633fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8f084200-7c45-4f67-a909-2c1465b031d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e481bee5-a053-4782-9e02-7ab9b2ba605e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8f084200-7c45-4f67-a909-2c1465b031d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_42eee4ff-91b9-4e87-8acf-98e666df753f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e481bee5-a053-4782-9e02-7ab9b2ba605e" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_42eee4ff-91b9-4e87-8acf-98e666df753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ab803193-50a0-4360-8618-7a1a495e8afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e481bee5-a053-4782-9e02-7ab9b2ba605e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ab803193-50a0-4360-8618-7a1a495e8afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9da1ad36-c884-4768-8dbe-b4d35081cbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e481bee5-a053-4782-9e02-7ab9b2ba605e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9da1ad36-c884-4768-8dbe-b4d35081cbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4a44e84e-4b9d-4a6f-8539-d7e518095a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e481bee5-a053-4782-9e02-7ab9b2ba605e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4a44e84e-4b9d-4a6f-8539-d7e518095a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4ab8d1f9-f3ca-4913-83fd-92e0a9865b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cb75a517-f784-45df-838a-e4b43c263e11" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4ab8d1f9-f3ca-4913-83fd-92e0a9865b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cb75a517-f784-45df-838a-e4b43c263e11" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bfa32fbc-a783-4881-8882-a973cf694ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_CommonStockValue_bfa32fbc-a783-4881-8882-a973cf694ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_17ff7363-4b22-4ecf-bd2b-c9b9d205c979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_17ff7363-4b22-4ecf-bd2b-c9b9d205c979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d929797f-f332-4c8f-a070-fc8718c1175b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d929797f-f332-4c8f-a070-fc8718c1175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_6f958183-4b3c-4054-b745-d03818b38de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_6f958183-4b3c-4054-b745-d03818b38de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4460873a-a053-48a3-82e5-46c34d7b612c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4460873a-a053-48a3-82e5-46c34d7b612c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_99daed5e-6661-4534-a663-8fd934a62a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_TreasuryStockValue_99daed5e-6661-4534-a663-8fd934a62a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bd9fcacc-2b3d-4409-87cc-bb00813205d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_StockholdersEquity_bd9fcacc-2b3d-4409-87cc-bb00813205d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0c5e61c5-e46a-49d1-be24-5545c9e90772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_MinorityInterest_0c5e61c5-e46a-49d1-be24-5545c9e90772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05038347-d6db-46a4-afad-c9af7babf3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_330f680d-c40a-4990-80d4-77d271947142" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05038347-d6db-46a4-afad-c9af7babf3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04a5e509-1380-40d3-8663-369ba863a8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cb75a517-f784-45df-838a-e4b43c263e11" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_04a5e509-1380-40d3-8663-369ba863a8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2ffe0872-7ecb-44df-956e-376e24227e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0884f21a-ebff-4aea-bbf2-eb4564ecf60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ffe0872-7ecb-44df-956e-376e24227e42" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0884f21a-ebff-4aea-bbf2-eb4564ecf60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cb63e364-036d-41c0-85f6-8dcf56e7ad3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ffe0872-7ecb-44df-956e-376e24227e42" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cb63e364-036d-41c0-85f6-8dcf56e7ad3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9a69a6f4-219a-46c4-9dee-91062379fa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ffe0872-7ecb-44df-956e-376e24227e42" xlink:to="loc_us-gaap_CommonStockSharesIssued_9a69a6f4-219a-46c4-9dee-91062379fa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofShareholdersEquityStatement"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6022cdc0-be65-4dbe-972c-5af0fd74bff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6022cdc0-be65-4dbe-972c-5af0fd74bff2" xlink:to="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b20001f9-fc3d-4f21-a83c-8f70e8b7dcd7" xlink:to="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e8cfd2a0-390d-4364-99e3-57ca8337f1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_CommonStockMember_e8cfd2a0-390d-4364-99e3-57ca8337f1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ba384e56-7dd1-4321-b2e3-4d485dec9386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ba384e56-7dd1-4321-b2e3-4d485dec9386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f42cc0db-73ad-4ac5-924c-30e6c5be7286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_RetainedEarningsMember_f42cc0db-73ad-4ac5-924c-30e6c5be7286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_f77c9ef7-458f-48b6-94d7-575a96b12134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_f77c9ef7-458f-48b6-94d7-575a96b12134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6590fb60-4b77-4bee-9cc1-0cc97a98c65c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6590fb60-4b77-4bee-9cc1-0cc97a98c65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_417c1144-3eaf-45d8-9478-8cbf958c0e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_TreasuryStockMember_417c1144-3eaf-45d8-9478-8cbf958c0e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_06ecd782-bafe-4047-9b18-1deace9cfa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b071449f-4716-4ce5-9d7e-0fc61091801e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_06ecd782-bafe-4047-9b18-1deace9cfa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e738b930-a874-4715-8fb1-8292d4ff9fd3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bda2ab6-4dfc-4d06-a3bc-14274e9c9f85" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e738b930-a874-4715-8fb1-8292d4ff9fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_15a2770c-031b-471b-bcd3-e08173b519d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e738b930-a874-4715-8fb1-8292d4ff9fd3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_15a2770c-031b-471b-bcd3-e08173b519d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_94a8bf07-499e-42cf-9f01-0e4028b8f07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b3d3dc1c-04e4-493c-933d-392cc1a1791e" xlink:to="loc_us-gaap_StatementLineItems_94a8bf07-499e-42cf-9f01-0e4028b8f07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94a8bf07-499e-42cf-9f01-0e4028b8f07a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8df9e29d-21f6-426f-838a-c4019ca91e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_SharesIssued_8df9e29d-21f6-426f-838a-c4019ca91e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14f41d87-f5fe-4330-8956-87117b451adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_14f41d87-f5fe-4330-8956-87117b451adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_85e1b42d-77da-44c3-a1c9-dca7d75ce2e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_ProfitLoss_85e1b42d-77da-44c3-a1c9-dca7d75ce2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abae81c1-f71f-47c3-8784-8d8c26a70376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abae81c1-f71f-47c3-8784-8d8c26a70376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_abc05e47-2c8d-4500-8506-eed3c546fc67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_Dividends_abc05e47-2c8d-4500-8506-eed3c546fc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_1ca507d1-e416-4503-8765-864c2e1974b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_1ca507d1-e416-4503-8765-864c2e1974b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_db4b7ed3-b4bc-43c0-bd7e-9c54738e9f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_db4b7ed3-b4bc-43c0-bd7e-9c54738e9f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1ddcb853-9c32-4d58-b26b-c3e5c1842406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1ddcb853-9c32-4d58-b26b-c3e5c1842406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e3c83d5e-3f4e-4b02-b257-2594f2741e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e3c83d5e-3f4e-4b02-b257-2594f2741e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_23e68e5c-a7fd-4b65-b42c-da85f7f1b43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_23e68e5c-a7fd-4b65-b42c-da85f7f1b43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e6faef54-dffb-40d6-b1fa-361204fef344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e6faef54-dffb-40d6-b1fa-361204fef344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_adcac459-7381-4ab8-9572-c57e16e10240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_adcac459-7381-4ab8-9572-c57e16e10240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6b75d3c-7b7e-4190-b7b1-135c89477f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6b75d3c-7b7e-4190-b7b1-135c89477f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer_c9a0981e-3594-4dc3-88d5-a15879dd882f" xlink:href="lly-20201231.xsd#lly_StockAcquiredDuringPeriodSharesExchangeOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_lly_StockAcquiredDuringPeriodSharesExchangeOffer_c9a0981e-3594-4dc3-88d5-a15879dd882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer_b423ba18-e56a-4311-a47e-8abe529b06f4" xlink:href="lly-20201231.xsd#lly_StockAcquiredDuringPeriodValueExchangeOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_lly_StockAcquiredDuringPeriodValueExchangeOffer_b423ba18-e56a-4311-a47e-8abe529b06f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_991c375a-3eb9-4e02-ad5d-115ae7e1a5e8" xlink:href="lly-20201231.xsd#lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary_991c375a-3eb9-4e02-ad5d-115ae7e1a5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_dd554dd5-a418-4a84-8e98-c25ae27c5b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockholdersEquityOther_dd554dd5-a418-4a84-8e98-c25ae27c5b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_43c20017-66cf-47e4-9a30-a3650ba5ac6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_SharesIssued_43c20017-66cf-47e4-9a30-a3650ba5ac6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61e7edf4-7178-4da5-b55f-f0203e503a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb421e62-af8b-4ed6-8f69-6e87ed75cf5c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61e7edf4-7178-4da5-b55f-f0203e503a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0ffe0239-e99e-4db3-ac64-59ccd898ee4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_0344289e-6ad2-47bc-8b33-8d9e8f882ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0ffe0239-e99e-4db3-ac64-59ccd898ee4d" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_0344289e-6ad2-47bc-8b33-8d9e8f882ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6af903f0-dc8e-447a-a4e0-e8b503c7d076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6af903f0-dc8e-447a-a4e0-e8b503c7d076" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ba104dc-4764-46b8-a0f9-818a45611ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ba104dc-4764-46b8-a0f9-818a45611ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac07b226-b0cc-432e-a2ee-db8932d3e10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ba104dc-4764-46b8-a0f9-818a45611ccd" xlink:to="loc_us-gaap_NetIncomeLoss_ac07b226-b0cc-432e-a2ee-db8932d3e10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ba104dc-4764-46b8-a0f9-818a45611ccd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_60e1d90f-7c03-4931-89a3-b816c5366b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_60e1d90f-7c03-4931-89a3-b816c5366b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_256490d3-ef3c-4a77-a9a0-fcd9ada0ac11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_256490d3-ef3c-4a77-a9a0-fcd9ada0ac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7f54695c-0eea-40e2-a4b0-e883daa2cc89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7f54695c-0eea-40e2-a4b0-e883daa2cc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_efad68f0-4c75-4ebd-bc7c-c2ff4f1e4d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_efad68f0-4c75-4ebd-bc7c-c2ff4f1e4d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8742371e-9267-4e47-bc1e-1090d1bd9c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_us-gaap_ShareBasedCompensation_8742371e-9267-4e47-bc1e-1090d1bd9c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_58a73528-c2fa-4958-80a7-532d5250b0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_us-gaap_GainLossOnInvestments_58a73528-c2fa-4958-80a7-532d5250b0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_e4ffa8c2-4ef4-496a-b0d9-c61deeaa1518" xlink:href="lly-20201231.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_e4ffa8c2-4ef4-496a-b0d9-c61deeaa1518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9f273d83-27c0-4503-9d2e-12f7bb6948fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9f273d83-27c0-4503-9d2e-12f7bb6948fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35bf1e14-c01b-4240-98d3-21c87504472a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4798aa0f-8047-492e-9cbe-5f1d8e706719" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35bf1e14-c01b-4240-98d3-21c87504472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_14ec1dfc-d63b-49b0-b789-1758cb189327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35bf1e14-c01b-4240-98d3-21c87504472a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_14ec1dfc-d63b-49b0-b789-1758cb189327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_df2b1324-013b-46e4-b813-9c955c09d2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35bf1e14-c01b-4240-98d3-21c87504472a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_df2b1324-013b-46e4-b813-9c955c09d2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7e1451d5-aa4b-4bbe-a767-267dde59aa89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35bf1e14-c01b-4240-98d3-21c87504472a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7e1451d5-aa4b-4bbe-a767-267dde59aa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_407aef2c-00a2-4356-a3c2-fbab2dbc89e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35bf1e14-c01b-4240-98d3-21c87504472a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_407aef2c-00a2-4356-a3c2-fbab2dbc89e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5e03a423-1d8b-4cec-9eca-fe7aadf95a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35bf1e14-c01b-4240-98d3-21c87504472a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5e03a423-1d8b-4cec-9eca-fe7aadf95a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1d6291b-f7e9-4a91-876e-86ddfae7a86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3ba104dc-4764-46b8-a0f9-818a45611ccd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1d6291b-f7e9-4a91-876e-86ddfae7a86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_e215e7e4-d05a-4af9-9824-d84fca0d7c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_e215e7e4-d05a-4af9-9824-d84fca0d7c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_f76d24ed-83cd-4561-9c59-a3afd5a7a722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_f76d24ed-83cd-4561-9c59-a3afd5a7a722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_60d2a16d-6b0a-4db6-a6f8-da487fe0fed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_60d2a16d-6b0a-4db6-a6f8-da487fe0fed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_8e9dfc1d-dc61-4a78-988f-ca295e71c143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_8e9dfc1d-dc61-4a78-988f-ca295e71c143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_d239577c-bd68-44a3-96ca-ac85bda21f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_d239577c-bd68-44a3-96ca-ac85bda21f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_161d45a5-3b68-441e-9e55-f0927ca49541" xlink:href="lly-20201231.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_161d45a5-3b68-441e-9e55-f0927ca49541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a9fb3ec9-9e66-4bca-aa8a-76142f898987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a9fb3ec9-9e66-4bca-aa8a-76142f898987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_a962b007-ffdf-4eef-aab9-2b7b941e2c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_a962b007-ffdf-4eef-aab9-2b7b941e2c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7982b44b-21e2-44c7-85f0-71e13f6833d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7982b44b-21e2-44c7-85f0-71e13f6833d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f9b4eba9-fe39-4d5a-8a9c-faefab064c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f9b4eba9-fe39-4d5a-8a9c-faefab064c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb60f8ef-2a25-4a4b-be22-d68eb5f294e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f17296d3-aee2-4a70-9dc9-913a3de340aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb60f8ef-2a25-4a4b-be22-d68eb5f294e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_f03f294b-1d5d-4286-a954-cf7ac50f800d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:to="loc_us-gaap_PaymentsOfDividends_f03f294b-1d5d-4286-a954-cf7ac50f800d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_29ff268e-f12e-42a8-be88-e60587cb2047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_29ff268e-f12e-42a8-be88-e60587cb2047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_37bdad1b-8928-4c82-a518-33702376313d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_37bdad1b-8928-4c82-a518-33702376313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d7e40626-9207-46b1-b1b7-bbdd1979491a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d7e40626-9207-46b1-b1b7-bbdd1979491a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1b48dfec-ffe2-4680-8120-47b0b763238f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1b48dfec-ffe2-4680-8120-47b0b763238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary_10547e0e-6c63-4877-908d-d7384857eb30" xlink:href="lly-20201231.xsd#lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:to="loc_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary_10547e0e-6c63-4877-908d-d7384857eb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f37882d4-ed15-4734-b9b2-4c8cff9ec51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f37882d4-ed15-4734-b9b2-4c8cff9ec51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8a072fa3-ebf9-4f3d-b64e-5e08118d1d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_721e6598-5ffa-415c-9003-3b3af8a4dfd5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8a072fa3-ebf9-4f3d-b64e-5e08118d1d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd2b6e87-92d9-4b90-84a1-c404c2b13d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd2b6e87-92d9-4b90-84a1-c404c2b13d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_00d2d2d1-3ff7-4c4a-8a86-b41ab8045921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_00d2d2d1-3ff7-4c4a-8a86-b41ab8045921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13343228-081a-40ed-b2a4-08765d451ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13343228-081a-40ed-b2a4-08765d451ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_d216bec1-d5aa-417f-8e3d-077d66e64761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_cf722e35-cf69-430e-a934-7561b4285455" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_d216bec1-d5aa-417f-8e3d-077d66e64761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="lly-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b74ff2ab-0797-40aa-a272-b60f05fda779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_62a07359-a25f-4d9a-a70a-cbd1aeeb1afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b74ff2ab-0797-40aa-a272-b60f05fda779" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_62a07359-a25f-4d9a-a70a-cbd1aeeb1afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7af47ca9-60d5-42e2-8853-7783ead5aac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_63f83538-b83f-4a8e-ac70-4eb95abb7f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af47ca9-60d5-42e2-8853-7783ead5aac7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_63f83538-b83f-4a8e-ac70-4eb95abb7f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_033bb709-5695-46ec-953b-5e36ff7f275d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_033bb709-5695-46ec-953b-5e36ff7f275d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0a265e9c-0449-45f6-aeee-90be5f79edf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0a265e9c-0449-45f6-aeee-90be5f79edf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_df235fbd-c22f-4e78-ac54-4471ac07c1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_df235fbd-c22f-4e78-ac54-4471ac07c1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_8aff5108-0915-4002-bfe7-84a62a59deab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_8aff5108-0915-4002-bfe7-84a62a59deab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2f6f7383-cae1-49be-a5b3-8e2dfe770dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2f6f7383-cae1-49be-a5b3-8e2dfe770dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_36c81b17-f83c-4f5d-adef-142045dd7f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_36c81b17-f83c-4f5d-adef-142045dd7f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_e66eded9-346a-40b4-b29e-660015223d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_e66eded9-346a-40b4-b29e-660015223d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_83db035a-fd31-44c2-aab3-024fdfe2e0ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_83db035a-fd31-44c2-aab3-024fdfe2e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_49c5bc1a-f0b4-4be7-93ac-5944a0bcc88e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_49c5bc1a-f0b4-4be7-93ac-5944a0bcc88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_6b308a28-e80d-4faf-adb0-0ac73b8e75fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_6b308a28-e80d-4faf-adb0-0ac73b8e75fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f1ed27e7-6087-4597-a9d5-9642bdfe2d15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f1ed27e7-6087-4597-a9d5-9642bdfe2d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e12674c0-f557-40c1-903b-cfa8f2dba0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e12674c0-f557-40c1-903b-cfa8f2dba0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a4cf9014-ee34-4719-b310-ac37ed3e5e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a4cf9014-ee34-4719-b310-ac37ed3e5e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_57f77229-55fe-4fa2-8c2c-14ac9ee1125b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_57f77229-55fe-4fa2-8c2c-14ac9ee1125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_a453adf7-e88d-4149-9137-2bd91d82d859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2621c296-a076-4368-a62a-e0714582c46a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_a453adf7-e88d-4149-9137-2bd91d82d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_67b8710c-146d-4821-9729-355c66ba3595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67b8710c-146d-4821-9729-355c66ba3595" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f89912be-838a-4c70-9613-9df6ac09d794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f89912be-838a-4c70-9613-9df6ac09d794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f89912be-838a-4c70-9613-9df6ac09d794" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_ac756347-fc18-49fa-985c-9c6bc9963009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_ac756347-fc18-49fa-985c-9c6bc9963009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_fb8e4ae8-0224-488a-b83e-6f823e1bb13a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_fb8e4ae8-0224-488a-b83e-6f823e1bb13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccountingStandardsUpdate201616aMember_79098087-e409-4ce7-859e-af4ecd91d570" xlink:href="lly-20201231.xsd#lly_AccountingStandardsUpdate201616aMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e8e6ffef-43cc-4d6a-8f99-6bab0a444459" xlink:to="loc_lly_AccountingStandardsUpdate201616aMember_79098087-e409-4ce7-859e-af4ecd91d570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_4c49954e-9c08-40f9-8775-f97e0f2981c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_4c49954e-9c08-40f9-8775-f97e0f2981c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_435c5e75-4b4c-4916-a722-f7da46b384ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4c49954e-9c08-40f9-8775-f97e0f2981c8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_435c5e75-4b4c-4916-a722-f7da46b384ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_19acf3e8-5114-4b3d-bf60-5be4ece779ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_435c5e75-4b4c-4916-a722-f7da46b384ca" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_19acf3e8-5114-4b3d-bf60-5be4ece779ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0eb189c1-d6bd-4765-b4cc-03797f29c13d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0eb189c1-d6bd-4765-b4cc-03797f29c13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93800b3f-f2fe-45b1-a503-0c982cd5220c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0eb189c1-d6bd-4765-b4cc-03797f29c13d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93800b3f-f2fe-45b1-a503-0c982cd5220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_a16f9081-3565-413a-a025-62f1b5d0d1d0" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93800b3f-f2fe-45b1-a503-0c982cd5220c" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_a16f9081-3565-413a-a025-62f1b5d0d1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68dcaef7-4b54-4b8a-95ae-6c2174577c9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68dcaef7-4b54-4b8a-95ae-6c2174577c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4bd7e5db-21f9-4fab-a01c-93e9a224a53a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_68dcaef7-4b54-4b8a-95ae-6c2174577c9e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4bd7e5db-21f9-4fab-a01c-93e9a224a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_bd815487-10fc-488f-b318-73aef3148cc8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_4bd7e5db-21f9-4fab-a01c-93e9a224a53a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_bd815487-10fc-488f-b318-73aef3148cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_733ab6fb-028b-41ba-ab25-6f28bfbe5006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_733ab6fb-028b-41ba-ab25-6f28bfbe5006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f08b2141-6819-4b3d-bd27-8cbc1a285d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_733ab6fb-028b-41ba-ab25-6f28bfbe5006" xlink:to="loc_us-gaap_EquityComponentDomain_f08b2141-6819-4b3d-bd27-8cbc1a285d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_48c4fabf-0609-41c5-badf-4178eba68572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f08b2141-6819-4b3d-bd27-8cbc1a285d9e" xlink:to="loc_us-gaap_RetainedEarningsMember_48c4fabf-0609-41c5-badf-4178eba68572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34d0ea5a-816d-4bc5-be33-764a9ff70063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f08b2141-6819-4b3d-bd27-8cbc1a285d9e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34d0ea5a-816d-4bc5-be33-764a9ff70063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9882bf43-f4f1-438f-ab44-2deec01ca13a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_srt_OwnershipAxis_9882bf43-f4f1-438f-ab44-2deec01ca13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ebaa9516-c19c-483f-8143-098087f5c307" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_9882bf43-f4f1-438f-ab44-2deec01ca13a" xlink:to="loc_srt_OwnershipDomain_ebaa9516-c19c-483f-8143-098087f5c307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember_e5c7e30a-af0b-4c37-8e65-59f04b79858c" xlink:href="lly-20201231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ebaa9516-c19c-483f-8143-098087f5c307" xlink:to="loc_lly_EliLillyAndCompanyMember_e5c7e30a-af0b-4c37-8e65-59f04b79858c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3f733b87-db9c-4030-a6b1-bd7b02d44fce" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_45a47247-1cf5-4b2a-bbd3-c76d1dda36fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_45a47247-1cf5-4b2a-bbd3-c76d1dda36fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_c58e4081-c95c-4941-87a0-00616c982de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_AdvertisingExpense_c58e4081-c95c-4941-87a0-00616c982de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AdvertisingExpensePercentageOfRevenue_92c59fa2-9e12-4ef4-bbc1-00129000bc0b" xlink:href="lly-20201231.xsd#lly_AdvertisingExpensePercentageOfRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_lly_AdvertisingExpensePercentageOfRevenue_92c59fa2-9e12-4ef4-bbc1-00129000bc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_65cda945-7749-409f-b43a-5a5079a8c4ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_65cda945-7749-409f-b43a-5a5079a8c4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5baa7f1e-950f-42dc-a976-2f70bffb1427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5baa7f1e-950f-42dc-a976-2f70bffb1427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7ed3f417-b69d-4113-a9fe-d639dc70d68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_OperatingLeaseLiability_7ed3f417-b69d-4113-a9fe-d639dc70d68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_7eb56712-1a98-47f5-9a47-ae9b7409d8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_7eb56712-1a98-47f5-9a47-ae9b7409d8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7ea649ae-a89e-437a-ad3f-b28b37cb3f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7ea649ae-a89e-437a-ad3f-b28b37cb3f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_0351871e-744a-446c-a386-6ed9abfd4617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_0351871e-744a-446c-a386-6ed9abfd4617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3d500192-f91d-4a0a-aa2a-b00b42967f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3d500192-f91d-4a0a-aa2a-b00b42967f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_bf09bd56-a674-47f7-9bf7-0fa64701d42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a87130ff-1e40-4f38-bb56-e73324606723" xlink:to="loc_us-gaap_DeferredTaxLiabilities_bf09bd56-a674-47f7-9bf7-0fa64701d42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20201231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a034e89-94c5-4489-ae30-db1b42944050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_c52c8973-d9cd-4e62-8a04-712635ec0872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a034e89-94c5-4489-ae30-db1b42944050" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_c52c8973-d9cd-4e62-8a04-712635ec0872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6c7d686-4587-4963-a2e8-24c81f0927d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4b524f2c-febb-40d6-b2d8-7b941f7072b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6c7d686-4587-4963-a2e8-24c81f0927d7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4b524f2c-febb-40d6-b2d8-7b941f7072b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_397e6cb8-da97-4928-b735-d97ed2c9296b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6c7d686-4587-4963-a2e8-24c81f0927d7" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_397e6cb8-da97-4928-b735-d97ed2c9296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fdcb6d41-9394-4eed-ac22-99c06471b7a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_13604448-380a-440a-9270-991cb3e1ac88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fdcb6d41-9394-4eed-ac22-99c06471b7a9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_13604448-380a-440a-9270-991cb3e1ac88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_13604448-380a-440a-9270-991cb3e1ac88" xlink:to="loc_srt_ProductOrServiceAxis_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6d1bbfd3-f95a-462c-b8ce-0d9333fe8a3e" xlink:to="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_943d6d05-958e-4d6b-9f69-9653bb3063d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:to="loc_us-gaap_ProductMember_943d6d05-958e-4d6b-9f69-9653bb3063d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_0f8680b2-dfc2-4f56-9d86-8c4ac230b1f9" xlink:href="lly-20201231.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:to="loc_lly_CollaborationandOtherRevenueMember_0f8680b2-dfc2-4f56-9d86-8c4ac230b1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_f8e1e062-a96d-4455-a592-2d6f81509152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56224341-5b83-4e91-9073-20de01467c96" xlink:to="loc_us-gaap_RoyaltyMember_f8e1e062-a96d-4455-a592-2d6f81509152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a8703edb-1d91-47b3-8c42-f43651ab27dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_13604448-380a-440a-9270-991cb3e1ac88" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a8703edb-1d91-47b3-8c42-f43651ab27dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4d17ee76-fa14-49b9-b78a-9fe0c23a0d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8703edb-1d91-47b3-8c42-f43651ab27dc" xlink:to="loc_us-gaap_Revenues_4d17ee76-fa14-49b9-b78a-9fe0c23a0d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f26b1545-15db-47d0-90b7-981ab32e28a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f26b1545-15db-47d0-90b7-981ab32e28a9" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a422ca25-dc47-440e-98e1-0109734f5d72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_srt_MajorCustomersAxis_a422ca25-dc47-440e-98e1-0109734f5d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3341a854-1863-4910-b241-de4408da8506" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a422ca25-dc47-440e-98e1-0109734f5d72" xlink:to="loc_srt_NameOfMajorCustomerDomain_3341a854-1863-4910-b241-de4408da8506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ThreeLargestWholesalesMember_20b13a8b-e195-4ef7-8d81-41d4c33f0941" xlink:href="lly-20201231.xsd#lly_ThreeLargestWholesalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3341a854-1863-4910-b241-de4408da8506" xlink:to="loc_lly_ThreeLargestWholesalesMember_20b13a8b-e195-4ef7-8d81-41d4c33f0941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddd34164-6004-414a-9f78-35fe3a17b459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddd34164-6004-414a-9f78-35fe3a17b459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_99b60396-a8b0-4c38-ae96-31d856b64e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ddd34164-6004-414a-9f78-35fe3a17b459" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_99b60396-a8b0-4c38-ae96-31d856b64e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0b65c364-23bb-41ee-99ed-9401f6f1bd52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_99b60396-a8b0-4c38-ae96-31d856b64e67" xlink:to="loc_us-gaap_SalesRevenueNetMember_0b65c364-23bb-41ee-99ed-9401f6f1bd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_49b61d80-2629-4509-a06d-ca82ed2a2bba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_99b60396-a8b0-4c38-ae96-31d856b64e67" xlink:to="loc_us-gaap_AccountsReceivableMember_49b61d80-2629-4509-a06d-ca82ed2a2bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_49760f71-bd98-4086-beb0-34c3cd94592f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_srt_RangeAxis_49760f71-bd98-4086-beb0-34c3cd94592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0fbe0d1-b1a7-43d8-85b6-8ff2d5b83847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_49760f71-bd98-4086-beb0-34c3cd94592f" xlink:to="loc_srt_RangeMember_d0fbe0d1-b1a7-43d8-85b6-8ff2d5b83847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b2574ff6-428b-4d0e-9b3e-e2dea6c3911a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0fbe0d1-b1a7-43d8-85b6-8ff2d5b83847" xlink:to="loc_srt_MinimumMember_b2574ff6-428b-4d0e-9b3e-e2dea6c3911a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fe56e820-b82a-4a00-8735-2f6295a8c1da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0fbe0d1-b1a7-43d8-85b6-8ff2d5b83847" xlink:to="loc_srt_MaximumMember_fe56e820-b82a-4a00-8735-2f6295a8c1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_srt_StatementGeographicalAxis_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6dfd6ce8-fc47-43db-8f6a-cabbeeb01eed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c3ad78e1-0cb6-4d29-8897-f5b02bee9fbb" xlink:to="loc_srt_SegmentGeographicalDomain_6dfd6ce8-fc47-43db-8f6a-cabbeeb01eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3c5d6fc8-10c0-4b86-9b58-923d0c12d5d4" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6dfd6ce8-fc47-43db-8f6a-cabbeeb01eed" xlink:to="loc_country_US_3c5d6fc8-10c0-4b86-9b58-923d0c12d5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5f20dca4-6024-485f-9762-97855114fe0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5f20dca4-6024-485f-9762-97855114fe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ca77976d-013e-4468-87fb-be82213fa22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_5f20dca4-6024-485f-9762-97855114fe0c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ca77976d-013e-4468-87fb-be82213fa22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_dc255c6e-2287-4ddb-bd6f-6081e841c157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ca77976d-013e-4468-87fb-be82213fa22d" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_dc255c6e-2287-4ddb-bd6f-6081e841c157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b0486279-3f9d-42e8-9c97-d4869580a52a" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMinimum_43497b5b-5ebf-4a26-93e3-df21b9258423" xlink:href="lly-20201231.xsd#lly_RevenuefromContractPaymentTermMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuefromContractPaymentTermMinimum_43497b5b-5ebf-4a26-93e3-df21b9258423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuefromContractPaymentTermMaximum_c384eb17-6d17-4b76-8db8-ba7a42ef2543" xlink:href="lly-20201231.xsd#lly_RevenuefromContractPaymentTermMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuefromContractPaymentTermMaximum_c384eb17-6d17-4b76-8db8-ba7a42ef2543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_11a89909-14b6-4c56-b5c6-3be078700750" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt_11a89909-14b6-4c56-b5c6-3be078700750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a5f595a3-7be5-4efd-91f5-f07398310cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a5f595a3-7be5-4efd-91f5-f07398310cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_8ee2d2b8-54a1-4af5-85ce-8f0da0e71e7b" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesRebatePaymentPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod_8ee2d2b8-54a1-4af5-85ce-8f0da0e71e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3b201008-2fa6-45eb-b0db-a4655f6337ab" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate_3b201008-2fa6-45eb-b0db-a4655f6337ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_8effe789-3a3f-49c0-ae7c-5a3feff20a94" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel_8effe789-3a3f-49c0-ae7c-5a3feff20a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_5495bf7d-c55d-470c-ae1f-5267570d33bf" xlink:href="lly-20201231.xsd#lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue_5495bf7d-c55d-470c-ae1f-5267570d33bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_7b8453a4-13ca-441f-a808-7d62b00c0934" xlink:href="lly-20201231.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_cfbac15c-c0ea-4cd8-a73a-d89a87ea7e72" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_7b8453a4-13ca-441f-a808-7d62b00c0934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f5bfe2c7-415c-4f6b-b048-90e5f31c2c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d93799c7-a0ce-4be8-b55c-e00e4e908e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f5bfe2c7-415c-4f6b-b048-90e5f31c2c3d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d93799c7-a0ce-4be8-b55c-e00e4e908e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4acfc197-7d08-47ea-9b4b-74549b5ddc60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4acfc197-7d08-47ea-9b4b-74549b5ddc60" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8400f3cb-a98b-438c-8074-480a39c49480" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:to="loc_srt_ProductOrServiceAxis_8400f3cb-a98b-438c-8074-480a39c49480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8400f3cb-a98b-438c-8074-480a39c49480" xlink:to="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:href="lly-20201231.xsd#lly_DiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_c892d4e7-c4ad-44d9-bf0b-ddb09edd2902" xlink:href="lly-20201231.xsd#lly_TrulicityMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_TrulicityMemberMember_c892d4e7-c4ad-44d9-bf0b-ddb09edd2902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_76aa0b74-dc3e-4d55-a8e0-4586408c476f" xlink:href="lly-20201231.xsd#lly_HumalogMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_HumalogMember_76aa0b74-dc3e-4d55-a8e0-4586408c476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_57624db1-4259-4cb1-a6cf-66c4a7ec30ca" xlink:href="lly-20201231.xsd#lly_HumulinMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_HumulinMember_57624db1-4259-4cb1-a6cf-66c4a7ec30ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_c44140d8-4f46-4a8a-b195-49c2993cbb66" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_JardianceMember_c44140d8-4f46-4a8a-b195-49c2993cbb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_a9df6af9-0def-4fb8-9c60-8d0f0076fa12" xlink:href="lly-20201231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_BasaglarMember_a9df6af9-0def-4fb8-9c60-8d0f0076fa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_9c1880a4-b884-4c73-97ab-230f0f741a1b" xlink:href="lly-20201231.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_TrajentaBIMember_9c1880a4-b884-4c73-97ab-230f0f741a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_bd5cf9e3-7876-4a46-a247-eda88d2e6d00" xlink:href="lly-20201231.xsd#lly_OtherDiabetesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6f75e94d-7470-46f1-a4ee-6270e8bf92d2" xlink:to="loc_lly_OtherDiabetesMember_bd5cf9e3-7876-4a46-a247-eda88d2e6d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:href="lly-20201231.xsd#lly_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_6c52288c-575f-478f-9a1c-a219e2c28ef7" xlink:href="lly-20201231.xsd#lly_AlimtaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_AlimtaMember_6c52288c-575f-478f-9a1c-a219e2c28ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_856bf81c-af96-431b-8daf-28548cfdd29b" xlink:href="lly-20201231.xsd#lly_CyramzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_CyramzaMember_856bf81c-af96-431b-8daf-28548cfdd29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_12cdf77c-b257-4bc6-81d6-2475907ca3db" xlink:href="lly-20201231.xsd#lly_VerzenioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_VerzenioMember_12cdf77c-b257-4bc6-81d6-2475907ca3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_140eccc0-578b-4c40-bbb6-1fba6fde1d14" xlink:href="lly-20201231.xsd#lly_ErbituxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_ErbituxMember_140eccc0-578b-4c40-bbb6-1fba6fde1d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_0d40e03c-5900-4f89-8442-bbeaf8b8e660" xlink:href="lly-20201231.xsd#lly_OtherOncologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_c2171a84-ba99-4a45-afd4-a74cd37d59d3" xlink:to="loc_lly_OtherOncologyMember_0d40e03c-5900-4f89-8442-bbeaf8b8e660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:href="lly-20201231.xsd#lly_ImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_aa23f541-8a16-4cf1-aa1a-f3896d46082f" xlink:href="lly-20201231.xsd#lly_TaltzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:to="loc_lly_TaltzMember_aa23f541-8a16-4cf1-aa1a-f3896d46082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_9f700b68-a01f-4f92-b755-fabbff7a1ba8" xlink:href="lly-20201231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:to="loc_lly_OlumiantMember_9f700b68-a01f-4f92-b755-fabbff7a1ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_42cc5200-9212-4b71-97ab-3d4854da0bc5" xlink:href="lly-20201231.xsd#lly_OtherImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_84a82a7e-17ac-451f-97df-c4a3630d3ebb" xlink:to="loc_lly_OtherImmunologyMember_42cc5200-9212-4b71-97ab-3d4854da0bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:href="lly-20201231.xsd#lly_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_ebe4d44f-0bb6-4503-8626-1483d66500af" xlink:href="lly-20201231.xsd#lly_CymbaltaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:to="loc_lly_CymbaltaMember_ebe4d44f-0bb6-4503-8626-1483d66500af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_bb6391a1-b2fd-47fe-8f0c-55834ef870c3" xlink:href="lly-20201231.xsd#lly_ZyprexaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:to="loc_lly_ZyprexaMember_bb6391a1-b2fd-47fe-8f0c-55834ef870c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_2d56c208-e58a-4981-aa7e-52b3bcca5399" xlink:href="lly-20201231.xsd#lly_EmgalityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:to="loc_lly_EmgalityMember_2d56c208-e58a-4981-aa7e-52b3bcca5399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_3e1a3d14-9c36-42f2-aad2-f5d3544b2519" xlink:href="lly-20201231.xsd#lly_OtherNeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_239fc662-f83c-4429-b3df-707bf64dd685" xlink:to="loc_lly_OtherNeuroscienceMember_3e1a3d14-9c36-42f2-aad2-f5d3544b2519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:href="lly-20201231.xsd#lly_OtherProductTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e7f6cb5-43bc-4a18-9929-df269ed43b71" xlink:to="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_16cdf599-70bb-4014-b08b-ecb9b9ed9eb2" xlink:href="lly-20201231.xsd#lly_ForteoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:to="loc_lly_ForteoMember_16cdf599-70bb-4014-b08b-ecb9b9ed9eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BamlanivimabMember_60c0d5c7-9fda-4924-a252-dd5701fce48f" xlink:href="lly-20201231.xsd#lly_BamlanivimabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:to="loc_lly_BamlanivimabMember_60c0d5c7-9fda-4924-a252-dd5701fce48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_8dbda9e4-14da-47cb-8483-5a05580eff46" xlink:href="lly-20201231.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:to="loc_lly_CialisMember_8dbda9e4-14da-47cb-8483-5a05580eff46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_1c0583b0-f32d-4fa5-8600-9c575d6e1a24" xlink:href="lly-20201231.xsd#lly_OtherProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_f5e9559b-6dbd-40e4-a474-91b5152ee2e4" xlink:to="loc_lly_OtherProductMember_1c0583b0-f32d-4fa5-8600-9c575d6e1a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dd36d851-e0c0-4bb5-8090-ddc317f43022" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:to="loc_srt_StatementGeographicalAxis_dd36d851-e0c0-4bb5-8090-ddc317f43022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2bbecf0d-c63a-4b8b-b753-c0b166b15024" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dd36d851-e0c0-4bb5-8090-ddc317f43022" xlink:to="loc_srt_SegmentGeographicalDomain_2bbecf0d-c63a-4b8b-b753-c0b166b15024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ba1974ce-16f5-41b4-b19c-eaa574f24352" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2bbecf0d-c63a-4b8b-b753-c0b166b15024" xlink:to="loc_country_US_ba1974ce-16f5-41b4-b19c-eaa574f24352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_90cbf493-ed45-43c8-ade2-4586493c6bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2bbecf0d-c63a-4b8b-b753-c0b166b15024" xlink:to="loc_us-gaap_NonUsMember_90cbf493-ed45-43c8-ade2-4586493c6bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_32160e1f-c0be-4177-8b65-32142990f313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b116acdc-651a-48e6-97bb-0ac35c6e60d3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_32160e1f-c0be-4177-8b65-32142990f313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fdd48509-7330-4c87-a404-05b0bc61595c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_32160e1f-c0be-4177-8b65-32142990f313" xlink:to="loc_us-gaap_Revenues_fdd48509-7330-4c87-a404-05b0bc61595c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e2485218-4302-43a1-a8fe-905f02718e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_64a3c4e8-155e-4563-b2fb-6ab64ab783e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e2485218-4302-43a1-a8fe-905f02718e29" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_64a3c4e8-155e-4563-b2fb-6ab64ab783e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5aac6c17-ede2-4501-a74f-79eb420f1d0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64a3c4e8-155e-4563-b2fb-6ab64ab783e8" xlink:to="loc_srt_StatementGeographicalAxis_5aac6c17-ede2-4501-a74f-79eb420f1d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5aac6c17-ede2-4501-a74f-79eb420f1d0c" xlink:to="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a6549c3b-b518-434f-a31c-c26934f064df" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_country_US_a6549c3b-b518-434f-a31c-c26934f064df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_9737faea-bf35-48d1-b9d6-0901c94eee54" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_srt_EuropeMember_9737faea-bf35-48d1-b9d6-0901c94eee54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_23fe7714-6431-4267-b900-ea51ee4ef660" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_country_JP_23fe7714-6431-4267-b900-ea51ee4ef660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_b941f0c9-8d63-4e96-ac7a-1369c2739633" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_country_CN_b941f0c9-8d63-4e96-ac7a-1369c2739633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_aa5c7a6f-a56e-4a34-80cc-62a449e69bb7" xlink:href="lly-20201231.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_85f61513-8b4f-4016-8f54-336967d60370" xlink:to="loc_lly_OtherForeignCountriesMember_aa5c7a6f-a56e-4a34-80cc-62a449e69bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_044fd680-b2f1-4565-8e9d-84ad41748105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64a3c4e8-155e-4563-b2fb-6ab64ab783e8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_044fd680-b2f1-4565-8e9d-84ad41748105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_94b89331-ec44-4bfb-be21-82bc0532888d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_044fd680-b2f1-4565-8e9d-84ad41748105" xlink:to="loc_us-gaap_Revenues_94b89331-ec44-4bfb-be21-82bc0532888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiture" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestiture"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiture" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_44d23cc2-d0a4-4bd9-aad6-14b99a1565dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5f4fb381-ddd6-480b-8dd6-61264bf83da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_44d23cc2-d0a4-4bd9-aad6-14b99a1565dc" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_5f4fb381-ddd6-480b-8dd6-61264bf83da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureTables" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d35cb252-69f8-4d79-b2c7-61178fed9657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_32bdf5b2-f00e-4e2e-b973-97253bb5e9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d35cb252-69f8-4d79-b2c7-61178fed9657" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_32bdf5b2-f00e-4e2e-b973-97253bb5e9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_6c3f600c-cd49-49cc-a8dc-7ffea2224a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d35cb252-69f8-4d79-b2c7-61178fed9657" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_6c3f600c-cd49-49cc-a8dc-7ffea2224a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3a0eb54e-8f39-4c68-b466-0fad59fdd590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3a0eb54e-8f39-4c68-b466-0fad59fdd590" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f75fe8ff-f266-40b4-8aab-161a8535e861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f75fe8ff-f266-40b4-8aab-161a8535e861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_af7ea9ef-30d3-49f8-8517-92cfa8110726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f75fe8ff-f266-40b4-8aab-161a8535e861" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_af7ea9ef-30d3-49f8-8517-92cfa8110726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_21c73359-5165-4aac-ad67-4a71d3148ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_af7ea9ef-30d3-49f8-8517-92cfa8110726" xlink:to="loc_us-gaap_SubsequentEventMember_21c73359-5165-4aac-ad67-4a71d3148ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1add8263-7021-4536-9c36-046a89976c01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_1add8263-7021-4536-9c36-046a89976c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7f89eb5e-35e4-4cb6-9fd2-e9fdb9963da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1add8263-7021-4536-9c36-046a89976c01" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7f89eb5e-35e4-4cb6-9fd2-e9fdb9963da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5b602f53-9552-4d16-9b0a-c5f2ba365ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7f89eb5e-35e4-4cb6-9fd2-e9fdb9963da4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5b602f53-9552-4d16-9b0a-c5f2ba365ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_39542dd8-748b-46cb-945a-345fdf430942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_39542dd8-748b-46cb-945a-345fdf430942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5411c11-21e3-4e95-9a9d-3fa2ff88f7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_39542dd8-748b-46cb-945a-345fdf430942" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5411c11-21e3-4e95-9a9d-3fa2ff88f7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_b47998a4-fe73-4c83-96d7-9dc2ae0147d4" xlink:href="lly-20201231.xsd#lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5411c11-21e3-4e95-9a9d-3fa2ff88f7b6" xlink:to="loc_lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember_b47998a4-fe73-4c83-96d7-9dc2ae0147d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_023af711-eafc-45ba-ab2a-7d7ef7937717" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_srt_CounterpartyNameAxis_023af711-eafc-45ba-ab2a-7d7ef7937717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20b2eca9-7dc8-480e-9d3f-5c2f68df6a4f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_023af711-eafc-45ba-ab2a-7d7ef7937717" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20b2eca9-7dc8-480e-9d3f-5c2f68df6a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EddingpharmMember_c948f9c6-6c2e-4f9d-9189-490c129abb34" xlink:href="lly-20201231.xsd#lly_EddingpharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_20b2eca9-7dc8-480e-9d3f-5c2f68df6a4f" xlink:to="loc_lly_EddingpharmMember_c948f9c6-6c2e-4f9d-9189-490c129abb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a3c6af9f-1a65-400a-8db3-dd7d8245ff24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a3c6af9f-1a65-400a-8db3-dd7d8245ff24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a3c6af9f-1a65-400a-8db3-dd7d8245ff24" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_29dd77b1-b728-4bc8-9f31-9bbeaee8d600" xlink:href="lly-20201231.xsd#lly_DermiraInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_DermiraInc.Member_29dd77b1-b728-4bc8-9f31-9bbeaee8d600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_5e22989e-69f3-4f50-97c5-ab22e98ff045" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_LoxoOncologyInc.Member_5e22989e-69f3-4f50-97c5-ab22e98ff045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBioSciencesIncMember_4e20919f-080e-4b96-8e4c-db51161555ec" xlink:href="lly-20201231.xsd#lly_PrecisionBioSciencesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_PrecisionBioSciencesIncMember_4e20919f-080e-4b96-8e4c-db51161555ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_c288d384-7ec9-403d-9d5d-781909979475" xlink:href="lly-20201231.xsd#lly_MerusNVMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_MerusNVMember_c288d384-7ec9-403d-9d5d-781909979475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_f08f279d-6401-4666-a0e5-4a2e4c65d2ee" xlink:href="lly-20201231.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_PrevailTherapeuticsIncMember_f08f279d-6401-4666-a0e5-4a2e4c65d2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember_56d2f9cf-fcf0-4f7a-a685-7cc5a675d6ae" xlink:href="lly-20201231.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b04f3079-0cc0-40aa-88fe-59dc34a8495e" xlink:to="loc_lly_AsahiKaseiPharmaCorporationMember_56d2f9cf-fcf0-4f7a-a685-7cc5a675d6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cb572c79-ac81-40a1-a5c0-d6f2986f914f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_srt_ProductOrServiceAxis_cb572c79-ac81-40a1-a5c0-d6f2986f914f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1f9c1df-dacd-4894-a90e-2f8138040856" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cb572c79-ac81-40a1-a5c0-d6f2986f914f" xlink:to="loc_srt_ProductsAndServicesDomain_f1f9c1df-dacd-4894-a90e-2f8138040856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_8e98b0aa-5f9a-4a7c-937e-d4efafc02a92" xlink:href="lly-20201231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1f9c1df-dacd-4894-a90e-2f8138040856" xlink:to="loc_lly_SelpercatinibLOXO292Member_8e98b0aa-5f9a-4a7c-937e-d4efafc02a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_948ed60c-06fa-4b6a-8068-31d1eb80f52c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_srt_StatementScenarioAxis_948ed60c-06fa-4b6a-8068-31d1eb80f52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6ebd7959-7e0d-4e84-a707-163f4e6f2c96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_948ed60c-06fa-4b6a-8068-31d1eb80f52c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6ebd7959-7e0d-4e84-a707-163f4e6f2c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2bb76717-59b0-4e8d-b757-dd93145a146c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6ebd7959-7e0d-4e84-a707-163f4e6f2c96" xlink:to="loc_srt_ScenarioForecastMember_2bb76717-59b0-4e8d-b757-dd93145a146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetAcquisitionAxis_0b767d31-6aec-44ae-bf5d-9f9dd591f067" xlink:href="lly-20201231.xsd#lly_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_lly_AssetAcquisitionAxis_0b767d31-6aec-44ae-bf5d-9f9dd591f067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetAcquisitionDomain_f9e45b84-0197-496b-bf20-99437d3b2f56" xlink:href="lly-20201231.xsd#lly_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AssetAcquisitionAxis_0b767d31-6aec-44ae-bf5d-9f9dd591f067" xlink:to="loc_lly_AssetAcquisitionDomain_f9e45b84-0197-496b-bf20-99437d3b2f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBioSciencesIncMember_545bcf3f-4562-4e4d-9ba4-2e90a27ff1d0" xlink:href="lly-20201231.xsd#lly_PrecisionBioSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AssetAcquisitionDomain_f9e45b84-0197-496b-bf20-99437d3b2f56" xlink:to="loc_lly_PrecisionBioSciencesIncMember_545bcf3f-4562-4e4d-9ba4-2e90a27ff1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_5b6496d0-b42b-441d-8604-219e7d74266c" xlink:href="lly-20201231.xsd#lly_MerusNVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AssetAcquisitionDomain_f9e45b84-0197-496b-bf20-99437d3b2f56" xlink:to="loc_lly_MerusNVMember_5b6496d0-b42b-441d-8604-219e7d74266c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_018e884f-f9c7-4576-8104-6493842b2a97" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_62debbff-176c-4712-b1ee-71f0cdb98630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_62debbff-176c-4712-b1ee-71f0cdb98630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b88dcf3-f68d-410b-8062-4338df25da9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b88dcf3-f68d-410b-8062-4338df25da9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a4e64398-6a70-4fb8-9635-b8bc57953432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_Goodwill_a4e64398-6a70-4fb8-9635-b8bc57953432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6a44202b-5abb-4422-a6c3-8bd5b623c67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6a44202b-5abb-4422-a6c3-8bd5b623c67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_089f6f5d-85ac-489a-bbb1-077e6c9cadc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_089f6f5d-85ac-489a-bbb1-077e6c9cadc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9f5b8fec-8d3a-417d-b719-8c5accafa6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9f5b8fec-8d3a-417d-b719-8c5accafa6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4106bd58-c7a7-4ae0-a97f-5f0bf1e27d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4106bd58-c7a7-4ae0-a97f-5f0bf1e27d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_b3098177-4a53-4ad1-9500-b97c2754b01e" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_b3098177-4a53-4ad1-9500-b97c2754b01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_12c0418c-d029-4d4a-9a7c-53a01e8998fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_12c0418c-d029-4d4a-9a7c-53a01e8998fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NumberOfMedicinesRightsToSold_3779e469-786f-4d7b-b2ad-da8898c91c19" xlink:href="lly-20201231.xsd#lly_NumberOfMedicinesRightsToSold"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_NumberOfMedicinesRightsToSold_3779e469-786f-4d7b-b2ad-da8898c91c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_d4244248-3a64-4f42-926e-8151989a58d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_d4244248-3a64-4f42-926e-8151989a58d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_3fc33790-b71c-4f58-9614-acaf80b88d76" xlink:href="lly-20201231.xsd#lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived_3fc33790-b71c-4f58-9614-acaf80b88d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_546691d1-ff94-43f0-8364-782357f5e188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_546691d1-ff94-43f0-8364-782357f5e188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b19b8251-d0d0-4f75-9234-619031d78411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b19b8251-d0d0-4f75-9234-619031d78411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_37c3d7b2-f2c2-4fad-a293-fcbd7077238c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_37c3d7b2-f2c2-4fad-a293-fcbd7077238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_f90d0845-c843-41a4-b441-6a1cee0efabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_f90d0845-c843-41a4-b441-6a1cee0efabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_a8fe8e1a-40eb-4b95-95d1-9d3ecb0401da" xlink:href="lly-20201231.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_a8fe8e1a-40eb-4b95-95d1-9d3ecb0401da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_c85c9176-d7bd-4315-9d64-732b56bd17a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_c85c9176-d7bd-4315-9d64-732b56bd17a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_6c1b1a38-a888-45fb-8937-5aa4e7c03bfe" xlink:href="lly-20201231.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cc7f199a-27e9-4a9c-b5ae-9e0072d7974f" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_6c1b1a38-a888-45fb-8937-5aa4e7c03bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestiturePurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_06e7fb8e-6355-4a9e-a864-84bcfd79e111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_06e7fb8e-6355-4a9e-a864-84bcfd79e111" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_52d908a3-bbce-4f96-bdb3-5b3709b3125d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:to="loc_srt_ProductOrServiceAxis_52d908a3-bbce-4f96-bdb3-5b3709b3125d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e978c7e5-d7e6-473b-a8bc-9a401a79297c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_52d908a3-bbce-4f96-bdb3-5b3709b3125d" xlink:to="loc_srt_ProductsAndServicesDomain_e978c7e5-d7e6-473b-a8bc-9a401a79297c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_46104873-1a35-4e30-be6d-f1dcde6f4669" xlink:href="lly-20201231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e978c7e5-d7e6-473b-a8bc-9a401a79297c" xlink:to="loc_lly_SelpercatinibLOXO292Member_46104873-1a35-4e30-be6d-f1dcde6f4669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e66bda37-8fc3-4c13-9cab-4892277d9fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e66bda37-8fc3-4c13-9cab-4892277d9fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d7d89ae9-b166-4c9e-98e6-7732799d305b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e66bda37-8fc3-4c13-9cab-4892277d9fd1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d7d89ae9-b166-4c9e-98e6-7732799d305b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_b437728d-492b-46d0-a241-b9c03ea61330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d7d89ae9-b166-4c9e-98e6-7732799d305b" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_b437728d-492b-46d0-a241-b9c03ea61330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8988dac7-674c-4b7b-9636-7d6b1c232c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8988dac7-674c-4b7b-9636-7d6b1c232c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116af751-58a1-4b8f-89de-1b7ea12208a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8988dac7-674c-4b7b-9636-7d6b1c232c28" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116af751-58a1-4b8f-89de-1b7ea12208a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_1a198aff-ca76-406c-9aff-9a1975f7f230" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116af751-58a1-4b8f-89de-1b7ea12208a5" xlink:to="loc_lly_LoxoOncologyInc.Member_1a198aff-ca76-406c-9aff-9a1975f7f230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_abb20be6-c18b-49a1-b702-8a93f5b20eb8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_7655b211-7011-43b7-807f-fa906580e2ff" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_7655b211-7011-43b7-807f-fa906580e2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e1c5464e-cbf1-4cdf-b1ca-66416b47d468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e1c5464e-cbf1-4cdf-b1ca-66416b47d468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_daf9f486-302f-4cfd-a5c6-7c7b09c31cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_daf9f486-302f-4cfd-a5c6-7c7b09c31cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_0266c633-92f0-4000-999c-bd31bdc81977" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet_0266c633-92f0-4000-999c-bd31bdc81977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c386893e-37e7-4a06-b2b4-bb8541e6be8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c386893e-37e7-4a06-b2b4-bb8541e6be8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_90a20990-3068-4feb-b82d-12d891da32fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_Goodwill_90a20990-3068-4feb-b82d-12d891da32fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_65c3ceea-7ed6-456b-99e0-21b5cddfe51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_65c3ceea-7ed6-456b-99e0-21b5cddfe51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_039a740b-0e66-4324-9019-cf4e76f340bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e542720-e3dc-4fb3-a4f9-45d647e229f7" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_039a740b-0e66-4324-9019-cf4e76f340bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AcquisitionsandDivestitureAssetAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_36c4e9a6-ca30-4029-97a8-7c5875bfe9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa13e22-62c7-4707-a162-df5919949710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_36c4e9a6-ca30-4029-97a8-7c5875bfe9e5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa13e22-62c7-4707-a162-df5919949710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4eee4757-28a0-4f1e-8e1e-a2b78981fd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa13e22-62c7-4707-a162-df5919949710" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4eee4757-28a0-4f1e-8e1e-a2b78981fd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4eee4757-28a0-4f1e-8e1e-a2b78981fd87" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember_919aa3d9-a36c-4726-ac2c-3a5629e3aa44" xlink:href="lly-20201231.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_SitryxTherapeuticsLimitedMember_919aa3d9-a36c-4726-ac2c-3a5629e3aa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_c493e44c-c09d-43de-a23b-6f70b0712f78" xlink:href="lly-20201231.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_c493e44c-c09d-43de-a23b-6f70b0712f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_9dc12937-5670-47a2-b303-7559cda75a59" xlink:href="lly-20201231.xsd#lly_JunshiBiosciencesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_JunshiBiosciencesMember_9dc12937-5670-47a2-b303-7559cda75a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UndisclosedAssetAcquisitionMember_deb8592a-29e6-4042-a05f-2b72c1336281" xlink:href="lly-20201231.xsd#lly_UndisclosedAssetAcquisitionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_UndisclosedAssetAcquisitionMember_deb8592a-29e6-4042-a05f-2b72c1336281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember_4fe5bbb4-8c3a-4783-8cfc-b17ddbb2d0d6" xlink:href="lly-20201231.xsd#lly_EvoxTherapeuticsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_EvoxTherapeuticsMember_4fe5bbb4-8c3a-4783-8cfc-b17ddbb2d0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_60a40347-315d-49c0-ab1c-a7931c915955" xlink:href="lly-20201231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_InnoventBiologicsIncMember_60a40347-315d-49c0-ab1c-a7931c915955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisarmTherapeuticsIncMember_a035ee10-7912-4d6c-b804-0bc968be7d5e" xlink:href="lly-20201231.xsd#lly_DisarmTherapeuticsIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_DisarmTherapeuticsIncMember_a035ee10-7912-4d6c-b804-0bc968be7d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FochonPharmaceuticalsLtdMember_f688aea7-e44d-4852-908c-ba5459348305" xlink:href="lly-20201231.xsd#lly_FochonPharmaceuticalsLtdMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_FochonPharmaceuticalsLtdMember_f688aea7-e44d-4852-908c-ba5459348305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ACImmuneSAMember_3209b12f-a86b-4d9d-b76a-d7634a1db6aa" xlink:href="lly-20201231.xsd#lly_ACImmuneSAMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_ACImmuneSAMember_3209b12f-a86b-4d9d-b76a-d7634a1db6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmuNextInc.Member_e13a7606-b33f-4564-bffa-234f01278e7b" xlink:href="lly-20201231.xsd#lly_ImmuNextInc.Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_ImmuNextInc.Member_e13a7606-b33f-4564-bffa-234f01278e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvidityBiosciencesInc.Member_ee9657bd-d41a-401b-9f56-8eede1f96186" xlink:href="lly-20201231.xsd#lly_AvidityBiosciencesInc.Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_AvidityBiosciencesInc.Member_ee9657bd-d41a-401b-9f56-8eede1f96186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CentrexionTherapeuticsCorporationMember_efedfb02-ed7a-470a-9eac-185e0577d851" xlink:href="lly-20201231.xsd#lly_CentrexionTherapeuticsCorporationMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_CentrexionTherapeuticsCorporationMember_efedfb02-ed7a-470a-9eac-185e0577d851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SigilonTherapeuticsMember_cf5b513c-08b8-43d6-86e3-5c040cd540dd" xlink:href="lly-20201231.xsd#lly_SigilonTherapeuticsMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_SigilonTherapeuticsMember_cf5b513c-08b8-43d6-86e3-5c040cd540dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AurkaPharmaMember_67f49d77-b454-4f1b-b6dd-0d989a641df1" xlink:href="lly-20201231.xsd#lly_AurkaPharmaMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_AurkaPharmaMember_67f49d77-b454-4f1b-b6dd-0d989a641df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ARMOBiosciencesInc.Member_ecf1a67c-3cae-4c55-a6c6-08d11f55498e" xlink:href="lly-20201231.xsd#lly_ARMOBiosciencesInc.Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_ARMOBiosciencesInc.Member_ecf1a67c-3cae-4c55-a6c6-08d11f55498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AnimaBiotechMember_9c3fc43c-9ed6-4bb4-a391-2eadf1b01a7e" xlink:href="lly-20201231.xsd#lly_AnimaBiotechMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_AnimaBiotechMember_9c3fc43c-9ed6-4bb4-a391-2eadf1b01a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SIGATechnologiesMember_4fefd56a-819f-4ca9-a392-3dc3699f5581" xlink:href="lly-20201231.xsd#lly_SIGATechnologiesMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_SIGATechnologiesMember_4fefd56a-819f-4ca9-a392-3dc3699f5581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ChugaiPharmaceuticalCompanyMember_4c85aa93-1692-40fb-b5e6-93d1e0b4db5b" xlink:href="lly-20201231.xsd#lly_ChugaiPharmaceuticalCompanyMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_ChugaiPharmaceuticalCompanyMember_4c85aa93-1692-40fb-b5e6-93d1e0b4db5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NextCureInc.Member_1b921ecc-558f-4236-99ef-4e3985861d28" xlink:href="lly-20201231.xsd#lly_NextCureInc.Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_NextCureInc.Member_1b921ecc-558f-4236-99ef-4e3985861d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DicernaPharmaceuticalsMember_318e213a-91d6-4667-97bd-ab5320c4dd83" xlink:href="lly-20201231.xsd#lly_DicernaPharmaceuticalsMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_DicernaPharmaceuticalsMember_318e213a-91d6-4667-97bd-ab5320c4dd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HydraBiosciencesMember_cd6b7f49-1f6c-4cd7-a155-cb406d61a8dc" xlink:href="lly-20201231.xsd#lly_HydraBiosciencesMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbdf7fa4-16f0-4b00-9a3d-39c5a81313a3" xlink:to="loc_lly_HydraBiosciencesMember_cd6b7f49-1f6c-4cd7-a155-cb406d61a8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c2d95828-8985-4353-b601-26bd3d5aaeea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_caa13e22-62c7-4707-a162-df5919949710" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c2d95828-8985-4353-b601-26bd3d5aaeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_83e38103-b1b4-4f32-b14c-b51bf9a31526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c2d95828-8985-4353-b601-26bd3d5aaeea" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_83e38103-b1b4-4f32-b14c-b51bf9a31526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af798e95-fdcd-41ce-b204-dfe24099b712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e62dcec8-7ccb-41ac-9a02-eb697b87a912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af798e95-fdcd-41ce-b204-dfe24099b712" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e62dcec8-7ccb-41ac-9a02-eb697b87a912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e4e1297-98ed-4ffa-b0da-b738af04f2bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_cbecab03-6ae3-4c21-87a4-bc76794abb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e4e1297-98ed-4ffa-b0da-b738af04f2bd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_cbecab03-6ae3-4c21-87a4-bc76794abb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4351c2b4-aff8-4f9e-97ac-b4662cc4e51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4351c2b4-aff8-4f9e-97ac-b4662cc4e51c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_870eb035-3bc6-48c6-8216-451f966175eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:to="loc_us-gaap_TypeOfArrangementAxis_870eb035-3bc6-48c6-8216-451f966175eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_334b7aa7-4ad3-4d9f-98e6-5708a72ce098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_870eb035-3bc6-48c6-8216-451f966175eb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_334b7aa7-4ad3-4d9f-98e6-5708a72ce098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_d13a96ba-ee70-421e-98b0-b9475336f0bf" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_334b7aa7-4ad3-4d9f-98e6-5708a72ce098" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_d13a96ba-ee70-421e-98b0-b9475336f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80a0687e-7277-47f3-932f-940f9718be29" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:to="loc_srt_ProductOrServiceAxis_80a0687e-7277-47f3-932f-940f9718be29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_80a0687e-7277-47f3-932f-940f9718be29" xlink:to="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_97ce74f8-12e6-4316-86ea-da6592d42052" xlink:href="lly-20201231.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:to="loc_lly_TrajentaBIMember_97ce74f8-12e6-4316-86ea-da6592d42052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_cb3e8116-212c-497b-a8dd-d1ffdb6b1a2c" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:to="loc_lly_JardianceMember_cb3e8116-212c-497b-a8dd-d1ffdb6b1a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_f9d0dbbd-5cd0-4a14-8fac-5bfc15769d4b" xlink:href="lly-20201231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_57ca24d7-ebcb-4216-8d9f-70fa46226892" xlink:to="loc_lly_BasaglarMember_f9d0dbbd-5cd0-4a14-8fac-5bfc15769d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66ce37dc-d405-4567-9dfe-82ec233e9bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fcdba8da-d479-456d-806c-aa84893ac174" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66ce37dc-d405-4567-9dfe-82ec233e9bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_bc1d4bc6-fe8f-4f57-9997-63fdb986427d" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66ce37dc-d405-4567-9dfe-82ec233e9bac" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_bc1d4bc6-fe8f-4f57-9997-63fdb986427d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsNetProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b64feac7-2856-4cb1-9ac0-88fb75fddb1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44e6c52b-8068-45a4-ac46-623e365013ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b64feac7-2856-4cb1-9ac0-88fb75fddb1c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44e6c52b-8068-45a4-ac46-623e365013ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44e6c52b-8068-45a4-ac46-623e365013ce" xlink:to="loc_srt_ProductOrServiceAxis_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b62f8e62-87ae-4578-b0ea-3f6a7b9e86ce" xlink:to="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_2245f154-2cca-4027-a09c-2476c7635fb7" xlink:href="lly-20201231.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:to="loc_lly_BasaglarMember_2245f154-2cca-4027-a09c-2476c7635fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_b481f150-d979-4fbf-8a24-f7bb3087bf25" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:to="loc_lly_JardianceMember_b481f150-d979-4fbf-8a24-f7bb3087bf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_2d1a04b7-f272-4bd7-a956-9c12a4c82955" xlink:href="lly-20201231.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:to="loc_lly_TrajentaBIMember_2d1a04b7-f272-4bd7-a956-9c12a4c82955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_cc9966e5-027b-40a4-b9b7-b1b888f55106" xlink:href="lly-20201231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5aac9be1-2247-424d-98fa-81d32f8bd037" xlink:to="loc_lly_OlumiantMember_cc9966e5-027b-40a4-b9b7-b1b888f55106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c63b4d8-84d4-4c6a-a9f4-49a7b1f0ccd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44e6c52b-8068-45a4-ac46-623e365013ce" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c63b4d8-84d4-4c6a-a9f4-49a7b1f0ccd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a1645c0-31da-411f-86c8-8e7c18aae84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c63b4d8-84d4-4c6a-a9f4-49a7b1f0ccd1" xlink:to="loc_us-gaap_Revenues_4a1645c0-31da-411f-86c8-8e7c18aae84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#CollaborationsandOtherArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c1de076-f2ea-4a11-b752-ac26ce17d79c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6c1de076-f2ea-4a11-b752-ac26ce17d79c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_921f2359-22ae-4fdd-b702-d39739785503" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_srt_ProductOrServiceAxis_921f2359-22ae-4fdd-b702-d39739785503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_921f2359-22ae-4fdd-b702-d39739785503" xlink:to="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_501fac1c-dfcd-4dc1-9ea5-698d3d4c95f8" xlink:href="lly-20201231.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_OlumiantMember_501fac1c-dfcd-4dc1-9ea5-698d3d4c95f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BamlanivimabMember_ee832149-a1eb-4340-9e08-d3ef2d65de34" xlink:href="lly-20201231.xsd#lly_BamlanivimabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_BamlanivimabMember_ee832149-a1eb-4340-9e08-d3ef2d65de34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_cce9d954-677e-4cf6-a216-03d2997c2e8d" xlink:href="lly-20201231.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_TYVYTMember_cce9d954-677e-4cf6-a216-03d2997c2e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TanezumabMember_b3bebe7a-52c7-47c3-b2c5-85f7fcb269f5" xlink:href="lly-20201231.xsd#lly_TanezumabMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_TanezumabMember_b3bebe7a-52c7-47c3-b2c5-85f7fcb269f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_835bd4b2-4aa7-4509-b1f9-f3f6dcea4397" xlink:href="lly-20201231.xsd#lly_LebrikizumabMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d9653ed2-8df1-417f-9b8a-a8c3fb48c552" xlink:to="loc_lly_LebrikizumabMember_835bd4b2-4aa7-4509-b1f9-f3f6dcea4397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a35e82c4-30e8-4f54-b2e8-47fb48e87fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a35e82c4-30e8-4f54-b2e8-47fb48e87fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a35e82c4-30e8-4f54-b2e8-47fb48e87fed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_94cca5db-c286-429f-b184-d0202accb7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_94cca5db-c286-429f-b184-d0202accb7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_675459c2-6422-4411-ae9f-9ff59a5b7e75" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_675459c2-6422-4411-ae9f-9ff59a5b7e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_975f6262-fdf7-43d5-830d-6ffc52b6b770" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_975f6262-fdf7-43d5-830d-6ffc52b6b770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_cd1748b6-9368-4f93-a881-83e036d145c5" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b6b17b4-f1df-4e4f-93fc-32b8d3f305ec" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_cd1748b6-9368-4f93-a881-83e036d145c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_15868057-0308-4347-9ae8-d8530dada784" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_cd1748b6-9368-4f93-a881-83e036d145c5" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_15868057-0308-4347-9ae8-d8530dada784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember_76892c16-0184-4315-a324-28e8907201b3" xlink:href="lly-20201231.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_cd1748b6-9368-4f93-a881-83e036d145c5" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember_76892c16-0184-4315-a324-28e8907201b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e39fbaec-26da-48e7-b2b3-bfc1dc37f033" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_srt_StatementGeographicalAxis_e39fbaec-26da-48e7-b2b3-bfc1dc37f033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e39fbaec-26da-48e7-b2b3-bfc1dc37f033" xlink:to="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember_1df20d58-f724-47cc-a2a0-c2ddb49f2d31" xlink:href="lly-20201231.xsd#lly_NonCHINAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:to="loc_lly_NonCHINAMember_1df20d58-f724-47cc-a2a0-c2ddb49f2d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_787d630c-2cfe-4964-acea-b8cc74133e52" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:to="loc_country_CN_787d630c-2cfe-4964-acea-b8cc74133e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OutsideUSAndJapanMember_88a46f89-32d7-4ee8-a3cb-aa8054fd67ee" xlink:href="lly-20201231.xsd#lly_OutsideUSAndJapanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6b8bd012-ece3-4983-9c1f-22409ceaa5cc" xlink:to="loc_lly_OutsideUSAndJapanMember_88a46f89-32d7-4ee8-a3cb-aa8054fd67ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f010ee98-a244-4bd2-bde3-c86956e3f231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f010ee98-a244-4bd2-bde3-c86956e3f231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b723426d-487c-41fe-ba95-c1b6b1b2850c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f010ee98-a244-4bd2-bde3-c86956e3f231" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b723426d-487c-41fe-ba95-c1b6b1b2850c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_2ba90391-c74e-4b0e-b8e3-1c3e21b29442" xlink:href="lly-20201231.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b723426d-487c-41fe-ba95-c1b6b1b2850c" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_2ba90391-c74e-4b0e-b8e3-1c3e21b29442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_ee455604-98dc-4a4f-a787-072555e27d78" xlink:href="lly-20201231.xsd#lly_JunshiBiosciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b723426d-487c-41fe-ba95-c1b6b1b2850c" xlink:to="loc_lly_JunshiBiosciencesMember_ee455604-98dc-4a4f-a787-072555e27d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c2c52750-83f4-4fcd-a7d8-02a7706a100e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_dei_LegalEntityAxis_c2c52750-83f4-4fcd-a7d8-02a7706a100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_eeab41ed-cfac-4226-9db8-5fd300e9859c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c2c52750-83f4-4fcd-a7d8-02a7706a100e" xlink:to="loc_dei_EntityDomain_eeab41ed-cfac-4226-9db8-5fd300e9859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_ee3a450b-2174-486d-8cf6-7abcd4b55826" xlink:href="lly-20201231.xsd#lly_InnoventBiologicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_eeab41ed-cfac-4226-9db8-5fd300e9859c" xlink:to="loc_lly_InnoventBiologicsIncMember_ee3a450b-2174-486d-8cf6-7abcd4b55826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_003e0c90-1bc8-412c-976f-4997b8533aa8" xlink:href="lly-20201231.xsd#lly_RocheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_eeab41ed-cfac-4226-9db8-5fd300e9859c" xlink:to="loc_lly_RocheMember_003e0c90-1bc8-412c-976f-4997b8533aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83ff6ec3-dc38-456d-a377-9d8638ed0f4e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_c119e9fb-33b0-46d3-91b8-cbad5f4c711d" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_c119e9fb-33b0-46d3-91b8-cbad5f4c711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_7211a385-5dc9-40d9-b611-f7a9d339e65a" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_7211a385-5dc9-40d9-b611-f7a9d339e65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f2b41964-0fad-42e7-b151-ec67525c57ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f2b41964-0fad-42e7-b151-ec67525c57ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ff4181df-b6f4-41e1-96b8-f74d475ce9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_us-gaap_Revenues_ff4181df-b6f4-41e1-96b8-f74d475ce9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_1b08f2ad-990d-4157-9369-3a9b7f86efd6" xlink:href="lly-20201231.xsd#lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_1b08f2ad-990d-4157-9369-3a9b7f86efd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6bfb2748-8cfd-4562-bb39-6e5d856bec67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f871e508-f3a4-47f9-abc4-b662c3249b1b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6bfb2748-8cfd-4562-bb39-6e5d856bec67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7172210e-2fac-47e1-804f-226fbc0febf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_c97a5711-a6d1-4431-95b4-551485961e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7172210e-2fac-47e1-804f-226fbc0febf5" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_c97a5711-a6d1-4431-95b4-551485961e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ef0e0950-c54b-41e3-9ab9-23e097f90f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_b3774e06-41d8-432f-bba6-c1e8b3e2ad96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ef0e0950-c54b-41e3-9ab9-23e097f90f8d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_b3774e06-41d8-432f-bba6-c1e8b3e2ad96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_22709a6a-5a68-4da0-996d-ad6f04447d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_bed311fd-e0a6-4ebf-9d18-f5954ebb6e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_22709a6a-5a68-4da0-996d-ad6f04447d87" xlink:to="loc_us-gaap_SeveranceCosts1_bed311fd-e0a6-4ebf-9d18-f5954ebb6e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_499ae907-5cb4-41b7-a780-9d0efdcdd5bb" xlink:href="lly-20201231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_22709a6a-5a68-4da0-996d-ad6f04447d87" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_499ae907-5cb4-41b7-a780-9d0efdcdd5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c3e8f255-4447-42ac-8bfb-ee628afb327b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_22709a6a-5a68-4da0-996d-ad6f04447d87" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c3e8f255-4447-42ac-8bfb-ee628afb327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b1723d1f-d6d5-4872-813b-2dc76f0d5e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c5f905c6-21be-425d-8ee7-ac85ef8a2474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b1723d1f-d6d5-4872-813b-2dc76f0d5e15" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c5f905c6-21be-425d-8ee7-ac85ef8a2474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_19250c6b-4767-4fc0-8f40-bc2e6030b19c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c5f905c6-21be-425d-8ee7-ac85ef8a2474" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_19250c6b-4767-4fc0-8f40-bc2e6030b19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fac00ae-0643-40d8-9f5f-8184b170b527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19250c6b-4767-4fc0-8f40-bc2e6030b19c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fac00ae-0643-40d8-9f5f-8184b170b527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_e4e9e0ab-c356-4bdf-a979-9f619e46f2c3" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fac00ae-0643-40d8-9f5f-8184b170b527" xlink:to="loc_lly_LoxoOncologyInc.Member_e4e9e0ab-c356-4bdf-a979-9f619e46f2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0007f5d5-593e-4375-a41a-39f47bcfe393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c5f905c6-21be-425d-8ee7-ac85ef8a2474" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_0007f5d5-593e-4375-a41a-39f47bcfe393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_a5bc149c-78ab-49fe-9ca4-5b8cf393a599" xlink:href="lly-20201231.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0007f5d5-593e-4375-a41a-39f47bcfe393" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_a5bc149c-78ab-49fe-9ca4-5b8cf393a599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Inventories" xlink:type="simple" xlink:href="lly-20201231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_470678b4-b3d2-45a9-9333-b316e33307f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_be234189-3ddb-42f8-ba24-95da12dc13c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_470678b4-b3d2-45a9-9333-b316e33307f0" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_be234189-3ddb-42f8-ba24-95da12dc13c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d92c1e81-c291-437b-b717-f12e6fec8917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4cf4f8b6-4ece-4db9-8613-bf79cbb29f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d92c1e81-c291-437b-b717-f12e6fec8917" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4cf4f8b6-4ece-4db9-8613-bf79cbb29f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/InventoriesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a74f5b6a-4303-4098-8095-e6e56d231ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_12e57519-fa61-4845-befc-80c854e6db48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a74f5b6a-4303-4098-8095-e6e56d231ecc" xlink:to="loc_us-gaap_InventoryFinishedGoods_12e57519-fa61-4845-befc-80c854e6db48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_1ea15c22-9ec9-4571-86ad-d3da45169290" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a74f5b6a-4303-4098-8095-e6e56d231ecc" xlink:to="loc_us-gaap_InventoryWorkInProcess_1ea15c22-9ec9-4571-86ad-d3da45169290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_fe65efc7-8d46-45ae-bfdd-ddbc40f192b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a74f5b6a-4303-4098-8095-e6e56d231ecc" xlink:to="loc_us-gaap_InventoryRawMaterials_fe65efc7-8d46-45ae-bfdd-ddbc40f192b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d7bd2534-1977-4d5c-9684-b12acfb5c532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a74f5b6a-4303-4098-8095-e6e56d231ecc" xlink:to="loc_us-gaap_InventoryGross_d7bd2534-1977-4d5c-9684-b12acfb5c532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_e4a9eb58-317c-495f-9b53-0e2f0bc3f536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a74f5b6a-4303-4098-8095-e6e56d231ecc" xlink:to="loc_us-gaap_InventoryLIFOReserve_e4a9eb58-317c-495f-9b53-0e2f0bc3f536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1aad09df-f9b4-4482-a91e-1736d127ab2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a74f5b6a-4303-4098-8095-e6e56d231ecc" xlink:to="loc_us-gaap_InventoryNet_1aad09df-f9b4-4482-a91e-1736d127ab2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_99d19fdf-8176-4d0d-ba3a-8feb64b95af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a74f5b6a-4303-4098-8095-e6e56d231ecc" xlink:to="loc_us-gaap_LIFOInventoryAmount_99d19fdf-8176-4d0d-ba3a-8feb64b95af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5637442-747c-434e-9e91-4ba0484f641f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_af87ac20-0065-43e1-8b65-a2806a89b880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5637442-747c-434e-9e91-4ba0484f641f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_af87ac20-0065-43e1-8b65-a2806a89b880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1761a896-c178-480a-accf-6b6fd5843b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1761a896-c178-480a-accf-6b6fd5843b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_73a7a99b-7c54-46f6-b2a6-5049a46c4d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_73a7a99b-7c54-46f6-b2a6-5049a46c4d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6be50b5d-7e84-4e55-9d14-a045da34ffbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6be50b5d-7e84-4e55-9d14-a045da34ffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1f52d40e-b4ef-4a3e-bd72-6ebbff702654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1f52d40e-b4ef-4a3e-bd72-6ebbff702654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6bc66ad8-b023-4732-a8ec-f3ca185918b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6bc66ad8-b023-4732-a8ec-f3ca185918b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_a1fe6d03-1c3f-433e-9818-f3daec7fd693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_a1fe6d03-1c3f-433e-9818-f3daec7fd693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4c299681-3644-4ff9-ad83-207144a1130a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4c299681-3644-4ff9-ad83-207144a1130a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7d2d869b-1beb-4982-b47a-a53327eb12ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7d2d869b-1beb-4982-b47a-a53327eb12ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_7dd6745e-19c9-4067-9904-556d8b858c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3fe7fa53-f5f1-44bb-9296-9251f4e7e8d5" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_7dd6745e-19c9-4067-9904-556d8b858c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_08e8a4ce-6b00-46f6-a316-56989bdc96b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_08e8a4ce-6b00-46f6-a316-56989bdc96b2" xlink:to="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e7cab13c-63e7-4c1e-9b59-fd43f2049031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e7cab13c-63e7-4c1e-9b59-fd43f2049031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_6a734148-ce4a-4402-ad54-10af80e2437a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e7cab13c-63e7-4c1e-9b59-fd43f2049031" xlink:to="loc_us-gaap_HedgingRelationshipDomain_6a734148-ce4a-4402-ad54-10af80e2437a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9069cce1-b6c1-4fee-90b8-4ec39f6ed42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_6a734148-ce4a-4402-ad54-10af80e2437a" xlink:to="loc_us-gaap_CashFlowHedgingMember_9069cce1-b6c1-4fee-90b8-4ec39f6ed42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6442544a-365e-4e41-869b-05ad9223d6a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_HedgingDesignationAxis_6442544a-365e-4e41-869b-05ad9223d6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d7546244-0340-4908-83be-a001edb5f0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6442544a-365e-4e41-869b-05ad9223d6a7" xlink:to="loc_us-gaap_HedgingDesignationDomain_d7546244-0340-4908-83be-a001edb5f0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0a4619fc-f023-41dd-9099-44c4aaab60d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d7546244-0340-4908-83be-a001edb5f0bb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0a4619fc-f023-41dd-9099-44c4aaab60d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3bf05728-a700-47f9-8516-a96418ec29b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3bf05728-a700-47f9-8516-a96418ec29b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a76b1746-4364-4ef7-a6c9-e32cff3a530a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3bf05728-a700-47f9-8516-a96418ec29b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a76b1746-4364-4ef7-a6c9-e32cff3a530a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_49f5de81-4247-444f-bfaf-8004f9b452b6" xlink:href="lly-20201231.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a76b1746-4364-4ef7-a6c9-e32cff3a530a" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_49f5de81-4247-444f-bfaf-8004f9b452b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_38687c4c-2e76-4663-b312-ad94ae7d4fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_38687c4c-2e76-4663-b312-ad94ae7d4fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38687c4c-2e76-4663-b312-ad94ae7d4fff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsdSellEuroMember_b5eb234a-75cc-445f-8af9-0c1b205aff5f" xlink:href="lly-20201231.xsd#lly_BuyUsdSellEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_BuyUsdSellEuroMember_b5eb234a-75cc-445f-8af9-0c1b205aff5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_127ed22c-63b1-454c-8299-3b164e677b57" xlink:href="lly-20201231.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_BuyEuroSellUsDollarMember_127ed22c-63b1-454c-8299-3b164e677b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_a029f8b3-ead5-48db-8997-cb1e29583ddc" xlink:href="lly-20201231.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_a029f8b3-ead5-48db-8997-cb1e29583ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyGBPSellUSDMember_31e24947-7e79-4477-b702-51a67222a390" xlink:href="lly-20201231.xsd#lly_BuyGBPSellUSDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_BuyGBPSellUSDMember_31e24947-7e79-4477-b702-51a67222a390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_d7f3fc25-c293-4c9f-9109-da7343fb5d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_us-gaap_CurrencySwapMember_d7f3fc25-c293-4c9f-9109-da7343fb5d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_897f4174-aed4-4ed7-abef-edfdcbdff094" xlink:href="lly-20201231.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_897f4174-aed4-4ed7-abef-edfdcbdff094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b2a91781-8165-44c7-98b2-e083f5c4ba75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_02f1c601-544f-42de-979c-6252dda92411" xlink:to="loc_us-gaap_InterestRateSwapMember_b2a91781-8165-44c7-98b2-e083f5c4ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a59049f8-dd20-4822-b22a-d3bcdadc3b26" xlink:to="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_41a2311b-1073-4b50-b195-8c79e88e288b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1_41a2311b-1073-4b50-b195-8c79e88e288b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_00d023da-1ae2-4ab3-8a1b-7f6d524fa524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_00d023da-1ae2-4ab3-8a1b-7f6d524fa524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_6e6c381f-1d50-49d4-88a4-b511a62f0d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_6e6c381f-1d50-49d4-88a4-b511a62f0d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_5a36fc09-7cd1-4ef7-82d0-1b27ec31441a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_5a36fc09-7cd1-4ef7-82d0-1b27ec31441a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2dbde5f4-17f7-4908-baa5-be80754276fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_LongTermDebt_2dbde5f4-17f7-4908-baa5-be80754276fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_0015c66c-ae7c-4f08-a701-2a4dbec89878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_0015c66c-ae7c-4f08-a701-2a4dbec89878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_c6f6e21c-b310-49fd-974c-63ea18aa5862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_c6f6e21c-b310-49fd-974c-63ea18aa5862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7bb14c19-1a69-4fc0-b6b1-526646efedf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7bb14c19-1a69-4fc0-b6b1-526646efedf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bc170394-bf90-4c83-a227-101d58db805a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_bc170394-bf90-4c83-a227-101d58db805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_1401e234-da22-4fa5-a18a-25d545aa031e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_1401e234-da22-4fa5-a18a-25d545aa031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_a4fa56bc-737d-4caf-a8fd-8bd10de958c8" xlink:href="lly-20201231.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_a4fa56bc-737d-4caf-a8fd-8bd10de958c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_88038ee0-295c-40c5-bce7-3524c79cf2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_88038ee0-295c-40c5-bce7-3524c79cf2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_d277339e-ef76-4c1d-8861-679f8b21953d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_d277339e-ef76-4c1d-8861-679f8b21953d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_7303e67a-f0fb-4c93-a681-641a9566fa0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7ff17b7d-7a12-4f2f-9ff8-45d89e90bb0a" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_7303e67a-f0fb-4c93-a681-641a9566fa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofEffectofRiskManagementDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0b610674-e0c6-489c-a674-ee61f0d46ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0b610674-e0c6-489c-a674-ee61f0d46ab2" xlink:to="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:to="loc_us-gaap_HedgingDesignationAxis_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_35f75017-aad4-4d97-b5f6-8bfb27cbfb60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_cb85bb6b-5c4e-4fc7-9578-095960ab9fb5" xlink:to="loc_us-gaap_HedgingDesignationDomain_35f75017-aad4-4d97-b5f6-8bfb27cbfb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_072135c9-cffe-4271-a910-85a7ded951f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_35f75017-aad4-4d97-b5f6-8bfb27cbfb60" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_072135c9-cffe-4271-a910-85a7ded951f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1b95e69a-3a10-49f8-8209-fe3aea62a5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_35f75017-aad4-4d97-b5f6-8bfb27cbfb60" xlink:to="loc_us-gaap_NondesignatedMember_1b95e69a-3a10-49f8-8209-fe3aea62a5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_400194c2-2714-4e91-bf22-f843830bb97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_400194c2-2714-4e91-bf22-f843830bb97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ffeaad6c-3890-4d1b-adee-ebe4037a0e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_400194c2-2714-4e91-bf22-f843830bb97c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ffeaad6c-3890-4d1b-adee-ebe4037a0e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_194129eb-c7b3-49e3-9eeb-4fd89fc39647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ffeaad6c-3890-4d1b-adee-ebe4037a0e69" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_194129eb-c7b3-49e3-9eeb-4fd89fc39647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c079e3a9-aa77-4f92-875b-5371962f54c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ffeaad6c-3890-4d1b-adee-ebe4037a0e69" xlink:to="loc_us-gaap_CashFlowHedgingMember_c079e3a9-aa77-4f92-875b-5371962f54c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8fc58b5d-1d98-4760-b9d7-f3bc7de28f67" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_ce7fbc2f-997a-4543-a2c2-20a2abf816cf" xlink:href="lly-20201231.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_lly_HedgedFixedRateDebtMember_ce7fbc2f-997a-4543-a2c2-20a2abf816cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_b8a20fdd-0cad-493a-973a-8cc72cdbe83b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_us-gaap_InterestRateContractMember_b8a20fdd-0cad-493a-973a-8cc72cdbe83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1ebdb07e-fb79-49e8-84ca-426ecfd66435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1ebdb07e-fb79-49e8-84ca-426ecfd66435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_0ad91bc7-607d-428f-9d03-e89fd0d4b0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_us-gaap_InterestRateSwapMember_0ad91bc7-607d-428f-9d03-e89fd0d4b0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_5c5c630b-d525-4d87-af1f-76e31a125214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b254b58-6569-4d3f-8617-46400e51bd9d" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_5c5c630b-d525-4d87-af1f-76e31a125214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2c33a30f-9211-4cac-a865-fc6a10770f2c" xlink:to="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_78912367-2a80-45b4-861c-7dda096a9011" xlink:href="lly-20201231.xsd#lly_FairValueHedgeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_lly_FairValueHedgeAbstract_78912367-2a80-45b4-861c-7dda096a9011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e9380273-18f2-44e9-a01b-7da8cf4d1619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_78912367-2a80-45b4-861c-7dda096a9011" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_e9380273-18f2-44e9-a01b-7da8cf4d1619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_493ad92c-515d-4fd4-a317-0914ae479c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_78912367-2a80-45b4-861c-7dda096a9011" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_493ad92c-515d-4fd4-a317-0914ae479c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_21f63270-1122-418e-b3d6-4cb6882e4a97" xlink:href="lly-20201231.xsd#lly_CashFlowHedgeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_lly_CashFlowHedgeAbstract_21f63270-1122-418e-b3d6-4cb6882e4a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_aa5658b7-9e4f-433d-9bdf-aa64b3f15c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_CashFlowHedgeAbstract_21f63270-1122-418e-b3d6-4cb6882e4a97" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_aa5658b7-9e4f-433d-9bdf-aa64b3f15c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_a83610ad-0341-425d-be44-d73b01ec8f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_CashFlowHedgeAbstract_21f63270-1122-418e-b3d6-4cb6882e4a97" xlink:to="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_a83610ad-0341-425d-be44-d73b01ec8f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f4d40d07-e95f-4ea8-a66b-df1a72b3c51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_f4d40d07-e95f-4ea8-a66b-df1a72b3c51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_80e7df07-63e4-4c54-b875-d0a356bccb64" xlink:href="lly-20201231.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_80e7df07-63e4-4c54-b875-d0a356bccb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1186a26c-4760-4b98-8472-eb5c61a09e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1186a26c-4760-4b98-8472-eb5c61a09e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7c814d36-8311-49ee-9a97-a2a285256e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_7c814d36-8311-49ee-9a97-a2a285256e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_4922c10e-f273-466a-84ab-c46a58614398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b05964a5-c2e9-4415-8003-df6678ce55da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_4922c10e-f273-466a-84ab-c46a58614398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bd0fb71a-a971-484c-a9b3-04934b01fc59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bd0fb71a-a971-484c-a9b3-04934b01fc59" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b3f9f593-83c6-4e39-bdc6-2501c718831e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b3f9f593-83c6-4e39-bdc6-2501c718831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b3f9f593-83c6-4e39-bdc6-2501c718831e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3c962fea-1032-45ce-9611-a235be8bc88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3c962fea-1032-45ce-9611-a235be8bc88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f5ca9c7a-f320-4699-a6f7-540411ab30cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f5ca9c7a-f320-4699-a6f7-540411ab30cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d88cf72f-08bd-4108-a02e-0211864f5126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d88cf72f-08bd-4108-a02e-0211864f5126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_7f0b5a65-42a6-4b88-b87a-0ac1dec1b0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_7f0b5a65-42a6-4b88-b87a-0ac1dec1b0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_c555876b-9ba9-4cc4-a9b3-f54e64361c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_c555876b-9ba9-4cc4-a9b3-f54e64361c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_be9934ff-f8ff-443e-ab82-1fc80589299c" xlink:href="lly-20201231.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_lly_OtherEquitySecuritiesMember_be9934ff-f8ff-443e-ab82-1fc80589299c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_9046a3e0-bb06-43e7-b6ae-e97cc96c258f" xlink:href="lly-20201231.xsd#lly_MarketableSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_lly_MarketableSecuritiesMember_9046a3e0-bb06-43e7-b6ae-e97cc96c258f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_cbb64d01-df21-4aac-b19c-c83049fa0305" xlink:href="lly-20201231.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02e1c257-aa87-448c-ae89-3a40503da3ad" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_cbb64d01-df21-4aac-b19c-c83049fa0305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_7a8728c7-3cee-409e-90d7-f04c3b494e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_7a8728c7-3cee-409e-90d7-f04c3b494e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_7a8728c7-3cee-409e-90d7-f04c3b494e51" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c2a447a2-7daa-4e1d-9ef4-d7f947f0131b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c2a447a2-7daa-4e1d-9ef4-d7f947f0131b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_17c3ef97-03a4-4ff9-917e-539fd00cb1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_17c3ef97-03a4-4ff9-917e-539fd00cb1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_e6fddf49-0060-4606-a3cb-9bc6a09a3bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_e6fddf49-0060-4606-a3cb-9bc6a09a3bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_df021bab-977d-4847-a68f-4bf4fdd4191a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_cebbfac5-3a00-437f-99c2-87cf7104f4b9" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_df021bab-977d-4847-a68f-4bf4fdd4191a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dcc344c-f996-49fa-91b0-13a038c2d8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dcc344c-f996-49fa-91b0-13a038c2d8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dcc344c-f996-49fa-91b0-13a038c2d8e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d59384f8-1cb2-46b5-a0c9-574e2227fdce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d59384f8-1cb2-46b5-a0c9-574e2227fdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_56f00ad0-23a4-4a5d-acc2-615b275c4c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_56f00ad0-23a4-4a5d-acc2-615b275c4c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0bec89f5-9d2d-4834-b297-c245805f0763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95343924-3224-40e6-b7c3-e6f41f16dc90" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0bec89f5-9d2d-4834-b297-c245805f0763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db86e73d-1695-4176-91d1-7aa7c2ee844c" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a28d63e9-be71-4a86-8cf9-4501df3f2d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a28d63e9-be71-4a86-8cf9-4501df3f2d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_9d5b1514-5dcd-4fbc-933d-bccc21317f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_9d5b1514-5dcd-4fbc-933d-bccc21317f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_632f0e42-6ef0-412b-8e22-54402ae308d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_9d5b1514-5dcd-4fbc-933d-bccc21317f8e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_632f0e42-6ef0-412b-8e22-54402ae308d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cc406fe0-44be-453e-804b-abf2b6603138" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_218459ad-bf34-46fb-9385-b030eb815f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_218459ad-bf34-46fb-9385-b030eb815f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_862b45be-b806-4e36-b9ca-186e12e2c05b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_862b45be-b806-4e36-b9ca-186e12e2c05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_507f4ea9-002a-4e0e-8319-43c1d129faa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_507f4ea9-002a-4e0e-8319-43c1d129faa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_ea3dcc23-8be3-4b73-b2a7-1713b636290f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_OtherLongTermInvestments_ea3dcc23-8be3-4b73-b2a7-1713b636290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_7955e9ae-60e1-4150-974e-a2d99974487f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b3533621-4a96-4e93-9cad-3c53f6b89cdf" xlink:to="loc_us-gaap_LongTermInvestments_7955e9ae-60e1-4150-974e-a2d99974487f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f2a88ea3-273a-454e-95b9-6a52ae091905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f2a88ea3-273a-454e-95b9-6a52ae091905" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_77b6cc90-331b-4204-86a3-be048ee22a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_77b6cc90-331b-4204-86a3-be048ee22a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_06b4232e-8b9e-4285-a883-3d94c7789f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_77b6cc90-331b-4204-86a3-be048ee22a9d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_06b4232e-8b9e-4285-a883-3d94c7789f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_492a06d1-a59a-4510-ba00-1c0ecef95e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_06b4232e-8b9e-4285-a883-3d94c7789f38" xlink:to="loc_us-gaap_CommercialPaperMember_492a06d1-a59a-4510-ba00-1c0ecef95e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44746e6d-ed00-48c0-a669-6b229391cd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44746e6d-ed00-48c0-a669-6b229391cd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_44746e6d-ed00-48c0-a669-6b229391cd4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e02bf01c-3c42-4cfa-b1ef-14cca2f500e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e02bf01c-3c42-4cfa-b1ef-14cca2f500e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_76c49c54-b392-49a5-9db1-8696472e1903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_76c49c54-b392-49a5-9db1-8696472e1903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_89a64327-98a2-435b-a955-fcc69ea49ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a7e837-83ec-4e1b-8afa-5438c5f5e1a2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_89a64327-98a2-435b-a955-fcc69ea49ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_10023e97-7a02-42d5-ac59-c98dc7fa36d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_10023e97-7a02-42d5-ac59-c98dc7fa36d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_10023e97-7a02-42d5-ac59-c98dc7fa36d6" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_979a0db4-9fdc-412b-959f-b8912902e1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_979a0db4-9fdc-412b-959f-b8912902e1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_34b80fae-d59d-426d-ab38-ae34b638f73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_34b80fae-d59d-426d-ab38-ae34b638f73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9fd40522-1723-4e6e-a02a-d7ec92be3f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_9968f4ad-50b7-41db-8cf0-086a81e9824e" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9fd40522-1723-4e6e-a02a-d7ec92be3f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3409fad6-ca0e-4a10-86ec-3e52691e940a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_948160d1-bf7d-4b10-bcc0-b222a6b6c576" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3409fad6-ca0e-4a10-86ec-3e52691e940a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_0b3f123d-6c45-4621-a08d-e4505d3f59d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3409fad6-ca0e-4a10-86ec-3e52691e940a" xlink:to="loc_us-gaap_CommercialPaper_0b3f123d-6c45-4621-a08d-e4505d3f59d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8e62fda2-80cb-4ba0-9e69-ebca93b05dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3409fad6-ca0e-4a10-86ec-3e52691e940a" xlink:to="loc_us-gaap_LongTermDebt_8e62fda2-80cb-4ba0-9e69-ebca93b05dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0174a56a-b927-4331-8db1-4d689b32e2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0174a56a-b927-4331-8db1-4d689b32e2fa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_152ba51c-fb98-46fc-8a28-cc5c66457b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_152ba51c-fb98-46fc-8a28-cc5c66457b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_152ba51c-fb98-46fc-8a28-cc5c66457b23" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_ce04602b-0ab7-444f-918b-a14bb2e72754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:to="loc_us-gaap_FairValueHedgingMember_ce04602b-0ab7-444f-918b-a14bb2e72754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_84988b99-bfeb-4fce-b2a5-3828d8ba4ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:to="loc_us-gaap_CashFlowHedgingMember_84988b99-bfeb-4fce-b2a5-3828d8ba4ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_7762570b-ae69-4c49-9171-48cbda9b9a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b427d90b-c123-4ef9-864d-0e7d84aa1125" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_7762570b-ae69-4c49-9171-48cbda9b9a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_aee0bbd4-249d-49e0-9a8e-2ae017261464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_aee0bbd4-249d-49e0-9a8e-2ae017261464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_aee0bbd4-249d-49e0-9a8e-2ae017261464" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6272fe78-42a0-4908-b095-1ce7f1852930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6272fe78-42a0-4908-b095-1ce7f1852930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_48bd50a4-9d97-4435-85a1-77c622d67d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_48bd50a4-9d97-4435-85a1-77c622d67d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_50b08165-cf4c-44c9-9b42-5c30a1009b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_276e7903-39ee-4e18-93d5-78bca1cea112" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_50b08165-cf4c-44c9-9b42-5c30a1009b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ca3073bd-534a-4835-ab2d-6bebed5502d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_HedgingDesignationAxis_ca3073bd-534a-4835-ab2d-6bebed5502d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_48fbdcee-87b1-49cb-a71f-861cc430a7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ca3073bd-534a-4835-ab2d-6bebed5502d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_48fbdcee-87b1-49cb-a71f-861cc430a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3d971aa4-eb87-432a-912a-7ef82c0b1eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_48fbdcee-87b1-49cb-a71f-861cc430a7bb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3d971aa4-eb87-432a-912a-7ef82c0b1eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_d0e246c8-3e1a-453c-9245-127b8163d68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_48fbdcee-87b1-49cb-a71f-861cc430a7bb" xlink:to="loc_us-gaap_NondesignatedMember_d0e246c8-3e1a-453c-9245-127b8163d68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_eaba030c-dc86-4f82-a462-af4749036f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_eaba030c-dc86-4f82-a462-af4749036f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_eaba030c-dc86-4f82-a462-af4749036f0c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_e100de9c-2378-4e76-9ec0-e6bb8e4f98d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:to="loc_us-gaap_InterestRateContractMember_e100de9c-2378-4e76-9ec0-e6bb8e4f98d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_2ee6c2c0-4797-4803-8fb8-972a81ab791a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_2ee6c2c0-4797-4803-8fb8-972a81ab791a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d07cb286-a70d-495d-aa22-0e797afe8168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_09d50247-84c9-459b-b737-663d124ca16a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d07cb286-a70d-495d-aa22-0e797afe8168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14dce7d2-a810-4806-a944-bb6761d41b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14dce7d2-a810-4806-a944-bb6761d41b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14dce7d2-a810-4806-a944-bb6761d41b4e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_997aae69-9488-4f07-9f42-1e36bdef7c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_997aae69-9488-4f07-9f42-1e36bdef7c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e6414c32-1fab-4cad-9264-3dcd6d7e99ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e6414c32-1fab-4cad-9264-3dcd6d7e99ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_915cad71-e044-42f8-8261-ad3367575e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bc35caae-03c7-485d-9d6d-431c1ad5e426" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_915cad71-e044-42f8-8261-ad3367575e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_44125f39-e869-476d-a679-8834dfc9eef6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_c06e0aaa-61df-4bfa-a161-452105961773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_c06e0aaa-61df-4bfa-a161-452105961773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_ea55a290-b366-44e4-8c2c-edb9b078e680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_ea55a290-b366-44e4-8c2c-edb9b078e680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_87365ffe-646e-4431-87e9-a7909ff2bc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_87365ffe-646e-4431-87e9-a7909ff2bc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_de9c8480-e0a8-4194-9e6c-11960ac50a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73fe56d2-8c7d-4a48-b60c-0e598c96746a" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_de9c8480-e0a8-4194-9e6c-11960ac50a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e8251ae6-9d60-441f-a83e-38fcd8cdc68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_895e0248-3188-4bb8-a959-fe3467fceca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e8251ae6-9d60-441f-a83e-38fcd8cdc68c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_895e0248-3188-4bb8-a959-fe3467fceca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5d1c07ac-fdea-4b7e-9d2e-ef0f39e1e65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e8251ae6-9d60-441f-a83e-38fcd8cdc68c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5d1c07ac-fdea-4b7e-9d2e-ef0f39e1e65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_805ede93-e5fa-4fe6-b149-360efc9381f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e8251ae6-9d60-441f-a83e-38fcd8cdc68c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_805ede93-e5fa-4fe6-b149-360efc9381f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1abd5101-3636-45fc-914e-4ca2f2d279f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e8251ae6-9d60-441f-a83e-38fcd8cdc68c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1abd5101-3636-45fc-914e-4ca2f2d279f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_dafb619e-a044-48e6-9a75-5c72f96029c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e8251ae6-9d60-441f-a83e-38fcd8cdc68c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_dafb619e-a044-48e6-9a75-5c72f96029c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_095401ad-368a-4efc-a8b7-3144aabaf606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bd9c4bf1-58cf-4a91-b15d-383ba0fa201a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_095401ad-368a-4efc-a8b7-3144aabaf606" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bd9c4bf1-58cf-4a91-b15d-383ba0fa201a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6aa3dffc-e959-4549-a378-12bdc2c54013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_095401ad-368a-4efc-a8b7-3144aabaf606" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6aa3dffc-e959-4549-a378-12bdc2c54013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_1dcc4fd2-d945-4384-bca7-099bb65a6f21" xlink:href="lly-20201231.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_095401ad-368a-4efc-a8b7-3144aabaf606" xlink:to="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_1dcc4fd2-d945-4384-bca7-099bb65a6f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b3f27ab7-a10f-4b7d-9510-9200f54f7f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_095401ad-368a-4efc-a8b7-3144aabaf606" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b3f27ab7-a10f-4b7d-9510-9200f54f7f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d3355964-7673-4c9e-804d-4a8b756fb6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_0d85f2c1-f2b7-4c2a-afaf-4378558ce9e4" xlink:href="lly-20201231.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d3355964-7673-4c9e-804d-4a8b756fb6a3" xlink:to="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_0d85f2c1-f2b7-4c2a-afaf-4378558ce9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_c60f267c-1fe8-4003-8c4a-de38c30019a6" xlink:href="lly-20201231.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d3355964-7673-4c9e-804d-4a8b756fb6a3" xlink:to="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_c60f267c-1fe8-4003-8c4a-de38c30019a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_30ef374c-9c23-47c7-ba53-14035885183c" xlink:href="lly-20201231.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d3355964-7673-4c9e-804d-4a8b756fb6a3" xlink:to="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_30ef374c-9c23-47c7-ba53-14035885183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ff9a37b5-6973-47ed-afdd-1af09576e641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1abb4c7f-700f-4473-96ec-3345feac1a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ff9a37b5-6973-47ed-afdd-1af09576e641" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1abb4c7f-700f-4473-96ec-3345feac1a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebc069c8-81da-451e-9816-28343f847c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7e107e4a-d848-4429-b2a3-276ca3655b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebc069c8-81da-451e-9816-28343f847c27" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7e107e4a-d848-4429-b2a3-276ca3655b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_61202972-23bf-43dd-bf1d-1e5ecffa93ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebc069c8-81da-451e-9816-28343f847c27" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_61202972-23bf-43dd-bf1d-1e5ecffa93ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_51470872-a3e8-4dbd-9b76-4d65a489b147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebc069c8-81da-451e-9816-28343f847c27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_51470872-a3e8-4dbd-9b76-4d65a489b147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fdb1664d-2969-4875-ac84-d505cf873cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebc069c8-81da-451e-9816-28343f847c27" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fdb1664d-2969-4875-ac84-d505cf873cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d686edfa-265a-4b31-96c5-8c3826d6f3c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d686edfa-265a-4b31-96c5-8c3826d6f3c5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc7109ec-60aa-4e03-87d4-95fd91b67032" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:to="loc_srt_RangeAxis_bc7109ec-60aa-4e03-87d4-95fd91b67032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ffa86eec-ad34-45ee-aba6-ac3980813155" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bc7109ec-60aa-4e03-87d4-95fd91b67032" xlink:to="loc_srt_RangeMember_ffa86eec-ad34-45ee-aba6-ac3980813155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_be45109d-741b-4f3a-9201-f1008943ac71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ffa86eec-ad34-45ee-aba6-ac3980813155" xlink:to="loc_srt_MinimumMember_be45109d-741b-4f3a-9201-f1008943ac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8c63a304-06ae-445c-b7f1-7316f10db836" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ffa86eec-ad34-45ee-aba6-ac3980813155" xlink:to="loc_srt_MaximumMember_8c63a304-06ae-445c-b7f1-7316f10db836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:to="loc_srt_ProductOrServiceAxis_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cefe3305-9f94-4188-aa9c-4e6e0802143c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5d8b07ec-8d1c-4aef-ae8d-1f2d250db5eb" xlink:to="loc_srt_ProductsAndServicesDomain_cefe3305-9f94-4188-aa9c-4e6e0802143c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SelpercatinibLOXO292Member_e22671f5-f5ef-455b-9d3a-6138d39d5b4a" xlink:href="lly-20201231.xsd#lly_SelpercatinibLOXO292Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cefe3305-9f94-4188-aa9c-4e6e0802143c" xlink:to="loc_lly_SelpercatinibLOXO292Member_e22671f5-f5ef-455b-9d3a-6138d39d5b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_636f8ffc-34ec-4e77-a1b8-7299560bda60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_636f8ffc-34ec-4e77-a1b8-7299560bda60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22c8c2af-62c1-4bea-9926-d80444f444b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636f8ffc-34ec-4e77-a1b8-7299560bda60" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22c8c2af-62c1-4bea-9926-d80444f444b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LoxoOncologyInc.Member_5781819c-7962-4d75-9787-d6cde1062fb4" xlink:href="lly-20201231.xsd#lly_LoxoOncologyInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22c8c2af-62c1-4bea-9926-d80444f444b7" xlink:to="loc_lly_LoxoOncologyInc.Member_5781819c-7962-4d75-9787-d6cde1062fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fdea96b7-df5b-406c-bb82-bae7cc3d27a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e95271c5-1585-4eec-b016-481e348108a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e95271c5-1585-4eec-b016-481e348108a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_618d9961-fae1-4bb7-8a13-61fd13528ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_618d9961-fae1-4bb7-8a13-61fd13528ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a3ff57c0-db0a-405c-941d-ab466af59665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a3ff57c0-db0a-405c-941d-ab466af59665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_13b56415-c805-400e-883f-1baf188eccc4" xlink:href="lly-20201231.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d0ef432c-854d-45ec-8979-a73008b00548" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment_13b56415-c805-400e-883f-1baf188eccc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_294cf017-c7ed-4721-b652-2de49d2a4443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ff89a932-18b8-4e1f-a4aa-27379fe68530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_294cf017-c7ed-4721-b652-2de49d2a4443" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ff89a932-18b8-4e1f-a4aa-27379fe68530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ae13608d-eb3f-49cb-b9d6-10996394da40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ff89a932-18b8-4e1f-a4aa-27379fe68530" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ae13608d-eb3f-49cb-b9d6-10996394da40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b7df04-0d98-451d-a221-03397d69973c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ae13608d-eb3f-49cb-b9d6-10996394da40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b7df04-0d98-451d-a221-03397d69973c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_785909dd-9148-432b-9444-cf2491a9efd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b7df04-0d98-451d-a221-03397d69973c" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_785909dd-9148-432b-9444-cf2491a9efd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1614095b-448e-49fa-b2bc-57087ace9669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3b7df04-0d98-451d-a221-03397d69973c" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1614095b-448e-49fa-b2bc-57087ace9669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ff89a932-18b8-4e1f-a4aa-27379fe68530" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3c907ffc-f985-4e34-a3fb-c02fde161921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3c907ffc-f985-4e34-a3fb-c02fde161921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_78ee7619-0512-4874-b780-f1fbe9a48759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_78ee7619-0512-4874-b780-f1fbe9a48759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_662f1024-5da3-4ee8-ad4f-22c740f1a787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ac688d0b-0e27-47f2-a8b6-0b4f53a74f98" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_662f1024-5da3-4ee8-ad4f-22c740f1a787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2b22b754-011e-40d4-ae74-a3ba354062a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_294cf017-c7ed-4721-b652-2de49d2a4443" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2b22b754-011e-40d4-ae74-a3ba354062a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2eb744c7-8a5f-4355-b404-bc45bbc207c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2b22b754-011e-40d4-ae74-a3ba354062a4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2eb744c7-8a5f-4355-b404-bc45bbc207c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7a7cc0f-d7a7-4008-82ea-0f97924245b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2eb744c7-8a5f-4355-b404-bc45bbc207c8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7a7cc0f-d7a7-4008-82ea-0f97924245b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d54c9443-3e85-4cf5-b0dd-4f8283384e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7a7cc0f-d7a7-4008-82ea-0f97924245b2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d54c9443-3e85-4cf5-b0dd-4f8283384e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_55787350-ec3c-491a-9d87-13fd87966f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f7a7cc0f-d7a7-4008-82ea-0f97924245b2" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_55787350-ec3c-491a-9d87-13fd87966f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_22746d9a-2204-457f-9cae-55f600630995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2b22b754-011e-40d4-ae74-a3ba354062a4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_22746d9a-2204-457f-9cae-55f600630995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_deaa4161-0b34-47aa-b250-db83fb96cd77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_22746d9a-2204-457f-9cae-55f600630995" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_deaa4161-0b34-47aa-b250-db83fb96cd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_54f66e97-a463-45ad-9cbe-b7f0c692ae2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_294cf017-c7ed-4721-b652-2de49d2a4443" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_54f66e97-a463-45ad-9cbe-b7f0c692ae2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_08942623-baa4-44b6-bb7e-8b73a453b685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_54f66e97-a463-45ad-9cbe-b7f0c692ae2b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_08942623-baa4-44b6-bb7e-8b73a453b685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7f7079a3-6cb8-4759-83e5-2b48a9a6e7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_54f66e97-a463-45ad-9cbe-b7f0c692ae2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7f7079a3-6cb8-4759-83e5-2b48a9a6e7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_193e25ca-6b41-4373-9519-84449f134ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_54f66e97-a463-45ad-9cbe-b7f0c692ae2b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_193e25ca-6b41-4373-9519-84449f134ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0d8f8b70-d706-4172-b702-5a5160965c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_000a087f-98a0-4f15-ae47-0f045d414c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0d8f8b70-d706-4172-b702-5a5160965c78" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_000a087f-98a0-4f15-ae47-0f045d414c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d08a108-8d21-4386-a2b6-0ec1540b06bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_be600827-9aa1-4a42-8197-adf61fa0f349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d08a108-8d21-4386-a2b6-0ec1540b06bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_be600827-9aa1-4a42-8197-adf61fa0f349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3d8de844-ec2d-4504-bebd-4ce032db0aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d08a108-8d21-4386-a2b6-0ec1540b06bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3d8de844-ec2d-4504-bebd-4ce032db0aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a9c3610b-e64a-4c47-9b07-da6b7beed62a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d08a108-8d21-4386-a2b6-0ec1540b06bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a9c3610b-e64a-4c47-9b07-da6b7beed62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_627cb7b3-ca41-4e6b-b135-55495be743b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d08a108-8d21-4386-a2b6-0ec1540b06bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_627cb7b3-ca41-4e6b-b135-55495be743b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3ed9ab35-9a74-4523-ad8d-744917e2df49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3d08a108-8d21-4386-a2b6-0ec1540b06bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3ed9ab35-9a74-4523-ad8d-744917e2df49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e303028c-da93-42a7-baac-08f56d360f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_19e7272a-4722-45f9-b307-36005b81f7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e303028c-da93-42a7-baac-08f56d360f5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_19e7272a-4722-45f9-b307-36005b81f7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ef45d185-b08f-441b-af53-e9591f2f2d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b6c8e50b-bd7d-4351-ba8c-65724585d5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ef45d185-b08f-441b-af53-e9591f2f2d86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b6c8e50b-bd7d-4351-ba8c-65724585d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_ad6efa00-7d93-4ec7-b15e-47dfedcf831d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ef45d185-b08f-441b-af53-e9591f2f2d86" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_ad6efa00-7d93-4ec7-b15e-47dfedcf831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_716f1bdc-f5c5-4a14-baf1-ab94932b04c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_716f1bdc-f5c5-4a14-baf1-ab94932b04c0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9387a858-14c3-402c-8919-5f490750a628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9387a858-14c3-402c-8919-5f490750a628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ec54cfc-688f-413c-8283-e7b47dc4088d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9387a858-14c3-402c-8919-5f490750a628" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ec54cfc-688f-413c-8283-e7b47dc4088d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_7df73a64-4751-465b-99fd-3a22aa20b519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ec54cfc-688f-413c-8283-e7b47dc4088d" xlink:to="loc_us-gaap_BuildingMember_7df73a64-4751-465b-99fd-3a22aa20b519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_91119fb0-5686-4f95-8a54-b89ebb1df805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ec54cfc-688f-413c-8283-e7b47dc4088d" xlink:to="loc_us-gaap_EquipmentMember_91119fb0-5686-4f95-8a54-b89ebb1df805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1789b1a-edac-4f55-ba85-750f105cf475" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:to="loc_srt_RangeAxis_d1789b1a-edac-4f55-ba85-750f105cf475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e36e7dd6-dff3-4653-bf29-00401bfc8464" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d1789b1a-edac-4f55-ba85-750f105cf475" xlink:to="loc_srt_RangeMember_e36e7dd6-dff3-4653-bf29-00401bfc8464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_723b8a37-1fdb-4f36-9d6c-0ac6e1810492" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e36e7dd6-dff3-4653-bf29-00401bfc8464" xlink:to="loc_srt_MinimumMember_723b8a37-1fdb-4f36-9d6c-0ac6e1810492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1586951c-aa9a-45ae-83ce-03bc770f1fc1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e36e7dd6-dff3-4653-bf29-00401bfc8464" xlink:to="loc_srt_MaximumMember_1586951c-aa9a-45ae-83ce-03bc770f1fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d768187-3dd4-4b81-aaa8-c62a75572f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9b7d046-c1bd-4150-9558-20ff0e909dc7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d768187-3dd4-4b81-aaa8-c62a75572f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_03bfa824-9428-410d-bfa6-0d95702108f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d768187-3dd4-4b81-aaa8-c62a75572f16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_03bfa824-9428-410d-bfa6-0d95702108f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa93a299-df9c-4141-99f0-26766d00e004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_2d4bc4ce-7e96-46a7-809b-14ebd5b3618d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa93a299-df9c-4141-99f0-26766d00e004" xlink:to="loc_us-gaap_Land_2d4bc4ce-7e96-46a7-809b-14ebd5b3618d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_26bc651d-fd85-415b-86a6-3b260dc09581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa93a299-df9c-4141-99f0-26766d00e004" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_26bc651d-fd85-415b-86a6-3b260dc09581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_86c50d32-02a2-4020-bfec-1cf337832397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa93a299-df9c-4141-99f0-26766d00e004" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_86c50d32-02a2-4020-bfec-1cf337832397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_94689429-54bb-49d6-8f64-ab79ca66d587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa93a299-df9c-4141-99f0-26766d00e004" xlink:to="loc_us-gaap_ConstructionInProgressGross_94689429-54bb-49d6-8f64-ab79ca66d587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d6bde0cf-8115-49e1-8993-9dd55bd2878a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa93a299-df9c-4141-99f0-26766d00e004" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d6bde0cf-8115-49e1-8993-9dd55bd2878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13d5a4ec-d2c2-43ec-b2e7-eda5e45aa63b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa93a299-df9c-4141-99f0-26766d00e004" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13d5a4ec-d2c2-43ec-b2e7-eda5e45aa63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b909c8b-0a70-40d3-b355-7e673ceb9ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa93a299-df9c-4141-99f0-26766d00e004" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b909c8b-0a70-40d3-b355-7e673ceb9ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5b567cc4-c01b-4990-8b86-a02bbd45d99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f333cb6f-8acb-42e9-9b63-94a6aee4610f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5b567cc4-c01b-4990-8b86-a02bbd45d99d" xlink:to="loc_us-gaap_Depreciation_f333cb6f-8acb-42e9-9b63-94a6aee4610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#PropertyandEquipmentScheduleofGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_05abcf17-33ed-416c-9773-8191031ac737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30aeca4f-e284-4b1f-a8dc-5931c22fc135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_05abcf17-33ed-416c-9773-8191031ac737" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30aeca4f-e284-4b1f-a8dc-5931c22fc135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30aeca4f-e284-4b1f-a8dc-5931c22fc135" xlink:to="loc_srt_StatementGeographicalAxis_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4da2c0e8-1af3-40d7-80a6-15e0f4093cb1" xlink:to="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_UNITEDSTATESAndPUERTORICOMember_a1074fee-ebac-4acb-8933-b0cc52abc84a" xlink:href="lly-20201231.xsd#lly_UNITEDSTATESAndPUERTORICOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:to="loc_lly_UNITEDSTATESAndPUERTORICOMember_a1074fee-ebac-4acb-8933-b0cc52abc84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_75cacc6a-417e-4d34-8d20-24927c79d3e4" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:to="loc_country_IE_75cacc6a-417e-4d34-8d20-24927c79d3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_f816bb93-715e-4b4c-8802-df376633fe89" xlink:href="lly-20201231.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2915f758-2cad-4c7a-934f-23faae47b05b" xlink:to="loc_lly_OtherForeignCountriesMember_f816bb93-715e-4b4c-8802-df376633fe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e1838f46-6063-4cad-8c94-2d312b69259d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30aeca4f-e284-4b1f-a8dc-5931c22fc135" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e1838f46-6063-4cad-8c94-2d312b69259d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_dde1fe89-a938-44aa-a379-8c1a2abd5acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e1838f46-6063-4cad-8c94-2d312b69259d" xlink:to="loc_us-gaap_NoncurrentAssets_dde1fe89-a938-44aa-a379-8c1a2abd5acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Leases" xlink:type="simple" xlink:href="lly-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1a07540f-9193-4b78-a7d1-0ae1a191006e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d0993df8-3769-4657-8190-25558c1e1a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a07540f-9193-4b78-a7d1-0ae1a191006e" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d0993df8-3769-4657-8190-25558c1e1a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_9a50fef1-6ec8-4380-86fb-46efcb81e710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a07540f-9193-4b78-a7d1-0ae1a191006e" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_9a50fef1-6ec8-4380-86fb-46efcb81e710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_53dec107-7a9c-48de-bbc0-945699b8864e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f857c8a3-33c6-4a0e-bc5e-1edf1c667ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53dec107-7a9c-48de-bbc0-945699b8864e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f857c8a3-33c6-4a0e-bc5e-1edf1c667ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e545063f-a850-47cb-9c23-f014918455a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53dec107-7a9c-48de-bbc0-945699b8864e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e545063f-a850-47cb-9c23-f014918455a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9bce453d-f00a-44ed-8d3b-930d469745a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LesseeLeaseRemainingLeaseTerm_a11dc6e4-1dcc-458b-b283-90e1b0fafb1b" xlink:href="lly-20201231.xsd#lly_LesseeLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9bce453d-f00a-44ed-8d3b-930d469745a4" xlink:to="loc_lly_LesseeLeaseRemainingLeaseTerm_a11dc6e4-1dcc-458b-b283-90e1b0fafb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_74d328b0-cb4a-4614-a2d6-b0f52dae3b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9bce453d-f00a-44ed-8d3b-930d469745a4" xlink:to="loc_us-gaap_OperatingLeaseCost_74d328b0-cb4a-4614-a2d6-b0f52dae3b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_ae8e55e4-e622-43a8-ae15-df61a6c7689a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9bce453d-f00a-44ed-8d3b-930d469745a4" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_ae8e55e4-e622-43a8-ae15-df61a6c7689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5ac66fe6-6060-4961-af76-b2c921f2c70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4968d879-e36e-4fbf-8ff6-7c3a3344099c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ac66fe6-6060-4961-af76-b2c921f2c70e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4968d879-e36e-4fbf-8ff6-7c3a3344099c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_81f729a1-0501-4bbf-a18b-ebf8bb79ec9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ac66fe6-6060-4961-af76-b2c921f2c70e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_81f729a1-0501-4bbf-a18b-ebf8bb79ec9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9d01582a-8812-4642-bbd5-9e3249b2456a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ac66fe6-6060-4961-af76-b2c921f2c70e" xlink:to="loc_us-gaap_OperatingLeasePayments_9d01582a-8812-4642-bbd5-9e3249b2456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_70a49f71-b006-41b9-9a87-7b1cec0b5a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5ac66fe6-6060-4961-af76-b2c921f2c70e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_70a49f71-b006-41b9-9a87-7b1cec0b5a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4cef4e5c-5f14-4668-9935-3a494829b5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4cef4e5c-5f14-4668-9935-3a494829b5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c2e5b64d-be39-4080-858c-eec328229c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c2e5b64d-be39-4080-858c-eec328229c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd4d32ef-f7a7-488e-b7af-ea23aa45523b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd4d32ef-f7a7-488e-b7af-ea23aa45523b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9426d20f-8175-4bf7-a758-e3cb04eec9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9426d20f-8175-4bf7-a758-e3cb04eec9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7028d3de-c4c4-4c58-ae32-d3ca101bcaca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7028d3de-c4c4-4c58-ae32-d3ca101bcaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b637765b-4403-4bf3-a535-9f105b278c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b637765b-4403-4bf3-a535-9f105b278c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6e77f5c-40aa-49f7-8742-acc6fd4f7dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6e77f5c-40aa-49f7-8742-acc6fd4f7dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b3cd889e-d5e5-4aaa-bf76-3bb2079202ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b3cd889e-d5e5-4aaa-bf76-3bb2079202ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d46bedf6-f483-491e-bafc-aa8a87e0e2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_OperatingLeaseLiability_d46bedf6-f483-491e-bafc-aa8a87e0e2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_11f40719-a9ba-4bb1-96be-882690a05781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82515835-b5e5-4ac6-9554-09eba5769dec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_11f40719-a9ba-4bb1-96be-882690a05781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lly-20201231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Borrowings" xlink:type="simple" xlink:href="lly-20201231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cc3f9db1-e85e-4b97-b510-cb9bea5ef2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_dd7822b4-2ce5-41cb-a7eb-03a67be5ee80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cc3f9db1-e85e-4b97-b510-cb9bea5ef2cc" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_dd7822b4-2ce5-41cb-a7eb-03a67be5ee80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bdf4f072-0eda-44d7-9896-3ed0b6de5334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_608e22ef-c06f-48da-87ea-816138b6054f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdf4f072-0eda-44d7-9896-3ed0b6de5334" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_608e22ef-c06f-48da-87ea-816138b6054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ff2e6977-bf58-4293-a93d-64f14884f328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdf4f072-0eda-44d7-9896-3ed0b6de5334" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ff2e6977-bf58-4293-a93d-64f14884f328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_583ec42f-095d-4ed0-9f57-fff9f82521eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdf4f072-0eda-44d7-9896-3ed0b6de5334" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_583ec42f-095d-4ed0-9f57-fff9f82521eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_ceb33ea5-30d1-4d87-a3e8-65a789ff03f4" xlink:href="lly-20201231.xsd#lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdf4f072-0eda-44d7-9896-3ed0b6de5334" xlink:to="loc_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock_ceb33ea5-30d1-4d87-a3e8-65a789ff03f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_ebf6ef76-fb72-4f90-af9a-6902be47be5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:to="loc_us-gaap_CommercialPaper_ebf6ef76-fb72-4f90-af9a-6902be47be5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_b939db06-126c-4917-9ad7-b88e4aed4a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:to="loc_us-gaap_NotesPayable_b939db06-126c-4917-9ad7-b88e4aed4a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNotesPayable_023ce9be-5ce0-4fec-b225-2e0639a3453f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:to="loc_us-gaap_OtherNotesPayable_023ce9be-5ce0-4fec-b225-2e0639a3453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_3d8a02ff-a877-4d0a-9163-5f825c2426f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_3d8a02ff-a877-4d0a-9163-5f825c2426f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LongTermDebtFairValueAdjustment_a095c3ed-8c5c-4d4e-be07-30e580ebc395" xlink:href="lly-20201231.xsd#lly_LongTermDebtFairValueAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:to="loc_lly_LongTermDebtFairValueAdjustment_a095c3ed-8c5c-4d4e-be07-30e580ebc395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_8c0758ed-d451-4761-8a5d-829877b378b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_8c0758ed-d451-4761-8a5d-829877b378b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c7386445-ee69-424d-8ff5-db9081bd1d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:to="loc_us-gaap_DebtCurrent_c7386445-ee69-424d-8ff5-db9081bd1d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9ca083f7-f07d-4b38-a01c-c3fbd7ea992f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4cd5e4c6-720e-4de0-81aa-d6064a1e1bdc" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9ca083f7-f07d-4b38-a01c-c3fbd7ea992f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsSummaryofLongtermNotesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_46fa1249-e3cb-4303-8521-e2eb15876c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_46fa1249-e3cb-4303-8521-e2eb15876c2e" xlink:to="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_396460c4-c602-46b6-b688-c297cfd7ac5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_396460c4-c602-46b6-b688-c297cfd7ac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba1f7c92-189b-48f4-b5af-52823402442c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_396460c4-c602-46b6-b688-c297cfd7ac5e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba1f7c92-189b-48f4-b5af-52823402442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5f56459f-0164-4a65-a800-12a95e876fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba1f7c92-189b-48f4-b5af-52823402442c" xlink:to="loc_us-gaap_SeniorNotesMember_5f56459f-0164-4a65-a800-12a95e876fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8c8036bf-e67e-4ea0-a579-72a67afb3abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:to="loc_us-gaap_DebtInstrumentAxis_8c8036bf-e67e-4ea0-a579-72a67afb3abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8c8036bf-e67e-4ea0-a579-72a67afb3abb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A235NotesDue2022Member_64cce021-6c9d-49fd-8cdb-e68e7240a7c8" xlink:href="lly-20201231.xsd#lly_A235NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A235NotesDue2022Member_64cce021-6c9d-49fd-8cdb-e68e7240a7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A30NotesDue2022Member_22a97083-2599-4d51-bb2c-8f4d82d36855" xlink:href="lly-20201231.xsd#lly_A30NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A30NotesDue2022Member_22a97083-2599-4d51-bb2c-8f4d82d36855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A10EuroDenominatedNotesDue2022Member_d1b21915-9125-408a-982d-a4affb6040f7" xlink:href="lly-20201231.xsd#lly_A10EuroDenominatedNotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A10EuroDenominatedNotesDue2022Member_d1b21915-9125-408a-982d-a4affb6040f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_d54e3cd1-8e67-4b1b-9005-449d8be3da5e" xlink:href="lly-20201231.xsd#lly_A015SwissFrancDenominatedNotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A015SwissFrancDenominatedNotesDue2024Member_d54e3cd1-8e67-4b1b-9005-449d8be3da5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A7125NotesDue2025Member_d178cd0a-1a3e-4e1e-b356-6d0a3e29224e" xlink:href="lly-20201231.xsd#lly_A7125NotesDue2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A7125NotesDue2025Member_d178cd0a-1a3e-4e1e-b356-6d0a3e29224e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A275NotesDue2025Member_ccc7a710-6cc6-47d6-9557-4eeae4cea38e" xlink:href="lly-20201231.xsd#lly_A275NotesDue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A275NotesDue2025Member_ccc7a710-6cc6-47d6-9557-4eeae4cea38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625EuroDenominatedNotesDue2026Member_34e69f0f-b62b-481a-8c22-c5007da0c8e0" xlink:href="lly-20201231.xsd#lly_A1625EuroDenominatedNotesDue2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A1625EuroDenominatedNotesDue2026Member_34e69f0f-b62b-481a-8c22-c5007da0c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A55NotesDue2027Member_e2ff3ef5-bad5-4e6c-b493-ed2f3f9ca829" xlink:href="lly-20201231.xsd#lly_A55NotesDue2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A55NotesDue2027Member_e2ff3ef5-bad5-4e6c-b493-ed2f3f9ca829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A31NotesDue2027Member_36e04b5d-0950-49d5-a253-89af9e4e69f9" xlink:href="lly-20201231.xsd#lly_A31NotesDue2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A31NotesDue2027Member_36e04b5d-0950-49d5-a253-89af9e4e69f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_8ef4bd92-fb6d-415c-ba01-6af5b3f3e970" xlink:href="lly-20201231.xsd#lly_A045SwissFrancDenominatedNotesDue2028Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A045SwissFrancDenominatedNotesDue2028Member_8ef4bd92-fb6d-415c-ba01-6af5b3f3e970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_18a6f09a-3dee-4b79-acfd-b37c6753c402" xlink:href="lly-20201231.xsd#lly_A3375NotesDue2029Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A3375NotesDue2029Member_18a6f09a-3dee-4b79-acfd-b37c6753c402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_b63e28fa-9eca-44df-9ca7-1d37efb962e6" xlink:href="lly-20201231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_b63e28fa-9eca-44df-9ca7-1d37efb962e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2125EuroDenominatedNotesDue2030Member_641c2a77-9a9d-4d92-ade6-ec9ae57f6c8e" xlink:href="lly-20201231.xsd#lly_A2125EuroDenominatedNotesDue2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A2125EuroDenominatedNotesDue2030Member_641c2a77-9a9d-4d92-ade6-ec9ae57f6c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member_c672d432-6231-4c0f-a0c6-c7d145902926" xlink:href="lly-20201231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A625EuroDeonominatedNotesDue2031Member_c672d432-6231-4c0f-a0c6-c7d145902926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_7fd00f9f-3c5b-4fac-a29c-8622e0c3db10" xlink:href="lly-20201231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_7fd00f9f-3c5b-4fac-a29c-8622e0c3db10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A677NotesDue2036Member_0b53505e-bcf3-45c9-b314-d60b463fe1db" xlink:href="lly-20201231.xsd#lly_A677NotesDue2036Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A677NotesDue2036Member_0b53505e-bcf3-45c9-b314-d60b463fe1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A555NotesDue2037Member_d5824e6d-5091-4db1-83d5-45f4398881fd" xlink:href="lly-20201231.xsd#lly_A555NotesDue2037Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A555NotesDue2037Member_d5824e6d-5091-4db1-83d5-45f4398881fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A595NotesDue2037Member_61922efe-0082-4b5d-bd8c-5ab536f9aa0a" xlink:href="lly-20201231.xsd#lly_A595NotesDue2037Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A595NotesDue2037Member_61922efe-0082-4b5d-bd8c-5ab536f9aa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_29e5ab42-4367-4695-975b-585775d97c80" xlink:href="lly-20201231.xsd#lly_A3875NotesDue2039Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A3875NotesDue2039Member_29e5ab42-4367-4695-975b-585775d97c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A465NotesDue2044Member_301dd9ff-72d0-411f-bace-98a05ca96595" xlink:href="lly-20201231.xsd#lly_A465NotesDue2044Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A465NotesDue2044Member_301dd9ff-72d0-411f-bace-98a05ca96595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A37NotesDue2045Member_63d37c96-d1f4-4e03-a799-0ad6c76a7912" xlink:href="lly-20201231.xsd#lly_A37NotesDue2045Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A37NotesDue2045Member_63d37c96-d1f4-4e03-a799-0ad6c76a7912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2047Member_e98cc603-1ca7-48ce-acec-90f3295ef307" xlink:href="lly-20201231.xsd#lly_A395NotesDue2047Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A395NotesDue2047Member_e98cc603-1ca7-48ce-acec-90f3295ef307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_20170da6-663d-481a-817d-5ece1156f4cf" xlink:href="lly-20201231.xsd#lly_A395NotesDue2049Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A395NotesDue2049Member_20170da6-663d-481a-817d-5ece1156f4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member_ccfb9027-3494-4bde-9657-dafe705d3e12" xlink:href="lly-20201231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A17EuroDeonominatedNotesDue2049Member_ccfb9027-3494-4bde-9657-dafe705d3e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member_b1b8147b-afb5-480e-93f8-81529b967f06" xlink:href="lly-20201231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A97YenDeonominatedNotesDue2049Member_b1b8147b-afb5-480e-93f8-81529b967f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_c950b1a5-61af-4ad0-9c61-9f003adae112" xlink:href="lly-20201231.xsd#lly_A225NotesDue2050Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A225NotesDue2050Member_c950b1a5-61af-4ad0-9c61-9f003adae112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_befe8c27-965b-48df-8f46-f2b02f586872" xlink:href="lly-20201231.xsd#lly_A415NotesDue2059Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A415NotesDue2059Member_befe8c27-965b-48df-8f46-f2b02f586872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_47ddd46a-4780-47b5-989b-cdea151b385c" xlink:href="lly-20201231.xsd#lly_A25NotesDue2060Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_31269840-a832-4dc7-acea-d737ffa0a741" xlink:to="loc_lly_A25NotesDue2060Member_47ddd46a-4780-47b5-989b-cdea151b385c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ff9290b3-6588-474d-9dbc-3d4ce0463cf2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6c3f5a58-1546-4838-9d77-42f4b4121694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6c3f5a58-1546-4838-9d77-42f4b4121694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f27daa6a-386f-46d4-aeb1-1795fd71285d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_NotesPayable_f27daa6a-386f-46d4-aeb1-1795fd71285d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ec204cee-7ecf-4a95-80b5-8b3aba592692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ec204cee-7ecf-4a95-80b5-8b3aba592692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3743459c-fdb0-4896-b8c5-e9f1472613b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3743459c-fdb0-4896-b8c5-e9f1472613b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_07d37a46-09ab-4f4c-863b-9aa7f402b9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40375f57-e2fc-401a-a207-84215f946004" xlink:to="loc_us-gaap_LongTermDebt_07d37a46-09ab-4f4c-863b-9aa7f402b9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a71aa77a-ed6c-4ba0-8964-a772aa229084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a71aa77a-ed6c-4ba0-8964-a772aa229084" xlink:to="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7c017f20-2384-48af-a813-3956b27fe1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_38813bcd-34c0-4ef7-bbe5-4f68a1a4ced8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7c017f20-2384-48af-a813-3956b27fe1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f2d93ac5-2a78-4f62-ba77-4c71535b28df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c017f20-2384-48af-a813-3956b27fe1d8" xlink:to="loc_us-gaap_SeniorNotesMember_f2d93ac5-2a78-4f62-ba77-4c71535b28df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_03ad286a-23dd-423d-ac91-23203f439676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_03ad286a-23dd-423d-ac91-23203f439676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c095e56f-246a-438a-a3f6-3a7d3736be33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_03ad286a-23dd-423d-ac91-23203f439676" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c095e56f-246a-438a-a3f6-3a7d3736be33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2023Member_b199fa65-eac8-4752-9970-98f35d744c14" xlink:href="lly-20201231.xsd#lly_MaturityDate2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c095e56f-246a-438a-a3f6-3a7d3736be33" xlink:to="loc_lly_MaturityDate2023Member_b199fa65-eac8-4752-9970-98f35d744c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MaturityDate2019Member_8c6a3185-3f8e-4de5-aecf-cedcb134e02d" xlink:href="lly-20201231.xsd#lly_MaturityDate2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c095e56f-246a-438a-a3f6-3a7d3736be33" xlink:to="loc_lly_MaturityDate2019Member_8c6a3185-3f8e-4de5-aecf-cedcb134e02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d61d74dd-5957-4c1c-ac7d-80e5332c4367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:to="loc_us-gaap_DebtInstrumentAxis_d61d74dd-5957-4c1c-ac7d-80e5332c4367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d61d74dd-5957-4c1c-ac7d-80e5332c4367" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_bd532273-fbe0-4c2e-9cef-f4ad6cf47297" xlink:href="lly-20201231.xsd#lly_SeniorNotesDueMay2050AndSeptember2060Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_bd532273-fbe0-4c2e-9cef-f4ad6cf47297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A225NotesDue2050Member_6502efc3-111a-4a35-91db-91dfd501d038" xlink:href="lly-20201231.xsd#lly_A225NotesDue2050Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_bd532273-fbe0-4c2e-9cef-f4ad6cf47297" xlink:to="loc_lly_A225NotesDue2050Member_6502efc3-111a-4a35-91db-91dfd501d038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A25NotesDue2060Member_da1112c4-138a-4867-b298-0fe4d327a63e" xlink:href="lly-20201231.xsd#lly_A25NotesDue2060Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_SeniorNotesDueMay2050AndSeptember2060Member_bd532273-fbe0-4c2e-9cef-f4ad6cf47297" xlink:to="loc_lly_A25NotesDue2060Member_da1112c4-138a-4867-b298-0fe4d327a63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_58632004-fc42-4e11-875d-582f1e5fa558" xlink:href="lly-20201231.xsd#lly_A3375NotesDue2029Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A3375NotesDue2029Member_58632004-fc42-4e11-875d-582f1e5fa558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3875NotesDue2039Member_054a0dd7-c95a-4bbc-a1d0-1c2cdc9f6bfd" xlink:href="lly-20201231.xsd#lly_A3875NotesDue2039Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A3875NotesDue2039Member_054a0dd7-c95a-4bbc-a1d0-1c2cdc9f6bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_207364eb-1048-49c6-aa3c-e1478e4e8e44" xlink:href="lly-20201231.xsd#lly_A395NotesDue2049Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A395NotesDue2049Member_207364eb-1048-49c6-aa3c-e1478e4e8e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_4c284468-6b01-4bb3-a9cc-75ab06ff294b" xlink:href="lly-20201231.xsd#lly_A415NotesDue2059Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A415NotesDue2059Member_4c284468-6b01-4bb3-a9cc-75ab06ff294b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019EuroDenominatedNotesMember_631e99c2-0db0-459e-9fcf-02d0de3c5b81" xlink:href="lly-20201231.xsd#lly_November2019EuroDenominatedNotesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_November2019EuroDenominatedNotesMember_631e99c2-0db0-459e-9fcf-02d0de3c5b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625EuroDeonominatedNotesDue2031Member_c7e605bf-4664-43ca-bd35-809b4bea6961" xlink:href="lly-20201231.xsd#lly_A625EuroDeonominatedNotesDue2031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019EuroDenominatedNotesMember_631e99c2-0db0-459e-9fcf-02d0de3c5b81" xlink:to="loc_lly_A625EuroDeonominatedNotesDue2031Member_c7e605bf-4664-43ca-bd35-809b4bea6961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A17EuroDeonominatedNotesDue2049Member_8d387d22-3821-4cc0-baf1-ebd27d4f65d1" xlink:href="lly-20201231.xsd#lly_A17EuroDeonominatedNotesDue2049Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019EuroDenominatedNotesMember_631e99c2-0db0-459e-9fcf-02d0de3c5b81" xlink:to="loc_lly_A17EuroDeonominatedNotesDue2049Member_8d387d22-3821-4cc0-baf1-ebd27d4f65d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_November2019YenDenominatedNotesMember_df1dc090-f89c-4984-81fa-09b2ab282079" xlink:href="lly-20201231.xsd#lly_November2019YenDenominatedNotesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_November2019YenDenominatedNotesMember_df1dc090-f89c-4984-81fa-09b2ab282079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A42YenDenominatedNotesDue2029Member_ed05a5ef-bf79-43d2-a9ff-8d033493a40e" xlink:href="lly-20201231.xsd#lly_A42YenDenominatedNotesDue2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019YenDenominatedNotesMember_df1dc090-f89c-4984-81fa-09b2ab282079" xlink:to="loc_lly_A42YenDenominatedNotesDue2029Member_ed05a5ef-bf79-43d2-a9ff-8d033493a40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A56YenDenominatedNotesDue2034Member_c002eeeb-c3d0-4f89-a2ee-9eb124ce4484" xlink:href="lly-20201231.xsd#lly_A56YenDenominatedNotesDue2034Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_November2019YenDenominatedNotesMember_df1dc090-f89c-4984-81fa-09b2ab282079" xlink:to="loc_lly_A56YenDenominatedNotesDue2034Member_c002eeeb-c3d0-4f89-a2ee-9eb124ce4484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A97YenDeonominatedNotesDue2049Member_fd3e9932-72b7-4b98-96d6-a0211eea6d59" xlink:href="lly-20201231.xsd#lly_A97YenDeonominatedNotesDue2049Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b269a78e-6fdc-40c9-8daa-d2c06b013914" xlink:to="loc_lly_A97YenDeonominatedNotesDue2049Member_fd3e9932-72b7-4b98-96d6-a0211eea6d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_103db49d-3604-4107-93fb-8b24ef1e4cb9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_f2de0863-2276-4d3a-987e-cd88f8f8deb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_f2de0863-2276-4d3a-987e-cd88f8f8deb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c519dbfb-ffc1-4633-b4d8-577dfaf823b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c519dbfb-ffc1-4633-b4d8-577dfaf823b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a694a1e6-189b-4436-a0fa-09bfaaeca70c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a694a1e6-189b-4436-a0fa-09bfaaeca70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_35302988-bd50-4a14-bdf6-6d6fa17f33ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentTerm_35302988-bd50-4a14-bdf6-6d6fa17f33ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1279dae-a597-4823-abfd-df6ba80bcc58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1279dae-a597-4823-abfd-df6ba80bcc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3318dd3-1b30-4491-ac2a-3a6e6e06c0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3318dd3-1b30-4491-ac2a-3a6e6e06c0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e415bdea-e38a-49dc-a864-5dd9f0e66f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e415bdea-e38a-49dc-a864-5dd9f0e66f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_7061cb4c-4c08-4a29-9f4e-0d0071f37b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfNotesPayable_7061cb4c-4c08-4a29-9f4e-0d0071f37b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_bcb4f433-218a-402e-b4a8-a618266678f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_bcb4f433-218a-402e-b4a8-a618266678f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_22c5f9b7-3098-46b9-946d-5e21938673b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_22c5f9b7-3098-46b9-946d-5e21938673b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_03515ef8-6e7f-4eb6-9cd6-de69f11edb10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_03515ef8-6e7f-4eb6-9cd6-de69f11edb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_e22c024a-b2c1-4e96-9075-e32e959bd54e" xlink:href="lly-20201231.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_e22c024a-b2c1-4e96-9075-e32e959bd54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fb93a9ff-0876-449b-af04-0e31b5a576fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e04bdb3a-2c1f-4a0f-9288-6c431b43b76d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fb93a9ff-0876-449b-af04-0e31b5a576fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_63946414-60fe-4af2-b011-cc0f53be1ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_88b827a7-3123-4de9-9d70-48286a47f1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63946414-60fe-4af2-b011-cc0f53be1ddd" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_88b827a7-3123-4de9-9d70-48286a47f1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9f130fc9-95af-462c-b770-71e21c5130a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_88b827a7-3123-4de9-9d70-48286a47f1fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9f130fc9-95af-462c-b770-71e21c5130a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ce42b8d8-55e8-4208-b942-10b02f7aadfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_88b827a7-3123-4de9-9d70-48286a47f1fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ce42b8d8-55e8-4208-b942-10b02f7aadfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ed5fb411-31fb-4a83-8f36-99a48f1c4c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_88b827a7-3123-4de9-9d70-48286a47f1fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ed5fb411-31fb-4a83-8f36-99a48f1c4c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_91d1f97d-b8f8-4eed-999f-f5b37e359816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_88b827a7-3123-4de9-9d70-48286a47f1fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_91d1f97d-b8f8-4eed-999f-f5b37e359816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ff2febd4-a8a0-4cb1-b308-7ff219b07981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_88b827a7-3123-4de9-9d70-48286a47f1fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ff2febd4-a8a0-4cb1-b308-7ff219b07981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b0b30e4a-0b5b-4814-9f91-281659da3d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e3aa981c-ce80-4706-b4b0-0e032e7623a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b0b30e4a-0b5b-4814-9f91-281659da3d2d" xlink:to="loc_us-gaap_InterestPaidNet_e3aa981c-ce80-4706-b4b0-0e032e7623a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_545a850b-c1ab-4d48-b481-7c1bb9ca4244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b465e863-8df6-49c0-9bc2-9f18d96a10f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_545a850b-c1ab-4d48-b481-7c1bb9ca4244" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b465e863-8df6-49c0-9bc2-9f18d96a10f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee22f9b2-da36-48a7-8a0b-40f491f9d74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_b661d29f-1103-41f7-b3a9-ecbd0df484a0" xlink:href="lly-20201231.xsd#lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee22f9b2-da36-48a7-8a0b-40f491f9d74e" xlink:to="loc_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock_b661d29f-1103-41f7-b3a9-ecbd0df484a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_8d74e3ea-9da1-4198-adeb-d21b7acf41ef" xlink:href="lly-20201231.xsd#lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee22f9b2-da36-48a7-8a0b-40f491f9d74e" xlink:to="loc_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock_8d74e3ea-9da1-4198-adeb-d21b7acf41ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717c2b29-884d-4241-b859-5e4f924ae68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_50c4b3b9-9fd9-414a-bfd6-cef6d60a793a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717c2b29-884d-4241-b859-5e4f924ae68f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_50c4b3b9-9fd9-414a-bfd6-cef6d60a793a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6a80d146-8093-446d-adc7-ccfcd933ef1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_717c2b29-884d-4241-b859-5e4f924ae68f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6a80d146-8093-446d-adc7-ccfcd933ef1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39c19172-7136-424d-9660-387496935aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f69748-374a-47d4-a47b-b5f3388c3d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39c19172-7136-424d-9660-387496935aec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f69748-374a-47d4-a47b-b5f3388c3d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e8c94fc5-d150-44e5-86f4-f13c2de11fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f69748-374a-47d4-a47b-b5f3388c3d51" xlink:to="loc_us-gaap_AwardTypeAxis_e8c94fc5-d150-44e5-86f4-f13c2de11fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e8c94fc5-d150-44e5-86f4-f13c2de11fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3a9c8ba5-65e7-42d3-b75f-655a526d8775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:to="loc_us-gaap_PerformanceSharesMember_3a9c8ba5-65e7-42d3-b75f-655a526d8775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_a855da74-39b0-4e63-95be-23ec73a58abf" xlink:href="lly-20201231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:to="loc_lly_ShareholderValueAwardsMember_a855da74-39b0-4e63-95be-23ec73a58abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_3b00bd8e-c9b5-45d8-b87f-09f0d3ccb038" xlink:href="lly-20201231.xsd#lly_RelativeValueAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:to="loc_lly_RelativeValueAwardsMember_3b00bd8e-c9b5-45d8-b87f-09f0d3ccb038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3f41c00d-ec7f-4702-854d-b91c1be180f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9098bee2-aa72-4225-89d7-cbb64a203627" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3f41c00d-ec7f-4702-854d-b91c1be180f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81f69748-374a-47d4-a47b-b5f3388c3d51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a5b007c-d53d-4356-9bdf-aab402d3754f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a5b007c-d53d-4356-9bdf-aab402d3754f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_acb3bf0e-d836-4ca4-afe9-d2581f7a11b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_acb3bf0e-d836-4ca4-afe9-d2581f7a11b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ced15353-f80c-4334-919c-6642a347f4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ced15353-f80c-4334-919c-6642a347f4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_fc788dde-2e19-4f4c-856f-49fcec8f77b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_fc788dde-2e19-4f4c-856f-49fcec8f77b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_eabf90d3-79e6-4fcc-ab9f-2da4a17858f4" xlink:href="lly-20201231.xsd#lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued_eabf90d3-79e6-4fcc-ab9f-2da4a17858f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9b9aec9-bc0e-4031-9c17-cc622cb7d0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9b9aec9-bc0e-4031-9c17-cc622cb7d0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4be82ec-a8b3-430d-91d4-efb6dfd776c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4be82ec-a8b3-430d-91d4-efb6dfd776c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dc109b95-1960-407c-b699-fdcaee9cc49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d787031-c2e3-4aa6-91d1-d76f9db55541" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dc109b95-1960-407c-b699-fdcaee9cc49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#StockBasedCompensationScheduleofAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3501faee-3051-487a-839f-999aac441b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932ada2d-4cd6-4b0d-ab51-33e853bbfbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3501faee-3051-487a-839f-999aac441b9e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932ada2d-4cd6-4b0d-ab51-33e853bbfbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_61765d3d-c223-48d9-add3-f37c472e5b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932ada2d-4cd6-4b0d-ab51-33e853bbfbe7" xlink:to="loc_us-gaap_AwardTypeAxis_61765d3d-c223-48d9-add3-f37c472e5b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324c1139-be0d-404b-bdbc-03b9d0667843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_61765d3d-c223-48d9-add3-f37c472e5b1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324c1139-be0d-404b-bdbc-03b9d0667843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ShareholderValueAwardsMember_7ce0b5b0-d2a8-4bb2-b58d-b64ac4ba838f" xlink:href="lly-20201231.xsd#lly_ShareholderValueAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324c1139-be0d-404b-bdbc-03b9d0667843" xlink:to="loc_lly_ShareholderValueAwardsMember_7ce0b5b0-d2a8-4bb2-b58d-b64ac4ba838f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RelativeValueAwardsMember_575955a8-a849-4757-ae13-51530eece7bd" xlink:href="lly-20201231.xsd#lly_RelativeValueAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_324c1139-be0d-404b-bdbc-03b9d0667843" xlink:to="loc_lly_RelativeValueAwardsMember_575955a8-a849-4757-ae13-51530eece7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932ada2d-4cd6-4b0d-ab51-33e853bbfbe7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f0581cfa-f69f-4eb8-9426-782fe855adf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f0581cfa-f69f-4eb8-9426-782fe855adf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_227214ad-73f1-4b8a-a0a1-4b57d721c3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_227214ad-73f1-4b8a-a0a1-4b57d721c3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_082003e2-87b5-4b28-ae13-c4cee68c55f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_128448cb-09c1-437a-bdb3-ae2d3ed5ded0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_082003e2-87b5-4b28-ae13-c4cee68c55f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="lly-20201231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0e847c4e-f3ec-42c9-84a9-9aed03aac7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9c0475dd-7c8e-4e75-89a7-49b0c12ac8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0e847c4e-f3ec-42c9-84a9-9aed03aac7b2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9c0475dd-7c8e-4e75-89a7-49b0c12ac8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f8b554fa-f0af-4780-a4f1-98ec9616a572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a4ba9ff4-f568-4973-8ebc-9c15df61f8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f8b554fa-f0af-4780-a4f1-98ec9616a572" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a4ba9ff4-f568-4973-8ebc-9c15df61f8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_b3336100-da41-47ec-8af4-1814e7af18eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a4ba9ff4-f568-4973-8ebc-9c15df61f8e6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_b3336100-da41-47ec-8af4-1814e7af18eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_05ed4af6-eade-4d09-9a37-1647c6e777c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b3336100-da41-47ec-8af4-1814e7af18eb" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_05ed4af6-eade-4d09-9a37-1647c6e777c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2018RepurchaseProgramMember_f80468a1-241d-4674-87e6-63fcb6d1da5b" xlink:href="lly-20201231.xsd#lly_A2018RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_05ed4af6-eade-4d09-9a37-1647c6e777c8" xlink:to="loc_lly_A2018RepurchaseProgramMember_f80468a1-241d-4674-87e6-63fcb6d1da5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a4ba9ff4-f568-4973-8ebc-9c15df61f8e6" xlink:to="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_03d42981-b766-40e6-8da0-c1be614c78f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_03d42981-b766-40e6-8da0-c1be614c78f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2da71079-5d5f-4f56-ad60-4998ff2e66a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2da71079-5d5f-4f56-ad60-4998ff2e66a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9610e14b-6a89-4f57-bdc5-817aa1a473f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9610e14b-6a89-4f57-bdc5-817aa1a473f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bb2e827a-ea54-4769-88f8-f7889c781914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bb2e827a-ea54-4769-88f8-f7889c781914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_aa53a966-d929-4f54-af5a-3b860eb002b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_aa53a966-d929-4f54-af5a-3b860eb002b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_2e8000ee-7df2-42ad-a4cc-eb7c8c30df3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrustShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrustShares_2e8000ee-7df2-42ad-a4cc-eb7c8c30df3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_5361d71a-3d50-40e3-b2ac-c41f938ae758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_27ec6955-6b4c-441e-83c7-34f844cb22f2" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_5361d71a-3d50-40e3-b2ac-c41f938ae758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_99a683f7-4747-4d66-ba8a-ddfd63120ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3b21f41b-bba1-42f5-8617-e07a4701dab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_99a683f7-4747-4d66-ba8a-ddfd63120ff7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3b21f41b-bba1-42f5-8617-e07a4701dab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4b1b59da-00cb-4a82-a26a-d33df222463d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_adddb874-dd65-4443-8fa1-091376222e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b1b59da-00cb-4a82-a26a-d33df222463d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_adddb874-dd65-4443-8fa1-091376222e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d2c0390c-c8eb-41cd-9b73-fa55e22c802b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b1b59da-00cb-4a82-a26a-d33df222463d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d2c0390c-c8eb-41cd-9b73-fa55e22c802b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_4ce173b7-d0ee-43e8-a81e-bfca07364aaa" xlink:href="lly-20201231.xsd#lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b1b59da-00cb-4a82-a26a-d33df222463d" xlink:to="loc_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock_4ce173b7-d0ee-43e8-a81e-bfca07364aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_906db942-2df4-4553-bd37-0094479cb74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b1b59da-00cb-4a82-a26a-d33df222463d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_906db942-2df4-4553-bd37-0094479cb74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_decba70e-9d80-495f-a880-24c5a44187e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b1b59da-00cb-4a82-a26a-d33df222463d" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_decba70e-9d80-495f-a880-24c5a44187e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38d95cc4-f809-48ed-93da-288883b3af36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38d95cc4-f809-48ed-93da-288883b3af36" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_87dd0ddc-0e74-4b25-b102-e2233eda25d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:to="loc_us-gaap_TaxPeriodAxis_87dd0ddc-0e74-4b25-b102-e2233eda25d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_10915aa0-2c73-4a7a-9df9-09d97227065f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_87dd0ddc-0e74-4b25-b102-e2233eda25d9" xlink:to="loc_us-gaap_TaxPeriodDomain_10915aa0-2c73-4a7a-9df9-09d97227065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxYears2013To2015Member_6761a44e-5860-4ba3-ac8b-f50372c3a0f1" xlink:href="lly-20201231.xsd#lly_TaxYears2013To2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_10915aa0-2c73-4a7a-9df9-09d97227065f" xlink:to="loc_lly_TaxYears2013To2015Member_6761a44e-5860-4ba3-ac8b-f50372c3a0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_4d5ad7a9-8ba3-4670-a135-2c54962cd18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_4d5ad7a9-8ba3-4670-a135-2c54962cd18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_4d5ad7a9-8ba3-4670-a135-2c54962cd18f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CarryforwardMember_c4443cf5-26b2-49c9-ae09-37356a1759dd" xlink:href="lly-20201231.xsd#lly_CarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_CarryforwardMember_c4443cf5-26b2-49c9-ae09-37356a1759dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationin6YearsMember_9102640b-5054-4412-a817-41e72a50a3c8" xlink:href="lly-20201231.xsd#lly_Expirationin6YearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_Expirationin6YearsMember_9102640b-5054-4412-a817-41e72a50a3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ExpirationIn12To18YearsMember_90f1757e-deb5-486a-9b8c-87e97b0b8ea9" xlink:href="lly-20201231.xsd#lly_ExpirationIn12To18YearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_ExpirationIn12To18YearsMember_90f1757e-deb5-486a-9b8c-87e97b0b8ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DesignatedUnusableMember_5abf33f4-b445-4975-bcb8-e1c2204ede6f" xlink:href="lly-20201231.xsd#lly_DesignatedUnusableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_DesignatedUnusableMember_5abf33f4-b445-4975-bcb8-e1c2204ede6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expirationwithin5yearsMember_cd3fcd4e-c57c-4375-9a0a-050cacd753f6" xlink:href="lly-20201231.xsd#lly_Expirationwithin5yearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_Expirationwithin5yearsMember_cd3fcd4e-c57c-4375-9a0a-050cacd753f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_Expiration5to20YearsMember_f3c90707-96df-4563-beed-e283842db2e9" xlink:href="lly-20201231.xsd#lly_Expiration5to20YearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_Expiration5to20YearsMember_f3c90707-96df-4563-beed-e283842db2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NoExpirationMember_6bdf7ade-af10-4693-aa45-8a51eea9ffae" xlink:href="lly-20201231.xsd#lly_NoExpirationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_99887c6c-204d-4270-9ec4-4b087dd65e21" xlink:to="loc_lly_NoExpirationMember_6bdf7ade-af10-4693-aa45-8a51eea9ffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5a8e2b8a-c543-4167-b547-803a6fa1bd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5a8e2b8a-c543-4167-b547-803a6fa1bd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5a8e2b8a-c543-4167-b547-803a6fa1bd8e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_30d010c1-5188-40a5-8a48-17b95c5528f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_30d010c1-5188-40a5-8a48-17b95c5528f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_88857d8f-431b-418f-a6aa-dc4b6ec45377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:to="loc_us-gaap_ForeignCountryMember_88857d8f-431b-418f-a6aa-dc4b6ec45377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_34e9e5c9-2165-43be-8476-95d88627fe54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_49d389a3-aaef-4e8c-8b52-f70c3cdfdd7d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_34e9e5c9-2165-43be-8476-95d88627fe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_4f1549c1-f636-49e3-ac20-1a22cdce60ba" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision_67287e0e-8cce-4e62-9634-21b084addcc7" xlink:href="lly-20201231.xsd#lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision_67287e0e-8cce-4e62-9634-21b084addcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_075d1e2b-36aa-47a2-81b0-048f4ca684d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_075d1e2b-36aa-47a2-81b0-048f4ca684d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a962ba67-a580-42e9-99dd-3af008a78972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a962ba67-a580-42e9-99dd-3af008a78972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2afb7135-e447-450d-9b0e-61aa4fb67efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2afb7135-e447-450d-9b0e-61aa4fb67efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_8a9b36fd-d014-40c4-984a-e0eb367bdc82" xlink:href="lly-20201231.xsd#lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes_8a9b36fd-d014-40c4-984a-e0eb367bdc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_9eb16902-94ae-48b0-bd3d-9b47657495b2" xlink:href="lly-20201231.xsd#lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible_9eb16902-94ae-48b0-bd3d-9b47657495b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_830c3144-456f-41ef-8e0a-0d4568ad0279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_830c3144-456f-41ef-8e0a-0d4568ad0279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_dea32564-771c-41fe-b91e-36578412224a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_dea32564-771c-41fe-b91e-36578412224a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentsForIncomeTaxSettlements_32a699aa-f7a6-4d45-b9d7-bbd7b7777ecf" xlink:href="lly-20201231.xsd#lly_PaymentsForIncomeTaxSettlements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_lly_PaymentsForIncomeTaxSettlements_32a699aa-f7a6-4d45-b9d7-bbd7b7777ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_67587a4c-a39e-41d5-978b-5c638edf4521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cb9f2b60-d6cc-4b38-802e-ccb82f04e64b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_67587a4c-a39e-41d5-978b-5c638edf4521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_77e62b4b-98a3-4177-8a5e-04e7c5087f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_82f04f15-0dd3-428b-a46b-c80996d8067c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77e62b4b-98a3-4177-8a5e-04e7c5087f65" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_82f04f15-0dd3-428b-a46b-c80996d8067c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f7244559-4e20-456d-8213-fb971262d1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_82f04f15-0dd3-428b-a46b-c80996d8067c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f7244559-4e20-456d-8213-fb971262d1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3f63fe67-a417-4dd9-b2f3-13812e19ec81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_82f04f15-0dd3-428b-a46b-c80996d8067c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3f63fe67-a417-4dd9-b2f3-13812e19ec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3b3a4fc5-fe31-44bb-98fb-30ffef6ced2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_82f04f15-0dd3-428b-a46b-c80996d8067c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3b3a4fc5-fe31-44bb-98fb-30ffef6ced2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_49756928-8407-49bc-9e45-923889898197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_82f04f15-0dd3-428b-a46b-c80996d8067c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_49756928-8407-49bc-9e45-923889898197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6f282ed4-a140-44b1-865e-d1935baed7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77e62b4b-98a3-4177-8a5e-04e7c5087f65" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6f282ed4-a140-44b1-865e-d1935baed7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6d318955-6043-4a7a-9af7-fa712c562408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6f282ed4-a140-44b1-865e-d1935baed7d6" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6d318955-6043-4a7a-9af7-fa712c562408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8d77df91-e49e-4817-a5b2-40144f236762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6f282ed4-a140-44b1-865e-d1935baed7d6" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8d77df91-e49e-4817-a5b2-40144f236762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_93f74a65-aa52-403a-b3dd-7a108286e5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6f282ed4-a140-44b1-865e-d1935baed7d6" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_93f74a65-aa52-403a-b3dd-7a108286e5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_924ed8d5-53bd-4099-adbf-e809cdf26a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6f282ed4-a140-44b1-865e-d1935baed7d6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_924ed8d5-53bd-4099-adbf-e809cdf26a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d885b80d-5c2a-48cc-b3d9-5d44d4147e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77e62b4b-98a3-4177-8a5e-04e7c5087f65" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d885b80d-5c2a-48cc-b3d9-5d44d4147e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_dcbdbdb6-8352-4c5e-b9ad-3fe53ef8b87a" xlink:href="lly-20201231.xsd#lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77e62b4b-98a3-4177-8a5e-04e7c5087f65" xlink:to="loc_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward_dcbdbdb6-8352-4c5e-b9ad-3fe53ef8b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_05e1d021-73ad-4112-959a-63802bf84a13" xlink:href="lly-20201231.xsd#lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77e62b4b-98a3-4177-8a5e-04e7c5087f65" xlink:to="loc_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_05e1d021-73ad-4112-959a-63802bf84a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_e5522bb9-27a4-4324-9476-28e03a810060" xlink:href="lly-20201231.xsd#lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77e62b4b-98a3-4177-8a5e-04e7c5087f65" xlink:to="loc_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct_e5522bb9-27a4-4324-9476-28e03a810060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2dac2b97-1dea-4834-abff-f8087c68a6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2dac2b97-1dea-4834-abff-f8087c68a6ab" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_63f43fd4-6011-4d17-868e-eb0535865c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_63f43fd4-6011-4d17-868e-eb0535865c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4ab5994f-cfd1-4e8f-85a0-1ba12fc5ab7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4ab5994f-cfd1-4e8f-85a0-1ba12fc5ab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2fd0c7ef-1ba9-4b74-b854-b2720aa76f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2fd0c7ef-1ba9-4b74-b854-b2720aa76f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a86ceda6-1221-4547-a4a8-699438a99354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a86ceda6-1221-4547-a4a8-699438a99354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_f1eb11f2-ea16-455f-a491-a4090aaa8fd1" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsSalesRebatesAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_lly_DeferredTaxAssetsSalesRebatesAndDiscounts_f1eb11f2-ea16-455f-a491-a4090aaa8fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_e47b4f24-1816-4d28-ab5b-bb4504c15f71" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsCorrectiveTaxAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_lly_DeferredTaxAssetsCorrectiveTaxAdjustments_e47b4f24-1816-4d28-ab5b-bb4504c15f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_a40d3f6b-caf2-4ad7-b452-c2fa4a87102b" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsForeignTaxRedeterminations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_lly_DeferredTaxAssetsForeignTaxRedeterminations_a40d3f6b-caf2-4ad7-b452-c2fa4a87102b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_3a928d48-2175-49f7-a191-cb4dac3f0d40" xlink:href="lly-20201231.xsd#lly_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_lly_DeferredTaxAssetsOperatingLeaseLiability_3a928d48-2175-49f7-a191-cb4dac3f0d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_69e41e1d-8267-4e1b-a97d-4f5ff12c0fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_69e41e1d-8267-4e1b-a97d-4f5ff12c0fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c3a45ba7-5dec-41ef-b38a-9f53f87ecc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c3a45ba7-5dec-41ef-b38a-9f53f87ecc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b8f21c64-545f-4a22-a5b3-054d9294bcd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b8f21c64-545f-4a22-a5b3-054d9294bcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e7c46b1-1c93-4280-aa7f-06ce954d3acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e7c46b1-1c93-4280-aa7f-06ce954d3acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8f2429dc-8fb4-497d-9709-13277ee8a880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e299c832-2c50-451c-a8e4-e7479ef5c1e2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8f2429dc-8fb4-497d-9709-13277ee8a880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2dac2b97-1dea-4834-abff-f8087c68a6ab" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_59347392-62d3-4bac-b36e-94d90591de1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_59347392-62d3-4bac-b36e-94d90591de1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_8928d028-67a6-4e58-a932-650c96472e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_8928d028-67a6-4e58-a932-650c96472e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_dbe8e625-210c-4995-9236-cd23d5aebb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_dbe8e625-210c-4995-9236-cd23d5aebb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_77ef8fd3-237d-4f7a-b256-8eab0b38ac87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_77ef8fd3-237d-4f7a-b256-8eab0b38ac87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7b81e560-2201-444e-a1d5-b16dd266a0f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7b81e560-2201-444e-a1d5-b16dd266a0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_c6b9d619-58b9-4755-aa04-53af111f732b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDerivatives_c6b9d619-58b9-4755-aa04-53af111f732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c485977e-a719-4632-81b3-b3de8486cdfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c485977e-a719-4632-81b3-b3de8486cdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0b318175-61e1-4160-9a24-4879ec988794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f1cae116-cc59-4d3e-a8f6-bf0f104f67ba" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0b318175-61e1-4160-9a24-4879ec988794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8dbf6eae-46a7-41d2-8d60-236e3508c105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2dac2b97-1dea-4834-abff-f8087c68a6ab" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8dbf6eae-46a7-41d2-8d60-236e3508c105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_068fd4e8-3ed6-4047-9fad-fbf41bd155bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_dc3f4979-6087-4d0f-bc09-46510e4a707b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_068fd4e8-3ed6-4047-9fad-fbf41bd155bc" xlink:to="loc_us-gaap_IncomeTaxesPaid_dc3f4979-6087-4d0f-bc09-46510e4a707b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7c1173b5-f039-47c4-9683-fc6b5cb3d602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_fe3f1f2e-b6f9-414f-8b62-d77a1532737f" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxPaymentDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c1173b5-f039-47c4-9683-fc6b5cb3d602" xlink:to="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_fe3f1f2e-b6f9-414f-8b62-d77a1532737f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaid_50690bde-86d6-4cba-9d67-726fc2401ce0" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_fe3f1f2e-b6f9-414f-8b62-d77a1532737f" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaid_50690bde-86d6-4cba-9d67-726fc2401ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_55f0655f-2b4f-4cbf-9347-0471e69ffbe4" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_fe3f1f2e-b6f9-414f-8b62-d77a1532737f" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear_55f0655f-2b4f-4cbf-9347-0471e69ffbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_279b3d0e-d941-4b08-af66-9272d4473e0a" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_fe3f1f2e-b6f9-414f-8b62-d77a1532737f" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears_279b3d0e-d941-4b08-af66-9272d4473e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_e2d28381-7c42-4575-83ba-220263181a12" xlink:href="lly-20201231.xsd#lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract_fe3f1f2e-b6f9-414f-8b62-d77a1532737f" xlink:to="loc_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears_e2d28381-7c42-4575-83ba-220263181a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b6f6fd5e-368f-4dd0-8c95-3c11cb8ce00d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c10eda78-5c80-44ab-8104-50fe234b076a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6f6fd5e-368f-4dd0-8c95-3c11cb8ce00d" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c10eda78-5c80-44ab-8104-50fe234b076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AddDeductAbstract_262742da-cbbe-47f6-ae92-a04d743a2634" xlink:href="lly-20201231.xsd#lly_AddDeductAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6f6fd5e-368f-4dd0-8c95-3c11cb8ce00d" xlink:to="loc_lly_AddDeductAbstract_262742da-cbbe-47f6-ae92-a04d743a2634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_af6c7b7f-7345-4e3e-b742-24431b36694d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_262742da-cbbe-47f6-ae92-a04d743a2634" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_af6c7b7f-7345-4e3e-b742-24431b36694d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_ab250504-c0b6-412c-90cb-78eb18c6cd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_262742da-cbbe-47f6-ae92-a04d743a2634" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_ab250504-c0b6-412c-90cb-78eb18c6cd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_9c1af1b6-8357-4c60-8ee8-9945caa5ce95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_262742da-cbbe-47f6-ae92-a04d743a2634" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_9c1af1b6-8357-4c60-8ee8-9945caa5ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount_410b8f20-3756-4c9b-a480-089ad727cc82" xlink:href="lly-20201231.xsd#lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_262742da-cbbe-47f6-ae92-a04d743a2634" xlink:to="loc_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount_410b8f20-3756-4c9b-a480-089ad727cc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_66e62d64-7fd0-4565-a622-d9c0deeb10ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_AddDeductAbstract_262742da-cbbe-47f6-ae92-a04d743a2634" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_66e62d64-7fd0-4565-a622-d9c0deeb10ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eef7a0af-e319-47bd-9eaa-7af030ec7b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6f6fd5e-368f-4dd0-8c95-3c11cb8ce00d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eef7a0af-e319-47bd-9eaa-7af030ec7b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ab2dd1d4-7279-42de-b068-db4ab0683257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ab2dd1d4-7279-42de-b068-db4ab0683257" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ed9aa38e-51ec-45e9-94c0-631909dcef18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ed9aa38e-51ec-45e9-94c0-631909dcef18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5c02c559-d896-4016-84ec-549d28f10928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5c02c559-d896-4016-84ec-549d28f10928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_abd3707c-96e7-44df-92e7-8be543d2e6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_abd3707c-96e7-44df-92e7-8be543d2e6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_db6428fa-4c00-4f71-b486-6f0a0cff727c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_db6428fa-4c00-4f71-b486-6f0a0cff727c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c98f1d92-eab5-40ef-9048-47ccb78497bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c98f1d92-eab5-40ef-9048-47ccb78497bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1ff69113-7b0f-4034-bf93-d008d522de2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1ff69113-7b0f-4034-bf93-d008d522de2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_082088cc-7d40-424e-86bb-83847cd31d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_082088cc-7d40-424e-86bb-83847cd31d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_ddb353f4-4ffa-48a6-a0e7-f308ac3c818b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_ddb353f4-4ffa-48a6-a0e7-f308ac3c818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_000d287e-794c-49db-bd12-fd12043eb0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0884779b-b149-486a-a6a0-75a6bdd27d3d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_000d287e-794c-49db-bd12-fd12043eb0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5a4c6706-410b-44f2-ae22-a9d9e9fece73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_66d37e6d-26ee-478e-8c59-5705b33dbfc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5a4c6706-410b-44f2-ae22-a9d9e9fece73" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_66d37e6d-26ee-478e-8c59-5705b33dbfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefits"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f9c18646-2552-40a3-9b54-a45190f986af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_980e1234-2980-4d9d-b488-6ef406211bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f9c18646-2552-40a3-9b54-a45190f986af" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_980e1234-2980-4d9d-b488-6ef406211bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_4e1c2d47-977c-4b52-a487-71a47006bb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock_4e1c2d47-977c-4b52-a487-71a47006bb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_ac2b53f4-0290-4a56-9b3d-684b619b07d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_ac2b53f4-0290-4a56-9b3d-684b619b07d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_a1cbe61b-7ee2-48bb-927d-d0aab1d0763b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_a1cbe61b-7ee2-48bb-927d-d0aab1d0763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_700a7a96-d430-4ab2-8f21-93bb41203a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_700a7a96-d430-4ab2-8f21-93bb41203a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_ac3e3026-187d-4e80-b7cb-849abd1fc69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_ac3e3026-187d-4e80-b7cb-849abd1fc69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d03c76b3-689a-4d0e-be9d-5513a9c5c384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d03c76b3-689a-4d0e-be9d-5513a9c5c384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_ce0cb303-c7f4-47a0-b610-584639862adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_ce0cb303-c7f4-47a0-b610-584639862adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_89840874-24ec-4351-ad4f-da6a8baf3cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_89840874-24ec-4351-ad4f-da6a8baf3cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_a86947ab-c293-4f4f-ba8a-346fefa9b383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_a86947ab-c293-4f4f-ba8a-346fefa9b383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_25f08d12-d255-4807-beb8-13a1524a6c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_25f08d12-d255-4807-beb8-13a1524a6c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_f03b82a9-e20b-43cd-9452-61d8b16332ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80698eea-0e0b-4676-a032-300120391985" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_f03b82a9-e20b-43cd-9452-61d8b16332ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4c75186c-13ec-4ada-b202-d0637fde95c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d3bd912f-f1e2-41ff-a5ed-38c42bcb1027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4c75186c-13ec-4ada-b202-d0637fde95c7" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d3bd912f-f1e2-41ff-a5ed-38c42bcb1027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a6d5fc3c-bd92-479a-bb78-c76823e832d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d3bd912f-f1e2-41ff-a5ed-38c42bcb1027" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a6d5fc3c-bd92-479a-bb78-c76823e832d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ce232f12-4fb4-4748-b4f7-13051a87b949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a6d5fc3c-bd92-479a-bb78-c76823e832d8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ce232f12-4fb4-4748-b4f7-13051a87b949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d3dcd93b-6291-4427-806b-599ca055583b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ce232f12-4fb4-4748-b4f7-13051a87b949" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d3dcd93b-6291-4427-806b-599ca055583b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_f57ff697-d947-45a3-b3de-39102ca9fbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ce232f12-4fb4-4748-b4f7-13051a87b949" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_f57ff697-d947-45a3-b3de-39102ca9fbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d3bd912f-f1e2-41ff-a5ed-38c42bcb1027" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a650f85f-d1f5-4e15-8286-b98f5581ece2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a650f85f-d1f5-4e15-8286-b98f5581ece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_99ce5c0c-c114-4960-934c-dcef4c53adf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_99ce5c0c-c114-4960-934c-dcef4c53adf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_3dc622ad-f70b-447b-bf8c-ab2f0b260dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_3dc622ad-f70b-447b-bf8c-ab2f0b260dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7f77128e-968e-46be-9b03-0cf08de54bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7f77128e-968e-46be-9b03-0cf08de54bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_31934fc7-b33e-4c66-bb52-27569cf0c119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_31934fc7-b33e-4c66-bb52-27569cf0c119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_5e35e221-35a8-4e29-bd98-c1082ea566a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_5e35e221-35a8-4e29-bd98-c1082ea566a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_e6f42554-d09d-4819-8a30-f16035c2a0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_e6f42554-d09d-4819-8a30-f16035c2a0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ddd1b1a3-2904-4948-a92c-dfa399e7770f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_c5eaa401-b340-4339-ac4d-ff966e8bc893" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ddd1b1a3-2904-4948-a92c-dfa399e7770f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_982a3d5a-94a3-49aa-bf20-81d998974dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_982a3d5a-94a3-49aa-bf20-81d998974dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_4169e698-110f-4fc5-a4cf-80179c4c3c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_4169e698-110f-4fc5-a4cf-80179c4c3c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1c4a41e1-3527-47df-b447-89e701fcfda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1c4a41e1-3527-47df-b447-89e701fcfda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_c55202b9-7e47-4292-a617-aa9bcfb3e1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_c55202b9-7e47-4292-a617-aa9bcfb3e1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_0e24abc6-288c-4696-8e8c-5c64475e207a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_0e24abc6-288c-4696-8e8c-5c64475e207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f6f47dea-5690-469f-a606-21c791e41775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_42a5eb6a-1340-4e94-84c3-10e46ccceda4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f6f47dea-5690-469f-a606-21c791e41775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_bab27178-70a2-416a-96b0-4ab94e963f78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_bab27178-70a2-416a-96b0-4ab94e963f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e19712e8-6917-4449-ac3c-afef30ebe06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_e19712e8-6917-4449-ac3c-afef30ebe06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_2ffabac4-bfe0-4f66-b203-acb3d76ff52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_2ffabac4-bfe0-4f66-b203-acb3d76ff52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_1a4f0cf9-7a69-48a0-bcb2-dd8d5696255b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_532d4210-94e1-45fd-9e71-778897fe67d9" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_1a4f0cf9-7a69-48a0-bcb2-dd8d5696255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2ffe6d66-82a5-4758-a101-44dede115a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4e150e1-af73-411e-9bfa-401766f1490d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2ffe6d66-82a5-4758-a101-44dede115a3a" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4e150e1-af73-411e-9bfa-401766f1490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_43470f8c-f971-4e59-aef3-fc759dce291b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4e150e1-af73-411e-9bfa-401766f1490d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_43470f8c-f971-4e59-aef3-fc759dce291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a1bc06b7-2150-4dd9-8a79-160035ca38a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_43470f8c-f971-4e59-aef3-fc759dce291b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a1bc06b7-2150-4dd9-8a79-160035ca38a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_0e9bc4d2-dbc0-4beb-b222-fbe6fd3870f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a1bc06b7-2150-4dd9-8a79-160035ca38a5" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_0e9bc4d2-dbc0-4beb-b222-fbe6fd3870f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_e0b481ab-e538-4c9c-b0f6-b99b9556910e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a1bc06b7-2150-4dd9-8a79-160035ca38a5" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_e0b481ab-e538-4c9c-b0f6-b99b9556910e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_64f574f6-48cd-4821-bb37-e9d68b8dcd79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_d4e150e1-af73-411e-9bfa-401766f1490d" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_64f574f6-48cd-4821-bb37-e9d68b8dcd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_64f574f6-48cd-4821-bb37-e9d68b8dcd79" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_205e8d71-4dab-42b5-b3df-cb7f27519716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_205e8d71-4dab-42b5-b3df-cb7f27519716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_159cdd7f-7cce-4d2d-854c-481dd8698f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_159cdd7f-7cce-4d2d-854c-481dd8698f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1605b090-d103-432c-a1d1-44926f023696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1605b090-d103-432c-a1d1-44926f023696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a204a9e3-7389-468a-8de4-225a6a900d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_a204a9e3-7389-468a-8de4-225a6a900d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_8442d22c-c6f4-4526-9a87-882fc6a0b8d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_36fe1939-39dc-4dcd-9f33-d2458df7fc72" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_8442d22c-c6f4-4526-9a87-882fc6a0b8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dfeb7956-7438-45c1-b87a-05a57f18c109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_dfeb7956-7438-45c1-b87a-05a57f18c109" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8a0fdf54-a56d-4b22-96d6-9f5c13363300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8a0fdf54-a56d-4b22-96d6-9f5c13363300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b0f8bd1c-c9b8-4e7d-9d83-ce621e558938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8a0fdf54-a56d-4b22-96d6-9f5c13363300" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b0f8bd1c-c9b8-4e7d-9d83-ce621e558938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_dda7db35-10ee-4b0e-9a99-af4c05180294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b0f8bd1c-c9b8-4e7d-9d83-ce621e558938" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_dda7db35-10ee-4b0e-9a99-af4c05180294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_3327694b-895a-4c82-87eb-c98478a8e7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b0f8bd1c-c9b8-4e7d-9d83-ce621e558938" xlink:to="loc_us-gaap_FixedIncomeFundsMember_3327694b-895a-4c82-87eb-c98478a8e7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b301f080-617f-4f22-a77f-cd79bbcbd7b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b301f080-617f-4f22-a77f-cd79bbcbd7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b754c730-870d-47de-94a1-03b572604351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b301f080-617f-4f22-a77f-cd79bbcbd7b5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b754c730-870d-47de-94a1-03b572604351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ed20c340-70e6-486c-be6b-657f0f8f8e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b754c730-870d-47de-94a1-03b572604351" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ed20c340-70e6-486c-be6b-657f0f8f8e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fae7bf72-64aa-45c0-8784-48cf00b0887e" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_63934817-8ef1-408d-b1f8-435707d6ccf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease_63934817-8ef1-408d-b1f8-435707d6ccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_b2faa2b4-e43e-4985-af95-f690af85fd38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_b2faa2b4-e43e-4985-af95-f690af85fd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_01cb3e15-b7a6-4746-817e-2d265440f75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_01cb3e15-b7a6-4746-817e-2d265440f75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_dd72947d-889a-4cd7-a762-075c2c7d5bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_dd72947d-889a-4cd7-a762-075c2c7d5bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_d6af318a-c9ee-4ce4-8e2c-80a21ff14c50" xlink:href="lly-20201231.xsd#lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets_d6af318a-c9ee-4ce4-8e2c-80a21ff14c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_3e3e9921-301d-47d1-ab64-ac4a786ba401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_3e3e9921-301d-47d1-ab64-ac4a786ba401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_793ca676-3e95-4362-b3c0-12bae14b149a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_793ca676-3e95-4362-b3c0-12bae14b149a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear_1fd56490-0cd4-42c8-9ea5-83e2a80d228a" xlink:href="lly-20201231.xsd#lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_98331c82-458b-412f-95ea-7fff89497871" xlink:to="loc_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear_1fd56490-0cd4-42c8-9ea5-83e2a80d228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2a6dd6d1-cc15-4edd-83fc-938c9eabeb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ada938a-6b25-4c29-8d4f-74759963788b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2a6dd6d1-cc15-4edd-83fc-938c9eabeb4c" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ada938a-6b25-4c29-8d4f-74759963788b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bb28200b-d1fd-4568-a7b4-77a16bf99421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ada938a-6b25-4c29-8d4f-74759963788b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bb28200b-d1fd-4568-a7b4-77a16bf99421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_71512360-316c-4b3a-a1d3-f52c4c57612c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bb28200b-d1fd-4568-a7b4-77a16bf99421" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_71512360-316c-4b3a-a1d3-f52c4c57612c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_808f4aa9-559f-47d2-bddf-66430277d416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_71512360-316c-4b3a-a1d3-f52c4c57612c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_808f4aa9-559f-47d2-bddf-66430277d416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_ffab9e49-d5a8-436a-91af-54daf6c86ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_71512360-316c-4b3a-a1d3-f52c4c57612c" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_ffab9e49-d5a8-436a-91af-54daf6c86ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2ada938a-6b25-4c29-8d4f-74759963788b" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_ab67f2ed-efbb-4628-81b2-b6f907b2040f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_ab67f2ed-efbb-4628-81b2-b6f907b2040f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_4d5e2d2d-40b8-428f-92b6-faf561048663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_4d5e2d2d-40b8-428f-92b6-faf561048663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_0414560c-8a16-4d25-988c-9e960b6b6de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_0414560c-8a16-4d25-988c-9e960b6b6de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_9b4d3be7-6e79-4a3c-9963-2158e4f294e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_9b4d3be7-6e79-4a3c-9963-2158e4f294e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_23ac4973-c6a9-4463-b091-8518a27f5016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_bb399505-3d12-4047-b8d2-83f0dccb5026" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_23ac4973-c6a9-4463-b091-8518a27f5016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c763c5d0-b702-43fd-b152-3b000ac32184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3bb9c622-9031-4dee-ada2-0590922dc45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c763c5d0-b702-43fd-b152-3b000ac32184" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3bb9c622-9031-4dee-ada2-0590922dc45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_d87f17cb-3e34-4502-a1b1-0cf50b8b1980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3bb9c622-9031-4dee-ada2-0590922dc45b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_d87f17cb-3e34-4502-a1b1-0cf50b8b1980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fa6b6a23-e566-45f1-a3db-f04a893fb8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d87f17cb-3e34-4502-a1b1-0cf50b8b1980" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fa6b6a23-e566-45f1-a3db-f04a893fb8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_16ce4632-fc45-44c3-a462-7f27079eacdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fa6b6a23-e566-45f1-a3db-f04a893fb8a7" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_16ce4632-fc45-44c3-a462-7f27079eacdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6ba0cdd6-dab6-4afe-92e6-589827f403ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fa6b6a23-e566-45f1-a3db-f04a893fb8a7" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_6ba0cdd6-dab6-4afe-92e6-589827f403ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3bb9c622-9031-4dee-ada2-0590922dc45b" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_020d5e4a-b86a-4895-aed0-3c02f2341881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_020d5e4a-b86a-4895-aed0-3c02f2341881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_edda9174-8907-4620-be89-56e538026ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_edda9174-8907-4620-be89-56e538026ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c075a7b8-1d2f-47db-8eae-ce39adbd21a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c075a7b8-1d2f-47db-8eae-ce39adbd21a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_3c32fbee-c548-47a2-9bce-be4d19420cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_3c32fbee-c548-47a2-9bce-be4d19420cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_955a1551-18b8-44c2-838f-1d57263e26f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_955a1551-18b8-44c2-838f-1d57263e26f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_bf28bea1-8fe0-4d98-ba8a-a4480f089af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_dd455c9a-3a26-49a5-b525-7cbb7f602468" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_bf28bea1-8fe0-4d98-ba8a-a4480f089af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_71c85809-36e4-435a-b3d1-20fa74bc109e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_71c85809-36e4-435a-b3d1-20fa74bc109e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_bde70d49-b690-48b3-9864-b0ceed9a4df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_71c85809-36e4-435a-b3d1-20fa74bc109e" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_bde70d49-b690-48b3-9864-b0ceed9a4df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_62d1492d-4260-46a1-990e-9a0153e31231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_71c85809-36e4-435a-b3d1-20fa74bc109e" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_62d1492d-4260-46a1-990e-9a0153e31231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_5bada99f-b628-4693-a8c8-4b10fc2225dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_5bada99f-b628-4693-a8c8-4b10fc2225dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_0f5281b9-b19e-4e66-aa5f-7490617ef934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_5bada99f-b628-4693-a8c8-4b10fc2225dd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_0f5281b9-b19e-4e66-aa5f-7490617ef934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d11b16a0-276c-4b59-8527-8c9facf7d8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_5bada99f-b628-4693-a8c8-4b10fc2225dd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d11b16a0-276c-4b59-8527-8c9facf7d8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_79bed6fc-577f-44f3-8eb7-43380c28adf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_79bed6fc-577f-44f3-8eb7-43380c28adf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_91ab4aa8-e654-446a-bf3d-06b96fb2238f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_91ab4aa8-e654-446a-bf3d-06b96fb2238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3852ec39-3499-4446-b208-808c5a50118d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3852ec39-3499-4446-b208-808c5a50118d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_62a1f1b9-2b05-4f2e-a5e6-a8c6aa2e733e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_62a1f1b9-2b05-4f2e-a5e6-a8c6aa2e733e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7559f0d4-311a-4307-a249-13274de292e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7559f0d4-311a-4307-a249-13274de292e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_32908f49-ff8c-4bf9-aae5-093cfdfeb673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_32908f49-ff8c-4bf9-aae5-093cfdfeb673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6c6c238c-fc8e-47b5-823c-f4178d6f5547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_0e64a320-357e-4391-ac93-2fd159e9ecb1" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6c6c238c-fc8e-47b5-823c-f4178d6f5547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_e7f59f6c-e6aa-4a33-8d8c-337931db1b19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_0cd171d3-0f9f-4ecd-a428-49948a0e5826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_0cd171d3-0f9f-4ecd-a428-49948a0e5826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9cb17065-9498-410a-b426-994abadff064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_9cb17065-9498-410a-b426-994abadff064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_dadbc059-1514-4776-8fc7-ffcdf6d4f92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax_dadbc059-1514-4776-8fc7-ffcdf6d4f92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_5c1be3dc-3d75-4333-8c15-fc8302550e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_5c1be3dc-3d75-4333-8c15-fc8302550e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_821e156a-29be-4bc8-831b-79dfa3bfc7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_821e156a-29be-4bc8-831b-79dfa3bfc7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_12ab264d-966f-47d4-b969-16e551a60ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_12ab264d-966f-47d4-b969-16e551a60ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_f46a9f22-b6f6-4ec8-973f-f63e725776d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract_8dbb44b8-c34b-4d61-9eed-faefa98c0c41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_f46a9f22-b6f6-4ec8-973f-f63e725776d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#RetirementBenefitsScheduleofFairValueDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7f9d760-628a-4f6e-9a03-341ac9e3e64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7f9d760-628a-4f6e-9a03-341ac9e3e64f" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_febb02da-a8e4-48c6-93ea-b864ac0e9d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_febb02da-a8e4-48c6-93ea-b864ac0e9d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_febb02da-a8e4-48c6-93ea-b864ac0e9d5b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a964a6de-002d-4f2b-b0a2-98ab99d5727f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a964a6de-002d-4f2b-b0a2-98ab99d5727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_503c6f84-513b-418b-8bc8-35bb81a6628a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_503c6f84-513b-418b-8bc8-35bb81a6628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_57aafad3-4d57-4b4c-afbf-ba8152bf7cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_57aafad3-4d57-4b4c-afbf-ba8152bf7cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_1fa9613e-2cca-4112-99b6-bafd574bcb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_047a2e95-8a7b-43d2-8e51-8925660fc51a" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_1fa9613e-2cca-4112-99b6-bafd574bcb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5b21f99f-5e58-4fae-bd11-ea1218cd8827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5b21f99f-5e58-4fae-bd11-ea1218cd8827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5b21f99f-5e58-4fae-bd11-ea1218cd8827" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_a30696c6-c71a-49f0-a3a7-8eaf8bd28c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_a30696c6-c71a-49f0-a3a7-8eaf8bd28c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_b1372b0d-a45d-4fb2-8542-5a87476aa642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_b1372b0d-a45d-4fb2-8542-5a87476aa642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeFundsMember_4de6ba04-b554-4302-85fa-2f81c6f6025d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FixedIncomeFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_FixedIncomeFundsMember_4de6ba04-b554-4302-85fa-2f81c6f6025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_50b72e5c-8d71-4476-a047-f64b38576cfd" xlink:href="lly-20201231.xsd#lly_FixedIncomeFundsRepurchasedAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_lly_FixedIncomeFundsRepurchasedAgreementsMember_50b72e5c-8d71-4476-a047-f64b38576cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FixedIncomeFundsEmergingMarketsMember_fb5d322c-f123-4d44-8eab-47378c9eefff" xlink:href="lly-20201231.xsd#lly_FixedIncomeFundsEmergingMarketsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_lly_FixedIncomeFundsEmergingMarketsMember_fb5d322c-f123-4d44-8eab-47378c9eefff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_4a6a9435-b02b-47a7-93ad-53985b8392a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_HedgeFundsMember_4a6a9435-b02b-47a7-93ad-53985b8392a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_d77bf397-7c44-4feb-9f26-96b14d017574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_EquityFundsMember_d77bf397-7c44-4feb-9f26-96b14d017574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_cc20082e-cb64-47b6-9cd7-64e9c91ac8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_OtherContractMember_cc20082e-cb64-47b6-9cd7-64e9c91ac8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_471c4ddd-378d-428b-be0c-d804eb714a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_471c4ddd-378d-428b-be0c-d804eb714a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DefineBenefitPlanOtherMember_877c3df7-a3c8-4d20-8db5-d54439f02ae5" xlink:href="lly-20201231.xsd#lly_DefineBenefitPlanOtherMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_f4f529c9-26f0-4e98-8be9-1889a677307b" xlink:to="loc_lly_DefineBenefitPlanOtherMember_877c3df7-a3c8-4d20-8db5-d54439f02ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_ee28453e-ed79-4311-b819-ba996372819d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_ee28453e-ed79-4311-b819-ba996372819d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0eca99ba-2c39-4799-9cd0-3fc3f78ea3e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_ee28453e-ed79-4311-b819-ba996372819d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0eca99ba-2c39-4799-9cd0-3fc3f78ea3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_58d893f8-6d63-4d16-a946-63440eec13c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0eca99ba-2c39-4799-9cd0-3fc3f78ea3e4" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_58d893f8-6d63-4d16-a946-63440eec13c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_9c24c8f7-3eba-4fb3-83f1-55b634561fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPostretirementHealthCoverageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_0eca99ba-2c39-4799-9cd0-3fc3f78ea3e4" xlink:to="loc_us-gaap_DefinedBenefitPostretirementHealthCoverageMember_9c24c8f7-3eba-4fb3-83f1-55b634561fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_35efa5e3-a814-4916-84cd-91c69e5ee547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_62d867bc-cfc6-42be-ac76-50ca7247253b" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_35efa5e3-a814-4916-84cd-91c69e5ee547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1224da3a-9f79-45d8-94bb-faaff18fbc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_35efa5e3-a814-4916-84cd-91c69e5ee547" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1224da3a-9f79-45d8-94bb-faaff18fbc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20201231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4737c858-9ba5-4bc9-be49-ade7c8d1637a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6f43e2b6-7862-4185-ab72-fd2da65b271b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4737c858-9ba5-4bc9-be49-ade7c8d1637a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6f43e2b6-7862-4185-ab72-fd2da65b271b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b5f98a53-d6d1-4050-a2cb-328012245ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b5f98a53-d6d1-4050-a2cb-328012245ca6" xlink:to="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7bef4c30-7a48-4e31-a50d-1e192c378871" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_srt_StatementGeographicalAxis_7bef4c30-7a48-4e31-a50d-1e192c378871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b96c2b9e-4154-4bd1-a47d-182657b7cfe9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7bef4c30-7a48-4e31-a50d-1e192c378871" xlink:to="loc_srt_SegmentGeographicalDomain_b96c2b9e-4154-4bd1-a47d-182657b7cfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_08526be9-6c11-493f-b236-b7db255d9a71" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b96c2b9e-4154-4bd1-a47d-182657b7cfe9" xlink:to="loc_country_BR_08526be9-6c11-493f-b236-b7db255d9a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4c4a48f4-027e-49d7-93e5-935ddc6020c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_srt_LitigationCaseAxis_4c4a48f4-027e-49d7-93e5-935ddc6020c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4c4a48f4-027e-49d7-93e5-935ddc6020c5" xlink:to="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember_ca657c31-212b-45fd-9164-fcde29ee869b" xlink:href="lly-20201231.xsd#lly_DrReddysLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_DrReddysLabMember_ca657c31-212b-45fd-9164-fcde29ee869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_7bdd423e-a621-4c32-bd1e-58cc0072051d" xlink:href="lly-20201231.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_EmgalityPatentLitigationMember_7bdd423e-a621-4c32-bd1e-58cc0072051d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_fc372fb9-cbf4-49ab-a061-15e795bcaa01" xlink:href="lly-20201231.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_fc372fb9-cbf4-49ab-a061-15e795bcaa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember_842b42bf-5987-426b-9ee2-335d4d14fa89" xlink:href="lly-20201231.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_WhyteEtAlVEliLillyEtAlMember_842b42bf-5987-426b-9ee2-335d4d14fa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember_87fb59e0-3e43-4fc7-8c71-a8fae77c7fe6" xlink:href="lly-20201231.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_WeilerVTakedaCanadaIncEtAlMember_87fb59e0-3e43-4fc7-8c71-a8fae77c7fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember_111e560b-446c-492d-a561-885b50ec582f" xlink:href="lly-20201231.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_EppVTakedaCanadaIncEtAlMember_111e560b-446c-492d-a561-885b50ec582f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_6dfe7c0c-cfd5-47b8-98ec-e206ed7f3e48" xlink:href="lly-20201231.xsd#lly_EmployeeLitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_65efbee7-247f-44ba-b9f1-de319fd2a810" xlink:to="loc_lly_EmployeeLitigationMember_6dfe7c0c-cfd5-47b8-98ec-e206ed7f3e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_srt_ProductOrServiceAxis_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_af2f0950-9e1b-4e6b-bfac-0ab28eaa73c4" xlink:to="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember_2137575d-5e5d-4b72-b598-383e0f0604e7" xlink:href="lly-20201231.xsd#lly_ActosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_ActosMember_2137575d-5e5d-4b72-b598-383e0f0604e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_7e8fa4dc-d6e4-418a-a32e-7128a891cdfc" xlink:href="lly-20201231.xsd#lly_ByettaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_ByettaMember_7e8fa4dc-d6e4-418a-a32e-7128a891cdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_4729820c-7476-4bba-86dd-31b2cfe0e42d" xlink:href="lly-20201231.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_CialisMember_4729820c-7476-4bba-86dd-31b2cfe0e42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_5a4b5ce3-d716-47e5-ace9-8fefe1a302ef" xlink:href="lly-20201231.xsd#lly_JardianceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_JardianceMember_5a4b5ce3-d716-47e5-ace9-8fefe1a302ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_7b376fda-a870-4619-b1c5-499d51e977ec" xlink:href="lly-20201231.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_349f46f6-5b8b-4ab6-9a47-7e1ce268e391" xlink:to="loc_lly_HumalogHumulinAndForteoMember_7b376fda-a870-4619-b1c5-499d51e977ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis_2418f0aa-3ec6-449c-bddf-4f89e45a9654" xlink:href="lly-20201231.xsd#lly_DomicileOfLitigationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_lly_DomicileOfLitigationAxis_2418f0aa-3ec6-449c-bddf-4f89e45a9654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:href="lly-20201231.xsd#lly_DomicileOfLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationAxis_2418f0aa-3ec6-449c-bddf-4f89e45a9654" xlink:to="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember_dcf206f6-be4e-4571-af0d-acbe1dea7b0a" xlink:href="lly-20201231.xsd#lly_LosAngelesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:to="loc_lly_LosAngelesMember_dcf206f6-be4e-4571-af0d-acbe1dea7b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember_f62f859c-a617-48f0-9758-216361a85d14" xlink:href="lly-20201231.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:to="loc_lly_SouthernDistrictOfCaliforniaMember_f62f859c-a617-48f0-9758-216361a85d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember_b3b29835-3e77-463c-819f-f73ba5304415" xlink:href="lly-20201231.xsd#lly_VariousStateDomicilesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_31a531f2-2a45-4b0f-bed3-1e3832fe2459" xlink:to="loc_lly_VariousStateDomicilesMember_b3b29835-3e77-463c-819f-f73ba5304415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis_10322fa7-5cea-4bf1-aefe-fec35cfdd20f" xlink:href="lly-20201231.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_lly_PlaintiffAllegationsAxis_10322fa7-5cea-4bf1-aefe-fec35cfdd20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:href="lly-20201231.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsAxis_10322fa7-5cea-4bf1-aefe-fec35cfdd20f" xlink:to="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember_78c593a1-aa76-490a-886f-7e652781743f" xlink:href="lly-20201231.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:to="loc_lly_PancreaticCancerOrThyroidCancerMember_78c593a1-aa76-490a-886f-7e652781743f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember_c9122585-dfc5-4c04-b1f8-101012fb1e16" xlink:href="lly-20201231.xsd#lly_PancreatitisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:to="loc_lly_PancreatitisMember_c9122585-dfc5-4c04-b1f8-101012fb1e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember_3ae6ede8-96ec-4112-93e7-703162352376" xlink:href="lly-20201231.xsd#lly_AmpullaryCancerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_a67a4f75-9feb-4e9f-983b-d51a5f03f828" xlink:to="loc_lly_AmpullaryCancerMember_3ae6ede8-96ec-4112-93e7-703162352376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bfd7a56a-4361-41b1-8802-679f5a933999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bfd7a56a-4361-41b1-8802-679f5a933999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6c632fee-e64b-4e4a-9b6a-4a12ac46fa53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bfd7a56a-4361-41b1-8802-679f5a933999" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6c632fee-e64b-4e4a-9b6a-4a12ac46fa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_e56f8373-1e69-448e-94d4-45393638f8ce" xlink:href="lly-20201231.xsd#lly_ProductLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_6c632fee-e64b-4e4a-9b6a-4a12ac46fa53" xlink:to="loc_lly_ProductLiabilityMember_e56f8373-1e69-448e-94d4-45393638f8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4c028499-d139-414e-a615-8134d408c92c" xlink:to="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_bcd09ec5-74fd-4957-99db-55216c4dd128" xlink:href="lly-20201231.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_bcd09ec5-74fd-4957-99db-55216c4dd128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_ab0e9b63-60bf-4b77-9649-27d1a7d71846" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfPatents_ab0e9b63-60bf-4b77-9649-27d1a7d71846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_70939202-2206-4052-9618-8ccaff39d266" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_70939202-2206-4052-9618-8ccaff39d266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_a0b68841-186a-49ae-bd18-c309601bd6a4" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_a0b68841-186a-49ae-bd18-c309601bd6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_ccaa5759-1606-4b07-8a5b-12046be7aa2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_ccaa5759-1606-4b07-8a5b-12046be7aa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_853d4332-48c5-43f7-9e85-00705a2badd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_853d4332-48c5-43f7-9e85-00705a2badd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants_93e9f1d4-ceb8-4ade-953e-ed9eb0c942f9" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfClaimants_93e9f1d4-ceb8-4ade-953e-ed9eb0c942f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9ec41a88-ada9-40ed-a017-51acaddb8ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_9ec41a88-ada9-40ed-a017-51acaddb8ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfRequestsForInformation_661836ac-a720-4d98-89b5-60665453c8fb" xlink:href="lly-20201231.xsd#lly_LossContingencyNumberOfRequestsForInformation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8269fbf3-9067-42c8-8059-0bea7a454c85" xlink:to="loc_lly_LossContingencyNumberOfRequestsForInformation_661836ac-a720-4d98-89b5-60665453c8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5b4e62ef-52e5-4f05-ad15-b7f453ebeb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_32ca0be9-9de0-42ee-8b95-bbbc3df8b5b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b4e62ef-52e5-4f05-ad15-b7f453ebeb8a" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_32ca0be9-9de0-42ee-8b95-bbbc3df8b5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d6e45b46-aad2-4a43-988a-3a0b347b967e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8b343a51-51df-4e72-8a06-c0636414c2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d6e45b46-aad2-4a43-988a-3a0b347b967e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8b343a51-51df-4e72-8a06-c0636414c2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_439887e9-452f-4713-830c-cd1800bfcd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d6e45b46-aad2-4a43-988a-3a0b347b967e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_439887e9-452f-4713-830c-cd1800bfcd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_05389000-3e36-4198-bf8c-83d0d1dda7c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_05389000-3e36-4198-bf8c-83d0d1dda7c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_679343f1-8c75-4156-aeed-c6c5ae5f6ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_679343f1-8c75-4156-aeed-c6c5ae5f6ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_4eadc59b-e4ac-42dd-b3fc-4a6db42c7d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_679343f1-8c75-4156-aeed-c6c5ae5f6ee0" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_4eadc59b-e4ac-42dd-b3fc-4a6db42c7d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_0550cb34-8900-4048-bd09-04f73aa7e745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_4eadc59b-e4ac-42dd-b3fc-4a6db42c7d92" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_0550cb34-8900-4048-bd09-04f73aa7e745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_e485935e-e5ce-488b-b453-9433ddbbee6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_4eadc59b-e4ac-42dd-b3fc-4a6db42c7d92" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_e485935e-e5ce-488b-b453-9433ddbbee6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e7db5be9-3de3-4aa0-89e1-f3796f254436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e7db5be9-3de3-4aa0-89e1-f3796f254436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6ddac66-abc9-45c7-8ae7-33dfd9f11438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e7db5be9-3de3-4aa0-89e1-f3796f254436" xlink:to="loc_us-gaap_EquityComponentDomain_f6ddac66-abc9-45c7-8ae7-33dfd9f11438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f6ddac66-abc9-45c7-8ae7-33dfd9f11438" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_668d56ac-5367-4961-bfbd-4aaa1e5ca5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_668d56ac-5367-4961-bfbd-4aaa1e5ca5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_897d7f55-db43-4c69-9db8-e450d6a126ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_897d7f55-db43-4c69-9db8-e450d6a126ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e6e0b291-cd44-4fdf-a484-d05e44668be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e6e0b291-cd44-4fdf-a484-d05e44668be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_2f1eeebf-c12e-45ad-ae6b-568fe7784063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_2f1eeebf-c12e-45ad-ae6b-568fe7784063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_454b1f59-7c09-4d68-8fec-8d53768f0427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_454b1f59-7c09-4d68-8fec-8d53768f0427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_994114f9-d9c1-4d59-b7b9-2b8beaad713b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_994114f9-d9c1-4d59-b7b9-2b8beaad713b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_01d6d0f2-0f2c-48fc-9cff-871af550fa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_b863d9cc-4e39-4018-9204-223495e9823b" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_01d6d0f2-0f2c-48fc-9cff-871af550fa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_15db9820-ae97-4111-8757-e16bc06a5da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0d60d0d6-c7ec-4d19-8a7b-23d145e012f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_15db9820-ae97-4111-8757-e16bc06a5da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_15db9820-ae97-4111-8757-e16bc06a5da5" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43995466-64fb-4678-b8c4-6ebeda598a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43995466-64fb-4678-b8c4-6ebeda598a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_52d86b9f-4509-4b46-bc5b-f135ff53c3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_52d86b9f-4509-4b46-bc5b-f135ff53c3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1cd42d7d-66ff-46a9-ba6d-34c4b57b800c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1cd42d7d-66ff-46a9-ba6d-34c4b57b800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6ae19699-69d2-4166-b1bf-e1af9aaa94fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6ae19699-69d2-4166-b1bf-e1af9aaa94fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c6d61da-c0c8-4d94-b642-8170d45e7040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c6d61da-c0c8-4d94-b642-8170d45e7040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c53b17b2-9d71-44ca-b62c-a29a559896bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_338c5974-6655-463d-8b29-91a6b63da8e0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c53b17b2-9d71-44ca-b62c-a29a559896bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e895d94-9f8c-4812-a380-2b55b4254cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_15db9820-ae97-4111-8757-e16bc06a5da5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e895d94-9f8c-4812-a380-2b55b4254cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a4cbc910-48ce-4efc-9cf9-3e2753a5f03b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_30ae7f1f-1df0-4c1d-8a8a-2f8dba01f0df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a4cbc910-48ce-4efc-9cf9-3e2753a5f03b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_30ae7f1f-1df0-4c1d-8a8a-2f8dba01f0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d54892ac-f06b-4a8d-a48b-ec01940a8c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_30ae7f1f-1df0-4c1d-8a8a-2f8dba01f0df" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d54892ac-f06b-4a8d-a48b-ec01940a8c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d54892ac-f06b-4a8d-a48b-ec01940a8c9f" xlink:to="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a7cba686-ab83-4281-b249-a984b1638f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_a7cba686-ab83-4281-b249-a984b1638f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_bee76e2a-0c50-4168-9498-5b201953b077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_bee76e2a-0c50-4168-9498-5b201953b077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_010c1e3c-5abd-4c28-b727-e164a6996c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_010c1e3c-5abd-4c28-b727-e164a6996c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c28d1138-e593-4ff8-8b5b-283eadb8595c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28c19a2d-1755-4ce0-83a7-48f3ce71ba12" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c28d1138-e593-4ff8-8b5b-283eadb8595c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22b6adfb-ac27-4d9b-88f0-ee2b4fe28db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_30ae7f1f-1df0-4c1d-8a8a-2f8dba01f0df" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22b6adfb-ac27-4d9b-88f0-ee2b4fe28db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_42112124-cd7a-4158-b457-637ed24bfbec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22b6adfb-ac27-4d9b-88f0-ee2b4fe28db4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_42112124-cd7a-4158-b457-637ed24bfbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_475683d3-5923-40a0-adbc-00498c4fc559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_475683d3-5923-40a0-adbc-00498c4fc559" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8d39068a-d41e-4798-a56e-31af285f675b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8d39068a-d41e-4798-a56e-31af285f675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f22716f-ccac-40c3-967b-686cf754a8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d39068a-d41e-4798-a56e-31af285f675b" xlink:to="loc_us-gaap_EquityComponentDomain_7f22716f-ccac-40c3-967b-686cf754a8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_58498748-f02a-41a9-b31b-58a6edc803b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f22716f-ccac-40c3-967b-686cf754a8b7" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_58498748-f02a-41a9-b31b-58a6edc803b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_c644efd6-d06d-414a-8ea9-84611ceefebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_58498748-f02a-41a9-b31b-58a6edc803b6" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_c644efd6-d06d-414a-8ea9-84611ceefebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_d454da43-1926-4496-bc4a-73a97b4f1720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_58498748-f02a-41a9-b31b-58a6edc803b6" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_d454da43-1926-4496-bc4a-73a97b4f1720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_37800a97-99b0-4baa-af83-7ee816422b1a" xlink:href="lly-20201231.xsd#lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7f22716f-ccac-40c3-967b-686cf754a8b7" xlink:to="loc_lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember_37800a97-99b0-4baa-af83-7ee816422b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_62df7962-7821-4a27-8f5e-9a1441f894a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_62df7962-7821-4a27-8f5e-9a1441f894a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37ee610f-3bf0-4dda-9428-fb0b8ae45d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_62df7962-7821-4a27-8f5e-9a1441f894a1" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37ee610f-3bf0-4dda-9428-fb0b8ae45d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_eaee1d99-1467-409c-abf7-d5cfe26cd1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_37ee610f-3bf0-4dda-9428-fb0b8ae45d8b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_eaee1d99-1467-409c-abf7-d5cfe26cd1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f3752938-6c7e-4d5e-a5bd-85676860a003" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8c3ca1d5-4d39-46b9-892e-8f7331c2e2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8c3ca1d5-4d39-46b9-892e-8f7331c2e2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a5b7806-8ffe-467e-a6b7-dcf6c9ad705b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a5b7806-8ffe-467e-a6b7-dcf6c9ad705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1c5f1fad-54fe-42ef-8d86-d976ded59290" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1c5f1fad-54fe-42ef-8d86-d976ded59290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_01258777-e216-4747-a5ae-3d604cd418dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_01258777-e216-4747-a5ae-3d604cd418dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a825f83e-4d01-4158-ac93-90a1f4af1229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a825f83e-4d01-4158-ac93-90a1f4af1229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f082b757-5043-45d2-8529-e05a4cacf5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_697d714b-bfc2-4491-96c9-adc32104371f" xlink:to="loc_us-gaap_ProfitLoss_f082b757-5043-45d2-8529-e05a4cacf5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpense"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c13a7374-cdc5-4cb2-bc27-a0efaea26a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2d8d2f86-fa42-49fa-9238-c8d74b67d2d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c13a7374-cdc5-4cb2-bc27-a0efaea26a65" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_2d8d2f86-fa42-49fa-9238-c8d74b67d2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpenseTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2204ec9a-364a-4258-ad48-b578fbd79564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3ddb6ce6-baf3-4aeb-bdf1-97d3dda2c808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2204ec9a-364a-4258-ad48-b578fbd79564" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3ddb6ce6-baf3-4aeb-bdf1-97d3dda2c808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#OtherNetIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7205171f-2dd4-4d73-9255-0068fa204674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fac99868-4021-4fd7-8471-3bd477213a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7205171f-2dd4-4d73-9255-0068fa204674" xlink:to="loc_us-gaap_InterestExpense_fac99868-4021-4fd7-8471-3bd477213a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cb17c988-2e3a-44e9-857f-90a911abe0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7205171f-2dd4-4d73-9255-0068fa204674" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cb17c988-2e3a-44e9-857f-90a911abe0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7640c842-c481-47d3-92a3-43ce6a0819ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7205171f-2dd4-4d73-9255-0068fa204674" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7640c842-c481-47d3-92a3-43ce6a0819ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_286d847f-9c3d-4eca-a6cf-927ea459873c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7205171f-2dd4-4d73-9255-0068fa204674" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_286d847f-9c3d-4eca-a6cf-927ea459873c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_d17ffc7d-fca7-4189-a00b-3903c091f3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7205171f-2dd4-4d73-9255-0068fa204674" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_d17ffc7d-fca7-4189-a00b-3903c091f3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1928778a-fe98-4a87-9588-b9525ca08a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7205171f-2dd4-4d73-9255-0068fa204674" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1928778a-fe98-4a87-9588-b9525ca08a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_84028cef-d3a2-44d7-baa0-e43c450cd6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7205171f-2dd4-4d73-9255-0068fa204674" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_84028cef-d3a2-44d7-baa0-e43c450cd6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c7d95d70-7f22-4cbb-aaf4-c43cbc207079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_4a83d41b-2fd1-4302-a0db-34a557e8a8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c7d95d70-7f22-4cbb-aaf4-c43cbc207079" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_4a83d41b-2fd1-4302-a0db-34a557e8a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0ed902b6-dc6c-494a-9beb-3fde846f7768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_51468d8b-ff45-4898-9af8-07060da2db44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0ed902b6-dc6c-494a-9beb-3fde846f7768" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_51468d8b-ff45-4898-9af8-07060da2db44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_65913972-0e6f-404e-a687-100d4f9e7ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_65913972-0e6f-404e-a687-100d4f9e7ed0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6b1138ac-cb6a-441d-970b-5172219b2ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6b1138ac-cb6a-441d-970b-5172219b2ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c9b848b-be52-496a-b402-cb96ecb06ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6b1138ac-cb6a-441d-970b-5172219b2ae7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c9b848b-be52-496a-b402-cb96ecb06ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_2bee06c3-bdd2-4129-99d3-bcb3e71b460e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6c9b848b-be52-496a-b402-cb96ecb06ce4" xlink:to="loc_us-gaap_IPOMember_2bee06c3-bdd2-4129-99d3-bcb3e71b460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ff10821f-c8d7-4206-ba3c-27cdc4dec61f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_dei_LegalEntityAxis_ff10821f-c8d7-4206-ba3c-27cdc4dec61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_30efe76f-e885-4ee1-9fee-de7aff4312b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ff10821f-c8d7-4206-ba3c-27cdc4dec61f" xlink:to="loc_dei_EntityDomain_30efe76f-e885-4ee1-9fee-de7aff4312b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_c95e3978-d578-41a8-8d74-493b7f3e2a83" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_30efe76f-e885-4ee1-9fee-de7aff4312b1" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_c95e3978-d578-41a8-8d74-493b7f3e2a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a2e00fa7-f376-4e25-94c4-517057b3fa32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a2e00fa7-f376-4e25-94c4-517057b3fa32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_373f0877-a90e-4be4-ae24-50d870117be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a2e00fa7-f376-4e25-94c4-517057b3fa32" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_373f0877-a90e-4be4-ae24-50d870117be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TermFacilityMember_81101154-f63e-490d-89fc-6ec5e46f3ffc" xlink:href="lly-20201231.xsd#lly_TermFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_373f0877-a90e-4be4-ae24-50d870117be3" xlink:to="loc_lly_TermFacilityMember_81101154-f63e-490d-89fc-6ec5e46f3ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_85866dd9-ec47-4fdd-be0f-8861a608b5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_85866dd9-ec47-4fdd-be0f-8861a608b5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a113d75-1ea8-4b30-9b33-19a29d513f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_85866dd9-ec47-4fdd-be0f-8861a608b5b3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a113d75-1ea8-4b30-9b33-19a29d513f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_ed1fcb4a-84c4-47a2-bbc7-afb3bc0d94af" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9a113d75-1ea8-4b30-9b33-19a29d513f66" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_ed1fcb4a-84c4-47a2-bbc7-afb3bc0d94af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6753f8b0-ce25-4d27-85df-f178918c94d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6753f8b0-ce25-4d27-85df-f178918c94d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c7ab893d-d0fe-4524-bdac-83db8437429e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6753f8b0-ce25-4d27-85df-f178918c94d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c7ab893d-d0fe-4524-bdac-83db8437429e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e25bb7de-5cd4-45ce-bd1b-abf7d9d17152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c7ab893d-d0fe-4524-bdac-83db8437429e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e25bb7de-5cd4-45ce-bd1b-abf7d9d17152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_srt_OwnershipAxis_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_00c5f62b-a58c-4b0d-ad96-a04657cd3c0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_ee7e7acb-24d2-4ee1-acb3-15a4a592dbd3" xlink:to="loc_srt_OwnershipDomain_00c5f62b-a58c-4b0d-ad96-a04657cd3c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EliLillyAndCompanyMember_e34a9b6f-366a-472f-b6d1-7f0bfdda1485" xlink:href="lly-20201231.xsd#lly_EliLillyAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_00c5f62b-a58c-4b0d-ad96-a04657cd3c0a" xlink:to="loc_lly_EliLillyAndCompanyMember_e34a9b6f-366a-472f-b6d1-7f0bfdda1485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d3d3be74-cdfc-4b3c-b281-7e4e68131dcc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_139c2975-0195-4eda-bd01-d222f46f1800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_139c2975-0195-4eda-bd01-d222f46f1800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SaleOfStockPercentageOfStockSold_909715c3-47dd-430f-ae65-e0f954d1df25" xlink:href="lly-20201231.xsd#lly_SaleOfStockPercentageOfStockSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_lly_SaleOfStockPercentageOfStockSold_909715c3-47dd-430f-ae65-e0f954d1df25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_db791345-5630-458b-9b31-6b596d5fadbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_db791345-5630-458b-9b31-6b596d5fadbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_e8d60803-03ea-47b1-af24-d59911a4a576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_e8d60803-03ea-47b1-af24-d59911a4a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_8d75786e-7670-4b72-917c-f86942d3ba8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_8d75786e-7670-4b72-917c-f86942d3ba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4c951ea5-d8a5-4982-9762-1fee4f030645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4c951ea5-d8a5-4982-9762-1fee4f030645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_90002d94-b150-4d71-a143-5f5b6024ad02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_DebtInstrumentTerm_90002d94-b150-4d71-a143-5f5b6024ad02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dca63257-edd1-4766-9c32-fa44d37a0e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dca63257-edd1-4766-9c32-fa44d37a0e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_82f16d0d-36e6-4f8a-97d7-ed3f9a599412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_82f16d0d-36e6-4f8a-97d7-ed3f9a599412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_4d0607e8-f83e-4ce6-948c-02ba03659882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_4d0607e8-f83e-4ce6-948c-02ba03659882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_9687c3f2-6043-4aa2-b896-550ffc1ed717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_9687c3f2-6043-4aa2-b896-550ffc1ed717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_a1872649-a1eb-4b64-b730-83f10c90a55a" xlink:href="lly-20201231.xsd#lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_54bc4525-80e3-4750-8d36-173d7e4ff292" xlink:to="loc_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm_a1872649-a1eb-4b64-b730-83f10c90a55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lly-20201231.xsd#DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9bad7cb5-66f8-49b2-8fd1-33a868fd3b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9bad7cb5-66f8-49b2-8fd1-33a868fd3b32" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_47343ab7-7a60-4a0b-8f58-6f90ac1987cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_47343ab7-7a60-4a0b-8f58-6f90ac1987cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbf4d138-73dd-40e3-91f6-917d578ec28a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_47343ab7-7a60-4a0b-8f58-6f90ac1987cd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbf4d138-73dd-40e3-91f6-917d578ec28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ElancoAnimalHealthIncorporatedMember_7c1ee6dc-443a-46cf-9062-96b0ab8ba520" xlink:href="lly-20201231.xsd#lly_ElancoAnimalHealthIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbf4d138-73dd-40e3-91f6-917d578ec28a" xlink:to="loc_lly_ElancoAnimalHealthIncorporatedMember_7c1ee6dc-443a-46cf-9062-96b0ab8ba520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f43061c9-04fb-4342-90bf-610f540631d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f43061c9-04fb-4342-90bf-610f540631d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_57cc07c1-37cb-4a1e-b6ec-2a5dc5812724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f43061c9-04fb-4342-90bf-610f540631d3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_57cc07c1-37cb-4a1e-b6ec-2a5dc5812724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_a7f3d211-ab95-4ec9-aa83-1903279df0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_57cc07c1-37cb-4a1e-b6ec-2a5dc5812724" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_a7f3d211-ab95-4ec9-aa83-1903279df0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bb2c025b-aab6-4e90-811b-9d55905c265b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_50c1ef73-8410-4686-9873-1bdcebf577d9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bb2c025b-aab6-4e90-811b-9d55905c265b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aa077792-9070-4487-b08e-e0ca4edacca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bb2c025b-aab6-4e90-811b-9d55905c265b" xlink:to="loc_us-gaap_Revenues_aa077792-9070-4487-b08e-e0ca4edacca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c16cfa01-e5f8-435f-890a-5710334691f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bb2c025b-aab6-4e90-811b-9d55905c265b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c16cfa01-e5f8-435f-890a-5710334691f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image1a.jpg
<TEXT>
begin 644 image1a.jpg
MB5!.1PT*&@H    -24A$4@   J0   #)" 8   #ULR $   @ $E$051X >V=
MK=/$.A6'5R!0# +!#.;**Y%,%1)Y)?*J#O)*_@/L.B02B5LD$HF\8@42B426
M.4E.<I(FV>Z^W8^VSSOSSK;Y.#EYDJ:_IFE[FOB#  0@  $(0  "$(# &PF<
MWE@V14,  A"   0@  $(0&!"D-()(  !"$   A"   3>2@!!^E;\% X!"$
M A"   0@@""E#T   A"   0@  $(O)4 @O2M^"D< A"   0@  $(0 !!2A^
M  0@  $(0  "$'@K 03I6_%3. 0@  $(0  "$(  @I0^  $(0  "$(  !"#P
M5@((TK?BIW (0  "$(  !"   00I?0 "$(  !"   0A X*T$$*1OQ4_A$(
M!"   0A   ((4OH !"   0A   (0@,!;"2!(WXJ?PB$  0A   (0@  $$*3T
M 0A   (0@  $( "!MQ) D+X5/X5#  (0@  $(  !"*PB2$^GT\0_#.@#] 'Z
M 'V /D ?H \<JP^L):57$Z1K.80="$   A"   0@ ('/)R 7'VO]K6)I38?6
MJAAV(  !"$   A"   2>1V!-_8<@?5X[81D"$(  !"   0CLE@""=+=-2\4@
M  $(0  "$(# -@@@2+?13G@) 0A   (0@  $=DL 0;K;IJ5B$(  !"   0A
M8!L$$*3;:">\A  $(  !"$   KLE@"#=;=-2,0A   (0@  $(+ - @C2;;03
M7D(  A"   0@ ('=$D"0[K9IJ1@$(  !"$   A#8!@$$Z3;:"2\A  $(0  "
M$(# ;@D@2'?;M%0, A"   0@  $(;(, @G0;[827$(  !"   0A 8+<$$*2[
M;5HJ!@$(0  "$(  !+9! $&ZC7;"2PA   (0@  $(+!; @C2W38M%8, !"
M 0A   +;(( @W48[X24$(  !"$   A#8+0$$Z6Z;EHI!  (0@  $( "!;1!
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M/WN9/ME:OD=3[=7%BPJR)&"][:M]AZ@(F]Y[2.WRC"@^37DQ+(G%)+Q,F)N
M-)^6=>\N+?W7_8)/3>"&&>/$QK^'-'N=JCP\= X/&3D!5_++6>O3ZB4O3:4\
MJ[?M,T&?^FV6]BX&AK$Z$'YY#VD!A%T(0  "$' $UM1_'R=(:6,(0  "$(
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M( "!@Q XMB#]<B.+B+0"]<L&,? " O??=@\7"_*@FWMY=SZ[&B>Y7^ [14
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M2)>U$:D@  $(0  "$(  !)Y$ $'Z)+"8A0 $(  !"$   A!81@!!NHP3J2
M 0A   (0@  $GD0 0?HDL)B%  0@  $(0  "$%A& $&ZC!.I(  !"$   A"
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M3V^]V_X@(G30M:;Q2SM^QC7.GAJA&BR%3^_Y=W_:!YAJ9=CRV(8 !"   0A
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M^Q87;+%<.ZXWV\BPD<*-;_9"Y=X^E5]T^5HE&Z%/]MHB@=C]%H)T]TU,!2$
M@:\3Z)WDOV@].QE]T=;6LA^Y[EMKJRWX2W_:0BLU?420-M$0 0$(0,#,E.AT
MS]I0CGP2/7+=U^Y'1[>G,YK/.DZ/SO<%]4>0O@ R14   A"   0@  $(M D@
M2-MLB($ !"   0A   (0> $!!.D+(%,$!"   0A   (0@$"; (*TS888"$
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MVTM)' 0@  $(0.!=!-;4?PC2=[4BY4(  A"   0@ ($-$T"0;KCQ<!T"$(
M!"   0CL@0""= ^M2!T@  $(0  "$(# A@D@2#?<>+@. 0A   (0@  $]D
M0;J'5J0.$(  !"   0A 8,,$$*0;;CQ<AP $(  !"$   GL@@"#=0RM2!PA
M  (0@  $(+!A @C2#3<>KD,  A"   0@ ($]$$"0[J$5J0,$(  !"$   A#8
M, $$Z88;#]<A  $(0  "$(# '@@@2/?0BM0! A"   0@  $(;)@ @G3#C8?K
M$(  !"   0A 8 \$$*1[:$7J  $(0  "$(  !#9, $&ZX<;#=0A   (0@  $
M(+ ' A\I2,4I_F% 'Z /T ?H _0!^@!]X#A]8"UA?5K+$'8@  $(0  "$(
M!(Y#0"X\UOI;S]):'F$' A"   0@  $(0.!0!!"DAVIN*@L!"$   A"   0^
MCP""]//:!(\@  $(0  "$(# H0@@2 _5W%06 A"   0@  $(?!X!!.GGM0D>
M00 "$(  !"  @4,10) >JKFI+ 0@  $(0  "$/@\ @C2SVL3/(( !"   0A
M  *'(H @/51S4UD(0  "$(  !"#P>000I)_7)G@$ 0A   (0@  $#D4 07JH
MYJ:R$(  !"   0A X/,(($@_KTWP" (0@  $(  !"!R* (+T4,U-92$  0A
M  (0@,#G$4"0?EZ;X!$$(  !"$   A X% $$Z:&:F\I"  (0@  $( "!SR.
M(/V\-L$C"$   A"   0@<"@""-)#-3>5A0 $(  !"$   I]'X/];"-L<RA7:
-U@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>lly-20201231_g1.jpg
<TEXT>
begin 644 lly-20201231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#;P]XDOI+IUU.#Q#K#6:0Q;?E9&4'<2W&/2O*O^%H_\%5/^C6?AE_X7$O\
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MK7ARWT_6="U"Q@FGEAF,!/G1,L!7+LV3*A7R]CJ_R=_P;Y_L^_\ !:CXA?\
M!-'PYXF_8H_X* _#SX?> 9/$6KI8>&?$7PXAU*ZAG6Z83.T[Q,6#OE@,\ XK
M]"/V)_\ @D1\;O 7[9:_\%&/^"BG[9]Q\</B[IGAV71/!?V/PO#HVD>%K24.
MLPMX(CAY&225-^V/Y9I-RNS!U /=/VL/^"H__!/G]AOQ)9^#/VK/VKO"G@_6
M[Z%9K?1+RZ>>]$3'"RO;VZ221QD@X=U"G:<'@X]1^"?QU^#/[2/PXL/B_P#
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MWN;*)H(U:1FE@CDE4*I^1&8X )J]\9?^"CO["G[/?P4\.?M%?&?]J;P?X?\
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MVX_^-T?\-#_\'''_ $CJ_9__ /#NW'_QN@#[^HKX!_X:'_X../\ I'5^S_\
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M=\/?&FI^!?B=;:='LMVUG3F0231K_"LD4L,A4 *'9U4 **PO^#=O7-&\0?\
M!%GX 7VA.C0Q>$I[:3RVR!-#?W44P^OF(^1V->3_ /!N>/[<U?\ ;2^(^BG.
M@:_^V?XPDT1T4>7(@>-RZ'N"LL8]/E^M 'Z54444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT_\ 8A^'.O>=X1^#6[^WOL\N8[SQ).@\_..&^S1%8!W61[E>]?T_5\(>+/\
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M+GAO]E?X*F\GTK08Y9;S5M3D#WFK7TTAEN+RX8 !I))&)P.%4*@^50*]BHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
MV**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:LZ
MV\-V,OB2YTEKFZ\J*W1U(NFSDGGO0!U-%8__  @^D?\ /S>_^!;4?\(/I'_/
MS>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_
M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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MYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
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M];BTV?7?#+2&:!K.XF/EB>WE+-AR2X6( -M*G] Z* /S@^$7P*_;@_X*.?\
M!2[X<?MW_ME_LMR_!/X:_ /2-4'PR\":[XBM=1UC7-;U")89[^Y%JQ2WAC1$
M*(QW;X8R-RNVW]'Z** "BBB@#P7]KG_DN'P,_P"Q[E_]$5[U7@O[7/\ R7#X
M&?\ 8]R_^B*]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Q[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#8HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK-\8_P#(L7O_ %P-:59OC'_D6+W_ *X&@"YIW_(/@_ZXK_(5-4.G?\@^#_KB
MO\A4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]'_Z_3_Z":V* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?P/_R")?\
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M&?\ 8]R_^B*]ZKP7]KG_ )+A\#/^Q[E_]$5[U0 4444 %%%% !1110 4444
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MGEG.3UY5L/3M[2,TN>";MS)Q24HW:YO=3COJKM?I'1117V9_,H4444 %%%%
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MW#]A\-ZI*MG>7MHR3!X)[>*95+[0 C %6YUO^"&/[:'AO]F'_@G%^T'XY_:
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M\@^#_KBO\A4U85EX+TJ6SBE:YO,M$I.+IL=*E_X0?2/^?F]_\"VH V**Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M#X&?]CW+_P"B*]ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Q[+_D=[W_KRB_F:V*Q[+_D=[W_ *\HOYF@#8HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K-\8_\BQ>_]<#6E6;XQ_Y%B]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#X/\
MKBO\A4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &/XE_P"0OH__ %^G_P!!-;%8_B7_ )"^C_\ 7Z?_ $$UL4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %8_@?_D$2_P#7[-_Z%6Q6/X'_ .01+_U^S?\ H5 &Q1110 4444 %%%%
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MLU7H\9?!O]FKP]INLVUW(+36;M);^\ML' ,4]V\LD1QQE&!/.>M?1%8_@?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_P#K]/\
MZ":V*Q_$O_(7T?\ Z_3_ .@FMB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K'\#_P#((E_Z_9O_ $*MBL?P/_R"
M)?\ K]F_]"H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "ODG]KS]MKXG^*?BK)^PE_P3\L[37/BO=0@^*O%,ZB32OA_9/PUU=L
M,JUU@YCM\$YP64\(^9^T[^V!\8_VC?BYJ'[!W_!.?4X?^$DLR(OB?\6FC,FG
M>!K=LAH8F'$^HL P5%/R,",AE=H?=OV1?V/_ (._L7?"J/X8?"73)G>>8W?B
M#Q!J4GFZAKE\W,EW=3$9DD8D^R@X4 5Y=2M5QU1T<.[06DIK\8Q\^\NFRUV^
M]P>78'A3"PS#-Z:J8B:4J.'ELD]8U:ZZ0ZPI:.II*5J=O:9G[%O[$GPP_8N\
M W6B^&+RZU[Q3K]R;_QQX[UIO,U+Q#?MDO/,[$D)N+%(@2$#'EF9W;V:BBN^
MC1I8>DJ=-6BMD?'YEF6.S?'3QF,J.=2;NY/=_HDEHDK)))))(****U.(Q_ _
M_((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\ 0JV* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#P7]KG_DN'P,_['N7_ -$5[U7@O[7/
M_)</@9_V/<O_ *(KWJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K'LO^1WO?^O*+^9K8K'LO^1WO?\ KRB_F: -
MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "LWQC_R+%[_UP-:59OC'_D6+W_K@: +FG?\ (/@_ZXK_ "%35#IW_(/@
M_P"N*_R%34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?I_\ 036Q
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MQ_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\#_ /((E_Z_9O\
MT*MBL?P/_P @B7_K]F_]"H V**** "BBB@ HHHH **** "BBB@ HHHH ***Y
M#X[_ !Y^$_[-'PLU7XS_ !L\96NA>'=&@\R\O;DDEB>%CC09:21CA51068G
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M*]ZH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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MO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\
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M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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M:;LC_:7_ &P?AA^R/\*;WXQ_'%+C2])M2(K>(.C7%_<L#Y=M;QY!EF?!PH[
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M_P#!$/X6:-\3[3]JK_@H7\6-8_:7^,T6)+?Q'X_@3^Q=!8D-Y>E:0,VUJBL
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M47\S0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5F^,?^18O?^N!K2K-\8_\BQ>_]<#0!<T[_D'P?]<5_D*FJ'3O
M^0?!_P!<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]'_Z_3_Z":V*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L?P/_R")?\ K]F_]"K8K'\#_P#((E_Z_9O_ $*@#8HHHH **** "BBB
M@ HHHH ***\%_;>_;L\)_LCZ1I?@[PUX7N?&OQ1\82&V\ ?#?1VW7FJS]/-D
MP#Y%LG)>5L#"MC)!QE7KTL-2=2H[)?U\V^BW9Z&5Y5C\ZQT,'@H.=26RVT6K
M;;LHQBKN4FU&*3;:2N:?[:?[;OPQ_8N\!VFK^)+&[\0>*_$%Q]A\#> M$7S-
M2\0WS$!888P"0@9EWRX(0,.&9D1O,?V0?V(OB=X@^*B_MU_\% ;ZSU[XMWD!
M7PSX:MV\S2O %DV2+2S7+*UQ@_O+C).<A6;YI'T_V+/V$_%G@?QW=_MB?ME^
M*+;QI\<O$-OLFOXQNT_PG:$'&FZ6AXB158J\@^9R6Y^9VD^HJX*5"KC*BKXE
M62UC#M_>EWEV6T?74^JQ^:X#AS!SRO)IJ=2:Y:^(7VUUI4;ZQH])2TE6Z\M/
MW64445ZA\*%%%% !117R!^V9_P %G_V9OV8?B&O[-?PBT'7/C?\ &^[+1Z=\
M(?A9!]OOXI!P3?S(&BTZ-<@NTIWHAW^65!- 'UY<7%O9V\EW=SI%%$A>661@
MJHH&223P !WKX/\ CM_P6]\.>+OB1??LO?\ !*?X(ZA^TM\4K5_)U*[\-W(A
M\(^&F)QYNHZPW[G /(CB9MY5D\Q'P*Y*V_X)P_\ !0C_ (*?3IXL_P""O_QS
M/@7X;W#"6V_9B^#>L206L\741:YJR'S+UL8WQ0MY6X!D>,Y6OO#X%?L^_!#]
MF+X;6/P?_9Z^%6A>#?#.FKBTT;P_IR6T*M@ R,%&7D;&6D8EV/+$GF@#XD\
M_P#!&+XH_M8^,M/^//\ P6R_:);XQZS9W N]%^#7ACS=/\ ^'9.H"VORR:E(
MO3S;C&Y25=91@U]^>%_"WAGP1X=LO"'@OPY8:1I.FVR6^G:7I=FEO;VL*C"Q
MQQQ@*B@<!5  J_10 4444 %%%% &/X'_ .01+_U^S?\ H5;%8_@?_D$2_P#7
M[-_Z%6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >"_M<_\EP^!G_8]R_^B*]ZKP7]KG_DN'P,_P"Q[E_]$5[U0 4444 %%%%
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M7_T17O5>"_M<_P#)</@9_P!CW+_Z(KWJ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'LO\ D=[W_KRB_F:V*Q[+
M_D=[W_KRB_F: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "LWQC_ ,BQ>_\ 7 UI5F^,?^18O?\ K@: +FG?\@^#
M_KBO\A4U0Z=_R#X/^N*_R%34 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 8_B7_D+Z/\ ]?I_]!-;%8_B7_D+Z/\
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M5    & !4] !1110 4444 %%%% !1110 4444 %%%% &/X'_ .01+_U^S?\
MH5;%8_@?_D$2_P#7[-_Z%6Q0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >"_M<_\EP^!G_8]R_^B*]ZKP7]KG_DN'P,_P"Q[E_]
M$5[U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5CV7_([WO_ %Y1?S-;%8]E_P CO>_]>47\S0!L4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^,?^18
MO?\ K@:TJS?&/_(L7O\ UP- %S3O^0?!_P!<5_D*FJ'3O^0?!_UQ7^0J:@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?P/\ \@B7_K]F
M_P#0JV*Q_ __ "")?^OV;_T*@#8HHHH **222.&-I99%5%4EF8X  ZDFOACX
MK?'OXO\ _!4'XAZK^RQ^Q)XNN_#GPET>[:R^*OQNT_(:_(QYND:*Y&'<@X>X
M&5"MD':5\_EQ6+AAHI6YI2TC%;M_HEU;T2/?R'A_$9Y5G+F5*A27-5JROR4X
M^=M7*6T(1O*<M$MVM'X_?M3_ !G_ &W_ (K:K^Q+_P $[_$YTS3M*F^R_%KX
MXVZ^9:^'D/WK#3F! GOF&Y2RG]WS@@@R1_27[+G[+'P8_8\^$=C\&?@?X8%A
MIEJ3)=74S>9=:C<M_K+JYEQF65SU8\  *H5551I_ +X ?"3]F'X4Z5\%O@CX
M.MM#\/:/#LMK2W&6D8_?EE<_-+*YY9V)+'K795EA<).-3V]=WJ/[HK^6/EW>
M\GOT2[<\X@P];"+*LJ@Z6#@[V=N>K-:>TK-:.6_)!>Y33M&[<IS**^8OVY_^
M"M_['_[!VJ6OPW\;>)-1\8?$[6-L?AKX0?#VP.K>)-5F<9C1;6(_N%8<AYBB
ML =NXC%?//\ PS#_ ,%9/^"L0&I_MQ_$>Z_9A^"E]\R?!3X9:NLWBK7+8]$U
M?5P-MLK*<-! /F5BDD:,NZN\^3/4/VL?^"V7P)^$GQ/F_97_ &0OA]K?[1?Q
MQ.Y$^''PS99H=,<':7U34L-;Z?&K<.6+O&<;T4'=7F^D?\$J/VR/^"BVIV_Q
M%_X+6_M"B7PO]H6YTW]F;X2ZA-8>&K7!#(NJ7B,+C4Y!QD!@J."4D*-MK[+_
M &3OV+OV6OV&OAC#\(/V4O@IHG@O0TVFXBTNW_?WLBC EN;ARTMS+CCS)79L
M<9QQ7J% '._"GX1_"WX%^ =.^%GP8^'>B^%?#>DP^5INA>']-CM+6V3T2.,!
M02>2<9)))R371444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/X'_Y
M!$O_ %^S?^A5L5C^!_\ D$2_]?LW_H5;% !1110 4444 %%%% !1110 445G
M^+/%&A>!_"NI^-?%%^MKIFCZ?->ZC=."1#!$ADD<XYP%4G\* -"BOQJL?^"I
MO_!<+]M7Q)\(/VA_V*_A5\'O!7PW^)?B_P 26?PJ\'>/;F]GU+Q=;:;I>H3/
M)JDL+".V1_L<OD+$8RMPJ;W:#]X_Z)?\$R/VX]0_X* _LC:3^T'XL^#^J_#_
M ,0QWUUI7BWPIK$3J=/U&V8+-Y3R*IDA8%71\='VGE30!]!T5^??C?\ X+Y?
M G7O^"J/PI_X)I?LM2:1X\?Q/K&H6?Q"\9V=VTECH\D%C-.EI:2QG9<W :,>
M:02D08+DN6$?T+^WC\:_V_/@UI/ANY_80_8HTCXS7=_<W*^)+;5?B':>'QI4
M:+&875KGB;S"T@(7[OEC/44 >_T5^37[2O\ P6\_X+$?LD:[X'\)?'#_ ((W
M^%+'6_B3XC30O V@:;\>+'4+_6+UL96*WM8I)-B[DWRL!&F]-S+N&?I[_@IS
M_P %)OCQ^Q3K?P1^#O[/G[+=A\3OBA\;->O=.T;P?=>+DTN./[):)/<N+EXV
M0A#*@)8JN"3GM0!]CT5\:?LH_M5_\%D_B3\?= \%?M6?\$IO#?PU\ WOVK^W
MO&MA\:]-U>;3MEK-)!MM(?GE\R=883C[HE+'A37V70 4444 >"_M<_\ )</@
M9_V/<O\ Z(KWJO!?VN?^2X? S_L>Y?\ T17O5 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/9?\CO>_]>47\S6Q
M6/9?\CO>_P#7E%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %9OC'_D6+W_K@:TJS?&/_ "+%[_UP- %S3O\
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M[06MR>'/#GBZ\\&VNC:UX9U[Y!#$Z6GR30RO+$N69C@N1Y?E;9?U#K\T=(^
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M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
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M6EIW_(/@_P"N*_R%34 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
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MW+_Z(KWJO!?VN?\ DN'P,_['N7_T17O5 !1110 4444 %%%% !1110 4444
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M%%% !1110 4444 %%%% !1110 4444 8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\
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MY\%MK]]XNTR+5;F.0-"UK+?31PS,75=B$YD. JMTKV7]N;P5HW_!2S_@NO\
M#[_@FU\;!<:G\&_A7\&Y_B=XN\&_:I(;3Q%J\E\ME:QW81E,L<(EMY%4G!W3
M*059@0#]*/ WQ$^'_P 3]"7Q3\-?'.C^(=,>0QKJ.AZG%=P%QU421,RY&1D9
M[UL5^4WQ5^ ?PJ_X(_?\%G/V;?$W[&?A*/P5\//VE)-8\%_$[P!HCO'I,M];
MPQ2:=?PV^2D,PEG"DH  D;@ >=(3^K- !1110!X+^US_ ,EP^!G_ &/<O_HB
MO>J\%_:Y_P"2X? S_L>Y?_1%>]4 %%%% !1110 4444 %%%% !1110 4444
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M-P3ZWNOGHK?B?L/%/T7.)<FRJ>,RS%QQ4H*[I\CIR:6_)[TU)^3Y6^EW9/\
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M6UMH@D<,:@*J*JX"J   !P *FH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
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MYF'[!]E^R_9O^G>;?N^T?[.-G?/ !],UC^!_^01+_P!?LW_H5?G+_P 1%?\
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M?^O*+^9K8K'LO^1WO?\ KRB_F: -BBBB@ HHHH **** "BBB@ HHHH ****
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MK/VK]JWX?OM'/V;Q7:S=L_\ +-VS4.G?\$_OV(M+Q]F_96\"MC_GY\.P3?\
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MT_M+QZT^WZ^2G/I^-?3-% 'S-_:__!8#4N;+PC^SYI@/;4;_ %F8C_OT/P_
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MO^N'@/QII'B8#_=-N8]]?H!10!^?X_X.&?@?X:R/C=_P3Z_:Z^'(CXGG\8?
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M^U#4Q/\ :/M>_KYOG?O-W][FOZ6OV4?B)^WC_P '*'P5TGQ9\1O'UO\  _\
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MC_O?W:,#T94!'K7O%% "(B1H(XT"JHPJ@8 'I2T44 %%%% !1110 5C^!_\
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MBV[O7U2(1/:QJDF>"03D4 =-16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
M"8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/A
MC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#4'_?
M5 &E17E_[0W[:W[)G[)W@E_B+^TC^T%X8\&:0H;R[G7=36)KA@,E(8_]9._^
MQ&K,?2OB[4/^"SO[5G[:ERWAK_@D#^P_?Z]HT[%$^.?QO\WP_P"%8UZ">VMN
M+S44Z?ZL(ZGJA'- 'Z+ZYKFB>&='N?$/B36+73]/LH&FO+Z^N%BA@C499W=B
M%50.220!7PU\7?\ @OE^SI?^.;OX%_\ !//X3>+_ -J7XC6[>7+I/PIM-^B6
M#DX5KW6I!]E@A)X\U/-4'@XKD=#_ ."-%Q^U#JUM\0/^"Q?[=WBGX]7L<ZW,
M/PUT6X?P]X)T^0'*JMA:%'NF0@ 32,A<#YT;)K[D^$7@?]GGX >!K3X9? WP
M3X9\'^';!<6FB>&M*BLK6+U(CB55W''+8R3R2: /B-OV*_\ @LA_P4';[;^W
MQ^V/:_L_^ +OE_A#^SK<'^UYX3_RROM>F#,KXRKK;AX9 >BU]-_L8_\ !,7]
MA?\ 8 TIK7]EO]GC1-!U.>,KJ'BFXC:\UF_+<N9K^X+SN&.6*;P@).%'2O:/
M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0
M:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#
M_OJC_A,?#'_0:@_[ZH TJS?&/_(L7O\ UP-'_"8^&/\ H-0?]]5G^*/%'A^\
M\/W=K:ZK$\CQ$(BGDF@#<T[_ )!\'_7%?Y"IJR+'Q=X:CLH8WUF$,L2@@GH<
M5+_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O
M_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_
MZ#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!
M_P!]5Y9^U9^WE^SC^Q[X%3Q?\4O%S3WM])Y'A[POHT)N=4UNY. L%K .78L5
M!8X12PW,,C.=6K2H4W4J.T5NV=F R_'9KC(83!TW4J3=HQBKMOT_%]EJ]#U3
MQ?XP\*?#_P ,7WC7QSXDL='T?2[9KC4=4U.Z2"WMHE&6>21R%51ZDU\3:O\
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MG6(R]H-3\A_LOGJK*6B\[9N 925SR.M=#10!^)'A[_@N_P# 3QIXJ_9IU?\
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M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
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M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A61X+LK.72I&EM(F/VR49:,'C=6[6/X'_ .01+_U^S?\ H5 &
ME_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\
M\^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C
M#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U%
M$/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_
M -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!
M#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\
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M0BW&%7H0F9(W^V=&T;1_#ND6N@>']*MK"PLK=(+*RLX%BAMXD 58T10%10
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M4?\ #1/_  4G\2_\BU_P3VT?0XV'[NX\2?%&TES[F.!-R_3K0!]-45\REO\
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M2=QQG'%WQ^-3?\.=_P#@HW_T;K_Y=VD?_)=?MGXE_P"0OH__ %^G_P!!-;%
M'AG_  39^#OQ'^ /[%?@OX2?%OP[_9/B'2?[1_M#3_MD,_E>;J5U-'^\A=T;
M,<B-PQQG!P00/<Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Q_ _\ R")?^OV;_P!"K8K'\#_\@B7_ *_9O_0J -BB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#'\#_ /((E_Z_9O\ T*MBL?P/_P @B7_K]F_]"K8H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!?VN?^2X? S_L>Y?_
M $17O5>"_M<_\EP^!G_8]R_^B*]ZH **** "BBB@ HHHH **** "BBB@ HHH
MH ***1F5%+NP  R23P!0 M%> _'K_@JE_P $WOV8O.@^.7[;OPUT*\M\^=I+
M>*[>XOUQ_P!.D#/.?P2OGJ7_ (.*?V8?B7*UC^Q'^RM^T'^T!,[%;:_^''PG
MO$TW<.\MU?>1Y2?[>P_2@#] Z*_/O_AK+_@X*_:!RGP*_P""8GPM^#5C-Q:Z
MU\<_BD=4D9#_ ,M&LM'42PL/[CDGCO0?^"=?_!9CX]'SOVI_^"TUSX1T^;/G
M^%O@)\-K32O*SU\O5+@M=>PRAQC/7- 'WOXA\2>'?".CS>(?%FOV6EZ?;+NN
M+[4;I((8AZL[D*H^IKY7^.O_  7:_P""1?[.TTECX_\ V[_ U[?1L4_LWP?>
MOK]R9>@B,>F).5<GC#8P>N*\]\/?\&WO_!.#4=8@\5_M,R_%'X\:Y;MO36OC
M/\4M2U24OW8I#)#$V?1D(]J^J/@5^Q-^QW^S##'%^SM^RW\/_!+QK@7/AGPC
M:6<[=LO+'&'<^[,2?6@#Y*_X?M>,OC"/(_88_P""37[27Q3$G_'GKVL>%(_"
M^A7.>FR_OG/U.8Q@$>M'_"<?\')O[0O'ASX'?LY?L\:7,3YI\6^);SQ9K5LI
MZ>7]A"V;L.^_ /:OT$HH _/K_AS[^W9\< 9/VV?^"XGQKUJ";FXT7X-:78>!
M[4+_ ,\2]JLKRQ_PDMAF'7!K)^*__!&O_@B-_P $]O@9XT_;-^/G[-4?CG_A
M#=!GU;6]?^)_B*\U^ZU$QK^[A\N\F:W:660I$@\H;GD4=Q7Z-U\@?\%F_P#@
MF%\1_P#@K+^SCI7[,7AG]K'_ (5;X>C\0)JGB?R_!9U=]:\E3]F@;_3;81Q)
M(QE(._<Z1'Y?+^8 _CK^.'Q3O?C?\8/$OQ=O_#.DZ(_B/6KB_31- L([6PTV
M.1R4M;:&-52*&)-L:(  %0"N6K]_O^(&/_K*+_YA/_[]53@_X,>?.UN?1O\
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M/-[JT7BGX]^(?%_Q7UF-MZWOC_Q)-<Q1L>HC@0I&J=@C!@!0!;\:_P#!4/\
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M3_Z":V*Q_$O_ "%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH ****
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MB@ HHHH Q_ __((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\ 0JV* "BBB@ HHHH
M**** "BBB@ K/\6>*-"\#^%=3\:^*+];73-'T^:]U&Z<$B&")#)(YQS@*I/X
M5H5G^+/"^A>./"NI^"O%%@MUIFL:?-9:C:N2!-!*ACD0XYP58C\: /QZL?\
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M!<W=ZR_\"=W^)P9CQCQ-FF'^KUL3)4?^?<+4Z7_@JFHT_P#R4V**Q_L7C?\
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MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C0 >)?^0OH_P#U^G_T$UL5RFN6OBE=1TU;K5+9
MW:Y(@98" K;>I]:T_L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^
MQ>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^
MQ>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^
MQ>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C
M?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^
MQ>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8K'\#_P#((E_Z_9O_ $*C[%XW
M_P"@W9?^ Q_QK,\*VOBF33I&L-4MHT^TR K) 2=V[DT =716/]B\;_\ 0;LO
M_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&
M/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO
M_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&
M/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO
M_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&
M/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO
M_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&
M/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO
M_ 8_XT?8O&__ $&[+_P&/^- !X'_ .01+_U^S?\ H5;%8W@7<-&D#')^V2Y(
M_P!ZMF@ HHHH **** "BBB@ HHHH *Y[XM^ ?^%K?"GQ/\+AXFU'1?\ A)/#
MU[I7]LZ/<M#=V'VB!X?M$$B$-'*F_>K*00R@@@BNAHH _#K1_B'_ ,%A_P!@
M[X@?LR_LL_'G]A74OC+XJ^%WC3Q7%\,_'>@_$.T$/Q"MY] U2.))GN6,EG+!
M',TCO. 6A@/R[AN?[[_X(J_L)?&[]C#X%>._&O[5-]I+_%?XV?%#5?B#X_L-
M!DWV6DW=\RL+&%P2'$>&9F!*[Y656=55V^N]3\+>&-:U?3?$&L^'+"[O]&FD
MFT>]N;-))K&22)HI'A=@6B9HW="5()5F4\$BK] 'Q1_P4$_9'_:%^-__  5'
M_8I_:,^%_P /O[3\&_"/6/&L_P 0M9_M:T@_LJ._TZRAM#Y4TJRS^9)#(N(4
MD*[<MM!!.C_P65_89^-O[6_PH^'_ ,6_V2[O2HOC)\#/B-8^-_AY;:W-Y5IJ
MTMN?W^FS29 C2=0G)(4M$JLR*S.OV-10!^5O[2/@G_@IA_P6MG^'W[)_Q\_X
M)]7O[/WPATCQEI_B'XS:[XH\<6&ISZXEDV]=(TZ*U.YXY).3.RA1M1N-NR7U
MG_@H]^RM^UU\,OV]/AO_ ,%:_P!@SX367Q&\2^&/!]UX)^)OPPFUN'3;GQ%X
M>EF:XBDM+B;$:SP3.[[7R7VQ !MI4_?-% 'YP?"+X%?MP?\ !1S_ (*7?#C]
MN_\ ;+_9;E^"?PU^ >D:H/AEX$UWQ%:ZCK&N:WJ$2PSW]R+5BEO#&B(41CNW
MPQD;E=MOZ/T44 %?PT_MT?'3_A=OQRO/[*O/,T70-VGZ3M;*R;6_>S#UWOG!
M[JJ5_<M10!_ '17]P7[7/_)</@9_V/<O_HBO>J /QJ_X,\OCI_PO#X&_%2;5
M;SS=:T/_ (1W3]7W-EI&5=2\N8^N],$GNP?TK]DYH8;F%K>XA62-U*NCJ"&!
MZ@@]13J* V/'_BC_ ,$_/V'OC1YDGQ,_9/\  6IW$V?,OSX9MX;HYZ_OXE64
M?]]5X[<?\$1OV0O#<[WW[/?C;XJ_".Y9BZS?#?XE7UJ%<\Y"W#3#&>P '/:O
ML*BN*KEV K2YITHM][*_W[GTV!XTXMRVE[+#XZK&'\G/)P?K!MQ?S1\=#]B+
M_@I7\,#YGP,_X*KZEJ]K'_J]%^*/@"SU/S<=-]ZA68>APO.:Q=?E_P""O'A/
M=_PM;]B?]GOXTP(<[O"NO2:3=3CU?^U(VC#GOCCFOM^BL_[-A#^%4G'TDW^$
M^9?@=W^NV)Q'^_X+#5_\5"--OUEA_8S?JY7\S\Z=?_:"_9UT,M'^UA_P0Q\<
M^$V&1<ZOX?\ ACI^MV,/J7O++8<>A"FL[PUX_P#^#=#XR7QTR;4O#'AK4E8+
M/9Z_/J_AV2V?T9IFAC!'LQ%?I/7-_$+X-?"#XMV?]G?%;X5>&_$]OMV^1XAT
M*WO4V^FV9&&*/89G3^"LI?XHZ_?%Q7_DH?VIP1B_]XRZI2?>C7]U?]N5J=63
M]/:+U/FKP%_P3[_88^(>G_VI^SK\?O%4=J$W1W/@'XM2W$:+QR&6248Y%=!_
MP[N\;Z(<^!O^"A/QVL\?<CUCQ7'J*+Z +)$./:J?C[_@BY_P36\>7_\ ;<7[
M-5CX<U)&W6^H^#=4N](D@;^\B6LJ1@_5"*Y__AU5\4_AX-_[,_\ P4Y^.GA,
M+S;Z?XFUB'Q'80>@2WND7"]."Q^M'M\RI_'14O\ #+7[I*/YA_97!&+_ -WS
M*I2?:O0?*O\ M^C.JWZ^S7H=9_PRC^WUH)W>$/\ @IC?2QKR+;7_ (8Z==;_
M &,F\,/P%'_" _\ !63P\,:/\?OA!XBV_=.O^%;RTW_7[*QQ^%<G_P *_P#^
M"X/PH_Y%G]H+X(?%FUC/S_\ "9>%+O0KV9?]C[ 3"K?[W% _;I_X*,_#'Y/C
MW_P2AU_4+6/&_6/A=XYLM9\T=REF0LR_1FYH_M*G'^+3G'UBW^,>9?B'^I.+
MQ'^X8S#5_P##7A3;](5_8S?HHW\CK/\ A-_^"M7AX?\ $X^"'P9\1%>"= \2
MWUIN]Q]J!Q^-)_PU3_P4"T$X\6?\$T+BXC'WKK0/BEIUQD=\1% WYGFN8LO^
M"WG[&6AW4>G?'SP_\3/A+=R,$^R_$GX;W]F0_P#=+0),H^I(''6O9_A=^WI^
MQ5\:3'%\+_VJO 6KW$N-EC!XHMDNOQ@=UD'XKVK6EF. K/EA5BWVNK_=N<&/
MX-XLRRE[7$X&K&'\W))P?I-)Q?R9P'_#PSXAZ&<>.O\ @GC\<K4#[[:)X;BU
M)5]\QRKD4?\ #UC]GC33CQU\._BAX7(^^-?^'MW'L]CY8>OIA'21!)&X96&5
M93D$>M+78?-'SMH?_!6+_@GUKS^3;_M%V5M(#AX]1T:_M2I]"98%'ZUVN@?M
MR_L:>)]HT?\ :F\ L[G"13^*K6%V/LLCJQ_*O1-;\)>%?$J>7XC\,Z?J"XQM
MO;*.48_X$#7$Z_\ L?\ [)_BG<?$/[,W@&[9AS+-X0LR_P"#>7N'X&@#J= ^
M*7PR\5[3X7^(NA:EO^Y]@U>&;=]-C'-;M>!^(/\ @EW^P)XEW?VC^S+H4>[K
M_9\UQ:?EY$J8_"L+_ATK^R#IO_(C6WC+PN!]P:!X[U"/8.P'F2O0!],T5\RC
M_@FW>Z,=_@7]N[X_:7CE8)_'@NH%/;]W)#^?/-+_ ,,=_MJZ$/\ BA_^"FWB
M6(+]Q?$'@+3M2S[$N5)^O:@#Z9K\S?\ @XK_ .:/?]S#_P"XVOIG_A5/_!5+
MP\,:/^UA\-_$6W@'7_ CVF[W/V5CC\*^&?\ @M!_PV(G_"MH/VLA\.7V?VS_
M ,(_<?#_ .W#S!_H/G?:%N^A_P!3MV<<OGM0!\-4444 %?T>_$SXU_"#X,:9
M_;'Q9^)VA>'+<J2CZSJD5N9/9%=@7/LH)-?SA5^]GPR_X)J?L<_#74_^$EG^
M%,7BG7&8//KWC>Z?5KF9QT<_:"T:M[JBT <Y=_\ !3[X=^-KN31OV5?@KX]^
M+-VKE!>>'= DMM,1P<$2W=R$$8SQNVD>]1_9/^"J7QQ_X^M2\ _!'29OX+:/
M_A(=9B!Z@EL6IX[C!S7TW9V=GIUK'8Z?:QP00H$BAAC"HBCH !P![5)0!\S:
M;_P2[^$/BB_B\0?M-_$_QS\6M1C<2*OB_P 1RK8POZQ6L!18U_V"6')KWCX>
M?"7X7?"/2?["^%OPZT3P[9X&ZWT72XK96]V\M1N/N<FNAHH **AU#4=/TFQE
MU/5;Z&VMH$+SW%Q*$2-1U9F. ![FOF_XP?\ !7K_ ()^?![5AX5?X^67BS7Y
M)#%;>'?A_;2:Y=SRCK&/LBO&K^SNO/%85\3AL-'FK345YM(]7*\CSG/*KI9?
MAIUI+=0C*5O-V3LO-Z'TM17QM_PW)_P44^/8,7[)?_!-K4_#NGS']QXK^.NM
M)H\<8/1FTV$M<NIZY5^@]Z/^&&O^"B/Q[S+^UI_P4FU3P]ITQ_?^$_@5HJ:-
M'&#U5=2F#7+J>F&7H/>N3^T?:?P*4I^=N5??*U_DF?0?ZF_4M<VQU##_ -WG
M]M4].2@JG*_*I*GYM'TM\8?VC/@%^S[I7]M?''XS^&/"=N4+1MK^MPVK2CTC
M5V#2'V4$GTKYOO\ _@LU\$_'E]+H'[&_P)^*'QPOUD,0NO!?A">'2XI!P1->
MW8C6)<\;PK+76_![_@D/_P $_/@[JW_"50_ *R\5>('<27/B+Q_<RZY=SRCI
M*?M;/&K^Z(OK7TAI^G:?I-C%IFE6,-M;0($@M[>((D:CHJJ, #V%'+FE;XI1
MIKRO)_>[)?\ @+#V_ 66_P *C6Q<N]24:%/YPA[2<E_W&@_);+X\&K_\%L?V
MB,?V;X6^%?[/6C3'F34[MO%.O0@]"JQ@6;8'4-@YQ[TZ+_@CMX2^*<JZC^W!
M^UC\5?C3*7#S:-JWB-]*T,MUREA9%?+R?23& !VK['HH_LO#S_CN53_$[K_P
M%6C_ .2A_KWG&%TRNG2P:[T(*,U_W&ESU_\ RJ>>?!#]DK]F/]FRS6T^ _P%
M\*^%2$V/=:/HL4=S*,8_>3[?-D..,NQ->AT45WTZ=.E'E@DEV6A\GB\9B\?7
M=?$U)5)O>4FY-^K=V%%%%6<P4444 %%%% !1110 5F^,?^18O?\ K@:TJS?&
M/_(L7O\ UP- %S3O^0?!_P!<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_
M^OT_^@FMBL?Q+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "L?P/\ \@B7_K]F_P#0JV*Q_ __
M "")?^OV;_T*@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH Q_ __((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\
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MM+G=Z;[V!A.?3I[U]BT5Q_V3@8_PXN'^%RC^$6E^!]+_ ,1 XIJZ8NK'$?\
M7^G2KO\ \"JPG)>JDGYGQU_PN7_@MA\*1CQU^QU\(_BG#%]Z7X=>/IM&E=?[
MVW4U(W8Y('?@4?\ #W#4_ !\C]I?_@GI\>_ VS_7ZI;>$%UC2XL=<W5J_/X(
M<U]BT4OJ6*I_P\1+TDHR7Y)_^3!_K+D.*_WW**5_YJ4ZM*7W<\Z:^5-'S/\
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M^,?^18O?^N!H N:=_P @^#_KBO\ (5-4.G?\@^#_ *XK_(5-0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^)?\
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M4 %%%% '@O[7/_)</@9_V/<O_HBO>J\%_:Y_Y+A\#/\ L>Y?_1%>]4 %%%%
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M^%?/0![U17@O_#NKX'_]#=X[_P#"OGH_X=U? _\ Z&[QW_X5\] 'O5%>"_\
M#NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\ A7ST >]45X+_ ,.ZO@?_ -#=
MX[_\*^>C_AW5\#_^AN\=_P#A7ST >]45X+_P[J^!_P#T-WCO_P *^>C_ (=U
M? __ *&[QW_X5\] 'O5%>"_\.ZO@?_T-WCO_ ,*^>C_AW5\#_P#H;O'?_A7S
MT >]45X+_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/0![U17@O\
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MT?\ #NKX'_\ 0W>._P#PKYZ />J*\%_X=U? _P#Z&[QW_P"%?/1_P[J^!_\
MT-WCO_PKYZ />J*\%_X=U? __H;O'?\ X5\]'_#NKX'_ /0W>.__  KYZ />
MJ*\%_P"'=7P/_P"AN\=_^%?/1_P[J^!__0W>._\ PKYZ />J*\%_X=U? _\
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M\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\ A7ST >Q>)?\
MD+Z/_P!?I_\ 036Q7QE\??V./AGX$^)OPO\ #>B>*O%[6_B7Q5)9:B;GQ--(
MXB$!<>63]QLCJ*]3_P"'=7P/_P"AN\=_^%?/0![U17@O_#NKX'_]#=X[_P#"
MOGH_X=U? _\ Z&[QW_X5\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\
M^AN\=_\ A7ST >]45X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7ST
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MNKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\] 'O5%>"_\.ZO@?\ ]#=X[_\
M"OGH_P"'=7P/_P"AN\=_^%?/0![U17@O_#NKX'_]#=X[_P#"OGH_X=U? _\
MZ&[QW_X5\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\ A7ST
M >]45X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7ST >]45X+_P[J^!
M_P#T-WCO_P *^>C_ (=U? __ *&[QW_X5\] 'O5%>"_\.ZO@?_T-WCO_ ,*^
M>C_AW5\#_P#H;O'?_A7ST >]45X+_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z
M&[QW_P"%?/0![%X'_P"01+_U^S?^A5L5X9_P3YGO)?@;J$5YJ%Q<FW\9ZM!'
M)<S-(X1+@JHRW/ %>YT %%%% !1110 4444 %%%% !1110 5Y3^V[^QS\'_V
M^_V7?%O[)OQTL[A_#OBVQ6&:YL75+FRGCD66"ZA9@0LD4J(XR"IV[6!4D'U:
MB@#\9U_X(S?\%7_&W[3_ (F_9D^(_P#P4JU27X:ZA\ =!\)ZY\5K7X7QQ:EK
MWAV+5=7/_"/"=IV1+Q$E<S7.]W>&[BWAOF#_ *4ZW^P_X(T+_@GGJ_\ P3S_
M &?]>D\$Z'-\+;WP5X=UDVIO9=*CGLI+47C)YD1N)09#*WSIO?)R,YKV^B@#
MR/\ 8+_9/TK]AC]CGX>?LCZ/XI&NP^ _#D6FOK:Z=]C_ +0E!9Y;CR/,D\K?
M([OMWOC=]X]:\7_;\_X)9>*OVD/VB_!O[=G[)/[2]Y\&OCIX'TB31K7Q4F@Q
M:KIVMZ0[N[:??V<C()4#22%7#97S"=K%8S']B5G^*?%GA7P/H4_BGQKXET_1
M],M=OVG4=4O4MX(=S!%W22$*N695&3R6 ZF@#XN_9O\ ^"4GQQO?VP=#_;W_
M ."DW[7Z?&;Q]X)TZXLOAEH.B^$X]%\/^$A<+LN+B*W61VN+EUX\U\$<9W&.
M)H_N&N#M_P!JC]F&[N$M;3]H[P%++(X6../QA9,SL>  !+DFN[CD25!+$X96
M *LIR"/6@!:*** //OC'\&=3^)OCWP!XOL=:@M8_!WB%]1N89HV+7"F(IL4C
MH<G/->@T44 %%%9Z>+?"DGBI_ L?B?3VUN*P6^ET87L9NTM6<QK.8<[Q&75E
M#XVEE(SD4 :%%4M<\3>'/#,"7/B3Q!8Z?'(^V.2^NTB5FQG +D9.*JZ5\0?
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M?G.N\\C@9ZT ='13+6ZMKZVCO;*XCFAFC#Q2Q.&5U(R&!'!!'((I] !1110
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M4KYUO*H9=RMAD<<JR, RLI4@$$5X+^PW\>OV8[/_ ((Z_#3XX2Z[HI^&.A?
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M\,3X=LX=2L=6M[C5Y+8PLUK=+)!F>22V_=^7&#R) 2 ?;5Q_P<(>-;?X6_\
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M,L62Y25F&(2: /O[]BK_ (*J^'_VF/COK7['GQY_9T\8? _XTZ'HRZRWP_\
M&TD$ZZKIA?8;S3KVW8Q7D:M\K;=I!W8#!'*\3\6_^"T&M7W[1?C/]F/]@?\
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M+F6YF)FNI)9I"TLTC?.[8#!1A54#T*BB@ HHHH **** "BBB@ HHHH ****
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M  )^U5^RC\!/VV?@?JW[-_[37@>3Q)X+UV2V?5M%36;RQ%R8)TN(MTMG-%*
MLL4;X#@$J,@CBO1** /@#_B%Q_X(4?\ 1C/_ )DWQ/\ _+.OISX<?\$__P!C
MOX4?L?)^P+X.^!NG?\*@2QO+/_A"=6N[G4;=H;JZENYE:2[EEF<FXFDD#,Y9
M&(V%=JX]CHH ^/?V;/\ @@__ ,$S?V5OC!HGQR^&GP3U.\U[PH6_X0O_ (2O
MQCJ6L6WAO)S_ *#!=SR1PL.-K[2Z$ JP/-?85%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>lly-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lly-20201231.xsd" xlink:type="simple"/>
    <context id="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i137275eafd4c40f59313788c6e8bc624_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ef7d2358d3d4624831eba2ba35e625c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf054c1e69d548fabc27199bc26a11da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3db037c2fb245969975a8e68da5d13f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fa23ebc91dc4948b44e17114afcbe93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6337489efeaf470db72beaad17305bf8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08c82f670af140a8bac93e72206aac4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9d00685b69642528d03b4781524325b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61b9de7700734098b07f8a46f43d9497_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i86a8c3eb7a2a4ef48d31b3028fe3303f_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iebfe9598260a447ba9e16ba1e9c6ed68_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8e0527046d9420eba85c2e7997c4b79_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5f87322c97e42a2b941ec910aed2655_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8341671b44cc41d5a18d4af59468c567_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e87e689a45f429e8cf9eefc3f7fadc6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab11f7e22e3d4369a89e0b9a64389e84_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i88bd65697e614b36971bc989aebab0f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70e7e33eb088468895e308da89cb151e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i184cadb6a52c45e68d6a9a4c2738bc68_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i27083e2ab25e4d04a25e1ef83d0b7877_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i045bb911bff14e9aa36f1a05bf3e92a5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib70725e180744eb1954d643e7a5a963a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iae684e1f51624a5884d558a8b1eea7ab_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i724dac2e02db4426bbe5e17f9903b032_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i03c1c5fc9e8a49c99deefea40e94e712_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i636193b834b64dd6bb822cf51cc578f7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i28716e79250245dd90132d730ab4c041_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4f64538c2968464bb7e99808fc376334_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id7bf2897e1304a7b9d39c16325786d60_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i157d7cc7dd0a4ce7a83fbaec2dded32f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ibe5ce62fdd544ff38d36deef307ad126_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i10e3cdfa36f041fc98dc2d1a6961d3d4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic8c9d052fc1b4535a183d69045981ee8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0d46f703015a40e68e2bbe1d001af462_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic1a89936fa8a4137a7ff3506ba792c52_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie93b724bf8864d4c9fa270f354b1916a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iafa5205837f6490198d5eec282d9367d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie391d487b3784a9b8e753e02edd132b4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i19bfa0a6cac84e13bceb037831a4f867_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d1c048117e4436eb1290866218298ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i473e4514c71444c9988eb5ff37da3471_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6fa49af8d0b4b4fb6114b249eda120f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida935f3e75bd41ffb87686123bd54de1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3987bdd473cd49b4a9449fe4eafc3bc0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i688adb3e04c845998ca0228971320c29_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i47de201d5d5443239956a13daaf044fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifefa16ca5afc4eaea5068a01f7896ad4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f62bf81439d4ae4bf4ba4e32bd50761_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa954877e0c7448982c196e66891eed8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if36805f1fb89427dbd2741f45ab5adbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i027fb322c12e404ab2d69c9acb6af89d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i036da0197efe483db4434ecbe172adae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba9187cdb56548338bf4141df49d64ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i787f9b28041442e7ad4a920214784c1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42e3601cdaa94bf89622d6fc8cfe46fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9627925923524961a92f6c7efb50a362_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84c0d14f77974e70adc19b8346937884_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50acc48e0eed414dafcaecf50e0217b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40e05a36e47a4388bbf774447f54fdf7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3dc6994314b0437780a92cc7d6dc54bd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="icf5a8d8b13ec45be88c05cc0494020eb_I20190311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lly:EliLillyAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-11</instant>
        </period>
    </context>
    <context id="ie8d870ddf29742b896587158690bd8a2_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i1aa7ce2db08d4fc7af3dfaea6237b261_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i01ed1b80ae7748c6ae7aefbbfc4c08c3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8e90af870b3d47a4bd1770c53c1a74b9_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">lly:AccountingStandardsUpdate201616aMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3ec2a6e9e71f43729a2ef0804b5d5688_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">lly:AccountingStandardsUpdate201616aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3b760635fa6d431c9dbbba9b762de382_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88f36d7a75f14e72b8ff0e498de5ad74_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1f006ccd7dcf492e906b2da535a904b2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i22c268eadac048a8bed666bf74cab1f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23a7d3b63876485d87034526a86d8ded_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i01ede8557fbe4f02a6f390d0e6822798_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie64e6e64f4cd4c3bb6d2fef573bc1cb7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08a61dcc93ff4861bcfc64e6431e4d71_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2123f59cc857450a91ae3b7c97124bf4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic6a3fa17ced44cf6911c558bcef7ce7e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i697978618d86456cbf1a2759d0f32502_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacf1ad720b4c43bf8e96a192f4292dde_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1d4d013544c649448fda0d85a40880f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9df231a5cbb94e458fd1cf844f24d8d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ae1b15ab56b43bc9a7777c2071ecf3a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i72b23fff2282489ca3c0f894bb18cc07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55059f768986433ba6bcc5c4b2726cb8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b9ceecaa70744b5b18f2b550ef85ab7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iddba0e6da38240e58e8ef1983e1c0432_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lly:ThreeLargestWholesalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia5562538495445b2b19f079d4c482ee1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2352e466ca6e45d1aefb7efed013e9cf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i56db8c7d699d4b908d30e96ead023336_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id23b300ee7c04c219019df6e1ab48341_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c0bb72cacc846c4b1660192fa13fb2d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i728a6f151f344cd5a4e1658f4456e4a4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6884b0346ff74a868a23cc494081187a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9d66c70ab574ec1a1e5591f1bb6849a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85836dd8d7c24266be724f2fd23636b0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie247b454823c4c899728fa1e7c3c6488_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1561cbf5143e496389f63ec127805cec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie24bf00d544347dd91396c4ce0a786d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1ec05ae419fb4e2fad130ef8bcbacb60_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia14247b991aa4660aaeff59ba9087029_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i28072632c66a42a99ffb45b515d993c2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i191e8f8614e54664b788c1acd1a1b343_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc75f49bc8dc4f318a19c8b6ce2d8bab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i715dfb4b6d894d1c879e0379cbf8a8f4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6c183a74083641c0ac1bf8f66c7aac92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c928d58286344fb8bcd47e90bf5d627_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id975590de3cd4ec99467e999df92c9e6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2830a10550f04092843207d0fdc28a94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e42ce139e604186891333c227fa7f7a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6a798b0c03524583b15477c45770fbf4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i27309ca3061448f8aed7d50699b44c3b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8238834ae2044c7c8f8d0f0b08cbd9bf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifde87f830aaa4e7e95c3b4d0b564bc58_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i64cbb8b5cf6f445e96a2f444f379af93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6e1e237c47e47c9828a59209311c512_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i085f2ef402e2415c9ef431e7b9de5970_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i134d638c9b8442bcb2b54a0dcf99244a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35093190cc994e6184aeba18c6d4e4e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3ca91803bf7b4a89952e0d15df9e7d20_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2b03da787f1046dda25e71c726ed0cc8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67ad299c9ff445079d8abfe019fefba6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id8cd43064bc54a9e901c418b624a14af_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1421efbb7afe46ce9044e5d41f1e6871_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8251cd1ee5a241ecacce9020401be466_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifa14db9f257a4f7b8ca0845e9421f91b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0bbd5d25f80c44ab94954c63d53de368_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb30e7b8f241492da7454e9da0b979d6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic12680d1b9124165bc4f6d955d85bd82_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i429185bfc6e449d7be22df700c5813fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie25dfe0449994ce68da67470b4776d8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie8b9545410a04c8da65e3c6e319a22d1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i22cfb8009ead41cca1ae3072cccf9499_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b8dc99127224767a2f12d03a5092d3b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ca7b28a537c43b2af1ddf727727ce40_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i85186ccd9d984ef4932e09feef978a06_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30e9cf6601c143cdb1b8d32ae6fd5480_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea814fafc7fb443db887570f7ea72927_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib05835511e414ca89be73a8916fad2e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6b3024a931a4657a4060b07b0425e72_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5c1fe9ccbbb45969203d906ca0f642c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i09cd8e4a702840b6b077b52bb0fc885a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie21841be70ab492085d716fac088fb9e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie73c0cb2f4924c719860a7896ccb64a1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i11ff519fc32f47c2a0c49159fe2e34b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie914cb56ec4e4ed1ba232fbfee390bd3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i966ea8089e9c4d68b34e188c500666d6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0f9679e5d6124967a685918cd9edf0fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ea5fe8155344887ba522b8118049b2f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3931b370dc143f9a310450ae75b2907_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i15d2a58303ae4d49b78490eb27aa3acb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibbcdae9c84da42e5aeffa936f33600fc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88519de09ce340f2a440994d3a26273d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8e9859caf33c4d129baaae6f1b8a77a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e90d63bd7f04d43b87e44bc9cf80dd9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee6f19b22df74b2997a2a5a704b7566f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iae16d89f887948a1bdfcbcfa51d0d3ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00a47ec3ac9242599fb0534acfcf50c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1e7e75f9a985435381e8a50f0510b63f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if18759d9c174433d92652e5cecea16b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i121c5d89d6f84862b7a81c70128ff4bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c089c556dbe4b988097309eea2debbe_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9f7338fb226246619bd2bbf15851f0e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if209842982b343139ff9db8653d11910_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic909dda5665e4ba29f047d0b8e1bcf5f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i86f3bd326f604139a90da118ac9c06c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1c0080f9e714abea664e5caa8d145d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6cb52b4c8c5542df810d31d40cd2b4b5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibf91ad79a82a4ec5b3a916c3289276f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2de717625dca44c78e1e0e949939a76e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i14b654e430e44c46b106bcb63224dd6a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id7fbcc61f59a45d9a37e569ed5965f58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d13169d2141455bb4a93b34de2a366e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia1a6364df78042fa901d2f1c28c93754_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0e09d571eb774bd5b689a1bb4eb4de7f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c2dc9d878a14c9ab4c5b052d73bad3f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie48cc43a68c8427793e98a1018af69e1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia14522eae3f4432ca88eefdbd852a7fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f778c41acb14e25af188e39dbcf6369_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6e201e3b4b174110a0451d32f28f8212_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifc9993567a2444faa53e3c75a8e44e1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7db6d4c2a25b4bb0bc740c90579b0f05_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf78497fb94a405aa4fa741353f71471_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6279b04ecce545a2a6ccd1edd954a346_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic653dbcb57f34df2a7cdbe7b36ad01d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e2f75b6ec544748a1740ef4680b574b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i382d0dc50c7442e584209c6d42e6be90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib27a0a7bc70a4f50a74d2e0dacdf5b43_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ca201e6a4584a94adee1b47b0e65d3a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i55d3783f314a422f9244251ce8f5d9f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76f653f3992f470ca575e3abea9ae426_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i78c414a5e65d42939a3f580b88d368a9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic54e1b52fe0945a18f903058aed5a173_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i092485a179404990a1b3f5d43565922d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idbcfad66d94c42699bde82b3cc71bb61_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia8d67124e0304de6aa72358898ffee74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7465980476074ec1b9f2cf051bd93aab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i405fef2f42e9480580d5e77115611bc8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie21029b52e3a4a25b8fa5ac32c01193d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3e3ba10cc2340fcb7a501bb4088f695_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i194d5e8204d94e729dce3e5167479788_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i42aed1d813ba440d989563043cbf63d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if93e5c1a7b044586b825fb8d87adef56_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6282183e9fda43d6a25c5ce5f92ff949_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3164ae1013b84936a3990cdd7069cef8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6226f69ada1b4d4293ca0d61745f5115_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i464b09a2e18141e18ffa754a848112c9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i471982bd0b034ecbbe77d99805441a0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia76bec07f3464f1c8021d24050c68ea6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia39a7fc11f9746e597092068de88f47b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic60748556476451f97a39a8498268861_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ce9eaf6546546d389e4f26520e4930d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i856f4e27d0e54f3f8f678504c46706a3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1246f125dde64914934faf191b569fad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac47103ffb8e4db3ba8420ae1884ba32_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i971612ddc6f84ff5ab4cebc6bc9b7489_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibd4460d0fbe7498caa8faf2ab1635509_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie954542f232d49269cf42f99d87610b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if596ee8084b746c1884dfb23161b95a2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad4c40ad02014289884f8f89f9cd98a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d98f1e0f63d4944acdd4049c11f843e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b22a1b043d84461acbaead22e49cd3a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib4c01d5260804ef2aefb47f37eac34b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c6ecf87283c4add86844acf0df92029_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9e5420c07a564b57bce98a24d8094aea_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib3730e62c21c49eeb0a31d079c88843e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11b39e0b4d84459b937f1252cad92e0c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe81f38456364de09c2c37f4eb63cfc5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaf1659ec78a740ca9d2960b4d4f4fea4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb82d9ffde3c4a3a8affb2c0815b56d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i576e907b609447808b7b5933c0df5f34_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id33620d8d08d44b8b383b1f866bf2e64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibbec8a0db57b47818082aea617fcb08e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia49f010469e74c1fbbb54018a3403a10_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9b1f8bd5f6e7439cbf1c41e604f947cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e9913b2677a470782bee3b901368718_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib8a98260337a41c7bf70c5041273cf30_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i69dd705bb5be40cda1cf159e67bfe51f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i254787900e9a4e7182dcb921c4b5d695_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5671e1d40a394d5aa617890df516c413_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5c4d6c27c076414ba7e9464801d0140b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51e1b22d70974fcc95c281ec5f6e788d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia67ee0b00db446ecacd2b9f627d621d3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icf51f9d513a64c25a6eeaf8e33921e20_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia079d10886be402287aaa123fc31ddf0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b37da845eb34ab9aa5276ef319e7926_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i91bd92d27afd4390915113b0bb32dba6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie311a24502de4314b71b45580255cb57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff5458bec1b144e5afafc2f8657e9b86_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifc8656193e314466a66ea72a95a19692_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i756013fb987e4ec49313e27c98887d9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48736069f07d435ea802718ad0061329_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8f15eb6661ce4b1abb626c73e242befc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55080d1515744962b9aef976d3cfdc53_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie546cf165ddd419e9f13ce7b33b842b3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1485142ec4594191aa24ebdd7a9ee8bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib7e49c0f20674d7eb574b88861a45d59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib5388a613eeb490eb1588c4dca37c078_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i16fbcb5755144a989fd1a37e01482bcf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e93087d035441c7b9196cf48b975ccf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i056be4f4187a4d8ba5795cb66a7c63e2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i61ff3b39dc584d80ad523e152d9aac2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9042f18954a44f338ab7c4c38402701e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i231c072e54b14e93bb61feda90673766_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i28f9aa8b13a844198c584392ffe612ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75eac947e5c24423826502ab09453d22_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3cf5ac51274948a2a524006ba7646b34_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie404784c5a4c4f23bdcd42cf33eca1b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f19444ca5d74e42b8447a4f2274754d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04bae10a0f824b3db0e8166ff0c20364_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if8d3b673fac540279a7f2aacdfaa0069_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i792013c79753444599d13628b640dc41_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id2b32d9391794988a11cc682565b7a80_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2a0d2e470af549b4881425b33c0ad415_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6137d276b0f47409d9ce0335e227625_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0163d1b6ab54735a54f26743f4772ea_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0447dee610924071bcc739ab2cface2b_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="ib39f7cc613994dd990be73fcc3b87286_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ibd24952151d6401a8d349f6aa9770ddb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic44351e94bb742d683da05ff0074d5c2_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i56fecb64135f4cca97024ac5ee838679_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:SelpercatinibLOXO292Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="i911edaec6d6642ce8d5278f65d8639f8_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="i6d91ff7b27004f208f75b0a5c87e5819_D20190215-20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="i9219272b6237462ebdaca8970a975081_D20190201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i817bc774c0a8475dbbe3fec31acb4ee2_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5ec4b9cb82304fe1a9d510e0419943f5_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4d4c539b649e4eb2b5f76577e83e9100_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="if2dc373598f440289cea2acfc3527726_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:UndisclosedAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i0e93668371324e1ca8c0ee4bcbd18801_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:EvoxTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibdb9be66049641c9ac68c3d117603a04_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="iba61e61e3baa4e2997fa60b1e4f4971e_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DisarmTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="iec4ba9fe07284d088597742e1436f206_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:FochonPharmaceuticalsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ie9280278cfd44c43961529cec49d61e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibdaa22fe62fc496280072ca3fca4be80_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ImmuNextInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ieb0a2d07df0d4feda7f5fd4749d43715_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AvidityBiosciencesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i639e2336e84c4b14a58a28b021459d91_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:CentrexionTherapeuticsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i840bb93977c84d32a309ff7a8196c494_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:SigilonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i9269ad1f97554a34afb28d633cb92685_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AurkaPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i6890b2b6dd4c4f7cb1263fb822f41093_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ARMOBiosciencesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i8da5e2bb6fb443248dc40e30fed39f7a_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AnimaBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ib406c368ebb248a6905e51cdc446be75_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:SIGATechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ib7a390840d5f4630bf6cdb7e10975ac5_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ChugaiPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ibbd61d5c90aa43c0a362a60341c2d2ad_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:NextCureInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i162940fb176e48c1a385b23fcc164f0c_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DicernaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic2e25f473eb845d2843f5335d4f49aed_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:HydraBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i28cd09163e9a470f87436cbc6e159574_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i9a68330743054dfd8a5f47bd40a19db8_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="i3922fb112aac468ba7f7550c759a6166_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:ACImmuneSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2ab202db20bf44e79b70b6fe34785936_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i24260a2966224f0aaff14390ed8899c7_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i0bd2f82569394ceb825c6ab486475ce3_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lly:EddingpharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i456272c8da464ab0977d30b650506a1b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:AssetAcquisitionAxis">lly:PrecisionBioSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i98a914a9a3184c15824f6ca6f22e6887_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:AssetAcquisitionAxis">lly:PrecisionBioSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i80f0e3d4afc04fa5958a6ff84edcb67c_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:AssetAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="id11c18de10e047e29fc8f48ccd7ad3d9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:AssetAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib592ca19ca78498fa6f8c390254088c8_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i5102763567ac4b82ad95c44a59000d4b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="if000a6bc5ce54a1b991ab37772234f3b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8269e026df1a41b2b0895893b55d57cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ea5f2373f024fc4b990b56206bdc2c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib012a6676aaa4eb8bc9506fa646b3402_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8456d682a58d41a3a50ddf018b0a4c6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i173297e573b146f7bc78c4ada3a83d7a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia4d4009f20bb48cf9ec030239f052ee7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7a5bdf1152ee426093323505e09cb233_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1fc8d9d4d2a4410ace81efc24eba1a9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7d36ed57bb9940dba66fd60498e5d762_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia4ed102c3ad148a0a31d237f28a5df12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i312288bed3e9413faa61bb6376a13576_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i308e5f2dc1ac4bf9bf1df82123fa7ad5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icfc2c951fea140efb3bf430c16795a63_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78597bb677aa4ac4a976a0e803853b22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c6e7782eae44e479a4ba6833152bf86_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85207b20c9354258883eacc250729894_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic88f51f077b644278fd68d0fa5ad4dc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i710d1f304d724efc85f13dc60bf62fad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82dbabd3686d4eb9b13b54382cf6bcc4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia93249b60bed44a7946fd8491b3b85d9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i55d0178a6cd14c4fa5fd77920bb4abbd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43add1f443e64f3db8290de104acfbce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BamlanivimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied1732da693a41bdab698fa5a39ba0a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iadf97eda073b42fda0623d5c29db2c5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id77a2552c6e24c67bf8d94ce91e0e5d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i252ecfb1d7a840d9806b0dc46157e963_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7bf82252c7f64ef49980a721ff43e8f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8457b21557264435b2547d9a774dabe2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id57723ff321a4ac09c2ddd06857d6267_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9040b40c375e44ec953ab4747d1dbaa8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c5e6e4c1ddb437a8f9faeba8093fafa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7c2329f83d54c2daf23fe9a43a89933_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OutsideUSAndJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if51e456d8c22452895dde4067048ed49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf9a899efcc14002a419189d81ad60c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02a5b403f3e84dd588ce7e797609bcbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i278ff628156c4188a73f68b4511dfb68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e398d4d6ace4b53b2313b073d764cee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e1db56f028e486bad99686da3f343bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifafea5b05f3f452394ff8d36dbcc9f7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5a7062879db495387dd023ff0ac4b13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:LoxoOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i76593a635ee74f569d9d5d26e369257d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsdSellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if292dce18b8742949a04f94a69f513e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie11921f0731440e8b2d7e35e232cb20c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c1ec7ea3e4544bebd2209221d0a8ad2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyGBPSellUSDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i734b5d697bdb4d96b38be8ba20e2e66a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i885be083614a4d18a19870c3bd50973b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib71d03b9d5404ef7859e43ce06d40102_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3781eb7aed394d3aaa09742b6bce2f1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15da0b294a6b4817b66312409c265245_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b4c33e1edc444e5b4e9a8500e0eab88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied0653ffc6e14aeca59c89fb6a86121c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic757ba5b7d1b442d93291ea03decee5f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i79bdb56a9d7144029b1e5522c593614e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60d9065de7764cc19c33a225a0d50880_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i177b2d67f8ba418284926e505024a276_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i559cde7a86934d01957c68c16475b1cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i089038df2aa140c192a89e32082775b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic259a5c22c4b4a7aa701a9d5367ffc26_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4a4d2134a40b4c75849277ff51f28c3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95c9ccd3865e45e69f040a91ca7dd298_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4d6995b66cf841668e6e05a116f49a16_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2b825c2201274dc188cf256f122e086c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f82f22527524999a91aa71e61c6641a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i325ca753011c477b8ba2959a5e5c7d2b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0813de855ef747abaaca53ef36e4c1f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i670c43f24d5e48ca995ca3f9f935644c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idfaa8924bd4f438b86a6705d72934fe8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia1e85a5c0bc9421ea34d9822b4a94e72_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c2513e6302b4030a3b2c52c6326a063_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i08a17ef8639b4116914b2853f39ee356_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie5eadeb2c29d4945b2f705b7dd6bac6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id899c3b3d5a645f5bb38fa729003c1d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0876e8c76a9c4c308a34aff4f59ba314_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i107cda2404e146cab37a3274549bd9d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1614e22518944c76b247484e7a60ca8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie269f3b3bfdf44ce9b4f6626338c067e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c51b75c2fa14c1684c56a1e7d8fc1f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ec12cf461774e1182bafa64c823d98d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i566cfafb34514a41ac32d09adc9ee29a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2ab34fc33aa445d9f82bf362c674439_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97251102c68a4c478e1a1be501688a22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82e0f1e2870e41769f1affa474d182bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i758fcf4cf3c74497807165838ee0ac9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i077c04533e3743c8b36a16e643d4b688_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e0432603227427ab677d8fa8d0e0872_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b249a1451654e4f94d47645b0fccafc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i867f4d052cf54d0c85d6df1946dbc24a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0b0011562854b1d95ba84ae4e1bcf37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ad918d4090746489ff767a295639e94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i436c38c65cce425daad44c655b754e71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9398ca058d0048cb85257c2485125ee7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id952bb8455ac4064b262c91cc977ddc7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2749eddf3fad4a5db6ba0abcec58bcf3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cdb65ba392744f79ff27b54d5a5f83f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc3a5cb729034c68b87c779b4e84d7cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2013b0dbf62424d9350c6b71c35d2d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79afb23fd84842b88431983432e6faca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec93f4a79eab4a1586228b07068c14db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8881e2925d8b4caf9fdfdf020b93932b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6e008d687ea4305ab1f7e75dfbff408_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30940c5e536f4d5ead427a4782d61c94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i435e18e4a6f549a399937585428a9956_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f46ae367c8745948b6623087118c537_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91d8fae795ac469da2155b12eb39aec8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie512126811f64a28b96cb6c61ff78085_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib53ce320a0cf45c193d1cff9384dd062_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f275b97cc004a86855de7192fb8f764_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fb5a016ad964daebc62766f4f82a19c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19985e9c706e44848bff87eb752a0939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33645495135840a59fbcf0e39deb55d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie198dbef2f4e4399a10d5932355eb939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44b7bb38ed4d4d11aeb324f32e415e81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia36eeb1bd9f04842a9851c91ab5e895e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icea21507ec1d49be826960b15a6c42f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3050ce166b0e433687c88c87676b070b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4081e5bd91e244058a3844645c6f7e8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e6b82be3c6d47cf90e800e560194078_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ef89d353cf247e0864a754f5b062e45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b870b023711491387d9d2d2fda73e1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24d94ce65a684af8bf51656da3e6449c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea3ae02f6cff4631aab6491d4ae1ea8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaca2871b4ff44e13a1ae66a9204f2c5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i36a35200b6214f8d862d1879f4522cf7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f04b7c762cb464abacab6b4977a1b29_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4686f8cb62994a9a9bc8e6b7817e8410_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9de1473493a442ab6ca0ee29d148543_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3ec43bf672b4ad99e62859afb69e618_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e269ce360814b8e84f97f774fd1c803_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia46aacafc18444898a49130e3d437b45_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11555512f15843b78cb5d74c0d0637cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i55e9794059e54793bf573b9748798eeb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd767fb99dc9410291e52fe3a05701b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25b9447fb59048a28d7f41123a0643b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea08714d01bb4abbaffdf5f5e1634598_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2af641dbca0f401696c62e23d843bbf0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if911451758b0451ba9dd43374b7caeb9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie85afc85494d45deac992b5b655352c6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe41ef9074154d9c86b0d0beee80732a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8beb739ebd1649a2aa6dbb7bed7cb98a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24b086fb17f3400d87543e41a70f9221_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2a79d730f284ce99e15280ddb18014c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i896ba5d04f154341a7f226e1768613b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia7430c4dd94c4647ae735ab5dcbe41a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11c04854fd114be5a2ed27c2c259efd8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if547dc6573ac4235ba2a0eca5f36102c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c8506c4f9b64daab27077e623773d22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia88b2998a44a42adadb3c56fdaf02670_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f61406987b0462d929eef8f4acd716e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3bcb5c5899344364a60904c18340c133_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60ba6d352d364d3494b2a7fe4c35e283_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i335aa482d73640a395372f1fe66486ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5991d2f6863348dd894ea4182e0e6ae3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1edb578fe2b146dfa9398c23136bd036_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5aa6955b8d2b4b22bd3c25a51caf5bfc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2fc3ed55b43049169f584d6511c15e2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ab7928a68fd4d8b989433ccbf30af4f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i037e599f78cf4eb193c194c14da7e6c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5595324df32f48359938231bb46a08db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8f10afd1f4e4de39bf7a81a91f20180_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a044b0ff45b498f991a1e4bc212927d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25b7565646be4ec6aee7375271c85a7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc2dd7aabbe1457a85f6382dfb21b03d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4e19515eb414ea3950645ec1bd6e029_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7e32fe5c4d1480b80157e3bf4f1e8fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e6474a7ae8a415c8a0c7443dcfb85d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0360e6926e5a4ee19a921dff273528d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7727cb3da004ae0a84be29679fa8e8a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieeacddff780c45eca88800cb052b4f1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3597dd720a74b66a0a24bd7e5f6336c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie2025050fac34c4bac2c4ba461347a3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i26823dabd1b64b328190517078c87d4f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8339c07c793c4080bbff3b4f3508d6c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff9b4655ccd1401e9984bb3b5ee74b96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9bd4cb1fd99f4fae868921a774fda59b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d3f83e4500c4b8785248a7a70fa84b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a2c22552802430ea404ce1f2936a291_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e9bed57fe694231ab6166019b90e496_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc63939ce42a42b4b7c2ce2910cbad4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78564906ca1644298e4c0fa5785b3dc8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e562e62e4d4490ca21252c3fad46bda_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f157e5e59dd4d41821a1ba8e732b05f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b9dad78832c4368859b28c2f6894c72_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id845d0c7f9964ee0bf08e79d645dd1ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf0dd8585de44468add60f95d78c62ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6df764752add48c48282f4351f5aea77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa54dda0cead4e039cb3c37fdbf005b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a5d2355fe924260b94ae1755b5115f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f99babb106943a48c2ef126347a18da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3140c9a521e845898dff7af991e1d21b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e14b4632c2342cd8bdd5d6e1be3f3d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc9ed839ea824eea97ca2b8fed80d1ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a345f6cc3914c7f9e7fe94738f6cb7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e42ef743d4049b8b98c528fd36eceac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99493aa1fbc341b58c3254bd5c14e0c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19aa55084b624b149f91667988733b94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7bb79e31f68c462a8bfdd0a9e8cb0126_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1161a1814827464d8d0bf447a827298e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5f85dff2b99430d9ea18be88db32363_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie54194fef9ee44f0baa1198b79b989cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49bb3cfe0c224730b91be93a08a94d91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ab9280585474937b6956aacac7dcc43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2a130b6c9674334bb31349bb3084485_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i698fbd8d92b24eaa80fb4794ec8b22db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91c44cbf91e34245b319839db6f762e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a7188b3764a4f06b9d801cc32c022eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47944dddbf22476e9864a6d86fca6c07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b04120333d14c7bb3721e9afbb4f200_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7f3f64f550448648f5d119e75baab9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie46ab1f4827641929600f4d8e579cba6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3a5e140926245c3b898ab1b8b0aa810_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i571b62f2272c4f0c9864c655bacb5f43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2faee0bc39a1435ab2737a04a112a0d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd7397b614fa4d0aa289843e505c0338_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i499a38e64d144a59b3902cd77fe676e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65a53f7cc64140b6ae991b885dbec6c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib769bb44d96b4ec6b1ff4f8945d14c74_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7790a8ee4fb2414eac30e7a9561da8aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f567bd4e42740019b3174c50d5bcd76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3567afa62a444c229ff7c02310132308_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a257a5c3988421daab1c5c94873c7b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea105f73e09247b896eb5002be1fa817_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i901470ea1dcc46daa707e313c0151f74_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id7d8bd5466554120bcef2a7280d5a0cd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i605c9e12226d4404b17da90d7bcf0a01_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9e8ea6d64d6b48f185da2f7945e93913_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if97d81ab32d741d5a50a9e919be3b610_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iedb8e2a45e4548bbba35a9682ef87298_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd8e5bcf3a7042e997ecff32c5ddeb26_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i68533791086c4a66b4e85509ed1bbd21_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i018a7fe95440493cb5b194a242c36530_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4080399399ba43068553348c4be8ea2f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc07496027d844728e4f422d09488b8b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6e3a32202c54bff815b9d7e2d3e22fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9a6f81ea634490dad4edeff649d1781_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic38207da496841d290edd3833837d8da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifec2b5844ba24dc08ff7dd52e6d6c8f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a1c802688094a8889c8d0228f9ee2c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i662262e67b5f40cea96bdb9a5cd66701_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5102bbe8737b4c2da4a4243cb207ce90_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1083cf7137cf44a588e913c40a07246d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4236ef82f62541ebab48555f05d6cb37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic42c7c598e6f49feaae76a07d1b3d85b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bfb71fb8b9f42c794f44a765001ec7e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b00c742d1fa4c71b1069e0936d163d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d4f0d9411ad485cb55e50fad753c51d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6440d866422d4fcea9a1a914dc919853_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic681b92a73ce4099bf3dcd5b07e95e90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6db0bc1ab684eb9bec935aafa00cbe4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibabdd19152304e26964b75c2240169f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib11faf3ad2f94548b0a09cf8f35a15f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2594deedacf54880b1db0ef581e435e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:UNITEDSTATESAndPUERTORICOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3d7beba7c48404cae7014e52512b95b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2cbfb7a17f9438a8d7adf6e5a09c448_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7c64ede2b9f24bd2bb0d6f97ff8dc7ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia528dbed284d4ed0b3acc05cf5e1b356_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie39118bdcc684cd68b2c6725d353ce58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8211a0f8b8da413db4f2efbb3213d634_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A235NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2de9e70275e246d6a582111588810286_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02f615487ab04c708fef493a3fa4ecef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A30NotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61c1211b430f4ba58b2eba2c97c976f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie245631a64f040e0bf885d77689fdecf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A10EuroDenominatedNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2eafba22b49e42f1a090d404e4b1ccd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fe45934df5346e4a6a0d715944c15b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A015SwissFrancDenominatedNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia221e6819a7d4e69b484d963df327dfd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida41079f1ceb4961915954043ad0b801_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A7125NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia71a0b4c817a43a9aee24da56d63c0e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id641d973aee741acb44e0f58ced70bf1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A275NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e0dbe73367c474aa66b9eb7c4937520_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba8e44c95e6f480eb82a83d06e179514_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625EuroDenominatedNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0fc9ebff5d804b3587da0025635f268e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3562490080194bc8b92c4d7b39b14b4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A55NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic52fe587003244e18fb9abdb9be4e63d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07507ae169e74357a231b2d9c239eedc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A31NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6bfd9e9e45a473a9f90d4f41a08ea48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1136f1586cde4061a489a0824879f7d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A045SwissFrancDenominatedNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2bfd288269624c7b86651f8fc813d3bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9cd37cd7aad40bda3f214b57cab2f2d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a50eaec3e7a4ba69d1ffdc4a120b39e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibea8fc22978f41d7932c87f65b0366c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id57c890b8a2244d1a7018e62567f926a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i451d9a3273804f14955cc5a82111caa6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A2125EuroDenominatedNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9d7b6ad2f874ca7ab2452e56d10ca29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb059df82e0b43cd84033edf1b400448_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3112631bb974c85a5318fe1efa3d51b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3c0b90ff61e4adeab7beb2122db8cc8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65c5eb420e4649c487d09089e7cf9f49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c6c23acfade4500ab9b57e874f2b87c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A677NotesDue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ee2a27f08884a89b9bf33bf08bd0da6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9874bc66d90145f4bd3eea521b23dad8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A555NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2078c3a852d54d1385e1a1b24d15e8c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7bb8be0259a04e968746158d9c7ebfdd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A595NotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7858b711bd2147f994af875c0dbac9d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94f9df676ae84ca4ab5a863a59e0e05c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i030c208576224dff9839b8198a359ca8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c29e053597c4404a0c3274d3ae71277_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A465NotesDue2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0d11e1f18c324cb68f63c1d7111e4aba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i867c6c8331db465fb6d11fa19654d49b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A37NotesDue2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie846943d9ed4494daf24040e9d7a4b3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i234b44d7a5c647d483338639b9fee082_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i656b092512744da59aaf0680fcbf4678_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d0bfcf2438249eda212a31a4a731f1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0965d791ab43490fb6cdab898b7eb5cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62a9613dbf90422496652cb4fe3df34e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7bf9bc896ba444c18c22af719b4f6ca2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9bcf1e62803246f8afcd362547cd42bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i655dc81cd7ca4a969575979d59347169_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i532a4d8d7fa0495f9850719f1d105b79_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idda582f88fad4b44bb89a7b65fa5e8b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f74451c169b4c4bb0905d735b168f81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f0b1156a4f441f3a4c0ef9e8fe20b38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85629be20441417e81c8bc15187610f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92154592e663424992dbf36c8086e56f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i576355b801554d9dace08e37a3e790a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc42a52c34fb4cbe8b9fc2a34c409158_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">lly:MaturityDate2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacba47193c1c41d9b33bebc61b930bc4_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i61181bb3188f4ceab623c97f733dd40b_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="id260d3c811084dc9bebde09aaeb73bee_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A25NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i3cdb23950c784a95a855f5d0ce652a38_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A225NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i66b0a7cb640f45d6b8c83fc4de5fec01_D20200801-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:SeniorNotesDueMay2050AndSeptember2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i781b0d1c65df4f598bf4ca78d40c03f6_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i7caac5fec4c34319b3ee7518fa0cee6d_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3875NotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i195f7ecf4b4c48a592446e3d876daf86_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="ie27939a1114f4155b7e6b1134d719999_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i01a37470a5b047e994577c37bc40b277_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i01dca931c8514af0bd8dca2a456bd02a_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A625EuroDeonominatedNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i0b0b3f18d85446cd9abefc7f5431210a_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A17EuroDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i7bfd42d26c474945ab26097d61bb99b9_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="icb88d176a73247459d0ce6d57d7f2362_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:November2019EuroDenominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="id425e417e4ad4c45a09f17f9caed0ff2_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i61be1551dd32425daa8be3c06f520dd7_D20191101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3b8c3ecb8934c7cb012f8fe970195e6_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A42YenDenominatedNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i3517b05124e542ba94be70caac0c6932_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A56YenDenominatedNotesDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i73d344ee1fd84e0a9a617d23c99aff1e_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A97YenDeonominatedNotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ifc7c545c888b441abae0763fd9a5afbd_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:November2019YenDenominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida5a3ee36c55473f9c1d1258483a8afa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c9bc19fd1fb41c9bce540130ed1021d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id85cea205afe42e1b0277f50024d6b30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7de296eb32347a98b984561470f50ad_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i487211e627d94b84b6b40cd96ed51f9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:ShareholderValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73f6fbe788a645a88588285341425783_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lly:RelativeValueAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id745c20da55347c7945337736eb25cfb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a21324627e04ff9b171760e0f6aa512_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id93c53abcafb49fba5f4a407366d5857_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3346772108a84c5d82eb7b473c264e9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">lly:A2018RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87a7cf1bd4cd4a2198d3b916f9809c4b_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">lly:A2018RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i846b4a3017ec4ae5aa560b3976992beb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:CarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63b7f44c96794ab582d1cdf6a9643b7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expirationin6YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0b893702d44405d985be5d52a729ef7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:ExpirationIn12To18YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d7fdc4cf740436c9e25779df853a90f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58e427ba0deb48549a21b2af98646bb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icdc037a98b204a1b85b9d162f20d5932_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idba58d0fe8d4499db02b60b0661239fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expirationwithin5yearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id87d4bdf6f7b4a8788ffa5277ada15bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:Expiration5to20YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdf7908d101449948e44a8d01c8ce72f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i847eca29310b48cda35b0cd11f7c52fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lly:DesignatedUnusableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8253b9821a464bffb6ab718d922a8b60_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lly:TaxYears2013To2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id11b4d29868245268d0dca888203dbf6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lly:TaxYears2013To2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i87fab925dba44dc0ae21de713975768c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic62914e39c2446a7965d109d4b06fac3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i860ee37306f64cf8a0c232ead17d7745_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i06f37af72aea43beb8bfcd105c157384_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3cda65ab919946c29f79a9a9dfba07ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5917c0f9aaa488a8f07e138effe57cd_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0be18783045647b39417db291e131c68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i134f03f4da5745c881d151356389c114_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i125f0871aaaa45a8a006a3aa90bec2b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fbb551c5b8a4f8e89d479bf7ee2465d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b85c4afc43f4f51a83ef0ea6a014ca7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b6c571cd27e4e94bc5717d1000ca256_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12e2651b0ae044eb8ad0fd855f1413bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbb25b81194d4853b020cf54c8f8f7ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4815fcd3e33549bca6c2313f6a96f168_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e92ae2ebc9d40ac889ffb3518784b30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03078573edd84526a0fb7f4dfd971e8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3287458586b346ae8b32053866574079_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2bff6b24d574258816b0a18efea4481_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b7c8721f31747da9656f229d82e19ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icccd9f0f2bc240d68bf932d1486745c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8fc4192c93948e58c908295ada7c788_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c7df1b1312447bdb91336635231a328_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44ddf32d59d541b2a516001cd682c531_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if54348410ce84f2fb7e320ea814b26a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40b8bd104f4d4282bb55fcd040b18ad7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie21defbad19c4c63a7ca3efa0bbb49a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dcfa724c16044a9a047270245e9f5d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i122ffbfb116d49aaa94e76c271df840c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia11541505d134091a7960e590f9c55a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i894a88d4a4a34371980d69bf29256285_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3721c158dd7b4d129f7d61430f4502a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if741b3f8c66d4f398ea1e526a37195c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if98890f41b7346c2906b80139874cde3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35b819438ccf430b853a4465244e6fdd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b85d3256ef6437c86432f6208104ca9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2f6978eac114b1a9a4b9b3e6d1c2d54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1a4fbe91fca4349a3619d62f21b5192_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c325faa849646d8877f6217a8e9e5fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8a1be41667140c28d82974e25d6f978_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fb1a00b260143129cd18a27fae9066d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab85a851be0049e384a77f9bed8c7112_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90ebb158dc6c4c529380297ca491bc83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i787b7132e99c493ca562e8bc24ca4fe8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic467e27a1bec45deaeede4746d725b3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacdcb2d995cf4fff8171cbe33cc965cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia422ad3b45604fe2b5412d14ccab5f5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ided7419ed04c4ee390c6ecdfeea4be0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5dde6acc2364d7895ab68140b8a940e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4c7762e89bc4b6c8400f5c82637267f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa71c7d9d0a44cfea6f52f788e4f63d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fa4144a81a64effba21e1069fac6bde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4cd95c05c6f044669e6cdc5f23c27a03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa4949f8ddfa462d8b08ae8a55ca4e3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i522080a183f64b32b7dbc33f0a805a7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09f8a5ddfd884b47966968ab578e45b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if438221acf6341a39b8a9a65a4e65e8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if47ad8d27d2d46cea9c0a971df416313_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20afb20108144023830d742a2375621b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82a506494bf44549a25ef7d8a77149fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i367a0762cac945bfa3136660561bb3ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i119de4bad3f6477f971e2f4b9d1269d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18771cf6e66e4cb7be08134942326069_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c7d6c9f167c4c5683298223b4ef8af1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1dd6bf74c204da0a0cd97309e7b08e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i313357f190a941efb7646635222fa28c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i434273c7f8d842699b6b037c72ff2cc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0d982e51da34404b680672535a771da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01c1b63878e543bab94f0bc61bd810c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd8fa233f8fa45ad8d9997db7e5e3cac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id10a4106c36d48c080be874880a0c5f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia95a10a1f5f14bf0974550095d634caa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6f8ae3d75184ec2b1e3758df93f149b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d1fcfa7a99c4781a6ff659d054315b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd5aba2572834b96bf2e805a8e72d50d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b41b01976fe4459b0b2e05e4a78ecec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe3ce3f963884db0be993dd43a273d48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie17084e6a4674e82adf22fef4ff88b90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice675a2c24d8440490e242dd88655d53_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0340e5bcf8b2492f877571f5e4badb72_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie290f1153a8746b4b6cd78f8378492fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie61e568a671e4a80821d53844eb24240_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8dd146d4e0d24f1eba383583c4714d33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idad95d8440b74627bd1f07f9cbaaf547_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bb310846a874a2896fe227840a6a94d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c0844638a1d4c2094a1f495d509e3a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1a23c7481934f7c9cbc0f8e5d7819cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e024a2361694af8af62b9b106fb4091_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i893d604481e5414a876d424c5bb3853b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i514ee23678874da6a78affbcc11e2d13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i782e6897c57141f3a206f658e2c32404_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3def2cfb16eb45eb825321e9107e8557_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if24f5a064fb248b9a1c67cd62d6ed476_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85c28a1b50d047e48ca4cc3357ad9d44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i933d218234f842788e1c269114faae5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37ceb71c1fa14063ba529ff4695b2287_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i685a0d4729324a28b26de39802342a21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic736258b57814a4182d5d6987fb420c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i045d7c5fdf0e49c18f983e9217f0b15e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f4c6c31184e47f3b704a0eae7e42331_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib384b4a9c4e24e259a0e4f91d0193602_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib28a156345f7417e99d42b66e3b9aceb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i058f847612d74099976ba37d7f71f906_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia708e12046a5423f8cffea676c33483e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife201fa234a44463aaae78e3178b7591_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1612094a408f4d40b21352521bf6c97e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedde0139af294cff8fdcea9f72f645be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ea7b43b8b5c450c817a947965d81b01_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c72734140b24d3f8f463831c8c59882_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i474e96cc45a343bd880e15f5e3e7dcb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i331eecd2fcab475bb2c445750bf65683_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd771e0257d642dcadc5d74119bdfefa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i41f3e1cb00c44d82927f246e6c5166c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e5945ce8ccc4948bac9a0451e12d1e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3273ded1db9c4c9596e118619286ba07_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b1995d069c040efab6457b44f15e8b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icba0bb9a358a4901bea4e4cd5c7f55f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea6960c498f4476188e66f546a6935bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd365bf0efab46af86e6bbb643db823c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i675961e5fc46462c956548b162c65ca8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbbec282c576404eb0ec8d2d0fdf9653_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f323b9fa21c499dbdf0daf714c57f36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadf32c3dcfc14cdaa8060800039f3e79_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf52a977346b49d798c932533814bf59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28c3e31523404f2ebfc936c17c16b324_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4629fb029e734ace817a97c424776664_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsRepurchasedAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4c387153e294bcb9eaecfe60743c646_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77389ce093254e6ab4f11f9dd0728471_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3313ee63caf64afab4f2c93fbc54124d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65e9fd581d4d433aae76ee66caa8183b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc3fcf315c0347f0b121686f96a2c53f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb8686f5c76e4a7c83ddc6959064840b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i19da2e5ec2ab4bb580c7155fdc8fdfa3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i006db6e632504a099cb649312ea0cba3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic37e46cbf2c242d8899925fc7a112670_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i847b2decf9404ab2a7d6680fdccdf305_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecfde700f02a48f7a31316d1f567cd5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id435bbff99ed49dfa19a3cb32dd76386_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f75c558ed1e49339a2e52215ae52fc0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i701917bbad004fc8b8d81a751eea303d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id65b328d8d2c49c1be2ef55b3625103c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c1221e8e34e4275b4db34697e4ca8b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i564ffd90f9084692ab88b0cf933a98f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f13162a2f8d4549a141594e5f80d879_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8ef9b73660f4b9fadce03cc33bd22f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1a8eb2e429e4d4b9559c6a8a87ef504_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie36e443e3d434b15af03feda51e6777d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50fb13104c73464cb06b6701e9af3093_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id60bea6be43f4ed4804c1fc6a9298e09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8724bdcd3854eaf92373c5d1a807169_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic42c51f1ef8b4c618cd8e6b21c234c55_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifada303dfc0a48749b857d690254e679_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5ba9215cf52449385b12a520287a98a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a44a9521bad4096b6d02caf364c65b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia19985d737da40e0bd8d5ac7bcda0e3d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia7b8e68d1946469abfb59f6c6fda184a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42a83760ddde47c48011002561464667_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf1c2c6447034265b3f50c7be9a87b41_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idabb35ff3f03404f8c6130a1eeb49f61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97e2cdb6c127441b909e910815d3dbbb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f03d4b0fdcb41bd9bebfa7ede027236_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i895e2b3cafef45acb1012b1e03d39ffc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1066e9b68a6348ab93c9493b56791fe8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1595e10ff0084e819adb888f4c577f76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4f8156acc564caab08a1624e564a10c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia81d715fd04f41c4b0fb15cbc97ded7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9bcd75701e244eda1dc59a0f6acf303_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i945c96b3eea1403fa18115aaefba9877_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8a5d8801736420b82120164f7c0089a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9181cc52ee8e454c89c0e1c42c853e15_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38af461ee606432d82a7474978332d8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i373b829238f74628b948e23e7d5c164c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74e4134c43ad43bab33caec94bc82d47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb2a002bc0ef442bb111f2a7206ee130_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i510f34cc51b4405db4a91992d32b1c34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:FixedIncomeFundsEmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22b766219ce347188ad03e3849166f80_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i708ee2efc8f448d3b331e38fcbd4a915_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8dc36c3791284cabb24ca762698700d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic1dc7058692f46668106cf1d6a1e73c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea800c25a6674e09a0af56692d7b5dd1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe300c1a64c647b69fe7bf20e0541942_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d6294050b0144ebb52f2b5cb557783a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69a0b8e765cb46099127a2188cb007e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6428acbb884c4334bce83f1ace7ab19d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id719e5a1d3de4031989293711aa38d3c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a2aaec08b63468499905c6159f8e3da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60dad62f6fb1485a99fd7d1430fc110d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifaff3c08ba9d4d03bd33fcb7a5bbd1fb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i534b8b956faa4f71ab4ccda780e39214_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib078dfc1c37e44c9a48bbe3f9a469f3c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id0406531f0094a13b3244c8fcabda0cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8e9def9531e94f7ea8588aedd9f265d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1c938f472b04e1ea9b5d3856f56cf27_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i500e87bc01cc4b5f93691f5fb1d50fad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id3858c30cf5044e598ca275f01991c28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i996aa7b86fc24b07a4288e7ba5f7df03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie7482d3bafbc41eeac363718494d0f83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i362e3e575b774c4397566b4c1a34e5c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibfef4993c67240b2a0bc234322e964af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id022f4c867cb4232a897b833e40eb0df_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">lly:DefineBenefitPlanOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4833bcba5f4d461da0967d8871780d3b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie600f398f9404e8fbfd23a4c663f06ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3b618356b1e4a8396dee41b547db32f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibcb89163b193490c80c31c918380523b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementHealthCoverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia08920fe3f514f89bc0bd568c9df9ba5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i563701b19f014569b06746781df763bf_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="id838bc258f094c568ea090ce38f5434e_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i0380a187e28a42edbd210299d61d308e_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iecb392cbb3fe4cb8a6314dcd6654394c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc7264a5345342d8aea87087c230aba3_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="i9ae544e01daa4812a088e089d18c14e7_I20120731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-07-31</instant>
        </period>
    </context>
    <context id="i4d2d51a9d7de4602a53112f3a2e3d04c_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="i411602cb723743c380152402a7c692f2_I20130131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="ib4cce461525f410b826a4889ad0f3ea6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icea9f6147fa941e4a11404f04d76bc42_D20090301-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i449428738c2940d49d82f1876796900e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f737098bb3145ceb2c97bdfcc33c357_D20090301-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib194555003c24fe5a77a184233bd6cba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e65f3f67c2d459f9a64e4b7a3a7d1b5_D20090301-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b680abb10c24ec5b54b2120fdc7058f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07adf913f1f54ca989ef31ee491cc698_D20090301-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i290630da973e431eb29fcd22cd423503_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89fbc9d584994ea8be0227e0a79821e4_D20090301-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb83157010844ce786703b9c9bb67d43_D20090301-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1409b6c99dad4d6da1691bc35c7de3cb_D20090301-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b0cea540b384bc08e0afbcf20bece39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib285d2fd260145229843a0c1bf1263f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaeccac6f45794f4a92f62a164ea4c0ca_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i8f52969f387d4ef7ad755da5ae0ffdbf_D20201231-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i684d16bbfe9e4db78119c3012111fe94_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="idfeb86b846074fb89e884673987dab5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if595b7685be743c89bc5dc09daf08440_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8916531131184faea7af74d7cde93d3f_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:DrReddysLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic6404d71a3154085b2ffbe7918c52fdf_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ida3f134ccefd4f4a994809b05af014c1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ied12274b6db14234b7de3a19eb3f0d2c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib4ce9bb84e004603a5019d1c6da66946_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i91a7d9b32f3a4db9a00591e1adce82a6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6923db7df05a4e6e922a6bb5db8a3b41_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7766703b17514542b192609b6e561393_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5d75213e1aba4f7eadb741cb0d1cc298_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib784e78bc05f4285945fc78bbb738f91_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icf4a4a1e1c3745e59d68927cad94276a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibc74b3eb01ad4e50bc04a6977d715d2d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ieb39193d2a16435281dd19dfabba3b42_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i20fb3a01e3c6484686b01e6156c1acd8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0cce948975cd45cfa58c1e76158f0f33_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8ae9df0fe048449392c43fb7186ca248_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic2a384242290465588799dfbd2e7ee83_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i39bb81b83d844b11b7cacd7fcb2e07d3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i022a194d782540f8a8fdfc2d9b226688_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7bbc0a2c1f894a5fa0c07c97d49cc299_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i080fb50d8cac4747bda1c482bee979d5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i615ad14cefcc4ce1a88ced50887fbf6d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24efbe2abb2349b59ae25141fedb34da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if749975463d649e68e1bc14730e552fa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7ae30dfeeb2e4879a0c3b21b26111cad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i569a261af70b4d8ba9f60a58c0e2b9f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i135c068cec7c43d3896b245ca3cde3bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ae1e86516684e95b54071890a6e557b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia22e1113b5f54e35a4a4df39e3e917bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb975f9779f54232a351634d3fd2cd32_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ad7ca588e4b4a668bd791165ae19818_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba7d4dca490147faac33fdce0f0d354d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i964f0a9d08134a599b06447de48f472d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba9496ec064a41e6bacfab535e35a9b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b2f813fac6448c7b98cc7598ddd6c1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib667086cf32f420988bbee8738114965_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie45e19b6d14441ea88cddc6e941da5ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4baa1ec009c445486118e3b4579ec89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8b131f4aa2c4cb88d271c82f1b47bc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f7cbd1f19a34b6789d5526dc3008179_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29a895cde5a54bb5be22a7b5806d3386_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbc47e8810d6412bbab29c0eacb89745_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic2c054d8c5c84127b1e160c82886953d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4da867daad1840d6b255ab18e08ebcd6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd7a83c1653f4b8eaedba242be6d6ff7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2bb8b4f8723f4f02a681499b646ccb15_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2a8513120f404c39a420b6b793e39fbc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i011e32aa84f34a07861fc5d8d38eae10_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c36f2ee8cff49ec82af74c218b0ace1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i007d6fe10f55466ebb1af3bb02b9b84a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i767785ec05f74127a9246bc6ce2f190b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i27dbf880100447d9bf589531096741f5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3bdb72715a234bc193e62ede32a5bbed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee3110d1c0a44663b08bc95d12a2e990_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i193696830a4742cdba4be29dcd7f5251_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic7a3ec013676433f815344f9f683499a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32ce3929549c42488c9d78815eb40512_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9dd52235d591400ebdc756d6a1cb0bc9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i27470f38a1f14522ba67a5d022af05bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia69664129e7348b3b8fd52f216426461_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i43b02af87ac54ca3a6bfb1bc0e3b200e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9799a363894e447a88d58efd03f0b2ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0433259992642cd84137af8b232a207_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c2fcfe7ae7240f8aea48b8993890007_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i42bc8b84cba2465299f8b30a76d2180d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id31f634abe9b49d087c5ebeb30996e11_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iabbc7b2ea00947e8b902df09566e6317_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i26304d3b80a542b5ab77edf4000be691_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a1e386970d94f0abc18ef065866675b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0df68c6465184e8b8f60cebcf0de49e4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifc4be7a2068245ffa89edf317572504d_D20180924-20180924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-24</startDate>
            <endDate>2018-09-24</endDate>
        </period>
    </context>
    <context id="i45097dbde81e4b5a8ddc8854e29196ac_I20180924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-24</instant>
        </period>
    </context>
    <context id="i601d8831c2a84dc6a94bf8abcae67dcf_I20180924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-24</instant>
        </period>
    </context>
    <context id="ia8d16807ca45467296773da1a768103c_D20180924-20180924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-24</startDate>
            <endDate>2018-09-24</endDate>
        </period>
    </context>
    <context id="i25de516d8b1a468d869b65f28c3c0ae4_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:TermFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i0841fa6d26e546d4acee688c1214ee2b_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:TermFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i4759a8743edb4111b4e4b16db8cb6680_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i52daa1d7665e48ae8d99c5d280d6bd5a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b83214520b341e28e9c3eb65c9a0efa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9a3e673a3e6740eba162b41a6b7818e2_D20190311-20190311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lly:ElancoAnimalHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-11</startDate>
            <endDate>2019-03-11</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="medicine">
        <measure>lly:medicine</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="patent">
        <measure>lly:patent</measure>
    </unit>
    <unit id="lawsuit">
        <measure>lly:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>lly:plaintiff</measure>
    </unit>
    <unit id="claimant">
        <measure>lly:claimant</measure>
    </unit>
    <unit id="brl">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="request">
        <measure>lly:request</measure>
    </unit>
    <dei:DocumentAnnualReport
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV8yLTEtMS0xLTA_a10b5315-74c4-4c71-a598-8178eca3f891">true</dei:DocumentAnnualReport>
    <dei:DocumentTransitionReport
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV8zLTEtMS0xLTA_c4ab0c30-64ed-414c-9a36-64e51b5f5cda">false</dei:DocumentTransitionReport>
    <dei:AmendmentFlag
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV80LTEtMS0xLTA_834b5404-fedc-4e0b-a427-de815c53980c">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV81LTEtMS0xLTA_e0fa3135-5fb7-4d12-8828-142be32315d7">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV82LTEtMS0xLTA_fe85aca0-36ef-45b7-b84d-60dc50f7f7ef">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV80L2ZyYWc6ZTI5YWJjNjYzMjM2NDA1YzkwMGQ4YjNkM2M5Y2UwY2EvdGFibGU6MGM4MTAzMjVmYzFlNGIxZGFiZWM1OWIwNzBhMzQ5N2UvdGFibGVyYW5nZTowYzgxMDMyNWZjMWU0YjFkYWJlYzU5YjA3MGEzNDk3ZV83LTEtMS0xLTA_b3c20d44-c2fd-403c-b090-89b82d08de61">0000059478</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="ie8d870ddf29742b896587158690bd8a2_I20190101"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8yMzIyL2ZyYWc6OGViOGRkYzQzMmRjNGNkMGFjZjEzZmFiYjNkM2Q3YzQvdGV4dHJlZ2lvbjo4ZWI4ZGRjNDMyZGM0Y2QwYWNmMTNmYWJiM2QzZDdjNF8zMjk4NTM0ODgzNTkz_058a92ba-a31a-4d16-8453-13f5785f1df7">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2b00c742d1fa4c71b1069e0936d163d8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ1MTk_0bf7a79a-03a8-4be9-83df-152315c973ca">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic6db0bc1ab684eb9bec935aafa00cbe4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3Mg_22167169-de32-49e2-8061-fe64a7bff538">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8yMjkyL2ZyYWc6MzZjZjY1NTliMzY4NDg5OTk0YjZmZDhjMjRiMzdiMWQvdGV4dHJlZ2lvbjozNmNmNjU1OWIzNjg0ODk5OTRiNmZkOGMyNGIzN2IxZF8zMjk4NTM0ODgzMzY4_49b0528d-255b-483a-8bd9-fcacd97eacff">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8yMjkyL2ZyYWc6MzZjZjY1NTliMzY4NDg5OTk0YjZmZDhjMjRiMzdiMWQvdGV4dHJlZ2lvbjozNmNmNjU1OWIzNjg0ODk5OTRiNmZkOGMyNGIzN2IxZF8zMjk4NTM0ODgzMzY4_54b56473-7004-4c68-b02d-7a1fe69533a0">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm
      contextRef="i8916531131184faea7af74d7cde93d3f_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODQvZnJhZzowZmFiODU4ZDhmOTA0NzdmODZjYTJjMDYzZTcyNDE2Ny90ZXh0cmVnaW9uOjBmYWI4NThkOGY5MDQ3N2Y4NmNhMmMwNjNlNzI0MTY3XzI1OQ_1925f4d9-883a-40db-a86a-cf8f536230e0">P21D</lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm>
    <dei:DocumentType
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTI3_2660f4bc-aa7e-499d-ba9e-dc27da129866">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8xMDk5NTExNjMwMzA5_a68ea918-356a-4587-bfac-fcf3b937b5e6">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8xMDk5NTExNjMwMzA5_3b0c9c93-e9f1-4a83-89d0-4d12c23e6683">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzI3_fa18864e-3030-4454-a669-e07d92bee8a7">001-06351</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8xMDk5NTExNjQ0MjE4_d0972d1b-781a-4317-a2b0-c03663306e5b">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWY1YWM0MDFhNDcxNGM2NGIzMTJhZmVkNTg1N2I1MjcvdGFibGVyYW5nZTplZjVhYzQwMWE0NzE0YzY0YjMxMmFmZWQ1ODU3YjUyN18wLTItMS0xLTA_c27a168f-f249-422c-a2c9-72106502cb8c">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWY1YWM0MDFhNDcxNGM2NGIzMTJhZmVkNTg1N2I1MjcvdGFibGVyYW5nZTplZjVhYzQwMWE0NzE0YzY0YjMxMmFmZWQ1ODU3YjUyN18wLTYtMS0xLTA_144b491f-67df-425e-b993-5987abadf30e">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTMw_a1622488-183c-4f26-9f8d-8c487dec0df5">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTE5_ebc0c27d-2ad5-472a-963b-9ef42ad49015">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTI2_553ad931-4eff-4df6-9b66-78ad965e4df3">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTIw_8725f42a-8b86-43c3-ad1a-4be13f228168">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzI5_1a561d19-149a-434a-bec7-2d8f7205a514">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzMz_c07d5673-b068-4fe0-91cd-dfae88708314">276-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i137275eafd4c40f59313788c6e8bc624_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8xLTAtMS0xLTA_b11cfa2b-78ba-4060-9add-f8f84822e4b5">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i137275eafd4c40f59313788c6e8bc624_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8xLTEtMS0xLTA_4eb82b06-c73b-4668-8604-c5df2fc5c3d8">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i137275eafd4c40f59313788c6e8bc624_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8xLTItMS0xLTA_0f8b2bab-936d-4684-967e-24040c99d4ac">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6ef7d2358d3d4624831eba2ba35e625c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8yLTAtMS0xLTA_7101f591-d1b0-4c40-bc95-4be5f5f3cd0e">1.000% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6ef7d2358d3d4624831eba2ba35e625c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8yLTEtMS0xLTA_34e290bb-faaf-411f-a3b7-f83aaba84a3b">LLY22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6ef7d2358d3d4624831eba2ba35e625c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8yLTItMS0xLTA_d66abeb6-fe3d-412f-b198-4d939cdd6e33">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="idf054c1e69d548fabc27199bc26a11da_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8zLTAtMS0xLTA_73a9a0c9-e6a4-4c38-8ecc-a4aa2c6ab5aa">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idf054c1e69d548fabc27199bc26a11da_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8zLTEtMS0xLTA_3373056c-898f-4ed2-82c5-2e1f54fd7f2c">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idf054c1e69d548fabc27199bc26a11da_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl8zLTItMS0xLTA_b5943dd0-8c48-4643-9464-5e124d7ed294">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ib3db037c2fb245969975a8e68da5d13f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl80LTAtMS0xLTA_39063de5-2e17-418d-a01b-826ac2d6bbd2">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib3db037c2fb245969975a8e68da5d13f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl80LTEtMS0xLTA_4ad636ef-bdf0-4875-a819-bd8100802410">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib3db037c2fb245969975a8e68da5d13f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl80LTItMS0xLTA_c5f26e38-f1e3-44da-bc96-e6e0078d22ac">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i7fa23ebc91dc4948b44e17114afcbe93_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl81LTAtMS0xLTA_f19b3440-5ad9-4b20-8905-e81472d350d2">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7fa23ebc91dc4948b44e17114afcbe93_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl81LTEtMS0xLTA_de05706d-ec89-4d52-9461-aabbc3793973">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7fa23ebc91dc4948b44e17114afcbe93_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl81LTItMS0xLTA_f20334fb-d4fe-43e5-9a4f-b0344dc7a70a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6337489efeaf470db72beaad17305bf8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl82LTAtMS0xLTA_3dac96bd-ad48-4b28-8510-fed9887aff27">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6337489efeaf470db72beaad17305bf8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl82LTEtMS0xLTA_ed6ecfba-1bc4-4b73-a6e7-cbf86b5bffea">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6337489efeaf470db72beaad17305bf8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl82LTItMS0xLTA_3484be37-b985-4c2e-992e-60ee130fbd8f">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i08c82f670af140a8bac93e72206aac4e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl83LTAtMS0xLTA_1cc1095d-0999-45ae-ae65-12ac5e541888">6.77%&#160;Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i08c82f670af140a8bac93e72206aac4e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl83LTEtMS0xLTA_dc7722b2-7088-4727-b3ee-d004c9651b48">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i08c82f670af140a8bac93e72206aac4e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl83LTItMS0xLTA_32a02ec2-e01e-462b-857a-54bfa7bd8a9c">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if9d00685b69642528d03b4781524325b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl84LTAtMS0xLTA_63bd2d93-0a5b-403d-91dc-f6b815a0a303">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if9d00685b69642528d03b4781524325b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl84LTEtMS0xLTA_4e982e47-42fb-4e93-a5e5-56c822c531e3">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if9d00685b69642528d03b4781524325b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6NjIzYmNhNWEwM2NiNGI5MTgyMDMzMjFiMTY1Yjk1Y2YvdGFibGVyYW5nZTo2MjNiY2E1YTAzY2I0YjkxODIwMzMyMWIxNjViOTVjZl84LTItMS0xLTA_8b696168-59ba-43a0-809d-40f072415caa">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTE4_645d9321-49d3-4daf-93be-082e3be54b58">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTIy_1e80f27b-9ccf-4b4d-afd3-b0047e4caadb">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTI5_5af5e9c0-1f5d-47e1-a55d-90e9156f420f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yNTIz_1acadc3f-d639-4f6a-bdda-43a543b87443">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWQ0YmJjODU1ZDIwNDJhODk1NDc1YjA1MTg5M2UzMjUvdGFibGVyYW5nZTplZDRiYmM4NTVkMjA0MmE4OTU0NzViMDUxODkzZTMyNV8wLTAtMS0xLTA_c6cf0fa7-34d8-44ad-8ecd-a0dedb485be8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWQ0YmJjODU1ZDIwNDJhODk1NDc1YjA1MTg5M2UzMjUvdGFibGVyYW5nZTplZDRiYmM4NTVkMjA0MmE4OTU0NzViMDUxODkzZTMyNV8xLTctMS0xLTA_858dc86f-ea91-436b-9f13-01b0a6f1b37f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGFibGU6ZWQ0YmJjODU1ZDIwNDJhODk1NDc1YjA1MTg5M2UzMjUvdGFibGVyYW5nZTplZDRiYmM4NTVkMjA0MmE4OTU0NzViMDUxODkzZTMyNV8yLTctMS0xLTA_ed50865d-3a8d-496c-a3d4-16f7056d03b7">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzI2_2c022f0e-5d3c-4ec3-9504-060f019ebf27">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjk4NTM0OTAxMzM0_9e41ff50-4dfe-4775-8aae-a3aca98f7625">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i61b9de7700734098b07f8a46f43d9497_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yMjQz_47af833f-fa58-4693-a110-3e52d578b6f8"
      unitRef="usd">138907000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i86a8c3eb7a2a4ef48d31b3028fe3303f_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8yMzAy_67901873-35d3-4759-96c6-73583d8d808b"
      unitRef="shares">958425693</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xL2ZyYWc6ODE2MTMwODVlNTcyNDg0ZmI2YjQ0ZDEyMDdiYTg0ZmUvdGV4dHJlZ2lvbjo4MTYxMzA4NWU1NzI0ODRmYjZiNDRkMTIwN2JhODRmZV8zMjQzNTU5MzAzNzM5OQ_8e71fa79-c438-40fb-a8ac-ee5eaa67c9ad">Portions of the Registrant&#x2019;s Proxy Statement for the 2021 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:Revenues
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMS00LTEtMS0w_3716c715-c3f4-488c-abc1-91b844baf37a"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMS02LTEtMS0w_f66e91ff-6da6-43a0-af55-196046989c79"
      unitRef="usd">22319500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMS04LTEtMS0w_537e5cc1-aa01-42c8-8dac-9a74a06ee98b"
      unitRef="usd">21493300000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMy00LTEtMS0w_d26383d9-edbd-4689-b7b0-afef5527b4bf"
      unitRef="usd">5483300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMy02LTEtMS0w_dd2a6442-137c-4bca-b716-8e0a88e226be"
      unitRef="usd">4721200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMy04LTEtMS0w_d6891eee-8b96-43dd-836e-086c9abde013"
      unitRef="usd">4681700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNC00LTEtMS0w_a3a58120-668e-47cf-b601-12aebb1a0c12"
      unitRef="usd">6085700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNC02LTEtMS0w_35354b43-c4ea-46b2-a0e1-bf4dd7b4afd1"
      unitRef="usd">5595000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNC04LTEtMS0w_4c360ba4-11c1-42f5-9739-2d8d46cc35f9"
      unitRef="usd">5051200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNS00LTEtMS0w_d58d7ecf-21e3-4580-ad51-f1e2c486e7ce"
      unitRef="usd">6121200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNS02LTEtMS0w_ca1965b3-9859-440d-9360-41ad89ae45be"
      unitRef="usd">6213800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNS04LTEtMS0w_b56c0318-25b7-48a4-af18-056a0496915a"
      unitRef="usd">5975100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNi00LTEtMS0w_7644fb85-2cef-46fb-86c4-b0a620b5739e"
      unitRef="usd">660400000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNi02LTEtMS0w_7bf7be82-e73a-42f0-8500-b4e7e2021415"
      unitRef="usd">239600000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNi04LTEtMS0w_555125b5-4da5-4c65-a1ce-6cff430afef1"
      unitRef="usd">1983900000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNy00LTEtMS0w_8fc23adb-8d3b-4cd1-b288-5a86a2eab1af"
      unitRef="usd">131200000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNy02LTEtMS0w_7b970192-df19-44d5-b010-96dd70c3134f"
      unitRef="usd">575600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfNy04LTEtMS0w_0bde3f06-10b1-4559-990a-34de17434d54"
      unitRef="usd">266900000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOC00LTEtMS0w_21e9ab5f-2bb1-4aa0-a13c-eda8cce85a8d"
      unitRef="usd">1171900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOC02LTEtMS0w_01871237-1092-465e-a3af-7623a6081fc2"
      unitRef="usd">291600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOC04LTEtMS0w_29458611-195f-4246-a3f2-0e3b8685ed8d"
      unitRef="usd">145600000</us-gaap:NonoperatingIncomeExpense>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOS00LTEtMS0w_e58cabb7-bfb0-4c75-a595-8aa918a9d7be"
      unitRef="usd">17309900000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOS02LTEtMS0w_253f6247-c839-438b-8f5d-6591adc34ceb"
      unitRef="usd">17053600000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfOS04LTEtMS0w_a3303a13-1e39-4c63-8482-1d5e48d460cd"
      unitRef="usd">17813200000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTAtNC0xLTEtMA_b3a03f5b-f8e4-419d-b124-557f8440d2c3"
      unitRef="usd">7229900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTAtNi0xLTEtMA_2b3f2ef5-dce4-4ece-a486-d8fc2bedb52a"
      unitRef="usd">5265900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTAtOC0xLTEtMA_3c25438c-6a0b-47ce-84db-8796fde029ac"
      unitRef="usd">3680100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTEtNC0xLTEtMA_169a7392-7255-4495-ad59-d4ee84e47b13"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTEtNi0xLTEtMA_95ff2293-7b6c-4708-b943-27faf82e646d"
      unitRef="usd">628000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTEtOC0xLTEtMA_71d7addd-422e-4450-a8f0-fe9cc627bf3a"
      unitRef="usd">529500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTItNC0xLTEtMA_65878936-09c7-4191-b971-33cc36ddd95a"
      unitRef="usd">6193700000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTItNi0xLTEtMA_66163094-7c65-4952-8c94-91266af63cc0"
      unitRef="usd">4637900000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTItOC0xLTEtMA_7461e336-ea60-4306-9064-618cecc0f968"
      unitRef="usd">3150600000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTMtNC0xLTEtMA_5f72cdec-5f2b-4bda-abb4-dbc896253f12"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTMtNi0xLTEtMA_b33271bc-a7d4-4811-a574-41ab536c1a82"
      unitRef="usd">3680500000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTMtOC0xLTEtMA_ffa4fe41-02d2-42bc-9026-99f0bb50fe48"
      unitRef="usd">81400000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTQtNC0xLTEtMA_aa9be0e8-1cd6-48a2-a963-c1892051c019"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTQtNi0xLTEtMA_67b28038-7fdf-4858-8f1e-2af9de4d04bf"
      unitRef="usd">8318400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTQtOC0xLTEtMA_0419c352-67cd-41e2-a26f-5f578afcb3ae"
      unitRef="usd">3232000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTctNC0xLTEtMA_327263a1-6320-4c51-ad1e-e9ff65c6bd14"
      unitRef="usdPerShare">6.82</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTctNi0xLTEtMA_2dc8b9cd-9baa-4453-81c8-809026fcd2e5"
      unitRef="usdPerShare">4.98</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTctOC0xLTEtMA_b51a4583-244a-4b6b-a444-b3b3c15f2f77"
      unitRef="usdPerShare">3.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTgtNC0xLTEtMA_01fd4b8a-0241-4d63-bd6a-069353b0eb65"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTgtNi0xLTEtMA_ed0a8182-f1a5-480a-975c-dd16de9c4f4f"
      unitRef="usdPerShare">3.95</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTgtOC0xLTEtMA_03c0ea5f-e5ee-43b7-a91e-dea51b06d3d5"
      unitRef="usdPerShare">0.07</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTktNC0xLTEtMA_845c2569-31a0-405f-b270-ac5790d76728"
      unitRef="usdPerShare">6.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTktNi0xLTEtMA_23f89dcb-28aa-4ca8-8ee8-fce14059f2cc"
      unitRef="usdPerShare">8.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMTktOC0xLTEtMA_23f267a5-6120-4a08-a19f-b11acfe82a94"
      unitRef="usdPerShare">3.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjEtNC0xLTEtMA_17f4c7bd-651f-4724-8a2a-4d80eb6582bb"
      unitRef="usdPerShare">6.79</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjEtNi0xLTEtMA_d8acaabb-c408-4eee-a692-65513f739c9c"
      unitRef="usdPerShare">4.96</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjEtOC0xLTEtMA_87fa2e7f-d2bd-4b50-b806-d611332c9663"
      unitRef="usdPerShare">3.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjItNC0xLTEtMA_3db66488-54ce-4d34-92d0-ec0fa41ac127"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjItNi0xLTEtMA_f5684416-7f0b-46f4-b82a-d6d9fc90c6f6"
      unitRef="usdPerShare">3.93</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjItOC0xLTEtMA_546fd9b6-dd62-4c45-96ea-475c436fdbee"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjMtNC0xLTEtMA_73dd2064-88d9-4a24-82b8-0a30ed487c27"
      unitRef="usdPerShare">6.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjMtNi0xLTEtMA_07f79549-a89d-438d-b09e-c007b0f9ec37"
      unitRef="usdPerShare">8.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjMtOC0xLTEtMA_08629497-44ed-4fb1-b656-bb8f4bd3fd40"
      unitRef="usdPerShare">3.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjYtNC0xLTEtMA_ad6f48be-d709-4427-8203-468a0b03d5e0"
      unitRef="shares">907634000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjYtNi0xLTEtMA_17f28502-ecf7-4286-bd4a-b8d7fdf15cf8"
      unitRef="shares">931059000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjYtOC0xLTEtMA_55d9f929-2364-4fe9-9fed-c65220a52a0b"
      unitRef="shares">1027721000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjctNC0xLTEtMA_6ef41d0a-ad6a-4796-ac82-8bb6797acc3c"
      unitRef="shares">912505000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjctNi0xLTEtMA_4f5a1c21-c7c0-40c9-8bf7-b018ef34f4d3"
      unitRef="shares">935684000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84NS9mcmFnOjJhY2Q5ZmYzYTlmZDQ5YTg5YzFjYmViNmM1OWFjZWUzL3RhYmxlOmY2MmVhMmMyNzAyMDRmOGQ5NDkxNGM5MjUyMTBkZTZjL3RhYmxlcmFuZ2U6ZjYyZWEyYzI3MDIwNGY4ZDk0OTE0YzkyNTIxMGRlNmNfMjctOC0xLTEtMA_ca500ee9-e0a4-4514-8d72-04f6e3a7d471"
      unitRef="shares">1033667000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMS00LTEtMS0w_a2c06e30-3e98-4462-a063-0d910978a3fc"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMS02LTEtMS0w_c3ba4f70-b78b-451f-99fb-04d3f1419e8e"
      unitRef="usd">8318400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMS04LTEtMS0w_ee6a7c7f-9bbc-47cd-bdbf-b3b1a90ad7f4"
      unitRef="usd">3232000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMy00LTEtMS0w_d9e8842e-3fe4-4aba-9ed4-c61bfefcc625"
      unitRef="usd">122100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMy02LTEtMS0w_36b5cb12-532e-4ab6-8bd4-9f82c3c38135"
      unitRef="usd">-89900000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMy04LTEtMS0w_b666d56d-2542-4fc8-bcde-3cbc73a560ee"
      unitRef="usd">-429600000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNC00LTEtMS0w_e23df812-a834-40d4-8bfa-4b692911cab9"
      unitRef="usd">14200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNC02LTEtMS0w_ea8034d2-d88d-410b-ae20-6ec8b5e6a108"
      unitRef="usd">34400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNC04LTEtMS0w_c8131ee0-5aee-438a-b9f4-128ff7573f8c"
      unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNS00LTEtMS0w_9b764153-c690-4bcb-ace3-e409be4f4102"
      unitRef="usd">157100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNS02LTEtMS0w_c3dee13a-1e98-4dc9-af41-389980e78458"
      unitRef="usd">970000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNS04LTEtMS0w_886c17b9-88d8-4aba-a78e-0683564dbcc7"
      unitRef="usd">-544000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNi00LTEtMS0w_c4bc9f59-eb71-4a30-b66e-5816d633b747"
      unitRef="usd">-152900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNi02LTEtMS0w_66a84d07-4b1c-4edb-891d-1a8857a7be29"
      unitRef="usd">34300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNi04LTEtMS0w_e27794e1-673f-4884-838e-74bc31c3a810"
      unitRef="usd">-6000000.0</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNy00LTEtMS0w_9b01297c-5613-4800-9cc0-cc9d8eee5a73"
      unitRef="usd">-173700000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNy02LTEtMS0w_5b777469-0fa9-4606-afbb-948bf970e4c1"
      unitRef="usd">-991200000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfNy04LTEtMS0w_c3ba6a5e-0045-4d55-afdf-f56dfeb3d3c0"
      unitRef="usd">99600000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOC00LTEtMS0w_de767a44-0fff-42b6-8a95-70f9551dceda"
      unitRef="usd">-200900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOC02LTEtMS0w_948c53a7-76f9-49bc-98ba-80d0327340cb"
      unitRef="usd">-151000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOC04LTEtMS0w_f0d84c71-af4c-4e21-b799-5374524b5ec1"
      unitRef="usd">30300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iebfe9598260a447ba9e16ba1e9c6ed68_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOS00LTEtMS0w_6bb8280b-e57f-4dab-a90e-ec528e754b4d"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic8e0527046d9420eba85c2e7997c4b79_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOS02LTEtMS0w_70d46e63-97b4-4e2a-854d-23da2486728a"
      unitRef="usd">-840200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if5f87322c97e42a2b941ec910aed2655_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfOS04LTEtMS0w_cb32b8d0-1f74-43ef-924a-3f955e9c00b3"
      unitRef="usd">69300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8341671b44cc41d5a18d4af59468c567_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTAtNC0xLTEtMA_3360dc8c-d98a-4c31-94e2-96f8dab95036"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9e87e689a45f429e8cf9eefc3f7fadc6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTAtNi0xLTEtMA_4aaec611-8df8-4f95-bf52-d82d081241e5"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iab11f7e22e3d4369a89e0b9a64389e84_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTAtOC0xLTEtMA_25d6ede8-58a0-4c8a-ab36-943fa330255c"
      unitRef="usd">14300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTEtNC0xLTEtMA_e46ed519-de8a-47fb-9b75-f0b5b0480649"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTEtNi0xLTEtMA_09d06c3a-db3b-44da-9431-661edc2b38f1"
      unitRef="usd">-783400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTEtOC0xLTEtMA_b3af3714-45c6-43b1-acb3-817cc874a42a"
      unitRef="usd">83600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTItNC0xLTEtMA_0a50aa7d-0119-490a-ba1b-4476cab37ebb"
      unitRef="usd">6220900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTItNi0xLTEtMA_cccd933e-229a-4d10-9884-ca4845512a40"
      unitRef="usd">7535000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV84OC9mcmFnOjQxZDQwNDlkM2Q3MTQ5NTBhMjExOGFiODI3NzQ5MjJjL3RhYmxlOmUyZGZjZjA5YTkxMTQ3ZjY5MmViMmMxY2M0ZDEyNGI2L3RhYmxlcmFuZ2U6ZTJkZmNmMDlhOTExNDdmNjkyZWIyYzFjYzRkMTI0YjZfMTItOC0xLTEtMA_60a05a0f-5be8-44d6-a0bd-94de329b40f7"
      unitRef="usd">3315600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMy00LTEtMS0w_1cd81659-9fbf-4b20-b784-a647e6479427"
      unitRef="usd">3657100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMy02LTEtMS0w_9b5a73ef-1f24-42a1-83ce-264aa4a00cf8"
      unitRef="usd">2337500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNC00LTEtMS0w_71fd4300-ea64-473d-901e-68e41bfadefc"
      unitRef="usd">24200000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNC02LTEtMS0w_988bd81b-510f-4ec0-a8c4-969dfabac3be"
      unitRef="usd">101000000.0</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNS0wLTEtMS0wL3RleHRyZWdpb246MDRhNjlkYWI3N2VhNDhlNDg5MDQyNmU0MWZkZjdlZGFfMTA5OTUxMTYyNzk1MQ_98c5b337-4dd9-4d35-95b1-3febac205697"
      unitRef="usd">25900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNS0wLTEtMS0wL3RleHRyZWdpb246MDRhNjlkYWI3N2VhNDhlNDg5MDQyNmU0MWZkZjdlZGFfMTA5OTUxMTYyNzk1OA_66bfd9d1-0599-4446-bcae-d6008f1e441b"
      unitRef="usd">22400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNS00LTEtMS0w_aceea3db-b987-4a27-bcb4-4b21add28d6c"
      unitRef="usd">5875300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNS02LTEtMS0w_429d6c71-0379-4d17-8bf0-6b48eb729b4d"
      unitRef="usd">4547300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivables
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNi00LTEtMS0w_e6003538-9b72-4956-8641-9ace94ae3c67"
      unitRef="usd">1053700000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNi02LTEtMS0w_12e1e60a-766c-40c8-8b23-57bf3945d7d1"
      unitRef="usd">994200000</us-gaap:OtherReceivables>
    <us-gaap:InventoryNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNy00LTEtMS0w_c12f5e6b-aa14-45dc-b61f-2ab2bb65f8b7"
      unitRef="usd">3980300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNy02LTEtMS0w_c66400b3-5a7f-439d-a375-835db4a0cb63"
      unitRef="usd">3190700000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfOC00LTEtMS0w_73c5b198-f9dc-4c63-bcc9-8f23bd224170"
      unitRef="usd">2871500000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfOC02LTEtMS0w_ff4a8e2b-8c2c-4c20-a576-8ca463e799a7"
      unitRef="usd">2538900000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTAtNC0xLTEtMA_6ce3a32d-4c28-45e3-bf6d-45abcfe379a2"
      unitRef="usd">17462100000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTAtNi0xLTEtMA_484bdcd2-a0a7-4298-bd54-6d43a5a7263e"
      unitRef="usd">13709600000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTEtNC0xLTEtMA_c6311356-1993-469c-9a7f-a3d7144ff155"
      unitRef="usd">2966800000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTEtNi0xLTEtMA_da7bb58f-c525-4ad0-a8a7-adbccf7602c5"
      unitRef="usd">1962400000</us-gaap:LongTermInvestments>
    <us-gaap:Goodwill
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTItNC0xLTEtMA_047ac968-c230-4072-81d8-04c6d468aa2a"
      unitRef="usd">3766500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTItNi0xLTEtMA_9b305c08-f9e9-4a35-9269-0ccc821c2306"
      unitRef="usd">3679400000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTMtNC0xLTEtMA_e6336d08-61ee-401b-a5bb-eca65373e4ec"
      unitRef="usd">7450000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTMtNi0xLTEtMA_612c59c9-b5eb-46a3-9312-c75259f01a7c"
      unitRef="usd">6618000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTQtNC0xLTEtMA_2726ad91-a489-4f3d-bf14-8f64ded9aff1"
      unitRef="usd">2830400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTQtNi0xLTEtMA_6bb53aeb-30b9-41fb-a29e-4945e54ed750"
      unitRef="usd">2572600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTUtNC0xLTEtMA_7de041b7-a343-469c-ba8b-6b9627e4f10f"
      unitRef="usd">8681900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTUtNi0xLTEtMA_67a0ef7e-701e-48fc-ba41-6aa16466e2d2"
      unitRef="usd">7872900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTctNC0xLTEtMA_c875b222-cd8a-46b4-8ded-af289179b759"
      unitRef="usd">3475400000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTctNi0xLTEtMA_7dd8fe8e-662b-419f-abe1-f470d3779c92"
      unitRef="usd">2871200000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:Assets
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTktNC0xLTEtMA_36fb666f-9db2-49e0-8dd1-1ceef39a4b94"
      unitRef="usd">46633100000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMTktNi0xLTEtMA_7f195467-779b-4a4b-828b-121458c724d4"
      unitRef="usd">39286100000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjItNC0xLTEtMA_9f4d687f-0735-450c-9797-1deb10f8c5bd"
      unitRef="usd">8700000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjItNi0xLTEtMA_f07d7174-ba43-4879-a48b-c00b393dc786"
      unitRef="usd">1499300000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjMtNC0xLTEtMA_864e0fd6-0729-415e-a488-97d587fa7433"
      unitRef="usd">1606700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjMtNi0xLTEtMA_eb76be37-bdaf-4419-ac38-144c5a4c34e5"
      unitRef="usd">1405300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjQtNC0xLTEtMA_f2fefaff-419e-40c9-8707-d69dd1316681"
      unitRef="usd">997200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjQtNi0xLTEtMA_c0727fb3-2982-4f32-ba8c-d85bc9569011"
      unitRef="usd">915500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lly:SalesRebatesAndDiscounts
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjUtNC0xLTEtMA_4a098dc8-d18e-4b7a-9483-79e323d51d3e"
      unitRef="usd">5853000000.0</lly:SalesRebatesAndDiscounts>
    <lly:SalesRebatesAndDiscounts
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjUtNi0xLTEtMA_cdbd8327-508f-4a01-ab11-bce085fba399"
      unitRef="usd">4933600000</lly:SalesRebatesAndDiscounts>
    <us-gaap:DividendsPayableCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjYtNC0xLTEtMA_c098d284-63db-4bbc-b995-3a22fd2d2706"
      unitRef="usd">770600000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjYtNi0xLTEtMA_4c4d9bbb-272a-41ca-87a9-a0a0e086514e"
      unitRef="usd">671500000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjctNC0xLTEtMA_e94b5e4e-2e6c-461d-85b8-cbacbadbba95"
      unitRef="usd">495100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjctNi0xLTEtMA_5c7beee7-0d35-4769-ad9a-13cd19166098"
      unitRef="usd">160600000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjgtNC0xLTEtMA_76110027-d9fc-4e35-87c8-e093ed81e911"
      unitRef="usd">2750300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMjgtNi0xLTEtMA_020acbaf-7f0c-4b6c-8849-c340f7a24fd4"
      unitRef="usd">2189400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzAtNC0xLTEtMA_693cbdd6-9e2d-4a4a-89be-7892c8233a24"
      unitRef="usd">12481600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzAtNi0xLTEtMA_84fea7be-60d4-4f30-953d-e598482ecdef"
      unitRef="usd">11775200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzItNC0xLTEtMA_0a4bd51c-cf2c-42d3-a9cf-4690fbe57c34"
      unitRef="usd">16586600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzItNi0xLTEtMA_17743dcb-3748-4232-ac2d-44a93e916653"
      unitRef="usd">13817900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzQtNC0xLTEtMA_af350e79-2490-4caa-91f2-b943a0bb42f8"
      unitRef="usd">4094500000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzQtNi0xLTEtMA_dac9a0cf-bec0-4121-9837-fb1063dd5d6c"
      unitRef="usd">3698200000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzUtNC0xLTEtMA_d4cacabe-001c-4807-a922-dc6b51a63faf"
      unitRef="usd">3837800000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzUtNi0xLTEtMA_08b57e5e-b423-4ab1-aed6-07457ec2e839"
      unitRef="usd">3607200000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzYtNC0xLTEtMA_3f9cba6c-9a7f-4e1a-bcf1-dae211a0e599"
      unitRef="usd">1707500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzYtNi0xLTEtMA_47d01b8b-2494-4dc3-af1d-01755dcead16"
      unitRef="usd">1501000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzctNC0xLTEtMA_b0d2f201-3ce9-47b2-ad25-d018ae62e39c"
      unitRef="usd">2099900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzctNi0xLTEtMA_4e39313c-dd02-4e3a-8ae7-65a96a138c35"
      unitRef="usd">2187500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzktNC0xLTEtMA_0ec23cb4-6a28-4f06-8c6e-c96dc46aefc3"
      unitRef="usd">28326300000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfMzktNi0xLTEtMA_bf606bac-6a20-4017-a7f4-a05c3e2b1dfc"
      unitRef="usd">24811800000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDAtNC0xLTEtMA_81d3ef60-ca54-4dd2-b67f-d5b834e1c968"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDAtNi0xLTEtMA_ee2291d3-0126-4404-ad39-e1b04b9a1b68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmU3NTQ1ODg5MDllNTQ5MDdhNGZlNjY2ZWFjMjRhNDlmXzEwOTk1MTE2MjgwMzU_8348d565-333e-42bd-9a55-f37203b4f74b"
      unitRef="shares">3200000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmU3NTQ1ODg5MDllNTQ5MDdhNGZlNjY2ZWFjMjRhNDlmXzEwOTk1MTE2MjgwMzU_f050bda0-b7ee-4f54-96ab-7d866ed24bc1"
      unitRef="shares">3200000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmU3NTQ1ODg5MDllNTQ5MDdhNGZlNjY2ZWFjMjRhNDlmXzEwOTk1MTE2MjgwMTY_dc0b96ad-25a7-445e-bcf1-1f08efd6d225"
      unitRef="shares">957077</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmU3NTQ1ODg5MDllNTQ5MDdhNGZlNjY2ZWFjMjRhNDlmXzEwOTk1MTE2Mjc5MDE_35c24d91-1fb6-484c-aafa-ea57170327d9"
      unitRef="shares">958056</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItNC0xLTEtMA_14336526-3ee3-4cbe-a7e4-6001605069c8"
      unitRef="usd">598200000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDItNi0xLTEtMA_047f8032-729d-42f1-b1a3-31bef468a73c"
      unitRef="usd">598800000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDMtNC0xLTEtMA_4a65b13a-db3f-4733-a5ba-4805d7abd6fd"
      unitRef="usd">6778500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDMtNi0xLTEtMA_b0196f9c-f29f-4bbc-80c6-bb900d65214e"
      unitRef="usd">6685300000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDQtNC0xLTEtMA_63471e39-09b3-4d17-8bd4-1c043be2f4bf"
      unitRef="usd">7830200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDQtNi0xLTEtMA_b155bb57-1379-43d3-a818-759bac10068d"
      unitRef="usd">4920400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDUtNC0xLTEtMA_bf4f7370-143f-49d3-9fd5-c0b62cbd882d"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDUtNi0xLTEtMA_55ebd3a1-889e-4a4d-8b53-184d5b490df1"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDYtNC0xLTEtMA_172fbd8c-4608-453d-b972-ce508d403393"
      unitRef="usd">-6496400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDYtNi0xLTEtMA_4d06fecf-5729-49ee-a83d-c7f3f234172f"
      unitRef="usd">-6523600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDctNC0xLTEtMA_f07949fb-0cb8-4862-a9d3-3b4acb91d8fb"
      unitRef="usd">55700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDctNi0xLTEtMA_88bc186c-3092-4e81-a40f-733e03146bcb"
      unitRef="usd">60800000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDgtNC0xLTEtMA_304b5a50-94ff-47d5-94cb-7e83969cfec7"
      unitRef="usd">5641600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDgtNi0xLTEtMA_6eb0eff1-b430-4de3-9f07-de6276dfe4d1"
      unitRef="usd">2606900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDktNC0xLTEtMA_a58e1f4d-ffaf-4890-95d7-1fb85248b840"
      unitRef="usd">183600000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNDktNi0xLTEtMA_4d21dd28-9fca-491a-a542-74e0fe4f65fb"
      unitRef="usd">92200000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNTAtNC0xLTEtMA_63e3dcf4-5b7f-4281-a935-51aecff9586e"
      unitRef="usd">5825200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNTAtNi0xLTEtMA_cbfd7755-a6e9-4dc5-ae42-3a9288a32289"
      unitRef="usd">2699100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNTEtNC0xLTEtMA_dda399b5-0f6c-4184-9458-756efaae2ac1"
      unitRef="usd">46633100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85MS9mcmFnOmUwMzRiZjkwMWJiNDQ4YmNiYjcwNTEzMTQ1NmVkMDZhL3RhYmxlOjlhM2RiNjA5ZGI0NzQ4NTA5NzAzYWIzZDcyNmVkNGFjL3RhYmxlcmFuZ2U6OWEzZGI2MDlkYjQ3NDg1MDk3MDNhYjNkNzI2ZWQ0YWNfNTEtNi0xLTEtMA_6c58ebf4-0c14-4a08-96fe-a9f6189dc36e"
      unitRef="usd">39286100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i184cadb6a52c45e68d6a9a4c2738bc68_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xLTEtMS0w_6438e784-7765-4f35-95aa-d5a769c3b90c"
      unitRef="shares">1100672000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i184cadb6a52c45e68d6a9a4c2738bc68_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0zLTEtMS0w_a44c43c1-53e9-4fd3-a1e6-8750a3854cd8"
      unitRef="usd">687900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27083e2ab25e4d04a25e1ef83d0b7877_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy01LTEtMS0w_cbc15713-e261-4c32-a93d-ccfdaf9642ab"
      unitRef="usd">5817800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i045bb911bff14e9aa36f1a05bf3e92a5_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy03LTEtMS0w_7f943f70-3f69-492e-af10-33656f4dc8d9"
      unitRef="usd">13894100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib70725e180744eb1954d643e7a5a963a_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy05LTEtMS0w_fe989f99-3e54-4394-8d7f-d42137fcd7c8"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae684e1f51624a5884d558a8b1eea7ab_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xMS0xLTEtMA_55217dfd-edb6-49d0-a6f1-846b0817a1a3"
      unitRef="usd">-5718600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i724dac2e02db4426bbe5e17f9903b032_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xMy0xLTEtMA_59ac2078-6063-496f-a51f-6a43aa830446"
      unitRef="shares">664000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i724dac2e02db4426bbe5e17f9903b032_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xNS0xLTEtMA_e87de40a-ad1a-4e5b-ae86-c61b09c83c7f"
      unitRef="usd">-75800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03c1c5fc9e8a49c99deefea40e94e712_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMy0xNy0xLTEtMA_2d042376-03d3-403d-be10-56b368b2e6cd"
      unitRef="usd">75700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i636193b834b64dd6bb822cf51cc578f7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNC03LTEtMS0w_bd7a8771-63ca-4db8-b40e-7d6ca2fd12ed"
      unitRef="usd">3232000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i28716e79250245dd90132d730ab4c041_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNC0xNy0xLTEtMA_f750fc8b-6a84-47e1-a496-9dea584f851b"
      unitRef="usd">3700000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNS0xMS0xLTEtMA_ad47df89-516e-4be5-b704-d080b2735705"
      unitRef="usd">85600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i28716e79250245dd90132d730ab4c041_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNS0xNy0xLTEtMA_497d60db-1843-49d0-ac52-11b04bf3cef4"
      unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNi0wLTEtMS0xNTIwMS90ZXh0cmVnaW9uOmVhZGUxMjk1NTA1MjQ2MzlhOWIxZDdjMjk4NzFmZWVmXzEwOTk1MTE2Mjc4MjE_604c94d3-b417-4a95-b85b-ed050dcc6f0e"
      unitRef="usdPerShare">2.33</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i636193b834b64dd6bb822cf51cc578f7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNi03LTEtMS0w_4d922175-c395-4327-ab98-4b572673cdcc"
      unitRef="usd">2372000000.0</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy0xLTEtMS0w_63d364de-941c-4783-a1f0-e2934fe3f2c4"
      unitRef="shares">45882000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy0zLTEtMS0w_d515327e-2dc3-4343-bb2a-7ad028350509"
      unitRef="usd">28700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i636193b834b64dd6bb822cf51cc578f7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy03LTEtMS0w_44d84af4-bd36-4963-b952-113fd5d7d1a1"
      unitRef="usd">4122000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy0xMy0xLTEtMA_c1ec5395-2532-42d0-b325-ca07b3dbad51"
      unitRef="shares">45882000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfNy0xNS0xLTEtMA_313a502b-8c63-4a02-9f4d-f563cff9736f"
      unitRef="usd">-4150700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOC0xMy0xLTEtMA_c584f2c1-a1e6-48e3-976f-83e51514c2fb"
      unitRef="shares">45882000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOC0xNS0xLTEtMA_7b152a10-1c78-4c69-a10f-732c475b00a9"
      unitRef="usd">4150700000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS0xLTEtMS0w_72dd5a7c-fff6-42d6-91aa-ecf7ccb06a4b"
      unitRef="shares">2849000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib6cb33647fe046d48bce225cafa8c5d4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS0zLTEtMS0w_71bc88e5-be55-41a3-a247-acb6610d3b39"
      unitRef="usd">1800000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4f64538c2968464bb7e99808fc376334_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS01LTEtMS0w_5db4372d-4994-47ac-86b1-74d2b078ba6d"
      unitRef="usd">-139000000.0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS0xMy0xLTEtMA_3db86d43-e4bf-418b-9eda-8bcb6da4569a"
      unitRef="shares">60000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icc5edae91bd9461e9f950e697459ba05_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfOS0xNS0xLTEtMA_7c077c99-0f04-4099-89a6-52ee68d01275"
      unitRef="usd">6400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4f64538c2968464bb7e99808fc376334_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTAtNS0xLTEtMA_a49a7fdc-876d-46e3-9b09-ed2f95ae26a5"
      unitRef="usd">279500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7bf2897e1304a7b9d39c16325786d60_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTEtNy0xLTEtMA_29c9c2cb-c060-427e-b784-40036b68eb38"
      unitRef="usd">763800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i157d7cc7dd0a4ce7a83fbaec2dded32f_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTEtMTEtMS0xLTA_7a4e40e1-b913-43f3-88d0-c32bd4b4a10c"
      unitRef="usd">-105200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4f64538c2968464bb7e99808fc376334_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTItNS0xLTEtNTE1_706a1cfd-7d37-472e-b1c4-6993cce80204"
      unitRef="usd">629200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTItMTEtMS0xLTUyNQ_42b1d2aa-cb0c-403f-9c52-89ade9264e6d"
      unitRef="usd">9000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTItMTctMS0xLTUzMQ_6cc78f28-6827-4049-aeb0-7c298e1b4843"
      unitRef="usd">1017200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityOther
      contextRef="i4f64538c2968464bb7e99808fc376334_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtNS0xLTEtNTIw_abb42499-bb89-4540-b0c9-927f5c399490"
      unitRef="usd">3900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i28716e79250245dd90132d730ab4c041_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTItMTctMS0xLTA_d7cff2d7-a184-4427-8ad5-98548173a095"
      unitRef="usd">14200000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="ibe5ce62fdd544ff38d36deef307ad126_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMS0xLTEtMA_142d1c20-2d22-4160-ab84-6ff66862de9b"
      unitRef="shares">1057639000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe5ce62fdd544ff38d36deef307ad126_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMy0xLTEtMA_6b0c6e4b-31e5-4f99-9db6-f99587090305"
      unitRef="usd">661000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10e3cdfa36f041fc98dc2d1a6961d3d4_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtNS0xLTEtMA_eca9bd04-8124-4d92-b13a-89d72cbd3947"
      unitRef="usd">6583600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8c9d052fc1b4535a183d69045981ee8_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtNy0xLTEtMA_132cd00d-cce1-497f-880c-3b9086fb1e4d"
      unitRef="usd">11395900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d46f703015a40e68e2bbe1d001af462_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtOS0xLTEtMA_3357b072-476d-453a-8536-c8b4f7bbf1b5"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1a89936fa8a4137a7ff3506ba792c52_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMTEtMS0xLTA_21e8decc-d723-469f-b575-49dc4d527bfc"
      unitRef="usd">-5729200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ie93b724bf8864d4c9fa270f354b1916a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMTMtMS0xLTA_c6024a0e-bd72-40a0-8419-1a2276153609"
      unitRef="shares">604000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie93b724bf8864d4c9fa270f354b1916a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMTUtMS0xLTA_428f09cc-5d97-404e-8d7b-dd85132d5f93"
      unitRef="usd">-69400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafa5205837f6490198d5eec282d9367d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTMtMTctMS0xLTA_613e6c22-d171-4b15-b796-637ceaec1e46"
      unitRef="usd">1080400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ie391d487b3784a9b8e753e02edd132b4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTQtNy0xLTEtMA_79f52ee5-1bf6-4d96-9b39-0e3af99e69f1"
      unitRef="usd">8318400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTQtMTctMS0xLTA_e1ee423e-444e-4563-907b-e537eac21bc6"
      unitRef="usd">37700000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i19bfa0a6cac84e13bceb037831a4f867_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTUtMTEtMS0xLTA_c957f3a8-5552-45ee-a310-33d104c23ff7"
      unitRef="usd">-794400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTUtMTctMS0xLTA_b8886d2b-eefb-4638-a647-0e355d3c61bc"
      unitRef="usd">11000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMC0xLTEtMTUyMDQvdGV4dHJlZ2lvbjo1ZThkMTRjOTQzNmE0ODAwYjU3OTA4ZGEyZjY5YTk3N18xMDk5NTExNjI3ODIx_84a78473-1e32-4f74-aafe-9e8d99e5b064"
      unitRef="usdPerShare">2.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="ie391d487b3784a9b8e753e02edd132b4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTYtNy0xLTEtMA_b15cf3b9-4e89-4b96-a07f-17ebf660bc01"
      unitRef="usd">2430500000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i1d1c048117e4436eb1290866218298ab_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMS0xLTEtMA_c463bdd7-a9db-43dc-99ba-b1fa955884c6"
      unitRef="shares">102640000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i1d1c048117e4436eb1290866218298ab_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMy0xLTEtMA_26a51516-a707-4e81-baad-b52006f6f65a"
      unitRef="usd">64100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ie391d487b3784a9b8e753e02edd132b4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctNy0xLTEtMA_c5a23c00-b0a0-48b9-8a0b-87afa99390b6"
      unitRef="usd">12363400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMTMtMS0xLTA_f9d92ebf-6343-46be-9364-b5daa0f07ebc"
      unitRef="shares">102640000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTctMTUtMS0xLTA_4833ca1f-5d71-408f-a596-b93033219413"
      unitRef="usd">-12427500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTgtMTMtMS0xLTA_3ff2a021-d8e3-466b-bce9-fafb531dbd53"
      unitRef="shares">37639000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTgtMTUtMS0xLTA_61e4dede-fd58-4014-a5b2-4f1cf928d57c"
      unitRef="usd">4400000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i1d1c048117e4436eb1290866218298ab_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktMS0xLTEtMA_ede2cb2b-5b98-44cf-93ab-ef2ee2ee7c20"
      unitRef="shares">3057000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1d1c048117e4436eb1290866218298ab_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktMy0xLTEtMA_c00f7ba7-90b5-48b7-b25b-23f2d5e7e906"
      unitRef="usd">1900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i473e4514c71444c9988eb5ff37da3471_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktNS0xLTEtMA_41c4f046-b105-4658-82a8-d50b8b4c9824"
      unitRef="usd">-210700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktMTMtMS0xLTA_e99a160e-11b8-49df-8997-0efd95ea7a4f"
      unitRef="shares">74000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMTktMTUtMS0xLTA_c423c48a-f9ea-4a49-abef-78e56e463559"
      unitRef="usd">8600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i473e4514c71444c9988eb5ff37da3471_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjAtNS0xLTEtMA_81c45727-e01f-4d4b-8ce3-32eb04405122"
      unitRef="usd">312400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <lly:StockAcquiredDuringPeriodSharesExchangeOffer
      contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjItMTMtMS0xLTUzOA_77fc9425-8c2e-43b6-96c8-8ca633de1940"
      unitRef="shares">65001000</lly:StockAcquiredDuringPeriodSharesExchangeOffer>
    <lly:StockAcquiredDuringPeriodValueExchangeOffer
      contextRef="i0b8a8b3c6ee948e08f3fa8acbeb25473_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjItMTUtMS0xLTU0MQ_604d0b86-7eb3-4645-9e95-e113b843e016"
      unitRef="usd">8027500000</lly:StockAcquiredDuringPeriodValueExchangeOffer>
    <lly:ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary
      contextRef="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjItMTctMS0xLTA_6c046717-06ee-4058-901c-cdfade3261fe"
      unitRef="usd">-1028900000</lly:ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary>
    <us-gaap:StockholdersEquityOther
      contextRef="ibc33a55644c74e658e2768f372cfffe4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjMtMTctMS0xLTA_79e867cc-74fb-4906-bae0-3be624aedfa5"
      unitRef="usd">8000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="ib6fa49af8d0b4b4fb6114b249eda120f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMS0xLTEtMA_d0d01fbf-39e8-43bc-b761-731729578cbd"
      unitRef="shares">958056000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6fa49af8d0b4b4fb6114b249eda120f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMy0xLTEtMA_4f881f4c-3fcf-4f21-8a76-37269370eb93"
      unitRef="usd">598800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida935f3e75bd41ffb87686123bd54de1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtNS0xLTEtMA_88f8b260-9582-4b6a-aaf5-82a17b33ab27"
      unitRef="usd">6685300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3987bdd473cd49b4a9449fe4eafc3bc0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtNy0xLTEtMA_a042aba0-8a88-4f86-82be-a1fa21286560"
      unitRef="usd">4920400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i688adb3e04c845998ca0228971320c29_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtOS0xLTEtMA_8ebec6e2-7bc5-482c-bcd7-43d76c92813b"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47de201d5d5443239956a13daaf044fe_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMTEtMS0xLTA_5ba285ae-eea7-43b1-8828-5eb28700de78"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ifefa16ca5afc4eaea5068a01f7896ad4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMTMtMS0xLTA_38397d90-fb27-4c7b-81cb-03b430c09f11"
      unitRef="shares">530000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifefa16ca5afc4eaea5068a01f7896ad4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMTUtMS0xLTA_f705ea90-5dd9-4ca8-91be-c9a0a2e4a903"
      unitRef="usd">-60800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f62bf81439d4ae4bf4ba4e32bd50761_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjQtMTctMS0xLTA_ca4011ba-d994-4d0e-8249-e84f42676a62"
      unitRef="usd">92200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="iaa954877e0c7448982c196e66891eed8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjUtNy0xLTEtMA_f779fde3-c085-4d87-b9d0-cf1ca9bce34b"
      unitRef="usd">6193700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if36805f1fb89427dbd2741f45ab5adbb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjUtMTctMS0xLTA_865d3883-be25-410e-8603-0eb0a563143f"
      unitRef="usd">126600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i027fb322c12e404ab2d69c9acb6af89d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjYtMTEtMS0xLTA_b8945587-55b7-4667-8c08-f227df819707"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if36805f1fb89427dbd2741f45ab5adbb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjYtMTctMS0xLTA_89f38857-11d7-4a91-9bb5-991f28f1e979"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMC0xLTEtMTUyMDcvdGV4dHJlZ2lvbjo1YTk4OWIyODUzOTk0ZTE4YmUwNzQ1Y2UyNWM2NTM4YV8xMDk5NTExNjI3OTAz_348886a1-7dac-4b41-aae7-749dd5cb5a75"
      unitRef="usdPerShare">3.07</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="iaa954877e0c7448982c196e66891eed8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjctNy0xLTEtMA_068b9a4d-9c64-459b-b780-4d488c4acf50"
      unitRef="usd">2786200000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMS0xLTEtMA_7bb9bfa3-be91-4e6f-a8b3-44b95d5b31a6"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMy0xLTEtMA_a4b00aae-f92f-4114-ae7c-53fccf2b1855"
      unitRef="usd">2300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iaa954877e0c7448982c196e66891eed8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtNy0xLTEtMA_d701c1bf-1d8a-4b51-881b-e5b4176d7a2d"
      unitRef="usd">497700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMTMtMS0xLTA_d12c6bd7-d7d4-44ca-942a-487fe84f10b9"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjgtMTUtMS0xLTA_88092319-c855-44ab-80da-85d8930db25c"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjktMTMtMS0xLTA_1df6c3a7-6e27-436e-85af-2a3e761473b3"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMjktMTUtMS0xLTA_aec1507b-d1da-466a-b575-9e8ef976232a"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtMS0xLTEtMA_aceedc53-bb95-4758-aa6d-fd38ac25c5dc"
      unitRef="shares">2648000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i342d4f92a718425b83823ed2f3b2fee0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtMy0xLTEtMA_da3609f7-01c9-4fa9-9736-fe1e73142f84"
      unitRef="usd">1700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i036da0197efe483db4434ecbe172adae_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtNS0xLTEtMA_3a0c3ac2-3a08-438a-97d2-5f121cb18f64"
      unitRef="usd">-212700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtMTMtMS0xLTA_21f358a6-bb69-401b-8766-5f9497561168"
      unitRef="shares">43000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibebf1021a0c84f1d82d76236cce263c0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzAtMTUtMS0xLTA_184bf3a2-2709-4e7e-8536-9ba73f55a393"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i036da0197efe483db4434ecbe172adae_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzEtNS0xLTEtMA_ec61e6f7-7e43-4ecd-b5ac-2efaf675c4b1"
      unitRef="usd">308100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i036da0197efe483db4434ecbe172adae_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzQtNS0xLTEtMA_ea1634a0-ab07-4a09-8ac1-e61a7142a91d"
      unitRef="usd">2200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if36805f1fb89427dbd2741f45ab5adbb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzQtMTctMS0xLTA_648df8b5-495a-411e-a684-6d69bac543c2"
      unitRef="usd">35200000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="iba9187cdb56548338bf4141df49d64ae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMS0xLTEtMA_d95be60f-5f3b-49f0-a9f1-fc1b98219bcd"
      unitRef="shares">957077000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba9187cdb56548338bf4141df49d64ae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMy0xLTEtMA_ce2ca0ed-5b16-4049-b621-f5ccd79eb551"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i787f9b28041442e7ad4a920214784c1c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtNS0xLTEtMA_05f70719-cd9e-4fa5-aa14-b0408871f811"
      unitRef="usd">6778500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42e3601cdaa94bf89622d6fc8cfe46fa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtNy0xLTEtMA_a53c6791-9286-41c7-b8e9-1ded009f3bb9"
      unitRef="usd">7830200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9627925923524961a92f6c7efb50a362_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtOS0xLTEtMA_0033707f-0cbc-4ba7-9ee0-87bdd2c9bdef"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84c0d14f77974e70adc19b8346937884_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMTEtMS0xLTA_a75d4512-dcc8-462f-9bed-41206fa56979"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i50acc48e0eed414dafcaecf50e0217b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMTMtMS0xLTA_7b5e88f9-1935-4451-8d57-34ee5a1b2439"
      unitRef="shares">487000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50acc48e0eed414dafcaecf50e0217b5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMTUtMS0xLTA_ff9debc9-92d2-482f-a19d-3c9a1185851b"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40e05a36e47a4388bbf774447f54fdf7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV85Ny9mcmFnOjc4NjQ3MGEzMjkxMzQxOWM5ZmE1YWM2N2IxZDk2MWE4L3RhYmxlOjYzMzc0OTM5OTI4NTRiZjZhYjM0MGQ4YmUwNWY5MDk1L3RhYmxlcmFuZ2U6NjMzNzQ5Mzk5Mjg1NGJmNmFiMzQwZDhiZTA1ZjkwOTVfMzUtMTctMS0xLTA_a0199618-fbc6-42a4-8cc5-5ede2993aab3"
      unitRef="usd">183600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzItNC0xLTEtMA_a2c06e30-3e98-4462-a063-0d910978a3fc"
      unitRef="usd">6193700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzItNi0xLTEtMA_c3ba4f70-b78b-451f-99fb-04d3f1419e8e"
      unitRef="usd">8318400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzItOC0xLTEtMA_ee6a7c7f-9bbc-47cd-bdbf-b3b1a90ad7f4"
      unitRef="usd">3232000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQtNC0xLTEtMA_38086779-3196-473b-b385-8ee8fbb2d486"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQtNi0xLTEtMA_69b5b4a7-80e1-43eb-a38a-9e872f8b557a"
      unitRef="usd">3680500000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQtOC0xLTEtMA_083d94e7-2c1d-446b-aa06-9b2fe9b83729"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzUtNC0xLTEtMA_4e679d30-f1a0-462d-a64b-a11b1a419bf8"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzUtNi0xLTEtMA_d6878d76-50b8-4e96-bd6a-50eb9bcee4ae"
      unitRef="usd">309800000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzUtOC0xLTEtMA_0530225b-f3b7-4b7a-8768-608988cdb168"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzYtNC0xLTEtMA_b936d733-3b45-4f18-850a-3b4e7b72d468"
      unitRef="usd">1323900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzYtNi0xLTEtMA_f529e6ff-2a46-44ae-97d7-1e0205f37782"
      unitRef="usd">1232600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzYtOC0xLTEtMA_5a22b79d-cb40-4f6d-97d1-0e98056ff610"
      unitRef="usd">1609000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzctNC0xLTEtMA_426ce563-6178-4684-a53e-39a30a4616db"
      unitRef="usd">134500000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzctNi0xLTEtMA_8a830f12-a7d0-4dc2-adf7-ca4758117b13"
      unitRef="usd">-62400000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzctOC0xLTEtMA_6fc01461-ea23-4784-b821-42061cec3b6b"
      unitRef="usd">-326800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzgtNC0xLTEtMA_70d0a707-9041-440a-b933-d2c43dbda207"
      unitRef="usd">308100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzgtNi0xLTEtMA_ba967001-08b3-43a6-88f4-613943c4c51e"
      unitRef="usd">312400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzgtOC0xLTEtMA_f5dcb4f5-6d37-4b25-a1fd-365d385f2b1c"
      unitRef="usd">279500000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktNC0xLTEtOTU1OA_05dec00a-32d8-454e-b982-d7ee59869254"
      unitRef="usd">1438500000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktNi0xLTEtOTU1OA_f432cc35-f273-49d1-b470-7665da0cf82e"
      unitRef="usd">403100000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktOC0xLTEtOTU1OA_53a3aef3-2b49-4b0e-b6f8-6d867092c23d"
      unitRef="usd">27000000.0</us-gaap:GainLossOnInvestments>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktNC0xLTEtMA_30290852-fe27-48d2-addf-7233cb4987d9"
      unitRef="usd">660400000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktNi0xLTEtMA_8e60da52-df7a-4c73-abee-de514a0e0ce5"
      unitRef="usd">239600000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzktOC0xLTEtMA_79b3bbb3-9b86-4d8c-b62b-eb26c7b6a638"
      unitRef="usd">1983900000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEwLTQtMS0xLTA_e2e08762-94c9-41ce-998c-c5396af105a8"
      unitRef="usd">333900000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEwLTYtMS0xLTA_99cf0607-3386-407e-9849-56f4c7841d6c"
      unitRef="usd">751800000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEwLTgtMS0xLTA_0e1a6ac6-d117-4dce-aa23-07b08c27587f"
      unitRef="usd">499000000.0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEyLTQtMS0xLTA_0738cc2b-d01d-4e34-857b-e318efac2256"
      unitRef="usd">1350200000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEyLTYtMS0xLTA_d9731918-a70f-4922-85c4-a34cecbede86"
      unitRef="usd">127200000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEyLTgtMS0xLTA_fcd6a242-f647-4490-800d-57f8bd3b86df"
      unitRef="usd">996700000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEzLTQtMS0xLTA_56434253-6030-433c-bb86-8d0ec87c112e"
      unitRef="usd">533400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEzLTYtMS0xLTA_11fc5a64-5839-47de-b936-b4ada2f136e4"
      unitRef="usd">258700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzEzLTgtMS0xLTA_37e31107-07b7-4128-94b7-865ea1a343aa"
      unitRef="usd">-7800000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE0LTQtMS0xLTA_f64704ae-6270-46b5-9b00-ae4a250405ac"
      unitRef="usd">457100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE0LTYtMS0xLTA_16d60b3a-52c3-4721-badc-3e958e84c37c"
      unitRef="usd">602300000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE0LTgtMS0xLTA_5c934388-9a77-4cc6-827a-78c89ea820c5"
      unitRef="usd">980000000.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE1LTQtMS0xLTA_efefdcb3-0b27-49d4-8dd1-e3ff12c3ca72"
      unitRef="usd">322000000.0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE1LTYtMS0xLTA_0a0572c2-0be4-412a-9c2b-58f99c82547e"
      unitRef="usd">-221300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE1LTgtMS0xLTA_de092e31-1735-4532-9ef2-0a9bfb6b7832"
      unitRef="usd">-125300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE2LTQtMS0xLTA_3bc959b0-5fad-4959-990d-0d89392785a0"
      unitRef="usd">1271300000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE2LTYtMS0xLTA_cf0990cd-cb83-48fe-9327-30b419edd411"
      unitRef="usd">-477700000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE2LTgtMS0xLTA_8acb78f4-5f0a-4045-82d0-cbb21d456fac"
      unitRef="usd">-284500000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE3LTQtMS0xLTA_74c065ca-0991-4f62-bc9e-61a0796aa435"
      unitRef="usd">6499600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE3LTYtMS0xLTA_81842bed-f5a6-42e2-a6ea-933ccc3b0545"
      unitRef="usd">4836600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE3LTgtMS0xLTA_95168ae9-c9ce-40e4-a7e4-4df9800a67b3"
      unitRef="usd">5524500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE5LTQtMS0xLTA_650ded70-7f50-46df-8d56-27541d90dcf1"
      unitRef="usd">1387900000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE5LTYtMS0xLTA_8fc76068-a9ee-428d-be53-28084bad710d"
      unitRef="usd">1033900000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzE5LTgtMS0xLTA_dcede2e6-2c18-4a74-a1fd-9998a549b43f"
      unitRef="usd">1210600000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIwLTQtMS0xLTA_bdf95827-f15b-4d56-9d95-d2aeb170bb05"
      unitRef="usd">129700000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIwLTYtMS0xLTA_4d3eea6a-bd92-477a-813c-be5fef661b79"
      unitRef="usd">136600000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIwLTgtMS0xLTA_ae1bc948-08c5-4c8b-a3ea-1d51db8f1a6a"
      unitRef="usd">2552500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIxLTQtMS0xLTA_8ea8e679-621f-4dc0-96ad-02d0155d9b77"
      unitRef="usd">11400000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIxLTYtMS0xLTA_5718b4f0-390b-434d-b1a7-9711a87be2e1"
      unitRef="usd">42700000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIxLTgtMS0xLTA_ba96172e-5373-400c-8e74-0edd681ad04b"
      unitRef="usd">112200000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIyLTQtMS0xLTA_6bce9f55-e175-4c19-9ae2-b1a2026df7f6"
      unitRef="usd">757100000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIyLTYtMS0xLTA_54d650ca-22c3-4f74-b31e-780407a708e1"
      unitRef="usd">609800000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIyLTgtMS0xLTA_2f321387-82fe-4938-8ce2-56a1519cf914"
      unitRef="usd">3509500000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIzLTQtMS0xLTA_829e707f-67f8-4a22-a7af-95cdd98c89a5"
      unitRef="usd">358700000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIzLTYtMS0xLTA_5b1f4842-275b-4793-a0d6-f164a8e1d707"
      unitRef="usd">247500000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzIzLTgtMS0xLTA_d8491619-6b30-4a3e-9124-8a868f3be503"
      unitRef="usd">837900000</us-gaap:PaymentsToAcquireOtherInvestments>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI0LTQtMS0xLTA_c87ccffb-5dc1-44cb-b418-e3121fce2fde"
      unitRef="usd">641200000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI0LTYtMS0xLTA_939b53f9-bad1-4f64-9aea-3fcf5a4353ba"
      unitRef="usd">319600000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI0LTgtMS0xLTA_234178b8-53d0-4500-985b-288f3d89cf27"
      unitRef="usd">1807600000</lly:PurchasedInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI1LTQtMS0xLTA_be6da1e7-958b-4969-8d30-809cabf92aab"
      unitRef="usd">849300000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI1LTYtMS0xLTA_a6c1593d-f2bb-4e07-8122-02b08d8b0551"
      unitRef="usd">6917700000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI1LTgtMS0xLTA_1f00e208-1aeb-4e02-ac93-47da759371a8"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI2LTQtMS0xLTA_187c9162-772c-4466-8d36-ca74da674c56"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI2LTYtMS0xLTA_2a276cb1-6041-4c91-83e1-e7cd9dc71643"
      unitRef="usd">374000000.0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI2LTgtMS0xLTA_032503da-f847-47df-9db0-d24efe2d96ff"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI3LTQtMS0xLTA_a1a13476-17f2-4aee-892c-23865b9bf725"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI3LTYtMS0xLTA_9c81307c-01e3-4c2f-8a17-307b7fdbeb96"
      unitRef="usd">354800000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI3LTgtMS0xLTA_9541390e-3533-40cc-b6c0-2f2e04c93bdd"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI4LTQtMS0xLTA_0075f099-581b-4b54-b4fe-76dbd49aaad8"
      unitRef="usd">-102800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI4LTYtMS0xLTA_6cacdac0-3b48-4a0f-9ae1-c2b1c1af0992"
      unitRef="usd">248700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI4LTgtMS0xLTA_b8ec6ecf-89b0-4ad8-9796-c89701ec75e5"
      unitRef="usd">187700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI5LTQtMS0xLTA_16853626-ffd4-4823-a7a2-8c55af47f310"
      unitRef="usd">-2258900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI5LTYtMS0xLTA_09e5bc0e-dadd-4bf7-8d34-717bfded2ad2"
      unitRef="usd">-8082900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzI5LTgtMS0xLTA_5e18d2ee-c6e6-4b15-a17d-b01dd4d3ae2a"
      unitRef="usd">1906000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMxLTQtMS0xLTA_84daed20-edac-48e8-9cd5-ace130d40ebf"
      unitRef="usd">2687100000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMxLTYtMS0xLTA_b2618dab-156e-4306-9026-2553ca7e28b8"
      unitRef="usd">2409800000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMxLTgtMS0xLTA_56be3403-8eca-49ea-8ace-2e88bb523d0d"
      unitRef="usd">2311800000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMyLTQtMS0xLTA_4b8caaaa-ba22-40ab-ab10-87568b5cada9"
      unitRef="usd">-1494200000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMyLTYtMS0xLTA_cd62e3e1-9641-40e2-ac4c-486f1b6602ca"
      unitRef="usd">995400000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMyLTgtMS0xLTA_f11db602-e535-44cb-adcf-04aea0de80dc"
      unitRef="usd">-2197900000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMzLTQtMS0xLTA_a13bfe78-72cf-474c-9fbc-2cbb5a2fa105"
      unitRef="usd">2062300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMzLTYtMS0xLTA_b829ec5f-7a9a-4380-9391-89407cfb1c77"
      unitRef="usd">6556400000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzMzLTgtMS0xLTA_9d2a467f-ede4-43c9-b389-d34fcee722e4"
      unitRef="usd">2477700000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM0LTQtMS0xLTA_96af561a-8d2f-493a-907f-6a9e0ef00fea"
      unitRef="usd">276500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM0LTYtMS0xLTA_e99fb89c-00d7-4bbd-8883-56fea366c26e"
      unitRef="usd">2866400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM0LTgtMS0xLTA_3e40ed1f-39a1-4ff7-9efe-4f18bd205ac8"
      unitRef="usd">1009100000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM1LTQtMS0xLTA_deecb998-03c0-4f61-aa3e-8838f13d1a35"
      unitRef="usd">500000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM1LTYtMS0xLTA_dd74fa3f-a66d-43fe-93c2-1e27de8f35de"
      unitRef="usd">4400000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM1LTgtMS0xLTA_524038fc-70f5-4987-873e-38952a1e36da"
      unitRef="usd">4150700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM2LTQtMS0xLTA_fc76254b-dad8-4f61-9bfe-dc5db637951b"
      unitRef="usd">0</lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary>
    <lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM2LTYtMS0xLTA_990e6204-5624-4c89-9c76-d9638f820978"
      unitRef="usd">0</lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary>
    <lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM2LTgtMS0xLTA_c6a59682-3201-40ac-9274-a100185554d3"
      unitRef="usd">1659700000</lly:ProceedsfromIssuanceorSaleofEquityfromSubsidiary>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM3LTQtMS0xLTA_b547b7b4-eacd-43b8-8967-ad1320938393"
      unitRef="usd">-241600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM3LTYtMS0xLTA_7eef07a3-b831-4977-9ce9-38bce6f62924"
      unitRef="usd">-200100000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM3LTgtMS0xLTA_fd45f3e6-35a7-4eaa-916f-41bbe69d2367"
      unitRef="usd">-372800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM4LTQtMS0xLTA_ca3ffb2c-edc5-48e7-b45e-cd3e5d25bde8"
      unitRef="usd">-3137100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM4LTYtMS0xLTA_fe228d33-e9d6-4ab7-910b-73b4fd6b6bbd"
      unitRef="usd">-2324500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM4LTgtMS0xLTA_2082d888-2e04-436d-b965-463bd764fb2b"
      unitRef="usd">-5904900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM5LTQtMS0xLTA_53824256-a965-4aa5-8171-adff000ce01f"
      unitRef="usd">216000000.0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM5LTYtMS0xLTA_e9d3baa5-5957-4f5b-94e6-f733b0dae262"
      unitRef="usd">-89900000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzM5LTgtMS0xLTA_8d2b939e-f6a7-44a3-94bd-3f911a8749b2"
      unitRef="usd">-63600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQwLTQtMS0xLTA_885c542c-0e65-44de-838f-af10172b90f5"
      unitRef="usd">1319600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQwLTYtMS0xLTA_076d860c-da5f-49c6-8742-5d84ab0834a1"
      unitRef="usd">-5660700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQwLTgtMS0xLTA_08014293-8c27-442c-b593-6457ad46de78"
      unitRef="usd">1462000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxODlhYzY4YTgxYzY0Mzk3OTNmNDkxZDY4ZjdjYTQxOV8xMDk5NTExNjI3OTA0_4079f89e-4dff-4b4b-8ce1-0076cd285bd0"
      unitRef="usd">677500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTAtMS0xLTAvdGV4dHJlZ2lvbjoxODlhYzY4YTgxYzY0Mzk3OTNmNDkxZDY4ZjdjYTQxOV8xMDk5NTExNjI3ODk3_4a827fc6-e122-4e11-8f25-732580330df1"
      unitRef="usd">324400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTQtMS0xLTA_a61fd90b-200d-4fd5-a610-644ea7553de7"
      unitRef="usd">2337500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTYtMS0xLTA_053c8ebe-9980-442e-b074-bacc8cd40ad0"
      unitRef="usd">7998200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQxLTgtMS0xLTA_bc83aa0a-038c-48e1-9322-ece799cd0dcb"
      unitRef="usd">6536200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQyLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NDY2ZjQ5MTNiYWM0MjdkOTUxNzIxZjQyMzg3ZWJjY18xMDk5NTExNjI3ODcz_6a0b5f7b-8111-4bc7-be25-21a008819603"
      unitRef="usd">677500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQyLTQtMS0xLTA_67cfa52e-04d7-4860-a298-dadfe79c522b"
      unitRef="usd">3657100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQyLTYtMS0xLTA_914dd172-7594-454e-91a0-825e1c4acd42"
      unitRef="usd">2337500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMDMvZnJhZzo3OGJhMTQwZjc4NGI0ZDk5YmNmNGIxZjQxMTQ4MDNmOS90YWJsZTowNzg2N2U2MTU1ODE0MzQ2ODI5MGI2OTkwODAxZDFjYS90YWJsZXJhbmdlOjA3ODY3ZTYxNTU4MTQzNDY4MjkwYjY5OTA4MDFkMWNhXzQyLTgtMS0xLTA_be98961e-7629-45da-b985-d8efcccde3a9"
      unitRef="usd">7998200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkzMDU_7e722dfd-6ad6-4ce0-b0f3-ae450f99348f">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders&#x2019; interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco Animal Health Incorporated (Elanco) common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the completion of the disposition of Elanco, we now operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Research and development costs, which are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D expense includes the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings Per Share (EPS)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate basic EPS based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses. Advertising expenses, comprised primarily of television, radio, print media, and Internet advertising, totaled approximately $1.1 billion, $1.1 billion, and $900 million in 2020, 2019, and 2018, respectively, which was less than 5 percent of revenue each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Implementation of New Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2019, we adopted Accounting Standards Update 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transitional practical expedients. The adoption of this standard resulted in recording of operating lease assets of approximately $530 million, which included reclassifying approximately $65 million of deferred rent and lease incentives, net of prepaid rent, as a component of the operating lease assets as of January 1, 2019. The adoption also resulted in recording operating lease liabilities of approximately $595 million as of January 1, 2019. Our accounting for finance leases remained substantially unchanged. Adoption of this standard did not result in a material change in net income in the year of adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and other related updates. This standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We applied this standard to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don&#x2019;t believe the effect of applying this practical expedient resulted in material differences. We applied this standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Adoption of this standard did not result in a material change in revenue or net income in the year of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, we adopted Accounting Standards Update 2016-01 (ASU 2016-01), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). We applied the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, we adopted Accounting Standards Update 2016-16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. We adopted this standard using a modified retrospective approach. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Change in Accounting Principle for Retirement Benefit Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective during the third quarter of 2020, we adopted a voluntary change in our method of applying an accounting principle for certain of our retirement benefit plans. Refer to Note 15 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="icf5a8d8b13ec45be88c05cc0494020eb_I20190311"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzE0OTQ_2045f3b1-6f32-4240-98eb-3d0879ffd079"
      unitRef="number">0.802</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkyOTY_b22027ee-9b7c-40d0-91aa-cf3e65c54704">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Research and development costs, which are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D expense includes the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkyNzk_9b860cc4-44de-4aa8-8be6-de3b94a2de79">Earnings Per Share (EPS)We calculate basic EPS based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkyODY_4ef10fd0-7d7b-4b02-9822-555d62be7f32">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkzMDA_a13c14df-1665-4b9b-b8b3-059c42846354">Advertising ExpensesCosts associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0MjQ_c1f934be-1fc0-4b21-935d-7bc27dc596a6"
      unitRef="usd">1100000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0Mjg_86bb26ac-05e5-4c29-8123-91fc67f20dbb"
      unitRef="usd">1100000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0MzY_8e57d252-427c-44c7-b0ed-403e4d1ffeee"
      unitRef="usd">900000000</us-gaap:AdvertisingExpense>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0OTg_091e8999-4bb2-499d-ab9c-61ce3a19a1f4"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0OTg_b4ba67e7-8175-4c00-acf2-8134b678e050"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <lly:AdvertisingExpensePercentageOfRevenue
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzQ0OTg_c3f59ece-931d-4f2a-aaef-146c4be43abd"
      unitRef="number">0.05</lly:AdvertisingExpensePercentageOfRevenue>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzkyODA_72c4b44b-a560-410b-91db-7b0a6af618d9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Implementation of New Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2019, we adopted Accounting Standards Update 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transitional practical expedients. The adoption of this standard resulted in recording of operating lease assets of approximately $530 million, which included reclassifying approximately $65 million of deferred rent and lease incentives, net of prepaid rent, as a component of the operating lease assets as of January 1, 2019. The adoption also resulted in recording operating lease liabilities of approximately $595 million as of January 1, 2019. Our accounting for finance leases remained substantially unchanged. Adoption of this standard did not result in a material change in net income in the year of adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and other related updates. This standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We applied this standard to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don&#x2019;t believe the effect of applying this practical expedient resulted in material differences. We applied this standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Adoption of this standard did not result in a material change in revenue or net income in the year of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, we adopted Accounting Standards Update 2016-01 (ASU 2016-01), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). We applied the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, we adopted Accounting Standards Update 2016-16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. We adopted this standard using a modified retrospective approach. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Change in Accounting Principle for Retirement Benefit Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective during the third quarter of 2020, we adopted a voluntary change in our method of applying an accounting principle for certain of our retirement benefit plans. Refer to Note 15 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie8d870ddf29742b896587158690bd8a2_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzUwODQ_2384afa2-93fc-4bfd-b732-f894af12378e"
      unitRef="usd">530000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1aa7ce2db08d4fc7af3dfaea6237b261_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzUxMzE_308a98b5-7cc2-4c4c-b456-0e70c444d654"
      unitRef="usd">-65000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie8d870ddf29742b896587158690bd8a2_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzUzNDc_d1bf8504-4ba0-4013-bffd-1d3a26716c9f"
      unitRef="usd">595000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01ed1b80ae7748c6ae7aefbbfc4c08c3_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzY1NTk_abf7b61b-6c0d-4712-b070-c3fe19f8a7b5"
      unitRef="usd">5000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzc2NDg_9e66f744-8880-4e22-bb73-32ad89ee6f03"
      unitRef="usd">105000000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzc2NDg_f43bcd07-607c-464a-ac85-f586c97cf69a"
      unitRef="usd">105000000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e90af870b3d47a4bd1770c53c1a74b9_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzgyMjI_667d0fc0-5869-4260-9997-2dbb94ea3634"
      unitRef="usd">700000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i3ec2a6e9e71f43729a2ef0804b5d5688_I20171231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzgyNDc_c2e59db1-afe3-4c2a-90c8-ed762c0b6466"
      unitRef="usd">2500000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i3ec2a6e9e71f43729a2ef0804b5d5688_I20171231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTIvZnJhZzo3MTZjMjQ3ZTFmMTQ0YTE0YWZhYTcyMjZlYWRkZjU0Zi90ZXh0cmVnaW9uOjcxNmMyNDdlMWYxNDRhMTRhZmFhNzIyNmVhZGRmNTRmXzgyNzg_d32efe12-51b8-4c8a-8490-95f4451ca66a"
      unitRef="usd">1800000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzMyOTg1MzQ4OTk1MzI_cc007d67-efc6-4afe-822c-93e179525231">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,694.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,377.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,866.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,845.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,942.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,539.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,493.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $135.6 million, $301.5 million, and $303.2 million during the years ended December 31, 2020, 2019, and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December&#160;31, 2020, 2019, and 2018, our three largest wholesalers each accounted for between 15 percent and 20 percent of consolidated revenue. Further, they each accounted for between 19 percent and 27 percent of accounts receivable as of December&#160;31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts and returns. The following describe the most significant of these judgments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sales Rebates and Discounts - Background and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, chargeback, and patient assistance programs in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sales Returns - Background and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. In the U.S. we allow bamlanivimab to be returned if the Emergency Use Authorization (EUA) is revoked. If the EUA were to be revoked, we could experience an elevated level of product returns of bamlanivimab, dependent on the amount of product remaining in the distribution channel. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Actual U.S. product returns have been less than 2 percent of our U.S. revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adjustments to Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to increase revenue recognized as a result of changes in estimates for the judgments described above for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods were approximately 1 percent,  2 percent and 1 percent of U.S revenue during 2020, 2019, and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration and Other Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;276.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract liabilities balances disclosed above as of December&#160;31, 2020 and 2019 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020, 2019, and 2018, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,835.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,155.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,232.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,485.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,140.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;866.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;393.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;620.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;533.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;842.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;282.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trajenta &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;95.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;162.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,909.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,529.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,925.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,602.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,265.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,064.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;381.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;618.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;294.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;480.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;461.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,792.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,403.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,527.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,857.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,288.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;575.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,372.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,089.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;725.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;360.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;325.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;220.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,344.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;510.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;536.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bamlanivimab &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;850.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;545.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;321.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,668.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,358.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,424.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,229.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,391.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,310.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,596.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trajenta revenue includes Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Bamlanivimab sales are pursuant to EUA.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,229.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,391.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,187.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,663.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,583.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,407.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,116.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,422.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,280.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,539.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,493.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzEzMzgx_8ae661a8-888f-41a6-b247-93b38001d41b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,694.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,377.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,866.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,845.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,942.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,539.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,493.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $135.6 million, $301.5 million, and $303.2 million during the years ended December 31, 2020, 2019, and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,835.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,155.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,232.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,485.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,140.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;866.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;393.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;620.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;533.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;842.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;282.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trajenta &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;95.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;263.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;162.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,909.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,529.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,925.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,602.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,265.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,064.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;381.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;618.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;294.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;480.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;461.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,792.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,403.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,527.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,857.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,288.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;575.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,372.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,089.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;725.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;360.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;325.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;220.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,344.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;510.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;536.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bamlanivimab &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;850.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;545.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;321.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,668.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,358.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,424.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,229.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,391.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,310.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,596.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trajenta revenue includes Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Bamlanivimab sales are pursuant to EUA.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,229.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,391.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,187.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,663.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,583.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,407.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,116.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,422.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,280.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,539.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,493.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i3b760635fa6d431c9dbbba9b762de382_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzEtMS0xLTEtMA_10d98997-87b3-4465-8c2a-a7ac63ceacc0"
      unitRef="usd">22694800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i88f36d7a75f14e72b8ff0e498de5ad74_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzEtMy0xLTEtMA_22b46cc7-eae4-4f63-bede-7811a747bdff"
      unitRef="usd">20377300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f006ccd7dcf492e906b2da535a904b2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzEtNS0xLTEtMA_f0e2e412-1271-4a05-81ab-af8c4334432e"
      unitRef="usd">19866400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22c268eadac048a8bed666bf74cab1f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzItMS0xLTEtMA_c8c5fc93-01c8-490b-ab27-51b9375f1517"
      unitRef="usd">1845000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23a7d3b63876485d87034526a86d8ded_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzItMy0xLTEtMA_ecde8a12-3dea-463f-ba8e-5c30e06ae71a"
      unitRef="usd">1942200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01ede8557fbe4f02a6f390d0e6822798_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzItNS0xLTEtMA_d4cbaafe-39b9-480e-b9cc-22fe8e45d1af"
      unitRef="usd">1626900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzMtMS0xLTEtMA_b6334512-8ebe-4b70-9c18-fe0925ac9ed3"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzMtMy0xLTEtMA_bc22b593-1aa2-4592-901d-4f26ad181672"
      unitRef="usd">22319500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToxYTAxNmQ4MTMzNGE0MWZhYTUzM2I4MmZjNWVkNmZlYi90YWJsZXJhbmdlOjFhMDE2ZDgxMzM0YTQxZmFhNTMzYjgyZmM1ZWQ2ZmViXzMtNS0xLTEtMA_bc20c4f0-2994-435b-8aac-0f0c00f06f44"
      unitRef="usd">21493300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie64e6e64f4cd4c3bb6d2fef573bc1cb7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzIyOA_d871e24d-0d88-42d8-a8e3-67ff5043482c"
      unitRef="usd">135600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08a61dcc93ff4861bcfc64e6431e4d71_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzIzMg_9dd45215-c7c9-4107-93e5-2d29349092e8"
      unitRef="usd">301500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2123f59cc857450a91ae3b7c97124bf4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI0MA_d386448e-ed4a-483a-9957-548c22420c2e"
      unitRef="usd">303200000</us-gaap:Revenues>
    <lly:RevenuefromContractPaymentTermMinimum
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzE0Njk_8a6ca513-b712-4366-8ad9-504f090334da">P30D</lly:RevenuefromContractPaymentTermMinimum>
    <lly:RevenuefromContractPaymentTermMaximum
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzMyOTg1MzQ4OTY3Mzk_cca368d8-3a31-4e52-b472-ab8ec8eef10a">P70D</lly:RevenuefromContractPaymentTermMaximum>
    <lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzE3MzY_e6e80b39-886a-4115-8435-f636ae9cd21a">P1Y</lly:RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic6a3fa17ced44cf6911c558bcef7ce7e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2ODY_24078815-2cd1-49c4-8bac-f13e8eee9c6b"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i697978618d86456cbf1a2759d0f32502_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2ODY_5ee05c04-680d-4b86-90c6-d1457bad6158"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iacf1ad720b4c43bf8e96a192f4292dde_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2ODY_e31c59fc-4637-44e9-81b9-d90f54c089bf"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1d4d013544c649448fda0d85a40880f3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2OTM_655c0aa5-da51-4a89-a0ba-4f92b5276b13"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9df231a5cbb94e458fd1cf844f24d8d7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2OTM_7b9ba721-ae42-4651-b62d-f2e7dbfb8edd"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4ae1b15ab56b43bc9a7777c2071ecf3a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI2OTM_fccd799f-6ddf-43bd-9273-4a6335a4abc4"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i72b23fff2282489ca3c0f894bb18cc07_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI3Njg_794f1c13-9a84-42c3-9883-0ba14e828a1a"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i55059f768986433ba6bcc5c4b2726cb8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI3Njg_c6e93746-a2f2-40dc-8e36-bd6736c2e676"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3b9ceecaa70744b5b18f2b550ef85ab7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI3NzU_00712337-3d52-4bbc-b6f5-d8dc70617cd0"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iddba0e6da38240e58e8ef1983e1c0432_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzI3NzU_7e97c758-1419-46e4-838e-c708d125fbcd"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <lly:RevenuePerformanceObligationSalesRebatePaymentPeriod
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzQ4MDU_0eab1310-7e73-48f3-a7b6-859392841f58">P6M</lly:RevenuePerformanceObligationSalesRebatePaymentPeriod>
    <lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzU3NTM_30124f38-773a-4995-bad5-e2391d6e50ba">P24M</lly:RevenuePerformanceObligationSalesReturnsProductExpirationDate>
    <lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzc1MTk_7fe622b9-b65a-4ac0-9412-2da3f6f572ef">P1M</lly:RevenuePerformanceObligationSalesReturnsAverageInventoryLevel>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzgxOTM_008d33fc-b3dc-4942-acb8-d8799d753750"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzgxOTM_0add62a2-5657-4e50-a4f2-a3edabfc9beb"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzgxOTM_83e324ad-e3cc-444c-801c-61f7a5617a84"
      unitRef="number">0.02</lly:RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="ia5562538495445b2b19f079d4c482ee1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzg3MTU_6952ddd5-8449-44ce-ae2e-bc6b7c1a4480"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i2352e466ca6e45d1aefb7efed013e9cf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzg3MjI_4d315b4b-a846-418d-8bc8-bd0677878a62"
      unitRef="number">0.02</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i56db8c7d699d4b908d30e96ead023336_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzMyOTg1MzQ4OTk1MTg_021a919a-7299-4567-9cfc-6a5c36cb4705"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90ZXh0cmVnaW9uOjRhOGVhYmE2MDA1MzQwZjZiOWM1OGZjMGNhNGQ3ODJhXzEzMzg4_a5872f4f-3c23-4283-98d3-d06aa309a40b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;276.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTpmNGViMTM4N2ZkNmQ0MmVkOTVkZjA0MDIyZjgxM2YwNC90YWJsZXJhbmdlOmY0ZWIxMzg3ZmQ2ZDQyZWQ5NWRmMDQwMjJmODEzZjA0XzEtMS0xLTEtMA_cb729596-dea7-42b2-a157-5bedef10fde7"
      unitRef="usd">276800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTpmNGViMTM4N2ZkNmQ0MmVkOTVkZjA0MDIyZjgxM2YwNC90YWJsZXJhbmdlOmY0ZWIxMzg3ZmQ2ZDQyZWQ5NWRmMDQwMjJmODEzZjA0XzEtMy0xLTEtMA_663a25ba-b9c0-4eb5-b5e5-08b91b56839c"
      unitRef="usd">264600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="id23b300ee7c04c219019df6e1ab48341_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtMy0xLTEtMA_994b54e4-6702-41ff-a973-10647821a186"
      unitRef="usd">3835900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c0bb72cacc846c4b1660192fa13fb2d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtNS0xLTEtMA_df12441f-5402-46b9-83f3-279acb86cfa5"
      unitRef="usd">3155200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i728a6f151f344cd5a4e1658f4456e4a4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtNy0xLTEtMA_8d8e4f8d-6e9e-4cf4-9d09-cc6968c749c4"
      unitRef="usd">2515800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6884b0346ff74a868a23cc494081187a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtOS0xLTEtMA_92736192-49bd-4d7d-94a6-f7cd383f289d"
      unitRef="usd">1232200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9d66c70ab574ec1a1e5591f1bb6849a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtMTEtMS0xLTA_44987abe-a4d7-4e9f-a6ae-66447d0c80d7"
      unitRef="usd">972700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85836dd8d7c24266be724f2fd23636b0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzYtMTMtMS0xLTA_240d8e26-8aea-4abf-b358-4df06bc98a8e"
      unitRef="usd">683300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie247b454823c4c899728fa1e7c3c6488_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctMy0xLTEtMA_5e88bcfb-2a4f-4e91-bc29-076dc71cf62a"
      unitRef="usd">1485600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1561cbf5143e496389f63ec127805cec_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctNS0xLTEtMA_127d913c-b217-4e34-9863-e1cca3acdceb"
      unitRef="usd">1669700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie24bf00d544347dd91396c4ce0a786d0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctNy0xLTEtMA_2a1a8ef2-b5e1-4bc9-a9cd-59a9daffce4d"
      unitRef="usd">1787800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ec05ae419fb4e2fad130ef8bcbacb60_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctOS0xLTEtMA_df7975fb-8369-4fcf-8796-c1dea83bf3a6"
      unitRef="usd">1140300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia14247b991aa4660aaeff59ba9087029_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctMTEtMS0xLTA_ae3d7412-62be-4191-8027-0fcc141a844f"
      unitRef="usd">1151000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28072632c66a42a99ffb45b515d993c2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzctMTMtMS0xLTA_a369895c-5b9f-4e08-b417-5528cb311428"
      unitRef="usd">1208700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i191e8f8614e54664b788c1acd1a1b343_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMy0xLTEtMA_4f812aea-b451-4cfa-a800-c27ac72d9c30"
      unitRef="usd">866400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc75f49bc8dc4f318a19c8b6ce2d8bab_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktNS0xLTEtMA_6e8509ea-8e4a-46a5-bccd-3164b2beda68"
      unitRef="usd">879700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i715dfb4b6d894d1c879e0379cbf8a8f4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktNy0xLTEtMA_0daf56d0-f1da-4458-ac0a-286aa1c27911"
      unitRef="usd">910200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c183a74083641c0ac1bf8f66c7aac92_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktOS0xLTEtMA_d572d04c-cf73-4750-9dc5-c66f7e1ec8d3"
      unitRef="usd">393200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c928d58286344fb8bcd47e90bf5d627_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMTEtMS0xLTA_f8736aab-2017-4699-896d-ee62e994030e"
      unitRef="usd">410400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id975590de3cd4ec99467e999df92c9e6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMTMtMS0xLTA_76bea735-ba30-4acb-95cb-8abac3698879"
      unitRef="usd">421200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2830a10550f04092843207d0fdc28a94_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMy0xLTEtNDQ0Mw_f5980449-4027-4853-b35d-975c911ca7b6"
      unitRef="usd">620800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e42ce139e604186891333c227fa7f7a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktNS0xLTEtNDQ0Mw_69200ec7-29e9-4b0a-85c3-40a6de4aab82"
      unitRef="usd">565900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a798b0c03524583b15477c45770fbf4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktNy0xLTEtNDQ0Mw_d9a0f27b-61a1-4283-b19c-f4e5eeaac913"
      unitRef="usd">400200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27309ca3061448f8aed7d50699b44c3b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktOS0xLTEtNDQ0Mw_7d1ff01e-611f-48ea-ad56-0d06c1a4865d"
      unitRef="usd">533000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8238834ae2044c7c8f8d0f0b08cbd9bf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMTEtMS0xLTQ0NDM_b4a724dd-ccca-4254-9b9e-77e690dd2155"
      unitRef="usd">378300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifde87f830aaa4e7e95c3b4d0b564bc58_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzktMTMtMS0xLTQ0NDM_0ec6ec3b-6b5d-4339-8aea-00bd95c61540"
      unitRef="usd">258100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64cbb8b5cf6f445e96a2f444f379af93_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTMtMS0xLTA_7bfd02f2-ad9b-461c-8046-67be2c3082ac"
      unitRef="usd">842300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6e1e237c47e47c9828a59209311c512_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTUtMS0xLTA_8c61888b-c9eb-40b4-960e-4f2dc2e94acf"
      unitRef="usd">876200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i085f2ef402e2415c9ef431e7b9de5970_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTctMS0xLTA_91d61356-2405-4af2-95db-cd8b940c4ecc"
      unitRef="usd">622800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i134d638c9b8442bcb2b54a0dcf99244a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTktMS0xLTA_036e435f-9004-4b01-85c7-bf32acaf7fc1"
      unitRef="usd">282100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35093190cc994e6184aeba18c6d4e4e5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTExLTEtMS0w_ef378304-2001-4fae-b25d-d95dea154fac"
      unitRef="usd">236300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ca91803bf7b4a89952e0d15df9e7d20_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEwLTEzLTEtMS0w_f3177f93-c8d5-4c1b-8219-6294c0a5f293"
      unitRef="usd">178500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b03da787f1046dda25e71c726ed0cc8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTMtMS0xLTA_09aee125-e9cb-4cf6-809d-42202f7e5f82"
      unitRef="usd">95600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67ad299c9ff445079d8abfe019fefba6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTUtMS0xLTA_9d87b4d1-cee6-4193-af6b-c77830de98d6"
      unitRef="usd">224800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8cd43064bc54a9e901c418b624a14af_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTctMS0xLTA_2dec32ee-e0e8-4a75-ae42-1509fd89fc65"
      unitRef="usd">224200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1421efbb7afe46ce9044e5d41f1e6871_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTktMS0xLTA_b8716674-81d8-45cd-9e8f-f80a770cfa2d"
      unitRef="usd">263000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8251cd1ee5a241ecacce9020401be466_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTExLTEtMS0w_4fe9819b-fd69-4fa1-8dc1-07e184a8ce69"
      unitRef="usd">365800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa14db9f257a4f7b8ca0845e9421f91b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEyLTEzLTEtMS0w_f1366d0f-b111-4f4a-903e-b4af5339ba4c"
      unitRef="usd">350500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0bbd5d25f80c44ab94954c63d53de368_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTMtMS0xLTA_cc65d603-6f60-4937-8f64-852266f743fd"
      unitRef="usd">162500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb30e7b8f241492da7454e9da0b979d6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTUtMS0xLTA_39a9a18d-c92b-426e-a42b-2f7413606eb1"
      unitRef="usd">158000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic12680d1b9124165bc4f6d955d85bd82_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTctMS0xLTA_eef3eb58-4390-4cde-9ae1-828d96f2fe25"
      unitRef="usd">146000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i429185bfc6e449d7be22df700c5813fa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTktMS0xLTA_c085f76e-0505-4ffc-8f31-b9e17d2eaddd"
      unitRef="usd">81500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie25dfe0449994ce68da67470b4776d8e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTExLTEtMS0w_27b93b22-6667-4455-a093-a38545e64b77"
      unitRef="usd">88100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8b9545410a04c8da65e3c6e319a22d1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzEzLTEzLTEtMS0w_c90ed063-660b-4e8c-9a71-7d32a7a95baa"
      unitRef="usd">112200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22cfb8009ead41cca1ae3072cccf9499_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTMtMS0xLTA_461135a3-d112-44fd-9d9c-7e4931be9979"
      unitRef="usd">7909100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b8dc99127224767a2f12d03a5092d3b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTUtMS0xLTA_064a3b6f-1e5f-4c46-8583-fd46dfe2c1bb"
      unitRef="usd">7529500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ca7b28a537c43b2af1ddf727727ce40_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTctMS0xLTA_8ea886b0-5ebd-45c9-8f15-ca2b3bc55724"
      unitRef="usd">6607000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85186ccd9d984ef4932e09feef978a06_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTktMS0xLTA_489a434c-0aba-4fe1-8e67-f77c9d36f005"
      unitRef="usd">3925300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30e9cf6601c143cdb1b8d32ae6fd5480_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTExLTEtMS0w_08a1377e-69b3-46db-94c3-b2f6e82eeb49"
      unitRef="usd">3602600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea814fafc7fb443db887570f7ea72927_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE0LTEzLTEtMS0w_6d334be2-4a32-474b-9544-68295788361e"
      unitRef="usd">3212500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib05835511e414ca89be73a8916fad2e3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTMtMS0xLTA_2361495c-49fd-46af-87b0-1be2261fef75"
      unitRef="usd">1265300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6b3024a931a4657a4060b07b0425e72_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTUtMS0xLTA_29a9f499-f49b-42a5-a76c-36bb24fcc4a0"
      unitRef="usd">1219500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5c1fe9ccbbb45969203d906ca0f642c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTctMS0xLTA_2ba580e9-255c-40ae-bf0a-3b8f98047128"
      unitRef="usd">1131000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09cd8e4a702840b6b077b52bb0fc885a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTktMS0xLTA_0e3b1ada-30ce-41e0-ae18-0c0bbd3ad7b0"
      unitRef="usd">1064700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie21841be70ab492085d716fac088fb9e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTExLTEtMS0w_b1a1c033-51b7-491a-a866-fdaea6fb421c"
      unitRef="usd">896400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie73c0cb2f4924c719860a7896ccb64a1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE3LTEzLTEtMS0w_0769f714-1e94-4f8f-83f0-5795f1f4ba8a"
      unitRef="usd">1001900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11ff519fc32f47c2a0c49159fe2e34b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTMtMS0xLTA_0b2fad3b-2bd8-4e8a-b581-8515b1626b17"
      unitRef="usd">381900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie914cb56ec4e4ed1ba232fbfee390bd3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTUtMS0xLTA_91097a02-6735-4e71-9f8d-ab0da15135e2"
      unitRef="usd">335300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i966ea8089e9c4d68b34e188c500666d6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTctMS0xLTA_83fd16fa-cd53-4f59-9c55-a69a477de1d9"
      unitRef="usd">291500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f9679e5d6124967a685918cd9edf0fa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTktMS0xLTA_1ac3baa4-97dc-4916-8f76-22d392fd94c4"
      unitRef="usd">650800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ea5fe8155344887ba522b8118049b2f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTExLTEtMS0w_f604d152-a153-471e-bce6-bfa80ddded8d"
      unitRef="usd">589900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3931b370dc143f9a310450ae75b2907_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE4LTEzLTEtMS0w_138dd6f2-e49b-4c59-ba72-3ab7ad30f53c"
      unitRef="usd">529900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15d2a58303ae4d49b78490eb27aa3acb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTMtMS0xLTA_7901db92-2e80-42f5-b6f2-10dcc7846123"
      unitRef="usd">618200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbcdae9c84da42e5aeffa936f33600fc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTUtMS0xLTA_fc24d5ed-050c-4b27-9d4d-bb322d836592"
      unitRef="usd">454800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i88519de09ce340f2a440994d3a26273d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTctMS0xLTA_bd3340c6-9a1a-4553-ac61-aad5498d1ef6"
      unitRef="usd">248500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e9859caf33c4d129baaae6f1b8a77a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTktMS0xLTA_575dd200-bf3c-4b73-9235-f70d77817d99"
      unitRef="usd">294400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e90d63bd7f04d43b87e44bc9cf80dd9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTExLTEtMS0w_42be6c0e-f97a-4433-8210-45efc5e54d81"
      unitRef="usd">124900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee6f19b22df74b2997a2a5a704b7566f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzE5LTEzLTEtMS0w_61119222-8eec-4281-8505-f5e35e8e37e7"
      unitRef="usd">6600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae16d89f887948a1bdfcbcfa51d0d3ff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTMtMS0xLTA_bdbb8f60-890c-4046-8318-2b20c2e99ec0"
      unitRef="usd">480100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00a47ec3ac9242599fb0534acfcf50c0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTUtMS0xLTA_241b0595-b46c-4c8d-8eea-f5af068c13db"
      unitRef="usd">487900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e7e75f9a985435381e8a50f0510b63f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTctMS0xLTA_9c98dc03-b4cd-41d4-9e42-c55ea936cfd8"
      unitRef="usd">531600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if18759d9c174433d92652e5cecea16b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTktMS0xLTA_99ec7790-ed05-4f3f-bacc-cfcfbd249d3f"
      unitRef="usd">56300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i121c5d89d6f84862b7a81c70128ff4bc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTExLTEtMS0w_be424126-6c4b-428a-ae6d-d59edfde9cd6"
      unitRef="usd">55400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c089c556dbe4b988097309eea2debbe_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIwLTEzLTEtMS0w_41f7f877-15f1-4b94-ac55-c467ca618973"
      unitRef="usd">103800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f7338fb226246619bd2bbf15851f0e3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTMtMS0xLTA_eb3f0a55-03d7-4e48-a88d-0914f291e31e"
      unitRef="usd">46600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if209842982b343139ff9db8653d11910_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTUtMS0xLTA_ee605673-87ab-47a1-8847-928b5a239e96"
      unitRef="usd">111000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic909dda5665e4ba29f047d0b8e1bcf5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTctMS0xLTA_35d0e3f4-0f80-4bfc-ae7e-972487a79a2b"
      unitRef="usd">200600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86f3bd326f604139a90da118ac9c06c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTktMS0xLTA_04d6d5ce-ac2e-4f5f-9dff-076cd8493974"
      unitRef="usd">461000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1c0080f9e714abea664e5caa8d145d9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTExLTEtMS0w_6777bd72-d805-4aaf-928e-d903adc7f075"
      unitRef="usd">339300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cb52b4c8c5542df810d31d40cd2b4b5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIxLTEzLTEtMS0w_4813b201-7861-458e-b8b9-ee495b5f6316"
      unitRef="usd">215100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf91ad79a82a4ec5b3a916c3289276f9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTMtMS0xLTA_4f23d55f-ecdc-4b1a-ad9c-fe2e6c936838"
      unitRef="usd">2792100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2de717625dca44c78e1e0e949939a76e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTUtMS0xLTA_9b4f9848-a24b-4f54-a8a0-86a0428d0681"
      unitRef="usd">2608500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14b654e430e44c46b106bcb63224dd6a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTctMS0xLTA_25f37a1c-f0e6-44b5-a271-03285fe2fb2b"
      unitRef="usd">2403200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7fbcc61f59a45d9a37e569ed5965f58_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTktMS0xLTA_b57a3705-92be-4e2b-b695-66fe298670a4"
      unitRef="usd">2527200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d13169d2141455bb4a93b34de2a366e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTExLTEtMS0w_e598c3ec-7e6c-44a2-b8cc-60a2ac1e816f"
      unitRef="usd">2005900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1a6364df78042fa901d2f1c28c93754_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzIyLTEzLTEtMS0w_19c97f89-d4ba-4c33-ae5e-854226876674"
      unitRef="usd">1857300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e09d571eb774bd5b689a1bb4eb4de7f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTMtMS0xLTA_289f6912-3dad-4bb0-96bb-2723aa531614"
      unitRef="usd">1288500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c2dc9d878a14c9ab4c5b052d73bad3f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTUtMS0xLTA_ff318635-95b8-4d58-94e0-e3f0a9074ea3"
      unitRef="usd">1016800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie48cc43a68c8427793e98a1018af69e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTctMS0xLTA_1778f9a7-a967-4c68-affd-6effa47f186a"
      unitRef="usd">738700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia14522eae3f4432ca88eefdbd852a7fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTktMS0xLTA_320cadc9-c946-4eca-977f-245748333850"
      unitRef="usd">500000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f778c41acb14e25af188e39dbcf6369_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTExLTEtMS0w_f0e21bbd-c0fb-4594-907e-b70cea1fd6c4"
      unitRef="usd">349600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e201e3b4b174110a0451d32f28f8212_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI1LTEzLTEtMS0w_dbf87b26-8e3d-4a7e-8119-1a710e55056e"
      unitRef="usd">198700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc9993567a2444faa53e3c75a8e44e1a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTMtMS0xLTA_ef0708b5-70e5-46db-8f8e-af45ef8534b4"
      unitRef="usd">63800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7db6d4c2a25b4bb0bc740c90579b0f05_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTUtMS0xLTA_4e8abba9-a12e-47d5-b1be-62dbaab18bac"
      unitRef="usd">42200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf78497fb94a405aa4fa741353f71471_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTctMS0xLTA_f249987f-5fd2-4912-a99f-bcaca83c2d16"
      unitRef="usd">6700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6279b04ecce545a2a6ccd1edd954a346_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTktMS0xLTA_97096b51-d9a0-4fa9-a9f5-a7a5da8b708d"
      unitRef="usd">575000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic653dbcb57f34df2a7cdbe7b36ad01d2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTExLTEtMS0w_9a29e9da-9d27-4b94-8bb0-5b1ec045edd4"
      unitRef="usd">384700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e2f75b6ec544748a1740ef4680b574b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTEzLTEtMS0w_8416b8af-cef1-45c9-90b0-1266b73dba42"
      unitRef="usd">195900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i382d0dc50c7442e584209c6d42e6be90_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTMtMS0xLTQyNzI_595d2745-ee81-4d19-a2ba-95d0d1886267"
      unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib27a0a7bc70a4f50a74d2e0dacdf5b43_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTUtMS0xLTEzMDgy_56af49a9-0988-4f1d-a32f-89c2f6bc0a6b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ca201e6a4584a94adee1b47b0e65d3a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTctMS0xLTEzMDgy_40888523-ddda-4b8a-99e3-e6b67586c16e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55d3783f314a422f9244251ce8f5d9f8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTktMS0xLTQyODM_ecb86832-aff5-43eb-a3d0-3db92b34ec55"
      unitRef="usd">14600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76f653f3992f470ca575e3abea9ae426_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTExLTEtMS0xMzA4Mg_75fa913c-5d54-4a9d-a296-3ff797b55958"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78c414a5e65d42939a3f580b88d368a9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI2LTEzLTEtMS0xMzA4Mg_0db45616-8fa6-4b74-a045-61287414db4e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic54e1b52fe0945a18f903058aed5a173_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTMtMS0xLTA_507942a5-49df-47ac-bc32-f7a192026e80"
      unitRef="usd">1372300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i092485a179404990a1b3f5d43565922d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTUtMS0xLTA_ebabc61c-76d1-4d48-9957-84fdc305c1d2"
      unitRef="usd">1059000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbcfad66d94c42699bde82b3cc71bb61_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTctMS0xLTA_746422af-76d4-455b-a31f-ef547e9a6090"
      unitRef="usd">745400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8d67124e0304de6aa72358898ffee74_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTktMS0xLTA_1340fcaf-eac0-4f1d-98c7-75903056ecf5"
      unitRef="usd">1089600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7465980476074ec1b9f2cf051bd93aab_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTExLTEtMS0w_833ee73e-b1f6-4527-a5ee-8e98ee2655d7"
      unitRef="usd">734300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i405fef2f42e9480580d5e77115611bc8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzI3LTEzLTEtMS0w_f3ff8a32-a17e-4370-ae1a-0b97e3108280"
      unitRef="usd">394600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie21029b52e3a4a25b8fa5ac32c01193d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTMtMS0xLTA_3f304877-0cc9-4ee2-8157-4b369178e93e"
      unitRef="usd">42100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3e3ba10cc2340fcb7a501bb4088f695_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTUtMS0xLTA_453a683b-09c0-4af8-8df2-95b305ff6add"
      unitRef="usd">49600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i194d5e8204d94e729dce3e5167479788_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTctMS0xLTA_78fe7c36-d51d-463c-abcd-5cd9b1e2a5f7"
      unitRef="usd">54300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42aed1d813ba440d989563043cbf63d9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTktMS0xLTA_52d9654d-fc76-4e4d-9a9f-6cb6f881a94d"
      unitRef="usd">725600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if93e5c1a7b044586b825fb8d87adef56_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTExLTEtMS0w_f2ceed23-fe5d-4e8c-8b4e-5762f8fc1f3d"
      unitRef="usd">675800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6282183e9fda43d6a25c5ce5f92ff949_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMwLTEzLTEtMS0w_a998712c-ebef-4391-a08c-06b092bd8f9a"
      unitRef="usd">653700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3164ae1013b84936a3990cdd7069cef8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTMtMS0xLTA_40cc25b0-74fb-4c29-bebd-6a4083e572fa"
      unitRef="usd">46100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6226f69ada1b4d4293ca0d61745f5115_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTUtMS0xLTA_a17bbefe-a81b-4e8c-a7e4-46f39eef9948"
      unitRef="usd">41000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i464b09a2e18141e18ffa754a848112c9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTctMS0xLTA_f90b1d9f-263d-4f9d-b801-936a7f5dd886"
      unitRef="usd">36200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i471982bd0b034ecbbe77d99805441a0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTktMS0xLTA_58e2720a-9ca8-43e6-ae4e-e0ea8ba19e76"
      unitRef="usd">360500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia76bec07f3464f1c8021d24050c68ea6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTExLTEtMS0w_6e66d44c-479b-404f-b0a1-d0ebaad8737a"
      unitRef="usd">377600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia39a7fc11f9746e597092068de88f47b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMxLTEzLTEtMS0w_5a206d26-6e7c-42b7-a1c1-2836aaf9f5fb"
      unitRef="usd">435100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic60748556476451f97a39a8498268861_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTMtMS0xLTA_31df4496-61e6-4b61-b3f5-0f7cc542e063"
      unitRef="usd">325900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ce9eaf6546546d389e4f26520e4930d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTUtMS0xLTA_bab4053a-a84a-4618-8d4f-c55b7952b6d9"
      unitRef="usd">154900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i856f4e27d0e54f3f8f678504c46706a3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTctMS0xLTA_6a580921-7184-45c9-82a1-ca5e7a53abdb"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1246f125dde64914934faf191b569fad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTktMS0xLTA_c94c62b0-cd0c-418f-8fc5-efda8a63aafc"
      unitRef="usd">37000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac47103ffb8e4db3ba8420ae1884ba32_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTExLTEtMS0w_1008d669-4f20-4dc3-8897-83200f3ff0a4"
      unitRef="usd">7700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i971612ddc6f84ff5ab4cebc6bc9b7489_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzMzLTEzLTEtMS0w_5036ea00-fde7-4d96-9d8e-fcf5ff611187"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd4460d0fbe7498caa8faf2ab1635509_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTMtMS0xLTA_bd85f2c6-e795-4ee8-afea-4ab77f3288e5"
      unitRef="usd">73200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie954542f232d49269cf42f99d87610b5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTUtMS0xLTA_e7cd4971-384c-4b51-87fe-a66b5c924a79"
      unitRef="usd">111000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if596ee8084b746c1884dfb23161b95a2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTctMS0xLTA_e38d1fa8-74b4-4842-8d02-c1406ce35cf7"
      unitRef="usd">182000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad4c40ad02014289884f8f89f9cd98a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTktMS0xLTA_503e9449-7455-4b48-a602-8207a0fc6589"
      unitRef="usd">220900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d98f1e0f63d4944acdd4049c11f843e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTExLTEtMS0w_3ae9949a-be3b-4db2-a3bd-6cac68cfc643"
      unitRef="usd">305300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b22a1b043d84461acbaead22e49cd3a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM0LTEzLTEtMS0w_492d2616-6460-43bd-955f-f2296abf520d"
      unitRef="usd">454500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4c01d5260804ef2aefb47f37eac34b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTMtMS0xLTA_62d35583-6545-4e29-888a-7c3a32f3e285"
      unitRef="usd">487300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c6ecf87283c4add86844acf0df92029_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTUtMS0xLTA_392ca81e-c068-4ac9-ac6c-62e833cae0f1"
      unitRef="usd">356500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e5420c07a564b57bce98a24d8094aea_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTctMS0xLTA_70030851-7cac-4fba-98b6-65bc2d61a4d6"
      unitRef="usd">277400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3730e62c21c49eeb0a31d079c88843e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTktMS0xLTA_2b491e86-52e6-49ce-912e-39e6190eabf2"
      unitRef="usd">1344000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11b39e0b4d84459b937f1252cad92e0c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTExLTEtMS0w_7dc921d3-9ed8-40dc-a7b2-c7f51c141757"
      unitRef="usd">1366400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe81f38456364de09c2c37f4eb63cfc5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM1LTEzLTEtMS0w_b239909c-a7ad-4252-bc1e-4f69e6ef24db"
      unitRef="usd">1543300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf1659ec78a740ca9d2960b4d4f4fea4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTMtMS0xLTE2NDM_bcb19323-4c1f-40f2-ad68-3b14132ffcd8"
      unitRef="usd">510300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb82d9ffde3c4a3a8affb2c0815b56d2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTUtMS0xLTE2NDM_23508da6-3fbc-4e51-a51b-bf934ddafb5b"
      unitRef="usd">645500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i576e907b609447808b7b5933c0df5f34_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTctMS0xLTE2NDM_953a188c-a327-4e67-985d-2ca215bf65e5"
      unitRef="usd">757900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id33620d8d08d44b8b383b1f866bf2e64_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTktMS0xLTE2NDM_948f1142-1bc0-4287-9f53-a228ea7ad40d"
      unitRef="usd">536000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbec8a0db57b47818082aea617fcb08e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTExLTEtMS0xNjQz_0b00d541-0e4f-4149-aa6d-4c686687e0ba"
      unitRef="usd">759100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia49f010469e74c1fbbb54018a3403a10_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTEzLTEtMS0xNjQz_89c31a8e-95cf-4161-a206-06b10a2d411e"
      unitRef="usd">817700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b1f8bd5f6e7439cbf1c41e604f947cd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTMtMS0xLTQ0NDg_7243adea-0cca-4b77-aaee-f199131ff267"
      unitRef="usd">850000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e9913b2677a470782bee3b901368718_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTUtMS0xLTEzMDkx_e0bc23b5-31e9-4f18-92ff-f793cec1b640"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8a98260337a41c7bf70c5041273cf30_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTctMS0xLTEzMDkx_61da493d-b610-4157-8d26-57de47c2a341"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69dd705bb5be40cda1cf159e67bfe51f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTktMS0xLTQ0NDg_28b86798-a69a-4398-8b05-9a198234f064"
      unitRef="usd">21200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i254787900e9a4e7182dcb921c4b5d695_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTExLTEtMS0xMzA5MQ_384fe1d8-3945-46d3-9c50-c1e1d2aee397"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5671e1d40a394d5aa617890df516c413_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTEzLTEtMS0xMzA5MQ_f7ce7d43-652e-46bc-a69c-980a50fc8ebc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c4d6c27c076414ba7e9464801d0140b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTMtMS0xLTA_c7ccb026-75e4-476a-aeef-9afc11ccf509"
      unitRef="usd">61800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51e1b22d70974fcc95c281ec5f6e788d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTUtMS0xLTA_86edb975-c759-4762-890f-4e3cedd67b12"
      unitRef="usd">231700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia67ee0b00db446ecacd2b9f627d621d3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTctMS0xLTA_4b95ad0c-cc99-464e-9e0f-06f78f8fb37a"
      unitRef="usd">1129200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf51f9d513a64c25a6eeaf8e33921e20_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTktMS0xLTA_5063afb7-d257-40bd-9600-7404e7db510f"
      unitRef="usd">545400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia079d10886be402287aaa123fc31ddf0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTExLTEtMS0w_437a8e40-0f05-41b5-b639-163a1c9fed4c"
      unitRef="usd">658800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b37da845eb34ab9aa5276ef319e7926_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM4LTEzLTEtMS0w_be582992-f9c5-4cab-a73b-e4b787596c81"
      unitRef="usd">722700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91bd92d27afd4390915113b0bb32dba6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTMtMS0xLTA_7ad1229b-db5a-4159-864d-c8f6f2d36e27"
      unitRef="usd">246400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie311a24502de4314b71b45580255cb57_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTUtMS0xLTA_afd4a6b6-90fa-4ec2-9c17-085a40c3c3f0"
      unitRef="usd">291900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff5458bec1b144e5afafc2f8657e9b86_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTctMS0xLTA_4051e24b-7aac-4ad1-8ef9-096b42a73038"
      unitRef="usd">471800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc8656193e314466a66ea72a95a19692_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTktMS0xLTA_c9564c60-6349-47ac-b4b7-9ab52d0f4d43"
      unitRef="usd">321800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i756013fb987e4ec49313e27c98887d9b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTExLTEtMS0w_612b29f0-5b20-4077-9830-b29a12c51add"
      unitRef="usd">469700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48736069f07d435ea802718ad0061329_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzM5LTEzLTEtMS0w_da080c31-1d6f-4876-8e5b-b440d9c6bbb3"
      unitRef="usd">553300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f15eb6661ce4b1abb626c73e242befc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTMtMS0xLTA_ead935c4-1900-4372-938a-35de2bff6663"
      unitRef="usd">1668400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55080d1515744962b9aef976d3cfdc53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTUtMS0xLTA_c40d600e-f4f5-49c9-b588-fc01fbc32ca0"
      unitRef="usd">1169100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie546cf165ddd419e9f13ce7b33b842b3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTctMS0xLTA_7250fade-b879-49b6-ad46-7da06d00fe6d"
      unitRef="usd">2358800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1485142ec4594191aa24ebdd7a9ee8bd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTktMS0xLTA_4960fc4f-0a7a-41e8-867f-7545f89766b4"
      unitRef="usd">1424400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7e49c0f20674d7eb574b88861a45d59_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTExLTEtMS0w_753f0ad4-ad8f-46a6-b051-a6a37e6dde0b"
      unitRef="usd">1887700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5388a613eeb490eb1588c4dca37c078_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQwLTEzLTEtMS0w_4f637647-7f05-4b18-885c-7d225660c7ed"
      unitRef="usd">2093700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16fbcb5755144a989fd1a37e01482bcf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTMtMS0xLTA_111520ec-23fa-4d0a-b92d-f3de40eb1329"
      unitRef="usd">14229300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e93087d035441c7b9196cf48b975ccf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTUtMS0xLTA_04deb0c4-9266-4613-b4ac-84ca523ecd82"
      unitRef="usd">12722600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i056be4f4187a4d8ba5795cb66a7c63e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTctMS0xLTA_dd6b5bfb-d85b-45bb-895c-d7f734dade41"
      unitRef="usd">12391900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61ff3b39dc584d80ad523e152d9aac2a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTktMS0xLTA_39c70f19-7293-483a-82ac-4e1928d04bce"
      unitRef="usd">10310500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9042f18954a44f338ab7c4c38402701e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTExLTEtMS0w_301156f1-c836-41ce-bf90-f79c13c5bfae"
      unitRef="usd">9596800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i231c072e54b14e93bb61feda90673766_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZToyOGVlMmYzNjQ0YzY0NDc0ODg5NzM3OTczYmNiNDY0Yi90YWJsZXJhbmdlOjI4ZWUyZjM2NDRjNjQ0NzQ4ODk3Mzc5NzNiY2I0NjRiXzQyLTEzLTEtMS0w_254a32d1-5780-4b92-9da9-8e49112d0b9a"
      unitRef="usd">9101400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16fbcb5755144a989fd1a37e01482bcf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzMtNC0xLTEtMA_6ff908a3-7e1b-47df-b1ae-d7dc195a86a1"
      unitRef="usd">14229300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e93087d035441c7b9196cf48b975ccf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzMtNi0xLTEtMA_a9e44b4d-5bd4-44f1-a80b-4eade618b6dd"
      unitRef="usd">12722600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i056be4f4187a4d8ba5795cb66a7c63e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzMtOC0xLTEtMA_ea5a6eca-548c-4834-923d-e85459909309"
      unitRef="usd">12391900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28f9aa8b13a844198c584392ffe612ae_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzQtNC0xLTEtMA_b2c8bfc5-2240-4b6f-b0d6-3cb21e26ec1a"
      unitRef="usd">4187700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75eac947e5c24423826502ab09453d22_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzQtNi0xLTEtMA_de6dc188-583e-434d-ac5c-7a24f90de4ac"
      unitRef="usd">3765000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3cf5ac51274948a2a524006ba7646b34_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzQtOC0xLTEtMA_c4343421-1885-4c37-98aa-555fe92e2853"
      unitRef="usd">3663100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie404784c5a4c4f23bdcd42cf33eca1b1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzUtNC0xLTEtMA_62e1901d-a5a5-403a-adf2-b883432c46b3"
      unitRef="usd">2583100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f19444ca5d74e42b8447a4f2274754d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzUtNi0xLTEtMA_fceda363-ef41-44c3-8146-1034d8005263"
      unitRef="usd">2547600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04bae10a0f824b3db0e8166ff0c20364_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzUtOC0xLTEtMA_fb4825af-ecfd-426c-9f3f-286b1badd79b"
      unitRef="usd">2407400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8d3b673fac540279a7f2aacdfaa0069_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtNC0xLTEtMzI2Mg_0ba17281-fb2a-4a90-994d-4fbe453fe1ac"
      unitRef="usd">1116900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i792013c79753444599d13628b640dc41_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtNi0xLTEtMzI2Ng_5d386193-3f8e-426f-936a-a3fab07c9cb0"
      unitRef="usd">939400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2b32d9391794988a11cc682565b7a80_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtOC0xLTEtMzI3MA_2a70f92e-d01e-4d7a-a786-00b361f4c73c"
      unitRef="usd">750800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a0d2e470af549b4881425b33c0ad415_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtNC0xLTEtMA_f16bbb89-d68d-4dd3-b2e9-9d1e96a0868e"
      unitRef="usd">2422700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6137d276b0f47409d9ce0335e227625_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtNi0xLTEtMA_f80b5dc3-f46c-42f7-9e2e-bd6e7f682dc3"
      unitRef="usd">2344900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0163d1b6ab54735a54f26743f4772ea_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzYtOC0xLTEtMA_dfdb378e-13ff-492c-8c33-993d684d1890"
      unitRef="usd">2280100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzctNC0xLTEtMA_5c23846b-f4d0-4a1d-9887-71939f8c0c76"
      unitRef="usd">24539800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzctNi0xLTEtMA_ad0b91e3-bf60-43c4-8cf0-ebe450fd9ad8"
      unitRef="usd">22319500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMTgvZnJhZzo0YThlYWJhNjAwNTM0MGY2YjljNThmYzBjYTRkNzgyYS90YWJsZTphMDY3ZDU2MjUxM2Y0ZWEwYjkyMmUyYjdkMTUyYjE4Mi90YWJsZXJhbmdlOmEwNjdkNTYyNTEzZjRlYTBiOTIyZTJiN2QxNTJiMTgyXzctOC0xLTEtMA_ad19d2f6-475b-453b-9d8e-dfef1f6ff86a"
      unitRef="usd">21493300000</us-gaap:Revenues>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzU4NDM_82371910-22ba-496c-b086-d141a1d11611">Acquisitions and Divestiture&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 and 2019, we completed the acquisitions of Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development in 2020, 2019, and 2018, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December&#160;31, 2020, 2019, and 2018, we recorded acquired IPR&amp;amp;D charges of $660.4 million, $239.6 million, and $1.98 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions of Businesses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dermira Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the U.S. Food and Drug Administration (FDA). We also acquired Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the year ended December 31, 2020. We are unable to provide the results of operations for the year ended December 31, 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included because this acquisition did not have a material impact on our results of operations for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Loxo Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we acquired all shares of Loxo for a purchase price of $6.92 billion, net of cash acquired. The accelerated vesting of Loxo employee equity awards was recognized as transaction expense included in asset impairment, restructuring, and other special charges during the year ended December 31, 2019 (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib (LOXO-292), an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. At the time of approval, we reclassified our $4.60&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived intangible assets to finite-lived intangible assets and began amortizing straight line over its estimated useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at February 15, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangibles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,032.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,590.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred - net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,917.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$4.60 billion of the acquired IPR&amp;amp;D relates to selpercatinib (LOXO-292).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contract-based intangibles (primarily related to Vitrakvi) which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of approximately 12 years from the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated statement of operations for the year ended December 31, 2019 includes revenue attributable to assets acquired in the Loxo acquisition of $136.7 million, primarily due to regulatory approval and sales milestones received. We are unable to provide the results of operations for the year ended December 31, 2019 attributable to Loxo as those operations were substantially integrated into our legacy business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included because this acquisition did not have a material impact on our results of operations for the years ended December 31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table and narrative summarize our asset acquisitions during 2020, 2019, and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatement and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undisclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical target that could lead to potential new medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evox Therapeutics Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical research collaboration for the potential treatment of neurological disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Innovent Biologics, Inc. (Innovent) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disarm Therapeutics, Inc. (Disarm)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disease-modifying therapeutics program for patients with axonal degeneration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fochon Pharmaceuticals, Ltd. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical molecule targeting  hematological malignancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AC Immune SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2019 &amp;amp; September 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ImmuNext, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novel immunometabolism target&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Avidity Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential new medicines in immunology and other select indications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centrexion Therapeutics Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sigilon Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encapsulated cell therapies for the potential treatment of type 1 diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AurKa Pharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK-01, an Aurora kinase A inhibitor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ARMO BioSciences, Inc. (ARMO) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancer therapy - pegilodecakin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anima Biotech Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation inhibitors for selected neuroscience targets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SIGA Technologies, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chugai Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OWL833, an oral non-peptidic GLP-1 receptor agonist&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NextCure, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology cancer therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dicerna Pharmaceuticals Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardio-metabolic disease, neurodegeneration, and pain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hydra Biosciences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TRPA1 antagonists program for the potential treatment of chronic pain syndromes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized the acquired IPR&amp;amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized acquired IPR&amp;amp;D expenses of $96.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in January 2019 upon entering into a license agreement and $30.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in September 2019 upon entering into an amendment to the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This research and development collaboration agreement terminated effective March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestiture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, we completed a transaction in which we sold the rights in China for two legacy antibiotic medicines, as well as a manufacturing facility in Suzhou, China to Eddingpharm, a China-based specialty pharmaceutical company. In connection with the sale, we received net cash proceeds of $354.8 million and $40.3 million from Eddingpharm in 2019 and 2020, respectively. We accounted for the transaction as the sale of a business. We recorded a gain of $309.8 million in Other&#x2014;net, (income) expense upon closing the transaction in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Events &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Precision BioSciences, Inc. (Precision)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we entered into a research collaboration and exclusive license agreement with Precision to utilize Precision's proprietary ARCUS genome editing platform for the research and development of potential in vivo therapies for genetic disorders. Under terms of the agreement, we paid an upfront cash payment of $100.0&#160;million and invested $35.0&#160;million in Precision's common stock at a premium. As a result of the transaction, we will record an acquired IPR&amp;amp;D charge of $107.8 million in the first quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Merus N.V. (Merus) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we entered into a research collaboration and exclusive license agreement with Merus to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. Under the terms of the agreement, we paid Merus an upfront cash payment of $40.0&#160;million and invested $20.0&#160;million in Merus common shares at a premium. As a result of the transaction, we will record an acquired IPR&amp;amp;D charge of $46.5&#160;million in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Therapeutics Inc. (Prevail) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we completed our acquisition of Prevail. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that will be anchored by Prevail&#x2019;s portfolio of clinical-stage and preclinical neuroscience assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We acquired all shares of Prevail for $22.50 per share (approximately $880&#160;million) in cash plus one non-tradable contingent value right (CVR). The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom (U.K.), Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting impact of this acquisition and the results of the operations for Prevail will be included in our consolidated financial statements beginning in the first quarter of 2021.The initial accounting for this acquisition is incomplete. Significant, relevant information needed to complete the initial accounting is not available because the valuation of assets acquired and liabilities assumed is not complete. As a result, determining these values is not practicable, and we are unable to disclose these values or provide other related disclosures at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Asahi Kasei Pharma Corporation (Asahi)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we entered into a license agreement with Asahi to acquire the exclusive rights for AK1780, an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies for the potential treatment of chronic pain conditions. As a result of the transaction, we will pay Asahi an upfront cash payment and record an acquired IPR&amp;amp;D charge of $20.0&#160;million in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzU4MzI_3a6a617d-fa61-4a62-a4c2-37b6a9c64930">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;amp;D was immediately expensed because the compound acquired had no alternative future use.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzExODM_87bd13f3-326a-4804-b6a9-653203cba8bf"
      unitRef="usd">660400000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzExODc_dffb96f4-6fee-4b1c-8f89-9277319d42f4"
      unitRef="usd">239600000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzExOTU_5b7904e5-20f9-40fb-a45b-6e55f05d0749"
      unitRef="usd">1980000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i0447dee610924071bcc739ab2cface2b_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzM3Nzg_5409bc59-3060-42b8-b597-08d4abbf7b57"
      unitRef="usd">849300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill
      contextRef="ib39f7cc613994dd990be73fcc3b87286_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUwMzA_60323d9c-7a3d-41ac-827d-239d00949aec"
      unitRef="usd">86800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ib39f7cc613994dd990be73fcc3b87286_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUwNTY_8d037ccd-0b70-41d8-964a-72099663258a"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ib39f7cc613994dd990be73fcc3b87286_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUxMzA_92cc5d6b-3423-4ca5-84cc-e178933e40fd"
      unitRef="usd">49500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="ib39f7cc613994dd990be73fcc3b87286_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUxNTc_a26167e7-0bae-4795-a476-ef98c90f4d35"
      unitRef="usd">375500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibd24952151d6401a8d349f6aa9770ddb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2MzUxOTU_3f742ad5-c397-48cd-8553-ba782458dce6"
      unitRef="usd">276200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ic44351e94bb742d683da05ff0074d5c2_D20190201-20190228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEzNTM_3b6e81ce-f97d-41a9-a901-3b2e8bc4c2c0"
      unitRef="usd">6920000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment
      contextRef="i56fecb64135f4cca97024ac5ee838679_I20190215"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTYzNzI_ef7db691-54c3-4bc8-9280-00252e6a3890"
      unitRef="usd">4600000000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzU4MjY_effe9acd-28c2-497b-9d55-4a07432c882b">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at February 15, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangibles&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,032.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,590.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred - net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,917.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$4.60 billion of the acquired IPR&amp;amp;D relates to selpercatinib (LOXO-292).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contract-based intangibles (primarily related to Vitrakvi) which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of approximately 12 years from the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment
      contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzEtMS0xLTEtMA_3cf8539d-5f8c-4972-b816-2c8f5f429a55"
      unitRef="usd">4670000000.0</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzItMS0xLTEtMA_98d85e65-f81c-4430-9b84-851d9fa94ea5"
      unitRef="usd">980000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzMtMS0xLTEtMA_f3896e36-78db-4585-a22e-fd500e76e6ab"
      unitRef="usd">1032800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet
      contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzQtMS0xLTEtMA_0eaf69b3-5ec1-4b90-b02b-775bbc7495e1"
      unitRef="usd">-26400000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzUtMS0xLTEtMA_b3efdcda-0b33-434f-92b5-75df3c70c4d5"
      unitRef="usd">4590800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzYtMS0xLTEtMA_06564147-114d-4e4b-90b7-61e481752cf5"
      unitRef="usd">2326900000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i911edaec6d6642ce8d5278f65d8639f8_I20190215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZToxNTc0NmZjNGViMWQ0OGNjOGZiOGY1ZWVlOGI3NTFiZC90YWJsZXJhbmdlOjE1NzQ2ZmM0ZWIxZDQ4Y2M4ZmI4ZjVlZWU4Yjc1MWJkXzctMS0xLTEtMA_7c480bf3-8d92-446f-b119-798437f45916"
      unitRef="usd">6917700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment
      contextRef="i56fecb64135f4cca97024ac5ee838679_I20190215"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzIwMzQ_01c8d46f-3325-47f1-a194-59392c71590b"
      unitRef="usd">4600000000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6d91ff7b27004f208f75b0a5c87e5819_D20190215-20190215"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzIzMzI_c6d14b35-0468-4a8a-9aa5-d4e1875e98cc">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i9219272b6237462ebdaca8970a975081_D20190201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzI2NzE_d76cf1fe-fa54-4a97-8690-f9813e726689"
      unitRef="usd">136700000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzU4Mzk_b26576bc-48a9-4842-86e5-8d62c952e537">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table and narrative summarize our asset acquisitions during 2020, 2019, and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s),Therapy, or Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatement and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undisclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical target that could lead to potential new medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evox Therapeutics Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical research collaboration for the potential treatment of neurological disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Innovent Biologics, Inc. (Innovent) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disarm Therapeutics, Inc. (Disarm)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disease-modifying therapeutics program for patients with axonal degeneration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fochon Pharmaceuticals, Ltd. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical molecule targeting  hematological malignancies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AC Immune SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2019 &amp;amp; September 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ImmuNext, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novel immunometabolism target&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Avidity Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential new medicines in immunology and other select indications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centrexion Therapeutics Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sigilon Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encapsulated cell therapies for the potential treatment of type 1 diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AurKa Pharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK-01, an Aurora kinase A inhibitor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ARMO BioSciences, Inc. (ARMO) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancer therapy - pegilodecakin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anima Biotech Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation inhibitors for selected neuroscience targets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SIGA Technologies, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chugai Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OWL833, an oral non-peptidic GLP-1 receptor agonist&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NextCure, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology cancer therapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dicerna Pharmaceuticals Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardio-metabolic disease, neurodegeneration, and pain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hydra Biosciences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TRPA1 antagonists program for the potential treatment of chronic pain syndromes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized the acquired IPR&amp;amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognized acquired IPR&amp;amp;D expenses of $96.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in January 2019 upon entering into a license agreement and $30.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in September 2019 upon entering into an amendment to the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This research and development collaboration agreement terminated effective March 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i817bc774c0a8475dbbe3fec31acb4ee2_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEtNi0xLTEtNjU4_62dde002-e847-4ab5-9f89-a94dde4024f0"
      unitRef="usd">52300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i5ec4b9cb82304fe1a9d510e0419943f5_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzItNi0xLTEtNjcx_c4fa1584-54fc-4978-b66b-1b7dbf9a7f69"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i4d4c539b649e4eb2b5f76577e83e9100_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzMtNi0xLTEtNjc4_7a2418a7-a1d8-4b96-8553-a4944b6f3568"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if2dc373598f440289cea2acfc3527726_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzQtNi0xLTEtNjg0_3b73d8b4-e4c7-411b-95a4-d21fc42e6df8"
      unitRef="usd">174800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i0e93668371324e1ca8c0ee4bcbd18801_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzUtNi0xLTEtNjkw_55d86e83-25ff-490a-a2ef-8c9e40e00351"
      unitRef="usd">22000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ibdb9be66049641c9ac68c3d117603a04_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzYtNi0xLTEtNjk2_0230e72c-1ecf-4704-8294-4b478900e0a8"
      unitRef="usd">200000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iba61e61e3baa4e2997fa60b1e4f4971e_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzctNi0xLTEtNzAz_a5036b92-21a5-44d3-8ecc-90dcd0d9877a"
      unitRef="usd">126300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iec4ba9fe07284d088597742e1436f206_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzgtNi0xLTEtNTQ3Ng_6be54d8c-87a4-43a5-b072-2067ad47516a"
      unitRef="usd">40000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie9280278cfd44c43961529cec49d61e7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEtNi0xLTEtMA_43c44e0d-4ed8-44be-a58c-e47bd46ff3e0"
      unitRef="usd">127100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ibdaa22fe62fc496280072ca3fca4be80_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzItNi0xLTEtMA_603face9-9ece-4618-adc5-1334b9fd9016"
      unitRef="usd">40000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ieb0a2d07df0d4feda7f5fd4749d43715_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzMtNi0xLTEtMA_c511f041-c57f-4d76-9bc2-faa79c2fb300"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i639e2336e84c4b14a58a28b021459d91_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzQtNi0xLTEtMA_c95ea8f5-a106-44b5-8833-9e78ef72b7ff"
      unitRef="usd">47500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i840bb93977c84d32a309ff7a8196c494_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzYtNi0xLTEtMA_793f590a-524e-4314-823a-00d6df0465a9"
      unitRef="usd">66900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9269ad1f97554a34afb28d633cb92685_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzctNi0xLTEtMA_ab6a9964-2d4c-4bd4-b159-fd7f4c8021e6"
      unitRef="usd">81800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6890b2b6dd4c4f7cb1263fb822f41093_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzgtNi0xLTEtMA_9672d73c-5363-46fe-982a-3e8d1b87bbfc"
      unitRef="usd">1475800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i8da5e2bb6fb443248dc40e30fed39f7a_D20180701-20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzktNi0xLTEtMA_be63775b-a9a4-4b8b-95af-186e95f14c93"
      unitRef="usd">30000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ib406c368ebb248a6905e51cdc446be75_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEwLTYtMS0xLTA_0c18d5bf-8fdd-4e2b-acdf-2ff69232f181"
      unitRef="usd">80000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ib7a390840d5f4630bf6cdb7e10975ac5_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzExLTYtMS0xLTA_c8499a8e-ab97-49fc-a551-b6cbf32d95d1"
      unitRef="usd">50000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ibbd61d5c90aa43c0a362a60341c2d2ad_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEyLTYtMS0xLTA_b3feba55-ed55-4277-b959-a93944eb68e3"
      unitRef="usd">28100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i162940fb176e48c1a385b23fcc164f0c_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzEzLTYtMS0xLTA_30b0567d-2938-46d3-821f-b8b6fa6a67c0"
      unitRef="usd">148700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic2e25f473eb845d2843f5335d4f49aed_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90YWJsZTowYTNmOWVjZWViMzE0NTNmOTQ3MWY3MmUwZDYyZmY4OS90YWJsZXJhbmdlOjBhM2Y5ZWNlZWIzMTQ1M2Y5NDcxZjcyZTBkNjJmZjg5XzE0LTYtMS0xLTA_61198c4c-cad6-40a1-b951-51db209ba3fa"
      unitRef="usd">22600000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i28cd09163e9a470f87436cbc6e159574_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTYzODc_9d9b4ac2-17c4-456a-a28d-4df730f00822"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9a68330743054dfd8a5f47bd40a19db8_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzM0Mzc_3d463f3a-ed0f-4c4c-833b-25286c43caa8"
      unitRef="usd">96900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i3922fb112aac468ba7f7550c759a6166_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzM0OTk_5f093905-ab55-4000-88a3-2e33f2a0020a"
      unitRef="usd">30200000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <lly:NumberOfMedicinesRightsToSold
      contextRef="i2ab202db20bf44e79b70b6fe34785936_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzQwNjQ_ef145467-29aa-4d35-84cb-b7de64b2583a"
      unitRef="medicine">2</lly:NumberOfMedicinesRightsToSold>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i2ab202db20bf44e79b70b6fe34785936_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzQyNzU_58c9abc3-6243-4305-bc21-9a3f26700366"
      unitRef="usd">354800000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <lly:DisposalGroupNotDiscontinuedOperationPaymentToBeReceived
      contextRef="i24260a2966224f0aaff14390ed8899c7_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzQ5NDc4MDIzMzQ1MzI_54912d7a-5fdb-4f29-9bf2-e0b6a4f2a857"
      unitRef="usd">40300000</lly:DisposalGroupNotDiscontinuedOperationPaymentToBeReceived>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i0bd2f82569394ceb825c6ab486475ce3_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzQ0Mzg_7920f962-1809-40d6-b392-bdafd90630c0"
      unitRef="usd">309800000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i456272c8da464ab0977d30b650506a1b_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0MDI_0f0b9755-8db9-41dd-af1f-6d24fddf70c5"
      unitRef="usd">100000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i456272c8da464ab0977d30b650506a1b_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0MTg_05498df2-6d35-495c-bd17-9513028c21b4"
      unitRef="usd">35000000.0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i98a914a9a3184c15824f6ca6f22e6887_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzEwOTk1MTE2Mzk0ODI_fd923d4e-8b52-44d7-97cc-80b579542389"
      unitRef="usd">107800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i80f0e3d4afc04fa5958a6ff84edcb67c_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0MzM_82e780ed-104c-41d5-9f94-19086c478f15"
      unitRef="usd">40000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i80f0e3d4afc04fa5958a6ff84edcb67c_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0NDY_bafa4090-701e-4707-9bd8-ccbaec53ddaf"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id11c18de10e047e29fc8f48ccd7ad3d9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0NTk_ad69a74a-0849-477e-8582-8fec9e273b08"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ib592ca19ca78498fa6f8c390254088c8_I20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0NzQ_15c346a1-d5a1-4858-8d1e-14cc1355fa1f"
      unitRef="usdPerShare">22.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5102763567ac4b82ad95c44a59000d4b_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0ODI_2094ad66-a860-44aa-9b91-ab3080541b57"
      unitRef="usd">880000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="ib592ca19ca78498fa6f8c390254088c8_I20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY0OTY_c8270c52-1642-498c-a494-0d06885bf0fe"
      unitRef="usdPerShare">4.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ib592ca19ca78498fa6f8c390254088c8_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY1MDM_f9e97552-157c-4078-8e34-1dc8122a1ab1"
      unitRef="usd">160000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
      contextRef="ib592ca19ca78498fa6f8c390254088c8_I20210131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY1MTY_0648b990-1c13-4abb-992d-7d3eb9bb56e7"
      unitRef="usdPerShare">0.083</lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if000a6bc5ce54a1b991ab37772234f3b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjQvZnJhZzpjZGI1ZTIxZTRmMDE0ODNhOWEzMjZhYjIxOGVjM2IxMy90ZXh0cmVnaW9uOmNkYjVlMjFlNGYwMTQ4M2E5YTMyNmFiMjE4ZWMzYjEzXzMyOTg1MzQ5MTY1MTg_3101cfbb-6151-40df-8a9d-02860a0b5a2c"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzMyOTg1MzQ5MTYwOTc_4f3c54e7-d364-46d1-b46b-2857a739f270">Collaborations and Other Arrangements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim Diabetes Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#x2019;s oral diabetes products: Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, and Trijardy XR as well as our basal insulin, Basaglar. Jentadueto is included in the Trajenta product family. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestones &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Deferred) Capitalized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December 31, 2019, in the most significant markets, we and Boehringer Ingelheim shared equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We recorded our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We recorded our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we recorded our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company was entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments may have resulted in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may have been reduced by any performance payments we made related to these products. Similarly, performance payments we may have received related to Basaglar effectively reduced Boehringer Ingelheim's share of the gross margin, which reduced our cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, we and Boehringer Ingelheim modernized the alliance. In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs and commercialization costs for the Jardiance product family. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales. For the Jardiance product family, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,124.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,153.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;358.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Olumiant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on  global net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In the first half of 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $210.0 million and $180.0 million were capitalized as intangible assets as of December 31, 2020 and 2019, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Olumiant to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;638.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 antibody therapies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. In connection with this transaction, we recognized an acquired IPR&amp;amp;D expense of $25.0 million in 2020. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales. Pursuant to an EUA, we recognized $871.2 million of net product revenue associated with our sales of bamlanivimab to third parties during the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of Greater China (which includes mainland China, Hong Kong and Macau Special Administrative Regions and Taiwan) and Junshi Biosciences maintains all rights in Greater China. In connection with this transaction, we recognized an acquired IPR&amp;amp;D expense of $20.0 million in 2020. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our future net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. As of December 31, 2020, Junshi Biosciences is eligible to receive up to $75.0 million of additional payments contingent upon certain success-based regulatory milestones and up to $120.0 million of potential sales-based milestones, contingent upon the commercial success of etesevimab. During the year ended December&#160;31, 2020, we recognized $50.0 million of research and development expenses related to development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Innovent to jointly develop and commercialize Tyvyt (sintilimab injection) in China. In 2019, we and Innovent began co-commercializing Tyvyt in China. We record our sales of Tyvyt to third parties as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We also report as revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. Our Tyvyt revenue in China, which is primarily recorded as net product revenue, was $308.7&#160;million and $134.0 million in 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, we obtained an exclusive license for Tyvyt from Innovent for geographies outside of China and plan to pursue registration of Tyvyt in the U.S. and other markets. We recorded an acquired IPR&amp;amp;D charge of $200.0 million in 2020 associated with the upfront payment to Innovent.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $75.0 million in China in success-based regulatory and sales-based milestones.  Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tanezumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. The companies equally share the ongoing development costs and, if successful, in the U.S. will co-commercialize and equally share in gross margin and certain commercialization expenses. As a result of an amendment to the agreement in the third quarter of 2020, Pfizer will be responsible for commercialization activities and costs outside the U.S., and we have the right to receive tiered royalties in percentages from the high teens to mid-twenties for net sales in Japan as well as low double digit royalties on annual net sales greater than $150.0&#160;million in all other territories outside of the U.S. and Japan. As of December&#160;31, 2020, Pfizer is eligible to receive up to $147.5 million in success-based regulatory milestones based on current development plans and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lebrikizumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2020, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones, and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.&lt;/span&gt;&lt;/div&gt;As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2020, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.As of December&#160;31, 2020, $29.7 million was recorded as a contract liability on the consolidated balance sheet and is expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the twelve months ended December&#160;31, 2020, milestones received and collaboration and other revenue recognized were not material.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzgwODE_90cfb889-9ee8-4e72-a48f-235680250422">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Milestones &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Deferred) Capitalized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,124.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,153.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;358.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;638.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i8269e026df1a41b2b0895893b55d57cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpjMjUxNzhkOGJmMmU0ZDExYTBkZmEzOGQ1ZWNlMWE1MS90YWJsZXJhbmdlOmMyNTE3OGQ4YmYyZTRkMTFhMGRmYTM4ZDVlY2UxYTUxXzEtMi0xLTEtMA_2b1b0ce0-266b-464a-973b-30d3adaba90a"
      unitRef="usd">446400000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i0ea5f2373f024fc4b990b56206bdc2c9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpjMjUxNzhkOGJmMmU0ZDExYTBkZmEzOGQ1ZWNlMWE1MS90YWJsZXJhbmdlOmMyNTE3OGQ4YmYyZTRkMTFhMGRmYTM4ZDVlY2UxYTUxXzItMi0xLTEtMA_69dde84f-c66c-4a9f-a2d8-ba811c19002f"
      unitRef="usd">289000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ib012a6676aaa4eb8bc9506fa646b3402_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpjMjUxNzhkOGJmMmU0ZDExYTBkZmEzOGQ1ZWNlMWE1MS90YWJsZXJhbmdlOmMyNTE3OGQ4YmYyZTRkMTFhMGRmYTM4ZDVlY2UxYTUxXzMtMi0xLTEtMA_a6774453-2ac9-4ce8-baec-68172c56d130"
      unitRef="usd">-250000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i8456d682a58d41a3a50ddf018b0a4c6a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzEtMS0xLTEtMA_6d7dc4f9-f96b-4b9e-8c00-6e43d526b9b5"
      unitRef="usd">1124400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i173297e573b146f7bc78c4ada3a83d7a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzEtMy0xLTEtMA_007abd23-c4ae-434b-9ee2-e27b6f61f467"
      unitRef="usd">1112600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4d4009f20bb48cf9ec030239f052ee7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzEtNS0xLTEtMA_dbacc5d7-2a78-4740-b1ca-9904604355da"
      unitRef="usd">801200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a5bdf1152ee426093323505e09cb233_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzItMS0xLTEtMA_bb1f3662-c77d-4437-8715-a0b6be732978"
      unitRef="usd">1153800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1fc8d9d4d2a4410ace81efc24eba1a9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzItMy0xLTEtMA_613004f8-35cf-42d1-9ebb-50a43e083957"
      unitRef="usd">944200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d36ed57bb9940dba66fd60498e5d762_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzItNS0xLTEtMA_57a1cc92-487e-4443-8123-2b61c92259c6"
      unitRef="usd">658300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4ed102c3ad148a0a31d237f28a5df12_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzMtMS0xLTEtMA_b0c43908-1cfb-465a-bcbe-e2a41d711c35"
      unitRef="usd">358500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i312288bed3e9413faa61bb6376a13576_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzMtMy0xLTEtMA_2c8bd339-1c7e-4447-864e-022a6d77460b"
      unitRef="usd">590600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i308e5f2dc1ac4bf9bf1df82123fa7ad5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZTpmNDkzZTk1OWU4Y2U0NTNkYjQwMjRkYTg2ZDQxZWY4NC90YWJsZXJhbmdlOmY0OTNlOTU5ZThjZTQ1M2RiNDAyNGRhODZkNDFlZjg0XzMtNS0xLTEtMA_ac629491-02e2-457f-a8b4-045a2245aa5f"
      unitRef="usd">574700000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsPercent
      contextRef="icfc2c951fea140efb3bf430c16795a63_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTM1OTE_d433276d-77e6-41f4-9513-cf43e8ae01c0"
      unitRef="number">0.20</lly:CollaborativeArrangementRightsAndObligationsPercent>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i78597bb677aa4ac4a976a0e803853b22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzQyOTQ_9d46865d-268a-4046-89e2-bab4db9cda5f"
      unitRef="usd">210000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7c6e7782eae44e479a4ba6833152bf86_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzQyNzc_dd23ee36-dc16-475a-817e-a6aa6c2c3013"
      unitRef="usd">180000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i85207b20c9354258883eacc250729894_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzY0MTM_212f0418-46c8-4811-be7c-2357b0d13177"
      unitRef="usd">100000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ic88f51f077b644278fd68d0fa5ad4dc6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzY1NjU_17f40311-103d-4353-8a03-4ddaf6a963bf"
      unitRef="usd">150000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i710d1f304d724efc85f13dc60bf62fad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZToxOTM3NTM1YjQwN2Q0MmY5YmU2MTNjOTA0NGRiNDE3NS90YWJsZXJhbmdlOjE5Mzc1MzViNDA3ZDQyZjliZTYxM2M5MDQ0ZGI0MTc1XzEtMS0xLTEtMA_2032683b-a29d-4b0b-a468-722cb911bf67"
      unitRef="usd">638900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82dbabd3686d4eb9b13b54382cf6bcc4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZToxOTM3NTM1YjQwN2Q0MmY5YmU2MTNjOTA0NGRiNDE3NS90YWJsZXJhbmdlOjE5Mzc1MzViNDA3ZDQyZjliZTYxM2M5MDQ0ZGI0MTc1XzEtMy0xLTEtMA_ae2b7fba-3fe8-4500-b6a9-f42ec752a56d"
      unitRef="usd">426900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia93249b60bed44a7946fd8491b3b85d9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90YWJsZToxOTM3NTM1YjQwN2Q0MmY5YmU2MTNjOTA0NGRiNDE3NS90YWJsZXJhbmdlOjE5Mzc1MzViNDA3ZDQyZjliZTYxM2M5MDQ0ZGI0MTc1XzEtNS0xLTEtMA_d9f678fe-972e-42d9-ad72-6e839ab0c8d2"
      unitRef="usd">202500000</us-gaap:Revenues>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i55d0178a6cd14c4fa5fd77920bb4abbd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNDE_1e5e6712-caef-45c0-bdd3-755da766ef07"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:Revenues
      contextRef="i43add1f443e64f3db8290de104acfbce_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwMzY_c6387fef-44af-4d22-aa9a-87f9657f3972"
      unitRef="usd">871200000</us-gaap:Revenues>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ied1732da693a41bdab698fa5a39ba0a2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNDY_4acd2ac5-06a8-41e4-90f1-10a94b345744"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="iadf97eda073b42fda0623d5c29db2c5d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNTE_c7e13a22-0e26-4651-86bb-800b7407189a"
      unitRef="usd">75000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="id77a2552c6e24c67bf8d94ce91e0e5d3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNTU_942cd18e-80a9-4749-b669-e53c901d3de7"
      unitRef="usd">120000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i252ecfb1d7a840d9806b0dc46157e963_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1NDUwNzI_88bf380d-6c29-4255-b832-5f24e69e948c"
      unitRef="usd">50000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:Revenues
      contextRef="i7bf82252c7f64ef49980a721ff43e8f8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzMxNzk_3de48adc-9ad7-4fd4-8387-dd915f828c43"
      unitRef="usd">308700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8457b21557264435b2547d9a774dabe2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzMxODg_ae32feea-5590-4848-86da-617b25f3661b"
      unitRef="usd">134000000.0</us-gaap:Revenues>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id57723ff321a4ac09c2ddd06857d6267_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzE3Nzk_fa0a8320-2129-4d7b-9220-a31d978c0ca7"
      unitRef="usd">200000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i9040b40c375e44ec953ab4747d1dbaa8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzM1MTA_92353d93-5b0e-417a-9dbe-7ef05c14bf6c"
      unitRef="usd">825000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i9c5e6e4c1ddb437a8f9faeba8093fafa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzE4MDA_4171c58c-ca09-4e49-9739-d6be6dd6cb85"
      unitRef="usd">75000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold
      contextRef="ie7c2329f83d54c2daf23fe9a43a89933_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzMyOTg1MzQ5MTU5ODA_ee576308-c486-47e5-be0d-66c02f0a4dca"
      unitRef="usd">150000000.0</lly:CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="if51e456d8c22452895dde4067048ed49_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzc5MTQ_66f8201f-2aa1-4e16-8149-ef43327b25e8"
      unitRef="usd">147500000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="icf9a899efcc14002a419189d81ad60c4_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzc5NjY_291bf4db-d4e0-4e56-bc2d-a177efd4e474"
      unitRef="usd">1230000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i02a5b403f3e84dd588ce7e797609bcbb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTExMjE_aaef3218-c5f7-4927-b955-68963af02047"
      unitRef="usd">180000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i278ff628156c4188a73f68b4511dfb68_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTEyMjc_a6c06f99-9819-4590-b342-02cfb780a103"
      unitRef="usd">1030000000.00</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i2e398d4d6ace4b53b2313b073d764cee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTE4ODU_7b42c101-37be-411e-b8d7-72c9e7bc4cba"
      unitRef="usd">85000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i4e1db56f028e486bad99686da3f343bc_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzE2NDkyNjc0NTE5ODQ_2c687932-1b38-4e4e-84db-1e2155e6bfd7"
      unitRef="usd">1250000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifafea5b05f3f452394ff8d36dbcc9f7a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMjcvZnJhZzo5Y2NkZDMxZDFjM2Q0OGI4OGJiNmRmYTVlZGQxZmE0ZC90ZXh0cmVnaW9uOjljY2RkMzFkMWMzZDQ4Yjg4YmI2ZGZhNWVkZDFmYTRkXzQzOTgwNDY1MzQ0MTk_368dbe96-f473-4cc9-ba1a-61185c3db00a"
      unitRef="usd">29700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90ZXh0cmVnaW9uOmQ0MjE0Y2VkNGQ1NzQyN2FhYjcyNTRhNzVkODU0ZTgxXzIyMDc_8d229bb7-411e-4f7f-a13c-8b553e9aac19">Asset Impairment, Restructuring, and Other Special Charges&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;151.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment (gain) and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;131.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance costs recognized during the years ended December&#160;31, 2020, 2019 and 2018 were incurred as a result of actions taken worldwide to reduce our cost structure. Substantially all of the severance costs incurred during the year ended December&#160;31, 2020 are expected to be paid in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairment and other special charges recognized during the year ended December 31, 2019 resulted primarily from $400.7 million of other special charges related to the acquisition of Loxo, substantially all of which is associated with the accelerated vesting of Loxo employee equity awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairment and other special charges recognized during the year ended December 31, 2018 resulted primarily from asset impairment and other special charges related to the sale of the Posilac&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rbST) brand and the associated Augusta, Georgia manufacturing site.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90ZXh0cmVnaW9uOmQ0MjE0Y2VkNGQ1NzQyN2FhYjcyNTRhNzVkODU0ZTgxXzIyMDA_55ecc9da-e251-47bd-98f4-8b42ff5e377b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;151.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment (gain) and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;131.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzEtMS0xLTEtMA_f042ea9e-814b-4d2f-8f79-6f9379bd9b1d"
      unitRef="usd">151200000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzEtMy0xLTEtMA_1e6e3b60-4db5-4428-a2eb-20272fa43d4f"
      unitRef="usd">77800000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzEtNS0xLTEtMA_a5fe8126-7139-45b8-9374-d2d16bf85644"
      unitRef="usd">127800000</us-gaap:SeveranceCosts1>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzMtMS0xLTEtMA_f906fd35-a414-46aa-b249-7976f56d1c6a"
      unitRef="usd">-20000000.0</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzMtMy0xLTEtMA_bec8608d-de54-490c-bc86-e0791197d903"
      unitRef="usd">497800000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzMtNS0xLTEtMA_83984f84-84e5-4e8f-a5ef-dc996208e0ed"
      unitRef="usd">139100000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzQtMS0xLTEtMA_a73f2c33-8bb6-42d3-a57b-637d1223f874"
      unitRef="usd">131200000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzQtMy0xLTEtMA_5903ec88-49eb-45a2-8c3d-bd4b39dfdcf0"
      unitRef="usd">575600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90YWJsZTozNWQzNTJlZjU2NjE0Y2U3YjUyMzM4M2QzMmZhY2NkOC90YWJsZXJhbmdlOjM1ZDM1MmVmNTY2MTRjZTdiNTIzMzgzZDMyZmFjY2Q4XzQtNS0xLTEtMA_188aaef2-4de9-4eec-b109-b23e4664fef7"
      unitRef="usd">266900000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="id5a7062879db495387dd023ff0ac4b13_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzAvZnJhZzpkNDIxNGNlZDRkNTc0MjdhYWI3MjU0YTc1ZDg1NGU4MS90ZXh0cmVnaW9uOmQ0MjE0Y2VkNGQ1NzQyN2FhYjcyNTRhNzVkODU0ZTgxXzkwNQ_6bc1f39a-bd34-4bbc-afd7-b802a9cb402b"
      unitRef="usd">400700000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzYwNw_f940e64a-6dc5-4493-86a5-220939c807eb">Inventories&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;758.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,535.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;651.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates replacement cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,945.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,980.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories valued under the LIFO method comprised $1.21 billion and $1.20 billion of total inventories at December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzYwOQ_13ef364b-5aa5-45b3-adce-2cd85d2ccba2">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzYxMg_ce91a548-f1a5-4c3c-96bb-35de9ef5891f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;758.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,535.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;651.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates replacement cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,945.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,980.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzEtMS0xLTEtMA_6536ac9e-3a57-40df-824c-c607e8461121"
      unitRef="usd">758900000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzEtMy0xLTEtMA_93182079-6e7b-48b2-bee5-3f0b2bf271c0"
      unitRef="usd">647300000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzItMS0xLTEtMA_29a44667-e0d7-4c67-9f94-9944b63011fa"
      unitRef="usd">2535400000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzItMy0xLTEtMA_ae4bb8c2-85ad-4120-a521-f66c86498c0c"
      unitRef="usd">2067600000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzMtMS0xLTEtMA_0aa485f0-3634-4d3f-906f-9e3a64695689"
      unitRef="usd">651200000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzMtMy0xLTEtMA_1c16bf2b-0524-46a2-a7ad-38270d3edb07"
      unitRef="usd">424600000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryGross
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzQtMS0xLTEtMA_d60a60f0-2537-4bf6-a00a-9aefef8e9a0b"
      unitRef="usd">3945500000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzQtMy0xLTEtMA_fcfcb484-4499-4187-9fab-5b1c11cd1ea5"
      unitRef="usd">3139500000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzUtMS0xLTEtMA_1c3d8e8f-e5fe-46b3-9b44-d41a7ac89b4a"
      unitRef="usd">-34800000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzUtMy0xLTEtMA_24cb87e8-8fb2-40f2-904a-ff07d2000b16"
      unitRef="usd">-51200000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzYtMS0xLTEtMA_c175eb43-6c56-4e96-ac80-ea92192bee57"
      unitRef="usd">3980300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90YWJsZTo0NGVhMmNjMjc1MTY0M2EzODhlYjFlMjAzYTc5OGZjMC90YWJsZXJhbmdlOjQ0ZWEyY2MyNzUxNjQzYTM4OGViMWUyMDNhNzk4ZmMwXzYtMy0xLTEtMA_6dd292ae-d7f1-4f8d-811b-e9fdc05aae44"
      unitRef="usd">3190700000</us-gaap:InventoryNet>
    <us-gaap:LIFOInventoryAmount
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzUzOA_ce55b729-3014-4dd8-9e8f-e2570b6496af"
      unitRef="usd">1210000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:LIFOInventoryAmount
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzMvZnJhZzpkYTk0MDcxMzE3ZWI0YTIyYjU2MzcyZmIzNDZkZGI0Ny90ZXh0cmVnaW9uOmRhOTQwNzEzMTdlYjRhMjJiNTYzNzJmYjM0NmRkYjQ3XzU0NQ_0b0712bb-901e-43ea-88f1-0308e64387a7"
      unitRef="usd">1200000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzI4_046f5be8-9547-463b-8e48-401edca6ca5a">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December&#160;31, 2020, we had outstanding foreign currency forward commitments to purchase 647.9 million U.S. dollars and sell 530.7 million euro; commitments to purchase 2.97 billion euro and sell 3.62&#160;billion U.S. dollars; commitments to purchase 180.7 million U.S. dollars and sell 18.64 billion Japanese yen, and commitments to purchase 272.2 million British pounds and sell 363.9 million U.S. dollars which all settled within 30 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $6.02 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.49 billion as of December&#160;31, 2020 and 2019, respectively, of which $4.50 billion and $4.10 billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations as of December&#160;31, 2020 and 2019, respectively. At December&#160;31, 2020, we had outstanding cross currency swaps with notional amounts of $3.76 billion swapping U.S. dollars to euro and $1.00 billion swapping swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December&#160;31, 2020, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 9 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of December&#160;31, 2020, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Effect of Risk Management Instruments on the Consolidated Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(102.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(123.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(209.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020, 2019 and 2018, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the next 12 months, we expect to reclassify $16.8 million of net losses on cash flow hedges from accumulated other comprehensive loss to other&#x2013;net, (income) expense. During the years ended December&#160;31, 2020, 2019 and 2018, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,097.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,097.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,097.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,097.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;74.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;126.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;106.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;101.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;106.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;106.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;31.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,664.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;311.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,664.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,664.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;373.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;471.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,966.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,962.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,494.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,491.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,491.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,595.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,823.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;158.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;158.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;158.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available. As of December 31, 2020, we had approximately $687&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;up to 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5      Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10    Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More Than 10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net gains recognized in our consolidated statements of operations for equity securities were $1,442.2 million, $401.2 million and $72.6&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The net gains/losses recognized for the years ended December 31, 2020, 2019 and 2018 on equity securities sold during the respective periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December&#160;31, 2020, 2019 and 2018 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess our investment in available-for-sale securities for impairment and credit losses.  The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 86 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2020, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;264.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,529.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable Factoring Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $754.9 million and $678.8 million&#160;of accounts receivable as of December&#160;31, 2020 and 2019, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2020, 2019, and 2018 were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzE1_4c421e99-4640-4b48-968c-7fb33d904b5e">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0Mzk3_42c746eb-33df-46c7-b3e2-b171946d709d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0NDIz_f2e86ef6-f2c1-4e78-98ec-abcee22a9839">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQzMzQ_a80bd846-8d79-45fc-8a41-ebe1938733b5">P12M</us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i76593a635ee74f569d9d5d26e369257d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ0MjA_6abdf07d-7220-4805-b693-a2366cb90d0a"
      unitRef="usd">647900000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i76593a635ee74f569d9d5d26e369257d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ0NDU_1b5401c6-2a00-41bb-acd4-3fadfc4ccb02"
      unitRef="eur">530700000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="if292dce18b8742949a04f94a69f513e9_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ0Nzg_fb6f66f2-aa75-464b-a72f-92c3328e5ef6"
      unitRef="eur">2970000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="if292dce18b8742949a04f94a69f513e9_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ0OTU_d409d6bf-8e0a-4af4-bd90-296ed763d227"
      unitRef="usd">3620000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ie11921f0731440e8b2d7e35e232cb20c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ1MzY_a27cabba-5fad-4d7d-a984-a2cf26e98273"
      unitRef="usd">180700000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ie11921f0731440e8b2d7e35e232cb20c_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ1NjE_2acd0464-cc4e-4134-a52e-ce55502c9081"
      unitRef="jpy">18640000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i2c1ec7ea3e4544bebd2209221d0a8ad2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ2NzI_72888664-5c9b-4c33-9063-c6d232757605"
      unitRef="gbp">272200000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i2c1ec7ea3e4544bebd2209221d0a8ad2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ2OTk_464a4bd5-158b-4bb9-96d6-9b723136af96"
      unitRef="usd">363900000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ3NDA_00b3b877-2597-4ec2-b4be-e80246da419d">P30D</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:LongTermDebt
      contextRef="i734b5d697bdb4d96b38be8ba20e2e66a_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ5MzU_5f5ab600-6bf9-4d56-8c7a-40f96cca6170"
      unitRef="usd">6020000000.00</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i885be083614a4d18a19870c3bd50973b_I20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ5NDI_ddec8255-d3d1-4644-a887-fed531461fa6"
      unitRef="usd">5490000000</us-gaap:LongTermDebt>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ5ODY_3c61f979-0254-4d06-a288-20f448b149ee"
      unitRef="usd">4500000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzQ5OTM_5ee26505-f051-4e85-a2b4-53e3f55ef74b"
      unitRef="usd">4100000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib71d03b9d5404ef7859e43ce06d40102_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzUyMzU_2498fb21-ffc9-4bc2-9331-63e8be03ae38"
      unitRef="usd">3760000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i3781eb7aed394d3aaa09742b6bce2f1c_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzUyNjk_afaf952b-ca38-43d2-aafa-9da46449599b"
      unitRef="usd">1000000000.00</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzcwOTc_fb4776cd-2926-40a4-82f2-afba6a058ae4"
      unitRef="number">0.09</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i15da0b294a6b4817b66312409c265245_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzc4MDY_3c51c509-4ce9-4669-a007-73753003aecf"
      unitRef="usd">1750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0Mzcw_57e829cd-dfe5-4712-9b6a-c686afc42b8c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(86.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(102.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(123.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(209.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i2b4c33e1edc444e5b4e9a8500e0eab88_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzItMS0xLTEtMA_c270e3bb-b8a7-4c5a-bd45-d3a694d71c4c"
      unitRef="usd">-86900000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ied0653ffc6e14aeca59c89fb6a86121c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzItMy0xLTEtMA_75aeddc5-be88-490c-a3ce-061aa8ff5d12"
      unitRef="usd">-112100000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ic757ba5b7d1b442d93291ea03decee5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzItNS0xLTEtMA_7dbc6fb5-56ed-4324-97f5-be61f805d09a"
      unitRef="usd">40900000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i79bdb56a9d7144029b1e5522c593614e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzMtMS0xLTEtMA_393c7206-92b2-4b75-a93c-6674d726a5ca"
      unitRef="usd">86900000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i60d9065de7764cc19c33a225a0d50880_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzMtMy0xLTEtMA_ac7ad74b-2184-4ab2-8d28-c83f9196ad3c"
      unitRef="usd">112100000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i177b2d67f8ba418284926e505024a276_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzMtNS0xLTEtMA_b94b5727-b587-49df-b2f0-2be9c8c0ec38"
      unitRef="usd">-40900000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i79bdb56a9d7144029b1e5522c593614e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzUtMS0xLTEtMA_7b01df9f-8514-4eea-910a-7a8b770a21f7"
      unitRef="usd">16400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i60d9065de7764cc19c33a225a0d50880_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzUtMy0xLTEtMA_12c7ac07-25f7-4e57-b01b-15eb84566a32"
      unitRef="usd">15900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
      contextRef="i177b2d67f8ba418284926e505024a276_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzUtNS0xLTEtMA_e82d7b0e-436c-4806-a28f-df3333a73631"
      unitRef="usd">14800000</us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i559cde7a86934d01957c68c16475b1cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzYtMS0xLTEtMA_dc49d149-9169-49b5-843a-820d67f5331f"
      unitRef="usd">-102400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i089038df2aa140c192a89e32082775b5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzYtMy0xLTEtMA_16d8d2c4-4d4e-4593-9552-ba4b8970daab"
      unitRef="usd">-17100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
      contextRef="ic259a5c22c4b4a7aa701a9d5367ffc26_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzYtNS0xLTEtMA_9fbcfc7d-e55e-4e43-bc62-07f995625e9e"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i4a4d2134a40b4c75849277ff51f28c3f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzctMS0xLTEtMA_635ddf17-dbb7-401b-9a5b-3d210a1cf39b"
      unitRef="usd">123700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i95c9ccd3865e45e69f040a91ca7dd298_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzctMy0xLTEtMA_38497af4-5725-48a9-8dad-5549f9295524"
      unitRef="usd">-61900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i4d6995b66cf841668e6e05a116f49a16_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzctNS0xLTEtMA_0727c002-26b6-4d1d-a532-5011a38ad86b"
      unitRef="usd">-100000000.0</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzgtMS0xLTEtMA_d16071a3-23f3-4a26-b2cd-95296f92f88a"
      unitRef="usd">209700000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzgtMy0xLTEtMA_138b6764-96c4-4a25-9483-18a889f4a15f"
      unitRef="usd">-60700000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo1NTk0MzAzYzUzNTk0ODhkYThmMmFhNGM2YjIzNjk1ZC90YWJsZXJhbmdlOjU1OTQzMDNjNTM1OTQ4OGRhOGYyYWE0YzZiMjM2OTVkXzgtNS0xLTEtMA_755dcd09-3aef-43ec-83c5-30439036a43d"
      unitRef="usd">-114800000</lly:DerivativeInstrumentsGainLossRecognized>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzQx_83e76131-ffc2-4a67-bd40-b65193eb2efc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzQx_e223c44a-5ae9-4388-8322-77fe752fa58d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(404.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(207.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(110.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2b825c2201274dc188cf256f122e086c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzItMS0xLTEtMA_c1f815cc-db4e-44ce-8f16-d14cd62ccce6"
      unitRef="usd">-404000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0f82f22527524999a91aa71e61c6641a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzItMy0xLTEtMA_ae09adc2-487a-4701-b8d5-dea6d3fc28b8"
      unitRef="usd">40100000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i325ca753011c477b8ba2959a5e5c7d2b_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzItNS0xLTEtMA_7d60324b-9aba-4809-b576-2bdbf5a0a284"
      unitRef="usd">110400000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0813de855ef747abaaca53ef36e4c1f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzMtMS0xLTEtMA_7741d314-34eb-4865-a142-377514ca7e33"
      unitRef="usd">-207900000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i670c43f24d5e48ca995ca3f9f935644c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzMtMy0xLTEtMA_70fc3fe3-3ced-4484-bbf9-897edb251acd"
      unitRef="usd">47400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="idfaa8924bd4f438b86a6705d72934fe8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzMtNS0xLTEtMA_792a5bbf-8e51-4490-9933-7e414a616856"
      unitRef="usd">96800000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia1e85a5c0bc9421ea34d9822b4a94e72_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzQtMS0xLTEtMA_8ef343df-c821-4a2d-b3ec-93e3e22775dc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8c2513e6302b4030a3b2c52c6326a063_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzQtMy0xLTEtMA_8cd9588d-b735-49bd-a9ea-7b8ed212d739"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i08a17ef8639b4116914b2853f39ee356_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzQtNS0xLTEtMA_cc9c754c-b5df-4c49-9f0e-74c2f67d9469"
      unitRef="usd">5700000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie5eadeb2c29d4945b2f705b7dd6bac6a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzYtMS0xLTEtMA_7489c743-63c2-4958-b35d-5ac0b5487678"
      unitRef="usd">-110900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id899c3b3d5a645f5bb38fa729003c1d1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzYtMy0xLTEtMA_0d6120dc-3135-40a6-898f-510764fac9f5"
      unitRef="usd">31600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i0876e8c76a9c4c308a34aff4f59ba314_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzYtNS0xLTEtMA_78bad62a-71ee-42cc-8512-c8e31c8c631f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0813de855ef747abaaca53ef36e4c1f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzctMS0xLTEtMA_9a0c30ce-cf7f-429c-a3d8-40c18b93f0ff"
      unitRef="usd">-53700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i670c43f24d5e48ca995ca3f9f935644c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzctMy0xLTEtMA_f4d555fc-cc41-4785-87b5-4cff935dd6f9"
      unitRef="usd">-8300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i107cda2404e146cab37a3274549bd9d0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZToxY2M3ZjBhOWNhMWE0NzRjYjFmN2YzNzIyYWJkNGIwYy90YWJsZXJhbmdlOjFjYzdmMGE5Y2ExYTQ3NGNiMWY3ZjM3MjJhYmQ0YjBjXzctNS0xLTEtMA_2046ed47-186c-49e0-aebd-66782057cc34"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzg4MTc_18bc4a9d-477a-4360-b50f-d4d214fd4962"
      unitRef="usd">-16800000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzIz_818527dd-5a31-4582-b349-333ec51eb92d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,097.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,097.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,097.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,097.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;74.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;126.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;137.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;106.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;101.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;106.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;106.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;24.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;31.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,664.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;311.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,664.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,664.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;373.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;471.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,966.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,025.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;405.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,962.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtMS0xLTEtMA_08e30268-5496-421f-be1f-ca1e81f136c4"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie269f3b3bfdf44ce9b4f6626338c067e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtMy0xLTEtMA_9306722a-bd4d-4724-8f53-9f6b2f1433fb"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3c51b75c2fa14c1684c56a1e7d8fc1f5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtNS0xLTEtMA_01942dd6-f809-4b74-aac4-b82f81d72bdf"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1ec12cf461774e1182bafa64c823d98d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtNy0xLTEtMA_8b181d63-06d2-4bfe-a136-1d7cbc8b30f5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i566cfafb34514a41ac32d09adc9ee29a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtOS0xLTEtMA_e9d98a30-3515-427a-83fd-283b865f220d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib2ab34fc33aa445d9f82bf362c674439_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMtMTEtMS0xLTA_1a14193e-5484-4f71-90f1-5cbe1d68290b"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i97251102c68a4c478e1a1be501688a22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtMS0xLTEtMA_5d01b58c-8de9-4cfa-a6da-04f9f3a28b4d"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i82e0f1e2870e41769f1affa474d182bd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtMy0xLTEtMA_4c44ba4b-ceda-4f0f-a9b2-27d83aeafdca"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i758fcf4cf3c74497807165838ee0ac9c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtNS0xLTEtMA_d61fd178-341c-4c5c-b5e8-f52b26d0942b"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i077c04533e3743c8b36a16e643d4b688_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtNy0xLTEtMA_43a1f4df-fd72-4341-83a5-99ca3dbcd769"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5e0432603227427ab677d8fa8d0e0872_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtOS0xLTEtMA_ace73098-006c-4911-abad-aa5624a4f368"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9b249a1451654e4f94d47645b0fccafc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzUtMTEtMS0xLTA_4c04f0c9-6c85-40d5-b91f-14ff9df1e881"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i867f4d052cf54d0c85d6df1946dbc24a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtMS0xLTEtMA_ec00bcac-e419-4e1c-992c-fd3d2473a206"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if0b0011562854b1d95ba84ae4e1bcf37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtMy0xLTEtMA_574824c1-b1cc-4e5e-b62c-80237be0fc86"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0ad918d4090746489ff767a295639e94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtNS0xLTEtMA_ed88043c-a8dd-4881-8f7b-593937074fe3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i436c38c65cce425daad44c655b754e71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtNy0xLTEtMA_f6dcbc78-a6e1-4241-a427-ec0ef005b90c"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9398ca058d0048cb85257c2485125ee7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtOS0xLTEtMA_ebd8abd8-70ea-42be-b86f-98f2114d3bc4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id952bb8455ac4064b262c91cc977ddc7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzYtMTEtMS0xLTA_e1827a5d-9d14-42d7-b5e2-86c346c18dbf"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2749eddf3fad4a5db6ba0abcec58bcf3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctMS0xLTEtMA_358e366c-64e5-4308-bfda-df792c0fc14a"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5cdb65ba392744f79ff27b54d5a5f83f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctMy0xLTEtMA_d3023208-2080-4819-81d5-5c11840caaad"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifc3a5cb729034c68b87c779b4e84d7cb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctNS0xLTEtMA_e4d6d259-331d-41a7-b84e-6288526bcdaa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib2013b0dbf62424d9350c6b71c35d2d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctNy0xLTEtMA_7875e884-3b84-4e7d-ab1e-479095287271"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i79afb23fd84842b88431983432e6faca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctOS0xLTEtMA_d7054803-0276-44e6-9445-0a8508a156d6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iec93f4a79eab4a1586228b07068c14db_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzctMTEtMS0xLTA_4393775d-dbf9-4d98-8442-c8c8fa58f326"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8881e2925d8b4caf9fdfdf020b93932b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtMS0xLTEtMA_19225a34-982b-420e-8725-ca9f18e3cff3"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie6e008d687ea4305ab1f7e75dfbff408_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtMy0xLTEtMA_f1262436-80b9-412b-81af-575fb13be95a"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i30940c5e536f4d5ead427a4782d61c94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtNS0xLTEtMA_670d1c4c-c288-4ea4-bb7d-0fa058c291aa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i435e18e4a6f549a399937585428a9956_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtNy0xLTEtMA_e637149a-7a9e-4f49-8a39-20f8c347e60a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6f46ae367c8745948b6623087118c537_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtOS0xLTEtMA_0300fc15-c8e9-4dbd-80fb-4de1816ab3cc"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i91d8fae795ac469da2155b12eb39aec8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzgtMTEtMS0xLTA_449befba-9cd9-426e-bba5-6a42e2129c1e"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEwLTEtMS0xLTA_f6c5bf20-bbe8-44fd-93b1-63732fff45b6"
      unitRef="usd">24200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i97251102c68a4c478e1a1be501688a22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTEtMS0xLTA_46423871-bc31-4bb6-b051-6e47a4a165f6"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i82e0f1e2870e41769f1affa474d182bd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTMtMS0xLTA_b9917f21-57c5-4707-81bb-11b7e42c54c3"
      unitRef="usd">74300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i758fcf4cf3c74497807165838ee0ac9c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTUtMS0xLTA_36c7f0ed-2c98-4cbe-9839-60d71fb33965"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i077c04533e3743c8b36a16e643d4b688_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTctMS0xLTA_34cf4a36-19a3-4ae4-a08f-30b9a3989def"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5e0432603227427ab677d8fa8d0e0872_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTktMS0xLTA_ef8edf95-7794-4e71-8ec1-c76c898a9c9d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9b249a1451654e4f94d47645b0fccafc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEyLTExLTEtMS0w_f1c4b941-15cf-4699-8d83-e4b88d6208fd"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i867f4d052cf54d0c85d6df1946dbc24a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTEtMS0xLTA_b32fc2bf-db62-488e-9b53-6ddbe36a9d3b"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if0b0011562854b1d95ba84ae4e1bcf37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTMtMS0xLTA_85aaf68c-6c19-4671-916c-9336a1e7958e"
      unitRef="usd">126800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0ad918d4090746489ff767a295639e94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTUtMS0xLTA_10811bd9-809a-4271-a4f7-b3c4df7fdb0e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i436c38c65cce425daad44c655b754e71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTctMS0xLTA_b7f0387f-67a7-4de8-9726-b32031a7cd43"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9398ca058d0048cb85257c2485125ee7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTktMS0xLTA_0969f498-9cce-4d4d-a963-35c1e0be7df8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id952bb8455ac4064b262c91cc977ddc7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzEzLTExLTEtMS0w_4b4a8781-f524-4b52-b39f-a0336cd9925b"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie512126811f64a28b96cb6c61ff78085_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTEtMS0xLTA_069c9203-8c16-4d9d-b99f-b8e67a199822"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib53ce320a0cf45c193d1cff9384dd062_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTMtMS0xLTA_cfee00c7-8ee6-42eb-89e8-6aac5b0d761e"
      unitRef="usd">101400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2f275b97cc004a86855de7192fb8f764_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTUtMS0xLTA_826fb5e2-9a0c-4f4a-8757-e62569d0fa50"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1fb5a016ad964daebc62766f4f82a19c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTctMS0xLTA_3886f324-0867-4e2a-a94d-dae06d150726"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i19985e9c706e44848bff87eb752a0939_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTktMS0xLTA_ec8f74ac-bdaf-46a9-8603-0c33ba0b21e2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i33645495135840a59fbcf0e39deb55d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE0LTExLTEtMS0w_478283da-5fe3-4146-a4d9-48e86b3321c1"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2749eddf3fad4a5db6ba0abcec58bcf3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTEtMS0xLTA_7896f9c0-a5ff-46b7-8b89-dd11b7b5542a"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5cdb65ba392744f79ff27b54d5a5f83f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTMtMS0xLTA_a582e7ca-d7d7-4a79-a4fc-c4ea4e25296e"
      unitRef="usd">23700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifc3a5cb729034c68b87c779b4e84d7cb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTUtMS0xLTA_c9fcdd62-f801-4ea0-9f1c-a26f8bdf9cdd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib2013b0dbf62424d9350c6b71c35d2d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTctMS0xLTA_7de6f129-f2bc-4757-be0c-09184d5bf97b"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i79afb23fd84842b88431983432e6faca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTktMS0xLTA_7d9d6b6e-0a73-49e3-bd55-451cb5d5b79d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iec93f4a79eab4a1586228b07068c14db_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE1LTExLTEtMS0w_ca63a5db-1d6f-48f7-aca9-c9d512d4621a"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie198dbef2f4e4399a10d5932355eb939_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTEtMS0xLTA_04aed329-7c3c-48ed-9a58-d3d33cd3510a"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i44b7bb38ed4d4d11aeb324f32e415e81_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTMtMS0xLTA_19eb5e3d-1f2d-4aeb-a3ac-05697cb023ed"
      unitRef="usd">31800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia36eeb1bd9f04842a9851c91ab5e895e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTUtMS0xLTA_bebf8305-7325-4de9-9ba0-757be3525411"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icea21507ec1d49be826960b15a6c42f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTctMS0xLTA_faceceac-1212-4725-8b18-b729e1f72d96"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3050ce166b0e433687c88c87676b070b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTktMS0xLTA_a4e6e314-7950-47b2-87b1-384473820adc"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4081e5bd91e244058a3844645c6f7e8d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE2LTExLTEtMS0w_504e7d9a-c34f-41af-a76f-ac39965a534c"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3e6b82be3c6d47cf90e800e560194078_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTEtMS0xLTA_0fdb2645-163e-4217-b983-d68f51b51944"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9ef89d353cf247e0864a754f5b062e45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTMtMS0xLTA_a1800663-c398-4e3e-9d52-5546439be777"
      unitRef="usd">311600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4b870b023711491387d9d2d2fda73e1d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTUtMS0xLTA_65eaccf0-fa82-4af3-9c17-8654c5f4b8c8"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i24d94ce65a684af8bf51656da3e6449c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTctMS0xLTA_a6726aeb-4bf2-4a04-977f-1a8776be7fb2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iea3ae02f6cff4631aab6491d4ae1ea8c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTktMS0xLTA_2e8636f6-90a8-408b-8bae-3436d6705fce"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iaca2871b4ff44e13a1ae66a9204f2c5e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE3LTExLTEtMS0w_70e42311-e93b-4074-980b-55fc7af3c7b9"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE4LTEtMS0xLTA_4a4992e5-d471-4388-9b3f-61b0dd9c1707"
      unitRef="usd">373900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="i36a35200b6214f8d862d1879f4522cf7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzE5LTEtMS0xLTA_678c7d8b-8e66-48df-8e48-ab4be9dbc1c0"
      unitRef="usd">471800000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIwLTEtMS0xLTA_6945c823-a343-4e09-a155-a56c53ff484c"
      unitRef="usd">2966800000</us-gaap:LongTermInvestments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTEtMS0xLTA_13878948-1c95-4b60-b50f-6ffce4cb7343"
      unitRef="usd">1025400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4686f8cb62994a9a9bc8e6b7817e8410_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTMtMS0xLTA_afbde8a6-622f-49f5-a76b-281b1a5d6e97"
      unitRef="usd">1025400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie9de1473493a442ab6ca0ee29d148543_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTUtMS0xLTA_f7412873-789a-4385-9ac1-56a51859b8b6"
      unitRef="usd">1025400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie3ec43bf672b4ad99e62859afb69e618_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTctMS0xLTA_c1194009-a1d2-4c74-906d-31ea4c118e07"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1e269ce360814b8e84f97f774fd1c803_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTktMS0xLTA_f45f35d8-a5c8-4b33-bf7a-5b9445ff4ce5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia46aacafc18444898a49130e3d437b45_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzIzLTExLTEtMS0w_278d8479-fe88-4540-af8a-7fdb41d73558"
      unitRef="usd">1025400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i11555512f15843b78cb5d74c0d0637cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTEtMS0xLTA_995569ed-e29c-4ee6-a35b-72675ee6de47"
      unitRef="usd">7200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i55e9794059e54793bf573b9748798eeb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTMtMS0xLTA_89cd70f6-71fc-492a-9287-eb28888d3a64"
      unitRef="usd">7200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifd767fb99dc9410291e52fe3a05701b9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTUtMS0xLTA_58c3f848-3dcc-48e2-bf44-285b6b407493"
      unitRef="usd">7200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i25b9447fb59048a28d7f41123a0643b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTctMS0xLTA_1553c472-fdb3-4ce9-b136-ac8496b33000"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iea08714d01bb4abbaffdf5f5e1634598_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTktMS0xLTA_10b9fd0a-579b-4ea3-bd9e-b772219d9c77"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2af641dbca0f401696c62e23d843bbf0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI1LTExLTEtMS0w_d8b9712c-04ec-4c1e-88ec-37f5b0d5c0a3"
      unitRef="usd">7200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if911451758b0451ba9dd43374b7caeb9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTEtMS0xLTA_ae08c955-284e-4d65-aa35-4e07661c17f9"
      unitRef="usd">81400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie85afc85494d45deac992b5b655352c6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTMtMS0xLTA_f5e0e13c-4b72-476a-890c-bee6f5573dae"
      unitRef="usd">81100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibe41ef9074154d9c86b0d0beee80732a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTUtMS0xLTA_8e6fe00d-ede9-4285-8922-b937bb03187c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8beb739ebd1649a2aa6dbb7bed7cb98a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTctMS0xLTA_3edeb394-8a57-409a-94e0-e08a72f2e6aa"
      unitRef="usd">81400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i24b086fb17f3400d87543e41a70f9221_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTktMS0xLTA_4680e83e-d69f-4538-b876-e4d171dd12b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia2a79d730f284ce99e15280ddb18014c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI2LTExLTEtMS0w_ab375140-2f9c-4d50-b111-3b5cc4014a0f"
      unitRef="usd">81400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i896ba5d04f154341a7f226e1768613b6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTEtMS0xLTA_23b6b160-3510-4219-9df7-480497003573"
      unitRef="usd">2600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia7430c4dd94c4647ae735ab5dcbe41a9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTMtMS0xLTA_cc60e746-0b59-4476-ad91-3b7360c8edd3"
      unitRef="usd">2600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i11c04854fd114be5a2ed27c2c259efd8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTUtMS0xLTA_20ddf265-9e4a-4dd3-9ad2-b34c410b82e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if547dc6573ac4235ba2a0eca5f36102c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTctMS0xLTA_36203e4a-2c43-492f-a507-9347d701bbca"
      unitRef="usd">2600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2c8506c4f9b64daab27077e623773d22_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTktMS0xLTA_ccef4cf0-7eae-4b25-b0fa-6a8d1729d5ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia88b2998a44a42adadb3c56fdaf02670_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI3LTExLTEtMS0w_feee1b1c-0ab3-43d6-9fb8-2ceca3749072"
      unitRef="usd">2600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8f61406987b0462d929eef8f4acd716e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTEtMS0xLTA_5acceaf3-073e-4b56-90c6-168dea1f59a0"
      unitRef="usd">9800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3bcb5c5899344364a60904c18340c133_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTMtMS0xLTA_1f56d977-537f-4e94-be67-f38ed580d639"
      unitRef="usd">9800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i60ba6d352d364d3494b2a7fe4c35e283_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTUtMS0xLTA_4a543960-2db9-4c69-86be-9957992c4615"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i335aa482d73640a395372f1fe66486ac_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTctMS0xLTA_bfa3357a-6456-4f2a-bc18-10d7ac506f09"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5991d2f6863348dd894ea4182e0e6ae3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTktMS0xLTA_68a17a6e-51f3-475c-af00-e3134bac7c71"
      unitRef="usd">9800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1edb578fe2b146dfa9398c23136bd036_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzI4LTExLTEtMS0w_36d68d24-a6f5-4cba-b81a-1cf74c693faa"
      unitRef="usd">9800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMwLTEtMS0xLTA_e22781d8-e69a-40d3-9d80-daf4303b2155"
      unitRef="usd">101000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i11555512f15843b78cb5d74c0d0637cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTEtMS0xLTA_86f27a48-6678-4793-8b64-3d7c88b6718b"
      unitRef="usd">77200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i55e9794059e54793bf573b9748798eeb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTMtMS0xLTA_86cd4385-561f-42dc-a759-ef81150127c2"
      unitRef="usd">76300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifd767fb99dc9410291e52fe3a05701b9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTUtMS0xLTA_157e55bc-4f87-42cd-9986-955dc14be2b0"
      unitRef="usd">77200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i25b9447fb59048a28d7f41123a0643b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTctMS0xLTA_3d63c5b9-1897-464b-a19e-59b20399169e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iea08714d01bb4abbaffdf5f5e1634598_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTktMS0xLTA_37bd5674-8009-4fe1-8aed-cf68957ca04d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2af641dbca0f401696c62e23d843bbf0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMyLTExLTEtMS0w_79388e53-28ab-437f-81b8-3897c6983626"
      unitRef="usd">77200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if911451758b0451ba9dd43374b7caeb9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTEtMS0xLTA_86e9e045-8bed-45ed-942b-ff6a2bf2d298"
      unitRef="usd">271100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie85afc85494d45deac992b5b655352c6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTMtMS0xLTA_6a5e8417-fe75-46f1-90b4-f9c355874a5b"
      unitRef="usd">267800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibe41ef9074154d9c86b0d0beee80732a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTUtMS0xLTA_e1d862a8-a357-44a5-9f2d-dfa5be7ef28e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8beb739ebd1649a2aa6dbb7bed7cb98a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTctMS0xLTA_08eebd41-e2f5-40d2-814e-81cf5476f16e"
      unitRef="usd">271100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i24b086fb17f3400d87543e41a70f9221_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTktMS0xLTA_cf9514ef-8d56-4c49-845a-d0aa8250a425"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia2a79d730f284ce99e15280ddb18014c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzMzLTExLTEtMS0w_5662574a-db5c-44e1-8213-4ac89ab1cb37"
      unitRef="usd">271100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5aa6955b8d2b4b22bd3c25a51caf5bfc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTEtMS0xLTA_8cba7b66-3a6f-4f85-b657-13e439dd6d43"
      unitRef="usd">101100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2fc3ed55b43049169f584d6511c15e2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTMtMS0xLTA_2fb6b7e5-1d3a-449b-a6c5-7e74516c9f3a"
      unitRef="usd">99600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7ab7928a68fd4d8b989433ccbf30af4f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTUtMS0xLTA_284f12f1-48ef-4ae2-9aa5-6d9e4a46d663"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i037e599f78cf4eb193c194c14da7e6c9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTctMS0xLTA_71660c35-c04a-4f91-9414-45b18b2a4b78"
      unitRef="usd">101100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5595324df32f48359938231bb46a08db_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTktMS0xLTA_c2f19be6-ac52-428e-acca-02e75c1b1ed0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if8f10afd1f4e4de39bf7a81a91f20180_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM0LTExLTEtMS0w_ba8c69a4-e643-46c3-b42a-5732543c17cb"
      unitRef="usd">101100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i896ba5d04f154341a7f226e1768613b6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTEtMS0xLTA_e66c3e51-0e80-4eb1-923e-b2fd47b41123"
      unitRef="usd">30000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia7430c4dd94c4647ae735ab5dcbe41a9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTMtMS0xLTA_bbc5790f-a12a-4e51-9994-4952fc96f5e1"
      unitRef="usd">29600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i11c04854fd114be5a2ed27c2c259efd8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTUtMS0xLTA_086b0916-f858-4a26-aa67-4ced85022c2e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if547dc6573ac4235ba2a0eca5f36102c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTctMS0xLTA_7bc501c0-b84d-4eb5-9fda-073ebd11f9da"
      unitRef="usd">30000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2c8506c4f9b64daab27077e623773d22_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTktMS0xLTA_4858fb8c-19b5-4282-8633-197430a727b7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia88b2998a44a42adadb3c56fdaf02670_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM1LTExLTEtMS0w_3a744013-c3dd-4d49-acff-856aba785781"
      unitRef="usd">30000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5a044b0ff45b498f991a1e4bc212927d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTEtMS0xLTA_776e1b37-9443-4ab2-a4ce-318f4e73d8b7"
      unitRef="usd">60000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i25b7565646be4ec6aee7375271c85a7b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTMtMS0xLTA_b3fa64a9-6165-4cfa-a54d-bb6b929013d3"
      unitRef="usd">27400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibc2dd7aabbe1457a85f6382dfb21b03d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTUtMS0xLTA_2574e6fa-87b7-4c6f-a0c9-8f33861a5bb6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie4e19515eb414ea3950645ec1bd6e029_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTctMS0xLTA_291aa530-1938-47a1-a0de-02bb1940e9bf"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic7e32fe5c4d1480b80157e3bf4f1e8fe_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTktMS0xLTA_aab72ca5-c0b9-44bf-86ab-c531e7d427b8"
      unitRef="usd">60000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5e6474a7ae8a415c8a0c7443dcfb85d4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM2LTExLTEtMS0w_6f4b6610-bece-483d-9819-29131b2fe8d7"
      unitRef="usd">60000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0360e6926e5a4ee19a921dff273528d3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTEtMS0xLTA_92dd7a2f-2738-4194-827b-23d5c0c53d24"
      unitRef="usd">718600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib7727cb3da004ae0a84be29679fa8e8a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTMtMS0xLTA_8b173c64-ee9a-4d69-a0b7-1b561ee5e758"
      unitRef="usd">254400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ieeacddff780c45eca88800cb052b4f1b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTUtMS0xLTA_cbe224ef-6750-47ac-b4f8-19929b92e19f"
      unitRef="usd">718600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie3597dd720a74b66a0a24bd7e5f6336c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTctMS0xLTA_583b10e0-dc4d-4554-9509-68c889ffcbaa"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie2025050fac34c4bac2c4ba461347a3f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTktMS0xLTA_0e3ab662-cb42-4e8c-b174-9730e9e2c41e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i26823dabd1b64b328190517078c87d4f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM3LTExLTEtMS0w_e8581075-2af4-436b-8291-ecfff7747cef"
      unitRef="usd">718600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM4LTEtMS0xLTA_05af70df-1553-45c2-a938-a7cd71483281"
      unitRef="usd">405000000.0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="i8339c07c793c4080bbff3b4f3508d6c4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzM5LTEtMS0xLTA_7cbadbac-34c9-4ba2-bafe-cff439518403"
      unitRef="usd">299400000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTpkNzlkMzJhZmZhOWM0MjllYjU5MmEzMjAyMjhlOTJiZC90YWJsZXJhbmdlOmQ3OWQzMmFmZmE5YzQyOWViNTkyYTMyMDIyOGU5MmJkXzQwLTEtMS0xLTA_d4781fb0-e70a-4709-928d-60ee0a4bdc2b"
      unitRef="usd">1962400000</us-gaap:LongTermInvestments>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0Mzgx_2667c65e-07ae-46d4-8db1-45bd8de91a10">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,494.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,491.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,491.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,595.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,823.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CommercialPaper
      contextRef="iff9b4655ccd1401e9984bb3b5ee74b96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtMS0xLTEtMA_c40436aa-caf6-41c2-a35f-c478c2d1cd01"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i9bd4cb1fd99f4fae868921a774fda59b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtMy0xLTEtMA_08bab8d5-5d3e-4402-87f6-0677ce46c650"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i0d3f83e4500c4b8785248a7a70fa84b9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtNS0xLTEtMA_653653f2-a734-48bf-a228-51b2b57fc7d7"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i8a2c22552802430ea404ce1f2936a291_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtNy0xLTEtMA_cc031c6c-363c-4ff6-b95c-15203abb5f9a"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i3e9bed57fe694231ab6166019b90e496_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzMtOS0xLTEtMA_a6751911-1ec1-43d6-9c5c-bf80da97856c"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="ifc63939ce42a42b4b7c2ce2910cbad4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtMS0xLTEtMA_dba2ca22-e268-4360-8cbe-3e5a1041aea1"
      unitRef="usd">1494200000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i78564906ca1644298e4c0fa5785b3dc8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtMy0xLTEtMA_3fc396ca-c9bd-4ca1-b702-b0a6aeb33337"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i5e562e62e4d4490ca21252c3fad46bda_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtNS0xLTEtMA_1068adf0-eb0b-42ae-9efe-d6a741d67080"
      unitRef="usd">1491600000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i4f157e5e59dd4d41821a1ba8e732b05f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtNy0xLTEtMA_4a76a385-a036-4241-8f44-b942caf1e48f"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i2b9dad78832c4368859b28c2f6894c72_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzQtOS0xLTEtMA_c3e2f887-9017-43eb-8462-f581fcb9d25e"
      unitRef="usd">1491600000</us-gaap:CommercialPaper>
    <us-gaap:LongTermDebt
      contextRef="i1614e22518944c76b247484e7a60ca8f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctMS0xLTEtMA_36382fac-392a-4847-bf7a-0493e5dd0ec8"
      unitRef="usd">16595300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3c51b75c2fa14c1684c56a1e7d8fc1f5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctMy0xLTEtMA_77454b6d-7a29-4a92-ab75-6cdaf032a7cc"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1ec12cf461774e1182bafa64c823d98d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctNS0xLTEtMA_7de83157-7345-4cf1-885c-369db53a709d"
      unitRef="usd">19038900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i566cfafb34514a41ac32d09adc9ee29a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctNy0xLTEtMA_ade1edb6-ccb5-4fc9-b5e4-b2497e0d1be3"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib2ab34fc33aa445d9f82bf362c674439_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzctOS0xLTEtMA_3bcf0614-8038-4e9e-a7ca-945dda10c986"
      unitRef="usd">19038900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3f04b7c762cb464abacab6b4977a1b29_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtMS0xLTEtMA_815bf512-6484-4f18-8937-175f92180e0e"
      unitRef="usd">13823000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie9de1473493a442ab6ca0ee29d148543_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtMy0xLTEtMA_34b2d2f7-47d4-4736-a54b-08036d9e811b"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie3ec43bf672b4ad99e62859afb69e618_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtNS0xLTEtMA_7b47680a-b21b-42a8-a8e2-7ef0c408c8e1"
      unitRef="usd">15150000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1e269ce360814b8e84f97f774fd1c803_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtNy0xLTEtMA_a67de47b-5d44-475a-9120-868267a6d1b4"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia46aacafc18444898a49130e3d437b45_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo5MjI1ODIyNDcyMzM0Y2VjYjljNWE4Y2ZjZmU3OWI5Ny90YWJsZXJhbmdlOjkyMjU4MjI0NzIzMzRjZWNiOWM1YThjZmNmZTc5Yjk3XzgtOS0xLTEtMA_0e332094-85df-4d6d-9606-d6c246842da4"
      unitRef="usd">15150000000.0</us-gaap:LongTermDebt>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MzY2_ea518941-2b31-4f97-bc83-e0eb7c260047">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;158.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;158.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;158.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id845d0c7f9964ee0bf08e79d645dd1ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtMS0xLTEtMA_b7fdbb18-ea60-42a1-a47c-7bc777ef017d"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iaf0dd8585de44468add60f95d78c62ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtMy0xLTEtMA_6e7a0cc0-0a60-495b-af67-b89c22d4412f"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i6df764752add48c48282f4351f5aea77_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtNS0xLTEtMA_be0e57d2-3c99-440b-875b-fa6928286de7"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ifa54dda0cead4e039cb3c37fdbf005b3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtNy0xLTEtMA_3c779bd0-fcf6-40e3-ac0f-05ee434735cf"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i0a5d2355fe924260b94ae1755b5115f1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzYtOS0xLTEtMA_4b245dd1-6db7-4e3b-843e-0e62ca6058e5"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1f99babb106943a48c2ef126347a18da_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktMS0xLTEtMA_ee547bcd-dc24-4ba5-9d88-9e0b77f26293"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3140c9a521e845898dff7af991e1d21b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktMy0xLTEtMA_84a0ced1-814b-4876-8650-b144725bef4c"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i0e14b4632c2342cd8bdd5d6e1be3f3d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktNS0xLTEtMA_46d43e35-28bf-4bd5-8ec2-eb80adb733c5"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="icc9ed839ea824eea97ca2b8fed80d1ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktNy0xLTEtMA_6409867e-7b59-4663-b2d8-561c48b35038"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2a345f6cc3914c7f9e7fe94738f6cb7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzktOS0xLTEtMA_ef0e8f7d-72a5-47f0-8d06-16c975fdc6f5"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1f99babb106943a48c2ef126347a18da_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTEtMS0xLTg5MDA_6e197e30-3294-44ed-b84f-9a014bd3f860"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3140c9a521e845898dff7af991e1d21b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTMtMS0xLTg5MDQ_9753e415-e44f-4de7-8ff9-75e3a6b86580"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0e14b4632c2342cd8bdd5d6e1be3f3d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTUtMS0xLTg5MDQ_8f3b962a-170b-4dc8-8d57-48def2a8842c"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="icc9ed839ea824eea97ca2b8fed80d1ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTctMS0xLTg5MDQ_2185bb7f-4b47-4f39-b863-bbb5417f94a5"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2a345f6cc3914c7f9e7fe94738f6cb7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEwLTktMS0xLTg5MDQ_c953497c-d378-4296-b79a-ad6386ca1295"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i8e42ef743d4049b8b98c528fd36eceac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTEtMS0xLTA_3e09babc-8b4e-425d-8807-2ea24287380b"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i99493aa1fbc341b58c3254bd5c14e0c4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTMtMS0xLTA_9155599e-c795-4638-bcb6-0a31947283bc"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i19aa55084b624b149f91667988733b94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTUtMS0xLTA_861f4d6c-f51f-4536-9fd4-32c1fa96bd0e"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i7bb79e31f68c462a8bfdd0a9e8cb0126_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTctMS0xLTA_23eccf6b-c888-4fb9-95a9-ba2577063fc0"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i1161a1814827464d8d0bf447a827298e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzEzLTktMS0xLTA_f43b149e-4fea-4472-ad62-67a33ac4f427"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8e42ef743d4049b8b98c528fd36eceac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTEtMS0xLTA_91a6812b-12c6-4408-9169-efc6580a99a0"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i99493aa1fbc341b58c3254bd5c14e0c4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTMtMS0xLTA_dc558b7f-d293-4495-b783-a3e8f1bb93cc"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i19aa55084b624b149f91667988733b94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTUtMS0xLTA_325aa439-8d0e-458c-8a63-01d3fe4ff0a8"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7bb79e31f68c462a8bfdd0a9e8cb0126_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTctMS0xLTA_987175c5-3aa4-4dff-96f5-d0a70216bf01"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1161a1814827464d8d0bf447a827298e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE0LTktMS0xLTA_2bd6f244-f10a-4e29-9889-10c30038b202"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib5f85dff2b99430d9ea18be88db32363_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTEtMS0xLTA_d56a9cf7-cec7-4d75-b49d-63fe7e897bf8"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie54194fef9ee44f0baa1198b79b989cd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTMtMS0xLTA_145f99f2-a5c7-49c1-a383-071fb5c6bb14"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i49bb3cfe0c224730b91be93a08a94d91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTUtMS0xLTA_c36bcf82-a354-4a1c-8a39-0aa5df1bc120"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9ab9280585474937b6956aacac7dcc43_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTctMS0xLTA_88c31712-14c9-463a-8a76-0a21bafd699f"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if2a130b6c9674334bb31349bb3084485_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE3LTktMS0xLTA_9196aa8f-5b74-43c0-b05a-c5b6eba6b889"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib5f85dff2b99430d9ea18be88db32363_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTEtMS0xLTA_52babded-3902-41e2-a0a8-1bc7ec221ac9"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie54194fef9ee44f0baa1198b79b989cd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTMtMS0xLTA_2915708f-e088-420f-bd8f-64e15fc398b9"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i49bb3cfe0c224730b91be93a08a94d91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTUtMS0xLTA_3dac4ea7-46b9-4bda-9dfc-1093c7c5faf5"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9ab9280585474937b6956aacac7dcc43_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTctMS0xLTA_96b56d41-c714-4a6b-b7bc-46682b407024"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if2a130b6c9674334bb31349bb3084485_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzE4LTktMS0xLTA_38a7e021-9f77-4af5-9930-bb38df85dfeb"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i698fbd8d92b24eaa80fb4794ec8b22db_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTEtMS0xLTA_c16e0071-794c-4973-bd9f-8cb0be1fab9f"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i91c44cbf91e34245b319839db6f762e1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTMtMS0xLTA_5f9c3c41-72e9-4f92-beb8-64425b7a7bb0"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7a7188b3764a4f06b9d801cc32c022eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTUtMS0xLTA_b34a973b-26fb-492f-a974-6fc456a5a72f"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i47944dddbf22476e9864a6d86fca6c07_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTctMS0xLTA_2063aa3f-4e9f-4996-b16b-046b4b2ed11e"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i9b04120333d14c7bb3721e9afbb4f200_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIwLTktMS0xLTA_f615d49e-8990-4358-964a-b620d27b0fbc"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i698fbd8d92b24eaa80fb4794ec8b22db_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTEtMS0xLTA_07bd9348-5929-4675-9376-a594c9ad1554"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i91c44cbf91e34245b319839db6f762e1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTMtMS0xLTA_eb195e9c-aa0e-4370-a044-0cedcaaf0c0f"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i7a7188b3764a4f06b9d801cc32c022eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTUtMS0xLTA_94ec149c-d47a-4024-bf8f-390fc24e4660"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i47944dddbf22476e9864a6d86fca6c07_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTctMS0xLTA_47de1eb8-bd67-4d02-bdb0-1d3ccee74a31"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i9b04120333d14c7bb3721e9afbb4f200_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzIyLTktMS0xLTA_136257f5-16cb-4e52-b492-be02318dbd96"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic7f3f64f550448648f5d119e75baab9f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTEtMS0xLTA_81ab73c3-0712-4f97-b527-85326c24ea81"
      unitRef="usd">72000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie46ab1f4827641929600f4d8e579cba6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTMtMS0xLTA_349a4913-17cf-41f5-9df6-781584c35896"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie3a5e140926245c3b898ab1b8b0aa810_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTUtMS0xLTA_04345392-4fdb-416e-b6e4-a9c4bb5d3a25"
      unitRef="usd">72000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i571b62f2272c4f0c9864c655bacb5f43_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTctMS0xLTA_01b74ca3-7932-4ea0-a078-f6ff3df6f36d"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2faee0bc39a1435ab2737a04a112a0d0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzMxLTktMS0xLTA_6dba116e-613e-409c-8bc8-659c89bcc3d6"
      unitRef="usd">72000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ifd7397b614fa4d0aa289843e505c0338_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTEtMS0xLTg5NA_9569b8a6-9c96-40ab-8702-0ab14edf5cae"
      unitRef="usd">43300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i499a38e64d144a59b3902cd77fe676e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTMtMS0xLTkxMQ_80a9c91e-9907-4860-b5dc-15e963488020"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i65a53f7cc64140b6ae991b885dbec6c7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTUtMS0xLTkwMA_53262f66-696e-4f17-ac1f-51f56cc34eec"
      unitRef="usd">43300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib769bb44d96b4ec6b1ff4f8945d14c74_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTctMS0xLTkwNA_0a5fa56c-fcea-48bb-8b62-2080f5b2ddc0"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7790a8ee4fb2414eac30e7a9561da8aa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTktMS0xLTkwNA_dbf0668b-a854-44d6-86db-0b70f2269cb6"
      unitRef="usd">43300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2f567bd4e42740019b3174c50d5bcd76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTEtMS0xLTA_63384865-c67b-463f-bf2f-00c007439c70"
      unitRef="usd">45100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3567afa62a444c229ff7c02310132308_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTMtMS0xLTA_3ad099c1-fb60-4fdd-9ab0-8bbf5ed26c78"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8a257a5c3988421daab1c5c94873c7b2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTUtMS0xLTA_06bb40c1-a821-40de-901d-1b6245b18372"
      unitRef="usd">45100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iea105f73e09247b896eb5002be1fa817_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTctMS0xLTA_9e14e41c-7e4f-43d7-8f56-2b9ed75fad99"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i901470ea1dcc46daa707e313c0151f74_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM1LTktMS0xLTA_aee7a27d-4d92-4f9d-8e6d-d3b614c8caf2"
      unitRef="usd">45100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i2f567bd4e42740019b3174c50d5bcd76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTEtMS0xLTA_411ac5d2-f69d-4c52-916b-577b89a9c9a1"
      unitRef="usd">21400000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i3567afa62a444c229ff7c02310132308_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTMtMS0xLTA_8bdafa76-74b6-43d2-9a5f-12fa880c4db2"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i8a257a5c3988421daab1c5c94873c7b2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTUtMS0xLTA_1f028823-76f2-4b36-a94c-684409fdf95f"
      unitRef="usd">21400000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iea105f73e09247b896eb5002be1fa817_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTctMS0xLTA_5c39c6ca-e436-4051-9fa7-5be01c831cc5"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i901470ea1dcc46daa707e313c0151f74_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM2LTktMS0xLTA_744bbec7-b629-41df-b656-3248a5b249bf"
      unitRef="usd">21400000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2f567bd4e42740019b3174c50d5bcd76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTEtMS0xLTA_3c50eddd-44b4-439f-a903-9491b140c6cd"
      unitRef="usd">5700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3567afa62a444c229ff7c02310132308_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTMtMS0xLTA_e332289d-68c3-4981-b7cd-565e5fba4ef7"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8a257a5c3988421daab1c5c94873c7b2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTUtMS0xLTA_0a2220f7-5b29-4f4e-ab70-7b772ac9f245"
      unitRef="usd">5700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iea105f73e09247b896eb5002be1fa817_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTctMS0xLTA_9bdeea02-cfa1-45a8-ac4f-b41003b2439a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i901470ea1dcc46daa707e313c0151f74_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzM3LTktMS0xLTA_b80cf94b-c2dd-41c9-8ff3-3619bf50dec2"
      unitRef="usd">5700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id7d8bd5466554120bcef2a7280d5a0cd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTEtMS0xLTkyNw_defaf9e3-3170-4256-8da6-12340821bed2"
      unitRef="usd">3000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i605c9e12226d4404b17da90d7bcf0a01_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTMtMS0xLTkyMg_d01676b1-365a-4a9a-b61c-d99ba8facf64"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9e8ea6d64d6b48f185da2f7945e93913_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTUtMS0xLTkyMg_072d74a5-adb1-4194-8c41-83e1fed60269"
      unitRef="usd">3000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if97d81ab32d741d5a50a9e919be3b610_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTctMS0xLTkyMg_f8cacc83-fa5e-49bd-80c6-acbb3936c2f5"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iedb8e2a45e4548bbba35a9682ef87298_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTktMS0xLTkyMg_0aec427c-22fd-40a3-b674-198352f48af2"
      unitRef="usd">3000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ibd8e5bcf3a7042e997ecff32c5ddeb26_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTEtMS0xLTA_559e3868-0e06-4e71-afce-a2267bd276f7"
      unitRef="usd">20100000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i68533791086c4a66b4e85509ed1bbd21_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTMtMS0xLTA_3ffb6787-bf72-4cd0-8652-8aa15dbf34ec"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i018a7fe95440493cb5b194a242c36530_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTUtMS0xLTA_407be0e1-d770-4f76-aaab-1159550531b3"
      unitRef="usd">20100000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i4080399399ba43068553348c4be8ea2f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTctMS0xLTA_5de777eb-c310-42a9-82cd-2a0e392baac9"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="icc07496027d844728e4f422d09488b8b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQwLTktMS0xLTA_fe6f804d-5f77-4258-a0a2-5a11a55f9d10"
      unitRef="usd">20100000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic6e3a32202c54bff815b9d7e2d3e22fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTEtMS0xLTA_a038cba9-d275-4882-818e-4d3f910a4641"
      unitRef="usd">18400000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id9a6f81ea634490dad4edeff649d1781_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTMtMS0xLTA_67114681-ee25-4fcc-8559-88f08151d779"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic38207da496841d290edd3833837d8da_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTUtMS0xLTA_a35e5908-0dbc-4268-a0b0-0909a1ee0dd8"
      unitRef="usd">18400000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ifec2b5844ba24dc08ff7dd52e6d6c8f0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTctMS0xLTA_bbd3f4c9-9658-4355-bbf6-c262ea27be7f"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0a1c802688094a8889c8d0228f9ee2c4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQyLTktMS0xLTA_d4e77216-6192-4632-b87f-5d317e383a7c"
      unitRef="usd">18400000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ic6e3a32202c54bff815b9d7e2d3e22fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTEtMS0xLTA_453919fc-7753-488b-9db7-808664412402"
      unitRef="usd">11900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id9a6f81ea634490dad4edeff649d1781_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTMtMS0xLTA_d7bce1e8-6e74-4e69-a76c-68a9c16b9a46"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ic38207da496841d290edd3833837d8da_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTUtMS0xLTA_7dc8b706-58ad-4230-8c9d-aa49cef4ce62"
      unitRef="usd">11900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ifec2b5844ba24dc08ff7dd52e6d6c8f0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTctMS0xLTA_1b475c8a-5476-45c7-9e1a-3212a95c624f"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i0a1c802688094a8889c8d0228f9ee2c4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo2MDQ3YWYwZDJlMmY0MzdiYjkzZDllNjhmMWE0ODc1My90YWJsZXJhbmdlOjYwNDdhZjBkMmUyZjQzN2JiOTNkOWU2OGYxYTQ4NzUzXzQzLTktMS0xLTA_5fdadd65-f4e2-4186-a18f-b01ff45abf58"
      unitRef="usd">11900000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzcxNDY4MjU1OTgyNTU_2ba51d3c-625f-4283-afcf-057cef27e0ed"
      unitRef="usd">687000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzMyOTg1MzQ5MDE1OTg_4151dd5d-b4af-46cc-8301-5634958ff30a">P10Y</lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0Mzc2_3a25fcad-3c1c-43e4-bd1a-c1c09f571833">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5      Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10    Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More Than 10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItMS0xLTEtMA_489759a0-aa49-4001-a6b6-34d91529d337"
      unitRef="usd">360300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItMy0xLTEtMA_51669176-2c48-48db-b736-35af5de451fb"
      unitRef="usd">13900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItNS0xLTEtMA_f280f347-319f-433a-be04-9628d9ca17ce"
      unitRef="usd">135600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItNy0xLTEtMA_0852e460-9c8a-4bf9-b937-c940ba900c67"
      unitRef="usd">82700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTplOTQ3MTdhZWEyNTc0ZWVkYTg5YWExYzJiMWMxMDFjNy90YWJsZXJhbmdlOmU5NDcxN2FlYTI1NzRlZWRhODlhYTFjMmIxYzEwMWM3XzItOS0xLTEtMA_d5271d9d-b797-4904-ba6a-b64837c36d7b"
      unitRef="usd">128100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzExMDA5_d2a294be-69de-429f-8853-fb074efa29e3"
      unitRef="usd">-1442200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzExMDE2_7dca2b6b-944d-4283-95e2-023937a68982"
      unitRef="usd">-401200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzcxNDY4MjU1OTgwMjc_5a8b2791-8376-47e6-8577-90be04b94514"
      unitRef="usd">-72600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0NDAz_2788039b-00f5-4fcc-a7e5-db599fa6156b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzEtMS0xLTEtMA_75a426ea-edb2-4c18-a388-91b26329365f"
      unitRef="usd">20900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzEtMy0xLTEtMA_461d38aa-6646-4536-8fc9-0ee7a70a047a"
      unitRef="usd">10300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzItMS0xLTEtMA_dc89a72f-4a8d-4f07-bd0d-f776ec3d86da"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzItMy0xLTEtMA_8500bde0-3735-4255-9b63-910312f719c1"
      unitRef="usd">4000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzMtMS0xLTEtMA_8a3c4579-6fd6-4c9d-a5ec-bceca4a41f3a"
      unitRef="usd">348900000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzMtMy0xLTEtMA_4ee5d1e2-e048-4651-8b02-06a8c8f6dfdc"
      unitRef="usd">429500000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzQtMS0xLTEtMA_67281714-2234-427d-a3e9-9e7c4e3a9c10"
      unitRef="usd">11400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0YWVjYzJlYWQ2MGM0ZGY0YTRhZWFhYTViMjQ4MTA1OS90YWJsZXJhbmdlOjRhZWNjMmVhZDYwYzRkZjRhNGFlYWFhNWIyNDgxMDU5XzQtMy0xLTEtMA_c1c37f92-4bd5-46a6-9333-93a5237ff6ca"
      unitRef="usd">141100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzEyNzA4_010b6894-7a9a-4429-897a-f72d122d7c8e"
      unitRef="number">0.86</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0NDE0_3c577be7-446e-4834-9382-5d50f6b039f8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;264.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,529.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzEtMS0xLTEtMA_8787ff31-1040-478f-983d-72921a5d0748"
      unitRef="usd">264800000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzEtMy0xLTEtMA_1adf09c1-7a67-452f-9950-013e1f0be2a0"
      unitRef="usd">431600000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzEtNS0xLTEtMA_11125705-8f05-48a6-afd0-5a547b4c6553"
      unitRef="usd">5529000000.0</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzItMS0xLTEtMA_7ece99e5-080b-4d8b-807c-fdb9a9d3e813"
      unitRef="usd">4500000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzItMy0xLTEtMA_151542a7-8d7a-4cdb-a7b2-2381ca781f74"
      unitRef="usd">4900000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzItNS0xLTEtMA_b946e0d1-d575-4f3d-9f39-c295c377d681"
      unitRef="usd">3600000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzMtMS0xLTEtMA_2cb9b981-36de-446d-9fe3-e3388fa6bcef"
      unitRef="usd">8200000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzMtMy0xLTEtMA_63ad286e-be31-416e-a962-3fc94c6246e3"
      unitRef="usd">3000000.0</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90YWJsZTo0ZTBhY2I2MTViYjc0MTdjODgyMTYwZWQ2NjJjZjQ1NC90YWJsZXJhbmdlOjRlMGFjYjYxNWJiNzQxN2M4ODIxNjBlZDY2MmNmNDU0XzMtNS0xLTEtMA_382624d7-0c7c-439b-ae36-586356535950"
      unitRef="usd">49200000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MDcz_76ac06aa-0254-46af-be8c-69ad0065042f"
      unitRef="usd">754900000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xMzYvZnJhZzoxYjNmZDYxMjg3OTE0MGNhYWY4YzI3NzRiOGM0ZDNlYi90ZXh0cmVnaW9uOjFiM2ZkNjEyODc5MTQwY2FhZjhjMjc3NGI4YzRkM2ViXzE0MDgw_0fe97e72-eb96-4e68-990f-c2a98b9e08ad"
      unitRef="usd">678800000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUwNjQ_c9debc17-e7e7-46dd-a46d-ceb51def33a1">Goodwill and Other Intangibles&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment. The changes in goodwill during 2020 and 2019 were primarily related to our acquisitions of Dermira and Loxo, respectively. See Note 3 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2020, 2019, and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,984.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,659.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,324.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,244.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,905.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,076.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,349.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,296.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,948.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,101.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,101.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,450.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,296.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,618.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D consists of the fair values of acquired IPR&amp;amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. The costs of acquired IPR&amp;amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;amp;D projects that had no alternative future use. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the &#x201c;income method,&#x201d; which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in marketed products and the decrease in acquired IPR&amp;amp;D in 2020 primarily relates to the reclassification of our $4.60&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived to finite-lived as it was approved by the FDA in the second quarter of 2020. This decrease in acquired IPR&amp;amp;D in 2020 was partially offset by the addition of acquired IPR&amp;amp;D for lebrikizumab as a result of the Dermira acquisition. The increases in marketed products and acquired IPR&amp;amp;D intangible assets in 2019 were primarily related to our acquisition of Loxo. See Note 3 for further discussion of intangible assets acquired in recent business combinations and Note 4 for additional discussion of recent capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ1MTk_0bf7a79a-03a8-4be9-83df-152315c973ca"&gt;three&lt;/span&gt; to 20 years. As of December&#160;31, 2020, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to finite-lived intangible assets was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;428.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUwODM_f7c173fd-7856-4e8b-9e49-7c3e98bf2116">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.The costs of acquired IPR&amp;amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;amp;D projects that had no alternative future use. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the &#x201c;income method,&#x201d; which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0Xzc5Ng_05ffae94-a015-4af6-bdc1-4a8d8554c727"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0Xzc5Ng_dfa13135-4cbb-4964-ae57-5be4d3c50595"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0Xzc5Ng_e5da0bf1-3a3e-45a3-b1ef-dc2352f1c9dd"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUwNjg_a31016bf-632b-4c55-87c0-7864d9f2cb80">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,984.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,659.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,324.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,244.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,905.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,076.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,349.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,296.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,948.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,101.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,101.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,450.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,296.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,618.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUxMDA_8a5762ca-0632-44f5-b492-328091a8bbe2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of intangible assets other than goodwill at December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount, &lt;br/&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,984.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,659.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,324.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,244.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,905.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,076.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,349.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,296.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,948.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,101.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,101.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,727.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,450.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,296.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,618.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i662262e67b5f40cea96bdb9a5cd66701_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtMS0xLTEtMA_d100e774-c595-4d8a-bbcc-8acc12c42f83"
      unitRef="usd">7984000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i662262e67b5f40cea96bdb9a5cd66701_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtMy0xLTEtMA_4e247705-8487-4789-b470-5dae40ee2bcd"
      unitRef="usd">1659500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i662262e67b5f40cea96bdb9a5cd66701_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtNS0xLTEtMA_76378924-2463-41e2-a43e-0a9c2870c316"
      unitRef="usd">6324500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5102bbe8737b4c2da4a4243cb207ce90_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtNy0xLTEtMA_64aa939e-33f8-412c-82d6-c9f1bdf38a2a"
      unitRef="usd">3150200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5102bbe8737b4c2da4a4243cb207ce90_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtOS0xLTEtMA_2ac98c29-fbc8-4855-991b-f9305e6a0474"
      unitRef="usd">1244600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5102bbe8737b4c2da4a4243cb207ce90_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzMtMTEtMS0xLTA_97d46b6f-26a9-4d63-bf8c-6476fc02cae8"
      unitRef="usd">1905600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1083cf7137cf44a588e913c40a07246d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtMS0xLTEtMA_1229b924-6e8b-4e97-a7cf-b3c5181d9256"
      unitRef="usd">92800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1083cf7137cf44a588e913c40a07246d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtMy0xLTEtMA_573becf6-485d-4fa4-8c28-4842a548a1c1"
      unitRef="usd">68300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1083cf7137cf44a588e913c40a07246d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtNS0xLTEtMA_554c99de-babb-4929-a268-e833e6228fc3"
      unitRef="usd">24500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4236ef82f62541ebab48555f05d6cb37_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtNy0xLTEtMA_a0065e92-eefc-4ac8-b31d-c0b3d18198ff"
      unitRef="usd">94200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4236ef82f62541ebab48555f05d6cb37_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtOS0xLTEtMA_7b25a8ed-905e-4193-a342-6625ba67c75d"
      unitRef="usd">51800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4236ef82f62541ebab48555f05d6cb37_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzQtMTEtMS0xLTA_384ab087-641c-44c6-a06b-1196b22f9555"
      unitRef="usd">42400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtMS0xLTEtMA_16834d2e-043d-4604-846f-cd7b07259aa0"
      unitRef="usd">8076800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtMy0xLTEtMA_e5e1a1d7-6506-45d8-b27f-76d9006de52d"
      unitRef="usd">1727800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtNS0xLTEtMA_c50489a4-15df-4142-bab0-7aba90a8d373"
      unitRef="usd">6349000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtNy0xLTEtMA_82b83aef-652a-4d3c-921c-bb1087e1341c"
      unitRef="usd">3244400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtOS0xLTEtMA_80cb9062-0738-44e0-8096-574c6a6d030f"
      unitRef="usd">1296400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzUtMTEtMS0xLTA_29ee2887-9435-4479-9e6c-b5b44e3ba4a7"
      unitRef="usd">1948000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic42c7c598e6f49feaae76a07d1b3d85b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzctMS0xLTEtMA_02038630-151c-429a-9ab9-03304998a124"
      unitRef="usd">1101000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic42c7c598e6f49feaae76a07d1b3d85b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzctNS0xLTEtMA_f87086d5-e9b2-46ea-93ab-62507a987dfb"
      unitRef="usd">1101000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6bfb71fb8b9f42c794f44a765001ec7e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzctNy0xLTEtMA_f05fbc0e-8111-4bf2-8fe1-a9a08591794a"
      unitRef="usd">4670000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6bfb71fb8b9f42c794f44a765001ec7e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzctMTEtMS0xLTA_503e51dc-07b9-4464-9bfd-c69565b1a382"
      unitRef="usd">4670000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtMS0xLTEtMA_aaae11ac-2d8a-4e7f-b249-08aacf65e7fd"
      unitRef="usd">9177800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtMy0xLTEtMA_00272a60-10d4-43bf-aa92-64ad28f3f969"
      unitRef="usd">1727800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtNS0xLTEtMA_9e4be299-19f9-44bf-91d8-587b44c3a22c"
      unitRef="usd">7450000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtNy0xLTEtMA_8259d02d-120d-4ba9-9cba-fb3149c25d33"
      unitRef="usd">7914400000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtOS0xLTEtMA_08bffc0a-3fc3-463a-a6af-62416b2abe32"
      unitRef="usd">1296400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTo3MDk0ZTNlNGEzNGY0NzdmYTdhODk2ZGExMDhhNjE2Yy90YWJsZXJhbmdlOjcwOTRlM2U0YTM0ZjQ3N2ZhN2E4OTZkYTEwOGE2MTZjXzgtMTEtMS0xLTA_576121f7-e176-44bd-b3e6-021566eaac11"
      unitRef="usd">6618000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment
      contextRef="i56fecb64135f4cca97024ac5ee838679_I20190215"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzMyOTg1MzQ4OTIyMDM_e2ea22f1-b712-4f33-b842-2933e442b8b9"
      unitRef="usd">4600000000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0d4f0d9411ad485cb55e50fad753c51d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ1MjU_f14d64c0-d2db-4c66-b196-6ad9af0fdb34">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ2NDM_d1b976da-606f-42a1-a26e-88e854f4f921">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUwODY_7dd0e223-f5f8-4b9a-85ca-ab83df6086a7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to finite-lived intangible assets was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;428.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTozNDk3YjdiM2FhMDk0YjkwYWJhNzJhZmY3OWUwMGU3Zi90YWJsZXJhbmdlOjM0OTdiN2IzYWEwOTRiOTBhYmE3MmFmZjc5ZTAwZTdmXzEtMS0xLTEtMA_7d916b59-afcf-4be3-aad9-41cfdc298d2c"
      unitRef="usd">428200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTozNDk3YjdiM2FhMDk0YjkwYWJhNzJhZmY3OWUwMGU3Zi90YWJsZXJhbmdlOjM0OTdiN2IzYWEwOTRiOTBhYmE3MmFmZjc5ZTAwZTdmXzEtMy0xLTEtMA_bc1b7249-0951-4d2e-82db-5a01639cae84"
      unitRef="usd">225800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTozNDk3YjdiM2FhMDk0YjkwYWJhNzJhZmY3OWUwMGU3Zi90YWJsZXJhbmdlOjM0OTdiN2IzYWEwOTRiOTBhYmE3MmFmZjc5ZTAwZTdmXzEtNS0xLTEtMA_49e4a51b-47b2-4162-8673-167dcffa15f8"
      unitRef="usd">361300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzUxMDU_fa411a9d-c40a-42a0-84fa-2165a45e2a00">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtMS0xLTEtMA_3390bc03-081d-4263-863c-84686e5aa297"
      unitRef="usd">517700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtMy0xLTEtMA_4c25b024-f2e1-4dd1-8ff8-c6ce77c815d4"
      unitRef="usd">513000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtNS0xLTEtMA_ee95b545-a928-43ff-b9c6-5d5a63bc0602"
      unitRef="usd">501200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtNy0xLTEtMA_4801f7c8-c22b-4bc1-aeb5-81099c6c8109"
      unitRef="usd">449100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90YWJsZTplYTcwZDEyZTIwZjg0YTk1OTM2MzkxNzFhYWYyMmZlNC90YWJsZXJhbmdlOmVhNzBkMTJlMjBmODRhOTU5MzYzOTE3MWFhZjIyZmU0XzEtOS0xLTEtMA_48c2cd27-eaf3-4735-9be6-13c1756b8049"
      unitRef="usd">432500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzEyMjI_9a7a23ce-654f-4890-8cc7-dadc513d602f">Property and Equipment&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3Mg_22167169-de32-49e2-8061-fe64a7bff538"&gt;three&lt;/span&gt; to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset&#x2019;s net book value over its fair value, and the cost basis is adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;226.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,326.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,067.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,560.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,913.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,138.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,252.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,034.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,570.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,161.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,681.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,872.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;765.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized interest costs were not material for the years ended December&#160;31, 2020, 2019, and 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-lived assets by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,113.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,786.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,747.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,648.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,808.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzEyMjc_414e68f8-487d-4dd8-9ae3-1cfa03827631">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3Mg_22167169-de32-49e2-8061-fe64a7bff538"&gt;three&lt;/span&gt; to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset&#x2019;s net book value over its fair value, and the cost basis is adjusted.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6440d866422d4fcea9a1a914dc919853_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI0NQ_c1ac3b35-d649-43e0-8815-32a5e2cd0e7f">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic681b92a73ce4099bf3dcd5b07e95e90_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI1MQ_d5e8929d-3eb8-4bc0-86c6-0a482b3f9f38">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibabdd19152304e26964b75c2240169f7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3OA_8d3f45b2-8412-4885-876c-11344efaabf0">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzEyMjg_ae09e36b-9afa-45ed-bcee-838bc5c91c42">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;226.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,326.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,067.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,560.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,913.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,138.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,252.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,034.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,570.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,161.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,681.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,872.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;765.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzEtMS0xLTEtMA_5afb0c6a-9efa-4ce1-9860-01531b2fbd89"
      unitRef="usd">226800000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzEtMy0xLTEtMA_3e9fcbd6-9006-410c-a008-50ad4ba2e3ac"
      unitRef="usd">169500000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzItMS0xLTEtMA_7fbf63f6-436e-420f-9038-9a648f6dd4a6"
      unitRef="usd">7326100000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzItMy0xLTEtMA_2864df8a-7e9b-40d1-b496-1c01529661e6"
      unitRef="usd">7067300000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzMtMS0xLTEtMA_94e8affd-b0cc-4042-a71f-d0dfb4c0d826"
      unitRef="usd">8560900000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzMtMy0xLTEtMA_ef8ca772-127e-48e5-8943-82a693346f64"
      unitRef="usd">7913300000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzUtMS0xLTEtMA_115df887-b280-48d4-9993-c1667433e0bd"
      unitRef="usd">2138800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzUtMy0xLTEtMA_49ef30ff-a2dc-4373-abc4-a5327413cc2a"
      unitRef="usd">1884400000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzYtMS0xLTEtMA_4a20eb34-c792-4288-a10b-412d9306223d"
      unitRef="usd">18252600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzYtMy0xLTEtMA_fe075439-b330-4f55-b350-2012945c7c33"
      unitRef="usd">17034500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzctMS0xLTEtMA_a2ea7f38-ff22-4bb1-991a-505a9bfdda04"
      unitRef="usd">9570700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzctMy0xLTEtMA_e9eee64c-e24f-4050-8294-685379f8be57"
      unitRef="usd">9161600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzgtMS0xLTEtMA_6b200c1b-eb05-459d-af30-c5856f39c7a9"
      unitRef="usd">8681900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTpkYTQ5YWZiNGQwNjE0NmVlYmZiZDljZmQxMjc1ZmFlNC90YWJsZXJhbmdlOmRhNDlhZmI0ZDA2MTQ2ZWViZmJkOWNmZDEyNzVmYWU0XzgtMy0xLTEtMA_221b85bf-ce0d-4b7a-86fb-68b4ceac9705"
      unitRef="usd">7872900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZToxZDZhMjRhMWJlN2I0NWJhOWYyN2I5NTUxZTc4OGQzYi90YWJsZXJhbmdlOjFkNmEyNGExYmU3YjQ1YmE5ZjI3Yjk1NTFlNzg4ZDNiXzEtMS0xLTEtMA_85bfde41-9765-44c3-ae0a-f625bcbea678"
      unitRef="usd">765200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZToxZDZhMjRhMWJlN2I0NWJhOWYyN2I5NTUxZTc4OGQzYi90YWJsZXJhbmdlOjFkNmEyNGExYmU3YjQ1YmE5ZjI3Yjk1NTFlNzg4ZDNiXzEtMy0xLTEtMA_6d077322-3931-40dd-b648-0413c8130445"
      unitRef="usd">814700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZToxZDZhMjRhMWJlN2I0NWJhOWYyN2I5NTUxZTc4OGQzYi90YWJsZXJhbmdlOjFkNmEyNGExYmU3YjQ1YmE5ZjI3Yjk1NTFlNzg4ZDNiXzEtNS0xLTEtMA_c4589f3e-d8f6-4cf6-9aa3-dc48af3c1e0f"
      unitRef="usd">797100000</us-gaap:Depreciation>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzEyMTA_f2f48dae-b0e3-4d3a-a54d-11ba1324031e">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-lived assets by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,113.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,786.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,747.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,648.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,808.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="ib11faf3ad2f94548b0a09cf8f35a15f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzMtNC0xLTEtMA_334149f7-f99a-4f1c-a938-0de2d2224734"
      unitRef="usd">6113600000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i2594deedacf54880b1db0ef581e435e1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzMtNi0xLTEtMA_19c8d74e-a8b5-4ad8-8799-1a1aef8ddd38"
      unitRef="usd">5595400000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie3d7beba7c48404cae7014e52512b95b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzQtNC0xLTEtMA_ce9c7410-3b86-486e-b3ef-e75e1e46cf40"
      unitRef="usd">1786900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="if2cbfb7a17f9438a8d7adf6e5a09c448_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzQtNi0xLTEtMA_46c0e993-45a5-4891-8c7d-7182491da891"
      unitRef="usd">1454800000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i7c64ede2b9f24bd2bb0d6f97ff8dc7ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzUtNC0xLTEtMA_a0074181-5b33-435e-a4ab-c40a94c0d853"
      unitRef="usd">1747700000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ia528dbed284d4ed0b3acc05cf5e1b356_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzUtNi0xLTEtMA_5addee84-6012-4790-85a0-bb03e215c907"
      unitRef="usd">1758300000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzYtNC0xLTEtMA_c93d62a1-a100-4523-82c3-e71b5421f130"
      unitRef="usd">9648200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90YWJsZTo2YzQ2ZGY3ODI3ODg0NzE5YTIwMDNmMjQ5MzU1YmViMy90YWJsZXJhbmdlOjZjNDZkZjc4Mjc4ODQ3MTlhMjAwM2YyNDkzNTViZWIzXzYtNi0xLTEtMA_5551204a-bb7f-4417-ad36-41897fafa2dc"
      unitRef="usd">8808500000</us-gaap:NoncurrentAssets>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzI2ODM_50f9de6a-ba8f-4d90-8f80-97f4bb8e354a">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. We have leases with terms up to 12 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $154.6 million and $172.8&#160;million during the years ended December&#160;31, 2020 and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2020 and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:17pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Year 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rental expense for all leases, including contingent rentals (not material), was $175.7&#160;million for the year ended December 31, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzI2ODQ_7daa3b72-b14a-43e4-98bd-89058dabda32">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. We have leases with terms up to 12 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $154.6 million and $172.8&#160;million during the years ended December&#160;31, 2020 and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2020 and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:17pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Year 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rental expense for all leases, including contingent rentals (not material), was $175.7&#160;million for the year ended December 31, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <lly:LesseeLeaseRemainingLeaseTerm
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzEwOQ_4a60e8d6-9db5-46bd-a7d6-59bca94d96d8">P12Y</lly:LesseeLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzE1NTc_b0ed7479-0e9f-4ea5-a51f-a779c9abfce9"
      unitRef="usd">154600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzMyOTg1MzQ4ODYzMTA_c80d393b-b933-4eef-a5c7-f0f2dcfc608d"
      unitRef="usd">172800000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzI2ODU_f5636e42-9210-4dc0-9125-f379312c5bfd">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases as of December&#160;31, 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;136.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTo1OTdiOTA1N2YxNzk0ZDhiODU5OGQwYTFiZjZmMDBjNi90YWJsZXJhbmdlOjU5N2I5MDU3ZjE3OTRkOGI4NTk4ZDBhMWJmNmYwMGM2XzEtMi0xLTEtMzMyNA_76e4bdc8-fdbe-4f53-9097-288942148d2c">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTo1OTdiOTA1N2YxNzk0ZDhiODU5OGQwYTFiZjZmMDBjNi90YWJsZXJhbmdlOjU5N2I5MDU3ZjE3OTRkOGI4NTk4ZDBhMWJmNmYwMGM2XzEtMi0xLTEtMA_88e20777-1ef0-4bfa-a1ba-c35e77dec95a">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTo1OTdiOTA1N2YxNzk0ZDhiODU5OGQwYTFiZjZmMDBjNi90YWJsZXJhbmdlOjU5N2I5MDU3ZjE3OTRkOGI4NTk4ZDBhMWJmNmYwMGM2XzItMi0xLTEtMzMyNA_3177714e-d079-4ca2-b110-0d658d5594fd"
      unitRef="number">0.033</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTo1OTdiOTA1N2YxNzk0ZDhiODU5OGQwYTFiZjZmMDBjNi90YWJsZXJhbmdlOjU5N2I5MDU3ZjE3OTRkOGI4NTk4ZDBhMWJmNmYwMGM2XzItMi0xLTEtMA_cce37c55-df38-4562-af01-c21e70cb08f2"
      unitRef="number">0.036</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZToxMTI3YjMzOTdmMTI0YTFiOGY2NTI4NTI1NjExZWUzZS90YWJsZXJhbmdlOjExMjdiMzM5N2YxMjRhMWI4ZjY1Mjg1MjU2MTFlZTNlXzEtMi0xLTEtMzM1Mg_8b19ed13-918f-487d-b6ff-73a142dd3a93"
      unitRef="usd">160900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZToxMTI3YjMzOTdmMTI0YTFiOGY2NTI4NTI1NjExZWUzZS90YWJsZXJhbmdlOjExMjdiMzM5N2YxMjRhMWI4ZjY1Mjg1MjU2MTFlZTNlXzEtMi0xLTEtMA_80eb5da8-799f-41c7-a164-36f1d62d4efc"
      unitRef="usd">153600000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZToxMTI3YjMzOTdmMTI0YTFiOGY2NTI4NTI1NjExZWUzZS90YWJsZXJhbmdlOjExMjdiMzM5N2YxMjRhMWI4ZjY1Mjg1MjU2MTFlZTNlXzItMi0xLTEtMzM1Mg_588e616f-322e-418b-b206-571d78f650cc"
      unitRef="usd">136700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZToxMTI3YjMzOTdmMTI0YTFiOGY2NTI4NTI1NjExZWUzZS90YWJsZXJhbmdlOjExMjdiMzM5N2YxMjRhMWI4ZjY1Mjg1MjU2MTFlZTNlXzItMi0xLTEtMA_94763843-ebc7-4248-9f0d-b22b033c28a2"
      unitRef="usd">81200000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzI2ODY_5d2a621c-16bc-466d-9d21-b90c74e854f3">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:17pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Year 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzEtMS0xLTEtMA_e898dee8-ee90-49a3-bb0c-97157bb7f4d1"
      unitRef="usd">150900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzItMS0xLTEtMA_e2018f97-969d-4464-931a-733d18efda1b"
      unitRef="usd">120700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzMtMS0xLTEtMA_acffa8ec-dc22-4423-82de-2e66ac881124"
      unitRef="usd">94100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzQtMS0xLTEtMA_56426b42-0130-42ed-9a23-0d1e65d52d11"
      unitRef="usd">73300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzUtMS0xLTEtMA_0a77aeed-f618-404d-9034-1f7be1204478"
      unitRef="usd">63400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzYtMS0xLTEtMA_1c18cfb0-d00e-45a1-85a6-c7a6a40027f5"
      unitRef="usd">258700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzctMS0xLTEtMA_a3ad1557-0645-4ee5-a6a8-202049f039be"
      unitRef="usd">761100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzgtMS0xLTEtMA_95b627b3-50a5-4edf-9124-abf550e7033d"
      unitRef="usd">97400000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90YWJsZTpmNTA5NjkyNDk1YmE0OTRkOGZjMjE4NTdmNjdiZDE4Mi90YWJsZXJhbmdlOmY1MDk2OTI0OTViYTQ5NGQ4ZmMyMTg1N2Y2N2JkMTgyXzktMS0xLTEtMA_0e5ac1da-8db4-4306-b95f-240d63f18d21"
      unitRef="usd">663700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTQvZnJhZzphMTdiMWM2N2JiNDc0NDFkYTZmZWU2MmFiNGIzOTIzNi90ZXh0cmVnaW9uOmExN2IxYzY3YmI0NzQ0MWRhNmZlZTYyYWI0YjM5MjM2XzMyOTg1MzQ4ODYzMjY_350507ac-e272-4896-af0e-911d8875c705"
      unitRef="usd">175700000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyOTg1MzQ4ODg2NzM_b1dea002-e5d0-445c-aba9-18dc47ea2f4d">Borrowings&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,348.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,638.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(89.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment on hedged long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;320.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,595.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,317.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,499.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,586.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,817.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-term notes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;750.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.00% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;99.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.00% Euro denominated notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;737.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;671.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.15% Swiss Franc denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;679.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;618.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.125% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;229.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% Euro denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;922.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;839.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;377.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;377.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;401.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;401.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.45% Swiss Franc denominated notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;453.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.375% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,150.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.42% Japanese Yen denominated notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;222.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;209.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.125% Euro denominated notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;922.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;839.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.625% Euro denominated notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;737.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;671.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.56% Japanese Yen denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;90.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;85.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.77% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;174.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;476.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.95% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;284.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;284.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.875% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;360.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;360.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.65% notes due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;412.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;436.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,500.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.7% Euro denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,229.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,119.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.97% Japanese Yen denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;74.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.25% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,250.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.15% notes due 2059&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,000.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.5% notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;850.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized note discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(76.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(55.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;16,348.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,638.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average effective borrowing rate on outstanding commercial paper at December&#160;31, 2019 was 1.65 percent. The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, we had a total of $5.24 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2024 and a $2.00 billion 364-day facility that expires in December 2021, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $2.00 billion facilities as of December&#160;31, 2020. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2020 and 2019 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we issued $1.00&#160;billion of 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $988.6 million for general corporate purposes, including the repayment of outstanding commercial paper. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we issued $850.0 million of 2.50 percent fixed-rate notes due in September 2060 and an additional $250.0 million of our 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $1.07 billion for general corporate purposes, including the repayment of outstanding commercial paper. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we issued $1.15 billion of 3.375 percent fixed-rate notes due in March 2029, $850.0 million of 3.875 percent fixed-rate notes due in March 2039, $1.50 billion of 3.95 percent fixed-rate notes due in March 2049, and $1.00 billion of 4.15 percent fixed-rate notes due in March 2059, with interest to be paid semi-annually. We used the net cash proceeds of $4.45 billion from the offering to repay commercial paper that was issued in connection with the acquisition of Loxo and for general corporate purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we issued euro-denominated notes consisting of &#x20ac;600.0 million of 0.625 percent fixed-notes due November 2031 and &#x20ac;1.00 billion of 1.70 percent fixed-rate notes due in November 2049 with interest to be paid annually. We paid $2.27 billion, comprised of $1.75 billion of net cash proceeds from the offering and proceeds from commercial paper, to purchase and redeem certain higher interest rate U.S. dollar denominated notes with an aggregate principal amount of $2.00 billion and a net carrying value of $2.01 billion, resulting in a debt extinguishment loss of $252.5 million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we issued Japanese Yen-denominated notes consisting of &#xa5;22.92 billion of 0.42 percent fixed-rate notes due in November 2029, &#xa5;9.28 billion of 0.56 percent fixed-rate notes due in November 2034, and &#xa5;7.64 billion of 0.97 percent fixed-rate notes due in November 2049, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $356.6 million for general corporate purposes, including the repayment of outstanding commercial paper.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amounts of maturities on long-term debt for the next five years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities on long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,590.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have converted approximately 9 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2020 and 2019, including the effects of interest rate swaps for hedged debt obligations, were 2.61 percent and 2.88 percent, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments for interest on borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;345.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt&#x2019;s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyODM_5ef7af4f-0012-44c6-8c7d-d69ce89e2f25">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at December&#160;31 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term commercial paper borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,348.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,638.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(89.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment on hedged long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;320.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,595.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,317.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,499.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,586.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,817.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:CommercialPaper
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzEtMS0xLTEtMA_efa00fb9-938a-4c3f-8dea-142776c86550"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzEtMy0xLTEtMA_c5f3ea80-6b45-4981-9dac-00c5f7b12646"
      unitRef="usd">1494200000</us-gaap:CommercialPaper>
    <us-gaap:NotesPayable
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzItMS0xLTEtMA_7794edce-15be-41c6-940b-4109c77185c9"
      unitRef="usd">16348700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzItMy0xLTEtMA_39d1a467-83b7-4520-9e9d-2990ca96e9b2"
      unitRef="usd">13638500000</us-gaap:NotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzMtMS0xLTEtMA_27c26db1-8cf9-4b1e-bdd8-e993d6270306"
      unitRef="usd">14800000</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzMtMy0xLTEtMA_4b4f020a-0851-4aec-ab67-eb24e0c170f1"
      unitRef="usd">12900000</us-gaap:OtherNotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzQtMS0xLTEtMA_9aad8dcc-1bb0-4fbd-ab29-ef8adb482941"
      unitRef="usd">89100000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzQtMy0xLTEtMA_b95a5951-7575-40c9-ae6a-ceb3abbb3187"
      unitRef="usd">73600000</us-gaap:UnamortizedDebtIssuanceExpense>
    <lly:LongTermDebtFairValueAdjustment
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzUtMS0xLTEtMA_f50a9621-76b2-4ad9-a810-a76b20a3a6a3"
      unitRef="usd">320900000</lly:LongTermDebtFairValueAdjustment>
    <lly:LongTermDebtFairValueAdjustment
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzUtMy0xLTEtMA_f1a661f6-edcd-42f0-8266-9fe7db65f94f"
      unitRef="usd">245200000</lly:LongTermDebtFairValueAdjustment>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzYtMS0xLTEtMA_02a73d0f-7243-4155-9ccd-db440b9d5b9d"
      unitRef="usd">16595300000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzYtMy0xLTEtMA_b8d2b17f-e3ef-45f2-bf21-3588332ee576"
      unitRef="usd">15317200000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtCurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzctMS0xLTEtMA_b40559a7-3df7-4c69-b5dc-0ebbd64856f7"
      unitRef="usd">8700000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzctMy0xLTEtMA_e43f5cd6-12b9-487f-a8d9-e1f30ecdbd91"
      unitRef="usd">1499300000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzgtMS0xLTEtMA_a1ba75f9-2b41-46ee-a51d-15d2aef1fb0d"
      unitRef="usd">16586600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo5ZWJiZmY3MjljYmM0YzcyYTM4N2FjYmQyZWQ3YmZlNi90YWJsZXJhbmdlOjllYmJmZjcyOWNiYzRjNzJhMzg3YWNiZDJlZDdiZmU2XzgtMy0xLTEtMA_bc05ed20-ce0d-4332-a0ba-3b65b65c68a0"
      unitRef="usd">13817900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyOTg1MzQ4ODg2NzI_5408f4a1-0bba-4313-ac7b-12c060155dd4">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-term notes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;750.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.00% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;99.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.00% Euro denominated notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;737.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;671.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.15% Swiss Franc denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;679.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;618.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.125% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;229.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;560.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.625% Euro denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;922.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;839.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;377.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;377.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;401.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;401.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.45% Swiss Franc denominated notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;453.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.375% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,150.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.42% Japanese Yen denominated notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;222.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;209.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.125% Euro denominated notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;922.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;839.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.625% Euro denominated notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;737.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;671.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.56% Japanese Yen denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;90.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;85.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.77% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;174.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;476.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.95% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;284.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;284.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.875% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;360.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;360.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.65% notes due 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;43.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;412.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;436.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.95% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,500.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.7% Euro denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,229.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,119.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.97% Japanese Yen denominated notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;74.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.25% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,250.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.15% notes due 2059&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,000.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.5% notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;850.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized note discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(76.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(55.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total long-term notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;16,348.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,638.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie39118bdcc684cd68b2c6725d353ce58_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEtMC0xLTEtMTM1ODAvdGV4dHJlZ2lvbjpmOGM5MjRhNThlZmM0ZGExOWM5YTg1YzZmNWQ1OGZiZl8xMDk5NTExNjI3ODAw_db964dec-97e5-4494-985c-74eef15ff675"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie39118bdcc684cd68b2c6725d353ce58_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEtMS0xLTEtNTY5NQ_d0ec2695-42d5-44ee-a93d-fa067ab0afdd"
      unitRef="usd">750000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8211a0f8b8da413db4f2efbb3213d634_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEtMy0xLTEtNTY5NQ_95f6fde1-f51e-4de0-a6c7-fe58ec8013cb"
      unitRef="usd">750000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2de9e70275e246d6a582111588810286_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzItMC0xLTEtMTM1OTkvdGV4dHJlZ2lvbjphMDY4YzdlOTRlNGM0N2U1OTEwOTBjNTJjZTZkYjIzYl8xMDk5NTExNjI3ODAz_27da027f-ae33-44bf-a8a5-ea32bc219601"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2de9e70275e246d6a582111588810286_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzItMS0xLTEtNTY5NQ_8eb4e784-1b27-46b7-a978-37d3ebe56dde"
      unitRef="usd">99200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i02f615487ab04c708fef493a3fa4ecef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzItMy0xLTEtNTY5NQ_94b32b2e-6c5b-4c28-8258-688aa0be45fb"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i61c1211b430f4ba58b2eba2c97c976f5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMtMC0xLTEtMTM2MDEvdGV4dHJlZ2lvbjozNWI1NmI5ZDhlZjc0Zjg1YTdiZTlkZmU5ZjJkOTA3M18xMDk5NTExNjI3ODIw_fc8c5334-d9e7-43f5-869e-3c9b49a75961"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i61c1211b430f4ba58b2eba2c97c976f5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMtMS0xLTEtNTY5NQ_ceb7a978-1f95-4243-9ca4-d23009cf1cfb"
      unitRef="usd">737900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie245631a64f040e0bf885d77689fdecf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMtMy0xLTEtNTY5NQ_e265da62-eca1-44a2-b582-34077a1fbecf"
      unitRef="usd">671800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2eafba22b49e42f1a090d404e4b1ccd1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzQtMC0xLTEtMTM2MDMvdGV4dHJlZ2lvbjo2MWMxYjk3ODk3OWU0MzQ0YmNmODA5ODVhNmMyYzBiOF8xMDk5NTExNjI3ODI5_30aef227-c610-450a-ab98-2e2e5bdac9f7"
      unitRef="number">0.0015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2eafba22b49e42f1a090d404e4b1ccd1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzQtMS0xLTEtNTY5NQ_3d9a6057-76b5-44a5-9237-177eed70c7ac"
      unitRef="usd">679700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5fe45934df5346e4a6a0d715944c15b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzQtMy0xLTEtNTY5NQ_4dde12c9-85c8-4f82-82fb-19fae12af794"
      unitRef="usd">618300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia221e6819a7d4e69b484d963df327dfd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzUtMC0xLTEtMTM2MDUvdGV4dHJlZ2lvbjoxZGM2ZDA2ZDJiMTA0NDA1YTJlYjE5ZjIwM2JkMzJhMF8xMDk5NTExNjI3ODA3_4f1739dd-0a2b-42ea-9a36-937022a00666"
      unitRef="number">0.07125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia221e6819a7d4e69b484d963df327dfd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzUtMS0xLTEtNTY5NQ_17cf2d8d-b61d-4d57-b0cf-eeb909eca4e0"
      unitRef="usd">229700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ida41079f1ceb4961915954043ad0b801_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzUtMy0xLTEtNTY5NQ_4c73d8d6-edaa-4340-87fd-bed83a745f6f"
      unitRef="usd">229700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia71a0b4c817a43a9aee24da56d63c0e5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzYtMC0xLTEtMTM2MDcvdGV4dHJlZ2lvbjo2ZDU4ZDQyZWQyOGM0MTNjYTNjYTc1ZTM5ZjU2MWE5Y18xMDk5NTExNjI3ODA1_cb5ce7f8-fe2c-4156-a9a4-b912b264b8c6"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia71a0b4c817a43a9aee24da56d63c0e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzYtMS0xLTEtNTY5NQ_a9af9a31-e501-4dd9-8c18-346852f16495"
      unitRef="usd">560600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id641d973aee741acb44e0f58ced70bf1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzYtMy0xLTEtNTY5NQ_80408ac5-275e-48eb-9e9b-373f00ddb12e"
      unitRef="usd">560600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5e0dbe73367c474aa66b9eb7c4937520_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzctMC0xLTEtMTM2MDkvdGV4dHJlZ2lvbjpiYmQ4MjAwNTQ4NTU0Njc5OTc3OTlmODdkMzUwOWU0N18xMDk5NTExNjI3ODI0_294f545d-7d10-481f-a091-0d4d357f29c0"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5e0dbe73367c474aa66b9eb7c4937520_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzctMS0xLTEtNTY5NQ_8c6fd0b6-1c4d-405d-a42f-259e864f3111"
      unitRef="usd">922400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iba8e44c95e6f480eb82a83d06e179514_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzctMy0xLTEtNTY5NQ_b2cac8d7-986d-40d2-9914-120c496d8781"
      unitRef="usd">839700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0fc9ebff5d804b3587da0025635f268e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzgtMC0xLTEtMTM2MTEvdGV4dHJlZ2lvbjo5MzZmNWU4ZGUzNDE0ZmJiOTIyOGVmZTY0OTc0NzFlZl8xMDk5NTExNjI3ODAz_f4591c27-e021-44da-a75b-f999e24151c7"
      unitRef="number">0.055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0fc9ebff5d804b3587da0025635f268e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzgtMS0xLTEtNTY5NQ_d37ccf6a-811e-4aa6-b7f0-4ae28b41392b"
      unitRef="usd">377500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3562490080194bc8b92c4d7b39b14b4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzgtMy0xLTEtNTY5NQ_5dc96634-d595-477e-a7ca-fa5199854853"
      unitRef="usd">377500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic52fe587003244e18fb9abdb9be4e63d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzktMC0xLTEtMTM2MTMvdGV4dHJlZ2lvbjo2ZGQyN2NiMzliN2Q0M2ExYWQzYTEzYzI5NjZhZDVhOV8xMDk5NTExNjI3ODAz_205535b1-701d-46fd-b5bc-d713f9fbc0a5"
      unitRef="number">0.031</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic52fe587003244e18fb9abdb9be4e63d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzktMS0xLTEtNTY5NQ_10815983-18a3-46ce-97fc-d8686aa86839"
      unitRef="usd">401500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i07507ae169e74357a231b2d9c239eedc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzktMy0xLTEtNTY5NQ_278b8a78-673c-4e92-af0b-3c57363a4673"
      unitRef="usd">401500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic6bfd9e9e45a473a9f90d4f41a08ea48_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEwLTAtMS0xLTEzNjE1L3RleHRyZWdpb246Nzc1N2NlMTY3NzU5NGRiZGI4NDhhMTRjNzQwNTQxNDBfMTA5OTUxMTYyNzgyOQ_bbeef7b5-195d-4541-9c8a-e978f67dbed8"
      unitRef="number">0.0045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic6bfd9e9e45a473a9f90d4f41a08ea48_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEwLTEtMS0xLTU2OTU_9bcaceb8-7b34-4990-ad32-dffc3b0e4783"
      unitRef="usd">453200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1136f1586cde4061a489a0824879f7d9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEwLTMtMS0xLTU2OTU_1da7e603-7ee4-4a9d-86fb-77c97b92dcaa"
      unitRef="usd">412200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2bfd288269624c7b86651f8fc813d3bf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzExLTAtMS0xLTEzNjE3L3RleHRyZWdpb246YTEzZGRlOGY2ZGQ2NGVjYjkwYzZjOTVmY2Y3OTUzNTNfMTA5OTUxMTYyNzgwNw_38f170b3-3323-452e-8ccd-fa8d27e1542c"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2bfd288269624c7b86651f8fc813d3bf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzExLTEtMS0xLTU2OTU_8dbfa7d8-2801-4ce1-99f1-54ed52e0454a"
      unitRef="usd">1150000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia9cd37cd7aad40bda3f214b57cab2f2d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzExLTMtMS0xLTU2OTU_5f50adeb-8277-48a7-8d36-02602b3b29ce"
      unitRef="usd">1150000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6a50eaec3e7a4ba69d1ffdc4a120b39e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEyLTAtMS0xLTEzNjE5L3RleHRyZWdpb246YTUxZGU3ZDViMTA0NDVhMmJiNjhlNDZkYWMzMjA0MjhfMTA5OTUxMTYyNzgzMA_80eeb3b9-c373-4b5a-8f6f-6b7c9d80c889"
      unitRef="number">0.0042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6a50eaec3e7a4ba69d1ffdc4a120b39e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEyLTEtMS0xLTU2OTU_f37a043d-9fda-4348-92c6-f3f0e8dc6441"
      unitRef="usd">222400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibea8fc22978f41d7932c87f65b0366c0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEyLTMtMS0xLTU2OTU_f3d58acf-1725-436d-a4e7-3235f1d893eb"
      unitRef="usd">209900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id57c890b8a2244d1a7018e62567f926a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEzLTAtMS0xLTEzNjIxL3RleHRyZWdpb246NzU0ZTIxMWUzMzg1NDRiN2IxMTJmMjQ4OTdlMjZlMDBfMTA5OTUxMTYyNzgyNA_a9d64f38-d09d-419c-85bf-92fd886756fe"
      unitRef="number">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id57c890b8a2244d1a7018e62567f926a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEzLTEtMS0xLTU2OTU_4fb29b4b-9a7f-49c8-b2e9-d3d6f427488c"
      unitRef="usd">922400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i451d9a3273804f14955cc5a82111caa6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzEzLTMtMS0xLTU2OTU_52f49af2-9665-4971-ba9c-e6be3921b744"
      unitRef="usd">839700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie9d7b6ad2f874ca7ab2452e56d10ca29_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE0LTAtMS0xLTEzNjIzL3RleHRyZWdpb246ZmY2ZGEyOTA3ZjhkNGExM2EwNzM1ODRmYWVjNDE3OWZfMTA5OTUxMTYyNzgyNA_154a6f95-5738-48eb-9d17-3ad31b7ca813"
      unitRef="number">0.00625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie9d7b6ad2f874ca7ab2452e56d10ca29_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE0LTEtMS0xLTU2OTU_ffe0370d-7b06-4c61-9862-23c65a32e266"
      unitRef="usd">737900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb059df82e0b43cd84033edf1b400448_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE0LTMtMS0xLTU2OTU_349bfb0a-ebe9-4dae-8ce0-684fa50f7d0f"
      unitRef="usd">671800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3112631bb974c85a5318fe1efa3d51b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE1LTAtMS0xLTEzNjI1L3RleHRyZWdpb246MDQ3ODg4YmVkNmNkNGQ5Yzg5Y2U0ZTQzODVkNTk1ZDhfMTA5OTUxMTYyNzgzMA_4daafe89-3d01-4795-98c0-32082e065314"
      unitRef="number">0.0056</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib3112631bb974c85a5318fe1efa3d51b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE1LTEtMS0xLTU2OTU_59b470b1-f7d7-4391-9610-79831a65c6b7"
      unitRef="usd">90000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie3c0b90ff61e4adeab7beb2122db8cc8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE1LTMtMS0xLTU2OTU_c2e3470a-736d-49ce-b800-9efceebca933"
      unitRef="usd">85000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65c5eb420e4649c487d09089e7cf9f49_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE2LTAtMS0xLTEzNjI3L3RleHRyZWdpb246OTY2ZTUzOWFhMGM4NGJjZmFhNjU5ZWM3MThlZjYxNmFfMTA5OTUxMTYyNzgwNQ_3dbd67c4-e9f2-453e-9107-00dbfb072df8"
      unitRef="number">0.0677</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i65c5eb420e4649c487d09089e7cf9f49_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE2LTEtMS0xLTU2OTU_b9ea561e-c9a4-4927-a8fe-e8eb12022dd0"
      unitRef="usd">174400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0c6c23acfade4500ab9b57e874f2b87c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE2LTMtMS0xLTU2OTU_b12e51d6-204d-4ef7-94dd-cba4f7fe4101"
      unitRef="usd">174400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6ee2a27f08884a89b9bf33bf08bd0da6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE3LTAtMS0xLTEzNjI5L3RleHRyZWdpb246OTUwZmVjMDVhNjM0NDA0Nzk1MGYzNjljMjJhNzNjMmRfMTA5OTUxMTYyNzgwNQ_34fafcb0-d298-4211-ab7f-e7ada1f1cee8"
      unitRef="number">0.0555</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6ee2a27f08884a89b9bf33bf08bd0da6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE3LTEtMS0xLTU2OTU_ad47ad8e-c0db-4afd-8295-14e195838772"
      unitRef="usd">476200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9874bc66d90145f4bd3eea521b23dad8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE3LTMtMS0xLTU2OTU_462a3558-9626-4c6f-b94e-4235dc123481"
      unitRef="usd">476200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2078c3a852d54d1385e1a1b24d15e8c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE4LTAtMS0xLTEzNjMxL3RleHRyZWdpb246MzhjMmM0MmJjM2IzNDMyZTg3YzI2ZmM1MjY3Y2ZiNTRfMTA5OTUxMTYyNzgwNQ_7f22f8b4-16ac-49c6-a276-abd304893b89"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2078c3a852d54d1385e1a1b24d15e8c5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE4LTEtMS0xLTU2OTU_ea22c800-dae0-42f4-a216-795baea5afca"
      unitRef="usd">284100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7bb8be0259a04e968746158d9c7ebfdd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE4LTMtMS0xLTU2OTU_af402e9c-5a79-4382-80cd-d97d3ef6e3bd"
      unitRef="usd">284100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7858b711bd2147f994af875c0dbac9d2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE5LTAtMS0xLTEzNjMzL3RleHRyZWdpb246ODFhNTgxODhlNjgyNDllNDg4MWE1N2M2OGU3MDhlZDZfMTA5OTUxMTYyNzgwNw_dc30aafb-3f50-4170-b3c5-d5201d99f10d"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7858b711bd2147f994af875c0dbac9d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE5LTEtMS0xLTU2OTU_d344dc66-74b5-4914-afef-861424e67e02"
      unitRef="usd">360700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i94f9df676ae84ca4ab5a863a59e0e05c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzE5LTMtMS0xLTU2OTU_423c3aa3-14ba-48b5-8b8f-f6562e9d96de"
      unitRef="usd">360700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i030c208576224dff9839b8198a359ca8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIwLTAtMS0xLTEzNjM1L3RleHRyZWdpb246OTYzZmQxOWEyNDhhNDY2YmE2YjIwMmMyZmQxNjFhN2NfMTA5OTUxMTYyNzgwNQ_bc5e902b-c5fa-4a4d-b107-3c93e8716d0c"
      unitRef="number">0.0465</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i030c208576224dff9839b8198a359ca8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIwLTEtMS0xLTU2OTU_8bc67439-990a-4dbb-a987-39685310b1a2"
      unitRef="usd">43000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4c29e053597c4404a0c3274d3ae71277_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIwLTMtMS0xLTU2OTU_f29ae576-f070-4303-8ee1-4eaecae9e3a4"
      unitRef="usd">43000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d11e1f18c324cb68f63c1d7111e4aba_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIxLTAtMS0xLTEzNjM3L3RleHRyZWdpb246YzliNTBhMWNiOGQ4NGJiOWE5MzEyNGNlZjlhY2Q4YTFfMTA5OTUxMTYyNzgwMw_dfdded98-bf37-4bb6-b6df-e7a9365e6a4f"
      unitRef="number">0.037</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0d11e1f18c324cb68f63c1d7111e4aba_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIxLTEtMS0xLTU2OTU_1a602c18-4cb6-4530-a102-0b6503831825"
      unitRef="usd">412500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i867c6c8331db465fb6d11fa19654d49b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIxLTMtMS0xLTU2OTU_a05ce4b4-755b-4515-a47d-25fea3f3649c"
      unitRef="usd">412500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie846943d9ed4494daf24040e9d7a4b3b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIyLTAtMS0xLTEzNjM5L3RleHRyZWdpb246ZjQ5YzFiNmJkNjMxNGY1OGI0ZmQ5MzEyMWUyOTU4ZGJfMTA5OTUxMTYyNzgwNQ_5bb415bc-446e-4045-847b-27f211d439c8"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie846943d9ed4494daf24040e9d7a4b3b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIyLTEtMS0xLTU2OTU_2f39a4b0-c861-4f2c-871b-14d0b9e9dfdc"
      unitRef="usd">436100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i234b44d7a5c647d483338639b9fee082_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIyLTMtMS0xLTU2OTU_3e204158-2f99-4b50-95cb-c2753694a4b7"
      unitRef="usd">436100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i656b092512744da59aaf0680fcbf4678_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIzLTAtMS0xLTEzNjQxL3RleHRyZWdpb246Y2IwZmFiOWRjYmU0NGVkNWEwY2IzNTk0MWZlNDAxOWZfMTA5OTUxMTYyNzgwNQ_17e44c56-4592-446d-ae54-ee119dc96687"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i656b092512744da59aaf0680fcbf4678_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIzLTEtMS0xLTU2OTU_a8677626-fd7d-432f-b355-5a6ba9ae0e77"
      unitRef="usd">1500000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1d0bfcf2438249eda212a31a4a731f1b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzIzLTMtMS0xLTU2OTU_f642a2f6-7121-46c9-84ed-0e6450522fc8"
      unitRef="usd">1500000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0965d791ab43490fb6cdab898b7eb5cc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI0LTAtMS0xLTEzNjQzL3RleHRyZWdpb246MGY1MTQyOTJhMjY0NGZiNGFkYmQyNDEyNWNkNGFhYWRfMTA5OTUxMTYyNzgyMA_28e9d0fa-a555-4e93-801d-15a1e98a30dc"
      unitRef="number">0.017</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0965d791ab43490fb6cdab898b7eb5cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI0LTEtMS0xLTU2OTU_612310cf-09a0-4b23-9cea-99bdee8fdbe7"
      unitRef="usd">1229900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i62a9613dbf90422496652cb4fe3df34e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI0LTMtMS0xLTU2OTU_49d3fbba-adef-4ecd-a061-8367338c4b00"
      unitRef="usd">1119600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7bf9bc896ba444c18c22af719b4f6ca2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI1LTAtMS0xLTEzNjQ1L3RleHRyZWdpb246YzVmODE5MGRlYzdjNDc1Mjk5NDQ3Y2YxYTEwZWFhZTJfMTA5OTUxMTYyNzgzMA_c8214367-26f0-448b-a8bf-39e1f484c364"
      unitRef="number">0.0097</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7bf9bc896ba444c18c22af719b4f6ca2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI1LTEtMS0xLTU2OTU_f95038a5-3380-4e3f-8a07-f7b0111ae9cc"
      unitRef="usd">74100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9bcf1e62803246f8afcd362547cd42bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI1LTMtMS0xLTU2OTU_eb5ee354-a466-41bc-9a05-5db7d8c8c8f8"
      unitRef="usd">70000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i655dc81cd7ca4a969575979d59347169_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI2LTAtMS0xLTEzNjQ3L3RleHRyZWdpb246ZGJjOTY4Yzc0YTJlNDFlOGI5ZmM4YTAyMGVlYzQ0NzZfMTA5OTUxMTYyNzgwNQ_7edf650c-f700-4426-af29-3e6f84c01f31"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i655dc81cd7ca4a969575979d59347169_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI2LTEtMS0xLTU2OTU_6a1e7c3c-0374-4a86-961c-4aa87b837a16"
      unitRef="usd">1250000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i532a4d8d7fa0495f9850719f1d105b79_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI2LTMtMS0xLTU2OTU_834123cb-e579-4e70-9476-5d34563ade25"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idda582f88fad4b44bb89a7b65fa5e8b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI4LTAtMS0xLTEzNjQ5L3RleHRyZWdpb246ZmUzMjAwYTE1MDRkNDZhYTk0ZDUyNzJjOGM5NTgxMDhfMTA5OTUxMTYyNzgwNQ_b9416d2a-2567-45fe-a2ad-9a8dc45a154f"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idda582f88fad4b44bb89a7b65fa5e8b7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI4LTEtMS0xLTU2OTU_f7dbb0f2-885a-4675-ad6b-d4da2c072cc6"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3f74451c169b4c4bb0905d735b168f81_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI4LTMtMS0xLTU2OTU_7d659c31-720b-4dc2-b273-cb55e55ac7b2"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2f0b1156a4f441f3a4c0ef9e8fe20b38_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI5LTAtMS0xLTEzNjUxL3RleHRyZWdpb246NzhkYzQ3M2Q4ODYwNDE4ZjgzNDdjZGQ4Y2I4YjVmMTFfMTA5OTUxMTYyNzgwMw_aa5a2b16-4511-4d6b-9ed7-50ca28f02f3f"
      unitRef="number">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2f0b1156a4f441f3a4c0ef9e8fe20b38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI5LTEtMS0xLTU2OTU_f9cae00c-5341-4343-b7c9-b4acf4124d4d"
      unitRef="usd">850000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i85629be20441417e81c8bc15187610f6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzI5LTMtMS0xLTU2OTU_5d5e0acf-97f0-4643-9902-0071bbcefd95"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMwLTEtMS0xLTU2OTk_b85924b0-f4c9-4914-96ca-c528aa013fe0"
      unitRef="usd">76700000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMwLTMtMS0xLTU2OTk_6ad42964-1e5b-434a-a463-d057a9eb3dd1"
      unitRef="usd">55800000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMxLTEtMS0xLTEzNTg4_b41da516-7f0c-4402-b63b-54ab5dbe8bc2"
      unitRef="usd">16348700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTplZGMzMTc1YTEzZDQ0YTQzYThkNjY3NGQ0YzdhNDY0MS90YWJsZXJhbmdlOmVkYzMxNzVhMTNkNDRhNDNhOGQ2Njc0ZDRjN2E0NjQxXzMxLTMtMS0xLTEzNjU1_c2d5cc2f-bd75-4c1b-a350-685a860effa5"
      unitRef="usd">13638500000</us-gaap:LongTermDebt>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODQ2Njg_1b6faa67-923b-490b-89de-e727cce46e75"
      unitRef="number">0.0165</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5Mw_100ffbd7-6cf6-4d78-986d-2253a45671d2"
      unitRef="usd">5240000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i92154592e663424992dbf36c8086e56f_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzI3MQ_94c37d9b-3e36-4730-8ea4-24af899697f7"
      unitRef="usd">3000000000.00</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i576355b801554d9dace08e37a3e790a4_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyNg_2b5cc853-96e9-4173-8265-272851bb1ed5"
      unitRef="usd">2000000000.00</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="icc42a52c34fb4cbe8b9fc2a34c409158_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyOQ_6cb4d973-a52f-4fdb-962a-839903fe0107">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i92154592e663424992dbf36c8086e56f_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzQ3NQ_94c37d9b-3e36-4730-8ea4-24af899697f7"
      unitRef="usd">3000000000.00</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i576355b801554d9dace08e37a3e790a4_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzQ4Mg_2b5cc853-96e9-4173-8265-272851bb1ed5"
      unitRef="usd">2000000000.00</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iacba47193c1c41d9b33bebc61b930bc4_I20200531"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0MDE_45ff1e1b-f309-4a17-b968-9e835f7c8027"
      unitRef="usd">1000000000.00</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iacba47193c1c41d9b33bebc61b930bc4_I20200531"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0MjA_63550cec-73a0-47be-8115-0b1710d90f71"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i61181bb3188f4ceab623c97f733dd40b_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0Mzg_f060b591-23e6-4b7d-af03-75fd08ef95e9"
      unitRef="usd">988600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id260d3c811084dc9bebde09aaeb73bee_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0NTY_c5b11355-76fb-4678-89f6-3e8260a97305"
      unitRef="usd">850000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id260d3c811084dc9bebde09aaeb73bee_I20200831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0NzM_2b4f7be2-aa1e-45f4-b9c1-97541a8c657a"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3cdb23950c784a95a855f5d0ce652a38_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU0OTA_039a1ab0-b5b8-4105-96e8-0bf114773347"
      unitRef="usd">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3cdb23950c784a95a855f5d0ce652a38_I20200831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU1MDk_9ea1690f-f264-45fc-80a5-84e2d990ac18"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i66b0a7cb640f45d6b8c83fc4de5fec01_D20200801-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzcxNDY4MjU1ODU1MjY_8f3d2a4d-5cfb-4124-8587-782e998e5337"
      unitRef="usd">1070000000.00</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i781b0d1c65df4f598bf4ca78d40c03f6_I20190228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzc5OQ_adaed2ae-f8fd-43ec-b488-4bcfd7ab618b"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i781b0d1c65df4f598bf4ca78d40c03f6_I20190228"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzgwNQ_a85a1100-c11d-4431-a0c3-fbd4c0536dac"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7caac5fec4c34319b3ee7518fa0cee6d_I20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzg0NA_04645026-81cf-4dc3-bca8-d14dd7983bbb"
      unitRef="usd">850000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7caac5fec4c34319b3ee7518fa0cee6d_I20190228"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzg1MA_041ffd08-3e0f-4b13-a30c-eb40b34c8e78"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i195f7ecf4b4c48a592446e3d876daf86_I20190228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzg4OQ_bbda21d5-0791-4743-b4be-12bb395316ae"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i195f7ecf4b4c48a592446e3d876daf86_I20190228"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzg5NQ_3328908b-e4e9-4090-84df-42d8c83d27c0"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie27939a1114f4155b7e6b1134d719999_I20190228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzkzOA_3f8fba34-2959-4f2b-950b-9db8cb846b55"
      unitRef="usd">1000000000.00</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie27939a1114f4155b7e6b1134d719999_I20190228"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzk0NA_2f4640bc-4681-48ad-bf82-506c42a5ec0c"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i01a37470a5b047e994577c37bc40b277_D20190201-20190228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEwNTE_cee8b95c-d492-4f0f-9d7d-da13c4e9b0de"
      unitRef="usd">4450000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i01dca931c8514af0bd8dca2a456bd02a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEyNjA_e0fa7c7c-d19d-4e12-8309-7f364ba8dbc8"
      unitRef="eur">600000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i01dca931c8514af0bd8dca2a456bd02a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEyNjY_deb22571-ed2f-48f1-8917-47e6092383c9"
      unitRef="number">0.00625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0b0b3f18d85446cd9abefc7f5431210a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEzMTI_94237870-ae47-4aa1-81fb-83d9c6d4fd31"
      unitRef="eur">1000000000.00</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b0b3f18d85446cd9abefc7f5431210a_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzEzMTg_d4f2994e-2b6d-4c03-ac6b-9db9580f9a0d"
      unitRef="number">0.0170</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="i7bfd42d26c474945ab26097d61bb99b9_D20191101-20191130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE0MTA_27219ad6-f0ec-4e92-91e5-d5d1b36c7f92"
      unitRef="usd">-2270000000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="icb88d176a73247459d0ce6d57d7f2362_D20191101-20191130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE0Mjc_02f884e8-c9eb-4b15-bd69-82cddbf8ba3c"
      unitRef="usd">1750000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="id425e417e4ad4c45a09f17f9caed0ff2_I20191130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE2MjU_7a11154f-172a-49d4-bb5e-3a1fcd918cad"
      unitRef="usd">2000000000.00</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id425e417e4ad4c45a09f17f9caed0ff2_I20191130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE2NTY_3241b47f-aa63-47e6-a880-4e5d65c859e8"
      unitRef="usd">2010000000.00</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i61be1551dd32425daa8be3c06f520dd7_D20191101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE3MDM_71b77143-340d-4d5a-931e-0f4591d45f64"
      unitRef="usd">-252500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if3b8c3ecb8934c7cb012f8fe970195e6_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5MjA_486f6219-d7bb-492d-820d-d19a866bcb51"
      unitRef="jpy">22920000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3b8c3ecb8934c7cb012f8fe970195e6_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5MjY_2e75261d-d71d-47a6-84df-b9d31bb464e9"
      unitRef="number">0.0042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3517b05124e542ba94be70caac0c6932_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5Nzc_770b621e-5538-44fc-a9bf-10b6c3b55d1b"
      unitRef="jpy">9280000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3517b05124e542ba94be70caac0c6932_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzE5ODM_12111e85-d704-442b-9ce9-173ee9911019"
      unitRef="number">0.0056</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i73d344ee1fd84e0a9a617d23c99aff1e_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzIwMzg_f94eb8fe-ac44-48b7-a81c-47e80123d17f"
      unitRef="jpy">7640000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73d344ee1fd84e0a9a617d23c99aff1e_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzIwNDQ_4bb3fd20-fc5c-4c16-888e-9f77b6c986cc"
      unitRef="number">0.0097</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ifc7c545c888b441abae0763fd9a5afbd_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzIxODU_8b0b94fe-a3fa-400e-9a19-0dcaf6d1bd44"
      unitRef="usd">356600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyNjk_cd6fd0c6-871d-4ebe-9ba4-849dfe67dc6c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amounts of maturities on long-term debt for the next five years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities on long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,590.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtMS0xLTEtMA_bae79c88-09aa-4496-8913-34598c8d54b9"
      unitRef="usd">6000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtMy0xLTEtMA_6a03aa33-0d82-4a5b-96a7-2cbdb3e57b84"
      unitRef="usd">1590200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtNS0xLTEtMA_d5599ed6-02b4-4c91-ae3b-342b1eb29389"
      unitRef="usd">2300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtNy0xLTEtMA_e6f40230-4692-40bd-a913-de66f2aaf2cc"
      unitRef="usd">681100000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo4ZmViZTkzZDgzODc0YWFiYTRhYmZiMTdkNWVkZjNiMy90YWJsZXJhbmdlOjhmZWJlOTNkODM4NzRhYWJhNGFiZmIxN2Q1ZWRmM2IzXzEtOS0xLTEtMA_9fecdf11-9e7e-491c-837f-97fb7b5815ad"
      unitRef="usd">790300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <lly:DescriptionOfDerivativeActivityVolumePercent
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzIzOTc_8c1bee7e-a3f1-4dc8-b6be-69428b608974"
      unitRef="number">0.09</lly:DescriptionOfDerivativeActivityVolumePercent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzI2ODc_b0c8331b-ff31-48f9-aca6-68fabe08b18d"
      unitRef="number">0.0261</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzI2OTQ_f104bd26-d1c0-4ef9-bff1-ec4f9982a730"
      unitRef="number">0.0288</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90ZXh0cmVnaW9uOmQ4NGIyMDk3YjE5MDQ0NjViMmYxZjJkZjhhMTEzNTNlXzMyOTQ_9a82e68c-0ea0-4165-86f8-03f4530f39c6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments for interest on borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;345.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo3ZGE5NzJmYWM4MjQ0NDc3YmE5YjZhM2Q1MjE4OWVkZi90YWJsZXJhbmdlOjdkYTk3MmZhYzgyNDQ0NzdiYTliNmEzZDUyMTg5ZWRmXzEtMS0xLTEtMA_44a63250-f2ec-4df2-a7bd-aac4b4e089bf"
      unitRef="usd">345800000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo3ZGE5NzJmYWM4MjQ0NDc3YmE5YjZhM2Q1MjE4OWVkZi90YWJsZXJhbmdlOjdkYTk3MmZhYzgyNDQ0NzdiYTliNmEzZDUyMTg5ZWRmXzEtMy0xLTEtMA_be183e35-2d1c-449c-b2e4-527a622b14c7"
      unitRef="usd">305500000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNTcvZnJhZzpkODRiMjA5N2IxOTA0NDY1YjJmMWYyZGY4YTExMzUzZS90YWJsZTo3ZGE5NzJmYWM4MjQ0NDc3YmE5YjZhM2Q1MjE4OWVkZi90YWJsZXJhbmdlOjdkYTk3MmZhYzgyNDQ0NzdiYTliNmEzZDUyMTg5ZWRmXzEtNS0xLTEtMA_d23ebc5f-0f2a-4050-bb31-fcfd5259336e"
      unitRef="usd">223800000</us-gaap:InterestPaidNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQxNjA_74ce4265-8b25-4102-bea8-94482cac3c57">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and the related tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;308.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 53.9 million additional shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2020, 2019, and 2018 were $137.33, $112.09, and $71.63, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately 1.1 million shares, 1.2 million shares, and 0.9 million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately 0.8 million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested PAs was $77.3 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Value Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2020, 2019, and 2018 were $139.14, $95.01, and $48.51, respectively, determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to this program, approximately 0.8 million shares, 1.0 million shares, and 0.7 million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately 1.0 million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested SVAs was $48.8 million, which will be amortized over the weighted-average remaining requisite service period of 20 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Relative Value Award Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, we granted RVAs to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the three-year vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair value of the RVA units granted during the year ended December&#160;31, 2020 was $179.90, determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested RVAs was $13.7 million, which will be amortized over the weighted-average remaining requisite service period of 24 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The fair values of RSU awards granted during the years ended December&#160;31, 2020, 2019, and 2018 were $135.42, $108.43, and $70.95, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 1.1 million, 1.5 million, and 1.3 million shares were granted and approximately 0.6 million, 0.8 million, and 1.0 million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately 0.6 million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested RSUs was $179.2 million, which will be amortized over the weighted-average remaining requisite service period of 31 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQxNjE_4dc1f443-ec0f-4b0c-b072-e47df5062aba">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQxNjc_6db8f9f3-35cb-439a-bf3d-52256ec4e690">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and the related tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;308.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzEtMS0xLTEtMA_3d03805b-9c55-4a03-bada-34de3e272916"
      unitRef="usd">308100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzEtMy0xLTEtMA_f7829951-c1b4-4968-ae58-fcc41718f8b7"
      unitRef="usd">306800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzEtNS0xLTEtMA_c11ff8a0-61ee-4774-ba08-94e56dfc996b"
      unitRef="usd">253500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzItMS0xLTEtMA_39d6a374-0bf5-4155-9b9b-1b36f06b3d73"
      unitRef="usd">64700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzItMy0xLTEtMA_698c5cb3-4448-4d45-a447-0fd23ed5c1a7"
      unitRef="usd">64400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTplM2RlMDhhMzBjZjg0OWViOWM1OTkwMmNmOGFlNTcwNy90YWJsZXJhbmdlOmUzZGUwOGEzMGNmODQ5ZWI5YzU5OTAyY2Y4YWU1NzA3XzItNS0xLTEtMA_19cb8c97-4cfa-4c7c-9976-d689048300af"
      unitRef="usd">53200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzY2MQ_307d144c-f50f-49a7-a9a6-b151d0a0c187"
      unitRef="shares">53900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMyOTg1MzQ4ODc1MjM_631d1fd3-183f-4a83-b049-67741f4e081a">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzExODQ_9ef743c2-cc15-400f-815c-4b2bfac53ba0"
      unitRef="usdPerShare">137.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ida5a3ee36c55473f9c1d1258483a8afa_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzExODg_9d53d152-3f48-4b2a-a2ba-6471cc926b1c"
      unitRef="usdPerShare">112.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c9bc19fd1fb41c9bce540130ed1021d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzExOTY_de43973b-377f-4eac-9182-fbb9421103f7"
      unitRef="usdPerShare">71.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzEzNzQ_b80bc483-1fbe-4886-b123-267f0ddb4221"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ida5a3ee36c55473f9c1d1258483a8afa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzEzODU_3b19c20b-31f8-40b8-8897-d6cf1835b5fa"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i6c9bc19fd1fb41c9bce540130ed1021d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzE0MDA_f8b77f91-1439-47ba-9068-2bbb94d0fb1e"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzE0ODk_8742400e-27cd-4b92-804c-56b46c6482a8"
      unitRef="shares">800000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id85cea205afe42e1b0277f50024d6b30_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzE2MjI_87be521f-79f4-4d39-963c-926f85657ad0"
      unitRef="usd">77300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8c3569509a52409891ef6a7b7613f188_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg5MDA_10bc7d89-6852-4317-9a75-f209660c2236">P12M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMyOTg1MzQ4ODc1MjQ_f7e659c9-dc7d-41f5-bc76-8bfc39d59a8a">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQxODU_d613ed5a-2a80-45b2-a9d2-0af3f87e5a5e">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2020, 2019, and 2018 were $139.14, $95.01, and $48.51, respectively, determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The weighted-average fair value of the RVA units granted during the year ended December&#160;31, 2020 was $179.90, determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</lly:SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI3ODM_753eb7ca-38a2-49f9-b48f-9e5e194c4db2"
      unitRef="usdPerShare">139.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI3ODc_b3d0b162-30c1-428d-b195-380a733a6ae2"
      unitRef="usdPerShare">95.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI3OTU_0932c3e0-2d05-43de-8ef8-ae8f231eb190"
      unitRef="usdPerShare">48.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzEtMS0xLTEtMA_ee468169-198f-44b6-9ab5-07617869de41"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzEtMy0xLTEtMA_52de12d2-dd82-4351-9123-a389bab5ea5a"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzEtNS0xLTEtMA_66754348-16e9-45b2-9363-a313af32ab29"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzItMS0xLTEtMA_a8550634-105a-4c52-a9b7-909eebd677ac"
      unitRef="number">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzItMy0xLTEtMA_bfa104de-3182-4713-a1c0-fe80543dafe4"
      unitRef="number">0.0246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzItNS0xLTEtMA_2b82afa8-a5d2-4f7f-9fda-46df4f256942"
      unitRef="number">0.0231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzMtMS0xLTEtMA_83000656-65e7-4542-a38a-6257193a3362"
      unitRef="number">0.2090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzMtMy0xLTEtMA_ff4a1394-9d8a-4026-aecc-7b981543fb6b"
      unitRef="number">0.2100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTphMGFjYjhhNzcyYjA0MTFjYTUyNDE4NGE0MWRjODkyZi90YWJsZXJhbmdlOmEwYWNiOGE3NzJiMDQxMWNhNTI0MTg0YTQxZGM4OTJmXzMtNS0xLTEtMA_e6568974-6d8e-4fa2-8a04-93630cfc4c29"
      unitRef="number">0.2226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI4OTk_f37e7a8e-217f-4207-982c-d06bdfdb5c5e"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ic997f5ebeecf415a91eac6fe34c6b73c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI5MTA_effa83f9-bcdd-4b39-a3da-7b8d6839cc38"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ia7de296eb32347a98b984561470f50ad_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzI5MjU_f966563b-604d-4ea8-99e4-443170c99ab3"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMwMTQ_5d188429-03ce-473b-a4d3-f4dd57518ffc"
      unitRef="shares">1000000.0</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i487211e627d94b84b6b40cd96ed51f9c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMxNDg_899b530c-0949-4b71-8e10-d701ba53a6e2"
      unitRef="usd">48800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg5MTA_15b47a04-6c21-4e28-aaf3-6997e207dc30">P20M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzMyOTg1MzQ4OTI1NjY_f61a097b-3155-4fc3-ac3a-d1b23a8f8178">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTgzODU_dc3078de-095d-4a64-894c-b64d05045ddd"
      unitRef="usdPerShare">179.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTo4ZjczNzk1ZmY3ZGM0MWZhODNiNWY5OTExYzkyMzkyMi90YWJsZXJhbmdlOjhmNzM3OTVmZjdkYzQxZmE4M2I1Zjk5MTFjOTIzOTIyXzEtMS0xLTEtNDcxOA_58ae272e-eec3-43fc-93ad-c193e13fdb5f"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTo4ZjczNzk1ZmY3ZGM0MWZhODNiNWY5OTExYzkyMzkyMi90YWJsZXJhbmdlOjhmNzM3OTVmZjdkYzQxZmE4M2I1Zjk5MTFjOTIzOTIyXzItMS0xLTEtNDcxOA_872a8008-ba38-46c4-b246-0807c5bb49c5"
      unitRef="number">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90YWJsZTo4ZjczNzk1ZmY3ZGM0MWZhODNiNWY5OTExYzkyMzkyMi90YWJsZXJhbmdlOjhmNzM3OTVmZjdkYzQxZmE4M2I1Zjk5MTFjOTIzOTIyXzMtMS0xLTEtNDcxOA_4ae34175-019f-4a4f-81d4-b267760dfec5"
      unitRef="number">0.1989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i73f6fbe788a645a88588285341425783_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg2Njk_2a4e5f41-06f1-4918-a756-7a65242b6ba8"
      unitRef="usd">13700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i718152c14b0547f79e8bebed6e235baa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg2NzM_1dba384d-6fbd-4bce-b1fb-7d0c2c9a110b">P24M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg5MjU_5116750b-fabf-4d11-bb37-52dc0a906ac4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM2MTE_082b89b6-26ae-4ecb-9006-28af744f748c"
      unitRef="usdPerShare">135.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id745c20da55347c7945337736eb25cfb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM2MTU_a39d5dd3-3b0e-4cbf-bd53-9b20c6e44115"
      unitRef="usdPerShare">108.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4a21324627e04ff9b171760e0f6aa512_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM2MjM_3ba7237a-67d0-4487-897e-89761817ed52"
      unitRef="usdPerShare">70.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM3Nzg_fe400b8b-1be1-4e18-a93b-0276cb0c3b42"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id745c20da55347c7945337736eb25cfb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM3ODI_13626383-df26-453c-9212-7663fd02a6a0"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4a21324627e04ff9b171760e0f6aa512_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM3OTA_d77e2aca-ce30-4c7b-a98e-f7870b700252"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM4MzE_ac7341b8-e891-436f-b7c5-120640b8bc39"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="id745c20da55347c7945337736eb25cfb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM4MzU_473ab111-93c6-4d10-980c-2304e6fd29f0"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i4a21324627e04ff9b171760e0f6aa512_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM4NDM_44707e1c-156a-4a15-91ce-d64891b7b698"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
      contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzM5MzI_7d59436b-f943-44c3-a6f4-735091e4d3d5"
      unitRef="shares">600000</lly:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id93c53abcafb49fba5f4a407366d5857_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzQwNjY_fe1b8e54-8eb9-4878-8425-06e2e7ba8f33"
      unitRef="usd">179200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4462e5f3991247648bf6e62ddffe817d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjMvZnJhZzozZTRmMTVlYzEwYTQ0M2ZlODJjN2Y1ZWI4NTk5YzU3Yi90ZXh0cmVnaW9uOjNlNGYxNWVjMTBhNDQzZmU4MmM3ZjVlYjg1OTljNTdiXzk4OTU2MDQ2NTg4OTY_c8dab340-3ebf-4ae9-940c-067832f30b82">P31M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzk4Mg_5639b1e1-c141-49dc-b2ce-3cbee32ca25d">Shareholders' Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 2019, and 2018, we repurchased $500.0 million, $4.40 billion and $4.15 billion, respectively, of shares associated with our share repurchase programs. As of December&#160;31, 2020, we had $1.00 billion remaining under our $8.00 billion share repurchase program that our board authorized in June 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have 5.0 million authorized shares of preferred stock. As of December&#160;31, 2020 and 2019, no preferred stock was issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an employee benefit trust that held 50.0 million shares of our common stock at both December&#160;31, 2020 and 2019, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01&#160;billion at both December&#160;31, 2020 and 2019, and is shown as a reduction of shareholders&#x2019; equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2020, 2019, and 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzcz_8cfc9479-34ee-480a-bbc6-18a6456294fd"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzc3_1c98faaf-8111-4dfe-bafe-318f46bc1bd6"
      unitRef="usd">4400000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzg0_4fb2c168-7913-4e39-85b3-c8267daf0ba3"
      unitRef="usd">4150000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i3346772108a84c5d82eb7b473c264e9a_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzE3Ng_bbcfad3c-680f-42be-8770-0c642a7aa6ec"
      unitRef="usd">1000000000.00</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i87a7cf1bd4cd4a2198d3b916f9809c4b_I20180630"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzE5OQ_0965ef56-260d-47ca-8117-3ca1a09e5b34"
      unitRef="usd">8000000000.00</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzI3NQ_89926e3d-7198-4ea0-a56f-76007295a08d"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzMzMw_334062cb-b985-4291-8205-5b9f48a056f6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzMzMw_6ef97fd2-b39e-478e-bfe1-cd7487ab54e8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesHeldInEmployeeTrustShares
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzQwOA_b518126a-d030-4e5a-9553-a3341e46f9ac"
      unitRef="shares">50000000.0</us-gaap:CommonStockSharesHeldInEmployeeTrustShares>
    <us-gaap:CommonStockSharesHeldInEmployeeTrustShares
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzQwOA_ca675058-2caa-43cc-9657-c841f7f40555"
      unitRef="shares">50000000.0</us-gaap:CommonStockSharesHeldInEmployeeTrustShares>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzYxNQ_7a5dc723-4ea0-4b40-a691-b59fc194ec32"
      unitRef="usd">3010000000.00</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNjkvZnJhZzpjMWFhNDNhYjZkOGU0MmVmOGZhMWVkMTlhOTQ4ZTMxYS90ZXh0cmVnaW9uOmMxYWE0M2FiNmQ4ZTQyZWY4ZmExZWQxOWE5NDhlMzFhXzYxNQ_b2b42988-121c-4cc6-811c-1c5f2ed03ec1"
      unitRef="usd">3010000000.00</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3MDc_b590acc0-6d26-491c-8e5d-bfbfc16ed9af">Income Taxes&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to GILTI, global intangible low-taxed income, are also recognized for the future tax effects of temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Tax Cuts and Job Act (the 2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, such as the reduction in the corporate income tax rate from 35 percent to 21 percent, transition to a territorial tax system, changes to business related exclusions, deductions and credits, and modifications to international tax provisions, including a one-time repatriation transition tax (also known as the &#x2018;Toll Tax&#x2019;) on unremitted foreign earnings and GILTI, a new U.S. minimum tax on the earnings of our foreign subsidiaries. In 2018, we recorded $313.3 million of income tax benefit, mainly attributable to measurement period adjustments to the Toll Tax and GILTI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is the composition of income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;567.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,170.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(134.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,036.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The 2020 and 2019 current tax expense includes $144.4 million and $153.1 million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards. The 2018 current tax expense includes $201.5 million of tax expense related to effects of the 2017 Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The 2018 deferred tax benefit includes $26.2 million of tax benefit related to effects of the 2017 Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,045.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;523.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;488.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;461.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Correlative tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;404.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax redeterminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;242.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;150.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;605.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,618.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,606.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(816.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,801.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,990.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,905.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,465.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,298.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(623.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(686.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(410.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(315.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(216.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,071.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,604.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets - net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;730.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, based on filed tax returns we have tax credit carryforwards and carrybacks of $887.3 million available to reduce future income taxes; $148.8 million, if unused, will expire by 2026, and $16.1 million, if unused, will expire between 2029 and 2039. The remaining portion of the tax credit carryforwards is related to federal tax credits of $84.8 million, international tax credits of $121.9 million, and state tax credits of $515.7 million, all of which are fully reserved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $1.52 billion: $162.6 million will expire by 2025; $781.7&#160;million will expire between 2026 and 2040; and $576.3 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $175.6 million are fully reserved as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic and Puerto Rican companies contributed approximately 39 percent, 44 percent, and 15 percent for the years ended December&#160;31, 2020, 2019, and 2018, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December 31, 2020 and December 31, 2019, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;954.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight year period beginning in 2018 through 2025. Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-3 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3-5 Years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act Toll Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2,403.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$253.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$729.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,420.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have additional noncurrent income tax payables of $1.69&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at the U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,518.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add (deduct):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations, including Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(297.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(627.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(150.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,036.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Non-deductible acquired IPR&amp;amp;D was related to the acquisitions of Disarm and a pre-clinical stage company in 2020 and ARMO in 2018. See Note 3 for additional information related to acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,108.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;225.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;310.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(72.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses of statutes of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes related to the impact of foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,551.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.67&#160;billion and $1.53 billion at December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months. For tax years 2013-2015, all matters were effectively settled in 2019. As a result, our gross uncertain tax positions were reduced by approximately $200 million, we made a cash payment of approximately $125 million, and our consolidated results were benefited by an immaterial reduction in tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:17pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, our accruals for the payment of interest and penalties totaled $196.7 million and $150.8 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMyOTg1MzQ5MDU2NjA_fc013fde-25b2-4c33-be09-44aac697507b">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to GILTI, global intangible low-taxed income, are also recognized for the future tax effects of temporary differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <lly:TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision
      contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzEwNTk_16a1e80d-5abf-4524-8f54-1a0483f6c466"
      unitRef="usd">313300000</lly:TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3MjM_5cc33cfb-1ee3-4df5-be74-373deb615b69">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is the composition of income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;567.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(47.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,170.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(134.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,036.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The 2020 and 2019 current tax expense includes $144.4 million and $153.1 million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards. The 2018 current tax expense includes $201.5 million of tax expense related to effects of the 2017 Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The 2018 deferred tax benefit includes $26.2 million of tax benefit related to effects of the 2017 Tax Act.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzItMS0xLTEtMA_9bd5dd7b-a4d5-4b8c-a4ef-fcb284b95048"
      unitRef="usd">567600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzItMy0xLTEtMA_25486c95-4c4a-4199-b35d-eca89b08b7ce"
      unitRef="usd">280200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzItNS0xLTEtMA_54b8ca99-9e0a-4c24-9bf5-346f89ac0dd5"
      unitRef="usd">169600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzMtMS0xLTEtMA_c4916387-8f02-44d8-99fc-dbbee35ed004"
      unitRef="usd">650400000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzMtMy0xLTEtMA_5858e569-cb3a-47eb-884f-d9715d1baf5f"
      unitRef="usd">299800000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzMtNS0xLTEtMA_882f7d99-9423-4ad1-8bf3-3651b1bf19a9"
      unitRef="usd">106800000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzQtMS0xLTEtMA_4a4396d6-5df5-4703-a9b4-8eb2fff55267"
      unitRef="usd">-47300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzQtMy0xLTEtMA_5179b96d-9756-432d-b76a-9737bc8a6a56"
      unitRef="usd">-14400000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzQtNS0xLTEtMA_d1a020f4-0047-4921-8245-ad70611b5a29"
      unitRef="usd">4700000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzUtMS0xLTEtMA_043e55b4-6d13-4601-82d1-e5cc36734ca3"
      unitRef="usd">1170700000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzUtMy0xLTEtMA_d1bd3a7e-8fba-4919-97cb-98277c4ab243"
      unitRef="usd">565600000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzUtNS0xLTEtMA_909f2944-18e7-41db-ad93-05276c264874"
      unitRef="usd">281100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzctMS0xLTEtMA_fd82e8bf-3f02-47a2-af73-7db59778e791"
      unitRef="usd">-97400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzctMy0xLTEtMA_01e9491c-c329-479d-b25c-b7b83f195a9e"
      unitRef="usd">141300000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzctNS0xLTEtMA_e563893e-e24b-4f13-baaf-b9783beb4849"
      unitRef="usd">-3700000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzgtMS0xLTEtMA_48a560b3-f5d8-40ce-9b44-ab9b97019805"
      unitRef="usd">-16600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzgtMy0xLTEtMA_34957e48-5deb-4fe2-a226-c6714503053f"
      unitRef="usd">-24100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzgtNS0xLTEtMA_544c76e6-6626-41ea-93e8-6f1328585916"
      unitRef="usd">248700000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzktMS0xLTEtMA_9a314aa8-0213-4a87-b7df-6fed77db9e51"
      unitRef="usd">-20500000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzktMy0xLTEtMA_4cf7ab72-a17e-4571-b744-3c959aa8131a"
      unitRef="usd">-54800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzktNS0xLTEtMA_0aa2d2f2-93e9-4518-972f-0ce4c05d1ba4"
      unitRef="usd">3400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzEwLTEtMS0xLTA_f9d12727-2bfb-4556-b71d-82475422de4f"
      unitRef="usd">-134500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzEwLTMtMS0xLTA_64f654e5-9470-44bd-b0ce-f247e722474b"
      unitRef="usd">62400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzEwLTUtMS0xLTA_3f0f4960-6aa3-4c2e-931f-2583c2ab63bc"
      unitRef="usd">248400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzExLTEtMS0xLTA_21ac9830-4cd3-4667-8a91-4b5633ee7b60"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzExLTMtMS0xLTA_4de90d24-d91f-4e44-aeef-17a366338e1c"
      unitRef="usd">628000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo4MzIzNzAwY2Q1ZWE0MjU4OThlOWU0OTQyNjYzMGQ1NS90YWJsZXJhbmdlOjgzMjM3MDBjZDVlYTQyNTg5OGU5ZTQ5NDI2NjMwZDU1XzExLTUtMS0xLTA_71340c32-2e6d-419a-9219-88075a47a6c3"
      unitRef="usd">529500000</us-gaap:IncomeTaxExpenseBenefit>
    <lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzE5NDc_479e9e08-2738-498f-aba0-877262f9fba2"
      unitRef="usd">144400000</lly:CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward>
    <lly:CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzIwNjY_2d0882b1-4485-4638-83b2-66f816af7526"
      unitRef="usd">153100000</lly:CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct>
    <lly:CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzIwNzM_22ec8431-fbcd-44e2-910b-bd510dc17df9"
      unitRef="usd">201500000</lly:CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct>
    <lly:DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzIxOTg_d7bb317b-8adf-467f-aafb-7c1c48e94589"
      unitRef="usd">-26200000</lly:DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3NDM_519b0300-5532-4cee-b52c-6fe7bcb6736c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,045.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;523.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards and carrybacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;488.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;461.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Correlative tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;404.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax redeterminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;242.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;150.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;605.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,618.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,606.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(816.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,801.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,990.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,905.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,465.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,298.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(623.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(686.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(410.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(315.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(216.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(134.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,071.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,604.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets - net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;730.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzItMS0xLTEtMA_ff6b48ae-1679-4073-91ff-8a6936e0c792"
      unitRef="usd">2560600000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzItMy0xLTEtMA_5a20c2f9-5c6e-444a-883a-03974a3ecdec"
      unitRef="usd">2512400000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzMtMS0xLTEtMA_d524fcf3-fc02-4cd1-8176-91cba25068cc"
      unitRef="usd">1045600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzMtMy0xLTEtMA_e6e3f851-c8a9-4614-a21c-09772cbca266"
      unitRef="usd">934300000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzQtMS0xLTEtMA_33971506-4cfb-4dc2-85b1-55961f0e4762"
      unitRef="usd">523500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzQtMy0xLTEtMA_4b4cabff-a3d1-4440-ace9-a3a61fa5f207"
      unitRef="usd">455800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzUtMS0xLTEtMA_8e5d4f82-2c8b-45d1-98ad-b8dd0d452457"
      unitRef="usd">488300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzUtMy0xLTEtMA_18c3a5a6-ebf7-4194-a073-f93a5291c970"
      unitRef="usd">318800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <lly:DeferredTaxAssetsSalesRebatesAndDiscounts
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzYtMS0xLTEtMA_a954738b-f5d0-44de-b400-4585d74a60cb"
      unitRef="usd">461300000</lly:DeferredTaxAssetsSalesRebatesAndDiscounts>
    <lly:DeferredTaxAssetsSalesRebatesAndDiscounts
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzYtMy0xLTEtMA_0ccf43a7-c38f-4726-9288-89585a4b77d2"
      unitRef="usd">197300000</lly:DeferredTaxAssetsSalesRebatesAndDiscounts>
    <lly:DeferredTaxAssetsCorrectiveTaxAdjustments
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzctMS0xLTEtMTI5ODg_eb053612-929c-49a8-8f55-4b089d869c18"
      unitRef="usd">404200000</lly:DeferredTaxAssetsCorrectiveTaxAdjustments>
    <lly:DeferredTaxAssetsCorrectiveTaxAdjustments
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzctMy0xLTEtMTI5OTI_41eafd46-14b4-4cf9-a979-18a5de98441c"
      unitRef="usd">219100000</lly:DeferredTaxAssetsCorrectiveTaxAdjustments>
    <lly:DeferredTaxAssetsForeignTaxRedeterminations
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzgtMS0xLTEtMTMwMDA_04852330-ede3-4746-9eca-93111539ce2e"
      unitRef="usd">242800000</lly:DeferredTaxAssetsForeignTaxRedeterminations>
    <lly:DeferredTaxAssetsForeignTaxRedeterminations
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzgtMy0xLTEtMTMwMDM_ae17d696-3660-4650-bb71-8fd4e1b1a416"
      unitRef="usd">156800000</lly:DeferredTaxAssetsForeignTaxRedeterminations>
    <lly:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzctMS0xLTEtMA_3eaedb88-c318-43d0-9a50-ae9b8f550dba"
      unitRef="usd">150700000</lly:DeferredTaxAssetsOperatingLeaseLiability>
    <lly:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzctMy0xLTEtMA_c29bc84c-55f2-4b74-bed9-b76e4b2d687c"
      unitRef="usd">140600000</lly:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzgtMS0xLTEtMTA5Nzk_0169d12b-83b8-4bc3-96a2-adf3558d0a11"
      unitRef="usd">135200000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzgtMy0xLTEtMTA5ODM_682b4e10-513d-4627-8d32-37326a6e15f7"
      unitRef="usd">75700000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzExLTEtMS0xLTA_41ce3b3c-dbcd-41c3-a38d-6a95f1aac09b"
      unitRef="usd">605800000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzExLTMtMS0xLTA_8b5490bd-d887-45af-8b88-97509494b3b1"
      unitRef="usd">595700000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzEyLTEtMS0xLTA_2fc73c2e-4948-4cb9-8d27-22f94348f1a2"
      unitRef="usd">6618000000.0</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzEyLTMtMS0xLTA_4fa8871c-ed1e-4737-bc86-cbe65379afe9"
      unitRef="usd">5606500000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzEzLTEtMS0xLTA_efe4a0ff-1fe5-44d0-ac7f-fda47e00b728"
      unitRef="usd">816300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzEzLTMtMS0xLTA_8fc5b578-ee7a-4c19-9e0c-64850facd301"
      unitRef="usd">616500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE0LTEtMS0xLTA_004d7677-75ef-4934-ad52-715e3c8d4955"
      unitRef="usd">5801700000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE0LTMtMS0xLTA_5f83205c-c48f-4346-bea0-0a8e60ee1420"
      unitRef="usd">4990000000.0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE2LTEtMS0xLTA_83d30737-03ca-4920-9b8b-2830be7bb439"
      unitRef="usd">1905300000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE2LTMtMS0xLTA_4951f57c-483f-4139-90ad-6f994d436a4e"
      unitRef="usd">1776400000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE3LTEtMS0xLTA_4343d4c5-2547-41a5-b9a2-da94eae1c0cd"
      unitRef="usd">1465700000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE3LTMtMS0xLTA_89353445-4b81-4319-bca9-6ae0bd73d42d"
      unitRef="usd">1298000000.0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE4LTEtMS0xLTA_daace6d8-7103-4846-9a61-e7c1e8d3ee98"
      unitRef="usd">623700000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE4LTMtMS0xLTA_d3931626-d6b5-4493-8166-1f040a1b33ea"
      unitRef="usd">686400000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE5LTEtMS0xLTA_28a4546c-92fc-4ccd-98eb-68e0c5d0296f"
      unitRef="usd">410100000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzE5LTMtMS0xLTA_578f6a52-e41a-4c82-ac64-bac01a15ef83"
      unitRef="usd">305900000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIwLTEtMS0xLTA_a889c689-772f-475b-a86d-bee442b76abc"
      unitRef="usd">315200000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIwLTMtMS0xLTA_6bd727d8-7d12-45f7-bf6a-7c7fbe6e0dc3"
      unitRef="usd">274100000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIxLTEtMS0xLTA_89ea3ba4-82b6-47e9-a208-0d94e09c41e9"
      unitRef="usd">216900000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIxLTMtMS0xLTA_4ee7d4f9-d181-40e4-bfda-d92df7819047"
      unitRef="usd">139400000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIyLTEtMS0xLTA_4bd14ca1-a1c2-4119-88ff-13622b892932"
      unitRef="usd">134300000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIyLTMtMS0xLTA_92801a2e-7c00-44cb-bf02-f218f3f871e0"
      unitRef="usd">124700000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIzLTEtMS0xLTA_e5b0a2eb-a8dc-4658-b5f3-d3f7ce4ddb85"
      unitRef="usd">5071200000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzIzLTMtMS0xLTA_77e31e80-3e1c-4902-87d6-203148ffae97"
      unitRef="usd">4604900000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzI0LTEtMS0xLTA_112ac5f4-5962-4347-8050-0266112d991f"
      unitRef="usd">730500000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1NDQ2MzU3M2ViMGE0NDE3OWY5NWIyM2I3YmRhZjQ1Yi90YWJsZXJhbmdlOjU0NDYzNTczZWIwYTQ0MTc5Zjk1YjIzYjdiZGFmNDViXzI0LTMtMS0xLTA_f3074e71-8666-4388-9383-db426ba9aef6"
      unitRef="usd">385100000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i846b4a3017ec4ae5aa560b3976992beb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI2OTU_bf769617-9fc6-4499-a198-2ce13a73e1db"
      unitRef="usd">887300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i63b7f44c96794ab582d1cdf6a9643b7a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI3Mzk_c73dd9c8-d48a-42fc-970d-077e8aff692b"
      unitRef="usd">148800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic0b893702d44405d985be5d52a729ef7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI3Nzc_8587314c-139f-4fe5-b623-ddc9b2e1aea2"
      unitRef="usd">16100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i2d7fdc4cf740436c9e25779df853a90f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI5MTQ_ce569530-7058-45f3-99e5-b64e716a2fd5"
      unitRef="usd">84800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i58e427ba0deb48549a21b2af98646bb0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI5NDc_38d1377e-39ff-4706-bd93-014f7e48e970"
      unitRef="usd">121900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="icdc037a98b204a1b85b9d162f20d5932_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzI5NzY_5b1f5c92-2279-40a4-b496-97632d8c0e3b"
      unitRef="usd">515700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i846b4a3017ec4ae5aa560b3976992beb_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMxNjU_052be866-28f8-4c59-9b1d-4054c862f2e1"
      unitRef="usd">1520000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idba58d0fe8d4499db02b60b0661239fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMxNjk_c6e1bbf7-f251-49ad-939b-f6a9e558282f"
      unitRef="usd">162600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id87d4bdf6f7b4a8788ffa5277ada15bb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMxOTE_ad6cb275-19d6-4691-a5a9-fcbd8fc9662a"
      unitRef="usd">781700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibdf7908d101449948e44a8d01c8ce72f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMyMjk_9cc1f768-8226-46d3-a854-7bada7f3d164"
      unitRef="usd">576300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i847eca29310b48cda35b0cd11f7c52fe_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzM0NTc_66d444f0-c4f7-4d11-a0cc-fad4cfb93474"
      unitRef="usd">175600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzM2MDI_eb1f247e-1524-4858-bb08-4a0aa42ca650"
      unitRef="number">0.39</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzM2MDY_efbb919b-68cc-4768-b4e3-d14bc0b5961f"
      unitRef="number">0.44</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzM2MTQ_c79028df-ae30-44b7-ba0d-acf1a66c2cd0"
      unitRef="number">0.15</lly:DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes>
    <lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3Mzg_e6d73361-8847-4dae-a6d2-ab46a984e614">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;954.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2020 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-3 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3-5 Years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act Toll Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2,403.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$253.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$729.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,420.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTowZDY5ZmNhY2U4Y2Y0NzI0YmQ3ZWMxY2EwZGU5MWExNi90YWJsZXJhbmdlOjBkNjlmY2FjZThjZjQ3MjRiZDdlYzFjYTBkZTkxYTE2XzEtMS0xLTEtMA_a45ac57b-abfb-468f-9a6a-a9d3308fa6ba"
      unitRef="usd">954600000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTowZDY5ZmNhY2U4Y2Y0NzI0YmQ3ZWMxY2EwZGU5MWExNi90YWJsZXJhbmdlOjBkNjlmY2FjZThjZjQ3MjRiZDdlYzFjYTBkZTkxYTE2XzEtMy0xLTEtMA_6f758c65-c078-4fa1-ac45-6a30ab62df6a"
      unitRef="usd">1180500000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTowZDY5ZmNhY2U4Y2Y0NzI0YmQ3ZWMxY2EwZGU5MWExNi90YWJsZXJhbmdlOjBkNjlmY2FjZThjZjQ3MjRiZDdlYzFjYTBkZTkxYTE2XzEtNS0xLTEtMA_92e595ff-f49d-4723-b2e3-a7206e2222a1"
      unitRef="usd">1076700000</us-gaap:IncomeTaxesPaid>
    <lly:TaxCutAndJobsActTollTaxToBePaid
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo5MzRkYmVlZjhmYTM0N2ZjYWJhYmRlNDk1NmIyOGZlZC90YWJsZXJhbmdlOjkzNGRiZWVmOGZhMzQ3ZmNhYmFiZGU0OTU2YjI4ZmVkXzEtMS0xLTEtMTA5MTk_c0f5da3a-8de1-4755-8f9d-5d9be1f5479d"
      unitRef="usd">2403100000</lly:TaxCutAndJobsActTollTaxToBePaid>
    <lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo5MzRkYmVlZjhmYTM0N2ZjYWJhYmRlNDk1NmIyOGZlZC90YWJsZXJhbmdlOjkzNGRiZWVmOGZhMzQ3ZmNhYmFiZGU0OTU2YjI4ZmVkXzEtMi0xLTEtMTA5MzM_c6bec15c-5670-406b-ad3b-fed512c3d42a"
      unitRef="usd">253700000</lly:TaxCutAndJobsActTollTaxToBePaidWithinOneYear>
    <lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo5MzRkYmVlZjhmYTM0N2ZjYWJhYmRlNDk1NmIyOGZlZC90YWJsZXJhbmdlOjkzNGRiZWVmOGZhMzQ3ZmNhYmFiZGU0OTU2YjI4ZmVkXzEtMy0xLTEtMTA5NDc_558d05da-6c03-4569-b1ee-b7b6b86333a8"
      unitRef="usd">729300000</lly:TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears>
    <lly:TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo5MzRkYmVlZjhmYTM0N2ZjYWJhYmRlNDk1NmIyOGZlZC90YWJsZXJhbmdlOjkzNGRiZWVmOGZhMzQ3ZmNhYmFiZGU0OTU2YjI4ZmVkXzEtNC0xLTEtMTA5NTc_e22c5f95-ba10-4e9f-9e42-3a581d591b68"
      unitRef="usd">1420100000</lly:TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears>
    <lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzMyOTg1MzQ5MDU2NDY_c2599e13-2313-42d3-8cb2-859d1110ebcb"
      unitRef="usd">1690000000</lly:AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3NDU_af6928e4-ecdd-4939-b37c-01a9fbe6cd70">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at the U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,518.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add (deduct):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations, including Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(297.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(627.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(97.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Tax Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(150.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,036.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Non-deductible acquired IPR&amp;amp;D was related to the acquisitions of Disarm and a pre-clinical stage company in 2020 and ARMO in 2018. See Note 3 for additional information related to acquisitions.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzEtMS0xLTEtMA_c3cb1048-7d10-4e98-bc1b-07628fa8f9f0"
      unitRef="usd">1518300000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzEtMy0xLTEtMA_c9db6a40-5d18-4805-b8b3-9e0b8f71a9b4"
      unitRef="usd">1105800000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzEtNS0xLTEtMA_2cffd046-31bd-4604-b7f2-5ef1c14dea7b"
      unitRef="usd">772800000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzMtMS0xLTEtMA_bad71b33-4151-45ce-9c74-309d63aa05a5"
      unitRef="usd">297100000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzMtMy0xLTEtMA_edd779ef-0c63-42e9-8999-a4ac9a687ffa"
      unitRef="usd">242000000.0</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzMtNS0xLTEtMA_0462c09b-cec6-4a8d-ab23-a7afbcd69383"
      unitRef="usd">627100000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzQtMS0xLTEtMA_5366d337-8151-4e2b-a02d-dab0c5cf100b"
      unitRef="usd">97900000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzQtMy0xLTEtMA_9cb1454b-14b9-4ce8-b9aa-873bab038f99"
      unitRef="usd">108800000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzQtNS0xLTEtMA_a7787dc5-af8f-409f-9559-d691c023b360"
      unitRef="usd">87400000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzUtMS0xLTEtMA_891a3191-c51f-43ba-8cd2-510b50f88b2a"
      unitRef="usd">63200000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzUtMy0xLTEtMA_89db4ace-fb75-4cd6-9144-70bd6b0f51c0"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzUtNS0xLTEtMA_0b1a3005-6258-4866-bc6f-a6c0ccb74c3a"
      unitRef="usd">309900000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzYtMS0xLTEtMA_a57c5063-4f5c-4864-b010-34e88cf32854"
      unitRef="usd">0</lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount>
    <lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzYtMy0xLTEtMA_c687b40c-d8a3-4520-bb63-c711440b28db"
      unitRef="usd">0</lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount>
    <lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzYtNS0xLTEtMA_6bd3d653-27f2-422a-89df-c6d85082ead3"
      unitRef="usd">175300000</lly:EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzctMS0xLTEtMA_8130dcc0-abeb-4687-abeb-840d4ba686ef"
      unitRef="usd">-150300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzctMy0xLTEtMA_3e3a0d97-f848-474d-ae17-5cef17065374"
      unitRef="usd">-127000000.0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzctNS0xLTEtMA_bcb90a2f-8951-433f-b2b2-1624564d2514"
      unitRef="usd">-14000000.0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzgtMS0xLTEtMA_65dac00c-56ab-432b-9706-c991dbaf3c3a"
      unitRef="usd">1036200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzgtMy0xLTEtMA_57cb8a23-1fc3-4032-8b9e-4aa94bc73312"
      unitRef="usd">628000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpmMDExNzZlNDkyZTM0ZWYxOThkZDhmMThkZGU5OTU0ZS90YWJsZXJhbmdlOmYwMTE3NmU0OTJlMzRlZjE5OGRkOGYxOGRkZTk5NTRlXzgtNS0xLTEtMA_ee64d283-cc4b-41e2-8ce2-257b09721086"
      unitRef="usd">529500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY3NTE_47dcfe8b-9d84-4690-bcc2-2d6dac02b553">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,108.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;225.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;310.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(52.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(72.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses of statutes of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes related to the impact of foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,551.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:17pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzEtMS0xLTEtMA_58797d5b-db56-4d81-9eb8-5fda544d4530"
      unitRef="usd">2108600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzEtMy0xLTEtMA_352fb7f2-612d-40e9-b886-5bc518bfa6b5"
      unitRef="usd">2034600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzEtNS0xLTEtMA_19bd4632-578b-4d05-95e9-a2539d3e03c4"
      unitRef="usd">1000800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzItMS0xLTEtMA_7991d76d-509b-4a7e-99c5-32f54aad947d"
      unitRef="usd">225600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzItMy0xLTEtMA_6842e49a-201c-47b2-9a2a-6457363118d8"
      unitRef="usd">187200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzItNS0xLTEtMA_2527d613-ca8b-4813-9a2b-91911f79b331"
      unitRef="usd">798200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzMtMS0xLTEtMA_6a583e17-a0ac-472e-bf21-ed850e6e5050"
      unitRef="usd">310800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzMtMy0xLTEtMA_f140f907-cfad-44c8-a947-31940d406fba"
      unitRef="usd">425300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzMtNS0xLTEtMA_e39261ed-355c-4bc8-9152-d7c09a10be0f"
      unitRef="usd">410900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzQtMS0xLTEtMA_ceb7398c-1a17-4025-9f4d-05cae88505b8"
      unitRef="usd">52400000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzQtMy0xLTEtMA_64e6eaa5-caac-410a-b8d9-af387e396cad"
      unitRef="usd">100300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzQtNS0xLTEtMA_be704a64-5b12-472f-be45-b4e924c6837f"
      unitRef="usd">115400000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzUtMS0xLTEtMA_bc8ed7d1-3cad-4896-af00-9b855dc2cd75"
      unitRef="usd">72000000.0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzUtMy0xLTEtMA_7247488f-251d-4375-be5b-2e3ae534823d"
      unitRef="usd">260500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzUtNS0xLTEtMA_f5a0256e-000a-48b8-b5a6-89c9272c4858"
      unitRef="usd">33200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzYtMS0xLTEtMA_6feb2f83-50a7-46ca-baca-bbae2076f78b"
      unitRef="usd">41700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzYtMy0xLTEtMA_3cd0045b-b7fa-4079-b113-93c6b2ca3354"
      unitRef="usd">161500000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzYtNS0xLTEtMA_e13881cd-cc10-4b18-9ad3-9ee7c1009d2a"
      unitRef="usd">20500000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzctMS0xLTEtMA_9bb6db4e-faf0-4d8e-b106-1449bd515567"
      unitRef="usd">73000000.0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzctMy0xLTEtMA_efc61705-7f35-4b2c-96ab-bb58be2b96ae"
      unitRef="usd">16200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzctNS0xLTEtMA_1b620b23-c4aa-4ceb-8089-ca77f60e8f37"
      unitRef="usd">6200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzgtMS0xLTEtMA_596497fa-dc4d-40a3-a7bb-b6a8b9b47a43"
      unitRef="usd">2551900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzgtMy0xLTEtMA_2643ec00-f2e6-4c36-9f98-041da9adddea"
      unitRef="usd">2108600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3dc6994314b0437780a92cc7d6dc54bd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTo1Yjk2ZDhiNDQ0NjY0ZjI3OTcyNzA3NWU5MTBkNWNjYy90YWJsZXJhbmdlOjViOTZkOGI0NDQ2NjRmMjc5NzI3MDc1ZTkxMGQ1Y2NjXzgtNS0xLTEtMA_4f2ae33a-6f2f-492c-a55f-e4f71253013e"
      unitRef="usd">2034600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzU0MTI_65fd55b6-4d5c-46f7-b3ab-c7d652e43732"
      unitRef="usd">1670000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzU0MTk_29a2ef4d-21b8-4817-b314-6ec83982da6c"
      unitRef="usd">1530000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i8253b9821a464bffb6ab718d922a8b60_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzU5Mjk_2f258978-3c7e-4274-b884-b6f0d10aef52"
      unitRef="usd">200000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <lly:PaymentsForIncomeTaxSettlements
      contextRef="id11b4d29868245268d0dca888203dbf6_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzU5NzM_65d20049-bdbf-4c88-9430-1ccddfdaddb3"
      unitRef="usd">125000000</lly:PaymentsForIncomeTaxSettlements>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpkMWQ3ZTcxOWRlYTA0ZDMxOTdmNGQ3MzBlYmFmMDM5MC90YWJsZXJhbmdlOmQxZDdlNzE5ZGVhMDRkMzE5N2Y0ZDczMGViYWYwMzkwXzEtMS0xLTEtMA_0ce0f22a-67e9-41e7-86de-182a81b9ad5a"
      unitRef="usd">34000000.0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpkMWQ3ZTcxOWRlYTA0ZDMxOTdmNGQ3MzBlYmFmMDM5MC90YWJsZXJhbmdlOmQxZDdlNzE5ZGVhMDRkMzE5N2Y0ZDczMGViYWYwMzkwXzEtMy0xLTEtMA_8df454dc-6844-447c-85b8-d1d784c2f228"
      unitRef="usd">-26400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90YWJsZTpkMWQ3ZTcxOWRlYTA0ZDMxOTdmNGQ3MzBlYmFmMDM5MC90YWJsZXJhbmdlOmQxZDdlNzE5ZGVhMDRkMzE5N2Y0ZDczMGViYWYwMzkwXzEtNS0xLTEtMA_c5156c86-4800-4a99-a15e-3c22a7bcd6fb"
      unitRef="usd">25100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY2Nzk_0c7326f2-4516-4acc-a272-76e039ba1f73"
      unitRef="usd">196700000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzUvZnJhZzo3NjdmMjk2MWE4ZmU0ODY5OWI1ZWJjN2U2YTg1OGI0Mi90ZXh0cmVnaW9uOjc2N2YyOTYxYThmZTQ4Njk5YjVlYmM3ZTZhODU4YjQyXzY2ODY_42ca805f-5d37-49c7-a3ad-5bb319f832aa"
      unitRef="usd">150800000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjk2_103227a8-5842-4b16-a8be-4db81bde35f1">Retirement Benefits&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,251.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,427.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,601.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;325.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;425.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,563.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(587.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(584.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment (gain) loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;245.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,225.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,251.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,753.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,858.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,932.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,768.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,398.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,802.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;539.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;318.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(587.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(584.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,579.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,858.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,227.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,646.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,393.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,473.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,515.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,177.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(349.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(177.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,884.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,802.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;946.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in the consolidated balance sheet consisted&#160;of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;299.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,697.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(67.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,878.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,491.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(216.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive (income) loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,530.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(526.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,884.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,802.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;946.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized net actuarial loss (gain) and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective during the third quarter of 2020, we adopted a voluntary change in our method of applying an accounting principle for certain of our retirement benefit plans. The new accounting method changes the computation of expected returns on U.S. dollar denominated investment grade debt securities and derivatives in such plans from a calculated value that includes changes in the fair values over a period of five years to actual fair value. This change in accounting principle is preferable because changes in the fair value of this class of assets will be amortized into net periodic pension and retiree health cost sooner. No change is being made to the accounting principle for the other classes of pension assets. The impact of the adoption of this change in accounting method was not material to our historical and current consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decrease in the discount rate was the primary driver for the $2.13&#160;billion and $2.89&#160;billion increase in the benefit obligation in 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans&#x2019; benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of $28.0 million, which was recorded in asset impairment, restructuring, and other special charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents our weighted-average assumptions as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026-2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,800.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retiree health benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,770.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,039.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,824.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,483.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health &lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,682.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,063.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;223.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,824.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,483.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total accumulated benefit obligation for our defined benefit pension plans was $17.03 billion and $15.17&#160;billion at December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit expense included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic (benefit) cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;325.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;425.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(901.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(842.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(158.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;396.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(136.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019, and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined&#160;Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree&#160;Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss) arising during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(663.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,461.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;238.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendments during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;396.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss) during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(335.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,158.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;178.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $164.3 million, $145.2 million, and $132.6 million for the years ended December&#160;31, 2020, 2019, and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2020, 2019, and 2018 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Benefit Plan Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 80 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 65 percent growth investments and 35 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets include cash and cash equivalents and mark-to-market value of derivatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,301.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2020. The activity in the Level 3 investments during the year ended December&#160;31, 2020 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2019 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,439.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,226.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,858.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,499.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2019. The activity in the Level 3 investments during the year ended December 31, 2019 was not material.&lt;/span&gt;&lt;/div&gt;In 2021, we expect to contribute approximately $40 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We expect to contribute approximately $10 million in additional discretionary contributions in 2021</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjg4_23a6d1a3-a567-45bd-badd-b32c1b79121a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in benefit obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,251.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,427.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,601.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;325.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;425.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,563.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(587.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(584.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment (gain) loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;245.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit obligation at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,225.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,251.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,753.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzMtMS0xLTEtMA_f8a0f044-7b49-4faf-9724-2250f73a5368"
      unitRef="usd">16251000000.0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ic62914e39c2446a7965d109d4b06fac3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzMtMy0xLTEtMA_50120889-9fcc-45e0-aa8c-79df6e3efaae"
      unitRef="usd">13427100000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzMtNS0xLTEtMA_2d464c44-9dcf-490e-b82a-3183294e07e0"
      unitRef="usd">1601400000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i860ee37306f64cf8a0c232ead17d7745_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzMtNy0xLTEtMA_900c65bb-3b01-43da-b637-c80d222f53ec"
      unitRef="usd">1540000000.0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzQtMS0xLTEtMA_9e04cdb9-a883-4fee-95cc-290a948a98ed"
      unitRef="usd">325500000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzQtMy0xLTEtMA_04a84695-dd91-4f2d-9c4e-05fe76118886"
      unitRef="usd">250400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzQtNS0xLTEtMA_990076b1-fe3c-4b37-a446-f6bb79a1826f"
      unitRef="usd">40800000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzQtNy0xLTEtMA_112dbfa9-6afe-4297-b242-667ee6f38f81"
      unitRef="usd">36300000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzUtMS0xLTEtMA_d41d4a43-5def-4fa1-a71f-6a26687653bd"
      unitRef="usd">425800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzUtMy0xLTEtMA_333501d9-5ae9-4f10-b64b-5b840c3f3d42"
      unitRef="usd">486000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzUtNS0xLTEtMA_5a07b1f4-78cd-4a3a-988d-8ecd47f195ed"
      unitRef="usd">43700000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzUtNy0xLTEtMA_e6ba1c02-a352-4f93-8f68-aa7f4a06a2ee"
      unitRef="usd">58000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzYtMS0xLTEtMA_c8cab360-769b-4327-adca-85cfd9f86c18"
      unitRef="usd">-1563100000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzYtMy0xLTEtMA_d6ce586c-d79d-4fd6-ae14-a3be6367a664"
      unitRef="usd">-2631700000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzYtNS0xLTEtMA_12645586-f60d-4fe9-8472-7f123cc7a56b"
      unitRef="usd">-142100000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzYtNy0xLTEtMA_f1d92298-3453-4651-add1-8fd9c8d774ec"
      unitRef="usd">-54300000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzctMS0xLTEtMA_5e058f91-cb44-43b3-bcd6-cc7c7aa1d29a"
      unitRef="usd">587200000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzctMy0xLTEtMA_3f6f7fe1-db86-4245-b42e-119d931876e8"
      unitRef="usd">584200000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzctNS0xLTEtMA_c4c54a19-3c7c-47ab-bb79-90d9f0b2fe51"
      unitRef="usd">75100000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzctNy0xLTEtMA_13cdac6b-0add-4934-8ece-97422d463c70"
      unitRef="usd">87300000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzktMS0xLTEtMA_cbab85cb-73c2-48af-97f0-7af6a08ffa54"
      unitRef="usd">2200000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzktMy0xLTEtMA_9c1f85cd-1852-441b-9125-41e8ce9bbf44"
      unitRef="usd">-16800000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzktNS0xLTEtMA_92d66a9c-7d24-40b0-86e6-bf66cbf90d02"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzktNy0xLTEtMA_5b9e5d3e-2946-43aa-bf55-9419cb10062e"
      unitRef="usd">-500000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzEwLTEtMS0xLTA_e3e018b5-1b62-477e-97fc-b33157f8d795"
      unitRef="usd">245100000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzEwLTMtMS0xLTA_f5520d6e-22b7-4fc2-9ec9-5c92b0fb8c2b"
      unitRef="usd">56800000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzEwLTUtMS0xLTA_16b9679c-0155-4cd1-b5a7-3050be3dd5e9"
      unitRef="usd">800000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzEwLTctMS0xLTA_4310c182-7037-4ece-ba42-ad0bf26e90e7"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzExLTEtMS0xLTA_61c84afc-ad4d-4063-b512-70737dbac5b4"
      unitRef="usd">18225500000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzExLTMtMS0xLTA_a003ecc6-6c9c-4849-87fc-cf0f82463f43"
      unitRef="usd">16251000000.0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzExLTUtMS0xLTA_3b4767ca-37c5-4080-99ae-ebb64bb822ed"
      unitRef="usd">1753700000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZToyY2ZmODk4MWU2ZjM0NjlhOWZmYmQ1MDc5NzkxODA1Yy90YWJsZXJhbmdlOjJjZmY4OTgxZTZmMzQ2OWE5ZmZiZDUwNzk3OTE4MDVjXzExLTctMS0xLTA_7bf82c53-f00d-4a77-8acc-8618edb114a6"
      unitRef="usd">1601400000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjk0_5dd3df4e-29f9-4c18-9beb-7f8f53c76b8a">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,858.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,932.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,768.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,398.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,802.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;539.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employer contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;318.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(587.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(584.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,579.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,858.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,227.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzEtMS0xLTEtMA_b172a5a6-526a-4193-8c92-85e6820e4e06"
      unitRef="usd">12858000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic62914e39c2446a7965d109d4b06fac3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzEtMy0xLTEtMA_5068ae42-d8d0-4451-a2c3-29e42aeb46f4"
      unitRef="usd">10932600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzEtNS0xLTEtMA_8642be6e-2bd1-4b9d-87d1-02bea6599903"
      unitRef="usd">2768200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i860ee37306f64cf8a0c232ead17d7745_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzEtNy0xLTEtMA_ec9bf1fe-87bd-4d92-8022-371f94c0b8b0"
      unitRef="usd">2398100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzItMS0xLTEtMA_875359b6-6877-4c2c-8fb2-d492f8edcacd"
      unitRef="usd">1802400000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzItMy0xLTEtMA_66c245fe-cb64-42c6-8895-b57738ff165d"
      unitRef="usd">2012000000.0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzItNS0xLTEtMA_0c979bc3-ea08-4805-ab71-115baca63581"
      unitRef="usd">539000000.0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzItNy0xLTEtMA_286adeed-d3c4-4783-be5a-f571fa682af9"
      unitRef="usd">444100000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzMtMS0xLTEtMA_e3abd34f-fca8-4316-b5df-32d031419452"
      unitRef="usd">318800000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzMtMy0xLTEtMA_af76b5ac-16ec-4375-8fca-40a7a7cda10d"
      unitRef="usd">429900000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzMtNS0xLTEtMA_1695d20e-c012-4e55-b272-e93e1dbfa211"
      unitRef="usd">-5100000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzMtNy0xLTEtMA_663f5594-bb10-429e-b5c9-32f23ade4ed9"
      unitRef="usd">13200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzQtMS0xLTEtMA_0486d4cf-4ce6-4de8-9d21-389a3d9ca7d0"
      unitRef="usd">587200000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzQtMy0xLTEtMA_a43a80a7-3ce3-4cb2-a418-e18076ee8d27"
      unitRef="usd">584200000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzQtNS0xLTEtMA_a23b6778-e0cd-43ec-9c11-c56d691e87d6"
      unitRef="usd">75100000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzQtNy0xLTEtMA_9a4a3100-926c-4e7a-be85-3aaa590d74d5"
      unitRef="usd">87300000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzUtMS0xLTEtMA_76e105ea-97c9-4cd8-ade5-b6969e10946b"
      unitRef="usd">187000000.0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzUtMy0xLTEtMA_5f1d5788-2f9e-46cf-b295-39d8757dd63c"
      unitRef="usd">67700000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzUtNS0xLTEtMA_71f79d7b-f1ad-4221-a011-6656f54601e8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzUtNy0xLTEtMA_729fde96-f857-4c48-8599-589f7fa7ec2e"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzYtMS0xLTEtMA_4f6d7847-9f98-4d6c-b9bb-06e4ed01b606"
      unitRef="usd">14579000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzYtMy0xLTEtMA_adb4d4ef-77dc-41a6-94ea-2202ddac12a9"
      unitRef="usd">12858000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzYtNS0xLTEtMA_f680c220-8129-42f3-9f73-3e7e398c1bf6"
      unitRef="usd">3227000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTpiZmYxNWI0MjA1ZWU0NmQ4ODFlYTJlNjQ4NDU4Zjc1OC90YWJsZXJhbmdlOmJmZjE1YjQyMDVlZTQ2ZDg4MWVhMmU2NDg0NThmNzU4XzYtNy0xLTEtMA_4a5309ff-2a54-4cb1-b0ca-2e4999e4d207"
      unitRef="usd">2768200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfNetFundedStatusTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjg1_6a99589d-1565-4735-b8e5-b141385cc391">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,646.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,393.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,473.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,515.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,177.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(349.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(177.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,884.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,802.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;946.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetFundedStatusTableTextBlock>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzAtMS0xLTEtMA_0783ca27-1e38-4f12-b8a1-7614886b98f2"
      unitRef="usd">-3646500000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzAtMy0xLTEtMA_3ff90730-0c06-4e28-8f2f-c29b3a3eb114"
      unitRef="usd">-3393000000.0</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzAtNS0xLTEtMA_8cf34c0a-f951-425c-8951-4b6fdb29c96d"
      unitRef="usd">1473300000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzAtNy0xLTEtMA_26a303e4-fe25-45aa-bc6e-c72f2d1543ec"
      unitRef="usd">1166800000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzEtMS0xLTEtMA_a633b061-4449-4a9f-a9a0-5cdb5cd2b068"
      unitRef="usd">-6515500000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzEtMy0xLTEtMA_81870b47-cc82-4071-9655-320e6573ae49"
      unitRef="usd">-6177600000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzEtNS0xLTEtMA_16c95543-99f4-405f-b32d-0ca759a1cd97"
      unitRef="usd">349100000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzEtNy0xLTEtMA_ee5f1299-3734-4cb7-8adb-e6b0602fcb48"
      unitRef="usd">111600000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzItMS0xLTEtMA_d39ee622-9159-4cb4-97d3-7e259bd4301c"
      unitRef="usd">15400000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzItMy0xLTEtMA_164b2a3d-f517-45df-bc66-c63e01cf3cbd"
      unitRef="usd">17400000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzItNS0xLTEtMA_de8d6779-f65c-4e08-8219-4350907058df"
      unitRef="usd">-177600000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzItNy0xLTEtMA_aec75df9-4249-42df-8356-6529bcbdc3a0"
      unitRef="usd">-236400000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzMtMS0xLTEtMA_59abed98-dc64-4630-928b-241bae44dfb7"
      unitRef="usd">2884400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzMtMy0xLTEtMA_f2dccf3e-a827-4b70-bbdb-7aaf7d02981c"
      unitRef="usd">2802000000.0</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzMtNS0xLTEtMA_fa0a9a10-6950-4248-a3f4-1d7ed71a8198"
      unitRef="usd">946600000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODhkMGZjNWM0MzM0M2NjYmI3NjVhM2IxNDRlZjY4NS90YWJsZXJhbmdlOjM4OGQwZmM1YzQzMzQzY2NiYjc2NWEzYjE0NGVmNjg1XzMtNy0xLTEtMA_7502d146-23ef-499a-834b-917f97ad24ad"
      unitRef="usd">818800000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzEx_fafa8aca-922a-4ba2-a5ec-41a4cbac4197">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in the consolidated balance sheet consisted&#160;of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;299.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,697.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,381.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(67.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,878.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,491.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(216.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive (income) loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,530.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(526.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,884.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,802.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;946.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzEtMS0xLTEtMA_8de1ab04-2ab1-47be-951f-84b419ef9947"
      unitRef="usd">299600000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzEtMy0xLTEtMA_67cfce7f-3e08-430a-9512-726840da3a04"
      unitRef="usd">163300000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzEtNS0xLTEtMA_cff18630-856b-4090-889b-9cf949ec73d9"
      unitRef="usd">1697000000.0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzEtNy0xLTEtMA_419f2f8f-5001-4f0d-8f07-d61e594db71b"
      unitRef="usd">1381300000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzItMS0xLTEtMA_d21d1efe-8fec-4a33-b3e8-54101dcd2cc1"
      unitRef="usd">67900000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzItMy0xLTEtMA_a8db8da3-caa0-4eba-8c50-9dc044c38d73"
      unitRef="usd">65300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzItNS0xLTEtMA_6cf9b457-3c38-4997-baf2-508130ad3ba2"
      unitRef="usd">7400000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzItNy0xLTEtMA_99859d12-876d-410e-a51e-6431dfbc87c7"
      unitRef="usd">7300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzMtMS0xLTEtMA_c83a92fe-5dda-49cb-a655-209d75dcbd64"
      unitRef="usd">3878200000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzMtMy0xLTEtMA_bbf0ade3-3d3a-45a9-8fdf-33516f697faf"
      unitRef="usd">3491000000.0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzMtNS0xLTEtMA_cfdd01da-ac5b-430c-bf27-774be5276d52"
      unitRef="usd">216300000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzMtNy0xLTEtMA_65b37c93-148e-486b-9e2d-8f12dac6b5f3"
      unitRef="usd">207200000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzQtMS0xLTEtMA_4118c8b1-b0a5-482d-89da-0859c52d6952"
      unitRef="usd">6530900000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzQtMy0xLTEtMA_f8dcf8b5-ad28-4741-8034-686dd2b71106"
      unitRef="usd">6195000000.0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzQtNS0xLTEtMA_03c99d36-bda7-45df-8efb-353cece832d7"
      unitRef="usd">-526700000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzQtNy0xLTEtMA_6ce97072-2e31-4d67-bbb1-18e04c9d0a70"
      unitRef="usd">-348000000.0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzUtMS0xLTEtMA_5454b63a-5e50-47ce-b8ad-95c91221a69e"
      unitRef="usd">2884400000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzUtMy0xLTEtMA_5a3f5d26-f2c4-4d1b-b8f6-0e2677cec7c0"
      unitRef="usd">2802000000.0</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzUtNS0xLTEtMA_1697502d-71d0-4a75-b44a-920ee54e1aee"
      unitRef="usd">946600000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTplNDYyYWZkNmM4YTQ0ZTFhOGJlYmMzYjdjYWMwYmZhZC90YWJsZXJhbmdlOmU0NjJhZmQ2YzhhNDRlMWE4YmViYzNiN2NhYzBiZmFkXzUtNy0xLTEtMA_8ddaf622-5e19-4f66-b2a9-dfd1729aa2ed"
      unitRef="usd">818800000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzMyOTg1MzQ5MDAzMzQ_dd653426-9065-41d8-a9cd-e84f0c43f647"
      unitRef="usd">2130000000</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzMyOTg1MzQ5MDAzMTk_9013f84a-9045-49f7-b269-3d9044be9c5a"
      unitRef="usd">2890000000</us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="if5917c0f9aaa488a8f07e138effe57cd_D20180701-20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzExMDQ_bf006258-b40d-4bde-96da-a8b12c7b3ef5"
      unitRef="usd">28000000.0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzEy_69bd6d51-3c0d-4a20-8e4e-700e03442763">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents our weighted-average assumptions as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Percents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets for net benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItMS0xLTEtMA_86931da1-8d6c-4dbb-9e8e-eefc8bec8299"
      unitRef="number">0.024</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItMy0xLTEtMA_1627e6f0-844e-4c13-ab28-6f01a2738efc"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ic62914e39c2446a7965d109d4b06fac3_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItNS0xLTEtMA_33777f56-1b0a-4218-8a2f-822ec3b17928"
      unitRef="number">0.040</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItNy0xLTEtMA_cb89034e-5c7a-4f61-9e44-8043ebaf7eaf"
      unitRef="number">0.026</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItOS0xLTEtMA_3de6af21-03c8-4366-b98f-67b78009adcd"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i860ee37306f64cf8a0c232ead17d7745_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzItMTEtMS0xLTA_a213aabb-576d-4504-844b-caa4f99ad15b"
      unitRef="number">0.044</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtMS0xLTEtMA_ee025de1-998d-49f2-a769-1c228c7b1111"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtMy0xLTEtMA_6452e642-cbfd-4757-9225-69b9458704e6"
      unitRef="number">0.040</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtNS0xLTEtMA_2ff5f720-c5c9-4ae6-a0d4-2ace1a3fdef0"
      unitRef="number">0.034</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtNy0xLTEtMA_1dc57971-05d8-4ccc-9ef5-2a33f9b59bc7"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtOS0xLTEtMA_03620a88-17ab-4504-a71b-9f5a5d1eff8c"
      unitRef="number">0.044</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzMtMTEtMS0xLTA_e9719a79-e53c-4434-a55a-c32bf2fcd362"
      unitRef="number">0.037</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzQtMS0xLTEtMA_8caec55e-5887-4b83-9f45-fb816ff1fce9"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzQtMy0xLTEtMA_6eb5160d-254a-460c-bba5-ece06d2ecf03"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ic62914e39c2446a7965d109d4b06fac3_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzQtNS0xLTEtMA_50760854-141f-404b-b153-a464aaebf52c"
      unitRef="number">0.034</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzUtMS0xLTEtMA_04436c59-2214-4736-a1ab-9cbce5024aaf"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzUtMy0xLTEtMA_f338a452-e359-4f78-9c6e-47403231c7d0"
      unitRef="number">0.034</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzUtNS0xLTEtMA_68ef9fd9-c73e-418b-80f6-f3fc502c0a0d"
      unitRef="number">0.034</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtMS0xLTEtMA_88bfe5e3-3912-4ea9-b37c-94a0933b5585"
      unitRef="number">0.073</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtMy0xLTEtMA_286c4392-a95d-4e20-8cc9-4a0295b06dae"
      unitRef="number">0.074</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtNS0xLTEtMA_4a099ae3-45a7-4e42-b687-fc41343802b6"
      unitRef="number">0.074</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtNy0xLTEtMA_0aecb511-87ba-4efd-9905-77b77b45855d"
      unitRef="number">0.060</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtOS0xLTEtMA_ba313f40-b5d0-48ee-85ac-b8693e5d0abc"
      unitRef="number">0.060</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo4ODNlZjQ1M2NmMTU0MzdkYTA5MzgwMWI4NTgwYTM5My90YWJsZXJhbmdlOjg4M2VmNDUzY2YxNTQzN2RhMDkzODAxYjg1ODBhMzkzXzYtMTEtMS0xLTA_fcf5e794-d76d-4d2e-86c3-498b4f5262e1"
      unitRef="number">0.080</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzE1_949498dd-e6d2-421e-b956-1e29c37ec223">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026-2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,800.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retiree health benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtMS0xLTEtMA_20385bb3-9163-4a7d-970a-7610ad9ed9c1"
      unitRef="usd">639200000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtMy0xLTEtMA_92839faf-6ea2-4c3d-be2d-c175d1b6d3f1"
      unitRef="usd">635300000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtNS0xLTEtMA_cd661f44-81c5-405a-aa1d-ae43b689835c"
      unitRef="usd">645800000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtNy0xLTEtMA_ea215675-cc47-4e91-9e9f-4e409cf41d9e"
      unitRef="usd">673100000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtOS0xLTEtMA_384271b3-779a-4d76-a9ee-cc04042db82e"
      unitRef="usd">689600000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzEtMTEtMS0xLTA_260da76b-f36b-4c6e-8480-58e1aeb0b47d"
      unitRef="usd">3800800000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItMS0xLTEtMA_fbe9a845-270f-49c8-ba6e-88700468ffe7"
      unitRef="usd">91200000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItMy0xLTEtMA_713d7edb-b73c-4c14-b3a3-bb629dd892fe"
      unitRef="usd">91200000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItNS0xLTEtMA_46ab9469-2f62-4525-91de-4ba9256df9ff"
      unitRef="usd">91200000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItNy0xLTEtMA_f77f1e3a-bc14-42ee-93c0-8c2fc263ff1a"
      unitRef="usd">94900000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItOS0xLTEtMA_08f9c169-dd37-40f9-a4b5-782d915766a5"
      unitRef="usd">95700000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozNWU3ZTI5M2M2Zjg0Mzg3YmIzZDVjMjJlNDdlMmFhNS90YWJsZXJhbmdlOjM1ZTdlMjkzYzZmODQzODdiYjNkNWMyMmU0N2UyYWE1XzItMTEtMS0xLTA_52daeee3-a73f-4c9b-bbb3-d9ad91a064b9"
      unitRef="usd">481800000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjI3_c5a19095-0dfd-4f09-a50f-0559bbb6dde5">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,770.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,039.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,824.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,483.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODk2YjExNWRhYTE0MjYyOWM4YzJjOTVjNDhiYWQ3OS90YWJsZXJhbmdlOjM4OTZiMTE1ZGFhMTQyNjI5YzhjMmM5NWM0OGJhZDc5XzEtMS0xLTEtMA_3688c5a9-47dc-4c26-a383-61bff4d53c06"
      unitRef="usd">15770700000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODk2YjExNWRhYTE0MjYyOWM4YzJjOTVjNDhiYWQ3OS90YWJsZXJhbmdlOjM4OTZiMTE1ZGFhMTQyNjI5YzhjMmM5NWM0OGJhZDc5XzEtMy0xLTEtMA_bb7550da-ec44-45b9-a211-e66e499ddd0c"
      unitRef="usd">14039700000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODk2YjExNWRhYTE0MjYyOWM4YzJjOTVjNDhiYWQ3OS90YWJsZXJhbmdlOjM4OTZiMTE1ZGFhMTQyNjI5YzhjMmM5NWM0OGJhZDc5XzItMS0xLTEtMA_db9a83f1-769f-472b-9970-846a2af150d2"
      unitRef="usd">11824400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i70e7e33eb088468895e308da89cb151e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozODk2YjExNWRhYTE0MjYyOWM4YzJjOTVjNDhiYWQ3OS90YWJsZXJhbmdlOjM4OTZiMTE1ZGFhMTQyNjI5YzhjMmM5NWM0OGJhZDc5XzItMy0xLTEtMA_9e1c40ee-abeb-4ef9-86e4-e49c491ad0f7"
      unitRef="usd">10483400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjg0_2aabed7b-df45-469b-a940-272160fefd84">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health &lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,682.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,063.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;223.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,824.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,483.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzItMS0xLTEtMA_0a3c5dae-d2b6-4bfe-8886-94f985d56d70"
      unitRef="usd">14682300000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzItMy0xLTEtMA_7508b166-a386-495f-a8d0-710f78897b75"
      unitRef="usd">13063700000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzItNS0xLTEtMA_0204d0ce-1031-4e02-8dc7-0e05303348d3"
      unitRef="usd">223800000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzItNy0xLTEtMA_caac2c2c-f71e-40ee-aaaf-f2bead27a503"
      unitRef="usd">214400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzMtMS0xLTEtMA_ae6aa316-c8e5-49f7-9438-c864bf09ef2b"
      unitRef="usd">11824400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzMtMy0xLTEtMA_695f40b5-8dc0-4bc9-9dbb-c40a5b967c6b"
      unitRef="usd">10483400000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzMtNS0xLTEtMA_4ee8e7ce-66f0-457a-96bd-e6d4f8256024"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1ZWY5ZTIyNjA3Mzc0NWZhOGM4NzVlNzFiOGEwMjAzOC90YWJsZXJhbmdlOjVlZjllMjI2MDczNzQ1ZmE4Yzg3NWU3MWI4YTAyMDM4XzMtNy0xLTEtMA_74c1f56b-0754-4aa5-b365-b1a015fd2ae8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzMyNDM_2a1d69a1-0f13-4a0c-b743-96b63354f9e6"
      unitRef="usd">17030000000.00</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzMyNTA_7bfc66fc-5032-4797-8a83-5895a54e3303"
      unitRef="usd">15170000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzQy_3a639348-d585-4ec6-99d2-82ad0d523882">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit expense included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic (benefit) cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;325.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;425.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(901.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(842.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(158.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss (gain)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;396.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(136.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtMS0xLTEtMA_e8c1e252-71d1-4c59-9d0b-937a7c087012"
      unitRef="usd">325500000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtMy0xLTEtMA_0f9562ce-a408-407d-9e82-34023aedb697"
      unitRef="usd">250400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtNS0xLTEtMA_c80ed05b-65df-4a1b-b07d-a09f238cddc0"
      unitRef="usd">292700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtNy0xLTEtMA_6eb8f6b2-eef3-4bbf-b705-0f0e82562733"
      unitRef="usd">40800000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtOS0xLTEtMA_56e627d0-b271-46fc-9fbb-53d2e35e5a55"
      unitRef="usd">36300000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzMtMTEtMS0xLTA_0e2e9bbf-653d-4281-b10b-c5d94f332736"
      unitRef="usd">41500000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtMS0xLTEtMA_ba8190bf-8685-40fb-9044-270fcfd60e11"
      unitRef="usd">425800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtMy0xLTEtMA_ac1ec527-434f-416f-b8e0-f98922985b2d"
      unitRef="usd">486000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtNS0xLTEtMA_630635c9-37df-495e-a706-edf198950735"
      unitRef="usd">458500000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtNy0xLTEtMA_7b7429f5-f179-4373-8bd7-289835c0c271"
      unitRef="usd">43700000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtOS0xLTEtMA_6cf185b8-6bdf-4c66-86fc-ad7ce70287e7"
      unitRef="usd">58000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzQtMTEtMS0xLTA_b8fd7f76-2753-414c-9040-3e467044792e"
      unitRef="usd">57300000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtMS0xLTEtMA_0da07c9a-6dbf-45c6-98dd-d953d750029b"
      unitRef="usd">901500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtMy0xLTEtMA_e51db595-b3e6-40cc-b303-44472973d3b8"
      unitRef="usd">839600000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtNS0xLTEtMA_c23e7e30-e48c-440a-93d5-7e786492cea8"
      unitRef="usd">842100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtNy0xLTEtMA_91c0ae50-b1c9-4615-8354-6359b3ebf3b5"
      unitRef="usd">158100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtOS0xLTEtMA_14e4489c-0528-4a50-a696-fd43a4baae89"
      unitRef="usd">144300000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzUtMTEtMS0xLTA_134b6b14-7012-4fe4-8c3d-9b63283f4f03"
      unitRef="usd">177900000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtMS0xLTEtMA_42b884df-eb39-45a9-9fb9-f06cfb0c3b12"
      unitRef="usd">4500000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtMy0xLTEtMA_d79d3bac-1605-41a9-9a07-3894fe47bd83"
      unitRef="usd">6100000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtNS0xLTEtMA_d841d8f4-9e06-4a1d-91bc-2a0c989907fc"
      unitRef="usd">4600000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtNy0xLTEtMA_c6e6a2b2-586a-4131-89c2-dbe6fcc2b647"
      unitRef="usd">-59500000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtOS0xLTEtMA_33a8a948-cb69-4418-802b-a5a2566da103"
      unitRef="usd">-62900000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzYtMTEtMS0xLTA_2af0e01e-451f-4385-852e-00fa57d69677"
      unitRef="usd">-79500000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctMS0xLTEtMA_df986b47-fce0-4fd9-a515-9493edce843e"
      unitRef="usd">-396300000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctMy0xLTEtMA_0286f4c0-f5ee-4d8f-84b4-6c45693ab13b"
      unitRef="usd">-284900000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctNS0xLTEtMA_dece6ef5-75b7-4d7b-927a-6e3cc2daf4cd"
      unitRef="usd">-332500000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctNy0xLTEtMA_35d6b7fc-2c98-4505-91a0-bc1021847622"
      unitRef="usd">3000000.0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctOS0xLTEtMA_f5de0868-fa6b-4387-80ab-ee0c86a17305"
      unitRef="usd">-1900000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzctMTEtMS0xLTA_7701421a-8330-4394-98f6-a8fb452d4c50"
      unitRef="usd">-6100000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtMS0xLTEtMA_f237bb54-2ac9-42dc-bb62-09391df34a8e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtMy0xLTEtMA_c37fdd66-5f05-407e-a788-b93cd06d8344"
      unitRef="usd">-2200000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtNS0xLTEtMA_83047f61-e69d-4f7f-ada5-b1b8c3fa9f05"
      unitRef="usd">-1300000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtNy0xLTEtMA_1c77832d-1e51-48fe-88af-845ed34bb200"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtOS0xLTEtMA_fc74bb6d-a4ce-49da-b52a-c82664e78267"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzgtMTEtMS0xLTA_6abb02f4-2be3-4ed7-aed1-688e314c5be4"
      unitRef="usd">29300000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTEtMS0xLTA_db12f3ac-3a19-4503-8cc5-4afeb6835365"
      unitRef="usd">250600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTMtMS0xLTA_d4962a9b-e72f-4948-af53-cc95fdbc0589"
      unitRef="usd">190000000.0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTUtMS0xLTA_d13604b5-ae5b-4d1f-abc5-96b82c8c9e9d"
      unitRef="usd">247500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTctMS0xLTA_4258bd22-f799-4a9b-a201-abf28f82be12"
      unitRef="usd">-136100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTktMS0xLTA_f4299a8a-8631-4e03-9287-dd7f9b548827"
      unitRef="usd">-111000000.0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0OGI4MDc3YTI2ZTU0OWVmODA5MDQ3ZjMxZjBiZjI1YS90YWJsZXJhbmdlOjQ4YjgwNzdhMjZlNTQ5ZWY4MDkwNDdmMzFmMGJmMjVhXzExLTExLTEtMS0w_15342f44-5d0b-4512-bea5-6ebfbaa081f6"
      unitRef="usd">-181800000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMzI3_767e4b33-87b4-480f-a33a-98a4ed1dbe4c">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019, and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined&#160;Benefit&lt;br/&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree&#160;Health&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gain (loss) arising during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(663.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,461.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;238.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan amendments during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailment gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (benefit) cost included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(59.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;396.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange rate changes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income (loss) during period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(335.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,158.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;178.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItMS0xLTEtMA_864c9679-f975-4fd4-8558-41007c55dabf"
      unitRef="usd">-663000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItMy0xLTEtMA_2fd18acd-dfa1-4a2d-857e-1886cfdb0c48"
      unitRef="usd">-1461000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItNS0xLTEtMA_637750a6-6cc3-4875-bfcd-86ef2a73b132"
      unitRef="usd">182800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItNy0xLTEtMA_73d4bd55-5fb2-4580-88b5-ab5d78e3ea9b"
      unitRef="usd">238800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItOS0xLTEtMA_16e8304e-67b3-4153-8240-caeed5209ef2"
      unitRef="usd">246100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzItMTEtMS0xLTA_65647110-f3f0-40b2-a10a-b870b93c82cd"
      unitRef="usd">37500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtMS0xLTEtMA_bcfe660b-ed59-474f-b081-b96c6c09cfa3"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtMy0xLTEtMA_db7d7466-dc90-49e1-b82a-fd1d84bb8c5b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtNS0xLTEtMA_f42adb1d-3fc9-4462-8def-a2104d69cd05"
      unitRef="usd">17600000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtNy0xLTEtMA_eb00e72e-aece-416d-8dbe-96c7c6fba800"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtOS0xLTEtMA_589b689d-3873-4fa2-8d1a-3bca68dc0356"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzMtMTEtMS0xLTA_5324ecc5-e67d-4f5b-8c15-a551c9a5e879"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtMS0xLTEtMA_2330e828-e69c-4b08-acd3-12c843966d47"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtMy0xLTEtMA_e3866293-6915-4319-90f7-492e1e88edde"
      unitRef="usd">19000000.0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtNS0xLTEtMA_01c4ce2d-2ee4-4753-879c-1b60d9a59577"
      unitRef="usd">45200000</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtNy0xLTEtMA_5cc67c9b-cd66-4919-b208-b9c5f312089a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtOS0xLTEtMA_d76dcb20-72d9-4dd2-a63d-ae83b5388fa2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzQtMTEtMS0xLTA_3c84b4e5-6933-4f87-ba55-ef360e65454e"
      unitRef="usd">-31800000</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtMS0xLTEtMA_aef36751-9ad5-4749-9116-02ce9e3e85d5"
      unitRef="usd">4500000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtMy0xLTEtMA_ff2bf147-900a-4188-bd9f-ec3665ce191e"
      unitRef="usd">6100000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtNS0xLTEtMA_f7a0fe7f-34e4-44c0-87f6-82bd43a05bff"
      unitRef="usd">4600000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtNy0xLTEtMA_e176b2f6-3d6d-4e11-85de-c24fc6cc04ae"
      unitRef="usd">-59500000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtOS0xLTEtMA_a6a653e6-ee49-4c79-a427-690a0ed37f64"
      unitRef="usd">-62900000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzUtMTEtMS0xLTA_3197ed15-a32d-40bf-8af3-ef80a35008b7"
      unitRef="usd">-79500000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtMS0xLTEtMA_089b233f-8b0b-4005-9a14-7df597a7db69"
      unitRef="usd">396300000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtMy0xLTEtMA_0900035e-a64f-4c07-8c8f-348660adbb2b"
      unitRef="usd">284900000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtNS0xLTEtMA_c8f977ec-fd50-47a8-b7ac-b87a3be1b7e1"
      unitRef="usd">332500000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtNy0xLTEtMA_5c5f8077-6b82-408c-9483-fe81730834a9"
      unitRef="usd">-3000000.0</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtOS0xLTEtMA_e13b98c8-10ca-4f87-83e0-c11ae4fe7a3a"
      unitRef="usd">1900000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzYtMTEtMS0xLTA_e1d171f6-9f84-49c1-b0ad-b653af4792cc"
      unitRef="usd">6100000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctMS0xLTEtMA_d89edfa6-e96d-4d10-9735-8212f7fc9e48"
      unitRef="usd">-71500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctMy0xLTEtMA_4747c10a-c2ad-40eb-b78d-69f8c2d198aa"
      unitRef="usd">-7700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctNS0xLTEtMA_91621666-3c1c-43e6-95c3-2ad191af50d6"
      unitRef="usd">47100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctNy0xLTEtMA_c16f58fa-6409-444f-a315-9fb30264ffb9"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctOS0xLTEtMA_b44323b7-b6fb-47f0-9546-02adddfc85a1"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzctMTEtMS0xLTA_d57821fc-6def-409a-91b9-bdeb17389aad"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtMS0xLTEtMA_28613181-4c90-4994-9590-cf7de3eaabb2"
      unitRef="usd">335900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="ic93756a9e2cd4074a4dc2fe08bc02c53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtMy0xLTEtMA_94221461-d2ab-4f29-963a-be7bd6707dc8"
      unitRef="usd">1158700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i5eae133aab0444b8a30188f98e3364ee_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtNS0xLTEtMA_5f1f1a50-3626-45c3-bc01-99dbf31ac3bc"
      unitRef="usd">-594600000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i3b426ffab01b46d6894d577b50e77204_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtNy0xLTEtMA_3c7c81fb-c888-4021-9a1e-a86915fe2c78"
      unitRef="usd">-178700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i282c187e98f34411aebeac5d5a2d3ce1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtOS0xLTEtMA_fa0a9620-0199-46ab-8b92-5f720ebcd9d0"
      unitRef="usd">-188700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i30df5df40e40410b8a471fb90e63b5e2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTozZmJiMTA3NTQxMjM0NTYyYTE1YTQ1NzE4M2NmZDgzOS90YWJsZXJhbmdlOjNmYmIxMDc1NDEyMzQ1NjJhMTVhNDU3MTgzY2ZkODM5XzgtMTEtMS0xLTA_5a370220-cdc4-4bd5-9460-2697f63d2d80"
      unitRef="usd">53700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzM4NTM_beb1ffa9-8d77-4cbe-8ebf-51905e82d366"
      unitRef="usd">164300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzM4NTc_21260903-feac-4ecf-a0d9-bf7043154abf"
      unitRef="usd">145200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzM4NjU_4ac56f3b-ccd5-4779-af1a-0edf833d938d"
      unitRef="usd">132600000</us-gaap:DefinedContributionPlanCostRecognized>
    <lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzQ0MDQ_340784d4-a785-4a61-a904-3c0b93deff24"
      unitRef="number">0.80</lly:DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i0be18783045647b39417db291e131c68_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzYwOTk_661667d1-a880-4cd6-815a-962d854d8a26"
      unitRef="number">0.65</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i134f03f4da5745c881d151356389c114_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzYxMjU_eebe54ad-b3d9-4bdf-923c-89b0a264cdb1"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMjUw_e485cc38-fd31-495f-8228-3465f4d63708">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for&lt;br/&gt;Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,635.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,301.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,670.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,331.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2019 by asset category were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Asset Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in Active Markets&#160;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Investments Valued at Net Asset Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,439.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets - repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,226.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,858.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,499.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private alternative investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-like funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash value of trust owned insurance contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i125f0871aaaa45a8a006a3aa90bec2b7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtMS0xLTEtMA_8b579fc8-3ee5-4d86-aabe-a399c6e276f9"
      unitRef="usd">737600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5fbb551c5b8a4f8e89d479bf7ee2465d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtMy0xLTEtMA_2b0b90e7-742b-4026-9ded-da2b6b360639"
      unitRef="usd">476100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b85c4afc43f4f51a83ef0ea6a014ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtNS0xLTEtMA_975a083a-c49f-44aa-b28d-f8c0b07a6bc8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5b6c571cd27e4e94bc5717d1000ca256_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtNy0xLTEtMA_408aefe1-7e2e-49cb-b5da-bc942b202fb2"
      unitRef="usd">1000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i12e2651b0ae044eb8ad0fd855f1413bb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzQtOS0xLTEtMA_ba631066-3433-46cd-b31c-6684b3ae2e44"
      unitRef="usd">260500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbb25b81194d4853b020cf54c8f8f7ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtMS0xLTEtMA_d51067c3-40b9-4f61-9087-fd8f5c9be231"
      unitRef="usd">2635800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4815fcd3e33549bca6c2313f6a96f168_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtMy0xLTEtMA_7bef72fe-8e88-4ba5-815f-d80d3b4eba2c"
      unitRef="usd">1102300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4e92ae2ebc9d40ac889ffb3518784b30_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtNS0xLTEtMA_868f6fa2-749a-4a94-9e6f-6cfe3f1ec8b8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i03078573edd84526a0fb7f4dfd971e8c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtNy0xLTEtMA_4922665d-7b54-49ac-a0a7-44e37610af76"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3287458586b346ae8b32053866574079_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzUtOS0xLTEtMA_b34b2d2d-6aca-4543-9153-30989ba107a4"
      unitRef="usd">1533500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia2bff6b24d574258816b0a18efea4481_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctMS0xLTEtMA_b8481692-b126-453f-b053-50c2dbb84437"
      unitRef="usd">4301300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b7c8721f31747da9656f229d82e19ee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctMy0xLTEtMA_41d9f3e0-f998-4d3a-b831-f4a63b66935a"
      unitRef="usd">2900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icccd9f0f2bc240d68bf932d1486745c3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctNS0xLTEtMA_96f6d7b7-6fa6-4a8d-83b6-bcc9a8d9e71b"
      unitRef="usd">3179200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia8fc4192c93948e58c908295ada7c788_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctNy0xLTEtMA_91a5c643-ded0-4ee5-a58c-b931a699bdc8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c7df1b1312447bdb91336635231a328_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzctOS0xLTEtMA_19cc55fa-a577-4dad-8f70-58972a5e4716"
      unitRef="usd">1119200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i44ddf32d59d541b2a516001cd682c531_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtMS0xLTEtMA_d91964c9-2c02-465e-9787-7ff47713cac7"
      unitRef="usd">-1670800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if54348410ce84f2fb7e320ea814b26a6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtMy0xLTEtMA_718cfa40-b0ae-4c4f-9907-e83b616d4ae0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i40b8bd104f4d4282bb55fcd040b18ad7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtNS0xLTEtMA_f1d0ec3e-0dcb-454f-bb74-898eeb632d86"
      unitRef="usd">-1670800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie21defbad19c4c63a7ca3efa0bbb49a8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtNy0xLTEtMA_93d73ffe-1495-4d76-9786-42390e630a35"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7dcfa724c16044a9a047270245e9f5d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzgtOS0xLTEtMA_f3a1ed8f-2320-4f05-9d34-a425a890985d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i122ffbfb116d49aaa94e76c271df840c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktMS0xLTEtMA_5b90a908-4325-47e8-9428-ccba808c2c6c"
      unitRef="usd">631000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia11541505d134091a7960e590f9c55a5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktMy0xLTEtMA_877d0a90-c2db-44fa-84d1-4eeb2008a0af"
      unitRef="usd">14200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i894a88d4a4a34371980d69bf29256285_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktNS0xLTEtMA_226ea21c-0e2a-48b4-ac2f-be6acd8c8e27"
      unitRef="usd">262700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3721c158dd7b4d129f7d61430f4502a1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktNy0xLTEtMA_5d058c9a-8259-4044-9c4c-711c7e7a36fd"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if741b3f8c66d4f398ea1e526a37195c9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzktOS0xLTEtMA_ae8855b9-72cd-484d-ae99-8e0028869d92"
      unitRef="usd">354000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if98890f41b7346c2906b80139874cde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTEtMS0xLTA_66a59b56-9b06-411a-8058-473e13591d31"
      unitRef="usd">2661300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i35b819438ccf430b853a4465244e6fdd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTMtMS0xLTA_3d94ad79-a343-4a05-b017-a38d5b31273d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2b85d3256ef6437c86432f6208104ca9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTUtMS0xLTA_2ab415a3-c99c-4404-b142-af0821ccb2d8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id2f6978eac114b1a9a4b9b3e6d1c2d54_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTctMS0xLTA_933abdb5-2ef9-499f-83eb-75bab83a7463"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib1a4fbe91fca4349a3619d62f21b5192_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzExLTktMS0xLTA_7bdc89ca-4e12-4dc6-baf5-73bf39f83234"
      unitRef="usd">2661300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1c325faa849646d8877f6217a8e9e5fc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTEtMS0xLTA_b6681a4b-0b8c-493f-8f55-f8fc1c0952c2"
      unitRef="usd">2844700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie8a1be41667140c28d82974e25d6f978_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTMtMS0xLTA_867e9bb6-6b49-4d80-9826-7e26578e173e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4fb1a00b260143129cd18a27fae9066d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTUtMS0xLTA_b993e0b4-08a6-495c-a184-a7c8934d0aad"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iab85a851be0049e384a77f9bed8c7112_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTctMS0xLTA_a9e08397-f88d-4a40-9f18-3a35c6633fea"
      unitRef="usd">16900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i90ebb158dc6c4c529380297ca491bc83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEyLTktMS0xLTA_47ebffa6-4641-4515-bcb4-9770f5082eb1"
      unitRef="usd">2827800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i787b7132e99c493ca562e8bc24ca4fe8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTEtMS0xLTA_d134f7e4-9825-41fd-b53c-0dd4b65968bb"
      unitRef="usd">558900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic467e27a1bec45deaeede4746d725b3b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTMtMS0xLTA_9aaa2dfc-b675-4e4d-a47a-0265fae335bc"
      unitRef="usd">259600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iacdcb2d995cf4fff8171cbe33cc965cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTUtMS0xLTA_c869ff71-17b5-4d14-8a1c-21fd2fad627a"
      unitRef="usd">6900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia422ad3b45604fe2b5412d14ccab5f5d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTctMS0xLTA_fd5b01ab-3b1f-4350-a440-f5645ed74951"
      unitRef="usd">5800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ided7419ed04c4ee390c6ecdfeea4be0a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzEzLTktMS0xLTA_f7748f98-5bf0-44f7-ab0c-d13314896abd"
      unitRef="usd">286600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5dde6acc2364d7895ab68140b8a940e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTEtMS0xLTA_302e2fb8-2423-4fb4-bae0-31add2bf78d6"
      unitRef="usd">1879200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if4c7762e89bc4b6c8400f5c82637267f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTMtMS0xLTA_cd3bcd18-94d9-4dfc-a4f2-edba3ad747de"
      unitRef="usd">60400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifa71c7d9d0a44cfea6f52f788e4f63d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTUtMS0xLTA_fbea8d21-6ba0-4fb8-9353-59d5e23d6174"
      unitRef="usd">301200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3fa4144a81a64effba21e1069fac6bde_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTctMS0xLTA_0877fa87-7224-421d-a1e8-d01ce4defef4"
      unitRef="usd">18000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4cd95c05c6f044669e6cdc5f23c27a03_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE0LTktMS0xLTA_224e6dba-eac1-437d-bc67-8bb5bc81e758"
      unitRef="usd">1499600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTEtMS0xLTA_b2361c1e-eaad-4527-9b9c-b1b6a5769b55"
      unitRef="usd">14579000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaa4949f8ddfa462d8b08ae8a55ca4e3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTMtMS0xLTA_3f711937-8615-413a-b603-464848565e35"
      unitRef="usd">1915500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i522080a183f64b32b7dbc33f0a805a7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTUtMS0xLTA_89db55d7-30e8-4308-b276-3d912161b8a7"
      unitRef="usd">2079200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i09f8a5ddfd884b47966968ab578e45b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTctMS0xLTA_75eb0608-250d-433f-8f1d-eba89547edae"
      unitRef="usd">41800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if438221acf6341a39b8a9a65a4e65e8c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE1LTktMS0xLTA_f25bb04b-8b6b-4ccc-af71-20d9e85ad2df"
      unitRef="usd">10542500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if47ad8d27d2d46cea9c0a971df416313_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTEtMS0xLTA_332a145f-28fc-42b7-aba0-1dc9c7289e1d"
      unitRef="usd">68300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20afb20108144023830d742a2375621b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTMtMS0xLTA_a0e7999d-1aa7-4e82-a21c-c6109705071f"
      unitRef="usd">45000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i82a506494bf44549a25ef7d8a77149fa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTUtMS0xLTA_ed162250-1fcf-485b-ba20-f252db2a54e0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i367a0762cac945bfa3136660561bb3ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTctMS0xLTA_8317d11a-a48a-4498-a8de-2c8d75942d2f"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i119de4bad3f6477f971e2f4b9d1269d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzE5LTktMS0xLTA_7e3b68dc-5cff-403b-99b1-26c0638cf6b3"
      unitRef="usd">23200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i18771cf6e66e4cb7be08134942326069_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTEtMS0xLTA_c1662dab-5f21-4aea-adc7-c2e4ef1bf767"
      unitRef="usd">162300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6c7d6c9f167c4c5683298223b4ef8af1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTMtMS0xLTA_cecd6747-a177-43df-b329-af7cc07461f4"
      unitRef="usd">58100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie1dd6bf74c204da0a0cd97309e7b08e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTUtMS0xLTA_ce96b644-4196-4538-abc8-eb17255315c8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i313357f190a941efb7646635222fa28c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTctMS0xLTA_cbd10663-6b30-4366-b590-6be1423a8210"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i434273c7f8d842699b6b037c72ff2cc8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIwLTktMS0xLTA_a66915a2-dc5e-4e3f-b45a-cfc6e01d55db"
      unitRef="usd">104200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0d982e51da34404b680672535a771da_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTEtMS0xLTA_a1698298-7105-4dd6-a65d-b5d172d095bc"
      unitRef="usd">101500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01c1b63878e543bab94f0bc61bd810c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTMtMS0xLTA_829ac603-7387-49a2-84c9-579a1d89c902"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idd8fa233f8fa45ad8d9997db7e5e3cac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTUtMS0xLTA_4e433328-0c32-4d02-828a-bf049dfdc23a"
      unitRef="usd">80300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id10a4106c36d48c080be874880a0c5f0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTctMS0xLTA_e0fc1845-cd71-4518-b82e-dee639cdf8cd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia95a10a1f5f14bf0974550095d634caa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIyLTktMS0xLTA_deb12f7b-ca1e-4e9c-ba0e-eea5d22c58bf"
      unitRef="usd">21200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia6f8ae3d75184ec2b1e3758df93f149b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTEtMS0xLTA_af8acfa6-e2d4-47f5-a8af-d29b772d9e59"
      unitRef="usd">53500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d1fcfa7a99c4781a6ff659d054315b6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTMtMS0xLTA_6b8c371a-3908-445e-ba37-d68e9e9b918b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idd5aba2572834b96bf2e805a8e72d50d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTUtMS0xLTA_892760ad-99e7-4908-b2cf-023d053563ef"
      unitRef="usd">24700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b41b01976fe4459b0b2e05e4a78ecec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTctMS0xLTA_af423a13-157e-4230-b00d-fc7c3bf04cd2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe3ce3f963884db0be993dd43a273d48_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzIzLTktMS0xLTA_1e52891b-ffe8-4825-92f9-d9913999234f"
      unitRef="usd">28800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie17084e6a4674e82adf22fef4ff88b90_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTEtMS0xLTA_d34fad04-8e08-4f34-a8b8-63db08d3c27b"
      unitRef="usd">229700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice675a2c24d8440490e242dd88655d53_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTMtMS0xLTA_19992d1c-5b4d-471f-ad60-75d3571910c7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0340e5bcf8b2492f877571f5e4badb72_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTUtMS0xLTA_f499dad1-6954-43b5-b486-0142c75188c8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie290f1153a8746b4b6cd78f8378492fb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTctMS0xLTA_e5c4bb12-5311-4e9e-bffa-72ec6f1c1ee7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie61e568a671e4a80821d53844eb24240_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI1LTktMS0xLTA_d7f4fe8c-93d1-45f6-b9a4-4eaaa262d298"
      unitRef="usd">229700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8dd146d4e0d24f1eba383583c4714d33_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTEtMS0xLTA_452053d9-bcb4-4e30-8bf0-a009f6d61156"
      unitRef="usd">223400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idad95d8440b74627bd1f07f9cbaaf547_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTMtMS0xLTA_e93dab7e-7334-4226-89f7-d72f2f3bca6f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5bb310846a874a2896fe227840a6a94d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTUtMS0xLTA_1ce9e65c-2e0b-4574-a139-7bce59d9efe5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c0844638a1d4c2094a1f495d509e3a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTctMS0xLTA_5ee74c8e-fcc3-45ce-91e8-bb8c90791782"
      unitRef="usd">1600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic1a23c7481934f7c9cbc0f8e5d7819cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI2LTktMS0xLTA_e0a60df1-5416-4044-abf1-0afec8006b79"
      unitRef="usd">221800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2e024a2361694af8af62b9b106fb4091_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTEtMS0xLTA_a4c0a45d-e6c8-4870-8454-9ebc99d36ca2"
      unitRef="usd">2204600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i893d604481e5414a876d424c5bb3853b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTMtMS0xLTA_f055bfe8-34a2-4415-83cc-40359b29d682"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i514ee23678874da6a78affbcc11e2d13_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTUtMS0xLTA_f5b258e9-5987-4533-ad67-a9d61a64b3bb"
      unitRef="usd">2204600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i782e6897c57141f3a206f658e2c32404_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTctMS0xLTA_4c4d3cb8-df55-40a2-b9d0-ae9655525484"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3def2cfb16eb45eb825321e9107e8557_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI3LTktMS0xLTA_25ed6360-6394-4136-9e47-2494678f442b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if24f5a064fb248b9a1c67cd62d6ed476_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTEtMS0xLTA_7cb416f8-9440-453e-af1f-9ce91aeeb0c9"
      unitRef="usd">25800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i85c28a1b50d047e48ca4cc3357ad9d44_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTMtMS0xLTA_4dbbdc57-22d2-46cf-badd-322a5737f5f8"
      unitRef="usd">24500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i933d218234f842788e1c269114faae5b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTUtMS0xLTA_f0e257d5-a5c2-47ad-a42b-318888895d8b"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37ceb71c1fa14063ba529ff4695b2287_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTctMS0xLTA_d8a95768-d5b6-4c61-be81-aa0feed4f8fd"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i685a0d4729324a28b26de39802342a21_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI4LTktMS0xLTA_d9b00e2d-6217-4089-8472-e066a8aeb2ba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic736258b57814a4182d5d6987fb420c2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTEtMS0xLTA_a601ac4b-3d40-47db-9705-9c881195df8f"
      unitRef="usd">157900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i045d7c5fdf0e49c18f983e9217f0b15e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTMtMS0xLTA_cfbdb7e7-a47a-4397-957f-fd1a45f1f2bf"
      unitRef="usd">14100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9f4c6c31184e47f3b704a0eae7e42331_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTUtMS0xLTA_0032745b-e933-4da5-8865-6896f0dfc0e5"
      unitRef="usd">21100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib384b4a9c4e24e259a0e4f91d0193602_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTctMS0xLTA_6e33fcb7-423c-4c0e-97ff-f7ceb45353c3"
      unitRef="usd">1700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib28a156345f7417e99d42b66e3b9aceb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzI5LTktMS0xLTA_bf1b414a-8823-4c29-8df5-43a8d7ab49f3"
      unitRef="usd">121000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3cda65ab919946c29f79a9a9dfba07ea_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTEtMS0xLTA_477c0b2f-8c52-4ad2-ade9-ea41eb0750ec"
      unitRef="usd">3227000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i058f847612d74099976ba37d7f71f906_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTMtMS0xLTA_2d8ac096-22f1-4796-8388-7b8a4d335d44"
      unitRef="usd">141700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia708e12046a5423f8cffea676c33483e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTUtMS0xLTA_017b2641-40e8-4913-b9f6-9e791d0e7de3"
      unitRef="usd">2331400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ife201fa234a44463aaae78e3178b7591_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTctMS0xLTA_dac33793-8dab-4381-9952-b6e41ed3f6d2"
      unitRef="usd">4000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1612094a408f4d40b21352521bf6c97e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo1YmE2NjMyNjNhZmQ0MWJkODgyZWMwYzQxYmRjZTBkZS90YWJsZXJhbmdlOjViYTY2MzI2M2FmZDQxYmQ4ODJlYzBjNDFiZGNlMGRlXzMwLTktMS0xLTA_b1d86ae2-57f8-4ca1-8c8b-ae5c7e0220af"
      unitRef="usd">749900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iedde0139af294cff8fdcea9f72f645be_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtMS0xLTEtMA_7fd3297f-f544-43a4-b854-5b7207241950"
      unitRef="usd">794200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7ea7b43b8b5c450c817a947965d81b01_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtMy0xLTEtMA_6f2bab8a-6c3e-4dd1-b986-2e915a8eaeca"
      unitRef="usd">532400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6c72734140b24d3f8f463831c8c59882_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtNS0xLTEtMA_d96803c2-9bf9-4eef-ba0b-09effa2f4366"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i474e96cc45a343bd880e15f5e3e7dcb2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtNy0xLTEtMA_bfc9ccbc-802b-4a84-bc8e-309f47a07618"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i331eecd2fcab475bb2c445750bf65683_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzQtOS0xLTEtMA_53b7405a-687e-4ef1-9f0f-1a2a4356e589"
      unitRef="usd">261700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd771e0257d642dcadc5d74119bdfefa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtMS0xLTEtMA_9fe58fc4-eb35-46c3-869c-8665174e389a"
      unitRef="usd">2439200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i41f3e1cb00c44d82927f246e6c5166c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtMy0xLTEtMA_59749e81-3b0f-4a5a-9b4a-ec823f949a73"
      unitRef="usd">1046800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e5945ce8ccc4948bac9a0451e12d1e8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtNS0xLTEtMA_15764aad-e638-447e-8f89-690bfc88a1b7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3273ded1db9c4c9596e118619286ba07_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtNy0xLTEtMA_078561c9-8a58-4a7b-a61a-9dde7df98970"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1b1995d069c040efab6457b44f15e8b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzUtOS0xLTEtMA_6ee34ec6-24ab-4944-97f7-99336d335c83"
      unitRef="usd">1392400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icba0bb9a358a4901bea4e4cd5c7f55f6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctMS0xLTEtMA_aa8ceff9-0fdb-4168-80aa-615fb96101a8"
      unitRef="usd">3661400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iea6960c498f4476188e66f546a6935bc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctMy0xLTEtMA_e574977e-d64a-400f-afbe-075d15828ae9"
      unitRef="usd">4800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd365bf0efab46af86e6bbb643db823c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctNS0xLTEtMA_05b1b7c4-fe06-4f91-8b24-395bd6135fe8"
      unitRef="usd">2658900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i675961e5fc46462c956548b162c65ca8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctNy0xLTEtMA_434bedf2-17be-44d7-abaf-b7f4873e1f2d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbbec282c576404eb0ec8d2d0fdf9653_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzctOS0xLTEtMA_0fc856ba-1c14-4fc8-8723-a73fe98db0b1"
      unitRef="usd">997700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f323b9fa21c499dbdf0daf714c57f36_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtMS0xLTEtMA_8840b71d-dff5-4b50-bd6f-c174ad7ac7e0"
      unitRef="usd">-1659100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iadf32c3dcfc14cdaa8060800039f3e79_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtMy0xLTEtMA_3f9d1f61-21ec-4955-bd9e-b729f6232dfc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf52a977346b49d798c932533814bf59_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtNS0xLTEtMA_2f3afc30-fe7a-4737-83dc-a0871baa74fd"
      unitRef="usd">-1659100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i28c3e31523404f2ebfc936c17c16b324_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtNy0xLTEtMA_099a6526-cf9d-4104-bc6b-fd2d39bf5808"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4629fb029e734ace817a97c424776664_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzgtOS0xLTEtMA_2e856961-8297-44ae-9340-aff70ad40ef1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic4c387153e294bcb9eaecfe60743c646_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktMS0xLTEtMA_0f869184-0d9f-4dac-83b7-8c60562e36ef"
      unitRef="usd">648000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i77389ce093254e6ab4f11f9dd0728471_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktMy0xLTEtMA_ee8a9cf7-5bcf-4789-8d8f-91f2d0ecbd3f"
      unitRef="usd">18500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3313ee63caf64afab4f2c93fbc54124d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktNS0xLTEtMA_e5190ddb-c83c-4de9-bda7-20381ba772fb"
      unitRef="usd">277400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i65e9fd581d4d433aae76ee66caa8183b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktNy0xLTEtMA_6f42135f-033e-422b-9cc9-2cb2a44d2aa5"
      unitRef="usd">4100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc3fcf315c0347f0b121686f96a2c53f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzktOS0xLTEtMA_e61a3992-ce38-48bb-8502-38d660a4fcfe"
      unitRef="usd">348000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icb8686f5c76e4a7c83ddc6959064840b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTEtMS0xLTA_867e9f7b-7620-4704-ae47-8bb567851cc1"
      unitRef="usd">2897900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i19da2e5ec2ab4bb580c7155fdc8fdfa3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTMtMS0xLTA_63b3bdc4-825f-4ed5-8495-306cc9a9094b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i006db6e632504a099cb649312ea0cba3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTUtMS0xLTA_dea9b1e0-8825-450a-9224-e89f1cfc7a93"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic37e46cbf2c242d8899925fc7a112670_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTctMS0xLTA_63d50b63-33b0-4aa1-ac54-ec1364b49653"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i847b2decf9404ab2a7d6680fdccdf305_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzExLTktMS0xLTA_ae4a2510-e2e6-42aa-bae8-b2a09d9748d8"
      unitRef="usd">2897900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iecfde700f02a48f7a31316d1f567cd5b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTEtMS0xLTA_99c90773-e84e-4cae-aeb3-6eee928c1751"
      unitRef="usd">2279300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id435bbff99ed49dfa19a3cb32dd76386_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTMtMS0xLTA_43368d0d-48af-4e28-8444-28ff517ae213"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4f75c558ed1e49339a2e52215ae52fc0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTUtMS0xLTA_44d1a532-a370-41a6-9367-6f989d74ca1c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i701917bbad004fc8b8d81a751eea303d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTctMS0xLTA_aec2709b-89ca-49e2-8111-4172a9783fd7"
      unitRef="usd">16800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id65b328d8d2c49c1be2ef55b3625103c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEyLTktMS0xLTA_6fe89335-a1d2-400d-bcd2-a0924d5aa228"
      unitRef="usd">2262500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c1221e8e34e4275b4db34697e4ca8b2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTEtMS0xLTA_2c234a80-fb67-4165-88b5-c77f2b2590c1"
      unitRef="usd">570300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i564ffd90f9084692ab88b0cf933a98f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTMtMS0xLTA_32e262a8-ef35-45d8-8fee-1cff82ae6d98"
      unitRef="usd">166200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9f13162a2f8d4549a141594e5f80d879_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTUtMS0xLTA_f8589e44-51af-495f-b02b-a3b0bdf035e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if8ef9b73660f4b9fadce03cc33bd22f6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTctMS0xLTA_331aae46-f71c-44e6-99fe-a23a88b48d30"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1a8eb2e429e4d4b9559c6a8a87ef504_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzEzLTktMS0xLTA_2adc88cd-df26-427c-8834-2a1d28ce7bdf"
      unitRef="usd">404100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie36e443e3d434b15af03feda51e6777d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTEtMS0xLTA_fbf0c576-738b-49e0-ad81-6d78397a79bc"
      unitRef="usd">1226800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i50fb13104c73464cb06b6701e9af3093_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTMtMS0xLTA_e5ad4b35-2aaf-46b7-b58e-43d94dae9ced"
      unitRef="usd">62900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id60bea6be43f4ed4804c1fc6a9298e09_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTUtMS0xLTA_3e053e36-f108-428f-9d4b-8338c8de2027"
      unitRef="usd">222600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia8724bdcd3854eaf92373c5d1a807169_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTctMS0xLTA_7c39b707-e38b-484d-9dfb-bbcafa2c2e53"
      unitRef="usd">6600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic42c51f1ef8b4c618cd8e6b21c234c55_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE0LTktMS0xLTA_9973b644-0e9d-4636-854f-ddef5e9f30f3"
      unitRef="usd">934700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i87fab925dba44dc0ae21de713975768c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTEtMS0xLTA_0204ec5e-7fc6-483e-bf24-565f32536ad7"
      unitRef="usd">12858000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifada303dfc0a48749b857d690254e679_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTMtMS0xLTA_f0864eb9-a9f6-4571-8b33-dd0799b70f9e"
      unitRef="usd">1831700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5ba9215cf52449385b12a520287a98a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTUtMS0xLTA_b77a1580-2843-4e98-aaff-d79cdbc42056"
      unitRef="usd">1499800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2a44a9521bad4096b6d02caf364c65b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTctMS0xLTA_e05515fb-77c4-4f89-9bc1-9cb1582ef2e0"
      unitRef="usd">27500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia19985d737da40e0bd8d5ac7bcda0e3d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE1LTktMS0xLTA_09e07d17-a07d-403b-927b-9208b86a5119"
      unitRef="usd">9499000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia7b8e68d1946469abfb59f6c6fda184a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTEtMS0xLTA_85e7cc29-de32-4b4f-90ce-00299f5373a6"
      unitRef="usd">76500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i42a83760ddde47c48011002561464667_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTMtMS0xLTA_a818c136-3349-4493-ad18-a848bbb9b4b7"
      unitRef="usd">52100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaf1c2c6447034265b3f50c7be9a87b41_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTUtMS0xLTA_aa015ba9-bc1f-48ab-98c2-f1e75756817c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idabb35ff3f03404f8c6130a1eeb49f61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTctMS0xLTA_a40777b4-473b-4fea-bdf8-c061707844fe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97e2cdb6c127441b909e910815d3dbbb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzE5LTktMS0xLTA_27d1a483-7451-43c7-ae9f-1307fff7badf"
      unitRef="usd">24400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8f03d4b0fdcb41bd9bebfa7ede027236_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTEtMS0xLTA_bc5886d3-a289-4fc6-8e03-59df51f39ae0"
      unitRef="usd">152600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i895e2b3cafef45acb1012b1e03d39ffc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTMtMS0xLTA_3f0ce0c0-818c-473f-bf74-52ca136e7488"
      unitRef="usd">60800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1066e9b68a6348ab93c9493b56791fe8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTUtMS0xLTA_e1fc2934-f85f-4288-ba83-5c1aa2e240bd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1595e10ff0084e819adb888f4c577f76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTctMS0xLTA_468e3da2-bdf0-42f2-b883-eba067a0d6d2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic4f8156acc564caab08a1624e564a10c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIwLTktMS0xLTA_b5949546-1399-4392-8975-3cc54108ee18"
      unitRef="usd">91800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia81d715fd04f41c4b0fb15cbc97ded7b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTEtMS0xLTA_95138b2f-f465-45e2-a470-02271be2aec3"
      unitRef="usd">82700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic9bcd75701e244eda1dc59a0f6acf303_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTMtMS0xLTA_b0a271c4-6b8a-437d-988f-250bcb205bf2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i945c96b3eea1403fa18115aaefba9877_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTUtMS0xLTA_2dfad43b-0e4c-4d00-97b9-39fa86fadf14"
      unitRef="usd">56300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia8a5d8801736420b82120164f7c0089a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTctMS0xLTA_7bf3a0fe-0ebe-4bb7-be30-718ed8a1bd39"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9181cc52ee8e454c89c0e1c42c853e15_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIyLTktMS0xLTA_27ebd551-5a6b-42de-a927-3511e45c4928"
      unitRef="usd">26400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38af461ee606432d82a7474978332d8c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTEtMS0xLTA_7bcf3fc7-d152-468b-b3ae-1bf2c6d21375"
      unitRef="usd">58500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i373b829238f74628b948e23e7d5c164c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTMtMS0xLTA_6ce344ba-b6cf-4a75-80d8-dd14c326a9aa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74e4134c43ad43bab33caec94bc82d47_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTUtMS0xLTA_d1c9d3e7-306c-46cc-82cf-5190d59a10de"
      unitRef="usd">27000000.0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idb2a002bc0ef442bb111f2a7206ee130_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTctMS0xLTA_6fa7314e-019d-4e0c-9d16-f8bd13916e9b"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i510f34cc51b4405db4a91992d32b1c34_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzIzLTktMS0xLTA_b15c045a-1c62-4d76-a97f-b347c1a06e10"
      unitRef="usd">31100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22b766219ce347188ad03e3849166f80_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTEtMS0xLTA_dffb0c03-3aa2-4d74-858b-3867789b3b6f"
      unitRef="usd">250800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i708ee2efc8f448d3b331e38fcbd4a915_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTMtMS0xLTA_d7961e21-dd72-4ba4-8e21-7898fd4816ec"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8dc36c3791284cabb24ca762698700d3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTUtMS0xLTA_71cea13c-bdbc-4682-ad77-0fef7fc4bba4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic1dc7058692f46668106cf1d6a1e73c8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTctMS0xLTA_a493a973-f2a6-4c13-a7b0-444923cddd63"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iea800c25a6674e09a0af56692d7b5dd1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI1LTktMS0xLTA_2faa0684-ba97-41d1-80ed-3710b937ac5f"
      unitRef="usd">250800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe300c1a64c647b69fe7bf20e0541942_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTEtMS0xLTA_3bb0fcea-a66b-4347-be98-654add83332e"
      unitRef="usd">187400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d6294050b0144ebb52f2b5cb557783a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTMtMS0xLTA_bfca8050-2595-4ae0-ae0b-4a3ffbd08da1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i69a0b8e765cb46099127a2188cb007e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTUtMS0xLTA_debfc842-eb39-49de-ac38-d9eef4388c72"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6428acbb884c4334bce83f1ace7ab19d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTctMS0xLTA_4e1f16e5-4915-433b-ad0d-8187f6dc850c"
      unitRef="usd">1600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id719e5a1d3de4031989293711aa38d3c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI2LTktMS0xLTA_cf22c072-f274-4af4-ac46-5ccc365bf37f"
      unitRef="usd">185800000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a2aaec08b63468499905c6159f8e3da_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTEtMS0xLTA_e5db59ca-e6e3-4f13-9af0-4a6ce06f78f5"
      unitRef="usd">1832200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60dad62f6fb1485a99fd7d1430fc110d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTMtMS0xLTA_78847bf6-a0a6-4b52-9286-4f363a744da8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifaff3c08ba9d4d03bd33fcb7a5bbd1fb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTUtMS0xLTA_50949a00-9b1d-40ea-b270-53d96fa915ed"
      unitRef="usd">1832200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i534b8b956faa4f71ab4ccda780e39214_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTctMS0xLTA_d7c33ddc-a217-4e10-8803-1d7cb79a4b01"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib078dfc1c37e44c9a48bbe3f9a469f3c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI3LTktMS0xLTA_00476075-f4a9-45d0-b5f8-6eebb7e0508b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id0406531f0094a13b3244c8fcabda0cb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTEtMS0xLTA_95b755eb-8769-4c5a-9af4-bee40997b063"
      unitRef="usd">31300000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8e9def9531e94f7ea8588aedd9f265d8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTMtMS0xLTA_922d4917-47fa-4d69-b6bf-811eb48b105f"
      unitRef="usd">16200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1c938f472b04e1ea9b5d3856f56cf27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTUtMS0xLTA_76da15d1-b8e3-4e42-bbe7-a5b716bad500"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i500e87bc01cc4b5f93691f5fb1d50fad_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTctMS0xLTA_25b57c10-36b2-480b-b7a7-6bf226076c6b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id3858c30cf5044e598ca275f01991c28_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI4LTktMS0xLTA_bae71877-f4d7-4a68-b1b6-79d1f059a5ad"
      unitRef="usd">15100000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i996aa7b86fc24b07a4288e7ba5f7df03_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTEtMS0xLTA_4643024d-3f7d-4f5a-8b66-0d34f71872b7"
      unitRef="usd">96200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie7482d3bafbc41eeac363718494d0f83_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTMtMS0xLTA_85afea80-48b8-459e-a783-4cf23efb0534"
      unitRef="usd">11400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i362e3e575b774c4397566b4c1a34e5c4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTUtMS0xLTA_5d51d8c4-c679-49c1-89cc-aaae104a5d19"
      unitRef="usd">7900000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibfef4993c67240b2a0bc234322e964af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTctMS0xLTA_518f58c3-4698-4134-b4cd-931b9446ae03"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id022f4c867cb4232a897b833e40eb0df_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzI5LTktMS0xLTA_a56e0fd4-ac3b-4c16-a671-909de364183b"
      unitRef="usd">76200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i15ed48ac9ec641ea85cb11221f6bab0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTEtMS0xLTA_e6858de5-9491-42bf-bc1a-a3a57541e30f"
      unitRef="usd">2768200000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4833bcba5f4d461da0967d8871780d3b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTMtMS0xLTA_a3ed6604-ce6f-47ce-94dd-1922c3796b5c"
      unitRef="usd">140500000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie600f398f9404e8fbfd23a4c663f06ab_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTUtMS0xLTA_701c5d2d-0a53-4fc7-9a67-bc25a8852cfa"
      unitRef="usd">1923400000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie3b618356b1e4a8396dee41b547db32f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTctMS0xLTA_0d58f454-c387-4b67-8b76-3d627570b686"
      unitRef="usd">2700000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibcb89163b193490c80c31c918380523b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90YWJsZTo0MDMwODdjNzQ5ZTU0OTQwYjcxNDlmNjY2NmY3ZDFmNi90YWJsZXJhbmdlOjQwMzA4N2M3NDllNTQ5NDBiNzE0OWY2NjY2ZjdkMWY2XzMwLTktMS0xLTA_4ee03074-fee6-4cca-8939-694ae357e030"
      unitRef="usd">701600000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1XzEyMDUx_334f7d4b-7a2d-47fa-89bb-d1d17be74df4"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <lly:DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear
      contextRef="i06f37af72aea43beb8bfcd105c157384_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNzgvZnJhZzo1YWRmZWYyMzI3ZmU0MjM0OTNhYTBlYzU4MTU5MDA4NS90ZXh0cmVnaW9uOjVhZGZlZjIzMjdmZTQyMzQ5M2FhMGVjNTgxNTkwMDg1Xzk4OTU2MDQ2NjYwMzU_80a4970e-1695-4984-8555-2cb62b1516fe"
      unitRef="usd">10000000</lly:DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzU3Mjk_81caf48c-f0f3-43e0-9d8d-f5df7d6ac841">Contingencies&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Alimta Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of manufacturers are seeking approvals in the U.S., a number of countries in Europe, and Japan to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers.&#160;However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail.&#160;An unfavorable outcome in the U.S. could have a material adverse impact on our future consolidated results of operations and cash flows.&#160;We expect that a loss of exclusivity for Alimta in any of the below jurisdictions would result in a rapid and severe decline in future revenue for the product in the relevant market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;U.S. Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alimta (pemetrexed) is protected by a vitamin regimen patent until 2021, plus pediatric exclusivity through May 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Apotex Inc. (Apotex) alleging infringement of Alimta's vitamin regimen patent for its application to market a pemetrexed product. In December 2019, the U.S. District Court for the Southern District of Indiana granted our motion for summary judgment of infringement, and in December 2020, the U.S. Court of Appeals for the Federal Circuit affirmed that ruling. Apotex did not request reconsideration or a rehearing of that ruling. However, Apotex could petition the U.S. Supreme Court to review the case. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;European Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal proceedings are ongoing regarding our Alimta patents in various national courts throughout Europe. We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that generic competitors may choose to launch at risk. Following a final decision in the Supreme Court of Germany in July 2020 overturning the lower court and upholding the validity of our Alimta patent, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;several generics that were on the market at risk left. We have removed the remaining generics from the market by obtaining preliminary injunctions in our favor. In September 2020, the Paris Court of First Instance in France issued a final decision upholding the validity of our Alimta patent and found infringement by Fresenius Kabi France and Fresenius Kabi Groupe France&#x2019;s (collectively, Kabi) pemetrexed product. The court issued an injunction against Kabi and provisionally awarded us damages. In January 2021, that same court issued a preliminary injunction against Zentiva France S.A.S. (Zentiva), the last remaining company with a generic pemetrexed product on the French market, and provisionally awarded us damages. In October 2020, the Court of Appeal of the Netherlands overturned a lower court decision and ruled that our Alimta patent is valid and infringed and reinstated an injunction against Kabi, thereby removing Kabi's pemetrexed product from the Netherlands market. Kabi has appealed this decision to the Netherlands Supreme Court. Kabi's generic pemetrexed product was the only at risk generic on the market in the Netherlands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our vitamin regimen patents have also been challenged in other smaller European jurisdictions. We will continue to seek to remove any generic pemetrexed products launched at risk in other European markets, seek damages with respect to such launches, and defend our patents against validity challenges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Japanese Administrative Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Japanese Patent Office (JPO) issued notices closing Hopira Inc.'s (Hospira) invalidation against our Japanese Alimta patents. As a result, Hospira filed a withdrawal notice with the JPO and the JPO accepted the withdrawal in November. This matter is now closed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Emgality Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, we were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in nine different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in ad&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ults. Trial is expected in December 2021. Separat&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ely, the U.S. Patent and Trademark Office (USPTO) granted our request to initiate an&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes review&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(IPR) to reexamine the validity of the nine Teva patents asserted against us in the litigation. In February 2020, the USPTO ruled in our favor and found that the claims asserted against us in six of Teva's nine patents were invalid. In March 2020, the USPTO ruled against us on the remaining three Teva patents, finding that we failed to show that the remaining three patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the USPTO&#x2019;s March 2020 ruling, and Teva appealed the USPTO&#x2019;s February 2020 ruling to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Court of Appeals for the Federal Circuit&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The district court litigation will proceed in parallel with the IPR appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Jardiance Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from Alkem Laboratories Ltd.'s (Alkem) and Ascend Laboratories, LLC's (Ascend) submissions of Abbreviated New Drug Applications (ANDA) seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, Alkem's and Ascend's ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. Trial was scheduled for April 2021 but has been postponed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Taltz Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, we were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;named as a defendant in litigation filed by Genentech, Inc. (Genentech) in Germany seeking a ruling that Genentech&#x2019;s patent would be in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fringed by our continued sales of Taltz in Germany. After it sold its patent rights to Novartis Pharma AG (Novartis) in June 2020, Genentech withdrew its infringement litigation and Novartis subsequently filed litigation against us in Germany asserting infringement based on sales of Taltz. In January 2021, we entered into a settlement agreement with Novartis whereby all pending litigation in Germany related to the Taltz patent has been withdrawn and this matter has concluded. We were also named in litigation in the U.K. in which Genentech asserted similar claims regarding its corresponding U.K. patent. Novartis purchased Genentech's U.K. patent rights for Taltz, sought substitution for Genentech in the U.K. litigation and then sought dismissal of all appeals. Orders to this effect were issued by the Patents Court and Court of Appeal in November 2020 and these matters have concluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Zyprexa Canada Patent Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the mid-2000&#x2019;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Canadian Federal Court of Appeals denied our appeal of a lower court's decision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hat certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. Trial is expected in 2021 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Actos&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), one in Quebec filed July 2012 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Whyte et al. v. Eli Lilly et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), one in Saskatchewan filed November 2017 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Weiler v. Takeda Canada Inc. et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and one in Alberta filed January 2013 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Epp v. Takeda Canada Inc. et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Byetta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in March 2009, we are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. involving approximately 810 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Three lawsuits, representing approximately four plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court's grant of summary judgment based on that court's discovery rulings and remanded the cases for further proceedings. In November 2018, the California Court of Appeal reversed the state court's grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. We are aware of approximately 20 additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cialis Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in August 2015, we are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#xae;. The JPML ordered the transfer of the existing cases to the now-renamed MDL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Jardiance Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately 95 product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#x2019; Fournier&#x2019;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Environmental Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;340B Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the alternative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. A hearing on our motion for preliminary injunction has been scheduled for February 26, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administration Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Brazil Litigation &#x2013; Cosmopolis Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Labor Attorney Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;300&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately&#160;950&#160;million Brazilian real (approximately $180&#160;million as of December 31, 2020). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#x2019;s appeal to the superior labor court. The cost of any such health coverage has not been determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#x2019;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#x2019;s immovable property or, alternatively, a security deposit of 500 million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted. In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#x2019;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Individual Former Employee Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in 2003, we have also been named in approximately 30&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;China NDRC Antitrust Matter &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2014, we, along with another pharmaceutical manufacturer, are named as co-defendants in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for February 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Health Choice Alliance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#x2019;s motion to dismiss the relator&#x2019;s second amended complaint. In January 2020, the relator appealed the District Court&#x2019;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a decision by the U.S. Court of Appeals for the Fifth Circuit on the aforementioned District Court appeal.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pricing Litigation, Investigations, and Inquires&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we, along with Sanofi-Aventis U.S. LLC (Sanofi) and Novo Nordisk, Inc. (Novo Nordisk) were named as defendants in a consolidated purported class action lawsuit,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re. Insulin Pricing Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re. Insulin Pricing Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; MSP Recovery Claims&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; litigation, the court dismissed claims under the federal RICO Act and certain state laws. Also, filed in the same court in November 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and anti-trust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Value Drug Co. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#x2019; motion to consolidate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Value Drug Co. v. Eli Lilly &amp;amp; Co. et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Minnesota Attorney General&#x2019;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. Additionally, in May 2019, the Kentucky Attorney General&#x2019;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;County of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Harris Texas v. Eli Lilly &amp;amp; Co., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, federal and state anti-trust law, and the state deceptive trade practices-consumer protection act. Harris County also alleges common law claims such as fraud, unjust enrichment, and civil conspiracy. This lawsuit relates to our insulin products as well as Trulicity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investigations, Subpoenas, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a subpoena from the New York a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market. We received two&#160;requests from the House of Representatives&#x2019; Committee on Energy and Commerce and a request from the Senate&#x2019;s Committee on Health, Education, Labor, and Pensions seeking certain information related to the pricing of insulin products, among other issues. We also received requests from the House of Representatives&#x2019; Committee on Oversight and Reform and the Senate&#x2019;s Committee on Finance, which seek detailed commercial information and business records. In January 2021, the Senate&#x2019;s Committee on Finance released a report summarizing the findings of its investigation. We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Corporation Technologies, Inc. &lt;/span&gt;&lt;/div&gt;In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. A trial date has not been set.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzE3NjAy_b7b78049-82f2-485b-833a-86a5f7be1d10">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <lly:LossContingencyNumberOfPatents
      contextRef="ia08920fe3f514f89bc0bd568c9df9ba5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQyNjg_002ea1ad-0786-4f79-85e9-76ef71e70b2e"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="ia08920fe3f514f89bc0bd568c9df9ba5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ2NzE_002ea1ad-0786-4f79-85e9-76ef71e70b2e"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatentsClaimsDismissed
      contextRef="i563701b19f014569b06746781df763bf_D20200201-20200229"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ4MjM_7260675d-dff0-4f07-9f49-064a96c54b70"
      unitRef="patent">6</lly:LossContingencyNumberOfPatentsClaimsDismissed>
    <lly:LossContingencyNumberOfPatents
      contextRef="id838bc258f094c568ea090ce38f5434e_I20200229"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ4Mzc_f4f9c49a-18a8-40ef-a27e-e86a0759c2a3"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatentsRuledUnpatentable
      contextRef="i0380a187e28a42edbd210299d61d308e_D20200301-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ5MjI_c53ad02c-3edd-4dd6-90a7-77add80aa81f"
      unitRef="patent">3</lly:LossContingencyNumberOfPatentsRuledUnpatentable>
    <lly:LossContingencyNumberOfPatentsRuledUnpatentable
      contextRef="i0380a187e28a42edbd210299d61d308e_D20200301-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEwOTk1MTE2OTQ5OTA_612db87a-f07c-4216-a558-fb641e23a3f8"
      unitRef="patent">3</lly:LossContingencyNumberOfPatentsRuledUnpatentable>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iecb392cbb3fe4cb8a6314dcd6654394c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxMzE_1d58944b-baa1-4cb0-bb25-71d4f7741be7"
      unitRef="lawsuit">4</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="icc7264a5345342d8aea87087c230aba3_I20111231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyNDM_df581c2a-e8a3-42eb-90dc-c3da9dc95895"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i9ae544e01daa4812a088e089d18c14e7_I20120731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNDA_7a38bf3b-7631-413d-83aa-8b9514876690"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4d2d51a9d7de4602a53112f3a2e3d04c_I20171130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNDE_bc40bbc0-be1e-480c-8ad9-3cbe715715f2"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i411602cb723743c380152402a7c692f2_I20130131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNTY_880be136-bcf1-4b15-9c79-bb0217948f7d"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib4cce461525f410b826a4889ad0f3ea6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNjU_29b82de7-be25-44ef-ad96-4488866607b3"
      unitRef="lawsuit">570</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="icea9f6147fa941e4a11404f04d76bc42_D20090301-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNzA_33120b5d-2258-41a2-aaff-fe19f4817920"
      unitRef="plaintiff">810</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i449428738c2940d49d82f1876796900e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNzU_032dbde1-71c6-49a5-84fa-644cf6f44ad3"
      unitRef="lawsuit">55</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i2f737098bb3145ceb2c97bdfcc33c357_D20090301-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxNzk_e3586447-5c84-4247-b07e-0a1eb685c531"
      unitRef="plaintiff">285</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib194555003c24fe5a77a184233bd6cba_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxODQ_bc6f02d4-bc08-46c6-b6b5-23179ef87158"
      unitRef="lawsuit">515</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i9e65f3f67c2d459f9a64e4b7a3a7d1b5_D20090301-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxODk_ad1167c5-a363-451e-9e14-4526fe9334f1"
      unitRef="plaintiff">515</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i6b680abb10c24ec5b54b2120fdc7058f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkxOTM_f10b8019-12d4-45d6-acc1-03ee23e63a13"
      unitRef="lawsuit">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i07adf913f1f54ca989ef31ee491cc698_D20090301-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyNTE_1b6f990f-d4e1-499d-94be-e8366531359d"
      unitRef="plaintiff">4</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i290630da973e431eb29fcd22cd423503_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMDU_021f11f0-4049-4dc1-a89b-46b0b22e1536"
      unitRef="lawsuit">565</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i89fbc9d584994ea8be0227e0a79821e4_D20090301-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMTA_61d408e5-65b9-4822-8d04-57f63200c99f"
      unitRef="plaintiff">800</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ieb83157010844ce786703b9c9bb67d43_D20090301-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMTQ_72ad4265-335c-4eb3-b391-c80d795c2fe8"
      unitRef="plaintiff">6</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i1409b6c99dad4d6da1691bc35c7de3cb_D20090301-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMjI_c3e20a35-a31f-49fe-ad92-fc5d04f439dc"
      unitRef="plaintiff">1</us-gaap:LossContingencyNumberOfPlaintiffs>
    <lly:LossContingencyNumberOfClaimants
      contextRef="ib4cce461525f410b826a4889ad0f3ea6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMzE_c55796ff-5005-4d5d-ab11-9fbe73da6675"
      unitRef="claimant">20</lly:LossContingencyNumberOfClaimants>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i1b0cea540b384bc08e0afbcf20bece39_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyMzU_18f75e3b-76e7-4ac5-92b8-8e68ad7d68e8"
      unitRef="lawsuit">350</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib285d2fd260145229843a0c1bf1263f4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyNDA_42b9f803-c397-4ca2-afe8-a9a2dab76f4f"
      unitRef="lawsuit">95</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="iaeccac6f45794f4a92f62a164ea4c0ca_D20180701-20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzA1NzU_fc3993f0-c60b-48c2-9961-75b1e4fb3366"
      unitRef="brl">300000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i8f52969f387d4ef7ad755da5ae0ffdbf_D20201231-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzA1MjM_e90cb376-98db-4e64-80a9-ef8dd5617474"
      unitRef="brl">950000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i8f52969f387d4ef7ad755da5ae0ffdbf_D20201231-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzU4MDI_33beda9c-7dbc-4138-8b2a-8afb7a838f3f"
      unitRef="usd">180000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i684d16bbfe9e4db78119c3012111fe94_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEyNTM5_a81df544-23a6-4750-80d5-95ac9d8e9b9f"
      unitRef="brl">500000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="idfeb86b846074fb89e884673987dab5f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzEzMzYx_8f649ba6-0ab7-4467-a3d7-e71fbd2c7c55"
      unitRef="lawsuit">30</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if595b7685be743c89bc5dc09daf08440_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMDkyODI_fe29b1c3-0268-4d0c-8811-4065eed972c5"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <lly:LossContingencyNumberOfRequestsForInformation
      contextRef="i88bd65697e614b36971bc989aebab0f8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODEvZnJhZzo2OTQ0OWQwYTA4YmQ0NGE3YThhM2M5ZTI4NmUyYTE2NS90ZXh0cmVnaW9uOjY5NDQ5ZDBhMDhiZDQ0YTdhOGEzYzllMjg2ZTJhMTY1XzMyOTg1MzUwMzA1OTQ_ec0fd51e-eb7b-43ef-83b4-6dc28f6d811e"
      unitRef="request">2</lly:LossContingencyNumberOfRequestsForInformation>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzIxMTE_80320188-7920-4620-b50f-12d06479e2e6">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="background-color:#d8d8d8;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2018 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,191.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,311.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,694.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification due to adoption of new accounting standard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,569.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,852.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,740.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(967.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(783.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(379.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(256.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;267.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(112.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(120.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of January 1, 2018 consists of $5.72&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This reclassification consists of $105.2&#160;million of accumulated other comprehensive income attributable to controlling interest and $23.7&#160;million of accumulated other comprehensive income attributable to noncontrolling interest. Refer to Note 1 for further details regarding the reclassification due to the adoption of ASU 2016-01.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of December&#160;31, 2018 consists of $5.73&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $11.0&#160;million of accumulated other comprehensive loss attributable to noncontrolling interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;128.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other &lt;br/&gt;Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(55.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;393.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;267.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications from continuing operations (net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications from discontinued operations (net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications for the period, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzIxMDQ_cb067180-8c37-437e-9efd-f3ad9e4a59a4">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="background-color:#d8d8d8;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1, 2018 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,191.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,311.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,694.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification due to adoption of new accounting standard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,569.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,852.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,740.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(967.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(783.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(379.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(256.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;267.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(112.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(120.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of January 1, 2018 consists of $5.72&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;This reclassification consists of $105.2&#160;million of accumulated other comprehensive income attributable to controlling interest and $23.7&#160;million of accumulated other comprehensive income attributable to noncontrolling interest. Refer to Note 1 for further details regarding the reclassification due to the adoption of ASU 2016-01.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of December&#160;31, 2018 consists of $5.73&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $11.0&#160;million of accumulated other comprehensive loss attributable to noncontrolling interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;128.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6404d71a3154085b2ffbe7918c52fdf_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItMS0xLTEtMA_9e4a9d09-5084-4701-a30f-39aed4052da9"
      unitRef="usd">-1191700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida3f134ccefd4f4a994809b05af014c1_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItMy0xLTEtMA_b86d44bd-2211-49f6-9e05-cf6f8f5fa881"
      unitRef="usd">113500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied12274b6db14234b7de3a19eb3f0d2c_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItNS0xLTEtMA_e6eb5fb8-6d4b-440b-a928-5c0a5331dabe"
      unitRef="usd">-4311300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4ce9bb84e004603a5019d1c6da66946_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItNy0xLTEtMA_ebff2d6d-09ee-4ed5-ba88-cc23660cefcf"
      unitRef="usd">-234300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91a7d9b32f3a4db9a00591e1adce82a6_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItOS0xLTEtMA_4cab86dd-44f9-4ee6-83e6-cf79bd35e6e5"
      unitRef="usd">-71100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6923db7df05a4e6e922a6bb5db8a3b41_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzItMTEtMS0xLTA_290e187d-ae1c-48d5-81e3-0e2395809f50"
      unitRef="usd">-5694900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="i7766703b17514542b192609b6e561393_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzMtMy0xLTEtODI3_5cc64403-d63d-4570-b61f-aeb7222b2d01"
      unitRef="usd">-128900000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="i5d75213e1aba4f7eadb741cb0d1cc298_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzMtMTEtMS0xLTgyNw_ab085f1c-8d89-4989-9d9c-4a6126702be0"
      unitRef="usd">-128900000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib784e78bc05f4285945fc78bbb738f91_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtMS0xLTEtMA_9b8aa326-8783-4072-9c64-83331f3fa93c"
      unitRef="usd">-378000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7766703b17514542b192609b6e561393_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtMy0xLTEtMA_83f2d6ef-dbce-4874-99b7-22b9351dc3be"
      unitRef="usd">24500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icf4a4a1e1c3745e59d68927cad94276a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtNS0xLTEtMA_c3e4ecb6-4a4b-48c2-aef8-3eb84f9b13ff"
      unitRef="usd">250700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibc74b3eb01ad4e50bc04a6977d715d2d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtNy0xLTEtMA_47d81836-7076-44cc-a313-227cb17de38b"
      unitRef="usd">-16300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ieb39193d2a16435281dd19dfabba3b42_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtOS0xLTEtMA_ae04af03-c703-43a9-907e-d3dcdea2f907"
      unitRef="usd">12200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzQtMTEtMS0xLTA_e7fb1e7e-7644-4fb1-9ebd-de50337e0dd7"
      unitRef="usd">-106900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib784e78bc05f4285945fc78bbb738f91_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtMS0xLTEtMA_3f45379d-29c2-4056-90a0-750e2e038d83"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7766703b17514542b192609b6e561393_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtMy0xLTEtMA_6b80cd3e-b1c7-4e16-86a4-405a9974c89f"
      unitRef="usd">31200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icf4a4a1e1c3745e59d68927cad94276a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtNS0xLTEtMA_f8676a36-af62-4a25-b169-83318e06afaf"
      unitRef="usd">-207900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibc74b3eb01ad4e50bc04a6977d715d2d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtNy0xLTEtMA_338b8673-e2a4-40fa-8efb-b26736de17a5"
      unitRef="usd">-11700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ieb39193d2a16435281dd19dfabba3b42_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtOS0xLTEtMA_6b8f32c4-916d-4119-9ec9-d3919d7122ab"
      unitRef="usd">-2100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzUtMTEtMS0xLTA_35cb8315-c3d9-4ce4-8116-0b7da9d59890"
      unitRef="usd">-190500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib784e78bc05f4285945fc78bbb738f91_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtMS0xLTEtMA_dfef44fa-4bb9-4b91-a34c-0b7c3809fc7f"
      unitRef="usd">-378000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7766703b17514542b192609b6e561393_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtMy0xLTEtMA_40085618-6c3c-45eb-b658-4a69c8bd3823"
      unitRef="usd">-6700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icf4a4a1e1c3745e59d68927cad94276a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtNS0xLTEtMA_a40e4b83-56cc-40d5-84dd-154993b9574e"
      unitRef="usd">458600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc74b3eb01ad4e50bc04a6977d715d2d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtNy0xLTEtMA_bf32a9b8-6800-47d0-ad48-02d9d1705516"
      unitRef="usd">-4600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieb39193d2a16435281dd19dfabba3b42_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtOS0xLTEtMA_4fe42d49-9d45-4925-ac51-09dfaeeaa853"
      unitRef="usd">14300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzYtMTEtMS0xLTA_b4b1b2d3-617a-4504-bc8f-a1e1798af7f3"
      unitRef="usd">83600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i20fb3a01e3c6484686b01e6156c1acd8_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTEtMS0xLTA_b7b45e64-c270-43fa-b23d-514d8531ac09"
      unitRef="usd">-1569700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cce948975cd45cfa58c1e76158f0f33_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTMtMS0xLTA_63f8bc5a-ab57-44de-b6da-2887edfd9090"
      unitRef="usd">-22100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ae9df0fe048449392c43fb7186ca248_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTUtMS0xLTA_dac0f0cc-64e0-44cd-90e8-bad817f5970f"
      unitRef="usd">-3852700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2a384242290465588799dfbd2e7ee83_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTctMS0xLTA_9377502d-9e31-4308-9495-3127be8e3141"
      unitRef="usd">-238900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39bb81b83d844b11b7cacd7fcb2e07d3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTktMS0xLTA_01b8c330-9598-44da-9e92-58f0e479a23d"
      unitRef="usd">-56800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i022a194d782540f8a8fdfc2d9b226688_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEwLTExLTEtMS0w_4e95fa00-6201-425b-874e-7afc777ffbc7"
      unitRef="usd">-5740200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7bbc0a2c1f894a5fa0c07c97d49cc299_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTEtMS0xLTA_e88c58c0-68dc-4605-929a-1070443cbf9f"
      unitRef="usd">-46200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i080fb50d8cac4747bda1c482bee979d5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTMtMS0xLTA_c070747c-0f4d-419a-bad1-dd669b82e662"
      unitRef="usd">28900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i615ad14cefcc4ce1a88ced50887fbf6d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTUtMS0xLTA_32c4f49f-fa3a-441a-92d9-3a2abe51ef29"
      unitRef="usd">-967600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i24efbe2abb2349b59ae25141fedb34da_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTctMS0xLTA_496a63f4-c2d6-40ab-9c66-a43dc9eb1e7a"
      unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if749975463d649e68e1bc14730e552fa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTktMS0xLTA_3febb46b-9ca7-4bb9-9be7-49824a819117"
      unitRef="usd">-27200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzEzLTExLTEtMS0w_053f1402-e031-4308-bf11-3e3294e59acc"
      unitRef="usd">-997600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7bbc0a2c1f894a5fa0c07c97d49cc299_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTEtMS0xLTA_5e329cac-c901-4aaa-82f2-93e9e72e62f5"
      unitRef="usd">62100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i080fb50d8cac4747bda1c482bee979d5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTMtMS0xLTA_9c28de0f-4dc6-4e67-a3ca-a48fca19e479"
      unitRef="usd">1900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i615ad14cefcc4ce1a88ced50887fbf6d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTUtMS0xLTA_c6f25008-c877-4208-b510-ceedc96d2db5"
      unitRef="usd">-181700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i24efbe2abb2349b59ae25141fedb34da_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTctMS0xLTA_10c97004-e81d-46fd-a2c0-6aea3d0805bf"
      unitRef="usd">-12500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if749975463d649e68e1bc14730e552fa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTktMS0xLTA_6039909b-c831-470b-ac11-52ba5a7a9b91"
      unitRef="usd">-84000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE0LTExLTEtMS0w_223ca3bf-8788-4286-9d73-56b1363775bd"
      unitRef="usd">-214200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7bbc0a2c1f894a5fa0c07c97d49cc299_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTEtMS0xLTA_e107b5a0-fef2-4901-a549-260220735695"
      unitRef="usd">-108300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i080fb50d8cac4747bda1c482bee979d5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTMtMS0xLTA_993615fb-64cb-4760-8cff-97198b3c7d49"
      unitRef="usd">27000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i615ad14cefcc4ce1a88ced50887fbf6d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTUtMS0xLTA_4502a3a1-a6ff-479e-9b48-689422c40327"
      unitRef="usd">-785900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i24efbe2abb2349b59ae25141fedb34da_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTctMS0xLTA_e4fb20f1-e54d-46e8-9600-40551f59f9ef"
      unitRef="usd">27000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if749975463d649e68e1bc14730e552fa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTktMS0xLTA_2c540b2d-1911-429b-8d8e-815d68169759"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE1LTExLTEtMS0w_c85fd865-0852-4117-a076-e9e2293b4af7"
      unitRef="usd">-783400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ae30dfeeb2e4879a0c3b21b26111cad_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTEtMS0xLTA_366af562-e90c-4c6e-8556-39e3236bfdcd"
      unitRef="usd">-1678000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i569a261af70b4d8ba9f60a58c0e2b9f8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTMtMS0xLTA_ab4d7ac1-5adf-4ea8-bcad-9e2115dbe5e1"
      unitRef="usd">4900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i135c068cec7c43d3896b245ca3cde3bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTUtMS0xLTA_4171b858-ed66-4285-92b1-b6f96af7f82c"
      unitRef="usd">-4638600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ae1e86516684e95b54071890a6e557b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTctMS0xLTA_4a6c97ad-9342-483d-aefd-a796188123a5"
      unitRef="usd">-211900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia22e1113b5f54e35a4a4df39e3e917bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTktMS0xLTA_300b1f00-ace9-4c93-a02b-12481c8f9896"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb975f9779f54232a351634d3fd2cd32_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE3LTExLTEtMS0w_be37815f-7908-455a-9280-ae2c8585a9e3"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2ad7ca588e4b4a668bd791165ae19818_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTEtMS0xLTA_c37349dc-07f3-426c-bb7d-326835ad5b45"
      unitRef="usd">250500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iba7d4dca490147faac33fdce0f0d354d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTMtMS0xLTA_8ea346df-4182-4938-b50e-bf2c4d0ba8e5"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i964f0a9d08134a599b06447de48f472d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTUtMS0xLTA_9932dfc2-b805-4ca2-99e5-ae360f8b501c"
      unitRef="usd">-379700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iba9496ec064a41e6bacfab535e35a9b1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTctMS0xLTA_30f5c06f-b11e-4c6f-9498-b9a9ef47e919"
      unitRef="usd">-133800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6b2f813fac6448c7b98cc7598ddd6c1a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTktMS0xLTA_7ab9933c-d1ef-4730-baf5-dd1c9f39f021"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzE5LTExLTEtMS0w_8948f375-6d91-4831-b076-40ea3c508852"
      unitRef="usd">-256200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2ad7ca588e4b4a668bd791165ae19818_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTEtMS0xLTA_3a7d6a63-7323-4142-a124-8b3fdc2af108"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iba7d4dca490147faac33fdce0f0d354d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTMtMS0xLTA_257493a3-2cf4-4e99-bd4d-e83e57f91676"
      unitRef="usd">-3100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i964f0a9d08134a599b06447de48f472d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTUtMS0xLTA_feeaaed1-5932-4353-aaa9-6f2821812621"
      unitRef="usd">-267300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iba9496ec064a41e6bacfab535e35a9b1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTctMS0xLTA_78ad7b09-78a9-48e1-ba2c-31ddb1a77a64"
      unitRef="usd">-13000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6b2f813fac6448c7b98cc7598ddd6c1a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTktMS0xLTA_3d3407a2-8ade-490c-b905-ad477fef6b0a"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIwLTExLTEtMS0w_7ac2d988-9cb3-4db8-9551-3a4610190dbe"
      unitRef="usd">-283400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2ad7ca588e4b4a668bd791165ae19818_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTEtMS0xLTA_f1ae42dc-2532-4bcd-b75a-0c6bf62c89df"
      unitRef="usd">250500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iba7d4dca490147faac33fdce0f0d354d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTMtMS0xLTA_7187b134-d4c0-4132-bd52-754cd010c269"
      unitRef="usd">9900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i964f0a9d08134a599b06447de48f472d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTUtMS0xLTA_9711eb95-b524-4b34-85e5-ff211430da08"
      unitRef="usd">-112400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iba9496ec064a41e6bacfab535e35a9b1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTctMS0xLTA_246e261b-b7a8-4072-9e9c-3fc197c11d0b"
      unitRef="usd">-120800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b2f813fac6448c7b98cc7598ddd6c1a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTktMS0xLTA_b8e15049-7076-417e-b33f-5926203e1804"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIxLTExLTEtMS0w_47d42d94-60df-40b0-8527-6f6041381457"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib667086cf32f420988bbee8738114965_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTEtMS0xLTA_343863d1-ae8f-4f51-a67a-59dfea9379d1"
      unitRef="usd">-1427500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie45e19b6d14441ea88cddc6e941da5ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTMtMS0xLTA_fe70c170-c46b-4c87-8150-0de802472648"
      unitRef="usd">14800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4baa1ec009c445486118e3b4579ec89_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTUtMS0xLTA_e18215c3-be44-4c6b-8b11-c5da61a992ba"
      unitRef="usd">-4751000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8b131f4aa2c4cb88d271c82f1b47bc3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTctMS0xLTA_130d128c-70bb-4364-808f-c58fba5ea7cc"
      unitRef="usd">-332700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f7cbd1f19a34b6789d5526dc3008179_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTktMS0xLTA_ca6f1e4b-c727-4b41-bc54-efc17d0e9594"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29a895cde5a54bb5be22a7b5806d3386_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTphNTlkNmY0ZDg2Y2Q0ZjBkYWQwNjI1ZjZkOGM2MjVlNy90YWJsZXJhbmdlOmE1OWQ2ZjRkODZjZDRmMGRhZDA2MjVmNmQ4YzYyNWU3XzIzLTExLTEtMS0w_c04c35b8-7f7f-48d8-84b3-76604e5f3274"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae684e1f51624a5884d558a8b1eea7ab_I20171231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc0OTA_6b5fa264-acc6-4679-90bb-ce8e628649cf"
      unitRef="usd">-5720000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idbc47e8810d6412bbab29c0eacb89745_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMxOA_44370a46-7118-4c5f-8db3-5f616b020244"
      unitRef="usd">23700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="i0b6c456db3554057845b3abb9ea2a86a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc1MzU_f084260c-8a40-414a-ae61-04177e03fbf7"
      unitRef="usd">105200000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idbc47e8810d6412bbab29c0eacb89745_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc1NTE_06406f7d-69fe-4756-9859-1a6946b09210"
      unitRef="usd">23700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1a89936fa8a4137a7ff3506ba792c52_I20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc1MDU_97166b8f-5c6f-4668-8b9f-b12649e5f2a6"
      unitRef="usd">-5730000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic2c054d8c5c84127b1e160c82886953d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzMyOTg1MzQ4ODc1MjA_a3e64c00-131f-4437-98a2-5ff2e6181871"
      unitRef="usd">-11000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i4da867daad1840d6b255ab18e08ebcd6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzEtMS0xLTEtMA_5c8e5481-1443-4ec8-ba05-b5ba7514a071"
      unitRef="usd">-128300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ifd7a83c1653f4b8eaedba242be6d6ff7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzEtMy0xLTEtMA_4c09b5ee-1487-46a7-992c-be2308ede0d9"
      unitRef="usd">18400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2bb8b4f8723f4f02a681499b646ccb15_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzEtNS0xLTEtMA_2000c26d-02f7-4559-9784-441c1838d169"
      unitRef="usd">-51600000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2a8513120f404c39a420b6b793e39fbc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzItMS0xLTEtMA_eeba1c34-8115-4a09-bb2a-a326722262d6"
      unitRef="usd">4300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i011e32aa84f34a07861fc5d8d38eae10_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzItMy0xLTEtMA_dc508c64-de66-40fa-984f-783b7c19c820"
      unitRef="usd">7400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i0c36f2ee8cff49ec82af74c218b0ace1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzItNS0xLTEtMA_0e361840-cae2-4ea8-9155-e99e1ae7cf9c"
      unitRef="usd">-2100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i007d6fe10f55466ebb1af3bb02b9b84a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzMtMS0xLTEtMA_3c362fcc-f0a6-4856-ae35-d94ac9930cd6"
      unitRef="usd">-44800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i767785ec05f74127a9246bc6ce2f190b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzMtMy0xLTEtMA_4339d4ec-1f41-44a3-8f15-2c192b905d15"
      unitRef="usd">-184100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i27dbf880100447d9bf589531096741f5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzMtNS0xLTEtMA_70dcac66-8c97-45ef-bdb9-a57ca698d6ff"
      unitRef="usd">85300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i3bdb72715a234bc193e62ede32a5bbed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzQtMS0xLTEtMA_ccaf45f4-0c12-43df-b578-058f0c8903fc"
      unitRef="usd">-32100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="iee3110d1c0a44663b08bc95d12a2e990_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzQtMy0xLTEtMA_a8070d8d-d95c-4961-bac0-29c96668c252"
      unitRef="usd">7300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i193696830a4742cdba4be29dcd7f5251_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzQtNS0xLTEtMA_63b788c2-c3a0-472d-8bf1-a180b7d89296"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzUtMS0xLTEtMA_d954552c-a519-444a-aca9-4d75f56613db"
      unitRef="usd">-200900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzUtMy0xLTEtMA_31505624-71c1-4f69-8d13-710a3726732d"
      unitRef="usd">-151000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowYWJhODI2OGUzMzg0NTgwYjQ1YmYzNjg5NDg0MWFiMy90YWJsZXJhbmdlOjBhYmE4MjY4ZTMzODQ1ODBiNDViZjM2ODk0ODQxYWIzXzUtNS0xLTEtMA_29457189-2445-496e-8845-2b4d7a30cbb7"
      unitRef="usd">30300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90ZXh0cmVnaW9uOjViY2VjNDJhMzQyYjQ3MmE5YTNiMTJmM2Q1Yzk2MWY2XzIxMTM_1a0b890e-1164-4a97-b24f-a3aa489cfa87">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other &lt;br/&gt;Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(55.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;393.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;338.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;267.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2014;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications from continuing operations (net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications from discontinued operations (net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications for the period, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic7a3ec013676433f815344f9f683499a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzMtMS0xLTEtMA_141b3a4d-6851-487d-9be8-25e35c8f6928"
      unitRef="usd">55000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i32ce3929549c42488c9d78815eb40512_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzMtMy0xLTEtMA_41b20357-2fe0-45f7-9ee2-7b55eb7f3d91"
      unitRef="usd">56800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9dd52235d591400ebdc756d6a1cb0bc9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzMtNS0xLTEtMA_b0442a90-d5f0-4223-bf39-884e2b94e2ed"
      unitRef="usd">74900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i27470f38a1f14522ba67a5d022af05bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzQtMS0xLTEtMA_f28ddc92-6430-45aa-ae6a-6aed757a0e7b"
      unitRef="usd">-393300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia69664129e7348b3b8fd52f216426461_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzQtMy0xLTEtMA_331aa270-7c8f-4e19-881a-e7db63dcde38"
      unitRef="usd">-286800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i43b02af87ac54ca3a6bfb1bc0e3b200e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzQtNS0xLTEtMA_a978c2ac-fea3-4055-9d77-891c76b2d817"
      unitRef="usd">-338600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9799a363894e447a88d58efd03f0b2ab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzUtMS0xLTEtMA_a71c9f13-4324-4c84-b2af-bbf6cab0e3b3"
      unitRef="usd">-338300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if0433259992642cd84137af8b232a207_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzUtMy0xLTEtMA_772cdecd-067e-403b-82f3-d8ff05a43e95"
      unitRef="usd">-230000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6c2fcfe7ae7240f8aea48b8993890007_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzUtNS0xLTEtMA_e3834310-e6f3-4809-a84c-9fb3ea3e3a4a"
      unitRef="usd">-263700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9799a363894e447a88d58efd03f0b2ab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzYtMS0xLTEtMA_9fe4fcf1-0817-426a-b1fb-ae1f919cff0e"
      unitRef="usd">-71000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if0433259992642cd84137af8b232a207_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzYtMy0xLTEtMA_9b0650c0-1b2d-4927-80ab-306bd233fb50"
      unitRef="usd">-48300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6c2fcfe7ae7240f8aea48b8993890007_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzYtNS0xLTEtMA_86f19703-8103-4a6b-862d-24fc244bb782"
      unitRef="usd">-55800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i9799a363894e447a88d58efd03f0b2ab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzctMS0xLTEtMA_202796d9-7346-46b1-b903-f345c9ac7fad"
      unitRef="usd">-267300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if0433259992642cd84137af8b232a207_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzctMy0xLTEtMA_27788ec2-032a-46f7-9bac-8fe7a55d272f"
      unitRef="usd">-181700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6c2fcfe7ae7240f8aea48b8993890007_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzctNS0xLTEtMA_fca0ec9a-2a9f-439c-9b2f-98a7d554fd8f"
      unitRef="usd">-207900000</us-gaap:ProfitLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i42bc8b84cba2465299f8b30a76d2180d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE0LTEtMS0xLTA_d718c51a-c1c8-42f6-8410-9d4f783844e3"
      unitRef="usd">-16100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id31f634abe9b49d087c5ebeb30996e11_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE0LTMtMS0xLTA_86f3caf2-653c-4a78-a770-8b889443269c"
      unitRef="usd">51500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iabbc7b2ea00947e8b902df09566e6317_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE0LTUtMS0xLTA_a2628da1-2e6f-44c1-8a10-2481a2047dbd"
      unitRef="usd">19500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i26304d3b80a542b5ab77edf4000be691_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE1LTEtMS0xLTA_28543e49-7b48-4aa6-9d28-8f4561149f93"
      unitRef="usd">-283400000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a1e386970d94f0abc18ef065866675b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE1LTMtMS0xLTA_d3da3b91-85ae-4a2d-88cc-ea9821435e4a"
      unitRef="usd">-130200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0df68c6465184e8b8f60cebcf0de49e4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE1LTUtMS0xLTA_55a8460f-dc79-4d2c-a08b-6830799dbe12"
      unitRef="usd">-188400000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i26304d3b80a542b5ab77edf4000be691_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE2LTEtMS0xLTA_75d4800d-a63a-41a0-92bb-10c13a544d5d"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5a1e386970d94f0abc18ef065866675b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE2LTMtMS0xLTA_84e65494-c1e3-42e2-a1a3-63f025c8c555"
      unitRef="usd">-84000000.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0df68c6465184e8b8f60cebcf0de49e4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE2LTUtMS0xLTA_766999a0-dfd4-4f37-aa90-370d75a7f972"
      unitRef="usd">-2100000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i26304d3b80a542b5ab77edf4000be691_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE3LTEtMS0xLTA_c6a20f87-c7e7-4e4d-ae08-d558a12813f8"
      unitRef="usd">-283400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5a1e386970d94f0abc18ef065866675b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE3LTMtMS0xLTA_6c89747c-64a8-446d-bb12-4670c5032475"
      unitRef="usd">-214200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0df68c6465184e8b8f60cebcf0de49e4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xODcvZnJhZzo1YmNlYzQyYTM0MmI0NzJhOWEzYjEyZjNkNWM5NjFmNi90YWJsZTowMzU5OWU1MzhmZmU0YjQ1YmExZTdlMjEyYmU4MTNhMC90YWJsZXJhbmdlOjAzNTk5ZTUzOGZmZTRiNDViYTFlN2UyMTJiZTgxM2EwXzE3LTUtMS0xLTA_b8929b75-1654-462c-9706-fec3b93e9a2b"
      unitRef="usd">-190500000</us-gaap:ProfitLoss>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90ZXh0cmVnaW9uOmI0MzVmYzBiNDc4MzRkY2FiNTUwODcyY2YwY2Y3MzAyXzIxOQ_5c5374f3-4b18-4556-b2cf-046fbea4456d">Other&#x2013;Net, (Income) Expense&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;359.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of antibiotic business in China (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(251.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,246.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(344.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,171.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;For the years ended December&#160;31, 2020 and 2019, other income was primarily related to net gains on investments (Note 7).</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90ZXh0cmVnaW9uOmI0MzVmYzBiNDc4MzRkY2FiNTUwODcyY2YwY2Y3MzAyXzIyMg_938dc167-07d5-428c-8897-0685abb6f828">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;359.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of antibiotic business in China (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(251.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,246.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(344.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,171.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzEtMS0xLTEtMA_4743c81d-7230-4c9b-b5d8-ea4ee88e9033"
      unitRef="usd">359600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzEtMy0xLTEtMA_74b34838-a0b6-4ccb-9cf4-9f850aa5f451"
      unitRef="usd">400600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzEtNS0xLTEtMA_e736fd46-dce2-4c15-a5d0-490df53b7ea1"
      unitRef="usd">242500000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzItMS0xLTEtMA_72af047f-e8cd-4a4a-b16e-84e4ea7aea2c"
      unitRef="usd">33000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzItMy0xLTEtMA_254c711e-e727-4d32-91da-f67099735b76"
      unitRef="usd">80400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzItNS0xLTEtMA_8ba6be90-8445-48d1-80ad-2ea496f0ff63"
      unitRef="usd">159300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzMtMS0xLTEtMA_35d72388-664b-46c9-aa4f-9286ee096a2d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzMtMy0xLTEtMA_163ca2d1-935b-4f53-a12d-fd7889045f6c"
      unitRef="usd">-252500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzMtNS0xLTEtMA_a0857295-2885-4bb5-b258-82a7ee5b8ac6"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzQtMS0xLTEtMA_c1fd906a-ec94-4278-8b00-b6693e193508"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzQtMy0xLTEtMA_884c3297-f407-49f6-9639-e8130c719702"
      unitRef="usd">309800000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzQtNS0xLTEtMA_edb11470-1d45-40bd-be4d-d418cff92bef"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzUtMS0xLTEtMA_730f2429-dbcb-4668-adf8-6904974816fe"
      unitRef="usd">-251800000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzUtMy0xLTEtMA_9ffcfbb6-a4e0-457c-a099-28f137b04ba4"
      unitRef="usd">-209900000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzUtNS0xLTEtMA_7f5cc7b6-5fef-40f8-8d8b-7d6f6985ca5a"
      unitRef="usd">-240500000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzYtMS0xLTEtMA_242aa58a-9adf-40bc-b164-5a6eae562c31"
      unitRef="usd">1246700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzYtMy0xLTEtMA_2ff7312c-5c67-4871-bad0-415d6ba4f8aa"
      unitRef="usd">344600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzYtNS0xLTEtMA_921621ff-cdf3-4fd8-8c88-fddd9d658d3a"
      unitRef="usd">-11700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzctMS0xLTEtMA_eeeee7e3-12eb-4dc9-8687-81db13dcd2c7"
      unitRef="usd">1171900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i628cbf421e5344fa9e2da4e85613e562_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzctMy0xLTEtMA_dfd7ea0c-7ab3-4b83-90ac-c1ccaf4361b5"
      unitRef="usd">291600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ife34c001d64a4b0fb7c3f8fb2c234348_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTAvZnJhZzpiNDM1ZmMwYjQ3ODM0ZGNhYjU1MDg3MmNmMGNmNzMwMi90YWJsZTo1ZmNlOGNiN2NhMGI0ODNjYjg1ZTBkNDg0ODdhYjI5YS90YWJsZXJhbmdlOjVmY2U4Y2I3Y2EwYjQ4M2NiODVlMGQ0ODQ4N2FiMjlhXzctNS0xLTEtMA_2626d07f-cfb1-453f-981e-cfcc8fee209b"
      unitRef="usd">145600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzMwNjA_8d4120c7-7241-48eb-978c-8868842ecb0a">Discontinued Operations&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 24, 2018, Elanco completed its initial public offering (IPO) resulting in the issuance of 72.3 million shares of its common stock, which represented 19.8 percent of Elanco's outstanding shares, at $24 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that formed its business.&#160;In exchange, Elanco transferred to us consideration of approximately $4.2 billion, which consisted primarily of the net proceeds from the IPO and the net proceeds from a $2.00 billion debt offering and a $500.0 million three-year term loan facility entered into by Elanco in August 2018. The consideration that we received was used for debt repayment, dividends, and share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was $629.2 million and was recorded in additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through March 11, 2019, we continued to consolidate Elanco, as we retained control over Elanco. We completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer that closed on March 11, 2019 (the disposition date). The earnings attributable to the divested, noncontrolling interest for the period from the IPO until disposition were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the disposition, in the first quarter of 2019, we recognized a gain related to the disposition of approximately $3.7 billion, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated financial statements for all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets summarizes revenue and net income from discontinued operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gain related to the disposition of Elanco in the consolidated statement of cash flows includes the operating results of Elanco through the disposition date, which were not material. Net cash flows of our discontinued operations for operating activities were not material for the year ended December 31, 2019. Net cash provided by operating activities related to our discontinued operations was approximately $500 million for the year ended December 31, 2018. The net cash flows of our discontinued operations for investing activities were not material for any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a transitional services agreement (TSA) with Elanco that is designed to facilitate the orderly transfer of various services to Elanco. The TSA relates primarily to administrative services, which are generally to be provided over 24 months from the disposition date. This agreement is not material and does not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ifc4be7a2068245ffa89edf317572504d_D20180924-20180924"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzE0MQ_f8768a98-faea-4172-806d-be19a16dba2d"
      unitRef="shares">72300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <lly:SaleOfStockPercentageOfStockSold
      contextRef="ifc4be7a2068245ffa89edf317572504d_D20180924-20180924"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzE5MA_83475924-997e-4244-afcd-c87d2643b773"
      unitRef="number">0.198</lly:SaleOfStockPercentageOfStockSold>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i45097dbde81e4b5a8ddc8854e29196ac_I20180924"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzIyOA_a4763655-a8a7-420c-8507-48722fa08035"
      unitRef="usdPerShare">24</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i601d8831c2a84dc6a94bf8abcae67dcf_I20180924"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzQ4OA_f71f889d-8e21-4066-a6c2-172a619b1107"
      unitRef="usd">4200000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ia8d16807ca45467296773da1a768103c_D20180924-20180924"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzU3OQ_45abfbf8-3b1d-4c02-8f22-455ce4a0cfb0"
      unitRef="usd">2000000000.00</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i25de516d8b1a468d869b65f28c3c0ae4_I20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzYwMg_06483919-89df-4dd5-9134-5ab7b9c20f5b"
      unitRef="usd">500000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i0841fa6d26e546d4acee688c1214ee2b_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzMyOTg1MzQ4ODYzOTA_47366ff6-1bb8-438c-913c-5d886e78e8c9">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i601d8831c2a84dc6a94bf8abcae67dcf_I20180924"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzg2Ng_827b6407-dc19-43f0-b331-a02744a4da06"
      unitRef="usd">629200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="icf5a8d8b13ec45be88c05cc0494020eb_I20190311"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzEyMDQ_3878daeb-a857-4519-9120-5a3433d22bda"
      unitRef="number">0.802</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i4759a8743edb4111b4e4b16db8cb6680_D20190101-20190331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzE1OTE_8c3125a5-b0e4-4ac0-9559-0fe5513915e7"
      unitRef="usd">3700000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzMwNjE_9f1f815d-04f0-49c5-9043-4462d9e9ba79">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets summarizes revenue and net income from discontinued operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:Revenues
      contextRef="i52daa1d7665e48ae8d99c5d280d6bd5a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90YWJsZTpiNDQwODBiMGJlMWM0ZjZjYjE5ODQyZThiMDViZDg5OC90YWJsZXJhbmdlOmI0NDA4MGIwYmUxYzRmNmNiMTk4NDJlOGIwNWJkODk4XzEtMy0xLTEtMA_2dfec65c-2e8c-4874-a00f-ca5d1cd24273"
      unitRef="usd">580000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b83214520b341e28e9c3eb65c9a0efa_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90YWJsZTpiNDQwODBiMGJlMWM0ZjZjYjE5ODQyZThiMDViZDg5OC90YWJsZXJhbmdlOmI0NDA4MGIwYmUxYzRmNmNiMTk4NDJlOGIwNWJkODk4XzEtNS0xLTEtMA_a4f25f2f-8685-4725-b457-cd6d8c9843fa"
      unitRef="usd">3062400000</us-gaap:Revenues>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i52daa1d7665e48ae8d99c5d280d6bd5a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90YWJsZTpiNDQwODBiMGJlMWM0ZjZjYjE5ODQyZThiMDViZDg5OC90YWJsZXJhbmdlOmI0NDA4MGIwYmUxYzRmNmNiMTk4NDJlOGIwNWJkODk4XzItMy0xLTEtMA_96b8a128-7d94-491d-8871-12b361bb03a6"
      unitRef="usd">3680500000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4b83214520b341e28e9c3eb65c9a0efa_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90YWJsZTpiNDQwODBiMGJlMWM0ZjZjYjE5ODQyZThiMDViZDg5OC90YWJsZXJhbmdlOmI0NDA4MGIwYmUxYzRmNmNiMTk4NDJlOGIwNWJkODk4XzItNS0xLTEtMA_2434c0f7-c35a-4733-8e92-d3e1045535ae"
      unitRef="usd">81400000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i4b83214520b341e28e9c3eb65c9a0efa_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzI0MDU_f9a44ff8-b00c-45fb-943f-62727d64e6c8"
      unitRef="usd">500000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <lly:DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm
      contextRef="i9a3e673a3e6740eba162b41a6b7818e2_D20190311-20190311"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xOTMvZnJhZzo0NjMzODUyNzkwODY0ZWRmYTg5YjE4YzEwMGNhMjE1ZC90ZXh0cmVnaW9uOjQ2MzM4NTI3OTA4NjRlZGZhODliMThjMTAwY2EyMTVkXzI4NjI_ad22ac06-98a6-4356-ac02-9a0801e632fb">P24M</lly:DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493759707368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,425,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s Proxy Statement for the 2021 Annual Meeting of Shareholders have been incorporated by reference into Part III of this report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member', window );">1.000% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77%&#160;Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77%&#160;Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493753921080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
<td class="nump">$ 21,493.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, expenses, and other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">5,483.3<span></span>
</td>
<td class="nump">4,721.2<span></span>
</td>
<td class="nump">4,681.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,085.7<span></span>
</td>
<td class="nump">5,595.0<span></span>
</td>
<td class="nump">5,051.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Marketing, selling, and administrative</a></td>
<td class="nump">6,121.2<span></span>
</td>
<td class="nump">6,213.8<span></span>
</td>
<td class="nump">5,975.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">660.4<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
<td class="nump">1,983.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Asset impairment, restructuring, and other special charges (Note 5)</a></td>
<td class="nump">131.2<span></span>
</td>
<td class="nump">575.6<span></span>
</td>
<td class="nump">266.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8212;net, (income) expense (Note 18)</a></td>
<td class="num">(1,171.9)<span></span>
</td>
<td class="num">(291.6)<span></span>
</td>
<td class="num">(145.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CostOfSalesOperatingExpensesAndOtherNet', window );">Costs, expenses, and other</a></td>
<td class="nump">17,309.9<span></span>
</td>
<td class="nump">17,053.6<span></span>
</td>
<td class="nump">17,813.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">7,229.9<span></span>
</td>
<td class="nump">5,265.9<span></span>
</td>
<td class="nump">3,680.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (Note 14)</a></td>
<td class="nump">1,036.2<span></span>
</td>
<td class="nump">628.0<span></span>
</td>
<td class="nump">529.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations</a></td>
<td class="nump">6,193.7<span></span>
</td>
<td class="nump">4,637.9<span></span>
</td>
<td class="nump">3,150.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income from discontinued operations (Note 19)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3,680.5<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,193.7<span></span>
</td>
<td class="nump">$ 8,318.4<span></span>
</td>
<td class="nump">$ 3,232.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings from continuing operations - basic (in usd per share)</a></td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="nump">$ 4.98<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings from discontinued operations - basic (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3.95<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share - basic (in usd per share)</a></td>
<td class="nump">6.82<span></span>
</td>
<td class="nump">8.93<span></span>
</td>
<td class="nump">3.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings from continuing operations - diluted (in usd per share)</a></td>
<td class="nump">6.79<span></span>
</td>
<td class="nump">4.96<span></span>
</td>
<td class="nump">3.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings from discontinued operations - diluted (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3.93<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share - diluted (in usd per share)</a></td>
<td class="nump">$ 6.79<span></span>
</td>
<td class="nump">$ 8.89<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">907,634<span></span>
</td>
<td class="nump">931,059<span></span>
</td>
<td class="nump">1,027,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">912,505<span></span>
</td>
<td class="nump">935,684<span></span>
</td>
<td class="nump">1,033,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CostOfSalesOperatingExpensesAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of sales, operating expenses, and other-net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CostOfSalesOperatingExpensesAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493654373080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,193.7<span></span>
</td>
<td class="nump">$ 8,318.4<span></span>
</td>
<td class="nump">$ 3,232.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss) from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Change in foreign currency translation gains (losses)</a></td>
<td class="nump">122.1<span></span>
</td>
<td class="num">(89.9)<span></span>
</td>
<td class="num">(429.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Change in net unrealized gains (losses) on securities</a></td>
<td class="nump">14.2<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Change in defined benefit pension and retiree health benefit plans (Note 15)</a></td>
<td class="num">(157.1)<span></span>
</td>
<td class="num">(970.0)<span></span>
</td>
<td class="nump">544.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Change in effective portion of cash flow hedges</a></td>
<td class="num">(152.9)<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax', window );">Change in effective portion of cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss) from continuing operations before income taxes</a></td>
<td class="num">(173.7)<span></span>
</td>
<td class="num">(991.2)<span></span>
</td>
<td class="nump">99.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations</a></td>
<td class="nump">200.9<span></span>
</td>
<td class="nump">151.0<span></span>
</td>
<td class="num">(30.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="num">(783.4)<span></span>
</td>
<td class="nump">83.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">6,220.9<span></span>
</td>
<td class="nump">7,535.0<span></span>
</td>
<td class="nump">3,315.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss) from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="num">(840.2)<span></span>
</td>
<td class="nump">69.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss) from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 56.8<span></span>
</td>
<td class="nump">$ 14.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493651812248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 7)</a></td>
<td class="nump">$ 3,657.1<span></span>
</td>
<td class="nump">$ 2,337.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 7)</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $25.9 (2020)&#160;and $22.4 (2019)</a></td>
<td class="nump">5,875.3<span></span>
</td>
<td class="nump">4,547.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,053.7<span></span>
</td>
<td class="nump">994.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 6)</a></td>
<td class="nump">3,980.3<span></span>
</td>
<td class="nump">3,190.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,871.5<span></span>
</td>
<td class="nump">2,538.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,462.1<span></span>
</td>
<td class="nump">13,709.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments (Note 7)</a></td>
<td class="nump">2,966.8<span></span>
</td>
<td class="nump">1,962.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 8)</a></td>
<td class="nump">3,766.5<span></span>
</td>
<td class="nump">3,679.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net (Note 8)</a></td>
<td class="nump">7,450.0<span></span>
</td>
<td class="nump">6,618.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets (Note 14)</a></td>
<td class="nump">2,830.4<span></span>
</td>
<td class="nump">2,572.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net (Note 9)</a></td>
<td class="nump">8,681.9<span></span>
</td>
<td class="nump">7,872.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">3,475.4<span></span>
</td>
<td class="nump">2,871.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">46,633.1<span></span>
</td>
<td class="nump">39,286.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and current maturities of long-term debt (Note 11)</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">1,499.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,606.7<span></span>
</td>
<td class="nump">1,405.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">997.2<span></span>
</td>
<td class="nump">915.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_SalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">5,853.0<span></span>
</td>
<td class="nump">4,933.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">770.6<span></span>
</td>
<td class="nump">671.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable (Note 14)</a></td>
<td class="nump">495.1<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,750.3<span></span>
</td>
<td class="nump">2,189.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,481.6<span></span>
</td>
<td class="nump">11,775.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 11)</a></td>
<td class="nump">16,586.6<span></span>
</td>
<td class="nump">13,817.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits (Note 15)</a></td>
<td class="nump">4,094.5<span></span>
</td>
<td class="nump">3,698.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable (Note 14)</a></td>
<td class="nump">3,837.8<span></span>
</td>
<td class="nump">3,607.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,707.5<span></span>
</td>
<td class="nump">1,501.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities (Note 14)</a></td>
<td class="nump">2,099.9<span></span>
</td>
<td class="nump">2,187.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total other liabilities</a></td>
<td class="nump">28,326.3<span></span>
</td>
<td class="nump">24,811.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value&#8232; Authorized shares: 3,200,000&#8232; Issued shares: 957,077 (2020)&#160;and 958,056 (2019)</a></td>
<td class="nump">598.2<span></span>
</td>
<td class="nump">598.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,778.5<span></span>
</td>
<td class="nump">6,685.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">7,830.2<span></span>
</td>
<td class="nump">4,920.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss (Note 17)</a></td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Cost of common stock in treasury</a></td>
<td class="num">(55.7)<span></span>
</td>
<td class="num">(60.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Eli Lilly and Company shareholders' equity</a></td>
<td class="nump">5,641.6<span></span>
</td>
<td class="nump">2,606.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">183.6<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">5,825.2<span></span>
</td>
<td class="nump">2,699.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 46,633.1<span></span>
</td>
<td class="nump">$ 39,286.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales rebates and discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493657498632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances</a></td>
<td class="nump">$ 25.9<span></span>
</td>
<td class="nump">$ 22.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued (in shares)</a></td>
<td class="nump">957,077<span></span>
</td>
<td class="nump">958,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658909240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity Statement - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Employee Benefit Trust</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Loss </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Common Stock in Treasury</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 687.9<span></span>
</td>
<td class="nump">$ 5,817.8<span></span>
</td>
<td class="nump">$ 13,894.1<span></span>
</td>
<td class="nump">$ 763.8<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (5,718.6)<span></span>
</td>
<td class="num">$ (105.2)<span></span>
</td>
<td class="num">$ (75.8)<span></span>
</td>
<td class="nump">$ 75.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,232.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,372.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,122.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,150.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">$ (4,150.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,150.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="num">(139.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of Elanco Stock (Note 19)</a></td>
<td class="nump">1,017.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 661.0<span></span>
</td>
<td class="nump">6,583.6<span></span>
</td>
<td class="nump">11,395.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(5,729.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (69.4)<span></span>
</td>
<td class="nump">1,080.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,318.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(794.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,430.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,363.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,427.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(4,400.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,400.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="num">(210.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_StockAcquiredDuringPeriodSharesExchangeOffer', window );">Acquisition of common stock in exchange offer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_StockAcquiredDuringPeriodValueExchangeOffer', window );">Acquisition of common stock in exchange offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,027.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary', window );">Deconsolidation of Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,028.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">2,699.1<span></span>
</td>
<td class="nump">$ 598.8<span></span>
</td>
<td class="nump">6,685.3<span></span>
</td>
<td class="nump">4,920.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (60.8)<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,193.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,786.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="num">(212.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 5,825.2<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">$ 6,778.5<span></span>
</td>
<td class="nump">$ 7,830.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (6,496.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="nump">$ 183.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impact on Equity of Sale of Noncontrolling Interest in Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_StockAcquiredDuringPeriodSharesExchangeOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Acquired During Period, Shares, Exchange Offer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_StockAcquiredDuringPeriodSharesExchangeOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_StockAcquiredDuringPeriodValueExchangeOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Acquired During Period, Value, Exchange Offer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_StockAcquiredDuringPeriodValueExchangeOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658614200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend declared per share (in usd per share)</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649176280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 6,193.7<span></span>
</td>
<td class="nump">$ 8,318.4<span></span>
</td>
<td class="nump">$ 3,232.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain related to disposition of Elanco (Note 19)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3,680.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of antibiotic business in China (Note 3)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(309.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,323.9<span></span>
</td>
<td class="nump">1,232.6<span></span>
</td>
<td class="nump">1,609.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="num">(134.5)<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
<td class="nump">326.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">308.1<span></span>
</td>
<td class="nump">312.4<span></span>
</td>
<td class="nump">279.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net investment gains</a></td>
<td class="num">(1,438.5)<span></span>
</td>
<td class="num">(403.1)<span></span>
</td>
<td class="num">(27.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">660.4<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
<td class="nump">1,983.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other non-cash operating activities, net</a></td>
<td class="nump">333.9<span></span>
</td>
<td class="nump">751.8<span></span>
</td>
<td class="nump">499.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Other changes in operating assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Receivables&#8212;(increase) decrease</a></td>
<td class="num">(1,350.2)<span></span>
</td>
<td class="num">(127.2)<span></span>
</td>
<td class="num">(996.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories&#8212;(increase) decrease</a></td>
<td class="num">(533.4)<span></span>
</td>
<td class="num">(258.7)<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets&#8212;(increase) decrease</a></td>
<td class="num">(457.1)<span></span>
</td>
<td class="num">(602.3)<span></span>
</td>
<td class="num">(980.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable&#8212;increase (decrease)</a></td>
<td class="nump">322.0<span></span>
</td>
<td class="num">(221.3)<span></span>
</td>
<td class="num">(125.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities&#8212;increase (decrease)</a></td>
<td class="nump">1,271.3<span></span>
</td>
<td class="num">(477.7)<span></span>
</td>
<td class="num">(284.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">6,499.6<span></span>
</td>
<td class="nump">4,836.6<span></span>
</td>
<td class="nump">5,524.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,387.9)<span></span>
</td>
<td class="num">(1,033.9)<span></span>
</td>
<td class="num">(1,210.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="nump">129.7<span></span>
</td>
<td class="nump">136.6<span></span>
</td>
<td class="nump">2,552.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(11.4)<span></span>
</td>
<td class="num">(42.7)<span></span>
</td>
<td class="num">(112.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of noncurrent investments</a></td>
<td class="nump">757.1<span></span>
</td>
<td class="nump">609.8<span></span>
</td>
<td class="nump">3,509.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of noncurrent investments</a></td>
<td class="num">(358.7)<span></span>
</td>
<td class="num">(247.5)<span></span>
</td>
<td class="num">(837.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_PurchasedInProcessResearchAndDevelopment', window );">Purchases of in-process research and development</a></td>
<td class="num">(641.2)<span></span>
</td>
<td class="num">(319.6)<span></span>
</td>
<td class="num">(1,807.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired (Note 3)</a></td>
<td class="num">(849.3)<span></span>
</td>
<td class="num">(6,917.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Cash distributed to Elanco upon disposition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(374.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash received for sale of antibiotic business in China</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">354.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="nump">102.8<span></span>
</td>
<td class="num">(248.7)<span></span>
</td>
<td class="num">(187.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used for) Investing Activities</a></td>
<td class="num">(2,258.9)<span></span>
</td>
<td class="num">(8,082.9)<span></span>
</td>
<td class="nump">1,906.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(2,687.1)<span></span>
</td>
<td class="num">(2,409.8)<span></span>
</td>
<td class="num">(2,311.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="num">(1,494.2)<span></span>
</td>
<td class="nump">995.4<span></span>
</td>
<td class="num">(2,197.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">2,062.3<span></span>
</td>
<td class="nump">6,556.4<span></span>
</td>
<td class="nump">2,477.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(276.5)<span></span>
</td>
<td class="num">(2,866.4)<span></span>
</td>
<td class="num">(1,009.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="num">(500.0)<span></span>
</td>
<td class="num">(4,400.0)<span></span>
</td>
<td class="num">(4,150.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary', window );">Net proceeds from Elanco initial public offering (Note 19)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,659.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(241.6)<span></span>
</td>
<td class="num">(200.1)<span></span>
</td>
<td class="num">(372.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used for Financing Activities</a></td>
<td class="num">(3,137.1)<span></span>
</td>
<td class="num">(2,324.5)<span></span>
</td>
<td class="num">(5,904.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">216.0<span></span>
</td>
<td class="num">(89.9)<span></span>
</td>
<td class="num">(63.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,319.6<span></span>
</td>
<td class="num">(5,660.7)<span></span>
</td>
<td class="nump">1,462.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year (includes $677.5 (2019) and $324.4 (2018) of discontinued operations)</a></td>
<td class="nump">2,337.5<span></span>
</td>
<td class="nump">7,998.2<span></span>
</td>
<td class="nump">6,536.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at End of Year (includes $677.5 (2018) of discontinued operations)</a></td>
<td class="nump">$ 3,657.1<span></span>
</td>
<td class="nump">$ 2,337.5<span></span>
</td>
<td class="nump">$ 7,998.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance or Sale of Equity from Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PurchasedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PurchasedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658459256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Discontinued operations cash</a></td>
<td class="nump">$ 677.5<span></span>
</td>
<td class="nump">$ 324.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649235496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</a></td>
<td class="text">Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity. We generally do not have control by means other than voting interests. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders&#8217; interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2019, we completed the disposition of our remaining 80.2 percent ownership of Elanco Animal Health Incorporated (Elanco) common stock through a tax-free exchange offer. As a result, Elanco has been presented as discontinued operations in our consolidated financial statements for all periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of the disposition of Elanco, we now operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development costs, which are expensed as incurred.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expense includes the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share (EPS)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic EPS based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses. Advertising expenses, comprised primarily of television, radio, print media, and Internet advertising, totaled approximately $1.1 billion, $1.1 billion, and $900 million in 2020, 2019, and 2018, respectively, which was less than 5 percent of revenue each year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, we adopted Accounting Standards Update 2016-02, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transitional practical expedients. The adoption of this standard resulted in recording of operating lease assets of approximately $530 million, which included reclassifying approximately $65 million of deferred rent and lease incentives, net of prepaid rent, as a component of the operating lease assets as of January 1, 2019. The adoption also resulted in recording operating lease liabilities of approximately $595 million as of January 1, 2019. Our accounting for finance leases remained substantially unchanged. Adoption of this standard did not result in a material change in net income in the year of adoption. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other related updates. This standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We applied this standard to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don&#8217;t believe the effect of applying this practical expedient resulted in material differences. We applied this standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Adoption of this standard did not result in a material change in revenue or net income in the year of adoption.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2016-01 (ASU 2016-01), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). We applied the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2016-16, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. We adopted this standard using a modified retrospective approach. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Accounting Principle for Retirement Benefit Plan Assets</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective during the third quarter of 2020, we adopted a voluntary change in our method of applying an accounting principle for certain of our retirement benefit plans. Refer to Note 15 for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644671288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,694.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,377.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,866.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,845.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,539.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,493.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $135.6 million, $301.5 million, and $303.2 million during the years ended December 31, 2020, 2019, and 2018, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements will include our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment. Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less. Any exceptions are either not material or we collect interest for payments made after the due date. Provisions for rebates, discounts, and returns are established in the same period the related sales are recognized. We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our products are sold to wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December&#160;31, 2020, 2019, and 2018, our three largest wholesalers each accounted for between 15 percent and 20 percent of consolidated revenue. Further, they each accounted for between 19 percent and 27 percent of accounts receivable as of December&#160;31, 2020 and 2019. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts and returns. The following describe the most significant of these judgments:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Rebates and Discounts - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We initially invoice our customers at contractual list prices. Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract. As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we must estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs. We estimate these accruals using an expected value approach.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, Medicaid, chargeback, and patient assistance programs in the U.S. In determining the appropriate accrual amount, we consider our historical rebate payments for these programs by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing. Although we accrue a liability for rebates related to these programs at the time we record the sale, the rebate related to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Returns - Background and Uncertainties</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically-identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuances, or a changing competitive environment. We maintain a returns policy that allows most U.S. customers to return product for dating issues within a specified period prior to and subsequent to the product's expiration date. Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires. In the U.S. we allow bamlanivimab to be returned if the Emergency Use Authorization (EUA) is revoked. If the EUA were to be revoked, we could experience an elevated level of product returns of bamlanivimab, dependent on the amount of product remaining in the distribution channel. Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions. We record the return amounts as a deduction to arrive at our net product revenue. Once the product is returned, it is destroyed; we do not record a right of return asset. Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries. Our reserve for future product returns for product sales outside the U.S. is not material.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual U.S. product returns have been less than 2 percent of our U.S. revenue over each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for the judgments described above for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods were approximately 1 percent,  2 percent and 1 percent of U.S revenue during 2020, 2019, and 2018, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Other Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our material collaborations and other arrangements. Our collaborations and other arrangements are not contracts with customers but are evaluated to determine whether any aspects of the arrangements are contracts with customers. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue related to products we sell pursuant to these arrangements is included in net product revenue, while other sources of revenue (e.g., royalties and profit sharing from our partner) are included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initial fees and developmental milestones we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third-parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). This royalty revenue is included in collaboration and other revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct. If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes. The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation. For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, subject to a constraint. These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into arrangements whereby we transferred rights to products and committed to supply for a period of time. For those arrangements for which we concluded that the obligations were not distinct, any amounts received upfront are being amortized to revenue as net product revenue over the period of the supply arrangement as the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">276.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.6&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities balances disclosed above as of December&#160;31, 2020 and 2019 were primarily related to the remaining license period of symbolic intellectual property and obligations to perform research and development activities or supply product for a defined period of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019, and 2018, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,835.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,232.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,485.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,140.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">866.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">533.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">842.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">282.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">162.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,909.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,529.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,925.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,212.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,265.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,064.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">618.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">480.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,792.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,527.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,288.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">575.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,372.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,089.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">725.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,344.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">510.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">536.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bamlanivimab </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">545.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,668.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,358.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,424.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,229.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,391.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,310.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,596.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,101.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trajenta revenue includes Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Bamlanivimab sales are pursuant to EUA.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:38.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,229.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,391.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,187.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,583.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,116.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,422.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,539.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,493.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644656792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestiture</a></td>
<td class="text">Acquisitions and Divestiture<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 and 2019, we completed the acquisitions of Dermira, Inc. (Dermira) and Loxo Oncology, Inc. (Loxo), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development in 2020, 2019, and 2018, which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use. For the years ended December&#160;31, 2020, 2019, and 2018, we recorded acquired IPR&amp;D charges of $660.4 million, $239.6 million, and $1.98 billion, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the U.S. Food and Drug Administration (FDA). We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue attributable to assets acquired in the Dermira acquisition did not have a material impact on our consolidated statement of operations for the year ended December 31, 2020. We are unable to provide the results of operations for the year ended December 31, 2020 attributable to Dermira as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our results of operations for the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Loxo Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired all shares of Loxo for a purchase price of $6.92 billion, net of cash acquired. The accelerated vesting of Loxo employee equity awards was recognized as transaction expense included in asset impairment, restructuring, and other special charges during the year ended December 31, 2019 (see Note 5).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired a pipeline of investigational medicines, including selpercatinib (LOXO-292), an oral RET inhibitor, and LOXO-305, an oral BTK inhibitor. In the second quarter of 2020, the FDA approved selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) under its Accelerated Approval regulations and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. At the time of approval, we reclassified our $4.60&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived intangible assets to finite-lived intangible assets and began amortizing straight line over its estimated useful life.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.018%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at February 15, 2019</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangibles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,032.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred - net of cash acquired</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$4.60 billion of the acquired IPR&amp;D relates to selpercatinib (LOXO-292).</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract-based intangibles (primarily related to Vitrakvi) which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of approximately 12 years from the acquisition date. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated statement of operations for the year ended December 31, 2019 includes revenue attributable to assets acquired in the Loxo acquisition of $136.7 million, primarily due to regulatory approval and sales milestones received. We are unable to provide the results of operations for the year ended December 31, 2019 attributable to Loxo as those operations were substantially integrated into our legacy business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included because this acquisition did not have a material impact on our results of operations for the years ended December 31, 2019 and 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and narrative summarize our asset acquisitions during 2020, 2019, and 2018.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatement and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical target that could lead to potential new medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Ltd</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical research collaboration for the potential treatment of neurological disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. (Disarm)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fochon Pharmaceuticals, Ltd. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical molecule targeting  hematological malignancies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AC Immune SA</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2019 &amp; September 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmuNext, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel immunometabolism target</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avidity Biosciences, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential new medicines in immunology and other select indications</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centrexion Therapeutics Corporation</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sigilon Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encapsulated cell therapies for the potential treatment of type 1 diabetes</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AurKa Pharma Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK-01, an Aurora kinase A inhibitor</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARMO BioSciences, Inc. (ARMO) </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer therapy - pegilodecakin</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anima Biotech Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation inhibitors for selected neuroscience targets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIGA Technologies, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chugai Pharmaceutical Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OWL833, an oral non-peptidic GLP-1 receptor agonist</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NextCure, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology cancer therapies</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dicerna Pharmaceuticals Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardio-metabolic disease, neurodegeneration, and pain</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hydra Biosciences</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 antagonists program for the potential treatment of chronic pain syndromes</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized the acquired IPR&amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expenses of $96.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in January 2019 upon entering into a license agreement and $30.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in September 2019 upon entering into an amendment to the license agreement.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This research and development collaboration agreement terminated effective March 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestiture</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we completed a transaction in which we sold the rights in China for two legacy antibiotic medicines, as well as a manufacturing facility in Suzhou, China to Eddingpharm, a China-based specialty pharmaceutical company. In connection with the sale, we received net cash proceeds of $354.8 million and $40.3 million from Eddingpharm in 2019 and 2020, respectively. We accounted for the transaction as the sale of a business. We recorded a gain of $309.8 million in Other&#8212;net, (income) expense upon closing the transaction in 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Precision BioSciences, Inc. (Precision)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a research collaboration and exclusive license agreement with Precision to utilize Precision's proprietary ARCUS genome editing platform for the research and development of potential in vivo therapies for genetic disorders. Under terms of the agreement, we paid an upfront cash payment of $100.0&#160;million and invested $35.0&#160;million in Precision's common stock at a premium. As a result of the transaction, we will record an acquired IPR&amp;D charge of $107.8 million in the first quarter of 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Merus N.V. (Merus) </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a research collaboration and exclusive license agreement with Merus to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. Under the terms of the agreement, we paid Merus an upfront cash payment of $40.0&#160;million and invested $20.0&#160;million in Merus common shares at a premium. As a result of the transaction, we will record an acquired IPR&amp;D charge of $46.5&#160;million in the first quarter of 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Therapeutics Inc. (Prevail) </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we completed our acquisition of Prevail. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that will be anchored by Prevail&#8217;s portfolio of clinical-stage and preclinical neuroscience assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired all shares of Prevail for $22.50 per share (approximately $880&#160;million) in cash plus one non-tradable contingent value right (CVR). The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom (U.K.), Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting impact of this acquisition and the results of the operations for Prevail will be included in our consolidated financial statements beginning in the first quarter of 2021.The initial accounting for this acquisition is incomplete. Significant, relevant information needed to complete the initial accounting is not available because the valuation of assets acquired and liabilities assumed is not complete. As a result, determining these values is not practicable, and we are unable to disclose these values or provide other related disclosures at this time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Asahi Kasei Pharma Corporation (Asahi)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a license agreement with Asahi to acquire the exclusive rights for AK1780, an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies for the potential treatment of chronic pain conditions. As a result of the transaction, we will pay Asahi an upfront cash payment and record an acquired IPR&amp;D charge of $20.0&#160;million in the first quarter of 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493652663032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">Collaborations and Other Arrangements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#8217;s oral diabetes products: Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, and Trijardy XR as well as our basal insulin, Basaglar. Jentadueto is included in the Trajenta product family. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.969%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestones </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Deferred) Capitalized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2019, in the most significant markets, we and Boehringer Ingelheim shared equally the ongoing development costs, commercialization costs, and agreed upon gross margin for any product resulting from the collaboration. We recorded our portion of the gross margin associated with Boehringer Ingelheim's products as collaboration and other revenue. We recorded our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we recorded our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company was entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments may have resulted in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product. Subject to achieving these thresholds, in a given period, our reported revenue for Trajenta and Jardiance may have been reduced by any performance payments we made related to these products. Similarly, performance payments we may have received related to Basaglar effectively reduced Boehringer Ingelheim's share of the gross margin, which reduced our cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, we and Boehringer Ingelheim modernized the alliance. In the most significant markets, we and Boehringer Ingelheim share equally the ongoing development costs and commercialization costs for the Jardiance product family. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales. For the Jardiance product family, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,124.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,153.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">358.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on  global net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In the first half of 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $210.0 million and $180.0 million were capitalized as intangible assets as of December 31, 2020 and 2019, respectively, and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Incyte is eligible to receive up to $100.0&#160;million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">638.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibody therapies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. In connection with this transaction, we recognized an acquired IPR&amp;D expense of $25.0 million in 2020. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales. Pursuant to an EUA, we recognized $871.2 million of net product revenue associated with our sales of bamlanivimab to third parties during the year ended December&#160;31, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of Greater China (which includes mainland China, Hong Kong and Macau Special Administrative Regions and Taiwan) and Junshi Biosciences maintains all rights in Greater China. In connection with this transaction, we recognized an acquired IPR&amp;D expense of $20.0 million in 2020. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our future net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. As of December 31, 2020, Junshi Biosciences is eligible to receive up to $75.0 million of additional payments contingent upon certain success-based regulatory milestones and up to $120.0 million of potential sales-based milestones, contingent upon the commercial success of etesevimab. During the year ended December&#160;31, 2020, we recognized $50.0 million of research and development expenses related to development milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tyvyt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent to jointly develop and commercialize Tyvyt (sintilimab injection) in China. In 2019, we and Innovent began co-commercializing Tyvyt in China. We record our sales of Tyvyt to third parties as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We also report as revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. Our Tyvyt revenue in China, which is primarily recorded as net product revenue, was $308.7&#160;million and $134.0 million in 2020 and 2019, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we obtained an exclusive license for Tyvyt from Innovent for geographies outside of China and plan to pursue registration of Tyvyt in the U.S. and other markets. We recorded an acquired IPR&amp;D charge of $200.0 million in 2020 associated with the upfront payment to Innovent.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $75.0 million in China in success-based regulatory and sales-based milestones.  Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tanezumab</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. The companies equally share the ongoing development costs and, if successful, in the U.S. will co-commercialize and equally share in gross margin and certain commercialization expenses. As a result of an amendment to the agreement in the third quarter of 2020, Pfizer will be responsible for commercialization activities and costs outside the U.S., and we have the right to receive tiered royalties in percentages from the high teens to mid-twenties for net sales in Japan as well as low double digit royalties on annual net sales greater than $150.0&#160;million in all other territories outside of the U.S. and Japan. As of December&#160;31, 2020, Pfizer is eligible to receive up to $147.5 million in success-based regulatory milestones based on current development plans and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of December&#160;31, 2020, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones, and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div>As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of December&#160;31, 2020, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.As of December&#160;31, 2020, $29.7 million was recorded as a contract liability on the consolidated balance sheet and is expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the twelve months ended December&#160;31, 2020, milestones received and collaboration and other revenue recognized were not material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493657897592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Asset Impairment, Restructuring, And Other Special Charges</a></td>
<td class="text">Asset Impairment, Restructuring, and Other Special Charges<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">131.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance costs recognized during the years ended December&#160;31, 2020, 2019 and 2018 were incurred as a result of actions taken worldwide to reduce our cost structure. Substantially all of the severance costs incurred during the year ended December&#160;31, 2020 are expected to be paid in the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment and other special charges recognized during the year ended December 31, 2019 resulted primarily from $400.7 million of other special charges related to the acquisition of Loxo, substantially all of which is associated with the accelerated vesting of Loxo employee equity awards. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment and other special charges recognized during the year ended December 31, 2018 resulted primarily from asset impairment and other special charges related to the sale of the Posilac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rbST) brand and the associated Augusta, Georgia manufacturing site.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644695928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories measured using LIFO must be valued at the lower of cost or market. Inventories measured using FIFO must be valued at the lower of cost or net realizable value. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">758.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,535.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">651.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,945.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,980.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised $1.21 billion and $1.20 billion of total inventories at December&#160;31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644376664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December&#160;31, 2020, we had outstanding foreign currency forward commitments to purchase 647.9 million U.S. dollars and sell 530.7 million euro; commitments to purchase 2.97 billion euro and sell 3.62&#160;billion U.S. dollars; commitments to purchase 180.7 million U.S. dollars and sell 18.64 billion Japanese yen, and commitments to purchase 272.2 million British pounds and sell 363.9 million U.S. dollars which all settled within 30 days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $6.02 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.49 billion as of December&#160;31, 2020 and 2019, respectively, of which $4.50 billion and $4.10 billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations as of December&#160;31, 2020 and 2019, respectively. At December&#160;31, 2020, we had outstanding cross currency swaps with notional amounts of $3.76 billion swapping U.S. dollars to euro and $1.00 billion swapping swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed rate debt to foreign-denominated fixed rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows. At December&#160;31, 2020, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 9 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of December&#160;31, 2020, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Effect of Risk Management Instruments on the Consolidated Statements of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(102.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(123.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(209.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(207.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></div></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12 months, we expect to reclassify $16.8 million of net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the years ended December&#160;31, 2020, 2019 and 2018, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,097.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,097.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,097.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,097.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">74.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">126.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,664.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">311.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,664.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,664.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">373.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">471.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,966.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,962.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term commercial paper borrowings</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,494.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,595.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,038.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,038.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,823.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,150.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,150.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.863%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.8)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.8)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.8)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available. As of December 31, 2020, we had approximately $687&#160;million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to 10 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"/><td style="width:42.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.618%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5      Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10    Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains recognized in our consolidated statements of operations for equity securities were $1,442.2 million, $401.2 million and $72.6&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The net gains/losses recognized for the years ended December 31, 2020, 2019 and 2018 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the years ended December&#160;31, 2020, 2019 and 2018 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment and credit losses.  The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 86 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of December&#160;31, 2020, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,529.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $754.9 million and $678.8 million&#160;of accounts receivable as of December&#160;31, 2020 and 2019, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated results of operations for the years ended December&#160;31, 2020, 2019, and 2018 were not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644336232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangibles</a></td>
<td class="text">Goodwill and Other Intangibles<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment. The changes in goodwill during 2020 and 2019 were primarily related to our acquisitions of Dermira and Loxo, respectively. See Note 3 for further discussion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No impairments occurred with respect to the carrying value of goodwill for the years ended December&#160;31, 2020, 2019, and 2018.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,984.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,659.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,324.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,150.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,244.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,076.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,727.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,349.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,296.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,948.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,727.8)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,450.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,296.4)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,618.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other finite-lived intangible assets consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of the fair values of acquired IPR&amp;D projects acquired in business combination, adjusted for subsequent impairments, if any. The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;D projects that had no alternative future use. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the &#8220;income method,&#8221; which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in marketed products and the decrease in acquired IPR&amp;D in 2020 primarily relates to the reclassification of our $4.60&#160;billion intangible asset for selpercatinib (Retevmo) from indefinite-lived to finite-lived as it was approved by the FDA in the second quarter of 2020. This decrease in acquired IPR&amp;D in 2020 was partially offset by the addition of acquired IPR&amp;D for lebrikizumab as a result of the Dermira acquisition. The increases in marketed products and acquired IPR&amp;D intangible assets in 2019 were primarily related to our acquisition of Loxo. See Note 3 for further discussion of intangible assets acquired in recent business combinations and Note 4 for additional discussion of recent capitalized milestone payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDIvZnJhZzo1NmFmMjNmZDZkMDU0Mzc2OTZiMzhmYzBmOTk2ZTBkNC90ZXh0cmVnaW9uOjU2YWYyM2ZkNmQwNTQzNzY5NmIzOGZjMGY5OTZlMGQ0XzQ1MTk_0bf7a79a-03a8-4be9-83df-152315c973ca">three</span> to 20 years. As of December&#160;31, 2020, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 15 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">428.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650397512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3Mg_22167169-de32-49e2-8061-fe64a7bff538">three</span> to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset&#8217;s net book value over its fair value, and the cost basis is adjusted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,326.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,067.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,560.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,913.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,138.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,252.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,034.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,570.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,161.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,681.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,872.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:69.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">765.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest costs were not material for the years ended December&#160;31, 2020, 2019, and 2018. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:38.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,113.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,786.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,747.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,648.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644408248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to 12 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $154.6 million and $172.8&#160;million during the years ended December&#160;31, 2020 and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2020 and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.955%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 3</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 4</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 5</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Year 5</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental expense for all leases, including contingent rentals (not material), was $175.7&#160;million for the year ended December 31, 2018. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. We have leases with terms up to 12 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases. We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets. Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $154.6 million and $172.8&#160;million during the years ended December&#160;31, 2020 and 2019, respectively. Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December&#160;31, 2020 and 2019. Short-term lease expense was not material during the years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.955%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 3</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 4</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 5</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Year 5</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental expense for all leases, including contingent rentals (not material), was $175.7&#160;million for the year ended December 31, 2018. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650397512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,348.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,638.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(89.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,595.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,317.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,499.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,586.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,817.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2019</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.35% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">750.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.00% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">99.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.00% Euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">737.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">671.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.15% Swiss Franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">679.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">618.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.125% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">229.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">229.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">560.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% Euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">922.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">839.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">377.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">377.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">401.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">401.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.45% Swiss Franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">453.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">412.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.375% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,150.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,150.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.42% Japanese Yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">222.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.125% Euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">922.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">839.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.625% Euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">737.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">671.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.56% Japanese Yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">90.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.77% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">174.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">476.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">476.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.95% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">284.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">284.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.875% notes due 2039</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">360.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">360.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.65% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">43.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">412.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">412.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">436.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">436.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,500.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,500.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.7% Euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,229.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,119.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.97% Japanese Yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">74.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.25% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,250.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.15% notes due 2059</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,000.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,000.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.5% notes due 2060</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(76.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16,348.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,638.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average effective borrowing rate on outstanding commercial paper at December&#160;31, 2019 was 1.65 percent. The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had a total of $5.24 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2024 and a $2.00 billion 364-day facility that expires in December 2021, both of which are available to support our commercial paper program. We have not drawn against the $3.00 billion and $2.00 billion facilities as of December&#160;31, 2020. Of the remaining committed bank credit facilities, the outstanding balances as of December&#160;31, 2020 and 2019 were not material. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued $1.00&#160;billion of 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $988.6 million for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued $850.0 million of 2.50 percent fixed-rate notes due in September 2060 and an additional $250.0 million of our 2.25 percent fixed-rate notes due in May 2050, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $1.07 billion for general corporate purposes, including the repayment of outstanding commercial paper. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we issued $1.15 billion of 3.375 percent fixed-rate notes due in March 2029, $850.0 million of 3.875 percent fixed-rate notes due in March 2039, $1.50 billion of 3.95 percent fixed-rate notes due in March 2049, and $1.00 billion of 4.15 percent fixed-rate notes due in March 2059, with interest to be paid semi-annually. We used the net cash proceeds of $4.45 billion from the offering to repay commercial paper that was issued in connection with the acquisition of Loxo and for general corporate purposes. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we issued euro-denominated notes consisting of &#8364;600.0 million of 0.625 percent fixed-notes due November 2031 and &#8364;1.00 billion of 1.70 percent fixed-rate notes due in November 2049 with interest to be paid annually. We paid $2.27 billion, comprised of $1.75 billion of net cash proceeds from the offering and proceeds from commercial paper, to purchase and redeem certain higher interest rate U.S. dollar denominated notes with an aggregate principal amount of $2.00 billion and a net carrying value of $2.01 billion, resulting in a debt extinguishment loss of $252.5 million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the year ended December 31, 2019.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we issued Japanese Yen-denominated notes consisting of &#165;22.92 billion of 0.42 percent fixed-rate notes due in November 2029, &#165;9.28 billion of 0.56 percent fixed-rate notes due in November 2034, and &#165;7.64 billion of 0.97 percent fixed-rate notes due in November 2049, with interest to be paid semi-annually. We used the net cash proceeds from the offering of $356.6 million for general corporate purposes, including the repayment of outstanding commercial paper.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have converted approximately 9 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December&#160;31, 2020 and 2019, including the effects of interest rate swaps for hedged debt obligations, were 2.61 percent and 2.88 percent, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">345.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt&#8217;s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645867224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), relative value awards (RVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 53.9 million additional shares. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Award Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December&#160;31, 2020, 2019, and 2018 were $137.33, $112.09, and $71.63, respectively. The number of shares ultimately issued for the PA program is dependent upon the EPS achieved during the vesting period. Pursuant to this program, approximately 1.1 million shares, 1.2 million shares, and 0.9 million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately 0.8 million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested PAs was $77.3 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Value Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2020, 2019, and 2018 were $139.14, $95.01, and $48.51, respectively, determined using the following assumptions:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.26&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, approximately 0.8 million shares, 1.0 million shares, and 0.7 million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately 1.0 million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested SVAs was $48.8 million, which will be amortized over the weighted-average remaining requisite service period of 20 months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relative Value Award Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we granted RVAs to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the three-year vesting period compared to our peers. We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair value of the RVA units granted during the year ended December&#160;31, 2020 was $179.90, determined using the following assumptions:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.89&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested RVAs was $13.7 million, which will be amortized over the weighted-average remaining requisite service period of 24 months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The fair values of RSU awards granted during the years ended December&#160;31, 2020, 2019, and 2018 were $135.42, $108.43, and $70.95, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 1.1 million, 1.5 million, and 1.3 million shares were granted and approximately 0.6 million, 0.8 million, and 1.0 million shares were issued during the years ended December&#160;31, 2020, 2019, and 2018, respectively. Approximately 0.6 million shares are expected to be issued in 2021. As of December&#160;31, 2020, the total remaining unrecognized compensation cost related to nonvested RSUs was $179.2 million, which will be amortized over the weighted-average remaining requisite service period of 31 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650397512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019, and 2018, we repurchased $500.0 million, $4.40 billion and $4.15 billion, respectively, of shares associated with our share repurchase programs. As of December&#160;31, 2020, we had $1.00 billion remaining under our $8.00 billion share repurchase program that our board authorized in June 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 5.0 million authorized shares of preferred stock. As of December&#160;31, 2020 and 2019, no preferred stock was issued.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee benefit trust that held 50.0 million shares of our common stock at both December&#160;31, 2020 and 2019, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01&#160;billion at both December&#160;31, 2020 and 2019, and is shown as a reduction of shareholders&#8217; equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December&#160;31, 2020, 2019, and 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645792328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to GILTI, global intangible low-taxed income, are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Job Act (the 2017 Tax Act) was signed into law. The 2017 Tax Act included significant changes to the U.S. corporate income tax system, such as the reduction in the corporate income tax rate from 35 percent to 21 percent, transition to a territorial tax system, changes to business related exclusions, deductions and credits, and modifications to international tax provisions, including a one-time repatriation transition tax (also known as the &#8216;Toll Tax&#8217;) on unremitted foreign earnings and GILTI, a new U.S. minimum tax on the earnings of our foreign subsidiaries. In 2018, we recorded $313.3 million of income tax benefit, mainly attributable to measurement period adjustments to the Toll Tax and GILTI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,170.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(134.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,036.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The 2020 and 2019 current tax expense includes $144.4 million and $153.1 million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards. The 2018 current tax expense includes $201.5 million of tax expense related to effects of the 2017 Tax Act.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The 2018 deferred tax benefit includes $26.2 million of tax benefit related to effects of the 2017 Tax Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">523.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">488.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">404.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">242.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,618.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,606.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(816.3)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616.5)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,801.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,990.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,905.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,465.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,298.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(623.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(410.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(315.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(216.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139.4)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,071.2)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,604.9)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">730.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, based on filed tax returns we have tax credit carryforwards and carrybacks of $887.3 million available to reduce future income taxes; $148.8 million, if unused, will expire by 2026, and $16.1 million, if unused, will expire between 2029 and 2039. The remaining portion of the tax credit carryforwards is related to federal tax credits of $84.8 million, international tax credits of $121.9 million, and state tax credits of $515.7 million, all of which are fully reserved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $1.52 billion: $162.6 million will expire by 2025; $781.7&#160;million will expire between 2026 and 2040; and $576.3 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses and other carryforwards of $175.6 million are fully reserved as of December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic and Puerto Rican companies contributed approximately 39 percent, 44 percent, and 15 percent for the years ended December&#160;31, 2020, 2019, and 2018, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2031.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations. At December 31, 2020 and December 31, 2019, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested. For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">954.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Act provided an election to taxpayers subject to the Toll Tax to make payments over an eight year period beginning in 2018 through 2025. Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years </span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,403.1</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$253.7</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$729.3</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,420.1</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have additional noncurrent income tax payables of $1.69&#160;billion unrelated to the Toll Tax; we cannot reasonably estimate the timing of future cash outflows associated with these liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div style="margin-bottom:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,518.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(297.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(627.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(150.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,036.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-deductible acquired IPR&amp;D was related to the acquisitions of Disarm and a pre-clinical stage company in 2020 and ARMO in 2018. See Note 3 for additional information related to acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,108.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">310.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(72.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,551.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $1.67&#160;billion and $1.53 billion at December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal, foreign, and various state and local income tax returns. We are no longer subject to U.S. federal income tax examination for years before 2016. In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2012.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months. For tax years 2013-2015, all matters were effectively settled in 2019. As a result, our gross uncertain tax positions were reduced by approximately $200 million, we made a cash payment of approximately $125 million, and our consolidated results were benefited by an immaterial reduction in tax expense. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:</span></div><div style="margin-bottom:17pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, our accruals for the payment of interest and penalties totaled $196.7 million and $150.8 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644624104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">Retirement Benefits<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,251.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,427.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,601.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">425.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,563.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(587.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(584.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment (gain) loss</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">245.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,225.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,251.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,753.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,858.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,932.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,768.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,802.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">539.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">318.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(587.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(584.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,579.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,227.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,646.5)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,393.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,473.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,515.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(349.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(177.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,884.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">946.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,697.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(67.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,878.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(216.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,530.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,195.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(526.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,884.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">946.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized net actuarial loss (gain) and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective during the third quarter of 2020, we adopted a voluntary change in our method of applying an accounting principle for certain of our retirement benefit plans. The new accounting method changes the computation of expected returns on U.S. dollar denominated investment grade debt securities and derivatives in such plans from a calculated value that includes changes in the fair values over a period of five years to actual fair value. This change in accounting principle is preferable because changes in the fair value of this class of assets will be amortized into net periodic pension and retiree health cost sooner. No change is being made to the accounting principle for the other classes of pension assets. The impact of the adoption of this change in accounting method was not material to our historical and current consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decrease in the discount rate was the primary driver for the $2.13&#160;billion and $2.89&#160;billion increase in the benefit obligation in 2020 and 2019, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we announced that we would amend our defined benefit pension and retiree health benefit plans to freeze or reduce benefits for certain employees effective January 1, 2019. We remeasured the impacted pension and retiree health plans&#8217; benefit obligations as of July 31, 2018, which resulted in a net curtailment gain of $28.0 million, which was recorded in asset impairment, restructuring, and other special charges.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,770.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,039.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,824.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,483.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,682.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,063.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">223.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,824.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,483.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total accumulated benefit obligation for our defined benefit pension plans was $17.03 billion and $15.17&#160;billion at December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"/><td style="width:38.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">425.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(901.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(842.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(158.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss (gain)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">396.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(136.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181.8)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019, and 2018:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(663.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">238.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">396.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(335.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,158.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $164.3 million, $145.2 million, and $132.6 million for the years ended December&#160;31, 2020, 2019, and 2018, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December&#160;31, 2020, 2019, and 2018 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit Plan Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 80 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 65 percent growth investments and 35 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate is composed of public holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets include cash and cash equivalents and mark-to-market value of derivatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,301.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,542.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December&#160;31, 2020. The activity in the Level 3 investments during the year ended December&#160;31, 2020 was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2019 by asset category were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,499.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2019. The activity in the Level 3 investments during the year ended December 31, 2019 was not material.</span></div>In 2021, we expect to contribute approximately $40 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We expect to contribute approximately $10 million in additional discretionary contributions in 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645909128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alimta Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of manufacturers are seeking approvals in the U.S., a number of countries in Europe, and Japan to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers.&#160;However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail.&#160;An unfavorable outcome in the U.S. could have a material adverse impact on our future consolidated results of operations and cash flows.&#160;We expect that a loss of exclusivity for Alimta in any of the below jurisdictions would result in a rapid and severe decline in future revenue for the product in the relevant market.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">U.S. Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) is protected by a vitamin regimen patent until 2021, plus pediatric exclusivity through May 2022. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Apotex Inc. (Apotex) alleging infringement of Alimta's vitamin regimen patent for its application to market a pemetrexed product. In December 2019, the U.S. District Court for the Southern District of Indiana granted our motion for summary judgment of infringement, and in December 2020, the U.S. Court of Appeals for the Federal Circuit affirmed that ruling. Apotex did not request reconsideration or a rehearing of that ruling. However, Apotex could petition the U.S. Supreme Court to review the case. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">European Patent Litigation</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings are ongoing regarding our Alimta patents in various national courts throughout Europe. We are aware that several companies have received approval to market generic versions of pemetrexed in major European markets and that generic competitors may choose to launch at risk. Following a final decision in the Supreme Court of Germany in July 2020 overturning the lower court and upholding the validity of our Alimta patent, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several generics that were on the market at risk left. We have removed the remaining generics from the market by obtaining preliminary injunctions in our favor. In September 2020, the Paris Court of First Instance in France issued a final decision upholding the validity of our Alimta patent and found infringement by Fresenius Kabi France and Fresenius Kabi Groupe France&#8217;s (collectively, Kabi) pemetrexed product. The court issued an injunction against Kabi and provisionally awarded us damages. In January 2021, that same court issued a preliminary injunction against Zentiva France S.A.S. (Zentiva), the last remaining company with a generic pemetrexed product on the French market, and provisionally awarded us damages. In October 2020, the Court of Appeal of the Netherlands overturned a lower court decision and ruled that our Alimta patent is valid and infringed and reinstated an injunction against Kabi, thereby removing Kabi's pemetrexed product from the Netherlands market. Kabi has appealed this decision to the Netherlands Supreme Court. Kabi's generic pemetrexed product was the only at risk generic on the market in the Netherlands.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vitamin regimen patents have also been challenged in other smaller European jurisdictions. We will continue to seek to remove any generic pemetrexed products launched at risk in other European markets, seek damages with respect to such launches, and defend our patents against validity challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Japanese Administrative Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Japanese Patent Office (JPO) issued notices closing Hopira Inc.'s (Hospira) invalidation against our Japanese Alimta patents. As a result, Hospira filed a withdrawal notice with the JPO and the JPO accepted the withdrawal in November. This matter is now closed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emgality Patent Litigation</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in nine different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in ad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ults. Trial is expected in December 2021. Separat</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely, the U.S. Patent and Trademark Office (USPTO) granted our request to initiate an&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(IPR) to reexamine the validity of the nine Teva patents asserted against us in the litigation. In February 2020, the USPTO ruled in our favor and found that the claims asserted against us in six of Teva's nine patents were invalid. In March 2020, the USPTO ruled against us on the remaining three Teva patents, finding that we failed to show that the remaining three patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the USPTO&#8217;s March 2020 ruling, and Teva appealed the USPTO&#8217;s February 2020 ruling to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Court of Appeals for the Federal Circuit</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The district court litigation will proceed in parallel with the IPR appeals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jardiance Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from Alkem Laboratories Ltd.'s (Alkem) and Ascend Laboratories, LLC's (Ascend) submissions of Abbreviated New Drug Applications (ANDA) seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, Alkem's and Ascend's ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. Trial was scheduled for April 2021 but has been postponed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we were </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">named as a defendant in litigation filed by Genentech, Inc. (Genentech) in Germany seeking a ruling that Genentech&#8217;s patent would be in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fringed by our continued sales of Taltz in Germany. After it sold its patent rights to Novartis Pharma AG (Novartis) in June 2020, Genentech withdrew its infringement litigation and Novartis subsequently filed litigation against us in Germany asserting infringement based on sales of Taltz. In January 2021, we entered into a settlement agreement with Novartis whereby all pending litigation in Germany related to the Taltz patent has been withdrawn and this matter has concluded. We were also named in litigation in the U.K. in which Genentech asserted similar claims regarding its corresponding U.K. patent. Novartis purchased Genentech's U.K. patent rights for Taltz, sought substitution for Genentech in the U.K. litigation and then sought dismissal of all appeals. Orders to this effect were issued by the Patents Court and Court of Appeal in November 2020 and these matters have concluded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zyprexa Canada Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000&#8217;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Canadian Federal Court of Appeals denied our appeal of a lower court's decision</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hat certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. Trial is expected in 2021 or 2022.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actos</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), one in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), one in Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and one in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Byetta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in March 2009, we are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. involving approximately 810 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Three lawsuits, representing approximately four plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court's grant of summary judgment based on that court's discovery rulings and remanded the cases for further proceedings. In November 2018, the California Court of Appeal reversed the state court's grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. We are aware of approximately 20 additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in August 2015, we are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#174;. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jardiance Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately 95 product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#8217; Fournier&#8217;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#cc0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">340B Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the alternative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. A hearing on our motion for preliminary injunction has been scheduled for February 26, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administration Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brazil Litigation &#8211; Cosmopolis Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Labor Attorney Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;300&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately&#160;950&#160;million Brazilian real (approximately $180&#160;million as of December 31, 2020). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#8217;s appeal to the superior labor court. The cost of any such health coverage has not been determined.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#8217;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit of 500 million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted. In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#8217;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Individual Former Employee Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2003, we have also been named in approximately 30&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">China NDRC Antitrust Matter </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, are named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for February 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#8217;s motion to dismiss the relator&#8217;s second amended complaint. In January 2020, the relator appealed the District Court&#8217;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a decision by the U.S. Court of Appeals for the Fifth Circuit on the aforementioned District Court appeal.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pricing Litigation, Investigations, and Inquires</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi-Aventis U.S. LLC (Sanofi) and Novo Nordisk, Inc. (Novo Nordisk) were named as defendants in a consolidated purported class action lawsuit,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. Also, filed in the same court in November 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and anti-trust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#8217; motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General&#8217;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. Additionally, in May 2019, the Kentucky Attorney General&#8217;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, federal and state anti-trust law, and the state deceptive trade practices-consumer protection act. Harris County also alleges common law claims such as fraud, unjust enrichment, and civil conspiracy. This lawsuit relates to our insulin products as well as Trulicity. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investigations, Subpoenas, and Inquiries</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a subpoena from the New York a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market. We received two&#160;requests from the House of Representatives&#8217; Committee on Energy and Commerce and a request from the Senate&#8217;s Committee on Health, Education, Labor, and Pensions seeking certain information related to the pricing of insulin products, among other issues. We also received requests from the House of Representatives&#8217; Committee on Oversight and Reform and the Senate&#8217;s Committee on Finance, which seek detailed commercial information and business records. In January 2021, the Senate&#8217;s Committee on Finance released a report summarizing the findings of its investigation. We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Corporation Technologies, Inc. </span></div>In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. A trial date has not been set.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645744552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:27.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#d8d8d8;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2018 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,191.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,311.3)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234.3)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.1)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,694.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification due to adoption of new accounting standard</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,569.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,852.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,740.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(967.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.3)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(379.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(133.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(256.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">267.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(112.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(120.8)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,427.5)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,751.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(332.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496.4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of January 1, 2018 consists of $5.72&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This reclassification consists of $105.2&#160;million of accumulated other comprehensive income attributable to controlling interest and $23.7&#160;million of accumulated other comprehensive income attributable to noncontrolling interest. Refer to Note 1 for further details regarding the reclassification due to the adoption of ASU 2016-01.  </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2018 consists of $5.73&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $11.0&#160;million of accumulated other comprehensive loss attributable to noncontrolling interest. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.3)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.230%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.3)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.8)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">267.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from continuing operations (net of tax)</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.4&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from discontinued operations (net of tax)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650368472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other-Net, (Income) Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other-Net, (Income) Expense</a></td>
<td class="text">Other&#8211;Net, (Income) Expense<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">359.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of antibiotic business in China (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(251.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,246.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,171.9)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>For the years ended December&#160;31, 2020 and 2019, other income was primarily related to net gains on investments (Note 7).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644383528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 24, 2018, Elanco completed its initial public offering (IPO) resulting in the issuance of 72.3 million shares of its common stock, which represented 19.8 percent of Elanco's outstanding shares, at $24 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the IPO, through a series of equity and other transactions, we transferred to Elanco the animal health businesses that formed its business.&#160;In exchange, Elanco transferred to us consideration of approximately $4.2 billion, which consisted primarily of the net proceeds from the IPO and the net proceeds from a $2.00 billion debt offering and a $500.0 million three-year term loan facility entered into by Elanco in August 2018. The consideration that we received was used for debt repayment, dividends, and share repurchases. The excess of the net proceeds from the IPO over the net book value of our divested interest was $629.2 million and was recorded in additional paid-in capital. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 11, 2019, we continued to consolidate Elanco, as we retained control over Elanco. We completed the disposition of our remaining 80.2 percent ownership of Elanco common stock through a tax-free exchange offer that closed on March 11, 2019 (the disposition date). The earnings attributable to the divested, noncontrolling interest for the period from the IPO until disposition were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the disposition, in the first quarter of 2019, we recognized a gain related to the disposition of approximately $3.7 billion, and we presented Elanco, including the gain related to the disposition, as discontinued operations in our consolidated financial statements for all periods presented. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets summarizes revenue and net income from discontinued operations:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain related to the disposition of Elanco in the consolidated statement of cash flows includes the operating results of Elanco through the disposition date, which were not material. Net cash flows of our discontinued operations for operating activities were not material for the year ended December 31, 2019. Net cash provided by operating activities related to our discontinued operations was approximately $500 million for the year ended December 31, 2018. The net cash flows of our discontinued operations for investing activities were not material for any period presented. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a transitional services agreement (TSA) with Elanco that is designed to facilitate the orderly transfer of various services to Elanco. The TSA relates primarily to administrative services, which are generally to be provided over 24 months from the disposition date. This agreement is not material and does not confer upon us the ability to influence the operating and/or financial policies of Elanco subsequent to the disposition date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648912232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development costs, which are expensed as incurred.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expense includes the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share (EPS)</a></td>
<td class="text">Earnings Per Share (EPS)We calculate basic EPS based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenses</a></td>
<td class="text">Advertising ExpensesCosts associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Implementation of New Financial Accounting Standards</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, we adopted Accounting Standards Update 2016-02, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using the modified retrospective approach, applied at the beginning of the period of adoption, and we elected the package of transitional practical expedients. The adoption of this standard resulted in recording of operating lease assets of approximately $530 million, which included reclassifying approximately $65 million of deferred rent and lease incentives, net of prepaid rent, as a component of the operating lease assets as of January 1, 2019. The adoption also resulted in recording operating lease liabilities of approximately $595 million as of January 1, 2019. Our accounting for finance leases remained substantially unchanged. Adoption of this standard did not result in a material change in net income in the year of adoption. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other related updates. This standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We applied this standard to contracts for which performance was not substantially complete as of the date of adoption. For those contracts that were modified prior to the date of adoption, we reflected the aggregate effect of those modifications when determining the appropriate accounting under the new standard. We don&#8217;t believe the effect of applying this practical expedient resulted in material differences. We applied this standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $5 million to retained earnings as of January 1, 2018. Adoption of this standard did not result in a material change in revenue or net income in the year of adoption.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2016-01 (ASU 2016-01), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard requires entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). We applied the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the year of adoption. Upon adoption, we reclassified from accumulated other comprehensive loss the after-tax amount of net unrealized gains resulting in an increase to retained earnings of approximately $105 million as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted Accounting Standards Update 2016-16, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard requires entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. We adopted this standard using a modified retrospective approach. Upon adoption, the cumulative effect of applying this standard resulted in an increase of approximately $700 million to retained earnings, $2.5 billion to deferred tax assets, and $1.8 billion to deferred tax liabilities as of January 1, 2018. Adoption of this standard did not result in a material change in net income in the year of adoption.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Accounting Principle for Retirement Benefit Plan Assets</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective during the third quarter of 2020, we adopted a voluntary change in our method of applying an accounting principle for certain of our retirement benefit plans. Refer to Note 15 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions have been included in our consolidated financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired IPR&amp;D was immediately expensed because the compound acquired had no alternative future use.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk</a></td>
<td class="text">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.&#160;We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div>We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.The costs of acquired IPR&amp;D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately. See Note 3 for acquired IPR&amp;D projects that had no alternative future use. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the &#8220;income method,&#8221; which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&amp;D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. ndefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount. If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&amp;D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the "income method" discussed above.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE4ZThiMDZmMDQ0MDRlNmZiMDllMzEzMTAzNDk1ZjhlL3NlYzphOGU4YjA2ZjA0NDA0ZTZmYjA5ZTMxMzEwMzQ5NWY4ZV8xNDgvZnJhZzoxY2M5MDU3YTE1Nzg0MThkOWY1MmU5NzljMWM3NDRlYS90ZXh0cmVnaW9uOjFjYzkwNTdhMTU3ODQxOGQ5ZjUyZTk3OWMxYzc0NGVhXzI3Mg_22167169-de32-49e2-8061-fe64a7bff538">three</span> to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset&#8217;s net book value over its fair value, and the cost basis is adjusted.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans</a></td>
<td class="text">We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, RVA, and RSU shares.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Deferred taxes related to GILTI, global intangible low-taxed income, are also recognized for the future tax effects of temporary differences.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644650184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,694.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,377.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,866.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,845.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,539.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,493.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $135.6 million, $301.5 million, and $303.2 million during the years ended December 31, 2020, 2019, and 2018, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,835.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,232.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,485.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,140.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,151.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">866.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">620.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">533.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">842.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">282.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">162.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,909.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,529.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,925.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,212.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,265.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,064.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">618.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">480.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,792.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,527.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,288.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">500.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">575.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,372.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,089.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">725.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">220.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,344.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">510.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">536.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bamlanivimab </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">545.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d4d4d4;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,668.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,358.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,424.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,229.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,391.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,310.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,596.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,101.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Humalog revenue includes insulin lispro.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trajenta revenue includes Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Bamlanivimab sales are pursuant to EUA.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:38.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,229.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,722.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,391.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,187.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,583.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,116.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,422.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,539.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,319.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,493.3&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Amounts Recorded for Contract Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">276.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.6&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644655112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed in the acquisition of Loxo as of the acquisition date:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.018%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at February 15, 2019</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangibles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,032.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred - net of cash acquired</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$4.60 billion of the acquired IPR&amp;D relates to selpercatinib (LOXO-292).</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract-based intangibles (primarily related to Vitrakvi) which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of approximately 12 years from the acquisition date. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to future unidentified projects and products and the assembled workforce for Loxo and is not deductible for tax purposes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Schedule of Research and Development Assets Acquired Other than Through Business Combination</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and narrative summarize our asset acquisitions during 2020, 2019, and 2018.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s),Therapy, or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatement and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.718%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical target that could lead to potential new medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Ltd</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical research collaboration for the potential treatment of neurological disorders</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovent Biologics, Inc. (Innovent) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection, an anti-PD-1 monoclonal antibody immuno-oncology medicine,  for geographies outside of China</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disarm Therapeutics, Inc. (Disarm)</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disease-modifying therapeutics program for patients with axonal degeneration</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fochon Pharmaceuticals, Ltd. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical molecule targeting  hematological malignancies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AC Immune SA</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2019 &amp; September 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmuNext, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel immunometabolism target</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avidity Biosciences, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential new medicines in immunology and other select indications</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centrexion Therapeutics Corporation</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNTX-0290, a novel, small molecule somatostatin receptor type 4 agonist</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2019</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sigilon Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encapsulated cell therapies for the potential treatment of type 1 diabetes</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AurKa Pharma Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK-01, an Aurora kinase A inhibitor</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARMO BioSciences, Inc. (ARMO) </span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer therapy - pegilodecakin</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anima Biotech Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation inhibitors for selected neuroscience targets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIGA Technologies, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chugai Pharmaceutical Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OWL833, an oral non-peptidic GLP-1 receptor agonist</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NextCure, Inc.</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology cancer therapies</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dicerna Pharmaceuticals Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardio-metabolic disease, neurodegeneration, and pain</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hydra Biosciences</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 antagonists program for the potential treatment of chronic pain syndromes</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2018</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized the acquired IPR&amp;D expense of $25.0&#160;million in May 2020 upon closing of the transaction. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognized acquired IPR&amp;D expenses of $96.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in January 2019 upon entering into a license agreement and $30.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in September 2019 upon entering into an amendment to the license agreement.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This research and development collaboration agreement terminated effective March 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493646010136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.969%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Milestones </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Deferred) Capitalized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,124.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,153.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">358.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table summarizes our net product revenue recognized with respect to Olumiant:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">638.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650346248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Other Operating Cost and Expense, by Component</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (gain) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">131.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645849592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">758.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,535.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">651.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates replacement cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,945.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase to LIFO cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,980.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645725688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(86.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(102.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(123.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(209.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(207.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></div></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(404.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(207.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></div></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at December&#160;31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,097.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,097.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,097.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,097.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">74.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">126.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">137.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,664.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">311.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,664.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,664.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">373.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">471.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,966.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">405.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.4&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,962.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term commercial paper borrowings</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,494.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,595.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,038.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,038.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,823.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,150.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,150.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.863%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.8)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.8)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.8)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"/><td style="width:42.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.618%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5      Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10    Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More Than 10 Years</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (Loss) on Investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,529.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649653624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-lived Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,984.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,659.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,324.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,150.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,244.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,076.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,727.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,349.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,296.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,948.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,727.8)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,450.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,296.4)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,618.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-lived Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of intangible assets other than goodwill at December&#160;31 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:26.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount, <br/>Net</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,984.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,659.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,324.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,150.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,244.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,076.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,727.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,349.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,296.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,948.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,727.8)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,450.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,296.4)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,618.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to finite-lived intangible assets was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">428.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644693256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, property and equipment consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,326.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,067.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,560.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,913.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,138.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,252.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,034.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,570.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,161.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,681.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,872.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:69.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">765.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Long-lived Assets by Geographic Areas</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets by geographical area:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:38.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,113.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,786.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,747.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,648.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment, net, operating lease assets, and certain other noncurrent assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658056760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Impact of Leases to Consolidated Condensed Financial Statements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases as of December&#160;31, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases during the years ended December&#160;31, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.955%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual minimum lease payments of our operating lease liabilities as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 3</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 4</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year 5</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Year 5</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645910536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at December&#160;31 consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term commercial paper borrowings</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,348.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,638.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(89.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment on hedged long-term notes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">320.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,595.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,317.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,499.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,586.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,817.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long-term Notes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-term notes at December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2019</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.35% notes due 2022</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">750.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.00% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">99.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.00% Euro denominated notes due 2022</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">737.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">671.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.15% Swiss Franc denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">679.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">618.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.125% notes due 2025</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">229.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">229.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">560.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.625% Euro denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">922.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">839.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">377.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">377.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1% notes due 2027</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">401.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">401.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.45% Swiss Franc denominated notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">453.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">412.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.375% notes due 2029</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,150.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,150.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.42% Japanese Yen denominated notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">222.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.125% Euro denominated notes due 2030</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">922.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">839.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.625% Euro denominated notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">737.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">671.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.56% Japanese Yen denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">90.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.77% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">174.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">476.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">476.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.95% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">284.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">284.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.875% notes due 2039</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">360.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">360.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.65% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">43.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7% notes due 2045</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">412.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">412.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">436.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">436.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.95% notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,500.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,500.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.7% Euro denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,229.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,119.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.97% Japanese Yen denominated notes due 2049</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">74.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.25% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,250.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.15% notes due 2059</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,000.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,000.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.5% notes due 2060</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">850.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized note discounts</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(76.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total long-term notes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16,348.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,638.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amounts of maturities on long-term debt for the next five years are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:49.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities on long-term debt</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock', window );">Schedule of Additional Borrowings Disclosures</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest on borrowings</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">345.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Borrowings Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644639768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock', window );">Schedule of Additional Stock-Based Compensation Disclosures</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense and the related tax benefits were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock', window );">Share-based Compensation Awards, Fair Value Assumptions Used</a></td>
<td class="text">The weighted-average fair values of the SVA units granted during the years ended December&#160;31, 2020, 2019, and 2018 were $139.14, $95.01, and $48.51, respectively, determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.26&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The weighted-average fair value of the RVA units granted during the year ended December&#160;31, 2020 was $179.90, determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.89&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658238200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is the composition of income tax expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,170.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(134.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,036.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The 2020 and 2019 current tax expense includes $144.4 million and $153.1 million of tax benefit, respectively, from utilization of net operating loss and tax credit carryforwards. The 2018 current tax expense includes $201.5 million of tax expense related to effects of the 2017 Tax Act.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The 2018 deferred tax benefit includes $26.2 million of tax benefit related to effects of the 2017 Tax Act.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:73.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934.3&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">523.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards and carrybacks</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">488.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">461.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Correlative tax adjustments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">404.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.1&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax redeterminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">242.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">605.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.7&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,618.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,606.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(816.3)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616.5)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,801.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,990.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,905.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,465.7)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,298.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(623.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(686.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid employee benefits</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(410.1)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(315.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(216.9)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139.4)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(134.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,071.2)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,604.9)</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets - net</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">730.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock', window );">Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments of income taxes</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">954.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Having made this election, our future cash payments relating to the Toll Tax as of December 31, 2020 are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years </span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act Toll Tax</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,403.1</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$253.7</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$729.3</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,420.1</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense: </span></div><div style="margin-bottom:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the U.S. federal statutory tax rate</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,518.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add (deduct):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations, including Puerto Rico</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(297.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(627.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(97.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(150.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,036.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-deductible acquired IPR&amp;D was related to the acquisitions of Disarm and a pre-clinical stage company in 2020 and ARMO in 2018. See Note 3 for additional information related to acquisitions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,108.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">310.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(52.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(72.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses of statutes of limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes related to the impact of foreign currency translation</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance at December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,551.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:</span></div><div style="margin-bottom:17pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Income Tax Disclosures [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649121816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock', window );">Schedule of Changes in Accumulated Postemployment Benefit Obligations</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a measurement date of December&#160;31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December&#160;31 for our defined benefit pension and retiree health benefit plans, which were as follows: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,251.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,427.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,601.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">425.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,563.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(587.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(584.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment (gain) loss</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">245.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,225.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,251.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,753.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Changes in Fair Value of Plan Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,858.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,932.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,768.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,802.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">539.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">318.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(587.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(584.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets at end of year</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,579.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,227.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock', window );">Schedule of Net Funded Status</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,646.5)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,393.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,473.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,515.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(349.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service (benefit) cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(177.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,884.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">946.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock', window );">Schedule of Amounts Recognized in Balance Sheet</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in the consolidated balance sheet consisted&#160;of:</span></div></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,697.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(67.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.4)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,878.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(216.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (income) loss before income taxes</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,530.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,195.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(526.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,884.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">946.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents our weighted-average assumptions as of December&#160;31:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Percents)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for benefit obligation</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for benefit obligation</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase for net benefit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets for net benefit costs</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026-2030</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension plans</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639.2&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673.1&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retiree health benefit plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,770.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,039.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,824.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,483.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health <br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,682.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,063.7&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">223.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.4&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,824.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,483.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Net Benefit Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit expense included the following components:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.382%"><tr><td style="width:1.0%"/><td style="width:38.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic (benefit) cost:</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">425.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(901.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(842.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(158.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost</span></div></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss (gain)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">396.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment (gain) loss</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(136.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181.8)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Amounts Recognized in Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents the amounts recognized in other comprehensive income (loss) for the years ended December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019, and 2018:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined&#160;Benefit<br/>Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree&#160;Health<br/>Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(663.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">238.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments during period</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailment gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (benefit) cost included in net income</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">396.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange rate changes and other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss) during period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(335.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,158.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2020 by asset category were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for<br/>Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Observable&#160;<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,301.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,670.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,542.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,331.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749.9&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our defined benefit pension plan and retiree health plan assets as of December&#160;31, 2019 by asset category were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:30.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Asset Class</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices in Active Markets&#160;for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments Valued at Net Asset Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets - repurchase agreements</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.1)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,499.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public equity securities:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private alternative investments:</span></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-like funds</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.4&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.8&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash value of trust owned insurance contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768.2&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.5&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923.4&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701.6&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the accumulated postemployment benefit obligation from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetFundedStatusTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644625768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:27.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Continuing Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discontinued Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#d8d8d8;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2018 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,191.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,311.3)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234.3)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.1)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,694.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification due to adoption of new accounting standard</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378.0)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.7&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378.0)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,569.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,852.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,740.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(967.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997.6)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.3)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785.9)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(783.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(379.7)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(133.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(256.2)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">267.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(112.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(120.8)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,427.5)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,751.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(332.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496.4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of January 1, 2018 consists of $5.72&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $23.7 million of accumulated other comprehensive income attributable to noncontrolling interest. </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This reclassification consists of $105.2&#160;million of accumulated other comprehensive income attributable to controlling interest and $23.7&#160;million of accumulated other comprehensive income attributable to noncontrolling interest. Refer to Note 1 for further details regarding the reclassification due to the adoption of ASU 2016-01.  </span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2018 consists of $5.73&#160;billion of accumulated other comprehensive loss attributable to controlling interest and $11.0&#160;million of accumulated other comprehensive loss attributable to noncontrolling interest. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.1&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.3)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.3)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of Amounts Recognized in Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.230%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other <br/>Comprehensive Loss Components</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></td><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.8&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.6&#160;</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">338.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.0)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.3)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.8)</span></td><td style="background-color:#d4d4d4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">267.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8212;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from continuing operations (net of tax)</span></td><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.4&#160;</span></td><td style="background-color:#d4d4d4;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications from discontinued operations (net of tax)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td></tr><tr><td colspan="3" style="background-color:#d4d4d4;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#d4d4d4;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d4d4d4;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493657352104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other - Net, (Income) Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.845%"><tr><td style="width:1.0%"/><td style="width:60.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">359.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.5&#160;</span></td><td style="background-color:#d8d8d8;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 11)</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.5&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of antibiotic business in China (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(251.8)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.9)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"/><td colspan="2" style="background-color:#d8d8d8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.5)</span></td><td style="background-color:#d8d8d8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,246.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,171.9)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145.6)</span></td><td style="background-color:#d8d8d8;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645978408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Summary of Revenue and Net Income from Discontinued Operations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets summarizes revenue and net income from discontinued operations:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493657914504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 11, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AdvertisingExpensePercentageOfRevenue', window );">Advertising expense, percentage of revenue</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 276.8<span></span>
</td>
<td class="nump">$ 264.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 663.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="nump">$ 5,825.2<span></span>
</td>
<td class="nump">$ 2,699.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="nump">730.5<span></span>
</td>
<td class="nump">385.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="nump">7,830.2<span></span>
</td>
<td class="nump">4,920.4<span></span>
</td>
<td class="nump">$ 11,395.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,894.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="num">$ (6,496.4)<span></span>
</td>
<td class="num">$ (6,523.6)<span></span>
</td>
<td class="num">(5,729.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,718.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Tax Cuts and Jobs Act, reclassification from AOCI to retained earnings, tax effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Elanco | Eli Lilly and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Disposition of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (65.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 | Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=lly_AccountingStandardsUpdate201616aMember', window );">Accounting Standards Update 2016-16 | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=lly_AccountingStandardsUpdate201616aMember', window );">Accounting Standards Update 2016-16 | Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AdvertisingExpensePercentageOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advertising Expense, Percentage Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AdvertisingExpensePercentageOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL116659650-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lly_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lly_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=lly_AccountingStandardsUpdate201616aMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=lly_AccountingStandardsUpdate201616aMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649182136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Summary of Revenue Recognized) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
<td class="nump">$ 21,493.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">22,694.8<span></span>
</td>
<td class="nump">20,377.3<span></span>
</td>
<td class="nump">19,866.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember', window );">Collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,845.0<span></span>
</td>
<td class="nump">1,942.2<span></span>
</td>
<td class="nump">1,626.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Collaboration and other revenue associated with prior period transfers of intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 135.6<span></span>
</td>
<td class="nump">$ 301.5<span></span>
</td>
<td class="nump">$ 303.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648389336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuefromContractPaymentTermMinimum', window );">Revenue, performance obligation, payment terms, days from date of shipment, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuefromContractPaymentTermMaximum', window );">Revenue, performance obligation, payment terms, days from date of shipment, maximum</a></td>
<td class="text">70 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt', window );">Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod', window );">Revenue, performance obligation, sales rebate payment period (up to)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate', window );">Revenue, performance obligation, sales returns, product expiration date</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel', window );">Revenue, performance obligation, sales returns, average inventory level (or less)</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue', window );">Revenue, performance obligation, sales returns, percentage of net revenue (less than)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Sales returns, rebates, and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent', window );">Revenue, information used to determine revenue recognized, change in accounting estimate, percent</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Revenue Benchmark | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Revenue Benchmark | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Accounts Receivable | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember', window );">Three Largest Wholesales | Accounts Receivable | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesRebatePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Rebate Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesRebatePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Average Inventory Level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Sales Returns, Product Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuefromContractPaymentTermMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract, Payment Term, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuefromContractPaymentTermMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenuefromContractPaymentTermMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenuefromContractPaymentTermMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lly_ThreeLargestWholesalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650364888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue (Contract Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 276.8<span></span>
</td>
<td class="nump">$ 264.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493734015368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
<td class="nump">$ 21,493.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">14,229.3<span></span>
</td>
<td class="nump">12,722.6<span></span>
</td>
<td class="nump">12,391.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">10,310.5<span></span>
</td>
<td class="nump">9,596.8<span></span>
</td>
<td class="nump">9,101.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">7,909.1<span></span>
</td>
<td class="nump">7,529.5<span></span>
</td>
<td class="nump">6,607.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,925.3<span></span>
</td>
<td class="nump">3,602.6<span></span>
</td>
<td class="nump">3,212.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,835.9<span></span>
</td>
<td class="nump">3,155.2<span></span>
</td>
<td class="nump">2,515.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,232.2<span></span>
</td>
<td class="nump">972.7<span></span>
</td>
<td class="nump">683.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,485.6<span></span>
</td>
<td class="nump">1,669.7<span></span>
</td>
<td class="nump">1,787.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,140.3<span></span>
</td>
<td class="nump">1,151.0<span></span>
</td>
<td class="nump">1,208.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">866.4<span></span>
</td>
<td class="nump">879.7<span></span>
</td>
<td class="nump">910.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">393.2<span></span>
</td>
<td class="nump">410.4<span></span>
</td>
<td class="nump">421.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,153.8<span></span>
</td>
<td class="nump">944.2<span></span>
</td>
<td class="nump">658.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">620.8<span></span>
</td>
<td class="nump">565.9<span></span>
</td>
<td class="nump">400.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">533.0<span></span>
</td>
<td class="nump">378.3<span></span>
</td>
<td class="nump">258.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,124.4<span></span>
</td>
<td class="nump">1,112.6<span></span>
</td>
<td class="nump">801.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">842.3<span></span>
</td>
<td class="nump">876.2<span></span>
</td>
<td class="nump">622.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">282.1<span></span>
</td>
<td class="nump">236.3<span></span>
</td>
<td class="nump">178.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">358.5<span></span>
</td>
<td class="nump">590.6<span></span>
</td>
<td class="nump">574.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">224.8<span></span>
</td>
<td class="nump">224.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">263.0<span></span>
</td>
<td class="nump">365.8<span></span>
</td>
<td class="nump">350.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">162.5<span></span>
</td>
<td class="nump">158.0<span></span>
</td>
<td class="nump">146.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">81.5<span></span>
</td>
<td class="nump">88.1<span></span>
</td>
<td class="nump">112.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,792.1<span></span>
</td>
<td class="nump">2,608.5<span></span>
</td>
<td class="nump">2,403.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,527.2<span></span>
</td>
<td class="nump">2,005.9<span></span>
</td>
<td class="nump">1,857.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,265.3<span></span>
</td>
<td class="nump">1,219.5<span></span>
</td>
<td class="nump">1,131.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,064.7<span></span>
</td>
<td class="nump">896.4<span></span>
</td>
<td class="nump">1,001.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">381.9<span></span>
</td>
<td class="nump">335.3<span></span>
</td>
<td class="nump">291.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">650.8<span></span>
</td>
<td class="nump">589.9<span></span>
</td>
<td class="nump">529.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">618.2<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
<td class="nump">248.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">294.4<span></span>
</td>
<td class="nump">124.9<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">480.1<span></span>
</td>
<td class="nump">487.9<span></span>
</td>
<td class="nump">531.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">56.3<span></span>
</td>
<td class="nump">55.4<span></span>
</td>
<td class="nump">103.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
<td class="nump">200.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">461.0<span></span>
</td>
<td class="nump">339.3<span></span>
</td>
<td class="nump">215.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,372.3<span></span>
</td>
<td class="nump">1,059.0<span></span>
</td>
<td class="nump">745.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,089.6<span></span>
</td>
<td class="nump">734.3<span></span>
</td>
<td class="nump">394.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,288.5<span></span>
</td>
<td class="nump">1,016.8<span></span>
</td>
<td class="nump">738.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="nump">349.6<span></span>
</td>
<td class="nump">198.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">638.9<span></span>
</td>
<td class="nump">426.9<span></span>
</td>
<td class="nump">202.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">63.8<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">575.0<span></span>
</td>
<td class="nump">384.7<span></span>
</td>
<td class="nump">195.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">487.3<span></span>
</td>
<td class="nump">356.5<span></span>
</td>
<td class="nump">277.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,344.0<span></span>
</td>
<td class="nump">1,366.4<span></span>
</td>
<td class="nump">1,543.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">42.1<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">725.6<span></span>
</td>
<td class="nump">675.8<span></span>
</td>
<td class="nump">653.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">46.1<span></span>
</td>
<td class="nump">41.0<span></span>
</td>
<td class="nump">36.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">360.5<span></span>
</td>
<td class="nump">377.6<span></span>
</td>
<td class="nump">435.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">325.9<span></span>
</td>
<td class="nump">154.9<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">73.2<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">220.9<span></span>
</td>
<td class="nump">305.3<span></span>
</td>
<td class="nump">454.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,668.4<span></span>
</td>
<td class="nump">1,169.1<span></span>
</td>
<td class="nump">2,358.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,424.4<span></span>
</td>
<td class="nump">1,887.7<span></span>
</td>
<td class="nump">2,093.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">510.3<span></span>
</td>
<td class="nump">645.5<span></span>
</td>
<td class="nump">757.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">536.0<span></span>
</td>
<td class="nump">759.1<span></span>
</td>
<td class="nump">817.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BamlanivimabMember', window );">Bamlanivimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">871.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BamlanivimabMember', window );">Bamlanivimab | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">850.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BamlanivimabMember', window );">Bamlanivimab | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">61.8<span></span>
</td>
<td class="nump">231.7<span></span>
</td>
<td class="nump">1,129.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">545.4<span></span>
</td>
<td class="nump">658.8<span></span>
</td>
<td class="nump">722.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">246.4<span></span>
</td>
<td class="nump">291.9<span></span>
</td>
<td class="nump">471.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 321.8<span></span>
</td>
<td class="nump">$ 469.7<span></span>
</td>
<td class="nump">$ 553.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrulicityMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_AlimtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_AlimtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CyramzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CyramzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_VerzenioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_VerzenioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ErbituxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ErbituxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TaltzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TaltzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CymbaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CymbaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ZyprexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ZyprexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_EmgalityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_EmgalityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BamlanivimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BamlanivimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493651308824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Geographical Area) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
<td class="nump">$ 21,493.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">14,229.3<span></span>
</td>
<td class="nump">12,722.6<span></span>
</td>
<td class="nump">12,391.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,187.7<span></span>
</td>
<td class="nump">3,765.0<span></span>
</td>
<td class="nump">3,663.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,583.1<span></span>
</td>
<td class="nump">2,547.6<span></span>
</td>
<td class="nump">2,407.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,116.9<span></span>
</td>
<td class="nump">939.4<span></span>
</td>
<td class="nump">750.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 2,422.7<span></span>
</td>
<td class="nump">$ 2,344.9<span></span>
</td>
<td class="nump">$ 2,280.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493734668024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>medicine</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660.4<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="nump">$ 1,980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,679.4<span></span>
</td>
<td class="nump">$ 3,679.4<span></span>
</td>
<td class="nump">3,766.5<span></span>
</td>
<td class="nump">3,679.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276.5<span></span>
</td>
<td class="nump">2,866.4<span></span>
</td>
<td class="nump">1,009.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain related to disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 309.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member', window );">Dermira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 849.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangibles acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,326.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,670.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc. | Selpercatinib (LOXO-292)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China | Eddingpharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_NumberOfMedicinesRightsToSold', window );">Number of legacy antibiotic medicines rights sold | medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from divestiture of businesses, net of cash divested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived', window );">Disposal group, not discontinued operation, payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain related to disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Precision BioSciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments for acquisitions</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Consideration transferred, equity interests purchased</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Merus N.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments for acquisitions</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Consideration transferred, equity interests purchased</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Forecast | Precision BioSciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Forecast | Merus N.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments for acquisitions</a></td>
<td class="nump">$ 880.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction', window );">Contingent value right, monthly reduction | $ / shares</a></td>
<td class="nump">$ 0.083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Asahi Kasei Pharma Corporation | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Additional Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Payment To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_NumberOfMedicinesRightsToSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Medicines, Rights To, Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_NumberOfMedicinesRightsToSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lly_EddingpharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lly_EddingpharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetAcquisitionAxis=lly_PrecisionBioSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetAcquisitionAxis=lly_PrecisionBioSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetAcquisitionAxis=lly_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetAcquisitionAxis=lly_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493651298360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions and Divestiture (Purchase Price Allocation) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 15, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766.5<span></span>
</td>
<td class="nump">$ 3,679.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="nump">$ 4,670.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangibles</a></td>
<td class="nump">980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="num">(1,032.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet', window );">Other assets and liabilities - net</a></td>
<td class="num">(26.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">4,590.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,326.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred - net of cash acquired</a></td>
<td class="nump">$ 6,917.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Contract-based intangibles | Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member', window );">Selpercatinib (LOXO-292) | Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="nump">$ 4,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648197832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestiture (Asset Acquisitions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="16">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660.4<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="nump">$ 1,980.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember', window );">Sitryx Therapeutics Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member', window );">AbCellera Biologics Inc. (AbCellera)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember', window );">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_UndisclosedAssetAcquisitionMember', window );">Undisclosed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_EvoxTherapeuticsMember', window );">Evox Therapeutics Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_InnoventBiologicsIncMember', window );">Innovent Biologics, Inc. (Innovent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_DisarmTherapeuticsIncMember', window );">Disarm Therapeutics, Inc. (Disarm)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_FochonPharmaceuticalsLtdMember', window );">Fochon Pharmaceuticals, Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_ACImmuneSAMember', window );">AC Immune SA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_ImmuNextInc.Member', window );">ImmuNext, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AvidityBiosciencesInc.Member', window );">Avidity Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_CentrexionTherapeuticsCorporationMember', window );">Centrexion Therapeutics Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_SigilonTherapeuticsMember', window );">Sigilon Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AurkaPharmaMember', window );">AurKa Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_ARMOBiosciencesInc.Member', window );">ARMO BioSciences, Inc. (ARMO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,475.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AnimaBiotechMember', window );">Anima Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_SIGATechnologiesMember', window );">SIGA Technologies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_ChugaiPharmaceuticalCompanyMember', window );">Chugai Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_NextCureInc.Member', window );">NextCure, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_DicernaPharmaceuticalsMember', window );">Dicerna Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_HydraBiosciencesMember', window );">Hydra Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_UndisclosedAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_UndisclosedAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_EvoxTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_EvoxTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_DisarmTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_DisarmTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_FochonPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_FochonPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_ACImmuneSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_ACImmuneSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_ImmuNextInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_ImmuNextInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AvidityBiosciencesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AvidityBiosciencesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_CentrexionTherapeuticsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_CentrexionTherapeuticsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_SigilonTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_SigilonTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AurkaPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AurkaPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_ARMOBiosciencesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_ARMOBiosciencesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AnimaBiotechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AnimaBiotechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_SIGATechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_SIGATechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_ChugaiPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_ChugaiPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_NextCureInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_NextCureInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_DicernaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_DicernaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_HydraBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_HydraBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493749410952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details) - Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Trajenta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="nump">$ 446.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="nump">289.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="num">$ (250.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493657819576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Net Product Revenue) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
<td class="nump">$ 21,493.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,124.4<span></span>
</td>
<td class="nump">1,112.6<span></span>
</td>
<td class="nump">801.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,153.8<span></span>
</td>
<td class="nump">944.2<span></span>
</td>
<td class="nump">658.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">358.5<span></span>
</td>
<td class="nump">590.6<span></span>
</td>
<td class="nump">574.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 638.9<span></span>
</td>
<td class="nump">$ 426.9<span></span>
</td>
<td class="nump">$ 202.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493734059000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660.4<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="nump">$ 1,980.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,539.8<span></span>
</td>
<td class="nump">22,319.5<span></span>
</td>
<td class="nump">21,493.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276.8<span></span>
</td>
<td class="nump">264.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member', window );">AbCellera Biologics Inc. (AbCellera)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember', window );">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116.9<span></span>
</td>
<td class="nump">939.4<span></span>
</td>
<td class="nump">750.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember', window );">Milestone Payments, Success-based Regulatory And Sales-based | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryMember', window );">Milestone Payments, Success-based Regulatory | Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638.9<span></span>
</td>
<td class="nump">426.9<span></span>
</td>
<td class="nump">$ 202.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Royalty Payments Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsPercent', window );">Collaborative arrangement, rights and obligations percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Milestone Payments, Development and Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Milestone Payments, Sales-based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BamlanivimabMember', window );">Bamlanivimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308.7<span></span>
</td>
<td class="nump">$ 134.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt | Milestone Payments, Success-based Regulatory And Sales-based | Outside of China | Innovent Biologics, Inc. (Innovent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt | Milestone Payments, Success-based Regulatory And Sales-based | China | Innovent Biologics, Inc. (Innovent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TanezumabMember', window );">Tanezumab | Outside US And Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold', window );">Annual net sales threshold (greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TanezumabMember', window );">Tanezumab | Milestone Payments, Development and Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TanezumabMember', window );">Tanezumab | Milestone Payments, Sales-based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Development and Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Development and Regulatory | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Sales-based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab | Milestone Payments, Sales-based | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,030.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Rights (Obligations)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BamlanivimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BamlanivimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_NonCHINAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_NonCHINAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TanezumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TanezumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OutsideUSAndJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OutsideUSAndJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_LebrikizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658403128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance</a></td>
<td class="nump">$ 151.2<span></span>
</td>
<td class="nump">$ 77.8<span></span>
</td>
<td class="nump">$ 127.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment (gain) and other special charges</a></td>
<td class="num">(20.0)<span></span>
</td>
<td class="nump">497.8<span></span>
</td>
<td class="nump">139.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Total asset impairment, restructuring, and other special charges</a></td>
<td class="nump">$ 131.2<span></span>
</td>
<td class="nump">$ 575.6<span></span>
</td>
<td class="nump">$ 266.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Recoveries) And Other Special Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493759716120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment (gain) and other special charges</a></td>
<td class="num">$ (20.0)<span></span>
</td>
<td class="nump">$ 497.8<span></span>
</td>
<td class="nump">$ 139.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment (gain) and other special charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Recoveries) And Other Special Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649890696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">$ 758.9<span></span>
</td>
<td class="nump">$ 647.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,535.4<span></span>
</td>
<td class="nump">2,067.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials and supplies</a></td>
<td class="nump">651.2<span></span>
</td>
<td class="nump">424.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates replacement cost)</a></td>
<td class="nump">3,945.5<span></span>
</td>
<td class="nump">3,139.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Increase to LIFO cost</a></td>
<td class="nump">34.8<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,980.3<span></span>
</td>
<td class="nump">3,190.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LIFOInventoryAmount', window );">LIFO Inventory Amount</a></td>
<td class="nump">$ 1,210.0<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LIFOInventoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LIFOInventoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493657860648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#8364; in Millions, &#165; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="3"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1', window );">Average remaining maturity of foreign currency derivatives</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term notes</a></td>
<td class="nump">$ 16,348.7<span></span>
</td>
<td class="nump">$ 13,638.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax', window );">Foreign currency-denominated notes, designated as hedge</a></td>
<td class="nump">$ 4,500.0<span></span>
</td>
<td class="nump">4,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Variable rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Losses expected to be reclassified in the next 12 months</a></td>
<td class="nump">$ 16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Unfunded commitments to invest in venture capital funds</a></td>
<td class="nump">$ 687.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod', window );">Unfunded commitments to invest in venture capital funds, anticipated payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Unrealized losses from equity securities</a></td>
<td class="nump">$ 1,442.2<span></span>
</td>
<td class="nump">401.2<span></span>
</td>
<td class="nump">$ 72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets', window );">Percentage of nonperforming assets</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Accounts receivable derecognized</a></td>
<td class="nump">$ 754.9<span></span>
</td>
<td class="nump">678.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember', window );">Buy USD Sell Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">647.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 530.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember', window );">Buy Euro Sell USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,970.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">3,620.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember', window );">Buy USD Sell Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">180.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 18,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember', window );">Buy GBP Sell USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 272.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">363.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Currency Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">3,760.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember', window );">Swap Swiss Francs to USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term notes</a></td>
<td class="nump">6,020.0<span></span>
</td>
<td class="nump">$ 5,490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Designated as Hedging Instrument | Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL6742756-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsdSellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyGBPSellUSDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649634968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Effect of Risk Management) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DerivativeInstrumentsGainLossRecognized', window );">Total</a></td>
<td class="num">$ (209.7)<span></span>
</td>
<td class="nump">$ 60.7<span></span>
</td>
<td class="nump">$ 114.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember', window );">Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(404.0)<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(110.9)<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(207.9)<span></span>
</td>
<td class="nump">47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="num">(53.7)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Hedged Fixed Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Effect from hedged fixed-rate debt</a></td>
<td class="nump">86.9<span></span>
</td>
<td class="nump">112.1<span></span>
</td>
<td class="num">(40.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Effect from interest rate contracts</a></td>
<td class="num">(86.9)<span></span>
</td>
<td class="num">(112.1)<span></span>
</td>
<td class="nump">40.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">16.4<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(102.4)<span></span>
</td>
<td class="num">(17.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</a></td>
<td class="num">$ (123.7)<span></span>
</td>
<td class="nump">$ 61.9<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CashFlowHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CashFlowHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DerivativeInstrumentsGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Gain(loss) Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DerivativeInstrumentsGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of loss reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558989&amp;loc=d3e80720-113993<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650641064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Fair Value Measurement) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">$ 2,966.8<span></span>
</td>
<td class="nump">$ 1,962.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,097.9<span></span>
</td>
<td class="nump">1,025.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">373.9<span></span>
</td>
<td class="nump">405.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">2,966.8<span></span>
</td>
<td class="nump">1,962.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,097.9<span></span>
</td>
<td class="nump">1,025.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,097.9<span></span>
</td>
<td class="nump">1,025.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,097.9<span></span>
</td>
<td class="nump">1,025.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">78.7<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">76.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">78.7<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">78.7<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">137.0<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">81.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">126.8<span></span>
</td>
<td class="nump">267.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">137.0<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">137.0<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">106.4<span></span>
</td>
<td class="nump">101.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">101.4<span></span>
</td>
<td class="nump">99.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">106.4<span></span>
</td>
<td class="nump">101.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">106.4<span></span>
</td>
<td class="nump">101.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">110.5<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">31.8<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">110.5<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember', window );">Other securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">110.5<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,664.2<span></span>
</td>
<td class="nump">718.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">311.6<span></span>
</td>
<td class="nump">254.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,664.2<span></span>
</td>
<td class="nump">718.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Fair Value | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,664.2<span></span>
</td>
<td class="nump">718.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Fair Value | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember', window );">Marketable equity securities | Fair Value | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember', window );">Equity method investments | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Noncurrent investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 471.8<span></span>
</td>
<td class="nump">$ 299.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649747928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Short-term and Long-term Classification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (1,494.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(16,348.7)<span></span>
</td>
<td class="num">(13,638.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(16,595.3)<span></span>
</td>
<td class="num">(13,823.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(19,038.9)<span></span>
</td>
<td class="num">(15,150.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(19,038.9)<span></span>
</td>
<td class="num">(15,150.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,494.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,491.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Significant Other Observable Inputs (Level&#160;2) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,491.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Significant Unobservable Inputs (Level&#160;3) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493651528056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Risk Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">$ 41.1<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">41.1<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Not Designated as Hedging Instrument | Foreign currency exchange contracts | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Not Designated as Hedging Instrument | Foreign currency exchange contracts | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">41.1<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Not Designated as Hedging Instrument | Foreign currency exchange contracts | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Carrying Amount | Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">158.9<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">158.9<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">158.9<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair value hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Carrying Amount | Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(97.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Carrying Amount | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">34.4<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(97.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(97.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Interest Rate Contract | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">34.4<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">34.4<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Carrying Amount | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(92.6)<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(97.2)<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(92.6)<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(97.2)<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Quoted Prices in Active Markets for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(92.6)<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(97.2)<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Fair Value | Designated as Hedging Instrument | Cross-currency interest rate swaps | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649204520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Contractual Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 360.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less Than 1 Year</a></td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">135.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">6-10 Years</a></td>
<td class="nump">82.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">More Than 10 Years</a></td>
<td class="nump">$ 128.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644430440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gross gains</a></td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="nump">$ 10.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized gross losses</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition', window );">Fair value of securities in an unrealized gain position</a></td>
<td class="nump">348.9<span></span>
</td>
<td class="nump">429.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of securities in an unrealized loss position</a></td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 141.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Gain Position</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493657543496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Schedule of Investment Portfolio Activity) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 264.8<span></span>
</td>
<td class="nump">$ 431.6<span></span>
</td>
<td class="nump">$ 5,529.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain', window );">Realized gross gains on sales</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss', window );">Realized gross losses on sales</a></td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 49.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale Securities and Equity Securities, FV-NI, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Equity and Available for Sale Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493651373992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 15, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member', window );">Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,670,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member', window );">Selpercatinib (LOXO-292) | Loxo Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648890824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">$ 8,076.8<span></span>
</td>
<td class="nump">$ 3,244.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,727.8)<span></span>
</td>
<td class="num">(1,296.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">6,349.0<span></span>
</td>
<td class="nump">1,948.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Carrying Amount, Gross</a></td>
<td class="nump">9,177.8<span></span>
</td>
<td class="nump">7,914.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,727.8)<span></span>
</td>
<td class="num">(1,296.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Carrying Amount, Net</a></td>
<td class="nump">7,450.0<span></span>
</td>
<td class="nump">6,618.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">1,101.0<span></span>
</td>
<td class="nump">4,670.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">7,984.0<span></span>
</td>
<td class="nump">3,150.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,659.5)<span></span>
</td>
<td class="num">(1,244.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">6,324.5<span></span>
</td>
<td class="nump">1,905.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,659.5)<span></span>
</td>
<td class="num">(1,244.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Carrying Amount, Gross</a></td>
<td class="nump">92.8<span></span>
</td>
<td class="nump">94.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(68.3)<span></span>
</td>
<td class="num">(51.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount, Net</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">42.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (68.3)<span></span>
</td>
<td class="num">$ (51.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650344856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 428.2<span></span>
</td>
<td class="nump">$ 225.8<span></span>
</td>
<td class="nump">$ 361.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650103736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 517.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">513.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">501.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">449.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">$ 432.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493643336984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645770648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 226.8<span></span>
</td>
<td class="nump">$ 169.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">7,326.1<span></span>
</td>
<td class="nump">7,067.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">8,560.9<span></span>
</td>
<td class="nump">7,913.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">2,138.8<span></span>
</td>
<td class="nump">1,884.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,252.6<span></span>
</td>
<td class="nump">17,034.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(9,570.7)<span></span>
</td>
<td class="num">(9,161.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 8,681.9<span></span>
</td>
<td class="nump">$ 7,872.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493646066616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Depreciation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 765.2<span></span>
</td>
<td class="nump">$ 814.7<span></span>
</td>
<td class="nump">$ 797.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493651792728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Geographic Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 9,648.2<span></span>
</td>
<td class="nump">$ 8,808.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">6,113.6<span></span>
</td>
<td class="nump">5,595.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1,786.9<span></span>
</td>
<td class="nump">1,454.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 1,747.7<span></span>
</td>
<td class="nump">$ 1,758.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_UNITEDSTATESAndPUERTORICOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658236760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LesseeLeaseRemainingLeaseTerm', window );">Lessee, lease, remaining lease term (up to)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease expense</a></td>
<td class="nump">$ 154.6<span></span>
</td>
<td class="nump">$ 172.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LesseeLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LesseeLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658202264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 160.9<span></span>
</td>
<td class="nump">$ 153.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 136.7<span></span>
</td>
<td class="nump">$ 81.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493743838072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Maturities of Operating Lease Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year 1</a></td>
<td class="nump">$ 150.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year 2</a></td>
<td class="nump">120.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year 3</a></td>
<td class="nump">94.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year 4</a></td>
<td class="nump">73.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year 5</a></td>
<td class="nump">63.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After Year 5</a></td>
<td class="nump">258.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">761.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">97.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 663.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648915176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Schedule of Debt) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Short-term commercial paper borrowings</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1,494.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Long-term notes</a></td>
<td class="nump">16,348.7<span></span>
</td>
<td class="nump">13,638.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Other long-term debt</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(89.1)<span></span>
</td>
<td class="num">(73.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LongTermDebtFairValueAdjustment', window );">Fair value adjustment on hedged long-term notes</a></td>
<td class="nump">320.9<span></span>
</td>
<td class="nump">245.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt</a></td>
<td class="nump">16,595.3<span></span>
</td>
<td class="nump">15,317.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Less current portion</a></td>
<td class="num">(8.7)<span></span>
</td>
<td class="num">(1,499.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 16,586.6<span></span>
</td>
<td class="nump">$ 13,817.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LongTermDebtFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment to carrying value of long term debt to arrive at total fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LongTermDebtFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493663288376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Summary of Long-term Notes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Long-term notes</a></td>
<td class="nump">$ 16,348.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,638.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized note discounts</a></td>
<td class="num">(76.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term notes</a></td>
<td class="nump">$ 16,348.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,638.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.35% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.00% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 99.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.00% Euro denominated notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 737.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.15% Swiss Franc denominated notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 679.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.125% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">7.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 229.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.75% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 560.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.625% Euro denominated notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 922.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.5% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 377.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.1% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 401.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.45% Swiss Franc denominated notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 453.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.42% Japanese Yen denominated notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 222.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.125% Euro denominated notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 922.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.625% Euro denominated notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 737.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.56% Japanese Yen denominated notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.77% notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 174.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.55% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 476.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.95% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 284.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 360.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.65% notes due 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 43.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.7% notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 412.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 436.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.7% Euro denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,229.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,119.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.97% Japanese Yen denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 74.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.25% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% notes due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.5% notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term notes, gross</a></td>
<td class="nump">$ 850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A235NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A235NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A30NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A30NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A10EuroDenominatedNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A10EuroDenominatedNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A015SwissFrancDenominatedNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A015SwissFrancDenominatedNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A7125NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A7125NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A275NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A275NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625EuroDenominatedNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625EuroDenominatedNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A55NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A55NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A31NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A31NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A045SwissFrancDenominatedNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A045SwissFrancDenominatedNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A2125EuroDenominatedNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A2125EuroDenominatedNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A625EuroDeonominatedNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A625EuroDeonominatedNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A677NotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A677NotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A555NotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A555NotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A595NotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A595NotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A465NotesDue2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A465NotesDue2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A37NotesDue2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A37NotesDue2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A17EuroDeonominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A17EuroDeonominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A97YenDeonominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A97YenDeonominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648263000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility, remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,240.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,817.9<span></span>
</td>
<td class="nump">16,586.6<span></span>
</td>
<td class="nump">$ 13,817.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 252.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DescriptionOfDerivativeActivityVolumePercent', window );">Description of derivative activity volume percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
<td class="nump">2.61%<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member', window );">Maturity Date, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2019Member', window );">Maturity Date, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Payments for repurchase and redemption of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,270.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchase aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due May 2050 and September 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,070.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.25% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 988.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.5% notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.375% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.95% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% notes due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | November 2019 Euro-denominated Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.625% Euro denominated notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.7% Euro denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | November 2019 Yen-denominated Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.42% Japanese Yen denominated notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 22,920,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.56% Japanese Yen denominated notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 9,280,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.97% Japanese Yen denominated notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 7,640,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DescriptionOfDerivativeActivityVolumePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DescriptionOfDerivativeActivityVolumePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=lly_MaturityDate2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_SeniorNotesDueMay2050AndSeptember2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_SeniorNotesDueMay2050AndSeptember2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A225NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A25NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3875NotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_November2019EuroDenominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_November2019EuroDenominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A625EuroDeonominatedNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A625EuroDeonominatedNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A17EuroDeonominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A17EuroDeonominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_November2019YenDenominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_November2019YenDenominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A42YenDenominatedNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A56YenDenominatedNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A97YenDeonominatedNotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A97YenDeonominatedNotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649653624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings (Schedule of Debt Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Maturities on long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,590.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">681.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">$ 790.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493652400344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash payments for interest on borrowings</a></td>
<td class="nump">$ 345.8<span></span>
</td>
<td class="nump">$ 305.5<span></span>
</td>
<td class="nump">$ 223.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658138168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 308.1<span></span>
</td>
<td class="nump">$ 306.8<span></span>
</td>
<td class="nump">$ 253.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit</a></td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="nump">$ 64.4<span></span>
</td>
<td class="nump">$ 53.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648614616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">53.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 137.33<span></span>
</td>
<td class="nump">$ 112.09<span></span>
</td>
<td class="nump">$ 71.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 77.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember', window );">Shareholder Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 139.14<span></span>
</td>
<td class="nump">$ 95.01<span></span>
</td>
<td class="nump">$ 48.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">20 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember', window );">Relative Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 179.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 135.42<span></span>
</td>
<td class="nump">$ 108.43<span></span>
</td>
<td class="nump">$ 70.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued', window );">Shares expected to be issued (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized</a></td>
<td class="nump">$ 179.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of the compensation cost not yet recognized</a></td>
<td class="text">31 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares expected to be issued in the next twelve months under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493651884632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Schedule of Assumptions Used) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember', window );">Shareholder Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.38%<span></span>
</td>
<td class="nump">2.46%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">20.90%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">22.26%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember', window );">Relative Value Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">19.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_ShareholderValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lly_RelativeValueAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648052616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase for treasury</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="nump">$ 4,400.0<span></span>
</td>
<td class="nump">$ 4,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrustShares', window );">Shares held in employee trust (in shares)</a></td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="nump">$ 3,013.2<span></span>
</td>
<td class="nump">$ 3,013.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=lly_A2018RepurchaseProgramMember', window );">2018 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrustShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16701-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrustShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=lly_A2018RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=lly_A2018RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493647165384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision', window );">2017 Tax Act, deferred taxes related to GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes', window );">Domestic and Puerto Rican companies contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible', window );">Long-term income taxes payable, estimated timing of future cash outflows not possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,690.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,670.0<span></span>
</td>
<td class="nump">$ 1,530.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accruals for the payment of interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.7<span></span>
</td>
<td class="nump">150.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember', window );">Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expirationin6YearsMember', window );">Expiration in 6 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationIn12To18YearsMember', window );">Expiration in 12 to 18 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember', window );">Designated Unusable | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets related to state net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expirationwithin5yearsMember', window );">Expiration within 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expiration5to20YearsMember', window );">Expiration 5 to 20 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">781.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember', window );">No Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 576.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=lly_TaxYears2013To2015Member', window );">Tax Years 2013 to 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_PaymentsForIncomeTaxSettlements', window );">Payments for income tax settlements</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentsForIncomeTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Income Tax Settlements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentsForIncomeTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_CarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expirationin6YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_Expirationin6YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationIn12To18YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_ExpirationIn12To18YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_DesignatedUnusableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expirationwithin5yearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_Expirationwithin5yearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_Expiration5to20YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_Expiration5to20YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lly_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=lly_TaxYears2013To2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=lly_TaxYears2013To2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649925432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Composition of Income Tax Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 567.6<span></span>
</td>
<td class="nump">$ 280.2<span></span>
</td>
<td class="nump">$ 169.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">650.4<span></span>
</td>
<td class="nump">299.8<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(47.3)<span></span>
</td>
<td class="num">(14.4)<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">1,170.7<span></span>
</td>
<td class="nump">565.6<span></span>
</td>
<td class="nump">281.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(97.4)<span></span>
</td>
<td class="nump">141.3<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(16.6)<span></span>
</td>
<td class="num">(24.1)<span></span>
</td>
<td class="nump">248.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(20.5)<span></span>
</td>
<td class="num">(54.8)<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax (benefit) expense</a></td>
<td class="num">(134.5)<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
<td class="nump">248.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">1,036.2<span></span>
</td>
<td class="nump">628.0<span></span>
</td>
<td class="nump">529.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward', window );">Current federal tax expense, utilization of net operating loss carryforward</a></td>
<td class="nump">$ 144.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct', window );">Current federal tax expense, effect of 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153.1<span></span>
</td>
<td class="nump">201.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct', window );">Deferred federal income tax benefit, effect of 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Federal Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Federal Income Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649826696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="nump">$ 2,560.6<span></span>
</td>
<td class="nump">$ 2,512.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Compensation and benefits</a></td>
<td class="nump">1,045.6<span></span>
</td>
<td class="nump">934.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards and carrybacks</a></td>
<td class="nump">523.5<span></span>
</td>
<td class="nump">455.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax loss carryforwards and carrybacks</a></td>
<td class="nump">488.3<span></span>
</td>
<td class="nump">318.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredTaxAssetsSalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">461.3<span></span>
</td>
<td class="nump">197.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredTaxAssetsCorrectiveTaxAdjustments', window );">Correlative tax adjustments</a></td>
<td class="nump">404.2<span></span>
</td>
<td class="nump">219.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredTaxAssetsForeignTaxRedeterminations', window );">Foreign tax redeterminations</a></td>
<td class="nump">242.8<span></span>
</td>
<td class="nump">156.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">150.7<span></span>
</td>
<td class="nump">140.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">135.2<span></span>
</td>
<td class="nump">75.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">605.8<span></span>
</td>
<td class="nump">595.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">6,618.0<span></span>
</td>
<td class="nump">5,606.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="num">(816.3)<span></span>
</td>
<td class="num">(616.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">5,801.7<span></span>
</td>
<td class="nump">4,990.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Earnings of foreign subsidiaries</a></td>
<td class="num">(1,905.3)<span></span>
</td>
<td class="num">(1,776.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(1,465.7)<span></span>
</td>
<td class="num">(1,298.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventories</a></td>
<td class="num">(623.7)<span></span>
</td>
<td class="num">(686.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid employee benefits</a></td>
<td class="num">(410.1)<span></span>
</td>
<td class="num">(305.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(315.2)<span></span>
</td>
<td class="num">(274.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Financial instruments</a></td>
<td class="num">(216.9)<span></span>
</td>
<td class="num">(139.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease assets</a></td>
<td class="num">(134.3)<span></span>
</td>
<td class="num">(124.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(5,071.2)<span></span>
</td>
<td class="num">(4,604.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 730.5<span></span>
</td>
<td class="nump">$ 385.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsCorrectiveTaxAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Corrective Tax Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsCorrectiveTaxAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsForeignTaxRedeterminations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Foreign Tax Redeterminations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsForeignTaxRedeterminations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DeferredTaxAssetsSalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Sales Rebates And Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DeferredTaxAssetsSalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493645998408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Cash Payments of Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash payments of income taxes</a></td>
<td class="nump">$ 954.6<span></span>
</td>
<td class="nump">$ 1,180.5<span></span>
</td>
<td class="nump">$ 1,076.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493644628552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract', window );"><strong>Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaid', window );">Total</a></td>
<td class="nump">$ 2,403.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear', window );">Less than 1 Year</a></td>
<td class="nump">253.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears', window );">1-3 Years</a></td>
<td class="nump">729.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears', window );">3-5 Years</a></td>
<td class="nump">$ 1,420.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, Payment, Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493658755864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Income Taxes) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax at the U.S. federal statutory tax rate</a></td>
<td class="nump">$ 1,518.3<span></span>
</td>
<td class="nump">$ 1,105.8<span></span>
</td>
<td class="nump">$ 772.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AddDeductAbstract', window );"><strong>Add (deduct):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">International operations, including Puerto Rico</a></td>
<td class="num">(297.1)<span></span>
</td>
<td class="num">(242.0)<span></span>
</td>
<td class="num">(627.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">General business credits</a></td>
<td class="num">(97.9)<span></span>
</td>
<td class="num">(108.8)<span></span>
</td>
<td class="num">(87.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Non-deductible acquired IPR&amp;D</a></td>
<td class="nump">63.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">309.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount', window );">2017 Tax Act</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">175.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(150.3)<span></span>
</td>
<td class="num">(127.0)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">$ 1,036.2<span></span>
</td>
<td class="nump">$ 628.0<span></span>
</td>
<td class="nump">$ 529.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AddDeductAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Add (Deduct) [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AddDeductAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493657822024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,108.6<span></span>
</td>
<td class="nump">$ 2,034.6<span></span>
</td>
<td class="nump">$ 1,000.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">225.6<span></span>
</td>
<td class="nump">187.2<span></span>
</td>
<td class="nump">798.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">310.8<span></span>
</td>
<td class="nump">425.3<span></span>
</td>
<td class="nump">410.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(52.4)<span></span>
</td>
<td class="num">(100.3)<span></span>
</td>
<td class="num">(115.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(72.0)<span></span>
</td>
<td class="num">(260.5)<span></span>
</td>
<td class="num">(33.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapses of statutes of limitation</a></td>
<td class="num">(41.7)<span></span>
</td>
<td class="num">(161.5)<span></span>
</td>
<td class="num">(20.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation', window );">Changes related to the impact of foreign currency translation, increase</a></td>
<td class="nump">73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation', window );">Changes related to the impact of foreign currency translation, decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.2)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,551.9<span></span>
</td>
<td class="nump">$ 2,108.6<span></span>
</td>
<td class="nump">$ 2,034.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493770755112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="num">$ (26.4)<span></span>
</td>
<td class="nump">$ 25.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493646361768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at beginning of year</a></td>
<td class="nump">$ 16,251.0<span></span>
</td>
<td class="nump">$ 13,427.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">325.5<span></span>
</td>
<td class="nump">250.4<span></span>
</td>
<td class="nump">$ 292.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">425.8<span></span>
</td>
<td class="nump">486.0<span></span>
</td>
<td class="nump">458.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial loss</a></td>
<td class="nump">1,563.1<span></span>
</td>
<td class="nump">2,631.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(587.2)<span></span>
</td>
<td class="num">(584.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailment (gain) loss</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="num">(16.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="nump">245.1<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at end of year</a></td>
<td class="nump">18,225.5<span></span>
</td>
<td class="nump">16,251.0<span></span>
</td>
<td class="nump">13,427.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">12,858.0<span></span>
</td>
<td class="nump">10,932.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">1,802.4<span></span>
</td>
<td class="nump">2,012.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contribution</a></td>
<td class="nump">318.8<span></span>
</td>
<td class="nump">429.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(587.2)<span></span>
</td>
<td class="num">(584.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="nump">187.0<span></span>
</td>
<td class="nump">67.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">14,579.0<span></span>
</td>
<td class="nump">12,858.0<span></span>
</td>
<td class="nump">10,932.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="num">(3,646.5)<span></span>
</td>
<td class="num">(3,393.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Unrecognized net actuarial (gain) loss</a></td>
<td class="nump">6,515.5<span></span>
</td>
<td class="nump">6,177.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Unrecognized prior service (benefit) cost</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">2,884.4<span></span>
</td>
<td class="nump">2,802.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at beginning of year</a></td>
<td class="nump">1,601.4<span></span>
</td>
<td class="nump">1,540.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">40.8<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">41.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial loss</a></td>
<td class="nump">142.1<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(75.1)<span></span>
</td>
<td class="num">(87.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailment (gain) loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation at end of year</a></td>
<td class="nump">1,753.7<span></span>
</td>
<td class="nump">1,601.4<span></span>
</td>
<td class="nump">1,540.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at beginning of year</a></td>
<td class="nump">2,768.2<span></span>
</td>
<td class="nump">2,398.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">539.0<span></span>
</td>
<td class="nump">444.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contribution</a></td>
<td class="num">(5.1)<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(75.1)<span></span>
</td>
<td class="num">(87.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency exchange rate changes and other adjustments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets at end of year</a></td>
<td class="nump">3,227.0<span></span>
</td>
<td class="nump">2,768.2<span></span>
</td>
<td class="nump">$ 2,398.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="nump">1,473.3<span></span>
</td>
<td class="nump">1,166.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Unrecognized net actuarial (gain) loss</a></td>
<td class="num">(349.1)<span></span>
</td>
<td class="num">(111.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Unrecognized prior service (benefit) cost</a></td>
<td class="num">(177.6)<span></span>
</td>
<td class="num">(236.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">$ 946.6<span></span>
</td>
<td class="nump">$ 818.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649253912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">$ (4,094.5)<span></span>
</td>
<td class="num">$ (3,698.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">299.6<span></span>
</td>
<td class="nump">163.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(67.9)<span></span>
</td>
<td class="num">(65.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">(3,878.2)<span></span>
</td>
<td class="num">(3,491.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Accumulated other comprehensive (income) loss before income taxes</a></td>
<td class="nump">6,530.9<span></span>
</td>
<td class="nump">6,195.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">2,884.4<span></span>
</td>
<td class="nump">2,802.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet consisted&#160;of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,697.0<span></span>
</td>
<td class="nump">1,381.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(7.4)<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits</a></td>
<td class="num">(216.3)<span></span>
</td>
<td class="num">(207.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Accumulated other comprehensive (income) loss before income taxes</a></td>
<td class="num">(526.7)<span></span>
</td>
<td class="num">(348.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Net amount recognized</a></td>
<td class="nump">$ 946.6<span></span>
</td>
<td class="nump">$ 818.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493651527944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease', window );">Defined benefit obligation, period increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,130.0<span></span>
</td>
<td class="nump">$ 2,890.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailment gain</a></td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense under the plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164.3<span></span>
</td>
<td class="nump">145.2<span></span>
</td>
<td class="nump">$ 132.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets', window );">Percentage of global investments in plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailment gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">$ (1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Total accumulated benefit obligation for our defined benefit pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,030.0<span></span>
</td>
<td class="nump">$ 15,170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected future employer contributions, next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear', window );">Expected future employer discretionary contributions, next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Plan assets, target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Plan assets, target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Expected Future Employer Discretionary Contributions, Next Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649118248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate for benefit obligation</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate for net benefit costs</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase for benefit obligation</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase for net benefit costs</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets for net benefit costs</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate for benefit obligation</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate for net benefit costs</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets for net benefit costs</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493734521672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,770.7<span></span>
</td>
<td class="nump">$ 14,039.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,824.4<span></span>
</td>
<td class="nump">10,483.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,824.4<span></span>
</td>
<td class="nump">10,483.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic (benefit) cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailment (gain) loss</a></td>
<td class="num">$ (28.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157.1)<span></span>
</td>
<td class="num">(970.0)<span></span>
</td>
<td class="nump">$ 544.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2026-2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,824.4<span></span>
</td>
<td class="nump">10,483.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,682.3<span></span>
</td>
<td class="nump">13,063.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,824.4<span></span>
</td>
<td class="nump">10,483.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic (benefit) cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325.5<span></span>
</td>
<td class="nump">250.4<span></span>
</td>
<td class="nump">292.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425.8<span></span>
</td>
<td class="nump">486.0<span></span>
</td>
<td class="nump">458.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(901.5)<span></span>
</td>
<td class="num">(839.6)<span></span>
</td>
<td class="num">(842.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service (benefit) cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial loss (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396.3<span></span>
</td>
<td class="nump">284.9<span></span>
</td>
<td class="nump">332.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailment (gain) loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.6<span></span>
</td>
<td class="nump">190.0<span></span>
</td>
<td class="nump">247.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Actuarial gain (loss) arising during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(663.0)<span></span>
</td>
<td class="num">(1,461.0)<span></span>
</td>
<td class="nump">182.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Plan amendments during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(17.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax', window );">Curtailment gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">45.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (benefit) cost included in net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Amortization of net actuarial loss included in net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396.3<span></span>
</td>
<td class="nump">284.9<span></span>
</td>
<td class="nump">332.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency exchange rate changes and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71.5)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(335.9)<span></span>
</td>
<td class="num">(1,158.7)<span></span>
</td>
<td class="nump">594.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2026-2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223.8<span></span>
</td>
<td class="nump">214.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic (benefit) cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">41.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158.1)<span></span>
</td>
<td class="num">(144.3)<span></span>
</td>
<td class="num">(177.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service (benefit) cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
<td class="num">(62.9)<span></span>
</td>
<td class="num">(79.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial loss (gain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailment (gain) loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(29.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136.1)<span></span>
</td>
<td class="num">(111.0)<span></span>
</td>
<td class="num">(181.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract', window );"><strong>Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Actuarial gain (loss) arising during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238.8<span></span>
</td>
<td class="nump">246.1<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Plan amendments during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax', window );">Curtailment gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (benefit) cost included in net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
<td class="num">(62.9)<span></span>
</td>
<td class="num">(79.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Amortization of net actuarial loss included in net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency exchange rate changes and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total other comprehensive income (loss) during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178.7<span></span>
</td>
<td class="nump">$ 188.7<span></span>
</td>
<td class="num">$ (53.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493647519784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Retirement Benefits (Schedule of Fair Value Disclosures) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 14,579.0<span></span>
</td>
<td class="nump">$ 12,858.0<span></span>
</td>
<td class="nump">$ 10,932.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,227.0<span></span>
</td>
<td class="nump">2,768.2<span></span>
</td>
<td class="nump">$ 2,398.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember', window );">U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">737.6<span></span>
</td>
<td class="nump">794.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember', window );">U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember', window );">International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,635.8<span></span>
</td>
<td class="nump">2,439.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember', window );">International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">162.3<span></span>
</td>
<td class="nump">152.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,301.3<span></span>
</td>
<td class="nump">3,661.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember', window );">Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">101.5<span></span>
</td>
<td class="nump">82.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember', window );">Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(1,670.8)<span></span>
</td>
<td class="num">(1,659.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember', window );">Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">631.0<span></span>
</td>
<td class="nump">648.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember', window );">Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,661.3<span></span>
</td>
<td class="nump">2,897.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">229.7<span></span>
</td>
<td class="nump">250.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember', window );">Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,844.7<span></span>
</td>
<td class="nump">2,279.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember', window );">Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">223.4<span></span>
</td>
<td class="nump">187.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember', window );">Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,204.6<span></span>
</td>
<td class="nump">1,832.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember', window );">Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">558.9<span></span>
</td>
<td class="nump">570.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember', window );">Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">25.8<span></span>
</td>
<td class="nump">31.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember', window );">Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,879.2<span></span>
</td>
<td class="nump">1,226.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember', window );">Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">157.9<span></span>
</td>
<td class="nump">96.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,915.5<span></span>
</td>
<td class="nump">1,831.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">141.7<span></span>
</td>
<td class="nump">140.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">476.1<span></span>
</td>
<td class="nump">532.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">52.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,102.3<span></span>
</td>
<td class="nump">1,046.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">58.1<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">14.2<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">259.6<span></span>
</td>
<td class="nump">166.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">60.4<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level&#160;1) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">14.1<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,079.2<span></span>
</td>
<td class="nump">1,499.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,331.4<span></span>
</td>
<td class="nump">1,923.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,179.2<span></span>
</td>
<td class="nump">2,658.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">80.3<span></span>
</td>
<td class="nump">56.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="num">(1,670.8)<span></span>
</td>
<td class="num">(1,659.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">262.7<span></span>
</td>
<td class="nump">277.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,204.6<span></span>
</td>
<td class="nump">1,832.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">301.2<span></span>
</td>
<td class="nump">222.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21.1<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">41.8<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10,542.5<span></span>
</td>
<td class="nump">9,499.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">749.9<span></span>
</td>
<td class="nump">701.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | U.S. | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">260.5<span></span>
</td>
<td class="nump">261.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | U.S. | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | International | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,533.5<span></span>
</td>
<td class="nump">1,392.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | International | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">104.2<span></span>
</td>
<td class="nump">91.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,119.2<span></span>
</td>
<td class="nump">997.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">26.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Developed markets - repurchase agreements | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Emerging markets | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">354.0<span></span>
</td>
<td class="nump">348.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Emerging markets | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">28.8<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Hedge funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,661.3<span></span>
</td>
<td class="nump">2,897.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Hedge funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">229.7<span></span>
</td>
<td class="nump">250.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Equity-like funds | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,827.8<span></span>
</td>
<td class="nump">2,262.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Equity-like funds | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">221.8<span></span>
</td>
<td class="nump">185.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Cash value of trust owned insurance contract | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Real estate | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">286.6<span></span>
</td>
<td class="nump">404.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Real estate | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Other | Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,499.6<span></span>
</td>
<td class="nump">934.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Investments Valued at Net Asset Value | Other | Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 121.0<span></span>
</td>
<td class="nump">$ 76.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementHealthCoverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsRepurchasedAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_FixedIncomeFundsEmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_HedgeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=lly_DefineBenefitPlanOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493663414536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> R$ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">142 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>BRL (R$) </div>
<div>lawsuit </div>
<div>claimant </div>
<div>patent </div>
<div>request</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>lawsuit </div>
<div>claimant </div>
<div>patent </div>
<div>request</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>patent</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>patent</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>plaintiff </div>
<div>lawsuit </div>
<div>patent </div>
<div>request </div>
<div>claimant</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jul. 31, 2012 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfRequestsForInformation', window );">Number of requests for information | request</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ActosMember', window );">Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfClaimants', window );">Number of claimants | claimant</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Pancreatic Cancer or Thyroid Cancer | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Pancreatitis | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Ampullary Cancer | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Los Angeles | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Southern District of California | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Various State Domiciles | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember', window );">Humalog, Humulin and Forteo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_DrReddysLabMember', window );">Dr Reddy's Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm', window );">Claims settled and dismissed, limited initial market entry, supply term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember', window );">Emgality Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatentsClaimsDismissed', window );">Number of patents, claims dismissed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatentsRuledUnpatentable', window );">Number of patents ruled unpatentable | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember', window );">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember', window );">Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember', window );">Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember', window );">Epp v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil | Employee Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="nump">R$ 950<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 500<span></span>
</td>
<td class="nump">R$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfClaimants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Claimants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfClaimants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatentsClaimsDismissed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents, Claims Dismissed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatentsClaimsDismissed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatentsRuledUnpatentable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents Ruled Unpatentable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatentsRuledUnpatentable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfRequestsForInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Requests For Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfRequestsForInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ActosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ActosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ByettaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ByettaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_PancreatitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_PancreatitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_LosAngelesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_LosAngelesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_DrReddysLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_DrReddysLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmployeeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmployeeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493647881064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 2,699.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(256.2)<span></span>
</td>
<td class="num">$ (997.6)<span></span>
</td>
<td class="num">$ (106.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">283.4<span></span>
</td>
<td class="nump">214.2<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="num">(783.4)<span></span>
</td>
<td class="nump">83.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">5,825.2<span></span>
</td>
<td class="nump">2,699.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="num">(5,740.2)<span></span>
</td>
<td class="num">(5,694.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Reclassification due to adoption of new accounting standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="num">(5,740.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="num">(5,729.2)<span></span>
</td>
<td class="num">(5,718.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Reclassification due to adoption of new accounting standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
<td class="num">(5,729.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociAttributableToNoncontrollingInterestMember', window );">AOCI Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="num">(840.2)<span></span>
</td>
<td class="nump">69.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,678.0)<span></span>
</td>
<td class="num">(1,569.7)<span></span>
</td>
<td class="num">(1,191.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">250.5<span></span>
</td>
<td class="num">(46.2)<span></span>
</td>
<td class="num">(378.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(62.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">250.5<span></span>
</td>
<td class="num">(108.3)<span></span>
</td>
<td class="num">(378.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,427.5)<span></span>
</td>
<td class="num">(1,678.0)<span></span>
</td>
<td class="num">(1,569.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(22.1)<span></span>
</td>
<td class="nump">113.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Reclassification due to adoption of new accounting standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(22.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4,638.6)<span></span>
</td>
<td class="num">(3,852.7)<span></span>
</td>
<td class="num">(4,311.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(379.7)<span></span>
</td>
<td class="num">(967.6)<span></span>
</td>
<td class="nump">250.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">267.3<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="nump">207.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(112.4)<span></span>
</td>
<td class="num">(785.9)<span></span>
</td>
<td class="nump">458.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(4,751.0)<span></span>
</td>
<td class="num">(4,638.6)<span></span>
</td>
<td class="num">(3,852.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(238.9)<span></span>
</td>
<td class="num">(234.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="num">(16.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(238.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(211.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(133.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(120.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(332.7)<span></span>
</td>
<td class="num">(211.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations | Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(56.8)<span></span>
</td>
<td class="num">(71.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">84.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (56.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL116659650-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493652752120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">$ 200.9<span></span>
</td>
<td class="nump">$ 151.0<span></span>
</td>
<td class="num">$ (30.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">128.3<span></span>
</td>
<td class="num">(18.4)<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">184.1<span></span>
</td>
<td class="num">(85.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="num">$ (7.3)<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493650250904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="num">$ (1,246.7)<span></span>
</td>
<td class="num">$ (344.6)<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="num">(7,229.9)<span></span>
</td>
<td class="num">(5,265.9)<span></span>
</td>
<td class="num">(3,680.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">1,036.2<span></span>
</td>
<td class="nump">628.0<span></span>
</td>
<td class="nump">529.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Reclassifications from continuing operations (net of tax)</a></td>
<td class="num">(6,193.7)<span></span>
</td>
<td class="num">(4,637.9)<span></span>
</td>
<td class="num">(3,150.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Reclassifications from discontinued operations (net of tax)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3,680.5)<span></span>
</td>
<td class="num">(81.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Reclassifications from continuing operations (net of tax)</a></td>
<td class="nump">283.4<span></span>
</td>
<td class="nump">130.2<span></span>
</td>
<td class="nump">188.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Reclassifications from discontinued operations (net of tax)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">84.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications for the period, net of tax</a></td>
<td class="nump">283.4<span></span>
</td>
<td class="nump">214.2<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Amortization of retirement benefit items | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">338.3<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="nump">263.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="num">(71.0)<span></span>
</td>
<td class="num">(48.3)<span></span>
</td>
<td class="num">(55.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications for the period, net of tax</a></td>
<td class="nump">267.3<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="nump">207.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember', window );">Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="num">(55.0)<span></span>
</td>
<td class="num">(56.8)<span></span>
</td>
<td class="num">(74.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Actuarial losses | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="nump">393.3<span></span>
</td>
<td class="nump">286.8<span></span>
</td>
<td class="nump">338.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember', window );">Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net (income) expense</a></td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="num">$ (51.5)<span></span>
</td>
<td class="num">$ (19.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493648850888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other - Net, (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 359.6<span></span>
</td>
<td class="nump">$ 400.6<span></span>
</td>
<td class="nump">$ 242.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(33.0)<span></span>
</td>
<td class="num">(80.4)<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 11)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">252.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of antibiotic business in China (Note 3)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(309.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Retirement benefit plans</a></td>
<td class="num">(251.8)<span></span>
</td>
<td class="num">(209.9)<span></span>
</td>
<td class="num">(240.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="num">(1,246.7)<span></span>
</td>
<td class="num">(344.6)<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">$ (1,171.9)<span></span>
</td>
<td class="num">$ (291.6)<span></span>
</td>
<td class="num">$ (145.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493647167416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2019</div></th>
<th class="th"><div>Sep. 24, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain related to disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 3,680.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember', window );">Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember', window );">Elanco | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain related to disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash provided by operating activities, discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm', window );">Transitional services agreement, term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember', window );">Elanco | Discontinued Operations, Disposed of by Sale | Eli Lilly and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Disposition of ownership interest</a></td>
<td class="nump">80.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_ElancoAnimalHealthIncorporatedMember', window );">Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_ElancoAnimalHealthIncorporatedMember', window );">Elanco | Term Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Elanco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_SaleOfStockPercentageOfStockSold', window );">Percentage of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SaleOfStockPercentageOfStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Percentage Of Stock Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SaleOfStockPercentageOfStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lly_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lly_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_ElancoAnimalHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_ElancoAnimalHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_TermFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_TermFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140493649906984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Summary of Revenue and Net Income from Discontinued Operations) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from discontinued operations</a></td>
<td class="nump">$ 24,539.8<span></span>
</td>
<td class="nump">$ 22,319.5<span></span>
</td>
<td class="nump">$ 21,493.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income from discontinued operations</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">3,680.5<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember', window );">Elanco | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580.0<span></span>
</td>
<td class="nump">3,062.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,680.5<span></span>
</td>
<td class="nump">$ 81.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_ElancoAnimalHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>135
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &1745('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !D5U%2\!O0N?     K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>R$Z[/YC4EXV>.ABLL+&;L=76-$Z,K9'T[9=X;<K8'F!'2S]_
M^@2J39"FB_@2NX"1'*:;P3=MDB:LV($H2(!D#NAU*L=$.S9W7?2:QF?<0]#F
MJ/<(%>=WX)&TU:1A A9A)C)56R--1$U=/..MF?'A,S899@U@@QY;2B!* 4Q-
M$\-I:&JX B888?3INX!V)N;JG]C< 79.#LG-J;[ORWZ1<^,. MZ?-Z]YW<*U
MB71K</R5G*13P!6[3'Y;/#YMUTQ5O!(%KPIQOQ5<WC[(Y?)C<OWA=Q7VG74[
M]X^-+X*JAE]WH;X 4$L#!!0    ( &1745*97)PC$ 8  )PG   3    >&PO
M=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$
M[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4
M\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4
MR]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C
M 1-702:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6
M:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+
MTHMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3
M:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@
M %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ W
MQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYK
ME']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;V
MD:4E,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?
MR"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:
M/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#Q
MK9P\'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-
MZ#,:P4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB
M&38:<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.
MBY 1OQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR
M- >CFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"
MP#E_+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,I
MV#F?P.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4W
MBA*>0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F
M.$KTL<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1
MN0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/
MPT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,K
MD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;
M\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\
MX^;'<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;Z
MEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10
M[I*0!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%
M(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^
M)F!+PWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#
M7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1
M/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO
M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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MSSUO1%)EX@R]4?>W>5$HXXNUA'&IZ.NT'\-U-P:R, 9,T"VOY%Z@#U7&LN,
M:P :J,@+U36Q1MRRU$$4GR'B$M<PH)N3W7%L<-^>[AY9:.B0(]K&HPOQ/E8I
M+]F8'?3/U;V0-2R9?RW1O2&ZUT;W%J)_98^L:I@I;9UCV#JJ#>1Q0SR?Q@Y
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MX-YUI\$Y^./^%KQ_]P&\ Z(!OXFJLI[7%RMC7^R:K];]2SYW+T$S+[GEZR7
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MRR$@%A-U2'HLAEW'M*.Q(ZM'QSJHFUT9KYMC?O!B7/61A\HMLXP'!2W^IY+
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MO,.<6IIG6NU ^VC'YC?A,0/:R>?2EWUIM3OE#F?SF9)&"<ZH109+ZQ974VM
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M35\88YK10#\K]+Y_JTOX-8-Q]>U:%97*LUU2RQWY5L,?V-2Z(FI/UDEU()_
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M#=>=W.*'W18'S NLLG^-X +?#VR6R'SC&G-,LA<;W"TVODJHF+MGKQ<00X0
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M+,"X #HOM<:CX>9Q_/VDOP%02P,$%     @ 9%=14D7TX(WC#0  U"<  !D
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MYBS #3C+9AG"EX)DB7+2.ZE R"6(5R-K I<?TIX+P<;L]'7QL(W2<\1$[P9
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MS(+<1A]%SMW!:520?Z.[&UH.JJUIN(L$YPIUE+)*[;T.09P &<,V8+D6L(]
M.?B"&;ZL3R#,$@'-PHITP;9._ )"0 P !???"+YIIAJ7 5PL 8]<E0) JETG
MF(7XHEG.$S+SZ\+P_#2@U1M<!A*2@Y*[& DNK>[ZUM%@*'$HD!*R]])\1E5>
M-N*PXH"B(1HT. ='I<%DV4"]1@]-VY'O,Z5-FU.,L<-):/GW-#W2ZJ;5,7$]
MS-/4>#DH"!9Z1J[.!D7F*).X"=AV27PGW?':Q\%=-6$)[ 1B;_41E)"E"%<
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M!X#&))_[?&]A QHDDV3X@*_GFN"^J%UR>FE@#J,O(V00E"G&;XNCY?X<<4+
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M'1^>HEOXUSIRM4]=:=S=7,_&E*R\)KI9X3L1$:[H%"=T&^?K-$)/QT=X6UE
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MTI P58X#H"/(1R(Q)3EKHN<H$#< G&HS/R%L@L5[&/=S-*PDAR^71!I^ WB
MS9P/B,9*,:+'1UE-V8<X5@5&^YU.I9?.\#Q,V(^G'-3-#,2KDMD+]YH!6%V
MS+0M:)R0SDB+OJ!Q'3:I\I;XE'C0J8Y -BSP^-7OSY\<4WO:=C\SK2K>085+
MN$*2Z' >4D->1X.TD"#&H?P<5OZ@1U3\^+HY@)84A $H0.CS'#+2J'J38(UB
M7SQJJKWZ*Z9M6'YK<CJ.QG0SK4#MUNE5^ZL]9U-,K3<Z@"L203]#:*?CT3]D
MEO4]IE=*<B'?'U]=#RMD5/DIE1ZI]CIL^:?WP%NGX[8)Z."E<=K:?,QQ66R<
MFU5!NRU.>V%9L</)>Q=/%SV>FGID6\QOJ6UKG_U^M6T08T<U^_V+@TJ,C6Q=
MRW=+W#Z[BN[0R'URF__C223?&BKPD)Z:A'LJ"V<$(XC_NLWC$VCN\:GK_IJD
M?#VEUSQ VT?6<76:Y/=3I=-QQ81N 5NKU&1%U!7/%@1NCING,DMEKC_I3$Y]
MZO2I'](0ONV=\K< (?P4A7Y>R+@S8*I."NG=%CZ#3L3SUV]^E-GRWI.ZB6"X
MNVCYL/:JCEI:NB%3[Y>;L5%;#9[WD)3EO)6QJT95)\<^V6!#OEB1RLEKWVQS
M^(9EN7%2TO'[UZW#8.CGZ6_7?:W=NKJD\K$5V4.!T"\-.A'=$7<CJA-^E8!%
M72L:H7!NW\#&:)?O[^WQ+\J\6&CQ2)LBUO3B0/%WN3X=C:IO=GPHUA44X]CE
MIS"R>[Q I2L./<%0$)$KZ#PE4GQ[)'XV8.(7$UX%>2EC68JW5'U ENMND_P&
MK6#U"LP[J5<R/_*UPJ;R:!=*)P4/?0./<-P.;W]5M(Z'HG6 R:UANQ&O&R%'
M'@]7#J^4=(*X,>C@IIPPM^[\1:7SSLIY:RDQP-/NLN+RXN:JXANJ"9:BJA8F
M7U@M#+__TT1)^\6>MF&>[ <N&Z#7KV9NFD%U)B'M^VU3O5M_6COQXP^GE^?W
M6MWT#7US;C[M_=*'W^$0_:_3*<.MSC_XJ*,>N!6.ONP.8]UZDRDZ$ K5XS99
M4J GW%#84KOYQX8*MY H0CLV4*$%#@@:J9G???P4YF.;^8Q>IZ' \X^T-K[Q
M&(^/')A]+PUSA@ZX;8".5)%X559+JDTJ!54C#1Y7::HB^3R@2<,#.73$O>VM
ML_%5=-EKN<[.-Y%N2_/$QGT5.T/N7;NV[WL]JJ+W3,N"XK[*FHWHW#1T;#%7
M9HZ$N. 95)-[?,[AUP219'@\2I4$=Z(AD7@]UXY3C[2;T5B8N'>/.X=Q/U[
M2A7L#^#^1@%"VY5+R ,Y@K>U_6QG"Q;$WXV65YUB<2]5#>%LY3%B%XCNGIPT
M[&YMTD)].C!(8F;[1Q&[) &,R5S]61*X[(EAKV? )IJLQY$X]!='V_#,E\OX
ML@MLKMYS<+H"$% &8;FPR%B(.4I)C(XT\+1\'87W+N@ E^2JSJO\Z=6-IU8H
MY6:5@69E.NJX]$KSB?=Q[PV\/.GMHGO'J.WAXF;%5Z46]E49SG3]>Y9^!);5
ML-2>D 7&/%9A>^O\T:_W[F +YI@/$0HDTX+]Q;\KVN>B]U:P5TCE%,U,B>ZM
M@CO<W"(1-9UWNIYZPK+0-$(9:GB8P\9308"G5^TW!&DRM]W+99Z7G5ZL.O5V
M"Y#IS3#(/B#JH0H/61H?]R*B VK,S Y@":J_8;9S?AE=M'G8I[+R]Z@<\V]T
M=ER8 +I;?$63,S%M22D*9<,9P[=77W6D1N)7-;7ZH_9QV_-A2L>,\X6N4L43
M93-MY:CVH\V9!H\#N^#R+$)K,YMEL.WQKQ(M<0S6?G4)2_R3RJE3C!>C@#Z$
M4_4!/3^[]?@A-.Y?<@J1M@2. BM?,S,([<;&Z* U&=@('0X;4E#E^LQ1*YBT
M=]>JZH ;-G#6Q]M=(THOU@U>?-6O[V\:2S*&\9LCJ@+U/3Q_U/7K\5_HUQW;
M#OV*Y:3UXR*LG_-/J$C0,G?^=T;UM_6OM*[]CY.:Q_U/O%YR>@":J1F6CJ/+
MBP/O/]6%,TO^J=+4.&<R_KA0*%@M/8#[,X-^*ES0!O5OUQ[^'U!+ P04
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M&/D0QT65EP&8F4 @B+H4!#" KDA_X=6B4EU@G@'8628 &$1<!UN9XT\ /2\
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M^("3-(01PR6K;>?A:#SNCM<W*14E1![3^!YAYC2=I)F"FX1<)+RQ-74#DD]
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M7O%W(>OA_'7-]T)MT4YE<@.OCD>+V1F7).U%61SH*Y'KHBR+/?W<068J%0Z
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MN#44(9_6;?RSVI)PJF'.V&0\.8<C.$P:[4##<JMRZ8,Z4]N014Y3 CI2=4T
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MFDZ%LISTY'P2%>-A/+[PH[1,X_+BE=9'U.+Z/@.ULDI![0SDJG&&T?MC0'[
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M8$,B/N2 &0''2!XWF4"P,H5TSK92F)*"DT1N!A@F(G.+2".((%*._ ,5I0U
MA?PEZTB<_+4/T&X4FW@XU82-3>+0$A0.;2EJ,!=RAJ1X/1?-3A*R]_;$87L'
M.S-Z(5N+"_FEU57)-940Q4U[TC1WMGC8ZUD#.#EVPDZ.693ZK^CCU!;0G$8&
M(>=PD^J\UJ);2E-SY>S@L4NU:W,B;CRBX@/G8.U:VLDLQZ5R=JDS=J N*J-3
MC5AA7Z2 8L^2""+O&!+J<V8=:)9,<X_@Z3+.%=R@EU(;%*=ZVBSD94L5+2/\
M@W&)8-X%<6"$P2^%=S>6T<]M^FJ_Z5W")*AY,"40IQ-X_:33H &\<#2<G"9G
MZ-/&L$6(WM%P.DK.NT=9[5KTD;(5M4^!YJ>*&;2V#9!E1X/AQ79Y)N(3,HB=
MM&UK:\%#/J+:3^(:^+*R)8?;UU2D""_&-7 TU1!5/+B0RXFY2=ZWU!]5+C&L
M ;>BE$YSZE9,=.@8@<LVU2ZM"Q]( QZDQ#%<4_/0N.EQ,",A@9B;+$48, )2
M" -&OD@"3=B8WGB1<MKR7<05!=G\S<+3A(YY+HM&J(90D&;0@(3\YA@\)KPN
MIRCJ_UEY756FJY9-9MNJ#Z<,<Q_"L)/%GGO2?,\FC!-_<VLPAOM7\2V_^<R#
MJ\I.P,^.@H#"E;'&-GAPVEASWOP^DLJT3VU=1BX0XV0LOL/_,_S?,B^5/A=S
M8'BQ:=_LT#VV/K!LA\-'*GZT[9$8G@V2"_J=D!UW3\P%=A;@J9BAZC[6!K,,
M!I.]76,X/DNFXGR8C,3'G,JNK.$;8K:B+AY1=&3AO=/ ,^'GW-]TQ>_PH!BR
M460<WX[0A0> PS=C<7&:#./UJ9A2'/EZ(L[&R:FXX9INGHPFYQ#[:"FN.YBG
M9T-H>8N&3DVB#NPCB"ITE8LI%$6I(W$&M5-Q%Y-CDZBE,=UL\3!W8@@@%U#)
M.Y;QXOO-\ONAY>'I!&I;TFW[.N7/T^DS/$_$3YKYL"NIG0D+?0\1".O=H=@_
M4$/7Z6+C;H<M@$,.<Z"H1W6S7J9FX7AG_J-G+QK!GD"[Q4-42KLZYBQ#;\'6
M0<4FN>=8-.F.19-_>2QZB=SA6'0X%AV.18=CT>%8=#@6'8Y%AV/1X5AT.!8=
MCD6'8]'_[UC4W_C.5BBWX*^)7G"!QT]NW=/N@^5-_$[WL#Q^[7PGW0(-!CCG
M$$6>X:3DXA?$>!-LQ5_M9C8$6_!EKB0F,UJ ]W-K0WM#&W2?<:__!E!+ P04
M    " !D5U%28J#)>>L)  #4'   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6S-66F/W+89_BO$=E/8P"Q7]V&O%["=&$T1-T8V;E 4_<"1.#.J)5$A
MI3WZZ_N\I.:09G<S+IJB7S@:BGS/YSU(7=TI_<5LI.S9?5.WYLW9IN^[5Y>7
MIMC(1ABN.MGBS4KI1O3XJ]>7IM-2E'934U\&GI=<-J)JSZZO[-PG?7VEAKZN
M6OE),S,TC= /[V2M[MZ<^6?;B9^J]::GB<OKJTZLY8WL/W>?-/Y=[JB452-;
M4ZF6:;EZ<_;6?_4NHO5VP5\K>6<.GAEILE3J"_WYOGQSYI% LI9%3Q0$?F[E
M>UG71 AB_#K2/-NQI(V'SUOJ'ZSNT&4IC'ROZE^JLM^\.<O.6"E78JC[G]3=
MG^2H3TST"E4;.[([MS9(SU@QF%XUXV9(T%2M^Q7WHQT.-F3>$QN"<4-@Y7:,
MK)3?BEY<7VEUQS2M!C5ZL*K:W1"N:LDI-[W&VPK[^NMW2F-'U:[-U64/>C1[
M68Q[W[F]P1-[_8!]5&V_,>R[MI3EE, ER.ZD";;2O N>I?BM+#@+_04+O,![
MAEZXTRZT],(GZ2U[]FUEBEJ904OV][=+TVL@X1_/$(]VQ"-+//J/3'?J7F9E
M%!!3%K)92@W]6:& >M/+DJD5ZS>2K51=V_6OK&DP^#F[V2C=7_12-]C0-%(7
ME:A9)SH06>X9G+,__B$+_. UGOQ%E$<\8#^H=NUVMJJ7AOG)(HPRGC(_7"1A
MQF/V(]AJ5N_6E22F'_&,^0'/V>=6-.!>_0LRVE>5,8-H"PE13&_8BRSG_DOV
M(@UY\I)]$)5FMZ(>)!/E/X%JA'7/$)0;6:Y!H9Z)$P8>> 11#%%_5CVT<NR3
M19S'/&1^O C]E/20QB!,M"9Z'0D$HB^@"%B3KCD/7QXH:ZF<6SI9PA-Z#!<9
M*.7LYT,KLUXL:SEF*NAHCB2<.NS0*P$/XV_&5244QIL C-+8X][N-^2>=[0(
MT@8[7_EVQ7>#5I"Z50A]07B8;4E#DCU)??C%XSX8W]S!$^R#AB^>WAAA2PYO
M)WX&:Z;<#^8BQRP(:,4X\O1X09QX,*$;?9X0B>?%35@>!#QB64@T8SXGF;(P
M30&]<>3^T?O(\_'&C1Z/3E4W8U$<PK81H!N <'BD38[(\*UGMK\@'WS#_BPZ
MT4HCV=]D^S1].-TJ%G@YP=:9\UE;A-[$%MX)YD-:F'H[3DZ4+XQ83BIE,8:$
MI^E4^1#N2R/(XD;X96:=$(9/$[*?'6.>'R\(LHC[XQCR;&[@,&<A@)*.8\23
MV8(H8A&"P@TAGXD8Q=9WVS$\DB "S3 !;S<^LH \''O.P^,O<7G6Y'8318"%
MAY\#Z,A+Z8EFQ^Z4S)$2,P!O)E%,D@06:]N8CVP$3Q819V\4V_T&\[A)R+.'
M9 YS,RUD)2J@&EI*R_ @Y<8XYMG+,;7.4]OYOAJ<[^L!Y<<[V^/(\D+<2HV6
MC<G52MJV:E]OF(8A*+6C S2]:$N:.RI/T_2Y<)GS3AA*)#'#B@()G7\E4[2H
M3(IBLZ]%8_4D#1EI>#$F[Z[3ZKY"3X<_M ""DO>J%HNDZ2TYSMX>"1EX"\C#
M-J)D@O76>F!QCC(5L655UU1],#&T@P$YTKKJB?!2M%]8H659]6PEBJJN^DH:
MT-I4$'=?[3M=4<&I'XB*8.=4)G:$I_L?(#BL*.^["B)#]+VL-L'#\D0A.*00
M)M%%*1Y.(P&%EZK?D"1.3($&2MR*JK:UL5<HCQV57'A:'WL8%EYKT7#V"]D+
MSH+I6:G%'3KQ-0X+L#)9?JHB"3T5>6\M!G1 EB./</:C\[*6= C9PNUYP]/Z
M0X N14V >9*)E<R!% BQNA!Z-/3E[+UJ<$8RHI]2:K<(L,W.2M+<;._"KJ).
M2X[O" P0%JH;YQV:ABV7UN@03174[A"G 4VW'GUC48X>TX#T ULB:JI^8ZW-
MV?<M^XC)'7HI.F":<__0SJ!,*6H;>FQ5W2/D;%CM<TVUI103)7#81PS@ *Z=
MJ$IF9%-=B+8=1%T_6/_;:" 16YPR"V$VI%$A96G82JO&>0-1;=6B@,JS#+FV
MV6( <;V6+:*_AGDT,$=B=0.>##FS:HMZL&YT,.C$@^LO5\\F(6N9M\,:[>BQ
M<5Q&;0ZM@X3]6]:YD5V_#:#$@48 U:7S*!B?!W.Z%#S_1Y8'*-)]\/V.AO\@
MEWH0^L%&U0R7?GR(2]NOG6 >C3B@9FSQB/=L2W(RC9!H^.3PB1CYZ12BW(7V
M49!1B3^92IS_MYQ-KD5SM[?KL?=!VGKP.)7;/$3%>?00)$26:L=[%2L@41+%
MKT-E+-*)WP_J7ED;/(\B"X:_J-MMV$S!(-&>71PW6&/%'$&+O@>5[77BS9QN
MN^J9L?=V/N")UIH$'>G,788^\;<C_X :^KXGG3;QEYU!N0MV$;<@XZ,),.[D
M#_2DDU X)8I)D^GKN4,7)!'L7VP$6EA:CP(I)19*W:.$L@TZ+J@R:8?89W[#
M68D3LM"/M+Q68\IUZ[66:^M@2%-4'9BB&QU<5IC6=M>B.)VT?B#AW1W!N-+?
MFP5B#+7U-\03[APO[VD"D-O8I%,KXW >Q'1&&'% /61EW$L+89NR'(@5%=X+
M\%^P%YA7C7Q)S1!*N76I:VM:H^JJM)K:+G&7X&!(X>IT.>AM#GR0L(ZDV[#C
M_O9YI!\>*4Y O)_$KW& S(-#>-"9]6N02KG2D<HY#LD32G'R-93":#&&$%%+
M>1)-J>7IUT70[UODPCCY7[07='K9QX.+ @M1M'^ C&UJP7]VQT;B.&7NR5BW
M#E2N=P2 W1V5L3=.OKL$PA"ZIM_>RWQ\COHY2^PU% [!N<?I8BK@(<UF*+MT
M/879<->S W4X=!$*#XY,.)WD.V^.'<R>RY%[X;I5K5QSK,<3EU;#VA4-^(YH
M3%.-N1.=^<K3G[&7\^4C*JME7:W'4"6,3GC-;_)F[?[<^XZ[>4)DZ[OQ2G/.
M>N%.#@%/_)WQ+!>>9=L)F^<ZIQYA^S$ $6N'<0=#QW0G#-3?7_TN;$38#5V%
MPZJ]$=@N73R&J.T=IN=G[/V)7(":,(IY1K]>C-0+3 5HN"C=B0(15=JS^*Y/
MT!)]@I:.+(3#*::Z%:2S\P\9D.R-U&YWNM/:]G)W!-P!S(Z<;/L5)/W1$U!1
MX/"WNX&VT_1>RQ5]''+%@'A,LOUXD&/VVXH]&%)Y<SZ !@AS(-M>'@S-]J*!
M1+&W,.EK,R]J73VXRX;5HY?AR"LP+9YL+MF(=NV.Y >K1R:' !-]KZOET&^/
MY TE46M8;&V$_@+_S_!NAJ6!_,1S5  0Q[EE-.Z. W_L$\GEP9<F9+NU_9Y&
MU0E6<1^==K.[3W9OW9>J_7+WO0]-+MR,TBQ7V.JATSECVGU#<W]ZU=GO5DO5
M]ZJQCQLI@!9:@/<KA?PR_B$&NP^9U_\&4$L#!!0    ( &1745+)W]6F,P@
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M@M-6M #OMP8%BOM"!_0_]7O[?U!+ P04    " !D5U%28\!"#34:  "I30
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M!)=0>=CEZ4X]Z)I(T1"\@JQ)\XHF$8"&7.J] ?*- ('TT+]@Y5R]>80PKWI
MPSVL9:VW>5GFY19$/^JD5C<JF'OA+)CZN(R\.%Q, UQZ<S^8QGPUBWUZ_*.N
M[_,4Y&I:%86SZ4R%,Y]>H:=+%<VGD?JV;&EA])C?B>F=I8J7<QH<1].%FBWI
MZG7:=DF=)X4JJJ8!]'E$,X;>/ KHG2 .Z=LL)FB]Z!R2/%.3V7(Q#6_Q&?/G
M8C8-Z(/N1K?J35>W25ZP4$VV9,-O!7PX#=4DF$^7M^H__FT9!N'?U,2?SFX5
MF4(R="69IKK697I4^J.1I1HR*=<-,[0B(:E5DOU&5@P3$-1X!B0)K/+Y;WZ%
MWAK##:6#I1<RU7J"!]YB!KI86K^Y),ROU-=)7JO[I.A859Q'ESD:A-Z2*1WX
MWBH*";?06\R71(C0BU9+0IQ94$!0N[I4U6@Z0F;IAX1,Z/E!2%!FT0K\BV,:
M^'9_**HC$8-4IJWS=<?KC((E^!RNIBOB#I@21#3;<]CWE[@1$ Q?S1=$2<MC
MGY!]E&PCQL3>;(%%]I2+B%. :0GWM6M.U"3RYO$<0D17T2J:^K1B+UY$)+.!
M%\PA%C^7CITI*29)>K%WQ7/NS0*(Q-P+%@OBU"2*5TR6( BF\]LQF$.=D_EI
MC!I.C-;?BK(1F%@%"_HW85 $(R2=C&_5]YB=C9]K^VYH<4MB12Q7?L@&8$7K
MFM/GDEGZ^D^83'Z4-[A?;5ZI'YA;954*9UO+ IITM>*I@CGHQ@9GM1 KY$7+
M@.[)6#NPR)-U7N1M3G(P(6:O:(7S&81GLL R)RQ(K].T[K0UPFP.UE8.B5O+
MQ9*%C^S<*@#?)B$9!\ (?19/&M_MNX+7)9*65GN*$G<P\/=$];RD&]JP;ZW)
M(4!A<4^UR4?-+(U\T@1BZ6I&ZYG,POET@3GC)6;\\^SXB0C?79<KQL@(%Q2E
MNRX[+#&# .T26EE9M:0.()<N3SB.>0Z:(&1YVKLZP!"-9&=&-"BZ3-Y/GB B
M8SKVK!(@,3@XMZEZN]EH#G15UM4P;Q"[=I?7F?J=%DQ^!OJ+0>13R9=FU0'3
M)>J^*HBV%)<[L0%<]EZWNXJ5/CD<BB- )HPJ6(%O1*(RS0^%9B^?:CB4$N]C
M]+D\B4.?,E=*"MH=2&8J:[5$8?:'KA6_0"#UQP.M3N24;' #(_SS],>IRB@@
M2!!?E!4%R4S!O+S78NK4MDXR(HA>M\1*4@S1!A M(_;<)Z!7@P4W'049C*#:
MU-6>R)(F16I8(C:QW1$'#->:'E>CWYO>=A)J]["W1@" _ 9<@>5L$*LEXDR&
M$2!)WCC4OTAC>H,D8J/K9$W?UCI-$!U>10/SM@RV( O"7!1#\I 7!0V'2M6M
M$5C"ZJ+(7HC.6!.:JBIU/57?5SW6T&UF)0A.\(#-55G!0R/GP$XS?OVDC*?(
M2;X_$+ED+49FC4"T5TEFA.F!HD6H*.5OFM6=D()@TKBVJG-B+R_/6LN1@:;0
MD@PT!L&#L1030J]):%+*?QMMR9WE32J&"4X7,^(NK15IKLI(PFB)=L$W%*=%
MBDQR84E+=Y:K_@X1: 3\/$C%DY'6>\2=YB!J7QRG%$ZJ?W3%$<^6HN5E2?BE
MM"267KKS4'4%8GOVYW\A, <Y-_3P#^(DM#WK4CUX#M<@:(F!B,FZ-U'_2,H.
M)&(S!NM%R0ZL!2<Z&2]?6 ]+?!TCQH1#F,7?+M"K0<9 LL(T$9/)=.&,@BA'
M^;NQORS^J1,2;XTINPD1WNR%17TRDHB+KZWYAL0RPGF-T<R6MNY(T6&)/2<,
M [<@5R2Y->FM2+DD-9#=6I..-QRD@3D/7%K0V1WYFSK9(@-JNOW!79OC$IY,
MBB;O=)T"^.TH/PJ6IU^_&LDUF'E!&!'S_KNB8([^Q_P?H3/N1'P'3\\!E7IP
M".(1 0'C(QJ!L3%_+M1[D^K"$Y (6 TP2G(%*0"0O_@3 %Q")C*(Q.KMV.><
MQOV7 5!0I1!4X@]Y'/X@0K^R,I+A)U'4L-! #G*N'Y_%..,_JZ9L$\Q\-B@8
M9C0$DIG98' P2KZ1S&9Y)'>2DJU$$IX3X*2W;$F9%$<*6IFZ-DXM$315OPEH
M>NV#Q+99SN+Z-Z,EUG]SA8'O$$FJ-+$OE:+]]RC" 7RADPR(#R8YR>YSBLL$
M!&DA''\#^TPDWB>$7-%4- T@G!E\1WT@%0F,C:S-9G@P"BB D*/4!4:(YW'U
M#BC6L)^@7Z,HIRO8CZZ/JLG)5% XTM<NN&Q!X1--3VY[JOY.UL_X#MT@@1N%
M2]=J('(W)73OV/^ZTV<5NSD.29/!VUG/*>(S4*_GB)AM7BXC0<Y?F'!JDWI<
MDB,[PL& ;E!A'<1ITQ%KM8V9F8:T]+HBJ2&LZ'OMR!ZY#PI".--URSIDB +\
M"_$OPK\8_V;X-[\+_<COC=RI*HA;NE%SRK]#_IQQGC2/456AST7$A9KY4O(H
M2FY\%"/>/^;E*.D)W7\Q)2J4I2Q43!F7F_ 51K^JJZHJ %G:!CVYY+3@,S^F
M6J(VUQ:<%,%.,H)7CA5_]\@$2!AGWF+ATRIND,O[1+#%(]E_$'C+$%8Y\+UX
M"<OX_&4_&4X8+1SRH'\J9?Y$M?#UH[@(Y>;+4%+QR//G$=,S#".6MC  Q9Y#
M5%N*L9_0PK9J8;8>1^6I&JLA,)'G)EA,_9,8-)A-@\5PZ[$D\S3<_%Y_DB."
MSI>-D_&V(_L"0TSI1-D^KZI['K6\Z0&!V*.$9ES[>34NS=Z8XNR-*<^BU!(R
M,[E0>R.E6OH6T$N/5&QG2WH^U&UG" 6>B"$F*S_@NMB2=! EJ"6JN2AG$0C^
MC&.NMJ!$M;J%XB%IZ]/B1RM<,>ID9/)BU,EF*YYG'G(=:,'?W@]%B\M5D6B%
ME8=+6+TH"@G>1(IW*-<0Y&M%9"O"*":C,'4JVI-PA55]?YU%AAE<[UKY7-L)
MXP4S:1(0/X@V-U+T\^4*YOCV>C3-3OQB=>Y2O<74IR98S&V?P$D&K[FR>:XD
MGE$1HRS+ORC,0]6?4Q&#"MUIL#)3XC$E!EK_?!Y92GCQW% E(//$MBA:RF<\
M9P\8@9#O6 R1!TI1> QR$J*XU_,KX +I*1N#^$0&7%3[E[@:/B-).)."B'GV
M+)EVJV;0<,.I)T7]=)(+E< KH)_2@6=7XB<+4?D%BIPQ-H]"3CCFV&@AN?Z)
M;?[38GDF Q$%/"LC [ ?"US/5K%HT6(I_GXIGQ-LI-PB9N;(T?J.T3Y%D]S3
M#(U-^%%!2+FX!6^CR?_D*$4-^?U#51?9 Z4/$D(>NOI0-:8217IHX%#:L"6>
MUIP*4>! P= ]C:&X7@)3U,:&^HM4[8YVM6Y9\6B&XKZ#! <2G.C16R ;S4$K
M(:1^Z,8;,8TM5)D8A6(([/-GL-(6X,D FY\4V'"UP3L%W>ENRK:^1#$+FQ^U
M YB].&K6P1S;='TUX29@O>B_BS_F'2AS[]-LSZGI.?73O^J>R'V5EL6+V-/*
M0L>%?\GS<N(/1W@2KF=Y(QL*Q^%%SN)X!Z''U(Y@=65IP5VKS@477%'0M0QS
MZ$9.L4IS'LU<%*D9QXE_BB 2'[K5P&EOE=D.?MN7C!N6$G=.MYY\J"B3XQ(R
M)SJMX,E%G0WY,)L]]V;&>'T.CO+F WW_O3/RR]&L!- T:I<?K# .O'.W<*92
M[@:D=QTQL5+O\[0R1.D=G21<'W,LD[BW]&$>H =65+=%M49V.*S7S4F+JMS>
M$8'VJDPXES.C'#R\D2ZS[>!PKM ?<R,=A-L^*;E<14M?DPST]:M,;^$!01F0
MPU0ZI0YP( M-OCNO4&IMI0;8HWG'E#^*WC$."/B9J3WYV:#0\G>$R'@?@"!^
M4SW0T%I*&3F8FN6D$=V(& 9OKGZ@$MR82EZ>#MI?4(K?VO)B;>R#E ]H>BP$
M-?X"+H&% _1S9JC6OPES"39)/8C,I& P5>$-<^ 66->GY5S?8+H"9D\NIG=>
MTI _]'A,3^?UL:^RH)1"]JFQ=!#:TQ.]K6J6LV_+WA3WU$KL&T<4B;#QD.6;
MC:X=FAG+>T]VH^H:<_=DR4!58W'8J%&H,*$&PKPKV\NXB]4V8CLV!2CV:(3C
MLH/A,((84\/MBIY-G+V>6Z"0D^T1U$3HT[$0&%&K:DON0T*Q S:#7*H#.:+6
M5\X^$L3!;'2P,'2-6,Z^YEC5PQ8"9445LQ_B,IJBH]0N5; 4[=$C7_B191FN
MWT- L*=P&0^J>H@Y3+EMC\W5.CGD6<'X%TB5)?UB5P ?CHU(; &L97^&2)$W
M.T[*ZJK;LM%E!IL]ES1I=@:\J0P)\4W52ZW)D_0ASUV+_;9,@AW2MCN"<,<%
M8&82:N)&'0%HGY"AZO8C2NA<NA7LBK!(&0\*'141CU9O K9&%$6(+,C6-6]4
M.EM@,*BI)AY1K"+:E5OIS*QXNZ+#($7;I%@%U;&&T,$E%W'>8PN?9J$\WZE4
MR *W-="TNX(V"AJDT<%,;,LA.9HO)^[*+M#HP8G!]&Q8,NQ! H IT W+Y!UA
MF6"-IDS!\D^6EIVZ;>^4+[HH4R FZ>-H-F=//W)3\UGOIHAD#S218[H97C2\
MP?IP9T+AD8DW)!^/=]'4)1=]><.Q1S4'0\O$1)XCY7/VC%&#S<@4L.WTH.7W
M,&'RWEV1?QCAXAGB$4#-.XB,'+QF;SZ<JC<S"VAP,--6=C<-&@39LR9\B'8S
M;"PV;#=;NR]5("#1'W@'M.(8A!5JEV]WPZ:Y#<?@Z!4<_918=7G%C!77P/O9
MC&;+0B51ND+&9D^(W[7578%M+JFUEPPT-3HA7D($N?<@ -2TQ\)NC%&D1,$J
M9SE(W^S.;\_F@9QY,T++\H>D5K"Z/Y&5KZ](D1/ZFKX<V<!WWG9(9 G0UKQS
M:7L+:#%ERD)#7J;>RK8XFS/N1'#L! PZ)4G,K'7%HK5.R@_$'Z[[(VG=$K2[
M=9)^0#^5(X_P!*02, ZGKXTF8(3*(9*G6+&KR5RCM13!F(V/!O&V?NQ>M+-Z
M*)FH39NWG>&OHU\RA)/#(:WCN+ 7PR(GX8+3&D\#<;7!&\W H9UT*JR;JNA:
M;</G6F^3.BM,W=>JQ=D6DZSU! DR<Z!Q'VASQCD2>>D&6;>#EW.1K#:DEV:]
MJNG6I,Z453)\XOZ0J!IL'">G)DU;I1_ 4N&L]=W"/G'=?.W$)R0R;3J])0_,
M_3:*UDKI5ETEV.Y!40$*4,N6&/>UY[TC,K'*:8 R+$:AZ9FB. S85&GG"CNR
M?9MJ.YWS& 0NR6Y-J3N"4$B@9](4F=I$'_=0W#=89@D5[0Y</B"4=Q>1,!47
MDP41L]AY472/E5%0)@PEL4#C,YHIRJEZ/WKW$K2DIO ?V0;OOXG7:Y*][D/=
M$MMT74&,U&2#"J2SQ"**?603DV0O0QU\B'")3"E8DZ2[7-^;1JB<U"]#L@J[
M3$Z1+)9!VT5*Q*=-/AB;RQ/LB$?(O?->(JW%KYWP^$3.F9TGAGX4-[I)Q@%B
MT)6L<F^9?@:GH_,,^($:^KXJB*#<]^2DLC#9Q[Z#1$2:VZ02BI_(K%F#G:2D
M1XVK@NWQ8+(Q4<&\;0OM:B'WXHR7EU&<D1KK D$R9@G!OR,\H[B@UJ;;R$2N
M-A@$3<@&<$Z=FW(]VVJ N*LV=\;\F X-VQ#&"+!:PVT.)F J)8(=B06+,P':
MG1A+EL5L*!YQ=9&ES81CD^]?_T*YA]-31OY<DSS)LHCOQFQ9Y.WNJ=DX]DS?
MX)!P)T.R3<)#9MQ$ER,*M8KF)?P?C5:L!3]A&MG-WFX+G\_HW5<+'(HW6,QO
M%1%10>Z8O*9SCDTHG'-5B9U/*5-I>V_2>VYCDLJJO!-+C<1%$@M4]$PU!#4V
MZ4ITEVR-@)F[GV*BDQKI>9ML[=IIZ"W9YNY8=:W7-^:0('?6==HH M[!,PT.
M<L<)[<9QQ9C4;A:\R>N]2V56&Q0Q)'2'EZOJ;8)]B7Z:(6Y"?DN3\G220&9#
M$&?;""_Q69C;-=W VJ37E"+?:-/@Z83C@7\7S*3 9@-9@ZK4&2AE<Z0'7BTW
M@@0+(FG(J2Z*)C\1-@\BQEGE6".-MI5#IGI5G9%'2FE%/.=)N(P5.XR1@'-H
M2.F#5"[@6G=ZP0I\RFJ,91!WSHTM[+8H""/ 8@9XFD&!/-.JCX8*4J4/)<5?
MDH5O9&L;'L2IFK![;'JB2#,)A\M(%#CW^$6,D*D!7YJTC_F,[O66S.WTP<R_
M==G6K(Y<IA10NHNJB$+2H6MMC;V1I?<;^:*FSE!82*_OJ$0!V:[9&>B9MAWN
M@36>PWT*%/L>H#X@<(X^;)RJB6>J"=Z)H9/:N/C;D166I.0^:1 K_E9QL#1L
M;AAI&%'5EMV[?E^BY/)4E^77^DP-VD9><MD#*G(^,, P^AY?$6::(J7H 7)O
M3Q*4IBX]8.[VQR*"S2B>;A!,.69,6J(J9OS&QLA6WD_>'5E<Q.>8MA[W7CO&
M"_:?+;B(U+!%Q@54M ";[+)1_\D;*P%>/&EHIMBK3BAS.3Z*BQB#OI.4)G9[
MHDUG;6(DFF3N3"O8(=LZ\#E^B(!L-@^1Y5?,\3N[;Y&+X ^,O"35'DK0^H"D
MW]3MD[RQ,6^?V_3"+HH(SR>G//KV0)%Q!LO]S+B 1:(5]^43@$,V[F@,VWTG
M\1#9YM&CXAE9U::]ZW/ KF9!M 4SZ4JW5L/UXT[I7IKPSUSYD'U=2:_M4KEH
M^?SR2W):-'"=MI5KV\S&7"0N=0WDGS<MN!\RTW"P>3GN\!_,H^44>U#$<V+I
M?^\JIPM21GDCLRU&IEIC8XP9;(0&!BJ'2' F4=4C&1">5R<;,J@J7S*;@\C\
M='I"8?-DP]"U=NO>1YYV'YLV"&PUN%L*Q_.CF]P4Q3Y)?3<<;6W4STRZUSSZ
M#9]:D*WP_Q)BON,L#++U6G;'OI-\G4GVHT-:]]K=V/M%?#&B8II!YA$T)L'M
M6;?&.T.,=USNOE8E>R4%H!NUB!:\SQXOI,?"-CG<*#DI&LY]VSW45\EPA!/]
M0X$7^.&%-IG FT41C?K:V0) 6XDU-J9@H6(O\M%F$Z)%P0L6*Z?9@F '^'X^
MZNYR*0C= _.%/SH >G;'?KX=U[<:A3.I/AI#0EHQFJAPL#":H;_[W>,UN5>C
ML@N19GZI<ZCO+#+/WYZ%NJ&WC&/G9&-/B#E1AQZ&"^[Y'$S!;+;$DQFZ0O$.
M.!(N<8Y,S$_@+9FB<_2&@="A"OBTJ!?SB3P1TIOA5"0.Y*T"TU'F^0MI1XT#
M[L$)?&\6HXODI!O(W8[^!'&;+Z4E;<;S#<+FL_"%.$XZEK5@#@E#5]DY97RP
MZRDA"]"IUH]9^@YS0M#D3!1FD?-^Z+(D1#O2\\0A7%U@:0^/GUX0A?!27V6
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ML.#LI6OSLF[[QF;_[WS1=@VTY/_?,>N3,.L3GO7)GV7KG:^3)?ZCW9C<_O
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M8,.E4B",8ZHO/X3B)O\[SRD:R!?)>Y#(+Q E10EREZ[5<K DOEM>$<&R5VO
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M/W3\[.C*E<B,#3@+C: =9"M5;U6/HT] J"7]?.SMI)U.E?:V36ARFE#@T\%
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M5&>R7:-U%%E(U$8NAD@A!!+] A]0D:8\8'DN^ZJ8/0CGIUB9"DMG<*07J64
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M 2/*ZAN<'W([ &^>^N/TG^V!_N?YJ"F"9]1\0"O \9340"P(>]K<H%WL<DF
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M_N?*TI8'/8#?ES4BEWZ@"<+?5_OQ?P%02P,$%     @ 9%=14F&L_OX\"
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M K: I=A4>*>WGZ#-)W=ZA:ZL']FVP6;DL=A8U'5+)KN6JIG%8UN' \(H?H;
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M4ANH#LM.I/8C%U/^S.9\.C^5;AH6NKRD7;6BVR6^(XR^!?Q*$Y.MO#OS!2Y
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MR)2E2>./)8UVU$Z!OJ^5LCO!$>Q_%HL_4$L#!!0    ( &1745+;)!Y8K0(
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M-6<QE]@!WB\%I&UE!2>H;P5>_0=02P,$%     @ 9%=14O$L-(H6!   /@T
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M$ &3)Y#=KB<(7(3CH(UP]W12>EWNF5P%^/0(<R0Z>F=ZH=O!G3IWI$X8$N]
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M0"(P!J[QL'L9-<W,V'2BG_4#BY+^%/UI^O/HSZ>_X)5RM=OA?+_2X'(" 2!
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M <^O"U!6<T$==!_<OOT/4$L#!!0    ( &1745(=I^>_:0<  -T4   9
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M'-'X!-HOM7;[P!/TSVWV!U!+ P04    " !D5U%2,YT(P'H&  #F'P  &0
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M)3 \W0!^GW.N'E]T!^NK_>/_ 5!+ P04    " !D5U%2:  5W30#  "5"@
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ME.85TS'J^5B5P^T9PW<V=-M( _QF0_%!1PKPP(WW'3T,PWYPT-YZPW#']UJ
MU_E>5R!R._=(E/(54_77KMUM9ZMS.U'L[5^8F<O. 5N:>F"[)B*G3*(2%IK2
M=X>Z@8IZ!JH7BB_M5'#/E9XQ[&VAYT80)D _7W"N-@N3H)U$I_\ 4$L#!!0
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M@9,#@-NKT39B&NZ)K]6]Z^RT[;IMH?3\'71OFQT-MYH#= \;9/%.W0\$3@X
M;O^Q:ILE"S?+@.ZU&@83 $^,2S[-X44[GK6MB=&?KSQK&Q-C;ZS\'H/T8I?R
M!P"W2;7MCX5+_^L%W+MU6=LMV/ =!&P[! O_\3I P+!!=K93P-<#*U+1QCU,
M :B*N\\RQ*].=>/1C#9W9A_]3=$/X]?T<E+=?+5FJHNX6Q1;2(-G[1F:C/MG
M&*NN[K:J%ZM*?]LS5=:JPC]FP%/0;@+^/E/*KE^<@^:&<?P?4$L#!!0    (
M &1745*:_(7I"@(  ($$   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM
M;(U436_;, S]*X+10PILD6.G25<X!EH'PP:L0)"@VV'807'H6*@^/(F)NW\_
M27:]#$BV7BQ2XGLDGREEK3;/M@9 \B*%LHNH1FSN*+5E#9+9L6Y N9-*&\G0
MN69/;6. [0)("IK$\8Q*QE649V%O9?),'U!P!2M#[$%*9GX]@-#M(II$KQMK
MOJ_1;] \:]@>-H!/S<HXCPXL.RY!6:X5,5 MHOO)79'Z^!#PE4-K3VSB.]EJ
M_>R=S[M%%/N"0$")GH&YY0@%".&)7!D_>\YH2.F!I_8K^\?0N^MERRP46GSC
M.ZP7T6U$=E"Q@\"U;C]!W\^-YRNUL.%+VBYV=A.1\F!1RQ[L*I!<=2M[Z74X
M 4RF%P!)#TC>"DA[0%".=I6%MI8,69X9W1+CHQV;-X(V >VZX<K_Q0T:=\H=
M#O,U'$$=@(P*K= X4<D7SK9<<.1@K\EH"<BX<-9[\K19DM'5-;DB7)%'+H3[
M#3:CZ*KP7+3L,SYT&9,+&9=0CDDZ>4>2.(G/P(LWPR<?_H93U_L@0#((D 2^
M]#\"5$9+,HC0<JQ)$>0'0[[?;VW8__&/A.F0, T)IQ<2#CG$'Z'/J=BQS .+
MOXO'/)G/QK<9/9Z*=29J-AW/AJBN1'HR(/YR/C*SY\H2 97#Q>.Y&V?3#7SG
MH&["S&PU.@F"6;LW HP/<.>5UOCJ^#$<7IW\-U!+ P04    " !D5U%2[#PC
M6+@-  "V9@  &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6RU76MOY+85
M_2L#-R@2H!WS\LUT=X&L)T%2-,TBFZ1 BWZ0;:T]S3Q<C;R[#OKCJQG/#*]T
M+R6M N9#UH]#CL3K>\A#WB.]^+"M?MW=EV4]^[A>;78O+^[K^N'+R\O=S7VY
M+G;S[4.Y:7[S;ENMB[KYMKJ[W#U497%[:+1>74HA[.6Z6&XN7KTX_.Q-]>K%
M]K%>+3?EFVJV>UROB^KI=;G:?GAY 1>G'_RXO+NO]S^X?/7BH;@KWY;USP]O
MJN:[RW,OM\MUN=DMMYM95;Y[>?$5?+F H/8M#I!?EN6''?IZMK^7Z^WVU_TW
MW]V^O!#[2RI7Y4V][Z-H_GE?7I6KU;ZKYD+^>^SUXORA^X;XZU/OWQSNOKF;
MZV)77FU7_UC>UO<O+_S%[+9\5SRNZA^W'[XMCW=D]OW=;%>[P_]G'XY8<3&[
M>=S5V_6Q<7,%Z^7F^=_BXW$D4 .PB0;RV$!V&^A$ W5LH,8VT,<&^C RS[=R
M&(=%41>O7E3;#[-JCVYZVW]Q&,Q#Z^;VEYM]X-_65?/;9=.N?O5C^;[</):S
MSQ?+77%W5Y5WQ2$>VW>STZ^NGV9OJNWMXTW]10,KZV*YVGTQ^_/LY[>+V>>?
M?3'[;+;<S+Y?KE9-N]V+R[JYJGW?ES?'*WC]? 4R<04@9]]O-_7];O;UYK:\
M;7=PV=S.^9[DZ9Y>R]X>%^7-?*;@3S,II& NZ&IT<PA,\\7XYK[G;M0Y0NK0
MGTKUEPS,O_[60&??U>5Z]^^>#]+G#]*'#]+]?PI<!)\;ND/#/96\?R6U46'>
MW-][/+ ,3BH(<]/&+1@<Z*#FZHQKW8$YWX'IO8.?YV_G/0-AS]W8O"/NSA_D
MIH[X<T./1@BTE &-T/.(,SCII)S;SHAS.!5@'O@1]^<[\+UW\,-CO5O>EK.!
MD0_G[D+>D0<1>4],'?MCR]9@"06B^V=\Q0"#"7;N0ORO$P>N"0B8:SX.@'@<
M>N]GL2RNR[K<S?XW% R0L4^9.1R1Y$!-#H<B0^:""'/H1H/!&4G)YXBS"&>M
M<(D 1/:$?OI$ 1B9%1!Y#4SF0$3N SLY$)8,L K2$$[B<%903N)P$B0*6/L>
M(JU"/Z_^5#VNEC?+^NF/?P"G_S(B)2+?@<\<B<B%$"9'(M"1\\K,0S<2# Z,
MF<MN)"A.&C!H?F\OQ"++RGZ6I9$8F1LR$I^$O!&1D0^EG!J18\O.!"N[(WW%
MX(*3<]<)" .S/KD^DI%F93_-?ONX+E;;N[%Y(2/[29TY"I$,9?\JKR\*AEDV
M>=-EGBL.9VV@86!PSKMD7D26E?TLVXW#V*R(%"A=YGA$2I3]:\"^>'@Z?J %
MF3&..-O"&>A&@^E-"C]/3-TR,JWL9]HF&@U-;<9FA8KTIT3>**A(@ZI__=<3
MA6-+/&[>6K3D? X"!W,T)QA8LX)%1->^@4BNJI]<NT$8F1(*Z>C,0EI%-E23
MI?2Q97L1I<@\P<!T,\JZ&PP&)B$9C,BQJI]C_UI4M\MB<U,^AZ-O4"+GJ<RR
M6D7V4Y.%M6*4,!A%MC(87-":K)P8F#4^-5&K2*JJGU0[ 1A!2I'M5&:1K2/_
MZ<DB6U,A;*6@.TH49BQ9Z"X8F!9)4M*1574_J](PC*0E'7E/9Q;9.C*@GBRR
M-17%1G6G:4T5MG*^.YLO&)AL<@(2P4#[D_VL^KIH1FI55(.<I"//Z<S"6D?Z
MTY.%M:9"&$!J,D.S.*#"FL%YD9P5=*15W4^K[0 ,<Y*.=*<SRVH=Z4]/EM6:
MRF"O)5FM<C!GR=3 P*R4*>U@(JF:?E(E41A)22:RGLDLJ4UD/S-94ANJ@:67
M9-N/@RE+2(F!-5(NM==D(J>:?D[]J2K^4V[J8I"43.0YDUE+&W1@,EE+&ZI]
ME?%D#YR!F2 ()7$PIU/2S416-?VLVA[^84HRD>Q,9@5M(ON9R0K:4,T;S-R$
MD#QBN&*:R&8R\=V(\+#$)&$BOYI^?B41&4E/-A*@S:RJ;61".UE5'UOB%9.T
MW:G"4K&LK"&QX&!&I,C)1G:U_>SZ0WU?5K/Q1T,VTI[-+*9MI$,[64Q;*G_!
M2L)11UAK>\F0&# @;1,1B 1K^PF61&!L-J##ZLRRVD9*M)-EM:4ZV ,-!(/R
M<]'#9@NFR7[)FZ I&SG7#IQ<;VZVJ^W=TXBDB-1G,RMK%SG035;6CFIAZ0)=
M.'$X*\@,O^!P6JA4"%PD5]=/KB@$([/"1>9SF56UBU3H)JMJQREAZ<AN'X<3
M@FYS,#CPQJ6VFUSD6-?/L5^MENOQBR@7Z<]EUM<N\J";K*\=HYNEI0?7+(XI
M7SKBVL<5*K&_X5 U4#^]=H(P-B<BY;G,(MM%)G231;:CLAB$U=USABL&YP,Y
MM5BPW8ET85-D6-_/L%=/5;'^;71.^$A[/K.Z]I$%_61U[:D>5AY(!0$'4R1S
M%@Q,!D@M8'WD5M_/K=T@C,P)'XG/9];:/G*AGZRU/57'UM#-< 9F?""S! >3
M(9D1D6%]/\/^4E:_E9OE=G1*1.;SF;6V1P6+D[6VIXK8@B>3-0/3ANIK!B9U
M<L/)1VKU_=1*HC"V!C,R7\BLKT/DPC!97P>JB66@>^(,;+]UWLT)!F;G"747
M(K^&?G[]NKI>UH\?QR9$B+P7,LOK$!DP3);7@3E=]H(("1;F: @HS"A(!B'R
M:NCGU6X0QN9#Y+V066&'2(1ALL(.5 @;LLU]Q:$,630Q*! J=301(KF& 5%]
MV.T8+ZT#*@S/7AF.2\-_1VTX<])L28'9"=:6"-V")JZS1O>E4@($J@87 ]JZ
M&XFQ-<D"58>+W.7A M6'B^D%XH(>7FM+RL,%<WJMB*-BP>$DF-3Q-0A4(2[Z
MJ?:[]?IQ,S(U0*#J<)&[/%R@^G QO4!<, ):.7J">@*VTD,8:I:@_3EMDF8)
M@2K$13_1MD(Q.C=0F;C(72<N4*&XF%XI+CA]W(@&RE@4Z)1FTH.I*6_692G.
MPHZ< 4O.3\6J_FUTR7[+&I-9<0/VS,!DS7UJVEZL>GJHR@(%6"(R.*!3R9)8
MP(:< 4=..QIC4P3[92"S] 9LH(')XOO4M%7[) 0)"7,>KDD>+3@<A)Z((.8=
ML.;\L'I<+XM-/5AJ -@J YFE-V#S#$P6WZ>F+876_"432PN#T](2M<'AI$B;
MB[ O9\"8TX[#&,,=XD"967L#<LZ G*R^3TW;X2 [4AQ,$]?+@NTMF1+(D ,#
MCAP2BK$\A2PS(#-K<4 V&I"3U?BI:8NG')DZ)%-@[LGV^H+#03"I74) _AP8
M,.@\:X]/6NPBYPS(S&H<D(L&Y&0]?FK:*@ ALP8#$B02?9C.I2.N';#E,%$8
MG1R("V5N78[<-*"FZW+%F+8U7>4JJLM)/'HQG8M'9#M@T/E[^5AM=S?+<G-3
MCL@(9)P!E=VFC7W:O\.H397S?B.0J#\&IXQEC-J,$G<N*?^0/P<&##J=8(Q-
M#&2@ 95;DR-G#:CIFEPQ4EOI[C;Z"=:6[M0EMF"!1B>]J8!<.S!@V[EZ6E\W
MJF/TF2L@/PVHW((<.6Q 31?DBNIG38MS6!BC-AB8T<E8(.<.#%AW2"S&Y@@R
MUX#.K<N1S0;T=%VN&14MJ6V8PUE'RSE9G%')!2]R\," A>>?3P]5^7%\AFC\
M_(K<>ASY;D!/U^.:*FAM:89H*MLUV6%G^E(V5;H&R,T# W:>;B!&IP>B0YU;
MFB,##NCITEQ3*:TL\S@<#M?,UX2T&)Q6Z1UVY.V! 7//U^N[8O4I#_Y MALP
MN:4Y<N" F2[-#5,M+IF'?S"X9J:F.R4,3B=U(++VP("WAP1C]'-Q$!^:W.(<
M^7+ 3!?GAHISU2UI.X%:\PQ5YDQ7*?UA\".$QJCR3U0AR(@#)K<N1]X<,--U
MN:&'VXX:[$^P@1-:#N53TP=R_," Y8>-QNC\0(1H<NMSY,L!.UV?6^:H6PI*
M6@Q."5IPR.'V55BI[5UD^8$!S\]S:(9S ]EPP.96Z,B9 W:Z0K=, ;FUGE15
ML4"PY*%K"PXH]S[!1"T)(-\/#!A_3H$8FQ;(E0,V^P/5\!/5?L<CU1@UK1GK
M-POTGID]&* 4(2T^D/T'!OP_WVRKNAQ=_@G(C ,VMSI'+AVPT]6Y9?0TT <6
M<3BK#=W"8G#.N.3J"AF 8, !U G&V"1!]AQPN>4Y\NN FR[/CTW;#Z<@XMPQ
M(MXPC,7@/+AD?B C$ PX@5X7ZU6Q6;Y?KHOKWF%!'.ARBW)DU@$W790[*J2]
M2SY3 I!O!P:,.WC41K"*PX^!S"V@D;D&W'0!?6R*_X"](6=%#(J<3?1B.M>.
M&'' KM,)P5@N068:\+G%,S+8@)\NGCU35@Y4'7CJ[B:QZ,5T+AX1X8!GYVK9
MB.;=^">7(GKRN;4R\M6 GZZ5/97!%FAM 0.3"NB*A\$!R)#D)F39@0'/3B<8
MHQ,#L9_/+9N1S0;\=-GLF<IQ34K'KSB<;:WW3U%A9+B4R6G6XT?PCM'.(U(#
M$:#/+9.1O0;"=)D<.+,U?58CBPO$OK?@<-I!4ITAYPX,6'<^59TA5PV$W'(9
M.6T@3)?+QZ;X105*,DS%X#3S.%D.9PP].KU$[_-8E]7=X;THN]G-]G%3/[\&
MX_S3\\M7OCJ\<:3S\]?[E[(<WA,2NWE^H\OW176WW.QFJ_)=TZ68[Y=WU?,[
M4IZ_J;</A[>&7&_K>KL^?'E?%K=EM0<TOW^WW=:G;_8?<'Y5S:O_ U!+ P04
M    " !D5U%2-TI-_W(#   I#0  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6RU5\UNVS@8?!5"Z*$!=B61E/53V :2N-OM8H,-$J0]%#TP-BT1E4B7
MI./V[9>D9$FQ92$PX$LL4C,?.4-E]&FZ$_*'*BC5X%=5<C7S"JTW'X) +0M:
M$>6+#>7FSEK(BF@SE'F@-I*2E2-598#", XJPK@WG[JY>SF?BJTN&:?W$JAM
M51'Y^X:68C?SH+>?>&!YH>U$,)]N2$X?J7[:W$LS"MHJ*U91KIC@0-+US+N&
M'Q8PLP2'^,+H3O6N@97R+,0/._B\FGFAW1$MZ5+;$L3\O-!;6I:VDMG'SZ:H
MUZYIB?WK??6_G'@CYIDH>BO*KVREBYF7>F!%UV1;Z@>Q^YLV@B:VWE*4ROT%
MNP8;>F"Y55I4#=GLH&*\_B6_&B-Z!!B?(*"&@ X)T0D";@CXK82H(43.F5J*
M\V%!-)E/I=@!:=&FFKUP9CJVD<^X/?='+<U=9GAZ_D!?*-]2\'[!%,ES27/B
MSD.LP?[6\V_PB8I<DDW!EJ0$U^;YNC($J@DKU17X$SP]+L#[=U?@'6 <W+&R
M-!74--!F?W:58-GLY:;>"SJQ%XC G>"Z4. C7]'5ZP*!$=:J0WMU-VBTXH(N
M?8#A'P"%*!S8T.V;Z3 ;H"_>3D]'U.#VK+"KAT_5.WE$W_XU4/!9TTI]'UDH
M:A>*W$+1^$,Q=((U,7%$FRDO<Q1-<.8;?2]]8P=P",/,G[S&+09P,,JPCUO<
M*P635L%D5,&3_^B/&!&W9>++.IZT"R7G.EX3TYY#,$(HZSE4.SZ 0PE"?GS@
M^! .9]#/AAU/6P7IJ(*/6VE>1B-69&VA[+*>P[#+OO!<UQMFWZ8(IHF?'+C>
MX.(>#B?QX5,^4 W',?;AL.>PE]YP5,$_9$/XF!>HJX0N;'L78Q"?;3L^,@I-
MTKY1C>U#N"@Y>MB'<%&8^-$)X[N$A.,1>5LP3L;<Z)(*3BYL?)=F,#[;^/@X
M%B",>ZG0&'^,RTS\1X>^'\.22=A[2[Q6T,4D',_)_W1!)3#MKNGG.%B*+=>2
M437F3A=@,+WP0701![.S#R(;>,.:&#\*G@$<CJ+# UL,X5 :'D5/T.LA*RIS
MUXNKVN*ZX6IGVW[_VG6Y!_,W]CO ]:9=F?HCXH[(G'$%2KHV)4,_,?\8LN[+
MZX$6&]>I/@MM^EYW69AO&2HMP-Q?"Z'W [M ^W4T_Q]02P,$%     @ 9%=1
M4M]H**@4"   824  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULM9IM
M3^NX$H#_BE6MKCA2MTV<E[8L( $%3I=R0+!G[Y6N[@<W<5MKD[C'=N"PVA]_
M)R^M4Y*X!=$OT":>\8QGYLG8S<D+%W_)):4*_8RC1)YVEDJMCOM]&2QI3&2/
MKV@"=^9<Q$3!5['HRY6@),R%XJB/+<OOQX0EG;.3_-J#.#OAJ8I80A\$DFD<
M$_%Z02/^<MJQ.^L+CVRQ5-F%_MG)BBSH$U7?5P\"OO4W6D(6TT0RGB!!YZ>=
M<_MXZGF90#[B3T9?9.4SRER9<?Y7]F42GG:LS"(:T4!E*@C\>Z:7-(HR36#'
MCU)I9S-G)EC]O-9^G3L/SLR(I)<\^C<+U?*T,^R@D,Y)&JE'_O*5E@[E!@8\
MDOE?]%*.M3HH2*7B<2D,%L0L*?Z3G^5"5 0<NT4 EP+XC0!N$W!* >>MP*A%
MP"T%W'UG\$H!;U\!OQ3P]Q48E *#?06&I<!P7X%1*3#:5\"VUI&S]A;9!/MM
MM-M%UN&V\WCWB\3*LW),%#D[$?P%B6P\Z,L^Y*F=RT,RLB2KPB<EX"X#.75V
M'OQ(F61914A$DA"-H2BD8BH5%!U](T*0K$R^H*,Q581%\@OZ!?617!)!)6()
M^IXP);MP$3[?L2C*%)WT%9B63= /2C,N"C-PBQDVNN.)6DITE80T;)"_-LL[
MN^2_[IA_IP&3'0JP04$?@K*)#%Y'Y@(;-?Y.DAYR["["%K:_/XW1T2]?]-(W
M6'AIUG=-9SV$1[D^J]37H&5LUG(?J+55]JC4$M.0!3"N0=O5/C8-M[0U!=^L
MY8Z(VDHU:+DQ:QG3H.994R)]BI;)WEI,L?K]4VRYW5_+L%W+=(](VY[!EJTB
M<3;X<G*U3HO:BU3"%2E1A6/HOU.XAB:*QO)_ACG<S1QN/H=K0J2@(9H\//Z+
MQ*O?QBB &EPT%N&DT#7(=64MT/.9[UL]]Z3_7 U<?11V1CU_>]1M,<JKC+)'
M0VLS:,L;;^.-9_3FAO/P!3C=5"!>S2K''XS>&O]UOV&38MBP.FS@^SWOS5(T
M#-O6MN6FOW'3-[KY2%?D%;I%)1&?HX@GBU\5%3$T:#/5%#:_9@4>U&UM&#4$
ME]YX?EL?9EO6J&<WNS38N#0P1PYZ:FA\(Z(@%Q5'(9,K7J1\DT>%,K]BA/7&
MFT$]CF#E\(TS@UH2MF3@<./'T.C'&.+ !#%4YFBC:72PZK<MW2%91GLOH:-A
M(<T:(5"O!$GDG K1V"5<EKJJBSIT1SVG><GL2IMF?[1L+TO1:KX-_4H<MZ?$
M>DILG'*2*)(LV"R"1H^4#&R<'M<RS89-8,OTFNRVLR--BE6&QC+@,46*_$01
M(S,609PSDR3L'%LL<FH+ C'P6BS2SP';_""8;E'$:$"=[\[ :[5 L]LVP_N]
M5+/KJ,ZPAEOLT'"US72=\I\<W4-<(KYX[:))$O1,I:8)9P\.5]":/[890.\I
MZ*M25Y5__@BW9;<FESWZ:#U/2]'M[@#[O5'SI%B3#)M)]O&2FI::MY]I#FZC
M#-9@PV:PU;NKQNGM&F-<?] 2!:P1A\V(>Z3/-$F;-BY?2\EJ$&S'[PU:IM18
MPV:L-90.^@<]T6A%10 9F; 9.IK>_^?^5SS"IA89:VYA]V!5A36;L)E->P;2
MJY63Z[<]++ &$C8#:9SW0B1"-X*GJRXJOH,Q@,G9*WHB$>VB;UQE-P+8IS.(
M>HCN5R4$)(1@2A<D>$7G<'/&N&(!NBOWM<7!"$%W)$GG)%"I8,D"79,@JYO7
M[.#C*?U[R=,NNERRA("NJS"$(2O8)<2FM=5<Q(?C(M9<Q&8N?DOC&17YDZ58
M"Z+7(MZLA<C.-262/ K!4\/>?UQ.5RW:EB</UMS$9FX^"!Y0&DHT%QR>>Y7#
MJBS2Y3)1V44)5=FE@,AE.:P1;&-<AZWCN6U<<S1KG1VL76?DHLC(!)(OK"8?
M7R=?%Y4/]:RIGU%H\0,*!C=:Z]3;2]=JZRX=#6%G1W?YKJW%3:FM?>>P;8;&
ML6/&\5,ZD_1'FBW%U7/V]Q_T *O!\B/_"\:? D:3((ONCH[#J9P?'.X P=$$
M=LR=X\.Z:YMS4?32Y9%KTTFIT[#M;R.DH_'LF/'<VO1T$2QYP3'H):%.)%JE
M(E@2V9B"%^4\_E;!M%BG^>V8^=T0^3LJ4HF^]?XT!EHCU#D<0AV-4,>,T/<%
MNLY'MRW.&I".&9"?%^=1G=XMUKF:BJZ9B@UQON90XD1^O-A=C3G7/MQIH::8
M:Z;8N\X+K]V&/M,:M+'4U6!SS7VF>:7W*BZW<D)ZN [3U0ASW]MA&A>V?K#H
M^FU;<%>3RGTWJ2!MGPF+T!]+*+L53:%?DCN35H/+/1RX7 TN]Q/!Y=;WQ,.V
M<VE7D\LUDVOC:&7Z;O%S%UH)%E!T!%U*R*.("& 7=*KYO2\0 >/O8A?EO*,J
MR7!;)GB:9=[.<T%HY199#CR3**5%9]Q%!)K_S';H_0JS-Z9^U('2D*U-4XOU
MFH6>N>5[O_5P;[$0L#-0%)&8ITG3D=-%.>U6]^*W_6:AF>J9F=IF;9S]YAJ]
M0N\:IL5K'3O7LIC(MJL'VCUKV-)#>QJXWKN!>R[)DJ%;>,(R])!M!@FZY&+%
MRX>S)K*AA#T-8>]P$/8J/Q]])H2]^G:_UD3T*V\OQ!0T9>_D2!1D&5;\2K>Y
MNGGOYSQ_^^'-]0O[^,INN'YM']\T79_8Q[?%VSYZVN+EHSMPB"42]L%S,,'J
M#< !4;S/4WQ1?)6_4S'C2O$X_[BD!-JN; #<GW.NUE^R"39O59W]'U!+ P04
M    " !D5U%2&?HU +4#   B#   &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6RU5V%OHS@4_"M/:'5JI4W )(&PET1J&_6N4E>-VMO;DT[WP8%'8JW!
M6=LTK70__FR@A&X)RI[4+PDVGC?S!CQQ9GLAOZDMHH:GC.=J[FRUWGUR715O
M,:-J*':8FSNID!G59B@WKMI)I$D)RKCK>U[@9I3ESF)6SJWD8B8*S5F.*PFJ
MR#(JGR^1B_W<(<[+Q#W;;+6=<!>S'=W@ ^HONY4T([>IDK ,<\5$#A+3N7-!
M/BW)U +*%7\RW*O6-=A6UD)\LX.;9.YX5A%RC+4M0<W7(UXAY[:2T?&]+NHT
MG!;8OGZI?ETV;YI94X57@G]EB=[.G:D#"::TX/I>['_'NJ&)K1<+KLI/V-=K
M/0?B0FF1U6"C(&-Y]4V?:B-: #(^ O!K@'\J8%0#1J<"QC5@7#I3M5+ZL*2:
M+F92[$':U:::O2C-+-&F?9;;Y_Z@I;G+#$XO+N+O!5/,/@,%-$]@:1Z#TDP7
M$N%L5<AX:UR%E60QP@7G(J9V[3F<+5%3QM4Y#.#+PQ+./IS#!V Y?&:<VVHS
M5QM]EL6-:RV7E1;_B)9K7 ^!3#Z"[Y&H W[5#U]B/(01L7#?ZX O3X;_R.X:
M4QMG_<99OZPW.E+OLE!F1BEH60Q_WYHYN-&8J7]Z.$8-QZCD&!_A^$V(9&_\
M[C*K0H8ETN[^Q\4H#(+A9.8^MDWI6!:$T7#<+'LE;-P(&_<*NQ5/ NYR\W:*
MS?-'N,GC84^[DZ;JY-TL#1J.H%=Y65IB C>K^U]HMOMUV?4B5S4F+=?&0>AU
M>Q8VS&$O\S7+F<8!-QLP,1M)TWS#UAP[-U)5*6CQ1],C]-.&?MI+O\04I2RI
M8Y$A:/K4S5V5F;:X!\0;^<-I-W_4\$>]_'=ZBQ*H4JBK).*,KADW#QF5R9@<
M=9>8Z*T8/SCV]A+OD(I>KY@_A*8<6(*Y9JG1P=$*J-5U)IOW1LAX$GG'3"&M
M?";_=XM?UM VJ3\R[4='2 _11?P3VH]-BAL+9)GXH"7-5?V*E(\#1 HQ55OS
MVUUMF4Z)_IM\"2(2#L,C$@_)1_JC[TKD1E&L!_97_]5^@7_AY^*''%*-C-\M
M@,@AY<BDM[6OY6'%-$4?C?D;A$)A6G"S(5+L]+B_'/'A&:E4?=H.Z4CZX_$!
M^0ZE/03D; UGMW=_W0W\R#__>=,/L4C"]S/]D'ZD/_Y.R_VZR.O@]WY,7K=U
M'K.GY\]4;I@Y7W%,#<P;A@8OJP-I-=!B5Q[1UD*; U]YN36'>)1V@;F?"J%?
M!O;4U_PM6/P'4$L#!!0    ( &1745("^,YL]P8  !\I   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4T+GAM;+6::W.;.!2&_XK&T]E)9[HV$@+;V20SB=TT
M;G-Q[73WP\Y^(%@QFN7B(CF7?[\" P(#@NY /S0VZ#V2WB,>ZP!GKT'X+W,(
MX>#-<WUV/G XWYV.1LQVB&>Q8; COCCS'(2>Q<77<#MBNY!8FUCDN2.D:>;(
MLZ@_N#B+CRW#B[-@SUWJDV4(V-[SK/#]BKC!Z_D #M(#*[IU>'1@='&VL[9D
M3?B/W3(4WT99E WUB,]HX(.0/)\/+N'IHSF.!'&+/REY9;G/()K*4Q#\&WU9
M;,X'6C0BXA*;1R$L\>>%S(CK1I'$.'XF00=9GY$P_SF-?AU/7DSFR6)D%KA_
MT0UWS@>3 =B09VOO\E7P>D.2"1E1/#MP6?P_>$W::@-@[QD/O$0L1N!1__#7
M>DN,R E$G&H!2@3H6(!K!'HBT-L*<"+ QP*]1F D J-M#V8B,-L*QHE@W%8P
M2023MH)I(IBV%4 MS9S66I(ENY3M6DF:;M@ZWS!-.&R=<9BF')9R7BM)DPY;
M9QVF:8>M\P[3Q,-2YLTZ29IZV#KW,$T^;)U]E&8?Q=D?'2[XF!9SBUL79V'P
M"L*HO8@7?8B1$^L%)*@?T7'-0W&6"AV_N+1_[BFC$:D8L/P-F M8,4[Y/B3@
MY)(Q >A\FX_@9$ZX15WQZ7?P8ST')Q\^@@^ ^N".NF[4Y&S$Q<"B\",[&<35
M81"H9A 0W 4^=QCX[&_(ID*_:M C18"1<"2S!:6V7"%EQ/O@90AT[1- &M(J
M!C13RQ]L+N2P5CY7R[_N?67OG]7R.^M=U?EUDSI4COV+6KXFNW3L<%HAOVF:
MNIOV7BE?J.67NU#9^]?6<Z^4?VL8O.4KY;=J^9S8F7Q2(;]KO68KY?>MUVRE
M_*%]XJKDR]9+OE+^O7W>J^2KULY7KOEU^\15Y?WQ?^>] "\]8[H>Q]-KXEWM
MF3C"6![<X.];<0PL./'8/XH^<-8'COO JM^-D&S 8KGZS?)V?\R![5CAEE3A
M?W6(-8YC1?OUEPO3U(;X;/22-[G<"NG3H5EL]7AH9>1:P>E$RQH59F-DLS&4
MLUE3'KZ_@4>'A-:.[#FU&;BE'N7*'Q,SBV[VEH]QUL>XNWQ<CTM.&VBH5WLX
MR48P48_@*:IQA('@B@9NL(T\7/AB99]D9SXJ)CK-NIGV9B;4Y*Y(Z\[.STFP
M_)I$1G'97K=HLTK:F-5MBE/);?"@>FT[EK]U+ H$8IE#H^PPFQ+?)@S,@N$G
M<,LW(DGELZIL022[1_WE2Q(/ZEWF2R_[K!WG0MFF.$P)3:BFY@]_0YGM!DS)
M%2BQ!8W^S)7X@F:7YIHEN, Q'DYJO). @VK"?7X)C@G-E2Y*<,%)?RY*;L%I
M=R[.DV %7*!J"Y&D&E)3;>'[P0OQN23TIP31Z1G5-8\D<A#LS5 DR8)0=X;.
MDF %0[7CB[ZA47&@$DY(#:<Y95;H%=9NZOOAE-)U"1>$^W-=(@>IMTJ_Z+I1
MA@$RZ[8:2"()J9%T'=B.F-U2].Q9=NRIY;+#;YEJFI(V:-R?F9(\J&'/]"MF
M7B7!\JL3URU.B274@*496'C>7LQK?:FJ/21D=*TWYW2)&%V]J_DEY[XDP?++
M4->&J'CU?ZMH-36'4RWW#QZ5+!42B,9#6)T57;)-5[,M2LD]>>,'3J@<RQ6%
M_56%NH20WF%=^%4O%W-U*UJ7A-(;"/5"-Y2_Y[>RS39*\NC]%7.ZQ(_>83FW
M2(+5U!;%(4@VZ6HVS<1V("1OT?0*NZY9$.Z"T(KFK9JJ!)#>7T&')95PAP7=
M31(L?UGC\;#&4BRAA1M*,;JE[I&?C4L32VC@_DHM+#F".RRUOB?!BK=^ZIA:
M'%'N5E0#<_;A-RO9"S2Z*3&"^ZNML,0)[K"V6N)R;36!=:45EK3!#;19W3U$
MN%P7< E.HN.JO2F6,,']E5A8H@1W6&(MDV"%WVX\-NKL-"1KC ;6^-2+[X)Q
M8CM-"]*0]##ZJZH,"1&CPZKJP2@73'K=O5A)&$--F/7BRR5X%-[Y<97:XN?;
MD*PP^BN2C-SMY Z+I/LD6-[$VAO:$BR&&BPS9[^UZ%&%)&_XJ:8IN6'T5R09
MDAU&AT72O5$NDHPZ,R58##58HJWX;!^2QH5H2DB8_95)IF2&V6&9=&>6JQDT
MJ2MF3(D44XV4.;5)Z%O'U7JCEQ(89G^EC2G18798VMR:Y:=9$$^&XQHS)5I,
M-5INWC>'1RQI;:.:6^X)57]5C2EY8798U=R:Y:=4".4>!QX&,<J]^^(1$2MZ
MUL2 '>Q]?GADFAW-WN:[C-]I.CI^!4^_PXKC*WCZ>'A73X8_O#IX)X9.?09<
M\BRZTH9CD;GP\#;>X0L/=O&;-T\!YX$7?W2(M2%AU$"<?P[$%B'Y$G60O1-Y
M\1]02P,$%     @ 9%=14N/$J;Z; @  DP<  !D   !X;"]W;W)K<VAE971S
M+W-H965T-34N>&ULS57?3]LP$/Y7K Q-($&3IND/6!N)4DTP#:V"L3U,>[@V
MU\3#B3/;;6%__<Y.R,($Y84'7A*?X^^[^[Z+SN.M5+<Z0S3L+A>%GGB9,>6)
M[^MEACGHCBRQH"\KJ7(P%*K4UZ5"2!PH%WX8! ,_!UYX\=CMS54\EFLC>(%S
MQ?0ZST'=3U'([<3K>@\;5SS-C-WPXW$)*5ZCN2GGBB*_84EXCH7FLF *5Q/O
MM'LR[086X$Y\X[C5K36S4A92WMK@(IEX@:T(!2Z-I0!Z;? ,A;!,5,?OFM1K
M<EI@>_W _M&))S$+T'@FQ7>>F&SBC3R6X K6PES)[3G6@OJ6;RF%=D^VK<\&
M'ENNM9%Y#:8*<EY4;[BKC6@!PNXS@+ &A*[N*I&K<@8&XK&26Z;L:6*S"R?5
MH:DX7MBN7!M%7SGA3$QJ!"RD NN19E D[(O)4+%3I:!(D1I@--N_Y *IE@)I
M/<,5*H7) 3N#DAL0_(\-:-\ %_J ';'F.)O#O:,X9#/<T#]0VLBEN<)T+<!(
M=7_8)FKQT_XZMV>H;VR/\<+R"EOGV#>DW2KPE[7.::4S?$;G#)<=UNL>LC (
M@YOK&=O?.WC,XI-SC7UA8U_H:*-G:+\J^$6"X/V[[C#ZL(.PUQ#V'&'OY7Z0
MZ%83G&?MN&J3R:!@CT$_/A,GNS"8ZY\[*HJ:BJ*=$ENM+^MF/F5_13)T)'84
M;.(H&G2BL;]Y(G>_R=W?F?L3J(1#L<0=.@8-U^"-.#ML*AJ^AK,5R:#E;#@Z
M?MK749-YM#/S%#2D M2+O^UQ0WC\1LSM!O\F6_ :]M8L_9:_1V$_^,]@OS5B
M[75U"2KE-# %K@@6=(:$5]4-4 5&EF[J+J2A&>Z6&=V:J.P!^KZ2TCP$=I W
M]W#\%U!+ P04    " !D5U%2Z0.4?E,#  "%#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6S-5UUOTS 4_2M60&B3((F=CS;05EI7$$,,IHV/!\2#
ME[A-P+&+[;;P[[&=+$W;-)OVM)?&=LXYN?>>VKD9;;CX+7-"%/A;4B;'3J[4
M\K7GR30G)98N7Q*F[\RY*+'24['PY%(0G%E223WD^[%7XH(YDY%=NQ*3$5\I
M6C!R)8!<E246_Z:$\LW8@<[=PG6QR)59\":C)5Z0&Z*^+J^$GGF-2E:4A,F"
M,R#(?.R<P=<S&!N"17PKR$:VQL"D<LOY;S.YR,:.;R(BE*3*2&!]69-S0JE1
MTG'\J46=YIF&V![?J;^SR>MD;K$DYYQ^+S*5CYVA S(RQRNJKOGF/:D3BHQ>
MRJFTOV!38WT'I"NI>%F3=01EP:HK_EL7HD70B7834$U ^X3P""&H"<%#"6%-
M"&UEJE1L'698X<E(\ T0!JW5S, 6T[)U^@4SOM\HH>\6FJ<FNEX4WW*!C0L2
M8):!SRHG IP)@=F":(N5!">?]#_P2O!LE2IP3=:$K<@I.)D1A0LJ3\$K\/5F
M!DZ>GX+GH&#@LJ#4R(T\I4,T#_+2.IQI%0XZ$@Y$X)(SE4OPEF4DVQ7P=&Y-
M@N@NP2GJ59R1U 4!? F0C_R.@,X?3(=)!WWV</JP)YN@L2NP>L']=JU)VR/K
M7'M>N:ARS, NZ<='K0DN%"GESYZ(PB:BT$84'HFH_C=T65T1!Y9HSI_U!(51
MD+BZ$.NV QTX%,#$C79QLPX<#)/ #1K<3@91DT'4F\$42[R@6+QX!@?AFYZ2
MQ(U@_$1,&C01#1YK4D4<MHH*(0K=<,^C+AA$;KQGT2%LZ$,7=1LT;*(?]D;_
M 8NLP"PE/95(&JWDB7@#_>T1[#_6G9JY6_<H.-A"';@D#%N%K^SI@,71\-@&
M@JV7".S-X(O OW3-\+U;"**M)'HJ1FT/7Q@\VJC@H+*!KFRT[],A+$K\@VW4
M!1N$[N"(3]NS&O8?UI_IJM0[2=WOT_;PA-%3\6E[_L+XT3[%!R^1.!BZR;Y/
MA[ 0Q?NP60=,MQDMUZL$O%9_5A*QL'VN!"E?,55U,LUJTTN?V0YR;WUJ>FS;
M]VUEJ@;]$HM%H1LX2N9:TG<'VC51];S51/&E[0)ON=(]I1WF^CN!" /0]^><
MJ[N)>4#SY3'Y#U!+ P04    " !D5U%2\<?]G6$'  #V+0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6S-6FUOVS80_BN$]X($R&R1HBB[2P(D<8-E
M:-8@:;</PS[0-F,3U8M+T4X][,>/DA6=;$FTNKF OB26='<ZWD,^=SSQ_"56
MGY*%$!I]"8,HN>@MM%Z^&0R2Z4*$/.G'2Q&9)\^Q"KDVEVH^2)9*\%FF% 8#
MXCAL$'(9]2[/LWL/ZO(\7NE 1N)!H605AEQMKD40OUST<._UQJ.<+W1Z8W!Y
MON1S\23TQ^6#,E>#PLI,AB)*9!PA)9XO>E?XS:WOI0J9Q.]2O"2EWR@=RB2.
M/Z47=[.+GI-Z) (QU:D);OZMQ8T(@M22\>-S;K17O#-5+/]^M7Z;#=X,9L(3
M<1,'?\B97ESTACTT$\]\%>C'^.47D0\H<W :!TGV%[WDLDX/35>)CL-<V7@0
MRFC[GW_) U%2,';J%4BN0/85:(."FRNX^PJL08'F"K3M&[Q<P6NKP'(%EL5^
M&ZPLTF.N^>6YBE^02J6-M?1'!E>F;0(LHW1F/6EEGDJCIR\-(@&?Q(JG.">(
M1S/T7B^$0E=*\6@NS"32"3KYC:M49"U.T<E8:"Z#Y!3]A#X^C=')]Z?H>R0C
M="^#(#5R/M#&L=3\8)H[<;UU@C0X@=%]'.E%@MY&,S&KT1\?T"<6 P,3D2(L
MY#4LU\1J\9YOD(O/$'&(4^//S2%MU;>IC^WJ8S&UJK]MK8Y'->JW[=6'EE"Z
MQ0QS,WONX1FV%N5IE4VV\O5VXND%C]"NTI_OC$UTIT68_&7QB!8>T<PCVN#1
MU?3S2BHQ0W</CS_R</GS&$T77,U%W=0=;VWYF:V4I]>7C#E]>CY8ER&I2A%W
MU&>[4K=;*:\DA4=#IQ#:&8U7C,:SCN91K$6T$G6N;Q6'9:>H9]P:[CE?(T=<
M/.I[>^[7R&$Z<OMN_0A8,0)F'<&-6;O*I!@42#Z1@=2R'@E6?;W/*H.ID6*T
MA,2.BW[AHF^?,I,T^0G%T;6,@W@NIPFZB\Q".2F>G%IFYK!XS; C:V54>#0Z
MWEJY'E7F-]F;0S>'1<9;$58OLC,*[$":<ZSC>#*1FB^X1+^NHF0A4QB3J131
M5"0F@/TS]$[/#)K5IS98<2G+XHX BPGX1(X(;6YL!SAG#[A<AM7+[+H)Z0.[
M=G98R(C;!@RTCVE70 #RQO^9O7&5;C'&K#_:([P:N9$A^;T,=5LCYGM.B3YW
M1P#DC>WL;<H^8<I4$Y8'OLG*Q3/TM)J:I9/\E-;\,_0HYJN ZUAMT)4)]!,W
M"OFC?]"W69C Z]CORIR )("'1ZQ/<F/E1><U+3I@?6RG_5I0OSUN!/B<.!W!
MC0#)$]PN: E:YE&K+?YQ!3#<1),$V)S8V?RKEN&W@@](G71E4T @/1#[MJ M
M?+0"G]]0GA!( \2>!MX'JU#R2/_X'?;IS[;A "\3UI40 ]L2>QEMR7:YYLX^
MRQU6DETN5LYBE%1RXFV--;.9[C?A!-1,[-2\BY-91X_QA@=Z4RPZL\JFPL3.
MVH0 &B:CCF#H O.Z]DIZUSP''\Z02MMXVR92/ GD/&\J+86:FN=UJ!]X%W'Z
MCO.#S6T@9]=.SA7DZ@AS;.9G$"^+" -EGJ$;OI2:!_)O0Z4G8_$LE$G1I^;^
M*DQE3#!L?@*/NZ0KD)<Z./82O"4SYE9VM@AX;X_P-A?:R7Y-+1 7N-NU<_?_
M1-<6)>!PU^L*<I $W);%^0'D6!44IPD48'O7SO:M0"E5E;81 T.[76FAN$#C
M;LMJ^@ *U<8';BKE*? UM7/H-0\#'LFU#/G$UCP%)J5=Z6508$UJKWXMA46N
M6:X8AC[NDX:X BE2.RE^V*PWVN9\J1W=E;X$!3*C_[DO0:N-!-<9]OW]CKA7
M;7:[M"'J0&C43FA9U)NHI'W7X?U*)W(F4/R,LOZ2N7471?$Z#7+1X3W+6[RO
M3VQ;'PJL2+O2<:! FM1>UK8D*%IM-0R;6K,4V)':V?%(D!X'1P]XU>M*!\(#
M:O:.TH'PJAV(IBVL!Q3LV2GX X_$WRN39$K+Z^-3!M2O?,DCVP"!=+VN] T\
MH&_OP.?$*%KQ $5"HR2=D>:E2B2+.##[A+D27.=^G-9"4>TF-.9\K_1)T,[>
M92R.5@E[0-)>5UH/'M"N9R]&VRZ-:G\!4[^I<> !PWIVACV$2+LRV -2];K2
M.6# F,Q>B;:$(+>RVQ]U&]8$ VYD=FY\)R9*?I(9"+;A .&QKNS4&? C._"Q
MK.VG=+?ZE7Q4*N%V7P]4R.Q46([Q,:F' ?.QKFS"6>EXPU$VX:RZ"1\V\ X#
MVF-VVOM?B&3]S>G"UMABP("L*QMS!BS)CK(Q9S4;\Z:>E0]TZ-OIL 4T[;*"
M#QSH=V7K[@.-^BT_7-DQ\*MG"S!IJI1\($S?3IA?!T*+!>$#6?I=V?;[0)^^
MO7!L"T;-WMZII.A!Z5AJ*-0\.T"<H&F\BO3V_&!QMSBD?)4=S=V[?XW?W.":
M^V/\YG9[!!G,;T]$WW,UEU&" O%L7N7T4X?5]I#Q]D+'R^Q0["36.@ZSGPO!
M9T*E N;Y<QSKUXOT!<51[\M_ 5!+ P04    " !D5U%2,G@-+-("  "F!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R-5=]OVC 0_E>LJ ^M1!.2
M0( *D/BQ:7VH5L&Z/4Q[,,E!K#IV9AMH__O93L@" <0+V,[WW=WG.]\-]UR\
MRQ1 H8^,,CER4J7R)\^3<0H9EB[/@>DO:RXRK/16;#R9"\"))674"]KMR,LP
M8<YX:,]>Q7C(MXH2!J\"R6V68?$Y!<KW(\=W#@<+LDF5.?#&PQQO8 GJ+7\5
M>N=55A*2 9.$,R1@/7(F_M,\,G@+^$E@+VMK9)2L.'\WF^=DY+1-0$ A5L8"
MUG\[F &EQI .XV]ITZE<&F)]?;#^U6K76E98PHS37R11Z<CI.RB!-=Y2M>#[
M;U#JZ1I[,:?2_J)]B6T[*-Y*Q;.2K"/(""O^\4=Y#S6"'UT@!"4A."5T+A#"
MDA#>2NB4A(Z]F4**O8<Y5G@\%'R/A$%K:V9A+].RM7S"3-J72NBO1//4>"*E
MKJWG+,=$Z&RJ%EJ 5&(;JZT@;--"F"7HNTI!H&4.,<$4S5(L-B#1_1P4)E0^
MH$?TMIRC^[L'=(<(0R^$4IU3.?24CM#X\>(RFFD137 A&C] +YRI5*(O+('D
MV("GI57Z@H.^:7#5XAQB%X5^"P7MH'TFH-G-=']PACZ_G=Z_HB:LLA5:>^$%
M>T>YL:E9 ,4*$C0Q[X<HHO/R>[+2*/V@_ESQV*D\=JS'S@6/2]B!P"R&<\DL
MJ#U+-?UE-_:[OAL,O5W]AINH7L_M'X/F9TP%==11\-TJ^.[5X(OB)E5QH_N-
M;H0/]N*XK6E9UG1<U/0YD86+J!;9HZFD(XD%IE_#= 9-C4V4'PY<_[S&J-(8
M7=7X@RL=/SY1VM(MN?&,;Y8<-9,1-O/:1'5[73<Z$=U$!5'D#DY$>[4.EH&.
MRTP"B6*^9:IX[-5I-6PFML>>G$_U$"IFQG\SQ01[T7()DXC"6IMLNSV=#E%,
MA6*C>&[[Y(HKW77M,M6#%(0!Z.]KSM5A8QQ4HWG\#U!+ P04    " !D5U%2
MX3C"C[,"  !:!P  &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6R]55UO
MVC 4_2M741] 8N2+C[8"I *;AM2N55&WAVD/;G))K#IV9AMH__UL)V30%M27
M[26QG7O.O<?'N1YMA7Q2.:*&YX)Q-?9RK<M+WU=)C@5175$B-U]60A9$FZG,
M?%5*)*D#%<R/@F#@%X1R;S)R:W=R,A)KS2C'.PEJ711$ODR1B>W8"[W=PCW-
M<FT7_,FH)!DN43^4=]+,_(8EI05R104'B:NQ=Q5>SH<VW@5\I[A5>V.P2AZ%
M>+*313KV EL0,DRT92#FM<$9,F:)3!F_:TZO26F!^^,=^Q>GW6AY) IG@OV@
MJ<['WKD'*:[(FNE[L?V*M9Z^Y4L$4^X)VSHV\"!9*RV*&FPJ*"BOWN2YWH<]
M0#@X HAJ0/0:T#L"B&M _%% KP;TW,Y44MP^S(DFDY$46Y VVK#9@=M,AS;R
M*;>V+[4T7ZG!Z<F54N9L+8J24&G<U!VX1Z7E.M%K27G6 <)3N-4Y2EB6F%#"
M8)83F:&"UC<B);&VM:$U1TTH4VWX! _+.;3.VG &E,,-9<SXJT:^-M7:G'Y2
M5S:M*HN.5!9&<".XSA5\YBFFAP2^D=EHC79:I]%)QCDF78C##D1!%+Q3T.S#
M\/#B'?C\X_#S$VKBQKG8\<5'^ Y\@IE0VGEEEE%N$'Y>FWA8:"S4KQ/9>DVV
MGLO6.WE.:'-.H)69GM)V*84['JH^'DEU/-XSO$K1=REL/]I,/EDC-OL>5#'#
MO9C>Q;![?A@U?QL5QA?=L(DZT-AO-/9/:KP6SP)NN?FE1/;2@05/NB=V;M"P
M#OZ#3\,FV_"?^S0;OO4@"+K#5[OK[W6= @V7[=X*$K'FNOHIF]7F@KAR??'5
M^M1<'%6?_TM3W3HWID3*%3!<&4I3@C%05IV\FFA1NM[V*+3IE&Z8F\L/I0TP
MWU="Z-W$)FBNT\D?4$L#!!0    ( &1745)*0;'OY0(  #L(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;(V676_:,!2&_XH5]:*5MGQ_40%2"ZJ&
MM&I5NZX7TRY,8L"J8V>V*>V_W[%#LP"!]H;$R7G?\YR3Y)CA1LAGM2)$H]>*
M<35R5EK7EYZGBA6IL')%33C<60A980U+N?14+0DNK:AB7NC[J5=ARIWQT%Z[
MD^.A6&M&.;F32*VK"LNW:\+$9N0$SON%>[I<:7/!&P]KO"0/1#_6=Q)67NM2
MTHIP105'DBQ&SE5P.1F8>!OPBY*-ZIPC4\E<B&>SF)4CQS= A)%"&P<,AQ<R
M(8P9(\#XN_5TVI1&V#U_=[^QM4,M<ZS(1+ G6NK5R,D=5)(%7C-]+S;?R+:>
MQ/@5@BG[BS9-;)PZJ%@K+:JM& @JRILC?MWVH2,(XB."<"L(/RN(MH+(%MJ0
MV;*F6./Q4(H-DB8:W,R)[8U50S64FZ?XH"7<I:#3XQE_(5P+28E"YU.B,67J
M GU%CP]3='YV@<X0Y>B6,@8]5T-/0THC](JM_75C'QZQGY+"15'P!85^Z/?(
M)Y^6!X-=N0>%MM6&;;6A]8L^J/8-3:DJF%!K2=#OJ[G2$MZG/R<R1&V&R&:(
MCV2XH9S"TRA1+46Y+G1OSQJ+S%J8S^QEG"6Y"P6^=%MS&)7&F1NU43M\<<L7
MG^1[@H_*/%+ *XCJI6L,\D[>,(D2-][#ZPGST\Q-^_F2EB\YR7>/-_!Z:R(I
M9@IA7L)\J6L&KV<?:G+ D":!&^Z1'D;%87P,-&U!TY.@/X7&#)WC&CKY2@VR
M@JE6,UP0&'(:%4+IBS[F]( F&L2)F^Q!]X0%T: 3MD.=M=392>H9+V#6*X*T
M0-]G-S\L9A]E=I@^=O,]QL.@G>[O$.8M8?X!83N0^KCRGN[E?N>K:,AZPH*!
M[V;];(.6;7"2S7;L_PRYJL2:]W:OL4DZZ8,P\/<8^X)\?X_0ZXQVLZW>8KFD
M7"%&%B"#BD OFZVJ66A1VVD_%QKV#GNZ@MV=2!, ]Q="Z/>%V4#:_POC?U!+
M P04    " !D5U%2WMI>D7,&  #P&P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970V,2YX;6RU67]/VS@8_BI6;W=B$FMC.TU;#I &!;9IG- X=II.]X=)W=9:
M$G>V2V&Z#W^ODU"G)3$!]?;':!R_3]Z?S^L?ARNIONLYYP;=ITFFCSIS8Q8'
MO9Z.YSQENBL7/(,W4ZE29N!1S7IZH3B;Y$)ITB-!$/52)K+.\6$^=J6.#^72
M)"+C5PKI99HR]7#"$[DZZN#.X\ 7,9L;.] [/ERP&;_FYF9QI>"IMT:9B)1G
M6L@,*3X]ZKS'!Q<AL0+YC*^"KW3E-[*FW$KYW3Y\G!QU JL13WAL+ 2#/W?\
ME">)10(]?I2@G?4WK6#U]R/Z>6X\&'/+-#^5R5]B8N9'G6$'3?B4+1/S1:X^
M\-*@OL6+9:+S_]&JG!MT4+S41J:E,&B0BJSXR^Y+1U0$"&X0(*4 :2M 2P':
M5B L!<*V OU2H-]6("H%HK8"@U)@D >K\&X>FC$S[/A0R152=C:@V1]Y?'-I
MB(C(;"I>&P5O!<B9XW.1L2P6+$$?,VW4$K+,:+3W!U.*V21YB_;&W#"1Z+?H
MMU^&- I_1R)#ER))()/T/@SBJ%\S1K?&WE0?#WL&=+<:].)2SY-"3]*@)R;H
M4F9FKM%9-N&338 >&+VVG#Q:?D*\B&,>=Q'%^X@$)+BY'J.]-V]K]#IMC8)'
MS2CC]BC#9I2S%UAT=O,%[941J\,Z?P'6IZMO%LL&N@[JX@50%R=7!13=AMH(
M(EVG+\VQ:2.V$G=YHJ*_/\,[]-'P5/_C00[7R&&.'#8@O[_C"K@8Z-82NLAF
M4'5FJ81Y0'**H < R650H4KQ+'X ]GM4I#:Y_=^"Y$[SY/;HW5_KW?=B7;)[
MD2[3'>GM_Q8-T(0]^+2.UEI'7J0_I0$*2F0V>V>X2E$F3;U"!<P@A[%M]NX8
M4BD<=@>'O;MJU=;,HQ$==OOK>1MZ#M9Z#KQZGF_Y[]V$9Q)HF1D^*93>!Y=J
MF)*/,(WF?#+C=984'^I7- S[0;!E1C$IJD["E4D;-@S7-@R]-GQE2K#;!%(;
M=*S3S"\^Z@;!KW7D]#JQ\]>)7;Q8;,-7H[6O1EZ<SU)KKA&_7\#2"0)J)+JU
MG! G3&LQ%3 $;<W,.<KXO4$-A5RX=523NMUA?2QQX/IWX-7P)ILN;4=$L4Q3
M88K^#6J*#$K:6.WN8&BI.(K90M@JL_/K.W#P)"6CX:!!P<H" _\?"NXCEAD1
MBT5>2 OV8 71 NA*3FJ5]VN! _3 F?)Q%2;.)/*,2;#J3\1/4"PI$F2J9(KX
MCZ6E6<UCR[>BGL!*Z(TT"$/2)5N57\X;5DL_P-O3QC5P ]+MCZK_&B+H>BRF
M7G.ON(K!^;8;0@O)9 91L)L@VUR@#+BI-]0/.HR>*5'L.C5^IE7'L5S:K(*Z
MY-#-++=!7^.QG&4V2+7:A4_]U@^[H^THA$^B$ V&C57KFC3V=\Z3Y0.RZ[QK
MV(.ALZ62/D>X)HJC':^&L&M\V-_Y*M@)M ^10*KOVY8'ZWFH69;:$-1Z>O#4
MA>&@VY25KHMA/\57%,J3\(DRZ-_''4M=MRK1,:GHU:=!MXGO7,? _I9A0VLC
M6L06@NS;JSB:)\&.0TL<0Q,_-[8*K=^;Y1<PK7B3C 8-*Q7BF);XF?;9(-=E
M7(E97371B#3IXFB0^!EKHV8_L07+N.;H&\]\07 D1L)=!]BQ#?&SS:MKM\2M
MUBX>-M8(<41%_,O]=K5K]YNU.]<"'(<;:D5A4X0=QQ$_Q]D(VPUJF\IU/$6&
MNPZLXQKBYYKVE6LWW+5;]^(#N+KH(X/J<F1S7^X(B_K7I:^JW!)SN%&YM*E7
M4,=PU,]PIX_;W>L56_B.'1PQ4;+CJ-+*F8:?:%Y=KB7N!O$-HH:RH(Z:J']]
M99T&GA-:HW/%LCA?OOO+@SINHOU=.]+1#&U-,R]T9/3$D;#M;G*DXQ?:[O1@
MG8[CRNG!F-\:G]6.<.BN"8<ZPJ%^PFE]3E/B5#T8!63[>*.<526??CAJ\'/H
MN"?T<\\ITW,T34 L/WW1P(#CC4.9#S!L=R_NS!NF0'163$W>:<.4L6]%!C;:
M/:H]*$$:JL"W?0P=&X5XUX>6CI?"M@NF5HE>HE4#@ ?][0#T*O<+*5>S_.I(
MHWS759S5KD?7UU/O\TN9K?$3?##&->-G^."BN'QR\,5=V"53$"F-$CZ%3\'2
M U15Q?52\6#D(K_=N)7&R#3_.><,MG]V KR?2DC1\L%^8'W)=_P?4$L#!!0
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MY.B>+F)5;DW(W#V\K":[-3<$ ;Z'UY;P:"@D427G2Y6HI)P*";A>7V)+UC;
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MB<J(ET?/Y8UDZ^(P]HE)R;+B<D5)1+DV4)_'C,FW&_V"^A\ YO\#4$L#!!0
M   ( &1745(:T?N S0L  *IE   9    >&PO=V]R:W-H965T<R]S:&5E=#8S
M+GAM;,6=;V_;.!*'OXJ06QQ:8&MK](]4+PW0;:_8 MO;W@;=>W&X%XK-)$)M
M*RO)R1:X#W^4(IMCBQK2$MW+BS9.1LQPAGXT(_$G7SX5Y=?J7HC:^W.]VE1O
M+N[K^N'U?%XM[L4ZJV;%@]C(W]P6Y3JKY<OR;EX]E");M@>M5_/ ]Y/Y.LLW
M%U>7[<\^EU>7Q;9>Y1OQN?2J[7J=E=]^$JOBZ<T%7.Q^\%M^=U\W/YA?73YD
M=^):U%\>/I?RU7P_RC)?BTV5%QNO%+=O+M["ZW>0MD>T)K_GXJE"WWO-7&Z*
MXFOSXN/RS87?N"168E$W8V3ROT?Q3JQ6S5#2D3^Z42_V?[0Y$'^_&_U#.WLY
MFYNL$N^*U;_R97W_YH)?>$MQFVU7]6_%T\^BFU'<C+<H5E7[K_?4V?H7WF);
MU<6Z.UAZL,XWS_]G?W:10 = -'! T!T0V!X0=@>$[42?/6NG]3ZKLZO+LGCR
MRL9:CM9\T\:F/5K.)M\T>;RN2_G;7!Y77WW(-]EFD6<K[^.FJLNM3%%=>2^N
MY7I9;E?"*VZ]#UE>>K]GJZWP/HFLVI:B,7KIO7@OZBQ?52^]5]Z7Z_?>BQ]>
M>C]X^<;[E*]6,D75Y;R6'C9_9[[HO/GIV9M@P)OW8C'S0OC1"_S UQS^SOIP
M2 \/G\NX[(,3[(,3M..% ^/]H]@LMF4I9RNG]2BJNHW.:V+D<#]RV(X<G32R
M+F#/X[!VG.9-^7@5I$DRXY?S1QR8OAFD23"+]F8';D9[-R/2S7=967[+-W?>
MVW6QW=3$Q./]B#$9TNLZJ]OUX_W[%_DK[Z-\5?V'&#C9#YP87*WN/?''-G_,
M5D.Q?!Z!XUCZ*9NE1['LFX$?Q$.Q9'L'&3WS^Z*L7]6B7-LN)KX?F9-3?R]N
M:J\2<D'E=2ZT,^?]F4>SX&C>ST;)P;Q!/^ET[UKJ^!T$OB*73T[[[S+9]3<\
MKF1G?2]/5EYS1LM7WR3/FWA+Q-U(E-TV''ML.*8GD]^+4<C"WN+HS'"4(C_6
M1PD0A<$1#[J!N D(&CN*"*"8" ']1BLJ"@2@$ BA6Q2 PA:8N&6&03>$D08:
M.PH'H$@(,>FD.J]2<U;\@\1Q.!6Y@$T/)[,,9]^.#*>"(- 41&7*?[U_;HM:
M++W/9;X055.3O&W+1>]35GX5$A2R /8^+N5<\H4L?=Y65?/#%[^(1['ZZU\@
M\?\&+ZG(*?P!S;^3DQ(H_ 4T_FR2$O29IDV*QHY*2J"X%M!<.TC*=7ZWR6]E
MQ&4X?JWO1>G]>E.)\K&E\\?-P_8H!P&5@P 5<705=WH.%,("NHRSRD'8.V'X
MQ^&G3 Y=4P@,: 0.1O[+IB"C'I)15W0+'!=Z@2)=,+W4ZX8@HTZ9'+JF2!G0
MI/PRNYYY=\6C*#?MW+/-TI/M\&;Q#15H,B'VA76@ !APQP5FH#@6I%-+S&X$
MS)"T#YJ^$4-UZ&$OI5 8^J[[-$6P<$QE]J,L+8T1"?LE&.,S=MRY::R&8Z*H
M%])EFO5*I,NY$'6TAG+NY.47*IB%-,PLEE_8+]/ZRT]C-!QJA;J01MV(Y:=8
M%]*LF[+\^GTLBV;A<4@T5@FR.O1;@3!T T*K(CA4# Q=,S!4# PG,S"T8:#&
M:' 11HJ!D6L&1HJ!T=D8&%DQ4&<U'!/%P,@- []CZQ IGD:N>1JARWJ3>1K9
M\%1C-)PVQ=/(-4\CQ=/H;#R--*34+&6-U7!,%$\CUSQUW7!%"L*1:PA'"L+1
M9 AW(U"E/VER>%U; 3AV#>!8 3@^&X"[D:EHD":''BOTQF= K[,V-5:4C5U3
M-E:4C2=3MAN!S YE<N@9N@GCFK"Q(FQ\-L+&YJ:=-#GT6+$U-ES>+,J'HLQJ
M<>SC28UZK/@8N^9CK/@83^9CW*\_@][M XT1AUGDHZ^!6T.)(F;BFIB)(F9R
M-F(F?1Q">'R:3S2W81C,AF*BN)F8[JX0:Y%NU1,%O<0U]!(%O60R]!+-G9?>
M M08R07HI_AK(-@*@XEK#";H=O39,)AH;D '_3M\&K,@8<CLT'.%PV0\#JW:
M]421,'%-PD21,)E,PL2&A!HC2Q(R14+FFH1,D9"=C83,AH3L)!(R14(VGH3?
ML6%GBJK,-569HBJ;3%5F+B5)DT//%$.9:X8RQ5!V-H8R<RE)FAQZC/;XN&"G
MZ]:<*> RU\!E"KAL,G"9#7 U1I; Y0JXW#5PN0(N/QMPN0UP^4G Y0JXW!%P
MG;7I7+&5NV8K5VSED]G*S6PE30X]4VSEKMG*%5OYV=C*S6PE30X]5FSE-%O;
M,_>KFVSQ59[M1S;I'.VI=$U*KDC))Y.2]R$(_0V;.IPF SLV%1M3UVQ,%1O3
ML[$QU6"O?SLS[1,T'%AYJ2)C2I.16'ET2YXJP*6N 9<JP*63 9=J-CGVEIO&
M:'BY*<BEKB&7*LBE9X-<JNFNP][='IU5.A@3A;IT+.JL&O!442YU3;D4;?V>
M3+G4AG(:H\%E!S[>/NZ:<^"C#=W^V4BW&]J NIV9#>O 1_N[_;&T^YY;;'VT
MC]QWS4[PT59R?S(]=T-0%1%M<^0=VD/NNZ8G^&A+N7\V?NZ&IF-B72:"CW:K
M^]/IZ;H%!Q]M5/==0Q=\M./<GXS=W1 T=W56P^#%NAUP#MX#)<WYP*L3UVC
M"R> %PMK#,J:$>MV4OL-6*MC$NN<OF:Q7,>@U[%9LV#!6-+FR#O$6'#.6"S;
M@?,Q%BP82]H<>8T8:Y $/0-S9!<.6-4#SF&)Y3DP'9:@@:6O@8)N[R?W+2Y;
M A+]@$'UHXN[09"'U#K0R74<!AOI<""@^683[&X(4[ U9M;!1M SR'LTP;83
M[2&9#G0Z'9<A1^@*:(VA5<ACNY#WS:Q#CFAHT/:0(3]_UX&4/A"XUG,#TO)
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MW!Y5;P=:K(O3WKG06J3%Y8J2A$IK8)XOA-GORX$]0*[^83#Y!U!+ P04
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M*NX!?3PCZ>,!?3QM]/':]'%<[DY.4W]M^'05'[#'ZZFF=A5?6U(=VUWW<7Q
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M$9&$1%*'P.KGF<Q)DNA("L>W,JA1S:D=F]>OT3\6R:MDEEB0.4O^HK'<3(S
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MTCJ8\Z40>KNQ 8;)GOT'4$L#!!0    ( &1745)]5JU16 (  +T%   9
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MM)\=H%R W2^D-)N)2Q ^9,9_ 5!+ P04    " !D5U%2^F/)1N<"  !\"
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M#KB[WK)_]=JMEB75>"/Y3U:::AI<!%#BBK;<W,O--^SUG#F^0G+MO[#I?<,
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M=DN5-<#]3$JSF]@#Z@8^_@U02P,$%     @ 9%=14O?\X 8> P  (0H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-SDN>&ULM99M3]LP$,>_BA7Q B3(<_J
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MO0'6EYRKUXEN^LU7X>0O4$L#!!0    ( &1745)=-S<F)@,  #D)   9
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M)([ZP<@%-WU*;!$I=^*^.)).<"0A(1O?D%.C*B(Z*PP4-)4ZP20/Q[H@;?D
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M8MVY"JWTK%*F';5:YZR5>MC*UVFK!3_,/$31@]<K#$>34:3?WTFMP9-60<B
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M.ZSTEP6$ >CW)>=J/S$!NF]5^@Y02P,$%     @ 9%=14I[?^(E'!0  UQD
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MU;1TKU,-WE/9M6]M#'*5%SF*!,:U^'A5O54A=9.7#P?]M^[UI"B'=C9%=?9
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MJ^95?0@+HM7+VM[PF9>I][).:;H;2D([0AEM0QD%0SG-,EVRW"!8F> ]=QF
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M:W-H965T<R]S:&5E=#DP+GAM;)U7VV[;.!#]%4+H0P*TDJBK'=@&$JO%]B%
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M1E"H_&UIP?5_=&IL70MMCUS0L@%+!F5>U;_DM0E$!R"%F@%> _"&@. *P&\
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M4P;R>T:I. _4!.V]<?4_4$L#!!0    ( &1745(TK0VY!@4   L3   9
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MP$L#]7W/F'R9E Z:-GCQ/U!+ P04    " !D5U%2Q>DCR_,#  "P#   &0
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M:0Y3V4Y6!(6I,8,1JA1@J;M:&[>529\V0[ >;5X,N] F#$[%/W 'CLWO0#X
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M+_=9NHX;T)#'8_F<B*I2YZX9<5U50A[(?U_?5W4I,>4_CD!I%RAM J660-L
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M(;$A0)$9UT8\"%!P<FTBL&.H]R9['S4*:%*-$HX$1P(]=3D3+P(4F?%LQ'X
M!2?/)D(]9EYF%^.9-F)&@ DS@B?C?&Q_&1(' A29L6C$=0 %)XLF?(8,_)4<
M<%$;K-W$A  3)@23,9ZZBHGQ ,K,R#/B,X"2DSR3 2,TKU,T%%4.-:<@\1W
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MRCI=]?6.8J!SB,[>:5)O5 >Y@8ROEZD>:2EXNGIX7J<1#I/9$9 ?4ODCP'$
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ML6R[<8T6/KQ,/'HEQLW5(;8D/:$Q(X:W?%]4. D *9AXMK$3&BG"C93A2D<
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MG^1EW.\%DV^)]!/+SV*+&;BBF<R:;1G.1PRN\YAF&)Q\HIR?@I-[F6M)D6)
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MDU@?9*)LC\J!X@?;,&RXTNV'?<QT2PG"&.CW.ZZW:34P >HF=?D#4$L#!!0
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M16P?MY3 !XL9 ._70NACP]P%%1>>TW\ 4$L#!!0    ( &1745+=_S;?)0,
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MU(TI1#6JZ7\TC^>.RH3-WQWA7U!+ P04    " !D5U%2EXJ[',     3 @
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M[G@ARN+.!,V?]EY1G#1YI;-U65ZY8Y^K6RVFN]^/V?WVS;M_ %!+ P04
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M>V^K8>E 7@+YY0,%"126#Q0E4%P^4)) :?E 60+EY0,5"526#U0E4%T^4)-
M;?E YE1&!XC480W0VI1K WAM"K8!Q#8EVP!FFZ)M +5-V3: VZ9P&T!N4[H-
M8+<IW@;0VZO>'J"W5[T]0&_?O6P#]/:JMP?H[55O#]#;J]X>H+=7O3U ;Z]Z
M>X#>7O7V +V]ZNT!>@?5.P#T#JIW .@=5.\ T#MT'TL >@?5.P#T#JIW .@=
M5.\ T#NHW@&@=U"] T#OH'H'@-Y1]8X O:/J'0%Z1]4[ O2.JG<$Z!V[C]T
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M4$L! A0#%     @ 9%=14M$:SVV(!   =Q$  !@              ("!<18
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &1745)DZ>.T
M^@<  (L@   8              " @2\;  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !D5U%2/RMI&68"  #5!0  &
M@(%?(P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 9%=1
M4KTCA\S("   ]RL  !@              ("!^R4  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( &1745);)T)/:@(  .(%   8
M      " @?DN  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !D5U%2KAJ,/7P)   1*0  &               @(&9,0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 9%=14N,5>(46 @  B@0  !@
M             ("!2SL  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( &1745)%]."-XPT  -0G   9              " @9<]  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 9%=14K018AR)&
M&$0  !D              ("!L4L  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !D5U%2Z'(O#_<3  "7.   &0              @(%Q
M9   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &1745+Z
M,,9!MP\  ,<V   9              " @9]X  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ 9%=14EFAQ;KA P  NPD  !D
M     ("!C8@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &1745*EK>)YC08  -(=   9              "
M@>*V  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 9%=1
M4F*@R7GK"0  U!P  !D              ("!IKT  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !D5U%2R=_5IC,(   %'0  &0
M        @('(QP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( &1745)QIBDYRP,  ,L(   9              " @3+0  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 9%=14K0<R \>#P  ]B<
M !D              ("!--0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !D5U%28\!"#34:  "I30  &0              @(&)XP
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &1745+_@I>=
M(B0  &MM   9              " @?7]  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ 9%=14F&L_OX\"   SA8  !D
M ("!3B(! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !D
M5U%2R($X3-<"  !%!@  &0              @('!*@$ >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &1745+#$;WA408  -8/   9
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M970S,BYX;6Q02P$"% ,4    " !D5U%2Q.".=-0"   X!@  &0
M    @('C80$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M &1745+;)!Y8K0(  '\%   9              " @>YD 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ 9%=14I#H*^%J"@  (2@  !D
M             ("!TF<! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !D5U%2\2PTBA8$   ^#0  &0              @(%S<@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &1745+[_1F*J@,
M #T(   9              " @<!V 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ 9%=14N$ RUEM P  +0@  !D              ("!
MH7H! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !D5U%2
M_M8@1%\%  "!#@  &0              @(%%?@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &1745)U\PNK9P,  ,P'   9
M      " @=N# 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ 9%=14MOK]'')"   ]Q4  !D              ("!>8<! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !D5U%2/["@F58-  !\*P
M&0              @(%YD $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( &1745(=I^>_:0<  -T4   9              " @0:> 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 9%=14C$<08CI
M @  0@8  !D              ("!IJ4! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " !D5U%2X!^$+&8"  !Z!0  &0
M@('&J $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &17
M45(SG0C >@8  .8?   9              " @6.K 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ 9%=14F@ %=TT P  E0H  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( &1745+?:"BH% @  &$E   9
M  " @13. 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M9%=14AGZ-0"U P  (@P  !D              ("!7]8! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " !D5U%2 OC.;/<&   ?*0  &0
M            @(%+V@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( &1745+CQ*F^FP(  ),'   9              " @7GA 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 9%=14ND#E'Y3 P
MA0P  !D              ("!2^0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " !D5U%2\<?]G6$'  #V+0  &0              @('5
MYP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &1745(R
M> TLT@(  *8'   9              " @6WO 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ 9%=14N$XPH^S @  6@<  !D
M     ("!=O(! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &1745)&*1; =@0  #P8   9              "
M@201 @!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ 9%=1
M4I<S]XVW"   WTX  !D              ("!T14" 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    " !D5U%2/G);=VT"  #A!0  &0
M        @(&_'@( >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( &1745+5PW YI0(  .$&   9              " @6,A @!X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ 9%=14LWR=VC5 @  F <
M !D              ("!/R0" 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    " !D5U%2I-SZGT\#  #R"P  &0              @(%+)P(
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( &1745),A*">
M+ 0  ,H1   9              " @=$J @!X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ 9%=14LU:CJEP @  Y04  !D
M ("!-"\" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !D
M5U%2?5:M45@"  "]!0  &0              @(';,0( >&PO=V]R:W-H965T
M<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( &1745(XX?R-A (  -0(   9
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M970W-RYX;6Q02P$"% ,4    " !D5U%2&5OIX>X"  #,!P  &0
M    @(&50@( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    (
M &1745+W_. &'@,  "$*   9              " @;I% @!X;"]W;W)K<VAE
M971S+W-H965T-SDN>&UL4$L! A0#%     @ 9%=14ETW-R8F P  .0D  !D
M             ("!#TD" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"
M% ,4    " !D5U%24,!A<"D)  !J0P  &0              @(%L3 ( >&PO
M=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( &1745(F,!YFG0@
M -8S   9              " @<Q5 @!X;"]W;W)K<VAE971S+W-H965T.#(N
M>&UL4$L! A0#%     @ 9%=14FIL=B(Q @  ?P4  !D              ("!
MH%X" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    " !D5U%2
M*VH?Y&8"  #?!0  &0              @($(80( >&PO=V]R:W-H965T<R]S
M:&5E=#@T+GAM;%!+ 0(4 Q0    ( &1745*B;NXLDP(  +<&   9
M      " @:5C @!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%
M  @ 9%=14I[?^(E'!0  UQD  !D              ("!;V8" 'AL+W=O<FMS
M:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " !D5U%2K$[IV@D#  #\"@
M&0              @('M:P( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+
M 0(4 Q0    ( &1745+N?,LA1@,  ((*   9              " @2UO @!X
M;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ 9%=14H.4""?+
M!0  N!@  !D              ("!JG(" 'AL+W=O<FMS:&5E=',O<VAE970X
M.2YX;6Q02P$"% ,4    " !D5U%23M=210<$  !##@  &0
M@(&L> ( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( &17
M45(TK0VY!@4   L3   9              " @>I\ @!X;"]W;W)K<VAE971S
M+W-H965T.3$N>&UL4$L! A0#%     @ 9%=14H3Q::1C @  TP4  !D
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M=#DV+GAM;%!+ 0(4 Q0    ( &1745)E75^NS 8  /4@   9
M  " @?Z1 @!X;"]W;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @
M9%=14DD]7??* P  J0T  !D              ("! 9D" 'AL+W=O<FMS:&5E
M=',O<VAE970Y."YX;6Q02P$"% ,4    " !D5U%20%_,W2,$  #8#@  &0
M            @($"G0( >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4
M Q0    ( &1745*IV(78?0,  "H/   :              " @5RA @!X;"]W
M;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0    ( &1745(+C!!]30D
M % S   :              " @1&E @!X;"]W;W)K<VAE971S+W-H965T,3 Q
M+GAM;%!+ 0(4 Q0    ( &1745*%K$H[WA$  (G!   :              "
M@9:N @!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM;%!+ 0(4 Q0    ( &17
M45(]AZ=790<  *TJ   :              " @:S  @!X;"]W;W)K<VAE971S
M+W-H965T,3 S+GAM;%!+ 0(4 Q0    ( &1745)/<)JLS @   LV   :
M          " @4G( @!X;"]W;W)K<VAE971S+W-H965T,3 T+GAM;%!+ 0(4
M Q0    ( &1745*;RZ?/RP,  #4.   :              " @4W1 @!X;"]W
M;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0    ( &1745)"_!EA 04
M (<7   :              " @5#5 @!X;"]W;W)K<VAE971S+W-H965T,3 V
M+GAM;%!+ 0(4 Q0    ( &1745)]GD^F=@,  + *   :              "
M@8G: @!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM;%!+ 0(4 Q0    ( &17
M45*B/?%.T@0  /P4   :              " @3?> @!X;"]W;W)K<VAE971S
M+W-H965T,3 X+GAM;%!+ 0(4 Q0    ( &1745+=_S;?)0,  .T)   :
M          " @4'C @!X;"]W;W)K<VAE971S+W-H965T,3 Y+GAM;%!+ 0(4
M Q0    ( &1745+$0JZFF@(  /L0   -              "  9[F @!X;"]S
M='EL97,N>&UL4$L! A0#%     @ 9%=14I>*NQS     $P(   L
M     ( !8^D" %]R96QS+RYR96QS4$L! A0#%     @ 9%=14C.C70,_!P
M?T<   \              ( !3.H" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( &1745(49*=F$P,   1    :              "  ;CQ @!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &1745+1G#.H=P(  )T]
M   3              "  0/U @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !U '4 -"   *OW @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1008</ContextCount>
  <ElementCount>619</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>249</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010002 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020003 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030004 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040005 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050006 - Statement - Consolidated Statements of Shareholders' Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210041002 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210111003 - Disclosure - Acquisitions and Divestiture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestiture</Role>
      <ShortName>Acquisitions and Divestiture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210161004 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210211005 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210251006 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210281007 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210381008 - Disclosure - Goodwill and Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangibles</Role>
      <ShortName>Goodwill and Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210441009 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210501010 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210551011 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210621012 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210671013 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210691014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210791015 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefits</Role>
      <ShortName>Retirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210871016 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210891017 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>210941018 - Disclosure - Other-Net, (Income) Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpense</Role>
      <ShortName>Other-Net, (Income) Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>210971019 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>220022001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>230053001 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Revenue</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>230123002 - Disclosure - Acquisitions and Divestiture (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestitureTables</Role>
      <ShortName>Acquisitions and Divestiture (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestiture</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>230173003 - Disclosure - Collaborations and Other Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</Role>
      <ShortName>Collaborations and Other Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230223004 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230263005 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Inventories</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230293006 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230393007 - Disclosure - Goodwill and Other Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</Role>
      <ShortName>Goodwill and Other Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangibles</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230453008 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipment</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230513009 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Leases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230563010 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Borrowings</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230633011 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230703012 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230803013 - Disclosure - Retirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsTables</Role>
      <ShortName>Retirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefits</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230903014 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230953015 - Disclosure - Other - Net, (Income) Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseTables</Role>
      <ShortName>Other - Net, (Income) Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230983016 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/DiscontinuedOperations</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>240034001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>240064002 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails</Role>
      <ShortName>Revenue (Summary of Revenue Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - Revenue (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>240084004 - Disclosure - Revenue (Contract Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueContractLiabilitiesDetails</Role>
      <ShortName>Revenue (Contract Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240094005 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240104006 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Geographical Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240134007 - Disclosure - Acquisitions and Divestiture (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestiture (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestitureTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240144008 - Disclosure - Acquisitions and Divestiture (Purchase Price Allocation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails</Role>
      <ShortName>Acquisitions and Divestiture (Purchase Price Allocation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestitureTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240154009 - Disclosure - Acquisitions and Divestiture (Asset Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails</Role>
      <ShortName>Acquisitions and Divestiture (Asset Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsandDivestitureTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240184010 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240194011 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Net Product Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240204012 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240234013 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240244014 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240274015 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/InventoriesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240304016 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240314017 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails</Role>
      <ShortName>Financial Instruments (Schedule of Effect of Risk Management) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240324018 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails</Role>
      <ShortName>Financial Instruments (Schedule of Fair Value Measurement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240334019 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails</Role>
      <ShortName>Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240344020 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Schedule of Risk Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240354021 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments (Schedule of Contractual Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240364022 - Disclosure - Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails</Role>
      <ShortName>Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240374023 - Disclosure - Financial Instruments (Schedule of Investment Portfolio Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails</Role>
      <ShortName>Financial Instruments (Schedule of Investment Portfolio Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240404024 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240414025 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240424026 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240434027 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/GoodwillandOtherIntangiblesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240464028 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240474029 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240484030 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment (Schedule of Depreciation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240494031 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails</Role>
      <ShortName>Property and Equipment (Schedule of Geographic Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240524032 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240534033 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails</Role>
      <ShortName>Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240544034 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases (Maturities of Operating Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/LeasesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240574035 - Disclosure - Borrowings (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofDebtDetails</Role>
      <ShortName>Borrowings (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240584036 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails</Role>
      <ShortName>Borrowings (Summary of Long-term Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240594037 - Disclosure - Borrowings (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240604038 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails</Role>
      <ShortName>Borrowings (Schedule of Debt Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240614039 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails</Role>
      <ShortName>Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/BorrowingsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240644040 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240654041 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240664042 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails</Role>
      <ShortName>Stock-Based Compensation (Schedule of Assumptions Used) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/StockBasedCompensationTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240684043 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/ShareholdersEquity</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240714044 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240724045 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of Composition of Income Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240734046 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240744047 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240754048 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails</Role>
      <ShortName>Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240764049 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240774050 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240784051 - Disclosure - Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxesTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240814052 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240824053 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240834054 - Disclosure - Retirement Benefits (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsNarrativeDetails</Role>
      <ShortName>Retirement Benefits (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240844055 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240854056 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240864057 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails</Role>
      <ShortName>Retirement Benefits (Schedule of Fair Value Disclosures) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240884058 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Contingencies</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240914059 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240924060 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240934061 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240964062 - Disclosure - Other - Net, (Income) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseDetails</Role>
      <ShortName>Other - Net, (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpenseTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240994063 - Disclosure - Discontinued Operations (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails</Role>
      <ShortName>Discontinued Operations (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="lly-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>241004064 - Disclosure - Discontinued Operations (Summary of Revenue and Net Income from Discontinued Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations (Summary of Revenue and Net Income from Discontinued Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="lly-20201231.htm">lly-20201231.htm</File>
    <File>lly-20201231.xsd</File>
    <File>lly-20201231_cal.xml</File>
    <File>lly-20201231_def.xml</File>
    <File>lly-20201231_lab.xml</File>
    <File>lly-20201231_pre.xml</File>
    <File>lly-20201231x10kexhibit1010.htm</File>
    <File>lly-20201231x10kexhibit1014.htm</File>
    <File>lly-20201231x10kexhibit1015.htm</File>
    <File>lly-20201231x10kexhibit102.htm</File>
    <File>lly-20201231x10kexhibit103.htm</File>
    <File>lly-20201231x10kexhibit104.htm</File>
    <File>lly-20201231x10kexhibit105.htm</File>
    <File>lly-20201231x10kexhibit106.htm</File>
    <File>lly-20201231x10kexhibit107.htm</File>
    <File>lly-20201231x10kexhibit108.htm</File>
    <File>lly-20201231x10kexhibit109.htm</File>
    <File>lly-20201231x10kexhibit21.htm</File>
    <File>lly-20201231x10kexhibit23.htm</File>
    <File>lly-20201231x10kexhibit311.htm</File>
    <File>lly-20201231x10kexhibit312.htm</File>
    <File>lly-20201231x10kexhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lly-20201231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>141
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20201231.htm": {
   "axisCustom": 3,
   "axisStandard": 44,
   "contextCount": 1008,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 1012,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 5,
    "http://www.lilly.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 12
   },
   "keyCustom": 67,
   "keyStandard": 552,
   "memberCustom": 159,
   "memberStandard": 88,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i06f37af72aea43beb8bfcd105c157384_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844055 - Disclosure - Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails",
     "shortName": "Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i06f37af72aea43beb8bfcd105c157384_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854056 - Disclosure - Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
     "shortName": "Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i06f37af72aea43beb8bfcd105c157384_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864057 - Disclosure - Retirement Benefits (Schedule of Fair Value Disclosures) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
     "shortName": "Retirement Benefits (Schedule of Fair Value Disclosures) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i125f0871aaaa45a8a006a3aa90bec2b7_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lly:LossContingencyNumberOfRequestsForInformation",
      "reportCount": 1,
      "unitRef": "request",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240884058 - Disclosure - Contingencies (Details)",
     "role": "http://www.lilly.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "icea9f6147fa941e4a11404f04d76bc42_D20090301-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plaintiff",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i70e7e33eb088468895e308da89cb151e_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914059 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Component of Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240924060 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Tax Effects) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i4da867daad1840d6b255ab18e08ebcd6_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240934061 - Disclosure - Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Schedule of Reclassifications Out of Accumulated Other Comprehensive Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i26304d3b80a542b5ab77edf4000be691_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240964062 - Disclosure - Other - Net, (Income) Expense (Details)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseDetails",
     "shortName": "Other - Net, (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994063 - Disclosure - Discontinued Operations (Narrative) (Details)",
     "role": "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
     "shortName": "Discontinued Operations (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i601d8831c2a84dc6a94bf8abcae67dcf_I20180924",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241004064 - Disclosure - Discontinued Operations (Summary of Revenue and Net Income from Discontinued Operations) (Details)",
     "role": "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
     "shortName": "Discontinued Operations (Summary of Revenue and Net Income from Discontinued Operations) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i52daa1d7665e48ae8d99c5d280d6bd5a_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210041002 - Disclosure - Revenue",
     "role": "http://www.lilly.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210111003 - Disclosure - Acquisitions and Divestiture",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestiture",
     "shortName": "Acquisitions and Divestiture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210161004 - Disclosure - Collaborations and Other Arrangements",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210211005 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210251006 - Disclosure - Inventories",
     "role": "http://www.lilly.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210281007 - Disclosure - Financial Instruments",
     "role": "http://www.lilly.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210381008 - Disclosure - Goodwill and Other Intangibles",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangibles",
     "shortName": "Goodwill and Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210441009 - Disclosure - Property and Equipment",
     "role": "http://www.lilly.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210501010 - Disclosure - Leases",
     "role": "http://www.lilly.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010002 - Statement - Consolidated Statements of Operations",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210551011 - Disclosure - Borrowings",
     "role": "http://www.lilly.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210621012 - Disclosure - Stock-Based Compensation",
     "role": "http://www.lilly.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210671013 - Disclosure - Shareholders' Equity",
     "role": "http://www.lilly.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210691014 - Disclosure - Income Taxes",
     "role": "http://www.lilly.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210791015 - Disclosure - Retirement Benefits",
     "role": "http://www.lilly.com/role/RetirementBenefits",
     "shortName": "Retirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210871016 - Disclosure - Contingencies",
     "role": "http://www.lilly.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210891017 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210941018 - Disclosure - Other-Net, (Income) Expense",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpense",
     "shortName": "Other-Net, (Income) Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210971019 - Disclosure - Discontinued Operations",
     "role": "http://www.lilly.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220022001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Pronouncements (Policies)",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpensePolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020003 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230053001 - Disclosure - Revenue (Tables)",
     "role": "http://www.lilly.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230123002 - Disclosure - Acquisitions and Divestiture (Tables)",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestitureTables",
     "shortName": "Acquisitions and Divestiture (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230173003 - Disclosure - Collaborations and Other Arrangements (Tables)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables",
     "shortName": "Collaborations and Other Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230223004 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230263005 - Disclosure - Inventories (Tables)",
     "role": "http://www.lilly.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230293006 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230393007 - Disclosure - Goodwill and Other Intangibles (Tables)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables",
     "shortName": "Goodwill and Other Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230453008 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230513009 - Disclosure - Leases (Tables)",
     "role": "http://www.lilly.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230563010 - Disclosure - Borrowings (Tables)",
     "role": "http://www.lilly.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030004 - Statement - Consolidated Balance Sheets",
     "role": "http://www.lilly.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230633011 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.lilly.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230703012 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.lilly.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230803013 - Disclosure - Retirement Benefits (Tables)",
     "role": "http://www.lilly.com/role/RetirementBenefitsTables",
     "shortName": "Retirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230903014 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230953015 - Disclosure - Other - Net, (Income) Expense (Tables)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseTables",
     "shortName": "Other - Net, (Income) Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230983016 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.lilly.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240034001 - Disclosure - Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Narrative) (Details)",
     "role": "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064002 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)",
     "role": "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails",
     "shortName": "Revenue (Summary of Revenue Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i3b760635fa6d431c9dbbba9b762de382_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenuefromContractPaymentTermMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - Revenue (Narrative) (Details)",
     "role": "http://www.lilly.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenuefromContractPaymentTermMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240084004 - Disclosure - Revenue (Contract Liabilities) (Details)",
     "role": "http://www.lilly.com/role/RevenueContractLiabilitiesDetails",
     "shortName": "Revenue (Contract Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040005 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094005 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i61ff3b39dc584d80ad523e152d9aac2a_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104006 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i28f9aa8b13a844198c584392ffe612ae_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134007 - Disclosure - Acquisitions and Divestiture (Narrative) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
     "shortName": "Acquisitions and Divestiture (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i0447dee610924071bcc739ab2cface2b_D20200201-20200229",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144008 - Disclosure - Acquisitions and Divestiture (Purchase Price Allocation) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
     "shortName": "Acquisitions and Divestiture (Purchase Price Allocation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i911edaec6d6642ce8d5278f65d8639f8_I20190215",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154009 - Disclosure - Acquisitions and Divestiture (Asset Acquisitions) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
     "shortName": "Acquisitions and Divestiture (Asset Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i817bc774c0a8475dbbe3fec31acb4ee2_D20200301-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8269e026df1a41b2b0895893b55d57cc_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184010 - Disclosure - Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
     "shortName": "Collaborations and Other Arrangements (Milestones (Deferred) Capitalized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8269e026df1a41b2b0895893b55d57cc_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:CollaborativeArrangementRightsAndObligationsRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240194011 - Disclosure - Collaborations and Other Arrangements (Net Product Revenue) (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
     "shortName": "Collaborations and Other Arrangements (Net Product Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240204012 - Disclosure - Collaborations and Other Arrangements (Narrative) (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
     "shortName": "Collaborations and Other Arrangements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i252ecfb1d7a840d9806b0dc46157e963_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234013 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240244014 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "id5a7062879db495387dd023ff0ac4b13_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i184cadb6a52c45e68d6a9a4c2738bc68_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050006 - Statement - Consolidated Statements of Shareholders' Equity Statement",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
     "shortName": "Consolidated Statements of Shareholders' Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i184cadb6a52c45e68d6a9a4c2738bc68_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240274015 - Disclosure - Inventories (Details)",
     "role": "http://www.lilly.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304016 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AverageRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314017 - Disclosure - Financial Instruments (Schedule of Effect of Risk Management) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
     "shortName": "Financial Instruments (Schedule of Effect of Risk Management) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324018 - Disclosure - Financial Instruments (Schedule of Fair Value Measurement) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
     "shortName": "Financial Instruments (Schedule of Fair Value Measurement) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i1614e22518944c76b247484e7a60ca8f_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240334019 - Disclosure - Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
     "shortName": "Financial Instruments (Schedule of Short-term and Long-term Classification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i1614e22518944c76b247484e7a60ca8f_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "ibd8e5bcf3a7042e997ecff32c5ddeb26_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344020 - Disclosure - Financial Instruments (Schedule of Risk Management Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Schedule of Risk Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "ibd8e5bcf3a7042e997ecff32c5ddeb26_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354021 - Disclosure - Financial Instruments (Schedule of Contractual Maturities) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails",
     "shortName": "Financial Instruments (Schedule of Contractual Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364022 - Disclosure - Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails",
     "shortName": "Financial Instruments (Schedule of AFS Unrealized Gain (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240374023 - Disclosure - Financial Instruments (Schedule of Investment Portfolio Activity) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails",
     "shortName": "Financial Instruments (Schedule of Investment Portfolio Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240404024 - Disclosure - Goodwill and Other Intangibles (Narrative) (Details)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
     "shortName": "Goodwill and Other Intangibles (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240414025 - Disclosure - Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Finite-lived and Indefinite-lived Intangible Assets other than Goodwill) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240424026 - Disclosure - Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Amortization Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240434027 - Disclosure - Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)",
     "role": "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangibles (Schedule of Estimated Amortization Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i6440d866422d4fcea9a1a914dc919853_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464028 - Disclosure - Property and Equipment (Narrative) (Details)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i6440d866422d4fcea9a1a914dc919853_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240474029 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240484030 - Disclosure - Property and Equipment (Schedule of Depreciation Expense) (Details)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails",
     "shortName": "Property and Equipment (Schedule of Depreciation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494031 - Disclosure - Property and Equipment (Schedule of Geographic Information) (Details)",
     "role": "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
     "shortName": "Property and Equipment (Schedule of Geographic Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:LesseeLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524032 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.lilly.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lly:LesseeLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240534033 - Disclosure - Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)",
     "role": "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails",
     "shortName": "Leases (Impact of Leases to Consolidated Condensed Financial Statements) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240544034 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)",
     "role": "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases (Maturities of Operating Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574035 - Disclosure - Borrowings (Schedule of Debt) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
     "shortName": "Borrowings (Schedule of Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584036 - Disclosure - Borrowings (Summary of Long-term Notes) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
     "shortName": "Borrowings (Summary of Long-term Notes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594037 - Disclosure - Borrowings (Narrative) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604038 - Disclosure - Borrowings (Schedule of Debt Maturities) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails",
     "shortName": "Borrowings (Schedule of Debt Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614039 - Disclosure - Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)",
     "role": "http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails",
     "shortName": "Borrowings (Schedule of Cash Payments for Interest on Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644040 - Disclosure - Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)",
     "role": "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation (Schedule of Stock-based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654041 - Disclosure - Stock-Based Compensation (Narrative) (Details)",
     "role": "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240664042 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used) (Details)",
     "role": "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails",
     "shortName": "Stock-Based Compensation (Schedule of Assumptions Used) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "iec5b059f25704f61ba927ea46297a4ee_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684043 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.lilly.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i3dc6994314b0437780a92cc7d6dc54bd_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714044 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i3dc6994314b0437780a92cc7d6dc54bd_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i3dc6994314b0437780a92cc7d6dc54bd_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i3dc6994314b0437780a92cc7d6dc54bd_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724045 - Disclosure - Income Taxes (Schedule of Composition of Income Tax Expense) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails",
     "shortName": "Income Taxes (Schedule of Composition of Income Tax Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734046 - Disclosure - Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails",
     "shortName": "Income Taxes (Schedule of Deferred Tax Asset and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744047 - Disclosure - Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails",
     "shortName": "Income Taxes (Schedule of Cash Payments of Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lly:ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:TaxCutAndJobsActTollTaxToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754048 - Disclosure - Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails",
     "shortName": "Income Taxes (Schedule of Future Cash Payments Relating to the Toll Tax) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:TaxCutAndJobsActTollTaxToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764049 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails",
     "shortName": "Income Taxes (Schedule of Reconciliation of Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i70e7e33eb088468895e308da89cb151e_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774050 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88a9bd6160434e6e8a6ffc7c2db6358b_I20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784051 - Disclosure - Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails",
     "shortName": "Income Taxes (Schedule of Income Tax (Benefit) Expense Related to Interest and Penalties) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i87fab925dba44dc0ae21de713975768c_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814052 - Disclosure - Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
     "shortName": "Retirement Benefits (Schedule of Benefit Obligations and Plan Assets and Funded Status) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i590b56b7edfd4b249c1ad788fdc3f3ed_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i88bd65697e614b36971bc989aebab0f8_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824053 - Disclosure - Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
     "shortName": "Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i06f37af72aea43beb8bfcd105c157384_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834054 - Disclosure - Retirement Benefits (Narrative) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
     "shortName": "Retirement Benefits (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20201231.htm",
      "contextRef": "i8dad6883d1a74f01a7b5b90d64f11d33_D20200101-20201231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 249,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "verboseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r828",
      "r829",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r828",
      "r829",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lly_A015SwissFrancDenominatedNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.15% Swiss Franc-denominated Notes Due 2024",
        "label": "0.15% Swiss Franc-denominated Notes Due 2024 [Member]",
        "terseLabel": "0.15% Swiss Franc denominated notes due 2024"
       }
      }
     },
     "localname": "A015SwissFrancDenominatedNotesDue2024Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A045SwissFrancDenominatedNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.45% Swiss Franc Denominated Notes Due 2028",
        "label": "0.45% Swiss Franc Denominated Notes Due 2028 [Member]",
        "terseLabel": "0.45% Swiss Franc denominated notes due 2028"
       }
      }
     },
     "localname": "A045SwissFrancDenominatedNotesDue2028Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.000NotesDueJune22022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.000% Notes Due June 2, 2022 [Member]",
        "label": "1.000% Notes Due June 2, 2022 [Member]",
        "terseLabel": "1.000% Notes due 2022"
       }
      }
     },
     "localname": "A1.000NotesDueJune22022Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A10EuroDenominatedNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.0% Euro-denominated Notes Due 2022",
        "label": "1.0% Euro-denominated Notes Due 2022 [Member]",
        "terseLabel": "1.00% Euro denominated notes due 2022"
       }
      }
     },
     "localname": "A10EuroDenominatedNotesDue2022Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625EuroDenominatedNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Euro-denominated Notes Due 2026",
        "label": "1.625% Euro-denominated Notes Due 2026 [Member]",
        "terseLabel": "1.625% Euro denominated notes due 2026"
       }
      }
     },
     "localname": "A1625EuroDenominatedNotesDue2026Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A17EuroDeonominatedNotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.7% Euro-deonominated Notes Due 2049 [Member]",
        "label": "1.7% Euro-deonominated Notes Due 2049 [Member]",
        "terseLabel": "1.7% Euro denominated notes due 2049"
       }
      }
     },
     "localname": "A17EuroDeonominatedNotesDue2049Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2018RepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Repurchase Program [Member]",
        "label": "2018 Repurchase Program [Member]",
        "terseLabel": "2018 Repurchase Program"
       }
      }
     },
     "localname": "A2018RepurchaseProgramMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2125EuroDenominatedNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Euro-denominated Notes Due 2030",
        "label": "2.125% Euro-denominated Notes Due 2030 [Member]",
        "terseLabel": "2.125% Euro denominated notes due 2030"
       }
      }
     },
     "localname": "A2125EuroDenominatedNotesDue2030Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A225NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Notes Due 2050 [Member]",
        "label": "2.25% Notes Due 2050 [Member]",
        "terseLabel": "2.25% notes due 2050"
       }
      }
     },
     "localname": "A225NotesDue2050Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A235NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2022",
        "label": "2.35% Notes Due 2022 [Member]",
        "terseLabel": "2.35% notes due 2022"
       }
      }
     },
     "localname": "A235NotesDue2022Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A25NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.5% Notes Due 2060",
        "label": "2.5% Notes Due 2060 [Member]",
        "terseLabel": "2.5% notes due 2060"
       }
      }
     },
     "localname": "A25NotesDue2060Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A275NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.75% Notes Due 2025",
        "label": "2.75% Notes Due 2025 [Member]",
        "terseLabel": "2.75% notes due 2025"
       }
      }
     },
     "localname": "A275NotesDue2025Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A30NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.0% Notes Due 2022",
        "label": "3.0% Notes Due 2022 [Member]",
        "terseLabel": "3.00% notes due 2022"
       }
      }
     },
     "localname": "A30NotesDue2022Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A31NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.1% Notes Due 2027",
        "label": "3.1% Notes Due 2027 [Member]",
        "terseLabel": "3.1% notes due 2027"
       }
      }
     },
     "localname": "A31NotesDue2027Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A3375NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes Due 2029",
        "label": "3.375% Notes Due 2029 [Member]",
        "terseLabel": "3.375% notes due 2029"
       }
      }
     },
     "localname": "A3375NotesDue2029Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A37NotesDue2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.7% Notes Due 2045",
        "label": "3.7% Notes Due 2045 [Member]",
        "terseLabel": "3.7% notes due 2045"
       }
      }
     },
     "localname": "A37NotesDue2045Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A3875NotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2039 [Member]",
        "label": "3.875% Notes Due 2039 [Member]",
        "terseLabel": "3.875% notes due 2039"
       }
      }
     },
     "localname": "A3875NotesDue2039Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A395NotesDue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due 2047",
        "label": "3.95% Notes Due 2047 [Member]",
        "terseLabel": "3.95% notes due 2047"
       }
      }
     },
     "localname": "A395NotesDue2047Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A395NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due 2049 [Member]",
        "label": "3.95% Notes Due 2049 [Member]",
        "terseLabel": "3.95% notes due 2049"
       }
      }
     },
     "localname": "A395NotesDue2049Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A415NotesDue2059Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Notes Due 2059 [Member]",
        "label": "4.15% Notes Due 2059 [Member]",
        "terseLabel": "4.15% notes due 2059"
       }
      }
     },
     "localname": "A415NotesDue2059Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A42YenDenominatedNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".42% Yen-denominated Notes Due 2029 [Member]",
        "label": ".42% Yen-denominated Notes Due 2029 [Member]",
        "terseLabel": "0.42% Japanese Yen denominated notes due 2029"
       }
      }
     },
     "localname": "A42YenDenominatedNotesDue2029Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A465NotesDue2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.65% Notes Due 2044",
        "label": "4.65% Notes Due 2044 [Member]",
        "terseLabel": "4.65% notes due 2044"
       }
      }
     },
     "localname": "A465NotesDue2044Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A555NotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.55% Notes Due 2037",
        "label": "5.55% Notes Due 2037 [Member]",
        "terseLabel": "5.55% notes due 2037"
       }
      }
     },
     "localname": "A555NotesDue2037Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A55NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.5% Notes Due 2027",
        "label": "5.5% Notes Due 2027 [Member]",
        "terseLabel": "5.5% notes due 2027"
       }
      }
     },
     "localname": "A55NotesDue2027Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A56YenDenominatedNotesDue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".56% Yen-denominated Notes Due 2034 [Member]",
        "label": ".56% Yen-denominated Notes Due 2034 [Member]",
        "terseLabel": "0.56% Japanese Yen denominated notes due 2034"
       }
      }
     },
     "localname": "A56YenDenominatedNotesDue2034Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A595NotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes Due 2037",
        "label": "5.95% Notes Due 2037 [Member]",
        "terseLabel": "5.95% notes due 2037"
       }
      }
     },
     "localname": "A595NotesDue2037Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77%\u00a0Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625EuroDeonominatedNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Euro-deonominated Notes Due 2031 [Member]",
        "label": ".625% Euro-deonominated Notes Due 2031 [Member]",
        "terseLabel": "0.625% Euro denominated notes due 2031"
       }
      }
     },
     "localname": "A625EuroDeonominatedNotesDue2031Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A677NotesDue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77% Notes Due 2036",
        "label": "6.77% Notes Due 2036 [Member]",
        "terseLabel": "6.77% notes due 2036"
       }
      }
     },
     "localname": "A677NotesDue2036Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A7125NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.125% Notes Due 2025",
        "label": "7.125% Notes Due 2025 [Member]",
        "terseLabel": "7.125% notes due 2025"
       }
      }
     },
     "localname": "A7125NotesDue2025Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A97YenDeonominatedNotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".97% Yen-deonominated Notes Due 2049",
        "label": ".97% Yen-deonominated Notes Due 2049 [Member]",
        "terseLabel": "0.97% Japanese Yen denominated notes due 2049"
       }
      }
     },
     "localname": "A97YenDeonominatedNotesDue2049Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ACImmuneSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AC Immune SA [Member]",
        "label": "AC Immune SA [Member]",
        "terseLabel": "AC Immune SA"
       }
      }
     },
     "localname": "ACImmuneSAMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ARMOBiosciencesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARMO Biosciences, Inc. [Member]",
        "label": "ARMO Biosciences, Inc. [Member]",
        "terseLabel": "ARMO BioSciences, Inc. (ARMO)"
       }
      }
     },
     "localname": "ARMOBiosciencesInc.Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AbCelleraBiologicsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbCellera Biologics Inc. [Member]",
        "label": "AbCellera Biologics Inc. [Member]",
        "terseLabel": "AbCellera Biologics Inc. (AbCellera)"
       }
      }
     },
     "localname": "AbCelleraBiologicsInc.Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AccountingStandardsUpdate201616aMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-16a",
        "label": "Accounting Standards Update 2016-16a [Member]",
        "terseLabel": "Accounting Standards Update 2016-16"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201616aMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible",
        "label": "Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible",
        "terseLabel": "Long-term income taxes payable, estimated timing of future cash outflows not possible"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrentEstimatedTimingOfFutureCashOutflowsNotPossible",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Other, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)",
        "label": "Acquired in-process research and development",
        "verboseLabel": "Acquired in-process research and development (Note 3)"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ActosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actos",
        "label": "Actos [Member]",
        "terseLabel": "Actos"
       }
      }
     },
     "localname": "ActosMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AddDeductAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Add (Deduct) [Abstract]",
        "label": "Add (Deduct) [Abstract]",
        "terseLabel": "Add (deduct):"
       }
      }
     },
     "localname": "AddDeductAbstract",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_AdvertisingExpensePercentageOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advertising Expense, Percentage Of Revenue",
        "label": "Advertising Expense, Percentage Of Revenue",
        "terseLabel": "Advertising expense, percentage of revenue"
       }
      }
     },
     "localname": "AdvertisingExpensePercentageOfRevenue",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_AlimtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alimta [Member]",
        "label": "Alimta [Member]",
        "terseLabel": "Alimta\u00ae"
       }
      }
     },
     "localname": "AlimtaMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AmpullaryCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ampullary Cancer",
        "label": "Ampullary Cancer [Member]",
        "terseLabel": "Ampullary Cancer"
       }
      }
     },
     "localname": "AmpullaryCancerMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AnimaBiotechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anima Biotech [Member]",
        "label": "Anima Biotech [Member]",
        "terseLabel": "Anima Biotech Inc."
       }
      }
     },
     "localname": "AnimaBiotechMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AsahiKaseiPharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asahi Kasei Pharma Corporation",
        "label": "Asahi Kasei Pharma Corporation [Member]",
        "terseLabel": "Asahi Kasei Pharma Corporation"
       }
      }
     },
     "localname": "AsahiKaseiPharmaCorporationMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "label": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "terseLabel": "Asset impairment (gain) and other special charges"
       }
      }
     },
     "localname": "AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AurkaPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aurka Pharma [Member]",
        "label": "Aurka Pharma [Member]",
        "terseLabel": "AurKa Pharma Inc."
       }
      }
     },
     "localname": "AurkaPharmaMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "label": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Realized gross gains on sales"
       }
      }
     },
     "localname": "AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "label": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "terseLabel": "Realized gross losses on sales"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvidityBiosciencesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avidity Biosciences, Inc. [Member]",
        "label": "Avidity Biosciences, Inc. [Member]",
        "terseLabel": "Avidity Biosciences, Inc."
       }
      }
     },
     "localname": "AvidityBiosciencesInc.Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BamlanivimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bamlanivimab",
        "label": "Bamlanivimab [Member]",
        "terseLabel": "Bamlanivimab"
       }
      }
     },
     "localname": "BamlanivimabMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BasaglarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basaglar [Member]",
        "label": "Basaglar [Member]",
        "verboseLabel": "Basaglar\u00ae"
       }
      }
     },
     "localname": "BasaglarMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "label": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "terseLabel": "Contingent value right, additional price per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightAdditionalPricePerShare",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs",
        "label": "Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction",
        "terseLabel": "Contingent value right, monthly reduction"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets and Liabilities, Net",
        "terseLabel": "Other assets and liabilities - net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsandLiabilitiesNet",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BuyEuroSellUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward Commitment to Buy euro Sell US dollar",
        "label": "Buy Euro Sell Us Dollar [Member]",
        "terseLabel": "Buy Euro Sell USD"
       }
      }
     },
     "localname": "BuyEuroSellUsDollarMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyGBPSellUSDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy GBP Sell USD",
        "label": "Buy GBP Sell USD [Member]",
        "terseLabel": "Buy GBP Sell USD"
       }
      }
     },
     "localname": "BuyGBPSellUSDMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSdollarSellJapaneseYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US dollar Sell Japanese Yen [Member]",
        "label": "Buy US dollar Sell Japanese Yen [Member]",
        "terseLabel": "Buy USD Sell Japanese Yen"
       }
      }
     },
     "localname": "BuyUSdollarSellJapaneseYenMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUsdSellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy USD Sell Euro [Member]",
        "label": "Buy USD Sell Euro [Member]",
        "terseLabel": "Buy USD Sell Euro"
       }
      }
     },
     "localname": "BuyUsdSellEuroMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ByettaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Byetta",
        "label": "Byetta [Member]",
        "terseLabel": "Byetta"
       }
      }
     },
     "localname": "ByettaMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Carryforward [Member]",
        "label": "Carryforward [Member]",
        "terseLabel": "Carryforward"
       }
      }
     },
     "localname": "CarryforwardMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CashFlowHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Hedge [Abstract]",
        "label": "Cash Flow Hedge [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgeAbstract",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al.",
        "label": "Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member]",
        "terseLabel": "Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al."
       }
      }
     },
     "localname": "CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CentrexionTherapeuticsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centrexion Therapeutics Corporation [Member]",
        "label": "Centrexion Therapeutics Corporation [Member]",
        "terseLabel": "Centrexion Therapeutics Corporation"
       }
      }
     },
     "localname": "CentrexionTherapeuticsCorporationMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ChugaiPharmaceuticalCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chugai Pharmaceutical Company [Member]",
        "label": "Chugai Pharmaceutical Company [Member]",
        "terseLabel": "Chugai Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "ChugaiPharmaceuticalCompanyMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CialisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cialis [Member]",
        "label": "Cialis [Member]",
        "terseLabel": "Cialis\u00ae"
       }
      }
     },
     "localname": "CialisMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborationandOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Other Revenue [Member]",
        "label": "Collaboration and Other Revenue [Member]",
        "verboseLabel": "Collaboration and other revenue"
       }
      }
     },
     "localname": "CollaborationandOtherRevenueMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.",
        "label": "Collaborative Arrangement, Rights and Obligations Percent",
        "terseLabel": "Collaborative arrangement, rights and obligations percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPercent",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsRightsObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Rights (Obligations)",
        "label": "Collaborative Arrangement, Rights and Obligations, Rights (Obligations)",
        "terseLabel": "Milestones payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRightsObligations",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold",
        "label": "Collaborative Arrangement, Rights and Obligations, Terms, Annual Net Sales Threshold",
        "terseLabel": "Annual net sales threshold (greater than)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CostOfSalesOperatingExpensesAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales, operating expenses, and other-net",
        "label": "Cost of sales, operating expenses, and other-net",
        "totalLabel": "Costs, expenses, and other"
       }
      }
     },
     "localname": "CostOfSalesOperatingExpensesAndOtherNet",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Federal Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act",
        "label": "Current Federal Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act",
        "terseLabel": "Current federal tax expense, effect of 2017 Tax Act"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefitEffectOfTaxCutsAndJobsAct",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward",
        "label": "Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward",
        "terseLabel": "Current federal tax expense, utilization of net operating loss carryforward"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefitUtilizationOfNetOperatingLossCarryforward",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CymbaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cymbalta [Member]",
        "label": "Cymbalta [Member]",
        "terseLabel": "Cymbalta\u00ae"
       }
      }
     },
     "localname": "CymbaltaMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CyramzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cyramza [Member]",
        "label": "Cyramza [Member]",
        "terseLabel": "Cyramza\u00ae"
       }
      }
     },
     "localname": "CyramzaMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "terseLabel": "Fair value of securities in an unrealized gain position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainPosition",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Federal Income Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act",
        "label": "Deferred Federal Income Tax Expense (Benefit), Effect Of Tax Cuts And Jobs Act",
        "negatedTerseLabel": "Deferred federal income tax benefit, effect of 2017 Tax Act"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefitEffectOfTaxCutsAndJobsAct",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsCorrectiveTaxAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Corrective Tax Adjustments",
        "label": "Deferred Tax Assets, Corrective Tax Adjustments",
        "terseLabel": "Correlative tax adjustments"
       }
      }
     },
     "localname": "DeferredTaxAssetsCorrectiveTaxAdjustments",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsForeignTaxRedeterminations": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Foreign Tax Redeterminations",
        "label": "Deferred Tax Assets, Foreign Tax Redeterminations",
        "terseLabel": "Foreign tax redeterminations"
       }
      }
     },
     "localname": "DeferredTaxAssetsForeignTaxRedeterminations",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DeferredTaxAssetsSalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Sales Rebates And Discounts",
        "label": "Deferred Tax Assets, Sales Rebates And Discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsSalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DefineBenefitPlanOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Define Benefit Plan, Other [Member]",
        "label": "Define Benefit Plan, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefineBenefitPlanOtherMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Expected Future Employer Discretionary Contributions, Next Fiscal Year",
        "label": "Defined Benefit Plan, Expected Future Employer Discretionary Contributions, Next Fiscal Year",
        "terseLabel": "Expected future employer discretionary contributions, next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerDiscretionaryContributionsNextFiscalYear",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance",
        "label": "Defined Benefit Plan, Percentage of Global Investments in Plan Assets",
        "terseLabel": "Percentage of global investments in plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DerivativeInstrumentsGainLossRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Gain(loss) Recognized",
        "label": "Derivative Instruments, Gain (Loss) Recognized",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognized",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DermiraInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermira, Inc. [Member]",
        "label": "Dermira, Inc. [Member]",
        "terseLabel": "Dermira"
       }
      }
     },
     "localname": "DermiraInc.Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DescriptionOfDerivativeActivityVolumePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2",
        "label": "Description of Derivative Activity Volume Percent",
        "terseLabel": "Description of derivative activity volume percent"
       }
      }
     },
     "localname": "DescriptionOfDerivativeActivityVolumePercent",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DesignatedUnusableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved.",
        "label": "Designated Unusable [Member]",
        "terseLabel": "Designated Unusable"
       }
      }
     },
     "localname": "DesignatedUnusableMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diabetes",
        "label": "Diabetes [Member]",
        "terseLabel": "Diabetes"
       }
      }
     },
     "localname": "DiabetesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DicernaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dicerna Pharmaceuticals [Member]",
        "label": "Dicerna Pharmaceuticals [Member]",
        "terseLabel": "Dicerna Pharmaceuticals Inc."
       }
      }
     },
     "localname": "DicernaPharmaceuticalsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DisarmTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disarm Therapeutics, Inc.",
        "label": "Disarm Therapeutics, Inc. [Member]",
        "terseLabel": "Disarm Therapeutics, Inc. (Disarm)"
       }
      }
     },
     "localname": "DisarmTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term",
        "label": "Disposal Group, Including Discontinued Operation, Transitional Services Agreement, Term",
        "terseLabel": "Transitional services agreement, term"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransitionalServicesAgreementTerm",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Payment To Be Received",
        "label": "Disposal Group, Not Discontinued Operation, Payment To Be Received",
        "terseLabel": "Disposal group, not discontinued operation, payment to be received"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationPaymentToBeReceived",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes.",
        "label": "Domestic and Puerto Rican Contribution to Income before Income Taxes",
        "terseLabel": "Domestic and Puerto Rican companies contribution"
       }
      }
     },
     "localname": "DomesticandPuertoRicanContributiontoIncomebeforeIncomeTaxes",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DomicileOfLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domicile Of Litigation",
        "label": "Domicile Of Litigation [Axis]",
        "terseLabel": "Domicile of Litigation [Axis]"
       }
      }
     },
     "localname": "DomicileOfLitigationAxis",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_DomicileOfLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domicile Of Litigation",
        "label": "Domicile Of Litigation [Domain]",
        "terseLabel": "Domicile of Litigation [Domain]"
       }
      }
     },
     "localname": "DomicileOfLitigationDomain",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DrReddysLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr Reddy's Lab [Member]",
        "label": "Dr Reddy's Lab [Member]",
        "terseLabel": "Dr Reddy's Lab"
       }
      }
     },
     "localname": "DrReddysLabMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EddingpharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eddingpharm [Member]",
        "label": "Eddingpharm [Member]",
        "terseLabel": "Eddingpharm"
       }
      }
     },
     "localname": "EddingpharmMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount",
        "terseLabel": "2017 Tax Act"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActAmount",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ElancoAnimalHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elanco Animal Health Incorporated [Member]",
        "label": "Elanco Animal Health Incorporated [Member]",
        "verboseLabel": "Elanco"
       }
      }
     },
     "localname": "ElancoAnimalHealthIncorporatedMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly And Company [Member]",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality [Member]",
        "label": "Emgality [Member]",
        "terseLabel": "Emgality\u00ae"
       }
      }
     },
     "localname": "EmgalityMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality Patent Litigation [Member]",
        "label": "Emgality Patent Litigation [Member]",
        "terseLabel": "Emgality Patent Litigation"
       }
      }
     },
     "localname": "EmgalityPatentLitigationMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmployeeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Litigation [Member]",
        "label": "Employee Litigation [Member]",
        "terseLabel": "Employee Litigation"
       }
      }
     },
     "localname": "EmployeeLitigationMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EppVTakedaCanadaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epp V. Takeda Canada Inc. Et Al.",
        "label": "Epp V. Takeda Canada Inc. Et Al. [Member]",
        "terseLabel": "Epp v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "EppVTakedaCanadaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EquityMethodAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method and Other Investments [Member]",
        "label": "Equity Method And Other Investments [Member]",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodAndOtherInvestmentsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ErbituxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erbitux [Member]",
        "label": "Erbitux [Member]",
        "terseLabel": "Erbitux\u00ae"
       }
      }
     },
     "localname": "ErbituxMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EvoxTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evox Therapeutics",
        "label": "Evox Therapeutics [Member]",
        "terseLabel": "Evox Therapeutics Ltd"
       }
      }
     },
     "localname": "EvoxTherapeuticsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_Expiration5to20YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration 5 to 20 Years [Member]",
        "label": "Expiration 5 to 20 Years [Member]",
        "terseLabel": "Expiration 5 to 20 Years"
       }
      }
     },
     "localname": "Expiration5to20YearsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ExpirationIn12To18YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration In 12 To 18 Years [Member]",
        "label": "Expiration In 12 To 18 Years [Member]",
        "terseLabel": "Expiration in 12 to 18 Years"
       }
      }
     },
     "localname": "ExpirationIn12To18YearsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_Expirationin6YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration in 6 Years [Member]",
        "label": "Expiration in 6 Years [Member]",
        "terseLabel": "Expiration in 6 Years"
       }
      }
     },
     "localname": "Expirationin6YearsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_Expirationwithin5yearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration within 5 years [Member]",
        "label": "Expiration within 5 years [Member]",
        "terseLabel": "Expiration within 5 years"
       }
      }
     },
     "localname": "Expirationwithin5yearsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FairValueHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Hedge [Abstract]",
        "label": "Fair Value Hedge [Abstract]",
        "terseLabel": "Fair value hedges:"
       }
      }
     },
     "localname": "FairValueHedgeAbstract",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "label": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "terseLabel": "Unfunded commitments to invest in venture capital funds, anticipated payment period"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_FixedIncomeFundsEmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS.",
        "label": "Fixed Income Funds Emerging Markets [Member]",
        "terseLabel": "Emerging markets"
       }
      }
     },
     "localname": "FixedIncomeFundsEmergingMarketsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FixedIncomeFundsRepurchasedAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Income Funds - Repurchased Agreements [Member]",
        "label": "Fixed Income Funds - Repurchased Agreements [Member]",
        "terseLabel": "Developed markets - repurchase agreements"
       }
      }
     },
     "localname": "FixedIncomeFundsRepurchasedAgreementsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FochonPharmaceuticalsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fochon Pharmaceuticals, Ltd.",
        "label": "Fochon Pharmaceuticals, Ltd. [Member]",
        "terseLabel": "Fochon Pharmaceuticals, Ltd."
       }
      }
     },
     "localname": "FochonPharmaceuticalsLtdMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForeignCurrencyDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt [Member]",
        "label": "Foreign Currency Denominated Debt [Member]",
        "terseLabel": "Foreign Currency Denominated Debt"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forteo [Member]",
        "label": "Forteo [Member]",
        "terseLabel": "Forteo\u00ae"
       }
      }
     },
     "localname": "ForteoMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HedgedFixedRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Fixed-Rate Debt [Member]",
        "label": "Hedged Fixed Rate Debt [Member]",
        "terseLabel": "Hedged Fixed Rate Debt"
       }
      }
     },
     "localname": "HedgedFixedRateDebtMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogHumulinAndForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog, Humulin, And Forteo",
        "label": "Humalog, Humulin, And Forteo [Member]",
        "terseLabel": "Humalog, Humulin and Forteo"
       }
      }
     },
     "localname": "HumalogHumulinAndForteoMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog [Member]",
        "label": "Humalog [Member]",
        "terseLabel": "Humalog\u00ae"
       }
      }
     },
     "localname": "HumalogMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humulin [Member]",
        "label": "Humulin [Member]",
        "terseLabel": "Humulin\u00ae"
       }
      }
     },
     "localname": "HumulinMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HydraBiosciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hydra Biosciences [Member]",
        "label": "Hydra Biosciences [Member]",
        "terseLabel": "Hydra Biosciences"
       }
      }
     },
     "localname": "HydraBiosciencesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmuNextInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ImmuNext, Inc. [Member]",
        "label": "ImmuNext, Inc. [Member]",
        "terseLabel": "ImmuNext, Inc."
       }
      }
     },
     "localname": "ImmuNextInc.Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact on Equity of Sale of Noncontrolling Interest in Subsidiary",
        "label": "Impact on Equity of Sale of Noncontrolling Interest in Subsidiary",
        "terseLabel": "Deconsolidation of Elanco"
       }
      }
     },
     "localname": "ImpactonEquityofSaleofNoncontrollingInterestinSubsidiary",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_InnoventBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovent Biologics, Inc.",
        "label": "Innovent Biologics, Inc. [Member]",
        "terseLabel": "Innovent Biologics, Inc. (Innovent)"
       }
      }
     },
     "localname": "InnoventBiologicsIncMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JardianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jardiance [Member]",
        "label": "Jardiance [Member]",
        "terseLabel": "Jardiance",
        "verboseLabel": "Jardiance\u00ae"
       }
      }
     },
     "localname": "JardianceMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JunshiBiosciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Junshi Biosciences",
        "label": "Junshi Biosciences [Member]",
        "terseLabel": "Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)"
       }
      }
     },
     "localname": "JunshiBiosciencesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LebrikizumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lebrikizumab [Member]",
        "label": "Lebrikizumab [Member]",
        "terseLabel": "Lebrikizumab"
       }
      }
     },
     "localname": "LebrikizumabMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member]",
        "label": "Legacy Antibiotic Medicines And A Manufacturing Facility In Suzhou, China [Member]",
        "terseLabel": "Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China"
       }
      }
     },
     "localname": "LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LesseeLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease, Remaining Lease Term",
        "label": "Lessee, Lease, Remaining Lease Term",
        "terseLabel": "Lessee, lease, remaining lease term (up to)"
       }
      }
     },
     "localname": "LesseeLeaseRemainingLeaseTerm",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_LongTermDebtFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustment to carrying value of long term debt to arrive at total fair value.",
        "label": "Long-term Debt, Fair Value Adjustment",
        "terseLabel": "Fair value adjustment on hedged long-term notes"
       }
      }
     },
     "localname": "LongTermDebtFairValueAdjustment",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_LosAngelesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Los Angeles",
        "label": "Los Angeles [Member]",
        "terseLabel": "Los Angeles"
       }
      }
     },
     "localname": "LosAngelesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term",
        "label": "Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term",
        "terseLabel": "Claims settled and dismissed, limited initial market entry, supply term"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_LossContingencyNumberOfClaimants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Claimants",
        "label": "Loss Contingency, Number Of Claimants",
        "terseLabel": "Number of claimants"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimants",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatentsClaimsDismissed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents, Claims Dismissed",
        "label": "Loss Contingency, Number Of Patents, Claims Dismissed",
        "terseLabel": "Number of patents, claims dismissed"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatentsClaimsDismissed",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatentsRuledUnpatentable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents Ruled Unpatentable",
        "label": "Loss Contingency, Number Of Patents Ruled Unpatentable",
        "terseLabel": "Number of patents ruled unpatentable"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatentsRuledUnpatentable",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfRequestsForInformation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Requests For Information",
        "label": "Loss Contingency, Number Of Requests For Information",
        "terseLabel": "Number of requests for information"
       }
      }
     },
     "localname": "LossContingencyNumberOfRequestsForInformation",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LoxoOncologyInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loxo Oncology, Inc. [Member]",
        "label": "Loxo Oncology, Inc. [Member]",
        "terseLabel": "Loxo Oncology, Inc."
       }
      }
     },
     "localname": "LoxoOncologyInc.Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities [Member]",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MaturityDate2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date, 2019 [Member]",
        "label": "Maturity Date, 2019 [Member]",
        "terseLabel": "Maturity Date, 2019"
       }
      }
     },
     "localname": "MaturityDate2019Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MaturityDate2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Date, 2023",
        "label": "Maturity Date, 2023 [Member]",
        "terseLabel": "Maturity Date, 2023"
       }
      }
     },
     "localname": "MaturityDate2023Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MerusNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merus N.V.",
        "label": "Merus N.V. [Member]",
        "terseLabel": "Merus N.V."
       }
      }
     },
     "localname": "MerusNVMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory [Member]",
        "label": "Milestone Payments, Development and Regulatory [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentAndRegulatoryMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]",
        "label": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Sales-based [Member]",
        "label": "Milestone Payments, Sales-based [Member]",
        "terseLabel": "Milestone Payments, Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBasedMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Success-based Regulatory And Sales-based",
        "label": "Milestone Payments, Success-based Regulatory And Sales-based [Member]",
        "terseLabel": "Milestone Payments, Success-based Regulatory And Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSuccessBasedRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Success-based Regulatory",
        "label": "Milestone Payments, Success-based Regulatory [Member]",
        "terseLabel": "Milestone Payments, Success-based Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsSuccessBasedRegulatoryMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Neuroscience",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NextCureInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NextCure, Inc. [Member]",
        "label": "NextCure, Inc. [Member]",
        "terseLabel": "NextCure, Inc."
       }
      }
     },
     "localname": "NextCureInc.Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Those operating loss/tax credit carryforwards/carrybacks included that have no expiration.",
        "label": "No Expiration [Member]",
        "terseLabel": "No Expiration"
       }
      }
     },
     "localname": "NoExpirationMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NonCHINAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-CHINA",
        "label": "Non-CHINA [Member]",
        "terseLabel": "Outside of China"
       }
      }
     },
     "localname": "NonCHINAMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_November2019EuroDenominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November 2019 Euro-denominated Notes",
        "label": "November 2019 Euro-denominated Notes [Member]",
        "terseLabel": "November 2019 Euro-denominated Notes"
       }
      }
     },
     "localname": "November2019EuroDenominatedNotesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_November2019YenDenominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November 2019 Yen-denominated Notes",
        "label": "November 2019 Yen-denominated Notes [Member]",
        "terseLabel": "November 2019 Yen-denominated Notes"
       }
      }
     },
     "localname": "November2019YenDenominatedNotesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NumberOfMedicinesRightsToSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Medicines, Rights To, Sold",
        "label": "Number Of Medicines, Rights To, Sold",
        "terseLabel": "Number of legacy antibiotic medicines rights sold"
       }
      }
     },
     "localname": "NumberOfMedicinesRightsToSold",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_OlumiantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olumiant [Member]",
        "label": "Olumiant [Member]",
        "terseLabel": "Olumiant\u00ae"
       }
      }
     },
     "localname": "OlumiantMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Oncology",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Diabetes",
        "label": "Other Diabetes [Member]",
        "terseLabel": "Other Diabetes"
       }
      }
     },
     "localname": "OtherDiabetesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Securities [Member]",
        "label": "Other Equity Securities [Member]",
        "terseLabel": "Other securities"
       }
      }
     },
     "localname": "OtherEquitySecuritiesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherForeignCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Foreign Countries [Member]",
        "label": "Other Foreign Countries [Member]",
        "terseLabel": "Other foreign countries",
        "verboseLabel": "Other foreign countries"
       }
      }
     },
     "localname": "OtherForeignCountriesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other Immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Neuroscience [Member]",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other Neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other Oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product [Member]",
        "label": "Other Product [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product, Total [Member]",
        "label": "Other Product, Total [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductTotalMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OutsideUSAndJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside US And Japan",
        "label": "Outside US And Japan [Member]",
        "terseLabel": "Outside US And Japan"
       }
      }
     },
     "localname": "OutsideUSAndJapanMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PancreaticCancerOrThyroidCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pancreatic Cancer Or Thyroid Cancer",
        "label": "Pancreatic Cancer Or Thyroid Cancer [Member]",
        "terseLabel": "Pancreatic Cancer or Thyroid Cancer"
       }
      }
     },
     "localname": "PancreaticCancerOrThyroidCancerMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PancreatitisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pancreatitis",
        "label": "Pancreatitis [Member]",
        "terseLabel": "Pancreatitis"
       }
      }
     },
     "localname": "PancreatitisMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PaymentsForIncomeTaxSettlements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Income Tax Settlements",
        "label": "Payments For Income Tax Settlements",
        "terseLabel": "Payments for income tax settlements"
       }
      }
     },
     "localname": "PaymentsForIncomeTaxSettlements",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_PlaintiffAllegationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Allegations",
        "label": "Plaintiff Allegations [Axis]",
        "terseLabel": "Plaintiff Allegations [Axis]"
       }
      }
     },
     "localname": "PlaintiffAllegationsAxis",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_PlaintiffAllegationsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Allegations",
        "label": "Plaintiff Allegations [Domain]",
        "terseLabel": "Plaintiff Allegations [Domain]"
       }
      }
     },
     "localname": "PlaintiffAllegationsDomain",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrecisionBioSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precision BioSciences, Inc.",
        "label": "Precision BioSciences, Inc. [Member]",
        "terseLabel": "Precision BioSciences, Inc."
       }
      }
     },
     "localname": "PrecisionBioSciencesIncMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrevailTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevail Therapeutics Inc.",
        "label": "Prevail Therapeutics Inc. [Member]",
        "terseLabel": "Prevail Therapeutics Inc."
       }
      }
     },
     "localname": "PrevailTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProceedsfromIssuanceorSaleofEquityfromSubsidiary": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance or Sale of Equity from Subsidiary",
        "label": "Proceeds from Issuance or Sale of Equity from Subsidiary",
        "terseLabel": "Net proceeds from Elanco initial public offering (Note 19)"
       }
      }
     },
     "localname": "ProceedsfromIssuanceorSaleofEquityfromSubsidiary",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Equity and Available for Sale Securities",
        "label": "Proceeds from Sale of Equity and Available for Sale Securities",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsfromSaleofEquityandAvailableforSaleSecurities",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofInvestmentPortfolioActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PurchasedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).",
        "label": "Purchased in-process research and development",
        "negatedTerseLabel": "Purchases of in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_RelativeValueAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relative Value Awards",
        "label": "Relative Value Awards [Member]",
        "terseLabel": "Relative Value Awards"
       }
      }
     },
     "localname": "RelativeValueAwardsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "label": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "terseLabel": "Revenue, information used to determine revenue recognized, change in accounting estimate, percent"
       }
      }
     },
     "localname": "RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt",
        "label": "Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt",
        "terseLabel": "Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTermsFinancingComponentPeriodBetweenTransferOfControlAndPaymentReceipt",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesRebatePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Rebate Payment Period",
        "label": "Revenue, Performance Obligation, Sales Rebate Payment Period",
        "terseLabel": "Revenue, performance obligation, sales rebate payment period (up to)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesRebatePaymentPeriod",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsAverageInventoryLevel": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Average Inventory Level",
        "label": "Revenue, Performance Obligation, Sales Returns, Average Inventory Level",
        "terseLabel": "Revenue, performance obligation, sales returns, average inventory level (or less)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsAverageInventoryLevel",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue",
        "label": "Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue",
        "terseLabel": "Revenue, performance obligation, sales returns, percentage of net revenue (less than)"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsPercentageOfNetRevenue",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "lly_RevenuePerformanceObligationSalesReturnsProductExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Sales Returns, Product Expiration Date",
        "label": "Revenue, Performance Obligation, Sales Returns, Product Expiration Date",
        "terseLabel": "Revenue, performance obligation, sales returns, product expiration date"
       }
      }
     },
     "localname": "RevenuePerformanceObligationSalesReturnsProductExpirationDate",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuefromContractPaymentTermMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract, Payment Term, Maximum",
        "label": "Revenue from Contract, Payment Term, Maximum",
        "terseLabel": "Revenue, performance obligation, payment terms, days from date of shipment, maximum"
       }
      }
     },
     "localname": "RevenuefromContractPaymentTermMaximum",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RevenuefromContractPaymentTermMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract, Payment Term",
        "label": "Revenue from Contract, Payment Term, Minimum",
        "terseLabel": "Revenue, performance obligation, payment terms, days from date of shipment, minimum"
       }
      }
     },
     "localname": "RevenuefromContractPaymentTermMinimum",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SIGATechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SIGA Technologies [Member]",
        "label": "SIGA Technologies [Member]",
        "terseLabel": "SIGA Technologies, Inc."
       }
      }
     },
     "localname": "SIGATechnologiesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SaleOfStockPercentageOfStockSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Percentage Of Stock Sold",
        "label": "Sale Of Stock, Percentage Of Stock Sold",
        "terseLabel": "Percentage of stock sold"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfStockSold",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_SalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales rebates and discounts",
        "label": "Sales rebates and discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "SalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Borrowings Disclosures [Table Text Block]",
        "label": "Schedule of Additional Borrowings Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Additional Borrowings Disclosures"
       }
      }
     },
     "localname": "ScheduleofAdditionalBorrowingsDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Income Tax Disclosures [Table Text Block]",
        "label": "Schedule of Additional Income Tax Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax"
       }
      }
     },
     "localname": "ScheduleofAdditionalIncomeTaxDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]",
        "label": "Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Additional Stock-Based Compensation Disclosures"
       }
      }
     },
     "localname": "ScheduleofAdditionalStockBasedCompensationDisclosuresTableTextBlock",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_SelpercatinibLOXO292Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selpercatinib (LOXO-292) [Member]",
        "label": "Selpercatinib (LOXO-292) [Member]",
        "terseLabel": "Selpercatinib (LOXO-292)"
       }
      }
     },
     "localname": "SelpercatinibLOXO292Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SeniorNotesDueMay2050AndSeptember2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due May 2050 And September 2060",
        "label": "Senior Notes Due May 2050 And September 2060 [Member]",
        "terseLabel": "Senior Notes Due May 2050 and September 2060"
       }
      }
     },
     "localname": "SeniorNotesDueMay2050AndSeptember2060Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares expected to be issued in the next twelve months under the plan.",
        "label": "Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued",
        "terseLabel": "Shares expected to be issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lly_SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]",
        "label": "Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]",
        "terseLabel": "Share-based Compensation Awards, Fair Value Assumptions Used"
       }
      }
     },
     "localname": "SharebasedCompensationAwardsFairValueAssumptionsUsedTableTextBlock",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lly_ShareholderValueAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period.",
        "label": "Shareholder Value Awards [Member]",
        "terseLabel": "Shareholder Value Awards"
       }
      }
     },
     "localname": "ShareholderValueAwardsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SigilonTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sigilon Therapeutics [Member]",
        "label": "Sigilon Therapeutics [Member]",
        "terseLabel": "Sigilon Therapeutics, Inc."
       }
      }
     },
     "localname": "SigilonTherapeuticsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SitryxTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sitryx Therapeutics Limited [Member]",
        "label": "Sitryx Therapeutics Limited [Member]",
        "terseLabel": "Sitryx Therapeutics Limited"
       }
      }
     },
     "localname": "SitryxTherapeuticsLimitedMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SouthernDistrictOfCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Southern District Of California",
        "label": "Southern District Of California [Member]",
        "terseLabel": "Southern District of California"
       }
      }
     },
     "localname": "SouthernDistrictOfCaliforniaMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_StockAcquiredDuringPeriodSharesExchangeOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Acquired During Period, Shares, Exchange Offer",
        "label": "Stock Acquired During Period, Shares, Exchange Offer",
        "terseLabel": "Acquisition of common stock in exchange offer (in shares)"
       }
      }
     },
     "localname": "StockAcquiredDuringPeriodSharesExchangeOffer",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "lly_StockAcquiredDuringPeriodValueExchangeOffer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Acquired During Period, Value, Exchange Offer",
        "label": "Stock Acquired During Period, Value, Exchange Offer",
        "negatedTerseLabel": "Acquisition of common stock in exchange offer"
       }
      }
     },
     "localname": "StockAcquiredDuringPeriodValueExchangeOffer",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_SwapSwissFrancsToU.S.DollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap Swiss Francs To U.S. Dollars [Member]",
        "label": "Swap Swiss Francs To U.S. Dollars [Member]",
        "terseLabel": "Swap Swiss Francs to USD"
       }
      }
     },
     "localname": "SwapSwissFrancsToU.S.DollarsMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TYVYTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYVYT",
        "label": "TYVYT [Member]",
        "terseLabel": "Tyvyt"
       }
      }
     },
     "localname": "TYVYTMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaltzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taltz [Member]",
        "label": "Taltz [Member]",
        "terseLabel": "Taltz\u00ae"
       }
      }
     },
     "localname": "TaltzMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TanezumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tanezumab [Member]",
        "label": "Tanezumab [Member]",
        "terseLabel": "Tanezumab"
       }
      }
     },
     "localname": "TanezumabMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaxCutAndJobsActTollTaxPaymentDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, Payment, Due",
        "label": "Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]",
        "terseLabel": "Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxPaymentDueAbstract",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaid": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaid",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": 3.0,
       "parentTag": "lly_TaxCutAndJobsActTollTaxToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years",
        "terseLabel": "1-3 Years"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaidAfterOneThroughThreeYears",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": 2.0,
       "parentTag": "lly_TaxCutAndJobsActTollTaxToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, After Three Through Five Years",
        "terseLabel": "3-5 Years"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaidAfterThreeThroughFiveYears",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutAndJobsActTollTaxToBePaidWithinOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails": {
       "order": 1.0,
       "parentTag": "lly_TaxCutAndJobsActTollTaxToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year",
        "label": "Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year",
        "terseLabel": "Less than 1 Year"
       }
      }
     },
     "localname": "TaxCutAndJobsActTollTaxToBePaidWithinOneYear",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofFutureCashPaymentsRelatingtotheTollTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision",
        "label": "Tax Cuts and Jobs Act of 2017, Deferred Tax Asset, Global Intangible Low-Taxed Income Provision",
        "terseLabel": "2017 Tax Act, deferred taxes related to GILTI"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017DeferredTaxAssetGlobalIntangibleLowTaxedIncomeProvision",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_TaxYears2013To2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Years 2013 To 2015 [Member]",
        "label": "Tax Years 2013 To 2015 [Member]",
        "terseLabel": "Tax Years 2013 to 2015"
       }
      }
     },
     "localname": "TaxYears2013To2015Member",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TermFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Facility [Member]",
        "label": "Term Facility [Member]",
        "terseLabel": "Term Facility"
       }
      }
     },
     "localname": "TermFacilityMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ThreeLargestWholesalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Largest Wholesales [Member]",
        "label": "Three Largest Wholesales [Member]",
        "terseLabel": "Three Largest Wholesales"
       }
      }
     },
     "localname": "ThreeLargestWholesalesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrajentaBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trajenta (BI) [Member]",
        "label": "Trajenta (BI) [Member]",
        "verboseLabel": "Trajenta\u00ae"
       }
      }
     },
     "localname": "TrajentaBIMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrulicityMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trulicity [Member] [Member]",
        "label": "Trulicity [Member] [Member]",
        "terseLabel": "Trulicity\u00ae"
       }
      }
     },
     "localname": "TrulicityMemberMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_UNITEDSTATESAndPUERTORICOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES And PUERTO RICO [Member]",
        "label": "UNITED STATES And PUERTO RICO [Member]",
        "verboseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UNITEDSTATESAndPUERTORICOMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_UndisclosedAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undisclosed Asset Acquisition",
        "label": "Undisclosed Asset Acquisition [Member]",
        "terseLabel": "Undisclosed"
       }
      }
     },
     "localname": "UndisclosedAssetAcquisitionMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VariousStateDomicilesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various State Domiciles",
        "label": "Various State Domiciles [Member]",
        "terseLabel": "Various State Domiciles"
       }
      }
     },
     "localname": "VariousStateDomicilesMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VerzenioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verzenio [Member]",
        "label": "Verzenio [Member]",
        "terseLabel": "Verzenio\u00ae"
       }
      }
     },
     "localname": "VerzenioMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_WeilerVTakedaCanadaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weiler V. Takeda Canada Inc. Et Al.",
        "label": "Weiler V. Takeda Canada Inc. Et Al. [Member]",
        "terseLabel": "Weiler v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "WeilerVTakedaCanadaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_WhyteEtAlVEliLillyEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Whyte Et Al. V. Eli Lilly Et Al.",
        "label": "Whyte Et Al. V. Eli Lilly Et Al. [Member]",
        "terseLabel": "Weiler v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "WhyteEtAlVEliLillyEtAlMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ZyprexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zyprexa [Member]",
        "label": "Zyprexa [Member]",
        "terseLabel": "Zyprexa\u00ae"
       }
      }
     },
     "localname": "ZyprexaMember",
     "nsuri": "http://www.lilly.com/20201231",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r98",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r178",
      "r185",
      "r265",
      "r503",
      "r504",
      "r505",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r178",
      "r185",
      "r265",
      "r503",
      "r504",
      "r505",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r178",
      "r185",
      "r265",
      "r503",
      "r504",
      "r505",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]",
        "verboseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r233",
      "r374",
      "r379",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r476",
      "r482",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r725",
      "r789",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r476",
      "r482",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r725",
      "r789",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r233",
      "r374",
      "r379",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r229",
      "r374",
      "r377",
      "r726",
      "r788",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r229",
      "r374",
      "r377",
      "r726",
      "r788",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r415",
      "r476",
      "r482",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r725",
      "r789",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r415",
      "r476",
      "r482",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r725",
      "r789",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r374",
      "r378",
      "r791",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r374",
      "r378",
      "r791",
      "r808",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r328",
      "r477",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Accounting Standards Update 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r28",
      "r57",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $25.9 (2020)\u00a0and $22.4 (2019)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r51",
      "r738",
      "r770"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable (Note 14)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r106",
      "r114",
      "r117",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Defined Benefit Pension and Retiree\u00a0Health Benefit Plans",
        "verboseLabel": "Amortization of retirement benefit items"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r105",
      "r114",
      "r117",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Actuarial losses"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r108",
      "r114",
      "r117",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Prior service benefits, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r72",
      "r312"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r100",
      "r114",
      "r117",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Gains\u00a0(Losses)"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r114",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Effective Portion of Cash\u00a0Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r101",
      "r114",
      "r117",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Effective Portion of Cash\u00a0Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r114",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Net Gains (Losses) on\u00a0Securities"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r60",
      "r110",
      "r113",
      "r114",
      "r772",
      "r801",
      "r805"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss (Note 17)",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r109",
      "r114",
      "r117",
      "r175",
      "r176",
      "r177",
      "r595",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r58",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r550",
      "r551",
      "r552",
      "r553",
      "r728",
      "r729",
      "r730",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expenses"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r485",
      "r496",
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r64",
      "r236",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowances"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r159",
      "r293",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r109",
      "r114",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "AOCI Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "AociAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r109",
      "r114",
      "r117",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r251",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r167",
      "r219",
      "r222",
      "r227",
      "r261",
      "r590",
      "r597",
      "r655",
      "r735",
      "r769"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r30",
      "r32",
      "r96",
      "r167",
      "r261",
      "r590",
      "r597",
      "r655"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gross gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized gross losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Noncurrent investments:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r246",
      "r249",
      "r759"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "6-10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r246",
      "r248",
      "r758"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "1-5 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r246",
      "r250",
      "r760"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "More Than 10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r246",
      "r247",
      "r757"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less Than 1 Year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r238",
      "r243",
      "r274",
      "r745"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r240",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r240",
      "r274"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Noncurrent investments, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.",
        "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets",
        "terseLabel": "Percentage of nonperforming assets"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_AverageRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average period remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Average Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Average remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "AverageRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r487",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r34",
      "r311"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r472",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r472",
      "r478",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r576",
      "r577",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent value right, additional price per share, aggregate amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income taxes",
        "terseLabel": "Deferred income tax liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangibles acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Finite-lived intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "terseLabel": "Long-term debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration transferred - net of cash acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r164",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26",
      "r68",
      "r161"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents (Note 7)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]",
        "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "auth_ref": [
      "r154",
      "r161",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "terseLabel": "Discontinued operations cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r154",
      "r161",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents at End of Year (includes $677.5 (2018) of discontinued operations)",
        "periodStartLabel": "Cash and cash equivalents at beginning of year (includes $677.5 (2019) and $324.4 (2018) of discontinued operations)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r154",
      "r658"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "negatedTerseLabel": "Cash distributed to Elanco upon disposition"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedges"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r17",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Cash provided by operating activities, discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r186",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Change in Accounting Estimate [Line Items]",
        "terseLabel": "Change in Accounting Estimate [Line Items]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r186",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 2.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Effect from interest rate contracts"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 1.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Effect from hedged fixed-rate debt"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r165",
      "r167",
      "r193",
      "r194",
      "r195",
      "r197",
      "r199",
      "r207",
      "r208",
      "r209",
      "r261",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r582",
      "r583",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r45",
      "r736",
      "r771"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "negatedLabel": "Short-term commercial paper borrowings",
        "terseLabel": "Short-term commercial paper borrowings"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r84",
      "r327",
      "r746",
      "r777"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r164",
      "r339",
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividend declared per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrust": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.",
        "label": "Common Stock, Shares Held in Employee Trust",
        "negatedTerseLabel": "Employee benefit trust",
        "terseLabel": "Employee benefit trust"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrust",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrustShares": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock held in a trust that has been set up specifically to accumulate stock for the sole purpose of distribution to participating employees but not yet earned.",
        "label": "Common Stock, Shares Held in Employee Trust, Shares",
        "terseLabel": "Shares held in employee trust (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrustShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock\u2014no par value\u2028 Authorized shares: 3,200,000\u2028 Issued shares: 957,077 (2020)\u00a0and 958,056 (2019)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r120",
      "r122",
      "r132",
      "r588",
      "r601",
      "r752",
      "r783"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r131",
      "r141",
      "r751",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r233",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r233",
      "r653",
      "r654",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r210",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration Risk, Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r211",
      "r212",
      "r233",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Contract-based intangibles"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recorded for Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r364",
      "r365",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/RevenueContractLiabilitiesDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r416",
      "r465",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r134",
      "r726"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, expenses, and other:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r416",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross-currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r547",
      "r556"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r547"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r547",
      "r556",
      "r558"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r547",
      "r556"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "negatedLabel": "Less current portion",
        "terseLabel": "Short-term borrowings and current maturities of long-term debt (Note 11)"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r737",
      "r740",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r49",
      "r343",
      "r740",
      "r766"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term notes, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r671",
      "r673"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r81",
      "r345",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate, effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Repurchase aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r82",
      "r170",
      "r353",
      "r356",
      "r357",
      "r358",
      "r670",
      "r671",
      "r673",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r670",
      "r673"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized note discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Sale [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleSaleAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r254",
      "r276",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair value of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofAFSUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r548",
      "r556"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r548",
      "r556"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r519",
      "r520"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets (Note 14)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r168",
      "r548",
      "r556",
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax (benefit) expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r52",
      "r53",
      "r537",
      "r739",
      "r765"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r519",
      "r520"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities (Note 14)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r548",
      "r556"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards and carrybacks"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred tax assets related to state net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r543",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards and carrybacks"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r520",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.",
        "label": "Deferred Tax Liabilities, Inventory",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.",
        "label": "Deferred Tax Liabilities, Derivatives",
        "negatedLabel": "Financial instruments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "negatedLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid employee benefits"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "negatedLabel": "Earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Total accumulated benefit obligation for our defined benefit pension plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r107",
      "r114",
      "r436"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "terseLabel": "Accumulated other comprehensive (income) loss before income taxes"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r114",
      "r436"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrecognized net actuarial (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r114",
      "r436"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Unrecognized prior service (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r405",
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r391",
      "r431",
      "r459",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Recognized actuarial loss (gain)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r391",
      "r432",
      "r460",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r389",
      "r413"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Net amount recognized"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Amounts recognized in the consolidated balance sheet consisted\u00a0of:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "auth_ref": [
      "r105",
      "r110",
      "r435"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "terseLabel": "Amortization of net actuarial loss included in net income"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r44",
      "r389",
      "r390",
      "r413",
      "r465",
      "r734",
      "r768"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate for benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase for benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r440",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Expected return on plan assets for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase for net benefit costs"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation at end of year",
        "periodStartLabel": "Benefit obligation at beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r400",
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease)",
        "verboseLabel": "Defined benefit obligation, period increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r443",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in benefit obligation:"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r407",
      "r416",
      "r418",
      "r463",
      "r465",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contribution"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCurtailments": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment",
        "terseLabel": "Curtailment (gain) loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r416",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": {
     "auth_ref": [
      "r416",
      "r418",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": {
     "auth_ref": [
      "r416",
      "r418",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, US [Member]",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]",
        "terseLabel": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "verboseLabel": "2026-2030"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r426",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected future employer contributions, next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r391",
      "r430",
      "r458",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r404",
      "r416",
      "r418",
      "r419",
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "netLabel": "Fair value of plan assets",
        "periodEndLabel": "Fair value of plan assets at end of year",
        "periodStartLabel": "Fair value of plan assets at beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency exchange rate changes and other adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r389",
      "r413",
      "r465"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "terseLabel": "Funded status"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r391",
      "r396",
      "r429",
      "r457",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r427",
      "r455",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "terseLabel": "Components of net periodic (benefit) cost:"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r451",
      "r452",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r451",
      "r452",
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r409",
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency exchange rate changes and other adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r415",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Plan assets, target allocation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRealEstateMember": {
     "auth_ref": [
      "r416",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Real Estate [Member]",
        "terseLabel": "Real estate"
       }
      }
     },
     "localname": "DefinedBenefitPlanRealEstateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r392",
      "r434",
      "r462"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailment (gain) loss",
        "terseLabel": "Curtailment gain"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r394",
      "r428",
      "r456",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r449",
      "r450",
      "r453",
      "r454",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Postretirement Health Coverage [Member]",
        "terseLabel": "Retiree Health Benefit Plans"
       }
      }
     },
     "localname": "DefinedBenefitPostretirementHealthCoverageMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense under the plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r159",
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r159",
      "r217"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r605",
      "r606",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r614",
      "r617",
      "r622",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r612",
      "r614",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 3.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective portion of loss reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion",
        "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "negatedLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "negatedLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r605",
      "r606",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r606",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r604",
      "r607",
      "r608",
      "r612",
      "r613",
      "r618",
      "r622",
      "r630",
      "r632",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r164",
      "r172",
      "r604",
      "r607",
      "r612",
      "r613",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Marketed products"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r309",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration received"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r159",
      "r309",
      "r314"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedLabel": "Gain on sale of antibiotic business in China (Note 3)",
        "negatedTerseLabel": "Gain on sale of antibiotic business in China (Note 3)",
        "terseLabel": "Gain related to disposition"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r24",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r472",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r359",
      "r761"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedLabel": "Cash dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r79"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r133",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r191",
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r753",
      "r784"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings per share - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r133",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r753",
      "r784"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings per share - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r164",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share (EPS)"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r658"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of the compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r180",
      "r188",
      "r190",
      "r206",
      "r265",
      "r352",
      "r359",
      "r503",
      "r504",
      "r505",
      "r552",
      "r553",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFundsMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.",
        "label": "Equity Funds [Member]",
        "terseLabel": "Equity-like funds"
       }
      }
     },
     "localname": "EquityFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Unrealized losses from equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r639",
      "r640",
      "r641",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r639",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r639",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r465",
      "r640",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r639",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair value hedges"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r416",
      "r418",
      "r423",
      "r465",
      "r640",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r416",
      "r418",
      "r423",
      "r465",
      "r640",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r465",
      "r640",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "auth_ref": [
      "r646"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "terseLabel": "Unfunded commitments to invest in venture capital funds"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r642",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r418",
      "r638",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Investments Valued at Net Asset Value"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r465",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r277",
      "r278",
      "r279",
      "r280",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Finite-lived Intangible Assets Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r294",
      "r298",
      "r302",
      "r306",
      "r727",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r302",
      "r731"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Carrying Amount, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r294",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r302",
      "r727"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Carrying Amount, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FixedIncomeFundsMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that pools funds from investors to invest in a combination of underlying investments, primarily fixed income investments.",
        "label": "Fixed Income Funds [Member]",
        "terseLabel": "Developed markets"
       }
      }
     },
     "localname": "FixedIncomeFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r164",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r416",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r614",
      "r621"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 4.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedTerseLabel": "Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r138",
      "r159",
      "r241"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Net investment gains"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (Loss) on Investments"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r159",
      "r596"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedLabel": "Gain related to disposition of Elanco (Note 19)",
        "terseLabel": "Gain related to disposition"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r159",
      "r346",
      "r347"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Debt extinguishment loss (Note 11)"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r286",
      "r288",
      "r733"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "terseLabel": "Goodwill (Note 8)",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangibles"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r164",
      "r290",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r159",
      "r287",
      "r289",
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgeFundsMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in registered hedge funds.",
        "label": "Hedge Funds [Member]",
        "terseLabel": "Hedge funds"
       }
      }
     },
     "localname": "HedgeFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r612",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r128",
      "r219",
      "r221",
      "r223",
      "r226",
      "r228",
      "r732",
      "r748",
      "r755",
      "r786"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTerseLabel": "Total before tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r167",
      "r179",
      "r219",
      "r221",
      "r223",
      "r226",
      "r228",
      "r261",
      "r588",
      "r655"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Reclassifications from continuing operations (net of tax)",
        "totalLabel": "Net income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r125",
      "r133",
      "r179",
      "r183",
      "r184",
      "r185",
      "r186",
      "r193",
      "r197",
      "r198",
      "r747",
      "r749",
      "r753",
      "r779"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings from continuing operations - basic (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r125",
      "r133",
      "r179",
      "r183",
      "r184",
      "r185",
      "r186",
      "r193",
      "r197",
      "r198",
      "r199",
      "r753",
      "r779",
      "r782",
      "r784"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings from continuing operations - diluted (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r20",
      "r23",
      "r563",
      "r780"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Reclassifications from discontinued operations (net of tax)",
        "terseLabel": "Net income from discontinued operations (Note 19)",
        "verboseLabel": "Net income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r129",
      "r133",
      "r194",
      "r197",
      "r198",
      "r753",
      "r780",
      "r782",
      "r784"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings from discontinued operations - basic (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r194",
      "r197",
      "r198",
      "r602"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings from discontinued operations - diluted (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r472",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r18",
      "r21",
      "r22",
      "r23",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r523",
      "r535",
      "r542",
      "r554",
      "r559",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r189",
      "r190",
      "r218",
      "r521",
      "r555",
      "r561",
      "r787"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income taxes (Note 14)",
        "totalLabel": "Income taxes",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/IncomeTaxesScheduleofCompositionofIncomeTaxExpenseDetails",
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r164",
      "r517",
      "r518",
      "r535",
      "r536",
      "r541",
      "r549",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Income tax at the U.S. federal statutory tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "verboseLabel": "Non-deductible acquired IPR&amp;D"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "General business credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "negatedLabel": "International operations, including Puerto Rico"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r156",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash payments of income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofCashPaymentsofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Receivables\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities\u2014increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable\u2014increase (decrease)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets\u2014(increase) decrease"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r296",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r296",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Carrying Amount, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r292",
      "r300"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other intangibles, net (Note 8)",
        "totalLabel": "Carrying Amount, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r126",
      "r216",
      "r669",
      "r672",
      "r754"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r152",
      "r155",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash payments for interest on borrowings"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofCashPaymentsforInterestonBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r637"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "negatedLabel": "Losses expected to be reclassified in the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r416",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Forward-starting interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates replacement cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedTerseLabel": "Increase to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r27",
      "r92"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories (Note 6)",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r93",
      "r164",
      "r205",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.lilly.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r137",
      "r215"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r260",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LIFOInventoryAmount": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.",
        "label": "LIFO Inventory Amount",
        "terseLabel": "LIFO Inventory Amount"
       }
      }
     },
     "localname": "LIFOInventoryAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r33",
      "r71"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Impact of Leases to Consolidated Condensed Financial Statements"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "After Year 5"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Year 1"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Year 5"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Year 4"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Year 3"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Year 2"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r63",
      "r167",
      "r261",
      "r655",
      "r742",
      "r775"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r80",
      "r167",
      "r261",
      "r591",
      "r597",
      "r598",
      "r655"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r49",
      "r50",
      "r167",
      "r261",
      "r591",
      "r597",
      "r598",
      "r655"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total other liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of credit facility, remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Long-lived Assets by Geographic Areas"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r49",
      "r344",
      "r740",
      "r771"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "negatedLabel": "Long-term debt, including current portion",
        "terseLabel": "Total long-term notes",
        "totalLabel": "Total long-term notes"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Maturities on long-term debt"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r174",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r174",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r174",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r174",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r174",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt (Note 11)",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investments (Note 7)",
        "totalLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r82",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r327",
      "r330",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r311"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r24",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Acquisitions and Divestiture"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestiture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r88",
      "r167",
      "r261",
      "r655",
      "r741",
      "r774"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "verboseLabel": "Disposition of ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r242",
      "r416",
      "r418",
      "r465",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Used for Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Provided by (Used for) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r154",
      "r157",
      "r160"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r118",
      "r121",
      "r130",
      "r160",
      "r167",
      "r179",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r196",
      "r219",
      "r221",
      "r223",
      "r226",
      "r228",
      "r261",
      "r655",
      "r750",
      "r781"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net investment hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Retirement benefit plans"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Implementation of New Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r359",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "verboseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other\u2014net, (income) expense (Note 18)",
        "negatedTotalLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r49",
      "r740",
      "r771"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Long-term notes"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r680",
      "r687"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r679",
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r684",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r683",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r674"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r25",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r108",
      "r110",
      "r435"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedTerseLabel": "Plan amendments during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r99",
      "r110",
      "r656",
      "r657",
      "r659"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Change in foreign currency translation gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r110",
      "r115",
      "r116",
      "r435"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Amortization of prior service (benefit) cost included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r102",
      "r103",
      "r110"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "terseLabel": "Change in net unrealized gains (losses) on securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r114",
      "r124",
      "r660",
      "r662",
      "r666"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r131",
      "r259",
      "r660",
      "r665",
      "r666",
      "r751",
      "r782"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss) from continuing operations:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r101",
      "r110"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "terseLabel": "Change in effective portion of cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r101",
      "r110",
      "r615",
      "r619",
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r110",
      "r115",
      "r620"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails": {
       "order": 5.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax",
        "terseLabel": "Change in effective portion of cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax": {
     "auth_ref": [
      "r110",
      "r115",
      "r435"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax",
        "terseLabel": "Curtailment gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r99",
      "r110"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "terseLabel": "Foreign currency exchange rate changes and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r623"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r119",
      "r122",
      "r124",
      "r131",
      "r352",
      "r660",
      "r665",
      "r666",
      "r751",
      "r782"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Net other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r119",
      "r122",
      "r588",
      "r589",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]",
        "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r107",
      "r110",
      "r435",
      "r465"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "negatedLabel": "Change in defined benefit pension and retiree health benefit plans (Note 15)",
        "negatedTotalLabel": "Total other comprehensive income (loss) during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r105",
      "r110",
      "r435"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Actuarial gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r111",
      "r131",
      "r521",
      "r560",
      "r562",
      "r660",
      "r663",
      "r666",
      "r751",
      "r782"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedLabel": "Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items",
        "negatedNetLabel": "Benefit (provision) for income taxes related to other comprehensive income (loss) from continuing operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r101",
      "r110",
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofEffectofRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherContractMember": {
     "auth_ref": [
      "r416",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is classified as other.",
        "label": "Other Contract [Member]",
        "terseLabel": "Cash value of trust owned insurance contract"
       }
      }
     },
     "localname": "OtherContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r253",
      "r275",
      "r416",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other securities"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r386",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other-Net, (Income) Expense"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other intangibles"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r36",
      "r79"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r69",
      "r778"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense",
        "negatedTerseLabel": "Other, net (income) expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayable": {
     "auth_ref": [
      "r49",
      "r740",
      "r771"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes payable classified as other.",
        "label": "Other Notes Payable",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "OtherNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other non-cash operating activities, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r143",
      "r146",
      "r173"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r144",
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments for acquisitions"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired (Note 3)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "terseLabel": "Acquired IPR&amp;D charges"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "terseLabel": "Consideration transferred, equity interests purchased"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedLabel": "Purchases of noncurrent investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r415",
      "r417",
      "r423",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r465",
      "r467",
      "r468",
      "r470",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r48",
      "r389",
      "r390",
      "r413",
      "r465"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Other current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51",
      "r389",
      "r390",
      "r413",
      "r465"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedNetLabel": "Accrued retirement benefits",
        "terseLabel": "Accrued retirement benefits (Note 15)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r387",
      "r389",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r441",
      "r443",
      "r446",
      "r450",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r470",
      "r471",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r443",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not measured at fair value.",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r29",
      "r31",
      "r284",
      "r285"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Cash received for sale of antibiotic business in China"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from divestiture of businesses, net of cash divested"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r148",
      "r151",
      "r173"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.",
        "label": "Proceeds from (Repayments of) Notes Payable",
        "negatedTerseLabel": "Payments for repurchase and redemption of notes payable"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sales of noncurrent investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Proceeds from sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r23",
      "r118",
      "r121",
      "r153",
      "r167",
      "r179",
      "r189",
      "r190",
      "r219",
      "r221",
      "r223",
      "r226",
      "r228",
      "r261",
      "r588",
      "r592",
      "r593",
      "r600",
      "r601",
      "r655",
      "r755"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Total reclassifications for the period, net of tax",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r72",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r317",
      "r812",
      "r813",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r71",
      "r311"
     ],
     "calculation": {
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r42",
      "r43",
      "r313",
      "r776"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net (Note 9)",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r164",
      "r313",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r42",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r42",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r114",
      "r117",
      "r124",
      "r660",
      "r664",
      "r666"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Net amount reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r513",
      "r824"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r164",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense and Acquired In-Process Research and Development (IPR&amp;D)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Asset Impairment, Restructuring, And Other Special Charges"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringSettlementAndImpairmentProvisions": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.",
        "label": "Restructuring, Settlement and Impairment Provisions",
        "terseLabel": "Asset impairment, restructuring, and other special charges (Note 5)",
        "totalLabel": "Total asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "RestructuringSettlementAndImpairmentProvisions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r59",
      "r359",
      "r506",
      "r773",
      "r800",
      "r805"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r180",
      "r188",
      "r190",
      "r265",
      "r503",
      "r504",
      "r505",
      "r552",
      "r553",
      "r796",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r441",
      "r443",
      "r446",
      "r450",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r441",
      "r443",
      "r446",
      "r450",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofBenefitObligationsandPlanAssetsandFundedStatusDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofComponentsinConsolidatedBalanceSheetsDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofExpectedBenefitPaymentsContributionsandExpenseDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofFairValueDisclosuresDetails",
      "http://www.lilly.com/role/RetirementBenefitsScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r127",
      "r167",
      "r213",
      "r214",
      "r220",
      "r224",
      "r225",
      "r229",
      "r230",
      "r233",
      "r261",
      "r655",
      "r755"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue from discontinued operations"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails",
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations",
      "http://www.lilly.com/role/DiscontinuedOperationsSummaryofRevenueandNetIncomefromDiscontinuedOperationsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r682",
      "r687"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/LeasesImpactofLeasestoConsolidatedCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Payments Received"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Collaboration and other revenue associated with prior period transfers of intellectual property"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Initial public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Sales returns, rebates, and discounts"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r211",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r451",
      "r452",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r114",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.",
        "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r451",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails",
      "http://www.lilly.com/role/AcquisitionsandDivestiturePurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "auth_ref": [
      "r186",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews.",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the accumulated postemployment benefit obligation from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.",
        "label": "Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Postemployment Benefit Obligations"
       }
      }
     },
     "localname": "ScheduleOfChangesInAccumulatedPostemploymentBenefitObligationsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.",
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNetProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r82",
      "r170",
      "r353",
      "r356",
      "r357",
      "r358",
      "r670",
      "r671",
      "r673",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Long-term Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r449",
      "r450",
      "r453",
      "r454",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r18",
      "r21",
      "r22",
      "r23",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Summary of Revenue and Net Income from Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of Expected Benefit Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r294",
      "r301",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r294",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-lived Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r305",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesScheduleofFinitelivedandIndefinitelivedIntangibleAssetsotherthanGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r305",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-lived Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r38",
      "r65",
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Net Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.",
        "label": "Schedule of Net Funded Status [Table Text Block]",
        "terseLabel": "Schedule of Net Funded Status"
       }
      }
     },
     "localname": "ScheduleOfNetFundedStatusTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r72",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.lilly.com/role/PropertyandEquipmentScheduleofGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.",
        "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Research and Development Assets Acquired Other than Through Business Combination"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r319",
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r319",
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Other Operating Cost and Expense, by Component"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r487",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r85",
      "r165",
      "r207",
      "r208",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r1",
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Marketing, selling, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails",
      "http://www.lilly.com/role/BorrowingsSummaryofLongtermNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r159",
      "r318",
      "r321",
      "r323"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r484",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.lilly.com/role/StockBasedCompensationScheduleofAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r164",
      "r487",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation, Option and Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofShorttermandLongtermClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.",
        "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r47",
      "r743",
      "r744",
      "r767"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments (Note 7)"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r165",
      "r167",
      "r193",
      "r194",
      "r195",
      "r197",
      "r199",
      "r207",
      "r208",
      "r209",
      "r261",
      "r352",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r87",
      "r175",
      "r176",
      "r177",
      "r180",
      "r188",
      "r190",
      "r206",
      "r265",
      "r352",
      "r359",
      "r503",
      "r504",
      "r505",
      "r552",
      "r553",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofReclassificationsOutofAccumulatedOtherComprehensiveLossDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofTaxEffectsDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r206",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r55",
      "r56",
      "r352",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under employee stock plans, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r55",
      "r56",
      "r352",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "netLabel": "Issuance of stock under employee stock plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r55",
      "r56",
      "r352",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of Elanco Stock (Note 19)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r55",
      "r56",
      "r359",
      "r486",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r56",
      "r61",
      "r62",
      "r167",
      "r237",
      "r261",
      "r655"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Eli Lilly and Company shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r167",
      "r175",
      "r176",
      "r177",
      "r180",
      "r188",
      "r261",
      "r265",
      "r359",
      "r503",
      "r504",
      "r505",
      "r552",
      "r553",
      "r586",
      "r587",
      "r599",
      "r655",
      "r660",
      "r661",
      "r666",
      "r797",
      "r798"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets",
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r359",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r667",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r667",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r667",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsandDivestitureNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r525",
      "r534",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Income Tax Contingencies"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect",
        "terseLabel": "Tax Cuts and Jobs Act, reclassification from AOCI to retained earnings, tax effect",
        "verboseLabel": "Reclassification due to adoption of new accounting standard"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossScheduleofComponentofOtherComprehensiveIncomeLossDetails",
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable (Note 14)"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": {
     "auth_ref": [
      "r707"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.",
        "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized",
        "terseLabel": "Accounts receivable derecognized"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r251",
      "r252",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax": {
     "auth_ref": [
      "r661"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax",
        "terseLabel": "Foreign currency-denominated notes, designated as hedge"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r86",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Common Stock in Treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r56",
      "r352",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r56",
      "r352",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r56",
      "r352",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r86",
      "r361",
      "r362"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Cost of common stock in treasury"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r352",
      "r359",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase for treasury"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement",
      "http://www.lilly.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrustForBenefitOfEmployeesMember": {
     "auth_ref": [
      "r443",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.",
        "label": "Trust for Benefit of Employees [Member]",
        "terseLabel": "Employee Benefit Trust"
       }
      }
     },
     "localname": "TrustForBenefitOfEmployeesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofShareholdersEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r550",
      "r551",
      "r552",
      "r553",
      "r728",
      "r729",
      "r730",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/SummaryofSignificantAccountingPoliciesandImplementationofNewFinancialAccountingStandardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsMilestonesDeferredCapitalizedDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r416",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsScheduleofFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BorrowingsScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r516",
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation",
        "negatedLabel": "Changes related to the impact of foreign currency translation, decrease"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accruals for the payment of interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofIncomeTaxBenefitExpenseRelatedtoInterestandPenaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation",
        "terseLabel": "Changes related to the impact of foreign currency translation, increase"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapses of statutes of limitation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r192",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r191",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL116659650-108580"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16701-113920"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117332851&loc=SL7495116-110257"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r825": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r826": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r827": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r828": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r829": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r830": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r831": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r832": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r833": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>142
<FILENAME>0000059478-21-000083-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-21-000083-xbrl.zip
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M,J[G!&CL;ZK#R> ST.STQ2$%B45/R*&OE'KG$4,DZYFH=YQM5[B9<HK!WJ5
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M8:^EK3<0JJV3@6: V>D+A$FA\='8RAIF]B1"C$Z]U59S57,9&TT&IJN<G;Y
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M [O0LJD 5+!7#:W1<_ L/HXES/GW5#GNT'IW1D4.)E!V;QCI:<4;43/25'@
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MR_U)EN9-0:CJG910'8#SV<5@'!6#$#R["52KNBK\AC&AOK9 -5B7 "&3H^#
MF%@H18AE"O6DK@R_0>RG@-';"#405&C.%ZX,KJH_(Y5LF5"KW!]^G);E-,TB
M %0*G$# %=4_#0.;TZ&8 HQEE]B@R T4MD,AL89,RPZ*YV(DVQA;,]49'R=@
M,Z\ N6&2#S/[HK%!4\GK85YO1^\T8.=&I*HWH683=W:F92T3*AR^)DS!0Z_'
MC6Q]=+E$,%S!3L=:7AYRPUA+=GT7"7JT"0%S)FMKC=F%&$JB/):R/L,B-TQL
M3H:=0#+4 F"!G"VX4'JQ66*P8?S6\OU*XOWE2F8O%W>.D9S))"<\2[0^L4NQ
MF 8)##)6,=X'49<SNK&4P]D\. ?:;&-L]&Q+I!(@^4!!8X>8P"NXR4VAX<U0
M< YB;(U&?RP2K4$')ME2:_)(16-YJN+.2LJX4V-KG,--@_-LLOKVX7JVD/7Z
M5OW?P]EZ=J!O?@#TKJSV9BMZN*C?7+Z1=><VLGJHPXLPLAY;4O_&>D1@1C1%
M--ZHU9?>ORS^Z^$->O\.O=E",=)C?P_(V3O_#2#L (.SP;*&"I8T @1LD0A3
M,LQC*-4T/#+#.R\5P <K"*4D<!RS9S*A-6,2<*AGZPSNU'GI)3%&">.CY=OE
MXT5=SI<OCRX?R^ZYG--&GASJ\@5@&6*3JH&[]:%!K3H2C0.J023['!-V&]DA
MM.$Z0'@N+^G?)T(^D;G>^DH'L\6L/'K\S\<.W66:YA,>V' !IAFM%2:ID6,$
M5R5S<"FW&#A'E=%\O7BP*:A$1MM:*BX9HQ&%R2V%8BC4G"1D>Y9LKJAL72=X
MSGW1^SH0#^31[(WPPX6"\')6YG)KO9:#]>VC;7JU7-V9DWZG3_([[B@"*ZH'
MMVG]^X]=A09\H,X?:L"'0_]*]I6SZ)(KT?D$T4EAJI15"50-@LGV,ST?K5NV
MR7I^87MI;2HU):B&,J3 I8A7A?>]^SN(G)5T\&>AJQ\IED]F!ZNCMT]W947[
M<G@PJ^M'LST=ZWSY#K<_?R#K+RJKO$+!6K+S*@-BJ1<E-&+ :F#K6Y@*J+?*
M'9G/%=+;LSY(%=2K":&N'E%@J,&C.MXH(,65T%(,*:G7+6C-66G)<(9H&"FB
M/QPNUKLSA?.T7>D53.:'\X,9+FCVUW'UR0?,#<"XC%7(46W5JP^=7)P*F,\6
M/%O7^5+=HF-GZ*.#I@BK$?0Q9I^L=R!67:)J1*#4PC9G<Y;.%<]@C=Z,$M9[
M;Y:?".GE8QG/CV7<\N8BIH*Y8)$8#6 $6Y%JS-6SM2D:3^:T&:,:WM.91S/2
M(?IPL5B^T?-]+*"7CJ<UYY^"-!>T?DK1BO[QA0C$(:9&T13;=W!ALC(5/._.
MUK3:^WAT3A30[N$2-C')96"3<T"-8IQ8\+'OM3\%]/W2@!VIL;V_K+O+Q8^[
MBBK58T1IOGYT</EAB_T3ZP3V8HRNH.MEOW)M#%#!8[3!J7-4 5G'[AC*E)XO
M;+GS<&_O<"%/;DTQMZ$PD7--HFNU%UW*1L=H)=\J09%\5M[<GZWVC#7X[!CN
MZ*^^FIFA<X:<)X=>4"][0XY-XF88^LZ\U((.S*2#$=3'/4LY@C,<8:06]M:;
M&>N7_2CFO!I$X?R(PL78U^A1G/=1LEK78H%")I>+<18",I[-VZ8S1--(1^8=
M/==*WNIK'SM"=Y:K_>6*+C_Z[(BE\X.;+F@B%TPIZ-4+JNH0>4?>8&N)<B\H
M 7BVL>%TN.;1#M<GLY>S^:?(7GY*V7G':KZPL8HN(K%MF$( \D"MN,S1^]X%
M,>9P"F<\@W.LDPFW#E>OZ<2]O7P8SSF/<'+HQ9C<C*:X$IG[%K]4BW71MY+5
M00)KT$\&QI^W'U^M@@X"9V8*XDJ)K0!X!YDK&/%&W:.>.WB6MYO.X!RK@MY:
MS/;ZHLJ!U-W+Q_&\8IDO3"P+F%A]S%**@D@139!@JZ()L4@ZM:ZGTT']P4AQ
M?/+PP:VGBN'B>';O"I*OSSL3='+H!158)(]&W1\.#=1^EA8KER1J7E/?'C\5
M+._L'KZDV:<S07>6>_NT.)HDK(6CY5#1$$'?M>2CHV@\V.K8$9_"^GZ+Q%@G
M^/H4PIW#E5R)9)YW4N_DT N13!L=@FG%IBB0JR6?0^G-[JJ-T$P]Q=%M\%:7
M<\Z\5UDMZ+.9VLM']+PI0Q?8YM*)4U.;O)0,@5WN*27>!^YK*20\%43_<<3'
MF257DXHP#)8N5S9HHQ<D2*;E!#[64J/8@"'!5%(1ALH4NOHL!*28O3>*HPG
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M(.K,'2 R8JHDA1"G\+4V>BS1&WX3\WX=7C2EK%&L.78;G()2BMH2,*:^0F7
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MM;CM-KD[,IX5W1JUY9B_T'$B;)(AUVQE3$?7U%<H+]AZY#;1/68A])@ '],
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MO,OHQT26033$CUTEG0I"NK8ZI,:4$@O[ (3O$W!=4>"2+=)&1ZQ@<#33M@E
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MZ<?K^"M<O2F10V_22YXK6?EQ&]!K]SYR:7FA=?QG!O>G5_]XL^$#_%/]XJ_
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M @3)A"<C*>-![@U&RZW2GX^'_BZ+?0'BC[DNBSA O2CES)-.).XQ_0WFQP]
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MF;C13HFXP<+8.NKB#,S8-(FB!*C+\SWJ@RSSB?!3X7'A>SM$73_U/GI41!P
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M5N@6&Z]GN;2($ZQI[P;KOW_[5>_^@JG^!V?ZQDST2,US)Z7+C>I-D@\A"0"
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M3Q^N+\E.LPFH4BRR\;J<T.)*;*Y&?)PU\#"^).;65[QPEZFO_U^<OI(_-)8
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MP31UEVCCSVA='M81/!70M9"#0^-GH)5!3._$3K5UN=VAEN&]V=!755;P; H
M>A$C:SV7TN0PR.HLXT-LUD] "(,,WH6=(FWZ@CM4*+LW&_KL\SAC6;-:3*'+
M)[/>\+$4LWR0PS\!,;A#5[!=V*DV,<$=JHS=FPU]7E880F/_QWHSFTQH-=_"
MG1W$[6;WW/6^VNKVEX:R7+;?]];?3(8$,-MI6:NB1X\KY>LZDT_.,]&,U4R7
M=TWOY&-G<0ME=9G/FHNW7+J=L!Q+BWF:3<!:.Y'GUNMR0HLKEU6-^#AK@'CX
MTD)'JPOMX5R\E:7I_1=?+!/_^^ :+87]!^U-XVK!!2-ILTK23S9-@8(?T_R<
MSNL'ORPMV20K[/YB7[:TP*\CN+0IIX\3Q7]ZUJSZ975SV[FO76'.+Z[P5\DU
M_LYU!6%S3BMAORC+3YB(NJ@>L#S=]:\8=J]X#0JY&;NIV9Z.L]HZ*(H9X-+7
M<EI6#>;1+@0F(M=R5EFE2C.8SA@L0CZWZ!G-<N0@2Y1\IA-RLX+G,R&Q(J]:
M@-PL0+THGX YNUFAZO5.)"WPUS+%$KO(,I87'>!'_'51==<ZX U^ZR:^;UP7
MYFKWV9JKGWWF*FFX=QNQ'O:_?:1=TK225CUC'V$TJRG5,#5-I36F%2LKBP/Y
MHB\;7UNRN:7DD+KJ596=861>[Z$OX)^1DE>PAIB(L7AZ$NQ;1X4UI2CX9SFM
M]F"=NEP-BTZGDE:X#OH!__./V/.<)VT_]CWUV7W2?M]O(]S]AF]C?K^5DF_M
M<\S^UE_9X'WK^>6;W]('S?/^U\V8-D!%5E$VEI*SL!%E+H'(8%N .N%=465:
MN"FSJD*S*845,"<+(UG _'.XF@/+, ER"Z[(T@SV#K8--VQ62WS1\[(2-6PY
M'UNT;A=L0N>K:\QDGLDSN?KU>9;GJ]_)SU,@G]5OIU7Y<<W7LFXRV/4+ V>@
MY NQ^BV6@T+WW<7KISDM5K_C)2:]SQ;7PF+5&0@)6EDPR4HJ,JCQZW36S(#T
M<37;#8;%!6#"8/>V44)]E:*0.XL&=C\KSK#QJP6*<FY5P"::G&<%U\=5BD\5
MJ?%RE@-XHT@60$<H^"K##D!P(DM3X$/<*)PZC)Q6Y03N+.%RLY1 6B#$OL8%
M?^&\]G3=@OGE5^Y9Y]V@<*6EZ4E+!M@@18DI4BM,S.Q;.U7X&8BT0#;(&@NX
MFE&<%]PXZ<N EF.0:/2*])X!]RZ]T:@L!? 6UE7 *PTC",6'%.N2P=-I#?2"
M<A^>E\&;_E&>PS65>A/DP!&&T!4E3+J>51BVK!<=ET&QWOI71.8RKX;?JH\,
MMV>L9P#?4<[+R33/ZK$4*%+/)$J&6@MH6&&0&F.ULRA'X'7AR2!29[AB>:8F
M4GY]ST['J+KRO#S'7UIA59<3>-=9HX9%R6543JJ%\)4DU>W3E<2UX'CQ^#I\
MZ"- U?:&C<:%1BP*/V=XP-H\MO&;'\JK2OR$3]KI_Z@'KZP#V5<).KA-V61*
MM2K&3Q)E!.[NTY=_'AW:;@)Z&99JDG%%\'C)*"^9WKXI,(C4Y-643X8=V<".
M+$OCRH0+ &,@PI0I<*?A$V"9O)Q:T[)!90[[T2 <TT(?&SZT^S=LRZ88I<Y&
M!: FCJ>$O*R;=>K3(/<I0.0)R->9<F4@JP"$Y5IGF)U3SNTI5H"H44$I68I\
MIVKV(&_U4#>@HK9>C[D#V;5D^%C\H9(CP,T@;.>(EJORC.;UL.^;%Y"4_SW+
MM/-";SXS1LC2IC:]V!YU5<O%"&-'VI+0!#3LT:;V"#!39E86]@D7.L^EAAE3
MW7][CG\TQC!& 6G85G$2R%;X5<RX86K$4;+)]+6(/Y0-I77@+XC)LK*U'=K[
MAKW<Q%[B3E"6Y1CU#,+/;)E&Y>@3 (R*\*^M,ZE=+FNW>]B/3>P'7Y27T^MN
MY?0<$;M1.4K&]5"*H V%*_DGL*^ *4&IU=E9-NS&AG:C%4M@0/8T#O "&$U<
MU?3KK-F^.%/R+9M*?,JP$YO8B8FN+CZ;-O23<IU5DFLO2TX!$8(!/BB&C2YX
MWR,,*F%<P Q&<ZN>UW@2G154R+]GE ,&W[/P7 6V /X"055JYRVP1DJS'(NM
M#1NR&4.5SIIQ6<$P CU/RHP170W1/6N2U<H8F<+S<=OVM$-U E_!3XII>%FD
MVAD-BKN_PV5[FJ+T"7JQM/L-!=G1J=EU>%XAF_.R^F0<W2GL?ZZ.&]2SM,](
M^36R2NCS!6F*HIZ/ =2=HT,,#SEP6'S20!F;H0SMP80MJW6G\%*Y+L 4YG/<
M<T#>:!G5=<DS!1S4EO1!^+ 1F]B(O#MS0P<#>H/-1R,9%8?U[!@N)0Y2FY,"
ME)E36C=[+:C8ZQV.=/A",_5$5NI$#,W>,WWB1VMD,&0O&'Z$AU6US%/8&A0/
M8MCAC6A%;,IJ1)K9$:O&VONPV" AE==(V:\36LS0'S]3!ZGH9,>C5K5/L($@
MMBN ,D@9P[YL8E_Z!RI*^]BH?>;:4EI*""MG30V2CRO_7E6AM:4@_; /F]F'
MSC':6K(+:-$SH(;5WO!JM^Y/^(I6HF>8@F32ME/?0KK6H?JP_%=Z!W2$ RYL
MI@2*.KA6/;':L[N^+UOO$/PY4@6T5+>6W!PRZ/B=*9VKN@*==Z$=N$SW8&NS
M"9M5M0[3!^QN@H:4*:"<=TN'( ./;62306K1?&8<;SK$ FXI#'L!OI9M'!?6
M1M/P;.'#0T\ID$.C?]0;!G:75DK#!FW88]K0S^@NW5-_F!7O!3NHH"X=[J P
MFO)] [].IA?<JCA &S8[B,O-;!0LM6R40,RJ1><JY(YJU@)EV$PP70;1=0MG
MJ2:*!!1$54I0726&F'3Q=D9C553(OG5BC)7I#'AI8(--RRNZW!JH4K'.)@:L
M$!1C0]%Y-\M'2BZ9V-%%.&ROM=";[H[?2OBGPQ^]B&#\J@LZ?EJ"L:H#<1^^
M>?;TD0K9'?9WPR:0B@Y4=BGL(\OE1#'4 OZM>(GV+]V 6\\ 69/J4^$CK[^/
MMYP:XE^>&K(]61Y;$)J\B$(UL:=@"906IY5,9QC="8LCEJ)%A:QYE3$I3+B_
MSC0\V%L7W[\(NT<ORU>3-##B@YK!IVV<2!L"HH.A%W&J (PG)9HYRE& ^1@C
M@&XZ>%6AM,MBHK\G$/K""JGW5B)73TD'+ZN8W1)$)$86J] (*3*N8H%-//]<
MIPU@"'&[F#A&+^87U&N=M4D:^J47RTU9:1HK7W_A81X8@ZPEB\2TA"YO&TU,
MF,XB/O&2B//+A<P=4NT!S/PK.3KU%%@:Z NS?.HV<E:@Q:Q/FU8IL4VF,30!
MM_V-O:M5!H:.&,S +(#EJ/"TQ.A57*^EC03Z4ZD(U7Q-RHA8SP3[J&+EM,%Y
M9FA2_#W+*JV[E65RWI^4.KVCV42%HH-^:!-VD-K:K"80\I*J4&S\^RS321,8
M?'_Y<L&OP.X8H-/:/DH:7K%J=ZA]MD7)D(WD'X8;R3_T]J-;54YF>UQO8ZP>
MK[#Z^C76K3@NTMHU%S=YL.:5EH"8'ZX"4O]2<?;#,C"U<-__"D3]05.Y %H3
M13YM=M]5RL%0#2[Q':J+9WEFO<@0SNC.!&#D@GA\"$)/5I7VX%"5AJ,4)?RV
MIR]'^:M<0K/ZD75.E3!OVQHH@>XFCHO_'H%93 N* X%^QW/:-C1<5+/1RNE>
M%Y2<EJC)16^ :9EG@&3,)Y5]Y<91B.K@*:Q0(7.K>Y=]ZR]E>_-2)2^9XY*]
MWL.D=B":6*CN1!@M20NF,,(4J'8NM1RA,D#@X'I/QC,8935*OAU 98,>JWAY
MSW$3G3=E (;&BN@",$*\#=\MNQ*Y\/AG.1@Y):B3; +C_B%IWHQAT-[:/M27
MJ$17^)^Z;JRO:Z=\)3#9#MI[B6$3,W@Q4,J9TK6S(FLPTZSJT@G:750QM3IM
MUYH@?,07U2!S@G%L $E@RR26!U: >2I+6'6 +DA(:N7/RRH7^]9Q67<90]V^
M8SB-!.#4E(+.X5.U(!^=GV9(2,,/LVE6S3-$/G6;K8K? R6.;)C$1%.[BJ_'
MDIBJ@?%*B+ Y]5"I8NWC=#*<@CH]PC6!W294 9882*4HSQ1JL K0X=V2[,C6
M_R7[S*B32V A <[/&KD<U-Z,80]'XUZ(5)NJ\A:I1>@4_-IZ^';_S?ZC?C[*
MJQE@]=)ZG?%2+V%LS"+EZZD0P5LOE^+G*Y6=K,2."@#[K')Z87M@UKV[KH/[
MDXTIRM45O00,F)?81IMD:9$-ZK]6%N3M373](AYF%&2(K+O9_FA'V(-?>P1\
MW25Z<@5HNU=>Q$LAVO7]BK_1OS%T;(/3"W'@:\SF@L6'.VC[ZN[5ZD%@JNK:
M//_S#S<B/]PEBY1(K8+6"&_*<Z'UZL1D3B@=J_+[VM1-U*DU)HM+:SR?EJ-\
MSN4DHR;](NL*A("<USRVQ<3]332V ^1>TU%.J]NA]V^<X,YQ@ )T5,>0:.R/
M8:"Y*OY \W*TGA-V@,AWF:3_@(V M1\D^%7T>_<;V&V6=9Q]MJ+@%R_8^_$K
ML54+\=9V'6>3B_"#Q?&6+::WV<7<18I"U@J<7P+G9Y4QK4[.LQI,MY^5')97
M0:6@P^,*>2?(:1$$<Y=+8JVLR:130K>S8U^=S#K\6'\=0%ZW:-N (+\90>(F
M# CR"CZ^^_T#'C:;947.+[ZSUWT\6?SY^B[8&5W*V[ ^[2*\M0/G+A# -JS!
M74OSVE12*"<,@TH;Z_#DP"JK;)1=XBL;/ 2W*M__C;E;5/6A&R3\UY':6O)L
MYE-I>0L8HD+Z,!A*S%353Q/DA9&(N-+E&:U5 61+P"!C=8 FL-[GLN]WW:BR
MQF+MJO+GA;&R6D5L#3QR*SSR8CZ;?)1G X=<[06NZ#03@QMXRPCXM*(?,?5S
MH.!-R/B!2&^)2$%,\*SY\=L^'_CBEK'/A'[$>"T!;U;+5?1B L8W"X7@<1.L
M?H+!;2N7]*/NMS&XYF7!=>6S(;CF'HN[@SR;#!KY^I(GS:JZL?&*A1!2T<W&
ME:"B;;3$."]-_"(=Z=X0F*@DSM#*Q22IPJXGF+?$,9(UGV$../Y460]/WCQ]
M\?21CHM=$D+JIK]G=%+.:GV?:LFBN!0%4E%:SWY__AJESL&+_V I897KW,PF
M*/:8K$QSF2??\3JTZ+W,FG=IIZ4FOWA C1G78N4)5]Y-:VM2Z@?2Z;P;;$)5
M?Q;=R>*:@RU'-*F$N58XCZE)=JO*49M!-\'07!U$NN@_P<=RTDVF>_ 34]3B
MBK5:K[0FBK2IZ@8B9Q7FI\L:[\JS<D('87<KPN[IO**3+X.T&SS$:Q^9JOP8
MN2I],._U2B:'>^@UA!WB0=E03%D$P3RB&$//6\&/&?+X36F#*)B.86 0"Q]G
MA:XD3X&G2\"0/ .I3I_<>$Z]>1BIN\$1U49A;Z'<O-P3?6]_7;\^V%B"U"Y1
MR2FTW'OQZTE=-?HZ]:;WXR+"7UT/,RB6F=15?>44,YHQ?V=4E>=-F_NL"C)/
M&X7T32NGP0-Z._+[6<6R9O9YD-]7FTT"9J1*IY3->%6@W0"VM'4,T!RN=6'E
M%4:O-8,N/W(]I.S#JKW+Q&Q%16:2PU?0X-<G-L9R#PH42_ZIG=N5B=XF]_CG
MK#02W$ZED=O.YQZ$Z7<)T]>RD6>3<A"FW^5TO( 6+O@-GZR_L8."O1' YISE
M.9;;:,;SJLQ$BPC!7FTK:9A2]&C.&SG8/5$5TE1F*X+)Q?-5I?KKSF'ER5<,
M_O69M55(4':7"D%)*RN!!.U*II5"3?,!(MW.\<7\;+[)LXN?B:=Q[M-:6VD+
M0K5X3NL:J/N/4HP^9:H#LQL]J:U\/IF.00\O\=EE%L=ZQ]0%M*/=L9J!EM 8
M7/QT#)<.;',K;/.GK+[((ANTX;4XY_I.$EF(DE>*&[Z&WO]X_7_O67\\>^W9
M?96$*+-N6HVTC6=D1Y/)K!A.R>Z]>'B9SR89+0;%^GV*52')ULU6"FR3)?,Y
M$*.M4]!S7<8?4&(UEK,);1"(TJH98P'7[PMTB;PMH.DD<KQMI&D2ZD1SK+'?
M9$7&[B !"XM0C2K@*<!;SR:R&JF:\F]!LQR8;E]:C3Q\]O;@$>H6S_&<2^H8
MS&K3!0I^S2G#RDNZ"FV18L5MT;6H7N^'JN1$2.P>6:G?QV4]52NK^HUITKW$
M"AK$[>T8,31OO@RR]B:R]A*"!6-"6*$UE[32#6IRK!2R))@78MF:YO3O&?Q3
M SO2&NNY]26Y$=GZ5\1KG<1>N:[X-,_+6I7JG):%F.?FFD*L&P\M)>4X .DP
M'>.PG[&HJ[FU_%:U\$/QX(F<5:6J,\;E@ COLXAZ.I\PD%)#+,%WND]5)*:0
MJB"P:C*<@1@1JORC"K%$H05/G*+5F%L%\A4(L;&295FQI]NDMSJZ^)QA.>/%
M&&G&JG(RI_DHHZ8<W[@J"W2USC#\LJP_R5SBH16.9HF9*G3=7I.7YQ:C_)/^
M4?6UT3_T+R[K1GZS,!JX[!L/?"<CBN47=[?XQMWRW20#)8K>%^ S#&]6<22F
MP.82/\HI\([ P(U\5F-13CP^Q=;&W4' 0.*W=0PW/RO/!S5R735".98<758F
MALKW3'M?#6C+66/16:5K#P\D?(LD_'X.XN7S+4&A^R^D+_HS^#C[4D['E2P4
M?%$4/\D^F_A!BE!$"VQYL;DURZ8E!LP=]> 0BOSV^UX,]39:4"]-(Q0\+,CD
M8#O=1WGQ&YWD0,1GV83>@>?Q,HLDRP6Z/EHW2.<S7*B/2V,A5%-L)7G0A6UZ
M]:A\8@R-L]X<O'YC/RW_M#WK+$-SIL'65\5(^38[)ZAQ<3X:B.[6B>YNBL_<
M_<H\^-7"Y$5Y9YQ'Q20K,C0P5%^)D41!O]T,Z6XA0WI7+;<;; U#PE16&-+?
M5ROQ%)Z3;5+!7\/P49/9%8BH-O$2YI!(QUDN+3&OTRY#!&$>8,91@;YG$T0Q
MGD]E-<UIG0VQ0[>C69Z752.'R*'O@UW*C3HM@5PSE7L/+X6_E5,ZPU+VYR5\
MT+U_\-_&&L.0)G6^Q"Z(O8XD^,4HG_&28S-97F8"27:FTJY6GM(.NNYIU^&2
M']TMY%@U/FK;Y1ZVK5=@\^_6AEN_U7^9]CP3T[MGJ3^,ZNMSG@FINCY10:>-
MNF#2O>($4$$IC'+7MUER,AU3LWEGM,I4 G3;X 7=\1,I&RLOL;L3G]4-;&1E
M%5*:8513I[G&!?HBTZSVZ\UG[Z@'SWH:P'XY6[K;V*NY-(V ],E.OT67ZOT#
MD^]: P&K2>P0B8<_6 \(99>.*.>8$#^;EMBQ:UYG/*.F/[<.A35]L["G*SXA
ME:J/,\UK34O8[[6="I"$OKJ]^ R3]PSS"]4%["-,%V_6#RA4S&[_"=@PNI!Y
MO=?O=91G#:+15N;4%+N%U?T,I$4GI++W%MH)(S^/,Y8U*,C:62#A8M=7U8L,
MU0O2I.I$INJ4-!E6*ED=6N/8O&U+5<\FYMVZM<:GG9N,>;SU7#+0%M)@XZS
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M'57':6<: R63D[H&*R6_ZYVM;,95/0"O@;N-RW"--HBD0ON%[N6-WH%<YDU
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M>TCWL/F\ZTACQ>O.D>(PFP.H*^WJ( (B>R?1Q)'=!!W/O/G@6M6%XHT,#7,
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M\U-Y<WV ;<Q5_(^<@B?H-P0CYC9N]]?D-HU$+G9!+5;HMR,.&V$RHW21D#_
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M!X\E\G-K8"L24A_MXK>3\&^*?6C!WGQ&RI[/FC3U:7>JEU9%HX@:83">2%K
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M#"ET_Y213;N,:=\8/'Q]TZZY-2DZ!28/M8\L+X.BX&:WBP^(2544U3GU&F(
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MA*4*6)M%SS/Z#'S4+0EAWILX06=]!D"4@G+LM<S#]!/I:(+DZX/X0TO4+ F
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M/J9F^X$DZ7?.VV?%97%((Q6!F4V.,\Z'?DQ:E)G:"C^^G ")-1>VK0NCV<4
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M(;-$JD([B(K)Z1.:H:H&E$XG(@F%*W-B* YF.])$=VZ-4J9-KG_/N%1==8]
MQEP4KXO4N9%!@/\5S@0VZ!#9P',ZJ=)^-_[62_(Q38U'$IK-O[;M?(V=84*-
M2OG141*'S#C,;Z:D:0$CX&8+: ,XF?@F%57">J[PN.X@!OQ M2#EJ*V\=5%,
MP/9^[#E#/PAH5OU;M55<A^?<(WL!L!*]:NL.#HT_M@OVX1L@3HF("2@)(!C1
M'S;/B*YEFO')+A!& &^XII83PI:<$6C5J7J&K4MS'?"V<2)" "_LDL;6CF5$
M+7F=$8[&=7VZO"Q/HK1-!*DN!4_A^5[!X,1T"DOBUZ&?JEW;%XTL#R\+ 0HT
M!>_&TRK0Q@E]3YT5X@@X&C)6;BX;AC*A7:2Y2U = MBQ<0) 5R(Z"G>&OT_%
M"-O, 9,&E(P(?@) [\-G\,9XR"T/\#T^]:( +,'E!/5V6&C>D.*C4S&3V 3"
M#X=YDBJ.C'U1L(?%6+;,+@%CIK0AH9-_8(.P!7<BHK$T@7S@L9*\5(4@P!OT
M1.+1^_ 9Q>QYXXH.X*NAS/#. 1Q3F7&WO8(Z#%D2(!CY\ G&1T+@*!\)%VZ1
M.U#XT8AT53[1B/%.9)1T0%]G0&P2G@>P3]'UD,#2Q,()J:EQ!*##9PMNF$:"
M/("[(N5$-X!N(+;\=,(D.\D3,)92ZGR!;S2WAQ2DKF^.\MO.:Y!+LVIFPX1K
MVFTHPL$]B$@1 ",AK8 \2:&NZH_,JP9((1H-I],XR?((8-\&-1[U/1)U@$Q,
M_D/I$&LP$*?^-PGJ$=@#Y%KBR<&,O<F80Z6+!ZICPY:_B+_#'2[GT^D4% OB
MEVX2(V_#'B\ K!'8SG%9K<+S&M4*^!'? %P X1Z@<:A38N)1BQA@'!$Z8R)\
MP8@T?<(A':9X45)TF+CP7G$O69S=)6;T]@&A&#>)'OWT6S5J7<?!=>&'6[JJ
MX=4WQ-5QUZ@3 M+/$/G]4"AM%,Y+M)>AOCANT4),G8KZ@!8 F*G%E+*8J#V0
M%0JM:M!TU[X0EK"Q"/D5H-&-7+*S48X[LVY/8S$Q=;H,0'HM%#R6DWAGBAV/
M\CN@KO;1=MX(EC5TPXF<<N_0E'F]($12<A_W1/P57JQ["#&\L+,GJORH6(.2
MG9/FB^<@MRKR>.I9%9$WA_:Z=%]H*42I;#M_37R<!4\SVP6(Y!#YF30=<I8N
MH.X.U7!]J@"_)MZ&[#.)")1T,""::9Z VBP94\*<. XH$B5T1CZDKJ8P.(,@
MYEX9\-,T#DG(W$Q\%S/) C($J.FJL5\BZ5-7'X0Q<AP?S09$ N"0"BK:HL+N
M^U/5P!UT+S2'D*3\-.1^2XF$P\B6@@[B-HGG-$?6YW./)853JO4K278\,N[K
M'H)D" YG&GXM_K<TAA3@0(I&E_Z;*)@X"#?!!T.(E$L'C:PQR*#E!D^EZOWD
M(65NA46W\5Z@]$Z?B?4O-8XJ'01DM(%JJ[Q;/X/N*!/V GPB%>&93W.?(/,D
M(@IBH*71<*LKP.>0.&ZU@@/_R'0I%BJ*2)"&TQ)3!(U.@#8S"N*;E)D2('<$
M!%Y3N8Z-V/#0R-5\"R)XO+= IW++TX >VW]OD^[&%4$(HL)/6!5X#;(Y' (>
M]3K=,[Y^Q W43#1@K:<O\C'R>7CV'/\,Q=\ = [DB4CW[S/F+X7Z?@$T51&^
M^3LS#Q9ON^-E5$P TDV2I'/1 DR( D"OR4.D$9=[\Q6FHI:]:%"Z_I0D!;PD
M(96<Q#^P6MS$T(<+!/ *RQHABC'=Z6"5(&;SU^P43%G,>LYF2J=*9='"\(JU
M+#$>@R$&/R"1HS9N?&=ZRR2564,AY81DDBCT .&AX""%"G\?1Y5J 1R8+9FI
M3"QQ6U#W2L+D&;PQS@78G$7R\FZ0[?:IU@%4@]4B:DH*^H8FT)92GBP$0_LM
M1J<MD)8JS66DG1,'#'BC/?V> S+BC):B> <Q:([,W3@'&O*EDA;ZQ^\%S7?I
ME?M8%%TH00\#\036#1$W.4N8/ &Q_\[!;$%[$['6$ ^O0"++_#BU5D1G3D *
M6VI,&R2,D;B.$\7+(K010FK3"=]B+3+\.H!;'Q.)$#^A; 0Q!HWO4\G!EZH.
MU ?TY2%[>+!I,BP$9,V>ACD>>H[ 3V66!9+JL+2%6;RR10HP<15^J3 N%YY3
M$"@>!0(]MOU)=(\^T+@V^=-,L"9NS]?I.0?Y%#>!NT0WPJVVBV#'@&#R&VB[
MTVDP.V0713Y,Y;]S/$D>Z7WP^\WR%U.P5VEMF_T:+K; 46T6:F=]*#5>65OP
M/KHH4K7C/'/1$E G5MAJ;AW5G569<8MYJ+:N,0KF\5&Q36LET\5OM\YS]Z;C
M]7&G"4RLJNBCN2MN\'^)O'1G8:0HL&(U]S-]>HV?L'#H:R)$["5\1"(!5I4E
M\I99Y)U:F\@6R#A.4G)DNY,XYM@!VDKA%,.(['5$GS_ZG=J@@&LB%<R>D=S\
MU.($7W(PB('2+S'A"S?W*Q961Z1#_9X',\XS0V\)^N<+<K\A3S'^AGQ;TTD<
M>/I;\@,HWS)2J1)KS!M:!HKJ8,JW?R,IR<3FL.H8N!6]*PQP$]=3@ _)$\X.
M-!0KN 6SKHFWJ/6L=<"^9W<]>4ZL(*L?_0T@9-9ARR^2@E_0F:%$2Z_3HK4_
M"=AC ;ZW5"U\%:'3W>5I:PG_*TVIP__\/:P!.@+U"/.7RMYU.,Q;\G;YH%[\
M2PQ]_4Y\?NZ;7T$[F$KU@)EP?8#9)I*D<0 <&Y\\M-%4B3AN$LW7KL\362 #
M.8RB/>-7X=M)[TEI<!]ZX8"4/(I<.)X(,<Y$8-6]H%'5:2E*$^'\BY9<DWGG
M_Z!S\5KHL^.$&!!R!^KC0[ZM0% C;8TJ3,@SEN7"D-KBR35F C21P!BA6JL?
M\:.;Q66\,1AS@4&M0-M&'R0*Y4!@-$U3'9W>)CF#/)1UD =2L8I%C '4))12
M)>",-)[*5D"P\6#,I9=(>TWD<,:TAC##C_^15L'(T)M]" 95FU%B@M8@G9>V
M3,D5ZBA*U;!_6N)-;?WB.R[I1G"G<G;Y*NZAGR_S%L7^K->U'71E+%'JE3Z"
M?>8KM&=V_:0A?F:Q\CDUNH[FWIS^J&WX.W5(RU)9+KX*]5"IF;:6R$H<!1@7
M[* X66+4KZM&MH%=PP7#PD[W1*-726$LHL]$!Z'Q6X'>&=.:("$"'B*+1I:F
MT4".=2Q0(N=.K8D VL"H;,Q?M ]$+T3B<9PFC.%YCG>V%DFXOFX"5[4HUY>%
MD/LM!R*(QXWOX![?P0%PV#S I L_!40Z),YH.=N8JHS[ZM<@'E*D0P7#%3_"
M$#%GI"B4%-D$M712"CE-P-&.-%L!+;\<PZ>%<EE,]A7SOUW\*?4?4(&L!19
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MD7,-@YTT3N1@B"/P1S(5Y!S$=&DPV]1/-%$IG'$!97W S 8'-H #6@PGDEP
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M94>"66O*MY3U^UFFP ^T&#,6\$6)!X%!_/G+Q6$I/^,UW0P@':<HZE8*YF-
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M*I9//T.?HU8!;+RA%A<ZA08QMNBIB?T\96+PI0*EBMU$<70T)<=^0LWF@(A
MF/KL3%=)D_1YX=2D>)#B">I5'N<E# -,CKZ$][+)A\K 7&BO: # K&O^JHI;
M09V)?,]*;1P"0^ F *IF%2QW]IBGYC2Z:6E+=RR%9]%)T>*&L7QC4GF401UK
M@;:7J>)4[1AG/9B"OVWG3Q'D(,T("(5WI&5ZC*LP2.KP(^20G?A2-0@_P%SS
M.#NDC')B*#Y3.+8(00A2GAGS5=#E [Y(E5\* ./1LT.9W4@JJ)TAFZ7$M&5
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M6GJ&9=/$ F:KV#0R#Q_-<)QO9L_!I1^;U5G:P86J5&:1)$+U1&7O((_CM/*
MRF,!3=)Q:J7(8,:R(-M;^<!I@<)AHP)RIG/,$ PI2ME "TD-$U+"<L+I*]C*
MBZ.+[">P'9>@=R [UGZARGU20I217I3\*%1KB6*D$K8Y+]^,R7U:'4N?F ;O
MBS9COW:RM @M,)*#;B2"'TF6=_%MK/HSZH(;9='B%,23]KD9A-AR(DD)'Z0*
MZ>7:SA\4[D3(X8@PXY R,9&YMQ<72O82(I[RB]F376V$3F4 $AGE7N0/$3]!
MMX-G/[_Y"@]-_*&?Z5;X[S[^]\>C?F=0//3+UW\5#YFN^U5M\G3B$*50Z7&
MI5<[!Y]E)J_#^%"%>#'E'GO&!&K&UH5N56TKGG;VO=7-6IE\_,V8>M-/05_!
M!GRZ )X+IJT4*(2]'JNDW;:DQ40C'S,<,6F3IXO?W\>G1@B*D%^.H*\QPS81
MRW'T[/B\W7?"E9!T!00-Y##QO_G?\U ,*6$<$"%HS6,JSFR(8C=0GI7,'\8>
M7B@Y1!3G\4QHN A[83?"V"-\ 8 ?J8YO<'53K-:6E*>:^5C\86V#>O".@6/A
MFDL&:1LS&/"7)SZ0PTR?ZG^#>G+[O>D/>%\V ]QH-L%KYR'A-&8-/RJN,J8,
MD?*5<M\T$'JW?D#QO<D,V,;$]Y(8(],'>:3<@P%'<)2Z3UQ$)*&3WK!WY7!W
MY$HYZ7\Y^7["8),?J#G@Y'9*U<@1]=7A4M*V9GN 0/_Q[*RCR9S8'E+X-*"6
M.I*R%;! A;SS%E<E[8!GH#H'EW]^/E2>KC\_<ZH1IC[J/:99['[3.4L@_(LA
M(X73:VY/W9-B3U,QP[>W;,>(SHADSJ-D@:>5,V+YE)]('>XKYMERGHG>H,YO
MP/;8+$ YN5&WA3;V[,_*\T =^EK _6CFR;_@&2\.6[IC?TOU=6\Y5Z##SR@N
M]65*B??K"O6A'QN%=V;:&2J-BYW'2JL*J#8"W=A''-^B\2L7?YZK4 ^Z.U4H
MWY?E4",[&"+L/^A)-=I254+@>CLC]4Q50W^]H@;=21P3G'+V;YB>UZI9H<M*
M>&$!K%D9O7^9J\?++7P\F>_]UP^^.)-GP\[)J'-\W#F6)Z-AYUSVN_UNIW]\
M/AB=R?][TOVA?FZ!2A"[[B-1>LF\3-,*\S/[4*F:L_>*2C+J..#S,T>5ZNA>
M_UKBZ1E)M#0/L3/K=YG:74D+<YN&26!L[]YF@(I&!V46V.W2(=7+-#5C5<01
M.0NFJ?Q9_^,55IX%8O:S']'FZ4?SNAPLJE#Y_+Q]<MY%;,X2^#]/+Z\0O4V(
M_E/F+7XWZ+9/SDZ6?MUI=Y=^=]>RW7[[O#MXT+)W?S<X[>_Y9H_;@_[92LO^
M1,C " &(A3C[7S_T?RAX)S4=^;GC,&+J]<RCYPN/]J:W^/ KRYGL4MON!3.#
M*& S)'UV'[,A/OY_L-KE#<9?B5_;Y;N&7.</N 8L[GGTL: N'E4<@1C&-'-(
M97$TS';@'E :K0#PE8ZY%^#JGC\-?M;XT)]D0DKT)45,2\>_AY"&POTVIH#P
MD=JA=X;__ZZKQJ9*3WGF^U6.SD(WZ3+K7GJJE;&[X]3AX-6W_>/3G?K5?%2S
M!L?M'K=ZO?-V?ZN>M0YW+\/TJ2>#-GZ[)M3O8MR/VL\\'WQAA%1]OR^6D*J/
MV^VU3GN]]LD>H_7&7_ L2L'*]_TX36!$_V\'-(&/:LI,E49@3MI;[Z25?*LV
M(K'3ZG?!'*Z]2*Q&H2=E#W.O7,H!=A,?JF_EO#4X/VF?O9S+>1Q;J@T'/MT3
M4VS>,;V>2J&\N[T%(;MC2N9FK;4-0*6.HJMWW!KTS]MGM1==F[Z-[:K%C]OO
M ZW!ET+(F[46=YZ0J\'1ZX$.>MX>-&3U8++:Y 9V01WJ=A;UH9\H$KNE8/:\
M-[TZEOV!RFBYJ _;M@!D3=,:O!D \TJETT^7'K!*#)YK.,-I'%$NCF[2:QK2
MZW \=QR17M%6DEOZS*1('AJ8/WZRP#P@4KO#>2;K1N9/NNVSD][FX\?==N_X
M8<'NYUJVB7971EF=Z[3M+,0/FTCT70&W%WC,E;R)+^>XEU8:YYZX*_[$J04+
MWHJ5/(,;"7_5187OGM8O%+2]T_^O!@&Z_08!]AL!'F>^OR@$>+GQ4>J)N0*R
M[PS:'@P.EV#LCN+>KM_'R5[<Q^X'BI<3SE.%AW>&F^^,]?)6M9XRW<&Q,#M]
MC"ZS,^BK"K0>IK/L*"(W=]G<97.7=3CEWI@+JIK$7:PF65,O>MJ\@+K@1;?W
ML,2[YXR!UYT#[A4"K>N&;?"GP9]R7D6#0&N)[1><=/),P^&X=0^/E.*\$KOQ
M.T77L2&8&E@QG%G3F*XI&J?Z4?EJ',?7),<^X]FLZ?YU-_Q;SE"$@8C\:Y^;
MOT6>\U4$V?<&<'<#KNV\N=7=&FT0:@1N<4-IC<[C1-XX QP-@KHQ-^2R45P_
MIVA6(37B/(V:H1Y2\6B4RHS:2>/ *>NW/%U C7[CQ>]XH-25_(9GQBC:J2(P
M-?X+MS46:I*M&15(HU#L<36J_;YPDYCG&SC8#G4$O#_F:=S87LP)X!F<?(@S
M++*6DT?%F)%4\E3RT+_EYF&J$3J.O$@SZD+&K:'TOJAEI)I_AP-UL-\^L$!8
M;*8F*^ =_9:'(HC'#P!.!?RQGV&*4^=PH!-/#%/@4N-G:104SRPSHW1QU?YQ
MYQ=]POM;=ST'0];I*T_"E6?7,[AMPYQ;SD7@AYE@MO,1?N&+QQ.'GL-5OM:*
MG=!;>0>+[U0OX7ZDR[&E:C$;*,5K>2PO3OO0\Q=QO6+0P]RT%#5=F_#Q<N)'
MX@YT:9J6'P_*P-F)IN6[TFA+TWHYU1<S'==(\'VZ3EMGG.>Z;CYO?]#NGSY!
MIZU.^ZSST 95=S>O>H+DXYW:;+?=[2[_NMGLXS9[O)6L[EYWE]*Z:]'$;$[*
MXY#J'Q[0;.JIHP/W^BGNJ*(T)^D.7DQB=--X;:.-UY+X9EE^TV;IJ]?=#?I:
MTLJ-VV7O0>'!)NLK]H"^E%W/_+>!W5JP^QIGUNC8C0C\?0-)C8_R_-TO 0NV
M&M):B(Z\T+9]3?]+.&Z_==8?M,^W&B%IVE\V=/32Z*C;ZO5[[5Y#1PT=-73T
MB.,.6IV3LW:WH:.&CC9[OR^6CJJ/>]SJ]D[7;MKYDK!ZXR^H<_.K7O]QENG#
MR@?8,EUG=MD&CJI2=;:;@=9Y< ;:0?=P+M[_,DI EZG!QV>#]DGMQ7>-NQ._
M+'3H'G=V8+A&@PY;08=>ZZ2W"\ZF!AVVH[2TSGJ=]@/KD^IX.2^DL?S!Z>$^
MQ#DX'?>%E5 O]4Z>#'9 #F^F:/LA%N"C&._NH4/GY+A]VJ!#@PXLA_N]\QU0
MRQITV)):UNT.'NHZK./E/$Y5J8U:5M7@?EL^OBUFG]CEI2_$_%FJE)V=-6/6
M]L\:7A+YQ.$##3(TR,"\X;3A#?N(#DM$?ZM_<M(^?CF7\T(\9?WN\SG*MA]V
MS>'370F[EAM_/"#R6E^KK5IBG"&#J+V\J+&5^)*0H7_>WYU<U 89GMS.')SO
M0$Y&@PY;TB5[YYUV]^5<S@MQ[QWT'AEUW:$<OM]%XODB*N:&U%V=M"_GY6?Q
MG?0Z.S!#N\;F[4M"AD&_W_@E&V0P"9V#?L,;]@\=JF_E_/BX_<#^]'6\FA?B
ME>SU]L8K^8M(Q3@0R:[HD?OGECSN-7F'^^=Z6))H=M;;G=+>!AF>7)7L'3<A
MB_U#AV5NR6ZWUSYY.9?S0MR2CXQP[T;2X=LXR62\%UF'@VY3D+F']OLRW]Y)
MX]MKD,%4!1V?-+QA_]!AF4)VW#ENJG-KIY =]$Z>L3QWR_Z]RUDBPN^B<>\]
M.Y-8DFAVUFT*!_?/A%^2-C#8A;2!!AFVI4WV>TW6X?ZAPY)(<6_0Y!S63I?L
M/C)2O!O>O3]E\EU&_G[X]TZZ9SN0^E]C,_$E(4/O?!<B; TR; 49SKN]'>CY
MTR##5FYE<'K>^/9JIX\-3O?&L_>+" ,1^==^*(:[XMX[Z#^F"J2^)MN2U+W!
M+C0DJ;&1^)*0H=?= :NBP87M,(;3!AGV$!F6W<I9K]M[]7(NYX6X]CZ\WP?7
MWN4L'(K@@5V<ZVNS5?/=XUW(GJ^QD?B2<.&TUXQ9:9!!(\/):>/9VS]DJ+X5
MY Q-I\"ZJ6,GS^?8V]XA/P9YZ(LHVXN9&B>[T >AQG;62\*%P>F@<94VR* 9
MPUF3$[M_R+!D#F_OI'W^<J[FA3C'!L\X2F/;%12P@I_N2H3UT044];76EJ7K
M[8 666/S\"7APN!XT&3K-<B@&$/GM/'V[Q\R5-_*V7FG/7@Y5_-"?'H'_<>V
M;-ZA?+TWR=#/\MN]423K:V@N"0Z?=79 7M38M'U)R##8A3X>#2YL!Q?ZS6"@
M/42&)8ZOX_[:P>$:7\T+<4<>=/=G],?_S*:)O-V?CB[U-367Z)$G.Z!&UMBV
M?4FXT#_I-#-H&V10C*%STB##_B'#DK!V]ZPI'ZZ?'MG?(W]D.(:W9[.]423K
M:VHN41YZ@R8-:O_\#DN0X;3)CVQP05L5O88Q[!\R+.E !\BP;F2[QE?S0AR2
MSUD\O&4]\FLB_@:P[YA#\N!XG^81GS>UKGOH>5C2B.:D&4?<((-6)0=GC4]R
M_Y!A26S[O+/V_+@:7\V+\4F>/Z-3<GOG_)A-9.),D]C+W2R=1\ =M]V6U2N<
M[4#;B1I;BR\)&;JMSOGY#M0R->BP)70X >[0H,/>H<.R87)GI\=-YF']M+/N
M8TM8[M"@N[UV;U _3>VSO)91+M>U$89QXLGDB"\)SIDY:1SXGJ.WJ;Y''UYW
MX<M[";4*,,_ MG]\/JC44HH=MWJ]\QVHI=CT;6S)"-[(?N=Y=$/(#2$O$'*G
MU>_N4#)K0\@-(3>$7!7^.6X-^KO@9V@(>6\)N1I_]I:0J\'1ZX%$/G]H5XN7
M1E:;B :M^HXZ^R.Z%8W9?LK$,) ZT653Z4%G]^VG1XE0>3B42>J$8N9$<>8
M"!TOETX6.W0% ,]V.1%GR_M[[QPY'V!CH101;&:4!PO;T1M1]W^$_/#G<XT
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M<.J;B>].G*$< \@#D4?N!+B87C&5@*F>\^\<0 -@@%?V.MUS_)9\.8C1#$P
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M4'VY6^5=6=>]UWA97]75<%Q!U3TN[J9X8_&UDH=D(*ZI]=ZYPWF!6?,;-\&
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M$E.ZOC>HJWG*'9_*X@<6+2[^KH77=L\Q;]#'J7$=MCF"?]7SRMZ3\@DP:#E
M=@']@T2Q%_J1GV8)':$X646H6%U@MS=_@8M,F=EPJ-_)SEM0E6OIG/@+K]"-
MQQ&)#.'^._=1Z%Q]^OP?(IR^>FU8,>#=CR<GG?:QP40-@ KF3.LP-Z1?OO93
MD80,<[24C]!:07:(7H"Q9&$7S9!AW, %X7]+5K]RFUU%47Q-NM(7'^R8VQ:8
MHNXD!KWA8G@)OP/D;3EOKN-;OM[?\RB=^,XO8-X0.^-0O9*E-^L<O-<_;Y^8
M@\\=N&JG%Y?.51CF$<C<2[2YY*V/V\3//H"^Q_N[N/:]._'BR>-0^B?SA2NK
MH^!3!ZA.FP#50^@X144*Y;"?A$0P@+.@("D)S^@7D[V=3B6YXVQT[_:[[=X\
MG;>=K^C,4X\1\R]8GR5,*/A%F?6<8P+2,$^216U N$POF?@&XN\F3@+OALP;
MXUUGYQ_877KKZ)\O.(3%9.@\J*B.E9=P\=6H9AJ/B/5+Y$XR"?U$+&4./PY.
M!Q;YX]X?#M\"9K!(#%]E6L?GG;DRH#@BV-*8=H,^4%!OX]O8D>$TB&<2Y!3L
M/H/?WXC$2^\Y&_ZREH*'O#W_\?^=];J]5Q$F AW ;<6A/#3& JJ6_!DC9;M[
MNB!\C94$6&,]VSOO6A>FK8@[TDY@!\Y8^)&R>!#TI.RD$C (@+E"#$NQW2YF
MU#XG7(%HV*Q#E283MV3)$3"[Q^W^HC%:-C1AFQ6_1BNUVSXO_Q@@6L 1 >CY
M*>A-&?]N*",Y\C-CP]VO&:X+0-=]$H>$RBT!PE,))PI)Z< [@@1O,:N7[B-/
M=7P#N6E2I-#$10H-_"L#W"<;(>:+1?X%_S@# I#.529#Y[3E_/!>1"!ID3#^
MD:).IU<G9282P0S=\+!V=:8./O76A'\NX\@C+O4#Y2K"YBZB*(<O/LMIC.PL
M<NXQBD>C#<.-\\%!^5>ZW,]YY,F$S?3_%,^\ V>2R!&HA%DV37_^Z:>;FYLV
M,*?V.+[^Z0+,-*##]"?IC47RDR<R\=/@_/CT["?"+OIGC_]Y^E,0S([PBKN]
M?O>VV[G]UIYD(6%,Z'0[1__ZSY_$/Y_!&Z&#G3.)F><1)M.^EJ[$TEFGWVTQ
M"UE2)GM/OO[^9'.=+5>6\62^]U\_^.),G@T[)Z/.\7'G6)Z,AIUSV0>%K],_
M/A^,SN3_/3G]81,:=J]]NEDE>YLRX.W5AXL/EU<7[YS+CQ]>7WV]^OC!N?CP
MVGEW];__N(*__T\=-2HP 88R\$'])G8JKH4?D)?7%2F[<>@?J#U>BP #[QB'
M&$M24TGXT\] Q4+M$B0!Q0A)_!N12"N,@OB&-5Q\'C36-"7%?P)\^PB0(U1!
M[FC,?X%MG%!&*'KVP6Q(<^5@)*_**%<K@8W,"B]%< ,1190),T7\!\E%!GK(
MV^:,>%4;]?.J/J=7I0*@_LE\!5#W;,LWAII%[V3KSM\R'$ K'."YP0+[QE=<
M!7&&-7YOF7K&(IF*61(' 2B3VJ^3X2;A=V7/,CHTU1>42"5N9?JJN;T-W)Z^
M-3*>0+'"3)0&LIN +&?G)'*:@YHE4I6M!\#T 3I> ^2- !G *V8ZQPT#W9F@
MSBBK")57#?_?" ?!@D=_F"NO7$PRV0,;'L6PLN8=],QHBP],?9 /TIE($623
MXA&0W U5;.1*8'&99K'*&DSB&0!ZYBA* ;R'3QLX;P#.TQ@S<- K,<Q33*-+
M2Q%/%<"CL&BA!]DQKI9#040YQHRZ(*!<Y+0U%QEJ68Y%I0"!78<$A:LE":9=
MT'?U]-?FE":@_#^Z?#'.TV#F2+ G<LX7@:<"'P#CD8<ZLA7X%+YTRS L&Q"8
M")5@DHGZ#:5) 7PP$?0&S1A,I@>ME*/BE#.O#0D,/Y-K244-*G38MG/!L<BR
M6P%=H#&=C553-G'L'U:'.0IU +,IX]A+51%;<DUI-YDN?%4%@KH(EF 28_YJ
MQD7 QD'6,MO&EUO!=J7.M0JE ^,-2P2F;6QQ+7*H?'OQ,/#'RA>GW2W 6XXP
MYYC6RZ@H";@[X'*D0@CHRCV@!(]O$=8KBY1^]X^O@-K.5W'[C\,BZ@M_.I>Y
M.N/O\3!U+N"0![U.]Y2^@[\.6TZ D7787!ZAY8<F7AR&/E,%N_&12- IB*%>
MO'L-%GQ>$0[+'CJ_<30?I"KU/'6Z<+7=8_@_N-Q3_D5WL'(^^B$EVA9ILPJE
MYM'"0H88L]6QRM*%1U-Y+W+8A%%]V5PD.>3=@EV,WQL;?8K)B %RJ-0D8'#<
MC/*\TGIF85PN<T-8"3.89=%OGYR80(\HT2PW22D(MQR[^+'7[A\7O\PJ?X:1
MB ]8 (^; *I$BO(P@E$X.0I^3V&3'T_:@\YBWL[<NX_;9\?EA]9[DPZI^+J7
MP%P.4/^DE /$BPI?A5RS+) /#2 :NG'6(I'/<L3M!19^8%5VZ)VBRXBY#LI?
ME4OHR4SX 87<J+& /XY\X.?8>4C)"D*77-$1+V3YB=,Y1W$9.W0,8X7(TW-0
MPU5D0*&5[3O\=#>H9@=XV9E*PE1Z!(<[V^=%8ADN )]T5J,A R4*84\Y\!?,
MK#J>T_7J>!;OMY;J#(#?+HWO$(B1I .)QV/%I"I+  _)(/RQ>]8^5<UGIQCI
M1T=!"SO<E$A7/]SNZ@O1_DMD+DH&9I,DSL<3OGEXWT1EBG.&;XKMN%RI2HY"
MF1#@IP+>2DD+UDE4]L*=)R%F@'?U8Z\_<,S6%W:.G.]\A4T+8$RW)*DUE7+.
MX#"ST*C_8#1:J62_''\]>=[PZ\6=0HMI&,'#XJ5[TC[I%&"FJJHB.QP0IW=F
M2'E.Z'0'[7Z/UU]![&'^CEFZ4JG%^\%(/B"!*R7(!J/;V3@(6^H4 A&3==N]
M09$:[-]*[XCB!A$I8R#9W@M-95;^SFHO$Y&-"S_V!IUV21#>_>XJ$OKQ;'&-
M0>?._5_DXQQ4+DZ# MTP)UUEZ?XQMUGEXZ1Z%:IBHX *F!AQ,HWI#: H3F-2
MATLA#4^I[DMT_'DFH/:C8BG"P0"Z.AJNH[5158E(Y7E+^9M%LMWN1FAVU:2)
M6A,M"F"!L&7J130:M'O'-A7D$5T#FS,(J*&(OCE ;@ 5[&N&<37R(< OR_2C
M[CZU8G:HU>53SH2@-+BY&P>D&R<BW,QM:4'M6"%$:O8B0FQ/DRH;W:>-*:9O
MHG4+6U.E?NBZS0-T'1JKO4#1:&9[=HW-"O0$A+0C7/ZM4D6[_4W.A'G28I-L
M\@RI'8B.NMP3U7;N^85I]^AMEE8L12O"I(Y,XL"3"2#E:_.UTG5/+)U%:;N#
M,^LSSDU%VTBG"2Y3<J_N*C]I69EPVNS06\6=#HN7T")^ B*BO$:7?3#J0TP\
MU+]7R8V6V=MIGUG*6,O*,J>6 /"_'MPIE=5PHA0)$%6(TR78]-O'G6*)'2&C
MRXK(I=(R^H55XW$ ><[T1KB!,M)?,+SO3092Z2E[FE5__C19]1O/^:DEPEY%
MA4Y0A(4Q3;PSIU<2&:8.)?$18_OQS);\\Y%E+=3M+I!%5SBP-IV5=)2R>E[X
M?WD;V<1/J[2'A]MG=3;S/Z+M@55L764%S5G'S--33=-%GJP&VEFG771PBF]
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MOA05GR>XGQKY431/X]2"/&%5D#1/;&WE?IFT4ZE\ YELKA&EKX_;4=4OL&[
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MTC5D-/D/LX*2?)O65TTZXSQ,E=Q6.ID.*VDZ2=)4/$IW%/FNVI553H)4[93
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MQ>\W=-")2M!*'>WONKYRFL0S2W3-/8.K9">=U9_QM)ZDGLF)YI3?<J*QSG)
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MD)&4&AV(T!%/Z38CT9C[[W_/[X/=>W48WJ;KX'WU>"_ >N]= 3<,6!>_[A+
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MMW;YCBSEVD\2]58U[]N'>LM;\->@WHINRX)Z]XUZ#58O9Z51T9171NM4\4J
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M'U]?_GW$WIT=H+=_'^%C?/CUW?Y'?/3W 9T%[-]^._IFX<N3(_;RY) >GZ2
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M ;S[&P,G;;G'(X*U98*::]#OKXEN%H"[7X!K6 =4"<>A,P!)2NK\+<LP0,A
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M=YXQ*X3DW"L>I="1*JD34]2#:1=O@^<%M%<$VDT[/I(8.641<0ZLGPO)D,%
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M^_UP,-_0@F<_R =RHRQ,#=:"HA2I0ER'G.<0$E*4,0_PIE4P.WM2X@7NQA*
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M3F>QY0L'ZA2QW6"Q7>LPG2*V*Q#;!LF5#G8/,Z2CMXB;:)$&38MHU-HY05G
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M&9O3BV73TUW"-F0E!+8(P-^@NG-M"H*!-%F6F43E<YO 0+WLUV;VD\XQ/%X
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M)TC1[%LQE\+?9L\TO\FDW''8X JS,HQ%5ZF$8][U)/^)/3T=QM/\=W4Z4/T
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MZ_&_9\31SY_\B__^]^?TW^]?")Z\JY$@9X-B $8S5Z,"2*:443$CF8V$?_+
M>%CC$-YID)?W0P0ZM\+GDK_ZVWO*X4=TVV;/<UUY?F70NGY_OUIH7?^Z]XFV
MNZ),LFAU$9"M#*X4GH',XZPQ6;BM:5N#UEU Z^426J4,8&*T+&,&!L4H%G+*
MS#I1W4XVI%(JM3Q0UAZJ&]#:@*X!W;<)=*)P3H*3;(H%O,R>FR 3:J71<PCR
MMLS3!G0[ +JG*PY)6DAF$)():04#Y,0A!0:&Q450"D#)O/](^ -GS"$\%*"[
MMXE?NO]]LA5_GP$:6Y#'OU37;S@]6\W?7!3$7C'KM_! I@[<NO6)UB1=U+UE
MJOOV]47#>:X7V'_T!W%MO-X-)27OMV5K5<8#-,2EC-*XC DC[U(<<C+&A%('
MC 113#/$OSB(_C@VQ*.+ND2O&!?1,?"<\#-(6W.TO*J47PM+('K@0!_>S-*<
MO!V^'AP_*P.]=LL/NJ(?)D!LS+*D0IM4,,I9 T[75BP*M#3H#"G8G)HY.06
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MTH;!1#:1L;++95'"KZEP;4#;@+8![9< VDUGTS6@W0'0CGP;!+0\DK'#I/?
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M+$J+T<KD8VWMZXPYA(=G!$TO'^6!8\#&I"I$LKG!A^A2A**$0^&C"R9FF5S
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M;\ZTA(JI4:<08L+LHX.$(+/&7 IZ98I2AO,2FSFS.Q!8>?Y+E)!T3G6L061
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MS#GF42:'362$Y?P+(Y*.!X3RC9^2SW+B\'[5)IR*['O#6,D:]DLM<RI)!/P
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M&M1VWZ@-SZ(V28C1GGOD;9"(8TNR[8D@08*CV#C+DMUX0>F67*WM:26B[39
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M 0- F@K-55C.SY)UN885/A^TX+6V/Y<B7\+[.F:M,B--<]9CY>L$I2>4VA?
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M\&R[I9>=3!J]\U$HHR(D;ST37H(P/&3E0X#G7M[X@. Y+6]TB7N=O2,B)T-
M4DJ\<I9DX"EHR='ECB]> 5<+P+.%LA;*GB>4.2LX6(]V7XH 3EM0.1JPS MO
M9+3/O2[TX:"L2?Q@T= S.1&K>2K-EY8XM-.)2D98YVDPD5>QC 7=&FL*9;-%
MHY>#KFLP#6%MAA[ TQQZ<.,0@[G /V6E\$ PIJ4M"0*7@D4#*AD6%:X,7_B$
MH_U4L^'WAZXKGA2<.7PAWX_5](&!.^FFX3HFC39[TQD-57BNFBY3YKW<I?;X
MM?\U'1WAZ]:%&&14H3A:@G2&(#!>EVZC8J_!$U]E:":<W5>4%M;5AR7CX]WQ
MD>MUO^"9X^L*X;K"&=^F%.[=NK+YBE&*W2$^ JYN#:"3\0&CU%$I6PS_/>N6
M-=O\_</_<<<G_WPSF0"P9,V<E)$R;9P*D4& [&2.6MN*=<EY?YNHRZVY4'X?
M)?1V^Z_KY]^<%.2\KNIQGOP)O8HRJ.TW'_'OM_LLR:0TXR2XE-%[".@]Q"B(
M+B1+6JF4J2[S9Z_+*7=K-=MH:,@-Q>@+R\\OE:BBD#55H);;4:4QG@+3FO3Q
MA)%N)'4%+=ZP^L?7HFXE9?OAJFSO])'=I>&G,TG?W\\&P[-1IAEUX^W'U_,:
MLXQ"@$#;@F4 D11D$;WAEL;$*."1X4-JR8&^H]QO7>SM!R6,SD7DP>$?D7/B
MG'4$OVF5U%F@"?KBE=&+.,::Q12+$O#S)>TS%0LS$GVI:B&>#<:%Y.>IS.:J
M:M(7EZ6M;>'V56?NK4_:?Y_UA@?=SK^Z_6'HIEZHY\H]Q)&;3M,PW?O Q1T_
M'1;; N_RVVA(W:\'W9[K_%1?<-1A4&"HVSLJEZI^_++S/WU\B/^O_%&^N>6"
M.^O\4<KY\5U>ST[6^9 ^51,YJQD>KOO5]7ZN"]TO+UZY2ZDL&U9C#D?/B* Y
M\VR/;R6D6&AGHU-6.& ^.J^L*;5GPGI'W6T8%%HKX3M8"7O[>"I%=&8DH<H9
M BP!L3272C1T>;P J0&*8WXK*V&!@%YI+ERR$RX=]06&$5_SV>G98&X&U%29
M%]ZTJIN\\LY+]2%=VX;T>G'Y]\M%S[2R"F,7L]4I.JJ%!Y[Q"\5%E(';Z'F0
ML:WD7 ?5VGV['W1BPJ'Y01-7A:&$$:.\)X92KX%J9JQ[\4I?:X!?46=\C_KB
M2J"7ESITZAR7D@>5. 2E?3;10DB6)9ID%*W4K874?=RWP-$5-PG%S-E"L6N)
M5\J2)$6PE$414ZEQOQ[1;U%+_/*2$(X&DH_LIK$LSL/UFR7LX/OX85SRA X7
MB]H9H-$:JCR- 123.MD;.Y-;D^/[2.C%YKXQ/@M#(U%X9A% 5"'>"$YDYI"4
M319,>/'JQF+WFV99SDQ4;/Y\;>KA%T=B=\^_G)\N6?MRN_B]VI"W>((%J8BR
M#$14OSV?$D%4*!>H:F<T_',=_=8I+<4-!!2]?O$HB[@<]M&M.CH?B\TEES!U
MJEWJ_#3$SW6/*H^_VSNL_:M")M%PO.H^P-'4W\E-?/KDBE-&FI<MP%A?>'J%
M*]HCZH\MZHT8Q2I&G>P+FB!&3U"<X,**,3=-=F:R^F1\ZN6HV5^I-K/KCS1N
MO&A$[<Q%JW'JU>/7;U,]F3^?V8"9M]KH[)R-?V5\D_$"C;E!JFFFW=) 4<TZ
MGP;[%H1Q7E:T $OU_J*YP_%$"3HK2!DL'B=.<Y8K^H1LVJ#>=^OIW?JV??%Y
M'ZT6,"X&8EW4!'($8H31)$;+).Z-"2!>O!+47,DK=->V;X,NL.=,2LT5@)">
M2]#1.JTA.I]X.R_G.V[]SIM/^RX)GE-R1$I+"1@PZ$9%1Q3#?9&%V)UY-&@%
MW")$<45C]EKVQ>'1L1-.^R6P,+&%:T*2.CJ7OH6CLV&)(8RCKU-@K?I09Y#^
M4^I_&KB3@VH*\#2&6<<NRZJ<'.$URVSND@VIZ#A& <D:Q2?'TF2>^G0X\6C<
M>^.LNC)^& YP09<.'T:I-1<Y"\X*,0>U@<<8J3)21\65;FWYAU?.MZ+@<G;4
MH>U."6?%EH_:$\OQGX4BUVH3:' ER;BPH_JR<LYE5XJHG9V@+*,,C^R8I@6S
MT5G+-,E-? ,CI5Q9/-!2H!YH$%H68I)@I7 >_7X=6?3.F38R\^BZLL7P^?<M
M%U)$*XCT-!%@VA$;?2(Z92H# Y\5^KWF^HS\K;#\#D(49%() HO1@]#.9)M=
M\LY0*[++KA6B1Q>BM[#UYO4^B@T+T@02'$7 36")U<*2J'Q2,:K@C;PIJ#SV
MG3K718RORWO,H-B5)!6C@I %Y(25X/;F.-"ND^K'3HA?$:EQO71QAK[_+3OL
MYTK\UC0.\GO&:PX*6<)&YZ?Z'S]?%1.I"WOPF[/!D=/QPBPFM^L/3U,?7?N#
M0?>T^.TE<U%%6,JPL4'U[YINL+!HNEX1B/3?L^H^PX-2S%.NV.]]ZI=X23.R
M5T(458+C9:>;QZ*=SXY>SABN7U$-YB,O=71F]B[X.S-QBR;3Y^7Z@''4L<H*
MNN)>G!U5;UL,X<) >#P);30)"D</5L<[\/:#DK6?D!F.]J)Z8I\JGP4!L5*T
M7%.5SCU%4?4OW3H45,6LAHV:A2E]7OG9UY$XW%S,5:Z&S]FLSYK01AUT"R_4
MHM*LZ@FG*HX7J(CZ2DSF:\+WP;\+,>+5\.!ZO;.9JK%/HZ*&TP.\S%+E!SIP
MP6TV(DI W\%E]":2=2"<L58\9/)J-PV.\5OES;;3Z1_EO7;'?(W/^*#;.L>#
MKC"XR:W=CW('#[J4I%:"&A+ %!:W)(E/)6F@ N69.HC!7<6),QOQ*:J+\E;[
MJB@_@T+S.W?*S'BUE9S.9_?G#?F1:J[,C,^2I3+TWH3"D\V-E3$FH$I3,"F"
M;2VP1Q',@ +Y?E^I;'#Q,^'.,;2ZF"*&H>F5<L6KZ[E,98(@Z 7M*TVSZS;Y
M^?IG):E_-AB4(Z)YPI4HS5U3^"'; G<I!W0V*"US4BPS-AKFHJ+A*FHZ_: 2
M9I^AA&T?[NUSRWR&Z$F$1%'"I"(>3RKBF$;_,!;"44 )V^"71V%U? /H.L4X
MK%-$]\_;3^RX&P.D#VWA+C;(_Y/\H/NY>RN;_)%"0TW+L"3*JAAIG6^M3YO!
M<7?@7DZLL\O]+!5SZ*S)_FZC\S_]G(_18B+_<9T/_8!;^I_36 '%;ZE7JG7#
MP<N135^L_W'DN_[LE0S[H\+]98CVCQI[L#%ZE+OT#(S*_BZU#C0Z RX9I)4Q
M6A9H;%!63]0P4;OU23_.!^+A/742YKV8>),%4+_;R@P !&3I@8HLDH$8I3$A
MZ:2M5M3ZX'UK #PZE_Y;O/_;?>=2R42@92JS)F"Y)MY*292Q2KB,FP3Z1G[A
M4F%U$VMHY2F&@RYJW]AUOH4!\?*.YD'A!,V*&R95 &:,TR(KXT$R%K-75\61
M6_/@ >7O'.^_[] #4ME:8@VS!$I6U O@A/*0O3;4,5KXK3?H0YH*,[ _UV#[
MJ#W0XU^9;^Z^_<'_O9NCY=HW1Z^'];2X1_O&GNOY'FV/NJ,R(K7)0-$?XEFP
MD+))V@A59D;>R4J;=$#-=18?E0\>';WL_+'Q&FVO\;_1XCKKQ31N0QI_>WR9
M.#67AHWRQ05U:$V]6Q1M'30;I?#1\9YEZM!1_],Y@D#LAAI@&YU2+SO^[+33
MZY_BPQQWZ_I)/%-PQ[MA].M5V!8AI)["4>7];QE*7&CCS00)ZVM>:^;-APUK
MN[,,61F''E=JYY72/7S*15;>HMK\)6L;>!+61(C*A02^S!D13'BJ1=0*0DJM
MV??XQR[LO/FXKSWP4$I,A/8E?<L0CTW41/-@D_8!@G<O7IGKL[=%?"?*OAI[
M[X[F'B06O51HKIH$1GD7K2WL7PX=$! ^M.;>X\N=W'GS?I\'9;05G# O3,GX
M)F)*H(BE4I68E,]15Y&A!:''AS+W[D@Y;A\W(7J%07$; ^&:XV*IH+_+";U^
M*K/((+FPD+.)0D4?@LWZ/F47XWJV7_%^Y4G^0G/DUS/<:=S-_W0=2D;W]/P9
M _S,W""ZM?MY7ZA"[V,5R: % =P!5!%6"DV9D4%$3RD"/+<+2HRG8X.J.OAI
M];FK]KM\#*VIT:)W)IK5JUBIJH(W[XY*]KLS/$BI#K*5P-*W4J):=[#XV>[L
M^1$]TVK,21G^ES08358['DVQ^_V@#+S<W-R<S2G4LWN:G5EH2!VA>7.,SWXP
MO*%%JW$2C<RBN(@'X-+S-8<9E&%+Q>(\+OE=U.L%D+*@ J226&>2\>@/4P *
M265/;4(+"GU@L!*5=I\)^N)Z1^9*KJ40ODN8>KM_FNI5E+^,R,UJ>=H^0^5$
M*WNV #VZJ(P1D3D-F>*?7GI+HX+,6!2+&]GFZ\J'IP,TA*L-WCP^<=U!V?ER
M"I<M>3TI&GC3'8:C_A"-\EV\_[^.^N'S8P/#Q>L1,)Q\WGZS^6W[M^VCO]]\
M^+R]&^C683S8^VM3;!U^I'N[@?W]YA/;QFMO_3$'#,?X7(=OZ1[_\_/V;^_9
M=AD4QM\=[!V&\^W=#P?;%W]^1@L/G^/3M_^]V#S?>A/V3>3<>J]K0P]R&63,
M1"#&2RF2=2XP.^]:FDR=9(I9X3)XD7V4 K173'KO(* KFA!N3THP8G"6RCDR
M1%V?[L?+SLQ&U8&\:H<F3!&_5O73PS$ C01F[KQ=>*S=^'"OOK,0_A$.4CP[
M2CMYYBU1"#_4?7J_EF*5YRUWK_?1HL.#)SJ2N&0$-R@2BW8(RAWPG&426OMY
M.5J3^,RX8JO?&_O!U2E72^R8&"56MF@E^-V&X \N"WY]6@Q'@C^]3!60F3D[
MAZ?XU\3Y[N-Y5KL1E=L><:T&75^.6#SQOOYR8R7A%>-PH%K-=HC-6LZ%>5(/
MVPZQ:8?8M$-LUFF(#5[D0=FL_T 7:%#<O7:$S8]$77[O$39WLK*OHRZ?"%IE
M6[/U"??<T;H>,9A?;/_U_F)[]]]'?Q]^Y-N5A?U1[!U^/-^ZV((M_OYBZ_CO
M@Q)&VOEUGL%\"Z^WQ;:._SS>WMWC6[L?#O_>C=WMW<V+K8M/%_BS\[^/WQWN
M\?<P-\DF4^#)V50*/WVAE<S$9&V)RE9HZZ/U+)9ZY$6TDNTDFW;\0SO^X6'&
M/RAN@L_ 69("(*/&\N@@&:F82%+=AJ^AQ="58NATH U+*@FO*,*GEP2 &^)X
M\N4PTSP[$!'RBU=:;YBG,@2B!;06T+XSH.4D(*#1AU:@ T^SUT%DDST/7(
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M H*3(MF2A;(4G8$0I#ZG@'"'[9K#UEFTIOJ<'2B0R2'%J%((MB3*+OLN5.\
MH,<'0F\_;C]\V2(I='5.N.A(0%5>8%956%6MR]D 4>Y"=3/1F3PK5 F@1)>
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MWU$[.'&Z>A]:!^@* +KPHJDJ=0C:".\JJ_W).($1LG !0,9::K2UB]/U .8
M'6@=K2M Z\*%UH@TNXR"P+2<**M$9/$J;"*I<C J9]O%Z7JA]E)ML%;N0^L
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M7:]UVKJY[%A78%)V:B[;MP"YE;E&SPXN'SCC [ >H4#_81B8V>I[)#6_!S%
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M<K*I1SX8=5A-L'A'WE&"Q?N Q1U7H5KRD+1%*AJ'. X$.6XD(AZ\.VJD)+$
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M$O?DWYXW$/=]@]L%(T/Z(I[PIMIR(VM?+A&Y=XF0'APF(9F,G")#"48\>(P
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M=1EK\.3Z56Q_C]5"%>.#<+7S3JW^2=1.3K,2)6ETMO'@A$?SI'JR#5PM=&K
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M3R914M]WM\_J./6EU:WM*>K;O:E]VR6USJYH;AVWF_GZDR-H4V@UZ^W39N=
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MQ 6VR#JC$8TT"A>L-SGA&6^062=?_KYJ]?L5^,&9?YCU\C("?#\"_"R[*Y?
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MLXS']=Y.%<,]3QK%'T_@O8'B'M#JMVW1N'>&X1,Y]$[XJ))&*5*?1;LE@FG
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MQ3L416[O&Q5&ABL)M)AQ(9D-,9?+_L]_:4KHOUXT)'RI LLEQ_>I]"J_<_Z
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M>LFG?4H$B_HP10?J <YB*QN(TGK8?JS9OVV[DUU6X"&UP>G)";!G< ?Z-]T
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MAJR7A9MFA,;)6!SR3JL%<G4F8(";VVGZ-89>_&6NHP"7 J>!@D^A.+!PZR@
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MW1JZI?/AWHK@Q.JY7!5.O Q.3#3A-MH+[QCBG&O$ Q?(<JX03CE[.0@/QJ#
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M]7Z/I8"^:<'<V?K1U(K#CN&(J/(!_ 1#D<;<(R$=EUYR3:W.@CECAL.48.;
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M^Z?Q5A&3S]?RL="H+V!=V@EL,+!7,!4GO6-@"05 ]4[[UPVA+;:_H,2=*P&
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MQE2O#P ?FRNR>@#XZ'0/A:.*C$6'M>92:R,BPSI8;;PC@L0,@ L>LU4 ^!P
M.#'HUE+L:3)(>!D1Y]PBK9E%F!G%+8L>]J< 0+*\,KB7*70I*>SK(99_]+HY
MPE\&'7.,9A1^OL$I']87Y.;CKTC-W:ND8_##^&^C@YC)[0*,&IW+5-@T'S;5
M)\E9$)0GGQA*/@_.\($@390$AN:=I0)+[7U1VL%GC;);>7)V!R(]60KQ]:]<
MK,/0RB+)"_*:"BY>"BZNJ$R4D24M"/+:@B\'Q@!92CS"1BGJG;=4RK4-P_@2
MIG<L3W5__0C9WBWI5@6I*?Z2'W(Q6K.Z+8Q?D-;<#T9_%-LQF;A:(<]\R+,[
M2508.$L$^ APE-Q$*'B*M' $"6$D23AR)6G.K&<S<LA6GJ:L7@SIE2/#2M.4
M"AF6@ P3K4H=]]:EA"P+.?N98V1]-/"K!62P(E&LUC:X$#-ZE5;!E:?E)$4^
M^-(9R>JZ1ZO+2&XMIZFP9S[L^3K)2G04@2=-$?4ZMS8$ #+:!N1T"#AP0;G(
MV*/U#']HY5E)%3QY,ZRD0H?EH<,5,R':,RNL1-$EE:N!.;+Y^#L9^#,UQ!N%
MUS88T8]G)E6T9)YQ*R#0@UH?3.HPEH0DM <>'FG!@Y_5]8->G(],EM=<HDVQ
M_I_+Y=\\#EOCQ:^P9BZLV9]D(M8(KAB0D"1";K0:(G(@_<!)M B*6XF] R8B
M9\U57GDF4L5'?C4F4N'"D^+"Q+QU[Q-G5B'/=$)<48D,U1K!CFEAN5,JY&8!
M1CW^Q*:*CLR5>M(?%QN6R>_AZ'0P[,9%.<CJ>CVKR4&*]2\Z&^0_72U^A35S
M88V_XB![VV)GZ[ ))D$P22C C/&(&PM8D_Y_]MZUJ8TD6Q?^*PK>?4[,1)!,
MWB_N'430QMW'$P/8;MS>\,615R.L"UL2MN'7ORM+ @H0-D)"E""G8VR,5%59
MF6L]^:R5ZR($XK!5F*"E\40#$<%\)4N%%I?(2R B!1P6!0YG-7#8?_LYMYQ-
M@4L$0,[S4:Y!UBB#B+8B1*,YSZ4G*3%3BM04C\CC*=RDY7+%1$ 1XB@.NNU>
M%3E57"++H".3!8!_?[@Q_05S9L*<+S5"LO-]9QLL(*X%90PCF%@&%A"@CXD^
M=[XFA AF?*0QMZ"@4[RPC2<DQ3/R(@A)@8?%P<-9'1YV/MM(5)!&(B8E1EP*
MC)Q3!(R6P"-QQ')2U<V3)7QDJ2JW=U54,-IAK)=/*0Z2)3"2JR/A//T7U8O.
M"MX\U#^R]9E%&X/3&GE&-.(L8&0LX(V-QF4?"0[.9JC!&VKUF$AQC;P()E)@
M8<&>D:W/GAKG-?=(B$01=XHC%X-!3LG('0U2JYR#QZ>51RA.D4<\HK$G59'%
M\QAR(>1H!_YH'"T2O\5._R2[!(MS9$GQJV][[P9]'X?##Y.5R ?$5^M0\.?!
M7I(ML7O^]3,F,K?I=KEH.' 3YQDRTE)D0V)"Z( M(;E)MUC%8YOB)7ENW*3@
MQ-+=)5MB;WOGL]34\4@P$H0%Q"552 =&$5.,2BLC$4FM;2HQQ80IWI)']):,
MCN*@^$66E4R39[M R4Q0<KVE+"<^,L<\"E5+" )TPS(=D+1&)&*MQ\:M;4H\
M+6FO\72CN$)>#-TH2/ P)+CJ1JJ=X :[@(+6"G%A$]+91VJ4P(8;P&T'AH<P
M"V 4#?5^$-,\/K'?']E."UYA.)Q6T'X>M\=\?4Q?% V9HY1C7KF"2[/ATMFU
MIO?)*^9I1(!!&G'O#!@Z8.U0FDSN0@0LA0)#69=D6I_DQG.4695Q2?Z2^>JK
M/T/T6<U"L@5]'H0^M1[MR0(=(A[%0 ""%%/(>2V1=U$*IHQ-T0 K6I=8SM]*
M>%E8\/S=,'_;SJ2%E<T=?&S/OY!HE7\TP2US.?M;%Y-?,&@V##JO,R"87FYQ
M2HBD*')*<2ZLI!)*P7(5,7:*ZK5-3>24U,%_%F=)LQC#+ KZ:-Z2HJ +4-":
MZR1YX832*$9EP40A!IF(/9)<"YRL#PP3,%'(-(KP) KZ,KPFQ5^R>OZ2W5B.
MAF>$(ESG"ACSH*122(F8$#>,(QL$18K WN%UX$:(;*]H3%8QN+5X2U8#>U;2
M6U*PYR'8<T6#1-*,8N&1Y[G$">,2N6@QPE9'B6,DG.*U3;YN#)[BJ6TH$BS(
M5](TAG2MX6<MI6>NKI^+Z+OY:/=X_G'2;^R@!R.MNG.F22+Y\-0-VZ%M!P]-
MUVIN[.-3.L >LLG4&L]_[(7V<#1HN]-1#).<THO5*UO0;%L0K=-?S<#6SDYZ
MS#Q8XH9B9)QVB&J&753.<69R&R6#Q5S.LA+(_(R<9469FZ3,M;,W(T@2RB.N
M&?!)P@PRV 8DDS&PS3-I><S*K)2<TJ_Q293Y^9^L734D+0=JC>$3I6'LPA"(
M78N.9IP%[@6B@N?"X58@9RQ%P1H>;20>^Y 1B,MI49'E[*W0B:++3ZO+M4,Z
MPP3C/!? U 1Q1@QRWAHD;<0N*-!S6NDR-=/B"%?^F*ZI;.);[(WZQ3NQG/"<
M&LS<[-%ZE6-_L29GK_O#@CFS8@ZO\X=@K8\R:*0(9F#&Y))W5A(4E2=1!Q:C
MT6N;DK*YV$-Q1CPC]E!T]TEU]XHO!&88D52B(%V.NC,,:2(E(@ES;(F#U;6@
MN[KX'I:F@>\&\<2V0RMV3SK]LQA;;M)*O'@BELH=)NLP@9\",S/"C+B6WJ0M
M%UQZ9&CRB'L?D-'1(:DC]B)@:F1:V^0$3ZG$71P,A2(4%7TD%:W%M2B=I!44
M14YR>*^FR'K)$<@K)I:(F#1;VV18;)AFJ.CS]QN\&_1/8 1G51FX^+^G[9=3
M!*Y)-&"\".\ZMC?:ZH4W%^M0T&8FM'G[O4X(+&P%7FJ#E**Y49APR&H9D(N1
M<^J4M,[G9J73"L 5GT$A!$59'UU9KZB!=$%1E1U\@5#$15+( 5= RJODHHPX
M>* &5/&YV'MQ$LS20J?=LST/MVFU>\/1X/3EM/)K#C/8AA?X5O54+);'C/!R
MK3J;-M$R9SG2U$G@ M$@2[%&.!@>L?&<Y.H#E,BF6![%.; *7*"HYSSJ60M0
MC%$%G@P*)(<4X,AA]P\6!4-#4IH8S%6NU6SF.B(HCH$YNM7,G_;;0'QI^O:?
M6U+ E&T-!K;W)9:.G0_ F6LET+@+A'M+D"4>K Q"#-(ZUP-ADE*G#34L]PYG
MO.0T-$E-FTX#BIHN0DVOZ("A&A-+(UC_&"/.O0,Z@"E*E.C$DE8D8E!3RIL2
M[;-(9\"*E %94/>Z5<O'7ZG<AK<]W^_&ZUA5@&DV8+I>0$PX#+B4#Q*"SZTU
M-7(B,1184C[R$)RNBH)@1>8Z5)A5.9;D97B\ZAPKB@8KE1U1T& A:'!%4Q2L
M'(D:(Q8)H($!AJ)5D(AB1CB8%38:E<MT2,P7X59L7H6.Z0RJ:>1E^W;ULA9J
M]>*M*(=[ED@93QJ\[<TUF ^]IDW5$U"9_WJZ66DBLVM"%=@:7I?*2C-#]K6J
M;H10ZT7B2!A)<V4EA306&&$J)7P6C"%I;5,Q/*7 Y(K5=)M?(9=;\VV^\=YD
MG2\,RZ?+SXO%\N:V5RI8/B>67]'OQ+#B41&DI92 Y;G%$M-@C#M.I;.P[R:Y
MMLFTF!(RM*+(6C'T?XVLZT3X.[2_;5Z\V>YI%Y3";_XW_/+B/;IV\*7=JX9C
M*G!<BJK1RF%X%*=4#:Z"C >Q8T?PVV^W.PNT;!=F'>@YV+:MCQM_;;12A FU
MG?56&Y1ST*N^G_^9;S0<P7TRCV_UK\XJ^_"<8?5Q?JJ'Q[?A?L.C_G=XCNM_
MBZTC^RWG.\4>C"2<>AA)?EIH)QAMS.T-X,/1]_QYN@R &L23_J!ZP,6=!W%T
M.LA?Z>3J1!N7DE2MR?0UD$M>@ZU1:SOZV'5Q,!9W1M9;F8*NMYP=PGOWJ_''
M^@L-6]\G,W0U?2UO!X,SF*3O=A#&<UO])JM)52+OOV8AR5PZ;ADF*GINH[!6
M2.R84=(8ZJ);@/<3L/9U-?#7M7%O59*U\GA[^#]'V'?_[ME/YG3OV--=>G"V
MMW_PXV#_J'NX_Y[O'G\5!\=_=PZZ.PR>?[2WG<?T_@RPD^[M?_SL$DRT) J9
MY&7.Q33($J,1]9$PJU@DP:UM:JVF'("V0#([E;Y^L^U.QJ#6J#]1HE8Z!?&)
MH*;9QY2%)PY_FTDP)',J<>Z-5(9;)S0-Q(<DK9$</K)%,!Y+,-C.^=?/7K$0
MC-<H<&T1SRET1N& L%)1VY0D:.?:)N%Z2OO2"\$ E$ZPQ*> +>NM7'FE%7^<
MM$$JW%G&'3F&[5F$PF.G#5.8!LXY%L%HX:((@EI%34RJ",6C"<7NN?^LA5:,
M<(\(,PGQW#3%20H,*WCC:"0VYHYQ1$XA6+^6B<DF"PMH*KF@F)F-5B8.@]BU
M[5SUKU7MNB BL,F,CGZR)[6'E[0"(&E"&JXQ@!FW*1I4"I[[I#CF3'H3J5#*
MA*0%LP:G(GB/)7AB9__]9Q^%-()AI+#0.1N (6,JZ<N$7UJ:@H!MBO\<C.J4
M<1YA$#IRJIS%(3JN!3>6$D=M,EH"FW&X",.C"</NMO_,=" ,MB$$()3SN+!$
M+AB&,.%)1:XC;%0Y&H1,.62YDH8KBV$.2?#!8Z:LT8YB;HF#[<@$(FFB. C#
M:)&$QY.$\X//PI$DO*&(4F40QY8CQXT$IB(9#=KCR("D"#*MAF!-$F 3@G7_
M?M3V1RT[R-RUTSF##03LK&\Q/#=;+MQM(O=SK^\;6VDVAJ\C9_YFW1BOD?S6
MR>G@I)]OMQPS4,V@2)<!S/^!%ZXKT]6AMWEQ>K3S8_?XXV<L8(ZUE(CJE#L!
M"X.,(P$T2G"O,YQ% HBZ(6['L+3<6(U>S;3<P5FA TY1AVQS!H>I@_7&4L(2
MFQ07@)OW6.Z7!YMYN<&VDY$XL/Q1HH(@H"\!&68<RL9U%&!I:YHRC:<;\FZC
M_[8])V8S\(-6@3NPZ),"U=<J!UY;096RP1+A%N'Y*3(P50;V]M]\MD%Z1Y5
MQ 2)N#0$66$-2MX%G;R1DMJU3:6G-;,:[SA3!>'*B),3(X[CWV8V\T$JE,%
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M %OCBA7\Y8]B..W$?MH*H3WV1%SN_-OMH>_TA["PP_T\4?OPU-\[??_UQ;$
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MS<B6FS?S>>:W7O7,YOE\];?3XFI^LW>V'5;^\&F2!O?]$+YSV-T].J#P3'J
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MR"WQS#N"N48JC)TV&CE/',)*4IVL3B;EBB[K@NB?.#Q+=DD)MR[AUL\PNZ3
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MI,E)^X<XC';@C[9Z83M^BYW^22X75W!U)ES]6#=2M"&6 0E%7A# 5> \2/M
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M4]$@3J)"6H:(B*96$V=L$'9MD_$5SKUJ3+A(:<Y>FK,_8=+:$%X3?BK ^X3
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M"W'IVL&7=@^-;_$J>WDFOZD&R"LXN';U#:8>;)!:LT"LX@G#GTXX@X/DB9#
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M__5TL])$MM;T:E=;E5 //UP*]=O>[Q9^[^-?1S&."G;/A-W7VGH+8UT,1J,
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M)RT;DFT/QM^#H<%6 #<88U<>?,JK<A;M %ZM/\;.3NV*/"7M86WVI\XQ? /
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M")DH-" 46#0HM$;M4LLUQ3L'"-@1_O#D1GM <QM#EIR!0NLEEYAQ\A*LTDR
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M"Z/G>#@JKB=X6SY&E06:^L-XKV/D^H7#:;;R419+?E L^5[*I)\_LPC-1'T
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MQMV\<O3A-,6R-#X>#^%],_6X)9 14@F]%8&*RAOR^F+8W4&UVV?NWRZ$9?.
M8URCP=+I-NN*ZFG'2WAIGS?+>4E"7_! =-V_[\HV*,HM0NZ'9OX68SKK?%;&
M5V8#WD]&.*%Y.CGI1IN*8"OH&*/U'!=.F=EI/,9Y'!2F78HU'Q%'LRX$YV?O
M%G[R%H+#^7P$71265[[T>@G-P[A@E[*1%LI8<2-U-L\%?7Y:G!$)SGT@2[="
MF1/D@";LU0AOO*01'^469)+)@GX0J+'$']K7: ?0P+KH.RL*V&T#B\>X+9KM
MC#<ZOD26S5Y,J_2KIHETL]L6AOUW!\]^G_T-9WM4UJH,$A4QP/W4OA:N^X*V
MEH-_4F89C5ODJ94+Y .L0B%^%0;!S8.29>&GN#!#\P$^MY?BYN<K-=^E4+FT
MCY#*ST5)N_4^V0+GH:7.)IB5^7TSP74=%"@T*][(JP6K%ZUJ,FE%3_3OBL_Y
MLLJU8$FT)$@K/(I7KO6:E32]10RU),Z-&D]6=Q66O+1X]ODCO@,_+;&<8M$M
M+L!+_X;BXO1L<CI_TF*QT G*W:6"L53_BL!J-\7R+QTSX:(]<W&JN_&)/)R>
M=&>Y07*)>+5^J2)X)],C7Y)FSA^S4GB+\Q8?VCRN]8ZFE4'0;OS+#V_7N5W<
MT]GI:FG].7A'P]P(N8N.'48)4VT&P](H6@RUC0"=GG1W3Q&TP\5&*J36^M@N
MTT-++E\PP59;K'&97B2)!0&,5V[8SS),<9*V<;A6F%\RO<H;=Q:FM13:+=[X
M I;619.5N93P:XCI.F^S(*M6PR@W;"4IJJIXXY:9FL>L (13WJ23XX?%0?=V
MC"IAZV+.B,F%<=.)9S42>W8^*<4%V]Z],3H;._;WEA<723;K'GJNABZP=TZN
M.$VC,S06FEV"3WYSFHX6;X=2O(T.G*Z%8@GQO3N=+Q-G9^VK+_3")4P[EQ;2
M?E*R>%H'<EJ]<^?")RTDIH6FE\*L^VD98HEY^-%LLM)1SM/SV_R<94C@R<)5
M_N02T;7)1ZT*<$$PM-;D>S\KZNN;2:._K3*6%[OAPJPN\YI.SY.-QTWLY30U
MZ.@D+Q<JZ5+88K\,VZJ HR%^#]I[9+_P8;>;&1\14:$I^WYAUY5-W3[M?.1-
M'.-TW.R)HE0G5/'[:1K]VF766?/RDV8OYJ4EL81@44_7LG";CG-49F)Z(6>@
MRZ=%)#5"I=WEJR9030+ ")E@X:F8#?YOD\#-RA>;O(CE_*.",$0U DW.LRO'
MTO+326-(0Z/M=FZQN"D"K@49PN 3H#9JRS*/X=/Q%3UQZ:PJ*&J^DLJ@)^^6
MN6K#%HNKO;4.:$]*"@6\*SZM10*2'\Z6EL&Y!7B.OY8;H)_[Z&4;)&L)?<D$
MS9N6EVE^*+R-BW#NKRYO6)Q-'5YII&/'8NQ5GD!?T@%P1 \S'^"+\?U+^0"E
M I>)SG&O0'((#IQBD8%/*6>=?&_R 0Z74>D+05Y4D&9S<NYA.ITV,F49V"UL
MNU( NBIY)V7KJ&',3[3RE6_G,_[$'E-$$^^_>:# 7_8E=TV"I8AJG/S%B"^$
MC(1[.BNBK,F?>U(,S 1%?<>!=23"K*-\+4FWT<^+ =OJD?][.BE+T^4I?%17
M*6Q5F$DH><T-5R_XOZ@_P\+NC>MD,KU YRU73B[E!I:$C'5*V6?8_\+1M0UD
MI5X,X?TGXDJ=CN!E7H7J7N9N& _?Y!"?^$_\].VCB]?]<+;_YK</?X*T*D9A
M24Z"$>E4)I9S2X34*LNDA:'V,K<IZJGWD'1,2@K@GE'EN;8:%TI+:G9P;Z,Q
M7=+2IJ?0*Z;K8F>1A/*Y[(@V!>+3%(GV[POKK[G+^J3])L>QF\MXUJ;M^P*M
M4;'/GGZ)Z18"OLBVSKRQ]IQ\DWJR4@6:HZ<X@2/_;@9/ES_\ _&( SY[.APW
M$])<M*:.^4)V.K=KI2KB<U$]?7'[A63=;23KI>.R[6>"[EHG/OLQW66?_>RJ
MVS*V:RW_JMM>_9DR7W?7.M@ZV&L,UEUO0%]H5'##?@2;+,A@;U&"ZE&\R6<[
MPC!UG;>.3:KMMWQO<ZU:>#\6@=@X_0;[K=>A]47\5K3'34S'%[[ZI58=%THN
M?+&JPEWNJ^O-;Z-K#KXO3IAKS.8M7K<O&ZII4K+!5[W&QOK2K6Y2EZ./4_I+
M8\.U#/5S$_(NIO:S]K3@?IL<T7Z*-EOCUGAQ;K>UMD[SQ^\6SLE/ZIY\JRFM
M2[?WGY6AW:S!RW,S>R%PFM5J#.[N&O&Z1O>W1K^-.\Z03]=&;&)M-CC]7RL"
MUY\>:Q?E+J>_<^JW542:L,<!2LU6=C9_VV!U5;FKU#4&ML8/7W8XX;M2OOMT
M5OT,RAUV]K[K\&OK5/ZJCF2+;FA?BZV>%)Y>I-$/SBL!+'PK32FTZ\#H5O-R
M'7#5!]0'/*H';&EOQ,^=*7CZ52QSZ9V_:H7J/1[G/;Y6U*\K$&EVC>H?ULII
MC]NT==V.@KOK7JR/-7-O4!&.<96I-<SC_TGEK:=4>^&]HP$B#V;]N<I/*^5^
M>GJRN!D;1;X;@7WP]=X6A6_9JY,?^,&;_;.#-P?'KT]P?'_\^^W+YT=GK__8
M__#JXR]_O3KY]<WKPW^^??U)X=O?AZ\.7W%\%M_G/YZ\?EZ^^XM\^?S?^*Q_
MOCEX_N/P]4\'H_V??AW]]^,OW0Z=-BCC<K1$ "@BD]7$^P#$"^>B!FYT=CM[
M1IAM[+Y>R68+R$;E$)1B497*W-F"=4D:%[(!X%*K5,GFGLEFU1>'!UKJIAMB
M) ^E+XXF+D$BR?.@@]!4"R0;:?2:!O"5;"K9W#_9F&!5E#Y'*;+,BGDK(%/P
MVE,FH[]"L^F6C/@(TTGRL^-*07=#09WVB<XH3ZWP)$J7B93>D\!M(ME&&JCQ
M.I3^MO_?_V,YX_^H)%1)J(<DI(*.RK"8N $)3H;RFTEX'QH]5[IJ//=,-RN-
M1U+K(0,C!C@0Z6(@027DG.A0!<)ERH'O[+'=3TNN5JJI5'/_5,,X<*U8H!ZH
ME( F5J(Y6:4RDTR$4*GF?JFFTUXN>"T8U9H(*021.I;B62P2K:T,PB/_2+FS
MQS7=_;1JUOV1S8;"2#WV<K_HEI?Z;!2)W^R5UQ+F ^27' )7P3+F9))6B8!L
M$K.2T6:;C8_7LZ=N6(*O4L_MJ>>WKA,Y*20>$Y%U:'!$9LV(H]80E!1911>@
MK-\>?Z*%VK4;ZFUY#^TIOQCJ>Z0@EI:I'), (91T(7H=<<%%UM[IS#Y79[6"
MN \@7IDJ)D V/)>V8:5I>?"JU&3-)%F:1$#=S_.(ILH31OF:%F(5Q \=Q.!X
M41+1,DV2^FBMRSD(52HHH_Y(JV>SC_CM>#:MMEEGSXF1SA/IG20.="8Z9A"9
M0;1A<Y[-BM^^X9<*:JPR E*R4G'M2R.^+%-.SC"PU]2D*W[O&+\=5Z'C7&N5
MB E*$L1P))YZ0Z0$832C/AM=\;NU^!7<&JFLLCH(J3W8(#A5PN*6,)(:5Y7H
MWH*XZX03,O#$$]$^HA!64A#'E""".NN"9]1X691H)<3MW7 ;!/&&DDW[YGO[
ML=.EY^LRN+\0Y*CWJ/?X[#VVW[?]_+SBWZ*V>O5O7Y3JGH><=> RH13GREJF
M _7,0@8OI655JO=4JL>N?SM87"KM. F,:Y3J(I. NAE1-/(4\%,IS,Z>?"(H
MJZZQ[0.Q#29:PUD6S$B3O--*9\Y=LAR8 ZA!\'M&:L>(9LEE 91DYRR127@2
MK& D2Z]%T-H)Y7?V^*Y[%"C=1C#&&'&):>8A<DF3MB$[P1.35I<>;J)*U-[B
MM)N&J[-.)ABBLT>)ZFTB%O%)0HP.?W%@6-C9$T^8<;O\9ECM-R0?E>#T-D?)
M'(]..&E!V>BHY4[YY$TT]IJ!X>J3OF.8KL2I8UY%+05)D"B1Y8B@QU4DP0GF
MM7,A;3!;OHK4>X(ICR9E%IA@7$H34G!,"*V%0F!ZP6O^1G^QVG$],Q>C4MDC
M0HU!U=>C2,V&$F6=::K'&Z:;_ UV+R)U^\L9?.(,&Y#U_2&_RDEVW:SYOO#/
M=S?)/9$I953BE4M*LH"[%3<C91&U>QZ5N,)+5@K0XT^5B>Z9B8XNI(,ZYK2,
MCO!(.9%: 7'&&F)REL8P$7TTA8FTH6O203\IB_> SKQL)9)ODLZMI)!6,AK!
MRLQS," X!6^9#%S[*TZF587_'J';20)E-F8O*2DG?HB,,A/GJ"%0K'.FD_1
MM_AX[%;B]T:2F 8;$J,RRR2YY:6T1HZ)XM^9]>F*\^U5$O<%SATW6V:)0A1
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M): %=D7GI1JCOD\ [Y\#6"0G?3*.%-<DD9XJ$B@S^*M-*@C&C=A<D+H"N&\
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M&G&KH_>6H54UX'3+.-TL5"UYR2@E5)1"U9P'XF)TA,? O92)>Z]*LOC%D/:
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M:&7_P+K^!OYU7@Y8U,>[A:P>.TY<]>'[7)Z-DRPER[<-R+:5'==!V54"5?G
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M3DN;XMCZ#F6N<)U2K6937KW :9OG=L!MI;B^\3KL;@TGTP]D!BT-X: ^3[6
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M2OAFE;3K>E57YD+'BC/3"^M+VRS=^F6']OQ !34/[;<X-B5'G2AR*E(MXI%
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M]^MR;&X1F)IJIC.(>8S%+%'=F$8ZGX6NMX6:.IY9X]5<;;SF!R@8QNJH'9;
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M\ W6].EB_[>_C_\^^%#X\S\?O.OLT4_GNP?_:O]]</ACE[X]FZE_)IPX9GE
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MD'0UM52EM"X:JJ8E@HL@M-"/ \0"GR4V15 ZLA0$7X/O8'BG#=?!($1,C)Q
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M\($JA4N.H7(*-$WX[MEI\+%$XQTA6/"]S=F<$72;FTQ\!U%JP4DXT\)<-B#
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M[N$FAGVPCKD]U^</ELA%I5?!^V[%5<.0NV)(HZ"*MRNW@8.].B-&TF.4#$%
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M[YM\JN+R_C*>CWSRU;%'E+GD,PT"/IO(]XPD,))@8TE@\JZ**PD 1D\P\PF
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M]1"PT/%X& <4I28A1NCHG!PK1V]E!%G0C;5,$D(!4=:"JB+<@JZ=7*W*VH<
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M[!*&MLYUD]53":A8&NBO*D4QEA"U4MY%X5(\" 1T JH>3,?$4X>O46CQ0HI
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MQJ;7.GK\\_R0^5V,9-V/'H YF+KG$38-X:0P92%8'+7<;8AEXX-.O_@1'=-
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M%#[C>@#38[$/N\6[(:KS44UK\Z/HU>6J]I1#T@ U/KY>IWOZ2&=I[/PAX..
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MET.9'M4E['PT4M7B>=_*--4B%<T5[VD^XB/:=*C(=Y8 F!Z+<"MG%6BPX$K
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M$PHU-%#/99C- #<GT-D(J3R)J=26Y *(Y>B TY2]\9"#;U.]>S5\'2:NY2C
MHQQQ>XT^H1R5PAF5T0ES^$5A4G:<M7%W-JGHDYM[A(X?>#9'2[A>D&:=^/AZ
M? 6K*RBS083DJ89(0$16LH<\"5;J\IMUG@-:5DW*@VZAI4]N;06%=Y5V-;67
M-CU?AJ/1(&1G9#2,9.H\@BY&XJU&(UJA9V2,\Y":W+J^)J!/7FD%!1\EUXJ%
M(^=^?#%$8VC%RAN8O_RZ+D-P0QE5)OD8$&41MU:9?3G*-KC3EKO_0O-D=1,G
M91_B^N2]5D!#=7VTR\6[(7 0N!/H4!LBXK+!@8UHA+ER),G1NS*@HFSBN>PF
MJ4]^; 545))]O?L&T]*48OZMY)J7/B;E"&K9(:=0I#TU*F1+&"_74)U7Q&8/
M1+'HLM:6:M7D.N=C1/7)H:V AVKRK^O-KCC[8SB+,$+*8++8S#FU,0:5I2$Z
M!H%(S0&];%S$+.=6<Z^3%4W<@:=)ZY./6P$=E771,$?WJ(I'U''+A6#HCQ?:
MF8\$?7U/$/:&9BV=EDU\C3KD5\\%%C1'!321I$S)U'"6>,49"4"S@.!2,$U*
M4']?N<#-D?9D_O A>CIE_K"VUH-AC&BE2KNQP(@W+A$+/LA(#>>JR73ZWO.'
M3XZHRKH\9<XQS5SJ#):8H-$DB11WLV2AW#ZD(2BAH4T6U_>><WQRC%76Y6GS
ME%,04983G&AE,6H2NL4J*R(U#4)0&W5NO1-^KWG*Y]P>ZRCT?+G-5#)7['-5
M.G7*7.(P 1TO82.'S)Q4O$GVS@^5VWSZS;2AEEOF0SL3&=<X!P3:DD2F8$F@
M$;?YQ)".S+/)3=)AO[M\Z),CJJ.RJH'FC^%X,ET*8,V441873)X)\E!NB*#/
MX9EF1-E2%\Z:X-H87_<)Z5.4I0=XZ:2G%AGWS\9IR[6"G+2442J"E"4BN9/$
M02D$S6E05KC$VI1@>(JP!E<-5)8B.F]+-;K2ST>RTBG*$.4XM3H".-ZDFL!Q
M23=GR,WOCI 'I]O=M-!B&FQ$21GR%0(3Q"7'T.I$G]K;TDY#!"5]DISS)B?=
MWU.!HZ:8.%(7?8M8!YZ<I:")4Z7J9? (:1<-\<B15 &L.U4EBE:]O\]P"Z ^
M\,Z@[:H!DN$J/0@%L^JC=P'CB((:9)NHDX81EDO9KU!JL:2DB6'4TJ2B<&VJ
M CY"4Y^R-IIBJI9>*N>9WEQRL39I(2UQS)1+HTP37$X%X8P"\H4F9V@3O-B=
MHGG$*GV)L_-^CIP!&1)5!H5;[L67HW!'62#&J4@I=3:V.6W>1DR?S+GC]?]@
MN>PJ]NK7+=]#A.%569S?P,T%T*0H3T$G9 PGKC1!XF\"61346N,C,-4DG_XQ
MHOIDR]4#1#4U5,QNO,*Q)]-O)2\FEFL<25)B@['(&JH,%]A =+(JZ,QQ.6^2
M6K])1)]LJ7J*/UK,%1/2X+,?IG67WFN>;)#"94@DV=*N!CT$W&#9TF? W3:*
M+%@3PV<K-7TR>>JIOKO@ZZ:@W:X]LP$U3#%:*F)87B()-A/OD3D5LHA&^>3;
MI*7>)Z1/1R_U--])W/7\'C^[+(8U_E.L]2L_6IK:\^=^.BTM*-:U^Z2(-J$C
MEE0A+2*S7BM/$*81R;8YF29EAO>BKG^YJ37@45\Q9^BB\,X7.5S"?(C#W*6C
M6TN%NP]NUU_A$09NFBW\TEEFFSW:EZ?Y=_SGF[]V%."^HS1K/[\W:R<3;4U\
M'C+2"45\>@1?=X/IVD-E^S.;B6X'V95ZJA1/#@=X-YV4*@KIUV]_SLIUE%?#
M,2XVI=53G ^OEC&T ?5H[T6O<3D'0Z3 U=T:BTN\IU)*H!!=DQ[;^Y/8V=OP
MWY9"?YMOBDH,HK+<T52.@M7R'DXB5D840HH2#9^D4VQR1VX++0>&F]IF9C0"
MS@,_I*-*:EZ-B@!I]@HE\1Y]HVNR;J)EI3C90&5&6;"1\)S0[M':D4 =)28$
M18VCT<<F2==[4=>GZ-2IX%-=:TT ]7HV6Q3C[FW>[#XT<$F"<SX2(WTJ/< I
M\<Q[ H%; 2%F:%,TXFG2^A3O.@.4*NBK8IK^+:SO4,,@,!EY).ANN5(A,1.G
M0BDGH3ES@2:KFJ2]["*H5ZG2)P)-%>746W+6M+R:3)&PQ31>^AEB>/.FB:%)
M,$_+VD<1PJ6W<HBXRSJAN31..LZ:FCN[23LPVO9#P*>RPIKL71LT+D.'VV00
M<0>EFEHB0R[M8:,@I=PP,4JJ3 -E3#6I$WX@G7V*V)UA5ZNMR2K5,Z\)S!O;
M[JHU_"2O(@GE+Q\6839,0S_]-C#1\."$(IR7VDG<&^(YE(+GU@9EM?;L7NK#
MUJJ:AX[;IRSHQMAIKI:JIPCW(M7O83:?#N,<TCJ2??>-C4^^@^EP4DISE L
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MFJIJXN>MB!NB?[ 1H5[>:!6**6Z)]1(),[P4F6:>@$W*"*H=;[0;/DW;]Y!
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M\N7[!]UJNC\/=!_2;"US)26=*%$.T*50).20B><A<!JE2VT.[KJ1W:=H0?]
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M<+R\ZE9F*771"9=P(:#:EXZ\@;A@<(4PBE&C/!6^2>K=?N1U;_T;YL_734V
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M2>YCH*0EV-KHLDH%S >T/I_@RU@\I/+6367&V2!'FXR(BD3/2_]3]+=]B)I
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MP-VH:*2-BJ+95-UZ@2P_@I_!O_W+_P-02P,$%     @ 9%=14N2HM0P8W@
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MY99G-JK#TA7U6D46+BRMY;D6(X@U)R 65"%IZ83EQ+@?[#2!W85]O0[CU[K
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M8TE#K>^: XNURU3.D=.\L@R\"VD;'WXX[O:5]*2EF!J_9?]^?@:CR<D2B+,
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M0$V+T%+6,J'5W<DF6JF2=7B@1::_61Z1ECY>[6@8?NACLB_Q<NW^"%^N_'+
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MGY2_OI,.=/37=^'B03RO+@"_^^OWXW-G%^P^9#R(UI28R7T S82MF2.Q9HZ
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M?7CUEV<?"<IX$1/#*^'.DDUMN%4;T>L$]=@Q2*9R4C:0F6<Z'0ML?OHQT=E
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MWBNF<M#).7+Q^_1]/Z@V/!'./YPR["+M#DJPYAW<A')TD, M[8!@0IV%57?
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MB7JMJ&]CJ&_[&PY[5C<2_ZRY[#I<7]T&!U>!O<7D:Z<=JVSQI22F--;U.<=
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MN+RP9+<(+C4S&>JP,/0,LBZ,C">G>1% )LZ!M8E@?5^:LRL/'7H![1*(*3Y
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MM(^+&P6W"G,\"C"*Z(5VD4&)Y$EY3@!5\:2<1H88K"M\4+QPP+O.@?36(MW
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M$FU.+C//T2@E4^W/T7]#/U^;<6<A=\^\O%=H-037=SV!;"?BA@Z=VD?JAYQ
M%J4-Y/(BLR778<TI,)\!6):)V\B%"NN']W/4AMTGD'51AEV$W=AVNQ?R^/D*
M?X<OM8KYQ32_PT_+U7%UKX@R9J.D=(J5B)S6+I&%A(457?O#%.UD&-*+98=7
M'ML@V)>C67\!MQY@MKF0W1HNL23%A!!D^H"J,YIRK+^4;+C(7 V;1'?<^O^N
M1#S=#F 7*3:?,+BI'#H#(:'-BHE5TJZWCD49/.,%=5;2@57#VCP?M8;\<*R.
ME6'KH65;.LH;;Y7D9*R65+OJH1#,.T-GE9=DKYH"9KV(YIFVXM]W,VXAN-8?
MZ);FB-QHX#D[EH(A]8J1# W:*)A(,N44BHW#6KV>?%?)_;D<+[CFW^66%EY.
M68V1":X]TR%9!J 20Z%IW1KI?T,"82??^6Q_)D>+K?4TP,W-8.C(\%I;S^IJ
MJFHI!B$EY@Q$;DN100]JI'WJ/73V)G*\V!J/ GP]^WQC!8BP:4S#U\:7 D-(
MDO$<R3(P@2R#D@KC,O.,M9.[%P.('?:V,R"Z@UA;CPX<.)[!H>4F%J:MU4RK
M!"QF,L\]#U%'!!OL$.)/;>I%+X[VF'^Q@X!;6U:#&BWZ3'9$EI(I+^N CL19
MA"(8QBQ=UL6:/$@#3JM[Y2$4H+EX&UMC]]>_86S'K1M71$X\<%9\H"TP>,V\
MN.Z"(2%*3U;(D'&$@UYV9CM_&Z$V+ H>.H@+,S=@R/./Q07:E+)DJTH G[E2
M.BC0?%#XXY0FFW4B9\<19[M(MO5V/V X3^)<(I)+D53M4T\"8$!_P )&(74B
MAV*]$/STIQT=@/C&DFWM=0_IK5NRHE-.2>9DK*/E@V?!YMKQ2 J!9(=D,VCJ
M[/-J5[RW(]=:I%O+^7NTU'R7/F"^NL39JG3T)@MC0O ;=-A\ZMGM&F[NM(JU
M_ILY:Q7IHT9K0?LBHXU)":%-*8'3EWBQUX)&DO$2%A_^N.D,46;SV_J\V?3N
M'[=E:(<7]J!MW_6N<2G10R0O2;ALM,^B=F?CF9<$62B3\D8N]UOZ#@2_6\[2
MOWZ"!>:7LX^?<+J Y;T$FQV(V_*@L80,P;<FZ)+!1"?) 2)!.RZ]<,DE^FI
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MFR7F9)@7#D" =JKTN9X<AN]\E6@<%1VN.OX@=G$^O\GDNLX?O@-Y0;X->NF
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M),UB09JDI=[225XKZD25G2W%R"9U1!J-YY7M)V7((#;]JMOV_,_;Q*+WDU^
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M0*%?-[RUSL\\0$$K[7@MBU1"=??0U$[G13&:Z8;6 )1!-+D^>I8!"OO0HEN
MPC[J&?(:N@NN%Q^@L)?RNMY''R+Y04-71$S<1L<DS04R(7*M[^$"(]^GUO<
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MH_%M*FJ?:+S#SZ^G1.L6,[(Q)QN<E&X;]N:->Z.3NW-X@8P#QZUA00<:E.#
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MC2_P0[GS>Y=FEJ2ENW  IK"6O-(AL9@S.=3%!]0&@C5=,O6V/?\9.)&]B6\
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MWNAMEO.;BPM<#735F$QP)64!Q\CK AIGH46%7"U6,"F32LZ2=W%+MSW_F5C
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MNR7QEH1!'MCJPPA]MMQSQ;A"(&%$P:!(S;()00C08%R3>+Y# ;]2<QLU!Z%
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M)ZAU<%.")GE\-P">=][V/DQ\V!;E !4UB\VHI3G>;5TC:!GY4#[#7Z,D;"I
MZD93/-/*%.8#!V:<X$II&T1ITF)O'Y"OE-L=)=% U2VRN@;RFPU/ HM3S&M!
ML\]ZRX*GCX(V78S%.)?#T]Q,GFTU@..GP'G1ZERJ 0P4.Z"=T@JB8PXLB09X
MK+WN/+.%EI<D2$PI/\T9]Q+.&?<B]FFB]/8AV!F%-W6!_1JE=\94ZBG.Z1 >
MG!&-2RPZ"^694[5C1BW80Z:BK?6[:VX:)NF[G.P^;?J>1Y3>*=B[C_I/$:7G
M:/M"FQ,YV@IH_TJ%_&Y+SK>-'**/8.1:>>07$*6WE]+VC=+;1^(GB-(K6G$K
M4F!<ETA^KJX',;&PVN[6:&Z5Z'0C_1JE-YP=V:=*6W?6V1CWT07@:Y3><7K=
M.^#J$*6<)$K/N)0XK:I,N41 02"+%A.38'(R7D@GF]2]>II1>FU)LX\N3AVE
M!ZZH+(5@$)==$$DF +[&XG,E7<B%@W^-TCM2Q\=$Z>VCH'T# JY_7+]$F./_
M^5__'U!+ P04    " !D5U%2_4=TWX,: 0!>F@$ $P   &QL>2TR,#(P,3(S
M,5]G,2YJ<&?LO =44^NV+[X0D*9&Z46)" B"@%*D$QO21%2D"U&0+J B36(B
M("!=0& #*DH1%3'2!8$ H0DJTCLIB$A/!,*2M+?<Y[U[W??<^^[99XS_^)_[
MQEZ.R6"9?&5^<\[?_,WO6POV")L([#0_978*X-C" 5R"_@'L96#'L2L!KNZ
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M[B8JI8.VT9Y@1<NF6+*!\@M0N4U4(.B9KR1JR#&I)(WKLWF,[L[IAR*N"$F
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MQ>J'8O**Y_3<R].-7CR_*.)Z__4P_Q-.F>2CXNHO<5W(ZHU$'+$<03D5P.F
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M1[VIIG39S,VY?;97/8$RX"%G1Q7@G%^VAKV'!H;5IOLJK79_V\@Z/]M5735
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MS_;LX'J1:VYP^J7(QLMZN8KSZ\G>&I>3S1<9HY":75!;AO5,##UR%W3=Z?A
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MX7#HLC/3&KV:3&/L!9.S_R:5<B_X#ZV_/_@M#/?/UG]?:UD&FO &7<O^"$+
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M5$X2ELY=X]"8]9"ET]&$6/LWC$$?EVJNVYKV/O152^RXIF#\E'/HA,V=L,D
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M^!&7$_,,@[QG+*Q)$-9)X*ZO8#\?[.8#)::KF;^RDN[$G N>(D0 "+^Q1#[
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M93F1407TH=FPDK<8\7"/!.9B;/B20/?SC^Y2E_,/ 1NM.D^@'BIN;?@,F5/
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M9$ZU;@QLV%SK_;K1K\)[]4O\46GO=[)^I]XT=/.J04J1%P;YJFCX4X[P(!A
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MHA70>68D=3*!BD5-=Y6WF#%_W!&_\_35@M5C%W.N\&X!IA7O*D@I(3*/;(I
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M4_/>X7E;@/?GI6W@&S6#Y76(P\5B;H37Z2!4Z>/=?:O/W<"+AQ4#9#.A>8.
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M>?$UP0SM[_NBFMW4$_:H: BB.B7&J-7EA)#&X5S5%S\+(2/.!OP::"UKE&L
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M:)+X8-RQY20)LBG ?2S "X9)@)T-AP%OY#<B>RL4P^B,!J1+U?OSN6J !\U
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M_]X*Y]_X-_Z-__] KX[]!U!+ P04    " !D5U%2%+0> /7J 0#!_Q, %
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ME7HA-+8]M!-.DD8IWBCNTP>JC^0H7??R7"[1!UJV.#\?7CG4<8UL=XWC57&
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MKH/MW<SM/:\E!5M1RWA4\*+^1M--_ *ZEQ?JPV V\LM_%B[S#=(6L/17S,.
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MP -^*OSN]:VH?F-RV2J=#.F1J?%L0,T"E&*7SI@[V;>?OVA\:)"PK-_ Z!O
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MVJSS-4Y8G-Q>D;R(C5P2GX<".UBN'MU06G.(PI!*N\YR/.+;D>NRP*@ZGJD
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MY1HYN'438V[TUY19;>@]**E!7HH-7I!2NY\!E1J8F=8=ATG/3AX?_)')ME(
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M]0&UXF6V_\;05[HOJMGC:O> -*Y:J)":&3X?^HX\<WQ.)G(/FMWS8N1_-/7
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MRUTIXW-;3[8(J'DH_#CKS(1_35>R&54F6^UI+CU$1<CD*!!'<@NR7":-1#N
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M&9+"VKJ;E*(T]#ZD()U;NE&,9+%,'=Z\Y>6_U\EUHBIWI9DDM"6W(FXCA\(
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MG10H=+O3C;7+]49_)N2*KO/BMU7Y*'FN<BD:OV]&$./2E%[%ICM\%DC(0II
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M:98(PIPR<2SFG-L7ZUVYR1^J0ZIM)2-8:B$]]4X[0MK.U^ 9OY$_+JW]TZY
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M"##F;D&SU*J2EBY!4;M BU5Y(?W"2SO!ERMBO1_SA_+<F@.:/]1J[-O'3M8
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MAG'*XU#!C,:5PR:$1%,IE-@46:,!"<+8K290+SGFQKOZ&4.NY8'Z+8 =@4P
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M/%53;@.@K:#RV?NFJZG<)O9)6>76"WL6\*J(D3]]_4X?FR<N2)( 12&#7)
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M*(NE0L)*O9#]0=1_W])J51*VFB6$8ZQ 0\0#I->%&%0"F$%*"(NB2"0B=%)
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MI5+:UWR_99X33)4TIY3E$&&=,2+/(BBX%#((!*'V67@/GGYMFORA! ;AOU9
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M29:$B<Q"QMI4='8C]]DVK;[INRGHQE[G$ M1DOGVG!>KD;H6F#Y'MMU([X?
MB:1"2L%,U$>-&N@:M5]5EX%=\#?F@QJ__WI%UHSYK4=]KM&)*U1;<G!8L]KV
MQM$.HGX1JSNI3V+6G^N05TGU"G4$*1*1\E!R#O,L0# /A"!!&',4Q9Y/IAZ
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M[^CPH9.\DB=M:5_#TQ<,#0!O-NU,KK%Z@GZ[7CTNR^)_!5?S92'SG.I\I2B
M""4QS,.0PU3-G!GFRH.QBV2T:^[:7M(-6E!IN#?M"AG9('9?K[8DWFX"YH_.
MD=_Z+9/?:B:;9>$M6)_AUS:D^ VT[FUQXI!J&^L/@Z>M[AJF,;VU:E*>48G2
M# :4ZF08:L17LZ$,9A(1&5'$<I*[*,S_2P6#O-0&\E )Z/^1NC_3E?B9NJ#/
M]93O&5*L9X32/)NT/:18Z#H/=XO/"WUDP^3(F"$:4$P##BD.4IT$3$(LHPSF
M#/$XYRA5GPU8-C[:V)6N#.L33,4&)7A0T%US?AVEUDXPAC,U428OA0^\T0C?
M@N4"=$!ZS-35QX'7I%Q'&YHV_U:?K0>IMGHO'CA-J7<3J^_+6_8_ZZ(4WY1K
MLE(OVE/WRYO&3(@DH) 3)B$*:0CS1" H68*#!(N(X]!M=\^JW>O;T+M7#WHD
ME:CJ;7T%N<X155B\"!?P;SEI\<;I1'.7!J]>2FP0@V];3D<1%R>.O$YEK!J>
M=D;CPL7!Q,;IYH%Q"*0H_TGF:]%YI#EI5HCJ^R-9O2=S9O:6U*!MMIO,Q6WA
MF=\74D?0\'K-NGF3L SC,,H3R&@:Z!2!&513H11B1BD-(IQQY%3-P3_$:YM+
MM1@!VZS]FS>VECP=OO1#_4J?!6?DN= ',O3UCC(X0D_;:>;K]M_( JN- P;P
M35=-;T!KH2YDLP(;&\WQ?6-E?5>WC-;F:[#= O(HR^-U@]<=??\HI]WQ'XWE
M@XB \5IRCQC8*=34B:K[6CP\KJK;!;^C\^+!;*E6>@!3OUJLR5Q!^T;F&J]Z
M)Q^7<S[#(@E3$0J8R21H @ST-P5'NDPWS1BU3]/O"]2U#1<U3).-I=) E<0T
M2,&;AU*H+J_+9SE$H7OKO_XAX;5Z9>1!X&1MLQM06V6R<G?LN@'&LAO0=*4>
M%(QU8&/>*_2=?:#%:_3A1'$9Y_ORUE]?.D5K^":])[C#6U.3Q8+X)J<;.N+]
MV<.F:J8NHHY>+\6C6%0*2WU8U=02)M7CI_GRSW\7_$&TBUBW4HT$7P73);@*
M63"#\)V0RU(?<)UA%$0A3C(8F/WQ+,1JGH82F.=)(HBDG&9.NU>>\5W;J/O^
M4?>[GHR)36["9QUNN5QLDJ))92)XU#8Z3LY\]ZW=S.P5>VSD$;FN(;IC6GO^
MOEY:OZD3J&D+@3'Q!G06WF\ T9:"?5-O #7&ZD/\_F9F(W6#SVF9;XB3SLE&
MXG=_0C96,Q<N[#5!X@O^:T%H,3?SP]\$J=:EX'<+U?RZ+(O%@[K@RW)1MC^^
M(U5A,@5_7HFG:H9C&6>4I)!++"%*U=R,)#+3B;VYI#(,HX%K>C[07=M(T5T3
M:I(3:?^_8R%H3=0[?!LCS55=,X&Q$_RA+07&5,=JL'Z_!([+?5-W[80K?9/U
MZO!5/I_LC[+ YP7@ZZSM^>3VY+*>UT8NKME][OAL=>K\;%/AFXLH0YS B(H$
M(JH+]&(<04&2)(ED%A.:#JSP?1FR:QL[=NI:=U(4G$IE4/7F,KBXAOB%W6XW
M8KQ*9XX\6DS<CY?4-/?#^4@5T"\$]UKUTOUPVE-=W5,# Q(0Z2#K)AZ!?UCK
M,>=>E,6R29#P\2<SZR1W4HIREN,,H2B+("9I"I%@,:0!RF$<,YZ&(I,\L3H2
MY=KPM:FZ@5T5F[6BY=.3^I<YF&$6E!KLZC,%?F >(9=^.;]+,Q;;8\NNH;3%
M#6K@H$;>'MS0"7X:O@W\D3AVR-8S$M<3[9AXY=PMT<X XOIRZ+@\;KKT. .,
MW,E\,^1^]YH"WTNBL_)^>WFBR_E,2A;I6BHPCXF ".4)S#,<P#0)69B2-,S"
MQ+:*P,Z3KTW9&W"@1F=?)V"7KGX]OHB$D077TGZGW/]';;T@V__N\R;+[W_4
MC&Y&_^,7N+MD9J6@XV)\6#Z10@TY,E:O6:Y>.D8C->?F <SS6,"<!;%4$W(N
M$ZO]O=--7-O+6,?5=9VM/VJ@#GDH3I!YWF.ZG**17]41V;'W=2YG:2*OYH M
M/RY+O_T]SLF)&R=S0_J!=QV.,U<.6XKL)#GJVV>KEYW".,X9S1)(1:0C&W3Y
M(BP)E AQ1(6:A@;29;71I?&KT\1.*K"SN^+#U@N=^L9N27 LQL>66*]D.R_J
M#6'-Y[J=4_N3+LT-869_]6W0,P86)2FJYV5%YO\HE^OG]SOQ <V(FZ$D33/E
MS:68)+K2MA([R@D,61PG:N;%$$(N$G>VQ6O3M18P,(C!+F1'S\:>=COU\DKF
MR))U(8_N]4ELN?%:H>1LH]/6*+'EX*!*B?6-PW3GJZA6Y9JMS"K1-[%:S<UF
MPNV"?WYZ)D6I?[@OES^49[=<5#,:X)0Q+B!-8UT;B>:0B)1!'"<XS)#Z,W6*
M('5K_MH4J9XQ%!ND-Z#LVG-C D&6QBNHG@4KU#O''DGY("KPYLMR)4#BF(;)
ML;<82UA$609CGC&(I%!#1L"5:QR0()5,8A9+ETI6(_;69(6MR. ^&[6K[(:9
M\3I@Y#'GZR['6^B&[BUXL$7O;P :QIK/T<@1P:1#TS!V]L>I@4\96L&/KCXO
M=(/F4(9X;A)(W#XMUXO5+(PB*1B.8)KE B(L4YB3E,(<<Y8G),(QLZJY9=?<
MM0U*6WR /#R4)H,'>%;=PHIGK7\&M&L!OUZ^+5UD;RR.[1\KH&"+] 9T&+WM
M9V] [3X;4OR6[NMM<>+*?3;6'Q;NL[IKX)&K\H$LFGSJ[Y52+><%KR-M%OQ>
M?<O:9>@[^:E8D(7V#[ZIW]01.+=4H2)L-<LIBA +&&1YG"O'*Z.0<$$@CT*4
MAI%4PF2U&>H5U;4)5=>H&[!CEO$*NH;I&)J-:6!K&_BCM<YQXN^GG^V4;_+>
M&UD@I^HX]V-5/HGV>IC*"[!ICU#YY/+@X)37AP]3^H__LRZ>]0/;9.Y")A)A
M 442)! 1P2 . Z2$.XDPHTF<99F+9N\]_]K4=P//33?W6;-3P NX&%G+-LA&
MR,MZPFJ?PK+?Q*02<<*^_9?]U&7N82\?1,7*XKE6A@^B+'[4!_3UT>QB]?+/
MY5RYA/="?374K(3R( D03F 61.I]ECR!>9*DD".1HP2E6#EHML$P+@U?VXO>
MP:X'8[Y!#T@#'_PP^,%S;8!];(A3?_0KQ9@LCSY?W"%X"QRTR$$-'=R/2K!]
M2,Y81$\4J&->F+\!>]X_-FN-GS_\#6QGD18<@'=$M<P$^*Z,^!M8$/"!K$CS
MT_W'K^\_?OG>Q#TWO^3KLO9[H8__*:.D+@.F'O@W\'DAE^53_7238N[/Y7K.
M@5CH[6=EE](2G4+0%#BM5MH1UU5.FW=;$:1_$CI=V,N_5L=DX!?P5:?5%]K>
M\&^@OZN?.UZ:N@W ^S6=%Y5>-O]T^^T=@%]4!V[]_=UIP"UC>JINHD@U4'W>
MZ8VZ[:VZK:[O&L:Q>B0IR4-)GA\!0@!^6]/GS2\B/[%90UZ$GH@MI\=-%L<U
MQ,AN=->@^]W#R4TFNY=OCV(^UW$69/$R2Y!,\IS'D(N(012%RAO/)5(_4I0E
MF8Q28AU3?OCX:QNH:X3 0 0-1OOP\B/T]8^XEY,RMFONPH=3N/EILR^(.3_R
MT,D"ST\;U(T^[[EJ0 @Z?:^>(TKRKEC.EP\%JSXOV"_M7!JSA*<I4G-I'$#$
ML@SB)"$PB6)*,Y&3C%L7C>QKZ-I>X0U6L &K(P!_ 6\VGS@<\.NE^+P[[8NX
MD5_SDYRY5Y3L)<PA8MT3<5/%K0\FT"V.W8*5OFCVOMNGBVFW,&(GLMWF>G?Q
M_/]?E/_\DS3?S Q%+,F1<FYPKMP<G*8PQRF%)&0)B2@2<6J5*N/@R=<FCPVX
MO_XES-#?[5_K7;;."]]@#D96N@;7 &';9<!>R08S,9%T63/BI%1'K>Z1IMWK
M)].BHS"[XG/\@J$S*S-!9Y_F2[*:H510+B6'21QQB$(401RE$HHLR)F:5"4I
M<YQ8=9Y^;:K3S"-JA,! =)U6=;FSG54-9&2:2945&0/F5$>,OGA*U7WFQ#.J
M(^8<3JB.731L2_+=NBH6HJK4[(P6BSJ]\/U2/?QEAG&(L,P"2'@8Z]*V <2Q
M\A%H3'",1,:2!+OL3IYNZMI>WQ8IZ$)UV[3LX=5N_](/6R._VD>) C5,\$?S
M]W?Q<P7>J6_Y?WO<Z#Q/C\\]SY[6)MW^/&_U_DZHQ1WNH_N'QE73^P\S3M4X
M'J(42A$IF6 40X)R EF4"_4)#AFUVO3<?_"UB4*+S>RZV(_F.UR='\B',C#V
MAJ.5\4ZC]S%++QBX=QXWV9A]S(CN<'WT<_<7[C.3Y>V:%XK-V]5*5/4DZ=.<
M/,P0"A!G0089TX70J)K)8XXSF%#)94Y)$&;<]O4[W<RUO8R?WW_Z"AJHH(,5
M:+#V+V</K^=?53]LC?SB#B/*Z44^S\,%KW7/PR=[R<\;V'WE+:Z^H#3'E^5B
M^2STAK\N)*V/@W_\J5,SBEF4)5&BCZ!D2<)U\!&&.,TEC*50?GPJ(TKC 36?
M^UNU^J9/7_S9@+XQQ:O>% ;O6R!JQ -*9ISF7*19)#"64+ L@D@$*:0D1S".
M*%>,QRB-N5L]7>]T3\'TN"3;S9<\$#=EU9 NTDW&C@;LZ?VZ854_SK+BO8C'
MZ1:GK\EQUOJC)3;.WS5,Q+^7)KOZBTF86"='_"I6.FOB+,F#G(<H4],G79P[
MSC&DH5#S*IQ%81+%L>1B@("?;O%*Q;M&UX9PK1KX3;):][RU%LS;*<R%1$Z5
M*K&ARZ#<9D9MD/I3EO-L^%25GM8F593S5N^KB<4=PY1$J9)^M/@@ZK\_+YH8
MQ^J>O.CXS-L%5[\IUZ);W&$F<,0#A$-(! \AXHBK?PD)HRQ+:!QG61@[I2T;
M!N/:YI,M9O!<@^ZD9)AO4?_U+WD41G\O&I/!&]X8[2A% [O.3J;&[Y"QIZP;
M>EL3WNK\Y9LNNN]T46-(MT"./XF[C$F?\C<0R:32>!E;^[)YX=,\.&=-Y -!
MA <XCR&+,($HH@+FF! ]R\8",\DXLJH5W=/&M8GA^[IRP+>V<D +^0)_R^GH
MWH443>IAC7"&K\?\T5RJUSC+UV-GKQ-U<2C<;?A+$ 0Z&U;U82W^SWHA(L51
MU(8Z<1:G,<M@CCB'*.'J7VKV!3'/8IG$",O *I7+V9:N[;4W6/\%&+2 KP70
M4!TB87M9[7_SO7(U\ON_0Y-""C14$-T8NH9$$/=_&^U#B'WQ-U$@WH4\N@42
MVW#3%TG<>_]TH<0V9NS$$EO=,,Q9NM<Y:4WZ!+-@=K^L5N5FY>:=6 A9K*H/
M1<7F2UU.4$>!F""061JD#,4)@6F@5!:E3!?P"',8\B@C,L%$!DY998<"N3;]
M[:Q[M:C=/*[!/6+GEDW!\\C:?81B\,<H\4F7DN73TQN,95)W\%+&]GW&BY_G
M[EC^5LQ%M5HN1%,+K_JV9DQ4E:F/]U4\Z+S>R_*E&=IQPD20T$C-+,-0S2Q)
M"'$4,AA*+J(88QXFS-;1=&KYVH1O [ZM1UG=@ 9_4Z=R:X&]7^76&>?]T]$H
M'EGS7-@=X+ZZT6SOSHY&]T3NK9<OM9.3.XBQ'J?7[7F3.<&#S.PZQ<,><&EQ
M:Y?"#EO/+$LQ9V$00)9%2(T120ZIC#AD@L9)'*0AXTYY92_$<VTC1[< LE-9
ME*&UJH?UHIU_/6'?C#SD#.Z6IEK-.$<&//$[3@WJ89!>J?+T1?R=KC=]V6.'
M[J+?ETNM_E]%)=3=CVJ^\$'\$/-E-^4@R;,,,;U0(6,"$16ZV'00P500'J=8
M_7]F56+:J=5K$]M-\=W/]U__2IZ>__[!==?;AFK;36[/!(Z^IPT:P*!%;/:O
M.YA'V$ER8LGO?K5-PQ-O3SMP<;@;[7+S!>'=[Y<+DVBV72*(:![&(H=)2CA$
M*(T@#3,.HT37%$BP%'9[43UM7)O*O"?5(_A!YNLZ@5RYKE9@^>="R4ZQJ-:E
M28W'&@L&A!GO$6RG-A?2-K*VM%Y5#6\$&>DQWWOD\%XSTX<+'[?S:(SPB4N'
MO?Z?2%'^4W_M/R^>UZOJ5ZTN<9NM1?D96:P4((RC#**$Q# /,(,B1"F->)Y)
MX12#TM/6M<G!M^)A8<J/J0'R]\625J+\8:8(-70U;]#@__J7, W^'CM.Z_HH
MMQ,&3T2.+! :)3 P;QK:;H"!"N(1U,*"$Y^JT=?<I.IA8?>^BMC<<NFZTTZ5
M).6V?!5F@O5^6:V:8KFQTA*4)@',,%'J0K&.=6$4IFF:9#R4$8K#86M,9]N^
M.K7I+%SL@#?.>@,?&/S#JAB[](OKJI%7MB=<(;J4Z L6@JPI&V?1YWSSK[3
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M34T6YV+SL:Y]I*XFF@K3MT 1 AI&@*;$G]1Z[Q>?6NP/W*1B[9W3?37WW\"
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MPD/PYNDQV!26AVOGL3[/W]X0')FS6_#:1G);\*I?!$9:7Z#94[,W\":BXTM
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MXN4=@YN0YRLIFD["G_7DOGTV?U;\_4X/<5>LC3UK6E!%,*8(R0B$F(4 2H8
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MT.J@$#0P7.VNN%F!!HJ@Q:*ZJX/&O%\@^_WNF;]($VVCS_F%<MJI?\7I[#D
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M1+:8+8:B\BUX%R7]ZRII\\VRM_':!&^$@^OV&O,\B=NWIUB;3UM':E\%1KW
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M.[)N$S^*K;27UC^=Z.6P6T?_-TSYR$OJB10MD\_S0^L?=-^&]IJ=(B95J\;
M)!YTDK:NSMPX9BG8:>=PW"JS$^GRR@5LIYVQ\[5Q)Y;'/=;-.+V/L@UU"Z%
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M<LR-:EHUS#K=*-+-QM +=Z-+4"GCV(YOX%S9T=,$,S R=3F"/ZI+>2&:7ML
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M@.S%!T]:?EWP'!1: _ F6P.^6:U(7AS^:MA0S\%<]N]*IYNAD1FM402T-%F
MUI25RH!OU90=] &E0KJ$.BA5FFQNS#>^T\W11/OBT>?*:O/L!MZ.O?65 TRV
M]78#1'MG[NB)0^.K6*X;=G]:_['.]QV#[LC/.JRK^%1\4_^NAJ6KY_UA*F5$
MQC@B,(P"K ]@4DA8',$DX"E))?*#R*K!]B IYK;R-4KHMEN[EAJE/[5NZE&
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M1!A)F(9J8YFFL?"%]-+0QW:MH 9*,C<6^D#R=;:^KZM:\+:[>W/(PH: :@W
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M=7*:<]7#AO'F;YL-_RM;K6[6)S7##J<_^S[1U$]"PGP. ^SIV@E<0!P'"+(
MT2#"G$>1E:5F-?K<K+9&^#)PX+2@WD$!DR;2#B;'C"9'@WQD>G2*MC4G#D+-
M)1?:"3 I!P["YIC[ACWDFE!QJ^/OM\]6!^QEARZ>Q@D-40QC7RCC,@PHQ$BJ
MF1525]%.9&K6KVA:L>?&LB^#=, 7=:E50[6))]V,A.<WE9.&6AG-XL 0VZE
M=1^<.[KDKQ#6.]5LG \(GFQT^X*Z[^LN7C?K]8ZLOHFG3;Y=HH"FE) (!HP@
MB"1#RKSV!"0R"/Q4R!AAHR"F2P/,CMMK&4$E)*BD-"^N>Q;$;@9V <W87&F'
MBE6AW2[5KRBV>_:QDQ7<[5*J772W\SK[;I5E2,NGQ\?=>K/:W#_79X*4X$"*
M2$"18/4-)_H<(XI32'PA$2=^C)!1(,G%$>;V$5>19@<IS5LKG@>P^_MU LO(
M'_ Q(@.Z3IZ'QKS;Y-403=1ETOCEL6HHV:E]1R/)\_=-UD"R4^QVX\CN"X=M
MBM]M'A]%KC/OOQ)EY-1OG">EP-1CT$\1AB@5BLV0CV$@4LI\Y/F26=5N.SO*
MW!CM("0HI;3;:)X'TFQ?>#4\(S/;,3(CQ'UT0N!RTW5^H$GW2)VZ'F]INB\>
MV#2R.56HHF_/Q[H=&BSIY,IS$9QA0M,P"B1,L0[@\",?8D)3&/L!C_V48!I:
MM8QS(];<:.7NT#7.LNFDFUDRHZ#IL1_[7-4P#G?1;B;GL.6E4SR=]LAT(]FT
M336=HGG2A=/MT^VWE-_%.MODNM"*+I[_.WD.O,B[6?/O"IJ2[P,O]FJ+(@PC
MP1@-8)H*M=$D3$(B10Q3$:@/020>PD9U["W'G1NK5J*#4O:R[822'FCQRX/"
MO0) :V"^_[*9B/X-ZTCPCDV<%Y&].4%VP!;7!F+SC>](4$^T';:!W,U6>0!>
M'1MHFZ=-MJT>H&)[LSWD]L%;\/U:H@;X=J@"?QKL$7(J4LD8%(DD$&%.(&9$
M0B^(O3B-(AQ08;DQ-QU[;BO 0=;&>BL&1]S83('QEGX,8$?F_H&8#MGMVZ+C
MV =@//S4G@%;7,[X"ZP?86^Q7HKK)EO=\.G=BF2/.H#G,2N4&;U,*:,>2P1,
MHT1"A+C.LHTP%(+'OA\JDU87I36S6:U&GAMGM3(^*GD7@)42ZY)QE<CFEI3=
M'/2;JZ,A.S)I74P(N97@:P-S)3YX/S;,YB;K:'!/9+2ZA=W*>AT$78?]:O>\
MR2S806JV;=AA#QB8B5-55M,MJ74,SAWY>1@Y:Y<H"X2G:Y-3F*0)A8AS"JGT
M,>01ISA-9>+QQ*JJG>' <UL+6J7HZM)SVA'Y0G;++!O3&3"S8,? =6S713^D
MXY9RLX3,:=:,Z=C3)LI8(G*2&V-[_]#R9'3[::VLXG+A+-^092)2%.,T@1X-
M.$2)Q)"&+("I%V.1!-*/ Z-6]QUCS(Z2ZKIR^@/ZO%G?0]T<!FC!P4'RYA.R
MW&*?@]B,B*X$;FS.<8/9@*I:%U%Q6Q'K=)B)JUE=U/.T$M7E2X?QPMM=D:V%
M-J(>:;8N#>I6'P,N= YS1O8I*S?LOW=JM\W5OKO5KK%LIE5V?5W&'DN%0,KL
M03C1C=XC2# /(0IX['&$0A8AF^XLCN6SXJ,)>K?<Z3'4I!ST*/L>DE(9._IQ
M/9-FU/6*\S,R[36:@99JBW:'E[9V3;9>HU]Y1M?2$-0JEN7;W5'D2.B[I%?7
M(DY*S2/A>TSK8PTS;$GX/5MO\FS[W/0*6(I0$!3S2/>45_\A4D)*0T7L'DTH
MCQD*F%44U/$ <S,2CWHF9+68EGQ\ J,9H5X#SMB&H$[1?]BLU*M4_&_P0;V$
MV^?I&TY< L@E:9V,,2GK7-+PF#8N7C?0OW4V*J@54?;V^7!)'7!V\Q?)>?4F
MM/8"91CWW0-9WU8=5G]3C]@6G]95V8>CGH+E/[XG6_&19'E9$F(9QSSE421T
M=S]/$0[V(&:IA"0,1)3P@/EFJ2:STVQN3+?OXMGT3KW7(@.N>S!+)33XH:4&
M;[(UX.J#)GD!='!TH<&R;+\TFSDP=0[.1=XY+0"MB-,7_;E;L)25$\]%IFIL
M%LVJT78<5*DR6P40J!%:@ HCW42QJ11TTG"VO 1HJ(#&JBHEY-#3.;?Y=^I*
MG8URT_IJ9Z/V)6?P[ 0<%#AQHZ1=B:*.<8Q(*D.4JO?0TPU[DX3!E",/BC0@
M2>SS*(F-ZON>>_C<%E0E'Z@%M#I_?XF8423#8!S&#U9H(!@0/'N"A56XP6!,
MIHLHZ'T];.,$SNK<'0KP\I8I3_O/"GMTH'_^FF%[FB]B^XX4#U_SS8^,"_[V
M^8]"M^?]M/ZA]DMJ?WK#MMF/RGVR#T EB4<H)3#$$D$4$*;K]7HP(#@D49#X
MD@0VFP][$>9&:EI\\'&U^:ONS;H7'1QDM]L,#)@6,ZM]7+!'9D[=HZ_$NA%?
MV])OM ;*$/[E+.RCQ*X.!]&EC3I BDF-R>$H'5M]5SQI>$K\9EVZ\TISLOB;
M6*D!FRRQNWQ7;)=!&.$HIB&,(NI!%'L(TB".U*^8\BB-/#_! UI6FXQM]$U.
MWZIZ7Z6V3G8%6RVL?1)]+_01"[G'%=82)6H)$H& 6'H,QIQ@M03YGA?;YD"X
MP7S"16<RL,T6%M<0CKR45.)6Y907E3^F %ID[5+90WO7">F@"@>F&+DN>- [
M[N3U#TR1.%<.P?C>JUL]G[0V:U4E+:H8)C\A+,4^A;ZR?R%*4P354Q,8I#X*
MT@@E$3+*QQTT^MQHJ1T,=:Y98;M@[\ X,KO9,?1FCX7YV!YGIW!?T[G8'+:1
M>@X;"/!:W8+-L>GH\VOQD(%Q#9M\>T_NQ5O"_B[X=\%V>6E4-Q6A:)*PD&#H
MQ3J%BY(4$BPC17."IYC$R)-6;<BZAYL;KS720EJ*"XJ]O)91#]T@&\9 .(-N
M=#-KI9N YF151H0U<H-*<'"0?(1Z4F8@.8V*Z!YQVA@)(^U/(B;,[IIK]?7/
MBB$_J:<7RS2)":8>@3$30NT0D;+)F%2,)2E')/!\-+<2['O9Y\9\=1[-7O<%
MJ+4'I?IE).<!@!?V!GT&+^M_%PNPAP%<Z#,(_M10@!*+V95Z/[QA9DP]T_=F
M9-J?YRLSP[KR)Y/WCU5<_B#^_\\JS)_,R_1EYD]%L \UN(FBIGR->D>2QI#G
M GDHQA"KKQ>BV"<0BR11;Q#B+/:3T*.^:;S!V1'FMH)%OT;_#-9E:26^$T +
M:G[@?A[#_@B$JY$9F:-+4 [UIK2, \(1SJ-C'I-P-4H3!2:<0<M-@$(G !U1
M"N?OFRQ4H5/L=KQ"]X5#6W[6M-LD!2O*U?%@N7@0ZR+[(>J_-D?C*)4(8R^"
M7NI)B'13)LQ##\9I',:^\-5_[.H-V(T_-SK<BZ^=AB_D;G+FAQ;1LIT80]_L
M>'"/[9UU@?2 -IZ#\'+;P--.A(E;=P["Y[1IY[#'#..\VC!<WW\6I!#%-S5N
M7756YZ(*&L1A$F$H&<,0"<P@CK" <>@S*9F(O, J(:1SM+GQF98.B$H\.[[J
M!M6,G9Q!-3(7[>4$E: Z55?AMJ^![33OU@@4EX33/>"D]&*D^S&9F-UDOP/\
MN,E%=K]^M\MS7?_IO5AO'G4&K>"Z5$)CKGN"$>$C&*4B@8AZ*201ES".TA@%
M?D $-NKU83K@W BDEADT0H.6U&4=#_/]D!'>_9M'URB.S"V]  [869J]N<8;
M3=>(3K3O=("LU7;4!J:.W:G18R;;K-HHU=Z[6MTWS*QKUR=8\W8">96QI/:N
MG 4^]F&,]$&6KU8_C$,"$Y\$:E-+*>78IEY,WX!6W#Q9 9A5JU*(/CP0I:QV
MQEXOU&;VGDL 1Z;EST>H?>A&S=K*,X7"I:'7.^:DMIXI L?FGO%]0XM692M]
MLJ ?_DGM2#<_RHUJ\5N^*8HE2UC N/2@3WVLRY5@2#E+(8](R'V<>FE@=3;>
M.=K<;+V]L+;%H[H0-6,.9SB-3!M[.4O2:$NJ\\Z5K"[K,QE XK;:4M> $]=.
M,M#]M!*2R4T#;9$7M8(5->V/()<TC'P18@)Q$"O*8)A#&L42D@!CIG:'(O6M
M*./R4'/CBZ,:UV6HVN>A\2D="!L:'TYP&]OL& B9O?W1BX93R^/R:-/:'+U:
MGU@;_7<,8XP;QC:[\KG?MVJM(#DO_GC2Q7%T@)V7-O$&"&$4!!2B%$40220@
MCE$ N3(_XB2-B,>-FMM;C3HW'CD(#?92@TILH.6&7FK')6;8F]&*<T1'9A@#
M,$<(*+9"R27SF T\*0E987',1W8W#Z:FW>-.!Y_SLM3+F9,Y38M?Q/96WI&?
MRT @FLA4O3J,4IW-Z\$4>0*&02 I3]6_1E;]KBW'GR%=->*#35E_BKTXOE[I
M-?Z-CNP ?F)9Z<QV:N(D3A,2$1B%L9J:,"%J:D)?6:"8)CCQ:1K&RQ\BIYL9
M3$Y;CM>;GJR*+GBCIVGDV3%>8<9"?/RU9@]U58GM;"#'&RW^+^4QJ@[V4#HX
M77B&@.=X";(28>K%: @^9Y:E08^Y)AM&/><0(GSHS^+%%"6!2"!%DD/DD1 2
MA"@,I$"<X"CR8JL:.UV#S6WI.?1ML<VMZX34C*=< 34R*;5ZVQP$!7^.TM+&
M!!+W:0L7QGN%/(-NS<\G!O3<<_59H2XB79Y*;I<R"0+!: 23 *O=-98I3&D2
MPXAAZ0DF0FG74.+L*/,\%:PLG];9X. #P1:>UJ> PU":[NAO 0X2CG+V=PK
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MS6C3\GKG-8U*Q\<UI5)U$^?REKU>HQ_/#$)Y@O,8.[GF<  S"$G#$Y=ASYZ
MNNM%Y,RWGRB.IB01D"0Z84/B$.)0T3B1,O!CWP^0;W4LXT:L^=)WU0A>>UI?
M<'@NJJR#[09L'\3>"M6,/B*A7Y[6$2C=R63-C]0;"WA&M-Z+]*L1^V7)YDOM
MO6A>1>[]3Q]&[Q^S=;85G[,?NGOJ5KWC6>-V_:,0<K?ZG$FQ9%X<,5TL.?12
M!!'Q%8W[H0\EEB1D3%)$K,C;9-"Y47,E,UQIH4&VEQH0+?8"[$K!P4I);D?$
M1A-@1K.N81V91&M$2WG!0>#J]&D!*IG!YRY$K?G1!B*7[&<T[J3<9H/$,7-9
MW3N,EZJ:5SK=;K-6O/=^\TBR]=(/HS",!8(QYSY$01C 5$BF[$GA4S\D6"#/
MAHC.CC(WYJF$!'LIP9^5G)8'*><1-6.6JW$:F4KL(;)FCDX(7%+%^8$FY89.
M78_)H/OB:X]BJQ/@5BY61-(PD9Z$1' !$=8%J%@2P<ACC#.1RBBQ*FM^>:BY
M\4"5:;[>RU>9'I:.O YD;8],K\%K9#XX"-E8$V/DN_5#,<[9Y\EHKW2^>4GK
MRV>8%^^XMB>W/JU@VT,K7/)<'I26+7 /^=YA*@.4\!#&4:+,!\(PQ+$?0#_A
M/B($!]2S.D&P'']NA-)N%-THT'@R0*/"T#[<9C-BQCDCXCPR$1E!7/?@!J.D
MZ@_$;IR&W&8BO%)+;BM\+C?EMGO,P.3??/,D\NVS;OFMFPMJ&^Q)#Z-C7H.0
M"X$E5182DQ"E'$/"B ^)CU*&)?8\)*RR?3L&FQNE-;+N*X(_5;U&=81R59HJ
MM:Q]U DU"WD@11Q!YJ58=Q'C,$4^5Q] PI"?RH2%ODTDC#.H)XB#Z8#:(<)F
M"X0KW$9>#1HQ%Z 4=%^ O4;.:0BU"21.TZ&[QILV_]E \Y.$9Y-[[%OMO!=5
MCL0=^5F9OG7["/7[-[5]58SX6,<_%\N(41%R3B!-"($H2$)(0LJ@P"+!-(["
M**"F'7<LQIT;@S?=3?2Y9WXDJWFG&!O@NREF1#A'WP37"3KZK+&2>P$:>/7?
MCF4?!U[S?CPCP3Q16QYW<%MUYQD 6D>3'ING3=:K9X"*[98]0VZWHWHNLN6'
M]3;;/JMG-ODKK'SDEUU9^R7V X1\99,+%"&(A++)*?(8Q)3+2.<K"\^H D_O
M2'.C\TK8\OU_*2ZHY#7CG'Z NTG<*6QCGV4,1<R8-HS1.-B'16,@%H+]>K_Y
M\:_J&95MJ'XX-@G[GS\)=1BKV9"%^0U#3S5DMCXX!M2L'W43^_"3/:A707PC
M6_&N_*FH+[ZEJ^R^7D&9%Q(D&?2]*(6*512+B"B&81"C($4)X=*J[X83J>9&
M.\VZRYH>>:)6 N2Z('SU<]7,IJH82/A_[8KM (^GFTDU/7N9>*K&MU"U/@>'
MJ/K7Q?ZW@\@'.VK?\_!.)Z!724] IT/5Q99='NXXQ-KM.9 +P28^,G*(Y>GI
MDLN'#V-VG88G/N[6O*AK_>'43T.6$L@2I#;SOA_"U&<44LH$D3$-XM2JXN+Q
M '/CVU(^(+6 =O1Y@IP9$UZ#Q\BD5D%1RC9"T<-+BKMDF),Q)B6+2QH>?_<7
MKQMHG.WK&MY*'<PBUD5=F*",N-=E;8KO#R07;W5D_OY49W^2R42B2T_YT$]I
MK(L.!I &(8:>D&%:%EHE5F?+5\HS-X(H^UG"4E;05L?2V+IRD@S-K.F@'_OX
M64L)JUR26DYPD^=Z#:R*LHYRY.P(/Z=&TY4B36LNN<'OQ%!R]-BAO2T4S8AB
M6UIAF_4V)ZSIV![$:O^:!BF4F#"UHXTI)$@0**4@<8CB)"5&)Q_]0\V-%1M)
M@185-++:=KBX"*P9W;F!:V0F.X_4" 96/QIN&UM<'&WBMA9]6I\VM>B]8QA1
M?!';0V.=):(B%3).8>)A3X?L13!5E !9*!1%Q!AYV*K7_8NGSRVD0C>*JMIT
MV5' 2\AD%";"]RB,".$Z6RN$)*#JUYB@P%,<&P16>\_AD$W H&X@,R/*P4",
MS(T:@Q<MQ\#-=IMG=+<MPPJW&V7[N8U\/HN$2UY\.<"D5'A6MV/V.W_1X*Y?
M9<+G>U']_Z?UOJ+J._*4*=JYH47)K\N014&4)@)R+U2?=HP%3!E2G[;OI4CQ
MHA=P;-D#S'#HN7WW53)$X\?/UF"S+_I;I464OOU5N^5-7:6T+%#:Y-/KBWCV
M0ZUCV589QL7_L>XN9CIUIK;8&!,RNFU6I[R_:<3^1<_(H0QS+3KXLQ'>;2LR
M2\0<-R8S'7WJ-F66J)QI6F;[A*'T]T.M39O\^5R'OI!028FB.9%X*42I5.9?
MJD-M$RHBQL- 1%8)GUV#S8WB&EFMFYAU(FK*0VYP&IUY:C&G:'G8CXA;9ND8
M;V(NZ=?\E#T,[AD03YLQD:_)UP>2/ZHW8K?-&%DU)T<<(8^0-( I1@PB'(<0
M(XQ@2), >8D,N31JU]TWT-QXHI85' FKMP2_6H1T=D';31HN 1N9,"YAU>M'
MLGP5S6->'>$V59#K4/SL8EH-0.D*8NVZ?;JH50,E7H2IFEQO'Y=:%P[ZJ'B8
MK/Y3D/S#FK\G6['D1*8!#S&,8R'57I)XD$J<*O;D*0[B) S-0U(O#3(WJFR*
M<%6" BTI4*("+:MY).I%2+MITA50(U/D((RL8D_[0+@B[/3BHR>+..U3KAUL
MVGNMO85T]Y__[S_OFE6(1E'BBPA23[=]]0,$TY!&,!8(>RAE0NVA3 VBUG/G
M]E'?/?]X-CPS.T:HWZX9J/?(WV@IU0"CY<7;86RC#,1@(I.DE,Z-W7%&T0XS
MHWWU9%;%&1';1L2Y?[8GD2K:_5;^+GC&=*>6;]G]P[:XVWS?K/C2"[@?2T&@
M)UD*D>>ED 8TA5% F90^CVEL9#CTCC0WHJF$+9NBBGO"=.;S-J/91EEJX+%1
M .2E!J!0"IA_F-V(]].4,QS'/JJJ(+R58"_I E2R@KO- GQWB)HYP3E#;R+*
MNPI%*T8T0J:#([OOGXPUC=1H\ZC9#?;,VEA\0G?26YVT6?ACFZVR_RG?GEOY
M16P/K14W1?&.Y/FSW.1_D9PO612P), 2"D9U/>TH@<07 L8I0Q$-)14R,25A
M5T+-C:^;G8RL%&OW:EF W4$KS>CEX>#^P&JE- .LI9HY)SF;X7[2?XUYFVKS
M64_9V48Q"]!23;.@#H!H-7W5D_?N=2?/?.UYC4F<:)F:=C*MUC77J'<L@<Z&
MFFRU= U.>V%U_FS[-?@K*8^VE=7^3OVD5OG\[N$YWV2\^K7>'H<T)E3&,8R$
MSMC'9:@-45L=@7C"_!BED5$^A_&(<UL]#T*#2DP%,*CEKO]B3JQFF/<O><Z1
M''D].P7Q]AC$ 6X<,S3-UR#GJ$ZTP!B@ZV:YL *H8RTP>\YD1&^E5IO%[6YT
M4#?KW4;]RG0)6?VG0Z[^,HIHQ"/N0>Z7A_XA@:E/8RAEP'F$!$V84?==JU'G
M1M6EG*NJWK'>Y%@7,[##O)^F1T%R9*H^6[_I('?UYW&!O:)4E@N 7[-0U@"@
MKRN3U0>839&LB\]ZO1)9?>IU%LCJO7E8I.? MN]GV[T?]1TIRGCPNP>R;IK$
M+T4:AUZ:$NCY,H*(D@C2B,402QPD+ @8I]PF='12Z>>VPAP$+JH >J6975#J
MM)/?O43-?DI'7NH:O4%+\04XJ [:NM<4#1KMRYR)EOZ@!F!QTL-)T7J5IK%5
M,( &!W<AN:\R?2YC?*=58-*@X5>9F^,HY-<18MCB>,.4\;4K,_'+1^L,_5P\
MB'6AEN%#KMEGI="GK7@LEH+%22H)APGUA2XXDD+B\P3&$J740ZGOF\7O#15@
M;DM42_Z:=EYH<)0A^:?6 Y2*6/;1LIXHL[5H3/A'7DY&0-YZ+1@*GTLZMY9A
M4D8>BM QJ0Y^SM"BF3_$:O.D=B>"/:PWJ\W]<W46W_CII8AH0BD,PLB'2,H0
MTB FD%'.F9=X! NCK _#\>;&>K^3_.]"?WA/^8;OF'WURFYTS;C+(6:C.WEJ
M2<%!U"9RQGTM$4-<W%:'[!YRXKJ/1OJ?5G0TNVUP%=Z7W@[UPSOU>[9MGR\6
M2ZP0CDD20<8CW=L%Z3J[(H;*YE*4DV*,0JNFQX;CSHU@M#>.E6*^"(BI4N?+
MOU#"_FY?--=H#DSIQSFRK^%KUC]78K\(>'#8'=X2*,=5:XV&GKHNK0T>9RK/
M6MT^N-<7$X(7N@O\=Z([C'U_V.3;.Y$_ZBS;YNP@3!$+,5+[/Q:I[2"-$4P#
MGZE? Y%$5'K,KD>[V;!S8ZM&:J G&Q1D51?Y?B3;75ZYJS82%%H3J!L_@.R@
MBW77*I-I,6,P]V"/'=?P F<MLL;U^P'73P:X#NEI90&3X^Y6)B-/W>?* HTS
M':]L[K8_P[]56T%MNM4["10GBHZ(A)32!"*<Q! 3[$.*J(AT;KZ7&O'3Z:/G
MQD&-=.8GQ$=0]9^O#P=@9%YH!!L0U'0$@OE9^' P)CKP_J;V,^M=68AMMR92
M9JNL])6Q7;'=/*HW<@%ZWQFKP^[SB'2<:!_=,-FQ]7E!VV?3%ZZPIZ/?,V4+
M;#=KT12V_;YC3!1%6>SVF[C7'JU-_GRSYIH-JS\WQ?QI+*,D4085"F*=\"8@
M9@)!063 4,HBDAJ'@@X78VXTM]=DW\=X 6IEZHK3!W6 TJ>T$NI_,F>%*Z:M
MGT:GF8R1*?>:>1A TU=,B#FE3S,Q$]'_*!^*U7IP/9P=:\<5#Y]LG;D>@/::
MY.!I]NM769G]8;-25_\_LMJ)F]*W4']9(O18R&.B]OTZ)9L+ 4D8(AA[41 I
MP]JCL5%=T+Z!YK8&M60%I;#@IMME9@=K_PKB"JR1UXA+. W@_T[ S!G>%7 3
M<?A% -6?P7U.UMJ>5_;]1EGW3+WXM=-I3>I&&_I7?>D3>2YCJK(U*/0C2W<4
MVSP^;M0?=(L40+9@^R" T)WI)" @!,\Y>!)YMN&7J[E9K08FT'?P?>?MDS&Z
MB1)MSC:Z_KJPUIM#8>$ZDDB\WSR2;+U,O83ZW/.A>KD41\=I $GJ^S#"@D9A
M$$GF6_EF>T><&T_O PY;$B^:B$(!_JRDM@S$Z<?=S/GJ%,V1B?Q:( ?'6/:"
M,T9<Y.5!7R66L1>#2_&'_3<.*/1%?K[;;96-^>\;J@;8WFU6.IVV-DG?*X9K
M*H][.,2"T00RSX\@DH3!-)4<QJ&,"?53SQ-&@?!6H\Z-@<K#U=VVW%]IV=4W
MLUT +;X^=UTT6[,%4#J8U"F_8C[ZK<I14!Z9F68$L$5ELS& GJKNF07@CLJC
MV:+553S-^%G3E5:S5>]%X37KFX<9FV4?Q4]%L1/\_2[/UO=?RZU!:=X6'QZ?
M5IMG(<J+OJH7[8$40G?$+9;83R(JD@C&F$N(1,0A"64"PU1W!/)E&'(K$W2@
M''-;%K0&.F6YC HH]U^[M=[CB5J#^H]/6O:J@\B;_=;M<K-IIS-G9L1.,!]C
M^RA*I"L50*4#J)18@$J-!6@4 =7%C2IEXW"'<097@NG2%!XJRJ0&\I5X'9O-
MUSYN<%SH41_Q#\I4WSY_%ZP.'?JC<7.I[3H1:9Q")H0NK(LHQ(&.:F"13+B@
M(2=6#2O-AYX;?_[QZW?#'@,#8#9COG' &YGL:J%!+75)8(K>2L'!0?(%^./[
M*''IMI Y#@4U'7WJ:%!+5,X$A-H^P7[C_\>:5SU5!"^C3EO.A?J[\6+"HM!C
M, E\'Z)$J V_)PB,]#]@IOMG&C="Z1UM=HQT$-A\;]F/:?^FW2E2(]-/2]8J
M_+SM3QQP*-2/G_F>W"F.$^W%._%TL_DVAJ5CT]W_C,DVV\;JM#?9YC<-#K5_
M$OGV63.WWLMK]G[2K\_G?3(O"E+/1VD$)?.5Z<<##--84&4$QC'C/.8XC"W#
M['N&G!O!-A(O2J.E.MK<2WU%7K4!^&8&H5M(1V9B!V@.":,W!,AQ"'W?J%.'
MSQNB<"9TWO1.>_/N)OXU2;YLMJ)XOQ/_3M8[DC_[@1?&]4)**5?[31S )"(1
M1"2(8.I'# 8T(.IMBQ./(%/CKF>LN3&/EO:?_^6?_-C[MU)HP'<":''-#94^
M=/O-/(>8C4PM)W#IDY=:XNK/_J*$;X#!UX>CN;GG$,^)C#V'N%I9@(9(==A_
M?4^8S/HS5*5M^YG>XMCRNU//JZ-)9!('E,L $L]/(6)^#!7G!A 30DE(8L%\
MJTH3!F/.C8$[K94%T((/#.8QF8 KS;]AL(Y,TI\WZWOX.?M1YH*WBZ>-$,MC
M@<PDAE]KV'E8?J<X&)M^9VYU=0Q1_WA+5]E]N;35?RB^DHPO@] +44A3R!*N
M&\$$")+$\Z#/PB1D'DXECI9K<:\SSH:>1G1*8/0QI=7'U)9CO&^JD0X\*?&N
M/9WH1G_H$<7UB+[F.47SVT'\_=\*\+4+= ='%4;0C7M>T2W"*Q]:&.'3?W)A
M]AC7UE;3(WXID4!,^"%$L=KA(L25L<49AA%->)(P(JA=R'3_D/]0MI8KXVJ/
M][6VU1 47]>U=E<F8FC!02GY)(;6,4S3V%G[46=B9AVC8&YEG=QY=0VP5J77
M]R+/?I1=%(JED'Z,F9"04.Q#Q#VL^"=D,$R"A(=I%"9^8&U6=8\Y/T/J8[8F
M:Y81!>"ZV.:[ 65R^I$V-J$<H/<*U;U:TBY 2]Y1JGIU0S-2/:\+@[Y6):]N
M##IJ>/7<.(QIO@FV(D61R8Q57<UVVUMI4$*U7)V6,0H1IEZH:SP3Q4+* ")2
M2NAY,L'8HX%F(0LKZ"IIYF8@'2L#-KNMCN,U+$=<&0"6;JKKIM.,ZB:;I)%I
M<.3YL>9))[BZY-#K!)J47YU@=\R];AXZC)?U4>VMK*HU?B1,\_[S-Z']=]GZ
M_NTFSS=_J1_>$?5NJW]9XIB3D-$48J&K3'LT@B2(0DAPB)&D:GL:^#9$;#?\
MW)A72U\FKE?52F6MP +DC0J -CH 5BMA1[26\V/&K..A/O8I00UX71[VXQ[P
MO?1@+SYXUP>X-7,.P\TE55I*,"DW#D/GF P'/F48^W45[E>6\)(RCR4L#B%B
MRMI$ 64P]9F$RN94!!BEL<=YL_O](K9FG-<SZ(#M;S/TZ$<)X,U3OOF1%6J1
M^@7(3:[VPZ6-LB4_10'*WHMU_8_2GF$O[)GZVC>KLOU%63!5O5G;;+W37VO=
M='[3D;\T: H]*L* )1X4**1JQ8H2B%,40H]Z?A@07WB$VSDPW,_?-)/WKYV3
M1U8E_YE.7Z;#N]S.E-G:Y0+]B6J ]K6 *4N=NUN=#)%QN1SU#3GI^F.H__&"
M8WK;L!7FHUJWMJ(,;#CNG/5;KD981AY"$='HIK&RJ$D80LH3#HG^NX]Q$A&C
MQKVF \[-ABY+Q.L%X.9QL]/!,Z64=LS2"[(9M;B$;F1NJ42M V;.]!OL!M&:
M6DR1<<DMO6-.2BZF"!RSB_%]KJ)D#/P&;X5:_75+VR7":<JPLHLD2SU%/DQ
M+ 6% C-$/)_((#4*HG8CSMRHJ>V@.V<1O:E,HE^ -HD +=5X851=&W-C-9?&
MYT<3S=#XATMG(G+Z?*IO/M53IE?W13-G3LTP-PB/&[AC)=$KQ_$,0:\_K&?0
M4P=DL1R&49OTWTBVUB^>5OL=*1X^KC9__4WP>U&0-?^H!LONU^]V>2[6[/G0
M;EQ)L]IQ7?YADY>ET[;;/*.[K?;^;C=?%*YJ%ZTP5B+<JS5&J*]LVR3)B"1)
M$R*AAQF'*!02XHA',$T"]9=([8N1<<FSUU5E;FM#^=)4E7 V4K.]1<[(Z[X3
MW>O$ZPLXHS6FO9HH)("&HFG?6OJO-!Y  P(J1,K8JAH3T( "#JB /2R@Q@6T
M@=&NEY?0@ :;(;E)K_N>6:0^_<.\;Q-E5OU#O7=VN5NSF.JNU+#7%7"ZS+-9
M3,2+Q+9Y2#30S4>RJIYV*WCJ=T&*7:[LR_4W7?=&%_!Z2XJL^&.]H87(?VBA
M/JV?=EOUSTJRLAN2DKD*D4$XBGP4<>@A+X HX @2$6$8(NG%"+%(I%;U%5P+
M.#=[3.M75:1?M$,-0:,C4)2WUQ*4:BY 6U%0:@I>JCHL.,KYRV#HOGS%*1[;
MW?DZLVOO)QUI"ISZ55W+.*T?=B2$3_RV8XTS;'VY^2%R<B_V@1"_5WU<GV_E
MT5K8BMCUEZDG6,!2"@5G J*8$$@%3:$7BH1%V"/J'VT6D4%2S&VEJ)5HQ6C5
M37&?]4Y>UD8T:XQH;A"J[G#*S*A^](D8>V-=S\$A;.OWUAR<;&1&21>X"D.7
MA#Q,D$E9]RJLCJGUNH<-Y,_#YN*]>,H%JZA9_:PV!GJCL.8WCWK/\#_EWR\F
M7BUY2).0)S$D')>9""G$*0UA&%*LTZ%(*ED33G1GP:R.Y!L0?'0W1:"L;M5"
M6EX-WE+2DE9=S:0ATTXY,=-[-=LZZ;2L6JO2G]36:P&.LD@7AGFX]K3L&'"G
M3.U*MFG)VS&B)WSN^OD3AD+4GJ9"NYI$<3A,)Y[/,?<E]%.IHT:%#U.&L?X/
M2:+4(TRB 33O4L:94OT?:_4&;.[7V?\H>M''8X1M=R37R;-O[I4:5;3$!)$1
MEZ9VQ#B):V9JSE$31U&KK>.(&850](#_Z@$5E^2;?WA%#[).@BWZQG"U)I0=
M,OXCVSZ<U'4I/JT__-3MBV]E*7,9H[?OI<5DS&,B&&0HC*I(.1J%'.+ 2WD8
MAA%-KVQU,5"RN;E7SC/,5SW7RJ[4OX&_E)+:GOPOP;;[ZP[JZJ:PE;[:&5#>
M4:ELW2[-_6LP=/&88')?9>68;%X=K"%7SL&X"\A0X5YY];@2T_ZEX]H![$/V
MONDL-K4NG7;U3A'#'HM"*&*A&X@B BFG' I))9*QGP3FW>4OCC(W/F\$'=A7
M_C*:_7%H3C :F1;/PC,@6.LR3N9Q5$[PFBC$R>ZULHHQZH6A(_SG\KV31>;T
MBM\.FNF_V)X WVU6ZL=-E8U+UI7)_DW\$.N=J-_)F'@)QRB  L4Q1#[U8.I%
M*91!&. (AZGBQN4/D=.-"1?V#VCS K>''>_]?2%SZ0NM,D3R2FSS#]\ [7ZF
M=(O@R)1Y"EWE<ZCE'4">!AB:LZA;+">BTZLQM6)8<X@ZJ-;@(9-QKKE";?*U
MN&N8^T('/&;K^XKDE<7[D#W5)>!#(8+(CSP8Z<A Y,D(IC$*=8%8'T5)[ >1
M46)'[TAS,T=K04%;TH&E]B^C:[;+=X+9R%P[#"[KS78O%"XWSY<'FW0SW*OS
M\>:V_X:!);S4'EB(VZI^ROK^LR#%/FKMN0FN*(/0#F6.,4X(CZ7"%OL"HE!W
M[N5(J)TMH9*G?B(CHZWL%3+,C5F^LP?!=ZNROE0ML0XQ5;_MU0*E7NT(5,MB
M7@-FRHR+1L9_9):JI%\< WV(]7U>' +$QBQ8?06,3JM\#1!CVE)?PW$ZJ?=U
MQ:.&\653//'GRS#=TGH[I)(4RP"%">=(ZE*SBB.]1'%DRE/( Q)Y0:*VN2(Q
MV^1:CCR_W6XIH1W7F:)LQF\C(#<RIWU0+PW;MD[/=1'L;V0KCI(0%O5.K:7%
MHJZ%XX[7+.%SR66F0T_*7Y9X''.6[>W#>.H_1';_L!6\CI?]LM,[REOY_8&H
M]_1VMRVV:L]9YR"PI>0H3DF$()>Q8BL:$(ACC\(@] *)4R("9E4BVVKTN=ER
MI5"Z/@LH2GE_L>,N.^3-&&PT/$?FL49NT,3L5Y)KN[B2';2$7Y2Y5\P=<0U"
MS25]V0DP*8D-PN:8RH8]9!BAE0]5#Q)<!P")=5&RYDV>J_=-:,9\^WRXY"MY
MUG\JSS3VR5@W1;%[?"IWS]^RXN\?<R&:-%Z]M"YCB2B*D \#EC"(>(P@83Z#
M) G2E!$F/2QL2'!TB>=&G%I&*)60(&L* "B[W/ X8[IY-J/<6<W>R#1=*@*I
MU@2TM04M=0%]!NWK:I6KP]<%."39@I;>"Z U!UKU0U&(;UWOA#7)3S9/+A>&
M\86>=#&9; Z.%Z#I!K9;M(I\N[S]:ZTX]R%[NOF9%4L6899Z:C41S*<0^<2'
MF!,!4Y+P-/(2X05&?8]/GCRW16 O'/A3BV=XK'(*6#=+7P7#R&QJC( QUUW4
MMH.3U#TM/E*_'7/1Z4,GX8R+NC3?]N4+[+Y!+K+E^_H _=-:;O+'DAP^9VOQ
M2=<?7T8ABWT_HC .6 R1H!ZD42S53U*7?1=$1$91V7T#S>T+;60%+6'!GUI<
M4,IK^,GVXMO]!;M$;>0/>CA@QE^X*1J'#[YHOOA"L%_O-S_^53VB^N#5#\??
M>N_C)_GT395LF,#X>OLPM:\ZTU 'G[_--M]9)I3<Q:<UJ^-]?!00S/T4<DK5
M8LT$A42&! J>$.'YJ8>YT6+=.]+<J&$O+&A)N]!.Z%_- ZJZL>UF!:>(C4P+
M'6 -"$/K1LT\ LT9>A,%GPUYY:SBS8P Z0@UZ[Y_LB@S(S7: 69F-PQSQK6+
MZNDB'-5+BGS*O%#Z,(X\#)':TT#*<0@)";P$42_UB6?C0#L[RMPHLZRF*74U
MS8>RPJ"=M^L\D&8>JJOA&9D?7]89U8$9[@))C3!PZ;$Y/]"D7I9.78\](]T7
M#XCK?]C=D^SK U%&&!.[;<;(2OM<R/JY?FE%D 1!D H8>8':1)'8ASC"'F2^
M3"1+2<)B:6HT]8XV.Q8H!08O)0;O-K\NP.<MMS">^G'N-Z"<HC<V25P KI1V
M2#1_+WX6P?PN<9PJEO\Z/.TB^4WQZ0KD[WW&=''\INJ\".,WOFE@?.ZF*-Z5
MC0[OE067B:(JZDJE8M. 4\@H43O4,.*0AE0979*&R(L(B^QZFI\?9FXLJZ4$
M+\0<5F/W JAF9M?U4(U,J0-0LH]U[03!:3CK^9&FC5CMU/8D*+7[ZJ$[KJK3
MW3?QM,EUR$49Y+<_QGJ?%6RUT05FF^8M22("KFPP2K#.\5$$@?U01W2A5/@R
M1DE*[/9B5N//C3F.&@7:;M+LL#?=OHV&Z,@$TTA<G_?7E8U+#_D8.[Q!,+G=
M^]F),/&N<! ^I_O%88^Q/Y/[H)AQ^_P?8K7ZO^O-7^OOZNW9K 7_5!0[]>UX
MV \0%3'TXLB'B/D(D@BED%(<QGZ81)@9'\IUCC0WAJJ$!5I:^'<M+FCD!97
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M:ANO@+$R: :2!_8#IQ^=@_#2N4<>V+5(//(QRK@EXZ.&\EG=5%*+U'O*ZX.
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M6-(S$W1V@G(%MI:"VM0KT#<6U-:"E^:>43PBR&^&G:A=>KX#:^,EI]J]5%O
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M$ME'LMHC'I73,01PB?Y0D;P#"ES(,?#"<)*\+;LZRG>5S&W"4[^!08NDV%
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MLKL[J/>I/+=;=/9[1-\-. [VR8[7U." ^/A.?IM1):)V]51/\YJ>(B8AFER
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M",PRT$5Z);W3Z-HZ9%>D] RE!K[7<5(> $YNEXYF98LQGD%AA8AG)!#/-8+
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MK[]MSL^N>!*^<&FJ(4V9U7JJ##YG"RD0M 4R'E&V\6!_3-P00I].$-2Y)@:
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M1SEKK7*USHI6E0KUG!J]@R2(#6&3CFTRV _0LQ_J_A!')EUHI'\3M[/FL;:
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M)+8]8KLZ=1OY(JS,3H*PB:T[LOA,\N.BV!B-5Z[$%G9P;PK[[2,Q&+BVU>P
MMNG[?N\5EYOY<M>98QW)Q>4*$JO-NH5BX%TF1GER5C.EK&ARSW]_$OMM0S$X
MT#;2[2!1>Y92;3*TH"UDM59)_CC^6@M(%R.N,/$Z02$;2<SY6"\\.@_<:I<B
MKP=O3:ZG'D3ET/HC=P.5'R*R*[T-(MJ^SU[UI*?T2[2D1[F(R*50A)3*CD%5
MSQAJCR*O=6*T2Z0F-96/4C6T+L=/!+MC]3)0F-UQ3Q8+I,C-DK0TKS>)@B*^
M(NT:P1H+PMB<4?L0VN3(]R-O:+V.GPAX)VMJH @D.SZ_O)4L?1^^KT:!*&8#
M%I& L4"AG-1UB!$%=26&*'),SM^]R-IP]]U-X]":&S_=WMN!S@;M#FX8JL=-
M:V;?CD,<3U8^]D@CDT$)">1*QSH$,(''%*"@#2$7KX-NTE/G.'*'UAOYB1W$
MSC0Y +SN7[8UHC#/"$]R+!8]J.!Y;=V+X$S.)1![](]^"X?[W<B?OIBSA>:.
MQ^2,5EY+3*Z/ G8+LG KO*&5'1!%+2VAA9Z3!\]ED!FE8J%)0NAP4ON-<H92
MU-Z5+@=@06DWV"3:-H<)*[^:&*:%N/Q>.P(N2>)5VINC!,$UULOPF>E [-%R
M]XY"ONQ428%EFUP3,WH@G8,LC.\,-G=GP#34X2"BI-7I%N;%KR3I=='IQ\^S
M^?(3SB]NGK 6:[)0F,')5 = &%Y;HGORN$/).MA AJ )-O<B;Y %[LT@V;W&
MAF@L=S)E6!:!FPPFLE"O+%/,9XJ#')2S!5G!O2;FGFXBCT;A4SN93V883];7
M(,TA&?>_A.7EO+8^*BO;?Y,]ASZ7Q#/D9&JC5.O(VKL"*0A/VP!/7#7)EA]$
M9;^)HYZ-8W?Z&Z*-O,=0%M)K:Q/$;!PH%21XDP*$Y'2=T\Y+FVK>'U+6;V*H
M;]MXDIYZM8NU%&K;P_R'M5#<\*QTT"#CBJM:!XI:0V%>V!24UW?1M[-8;=_W
M]5L:^428:J: _NL@'UPNVVMON)YEN$I-;*?F!%^BQ"HT- 94K(LFN #6<"6*
M\_1?DSJ)0XCLMXRR;V/7E?8&X0]6ZE^-J^0P5Y_B52V9VO366;7*]T9$QBR4
MD@LHQ$(,10\BVNCK#)W$FW5S>82N?BLCGQB!7>IH0%;QAB>[YFY,?NR-2\&X
M&%GO1%0J@N!5:BI9<+HPL!RY+,9)V2@<_C%M_98Y]AAU=*&K <4:O\[F-[F[
MX<G>.4GR46$,'@I*7Z?9!7#!)Z@3;T)D1B7?I%C\0#I['JS5T][<0HF#V)[W
ME^<H1L.*(]LO@M D1UJ)$84 "L PZB*\PB:V<G\2>YZ?]<38;*2ZX9Y2_SJ>
MAFG:+4A;&Q5K[T"7>H&-ZP2>**,X3H;B@LJES49^.*G])KF'<DK=E2X'M-&_
M*]?CW@N3=55%X'5<!(G(D,2T(@':D#2M1<::GD3?H&60I\V=J?^!_?I870QB
M3[[I:7S +U<L71T0O<*X' E?BB#[#84+)+:"(YON'*!AVMD4!5-M\CC[4#?(
M\^1FH.M<7T.P:C>8JE,G2'(4CKV=3<^O.)(VYI!Y!.>% Y6<@*"Y RDM$](:
MR64;(_=#T@9YD/P4\.M 4P/ WLU%=(N/;%$Q(PQXP6PMZN00>;008\[<6Z\\
M;U*+^!!!@SP9;H6S3K0RC WV.JHGIC9G0^_*C9;\(_)K72Y(D7NI@9EQ#!PG
M;"@;6:0%(Z0K+1VXATD;Y$%P:W^N(TWUGYQ>G49N#':Y8;!G\_50NO6$B?J3
M&V/H.-/*(D5=)AD)REE+$G09LI5..6TQRCM76'8?"Q_XWD$>#W>-M.8*&<!^
M>M-#N+&B5EG,'?(<%6F=$UD!9JYI(5&H'WT4U7%(I7A,FC=W[/:@<Y"GQ$_A
MY76MPP% =']ICEQ@5I0@ 6/QH(K,$(U"T,@<YR[SS)K4#.Y/XB /CUL!LY'F
M!I"&?DT>15J^*]OIQ!_(!7@WK<S>29]^0)+C.)&#L$FOWO[&C4^.4A:QCL\C
M7SF3"*(G;T4%#DDQE6J'@MQFZ%@#7OH-?IX\D=TW&@9@I$]B=K=JKH9"WA3K
M6M0CQK*@_PC+I5!<F50]3'4&HN(A.J:T%TUJ<9^6S7[CN2=?1@/&T "VG).D
M<R6'6UWD:X7KKB[RBQ&74DDA'-#NNVK'3=NQ"(J^M$9GI7G(PUM?!S+9;PS[
MO%972_R<.)OWXS+,E\]OA67!3<3$(>M0_6I;P"%YO<S:; P:9<U_C176+ K_
M8Z^P0_#S[*9?7XVD;#7T^H$7/,%TV"<=<7WUUBM\1ZM*$2$23CPY/8RP$X05
M4*O F"XY6-ND)USK4;%'K[M;R^WF(MRUZ(P(S,IZT5OH BI[DIYE 5+,/"!&
M'MIT;7XR#@<\E/80Y'9JF9LA9)!CN3]>7ER$^?=9^3@^GXX+6:GI<M."B[A^
M3[8MC7$1IOE--;\7V_?-RF_X^R:Q%R;7OT JG>8PS\=,\VY&RNEF_FFDU-&&
M<)^PZ^QN*,JFX,&PK$$)%."<EF"MDQBJ:Y&:5(H]3-+)+?CGYV&ZF2KU\N95
M)5KB[V\H^UVYTL/U/ET7]62VN)SC)Y+]BTD]1#:R.*FE@^@DK>C@R"-,EM7A
M/UZ'&&UAV$)$73/2\SC(;C!XKRU_G]K^KV"_W\_I9Y?3M);8]M?[-^8/T#4X
MR[Z/_-J;>6$$3\(;(.?$4%1K' 3R5 "9Y4H[D91I4AS7SLSOOJ3_^EL=EX6K
MEWT?,2EIP3(/VGA=^WHG\%I&T"A-*;8(JYL<J.U!VV"-\2%(N5\%V*U.!G"L
M]3K,IR2FFC5:365;<W&]7; @C$:?@"GE0>EBZG4M!,\BZF(]YJ):0.P'=/4\
M.K<-O+K4Q0"@]>MLCK3%O+RD=T^)CWF8+DA$-8JD!;3Z<K(.*N\RFHN0NL0,
M28AZY]Z2$)-6H)3E(3&;>)O#F:,I[GD@;ALX/HW^!@#4L_P5Y\OQHG;ZGBV6
M]]AQH13-F0/F:SD98P)B05O+%4B6VF<,39)B/Z"KY_FV;4#7I2X& "WRF1]U
ME;_?Y4\44ZQT$E) 7B<"47BFHP2'(A.?EA&#;0K\#B.TYXFV;<#75%L#0..V
MH<C+V46D2.Z&[1Y)DQR/W$)Q,H$J.D/(6( KP93.V1;;I$7OPR3U/+NV#<(Z
MTL  L+2=+W5O3: Q2+&^!TER( L=%43A$8QAC&LA9&:-9H[L)JCGL;1M<-2)
M] > HI<S,K#3Y?IPZ<-X\?>71,-X6?\U<C)')G6 DB6O/8]$[;PE@0E5R+H*
M9+')5O@(33W/C&V#I:YT,  X77=)O;LNE$\Z)DZ,U"6A(KF,7H8$VBL56$S)
MN2:'' ]2U/,DUW9FZ73Y#P!(KW ^_DK:(';N<F*B9"X(!^A8IGTZ%-JG(^D^
M)"NC0ZM+$[/T,$D]MR5KA*6.5#  ,/UY-LN_CR>3LVE^0XJ9GH_KF*_58,2[
MG!6.65A:'(8Y"TI["\%G#=XH$:O!S6TZ@NY/8L]]QAJ!K9&*!@"^!Z?-W/,<
MN3!6)09%ZUI^E#AX)B.D$EP1.0;6K!WH7@3N![SGEO-OHIX!P&YU@/&BMAVG
M4+>>CZVK%+YL2A?>K%Q.LNV5[VT$'%0JGG$%B))\!,L]1,D9A"0M9HD:69.T
M_Q&T[@?&YY;Q;ZVT >#R:A3LW?6E;;%6" ]:%ZP^A0"71 *N0O*(G O=),G_
M$$'[(>RYI?<[$?\ 8%2;L(S7XSCJ#8Q5G>PY3JN<[G(6E)8A%TO.JB-GE:M5
MAU,+Y"QXGIW(3C<I2-^?Q/V@]MR2^8U4]%^A)NZJ6O>W,)^O0K!7N SCR0#*
MXAXF;7"5<7M*L7UQG+'16<ZJ,34$;R?(=;1D:J76R9@8I/9-//MVQ7'K;>2J
MT/5%F-2V11\_(U8?^BSG<55,F%P7P"Y>?+]US6'Q@WL.GU93XF6Q4I+P($>?
MR.F6Y->L6KQE&YG(2I74*&OX)/P-MDCO$,3N=C&&A8T!>"QG^3\O-P/$?IW-
M'SGI/OLV7HR*\YZ+B."D"Z!J@;@W7(+/Q83$?+:^2=G?053V"]]!XNQ>-4TK
MI0\ T9_H<^_*69ZMXM._X$7$^0@=FE*PD+.82%K9!'#%>R"C$5E0]+\VWO8N
M8GHVK^UT/^M8$0, TPZW[:]?ZB5G<F4-$QNF0K+:2&6A).Y ^1+ N]HP+)F8
MO#>2L2;HVHNZ?N%V.@CNVJ[.-3)PF"GF-TR5Z% %=,"$4.3^T(J,3B*8XH1$
M'B.7C6^S/$)=OZ7W3PJSXS32(\QJ0]='UPTW8<.1]<R[>H*%Q"49_%I#JSU"
M* I337MHNT]?W?W>UF]]?&>8:23> =BE6W[IRTE8+%;YCY6&JGN@DO)>*R2[
MRLC,LN+!6:NA>(NL".]X<BTLT@_HZM<6/8<(H$O%#ANGKV8783P=*:F31N)
M147"\MQ L$) L3DH$Z53J4UYSH\HZ]<]ZQ0'^V/L"*4, V4[%N.:3?I.>?&]
M]D??6'KN0RJ27 /->:ULJXU]BV&@(Y*I1VM]FS+50X@<+/:.P<=]]+51U@"
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M]R6HW_OT0_83FJBT1Y.W#S_;R(3D@CI'$'PUMB5$6G8\@9?H@Q JZ+U2\9V
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M+3?;H3T^&B:] 5I K';V<_7JI2%L9*=-- I-J_8'CQ+6KQ/4+0Q^B+$3=#(
MC-7YDHMMZ(S;0Q<6C4Z2)"1D+:/C2'N_QPQ>,5Y,X3&WR4?OI&9H:#I%X7=C
MLI.E/P (;4PY\9%P_+5:\6T[=9(,"8&!,,*#TLQ#8"9#"DY@%D'$-M-E'R*H
MWSVP*9 ZT4'/P=F'ZAFL!SI[:UBQM7UG[2O G(&()!-)0DG9DWD6^]RPWRL8
MNWIKOVW0VD?NQXEW")C80#FS$I%E(IL'"DAE=N!T-.!*$;F>#SK564/P&^_M
M+Q0[4F-W=7Z$^/K.ZHVGXXO+B^W(*J&M*L40UNN(F%P3$5$BH,@83)*>\\X&
M#=QZ<\^:/T9OLRZ$V+?VP[<;A!?4!ATI*CH1ZC5K!JY6RXM"&YH.+O'<G?9O
MOKF_"II.M'^T$'O6_M7=ZS_C['P>OGP>IS!9&<$D0[:K#&0B :A,_HQSM/$5
M'9F(B+[$?2Z^[(6$!ZGHMP5E>R^A&_'WC2$\O\O"QL<VN6232!AEE=26.=)*
M,H'<X4@L1$:QUCX-^?;#T$-4]+>O=*3=6=>B[A$OJ^4S_S[ZZ\>13#J;DAQP
MEE@=_VIHC]2T<(3,+'&RMUG=!\=BBXX%II_/9U]_V3QQ#9#-%W?Q<?W6'L'0
MC>IF)\EQ$,68#QO3%]\_T3-6*T07P7(*-6LH%"BG"Y!7+N@/IS7GJM;R-$FV
M[D%<ORUGGRB[W[62!I Z>T1>](3-:DS!6F(B$S;(85?*D MH2Z0(T G!90E"
M-&DBNP]Q/>=F.X?$WI@[4C\#P-PFY[R\G$]KP?799#+[O38YVI[(YB2T3@9!
MB'H=.I/QCV3.27R.HU,\<=WD4.D'= T5:<<"8?=)0"=:&0#('I;7VZO2VE1B
M(+(3)(84E"8*;8.5 ;+SP5D,%MOT]MF#MGX;9?>]GQZGHIXK=C:G:.5&">7[
M\+TZN)]P?K%)AHV45-Y&'4%C+*""(-=4HH1<!(]>:*?N#GS;6;JSU\N&:K&.
M5.^LI:R'#9YU+HUB9*<P<@LFTQ\J6@,N1P<QV$!KKPBM.@#/^F4]GU7V!YXC
M9#T,\+S'>9G-+^JF_2Y.QNL;)3<X6VRZJ4_/KP9-TZ^,9_D%+G]'G'Z:A^F"
MB">KO^XD36[ YM=7I[I?EB/.@_.>>>"J)FF2-A#)*0 9D5EG&;-WNP(^!L#V
M!/=[I/H$(!Z8SH?@^-VM<KB>E,5'01?M=9!@(ZZ*/3-X7C049J5WDK-4FG2U
M?(RH?A/ZK3#:N3H&;&,WH5,DH6W6SGJ-C1RBR((V#:T")P>$6',Z(;C"<F!H
M.=I]AN@=\^Y^$W)]6;Y.-#%\I*V"],V=]=??OHS7J^L5<3V2D<##F -10FTH
MAQ2F,XK5@S):%R.E#1U![F$B^@U>>\9>1[IY)B \^XKS4*5-'Z>G?7]+OS>A
MU58*6N=!!DF!ET\, MH$9.H+_4BPX%6'(-Q)1+\CF(8 PM-U\TQ >',6ZF^X
MW(Y#U<KK6&R&I'4&95DB3GD!+8S5EF4I8^G2%.ZDHM]I1T. 80?:&08.WTQ7
MC%;^_KK _&GV"NGY%R3(>YT['Y;[1AHC&YW2,BC@,M56(,1Y<+0UV&Q$9"PQ
M+P\PD5V2UN_0H2= ;&]Z'')GC6TF[,8PCY-[;#SRS,ZZ;>Q+]U/WW2#;AB)9
M4!6GJICJZBD'GJ$NDB>19),C\R?JN_'X[-SLI?6>F ^,0BP5T4'4) 9D#!5Z
MYI"U.5<[>2AR__TU#L#-80.-#U%*AS51#4S5[99)5WVSX_=-U'6RW=KW!9T9
ML:,X>F*+ID(JB7M+.QNKHU9IY_511;"*/+FH<T[F.0\$>K1O6^3<A)03U(Y;
MH!P:\#9&8"')6A-AR%UMP?OS;P1^"&H.:@1^B$J&T>#Y=A]CIQ@K,D4(OEZ'
MD2Z!8W5DFF-!^J0\_:.K.O!GU@C\(-7^J!'X(7(>!DYV-"&E@*:8%#71'\DK
M")P< B]\+60P'C-]U_*.P3+X1N '*7:O1N"'2+GGC,0K<NLH:-W6YIEB-7J5
MR:Q:!LH4#D$A@A&6H8O%BRQ^X/K<?VKO^CY51;-.Y-5W'ZCYY62<QMLNPAL&
MDB,2%5I(*M1>PME#+"Q"SI&1'++P=R.LW0V@=CV\'[V?JJ59ER+K6>?_=GD1
M)K/S#>'6A, B6;:<:E%OKGVC*5BKPZ*,8BXI:_9)8]]Z:#_%71WJ^'@1]:];
M0N=T0[BV1J@<.2BA/:A$_PHF%3"&4&HQ29;"?KJ]?F@_-4_=ZO9($?6LVW\/
M\SRN!R%;DZ,45RQ3W%.4H=W*!8BK)G,^">_)=XG&[*'=.X_MIUZH0_V>(J9>
M;^M5XE\$BEPF8;NK!)^+"<4#RUB(@5CKWPT#EUEAC,Q.X/MLQ+>?VD_M3H<:
M/D%(O2OXTSS\9Q7WBS?;^2^).XHI%$3G*+Q(5E(X&B((2=07JWC@^U34W'UN
M/T4RG;I9)PBJ=S6O1KC<D43,.A6/$JRSU1"1-0I"6< <G,L"36;[5#?O>'0_
MQ2@=*OM4<?6\,[^;IAFYB]M1+$EPRP.!- ;O*^7D+Y:L(%B5LK19^[OYW-V*
MOO74(0X\.C9>/D%>/6OZ;#*^6(8MVI,6PKD$VFK:>*PKX -/!%/N423AL-@]
M]'SSF?U%QZ?H9-:!@/J>;?9]'B[^L26\]B,LKE):/-D>R2-Y$Z& <%JY5&HX
MO\^F?.NA_07%':GV>!'UK-O_P/D_<#J>;2CG(N5B;8+:,PQ43 8<SP9H<]&>
MV11DWD>YMY_:7UC<D79/$%+/ZGT]C^/EY;<MX8IA2HF1S:F)^Z081 KQ@)<8
M3,G(,]^G\NW60_N+B3M2[O$BZMNSJH[A'2&P3/0S2;N*9^1D%N?!*26(!PS%
M18?F;JG PW[T$3Y6D\BX(SV?*JZ>M?WFXN)R>I-VIX(3P2)P&\C!U+SV-LFE
M)MFED2Q+O-L2;Z>J[SYWB),@C_6E3Y)9WZ=/8;+\QS:+$X0L6G%P@==[H#5T
M##Q D<Z;K QS=WLB[\Z#7#^R/U_Z-)W,3A=0WU9[<GDQ#M.K$<?%,A:-@\!X
M3=!Y,CY6:R@AQE)LX#&X?0SVK:?VYTYWIMT3Q-2W@NL^<T\.2B0*^&B3\8*+
MVM. KS-T,BL*"G)@,>E]-^9AF.QNU7VRT'K6^F]X.9\MTABO#U>$]"49(Z X
M\C#(K? 0)<G",AN+43D;MX_*[S^Y'Y>[S19]HMQZSXQ<1-J&MG$_1E19J0*L
MA@Q*,PG." H>E)/9&,U8V&>?OOW4_K;J4W4SZT10/:OX?W^GMW[;$D[D2L\#
MI]"_U*MS976/G>('[:3"XBQ+^Z2O;SVTO]VZ0P4?+Z:^,R07YV%R5;$T$EF;
M))@#U"Z \JYZDK2?:1')L*6@I?=[*/CV4_O;H#O4\ F"&H)'MD,2=>R[S%R!
M3[(.1RB"6,@D&)VE5BH*S??1]0./[R\QUJ'2NQ#=$+2_<5P^S99ALIV+H-%K
M[2.8',E&,500E"6.>-1<"T2!^R1#'WA\/^FR1D>2'4BP9Q#\.ILO\2I_;U(N
MVGM"?YVQQ@C&D=4QI"GZ2(+P&/>I'+KYS![/)KM0SJP#2?6LX1?A8A*FXZ_C
MBQ"W1ZPLL:R3!5]RW:($B4!H 3EKRWA)J-P^[OC])_=X7-FQMD^46M_AUY@\
MDFU-C"/.@R?&N:ITVQ3!43@!.C!R.QF6HO8I^;SYS!X/+CO6\]&2&M#FO;5)
MB5$4$1D4*4@$)6B*'6N.*&FKLR''1!RZ;_?ML'6M[1.EUO<$GP<'U>0L37::
M ZZ'BY KXYAG9)J2Y+8HR<0^W0V>8 I4L^Z\3:YO=B/QOF'SX$@;$2.FPC(D
M(T.=21/KX8&$Q"(W)G+-[EJ,_R*#GP[2[EZ#GPX1]3 &/\7 O54)@9M"D1&/
MJEZ!2( AU*F)0LE=XZ[_@(.?#E+=_<%/A\AQ$(.??JL]J+;'BRS%HKP$BH)K
M>)P<A(QB?8O-RV1BV>>6]\%=)F[0T%\-<[>0.%6\ ^AC_< >^_:J"YH4W+#:
M,8\$@81U:\%%HX&^KX3WK$C^E$U)WAXTNJ19S_7.79,F^A@ OC;T+T8EUX-L
MYL%*6:>^.TO^/5/ =&0Q&:Z];C)6;DO (#N1'*G660<R'G*7P <;5=WRZN88
MVO7@>NA-[9MQ[<7C$W?E0D&X$MQ!=9/IC\ AN(+@F2Y,6.Y0^(:+M]>N7$8%
MF10ZX%K3RM1&UI/>""9$^E&T3J)[P@WP&77E.@0U!W7E.D0E?4?J#P:D.H1D
M$J\7&5?N(2$@4/  UF-4@A6>]YJS^@0)GG[Z<QVDY+T2/(=(O&_8/!BG.%UH
M(^>2W ,B73%NP!6M0$KCC<V&2=M91[=GE> Y2+M[)7@.$?4P$CS!:.63I-!5
MK\PND1TD3Y"$\?0%,RJ7^^#X R9X#E+=_03/(7+L-<%3I?#Z<C[[LBU6\5;:
M$C! +%)3[)DY1)\-,,]X\@H1=6?YWYLO'F)*YQ@0G"30 1B!?W\_$K*@M5R!
M4;+V,S*6*&8,,&B.J+#<NQ=WLA'X]_?]7:5J8P0.E&.O1F!+\\O?1M$K7ECR
MX/+_9>]-N]M(<K317X2YL2\?;5>YQG-==EW;-?/.)YU8$!*G9-)#2NYR__H7
M08G:3,E),H,9\NUSNEE:K$PL3R  ! (@?TFA-Q"2#<")Y22L]$9NR=8=I/M7
M[Z:KT6^C^QWEV$/9P.O%$F>G\U=K#F8WO5-"T$2UH=U+&_*A@U3@6$I@1%#*
MH_$Q#NE,\<0KIJO]&U?W8TJR@[3K#_.-3*F2C6,UIN(UNM+@T&=P*F3%K7*<
MZ0%^PC1I_6DJ#O8)2)OHHP-\W:2<O8K.2]H?,2D%*I(\(@H.3L3$M!3.N983
M2/I,8.RIUL?2^KO(N,NT_HOTOY>SU:P^8Q7F^9?95UQ=S"XNEWB?[$&9^R<>
M=GAR?BBE(^7?7UZN""JKU:O%YSB;KXE=W0XU4%G(E 3DVNU.Q>SKO8-Z<2QZ
M'SAA*3<Y,7N*J$/MQN^X/"6@W17SBRKFU9?%];?T=3I?K$CBJT\DY9?TUW^=
MZ*)*E(Y#SB0 Y5AM,D1?&2X,K0<G<VBR6^U'[K0V:31,/;1'1]#=,[->:[]@
MG]/''SZRI27;1O4Q[%F6.L5:76]\<:"R];0K)DM X-85S-YH^]SLV<=TAOGR
M'.O6OYGF]R:3NF9EAOG%:H475PN&@$R+Y<[X./K=Y6?,:V7<+A8I8BXZ"BB,
MD8^) B'Z=8=3H66,&GUJ(J.1^>C8 NZ"PH<6<$IM=^#TWV5_A43*6;7_==SO
MXDL-Q>\+8!U-?SH+\T]GR\7EZ=D6K=Q*PB19#&,)4E:^MN1.$%Q.8$O!((10
MP38)(]JQ-&T@>Y0E,"$&GIFC\"XLZX#VK[A_P=(.#V_I/#S-R3'<"!D81JUJ
MEP59)S48!U$9 ZR$K'W)]-%D0N!QW(C-6^YJX.6W.]]=Y:(8=^B<*E#JK$VE
M;6W+R>I1A9=.B2B";^PG#".T8T=@%QP];@4;Z*N'G?XRKO!_+TG$OWZECT_T
M9^L:BV)U05>(#4&24BPJ<"%$X(8'IZ5&9YK<'7B$GFG1U18$#Q$W@D;Z!-;U
MH4TH%H/' K5S&NW^Y)DXS2UXD4IPG#,KS)&@-66-TZCZ_C&&]A!^?RC:]'WA
MR4JI/6AN-*@0R'_,AA9:L#Q+KAR68R!HRB89(VOZ:?SL(?8.L'.5KPSGOU%
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M3>1)2)%$D\3$(5/?^IEK?L@F/(9&.@76_8$"G)M0K.:@'<E'15? ^8S H\7
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MR9/GVFL] !&/OZ&[\[^14#&23*?O#A^6G^^B^Y:-P*1&Y RLYP)4)I\Z.J:
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M.?DF]ZMVHK*36&9$F#R&Q-%UUA,@W\R_7%ZLUA+C&ZNNO72J.. I"O(PHH;
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MTAAT;XJGW96/C,4V>NP L.NRHK>+^>DGXNC._883##*3VRS!192@HI401;#
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MHRX[ZZ%VAP)58@%7B@&;9)!2*>9]DQ/C70GMRKG:!2O/V[N1-=3=7OJ OSJ
MJ5[X?Z(%_A%7J9:FU1%+P@<.3!-,5"3^ B?'$F-Q,5J/:0($;B&T*W^M&0(/
MU5!W"/P8?FRVDIG/C&LG CC'R94P2D",68-'*92/0FES!#?NAIRN_+?QT+27
MM#O S*>Z"#Z4/]97XRP_1/([%G7*Y9N_TM?:0_'M<O7$<=G,LJ!\L9RB&V9
M\>C!!V?!1IXP,0IU?)-I# ?0/&T+B1'1=RR]=9W <7U@.\?ULFQGEKYU:"BQ
MTTO&BAOVYZQ-D."$)JLF-42-=6!-,K73I0+F,09MC<_8*+^B=1+)[;*XL>"_
M7E( _M?%YS_Q[#O^<[FX^+J>J81%H4Z@"U=DU(T#[TD:DA:2<L)'/:CH9MRK
MFF<([BIHV 4[.]W7C*6Q#K;AH7S6T=*?_US.DD =C<H047I0K.9*:)< ,4GA
MA/"I99;*8#J["AV.@<-]]'-J\",\X2SG>M*-!8H-%I1S"-&& AB$#$%I+=HT
MS]F9TJ[BC:-!<&<=G1@(WRXO5S.OA,F"U<95EJ09BX50JS)0IL@4UNA\TEWY
MAM"N@HYC07!G#9T: N??D2(IX;+,"$DE\C*2KK<T4D"6*7#&8PJIR='*KH1.
MV]UN*@3NJJ$30N"K0N^\93(::6V=9*84JRFY14+0)&!?!]M$85U2<DH8_D3M
MM&WK)L#B_KHZ(4 27VAMH8!+L1"@GB^!LTI K7(M615+WLB4&)RV0]T$L-M)
M(QWT]7R6KS\6^?I^!O.;OQ+]Z*OS^J]9E"D[YQ'RE22)TUC/4&6,@EE/H E'
M*_QYD=I!&'2GCL%1=-6!Z7OJ^#PK$S$7 T4YLN">8QW>7>="N> L,A3Y"/>V
MNUUI^!, U1CR[J(R_@E&;K-[/I3;C)^/R_7\JNOD!2[6\WA&/[Z^F'%>%+.\
MEMC&4"^>.7@2 C@GC&>!:=MF4L3!E \[>&:GB\9&2NPXA6^7JZC9 X8:7;/-
M^"07;0^YN[UJ^Y][B?>7Y6JU_+..)]E#:/=^^7!1/$7)2'>)OV*\J.DU9\OU
MY0IO5V=*LOA,JP+=IN.)M[1.>4V=]A&#QB)2DWUT.SF'=[:]_]1[M='9.B&B
M I&J#>(I0K 8@<E@;$2-Z)K<U#Q!S[0W@R,@X7&3V\/EWJ7UO5N4>U<4/WK$
MF*:B867Q$S")N:C"K "&N6;;9PO>>8H?,+-H,FHIFQPQM#$8=TV ZO,?U!P:
MYE#4JYO$3*DUCH%B=Z0/W'#IHF%:-6F-_1Q179J.73#Q=./8 S700;#Z,R_O
M-L.$-B=!]TJJBT#C+=G6HATHX67MX)/!J,*5<ZI(T21=[V72IDT3:(ZL@[71
M%;[N/.8/Y?UR\:4FZV]9/Q1W85*B4+"E,R@2&OBB+912?*' 3'!LDB"P*Z'3
MY@<TQ5X#34W<BO*N"_ZKG#<Q=SB[\TCN!+E^P&+"*"5YDB!9YJ"RLQ D.C Z
M6.=+8;*H%WRI UX_[?W_B! [E@HZ]\?O#XZ)!\R0?NF)8WKK VANZ[RKE#6J
M9, *5AO>(B-7*@3(AAD5./+8YM2\C?/^>GE^CJO-X5_XAJL9QF*PWF642$M*
M%<\@%!_ >"9B[0B+@UJJ[\S= SJZ=-%WT?SCL9C[R[D#K^FWY06N/X8?FV:N
MT4N?(S/ A4GU'H,L;B"S&YU#%3"KH)M,2;E/1)>>]B$ V5O"':!CTP[Z)P:8
MD E]1-")A*#*9EJAT""0&>F#5%HV"?L?4=*E5WP(3@Z3=0=@^6,1K@9>UHF8
M%%.NUY>UB>)URXB9S"XP46J3*HHI568!/#<2=/7@DU#"E"9#(9\GJTO/]Q 8
MC:B%0Z>-'AQ,W0\)WX;YZE_A[!)?Y?^\7%]L1J<&B@=3'<?D4DTBR@HA(K/D
MP*-V#&.27K_@X0YXS;2IJ2-"9&R1=F!S*AN5)7KB^:M%_OTK0;]^3EY9K-6F
MUWD]+C&K'7&5E:;0SAH.+FAB4GA:!E%:%YO8GF'D39MOVL &-=!*!^E_E:O7
M5WWF9\E*9Y32@%C[20N5:^</#3EZYD@T/-MF=Z;7-$R;+MH(-?O(=])MZC:O
MYYY=O9M',/,I,">+A<)L!A6E@\!X@B1+S!:#]Z*)N[R=G&FS.QM 9@2I=]H^
MX(5SL;W2F%Y^9O/SO&8)2K]?GI^'U8]EN=EW-I'4*">?SSYY5(D-YZ'Q2:@I
M@0OE-U5PH"23X+3@@ (CU\Z:))HT7&N7]W1WP7DUMJ@4+SR+$HQVCEP/VE]\
MC@ED5A1K*R-3$:TX?$!+GR>B.R!@VSY^B+P[""MN%N#F+I)^9S-[4WJC#*N#
MS@VK?9.B@6B(FR2\327;D'2;-H1;B)D>- =I>,LV?I"X.X3,]2"^&'BQR0O@
MSM-"<D5!U*& %DY(Q812HDWUSU9R)NZZ<K":7\#-'C+O #F_XV*^O#KYO9ZT
MJ(LV2OM">C4*5# :@F,,N A>(UG?DII$EX\HZ0LO^ZCW8>K)0;+N "P_F][-
M"G+),6EB 31U4"L&!D%;3_%4,#:4*$-L<K/[F)3I[^[&W)4.%'5W8/DMG-\L
M(<F%\4X1]4Z2T<W)0DA(,;>5MI3 @E5-JK>>(J@G=V9W13^+FSVE/G$:VRLA
M]57T>8FD2W%M+(U*M&PH#C#)YUJP7>\)<B0I.;1"$0?I08+NU@N7[4_O"03[
M:FTYJ@BG!H%D6Q@0M#%:YB0([3W)0W.(422@?3@[D:5Q>LBEV]:'][2!C &!
M@P4X-0(X>W.Y6OZ*B^7Y?%$/R[?PDWD4W',-G@M=.\D%\,0'!!5*B88I5NP0
M0 QXU_1)'^/B8VSQ3@T7QO7O?\[7Z[>KL$C;V5(W;&F%,F4.CK;8.C@\@F>,
M&%0^NX@RAX>G*=M1,_R5TZ=ZC N>1L*>&D.68'Z/!7V[#"SMDRP #[)Z9+7'
M@M0&#'U-HO!"/!S>N1TOVQ\_?8['N-@808A3XT#8;1RDE&RPG)'[5*=NVKQI
MF$"81@Q(,5V0;A ,MCY]^D2,D3W0@T4X-0BX$?KI+=)<<R05&E]8@6A$/1'B
M@7QJ(2!IQFP.+#ED@SR0(6^;/N]B9!]D=!%/#1I]'_7VF@$4I4@L&F+(M/&A
M21"5EX!9%%E\"D[X(1C9]O#I\RK&A<3! IP: 9)O84 :9"KJ7*L(ZS +XB((
M+<'Y4#QN\#T( =L>/FV+JP:!ZZ$"G!H!3+WH'+MKMAP6%;,70-%4!L4U 3LP
M#B84'25AWC_,Y7LB$AG\RHE[4#4(1=I(>VH02?F3 ^6O6> NF,)\ )FQ-H.Q
MGL14,KG2-AFK95),##(D6Q\_#!PG= XZ@A2G!H(2_\;%=ES?L!,-!5"N!/"8
M-M7*!6A/M,"SM%BB-P+-$%"\_*IA #FA4]*1I3LU6 1_QJ&6[/8>@"<1;*W_
MJ_< U2*&C 8P^8#:%I,&!K)#WC8,,B=T<#J^C*=&S6T4MMS&$;^)W8T569&L
M#($ 5** C&(O \EFKK2G!2,&69E!;QN&FA,Z,1U?QE.C1ING3*>\.?NU)3-6
M? &9:D_W$A)Y[3Z!,T(@2S+'AX.8G@A\7WS5,+R<T"GJR-*=&BS&VGL<W)SL
ML*BE9AHAIB)!Z>3)!>.JUE]$961!GN,@D[+MZ<,@<4)'JH?+<&H4Z/NG._(F
MML_:"8K@,VCF:_.;R,')>LZCBY+>.<=+'F0EMCU]& I.Z,ST<!E.C@*_C0/#
M?>THB,"8(X'4LYZ870(="."F^$ R&82";4\?AH)3.B8]6(93HT"Z^Z&YO(FV
MA$>B5A'ULEX7&Z_!6]K>M-/6ZNQM>M@1^(D#CJV/'X:#4SHL/5R*4P-!F7L<
MJ!OG1C*>LR\%R"%FH#@O$$DDX%U@.@5O]*#^"MN?/BS7ZX0.00^7X=0HD/=\
M&W5S76QDEC9Y YD7!0J9A&"]!Q:R2=;0YWS8:>>6AP_#P"F==1XJP<DA<']/
M4[=W?]ZE9(ANGC9S.@F_)(\$GA4IO,8BV: 4OZU/'P:"$SK//%R&?:'@=D-C
MW+(<#!A"]'4. +?D[F)"SK4I*I7=4;"+5R!.Z(CR<!E.C0)NGSXMNV4HI1(]
M$Q:D\F3<8J:MS6@+.12T3&>)P[:'(2\;AI$3.I <7<)30\;;S8G9L_Q$'AU7
M-D(HD8)CQX@?61RM RU\],86-N@,>\"[A@'FA$XDQY;OU'@1]]-4]<V]3?*:
M11XT&!X*J%#[?2?#P1=Z?\B!+.4@F[+UZ<,P<4)'DH?+<&H4*'Z?@UL<$R4N
MD=WSFV&T+I=:(F.@B,A$T<XX.P@%6Y\^# 4G="1YN RG1L%]&)L;&"N;<U8F
M@+*.PF=+%LW7LN^4,7#-HW0Z#3(%6QX^# ,G="!YL 2[JUE^/U_@NPL\7\\4
MDU;7H0\H2AT83(YS$,R"4X+KXI5AK-EHI2WT]%2)-G:I^WY"[PX[[Q;T9%Q?
M?"(_:3,4,W_$5:IJ^H(SDV3103O@FLRA<M*1M&I'7%%45%QPXX\ I^=([*D<
M>D]$/(NRT=33 ?!^:MM=A,TAD,&5KL[E,EE!P,B!6Z]+MEPXG5M JZ\N^F.#
M9V\1=P"/G^7Q.JQ6/^:++]==<#%1[)80P6*JCKK7X!AMTJXVF0C:DR]PA%9T
M/Q/5T^[6PO8<H(+NX'2_X?OU5/N9M$HJ[1.4',GGJU.3HDL:T!>NK#!<1MT>
M4ULHZZD&NP6P#E7&H;V,/X_:S^ZFM>Z,V2QMH)V8^5"SW%1-<),1? BV*":B
M#TT&P]PGHJ<2[7&@L[>(1VN&WJ9C\6]D7>E9WW&,]KN/'C9FQ]WG*6W;9#=8
M3JJU 3#744 Q,"#30(Z,M2($0;&<.Z%9P=LB4LYDCLIGD(8I4)R6A9<ETK8J
M%!:.*K6;NG *379W0<"0)KN[R+L#-V9[.U#G:#],Q(-*M%EBL1!C'8]>C L\
MD)>6FXP /HTFNSMI>%"3W1W$W2%DK@],;6+<%M*KD([$XD(=;\0E2*]-%+:F
M7Q\%-#TT,SQ<S<.:[.XB\PZ0\[CQ:Q'9RT!^N C654D(B+563"7+M=11N-QF
M@/U)--G=2;TO-MG=1=8=@.5GT_L),YY_J_KXB*OY,F]65+U#%<X$DD_.H.@C
MA.0Y_5/4.<'2&VO:^S;;2.OIZ._P76MD570/KNOEEYC7J$T!L;FYDX["2ED,
MR%##1&DB2GE\>/6POXT-B)WPMH=V)KY5_V>XN%S-+W[\&BYJ/;V\S1'ROM1>
MYQA2O2S4 KRW#+PK4F>K5.)#QLUO?WK/ -E'@\M1Q=D5(/A-HHA+)DCN-,CB
M-E.X-(1Z&$Z>88I<*F1B2/W?]J?WM"4U!<1>XNQN3]H8T6PX 9?LI_:U-V#B
MB8RHS> 8:BE%JD5-[7>@P0[-45,MQG-H=A9U=V"YE[<4A?'DWR.8DNM9>/+@
M<IWD)Q(SD7'I'VXJ_X]-%=A)T4.G"NPB]8GWGGN!X:^7^,_PH^:KU@&Q^.UB
M8S?OI:W%K*405D*)=?AY$@@^88&B:M5445;X(25'.[RR)[CLJ]]E>V%/GB:Z
M-=W9:":P) F<<]J_@ZS]TG.L'TK6C&<FATVFV#ME?'1D-%7BRPGDNTAT<DQL
M2WS-@2@GHPJ\>G/*&0M1> >LH,I2V&#DL Y;>Z<.GRXB#I7GU(!XHN>@=D;2
MNQ245.ORD7-P5M-^[ 2Y;;H$K0=9B0,Z-QZ_CG7?#60,(4Z.@^VM&9A6@>5L
M(7E-4(Z1'#$R:,"32#GY8N*P;C<'-+@X?B7K_C@X7(B3X^")8ER*[!5&X$PY
M4#X9"$$F0*Y(3@KI_R&G8 <4-!^_5G5_%!PLPJE!L+U$BK9%IY1Q4+FO,)80
M?$I@=8C,E"*\&M3_;/\RL^/7G^X-@L-%.#$(?EM^O_:2N-_60/2V90='[Y,
MMLG9U)X\IY(*,)%9QMKKS_$!H!CVMD['CNP+D@8BGMIR#&P<:M$P'6M!0ATE
M*U. F&7-)?=110S&FR&@&;,Y:XL(I(5^]^C2NH.PIX;/H#8/+I.?E84 Z41M
M.YL8Q% X8,S"9E6,SH/0,UXCC5,$S^BB[FB_VM*,]B8T+SPGYAD4Y\E4>Z?
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M+277I-'.(.HF[K<S)2X/T5/7\%M^P]7%CX]G87%!&\:;_[Z<7QV.V^@X:L-
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M-[V-K">N;7B"J<_+7W!CG34SGL6,X$RU]"D&\-E8L,*4)!3C"8>4-+SPFFG
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M8Z)W1_*GO38Y1;"WQ$>_1GH[UQ^)V]46GD/,TC*;P!NTH%0NX 5]YB)J);-
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MN%B^6]#6@>N+L,@?<1'.KAHTCIJ4< @)C3(61I/*$=(9=%#)6%;SFED$I8J
M@'7:D\\>?<&$;3S,AND,3[M65V^\E?E5+_J-*JY5-#,F2XLF@S!8$]D<N5.U
M09^V3$<I<RS)'-?A?I'F?I,0=L'6</]X7"5V6<%+^])\M3E/NMUU=[>66QYR
MN+U[B;*1+%9MI$FJO$+Q(M^]=0O*BD_<&65 :"U L2#!1ZT@*,T]*YZV\"8G
ML3O0>*A%(["OK]ZRR8K]N*3'/E+$W6L_DQ9^H=__KYEW# D0"H2O19?9YWI(
M[\!@4<P(SF/Q+62S+\'3#_%I@;J'MNTHZCP1P_:Y'OJ-8]ZN']7"R&VC<@)3
MYYCQ#C$ P[JA&EMC6BE ,I(+DYY[UZ0LZXBF[L:+_E!>?ZW=LVG'?Y72Y?GE
MQG>N2P4)',L?][3S(9[-OUR=%&_T=+=>%/(D<NTI:2T%7I%6:E#.@N5!6<9,
MC+Z)^1N3B=,QB;N@\Z%)G$SM'9R);N'];9BOZJQ4^EH=I''5A?D!E[6_\^:
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MG7%H0>D@(<J,0*$@$RGX$E.3;-Y="9VZUUX#[#7557]8'.9Q_'R(0%$IOKO
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M-^ R_:2CH<.HLV"VR;[:X\CN-=T_&88'UG27]G:[!UY,H;LC(VA3!U\:7^C
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M9G_66*@&[[6I\IH+*84U7@5P7I/QCTZ0\<^!).>4=>CH:FA2TKF=G&FSZ6T
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MV%M]W(3X/%1SQQK33PVQN>.B<RE\W4O@H117$P[% V+6P+R,)94<C!UIYNV
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M2R'G<]_361JAV<5WF&#[LT*_X5?\G%<O_H&DFK29K7]&0:?BZ!Q@0D_>8$Z
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MC-6)F=* XA1YAN(B83.QQ%-"&YMLP!K60=CG6CECR3!BCJX/6PNR$_=TF]@
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ML^>_+\+J15VP)1BW6W5$CMRGQ1^UUV6>TVM<SHE[NH+_?%THTEV?:9&<";Z
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MO'P[^.U2-+>3_P.WT3L'(DLRS"I["DUMJ>D.SSE]$(M-^C4?(VC:A[36&!I
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MPKWO]RC[=C#:TY\3/6DBT$LER/WJ.JLUZ)#R*DM!.X'J:%"E9050 OD(_4;
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MRLKJ$=QFGBBB.H$OIKD!A'EW'&A&5B"X:YI;R >O04?3B;!-;AIZ,QHLQ!T
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MFR%I>G>)%\X/[Q@*O.CG!O'SDJ>#=I=45P*A-8B1OY<EC@W&CHUN@!G=P>8
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M%FQ)759?^*X#/:19,FXKA:=:X[Y<GXWM9Z0C&O=)AAG6%M'6>6&QFM!)[[C
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MS2:RK=8)F+)-YD_E$@L5AWG(S"GZGG,JQ(T_UOZ%:,7FF6$?-#)-KTU['U2
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M7!K7R67I+^F>N)'?;3/*Z/G:)8>>NLT["D?]/0JH+O7@(+2;Q624PN:K8JC
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M'( 0@?2"(B8"*L^H OOT@.CG"#3[33523WI*)1>10HX9]H 6JAQ[/DG)2)D
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M[7WK<]O(L>_W^U?@;.IFI2I(EN2WO6>K:(GV*F7++DF;O?OI%@@,1<0@P&
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ML2PA0 @S+&5<HAS"09-BJME14R%;G1-H!-F\S_*,+C(8^/ DLB,91JC2DW!
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M_^%N@ ??Y8:$43=!57IG.\-RZ3JLR7<J%K60V$X;?:GWJR/U8E4<GTST;,D
M<:=+NCNFM@J;>AHYOFDRCG),89LEQ3140\M4)\12EIS*C9TR5M9UML3KS"97
MQ3)UJ0ZRV; .HTG 0TT+NUU1_P],)F>V,%#K4E552VK=;L4.0LK"\$2\69)Y
M2XU/EU7K$&.$A89JK %!E5/<X0TQ>B.I-$25A$$E:7"XP58.1.6DD+J.O*H%
MN0GWY3=S7\Y!'P;:W#N>E?!3VN!3EC=ND2Y0%4<B;[@[8MV-D6D/2&WMNSAR
M>SOT^.$TR8NV%LZN.U:T+PY)^O9$G*I_PHX"5'%5<E(S&S)%=!484LS\*C"=
MR@XQ.9MA7X13YH<K?;OJ&J?0IL;8MN3#?FBB+\(CK)59#(SF.'4P03XSK>8\
M-T:02+L] ]#K-H>C<6$;Y4"?)G+&E<%6Z1!#!7-ZUB(Z=92#P_'IH -*U>4-
MSGD#+NGQ/?=VT__Y/K,8\,M>SY)6TA$_94Z >L[]YO:?5/=)D7M=NM(7$ZYR
MBARAP08YJ@T2RL!+X23O#Q?*T-6T)M2TN^'*@J'F*U0&>84^@#)!5--MQ=P&
MU T<97 (U%H$GS.163[&T-  8M2K!^"5KMY_\K7;ASW@![KX@?V]'PM <(L2
M+D^U-G<^/OU !5Q&'\8G1]C=+5JS@C0WE(R<B!2!9K;!24**^#]:4!OVX^A@
M;^\)AV.JLECJIU5UK4O1;]88:BV:8A=%*@9+GF6.W'Q(:F <_(KGL=61$LE0
M?M,JAE+-D1V SEFULB!%1=6)Q?".5OE4M52O9.R;*JDS9:KI@6 !5-,R_##^
MX\ATR.Q6B"^CC_#%!*:__P)GOK_7)^"7DZ0S]L'N5YSWD4C%G 8GDN\_-P6:
MJ&BAG3YN?E*VF)+!3[YPIL&_X:+>K>[<8W^KU%V[(7FIZF]2TTU5MM%EWT_5
MYO :.M7>R(<2<_-+XI5Y99OUF5B%;J^)VK-^,]$4Z=6I'G&/GJ2'1NQ?1)OU
M:L1N%"G%#=VSKH\<%\<=[+1LBF27/ CV1^^QC)*'TK5P>P$VOK72O7JZNKZ$
MK^ %6P=EAOTG2D1.2:>LHVY@Q3>.L\:30FMU!,??RF%.?DL54\/;SBN7W-6U
M$>FLS%/.M@(]KE:86I@O*&\Q!QZY-Z"TU]I7574#95WVNN^\8[(9*U?5G(6]
M+:EON^F@-S!XJ(AI#/RJ(!>^PRI1-37MMU1\G<!E-IFAE%0^FRKBP1(Y@$YE
M_'&*V)^-// :6*&JB]V\Q$#A59_DNUA:V"LAR_%54P,W=QM9T>8$CE\SP,R-
M5#5U@[TX?NT>R6EW%!)HL>/OP$K/<FH%%3XD\29SM^AP(PK=#3E &VP45]7*
MB&&1Y500Z]4$_%U?!Y:T0O5\#LEBQ[V%"W87UR.6*L^^0O^A39M(=.$ H7IO
MVP0OB*?I/M.:[MGOAX?CL[./IURP<'1V=OSN9+WJ%=Z@ZH:;U5#Y8_)/Q]Q(
M"%F'[F/!: 9)?7<IW&=Q-^:9RI;"[BI>L>VF)"G>0/U2!\YAOQN1J4)-%?Z6
M_3GXU0HGPFOX1'V8A#W!G?IQLZK457A-*X.>XKBZ=8JTM=)5 Z(5#6:<ZMB#
M_65"):R!-]7&K>Q4.G=+)6)<!B6$Q"@(0NVHMBZR#5AB(2[(8^UZ(.1=RX;>
M&_1SH#?)<WTMQR=O/YX>CD=OCM\?G_^Y(=?1>IRQ68&T6]YI6L![!TJ20#]R
M*DBN.ITW)J*YPN!7SL'Z<)U.K7"Y*AR\9 KGYI(##5IG*(<J?0;-F$ G<49B
M#HW"W:T3M(#J;(=;C/&!YI+62@5S.@@XY>#C2&G"\4!# ;4DQ=%"\;^E!3RX
M0I\T!GJ*.=.*UN5L=!LU:^7SGCEFWZ%56M4$W9)1U;3DT('L='@:" @J>L-P
M.@"AH6KP@J25!*]<I8HK5HK01:MNI:I'A5,NMO_+3H]OT@I1YF,C)H4"LA$6
M4DHVY&[V^G>I(T87C*]AT*[G!' M,+@_%=^,LT:9'!JBWNG66"&B5<!N*Q<.
MC10K,#,IZ&H@](!SLS(^?5H\@O(-%Z/L@V!@\TLXF04+ K\7:CJK]$F!FP._
MH%.&K\BJM*E1MJ-OHF<%>2W"FQ[!\A(,@)RLP;9TV9::G-]$G)J+YXU/;X7&
MSD1!'4V0*W"[!72.HZY-&D6WLVMW(FUI3 U;CMN]]]0^EN;'>TM/?SUO^@_M
M,=]?+X_Y#=K+%ZD\W^]'WUVY>K$;G8T/J=G;D[V7H^CPXX=/[X]')X?C.[JA
M;@>!HW%>Y0T<W/0V8>)-$"0^VS0,CYB=UZ7*4\LTAS-FA.W%A'V@BJ75O6H;
MFY9N:U3<,-N'KLN;.WVB<%X#;1D3[5M*>VV']/S)"\5X)]0O+JN<7TH-B_.!
M0DA-<MT!_^&,$=#A-R%/5DF;? #&H:;?4+7W'LD<N;.:>OYH':>\Z51K-"='
M:U+%?=RNR[I_I=O8*9&==V0@_J7?M]F=/0WDSIGI9;H&7@&Y9(7:L9JM:\-.
ML,A0HKM/4)^MY#JV[:M0,Q"P-=0HP^V%JAM/#[8MG:B>P4O3'!'?@$@GE:+E
MKL'?[I6./#7JG9I#Y0.0.3@J#8@8.O).%V>KH@H'DDAMG(T^H3W%;H.H;F,K
M]&/''87. LAXBI@ EPJKQP^-9B\JJ#[)DEHD>O I[8V1^76T]6P[FL/J9VXA
M&W?6P2TS<+0S@7VL6=%'W>I,U)>@#GX?,,'#=P_?/7QW?]_]T*;)P1J;)M^4
M/ONW4/Y71:+'_^^WXS?'Y]'HRQW':[V^L_$_QZ=HY$2C=Z?C,6&9,-+SUYK=
M_]!W[?'P77LTJ;(E_-^LF1>__B]02P,$%     @ 9%=14B[Y\)SK.0  DHL!
M !X   !L;'DM,C R,#$R,S%X,3!K97AH:6)I=#$P,BYH=&WM?5MSVT:V[OOY
M%=A.G8E41<FZV[*S4Z783L;[.!YO6YG4/.UJ DT1,0AP<!'-_>O/NO4-!"C*
MUH6BE0>'(H%&HWOUNGYKK9_^X_4_7IW_Z\.;:%Q/LNC#'[^\>_LJ>K+S].F?
MAZ^>/GU]_CKZ^_GO[Z*CW;W]Z+Q4>976:9&K[.G3-^^?1$_&=3U]\?3I;#;;
MG1WN%N7%T_./3W&HHZ=9451Z-ZF3)S__A-_ OUHE/_^?G_YC9R=Z7<3-1.=U
M%)=:U3J)FBK-+Z(_$UU]CG9VY*I7Q71>IA?C.CK8.]B/_BS*S^FEXM_KM,[T
MSV:<GY[RWS\]I8?\-"R2^<\_)>EEE";_^20]57LG>N]D^'ST[-F1.MX;[N\/
MCTZ/#I+CY\_W]?/G_[,/DWP*E_,]53W/]'\^F:3YSECC\U\<'>P^.Y[6+V=I
M4H]?[._M_=\GP:6U_E+OJ"R]R%_$,!U=PL^C(J]A)B6,S!_M WI_:UUA1H^+
MK"A?_+!'_[W$7W9&:I)F\Q<_GI6IRGX<5+ S.Y4NTQ'_7*7_JV&:,&/Z<\9O
M\0SNSM)<F[?:/\#W>/-EG [3.MK?VSV(?BW*252,H@^Z',%'E<<Z.INI$G8H
M3W09U6,-F[%W$+U+LVP>?:J+^'/T(5/YPDM^W=)<==>W+LG)54NR?XQ+DJ7R
M@BI/@ PG4Y7/UW2NBSMU=E%JS:=B+6>\!?.-WGS1<5.GESKZQVB4QKJLME<_
M)RO]=M.GYZCS9<[':=5Q6L:JBH9:Y]$%,$UD<$4>_>V'T_V7?_OA^<'!"?SO
M]/!EM$5_[;W\#2^*7@,GI"_V7VY'PWG4284#^"-ZFR>IRE44%^6T*!6RY$$T
M2^MQE-95-"W3/$ZG*H.#C$M;1:F]95ID:36P Y@)T&/DV5'!QUQ^DN>:B0VB
MNJ"?8787Z3#3--9EFC3PO-FXH#<O=:QA:Q.XL'-U+(5&6]Z3:!6T78+=M=US
M_X7>Z4N=57_[X?CYRXXYI9.+2&4UB*")NM#[:O>OZ<63J"KC]C<\;7G*P=[Q
M],O+B2HO0 (-B[HN)B]0^ESJLDYCE<G1I5/,/XM@.GE^.OWRY.&<()(__FK"
MY[1(:#6!*O9/]EXN_OM?*F]4.8_V!ZP6(+WL ]F^!J*;#$%&'?(O!VO[QI]T
M>0GG,OJGKFI4>_C@+WOG7_6P]%[ZZ(99Y>-O=_%;ZY0;G7):L%+]HM290HG8
MJV4**]ASMZAA561-W7_+>FE?JQV/_2ZEV,UQ-8W^V;'E@^/2S'L*+'=G"";'
MYQTU@M=ZH;*9FE?ADGEJ__&SW9,.K?\F=/MUWH!SA7(=K(!7<"D\ONJ=YU0E
M"7"PG9+OWGT.XWMSIZ]7HKA0V,&BPUTU3</2?@GVQPZ\>*:FE7YA/KQ,TFJ:
MJ?F+-*<7H9N^1G:>'NX>[9W@#M<PSSHQ#Y;-WZ7-?UHGB[^='NR>G/;_O+>[
MW_O;LF&/=_?W5QOU*<V89PWK4H&^]I]/#I^T-NG%P?1+M!]N4*9'BTM33)_<
M@TB,D:%%^[M](I!UY"[3M'7.9+4>Z$(<=KR-[&]+?NP?\RE9^JI[^*)/5EJ5
MX-(-(JF#7I(2_>N1?A[I9PG]'/;2SUNPC&/B2:]@O@JL[#>3:5;,R;+]5*NZ
MJ:)78Y5?Z&JC:.SHD<9NF,:.>FF,Z0<].*B,E46V491T_$A)-TQ)Q[V4]$G7
M==;A%W[@)'3R2$(W3$(GO23T$:^N4."AVU;\M1M%3<\>J>F&J>E9+S5]* N*
M/.)59Q>@/E4UQYA'NGPDJD>B6D)4S_M9E*ZF15X!765I/8\PU'BNOFR8 OY(
M4#=-4*=+U"91T?=.SR@(FZ7H>MHH>CI]I*>;]F/N+7=D<IA[_]G+*CJ+/^?%
M+-/)Q631U_Y(6(^$%1)6OX?\M:I5]*%,+U4\WR@JVM][)*.;)J-^K_@9O 6#
M/*-S74XJ01_E_.UF\:?]=JSYD;*^F;+Z_>6_%3#1'!$O[]2,R6I<(!"F&$7_
MU'FS64K5(VW=/&WU^\E_3ZM89YG*==%4( 6+R[1Z9%>/)'4E2?4[S-'8TWE%
M\-KHHXZ1>VV88G7P2$\W34_]WG/&/G]JAG_!M0BC=I8?@Z%!#)[%L9[6&^=@
MV.^%)3PEP);YO@-:AN_PXMG)[K%YM31/8+%>[)P<[3)-\L"KH\L.823Y!A8#
M9KCB*/)&SPYN"[2Y\HZ\TIFN:MVW)P=7[0D]L8],S?O?"7703-I<R/OW[K";
MUR>:EP&)GNZU"?29(ZR[!M'=Z1["L\.E.'BV>_P,WWU5S-[BJN,:G[27^.!@
M]S!D<'\U59V.YG>ZRM=*R_FJ#!M,H3%Y0W>5;1,I_\Z=7U0% _+]_ET+HW>_
MDO_3-F<FE;J:BMS#"VO89UU'>4,I&T BU5C!)?B)%Q=690+KQQF&_A0^T85V
M\'JL:C\<'4W4/+I,]0Q3J++BX@+M31A(GON[+DL8/WHWS^-Q---#8,HZ@B&N
M.#*CT4T?&2+C!-1*II07E&")5SWY&=-J*2'D;S\</>-_)G/][R:MY[L9KLYN
M7$SN^HP_^=ELP^'1RW/>OO=V^\RNP&_;NU$4/> #?CXV)P>.TT0E.IHV9=4@
M*P,BPD-?.1V.:-FZR6+K)HLJ6!XX*IB3E]-59W $$SA4>-U'$-^4]]R92QN>
M./C"'=(\N<Y#E[.# 5P49PTN?Z3@2*@IF#L))@P.(LU)P?P V"+X045C76IX
M^E;[H+LA;>Y>!(R*IJDO1;,%#H<S'64I+-Q0US/,CG0O(I@2>GUZ2YS\PH2[
MKP?6 =._(._2;C_E]9+5<K6O3:'']T^A9[B6:IK6,(7_1<9/2](@RQXVP%2+
M.DKT"&Y++!VT10&OV5A=:EK'B5;HF.L@6USAW:O/\P-4DP[614WJQ*$O2XYY
M>04370<2!5(J8)%)/U%5D8.9-X^FI8K1&$5-9E1D63%#YD-\ LZ\.=,+":%\
M\%$C2&L4\4R\B4:ZAR?3KTZ3:')D7-IH3,"Q+F&!K2;F#_\'7NIRKDGI*9CN
M8:*H9,7-I&$++WJC2CXC, ++.QP3!-Z;#Y]8\!'<I/L5B*EQE0N\X'V1[_QV
M=O8A@GNC+5@DE> N.84/=@^/J7W'!-698!7<T^9:E5$ZF6A0/VM-RYSB3SP2
MJ IPXF/K8NB;'\P!MFH$/!Z_G18I*HSP;34N9CFN"EI@T3X/ 1PED=H;VW9E
M\5U^*XM9/?:RQ6D&94FP'!(U4S4O@$G!LM;I%/:'N;V.>E2*Q33PKSL69+8O
M'HJ0%QV>W#$O4O?/@TZ(!YUWDSSLZ!*:YG,X)!J;-JZ."U[NCO>T+&*=-*0>
M=J7)?]U^[N\]7V%#@1F>GM[QGJ;WO*?[S_&%SRSO8$,453##8T /JXHL34@%
MS>'0@2)83(  JI@36>#K45E,#,-!\_1'X ^@*R[<#FH&D 2\0$0J+6%8'&&0
M^HP4I!686Z.TBN%"YE=Y'U7!+RH&GI'0EV0\XM]-7C,U476+#&S%N &^DM=H
MB4^GF8@5&1<Y.\P.LW#@2N;3?P![ I[+O'K0SW+A)1(<LBS@87#_ NNE-T*%
MMLF;"H\,/ L4,+FS FI,1S =&*Q]YTUQLQ6I_WCW8/^NJ7\]R/\\4 F<<P%$
M#] I2Z(.1P/IT$ /PM!"4D=N:"G;D\S*FB.BQ5R#V%%%BI(T(^X)"@@(5J M
M4F# WK]4&9)DQXD06KYC>GJV>W1XY_2T)@0%1*&R&"5C!UE<C\6Q6G0E.W:T
MABX_IP)^!5T#B5H9W4%-53.LQ"K:2M/M2 W!F+::V;^;HDZ1#LNB(1>&,,Q<
MX]/K"$L4W#DAWKU8OUP7.@P-GY75-:8ZO$9-4)I6W52KJH"W$2582D174++9
M*OEPG53RMK$4FE(F.&#MKA4--MY.N#6G/47ER9WJ[](.B^][TY_O'APNZBT+
MO@I;AK'3M3M+^91Z0@)V#FD'B,4J]$:,(;=/=!67Z9"E@B\%AB($EOA3-V'?
MD_O>=W/8 W>Y%\ZR:0*F:!ALO#'K8-<"3T]773%KJK 7CI3+G)WQ:0G\H"*P
M253 _4A6*F?^[U&%K8, E 46/4L1HK<@@  C@E91-G#3:U)70'EXXU183AT=
M.$D"\QIIM-&6.9=O'7+1$1NXAX)+;73,(P#B6TMVW/NI9L_^-2J$W!2?70_W
M_Q]YIJNJY36Q:F6%G(.,7#B6:-X N]%<Q93"^54#.FF-I:%IH8#E84A+)9=I
M13X>HG\RFX#/E-:_=>:\0._4K!JTC"768_@)Z+Q?B! T4[+&8UMR0[O-JGBS
MPM3W*&E*X^_LL.V-.%:5>$/9 ;K9$G5-/-K+X!7OM+IDJ_D,%!X/:WEWJ]0.
MD/M$A2X@%-'L@D1@3X83)@\NSW<YW?70_0*Y6U'L7>Y9?AUN ALY%=UPHPEY
M3>S 983\&CCD&'C*Z4O0N8 U4L[[6A'S%>KK5KH-M*R- MN^*<'W&Z#.2EZI
MH=-B1PO7N@78%/J_4VJ7$*Y;10/L0_MAVI2@2NO*NA+::!*$CU2+4+Q9T61)
M].\&7FLTQW47J"(L>JY':8WN#0X8N>X"60'+@IN :H',)9HBS <G4H" 1[!E
M!=H#(?U0O JPB@W<=,+D!/\?&'$M(2P#4CP;C6!8-(YHQBSEJV#F/L:)539=
M^N"FSG'-A5%2:%99"%^C5GNGWAWH6=P45TT)0<>J+.?H!*9+2K\(1JH9Q35J
M\IA18K(JQCJ*QCJSOF4S>G#6\!T171 K="Q[9V0ZGE?X+;X';B2&PF!)TI*H
M@DS/:"J!CA&B+$&2P<G+X698@:W3O6W2XDPK@ 3LF9;_T070S$J;589M./<F
MS*<9%WVHK6K(7BW:!3!5,5R8P(S<$L,*DIX*X\#(%8:MFS)/X0.6T2_0KSYB
M;=1[K:K!LOKD$(?!,3^H&H6S9/)TZFZ/MKO9\G--7&K+Y.=_,V="5>K<A<K7
M4X!ZM@B<? ^!JJ+NUR!?L($!DNM&X#B+3D4^.R@4!TCV'&PBAI,RJ^AY0A'#
MF:I")U2&!QP.\E5HKCN0SP-@84D3DYNLF!8E9[5G<QLCD>_,5.L"&1@QH>6&
M'3QZ-D[11O6%G6*>3_,B=B8ZSR:I";^NH V >#;"K)MNVH)-1RV@BK>L/SK5
MD74$D@*Y-I<YF)'OS[P'I!%'Y[XGF-'A[AZ!2U"8E:P'$HA0]IZ_U@.SVWQB
MTHI5 M0L,($%_MXZVR;H(5Z>")_3VE,).9[]T3V&,?%H]FS]<L6]WN2LPE46
M%Z6:L&+CE$$9\-62 54PG R#:2T$]\D8B,0F>QOX(Z._WH8A_MVDHIGP<#)Z
M5J FE:G9H(5(4DT]+DI">K?4(63_25*B"D-:"@\A3V#-&HVG-]OLX)^E50!<
M@=M1?UY\74$NM/25ECK-K[3AA^S>3]G>[C-".HB9K(B,ZRC."H):%B4+.=H?
ME$M%^1G$%;#+1?%/&[;I^W7?&_9<7/^"I\;H:TND695NI-*L*6E;\>!B'IHS
MRE"AD6/H&3\^PVHAZ($N0I"W44Q@,##E,GI$RB% ,>;(Q$.XXD109AW(282(
MN#!>GW$FD/2;5'7NP_WQP3];BVJ*/70C>PXI?1#6B .H)O-31W:U28U.@+W&
M"%1E@B"#L%_G:3O-;C0&?Q_+^K&30RVN+Y@  5Z9KHTNRJ*9#JS_@KT-0T2:
MH]S#; ^W <.R4$D(" [8XU_%T!ZQZF;V9K/#.6L"D%AFQ3O%\,[G^N3G*'I?
MU,BK+?K2!J&WXNVM='M@^.J":?]CGU=<1/URO=J<'E_,^V@->/HV(WK^W8BK
M:C7SG%((K\25]+@2!N@QH'QXMM[C E'[HKH0/&0).L0"3A<]%/C+DAN= \.D
M;W7-N5\Z?2<XDW;CCG7$F3P$+\B9<_I(#09T_-@Z#(J M#M(JJDKUS#UB!J9
M&(&F. 3&$5_,I,FB68FJ%(A)SC:\I@)&KJTF9Z>TBNNBG </QB?J#'A$Y9F?
MP#:R5#<L<ENBS[D=V=PSL;AE@_0. 79(K)I*B^GMIRS*/=QX;J1SN&A+[U[L
M#FS,FQA6J25*@"RWX%QG..;(9('7%64BSQU$EVF1V2D@'V2@FQKB\TW,!0YN
M!4J$7#6"]U#E!)C8!&S>(D>]89M1'/UQA:OXML/28?I\NN%.?[W^ZL)K/2E(
M_1M@( A3R6#[X)B<270,C\CO=O_O)1AP[AE]$S7O1TO%2--9'QS8^ ;:"=(=
M4GM:DMF2B$O=@,LQF&IU:]#3*S176PD"G7ER7!,'= %QI..;2"#P:LBJ;[S:
M1MK )[D^E1?Z2/S]4ZSX+ 8,B5^%7B\ZN;%P3638$W@N;EW(-C(UPP',6,PU
M(IX]#8$6/(^(BP 4AON5(^P>C>P"UE8B#4)-POBLG\V(CZ^=R@QYRI )1*=L
M@JH*V"%Y \U#B>=605[B&/B<V0-7PJAJQ5>N]@%N-C<;W3,W.]S;/3I9SLU^
M):7A3U$:_F2EX7XBF*'7"3@2>:22Y:I-*]/Q*O4&H9OH]T;&=-O&38@L$+SZ
M5]HG\1@8L;"*J\R4EO??PNW)2J2TNR^U__)2I6N&Z3R8Y*=$/6&N3;]671@/
MJ9V5=DTO="TF%BMSW1U.46W"3T2R55T4$EC&)?4GZ Q'B\^]WJ+Q+JFL*H+L
M@AMS2:X'KOH\C"E9G)RO<BM2RX$<:'FW]C&@M8 @)6A.+=V6%K1TKL[DJMP%
M;F?TOLD5]LN*5.,ZK1O\O&!%R(X-HJV#[:7P0"ON/;4Z@")YV!U2;XRJ#4,?
M7G]H\JNP ]#SU8LD[0BUJ-";2&[, 9MQ1\'3?\1*2E<\-PP.W%PP8"5GO\O#
MH8.+KS!,V8$EITS>9#-K/QW=OYW"8:(K^GL^7':U9]C5U-9B9TY@VP0<A$7?
MIM-LSJ+/0DH(U!.B/"9%0CHLV6HWB?)83PUT3;(I>">+',L*M G6.K:5X2K"
MV! (99&^7MZJ/8,AP@L%2#.9>-&?B2XO=#G@*@>@#G%B#N'!7<F$19M$#)D%
ME_C![LE6O!T0W9;UJE/C038A+<YWHREK3=(;6IFOM._>7C!9?0O.T'IJ)1D+
M[%BN8L2%A8!&V5<RHJ*<91IS\!N+9K!JKQ&_;DM>+'.B,)S&5@EAB"(Z!'*3
MK5:11A]B%0=DD] )""LY\.F0Q_NP&U%L6I?K+UA?%YYJXIA;RY#4=A1:1PM;
M@E?2,7[3*B$7'DW\SMND ;E'C6_4& VIS7UL7;X=H.M?F?WX^.F/H*3PMG&$
M+5S@^,8"9E1TEU6(HU7$M:TVFLA58A7(>EP6S<5XY0< P])3,FDMII9P.(_8
MQ+O#)K9@U6+!=I"4Y)C"KF._!)V@$ &:UTPH8MG 'XXLR/P0 QC.ED*?6ZRK
M"OVE)?P!1'-)N%17#7S -@1:Z'G-5PWAS*3HOD230Q<C<N7!0W)A#\REPM-6
MHZ7?6^^Q?6G_ :(3HQJ@,U4+?A&-FB;+EBG]#X+^[IT #6SO.@2XGL37HBD;
MI/?<0$$VPO<>9#]>RR#[2J?V3M?I%=;K!O)=GK+R54I?R!U=>3[R8UIC8>'Q
MW\ NO[L4#]N[8F$5#3")%PW!?;W^P+Y:,U5T2 6(T*\6;P\6=+.>T0PFX!5C
M#,I.O0ZT8UA9OA?!$K^A2_HC^1=!ZIG7PA',B^ T3-,,=W'XFHN%U)5Y+2;=
MB8FG=;8/P3X SSI,ZT\@-TJF;B!Z,EEQSI\(?6$R(36K^KUIL-N1E !R,L*D
M0JBRQ$=.),Z Y?TWV^I=DZ1$]J<XKY8$+\@%EJYL#]]> .S11+EO$Z4CQ%CJ
MC351EJ6D]HC<1_OD%NV3;NI;3\J[KGW2I7>NA@CX)K7R)DG\X<;=CN];_IJX
MVR==UQDK/IN=P+$V$:0W/>Y03!?'0V#[S5GO[E2E2<L]B[>;OC)>,QGVH<.Y
MR0MA9>B EX*65?H%BXV<[&TS=#C$MG2?=E?84BH@\-1PGE70#BRT6(")8.+%
MAA=-79_0T4I[PUOS-<JR5^MT.54"V:U,<+ZT6-&PY>"I_SH]=3I\5Z(!JB/0
MOM:4[IX7.1=CPG+/"?;Z*:G\O-?GVA.5-DZ[=WKFQ%NB;;^?]_\=O3:#^,VR
MP^X_7<LG>)85%LI?98QPE2G"E[QTJ$J#QB#F/%J^ KNQ50<<<D9,<Q^%L/AJ
M=ESZZ9,=W+U3N/!FY3UMPTV-*P-XB?5?.2NG:DC!+%J;Q>5-<V"C*K'++-$P
MK<HLI>C8B-)-"%&1ED+]X:+#EL"&;"-XF<*C>0KZ3(4Z6&\>I#=IMUZ2VR)/
M6T;S4N0-/1@V:?/1"7$G3H@5^><1,!RDFZ+TOI+DQA49Y&JFX,H\K8_SN&9B
MGD%@J[$YB*([HZ[8:^S#6<Q!#3GO5>SBU=M7 >_+>Y<'GZ>J<;3EH06"]G.7
M*FOLD3$5DBILEH[5R1);PB@L@LL(!+,!XR)#T*U78TEX3A",7Y8PN>&Z\9HD
M-U_S(':=Q&L<Q1O7H!?D] H6]U5GO>^ #ZP NRVUHB7'!E:0<?;10Q/W^W<I
M[@]6E/;??2+VR5K&B#>!I:]) NJ3G\_8D\HIE"/LJVS\39;SF=[,UCDVD,B@
M'.^J:CB,:=(T1(H;T8\*A,N=&G"3+Z!EX#ZD4(3*R_'6:-NV\ A$PA7%R.&K
MM)8T' 5&EC)E6&@ZS);,MZ8F;Z#DH#.8.X?98A@=.2S?25G4-<DI) *UJ717
MY^1268$ZS9:$!\R>MZMRMFD\V'_);QYAP=RJD+(" [_%68%2$,,"%!2@O+%%
M?PW/PA"<5XL #Y$D[YAC1 A5:6K%$%/NAX:7T^VNK6V/<OZK2LOH=U5^UG7T
MSPY%O0>%:@#&N ZNDJ@<91K#R/LNY>]X2S$D0D8W4M;<TQI*73'8S67&K><Y
MNU@70;"L&U*8\\CU<3#4Q9S;TB$+#\M0-WOCQNNR<>W$!#ITJ+ZV=-N!KZK[
M@*96[T3JA2P\U@N'!F-M8LSOY/XWE&-^DHP=KOA&GZ4U"?XM*V#POF"IR<XJ
MX8SW5G5EL8B*]1Z*&AQHQZ@18V\]2UB*D]7D9> +5NA9=>*V5BDU6E_08*SK
MPS![%/6B3Z!V1=9 $N@QNNW;V6S!L"9AQZ6UA7IE_;U0]#]R;N\;UF^P-62H
MVP:KO(F9>*?;V*N&+T5\L&"-SF,O7=RZU99U+T5"]E+2!"_$8[OD*CM4]P!R
M0+J*="SD]RVIR9%RCRU6_8,D/^X#L#353QKRIBZO+BFR#+LG6U/"FNAV;<E
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M-"DC1)UP-3@J TOP)V,0"3*\?2$+@2*% ^R)6J9 B])A_"YMC4,#T^+5SNV
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M=M^XG<-]\2OFA23^H_@-X]:!$(:?$S4A7*!41RD1-D/H,ZFQ@901@/,XG2*
MYQKN$FLP^-&[YQ!R(1-C"TT$:Q7 Y\(\"*,=E-0T,IH!'ZL*%/E@SXTUC5*4
MK"10O>T1%DHU",,<*#DE!Q(P0XQOQ51[CE,A,S6$'RB5NP.)@*.7"V6YA5<F
M9IXVT:5MO7AOJYS$8$MT>_/I_Z]UH?_10C-6W>%M[MHVXRWPNB9X7LA6\[(
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M@4B=.*0+L2"OT!CN/15[D3ID,]EULU@],V9?3JN:-2.+OG=HR_[>([;EEIB
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MPW!4-SU0P>OO./C ;=(\N<I#5ZN#$5P49PU.?Z1@2Z@Y.#L)UAV.(LVER/P
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MD^^_.WWZLBA9T#VJ#Q9LC(@+@:ION4M]/,74DX89V0L\C9/HO('?I<J2#2"
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MOP:X4C UE<;I7!G#BUP&8O7*L;_YN6G[:M1O"UED<,$@RM$'>=1;?' ("+9
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M H($_X$CU[\O'J@I#"=FC$HEP&D38/U8%_%G_JD 8 0^V ^PWTGHW=&F1<=
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MKWO5!BY("J(YBIH2MT6"+/P4_< %&_'*Z\^4.L[%CG1</5:7H;'8JSGQV_T
M@V6*P(NR0@;6<?#W&+-$J 4QY8S%-",G*'P!];FJ1MX6K7@;M'U7O :FOIC1
MY7"N)O)$HKLN6V!J$2D2C<74'&51WVMQ^,4--6 :,BT\^":!:X+!(,61DZ\X
M![O#0(_!L$7@O=(>TJ,11R?]SLD465AQ6XY%,&A\9)-U(^F>.^+@JS C,%2-
M",*)7G?I*B=Y0G^HW#RM-9[>W7C-6_%V">A]6\COTMLN\,*9XVEP:T&MNWV.
M^K1,'N+66$IE:FRHL_KIP]@/%(RG1L,G;JM;LU[VH7 2,F$9NK/8U9@O_*N
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MW/\*]60X,;INN3MJ:;=>I"72AG&#8$HY6P6-80%A'Z..Q32)4@A*&Q<L+^]
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MY,D*2]$ \ZQ!Y 5]\ZRY1<T_;9;.C@,GJ=233,>B=<.SY2L)7B^MP'I\VJ[
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M;4Y_7G*%_O\,_>\*[[+6%'PK5O+C82OYT;A(EO!_TWJ6_?3_ 5!+ P04
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MI,F>8R'DO)R@;H:"#IY?TI]\,X\[.A@>'=X]Q6X(R0+9J2Q&$=Q#>%?CI*R
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MH?\[I78)U+A5-, [M#UF30EZNZZL[Z$-^$"$1]6%RLV+)DNB?S?P6N,%KKM
M"6'1<SU.:_2'L(QW]?6R I8%-P$U YE+-$/,#4ZD  &/8,@*% A"XJ%X%903
MV\3IE,D)?@Z,N)90F@$1GHS',"PZ>FG&+.6K8.8^X(A5-%WZ2*/><<V%45+
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MT^ZT*+D85V!0:-0, OQ!+Z7AS0QNP!+)?S9E6B6IESZY6G3:'(I0H7&'!3Y
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MY1^+:U%\VWX4 8LRX5 (J^1\@H$MLV :D%:F"/C KX@^\$NK#PBBF:-%#&(
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M::=;5,NFO ";5,R]TJ#>V^/)#%\?C,?KO]=((Z(BJMV*25WK'@/N 0FP-B3
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M_8H8@#:IJ^ZO_ 5$WW4RD67P0<Z"3SE(N[\F-/O^4;C_C@LKYT;R8%!(\>5
M#&&O+T0Z$_/2?Z*_ -9="\A[WUC(-3&!A#\"%_TU7 JW+^^<M38 ]73>NSSN
M_QG4T^51[^SR[E%/I[U^?[U55\27;AD$ LO0I=R'H;#/,D(1$O1[788+@TF[
M(>4-!NJVKI_"<1RW/(UZRPVAW3]E7EGZJ&L@E5HOW2+".NHDK-]D6<%3[.AG
M1S]+Z.>XDW[>3:8B(LGT&O8KDBQX.YFF^9P@X)\K4=5E\'HLLI$L=S2VH[$E
M-';226-,/UCP@!98D:=;14DG.TJZ8THZ[:2DS[*JTI:ZJR=.0J<[$KIC$CKK
M)*%/>'6)"@_KFU1ATXZ:=M2TA)K..ZGI8Y%3_3!>=34"\ZFLN.1[*(NM(JJS
M'5'=,5%==(LH64[SK 2Z2I-J'F I[[7XNF4&^(Z@[IJ@+I>83<I$/[R\HIKE
M-,&4VU;1T_F.GNXZFGFX/)S)]>#]\Y=E<!5]R?)9*N/1UMGF.[JZ<[KJ#I._
M$97 \I ;$<VWBHHN=E1TUU34'1._@J?@CDO!M2PFI6K5D?%?M\N,NMP1UET3
M5G>P_.<<-IIATZWW8L94-<ZQYT<^#'Z36;U=%M6.M.Z<M+ICY+\D92335&0R
MKTM0@?E-4NZ$U8ZB5E%4=ZP<_3R9E=2(*O@D(Y1=VV54]0]W]'37]-0=..?^
M8)_KP1]P+38<LTX?-PP#)7@517):;5ULH9O0.H';"Y P@S%F*/=Q[_ST+X"'
M&Z?W0'#FIP2Y? U?&Q1)UXOOK_7BCQKOO0%O7*\1V^GA,_VE/X_//#GN'=T;
M/M,GUF.XC_H+U5D<-8GW\E 3DR:=\Z,';KMG$7?ZT1[JW@T^/N^=GN.SWP[@
MMWCV>-*+4N*H=^SS[6/TU+Q5R\L_U;T2VU/JGIP/V\DR$&Z_QH,?10G+\O?=
M;W7<H_WQW(_VN0-H(<NITIIX846UPD%64\T*$$V)ZU-2F@\:3F@"9\GM4A8V
M4IK%J[&HW#QV,!'SX":1,VQ5FN:C$?JJL)"Z[R^R*&#]X/T\B\;!3 Y #LL
MEEC!1,/A73,1D70,1BE3S0OJJ(Q7/7N%[;&I"NC[[T[.^9_)7/Z[3JIY+\73
MZ47YY*&Y_MDK_1J.3UYRJ7?PP;P^_5;@LR6]43>?TZ_'FGF KR8BEL&T+LH:
M)1M0$')_:<T_(F037HM,>"THX6R H[#Q;49770$7QL!7>-TG65;4O+RU<[9'
MZ_@'RZ=9?)N;KB,70K@T2FM\"8$ KA!3\)=B[,T;!I+;@O-MX$7!!R(8RT+"
M'O::O&Z7- UR Y!;M%EYHTQC$'BXWV&:P/$-9#7#1L3V<10>A0Z!GA4?86'#
M[=>#](#MCR@XU0O6LQ6!X$Z7$=PMS,Y52ST,[5[A^8II4L$6_A=U QU3C?)\
M4(.LS:L@ED/X6FPHI*DG^!S'XD;2V4ZDP%A?"T'CJ<,K7K,>Y"G94T>;8D^U
MXMHWG *!4G(X0[)01)EGX!K.@VDA(G1@T989YFF:SU#>D&@ -M=LO% 'R[R.
M=D!2H6)GVHPEDC7<F3[-&@J(S0'X*9#:>@)Q=0,G":93 AJ?%QG Y_]&>TK)
MTVF1QS5CP/>2??I3AX8+@TF=5LDT39"KYG!YLL_! ?40?C.4$&X+(I-+>M?E
MEC.?6Q8T);)&RYOV^>?DL'=Y^< LE#PRZQQ3W9G22P^^E24&76>3G(=[-]I0
M9P9 P<Z4SSL#5WQ1QJ_3V#U017[FNSE_=Y@4P'/HXC.#@ZZ)]?"60DZ!D^ G
M+09$A647]%E*K2.53.CHFXB[+^L"S2F%-U1/8O8VRN%[S55;M!AM?J6Y>J=L
M>=P[ZC\T6^[XLH,O5S3F?'3N!#NL,"PD@RC-:=[1M% 95\%N<X?7K%@1:Z[_
ME1=?U%_??HVX& 5!E5* 3JP*01Y #)ZS8HQ4(%?-\@!6J\;E,B5=Y#6Y-DJ5
M9A+59!6@5%EBB:_P!#? EO&\%R? 8!!?GV5Q@^\!1!N;).34P;O!6$B^VKZA
M%X ^$9M*&$)),G:2D@)$94E9A""';V-P19!9%<LR*I(!F_"FM@T,&K"JV&!B
MD][8.7"3H4Q@9]MIK1]OBK7^IZL(GQ13_)JELBP;AKDQR4N,)]"LGS('HR!.
M@%8E3P$BN[RL2=I(4=&I ..@3RKBFZ0D*X+2 !@B*!,0T1Q,Q93:%,QM=A_>
MBUD9WM;RKZ?HD@21J<&3]LV4_&;\6I@@K@MMF[3P[2QAU@)V9'>&Q]L\J'E_
M_-!3?L3C,]K9N3Z8=FW^7H*^I'=Y-0#S\C'T>#/JY1(5D#O28891MB+'X'V*
M&R8]SOM=3G<==+] [D;T.Y<;%B6](2(XOIB6IMB\"7W 1F!C#VH0/S@A#S:?
MD-^ A!R#3+E\&;Q!T4A%,!M%S"N,( RBQ+749E#S2S$^7X@&#X9/,(RB3:#A
MPK7V +:%_A^4VI7394]1>QIH?$[K8IJ7LC0N>C,<C(Y(N9ABF^5U&@<80(/'
MP7-7Z4@X]$P.$_3[2;N6SIC0-(=CP9> 9H':2S#%V#UN) <%CPG5$JP'RN"A
M>E4YDV&13X(JF3 YP?]#K:Y5%E4G'Z^&0U@6")!WS%J^]';N)B[8/I.%F[%H
M75=?&,2Y9).% N1BO6?J? ,=AYO@J0E%T)$H"MA'S9<4;E5<(CDU,ZRSB!-
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MR82B' [XQ9(%>0445";/0:"C&<FRQ/A  ;\ T=Q02MRV^@C9M)\"7V057S4
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MZ:TM5#U<CJ#>*AM&\^0<$)IG*.[Y3;#,$PPDZ+PAFZCM<R"XFQ@]3-,$UJ_
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M>%GY[7^M&]-$X%:O-30.M,+(XZ^F!UXIR!13;YZ;:6#+09#2I-6QW12-/_$
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MB+&'IA1KZ4$*_4H1;1VH<:PSD&-ECBH_-.-F\X*-!&K;.<3^;QIUF0$E)Q1
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M;+&L5/4C-5;+Q$B;L.@.*!*GUG$XL2(I0Q6^T07NSHV8PE5+,>+<I+VE&Y4
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MZS21MNLKWBFDL0WF"CZ(0O>[A>_N,'07.PS=(TB2LIZZ$2;#&8M\0)*%6O<
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M_6Y!_'R0QW/XW[B:I*_^/U!+ P04    " !D5U%2KK!"&2I!  # L@$ '@
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M[1$O<5T-.<G[=^8ICD!\)$U,SELQ+TKN/\T8XH.E3^E;MW6!PH,$P/(@J"W
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M=@7F"B)PY*.$*%(RA4;6DY?TV/! )X,1L.L'OC4N\LVJ4WWYLON'M#7(#4[
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M6W7;0M=$G]=3H]>COM?B6)1;:H .9,9$\$T"/PTC8XK#2%]@%'27@>Z3 0O
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M1' $P- V3&"A;GP$N"OMXE[2I2KK#;B$^Q/C1J83*-=%8C'S*@Y.)-@U^XE
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M8@I7**O$N7$SRBUA)) ^^]-;2T46:_ +'5Z++/6DH. !QD"0!W@X@N(DFDP
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M$GIP79A4^ 8"!3RA)N#-1#C'J!=HGFO&]X"W!!^H8*1S#1O8:G*Z6]+.$PI
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M6[7)-E[3VOW+/@7XR4N&))82; \^.3F@_V%8K*"'(GTCL2=5C )[U&!0XFM
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M #H"QVLA*:%P>.LXV ;91+I!$:%(/ %^<61!3C\ED"@PH)# 0UT4R*+@)E9
M-->$LG#C'7KLL&,'EK3DJP8@KV(,R2%7ZVQ(X2FX22KBDJ6VSZ/$=FF#R3P=
MT;RTFX&(8U0%=*9*R<5C!*%*DKNR M:5/%=.GR9#?1OZ7$_:[-*@'N2U!GM[
MC2V08%OS,6^W-7OJ_."*94D?64MYYL[?SB";E$M<#J)FQ\_,G&);K71'W+6K
M_K0(#K8&/*P"W)7>C#;N6 TI$ '4KS%J;R#=S>^"J0<GR]]%0_'7+,-Q&AC'
M!1/#/!:N8!X$MV&&WKB+ZX\Y._! F<=BJAT;^[)U A".\3AI\2LO-#9,(>H&
MZX+\-=SSA:8>AX*C1@L-XV==(/KM0,J"'=L;()?*<[SE6 "K.)ICLUV^-0$T
M@Z@?-N4B-A H$X-JXRH+[F(I$DN%"$I#04V7WK!8-J^TGI(*6@*JDJMWX0(_
M$"%R,]?228YR-;YGU#GK@YIC*MHV,7MMSW>D:11GEZ>X10<Y6)94'U,<]FC5
M!&KBL!>Z!&JD][S9R(NUB2^^[? 06[LPF#B&+T24&Y[B34SA" OP<)J)98GA
M&6D 4<1?L8SG>'>;D/N]!B)NL6.[V>IB?2*$0X\(T! M:C/%K!@'LVDKWEZ:
M8I9S&RTYDDL2^UMA1\14:F'DJ=2$"T^S=(?+!K$G3H1J!:\(_7''GB=@'V#W
M[-Q9Z)&V(Q __G?PQBSBSTRN3S9K>!^VBL^! !RZ/K365NA'\1W:WJ48Q:@S
M&_NM?]&'^Q"4!U'U5]+3N?""Z?0@K]^]=H,92;]VO1?<!?;5VO+BIP.:H2@Q
M+!OOQ%_N,>:Y;6ZH59[$%$3S?*>9$D;]%8L#V6"PSUYHT.9B8:,Q6K!]/O]@
MNRG KEN[Y,+>Q)+ 5B.(!\(-1-NV]-F,=*)NVMO='&%2A&0M4K=GD[E'XA(%
M#^%?>[$US[*U"MK2)UU9FQOC=J&V_PJ%^>MF@R\G5&\A5>]>#]OH?%<<Y0FG
M<[CA.)UU" VUQLSF6P==>KMG)X*T,92HB 97+&**NC+JT!8]#BO9J7OQC".^
M6.C?5H6Y"*2T2_ R9O[CX^@Q=*7-,;2H8H1-ND0;FN;U0ZGK/)6FP.1Y08T\
MN_#UK<?$IR2HR(7:;;,5UII@\Y^].F?CBR'E0[0BC(MNF=#$:JQ1T7OHJ=3/
M7BT:A'T/KX@CJL)%.(^%PK\&1BS6KC&1T=!V%5D474(7 )F<#&\&ZCBS3&];
M1[RFZ!<T@?(#>@HL867*:F@[DB^7OYI.*#5G /,VW"NZ%SBP8Q-C[9I1;#03
MKLV AG.O6?$M>G/"=1401%)7C^9]-WLQ-'BX_NZEL&6(+4H*,"8Q&0 FHS?8
M-D-%@S%5BJ@B4V0UO2P$!O^"8JGP0V0:P9 ;MJ%0,[..@"_4&,B1U!!]W>KL
M+J?U%Q7GP0?&IORKQ8%=&I_AID 5M(91HVWF.KM1:51#MGC?:2RE%BP6;F_X
MU,&U&:?01,'1RR/?N6YZ]'Q+RD\@DN_LJ'*L(MN9S,M##!LB? .3",>KEY6<
M1/B,%S2;;FXT-ZU)-F%>'>?'K#YJC-[1RLHU6VLO;>!6;*B::87F%#:YMK2E
M_+D";MP/JUON0XO*6N9HM=XP+L2:YO[MHI\0.$G69%33B[H9\=GTXN0U28,L
M(.K+' Z+6ZHTG5210[]1HSIX?P_^/#@#\Z.4[;7FTE/!:"A;N]=J$G:FX"G#
MD5=,FB&V7=8$T*V*TO3_^P+T(TQ'O-/L<N'A#JQR-:9>9ITHWTJ:OR65 @O*
M@0=AHN)Q;;SZE4YUCI56!7!>X>(EMZJ.?4Q:^63U7,1:^5.>C>(!%]*=RQNY
M%.'VK?W*#UKEUH/7(%O"5HO(VHCX-/KQA\.3EUG.A.X5Z3!AHV,N/2E]!2!P
M;G+MHXH[8> P1OCHJH+OX=!$(6E,T\W$SZ067G5:IHC4I*H-B5IXG382-:5'
M0,N76LK0 %LLWQA4/NHRY7*E1E:L7HS6QL(@),[M-LSS<ZED#]1DDO2""6A*
MOP*!^F*UQ%OH3*GJ&UN7C6R33@EWV! ) GWXZ)U+;8O <^NB"2"HH7Y[4@M^
MP\I>E1C*X3)J4]X)^U:8@N%]UX)#5EY=9_'2<(;')'=.UT7N?/:;VG(?R4OU
M=?&,A$=M.ZV)0X"G?P5<3LURQ2 06\.B48T@))BJZ81<JB_ RF2!8%-BDW&4
M@FM*6H09@DW5UV#+#5L?:@0A@*0@X=>3OGK(IX@,(00%?&,;/L]";-D!2J@B
MI"M.6+_),U@8/N\%0XQ"V7;3!?_1B(.,K:0J]3H3X3XHNXG!<! $A?VMH[0'
MHV1Q&$^4,;PH!$7UN"FV[K\R;0F-^&UD>PU"!4B9?0NXU3N\<1TA8)/#X9<T
MFY(8\EI"5PFX*-3B*E8>>^#YSJQ+.2H:7#]&W=V%<O99C692@<A%K:49AR"Q
M/*"!BAX0W[!I(VUGN?F4T.C6/*QR.N_9YW'HYAHA;9F,VQ@H"I/@N9[ -K'G
MM#2USEG[ L41@CHG@C6)+3=*1*BWY5Q::F4("DM4ZT= ,9YN*)5L49JB)5>T
M.8C\#A$CX.& NB^TR@5/ 3U(,XD9]\/:D2\DRV1BGXG495L\TMMYR]?<-#YS
MZJCMZO<3^#"V\VVUX-EQJN=&HTS04QAX9K:/R"EF50WO,!N J+58(_1 @)YR
M]M<Q&FWM>CGAO.N-L)E&[9:P7YXT*-.MQ%WGD5DZP+N$HUACY_;T1AB\2I01
M#@B*!FK^A2EXG.7<9*EF?&D4:C6012N]X9<9P8$]=?^H\KB(8J_::C[76[!V
MA^S%PDN,A,./DH'.&T.&MXTEY?=$)5;.DH@/@N5C^TG-?8+-SB>M24P#O3$O
MA^2K&?65_LV8;,U+)?S_M<E;^N.F?7ICHQ:30-CO! 6NBK!*&:,"KN:CD-[W
MH 2RG#I/++ %7+/\5LWT-!$.=G*TX4"D=:WB7'41IRTR[C8.;,:W"<.>S<?Z
M1H)5(J:+=;&,]NB) 1?GQG#'W0#=I9@L9@T$G]4&MWG\C0:^4^[MZF-P4Q-+
M=F G/8P8F&W/VVK9X';M"DV5/U57'%"0EK!X@QJ6O.TVC8:&'>?T5-W\4-7-
MW\08+D[7Q->@:=I$? -_P$ZGW'\CPZX[>97H>MNE8ZPM%=O3]-+ )J:=S#97
M*7X;FV''?FNFK8+J>]SXGVT!6SU@W 8S9I'*!R0#1I,5/<A9S7K?JO=(LT\P
MT&"(#-EO:)^)PLT-Z6&:?HEY!;9Q&X7W^"SJGZGZ[*<6FU@ <L[&P9XFC!Z@
M<F"$KN39%TTC<[,<W9NAN2.="I\%SU]&.RIBD,GL2X0[H9-=V,%#''G$L0CV
M8D?7+GI*;F)+?*'=7>OY+Q:'(G#S,!+;)7>:A0,B0)(OHKOG,L%RS:D)]OS@
MTL9<3A,<P#A)KWMFP\;+UE4+5],K_ZYEZ]W*5>8XRF;<*0M4;D)MQ6@N8CB?
MX(4-\ QR<ILZR1D[H)H.PLA)$0*GM7&@#38.;"":=X:#T$,9@LO)#0*4X5;\
MVR\TH414L=D5\^9H/ \618.L'S3:H_/S%.T51*=2J4+S8#"2\_-30=%#N/*F
MH.@--=WR6H;.4F)O@8N-]+!\_ :(Q13\47]P1]4T[IB\>FL^^)O!1N6%'P4%
MG1"/JS&'"[[2CW2-"8C[@:&M8KL['MX$1>,$/N"D'>_NO1EE;1*TV+)@6#&.
MEE29_29&IL6CL+62IM\'IEUS:LXB"AG_**G%L79NAC^%PR[%0L@;";F09>.B
MSJ[^N1JW;2BRPC12:>_&%V&^U;55I_[+8FWAY=A:IF7V]6PVU0>;=\E*L)9Q
MHSC?2\+>.$)[=GD,[]H3;TQ'7'0TFXZ#6IM"$)8AS#E#5'W8TE\G6.OC)=]G
M,@I-"Z >\\:&RT1>Z&)(1JC59/?(H*L%U S3-#O]U #NITM#K!]3WOUL]=1B
M6GEX)5YH[R>Q\J:FSQSY>G519FQ/?9R;%_6.:98FJH#4%B%ZH)8F+=<GN[77
M[%%V^ATJ%:S6^8QZK))*/KAB[^STF&/OTG#)=1YHZ0A A0BD?J^JF-%\3L(;
MS,M62X%[H[&!?2 +5R&M!T9M*5N@0VGQP>;V8:6%Z?!*Y_ABH@_!,+1./+9-
MUPUL *A#*IE0Q=6KI7#KFPBBV=M=-3?O2WRY*8W/;6H1B?HQ,?4[@F_H2<GV
MB+-5NC*G/28VLF&8M11BUCBC.K^1ZJT>OSVALDF6S-J@DBS8)J[W,[G.$C#0
M50XWMX@4(^Q=+!7KFK&C@B+0 8$M[%!Y;I-/_3%94&-_S&+",AO-\]HD%_'*
M7&U?K]:(R8,%W>4,R/4DCK5)C;OX,KQU0Q$,+<I"L&Q9"1'\U7;Z$>A[>L-M
M?1C?Y)Q@!@A[F.!A1;3CU1SN_$PUC'3CHL=CA01]9A)TI6E,A[8!VM%=7_<<
M.T+ .%*:*"E6V&A26IO0#!I-D0X%^-R$,RX@ D<^2H@B)E.H9SUY26YTC_SR
M9AAO] M?&Q?Y=E!/7[YL_DM:FUIZ)^ -@E^B%XW\@UR3:Y+QSMG+3&-K!OKI
M%-G;5@;FM63I_-?ZEX$G'6\X/&D].6YMBNQOQ7$]&]L0D#_^:CL1%HJL9&%*
M;C:!C1]!@9+!A>V8:)Y,#;(PE,"D1,;]' 3V1\.E$/S+@'TW3\:,/RU,1^R>
MW\F[Y[<$[Q&0.,5@"VAHT,;CN"BP%$$:=$@[0EL-U@L&65I1D#[)X,#,YT;7
MCVC*$N*(83D>6$D_&G$##S35R9!&O/BC'YW9B&%Z>"9$((-Q$2G*RYC;;[ZZ
MN5H7=2/Y8I=PIO"!#$,2%_/>&,38_ZIH-.D$CB O8S:6SKLI[,29>M+,0%JH
MU3?#:+B*T!^#N/G4-5H7ZDIM?;>A(%/4;4LNN^<I6$M4$L(TICC&?%R442UC
M$S/)R!L@&"PS(6Q6+6IF&B3,N#K>/%T>(H=#0BS$(*QRZL/NKF(2CULGDS3
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M*D=SVA_AM0%=AF^I7>^IKOF>HPH:"<HJ#_&&5O\@Y/C\?%/K".>#CN&]$P_
M!T8J7,<US>SZDZ:XN*Q$^ ^2-9$-;WOV1T3'81OB.E:0SG*6C;NS#JZOJ;A9
MC#05U\N:,P9"U/-7,8$3HQ)FF_*WA_9D59 1,=@0>)\QAXG0F,*.WWY,P[L*
MV5B:4'$TD_$(+-VYB#>B(6PX_M!,C$HT: N\M2>U2,*KX&T%ZA!$*XTJ8V?'
MS'?<GI%TB9H2@DB&9+2 1-Q1WJIM^:."(NZO"Q3QW/7QO+3)M=?6[/ZF2=!'
MIQV=%5<\J6'5_0[/%LKEUYQ<V+D [D!UW_(F'NZX)-#;Z#CK>6@$;<.=8A-8
M2SP-G\W.)R!,]H1<P:^=<^.''4:>9%U@2Q^R7&=4K=L(0^6:Y1I)6YJ>,!2A
M:T2<6*PVW6-V(QTVYCV)Q:V8] ^%G7C<2G,.=7U^BB_);168%TV2J@.CBFU1
M8S&_J. O _XZ?:S@K]N)QH=MR.@(NY:3H6#D=5S8*@F;,_&A!->F7-<D*BU7
MH[W#U52%;075.EM^N0Z]BPYK?H?>1Z&25MUE=;%*>L=%HICB)SN2X$_!!Y5_
M >%^/D"[%>-OJU!/+=@A3SO%LO%2-FYB1:8CN\%QC?E1%#V**2WV:L'\+'\Q
MOU-92P%05]6]A1$,#< <NYFQ$=XH%&I^U0,F,8I<!IFEYK=>4XW25$4:)@3<
M"(R(O(GUDES_0\Z.3A).H):E'D\8/F[^YLI'H[A &]V?32D18XIM\G)2723P
M>=Q&&W1]VV19358+/#.J,R8%&./<Y<9 M]CUS/+FI0C8CM^V7[Y@RLOKL6RC
MBK=H%H6=@^;VDL@DJ-SKWR_V0A=1;/>Y*#HXI[8B'IG998OVA1&!8L%M[$UQ
MGR737M^86;55;3790#KSVP<@=]'MTCQLDQ6HK]2-V;7/1K,CJCF2[06!&E/E
M&UGVQ@[\??=F<I4NTH1]7W@![TZV*(75$*DF)$<9'#)&6IT#&:NG;URD: /4
MQJH[*N_M+D:)U49&_).B I^]N1LK\V<,4V#,,K^6,;HVALO\9$LW_#DA:2,8
MU5I)69-I2_H"S&+?;H;95('LMYX!HB!Q6$G5O3>WPV)@B>%HYZ7Z0J!^7\+4
M(#O8UP%'QQ0<#\,*VJL,OH)U-#.9-O/T]JK&4 <WMJ%32]B#]MMHVN&:S92?
MB9:[H2IM;JO7?<HS W+=&)#DI9F\5]B%+F**\LBE+IA;1@UR6P&O8Q;L'AW;
M&Q'/7M]PW@>>4ZZ'"4%^)7ER+;W,$;#>*)_8Q+#9P;J$S7[%-Y6B+H6SYIC9
M*(L97_(OG!3T38$S6/Y@]=XA"DGJF83JW82QR[P*7?^GELB-Y;0K.AK7QXCM
M'J9E,HKQEW=@K*I4]6C,TGG?ING96*-D&GZ-Y1#)YE!55BYC#!FQ-G0G8_HX
M\I^ (1G&$QE-BMTQ$\P18Y\VKBOZI=$_!PP9UR#BAJS<JI3D.;6M<Y9<5]M.
M@B5J!ED-J-,E2$&VWFP>P(B2&FZX\V3L9!O>!]G%9J-8$V'.&YWY*O2&2H!K
MD7-1 'AI]P4:%0HZ::6@X.&5.T5.P:>QQR<>T%!CB]W$'(IQC.I.FOGK!9#@
M"$GJ32RX@N8+23,SAIO6<ZEL2Q?P@VWRZXWWI)K1"8^6T-%&"N?#=1'.'^(B
M!-]5I3JK"BX_*Y9)9JQ[9GJMDQM+9)T_9J5M3?<6S9@\2^,P>,,S*UG7U%"O
M*_$1SEUS/.;:JQCG^X@V\R(J()'1,H:?G#]KQ_(%4RSAIA)WL6!E37M-V]Q7
MOA4%I2(!KU)O%C)L)V0FX\@AER$V7:F "7-=^HV5<1H-_^"N>DWA>RLDT<XL
M[&_!X?'^Z9'5R/XY\!"-<96:1(6=E>4>=)D',PI*L#>UX,X0D:\)0XADBJF+
MJ5F7H31.#+6%*#A-QJK/[,-V?FV\,9IMW]B!M!BKO\:>&>1SJ]O,+,,X(^-O
MF9'/8QP:(,W5&H.">C2;**K-<25S) LK]BERF:9:'XB21G-FVL#NM&,U D#Y
MZ,-YF.?NPL>V56>!&^VC_,1 \J$1QFWCPG#[M/6;1+Z4,*YC]P[+49Y55^B7
M 1OM$!0$0>5NO>*F*/6X-FZ.*T\8?NT/A&M&3A&A0$,GO(L>/>QIK=,42RB7
M]RJ]JNZK)<\R<:7N$.K([^4+3OL0F_JGI:'7M^D5!502>0*R74<R(:)*;%\=
M0N-P"'0ZRJCE7364M1C'Z2TLBV(;'(JC9]A#)ILV0T,.!L@0H[;<=U<2;Z98
M9$355\3+4>M7ZMUJ#*<WQ1KS+X*=$H$IX>[M\<BWJ732'!U%S7DS*(P\"+"W
M#DB/0MH$NQI-6X%IEI*K>FU_Y*P_M;[-DLWF^%5'F)>H0_Y=H4)X8/AEA\.[
M H\79<Z4CL#35,/E1HWX,TYM<M#-8_(F<6033::C*G@&I@D&:=-?6YE-",/A
MO)LZGR^]&Z];87-CLA)O;[,Y;TV&)\[M^4+SMR0!B++7Q #^H2G!N)KD#FBC
MC,V\<>8F2]2#Y/-#E]*&C8*?8*4G-N]2I1H3RZ&F^** V62>#FL*$S#M<;+&
M'(S]6JUD(\?.=2D#B.WN',_)^E-IAR)%C93C'T\49Q_$C':3IV8W_80=.WNL
MV+'U:APV]XSKK#%#SRX>D%8)CVF^SF*IT!UE4QZ\4L^Q33 Q6G +YP&5W??J
M:LV@U4."#W3<0C8PC,&^K2FN7FVV%#G#U]@"$:?VY9DMDD+G$C=2M@L-UGY.
M&UH[>YA1*2]S96D[[;2I/6%>:L%SOSKMP1-(A6B$D6@$=G;:#B'G'#><Y+5.
M8Z](&PWT4*)@TEO(E7K+&U<&9TA.TY7&N<W:=A:U[]F.)&I-9<7TM_G Q$VP
M+-9DXN_\$'%P'E&;GL\6MD7NY4HL"HEQ<KVCZZI EK/ZVG.XC&&<JI30XXIV
MWZ,NY/!%$_3[8KZ'2?XQD%HD"+ Z.FWY6=4=.'D"HAC836Z;?N.E,V/7&G&+
M!6"L;.IU"?:>'CFS_OA%EG_[<PTTHD6"TIV8S%IH"1)L9!;M:-5,:K)HKWUL
MRF?!IMR1?(2;K $,_MQS@@5]2B&C$2;=;[3*,3.,43/S"7>83L7ZP+](JVB+
MAPTT/$TLO4"PC_(L< "C9)03F8&?&AK8-]5[/ORG':YFDAI>23HE-S SC;$J
M[,I"($Q$Y8O.0RU*%> ,T/=@;!RMM$D;L,$JMI!P:(KY5'9/@\'JXPA<#GP(
M]MWI9D]!69-\Z[-7V,"BE11%1? T"5L-A6_2(-VF&&26V=J8RU#4JJ(+5&[G
MRZIP%(/=;KI(.NG/\QN%CJ8(C' AG<2DR1B'AX1'A EW-@L)8:KFK+EF::^[
MH?UZ(3TS_'"T3J_ M:.D'1OB#'L$UT(@,[Q/ A9%AB-@5>P8Q'^C8]4\&DCZ
M\?A[=K-?N G&<F^A]@;XI$CQMO$=,5DC!SI2O+'98V>^Q%K<G ;AX#%B\J"Q
M/ @T$S]OW3%/=2/#Q^RCY0GL5;A'/HDLWVB.7Y,D6'WP49LV,9GW4*9YH9N$
M#3!P.\%UG"6VVA"!=/!ZC8XQP-/<+C'DG#Q/766ZDMY\%&9+XU*HP[ 43QZW
M$Z Q4<6IK&_;RI3C7*3C9/(/JK<><Z/'RL2Q18!Y6>J3D:*JRL>N\IZ6O2O_
M;CWL%VD4@M%.BVPPP[E;^+JASN<J\**-GHC.;%L6\QH)!6*Z"[7*9M<#S;Y=
M!L)16P:9>\E7I58?(5GH/$=?8LN@0ZD;L7OGHHY<I:%EB^V[L)VVSK=;[2="
M"EKAOO LFR4 :N'K\:0M+:R_(MS=Z*/F]Q:H$&^QUBOI#D:GF!?)0H".G[-
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M;=PS&E(@)G&>HS?5I)6V?PNJ'NPL_Q85Q;\7!;:60O\:J!AF63B"60A.PS2
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M3:@$RT&K6JI*"08Q5Q?&VD'+4>B;@!ZQ?4E:#<0'8T #O!<Q>0LZ&[%MV@W
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M+2]G(BTB[EE)7(N)NR@0O;[ #,\EQ3O(#V,/M:+0-087'K",P?<0]R/*:)+
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M!A;6VTGB&0E)C)HMUT U=MM*V"]<*GYC<JM==$9B,G5M 94#.=;2*KF0H$Q
M*-N48!24W*LJK-)0LB!,?X_U%V#T74J8FZ=++ZRWB]AG;!Y V,:22B<715JH
M0'HF"(E'E+#P_O#PCP]."P^Q:T#;>5QXMWWE.[S<]2N6$310/2V<]8)AG;09
MCXF+M00[MVL7@/9Z;<?PM+"#+<#TYU*1B5PL2"\3*#OQ+4E[#VJI#%PJ Y?*
MP!O7TRV5@4MEX%(9^!=6]5-I=))<G+GT$TPM&Q_W.N>HZ_"\AX5)=W%:=(3C
M<83I#KK ,61I$_ W .WMNK@^NAW1M>[EW@1S[P^U^P(^3@61Z&,:AZ@+"'M]
MYQ#&\PF.45?:MBMI-<XET)8"'3]"NH1ZK5!O+'SG%A;SGB6^-E&Y#4X6Q*A^
M+\2A^Y&I'\.GC^>H/SCU4&_0<8W7/K0.PX##,H6L''6=:J)K(@D6061.E^Z0
M*6$\^2X#=PQR:Q/PD#"(XH(.B9-%*\M#>(>D2@:1T7EP< G!&8'.*K9,<R=7
M 1=:!-S,8CJG!9#9;AU9SQ@?0HIUK\RRT+<K)5ILHV^.=;&'S<F^=_T2E1N#
M-V=NV>?:B&H9CRV$-H4AO9;,^O1QX!BRF>DV22MED%*&7VWO[=>/D&Z+( JQ
M;&LX>K6]_Z9^1,4-4=0QL <I6&T?UIGZ:'8RDNEW2QU2.X#]Q 5Q4L?0&&X=
MG/=CV_P4LS*5<@%@5$%G;=>6SKL!<S'2+7EL%<!9G==TO,@Q6*]3*:U2VRE4
M2+-MSQ"+R\W@"]\\PV;PS<!=+F^W!<CT+N)IL?#&<-4<;.6Y."I:]S*,S4 \
M$-CD4 ;40:?$U ),/_O-70?W"]MW[%RN:/?]@F8'D;5QIQ&_Y>@JSE:S.EF"
MMQ#4JV_H7K?N(XW-+(5S^J*YX1;AVB=*X&)>HMSP:1.R!E.X>$HJ]X/7MM=U
M+1IKO3ZKUC7V!QY:/IHYY#%Y.+=F/ZQ/V_VRD?7/_OM@2L+--8P6AF,_P4#6
M%N7_I'0"[7!2Y->VN<3/S=92).Y1HE+G--E[5$6I90<9?<$,:%HJVM@")U6+
M3;99F2YX5*=S#.+5%;J5"H2_H KXLG0+JT,>SN%;I";LY/]02P,$%     @
M9%=14HBE=2T5 P  ?P@  !T   !L;'DM,C R,#$R,S%X,3!K97AH:6)I=#(S
M+FAT;<U6;6_;-A#^OE]Q=;"T!2+K-7%BNP8RV\&*N9V1> CZ::#$DTU4(@62
MBNO]^ATI.>V6(44_K*@^$*+N[;F[YTA-7RQ^GV\^K)>PLW4%ZS]^6;V=PR (
MP_MT'H:+S0)^W;Q;03:,8MAH)HVP0DE6A>'R_0 &.VN;<1CN]_OA/ATJO0TW
MMZ%SE8654@:'W/+!;.J^T(J,SWZ:O@@"6*BBK5%:*#0RBQQ:(^06[CF:CQ $
MO=9<-0<MMCL+293$<*_T1_' .KD5ML+9T<\T[/;3T >9YHH?9E,N'D#P-P,1
ME7@1CS ]+TJ>\82QHK@JDX@>?ID5>/EG3"!#4N]LC#U4^&90"QGLT,4?CY+&
M3O:"V]TXCJ*?!UYO-BV5M!1,DW'WVOEX]-1I'/T5JE)Z?!+Y9^(D0<EJ41W&
M+Z^U8-7+,T,%#@QJ479B(_Y""DBQ_7;?@R'K2D@\@HNSC! M/^U$+JA4Z3_!
M/ ?T.T.<*VE<TU4);R7'!FFA[2UNA;&HB0;K-J]$ ==%H5II'25NA*Z?@'[L
M$--;:I)5S?BBL8/_)Y?LW[F,7"[W"$6?CE5@=PA"%DHW2C,W(9 ?0&-)2<G"
MB;Q&EVBO<&>)^(Z[!E[=*%W#79#"]=TMO%=#2-,T2)*K47I^>G)^-0$F.?1*
MEZ1@.HTXRJ+SD1?Z[2C)DN2U*^^R$K 2577PPKFJ&R:[]QZ*QLK/W5HKTV!A
M6^/,5*M)0CD0*.[E-YCKENG#Z4E\$4WBT9D?Q3/8"[LC56][+("KAZI$9U@*
MR61!9:9V/";Z+#+3YD9PP;1 <^:_.*=8EA1"/*!$XQT(252A$\B%LUI5H!Y0
M?Q&NP^^H\PW1J'=5R[$OCS!P+65+SFZ],W@51\%OKZ%4VF,Z(-/@R,MA@076
M.>JN/FGLZQ,-OXVQSTWF]YS:)TSW4WMZDHTFQJ^PU-)87[\/-*!;6*W6/RQN
M.F($DZPA2E*'^]T/=I1XH/\]8_ UJ+FR5M4^R+,\.II]>94UJKO(Q_X<H.EZ
M<KD=K?HHT6<3EM.4M_:IR5?NPW[MKF;_DS#[&U!+ P04    " !D5U%2NB[<
MC/L'   -*   '@   &QL>2TR,#(P,3(S,7@Q,&ME>&AI8FET,S$Q+FAT;>U:
M77/;-A9][Z] E6GBS.B+LBS9LN,9QW:FGLTVF:QWTGW:@0A0PI@D6 "4K/WU
M>RY 69(E-TJ<NG*G>5!,X@*X'P?GWDORY,>+#^?7__EXR<8N2]G'?[]]?W7.
M:HU6Z_/^>:MU<7W!?K[^YWO6;;8C=FUX;I53.N=IJW7Y2XW5QLX5@U9K.ITV
MI_M-;4:MZT\M6JK;2K6VLBF<J)V>T!W\2BY.?SCYL=%@%SHN,YD[%AO)G12L
MM"H?L<]"VAO6:%12Y[J8&34:.]9I=R+V69L;->%AW"F7RM/Y.B>M<'W2\IN<
M#+68G9X(-6%*O*FIH\.#7M(;]H><][N]GCSL"M$][,BC?K?/13OY;P0E6Q /
M<ZR;I?)-+5-Y8RQI_T&WT^P?%.YXJH0;#Z)V^Z>:%ST]273NL)_!_/!G6.9N
ML2 Q7S+6J3:#%VW_[YA&&@G/5#H;O#HSBJ>OZA8^;EAI5!*&K?J?Q(;8VU].
M@SY]S$Y5+N?Z11W2Z/+7GZ_>7EVS_:@9L4]E*EFTSQM1=X^_9N?2.)6HF%/\
MF$[8!9\HP<Z:[).*;VR=G8^Y,AG/Z^RCD58)>+7.>"XPH&3"+F]E7#HUD>Q#
M@F6D8:L&+_N-FQ%<YW0Q."I<[2D]<'[YZ?KJW=7YV?75AU_^M96*W>;!'Z9D
M=Z.25_5'.[_.8A_/&7-C[EZ^.#@\WM[8XX(+@>/62&7B!OL]W''RUC543OL.
M&M'A$SLD:LYU?ZH]5UUPU.SUR>0K-N;PL9$3):<@)3=6%E>%-H[AT+S3)F-1
MN_$/.CZ7J6+O59K.0IAT5O!\AD <'3_?.'1V) YON87WX?%LQFYR/4VE&,GZ
M2CB$EI;E&@D$.W"5(PHS5N;.E!)Z(Z7X[((X<9;ABO1D"8]QRS"=*<><#G)K
M KF,I;7<S$@DXS<2^RZM:7%/0!ELF?K4A#U((%8&J0AB.:9#$P&&G(Y5/&:V
MI)_%_*DTLEJ$#,B439&S*/U-E1O#0%O(V"M(ZQ9030N8.<$TP8:S93<\<[SM
M[SK>)$M4CH@2.!81#,RL,6R6QE6>@!]">E5YG)8":P(E2^&J V'*@#(*!)GP
M2;A-TP4 J]C;>UL#X\+77762*%,( '4:T/#;50K%W(Y9DNJIG6/2R)&R#E6;
M8YQN!CFH65^"EIUKLZ;N,T=7=T?0=;T2B5>V0DZ5P.G<ZY#4]^QK'Z KQHWT
M6$!LU1!E'$+&)  X3)4=TPP2RT![1'UT+92-4VU+S"-"-#JU7J8P.I8"MRW;
M P2$!*A"G"]OXS'/1Y*=@6NH5K2A6#S8DT&+Z$"$JW")O:3) QAI?4:$M(31
M !G29>N-DI6-$FQ$=MX'+B0H*_L:YQO!V._\Z6#D.P+&"U27(XJ,STI?ADV=
M$F;,2[O]%,I<0PD(5#N%7*A+@P5 .1-E/9-!2N9^'2IA%QRXS*-&IMQCJDJ&
M"US4*XZE004^A"Y6ITKX9M*60]30BAM%!JB0LCVSY[12:2F-^E-H?<[UM(=N
M%0JAC?23"@XPQV7*B:YAEE=BD8XQ(R3WY9H$?PTE"8)0,5^*QQ#H#F!VN).8
MW9J(UJ"[/85MC6"@'HT< 9-;G7/B:FX!:JH"":W<B#ER@&7%ARI5;D;Y>=.V
M=(X\R#Q^[CKU335(2 FWE4%%:0K@U_J"(HZU$5X!7T^.9(XZP3<J<2P+.A\D
M@EHY0!7G2!5@Y6<.UOA/!FO4;G;VR>;+"4]+3T,42IDD*.C0N>=H*M;K,E0#
M6Q!JN-Q<I'E88B+(D% )X:$NW<-[;T/Y_$Y:4J&;?+D18<-Y">U/F@P^@#X>
M5;3!\T66V!4:#)%;1P"UOE6-Y4?N >PK:(\2L8[CTE"$E[+>RGJ9M@YW8FI@
M$NB$)7XKD2ZQZ-Z:< )X@H3NR55JHF.1OD>G]CTO[W1Y'309<WM7%A!]>3A+
MX7G=6U]Q[@R=^(U,JX;]GGS]$0YY+'AWH DZV!'P?D,3Y)_%B3GHZPN*(<9;
M!N&";0A,7U$?K%65T(NCIG3:V+MD[&]@L2Q3SDFYD<.'&HF>1H2"3G[Z'D *
MRK1$R?B?:MKY:9*_E0HJ^_-3YK%OX5__W=]\%YR=I:B24+7Y5QU0A!K16$F$
MOLJC=WW&5/(;2HRA:O*IT==[_@GA_-'*5P&J:@E"\[Z!F[C 1"OOJ&D#^*KZ
M$,+ $<JX>LC+%DG9EAE0 /=X,RKJW_CXZ2^0<W>E]3A#:DT,**".X$I/68"'
M?VQ;X:@><I7*)SJ=2$I8.1]53Y]-Q7(R*U(]DQB=CG7@-;Z"4J#JD;F[N1;K
M[^*Z[E;1>ODBZK4?)B\/)9["W@'QM32U!U^;;L9HM/_D[^@N$-[P6NV='!J4
M+;-@9-2OAY?17])[J)W3V8 .UY(EP0SG&\5*?HAC+DT#YJ2\L'(P_^,8J:](
M^6R@<J^>GW0\H82)4JKR)]:LWDD?=)K]?I]>2SLXU8GY\M4;ZZ9_8]UR8GVL
MU^P=]!X<;3>C;QKK--O1MZWZ>[H>'C:/.H=;+=OR?@B^@$]MP?,WM?W:?$)U
MW >=XI9%<[X+3B4&N._H$,ZG@J#_ON#M;+4FJ S>+5OZ6YERCR!VTI(MH_+R
M1;=_;/WOO;?X*^9MB;XV65G;59=\Y^!63.<9O8!N]+R6S97:_<C_'>V_V%'^
M_8]N@J%K7]ZLQ[WE,_.&2N#>MV.%#A_/#<);C8E<^YIL<5!\[=!>3.%#G);2
M/3SE*VJLE=_PH9S_9._T_U!+ P04    " !D5U%2&T(<9_ '  "P)P  '@
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M\Q F/2EX/D<@CD^>;APZ>Q*'-]QB];'BDSF[R?4LDV(DZQOA$%I:EFMD$,S
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MIO+.!U^KS106936$Q]A1I;M_R%H$J&N5YOXZ;.,W?,OFOZH[^QU02P,$%
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M493 GJFRE8:!/?*B3IM("GO9:H%;US9=.9J0%Z2T3$.W[1TX^$!\T(0/DCM
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M              "  ?KS!@!L;'DM,C R,#$R,S%?9S$N:G!G4$L! A0#%
M  @ 9%=14A2T'@#UZ@$ P?\3 !0              ( !K@X( &QL>2TR,#(P
M,3(S,5]L86(N>&UL4$L! A0#%     @ 9%=14M@-XO)])P$ [ZD- !0
M         ( !U?D) &QL>2TR,#(P,3(S,5]P<F4N>&UL4$L! A0#%     @
M9%=14HT."Q-Q.   UG0! !\              ( !A"$+ &QL>2TR,#(P,3(S
M,7@Q,&ME>&AI8FET,3 Q,"YH=&U02P$"% ,4    " !D5U%2Z3@XIA0T  #Y
MB@$ 'P              @ $R6@L ;&QY+3(P,C Q,C,Q>#$P:V5X:&EB:70Q
M,#$T+FAT;5!+ 0(4 Q0    ( &1745+3O&\ZL34  )5" 0 ?
M  "  8.."P!L;'DM,C R,#$R,S%X,3!K97AH:6)I=#$P,34N:'1M4$L! A0#
M%     @ 9%=14B[Y\)SK.0  DHL! !X              ( !<<0+ &QL>2TR
M,#(P,3(S,7@Q,&ME>&AI8FET,3 R+FAT;5!+ 0(4 Q0    ( &1745++H4^/
MQ40  $J] 0 >              "  9C^"P!L;'DM,C R,#$R,S%X,3!K97AH
M:6)I=#$P,RYH=&U02P$"% ,4    " !D5U%2V%P]1ATU  #D6@$ '@
M        @ &90PP ;&QY+3(P,C Q,C,Q>#$P:V5X:&EB:70Q,#0N:'1M4$L!
M A0#%     @ 9%=14IL80/1Q-@  *8 ! !X              ( !\G@, &QL
M>2TR,#(P,3(S,7@Q,&ME>&AI8FET,3 U+FAT;5!+ 0(4 Q0    ( &1745*N
ML$(9*D$  ,"R 0 >              "  9^O# !L;'DM,C R,#$R,S%X,3!K
M97AH:6)I=#$P-BYH=&U02P$"% ,4    " !D5U%2W0SX7/XV   (FP$ '@
M            @ $%\0P ;&QY+3(P,C Q,C,Q>#$P:V5X:&EB:70Q,#<N:'1M
M4$L! A0#%     @ 9%=14C ,'(Y=/   4;P! !X              ( !/R@-
M &QL>2TR,#(P,3(S,7@Q,&ME>&AI8FET,3 X+FAT;5!+ 0(4 Q0    ( &17
M45+F 4R[8$<  &SV 0 >              "  =AD#0!L;'DM,C R,#$R,S%X
M,3!K97AH:6)I=#$P.2YH=&U02P$"% ,4    " !D5U%2]-4@'Q<,  #%^P
M'0              @ %TK T ;&QY+3(P,C Q,C,Q>#$P:V5X:&EB:70R,2YH
M=&U02P$"% ,4    " !D5U%2B*5U+14#  !_"   '0              @ '&
MN T ;&QY+3(P,C Q,C,Q>#$P:V5X:&EB:70R,RYH=&U02P$"% ,4    " !D
M5U%2NB[<C/L'   -*   '@              @ $6O T ;&QY+3(P,C Q,C,Q
M>#$P:V5X:&EB:70S,3$N:'1M4$L! A0#%     @ 9%=14AM"'&?P!P  L"<
M !X              ( !3<0- &QL>2TR,#(P,3(S,7@Q,&ME>&AI8FET,S$R
M+FAT;5!+ 0(4 Q0    ( &1745*2DQ8OU@0  +X;   =              "
M 7G,#0!L;'DM,C R,#$R,S%X,3!K97AH:6)I=#,R+FAT;5!+!08     %P 7
+ (4&  "*T0T    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
